<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Bersama Kita Sehat &#45; : Biotechnology</title>
<link>https://edusehat.com/en/rss/category/Biotechnology-136</link>
<description>Bersama Kita Sehat &#45; : Biotechnology</description>
<dc:language>en</dc:language>
<dc:rights>2025&#45;2055 PS Global Media &#45; Hak Cipta</dc:rights>

<item>
<title>Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development</title>
<link>https://edusehat.com/en/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development</link>
<guid>https://edusehat.com/en/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development</guid>
<description><![CDATA[ Age-related changes in CD8+ T cells may hold important clues to understanding cancer immunity, with new findings revealing distinct chromatin signatures of dysfunction and the emergence of a unique regulatory population. 
The post Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-1321240646.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Aging, Study, Mice, Reveals, Clues, Cell, Dysfunction, and, Cancer, Development</media:keywords>
<content:encoded><![CDATA[<p><span>Data from a new study led by scientists at Monash University looking at immune aging in mice helps shed more light on why bodies become less effective at fighting cancer and infections with age. The preclinical study, published this week in <em>Science Immunology</em>, identified unique genetic signatures in aging immune cells that cause them to become less effective over time, making older individuals more susceptible to disease. The paper is titled “</span><a href="https://dx.doi.org/10.1126/sciimmunol.aej5412" target="_blank" rel="noopener"><span>Aging drives distinct chromatin signatures of CD8 T cell dysfunction and the emergence of a unique CD8 Treg cell population</span></a><span>.” </span></p>
<p><span>“Our immune system is constantly surveying our bodies for potentially cancerous cells and eliminating them, often without us ever knowing,” explained Daniel Thiele, PhD, first author on the paper and a researcher in the laboratory of Nicole La Gruta, PhD, at Monash Biomedicine Discovery Institute. “As we age, this natural defense system becomes less effective, making us more vulnerable to cancer and infections and reducing our ability to respond to vaccines. This study provides a blueprint of immune aging, from which we can now identify potential targets to reverse aspects of that decline.”</span></p>
<p><span>As the title of the paper indicates, the scientists focused on CD8+ T cells, which are part of the body’s frontline defense system for identifying and destroying infected and cancerous cells. According to the team, they identified three distinct ways that aging disrupts the genetic instructions that control how immune cells function, which affects their ability to adapt to new threats, regulate immune responses, and remain healthy. They also discovered a previously unidentified group of aging immune cells that both lose their ability to protect the body against disease and actively suppress the responses of other immune cells. This was true even within the same ageing individual, Thiele noted. </span></p>
<p><span>This research supports findings from separate research also from scientists in the La Gruta lab. That study, </span><a href="https://www.cell.com/immunity/fulltext/S1074-7613(26)00440-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761326004401%3Fshowall%3Dtrue" target="_blank" rel="noopener"><span>also published this month in </span><i><span>Immunity</span></i></a><span>, found a link between the Granzyme K protein and signs of aging in the heart, liver, and kidneys in preclinical models. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/immune-aging-study-in-mice-reveals-clues-to-t-cell-dysfunction-and-cancer-development/">Immune Aging Study in Mice Reveals Clues to T Cell Dysfunction and Cancer Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity</title>
<link>https://edusehat.com/en/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity</link>
<guid>https://edusehat.com/en/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity</guid>
<description><![CDATA[ Studying postmortem brain tissue, researchers found variations in DNA methylation in different brain areas that may help explain the development of post-traumatic stress disorder.
The post PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/02/Getty_1402264698_DNAMethylTransferase.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 21 Nov 2026 05:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PTSD, Brain, DNA, Methylation, Patterns, Linked, Age, Trauma, Exposure, Sex, and, Ethnicity</media:keywords>
<content:encoded><![CDATA[<p>The results of research headed by a team at the University of Texas at Austin indicate that stress and trauma can leave molecular marks in the brain that may help explain the development of post-traumatic stress disorder (PTSD).</p>
<p>The researchers analyzed specific regions of the postmortem brains of people with PTSD, those with major depressive disorder (MDD), and those without psychiatric disorders. The identified specific molecular features of the PTSD and MDD brain, and showed that the molecular signatures of PTSD also varied significantly between individuals—more so than for individuals with major depressive disorder. The results suggested that within the PTSD group, factors such sex, race of the person, and when in their lifetime trauma exposure occurred, may all impact on the epigenetic signature.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“The question that our research aims to address is ‘What is really different about the PTSD brain?’” said Frances Champagne, PhD, at the University of Texas at Austin. “The study found greater variation in DNA methylation patterns across brain regions in people with PTSD than in people with major depressive disorder. It also revealed considerable differences among individuals with PTSD.” The variance could open the door to more individualized treatment options for people with PTSD in the future, the researchers suggest.</p>
<p>Champagne is corresponding author of the researchers’ published paper in <em>Cell Reports</em>, titled “<a href="http://dx.doi.org/10.1016/j.celrep.2026.118270" target="_blank" rel="noopener">DNA methylation profiling of human brain in posttraumatic stress and major depressive disorders indicate specific molecular features</a>.” In their paper the authors stated, “Overall, our findings illustrate an approach to characterizing distinct epigenomic features within the postmortem brain and the association between variation in DNA methylation and psychiatric diagnoses.”</p>
<p>Epigenetic mechanisms, which are molecular pathways through which gene expression is regulated, have been increasingly implicated in the pathophysiology of physical and psychiatric disorders, the authors wrote. One of these mechanisms, DNA methylation, acts like a genetic “dimmer switch” for genes, sometimes blocking genetic code entirely. “Beyond the role of these mechanisms in gene regulation, epigenetic marks such as DNA methylation exhibit plasticity in response to the environment, thus serving as a potential mediator of the gene-environment interplay that is considered fundamental to disease risk and resilience,” the investigators explained.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Interestingly, PTSD studies have uncovered associations with variations in DNA methylation in peripheral blood (blood and saliva), particularly within genes involved in immune functions such as inflammation and innate immunity, the team continued. However, they pointed out, “While analyses of DNA methylation in peripheral tissues have revealed associations between PTSD and variation in the epigenome, the limited availability of brain-based analyses constrains the potential to reveal critical pathways in the pathophysiology of PTSD.”</p>
<p>For their newly reported study the team carried out detailed methylation profiling of postmortem brains from 302 individuals. All brains were obtained from the Lieber Institute for Brain Development and were matched with the donors’ life history and medical records to assign diagnostic criteria. The analysis included brains from 101 people with PTSD and two comparison groups—100 brains from individuals without psychiatric disorders and 101 brains from people with major depressive disorder. For each brain, three different regions were analyzed—the prefrontal cortex (PFC), the amygdala, and the hippocampus.</p>
<p>“These are the brain regions that seem to be uniquely informative of the PTSD brain,” Champagne said. “Many studies of epigenetics use blood and saliva as a proxy to see what’s going on the body, but we think it’s incredibly important to actually look at the brain for these kinds of mental health conditions.”</p>
<p>The study uncovered specific changes in the brain linked to PTSD, including a relative reduction in oligodendrocytes in the amygdala of people with PTSD, particularly in those exposed to trauma in adulthood. The researchers also found that PTSD was associated with more pronounced DNA methylation differences in the prefrontal cortex, while major depressive disorder was associated with methylation differences in the amygdala. These molecular patterns were associated with differences in the composition of different cell types in the brain.</p>
<p>Within the PTSD group, the molecular variations appeared to be driven by a number of factors, including the sex and race of the person and whether the trauma exposure occurred in childhood or adulthood. One future research focus will be on using these variables to refine and enhance diagnosis. The researchers say it could eventually lead to a more personalized approach to treating mental health conditions.</p>
<p>“Overall, these analyses reveal epigenomic features of the PTSD and MDD brain that can guide cellular and molecular mechanistic understanding of the pathophysiology of these disorders,” the authors stated. “This understanding can inform clinical interventions by identifying unique and shared biological processes that characterize the brain epigenome dependent on mental health diagnosis.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Because the study analyzed postmortem brain tissue the researchers were not able to confirm whether the methylation differences contributed to PTSD, resulted from PTSD, or were influenced by other factors. The authors also noted that they lacked detailed information about symptom type and severity for each individual, which would be important for developing more personalized methods of diagnosis.</p>
<p>“The more we know about all the variables that impact clinically relevant outcomes, the better we can assess patients and tailor their treatments,” Champagne acknowledged.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ptsd-brain-dna-methylation-patterns-linked-to-age-of-trauma-exposure-sex-and-ethnicity/">PTSD Brain DNA Methylation Patterns Linked to Age of Trauma Exposure, Sex, and Ethnicity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genome Writing Inserts Human X&#45;Linked Disease DNA Into Mice</title>
<link>https://edusehat.com/en/genome-writing-inserts-human-x-linked-disease-dna-into-mice</link>
<guid>https://edusehat.com/en/genome-writing-inserts-human-x-linked-disease-dna-into-mice</guid>
<description><![CDATA[ By swapping 78 kilobases of human DNA into mice, researchers recreated key features of X-linked dystonia-parkinsonism and showed that boosting TAF1 expression may counter some cellular effects.
The post Genome Writing Inserts Human X-Linked Disease DNA Into Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/01/thumbnail_GettyImages-1023097228-e1695336230594-1068x712-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 22:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genome, Writing, Inserts, Human, X-Linked, Disease, DNA, Into, Mice</media:keywords>
<content:encoded><![CDATA[<p>By assembling and swapping in long stretches of engineered DNA with genome writing, researchers can reconstruct human disease-linked regions in another species—an approach that has now produced a mouse model of X-linked dystonia-parkinsonism (XDP), a rare neurodegenerative disorder that causes movement problems that worsen with age. The model compresses a disease course that can take decades in people into less than two months in mice, potentially accelerating studies of disease biology and treatments.</p>
<p>For the study, “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)00926-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426009268%3Fshowall%3Dtrue" target="_blank" rel="noopener">Genome writing reveals SVA retrotransposon consequences in X-linked dystonia-parkinsonism</a>,” published in <em>Cell</em>, an NYU Langone Health-led team rewrote part of the mouse <em>Taf1</em> gene with a corresponding 78-kilobase segment of patient-derived human <em>TAF1</em> DNA. That segment included a disease-causing SINE-VNTR-<em>Alu</em> (SVA) retrotransposon insertion. Because SVAs are found in humans but not mice, conventional mouse models cannot readily reproduce their effects.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>In mouse embryonic stem cells, the researchers found that the intronic SVA—not the hybrid human-mouse gene structure itself—reduced <em>TAF1</em> messenger RNA. Chromatin and transcriptome analyses indicated that the insertion is actively transcribed and acts as a barrier that may prematurely halt transcription, lowering TAF1 expression and triggering cell death. In mice, nervous system expression of the humanized <em>TAF1</em> allele produced severe atrophy centered in the striatum, the brain region affected in people with XDP. Male mice died within two months, versus the roughly 30 years it can take for symptoms to emerge in humans.</p>
<p>The team also used CRISPR activation, or CRISPRa, to increase <em>TAF1</em> expression in the engineered stem cells. Restoring expression rescued cell viability, offering proof of concept that boosting <em>TAF1</em> transcription could be explored as a treatment strategy. “Our experiments establish a rationale for the future development of new therapeutic approaches for XDP patients,” said senior author Jef D. Boeke, PhD, director of NYU Langone’s Institute for Systems Genetics.</p>
<p>A companion <em>Cell</em> study, titled “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)01339-5" target="_blank" rel="noopener">Myelin pathology is a key feature of X-linked dystonia-parkinsonism</a>,” using the same model further implicated oligodendrocytes—the cells that produce myelin around neuronal axons—rather than neurons alone in XDP. The researchers also detected myelin loss in banked human XDP brain tissue, a feature reportedly missed in earlier studies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The work positions genome writing as a way to build models for diseases driven by large or human-specific DNA elements that are difficult to reproduce through conventional editing. Important questions remain, including what factors drive variable progression rates in XDP, whether raising TAF1 levels can safely produce durable benefits in animals, and how broadly the method can be applied to other rare diseases.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/genome-writing-inserts-human-x-linked-disease-dna-into-mice/">Genome Writing Inserts Human X-Linked Disease DNA Into Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Maryland backs upper payment limits as other states have second thoughts on PDABs</title>
<link>https://edusehat.com/en/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs</link>
<guid>https://edusehat.com/en/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs</guid>
<description><![CDATA[ The recent decision by Maryland’s Prescription Drug Affordability Board (PDAB) to set upper payment limits (UPLs) on two prescription drugs is not expected to […]
The post Maryland backs upper payment limits as other states have second thoughts on PDABs appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/04/pharmacy-benefit-manager-pbm-e1795107738637.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 15:00:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Maryland, backs, upper, payment, limits, other, states, have, second, thoughts, PDABs</media:keywords>
<content:encoded><![CDATA[<p>The recent decision by Maryland’s Prescription Drug Affordability Board (PDAB) to set upper payment limits (UPLs) on two prescription drugs is not expected to impact what patients pay for their medicine.</p>
<p>The limits, approved Nov. 16, only apply to what state and local government purchasers pay for the drugs, not the amount patients are charged at the pharmacy counter, according to the<a href="https://www.baltimoresun.com/2026/11/16/maryland-drug-payment-limits/"> Baltimore Sun</a>.</p>
<p>Set to go into effect Jan. 1, the limits would make Maryland one of the first states to enforce UPLs. The other state being Colorado, which established a UPL in 2025, which is temporarily being blocked by the courts. Maryland stands out for leaning into its PDAB at a time when <a href="https://avalerehealth.com/thought-leadership/state-pricing-controls-at-an-inflection-point-maximum-fair-price-and-the-shifting-prescription-drug-affordability-board-landscape/">other states are finding PDABs unworkable</a> and are closing them or choosing against implementing them.</p>
<p>As their name suggests, Prescription Drug Affordability Boards (PDABs) are supposed to target affordability, but the question has become: Affordability for who?</p>
<p>Patients <a href="https://schaeffer.usc.edu/research/prescription-drug-affordability-boards-reshape-reimbursement-while-leaving-core-problems-unresolved/">are not seeing reductions</a> in out-of-pocket costs due to PDABs. State governments, which often spend millions on these boards, <a href="https://www.multistate.us/insider/2026/6/8/pdab-implementation-challenges-slow-state-drug-cost-efforts">have yet to realize savings</a>. Meanwhile, the price controls attempted by PDABs can limit access to drugs for patients and have a dampening effect on investment and innovation.</p>
<p>“PDABs target the wrong problem,” explains the Biotechnology Innovation Organization (BIO) <a href="https://www.bio.org/sites/default/files/2026-11/pdabs_promised_cost_savings_-_patients_are_still_waiting.pdf">in a new infographic</a>. “PDABs limit what insurers and other institutions pay for a medicine. But a lower payment limit does not necessarily translate to lower out-of-pocket costs for patients.”</p>
<h2>The wrong lever</h2>
<p>Nine states have passed legislation establishing PDABs. While the rules vary, the basic concept is that a PDAB can review the price of individual drugs and set limits on the amount paid for that drug by state institutions or private insurers. The approach has not achieved the desired results.</p>
<p>“The lever that they’re pulling has a single effect: It reduces the amount of money that insurance companies and their PBMs pay for prescription drugs. But they are not legally required to pass those savings on to consumers,” according to Brian Warren, BIO VP for State Government Affairs. “This can allow PBMs and insurers to be more profitable without improving affordability for patients.”</p>
<p>Furthermore, UPL caps established for drugs through a PDAB can reduce access to that drug, research in <a href="https://www.ajmc.com/view/upper-payment-limit-implementation-risks-for-patients-pharmacies-and-providers">The American Journal of Managed Care</a> shows.</p>
<p>“Given existing incentives in coverage decisions, payers may remove UPL drugs from formularies, shift them to higher cost-sharing tiers, or impose stricter utilization management,” and pharmacies may choose to stop stocking drugs if they might lose money by selling them, the research says.</p>
<h2>Maryland moves forward as others wind down</h2>
<p>As states rethink PDABs, many are closing them or choosing not to implement them:</p>
<ul>
<li><a href="http://law360.com/healthcare-authority/articles/2364855/amid-budget-woe-new-hampshire-shutters-drug-price-board">New Hampshire</a> voted to close its PDAB last year for being costly and ineffective.</li>
<li><a href="https://www.lsc.ohio.gov/assets/legislation/136/hb96/ps/files/hb96-otherboards-and-commissions-bill-analysis-as-passed-by-the-senate-136th-general-assembly.pdf">Ohio</a> defunded its PDAB last year after years of inactivity.</li>
<li><a href="https://gmcboard.vermont.gov/sites/gmcb/files/documents/Act%20134%20Final%20Report%20on%20Prescription%20Drug%20Affordability%20in%20Vermont_0.pdf">Vermont</a> decided against a PDAB after a state study found it unworkable.</li>
<li><a href="https://bio.news/latest-news/patient-groups-praise-virginia-pdab-veto/">Virginia’s</a> governor vetoed efforts to pass PDAB legislation.</li>
<li><a href="https://www.reuters.com/legal/litigation/judge-blocks-colorados-first-of-its-kind-price-cap-amgens-enbrel-2026-07-01/">Colorado’s</a> first attempt at setting a UPL was blocked by a federal judge.</li>
<li><a href="https://www.ourquadcities.com/news/local-news/illinois-law-to-lower-prescription-drug-prices-struck-down/">Illinois</a> legislation to lower drug prices was struck down in court, and related PDAB legislation <a href="https://www.ilga.gov/legislation/BillStatus?DocTypeID=SB&DocNum=3496&GAID=18&SessionID=114&LegID=166497">failed in the legislature</a>.</li>
</ul>
<p>“PDABs are difficult to implement” and require significant resources, says BIO’s infographic. “PDABs across six states have cost more than $28 million to establish and operate.”</p>
<p>Nonetheless, Maryland is moving ahead with PDAB price controls.</p>
<p>As <a href="https://mdtechcouncil.com/statement-from-the-maryland-tech-council-on-pdab-upper-payment-limit-action/">the Maryland Tech Council</a> noted when the state’s PDAB recommended the first UPL in April, price controls can harm innovation, something a state that relies on a robust biotech industry should avoid.</p>
<p>“While tech incubators, centers of innovation, universities and elected officials are working hard to increase the state’s competitiveness, Maryland’s unelected PDAB is putting Maryland’s future as a life sciences leader at risk,” says a statement from the Maryland Tech Council, a BIO affiliate.</p>
<p>“Policies that may alter reimbursement structures or limit market viability can have a chilling effect on investment particularly for early-stage and mid-sized firms that drive much of Maryland’s innovation economy,” says the statement, noting that barriers to innovation also deter America’s efforts to compete globally for biotech leadership.</p>
<p><a href="https://www.bio.org/sites/default/files/2026-11/pdabs_promised_cost_savings_-_patients_are_still_waiting.pdf"><strong>Read: BIO’s PDAB infographic.</strong></a></p>
<p>The post <a href="https://bio.news/state-policy/maryland-backs-upper-payment-limits-as-other-states-have-second-thoughts-on-pdabs/">Maryland backs upper payment limits as other states have second thoughts on PDABs</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Type 1 Diabetes Delayed in Mice by Stem Cell&#45;Derived Vesicles That Calm Immune Response</title>
<link>https://edusehat.com/en/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response</link>
<guid>https://edusehat.com/en/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response</guid>
<description><![CDATA[ Extracellular vesicles produced by certain types of pluripotent stem cells (PSC) were found to help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model.
The post Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_extra-cellular-vesicle.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 07:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Type, Diabetes, Delayed, Mice, Stem, Cell-Derived, Vesicles, That, Calm, Immune, Response</media:keywords>
<content:encoded><![CDATA[<p>In people with type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as foreign and attacks them, leaving the body unable to properly regulate blood sugar. While insulin therapy helps manage the disease, it does not stop the underlying immune attack.</p>
<p>UCLA researchers have identified a potential new way to protect these cells by harnessing extracellular vesicles—tiny particles naturally released by nearly all types of cells that help them communicate with one another.</p>
<p>Their preclinical study found that vesicles produced by certain types of pluripotent stem cells (PSCs) can help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model. The research was inspired in part by a feature of pregnancy, which means that the mother’s immune system generally tolerates a developing embryo, even though it carries genetic material from the father that the maternal immune system could recognize as foreign. The findings suggest a possible strategy for preserving insulin-producing cells before they are destroyed.</p>
<p>Song Li, PhD, associate dean for graduate and professional education and a professor of bioengineering at the UCLA Samueli School of Engineering and a member of the UCLA Broad Stem Cell Research Center, is senior and corresponding author of the team’s published paper in <em>Nature Nanotechnology</em>, titled “<a href="https://doi.org/10.1038/s41565-026-02320-z" target="_blank" rel="noopener">Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy</a>.”</p>
<p>Embryonic development is characterized by “remarkable immune tolerance,” the authors noted, “… yet whether this property extends to pluripotent stem cell-derived extracellular vesicles (EVs) has remained unclear.” Li added, “Nature has designed something amazing. If we can better understand how an embryo avoids rejection by the mother’s immune system, it could be very useful for a lot of immune-related diseases.”</p>
<p>For their study the team investigated whether extracellular vesicles released by pluripotent stem cells—which share characteristics with cells found in early embryonic development—might also possess immune-regulating properties. The researchers compared vesicles from embryonic stem cells (ESCs) and induced pluripotent stem cells, or iPSCs, with those from mesenchymal stem cells (MSCs), which have been widely studied for their ability to regulate inflammation. “Extracellular vesicles (EVs) secreted by adult stem cells, particularly mesenchymal stem cells (MSCs), have been extensively investigated for their regenerative potential across a wide range of pathological conditions,” the team pointed out.</p>
<p>In experiments using mouse and human immune cells, vesicles from both types of pluripotent stem cells showed stronger anti-inflammatory effects than those from mesenchymal stem cells. They also promoted the formation of regulatory T cells (Tregs), specialized immune cells that help prevent the immune system from attacking the body’s own tissues. “… we show that EVs from pluripotent stem cells (PSCs), including embryonic stem cells and induced pluripotent stem cells, outperform mesenchymal stem cell-derived EVs in suppressing proinflammatory cytokine secretion, reducing T cell activation and inducing regulatory T cells,” they stated.</p>
<p>Further analysis showed that the vesicles carry distinctive proteins, lipids, and genetic material that may contribute to their immune-regulating properties, providing insight into how these naturally produced nanoparticles influence immune cells. “… PSC EVs display distinct molecular signatures, containing unique proteins and microRNAs absent from mesenchymal stem cell-derived EVs, including the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family,” the investigators continued.</p>
<p>To test whether these immune-regulating effects could help prevent diabetes, the researchers introduced immune cells that attack insulin-producing pancreatic cells into mice, then treated the animals with extracellular vesicles derived from iPSCs.</p>
<p>Because extracellular vesicles are rapidly cleared from the injection site, the team developed an injectable hydrogel that gradually releases them over several days. “Soluble EVs are cleared rapidly from subcutaneous tissue, and therefore, we developed an injectable hydrogel composed of hyaluronic acid (HA) and Pluronic F127 that transitions from a solution to a gel state at body temperature,” they explained. “Both polymers are widely used in biomedical formulations, which further supports the translational potential of this platform.”</p>
<p>The treatment was injected beneath the skin near the neck, where the vesicles could interact with immune cells in nearby lymph nodes. These immune cells could then circulate throughout the body, potentially reducing harmful immune activity in the pancreas. The researchers found that two treatments with extracellular vesicles, either alone or delivered through the hydrogel, significantly delayed the onset of diabetes compared with untreated controls.</p>
<p>At the end of the 90-day study, 55% of mice receiving vesicles in the hydrogel remained diabetes-free. Mice receiving vesicles in the hydrogel also had more regulatory T cells in their lymph nodes and retained more insulin-producing pancreatic tissue than control animals. “Delivered via a biomaterial scaffold, two local injections of induced PSC EVs significantly improved diabetes-free survival in an antigen-specific type 1 diabetes model, increasing regulatory T cell populations in draining lymph nodes, as well as inducing systemic immune modulation and preserving β-cell mass,” the scientists stated.</p>
<p>“One thing that surprised us was that a local injection could provide protection throughout the body,” said Li, who is also a member of the UCLA Health Jonsson Comprehensive Cancer Center and the California NanoSystems Institute at UCLA. “That’s the beauty of this approach.”</p>
<p>The researchers also addressed a major obstacle to developing extracellular vesicle-based treatments: producing sufficient quantities of consistent, high-quality particles. Rather than growing stem cells on flat laboratory surfaces, the team grew them in three-dimensional clusters suspended in gently moving liquid. “Suspension culture allows PSCs to grow as floating aggregates and maintain pluripotency without differentiation into embryoid bodies,” they explained. This approach increased vesicle production 3.4-fold per million cells while preserving important characteristics of the particles.  Because iPSCs can multiply extensively in the laboratory, they could provide a more consistent and scalable source of therapeutic vesicles than adult stem cells, whose growth potential is more limited.</p>
<p>The approach remains experimental, and further studies are needed to determine whether it would be safe and effective in people. Li envisions the greatest potential for patients in earlier stages of type 1 diabetes, when some insulin-producing cells remain functional.</p>
<p>“In the early stages, you still have some pancreatic cells left,” Li said. “If you can regulate the immune cells, you may be able to keep the remaining cells functional.” In more advanced disease, immune regulation alone would not replace cells that have already been lost. However, the approach could potentially help prevent immune rejection of transplanted insulin-producing cells.</p>
<p>The team hopes to test the approach in larger animal models and investigate appropriate dosing, long-term effectiveness, and whether the treatment could weaken the body’s defenses against infection.</p>
<p>Beyond diabetes, the findings could inform research into other autoimmune diseases and strategies for protecting transplanted cells from immune rejection. Acknowledging questions that still remain to be addressed, the authors concluded, “These findings establish PSC EVs as a scalable immunomodulatory platform for autoimmune disease and for immune tolerance in cell therapy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/type-1-diabetes-delayed-in-mice-by-stem-cell-derived-vesicles-that-calm-immune-response/">Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Former Verily Leaders Build AI Platform to Get More from Proteomics Data</title>
<link>https://edusehat.com/en/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data</link>
<guid>https://edusehat.com/en/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data</guid>
<description><![CDATA[ Tesorai’s AI platform reanalyzes massive proteomics repositories, letting researchers mine raw mass spectrometry data instead of condensed forms. In an Alzheimer’s project, it found phosphorylated tau 217 in four datasets where the original authors did not report it.
The post Former Verily Leaders Build AI Platform to Get More from Proteomics Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/08/GettyImages-1064220756-1024x768.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 07:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Former, Verily, Leaders, Build, Platform, Get, More, from, Proteomics, Data</media:keywords>
<content:encoded><![CDATA[<p>Before founding Tesorai in 2024, its three co-founders were long-time colleagues at Verily, Alphabet’s life science company. Melissa Miao, Tesorai’s CEO, led business initiatives and strategic partnerships; Peter Cimermancic, PhD, Tesorai’s CTO, led artificial intelligence teams, and Charlie Kim, PhD, Tesorai’s CSO, launched and led Verily’s molecular science program. While at Verily, they recognized opportunities to use advanced AI to maximize signal extraction from massive laboratory datasets, particularly in mass spectrometry-based proteomics. As Miao told <em>GEN</em> in an interview, “That’s what inspired us to leave and build our own team specifically focused on building AI models to maximize the insights that you could extract from those data sets.”</p>
<p>Today, Tesorai’s AI models process raw mass spectrometry data from labs’ new experiments, public repositories, and company archives. This week, the company announced that it had raised $5.3 million in fresh seed funding, bringing its total funding to $8 million. Investors in the current round include Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures, and ZAKA. The company’s representatives also say that they have signed contracts with both biopharmaceutical and research organizations. Its list of named collaborators includes teams at MD Anderson Cancer Center, New York University, and the Michael J. Fox Foundation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The company plans to use the new funds to expand its work with biopharmaceutical and research customers, grow partnerships across the life sciences, and to extend its platform beyond proteomics to other kinds of molecular data. When asked what kinds of partnerships best fit the company’s offerings, Miao said, “We see applications across all drug development or most drug development stages,” and that spans “target discovery to biomarker discovery all the way down to more development stages.” Besides biopharma, she said that the company is currently expanding into the agrolife sciences space as well.</p>
<p>Focusing on proteomics made sense given the growing interest in these types of studies coupled with several technological advances made in recent years,” Kim said. “We can finally see the whole proteome in the way that genomics was able to 20 years ago,” he said in an interview. But mass spectrometry data “is very challenging to analyze, and there are a lot of opportunities for AI to help.”</p>
<p>But Tesorai plans to expand beyond proteins to other types of omics information. “One of the things we’re really excited about is integrative analysis,” he said. Specifically, “being able to combine different layers of biological data to assemble a mechanistic understanding.” With that in mind, the company plans to take on transcriptomics data next and eventually genomics data as well.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“We are part of an ecosystem of efforts that are really trying to dramatically accelerate the pace of life science research,” Kim said. “If you think of every experiment as a step forward, what we’re trying to do is make every step bigger by getting more information out of every sample, and we’re trying to make those steps faster, both by our engineering and ability to process massive volumes of data quickly,” as well as “through our agentic interface and making it so that you can execute analysis very quickly in natural language.”</p>
<h3><strong>The platform’s architecture and components</strong></h3>
<p>Anchoring the company’s platform is a proprietary AI model built to analyze proteomics datasets. The components include Tesorai Search, a deep-learning engine that is described in a <em><a href="https://www.sciencedirect.com/science/article/abs/pii/S002228362600313X?via%3Dihub">Journal of Molecular Biology </a></em>paper. According to the company, the engine reads full spectra, enabling it to find more peptides, and its model works out most of the 20 to 40 settings adopted by standard analysis tools. In the paper, they report that Tesorai Search “consistently identifies more unique peptides compared to established search engines like MaxQuant, FragPipe (+MSBooster), PEAKS, and Proteome Discoverer” and that it achieves “average increases of 12–68%.” They also claim that it shows “strong performance even on data not encountered during training.”</p>
<p>The platform also includes Tesorai Trove, which catalogs curated public proteomics datasets from human tissue, and structures studies’ metadata into searchable tables that can be used both by humans and AI models. Most tools available today “only query and mine” the condensed and reduced datasets available in the scientific literature, Cimermancic noted during a conversation with <em>GEN</em>. With Trove, “we can really boost the number of insights and discoveries in biology by allowing scientists to mine raw data directly.”</p>
<p>Key to making this type of analysis possible is the way that Tesorai trains its models. Cimermancic explained it this way: Instead of training models on the fly, which can lead to overfitting and inaccuracies, Tesorai pre-trains its model on data from public repositories and other sources to ensure that it generalizes across experimental conditions and instrument types. Because the data is “heterogeneous to begin with,” the model “doesn’t necessarily have any biases,” he said. Trained models are also validated in different ways. For example, if models are only trained on data from one manufacturer’s instruments, their performance is validated using instruments from other manufacturers. Additionally, the company’s academic partners have designed ways to experimentally evaluate its models, for example, using the AI to detect single gene knockouts in cell lines.</p>
<p>A third tool, Tesorai Chat, runs quality checks, statistics, and charts using conversational prompts. Tesorai shared some benchmarking results for Tesorai Chat earlier this year. On a 94-case proteomics benchmark, Tesorai Chat reached over 92% accuracy ahead of tools like Phylo and GPT-5.4, among others.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Tesorai received the first patent for its platform last year. In addition to data, the company has also invested in the underlying engineering and infrastructure so that it can process data at scale. “More and more data is being generated in large part because instruments are getting more advanced,” and “what we observed was that software wasn’t keeping up,” which is “why we started building out this proprietary AI model,” Miao said. Furthermore, “because it’s so scalable, we’ve been able to now reprocess massive repositories of data,” enabling scientists to dig deeper into both the scientific literature and the raw data.</p>
<p>The company has also shared data that demonstrates the types of results its platform can provide. “We’ve been able to show that we can increase the number of peptide and protein identifications,” as well as how the platform improves accuracy, Miao said.</p>
<p>Tesorai operates a token system where customers pay for what they use. It’s a new model for proteomics software and one that is more accessible than the traditional annual licensing structure, according to Miao. “We’re looking to be more generous with the credits that we offer for free for academic research teams,” she said. Because “biopharma tends to have slightly different needs, oftentimes, we’ll enter into specific service engagements that might include working within their cloud environment or creating mechanisms where it’s easier to share analyses across departments and divisions. But for the most part, we’re token-based pricing.”</p>
<h3><strong>Searching for Alzheimer’s biomarkers</strong></h3>
<p>To help elucidate the value of the platform, Kim pointed to a recent application of Tesorai’s platform in Alzheimer’s disease, where the team used it to test a newly published Alzheimer’s blood panel against data from five existing brain studies. The multiprotein plasma panel, which could be a tool for distinguishing between early- and late-stage Alzheimer’s, is described in more detail in a <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1001%2Fjamaneurol.2026.2650&data=05%7C02%7CUduak.Thomas%40sagepub.com%7C42aab5ce855d45ebcd0108df44f9ada6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639305511318547563%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=K7VEYJF%2B%2BkEU6VaTsK9qMkNMBMf0dgNi%2Fbyd3G9vgxo%3D&reserved=0"><em>JAMA Neurology</em></a> paper published this year.</p>
<p>Details of Tesorai’s work are published in a bioRxiv preprint titled “<a href="https://www.biorxiv.org/content/10.64898/2026.08.31.748393v1">Rapid Mechanistic Bridging of an Alzheimer’s Disease Plasma Protein Staging Panel Across Brain Proteomics Cohorts</a>” that was posted in September. For the study, “we were interested in understanding whether the biology of those proposed proteins was also reflected in the brain and whether or not, in the brain, that also tracked with the severity of Alzheimer’s disease,” Kim explained.</p>
<p>An initial read of the five datasets in question showed that they appeared to be missing p-tau217, a well-established plasma biomarker for assessing amyloid-beta pathology in people at risk of developing Alzheimer’s. “Because phosphorylated tau 217 (p-tau217) and amyloid beta 1-40 (Aβ40) were not reported for any studies, raw spectra were reprocessed to quantify these proteoforms,” the scientists wrote. As it turned out, p-tau217was present in four of the five original datasets but had not been reported in the original protein summaries.</p>
<p>Additionally, there was evidence across the cohorts that the plasma-derived biomarker panel could “distinguish early from late-stage Alzheimer’s disease,” Kim said. This was also true for other proteins analyzed in the study. The analysis “provided a mechanistic explanation for why these proteins were changing in the blood in association with Alzheimer’s disease severity.”</p>
<p>Furthermore, Tesorai completed the analysis in three weeks, without having to perform a new study. It is one example of the value that Tesorai’s platform offers, according to Kim. Much like this case where a reanalysis of raw data was fruitful, there are likely other instances “where the original intent of the study authors wasn’t necessarily to ask this kind of question, but the questions can be answered because the information is in the data.” And by combining “multiple data sets in this way … there can be major accelerations in being able to validate and answer questions like this.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/former-verily-leaders-build-ai-platform-to-get-more-from-proteomics-data/">Former Verily Leaders Build AI Platform to Get More from Proteomics Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AMR Awareness Week: C. diff patient finds her voice in advocacy</title>
<link>https://edusehat.com/en/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy</link>
<guid>https://edusehat.com/en/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy</guid>
<description><![CDATA[ “My whole childhood, I got lots and lots of infections: ear infections, eye infections, skin infections, UTIs, lung infections—anything opportunistic, I was getting it. […]
The post AMR Awareness Week: C. diff patient finds her voice in advocacy appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/1000031701.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 20 Nov 2026 00:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>AMR, Awareness, Week:, diff, patient, finds, her, voice, advocacy</media:keywords>
<content:encoded><![CDATA[<p><span>“My whole childhood, I got lots and lots of infections: ear infections, eye infections, skin infections, UTIs, lung infections—anything opportunistic, I was getting it. So I was always on antibiotics,” says Minnie Hatch, a patient advocate from Ogden, Utah. </span></p>
<p><span>Eventually, her prolonged antibiotic use led to another, lesser-known infection: </span><i><span>Clostridioides difficile (C. diff).</span></i><span> Her story shows not only the challenges some patients face with </span><i><span>C. diff</span></i><span>, but also the work that still needs to happen when treating these patients.</span></p>
<p><span>November 18–24 is </span><a href="https://www.who.int/campaigns/world-amr-awareness-week"><span>Antimicrobial Awareness Week</span></a><span>, an annual global campaign aimed at increasing understanding of antimicrobial resistance (AMR) and promoting best practices across human, animal, plant, and environmental health. Additionally, November is </span><a href="https://cdiff.org/see-c-diff/"><i><span>C. diff </span></i><span>Awareness Month</span></a><span>, and as such, Bio.News is sitting down with Hatch to discuss her experiences as a patient and an advocate, and understand more about this misunderstood infection.</span></p>
<h3>Understanding C. diff</h3>
<p><span>“I first started getting sick when I was 19 years old,” Hatch says. “I’m 32 now, and my </span><i><span>C. diff</span></i><span> went undetected for a really long time, at least a year, because I was so young, and my symptoms were so broad.”</span></p>
<p><i><span>C. diff </span></i><span>is a germ that causes diarrhea and inflammation of the colon and while it is more common in senior populations, it can affect anyone. It’s estimated to cause more than 400,000 infections in the United States each year and can be life-threatening.</span></p>
<p><span>This year, the Centers for Disease Control and Prevention’s (CDC) recent </span><a href="https://arpsp.cdc.gov/artr/cdiff?ACSTrackingID=USCDC_426-DM160173&ACSTrackingLabel=November%20is%20C.%20diff%20Awareness%20Month&deliveryName=USCDC_426-DM160173"><span>Antimicrobial Resistance Threats Report</span></a><span>, designated </span><i><span>C. diff </span></i><span>at a threat level of “serious,” indicating that the CDC considers it to pose a significant health hazard to the public, requiring aggressive tracking, prevention, and public health action.</span></p>
<p><i><span>C. diff</span></i><span> causes more than 11,000 estimated deaths in hospitalized patients, and more than $6.4 billion in healthcare costs overall every year, </span><a href="https://arpsp.cdc.gov/artr/cdiff?ACSTrackingID=USCDC_426-DM160173&ACSTrackingLabel=November%20is%20C.%20diff%20Awareness%20Month&deliveryName=USCDC_426-DM160173"><span>the CDC reports</span></a><span>. However, rates of </span><i><span>C. diff</span></i><span> have declined 21% overall from 2018–2020 and remained stable from 2020–2023, per CDC reporting. </span></p>
<p><span>“This is due in part to improvements in </span><i><span>C. diff</span></i><span> diagnosis and the success of efforts to prevent infections. U.S. progress against this threat shows that a comprehensive public health response—grounded in targeted infection prevention, antibiotic stewardship, diagnostic excellence, and increased treatment options—works,” the CDC writes.</span></p>
<h3>An ongoing struggle with C. diff</h3>
<p><span>Hatch herself has seen these numbers play out firsthand, but, as Hatch explains, numbers aren’t the whole story; the patient experience is also incredibly important.</span></p>
<p><span>After months of gastrointestinal issues, the lightbulb finally went on in Hatch’s gastroenterologist’s mind. “He said, </span><i><span>Oh, I didn’t see the forest through the trees. I think you have C. diff</span></i><span>” Hatch explains. </span></p>
<p><span>And indeed, when they sent out a stool sample, it tested positive. Hatch’s doctor was confident that after treatment, she wouldn’t have to deal with </span><i><span>C. diff</span></i><span> again. “But that is not what happened for me. It just got worse,” she says.</span></p>
<p><span>Hatch dealt with years of </span><i><span>C. diff </span></i><span>and she tried a number of treatment options. </span></p>
<p><span>“During COVID, I got </span><i><span>C. diff</span></i><span> again, and this time they weren’t able to treat me,” she remembers. “I wasn’t responding to the antibiotics. I dropped down to 94 pounds, and my doctors told me to put my will together. They said, </span><i><span>There’s nothing we can do. We are waiting for you to go septic.</span></i><span> Luckily, I had found the Peggy Lillis Foundation (PLF).”</span></p>
<h3>The Peggy Lillis Foundation</h3>
<p><span>Hatch had started working with PLF in 2017 shortly after the birth of her son. When the nurses saw that she’d had a previous </span><i><span>C. diff</span></i><span> diagnosis, they put Hatch into quarantine. </span></p>
<p><span>“It put the nurses around me into a panic. They thought I was going to get all the babies sick,” says Hatch. “My son needed NICU care, and they refused to put him in the NICU. The nurses wouldn’t touch me. Ultimately, I ended up asking to be discharged as soon as I could, so I could take my son somewhere that would provide care.”</span></p>
<p><span>Hatch knew her experience wasn’t right, so when she got home she started researching, and found PLF.</span></p>
<p><span>PLF was founded by Christian and Liam Lillis after the death of their mother in 2010 from </span><i><span>C. diff.</span></i><span> When Hatch reached out, they immediately offered to help, and just three weeks after the birth of her son, Hatch and her husband were headed to New York City to participate in a training on advocacy.</span></p>
<p><span>During her COVID-era </span><i><span>C. diff</span></i><span>, as doctors were telling her to get her affairs in order, Hatch was able to tap into her advocacy skills and network to save her life and find a treatment that worked.</span></p>
<h3>Finding her voice as a patient advocate</h3>
<p><span>Ultimately, the cause of Hatch’s repeated infections was discovered to be an autoimmune disorder called “specific antibody deficiency,” which causes Hatch’s body to not create antibodies, leaving the door open for opportunistic infections. So by all accounts, Hatch will potentially have to navigate </span><i><span>C. diff</span></i><span> in the future, making her advocacy work all the more important.</span></p>
<p><span>“When I first started getting sick, less than one in five doctors had even heard of </span><i><span>C. diff</span></i><span>, and only two doctors in my state could treat it at the level I had it,” she says. </span></p>
<p><span>Luckily, Hatch’s voice has gotten more powerful, both for herself and others like her.</span></p>
<p><span>“Nobody can make me cry like a doctor can,” she says. “I find that I still have to advocate loudly. There are many times when, if I have a new doctor, I won’t go to the appointment on my own. Sometimes advocating for yourself is enough, and sometimes it’s not.”</span></p>
<p><span>Hatch didn’t want other people to go through what she had been through. </span></p>
<p><span>“I knew that the best way that I could help other people was to share my story so that doctors could hear it,” she says. “Maybe they would think, </span><i><span>Oh, well, that’s wrong. We shouldn’t be treating people that way.”</span></i></p>
<p><span>Hatch says that more important work she is doing today is peer-to-peer support for </span><i><span>C. diff</span></i><span> patients and their caregivers.</span></p>
<p><span>“For the patients at home,” she continues, “I think the key is not to live in fear and to let yourself live your life. People come into contact with </span><i><span>C. diff</span></i><span> every day and are typically OK.”</span></p>
<p><span>The big issue, Hatch asserts, is misinformation. </span></p>
<p><span>“We can’t treat </span><i><span>C. diff </span></i><span>patients like they’re gross or contagious,” she says. “I’ve had providers refuse to touch me, refuse to work with me, didn’t want me to touch anything, and that is a rhetoric based in fear, not fact.”</span></p>
<p><i><span>If you are interested in learning more, or getting involved, visit: </span></i><a href="https://cdiff.org/"><i><span>https://cdiff.org/</span></i></a><i><span> </span></i></p>
<p>The post <a href="https://bio.news/latest-news/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy/">AMR Awareness Week: C. diff patient finds her voice in advocacy</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Loss of measles elimination status signals growing vaccination crisis</title>
<link>https://edusehat.com/en/loss-of-measles-elimination-status-signals-growing-vaccination-crisis</link>
<guid>https://edusehat.com/en/loss-of-measles-elimination-status-signals-growing-vaccination-crisis</guid>
<description><![CDATA[ America’s loss of measles elimination status is a warning sign of a growing and entirely preventable public health threat that extends beyond measles and […]
The post Loss of measles elimination status signals growing vaccination crisis appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/cdc-83YXJwzKwmY-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 21:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Loss, measles, elimination, status, signals, growing, vaccination, crisis</media:keywords>
<content:encoded><![CDATA[<p>America’s loss of measles elimination status is a warning sign of a growing and entirely preventable public health threat that extends beyond measles and is caused by low vaccination rates.</p>
<p>Measles, which had been officially declared eliminated in the U.S. in 2000, is once again endemic in the country, the Pan American Health Organization (PAHO) <a href="https://www.paho.org/en/news/17-11-2026-paho-urges-countries-step-efforts-stop-measles-outbreaks-and-move-towards">officially announced Nov. 17</a>. The decision is based on proof that <a href="https://www.cnn.com/2026/11/13/health/us-measles-elimination-status">one specific strain of measles virus </a>had been in circulation within the U.S. for more than a year.</p>
<p>“The loss of measles elimination status is a completely preventable setback that reflects our failure to protect thousands of Americans, especially children, from a disease for which we have had a safe and highly effective vaccine for decades,” <a href="https://www.bio.org/press-release/bio-statement-loss-measles-elimination-status">said Phyllis Arthur</a>, EVP and Chief of Global Health at the Biotechnology Innovation Organization (BIO).</p>
<p>“Measles is the canary in the coalmine,” Arthur added. “It is the most obvious sign of the broader risk of low vaccination rates.”</p>
<p>The loss of measles elimination status in the U.S. was no surprise, with outbreaks causing 5,412 reported cases so far this year—the most in since 1991—according to the<a href="https://www.cdc.gov/measles/data-research/index.html"> Centers for Disease Control and Prevention (CDC)</a>. The cases led to<a href="https://beaconbio.org/en/report/?reportid=2090bc17-2eeb-42ef-8021-1248721f25e1"> 10 reported</a> deaths, with six thus far<a href="https://www.cdc.gov/measles/data-research/index.html"> confirmed by the CDC</a>.</p>
<p>The measles outbreaks have been caused by a reduction in vaccination that is also causing concerning increases in other vaccine preventable diseases.</p>
<p>“We need to act as one country with a unified goal of protecting public health,” Arthur said. “Rather than debate how we got here, we must move forward together to reestablish the norm of routine vaccination for a host of pediatric infectious diseases that used to cause significant morbidity and mortality and are starting to cause them again.”</p>
<h2>Unknown danger</h2>
<p>We do not yet know the full extent of the threat, according to Arthur.</p>
<p>“The measles cases we’re hearing about are just the tip of the iceberg. There are many unreported illnesses,” she said. “Adults who were never vaccinated but were protected by herd immunity and kids who should have been vaccinated are being surrounded by this highly contagious disease, and it’s spreading.”</p>
<p><a href="https://evidence.nejm.org/doi/full/10.1056/EVIDpha2600416">A preliminary study</a> of measles outbreaks between January 2025 and September 2026 found 112 cases among pregnant women and 13 congenital cases of measles passed on to newborns. The outbreaks were mostly in communities with low vaccination rates, and 98% of the women involved were unvaccinated or had unknown vaccination status,<a href="https://evidence.nejm.org/doi/full/10.1056/EVIDpha2600416"> said the study, released Nov. 16</a>.</p>
<p>Meanwhile, other preventable diseases are raging. Pediatric influenza, which can be controlled with a seasonal vaccine, hit a near-record last year.</p>
<p>“The 2024–25 influenza season had the highest number of pediatric deaths reported (280) since child deaths became nationally notifiable in 2004, except for the 2009–10 influenza A(H1N1)pdm09 pandemic,”<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7436a2.htm"> according to CDC</a>, which recommends flu vaccination. Of the children who died of flu last year, 89% were not fully vaccinated, CDC said.</p>
<p>Pertussis, or whooping cough, which is especially dangerous for infants, saw<a href="https://jamanetwork.com/journals/jama/article-abstract/2822941"> an alarming increase in 2024</a> followed by<a href="https://www.cdc.gov/pertussis/php/surveillance/index.html"> another heavy year in 2025</a>, even though the vaccine is<a href="https://my.clevelandclinic.org/health/drugs/21639-pertussis-whooping-cough-vaccine"> highly effective</a>.</p>
<p>Another routine immunization for babies is the Haemophilus influenzae type b (Hib) vaccine.</p>
<p>“Before the vaccine, Hib was the leading cause of bacterial meningitis in children less than five years old,”<a href="https://pauloffit.substack.com/p/the-return-of-hib"> according to pediatric vaccine expert Paul Offit, MD</a>. “Hib also<a href="https://www.cdc.gov/hi-disease/about/index.html#:~:text=The%20most%20common%20serious%20infections%20caused%20by,infection)%20Infectious%20arthritis%20(swelling%20of%20a%20joint)"> caused</a> pneumonia, sepsis, cellulitis, and arthritis.”</p>
<p>The Hib vaccine became available in 1987, leading to a 99% decrease in infections, so there were typically about two deaths a year in the U.S., Offit said. Yet in 2025, a doctor<a href="https://www.usatoday.com/story/life/health-wellness/2026/04/04/new-hib-cases-concern-deadly-disease-vaccine/89466803007/"> reported two cases in Florida alone</a>, impacting unvaccinated children, one fatal and one causing permanent brain damage. This alarming increase indicates a return of Hib due to low vaccination, Offit said.</p>
<p>Vitamin K shots, routinely given to newborns since the 1960s, protect infants from vitamin K deficiency, which can cause bleeding that leads to permanent brain damage or death. Babies without the shot are<a href="https://okckidsurology.com/vitamin-k-for-newborns-why-it-matters-shot-vs-oral-drops/"> 81 times more likely</a> to experience bleeding due to vitamin K deficiency, with<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7041551/"> as many as 1,700 out of 100,000</a> unprotected babies impacted. But parents increasingly<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7041551/"> decline the vitamin K shot</a>.</p>
<p>“The number of babies that did not receive the shot rose from 2.92% in 2017 to 5.18% in 2024,”<a href="https://www.nih.gov/news-events/nih-research-matters/protective-vitamin-shots-newborns-decline"> according to research.</a> “That’s a 77% increase in infants not receiving the shot over the eight-year period.”</p>
<h2>The need to work on messaging</h2>
<p>The declining vaccination rates that<a href="https://bio.news/health/low-vaccination-rates-put-40-million-children-worldwide-at-risk-of-measles/"> began during COVID</a> dropped even further following this year’s<a href="https://bio.news/bios-view/bio-warns-of-risks-from-change-to-cdcs-vaccine-recommendations/"> changes in federal recommendations</a> for vaccination,<a href="https://www.kff.org/medicaid/kindergarten-routine-vaccination-rates-continue-to-decline/"> according to research</a>.</p>
<p>The solution, Arthur said, is unequivocally proclaiming the necessity of immunization.</p>
<p>“We need to have clear, consistent evidence-based messaging on the value of the measles-mumps-rubella vaccine from senior leaders within and outside of government. We need to have a better discussion of the danger of measles and the benefits of vaccination,” she said. “You hear talk of the risks of measles vaccination, but let’s talk about the much greater risks of measles.”</p>
<p>Along with appropriate messaging, federal authorities need to support state authorities in responding to outbreaks and providing education, Arthur said. She noted that communities with a 93% vaccination rate instead of the recommended 95% are concerning, but the real problem is communities where vaccination rates are in the low 80s.</p>
<p>“State leaders are aware of these communities, and they are better placed to make partnerships with leaders in those communities and reach people with the message that vaccination protects them and their children,” Arthur said.</p>
<p>Beyond the measles vaccine, this same community effort is necessary to encourage the use of all vaccines, according to Arthur.</p>
<p>“We know these diseases cause morbidity, and mortality,” she said. “And all of them are preventable with a very simple intervention, which is the vaccine.”</p>
<p><a href="https://www.bio.org/press-release/bio-statement-loss-measles-elimination-status"><strong>Read BIO’s campaign: Invest in America. Vaccinate.</strong></a></p>
<p> </p>
<p>The post <a href="https://bio.news/health/loss-of-measles-elimination-status-signals-growing-vaccination-crisis/">Loss of measles elimination status signals growing vaccination crisis</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A human liver has been kept alive outside the body for a record seven weeks</title>
<link>https://edusehat.com/en/a-human-liver-has-been-kept-alive-outside-the-body-for-a-record-seven-weeks</link>
<guid>https://edusehat.com/en/a-human-liver-has-been-kept-alive-outside-the-body-for-a-record-seven-weeks</guid>
<description><![CDATA[ Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering. The feat, whose details are pending publication, was carried out in Sydney after a team led by surgeon and inventor Carlo Pulitano connected a donated liver to a… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/EOPS-V1.1-.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 21:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>human, liver, has, been, kept, alive, outside, the, body, for, record, seven, weeks</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Record-breaking liver survival:</strong> A Sydney surgical team kept a human liver alive outside the body for seven weeks using an automated system of pumps and sensors that mimics the functions of a living body.</li><br><li><strong>Automation was the secret:</strong> When the team compared manual versus automated life-support systems across 55 donated livers, automated perfusion tripled average survival time to four weeks, with one organ reaching seven.</li><br><li><strong>Organs that heal:</strong> Organ perfusion has become more common over the past decade. Researchers have found some evidence that extended perfusion may allow damaged organs to repair themselves before transplant.</li><br><li><strong>A new frontier in medicine:</strong> Long-term organ life-support is attracting serious scientific interest. Two new scientific societies were recently founded to explore the concept. </li><br></ul>" data-chronoton-post-id="1148934" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Researchers in Australia claim they’ve kept a human liver alive, on life support, outside the body for seven weeks, opening up speculative new possibilities in biomedical engineering.</p>



<p class="wp-block-paragraph">The feat, whose details are pending publication, was carried out in Sydney after a team led by surgeon and inventor Carlo Pulitano connected a donated liver to a system of automated pumps and sensors that fed the organ nutrients, supplied it with blood, and whisked away waste. </p>



<p class="wp-block-paragraph">In an interview, Pulitano, a transplant surgeon at the Royal Prince Alfred Hospital and a professor at the University of Sydney, likened the life support system to “an artificial body.” Its official name is the Extended Organ Perfusion System.</p>



<p class="wp-block-paragraph">“Our group is the only one in the world to have maintained a human liver under fully normothermic, physiological conditions for seven weeks,” he says.   </p>





<p class="wp-block-paragraph">Normothermic means body temperature, or about 37 °C. The previous record for keeping an internal organ alive outside the body was set in Switzerland several years ago. That organ—also a liver—lasted around two weeks. </p>



<p class="wp-block-paragraph">Most organs destined for transplant survive only a few hours in special ice buckets and need to be raced to their destination. Over the last decade, however, surgeons have been switching to perfusion systems, which pump warm or cold fluids into an organ. This can double the time it can be held before it must be transplanted. </p>



<p class="wp-block-paragraph">Pulitano says the key to breaking the record was to automate the systems used to keep the organ thriving. During <a href="https://easl.eu/event/ilts_congress_2026/">a meeting in Switzerland</a> earlier this year, the Sydney team described perfusing 55 human livers, one after the other. Some were connected to a system that needed to be adjusted manually, but for those placed on the automated system—which produced the seven-week survivor—the average survival time tripled, to about four weeks.  </p>



<p class="wp-block-paragraph">Perfusion has already enabled doctors to <a href="https://www.technologyreview.com/2015/09/01/166380/transplant-surgeons-revive-hearts-after-death/">restart hearts</a> from dead people and keep them beating outside the body. Paulo Martins, a transplant doctor at the University of Oklahoma, says about half the kidneys he transplants are now perfused, even though the process can add $100,000 to the cost of a transplant.  </p>



<p class="wp-block-paragraph">While the research awaits formal publication, the eventual goal is what Pulitano and colleagues call “time-unlimited liver preservation.”</p>



<p class="wp-block-paragraph">Scientists have already discovered possible medical benefits to keeping organs on life support longer than usual. One, they say, is that perfused organs apparently <a href="https://www.technologyreview.com/2026/09/14/1144010/donated-livers-can-be-made-biologically-younger/">start to repair</a> themselves and become stronger after a day or so. That’s what led a Swiss team, in 2022, to transplant a damaged liver <a href="https://www.nature.com/articles/s41587-022-01354-7">that had been kept on perfusion for three days</a>—the longest time any internal organ had remained outside the body before a successful transplant, says Waldemar Hoffmann, the CEO and cofounder of Apersys, a startup formed to commercialize the technology.</p>



<p class="wp-block-paragraph">Pulitano says his own startup, Aeternum Life Technologies, will be helping with a planned trial in Sydney to transplant low-quality livers kept on perfusion for four days.</p>



<p class="wp-block-paragraph">What’s less clear, says Hoffmann, is whether any transplant surgeon would ever want, or need, to use an organ kept alive for nearly two months. He says people in the field believe Pulitano’s record is real, but they don’t know how healthy the organ was at the end or even what so much extra time is likely to achieve. “The key question is what the purpose for a seven-week perfusion would be,” he says.  </p>



<p class="wp-block-paragraph">Yet that’s where things could start to get interesting, <a href="http://pubmed.ncbi.nlm.nih.gov/40259786/">says Martins</a>, the Oklahoma surgeon. Long-term life support could enable far-out concepts like artificial wombs, new types of organ manufacturing, and the chance to experiment directly on human organs outside the body for extended periods.</p>



<p class="wp-block-paragraph">For his part, Pulitano says long-term machine perfusion could help grow new organs. In living donations, surgeons commonly take half of a person’s liver to give someone else. After about two months, both parts will have grown back almost to their full volume. Pulitano says he’s tried dividing a liver and then attaching the sections to the machine. If that works, he says, it could be a way to multiply one donor liver into several full-size organs.</p>



<p class="wp-block-paragraph">“It’s important to have people thinking outside the box and pushing the limits and creating possibilities for things that, right now, sometimes we don’t even have a need for but are going to be needed in the future,” says Martins. “That’s how science moves.”  </p>





<p class="wp-block-paragraph">He’s not the only one who thinks so. For instance, a US company, Bexorg, has been reanimating human brains using perfusion pumps. The idea is to study what effects experimental drugs have on them. That company perfuses brains for about a day but has said it wants to extend the time to two weeks.</p>



<p class="wp-block-paragraph">Similar experiments can be done on livers, says Pulitano, who has already tried adding gene therapies to the organs. “It gives us a living human organ model for translational research that no animal system can match, because the biology, the immunology, and the drug responses are human from the outset,” he says.</p>



<p class="wp-block-paragraph">Meanwhile, in Silicon Valley, patents <a href="https://patents.google.com/patent/WO2024155957A1/en">filed</a> by <a href="https://www.technologyreview.com/2021/09/04/1034364/altos-labs-silicon-valleys-jeff-bezos-milner-bet-living-forever/">Altos Labs</a>, a billionaire-backed longevity startup, describe attempts to introduce reprogramming genes into animal livers maintained outside the body. Eventually, Altos scientists <a href="https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(25)00445-X"></a>have speculated, they might temporarily disconnect a failing organ while it’s still in a person’s body, connecting it to a perfusion machine in order to douse it with ultra-powerful genetic treatments without risking the rest of the body.</p>



<p class="wp-block-paragraph">Doctors probing the limits of organ life support have now formed two new scientific societies to explore the concept. One, founded by Martins and called the International Society for Organ Preservation and Perfusion Therapy, will hold its inaugural meeting this year in Italy. The other, based in China, was <a href="https://info.newsgd.com/node_91423f6a55/e6458c1195.shtml">launched in August</a> to advance what doctors at the First Affiliated Hospital of Sun Yat-Sen University have termed “<a href="https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000003524~organ-medicine-new-concept-of-life-sciences">organ medicine”</a>: research at the level of whole organs kept alive by “bionic maintenance.”  </p>



<p class="wp-block-paragraph">“What is exploding is the idea of this technology that clearly goes beyond simply organ preservation,” says Pulitano. “Basically, that’s a concept that’s entirely new.”</p>]]> </content:encoded>
</item>

<item>
<title>Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus</title>
<link>https://edusehat.com/en/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus</link>
<guid>https://edusehat.com/en/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus</guid>
<description><![CDATA[ Researchers combined measurements from brain images and single cell transcriptome maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.
The post Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/06/Jun25_2020_GettyImages-91560048_brain-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 10:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alzheimer’s, Disease, and, Aging, Linked, Changes, the, Hypothalamus</media:keywords>
<content:encoded><![CDATA[<p>Before their memory is affected, many individuals with Alzheimer’s disease (AD) may experience trouble sleeping, lose their daily rhythms, and show changes in metabolism and stress hormones. These functions are regulated by the hypothalamus, a structure at the base of the brain. A study headed by researchers at the Buck Institute for Research on Aging has now found that the hypothalamus is not a bystander in Alzheimer’s disease, and its circadian and metabolic control centers show specific age-related changes in volume and gene activity early in the disease.</p>
<p>For their study, the team combined measurements from brain images and single-nucleus RNA sequencing maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Ashley Webb, PhD, associate professor at the Buck Institute for Research on Aging, is senior and co-corresponding author of the team’s published report in <em>Nature</em>, titled “<a href="https://doi.org/10.1038/s41586-026-11305-w" target="_blank" rel="noopener">Hypothalamic volume and cell-type changes in aging and Alzheimer’s disease</a>,” in which they concluded, “Our findings provide a multimodal view of how the hypothalamus is altered in aging and early AD, illustrating region-specific and cell-type-specific changes that have not been observed previously.”</p>
<p>AD is an age-associated neurodegenerative disorder with a prevalence of roughly 10–30% among individuals older than 65 years, the authors wrote. And while the main feature is cognitive decline, they stated, “… AD manifests as a systemic condition involving profound disruptions in sleep, circadian rhythms, metabolic homeostasis, stress responses, and neuroendocrine functions.” These key processes are regulated by the hypothalamus, a small, complex part of the brain that orchestrates a wide range of physiological and neuroendocrine processes that are commonly dysregulated in aging and AD.</p>
<p>“Emerging evidence suggests that hypothalamic dysfunction not only correlates with but also actively exacerbates AD pathology and cognitive decline,” the team noted. However, they pointed out, “Despite its central role in homeostasis and brain aging, the hypothalamus remains an understudied region in the context of human aging and AD.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Webb noted, “Most of what we know about Alzheimer’s comes from the hippocampus and cortex, because that’s where memory is organized and lives. But patients and families often report disrupted sleep, a change in appetite, or different responses to stress alongside memory changes.”</p>
<p>The hypothalamus is made up of many specialized sub-areas called nuclei. Each nucleus runs a different job. The suprachiasmatic nucleus (SCN) is the body’s master clock, while the arcuate nucleus (ARC) handles appetite and energy balance. Very little is known about how the individual nuclei and their cell types change in human aging and Alzheimer’s.</p>
<p>“No single method can answer this question,” said co-senior author Manu Goyal, MD, director of neuroimaging labs at Washington University School of Medicine in St. Louis. “MRI can tell you what’s happening in living people but is limited in its resolution. Single-cell sequencing tells you what’s happening inside each cell type but requires actual tissue. The goal here was to put them side by side to let us see things that neither could show alone.”</p>
<p>Noting that recent studies even suggest that changes such as circadian disruptions may precede the development of other common clinical symptoms, Webb added, “We wanted to look directly at the part of the brain that controls those functions, and to do it with enough resolution to see which cells are changing with age and in the disease.”</p>
<p>To better enable this insight, the team created HypoAD as an atlas of the human hypothalamus in aging and AD, by combining high-resolution magnetic resonance imaging from hundreds of individuals and single-nucleus RNA sequencing of more than 600,000 nuclei from young participants, patients with AD, and age-matched non-dementia control participants.</p>
<div class="wp-caption alignright"><img decoding="async" aria-describedby="caption-attachment-340774" class="size-medium wp-image-340774" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes-300x160.jpg" alt="Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s Disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann] " width="300" height="160" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes-300x160.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><p class="wp-caption-text">Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann]</p></div>
<p>Using MRI scans from 458 living adults and a high-resolution atlas, the researchers measured the volume of 13 separate hypothalamic sub-regions. Participants were grouped by cognitive status and by levels of amyloid-β, the protein that forms plaques in Alzheimer’s disease. The team then sequenced about 614,000 individual cells from post-mortem hypothalamic tissue. This method shows which genes are switched on in each cell, so changes can be traced to specific cell types and cellular functions. Donors included seven people with mostly early-stage Alzheimer’s disease, seven age-matched healthy controls, and three younger people from published data.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The researchers validated their findings against spinal fluid protein measurements, a prefrontal cortex dataset from about 800 donors, spatial gene-expression maps, and a mouse model of Alzheimer’s.</p>
<p>The scientists found that though overall hypothalamic volume barely changed with age, different areas of the hypothalamus did either change or increase in volume. The lateral hypothalamus shrank with age, while the SCN, arcuate, paraventricular, periventricular, and dorsomedial hypothalamic nuclei (DMH) grew. Webb said this phenomenon held after accounting for Alzheimer’s disease status, suggesting it is a feature of typical aging. “Together, these findings suggest that hypothalamic nuclei undergo differential volumetric changes with aging, even in the absence of AD,” the investigators noted.</p>
<p>Volume differences tied specifically to AD also occurred but weren’t statistically significant, suggesting that a more sensitive method might be needed to determine what happens with the Alzheimer’s hypothalamus. “… in comparison to aging and sex, differences in the volumes of hypothalamic nuclei in the context of amyloid-β deposition and cognitive impairment were more modest or absent,” they noted.</p>
<p>“If you only measure the hypothalamus as a whole, it looks like nothing is happening,” Webb said. “When you zoom in, you see some regions shrinking and others growing. That tells us aging is reshaping this region in a very specific, structured way.”</p>
<p>The researchers applied machine-learning models to distinguish Alzheimer’s disease cells from control cells using gene expression alone. Their findings indicated that the most important genes centered on two themes, inflammation and circadian rhythm. “At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD,” they stated.</p>
<p>Microglia, the brain’s resident immune cells, showed the largest number of altered genes. When the researchers ordered cells along a young-to-old-to-Alzheimer’s path, microglia gradually shifted from a resting state toward the “disease-associated” state seen in other Alzheimer’s disease studies. “This finding suggests that the hypothalamus transitions to an inflammatory state early in Alzheimer’s disease, just like the brain regions involved in memory,” said Webb. The authors further noted in their report, “Consistent with other brain regions, microglia, which are widely recognized mediators of brain aging and neurodegeneration, emerged as particularly prone to transcriptional reprogramming in the hypothalamus in early AD, although our unpaired, cross-sectional data cannot establish a causal or directional relationship.”</p>
<p>The hypothalamus is a diverse area of the brain, harboring many distinct cell types critical for its varied physiological roles. The scientists identified 254 neuron subtypes and found that inhibitory (GABAergic) neurons changed the most, mainly in neuropeptide and receptor signaling. One prominent group of neurons in the SCN showed disrupted signaling by vasopressin, a key output of the body’s clock.</p>
<p>“Sleep and circadian problems are some of the earliest signs of Alzheimer’s, and circadian behavioral changes known as sundowning, occur later in the disease,” Webb said. “But we’ve never had a good molecular explanation for why. Seeing vasopressin signaling disrupted in the brain’s master clock, in people at early stages of the disease, gives us a concrete place to start.”</p>
<p>Total cell numbers did not appear to change. Instead, the data point to cells getting larger through increased activity of mTOR, a growth pathway, along with remodeling of material between cells and inflammatory activation of glia. The authors present this as a hypothesis for future work.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>They also noted several limits to their study, including the small autopsy cohort of 14 donors, which is typical for this kind of study. The MRI and sequencing data come from different people, so the two are compared side by side rather than combined statistically. And because the design is cross-sectional, the results show associations, not cause and effect.</p>
<p>“This is a starting point, not the final word,” Webb said. “Our next step is to follow these changes over time and test whether protecting the brain’s clock, and neuropeptide signaling in particular, can slow the disease or help manage symptoms. If circadian disruption is one of the first things to go wrong, it may also be one of the first places we can intervene.”</p>
<p>In their paper, the team commented, “HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression … We highlight notable vulnerabilities in GABAergic and/or inhibitory neurons, SCN and DMH circadian regulators, and inflammatory microglial cascades, underscoring their potential roles in instigating early hypothalamic dysfunction.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/alzheimers-disease-and-aging-linked-to-changes-in-the-hypothalamus/">Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>London Calling: Flagship Expands in U.K. to Build AI&#45;Native Platform Companies</title>
<link>https://edusehat.com/en/london-calling-flagship-expands-in-uk-to-build-ai-native-platform-companies</link>
<guid>https://edusehat.com/en/london-calling-flagship-expands-in-uk-to-build-ai-native-platform-companies</guid>
<description><![CDATA[ Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&amp;D across the kingdom.
The post London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/109A8287_2026-10-13-193415_wksy-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>London, Calling:, Flagship, Expands, U.K., Build, AI-Native, Platform, Companies</media:keywords>
<content:encoded><![CDATA[<p>Flagship Pioneering, which for more than 25 years has created and nurtured startups—most notably mRNA vaccine giant Moderna—from Cambridge, MA, has launched its first dedicated company creation unit outside of the U.S. with an initial commitment of £100 million ($131.66 million) that the venture capital giant expects to quintuple in coming years.</p>
<p>The new London-based Flagship Origination Lab U.K. has been established to conceive, test, fund, and build artificial intelligence (AI)-native platform companies that advance human and planetary health and other frontiers of science and technology.</p>
<p>Flagship said the U.K. Lab will operate as part of Flagship Labs, the company’s innovation foundry, with the goal of creating a locally rooted company-creation ecosystem in the United Kingdom that connects to Flagship’s broader global ecosystem, including business units and:</p>
<ul>
<li><strong>Pioneering Intelligence</strong>, Flagship’s AI and machine learning innovation effort designed to originate new companies by harnessing advances in computation integrated with a variety of scientific domains. Pioneering Intelligence was launched in 2023.</li>
<li><strong>Pioneering Medicines</strong>, Flagship’s in-house drug development unit founded in 2020. Pioneering Medicines explores and identifies new product concepts, then works jointly with Flagship’s companies to form integrated teams that advance new treatments through discovery and early clinical development. Medicines also partners with external collaborators.</li>
</ul>
<p>“I think this announcement by Flagship is a testament to the quality of British life sciences research and the investment will be welcomed in the U.K.,” Tim Harris, PhD, DSc, a molecular biologist, biochemist, and geneticist who is an operating partner with SV Health Investors specializing in work with therapeutics startups, told <em>GEN</em>.</p>
<figure aria-describedby="caption-attachment-340769" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340769" src="https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris-219x300.jpg" alt="" width="219" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris-219x300.jpg 219w, https://www.genengnews.com/wp-content/uploads/2026/11/tim-harris.jpg 540w" sizes="(max-width: 219px) 100vw, 219px"><figcaption class="wp-caption-text">Tim Harris, PhD, DSc, a molecular biologist, biochemist and geneticist who is an operating partner with SV Health Investors specializing in work with therapeutics startups</figcaption></figure>
<p>“Labs and people turn ideas into companies so I look forward to seeing some new ones come out of this initiative from the Flagship Pioneering team,” Harris added.</p>
<p>Founded in 1999, Flagship Pioneering has founded and nurtured more than 120 companies—between six and eight each year—employing more than 9,000 people. Thirteen Flagship Pioneering-launched companies have gone public through initial public offerings (IPOs) since 2013.</p>
<p>In London, Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&D across the kingdom.</p>
<p>Flagship is not the first U.S. VC firm to establish an outpost in the U.K. for nurturing startups from the kingdom: Harris noted that SV venture capitalists led by Kate Bingham, managing partner and co-leader of SV’s biotech franchise, have been creating and investing in U.K. and U.S. startups for many years.</p>
<p>Flagship’s new Origination Lab adds to the capital available, creating further opportunities for early-stage companies, Harris added.</p>
<h4><strong>‘Natural home’</strong></h4>
<p>“The U.K. is a natural home for AI and life sciences companies, and we want to see more new businesses across these sectors turning cutting-edge research and technology into new jobs and economic growth,” Chris McDonald, a chemical engineer and member of the U.K. Parliament (Labour Party) who is the kingdom’s Minister for Science, Innovation and Investment, said in a statement. “This new commitment from Flagship Pioneering will kickstart companies of the future in the U.K., who will take breakthroughs in AI and life sciences to the rest of the world and deliver innovations that can save lives.”</p>
<p>Flagship’s announcement comes weeks after AbbVie announced plans to expand its R&D facility in Oxford, U.K., as part of a £120 million ($158 million) investment into life sciences activity within the kingdom. AbbVie plans to expand its existing Oxford campus by constructing a new 12,000-square-foot site focused on research in immunology, neuroscience, and oncology.</p>
<p>However, since last year two other biopharma giants, AstraZeneca and Merck & Co., have dropped plans for large facilities within the U.K. AstraZeneca cited government funding reductions in halting plans for a £450 million vaccine manufacturing center in Merseyside.</p>
<p>Merck aborted plans for an R&D site set to employ 800 (including 180 researchers) at Belgrove House near King’s Cross in London, citing what it called high rebate clawback rates for voluntary and statutory medicines by the NHS, and insufficient government investment in life sciences, reflected in a decline from second to eighth since 2017 in SCI’s global foreign direct investment ranking in life sciences.</p>
<p>Flagship began expanding beyond the U.S. in 2023 when it opened offices in London and in Singapore. Since opening the London hub by signing a Memorandum of Understanding with the U.K. Government, Flagship has announced an agreement with Cambridge University Health Partners and the Milner Therapeutics Institute to collaborate to jointly advance breakthrough scientific research and technologies.</p>
<p>Also from the London hub, Flagship has launched its first transatlantic company, Quotient Therapeutics; accelerated first-in-category clinical trials across the U.K. by Flagship-founded companies such as Generate:Biomedicines; and developed numerous strategic partnerships across academia, data, and regulatory innovation.</p>
<p>Generate was founded in 2018 as a Flagship Pioneering company, and emerged from stealth operations during the COVID-19 pandemic two years later, when it announced that it had built a portfolio of therapeutic candidates for neutralizing SARS-CoV‑2, including antibodies and peptides targeting multiple epitopes on the spike protein peptide, in less than 17 days.</p>
<p>The biologics developer was an early comer applying AI-based approaches to rationally design sequence, structure, and function for protein therapeutics. In February, Generate <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-ai-drug-developer-generates-400m-ipo/" target="_blank" rel="noopener">went public on the Nasdaq Global Market</a> through a $400 million IPO that generated $369.3 million in net proceeds.</p>
<h4><strong>‘New chapter’</strong></h4>
<p>“Today marks the beginning of a new chapter in Flagship’s relationship with the U.K.,” declared Noubar Afeyan, PhD, Flagship Pioneering’s founder and CEO. “Over the past three years, we have seen firsthand the extraordinary depth of scientific imagination, talent, and ambition across the country. With our £100 million initial commitment, which we anticipate scaling through partnership to attract an additional £500 million [$658.6 million], we are now making a long-term commitment to build on that foundation.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Afeyan announced the new U.K. Lab on Monday at a conference of the U.K.’s Drug Information Association (DIA) and Medicines and Healthcare products Regulatory Agency (MHRA). The DIA-MHRA Global Summit is set to conclude Tuesday during London Life Sciences Week.</p>
<p>“Since first opening our London office three years ago, we’ve been impressed by the talent, imagination, and ambition that make the U.K. a leader in our field—and we are excited about the groundbreaking ventures that will come from combining our unique Flagship model with the U.K.’s distinct strengths,” Afeyan said in a <a href="https://www.linkedin.com/posts/noubarafeyan_for-26-years-every-flagship-pioneering-company-share-7528074845851385856-TGOI/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAAijXMBke7yaGhNnsp7P32n1gHV4SXeNno" target="_blank" rel="noopener">LinkedIn post</a>.</p>
<p>Added Avak Kahvejian, PhD, general partner, Flagship Pioneering and president of its internal innovation foundry and company-creation unit Flagship Labs: “We have developed company origination into a discipline, one led by teams of scientist-entrepreneurs who begin with bold questions about what could be possible.”</p>
<p>“As we extend that capability globally, the U.K. was a clear and deliberate choice for our first expansion. Its exceptional science base, clinical-trial infrastructure, genomics and health-data assets, agile regulatory environment, and brilliant scientists and entrepreneurs create a powerful foundation for innovation,” Kahvejian stated.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/london-calling-flagship-expands-in-u-k-to-build-ai-native-platform-companies/">London Calling: Flagship Expands in U.K. to Build AI-Native Platform Companies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice</title>
<link>https://edusehat.com/en/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice</link>
<guid>https://edusehat.com/en/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice</guid>
<description><![CDATA[ Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse models.
The post Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/May_ADC_GettyImages_JL_2147604791_AntibodyDrugConjugate-e1775154897927.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Targeting, Folate, Receptor, Reverses, Colorectal, Cancer’s, Resistance, Immunotherapy, Mice</media:keywords>
<content:encoded><![CDATA[<p>Colorectal cancer (CRC) is the third most common cancer worldwide. Although immune checkpoint blockade is promising, responses to the treatment have been limited: treatments such as anti-PD-1 have resulted in only 15% of patients experiencing substantial benefits.</p>
<p>Now, a new study shows that a receptor for folate sustains colorectal cancer’s ability to evade a form of cancer immunotherapy—and finds that targeting this receptor with an approved compound can restore the treatment’s cancer-killing power in mice. The data add to the understanding of what factors can shape colorectal cancer’s response to immunotherapy and suggest that integrating folate receptor-based treatments into existing regimens could improve outcomes in patients with treatment-resistant tumors.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.aed2106" target="_blank" rel="noopener">Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer</a>.”</p>
<p>Colorectal cancer tumors possess many properties that stall immunotherapy’s ability to enhance anti-tumor immunity, including defects in the expression of MHC-1. Indeed, loss of MHC-I antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade in colorectal cancer.</p>
<p>Previous research has connected folate receptor α (FOLR1) to more aggressive disease progression and poorer prognoses in various types of solid tumors. In this study, researchers conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. In the study, they found that “high expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes.”</p>
<p>In addition, the team’s proteomic analyses revealed that “FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701.”</p>
<p>The group also tested the potential of mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. <em>In vitro </em>experiments revealed that FOLR1 indirectly impaired the activity of the STAT1 signaling pathway and dampened MHC-1 activity, which supported the cancer cells’ adaptability and prevented CD8+ T cells from engaging tumor cells.</p>
<p>However, mirvetuximab soravtansine restored anti-tumor immunity and resensitized colorectal cancer tumors to anti-PD-1 blockade in mice.</p>
<p>“Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer],” the authors<em> </em>write.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice/">Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk</title>
<link>https://edusehat.com/en/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk</link>
<guid>https://edusehat.com/en/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk</guid>
<description><![CDATA[ Researchers studying human induced pluripotent stem cell-derived microglia-like cells showed how genetic variants can impact cell behavior and used CRISPR gene editing to show how one gene’s effect depends on its cellular context.
The post CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-2204954826-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 06:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CRISPR, Screening, Reveals, How, Genetic, Variants, Drive, Neurodegenerative, Risk</media:keywords>
<content:encoded><![CDATA[<p>Research has started to bridge the gap between identifying genetic changes that can increase the risk of brain conditions, such as Alzheimer’s disease (AD), and understanding how they might impact specific cell functions. Researchers at the Wellcome Sanger Institute, Open Targets, and collaborators, differentiated human induced pluripotent stem cells (iPSCs) derived from different donors into microglia-like (iMGL) cells, and showed how genetic variants impact cell behavior, and more specifically, how they can lead to differences in the ability of brain immune cells to move and clear away biological debris.</p>
<p>Through their research the team also used CRISPR gene editing to show how one gene’s effect depends on its cellular context. They found that the impact of a genetic mutation can be completely opposite depending on the precise cell type and its environment, which is highly important for designing future targeted therapies. The study provides an indication of how to connect genetic risk variants with their downstream effects, as a next step in understanding how genes impact health conditions.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Andrew Bassett, PhD, at the Wellcome Sanger Institute and Open Targets, said, “While genetic studies have identified around a hundred genomic regions linked to Alzheimer’s, pinpointing the exact genes involved and how they alter cell behavior has been more of a challenge. By growing brain immune cells from stem cells across hundreds of donors, we’ve built a framework that directly connects genetic risk to real cell functions, such as how effectively these cells clear debris in the brain. We also discovered that the impact of a genetic variant can change depending on its cellular environment, in some cases having the opposite effect. This suggests that we can’t just look at the impact of these genetic changes in isolation or in one cell. Instead, knowing the exact cell context is essential to understanding how these genetic changes impact health.”</p>
<p>Bassett is co-senior author of the researchers’ published paper in <em>Nature Genetics</em>, titled “<a href="https://doi.org/10.1038/s41588-026-02843-0" target="_blank" rel="noopener">Integrated QTL mapping and CRISPR screening in pooled iPSC-derived microglia reveals genetic drivers of neurodegenerative risk</a>.” In their report the authors concluded, “By contextualizing variant effects within iMGLs in different inflammatory states, we provide a comprehensive framework for interpreting the function of risk loci in neurodegenerative disorders.”</p>
<p>Genome wide association studies (GWAS) scan genomes and highlight which differences, known as genetic variants, are more often found in patients with specific health conditions. However, while they can signpost regions of the genome they do not explain how those regions alter gene and cell function. “Genome-wide association studies (GWAS) have identified thousands of variants linked to complex traits and diseases, but translating these into biological insight remains challenging,” the authors wrote. “Most variants are non-coding and probably influence disease by regulating gene expression in specific cell types, states or environments.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To bridge the gap, the researchers developed a framework to map GWAS data to changes in gene expression and cell behavior. For this, they used 261 human stem cell lines to derive brain cells known as microglia, which are a type of specialized immune cell that move around the brain and remove cellular debris or misfolded proteins. This process,  phagocytosis, is an important part of maintaining healthy neuronal function. As the team pointed out, “Mounting evidence implicates microglia in neurodegeneration, but linking disease-associated genetic variants to target genes and cellular phenotypes is hindered by the inaccessibility of these cells,” they pointed out.</p>
<p>First, the team identified which genetic variants change the levels of different genes in microglia cells. Next, they asked if genetic regions that have been previously linked to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) also modulate gene levels. This analysis identified 79 regions. “Expression quantitative trait locus (eQTL) analysis identified 7,121 eQTL-associated genes and 79 colocalizations across four neurodegenerative disease genome-wide association studies, half of which had limited prior evidence of causality,” they stated.</p>
<p>These links alone do not inform of the impact on cell function, so to further understand how these changes in gene expression alter cell behavior, the researchers conducted laboratory tests on the microglia, measuring the cells’ ability to move and undertake phagocytosis. Through these tests and computational modeling, they were able to map 34 genes to changes in cell behavior. This highlighted disease-relevant variants at <em>TREM2</em> that were linked to changes in phagocytosis.</p>
<p>To understand further how these genes impact behavior of microglia, the team conducted CRISPR screens, knocking out 251 disease-relevant genes. This also allowed them to show that the impact of the gene depends on the cellular context. For example, knocking out <em>TREM2</em> increases phagocytosis in microglia but decreases it in macrophages, a different type of immune cell. “These results demonstrate that modulation of TREM2 leads to different phenotypic outcomes depending on the cell type, and emphasize the importance of cellular context when interpreting its function in neurodegeneration,” the authors stated.</p>
<p>This research gives a scalable blueprint for studying brain immune cells, which are impossible to safely take samples of in living patients. It could also help find new pathways and drug targets from disease genetic data, giving insight into the cellular mechanisms that are linked to diseases. In their paper the investigators stated, “In summary, this multifaceted approach enabled us to connect genetic variants to effector genes and gene programs, down stream cellular phenotypes and potential disease mechanisms.”</p>
<p>Co-senior author Gosia Trynka, PhD, at the Wellcome Sanger Institute and Science Director at Open Targets, said, “Brain conditions such as Alzheimer’s are incredibly complicated, and understanding how different parts of our genome are linked to these conditions could help us find new ways to identify or treat them. Identifying the associated part of the genome is the first step but it leaves a large translational gap, and our new research has found a way to bridge the gap between association and understanding the impact on the cell function. Connecting this allows us to start to build a full biological picture of disease and will help design future research to accelerate drug discovery.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Co-first author Marta Perez-Alcantara, PhD, previously at the Wellcome Sanger Institute and Open Targets, further commented, “This ambitious study showcases the potential of iPSC-derived cells for genetic analysis, linking genetic variation to expression, cellular survival and function, and disease susceptibility. This approach is particularly valuable for difficult-to-access tissues such as the brain, allowing us to investigate genetic effects across multiple donors and stimulation conditions in microglia, which are challenging to obtain in sufficient numbers and under the right stimuli from primary human tissues. This framework has the potential to be extended to other diseases, tissues or cellular phenotypes, enabling research that would otherwise be extremely difficult to undertake.”</p>
<p>The authors added that in a broader context “… our study demonstrates the feasibility and value of integrating genetic association data, single-cell transcriptomics, and pooled functional genomics to investigate genotype–phenotype relationships at scale. This framework is also applicable to other cell types and diseases.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/crispr-screening-reveals-how-genetic-variants-drive-neurodegenerative-risk/">CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Growing Apart: Culture&#45;Based Sterility Test Alternatives</title>
<link>https://edusehat.com/en/growing-apart-culture-based-sterility-test-alternatives</link>
<guid>https://edusehat.com/en/growing-apart-culture-based-sterility-test-alternatives</guid>
<description><![CDATA[ Growth-based sterility testing works for traditional biopharma but is too slow for the cell therapy sector. A new parallel testing pathway and rapid, molecular assay-based testing are a better option.
The post Growing Apart: Culture-Based Sterility Test Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/06/GettyImages-521677434.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Growing, Apart:, Culture-Based, Sterility, Test, Alternatives</media:keywords>
<content:encoded><![CDATA[<p>In the biopharma industry, culture-based microbial sterility testing methods are not fast enough for personalized cell therapy production, say the developers of a new parallel analysis pathway.</p>
<p>Bacterial contamination is always a risk in biopharmaceutical production. The complex, multi-step nature of processes, the nutrient-rich, aqueous environments in which cells are cultured—and even the raw materials themselves—provide potential entry points for microorganisms.</p>
<p>As a result, regulators require that biopharmaceuticals undergo extensive analysis using standardized procedures. Typically, product samples are cultured to allow any bacterial or fungal contaminants to grow, enabling full identification.</p>
<p>For high-volume products made in multiple, sequential batches—protein therapeutics, monoclonal antibodies—these long testing processes can be incorporated into the manufacturing lifecycle without interrupting market supply.</p>
<p>For firms making single-batch, patient-specific therapies, any steps that delay release, including long sterility testing processes, are hard to accommodate, according to Athena Stathoulis, a researcher at the University of Melbourne in Australia.</p>
<p>“The gold-standard sterility test for cell therapies, USP <71>, takes 14 days to give a result. Fresh CAR T products often have to be infused within 24–72 hours, so the product reaches the patient long before its sterility is confirmed,” she tells <em>GEN</em>.</p>
<p>In practice, the need to deliver CAR T cell therapies to patients as soon as possible means they are often released early, under exceptional protocols based on interim culture results at around 48 hours, Stathoulis explains.</p>
<p>“This approach shortens the detection window and risks missing slow-growing organisms, with full sterility confirmation only arriving after the patient has been infused. This matters because vein-to-vein time is linked to outcomes,” she adds.</p>
<p>Stathoulis, who examined cell therapy sector practices in a recent <a href="https://www.sciencedirect.com/science/article/pii/S1045105626000461" target="_blank" rel="noopener">study</a>, also points out that, unlike steps like leukapheresis, transduction, and expansion that can be optimized, the timelines for sterility testing are fixed by regulatory mandate.</p>
<p>“Sterility testing is the one manufacturing bottleneck that process optimization can’t fix, because the incubation period is set by regulation, not biology. That makes it the rate-limiting step for point-of-care and decentralized CAR T manufacturing.”</p>
<h4><strong>Solutions</strong></h4>
<p>Cell therapy firms do have potential alternative testing options, Stathoulis says, with the most promising being assays that do not rely on bacterial growth.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“The main alternatives are ATP bioluminescence, solid-phase cytometry, and molecular assays targeting conserved bacterial and fungal ribosomal RNA genes (16S/18S rRNA).</p>
<p>“In our view, the molecular assays are the most compelling. They are not growth-dependent, removing the need for incubation altogether and providing results within hours,” Stathoulis explains.</p>
<p>Another potential alternative, which Stathoulis and colleagues propose in the study, would be to run a combination of sterility testing methods in parallel.</p>
<p>“Our review proposes a three-phase pathway that moves toward this: comprising analytical qualification; then parallel testing alongside compendial methods; and then conditional release,” she says.</p>
<p>Measures set out in the proposed pathway include testing against a facility-specific panel of at least 20 organisms, including skin flora such as <em>Cutibacterium acnes</em>, Gram-negative bacteria, fungi, and slow-growing organisms.</p>
<p>The pathway also calls for the use of viability dyes and enrichment steps to reduce the risk of false positives and false negatives, as well as compendial testing after infusion as a safety net, with a predefined plan for when the rapid and compendial results disagree.</p>
<h4><strong>Adoption</strong></h4>
<p>The degree to which cell therapy firms can use alternative methods depends on regulators, according to Stathoulis, who says, “The barriers to adopting rapid sterility methods are regulatory rather than analytical, and regulation can be reformed. The main obstacles are regulatory fragmentation between the FDA, EMA, and TGA, and a lack of real-world validation data in CAR T products.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/growing-apart-culture-based-sterility-test-alternatives/">Growing Apart: Culture-Based Sterility Test Alternatives</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>One Record, From Factory Floor to Patient</title>
<link>https://edusehat.com/en/one-record-from-factory-floor-to-patient</link>
<guid>https://edusehat.com/en/one-record-from-factory-floor-to-patient</guid>
<description><![CDATA[ ParkourSC acquired manufacturing-AI company Quartic to track a drug’s quality across its whole lifecycle. CEO Mahesh Veerina explains how linking factory and shipping data could flag at-risk batches before problems reach patients.
The post One Record, From Factory Floor to Patient appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-ParkourSC_GBPN_IMAGE_19NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>One, Record, From, Factory, Floor, Patient</media:keywords>
<content:encoded><![CDATA[<p>A drug’s life story is usually told in pieces. How a batch was made lives in one set of manufacturing systems. What happens to it afterward—where it shipped, how warm it got, how long it sat—lives in another. When something goes wrong downstream, quality teams must stitch that history back together before they can decide what to do, and the delay can cost product, time, and confidence in supply.</p>
<p>San Jose–based ParkourSC says it acquired Quartic to close that gap. The deal combines ParkourSC’s clinical and commercial supply-chain AI with Quartic’s manufacturing AI on a single platform aimed at regulated life sciences. The company says the result is one continuous record that can predict which batches, lots, and shipments are at risk, then recommend a response.</p>
<p>For Mahesh Veerina, president and CEO of ParkourSC, the move was less about reaching manufacturing data than about making sense of it. The company could have built its own connectors to the systems that hold batch records, he said, “but it’s not about the data itself.” Quartic, he explains, “consumes this data, contextualizes it around batches and campaigns, and creates intelligence about the key quality attributes” that ParkourSC’s downstream decisions depend on.</p>
<p>The timing reflects where the industry is heading. Companies are shifting more of their portfolios to biologics, and production is spreading across more internal and contract sites. “Supply chain systems, both clinical and commercial, need to become more dynamic in their decision intelligence,” Veerina says.</p>
<p>A temperature excursion shows what that could change. Today, a quality team often judges a cold-chain breach by what happened on the last leg of a shipment. Linking manufacturing and distribution data, Veerina says, “turns a temperature excursion from an isolated event into a decision made with the batch’s full story.” Teams can see the cumulative time a batch has spent in and out of refrigeration from the plant onward, while the platform predicts the remaining stability margin “as excursions occur, so teams know early how much margin a batch has left.” Decisions to release, restrict, or reject product, he adds, become “faster and better justified.”</p>
<p>The approach also reaches upstream. Because Quartic uses shared models across research, clinical, and commercial manufacturing, Veerina says, the multivariate models built for clinical batches “act as the starting point, rather than developing models from scratch,” speeding scale-up and process qualification. He attributed the 15 to 20% gain in biologics batch yield the companies report to models that let operators “run the process close to the ideal-yield batch, repeatably.”</p>
<p>In a GxP setting, meaning one bound by good-practice quality regulations, trust is the harder question, and Veerina draws a firm line. “AI recommends, and a qualified person decides. AI never makes the GxP decision,” he said. The platform relies on interpretable statistical methods, “never black-box models or LLMs,” keeps every recommendation within validated ranges, and attaches a confidence interval and the factors behind it. A human approves each decision with an e-signature, and an audit trail links the data, the recommendation, and the call that was made.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/one-record-from-factory-floor-to-patient/">One Record, From Factory Floor to Patient</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tuning Extracellular Vesicle Production and Analytics for Compliance</title>
<link>https://edusehat.com/en/tuning-extracellular-vesicle-production-and-analytics-for-compliance</link>
<guid>https://edusehat.com/en/tuning-extracellular-vesicle-production-and-analytics-for-compliance</guid>
<description><![CDATA[ The complexity of extracellular vesicle products developed from umbilical cord blood can potentially be reduced through production processes and simplified quality control strategies, helping to boost this new product class.
The post Tuning Extracellular Vesicle Production and Analytics for Compliance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Vivienne-PR_Exogenus-T.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tuning, Extracellular, Vesicle, Production, and, Analytics, for, Compliance</media:keywords>
<content:encoded><![CDATA[<p>A company developing extracellular vesicles (EV) derived from umbilical cord blood cells says that producing a non-conventional product shouldn’t be a barrier to streamlined production processes and quality control analytics.</p>
<p>Exogenus Therapeutics, which is currently developing products targeted at inflammatory and degenerative conditions, says that they’ve managed to implement a production and quality-control (QC) workflow that turns their complicated high-screening analytics into a more sustainable assay panel.</p>
<p>“I think our main message to the corporate EV community is it’s possible to develop and produce an extracellular vesicle-based product that falls outside the mainstream,” explains Andreia Silva, PhD, head of research at Exogenus, who spoke at Cell & Gene Therapy International Europe.</p>
<p>According to Silva, complexities of their production process include the raw material of umbilical cord blood, which has a higher level of variability than conventional EV cell sources as it’s derived from different donors, but which needs to be sculpted into a safe and consistent-quality product.</p>
<p>The product is also complex, she explains, as unlike small molecules, extracellular vesicles are made of thousands of molecules of lipids, proteins, metabolites, DNA, and RNA, all of which may be functional once they reach a target organ.</p>
<p>To overcome this complexity issue, as they move toward the clinical stage of development, the company says it’s managed to develop a production strategy including a panel of assays that can be run using standardized techniques, such as ELISA and Western Blot, to provide efficient and sustainable QC of product batches.</p>
<p>“We can’t do omics on every single batch of product we are going to release because it would become too expensive down the line,” explains Silva. “We’ve been looking at the molecular data generated at the omics level and then selecting specific targets to pass that into the simpler QC panel.”</p>
<p>Although their target choices and QC panel are product-specific, Silva hopes the general lessons will inspire other companies in their QC development. Going forward, she says a future challenge for the EV industry will be developing potency assays.</p>
<p>“Potency assay development for GMP production, so you can use your product in later clinical phases, is still something that needs a lot of development because EVs are such a complex modality,” she says.</p>
<p>“As companies work toward getting an EV product to clinic, we can definitely see strategies emerging for what might be the right way to go.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/tuning-extracellular-vesicle-production-and-analytics-for-compliance/">Tuning Extracellular Vesicle Production and Analytics for Compliance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Advent of Automated, Gene&#45;Engineered TIL Manufacturing</title>
<link>https://edusehat.com/en/the-advent-of-automated-gene-engineered-til-manufacturing</link>
<guid>https://edusehat.com/en/the-advent-of-automated-gene-engineered-til-manufacturing</guid>
<description><![CDATA[ Automating engineered TIL manufacturing in a way that maintains their tumor-fighting capabilities may move this emerging therapeutic class into a commercially reproducible, economically viable therapeutic option.
The post The Advent of Automated, Gene-Engineered TIL Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2179695031.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 19 Nov 2026 03:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Advent, Automated, Gene-Engineered, TIL, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>Tumor-infiltrating leukocytes (TILs) tend to be manufactured at small scale in labs using manual, bespoke processes to account for inconsistent starting materials and conditions. As TIL-based therapeutics move to clinical scale, however, automation and the reproducibility and efficiency it provides become invaluable.</p>
<p>A handful of companies are working to automate the TIL production process. The latest, Terumo Blood and Cell Technologies (Terumo BCT), is using its Quantum Flex<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Cell Expansion System to automate the production of genetically engineered TILs in partnership with TrAMPoline Pharma and the University of Colorado.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Automation could help bridge the gap between development in the lab and clinical scale by utilizing the same scalable technology for both phases to ultimately preserve product quality along the development pipeline,” Mindy Miller, PhD, head of cell therapy scientific development at Terumo BCT, tells <em>GEN</em>.</p>
<p>The challenge is that TILs are produced from T cells that have infiltrated tumors. These T cells typically don’t expand as efficiently as T cells found in the bloodstream, so vastly greater quantities of T cells are needed to produce potent doses.</p>
<p>“We recognized that a process dependent on extensive manual handling would inevitably limit clinical translation,” Eduardo Davila, PhD, professor of medicine at the University of Colorado, and co-founder and CSO at TrAMPoline Pharma, adds. His research into T cell infiltration is the basis for TrAMPoline Pharma’s TIL program. This collaboration “aims to make engineered TIL manufacturing more reproducible and efficient while preserving the cells’ tumor-fighting capabilities.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To that end, Davila says, “We are focusing on standardized culture conditions, automated feeding, and fewer manual manipulations. Our goal is to preserve engineered TIL identity, viability, and antitumor function.”</p>
<p>The automation process is being undertaken in phases. The first step is to validate automated cell expansion against the existing process. Then, additional steps will be validated and integrated into the workflow.</p>
<p>“We anticipate a substantial reduction in hands-on labor and expedited TIL expansion. Whether total manufacturing time also decreases—and by how much—must be established experimentally,” Davila says. But, Miller adds, “it is still being evaluated.”</p>
<p>Today, it takes about three weeks to manufacture TILs. While neither Miller nor Davila will suggest a target timeframe for engineered TIL manufacturing within this partnership, Davila says, “We anticipate more consistent yield, fewer manual interventions, and greater manufacturing capacity, with the potential to reduce cost and turnaround time.”</p>
<p>Additionally, he continues, “We will evaluate these gains alongside gene transfer efficiency, viability, phenotype, and tumor-specific killing. Improved potency is an outcome to test, rather than assume.”</p>
<p>Miller emphasizes, “Our focus is adapting automation to the particular requirements of engineered TILs.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/the-advent-of-automated-gene-engineered-til-manufacturing/">The Advent of Automated, Gene-Engineered TIL Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti&#45;PD&#45;1 Response in Mice</title>
<link>https://edusehat.com/en/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice</link>
<guid>https://edusehat.com/en/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice</guid>
<description><![CDATA[ In mice, alcohol cut the efficacy of anti-PD-1 immunotherapy by roughly 50%, suppressing tumor-infiltrating and memory T cells while boosting TIGIT-carrying ones. Blocking TIGIT restored the response.
The post Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-544546123.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 09:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alcohol, Suppresses, Some, Cells, Boosts, Others, Blunting, Anti-PD-1, Response, Mice</media:keywords>
<content:encoded><![CDATA[<p>Regular alcohol use may undermine a widely used form of cancer immunotherapy by dampening some T cells while boosting others, according to a new study in mouse models and a retrospective patient cohort. The findings point to a molecular route by which drinking weakens anti-tumor immunity, and to ways it might be countered.</p>
<p>The work, from researchers at the University of North Carolina at Chapel Hill, was published in <em>Science Signaling</em> in a paper titled “<a href="https://www.science.org/doi/10.1126/scisignal.aef1375" target="_blank" rel="noopener">Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity</a>.” Immune checkpoint inhibition has improved outcomes for some patients with advanced cancers, but relatively few have a complete response. Alcohol use is common and impairs adaptive immunity. Recent studies suggest that as many as 76.4% of patients with cancer still drink, and medical societies have called for more research on how alcohol affects treatment outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>To probe the link, the team gave mouse models of lung and bladder cancer a moderate-to-heavy amount of ethanol while treating them with anti-PD-1 antibodies. In both models, alcohol reduced the efficacy of the immunotherapy by roughly 50% and increased tumor recurrence.</p>
<p>In mice with MB49 bladder tumors, ethanol reduced the number of tumor-infiltrating T cells and shifted tumor-associated CD4<sup>+</sup> T cells toward a T helper 17 profile over a T helper 1 profile. It also reduced tissue-resident memory T cells while increasing the proportion of T cells expressing TIGIT, an alternative immune checkpoint receptor, and induced SREBP-mediated lipid signaling in tumor-associated T cells, according to the paper.</p>
<p>Targeting those changes helped. Blocking TIGIT with antibodies restored the efficacy of anti-PD-1 treatment in the animals, while inhibiting SREBP signaling with betulin improved it to a lesser extent.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers then retrospectively analyzed a cohort of patients with skin, lung, bladder, or head and neck cancer treated with immune checkpoint inhibitors. Patients who self-reported eight or more drinks a week had poorer survival after starting treatment. In patients with lung cancer, regular alcohol use was associated with a reduced survival benefit from immune checkpoint inhibition. The effects were less definitive in the other cancers because alcohol use reporting was too limited.</p>
<p>“This work is an initial resource toward establishing the risk of regular alcohol use on the efficacy of [immune checkpoint inhibition] and identifying the mechanisms that might be targeted for intervention,” Gilley <em>et al.</em> wrote. As next steps, the authors say that incorporating patients’ alcohol use into cancer databases will help define its effect on outcomes of various therapies, such as chimeric antigen receptor T cell therapy (CAR T cell therapy), chemotherapy, and radiation, across multiple cancers.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/alcohol-suppresses-some-t-cells-boosts-others-blunting-anti-pd-1-response-in-mice/">Alcohol Suppresses Some T Cells, Boosts Others, Blunting Anti-PD-1 Response in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genetic Barcoding Reveals How Pre&#45;Bone Marrow Transplant Conditioning Impacts Immune System Regeneration</title>
<link>https://edusehat.com/en/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration</link>
<guid>https://edusehat.com/en/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration</guid>
<description><![CDATA[ Researchers used genetic barcoding to track human blood-forming stem and progenitor cells transplanted into mice, revealing how the different cell types regenerate the blood and immune system, and how different forms of pretransplant conditioning affected blood and immune cell recovery. 
The post Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/GettyImages-1489195647-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 05:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genetic, Barcoding, Reveals, How, Pre-Bone, Marrow, Transplant, Conditioning, Impacts, Immune, System, Regeneration</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Southern California have used genetic barcoding to track individual human blood-forming stem and progenitor cells after transplanting them into mice. The results has revealed how different types of human blood-forming cells regenerate the blood and immune system, and how different forms of pretransplant conditioning—treatment used to prepare a recipient before bone marrow (BM) transplantation—affected blood and immune cell recovery.</p>
<p>The study is one of the first to systematically examine how human stem cells (HSCs) and human multipotent progenitors (hMPPs) respond to various forms of pretransplant conditioning, including chemotherapy and radiation, and contribute to the production of blood and immune cells. Down the line, the results could support the development of more effective and personalized approaches to bone marrow transplantation, which is used to treat blood cancers such as leukemia and lymphoma and certain inherited blood disorders.</p>
<p>“We found that human HSCs and MPPs don’t always behave as we would expect based on previous studies in mice,” said research lead Rong Lu, PhD, professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC. Lu is also a professor of biomedical engineering, medicine and gerontology. “Our findings underscore the importance of studying human cells directly to understand how they function in the context of transplantation.”</p>
<p>Lu is senior and corresponding author of the team’s published paper in <em>npj Regenerative Medicine</em>, titled “<a href="http://dx.doi.org/10.1038/s41536-026-00522-6" target="_blank" rel="noopener">Tracking human HSCs and MPPs in mice reveals distinct clonal dynamics and responses to pre-transplant conditioning</a>.” In their paper the team wrote, “These findings advance our understanding of human hematopoiesis and provide a framework for optimizing experimental models, improving transplantation conditioning strategies, and informing the preclinical evaluation of HSC-based cell and gene therapies.”</p>
<p>Human hematopoietic stem and progenitor cells (hHSPCs) sustain lifelong blood and immune cell production and are central to bone marrow (BM) transplantation therapies, the authors wrote. However, they noted, “While the functional hierarchy of mouse HSPC subsets is well characterized, the distinct roles of human HSPC populations remain less well defined, particularly at clonal resolution and in the context of transplantation conditioning.”</p>
<p>For their newly reported study, first author Mary Vergel Snodgrass, PhD, and colleagues used genetic barcode-based clonal tracking, which allowed them to follow individual cells and their descendants to see how they contribute to blood and immune cell production over time, comparing two cell types, hematopoietic stem cells and multipotent progenitor cells. Both HSCs and MPPs can produce multiple types of blood and immune cells, but HSCs are thought to have unique long-term regenerative capacity, based largely on animal studies.</p>
<p>The team transplanted human HSCs or MPPs into mice, then used clonal tracking to compare how the two cell populations contributed to blood and immune cell production over time. They found that both HSCs and MPPs produced multiple types of blood and immune cells over an extended period after transplantation, suggesting that human MPPs may have greater long-term regenerative capacity than previously observed in mouse studies. However, HSCs generally produced more blood cells and were better at producing multiple types of blood and immune cells than MPPs. “We found that hHSC clones generated more blood cells, initiated lymphoid production earlier, and exhibited more robust multilineage differentiation than hMPP clones,” they wrote.</p>
<figure aria-describedby="caption-attachment-340738" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340738" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop-300x169.jpg" alt="Study authors Rong Lu, PhD, and Mary Vergel Snodgrass in the lab " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Rong-Lu-and-Mary-Vergel-by-Chris-Shinn-big-crop.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Study authors Rong Lu, PhD, and Mary Vergel Snodgrass in the lab [Chris Shinn]</figcaption></figure>
<p>The researchers also compared several approaches to transplant conditioning, which helps reduce a recipient’s own stem and progenitor cells and makes room for donor cells. Mice received either radiation treatment, chemotherapy with the drug busulfan, or no conditioning treatment. The conditioning approach influenced how many and which types of blood and immune cells were produced, and how quickly blood cell production occurred, without significantly affecting donor cell engraftment in the bone marrow.</p>
<p>“We also found that HSCs were less affected by conditioning, while MPPs were more sensitive, shifting the types of immune cells they produced,” Lu said. “This suggests that human HSCs can maintain more consistent blood and immune cell production under different transplantation conditions.”</p>
<p>These findings could eventually help clinicians tailor pre-transplant treatments to individual patients, supporting more effective blood and immune cell recovery while minimizing treatment-related complications. While further studies are needed to determine how these findings translate to patients, they could help guide the development of safer and more effective transplantation strategies.</p>
<p>In a final experiment, the researchers transplanted HSCs and MPPs from the initial recipients into a second group of mice to test their long-term regenerative capacity. They found that both cell types continued producing blood and immune cells, but at substantially lower levels. “During secondary transplantation, hHSCs and hMPPs contributed comparably to hematopoietic reconstitution but with substantially reduced output and increased clonal diversity,” they wrote. Their collective findings “… suggest that secondary transplantation is characterized by weaker contributions from a larger number of clones, whereas primary transplantation is dominated by stronger expansion of a smaller number of clones.”</p>
<p>An unexpected discovery was that in mice receiving a second transplant, blood cell production occurred not only in the bone marrow but also in other tissues, including the spleen, which became substantially enlarged. “Extramedullary hematopoiesis was observed in all secondary recipients,” the team stated. Lu noted that this phenomenon has also been observed in human diseases and may indicate that the mouse bone marrow environment does not fully support human blood cell production. “In humans, EMH is associated with pathological conditions such as hematologic malignancies, BM failure, and systemic infections, highlighting its relevance as a compensatory hematopoietic response under stress and disease,” the authors stated.</p>
<p>Next, Lu and her team are investigating how blood-forming stem cells communicate with surrounding bone marrow cells to regulate blood and immune cell regeneration. This work could help explain why different conditioning treatments lead to different patterns of blood and immune cell recovery. In their paper, the team wrote in summary, “Through quantitative <em>in vivo</em> clonal tracking and multi-tissue analyses, this study advances understanding of human hematopoiesis and provides a framework for optimizing experimental models, improving transplantation strategies, and informing the development of HSC-based cell and gene therapies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/genetic-barcoding-reveals-how-pre-bone-marrow-transplant-conditioning-impacts-immune-system-regeneration/">Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy&#45;Based Approach</title>
<link>https://edusehat.com/en/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach</link>
<guid>https://edusehat.com/en/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach</guid>
<description><![CDATA[ ImmunoBrain&#039;s approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology. 
The post Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/CO_JanFeb18_GettyImages-687788463_CHRISTIANLAGEREK_SCIENCEPHOTOLIBRARY_HumanBrainCircuitBoard-e1559053521129-1024x831-1-e1794949818926.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 05:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Amyloid, and, Tau:, Alzheimer’s, Drug, Developer, Sees, Early, Clinical, Success, for, Immunotherapy-Based, Approach</media:keywords>
<content:encoded><![CDATA[<p>Twelve years after a widely quoted <a href="https://alzres.biomedcentral.com/articles/10.1186/alzrt269" target="_blank" rel="noopener">Cleveland Clinic study</a> showed a staggering 99.6% failure rate for Alzheimer’s disease clinical candidates, the percentage has hardly budged.</p>
<p>But ImmunoBrain, an 11-year-old company, has generated early-stage clinical data showing success for a first-of-its-kind, immunotherapy-based approach to treating Alzheimer’s that goes beyond aiming at the two most common targets, amyloid plaques and tau neurofibrillary tangles.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>ImmunoBrain develops treatments intended to address Alzheimer’s and other neurodegenerative diseases by restoring the body’s peripheral immune system to facilitate brain protection and repair. The company uses a novel approach that targets the peripheral immune system to break the vicious cycle between neuroinflammation developed in the brain with neurodegenerative diseases and the progressive decline in peripheral immune function that together derives disease progression.</p>
<figure aria-describedby="caption-attachment-340728" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340728" src="https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-300x298.jpg" alt="" width="300" height="298" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-300x298.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-1024x1018.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE-768x764.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Prof-Michal-Schwartz-CROP-SQUARE.jpg 1204w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Michal Schwartz, PhD, ImmunoBrain’s scientific co-founder and chief scientific officer</figcaption></figure>
<p>That approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology.</p>
<p>“It’s not just a disease of only accumulation of toxic protein,” Michal Schwartz, PhD, ImmunoBrain’s scientific co-founder and chief scientific officer, told <em>GEN</em>. “We know now that the disease is dormant or asymptomatic for 10 to 20 years before symptoms are seen. Once symptoms are seen, the disease progression is driven not only by the amyloid plaque, but an additional major factor, local inflammation.”</p>
<p>“It’s not the primary cause, it’s not the trigger, but definitely a catalyzer,” said Schwartz, who is also a professor of neuroimmunology at the Weizmann Institute of Science in Rehovot, Israel.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Alzheimer’s starts in the brain, with the accumulated of the toxic proteins such as amyloid and tau. At this stage, local immune cells—microglia—within the brain, supported by the peripheral immune system, can help prevent or minimize damage to neurons, the brain’s functional cells. When the immune system ages and declines, its ability to help the brain is reduced, fueling the brain pathology.</p>
<p>That happens, says Schwartz, when the brain’s own immune cells known collectively as microglia become the source of inflammation.</p>
<h4><strong>Antibody approach</strong></h4>
<p>“Our approach is, we developed a new antibody that targets the inhibitory checkpoint, thereby we boost the level very transiently of immune cells that can facilitate a homing of immune repairing cells from the peripheral immune system to the brain. They are facilitating dampening the local inflammation and thereby creating a supportive milieu within the brain that can rescue neurons and synapses that are still healthy but not functioning well.”</p>
<p>Schwartz’s lab was first to show that the brain is not immune isolated, but tightly dependent on the immune system for its daily maintenance, daily function, protection and repair, as it is the gatekeeper of the brain: “The meaning of it is that aging of the brain reflects more the immunological aging than the chronological aging.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>ImmunoBrain’s lead program applies IBC-Ab002, a company-developed anti-PD-L1 monoclonal antibody engineered specifically for use in chronic neurodegenerative disease settings. Specifically, IBC-Ab002 is engineered for transient, intermittent blockade of the PD-1/PD-L1 pathway. The transient checkpoint blockade allows for triggering of the immune system, initiating an immune cascade by facilitating the homing of immune-repairing monocytes and regulatory T cells (immune system regulators) that clear senescent microglia, and resolves inflammation, thereby helping the brain protection and repair.</p>
<p>IBC-Ab002 combines high-affinity PD-L1 binding with Fc effector silencing and reduced FcRn binding modification designed to eliminate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.</p>
<h4><strong>Positive first-in-human data</strong></h4>
<p>At the 2026 Alzheimer’s Association International Conference (AAIC), held July 12-15 in London, and in a <a href="https://www.nature.com/articles/s41591-026-04547-8" target="_blank" rel="noopener">study published in <em>Nature Medicine</em></a>, ImmunoBrain shared positive data for IBC-Ab002 from a Phase Ib first-in-human study (<a href="https://clinicaltrials.gov/study/NCT05551741" target="_blank" rel="noopener">NCT05551741</a>) in patients with early Alzheimer’s. Forty patients were enrolled across five ascending dose cohorts (1–30 mg kg<sup>−1</sup>), with dosing administered four times at 3-month intervals, and patients followed up for one year. The study’s primary endpoints were safety and tolerability.</p>
<p>The data showed the antibody to have a half-life of approximately four days across all dose cohorts. IBC-Ab002 generated encouraging fluid biomarker data, as well as reductions of biomarkers associated with neuronal and synaptic damage, with no brain hemorrhaging or ARIA (amyloid-related imaging abnormalities) seen.</p>
<p>Exploratory CSF biomarker analyses at 48 weeks showed reductions in neurogranin (−23.1%), tTau (−12.4%) and pTau181 (−11.0%) at the 30 mg kg<sup>−1</sup> dose compared with pooled placebo, with intraindividual consistency across the three markers in participants treated with IBC-Ab002. A pre-synaptic biomarker, VAMP2, showed a similar trend to neurogranin, with strong correlation between individual responses to both markers.</p>
<p><strong>‘Beyond our expectation’</strong></p>
<p>“The biomarkers show an encouraging result, mainly the Neurogranin that is Alzheimer’s characteristic marker and prediction of cognitive performance. Yet, we cannot speak about statistical significance because of the small number of patients and the short duration of the follow-up, but it was beyond our expectation to see from such a small study,” said Schwartz, one of three corresponding authors on the <em>Nature Medicine</em> paper.</p>
<p>“IBC-Ab002 is intended to transiently re-engage the peripheral immune system, whose ability to support the brain declines with aging, thereby restoring its capacity to protect the brain and dampen brain inflammatory processes,” Schwartz and colleagues wrote. “Because this strategy does not rely on directly targeting a specific brain proteinopathy, it has broader applicability across other chronic neurodegenerative conditions in which neuroinflammation contributes to disease progression.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Schwartz said she and colleagues are planning a Phase IIb trial for which they have submitted paperwork to the FDA, and for which they are raising funds. That study would include a two-year follow-up of participants: “We are aiming to do a big study, very rigorous, with a very ambitious endpoint, so if successful, as it seems based on the Phase Ib, it may speed up approval of this drug and may be considered as a pivotal study.”</p>
<p>In September, Schwartz was corresponding author of another paper, which <a href="https://www.nature.com/articles/s41593-026-02417-7" target="_blank" rel="noopener">was published in <em>Nature Neuroscience</em></a> that showed in both a mouse model and in Alzheimer’s patients the body’s “factory” of the a potentially protective immune response—the production of monocyte-derived macrophages in the bone marrow and their recruitment to the brain—key processes that help protect against disease progression are compromised: “Our results reveal a dysfunction in bone marrow myelopoiesis in AD and reinforce the concept that AD progression is driven by maladaptive systemic immune processes.”</p>
<p>“We wanted to see whether the deficiency in homing of macrophages that we are boosting with the anti-PD-L1 is reflection of some impairment in the factory of these monocytes, which is in the bone room,” Schwartz said. “When we saw that there is really impairment in production of monocytes in the factory of the monocytes in the bone marrow, I was, wow, very excited, because it further supports the notion that disease is not just disease of the brain. Then we found that the cause of this impairment is elevation of type 1 interferon, which all of us produce when we are encountering viral infection.”</p>
<p>Type I interferon signaling is an essential part of the body’s natural protective immune response. However, when this response becomes chronic, Schwartz explained, its protective effects can turn harmful—transforming a friend into a foe.</p>
<p>“If you have an inflammation in the body, the immune system produces type 1 interferon to dampen inflammation. But if this type 1 interferon is chronically produced, it becomes an enemy of the bone marrow. And we found the same situation in mice and in humans,” Schwartz explained.</p>
<h4><strong>Earlier research</strong></h4>
<p>That finding was in sync with <a href="https://pmc.ncbi.nlm.nih.gov/articles/pmid/25147279/" target="_blank" rel="noopener">earlier research published in <em>Science</em></a> by Schwartz and colleagues in 2014, showing that aging of the brain in both humans and mice was also associated with type 1 interferon.</p>
<p>“And in a way, it’s also linking what we know, that viral infection can catalyze Alzheimer’s disease … It is more likely the uncontrolled immune response to the virus, rather than the virus itself, that causes the damage.” Schwartz added. “It’s not just a disease of the brain. The brain affects the immune system, the immune system is impaired, and they enter into a vicious cycle.”</p>
<p>Last month, ImmunoBrain named to its board Francis Collins, MD, PhD, whose tenure as NIH director from 2009 to 2021 is the longest of any presidentially appointed director of the agency.</p>
<p>“One of my jobs as NIH director was to look across the entire field of biomedical research and say, ‘Are there some really serious gaps here that need to be filled?’ Alzheimer’s disease, because it is so common and so devastating for individuals and their families, obviously has been a high priority for research, particularly through the National Institute on Aging,” Collins recalled. “But despite massive efforts, it didn’t feel like we were necessarily making progress of the groundbreaking type that people were hoping for.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>The Cleveland Clinic’s reported 99.6% failure rate showed little improvement in a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9198803/" target="_blank" rel="noopener">2022 study</a> that found a 98% failure rate among candidates studied in Phase II and III trials. And a study by Michael A.S. Guth, PhD, JD, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13532280/" target="_blank" rel="noopener">published in August</a> blamed the high failure rate on “structural and institutional forces that sustained investment in repeatedly ineffective mechanisms of action across 567 Phase II and Phase III Alzheimer’s trials from 2010 to 2026.”</p>
<p>“The 567-trial record constitutes a structural verdict on a model of drug development that was never designed to solve a problem of this complexity,” Guth asserted. “The uniformity of negative results across all mechanism categories—amyloid, tau, neuroinflammation, metabolic, and synaptic—points toward deeper problems of disease definition, intervention timing, and endpoint validity that institutional and financial pressures have prevented the field from confronting.”</p>
<figure aria-describedby="caption-attachment-340729" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340729" src="https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-300x300.jpg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/11/Dr-Francis-Collins-CROP-SQUARE.jpg 1836w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Francis Collins, MD, PhD, NIH Director from 2009 to 2021 and Board Member of ImmunoBrain</figcaption></figure>
<p>Recalled Collins: “Most of the efforts I saw happening as NIH director were in terms of developing and testing monoclonal antibodies against amyloid. While they provided some positive signals, they certainly didn’t provide the breakthrough benefit that people had hoped for.”</p>
<p>There must be something more going on here, Collins concluded. Maybe genetic research could provide clues?  Studies of large numbers of affected and unaffected individuals using the GWAS (genome-wide association study) approach have now pointed to more than 100 such signals. The dominant pathway relates to microglia and innate immunity.</p>
<p>Yet the field of Alzheimer’s research has done relatively little to explore that area therapeutically, and remains focused, he said, primarily on amyloid and tau and lipids such as ApoE: “The field seems to be stuck on the amyloid hypothesis, but so far that’s not curing people or significantly preventing progression like we hoped.”</p>
<h4><strong>Milestones and growing pipeline</strong></h4>
<p>Alzheimer’s drug development has achieved several milestones during this decade.</p>
<p>Biogen and Eisai made history in 2021 when the FDA <a href="https://genengnews.com/news/biogen-alzheimers-drug-wins-historic-approval-but-fda-requires-new-trial/?_gl=1*1a12h21*_up*MQ..*_ga*MTI1OTkyNTY2Mi4xNzk0NzY0ODEy*_ga_F1EYPPYL3X*czE3OTQ3NjQ4MTIkbzEkZzAkdDE3OTQ3NjQ4MTIkajYwJGwwJGgxNTYyMTY0MjMw" target="_blank" rel="noopener">approved</a> their <a href="https://genengnews.com/news/fda-seeks-review-of-staff-biogen-talks-leading-to-alzheimers-drug-approval/" target="_blank" rel="noopener">controversial</a> human immunoglobulin gamma 1 (IgG1) monoclonal antibody Aduhelm<sup>®</sup> (aducanumab-avwa) as the first therapy indicated for reducing clinical decline in people with Alzheimer’s disease, and the first therapy to tie improved clinical outcomes to removing amyloid beta. But Aduhelm sales never matched forecasts and failed to the drug failed to obtain coverage from the Centers for Medicare and Medicaid Services (CMS).</p>
<p>In 2024, Biogen halted development and commercialization of Aduhelm in order to shift resources to other Alzheimer’s treatments—a year after the companies’ Leqembi<sup>®</sup> (lecanumab-irmb) became the first disease-modifying therapy to receive full FDA approval for patients with mild cognitive impairment or mild dementia.</p>
<p>The FDA has since approved a weekly subcutaneous maintenance dose last year and a subcutaneous starter dose in July, the latter marketed as Leqembi Iklik. The new subcutaneous doses have propelled Leqembi sales to finally outpacing sales forecasts after a slow start for the drug. During the third quarter, Eisai reported $202 million in global sales, up 67% from $121 million in Q3 2025. That includes $68 million recorded by Biogen in “Alzheimer’s collaboration” revenue—the sum of Biogen’s 50% share of net revenue and cost of sales, including royalties, from its Leqembi collaboration.</p>
<p>Another milestone occurred when Eli Lilly <a href="https://www.genengnews.com/topics/drug-discovery/fda-approves-lillys-amyloid-targeting-kisunla-for-early-alzheimers/" target="_blank" rel="noopener">won FDA approval in 2024 for Kisunla<sup>®</sup> (donanemab-azbt)</a>, a once-monthly injection treatment indicated for adults with early symptomatic Alzheimer’s, including mild cognitive impairment or mild dementia stage of disease with confirmed amyloid pathology. Kisunla was approved as the first amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.</p>
<p>Among current Alzheimer’s candidates in Phase III development, AriBio on Monday trumpeted data from the Phase III POLARIS-AD trial (NCT05531526) at the 19<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Boston through Thursday. The data showed that its once-daily oral small molecule phosphodiesterase-5 (PDE5) inhibitor AR1001 showed statistically significant treatment difference of −0.44 points versus placebo on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at Week 52 (p=0.0266), representing 31% slowing of clinical decline.</p>
<p>But in the trial’s overall 1,535-participant population, the treatment difference vs. placebo was −0.11 points (p=0.4015), which did not reach statistical significance. AriBio said it plans to discuss the results with the FDA before deciding next steps.</p>
<p>AR1001 is among numerous Phase III Alzheimer’s candidates. Two examples:</p>
<ul>
<li>Roche and its Genentech subsidiary anticipate primary completion in February 2028 for the TRONTIER1 (<a href="https://clinicaltrials.gov/study/NCT07169578" target="_blank" rel="noopener">NCT07169578</a>) and TRONTIER2 (<a href="https://clinicaltrials.gov/study/NCT07170150" target="_blank" rel="noopener">NCT07170150</a>) trials for their anti-amyloid monoclonal antibody trontinemab (RO7126209) in 2028. A prevention study, PrevenTRON (<a href="https://clinicaltrials.gov/study/NCT07717411" target="_blank" rel="noopener">NCT07717411</a>), estimates primary data completion in 2032.</li>
<li>Eli Lilly expects releasing data in 2029 from its Phase III TRAILRUNNER-ALZ 3 trial (<a href="https://clinicaltrials.gov/study/NCT06653153" target="_blank" rel="noopener">NCT06653153</a>) assessing its beta-amyloid plaque targeting next-gen antibody remternetug (LY3372993).</li>
</ul>
<h4><strong>‘Pretty excited’</strong></h4>
<p>“The ImmunoBrain approach is, for me, a completely compelling and novel approach. It is built on a sweeping redefinition of what the fundamental problems are with Alzheimer’s disease. It builds on basic science data that implicates the immune system as a major player in progression, and even as a signal for aging itself,” Collins explained. “I am pretty excited about that.”</p>
<p>Collins said his departure from the NIH—a <a href="https://www.genengnews.com/topics/omics/former-nih-director-francis-collins-praises-the-institution-as-he-abruptly-departs-after-three-decades/" target="_blank" rel="noopener">sudden retirement in February 2025</a> after 32 years with the agency—offers him the opportunity to serve on company boards like that of ImmunoBrain.</p>
<p>“The need for progress in Alzheimer’s disease has been compelling to me for years.  In this new life chapter, I wanted to get more engaged to see if I could be helpful in some way. The data that Michal and her lab have generated over 25 years, building this case for a critical role of the immune system, points to a wholly new vision of the pathogenesis of this common and devastating disease.  Now that we see the encouraging result of biomarkers in a Phase Ib trial, published in a highly regarded peer-reviewed journal, it looks like we’re on the right track,” Collins said.</p>
<p>“I am now really excited about seeing this go forward to a Phase IIb trial with a clinical endpoint. The question is: can we show that this intervention changes the course of the illness?” the former NIH director added. “It will take a big push to answer that. It’s going to cost a lot of money. But of all the things I look at right now that are happening in Alzheimer’s, this feels like an exceptionally novel, encouraging, and potentially groundbreaking way to look at the disease in a new way that hasn’t been adequately explored before.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/beyond-amyloid-and-tau-alzheimers-drug-developer-sees-early-clinical-success-for-immunotherapy-based-approach/">Beyond Amyloid and Tau: Alzheimer’s Drug Developer Sees Early Clinical Success for Immunotherapy-Based Approach</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mapping the Hidden Viral Communities of the Human Gut Microbiome</title>
<link>https://edusehat.com/en/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome</link>
<guid>https://edusehat.com/en/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome</guid>
<description><![CDATA[ Researchers identified over 116,000 gut viral groups, revealing previously unknown relationships between viruses, bacteria, and metabolism, with findings offering new insights into gut health and irritable bowel syndrome (IBS).
The post Mapping the Hidden Viral Communities of the Human Gut Microbiome appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2289175590.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 18 Nov 2026 01:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mapping, the, Hidden, Viral, Communities, the, Human, Gut, Microbiome</media:keywords>
<content:encoded><![CDATA[<p>When people hear “gut microbiome” their first thought is likely the bacteria living inside our intestines. However, the human gut microbiome is home to a vast and largely unexplored world of viruses, which could determine how the gut ecosystem works.</p>
<p>New research has characterized a largely unexplored community of bacteriophages within the human gut. The findings provide an integrated picture of the gut ecosystem, connecting its viral, bacterial, and metabolic components, which influence health and conditions like IBS.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p> “Our research highlights that to fully understand the gut microbiome and its links to health and disease, we need to look beyond bacteria and consider the viruses that live alongside them,” notes Cristina Menni, PhD, who leads the metabolomics research group at the Department of Twin Research, Ageing and Genomic Epidemiology, King’s College London. “We reveal a fascinating and largely unexplored dimension of the gut microbiome—discovering that viruses are not only closely associated with bacterial communities, but also with the metabolites that connect the microbiome to our health. This opens exciting new avenues for understanding how the gut ecosystem works.”</p>
<p>The study is published in <em>Nature Communications</em> in the paper<em>, “</em><a href="https://www.nature.com/articles/s41467-026-79230-0" target="_blank" rel="noopener">Population-level characterisation of the human gut phageome and its association with microbial metabolites</a>.”</p>
<p>Research into the human gut microbiome has traditionally focused on bacteria, but little is known about its enormous population of viruses, particularly bacteriophages.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>This work identified over 116,000 viral groups in the gut. More than 99% of these had no close match in the largest existing catalogue of gut viruses, highlighting how much of the viral world within the gut remains unexplored. They found that certain viruses were consistently more common alongside particular bacteria, while others tended to be less common.</p>
<p>“Gut viruses are difficult to study, so most of what we found simply isn’t in existing catalogues,” notes Panayiotis Louca, PhD, Research Associate at King’s College London. “What stands out is how closely they track with gut bacteria and with the chemicals those bacteria produce. We can’t yet say whether the viruses are driving that, and testing it is our next step.”</p>
<p>The team used data from over 1,000 TwinsUK participants, the largest UK Twin Registry with data on gut bacteria, health measurements, and diet. By studying twins, the researchers also found that environmental factors play a major role in shaping the gut viral community, while genetics also contributes to certain aspects of viral diversity. Although genetic factors were estimated to explain around 47% of the variation in overall viral diversity, most individual viral populations appeared to be predominantly influenced by environmental factors.</p>
<p>The researchers also identified a small group of viruses carrying genes linked to harmful bacterial behavior. These viruses tended to occur alongside bacteria that can sometimes cause infections and were less commonly found alongside bacteria involved in breaking down dietary fiber.</p>
<p>Differences in the microbiome might influence conditions, such as irritable bowel syndrome (IBS). IBS affects around 10% of the population and can significantly affect quality of life, yet its underlying causes remain poorly understood.</p>
<p>In a second study, published in <em>Gut</em> today, the research team identified 50 gut viral groups associated with IBS, most of which were less abundant in people with the condition. There were also differences in the patterns of relationships between bacteria and viruses, with many viruses infecting bacteria already linked to the condition, suggesting that IBS may involve changes in how the wider gut microbial community is organized, rather than changes in bacteria alone.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The next challenge will be to understand whether these viruses actively influence bacterial metabolism and how their relationships with bacteria change in different states of health and disease. Future studies will investigate whether these findings can help explain individual differences in microbial function and ultimately contribute to more personalized approaches to gut health.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/mapping-the-hidden-viral-communities-of-the-human-gut-microbiome/">Mapping the Hidden Viral Communities of the Human Gut Microbiome</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Toward Connected Laboratory Ecosystems</title>
<link>https://edusehat.com/en/toward-connected-laboratory-ecosystems</link>
<guid>https://edusehat.com/en/toward-connected-laboratory-ecosystems</guid>
<description><![CDATA[ In this GEN podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. 
The post Toward Connected Laboratory Ecosystems appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_2239922126_ArtificialIntelligence.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 11:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Toward, Connected, Laboratory, Ecosystems</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>

<p></p>

<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph">These days, many laboratories are eager to apply AI, but the systems and workflows that they have implemented often stand in the way. When systems run separately, information gets trapped in silos and scientific context is lost between steps. Also, manual handoffs slow the work down and introduce risk at various points in lab processes. Connecting those systems and workflows first gives AI the operational and scientific context it needs to deliver value that can be both trusted and scaled.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. The discussion covers workflow orchestration across laboratory functions and ways to reduce manual handoffs and information silos, while offering some practical starting points for AI adoption. It also looks at how bringing LIMS, ELN, LES, and SDMS together in a unified laboratory execution environment enables workflow intelligence and AI assistance in the right scientific and operational context.</p>


<p class="wp-block-paragraph"></p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading"><strong><strong>Podcast Guests:</strong></strong></h4>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-medium is-resized"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-300x300.jpg" alt="Denise Bell" class="wp-image-340716" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Denise-Bell-VP-Product-Management-and-Marketing-e1794865379160.jpg 800w" sizes="(max-width: 300px) 100vw, 300px"></figure>


<h6 class="wp-block-heading has-text-align-center"><strong><strong><strong>Denise Bell</strong></strong></strong><br>Vice President, Product Management & Marketing<br>LabVantag</h6>
</div>
</div>
</div>
</div>


<hr class="wp-block-separator has-alpha-channel-opacity is-style-wide">


<p class="has-text-align-center wp-block-paragraph"><br><strong>Produced with support from:</strong></p>


<figure class="wp-block-image aligncenter size-medium"><a href="https://www.labvantage.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="57" src="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg" alt="LabVantage logo" class="wp-image-131319" srcset="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-696x132.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-741x142.jpg 741w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo.jpg 750w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>

<p>The post <a href="https://www.genengnews.com/topics/toward-connected-laboratory-ecosystems/">Toward Connected Laboratory Ecosystems</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Enhancer&#45;Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</title>
<link>https://edusehat.com/en/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model</link>
<guid>https://edusehat.com/en/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model</guid>
<description><![CDATA[ In lab-grown human neurons and organoids carrying CHD8 or SCN2A mutations, researchers reduced organoid overgrowth and moved neuronal electrical activity closer to wild-type levels.
The post Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/10/Nov1_2011_3769185_BlueBrainDNA_AutismGeneStudies_AI2888221221.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 11:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Enhancer-Targeted, CRISPR, Turns, Healthy, Gene, Copy, Autism, Organoid, Model</media:keywords>
<content:encoded><![CDATA[<p>When a mutation hinders one copy of a gene, the remaining copy has to do the work of two. Researchers at UCLA have now shown, in lab-grown human brain cells, that a CRISPR-based tool could help that remaining copy in models of autism.</p>
<p>The proof-of-concept study, published in <em>Nature Neuroscience</em>, is titled “<a href="https://www.nature.com/articles/s41593-026-02504-9?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20261113&utm_content=10.1038/s41593-026-02504-9">Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism</a>.” It was led by Daniel Geschwind, MD, PhD, at the David Geffen School of Medicine at UCLA. George Chen, PhD, now at Children’s Hospital of Los Angeles, is first author. Collaborators at the New York Genome Center and New York University also contributed.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Approximately 15% of the genetic susceptibility of autism spectrum disorder (ASD) is imparted by <em>de novo</em> haploinsufficient mutations of major effect,” the authors wrote. The team focused on two high-confidence autism genes: <em>CHD8</em>, which helps regulate other neurodevelopmental genes, and <em>SCN2A</em>, which is essential for neurons to fire electrical signals.</p>
<p>Instead of editing DNA, the researchers used CRISPR activation, pairing a catalytically inactive Cas9 with the activator p300 (dCas9-p300) to turn genes up without cutting them, and aimed it at fetal-brain enhancers. The team’s concern was that promoter targeting risks overexpression, a particular problem for haploinsufficient genes, which are often dosage sensitive.</p>
<p>“We mapped enhancers of two high-confidence autism genes, <em>CHD8</em> and <em>SCN2A</em>, and used CRISPR-based gene activation targeting enhancers (eCRISPR-A) in human pluripotent stem cell (hPSC)-derived excitatory neurons and cerebral forebrain organoids to correct the effects of haploinsufficiency,” the authors wrote. “Here we show that eCRISPR-A induced a sustained increase in <em>CHD8</em> and <em>SCN2A</em> expression specifically in mutant neurons and cortical organoids, with rescue of gene expression levels and mutation-associated phenotypes, including gene expression and physiology.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In <em>CHD8</em>-mutant organoids, which grow abnormally large because progenitor cells overproliferate, treatment reduced organoid size in most treated lines and shifted gene expression toward wild-type patterns. In <em>CHD8</em>-mutant neurons grown in two-dimensional cultures, it increased markers of neuronal maturation. In <em>SCN2A</em>-mutant neurons, it showed restored excitability: firing approached wild-type levels in patient-derived neurons. Interestingly, “patient-derived iPSC neurons required higher current injections to achieve sustained firing compared to HUES66-derived neurons across conditions, indicating a line-dependent difference in baseline intrinsic excitability rather than incomplete functional rescue,” reported the authors.</p>
<p>“Our results show that, in human cell models, it’s possible to turn up that remaining copy and move cells back toward typical development,” Geschwind said in a press release. “This is a key first step, and it gives us a new way to think about addressing the biology underlying these conditions.”</p>
<p>The authors call the work “an important proof of principle” and note they were able to “moderately increase the expression of each gene.” However, “the effect of eCRISPR-A decreased over time,” and “an open question remains regarding the effect of introducing CRISPR-A after the expected peak in expression.” They say “further optimization of viral infection, constructs, and use of alternative Cas enzymes” would increase the approach’s clinical utility.</p>
<p>“We are still a long way from the clinic, and there is a lot of work ahead on delivery and timing,” added Chen in a press release, “but these findings provide hope and give us a clear direction.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/enhancer-targeted-crispr-turns-up-healthy-gene-copy-in-autism-organoid-model/">Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gut Microbome and Bile Acid Modification Linked with Longevity</title>
<link>https://edusehat.com/en/gut-microbome-and-bile-acid-modification-linked-with-longevity</link>
<guid>https://edusehat.com/en/gut-microbome-and-bile-acid-modification-linked-with-longevity</guid>
<description><![CDATA[ Researchers studying how gut microbes modify bile acids have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.
The post Gut Microbome and Bile Acid Modification Linked with Longevity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1683059833.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 17 Nov 2026 07:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gut, Microbome, and, Bile, Acid, Modification, Linked, with, Longevity</media:keywords>
<content:encoded><![CDATA[<p>Researchers from the University of California San Diego have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.</p>
<p>“Many studies of aging focus on what goes wrong as we get older, but our findings suggest that some changes in the gut microbiome may actually represent the body’s attempt to preserve metabolic health,” said Amir Zarrinpar, MD, PhD, Stuart and Barbara L. Brody Endowed Chair in Circadian Biology and Medicine, and professor of medicine at UC San Diego School of Medicine. “If we can identify those beneficial functions and safely strengthen them, we may eventually be able to develop new ways to promote healthier aging.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Zarrinpar is senior and corresponding author of the researchers’ published paper in <em>Cell Metabolism</em>, titled “<a href="https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00453-5" target="_blank" rel="noopener">Microbial bile acid deconjugation counters metabolic decline in aging</a>.”</p>
<p>For their reported study the researchers focused on how gut microbes modify bile acids. Gut bacteria produce enzymes called bile salt hydrolases (BSH) that chemically modify bile acids, allowing them to influence pathways involved in metabolism, inflammation and the body’s internal clock. “Gut microbes modify bile acids through several reactions, including deconjugation by bile salt hydrolase (BSH),” the team wrote. “Deconjugated bile acids can regulate host gene expression and signaling pathways, including those involved in metabolism, inflammation, and circadian rhythms.”</p>
<p>The gut microbiome—the community of bacteria and other microbes living in the digestive tract—changes throughout life and plays an important role in metabolism, inflammation, and other aspects of health. Previous research has linked age-related changes in the microbiome with frailty, chronic inflammation, and disease, while other studies have found distinctive microbiome features among people who age exceptionally well.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers first studied young and aged mice and found that aging was associated with increased microbial activity related to BSH and greater bile acid modification. To determine whether a similar pattern occurred in humans, they reanalyzed publicly available data from a human aging cohort. The analysis included bile acid measurements from 48 young adults, 107 older adults, and 125 centenarians. The centenarian group showed higher ratios of certain modified bile acids than both younger groups.</p>
<p>Analysis of microbiome data also found greater abundance of a gene associated with BSH activity among centenarians compared with the older adult group. “Individuals with exceptional longevity show a similar bile acid deconjugation signature, suggesting an association with resilient or exceptional aging,” the team pointed out.</p>
<p>They then asked whether enhancing this microbial function could produce health benefits. The researchers engineered a strain of bacteria native to the gut to continuously produce BSH, and introduced the bacteria into 82-week-old mice—considered aged. A single treatment resulted in stable colonization, allowing the bacteria to persist and produce the enzyme over time.</p>
<p>Approximately 20 weeks after treatment, mice receiving the BSH-producing bacteria had significantly improved insulin sensitivity and modestly improved glucose tolerance compared with mice receiving a matched control bacterium. By 32 weeks, the treated mice also showed changes consistent with lower body weight and fat mass and greater lean mass. Other findings pointed to increased use of fat for energy, improved mitochondrial function, and changes in gene activity related to inflammation and the body’s internal clock. “Using engineered native bacteria, we further increased luminal BSH activity in aged mice and improved insulin sensitivity, accompanied by supportive changes in body composition and other metabolic readouts,” the investigators commented.</p>
<p>The results do not show that the microbial changes caused exceptional longevity in humans or that the engineered bacteria can extend lifespan. The authors note that centenarians and aged mice are not directly comparable, and the human findings provide supporting rather than definitive evidence. “We also acknowledge that aged mice and individuals with exceptional longevity are not directly equivalent and therefore consider the centenarian data corroborative rather than definitive evidence,” they stated. “From this perspective, increased BSH activity may serve as a marker of, or potential contributor to, metabolic resilience during aging. More studies in people will be needed to determine whether increased BSH activity is a marker of healthy aging, a contributor to it, or both.”</p>
<p>The study also points toward a broader possibility: rather than attempting to replace the entire gut microbiome, researchers may eventually be able to identify beneficial microbial functions and selectively enhance them. In their paper they noted, “Together, these findings suggest that elevated BSH activity may have a protective role during aging. They challenge the view that age-related changes in bile acid biotransformations are uniformly detrimental, highlighting microbial bile acid modulation as a potential strategy to improve late-life metabolic health.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Future studies will investigate how different forms of BSH affect bile acid metabolism, inflammation, energy use, and other aspects of aging, as well as whether the approach works similarly in females, given established differences in aging based on sex.</p>
<p>“The goal isn’t simply to live longer—it’s to understand the biology that allows some people to remain resilient as they age,” said Zarrinpar. “The microbiome gives us an intriguing opportunity because, unlike many aspects of aging, it may be something we can modify. This study gives us a starting point for asking whether beneficial microbial functions can be amplified to help preserve metabolic health later in life.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gut-microbome-and-bile-acid-modification-linked-with-longevity/">Gut Microbome and Bile Acid Modification Linked with Longevity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Cell Method Reveals On&#45; and Off&#45;Target Effects of Cas9 Edits on Gene Expression</title>
<link>https://edusehat.com/en/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression</link>
<guid>https://edusehat.com/en/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression</guid>
<description><![CDATA[ A new method called Superb-seq pairs Cas9 editing with single-cell RNA sequencing to show which edits, including off-target ones, occur in each cell and how they alter gene expression, offering a clearer view of genome editing’s potential consequences.
The post Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/CO_MarApr17_Getty_182516812_Henrik5000_BlueCells-1068x801-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 21:00:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Cell, Method, Reveals, On-, and, Off-Target, Effects, Cas9, Edits, Gene, Expression</media:keywords>
<content:encoded><![CDATA[<p><span>Scientists at the Salk Institute and their collaborators have published a paper in </span><i><span>Nature Methods</span></i><span> describing Superb-seq, a method of reading out both on and off target edits made by CRISPR/Cas9 technology. According to the developers, the tool makes it possible to read changes made by CRISPR at single-cell resolution to identify unwanted edits and assess how those edits change gene activity. Their paper is titled “</span><a href="https://www.nature.com/articles/s41592-026-03319-z" target="_blank" rel="noopener"><span>Joint single-cell capture of Cas9 edits and transcriptomes reveals on- and off-target effects on gene expression</span></a><span>.” </span></p>
<p><span>“What really inspired Superb-seq was a frustration with the existing state of affairs,” said Graham McVicker, PhD, senior author of the study and an associate professor at Salk. “We knew there were problems with CRISPR making unwanted edits, but also there was no good way to see what those edits were and how they affected the cell—what we wanted to see was invisible using current technologies.”</span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>According to the developers, Superb-seq is able to show where unwanted edits are located as well as how those edits disrupt key genes that protect against unhealthy cellular states. Specifically, Superb-seq integrates Cas9 editing, T7 transcription, and single-cell RNA sequencing to capture single-cell edits and their impact on gene expression. The team has tested it on 34,000 cells from three different cell lines. “There are some people that have worked on this off-target issue before that have an awareness of how bad it is, but for many people that pick up CRISPR to use in the lab, the extent of this problem will really come as a surprise,” McVicker said. “I knew off-targets were an issue, but they were far more frequent than I was expecting.”</span></p>
<p><span>Using seven guide RNAs to target genes in one group of 10,000 human leukemia cells grown in the lab, Superb-seq detected 43 edit sites, including 36 of which were off-target, and 5,761 edited cells. Additionally, Superb-seq detected gene expression changes caused by genome edits that are invisible to existing edit detection methods. It also improved interpretation of the effect of edits compared to Perturb-seq, which reads out gene expression and guide RNAs but not the resulting edits.</span></p>
<p><span>The Salk scientists anticipate that Superb-seq could support applications in basic research, drug development, and personalized medicine. For existing studies that have used CRISPR to study different aspects of biology, “Superb-seq could reveal the extent to which off-target edits color all those findings,” said Michael Lorenzini, PhD, one of the first authors on the paper and a staff scientist in McVicker’s lab. Beyond basic discovery, “our tool could be immensely helpful in establishing the safety of genome therapy candidates early on in development. Superb-seq could be used to profile candidates and learn what their off-target edits are, as well as their effects,” he added. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The team also envisions Superb-seq as a valuable tool for generating training data to improve the accuracy of machine learning models of cellular function. McVicker, Lorenzini, and another co-author, Brad Balderson, PhD, have filed a patent for Superb-seq. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/">Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</title>
<link>https://edusehat.com/en/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations</link>
<guid>https://edusehat.com/en/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations</guid>
<description><![CDATA[ While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years.
The post StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 16 Nov 2026 06:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Amid, Nvidia, Turmoil, What, Happens, Its, Life, Sciences, Collaborations</media:keywords>
<content:encoded><![CDATA[<p>Shakespeare and Greek mythology have met their match with the dramatic personal downfall story that culminated in Jensen Huang’s sudden resignation as CEO of <strong>Nvidia (Nasdaq: NVDA)</strong> amid turmoil caused by up to three reported extramarital affairs. While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants <a href="https://www.genengnews.com/gen-edge/from-model-to-molecule-nvidia-doubles-down-on-ai-drug-discovery/">stretching back at least five years</a>.</p>
<p>Nvidia’s board named Colette Kress as interim CEO. Kress has served as executive vice president and CFO since joining the company in 2013.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“The Board has full confidence in Colette and the leadership team, and we expect the company’s operations, customer commitments, and product roadmap to continue without interruption,” Harvey C. Jones, an Nvidia board member since 1993 who was named chair on Thursday, said in a statement. Jones is an entrepreneur, technology executive, and active venture investor who had served as CEO and executive chairman of silicon design provider Synopsys.</p>
<p>The first reported affair raised national security issues after Huang disclosed in a <a href="https://nvidianews.nvidia.com/news/a-message-to-our-company">letter to Nvidia employees made public November 8</a> that he had conducted an extramarital relationship with Alice Huang (no relation), founder of Megaspeed International, an Nvidia customer and Singapore-based provider of cloud computing and AI infrastructure services. The disclosure touched off an investigation by Nvidia’s board into Jensen Huang’s relationship with Alice Huang, who according to U.S. intelligence officials may have passed along sensitive information to China’s Ministry of State Security; Beijing has denied she carried out any intelligence activity for China.</p>
<p>Three days later on Wednesday, <em>The New York Times</em> cited five unnamed sources in reporting that Huang had an extramarital relationship with an Nvidia executive identified by the newspaper as Kimberly Powell, who as vice president of healthcare and life sciences served as Nvidia’s top executive overseeing its hardware and software platforms for accelerated computing, AI, and visualization in applications ranging from drug discovery to medical imaging and healthcare analytics. The following day, Reuters cited two unnamed sources in reporting an affair between Jensen Huang and a second Nvidia employee whom it did not name.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“OK, this is very, very, very sad, and may and will have dramatic consequences for the entire industry,” Alex Zhavoronkov, PhD, the founder, CEO, and CBO of <strong>Insilico Medicine</strong> <strong>(Hong Kong Exchange: 3696)</strong>,” <a href="https://x.com/biogerontology/status/2120817926005571686">posted Thursday on X</a>. “Now, half of the massively overvalued AI drug discovery startups with no productivity metrics, no drugs, and no long-term moat will not be able to fundraise from Nvidia for a while.”</p>
<h4><strong>Bedroom bubble burst</strong></h4>
<p>“Who knew that the AI bubble would burst in the employee bedroom…,” added Zhavoronkov, who also leads Insilico’s board as chairman and executive director. He added in a <a href="https://x.com/biogerontology/status/2120875228981010472">separate post</a>: “Let’s hope it all settles without too much drama and Jensen keeps working hard (and probably even harder).”</p>
<p>On Friday, Zhavoronkov recalled how during his company’s struggling early years, Jensen Huang <a href="https://x.com/biogerontology/status/2121323131801333922">recorded a video</a> marking the launch of Insilico’s Pharma.AI drug discovery platform: “When Jensen recorded this video in 2022 2 weeks before the launch of consumer ChatGPT, I honestly could not hold my tears. When I watched it today, I could not hold my tears either.”</p>
<p>“Some of my followers on LinkedIn are even celebrating. There is nothing to celebrate. This is a real tragedy and it will have industry-scale consequences. I truly hope that Jensen comes back in some capacity,” Zhavoronkov added. “To all my friends at NVIDIA—please stay strong and let’s work together to solve aging. Support Jensen and his wonderful family. We respect you and love you even though we [are] not a buyer of chips.”</p>
<p>The reported affairs and resignation of Huang sent Nvidia shares sinking this past week. The declines compounded a month-long Nvidia stock slide stemming from investor worries about whether the spending of tech giants on AI infrastructure will result in <span data-subtree="aimfl,mfl">sustainable cash flow, profits, and revenue quickly enough to justify the expense. </span>Those fears have caused Nvidia stock to <span><strong>nosedive</strong><strong> 32% </strong></span>since hitting a record closing price of $239.24 on October 6.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Nvidia shares began the week <span><strong>slipping 4%</strong></span> on November 9, from $186.64 to $178.67.  Shares <span><strong>slid another 5.5%</strong></span> Tuesday to $168.89, <span><strong>rebounded nearly 3%</strong></span> Wednesday to $173.73, then <span><strong>fell again 4%</strong> </span>Thursday to $166.19 after starting that day <span><strong>tumbling 14%</strong></span> following Huang’s resignation. Shares finished this past week <span><strong>dipping 2% </strong></span>Friday, closing at $162.85—a <strong><span>five-day decline of 12.75%</span></strong><strong><span>.</span></strong></p>
<p>“The stakes behind Huang’s resignation reveal the murky waters that businesses using AI are swimming in,” Asa Hiken, senior analyst with Emarketer, wrote in a commentary posted on the website of the market research and digital intelligence company. “On the surface, AI is a tool for powering productivity, creative production, or novel customer experiences, but in the depths it’s a swelling geopolitical powder keg. Disentangling these two sides of the technology is impossible.”</p>
<p>Stacy Rasgon, managing director and senior analyst, U.S. semiconductors and semiconductor capital equipment at Bernstein Research, cautioned that Nvidia’s challenges have not ended with the resignation of Jensen Huang.</p>
<h4><strong>“Considerable uncertainty”</strong></h4>
<p>“We see considerable uncertainty around further news flow that is probably going to be coming down the pipe, as well as the ability of any new CEO to truly fill Jensen’s shoes given how tightly he managed the direction of the business and its relationships with customers, suppliers, employees, and the broader industry ecosystem,” Rasgon wrote in a research note, as reported by <em>Bloomberg News</em>.</p>
<p><span data-subtree="aimfl,mfl">Nvidia and its venture arm NVentures </span>participated in 122 startup funding deals in 2026 as of Friday, according to Crunchbase, while PitchBook counted 67 such deals in 2025 and 54 in 2024. Given Nvidia’s investment in AI startups, Rasgon wrote: “We wonder what will happen to the company’s myriad of investments in the space, various backstops and residual guarantees.” Rasgon downgraded Bernstein’s rating on Nvidia stock to “Market Perform” and lowered the firm’s price target to $200.</p>
<p>“Our gut tells us that we probably haven’t yet fully probed the depths of what might be found here,” Rasgon commented, adding: “We’ve had enough, and prefer to watch from the sidelines.”</p>
<p>A recent example of Nvidia’s life sciences footprint came earlier this month when <strong>10x Genomics (Nasdaq: TXG),</strong> a developer of scalable single-cell and spatial biology platforms, launched Sentira Single Cell, a cloud-based agentic analysis application for users of the company’s Chromium single-cell platform, powered by the Claude models of <strong>Anthropic (Nasdaq: ANT; IPO pending)</strong>. The launch came weeks after 10x unveiled Sentira Spatial Analysis for users of 10x’s Atera <em class="zhvwWe" data-sfc-cp="" data-sfc-root="c" data-complete="true">in situ</em> spatial biology and transcriptomics platform.</p>
<p>Both applications apply Nvidia’s accelerated computing capabilities with the aim of speeding up widely used biological analysis methods; Sentira Spatial Analysis, for example, can reduce the analysis iteration cycle from hours on CPU alternatives to minutes. Underpinning that speed is rapids-singlecell, an open-source, GPU-accelerated Python library designed for large-scale single-cell omics analysis such as single-cell RNA sequencing. Rapids-singlecell was co-developed by Nvidia with scverse, an open-source, community-governed ecosystem of packages for single-cell and spatial omics.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p><strong>“Incredibly powerful company”</strong></p>
<p>“Nvidia is an incredibly powerful company, and it’s not just one person who made it so,” Serge Saxonov, PhD, 10x’s co-founder and CEO, told <em>GEN</em> when asked whether recent Nvidia news including Huang’s resignation would cause 10x to review the partnership. “We’ve had an incredible relationship with the people over there. They’ve done incredible work in this collaboration.”</p>
<p>Over the past five years, Nvidia has initiated a variety of partnerships with tools developers, drug developers, and others within the life sciences. During the J.P. Morgan Healthcare Conference in January, Nvidia <a href="https://www.genengnews.com/topics/artificial-intelligence/jpm-nvidia-launches-ai-collaborations-with-eli-lilly-thermo-fisher/">launched a pair of collaborations with life-sci giants</a>: The company joined <strong>Eli Lilly (NYSE: LLY)</strong> in committing $1 billion over five years to create a “Co-Innovation AI Lab” designed to address key challenges in AI drug discovery. Nvidia also announced plans to integrate its AI technology into the lab instruments of <strong>Thermo Fisher Scientific (NYSE: TMO)</strong> through a collaboration intended to develop intelligent and increasingly autonomous laboratories.</p>
<p>Through a spokesperson, Thermo Fisher confirmed receipt of <em>GEN’s</em> query but offered no comment.</p>
<p>Also on the tools side, <strong>Danaher (NYSE: DHR)</strong> <a href="https://www.genengnews.com/topics/artificial-intelligence/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science/">agreed to partner with Nvidia last month</a>. Danaher agreed to combine its scientific instrumentation, automation technologies, laboratory workflow software, and domain expertise with Nvidia’s accelerated computing and AI technologies.</p>
<p>Nvidia in recent years has also partnered with the Novo Nordisk Foundation, the nonprofit majority owner of Lilly’s arch-rival in obesity and diabetes drug development <strong>Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO). </strong> The foundation agreed in June 2025 to house an Nvidia supercomputer at the Danish Centre for AI Innovation, which last month announced it had invested in 32 NVIDIA DGX Rubin NVL8 systems, giving Denmark access to the latest generation of AI infrastructure.</p>
<p>Earlier, Nvidia partnered with British-based pharma giants <strong>AstraZeneca (London, Nasdaq Stockholm, and NYSE: AZN)</strong> and <strong>GlaxoSmithKline (London: GSK)</strong> to <a href="https://www.genengnews.com/topics/nvidia-powers-up-in-drug-discovery/" target="_blank" rel="noopener">build the U.K.’s most powerful supercomputer, Cambridge-1</a>, in 2020 through a partnership that also included the kingdom’s National Health Service (NHS).</p>
<p>Spokespeople for Lilly, AstraZeneca, and GSK at deadline had not responded to <em>GEN</em> queries about whether they would review their partnerships with Nvidia. Novo Nordisk referred <em>GEN</em> to the Danish Centre for AI Innovation, which at deadline had not responded either.</p>
<p>“Nvidia’s strength has always come from its people, and together with our leadership team, I am committed to building on the extraordinary foundation Jensen created over the last 33 years,” Kress said in a <a href="https://nvidianews.nvidia.com/news/nvidia-announces-ceo-transition">statement</a>. “We will continue advancing the work that has made Nvidia a leader in accelerated computing and AI, and execute on the opportunities ahead. Our focus remains on serving our customers, partners, developers and shareholders.”</p>
<h2><strong>PepGen nearly doubles on record-setting data</strong></h2>
<p><strong>PepGen (Nasdaq: PEPG)</strong> <span>nearly doubled </span>its stock price this past week after announcing dazzling mid-stage clinical results for its lead pipeline candidate PGN-EDODM1 that included the highest level of splicing correction ever reported in a multiple dose trial in patients with myotonic dystrophy type 1 (DM1).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>PepGen shares <span><strong>rocketed 82%</strong></span> from $2.39 on Tuesday, when it announced its record-setting data, to $4.36 at Friday’s closing bell. The stock surge began when PGN-EDODM1, an enhanced delivery oligonucleotide (EDO) designed to address the underlying molecular mechanism of DM1, aced the Phase II FREEDOM2-DM1 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fstudy%252FNCT06667453%26esheet%3D54638669%26newsitemid%3D20261110113813%26lan%3Den-US%26anchor%3DNCT06667453%26index%3D2%26md5%3D5a92794d5b85f74e98acc93436221eb2&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903378491%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=R4jhElEbO8HDvsmXhtBQ34iSQ8Wb3z%2BqB4o5dxECqvI%3D&reserved=0">NCT06667453</a>). PGN-EDODM1 attained a record-breaking 46.5% mean splicing correction in muscle, with four of six participants showing more than 50% splicing correction and all but one of the six, more than 20% splicing correction as measured by the 22-gene panel at Week 13.</p>
<p>In contrast, a pooled group of four participants receiving placebo (combined from Cohorts 1 and 2) showed a mean splicing correction of just 6.8% was 6.8% at Week 13.</p>
<p>Participants also showed sustained improvements in the video Hand Opening Time (vHOT), hand grip strength, 10-Meter Walk/Run Test (10MWRT), and Timed Up and Go (TUG) functional assessments—data that PepGen said offered compelling evidence of PGN-EDODM1’s potential to address multiple clinical manifestations of DM1 and supporting continued development.</p>
<p>“Our ambition is to fundamentally change how DM1 is treated through greater targeting of the underlying molecular mechanism of the disease,” James McArthur, PhD, PepGen’s president and CEO, said in a statement. “The 10 mg/kg results mark an important milestone in that pursuit, with robust splicing correction accompanied by encouraging improvements across multiple measures of muscle function.”</p>
<p>McArthur said the data strengthened PepGen’s confidence not only in PGN-EDODM1’s potential, but in the company’s broader development strategy.</p>
<p>“With our 12.5 mg/kg cohort fully enrolled and the ongoing FREEDOM-OLE study exceeding 135 doses administered, we believe we are well positioned to continue building the evidence needed to advance toward pivotal studies,” the CEO added.</p>
<p>PepGen quickly sought to cash in on its clinical triumph by launching a $125 million public offering of its common stock—though some investors could instead opt for pre-funded warrants to purchase shares of the stock. Net proceeds from the offering are intended, PepGen said, to fund ongoing clinical development of PGN-EDODM1, as well as provide working capital and address other general corporate purposes.</p>
<p>PepGen also granted the underwriters of its offering a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the proposed offering.</p>
<p><strong>“New bar in DM1”</strong></p>
<p>PepGen’s clinical success quickly won over analysts and investors.</p>
<p>“PEPG’s best-in-disease splicing and vHOT with favorable (renal) safety at 10[mg/kg] sets the new bar in DM1,” declared Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer.</p>
<p>Similarly, Debjit Chattopadhyay, PhD, a senior managing director and equity research analyst covering the biotechnology sector at Guggenheim Securities—one of the joint bookrunning managers for the $125 million public offering—hailed PepGen’s results as “potentially the new benchmark for splicing,” according to several published reports. Chattopadhyay contrasted PepGen’s 49% mean correction with the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dyne-tx.com%2Fwp-content%2Fuploads%2FLilleker_2025_MDA_ACHIEVE_Poster.pdf&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903390053%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NxeNPbdQGBLGYN4KvuC6p1jaL7W7C60BWHbr7UtmPd8%3D&reserved=0">25% mean correction at three months</a> reported last year by Dyne Therapeutics (Nasdaq:DYN) from its Phase I/II ACHIEVE trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05481879&data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903400969%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FLMs4PEuSozS%2FHMrQAKPpGb27YGnFuwqTWRvDGgkjzM%3D&reserved=0">NCT05481879</a>) evaluating a 6.8 mg/kg every eight weeks dose of DM1 candidate DYNE-101.</p>
<p>Tazeen Ahmad, a senior research analyst covering large-cap and small-cap biotechnology companies with BofA Securities, upgraded PepGen shares from “Underperform” to “Neutral,” and raised her firm’s 12-month price target on the company’s shares 140%, from $2.50 to $6.</p>
<p>Investors responded with a buying surge that sent PepGen stock nearly doubling on November 10, <span><strong>rocketing nearly 93%</strong></span> from $2.39 to $4.61. Shares <span><strong>soared another 14%</strong></span> Wednesday, reaching $5.26 before <span><strong>dropping 4%</strong></span> to $5.04 Thursday and <span><strong>skidding another 13.5%</strong></span> Friday.</p>
<h2>Leaders and laggards</h2>
<ul>
<li><strong>Capricor Therapeutics (Nasdaq: CAPR)</strong> shares <span><strong>jumped 26.5%</strong></span> from $8.87 to $11.22 Wednesday after JonesTrading upgraded its rating of the company’s stock from “Hold” to “Buy” with a $25 price target. JonesTrading cited the upcoming Prescription Drug User Fee Act (PDUFA) target action date of November 22 on the company’s re-submitted Biologics License Application (BLA) for its lead cell therapy candidate deramiocel in Duchenne muscular dystrophy (DMD). In August, Capricor proposed narrowing its indication to treating upper limb impairment in DMD patients >9 years old, the population studied in its HOPE-3 trial (<a href="https://clinicaltrials.gov/study/NCT05126758">NCT05126758</a>) and the focus of its primary endpoint. The company also submitted two-year open-label extension data and additional robustness analyses from HOPE-3, and an integrated summary of efficacy across HOPE-3 and the earlier Phase II HOPE-2 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03406780&data=05%7C02%7Calex.philippidis%40sagepub.com%7C4571c158c0f349617bec08deee5ea16e%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639210287674957401%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jfCAmFpi0Jb9AWfISbsBGxnx0L0%2F7atGyRuFk8m9bMw%3D&reserved=0">NCT03406780</a>). The FDA classified the August submission as a major amendment, extending the review by three months from the original August 22 date.</li>
<li><strong>Oragenics (NYSE American: OGEN)</strong> shares <span><strong>plummeted nearly 43%</strong></span> from 35 cents to 20 cents Friday, after the developer of intranasal brain-targeted therapeutics announced third quarter results showing a net quarterly loss of $2.603 million, and a nine-month net loss of $7.333 million. The stock plunge occurred despite positive news: The NYSE Regulation rules enforcement arm had accepted its plan to regain compliance with NYSE American listing standards and granted an extension through February 25, 2028 to do so. “We believe this approval allows us to maintain our NYSE American listing while we continue to pursue our strategic priorities, capital raising initiatives, and investment strategies designed to enhance long-term value for our shareholders,” CEO Janet Huffman stated. Oragenics lost compliance due to a low stockholders’ equity of $3.7 million as of June 30, plus losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/">StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</title>
<link>https://edusehat.com/en/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression</link>
<guid>https://edusehat.com/en/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression</guid>
<description><![CDATA[ Researchers created a detailed map of the tumor microenvironment surrounding estrogen receptor-positive ductal carcinoma in situ, which may help better predict progression to invasive breast cancer and inform on future therapeutic strategies. 
The post DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_NavinDCIS.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 07:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DCIS, Cell, Atlas, Reveals, Clues, Invasive, Breast, Cancer, Progression</media:keywords>
<content:encoded><![CDATA[<p>Researchers at The University of Texas MD Anderson Cancer Center have created what they say is one of the most detailed maps to date of the tumor microenvironment (TME) surrounding estrogen receptor-positive (ER+) ductal carcinoma <em>in situ</em> (DCIS), the most common form of preinvasive—stage 0—breast cancer. The atlas was created by analyzing samples from normal breast tissue, DCIS and invasive breast cancers.</p>
<p>The study findings may help to explain why some lesions progress to invasive breast cancer and others do not and inform strategies for improving patient risk prediction and developing better targeted approaches for those at higher risk of invasive disease.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“DCIS is considered a snapshot before breast cancer becomes invasive, but not all DCIS cases progress to invasive disease, and the biology surrounding these lesions has been challenging to examine,” said research co-lead Nicholas Navin, PhD, chair of Systems Biology. “This atlas reveals the surrounding cells and structures that may help disease become invasive. In the future, these findings may allow clinicians to better identify and treat patients with DCIS who are at higher risk of invasive progression while also avoiding unnecessary treatments for those at low risk.”</p>
<p>Navin, together with research co-lead Savitri Krishnamurthy, MD, professor of Anatomical Pathology, as well as co-first authors Siyuan He, PhD, and Aatish Thennavan, PhD, postdoctoral fellows of Systems Biology, and colleagues, reported on their findings in <em>Science,</em> in a paper titled “<a href="http://dx.doi.org/10.1126/science.aef4622" target="_blank" rel="noopener">A cellular atlas of the preinvasive breast cancer microenvironment</a>.” In their report the team stated that their data “… greatly improve our fundamental understanding of the DCIS microenvironment and the progression of invasive disease.”</p>
<p>DCIS occurs when abnormal cells grow inside the breast milk ducts but have not yet spread into surrounding tissue, and is considered to be a precursor to the most common type of breast cancer. “Ductal carcinoma <em>in situ</em> (DCIS) is precursor of invasive ductal carcinoma (IDC), in which the preinvasive cells are confined within the basement membrane of breast ductal-lobular structures,” the authors wrote.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Mammograms and other breast examinations have increased the detection of DCIS cases, but many of these lesions never progress to invasive disease, making it challenging to determine which patients actually need more aggressive treatment. “Over the last three decades, routine breast mammography screening has led to overdiagnosis of DCIS that now represents up to 25% of all diagnosed breast cancer cases,” the team continued. “If left untreated, only 10-30% of women with DCIS will progress to invasive disease.”</p>
<p>While genetic changes in DCIS have been well-studied, little is known about its tumor microenvironment—the community of immune cells, blood vessels and tissue cells that surround and interact with the cancer cells. The researchers set out to generate a comprehensive cell atlas for DCIS. Using advanced single-cell and spatial profiling technologies, they mapped more than 850,000 cells from samples of normal breast tissue, DCIS and invasive breast cancer. They identified extensive changes in cancer cells and the surrounding microenvironment as disease progressed. “We analyzed 854,911 cells from 159 patients by single cell RNA sequencing and 39 samples by spatial transcriptomics, which identified nine cell types and 60 cell states,” they reported.</p>
<p>The resulting detailed atlas suggests that important biological features associated with invasive breast cancer begin to emerge earlier than previously known. The study also uncovered previously unknown “cancer stromal loops,” ring-like structures made of supportive tissue and vascular cells that surround DCIS lesions, which create conditions that support tumor growth. “Our data reports on remodeling of specific immune, stromal cell types and myoepithelial cells in the DCIS TME, along with changes in cancer cell metaprograms that form cellular ecosystems and spatial niches to support the growth and progression of DCIS,” they wrote in summary.</p>
<p>Additional research is needed to validate these findings and evaluate their potential use in future diagnostic tools and prevention or treatment strategies. The findings could one day help doctors predict which patients need aggressive treatment and which patients may safely avoid it.  The team said researchers will continue studying the cellular features identified in the atlas to determine whether they can predict which DCIS lesions are most likely to become invasive, to help better determine the best strategies for individual patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression/">DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Vancomycin&#45;Resistant Enterococcus Evolved in a Danish Hospital</title>
<link>https://edusehat.com/en/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital</link>
<guid>https://edusehat.com/en/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital</guid>
<description><![CDATA[ A genomic study reveals how genetic mutations, recombination, and resistance-carrying plasmids shaped the evolution, diversification, and decline of vancomycin-resistant Enterococcus faecium in Danish hospitals between 2012 and 2020.
The post How Vancomycin-Resistant Enterococcus Evolved in a Danish Hospital appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_vre-labeled.png.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 14 Nov 2026 04:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Vancomycin-Resistant, Enterococcus, Evolved, Danish, Hospital</media:keywords>
<content:encoded><![CDATA[<p>Vancomycin-resistant <em>Enterococcus faecium</em> is listed by the World Health Organization—in its 2024 Bacterial Priority Pathogens List—as one of the highest-priority bacteria.</p>
<p>In a new study published in <em>Genome Medicine</em>, researchers from Instituto de Tecnologia Química e Biológica António Xavier from NOVA University of Lisbon (ITQB NOVA), in Portugal, investigated the genetic mechanisms behind the rise and fall of the dominant vancomycin-resistant <em>Enterococcus faecium</em> clone (VREfm ST80) from 2012 to 2020 in Danish hospitals. The team assembled and performed whole-genome sequencing and phylogenomic analysis of 334 ST80 isolates collected from colonization (83%) and infection (17%) cases across nine hospitals in the region between 2012 and 2020.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The results identified two major clusters (Clusters 1 and 2) and nine sub-clusters (1.A–G and 2.H–I). Sub-cluster-1.A (169/334) was the dominant lineage, accounting for 72% of isolates from 2012–2015. The isolates from 2016–2020 “were distributed across all sub-clusters, indicating increasing diversification over time.”</p>
<p>Genetic variation, the authors write, was “driven by accumulation of mutations, recombination and gain/loss of accessory genes and plasmids.” Eight recombination hotspots were identified in core genes involved in cell wall synthesis, phosphotransferase systems, amino-acid biosynthesis, and several transporters.</p>
<p>This work is published in <em>Genome Medicine</em> in the paper, “<a href="https://link.springer.com/article/10.1186/s13073-026-01747-2" target="_blank" rel="noopener">Recombination and accessory genome turnover shaped the rise and decline of <em>vanA Enterococcus faecium</em> ST80 in Denmark.</a>”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The team also found that this bacterial clone carried a mosaic phage-like plasmid element that made it resistant to several antibiotics at once. The element harbored the <em>vanA</em> operon with <em>ermB, aadE</em>, and <em>aph(3’)-IIIa</em> suggesting “a unique mechanism for co-mobilization of antimicrobial resistance via transduction or conjugation.”</p>
<p>“Using any one of those antibiotics can select for bacteria carrying the whole package, including vancomycin resistance,” explains Maria Miragaia, PhD, leader of the Bacterial Evolution and Molecular Epidemiology lab at ITQB NOVA. “This means that simply reducing vancomycin use may not be enough to reduce vancomycin-resistant bacteria if other linked antibiotics are still being used,” she adds.</p>
<p>The study suggests that targeting the strategies that helped the clone persist—forming biofilms, altering its outer surface, and using alternative sugars in the gut—could help to clear these resistant bacteria from the gut and reduce their spread in hospitals.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/">How Vancomycin-Resistant <i>Enterococcus</i> Evolved in a Danish Hospital</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</title>
<link>https://edusehat.com/en/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave</link>
<guid>https://edusehat.com/en/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave</guid>
<description><![CDATA[ In this GEN webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves.
The post Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_2300126174_MonoclonalAntibody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 23:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Downstream, Processing:, Purifying, Complex, Antibody, Therapeutics, When, Target, Molecules, Misbehave</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
         Panelists    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png" class="h-full w-full object-cover" alt="Image of David Scherr, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">David Scherr, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Sr. Scientist<br>Bioprocess Technologies & Engineering<br>Biopharmaceutical Development<br>AstraZeneca</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png" alt="Image of David Scherr, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">David Scherr, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>David Scherr, PhD, is a senior scientist at AstraZeneca focusing on downstream process development for the Integrated Dynamic Bioprocessing (IDB) platform. He joined AstraZeneca in 2023 and has been a part of CMC teams for GMP implementation of continuous antibody purification. David has also led efforts to implement high-throughput process development and AI-first ways of working. David earned his BS in biochemistry and chemistry from the University of Miami followed by a PhD in biological systems engineering at Virginia Tech.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg" class="h-full w-full object-cover" alt="Image of Anupama Kante, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Anupama Kante, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Scientist<br>Avid Bioservices</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg" alt="Image of Anupama Kante, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Anupama Kante, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Anupama Kante, PhD, is a scientist in downstream process development at Avid Bioservices specializing in biologics purification, formulation development, and analytical characterization. She has extensive experience advancing monoclonal antibodies and complex biologics from early development through process optimization. Anupama is passionate about building scientific capabilities, driving innovation, and translating technical insights into practical solutions.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg" class="h-full w-full object-cover" alt="Image of Sam Ruesing, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Sam Ruesing, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Sr. Staff Scientist<br>Thermo Fisher Scientific</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg" alt="Image of Sam Ruesing, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Sam Ruesing, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Sam Ruesing, PhD, is a senior staff scientist in downstream process development at Thermo Fisher Scientific. He holds a bachelor’s degree in chemical engineering from the Missouri University of Science and Technology and PhD in biomedical engineering from Saint Louis University. Sam’s experience spans all aspects of downstream development, including early-phase development for first-in-human production, adapting processes to new facilities, and late-phase optimization and characterization in preparation for commercialization.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, December 8, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-08T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">As antibody-based therapeutics move beyond IgG monoclonal antibodies, downstream process development teams have to purify molecules that do not always fit established platform assumptions. Bispecifics, multispecifics, antibody fragments, Fc-fusion proteins, ADCs, and other engineered formats can introduce new challenges in assembly, stability, impurity profiles, and scalability. Separation of the target molecule from mispaired chains, homodimers, aggregates, fragments, free light chains, persistent host cell proteins, and format-specific product variants can fall outside the limits of standard Protein A, AEX, and CEX purification workflows. For many PD teams, the platform process remains the proper starting point, but the molecule does not always behave like the platform expects.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves. The discussion will explore how teams decide whether to stay with a platform, adapt it, or move to a more molecule-specific toolbox, how alternative affinity approaches can help when Protein A lacks selectivity or is not applicable, and how polishing strategies with IEX, HIC, and mixed-mode chromatography can be used to address difficult product- and process-related impurities. The panel will also discuss how to balance speed, yield, purity, cost of goods, analytical burden, scalability, and regulatory expectations from early development through tech transfer and manufacturing of standard mAbs and beyond.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.thermofisher.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="138" src="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png" alt="Thermo Fisher logo" class="wp-image-221790" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo.png 558w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/">Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>More autonomy, fewer NDAs: Volunteers have new requests for brain implant trials</title>
<link>https://edusehat.com/en/more-autonomy-fewer-ndas-volunteers-have-new-requests-for-brain-implant-trials</link>
<guid>https://edusehat.com/en/more-autonomy-fewer-ndas-volunteers-have-new-requests-for-brain-implant-trials</guid>
<description><![CDATA[ Scientists have been working on ways to decode brain activity for decades. Teams have developed brain implants that can be used to control robotic limbs and computers, and even to “speak.” The people who volunteer for trials of those devices play a vital role in that research, and they ought to be recognized for their… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/Ian_0010.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 19:55:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>More, autonomy, fewer, NDAs:, Volunteers, have, new, requests, for, brain, implant, trials</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Brain implant volunteers want more respect:</strong> Ian Burkhart, who had a brain implant for seven-and-a-half years, helped develop new guidelines pushing for trial participants to have the option to be recognized as genuine research collaborators and listed as coauthors on scientific papers.</li><br><li><strong>Your brain data should be yours:</strong> The guidelines argue that participants' neural data is personal information, and that NDAs or embargoes should not block someone from sharing their own brain data with their doctor.</li><br><li><strong>Losing an implant can feel like losing a limb:</strong> When funding dried up or companies collapsed, participants like Burkhart lost devices—and abilities—with little warning. The guidelines call for researchers to fund and plan removals carefully, giving participants real time to prepare</li></ul>" data-chronoton-post-id="1148474" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Scientists have been working on ways to decode brain activity for decades. Teams have developed brain implants that can be used to control robotic limbs and computers, and even to “speak.”</p>





<p class="wp-block-paragraph">The people who volunteer for trials of those devices play a vital role in that research, and they ought to be recognized for their contributions, says <a href="https://www.technologyreview.com/innovator/ian-burkhart/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">Ian Burkhart</a>, who had one implanted in his own brain back in 2014. He’s been working on a set of guidelines for researchers developing brain-computer interfaces (BCIs).</p>



<p class="wp-block-paragraph">Ethics guidelines for clinical trials already exist. But BCI trials are different, says Jennifer Chandler, a professor of law and neuroethics at the University of Ottawa who also worked on the guidelines. “These are people who have a device embedded in their brain, are in trials sometimes for years and years … [and contribute] a significant investment of time, of the body, and of intellectual effort.”</p>



<p class="wp-block-paragraph">Burkhart was left paralyzed from the chest down following a diving accident in 2010, when he was 19 years old. Around four years later, he volunteered to become the first person to trial a brain implant designed for hand control.</p>



<p class="wp-block-paragraph">He had an array of 96 electrodes inserted into the part of his brain that controls movement. The electrodes were connected to a computer via a cable that essentially plugged into his head. Algorithms on the computer were designed to interpret those signals and deliver them to another sleeve of electrodes worn on Burkhart’s arm, <a href="https://www.nature.com/articles/nature17435">allowing him to control it</a>.</p>



<p class="wp-block-paragraph">The first movements were small, but Burkhart was ultimately able to use the system to pour beads from bottles, move small and delicate objects, and even play Guitar Hero, if only during lab visits. It was <a href="https://www.technologyreview.com/2016/04/13/161014/video-shows-paralyzed-man-move-hand-with-brain-implant/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">a scientific breakthrough</a>.</p>



<p class="wp-block-paragraph">Burkhart took part in two years-long clinical trials over the seven-and-a-half-year period he had the electrode array implanted in his brain. “It was a fantastic experience,” he says. “But there’s certainly some things that, knowing what I know now, I would want to do a little differently.”</p>





<p class="wp-block-paragraph">In 2022, Burkhart cofounded <a href="https://bcipioneers.org/">BCI Pioneers Coalition</a>—an organization through which people who have taken part in BCI trials can share their experiences, both with each other and with researchers. Over the last year, members of the group have been developing a set of guidelines based on those experiences. The idea is to help academics, clinicians, and companies run ethical trials that respect participants’ autonomy.</p>



<p class="wp-block-paragraph">The guidelines, <a href="https://bcipioneers.org/our-bci-recommendations/">published on Tuesday</a>, lay out a list of recommendations that fall within 13 categories. One, for example, focuses on recognizing and compensating trial participants. During the trials that Burkhart participated in, “I was going into the lab two or three days a week, for four hours at a time,” he recalls. “That’s [easily] a part-time job if you just count the hours you’re putting in.”</p>



<p class="wp-block-paragraph">As the trial progressed, Burkhart says, he learned more and was able to give more constructive feedback on what was working and what wasn’t. He says he was a key member of the research team. Others who find themselves in a similar position might appreciate being listed as a coauthor on scientific publications or publicly named as a research collaborator, he says. Burkhart and his colleagues acknowledge that not everyone will want this, however.  </p>



<p class="wp-block-paragraph">The guidelines also address the thorny question of privacy. That’s important: The public will always be interested in cutting-edge biotechnologies like these—and the guidelines say researchers also have a duty to prepare participants for the possibility of media attention. In some cases, it might be difficult to completely conceal the identity of trial participants.</p>



<p class="wp-block-paragraph">Things get even more complicated when it comes to the privacy of participants’ <a href="https://www.technologyreview.com/2024/10/04/1104972/law-california-protects-brain-data-doesnt-go-far-enough/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">brain data</a>. Research teams will need to access, analyze, and—at least temporarily—store this data. Burkhart wasn’t too bothered about that in his case, where scientists were collecting neural activity related to movement. But people who have brain implants designed for turning thoughts into words might feel differently. </p>





<p class="wp-block-paragraph">The guidelines state that brain data “should be understood as the participant’s personal information.” They are pushing for participants to be able to access their own brain data whenever they want—something that has not always been possible—and want to make sure people aren’t prevented from sharing it with their own doctors because of embargoes or nondisclosure agreements (NDAs) designed to keep findings under wraps from competitors.</p>



<p class="wp-block-paragraph">“It’s not super common for there to be firm NDAs within a lot of the trials,” says Burkhart. “But it’s something where we want to make sure that that does not happen.”</p>



<p class="wp-block-paragraph">The guidelines also address what comes <em>after</em> a trial. Around five years after Burkhart had his device implanted, the research team ran into some issues with funding. When <a href="https://www.technologyreview.com/2023/05/26/1073655/how-it-feels-to-have-a-life-changing-brain-implant-removed/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">we last spoke a few years ago</a>, he recalled how he was told he would have to have the implant removed and could have it put back in once the team had secured funding. (And we’re talking about <em>brain surgery</em> here.)</p>



<p class="wp-block-paragraph">Ultimately, he kept the implant until 2021, when it was removed after an infection started to develop at the point where the cable led into his scalp. But losing the device after all those years was difficult; he’d regained the ability to move his arm—and then lost it again.</p>



<p class="wp-block-paragraph">Rita Leggett, an Australian woman who had a device implanted in her brain to treat her epilepsy, has said she felt she “became one” with her implant. When the company that made it went bust two years later, <a href="https://www.technologyreview.com/2023/05/25/1073634/brain-implant-removed-against-her-will/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">the device was removed against her will</a>—an act ethicists have described as a potential breach of human rights.</p>



<p class="wp-block-paragraph">Researchers should instead commit to maintaining brain devices for a “reasonable period” after a trial ends, according to the guidelines. Participants should be given plenty of time to prepare for the surgery to remove it. And researchers should set aside extra funds to support trial participants who have to do that.</p>



<p class="wp-block-paragraph">Some of the guidelines are vague and may overlap with existing ethics standards. They don’t all spell out explicit solutions. They were also developed with feedback from a small group of individuals—the number of people living with BCIs is still <a href="https://www.technologyreview.com/2025/04/01/1114009/brain-computer-interfaces-10-breakthrough-technologies-2025/">very low</a>. The team hopes to grow and expand on the guidelines over time. Burkhart also plans to discuss them with researchers at an <a href="https://www.sfn.org/">upcoming neuroscience conference</a>.</p>



<p class="wp-block-paragraph">“This is a living document, and this is version one,” says Chandler. “It’s just the starting point.”</p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Reference Genomes of Malaria&#45;Causing Plasmodium Parasites Completed</title>
<link>https://edusehat.com/en/reference-genomes-of-malaria-causing-plasmodium-parasites-completed</link>
<guid>https://edusehat.com/en/reference-genomes-of-malaria-causing-plasmodium-parasites-completed</guid>
<description><![CDATA[ Using DNA sequenced from patient blood samples, researchers assembled complete reference genomes of neglected malaria parasites, uncovering genetic regions potentially involved in immune evasion and providing new tools for disease surveillance.
The post Reference Genomes of Malaria-Causing Plasmodium Parasites Completed appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/Getty_476872691_PlasmodiumCausingMalaria.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Reference, Genomes, Malaria-Causing, Plasmodium, Parasites, Completed</media:keywords>
<content:encoded><![CDATA[<p>Researchers have generated the most complete chromosome-level reference genomes to date for two understudied malaria parasites, uncovering previously inaccessible genetic regions that could help explain how the pathogens evade immune defenses and persist in human hosts.</p>
<p>The study, titled “<a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014754" target="_blank" rel="noopener">High quality chromosomal genome assemblies of three human <em>Plasmodium </em>species directly from natural infection</a>,” and published in <em>PLOS Pathogens, </em>describes a method for assembling chromosome-level genomes directly from patient blood samples without laboratory culturing. The findings could improve parasite identification, genomic surveillance, and efforts to monitor emerging drug resistance.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Although <em>Plasmodium falciparum </em>is responsible for most malaria-related deaths, other species, including <em>P. ovale </em>and <em>P. malariae</em>, also contribute to the global disease burden. These parasites can cause chronic infections but remain comparatively poorly understood, partly because researchers lack reliable methods for growing them continuously in laboratory cultures.</p>
<p>To address these limitations, scientists at the Wellcome Sanger Institute and the Parasites and Microbes Research and Training Center in Mali collected blood samples from patients with naturally acquired malaria infections in Faladie, Mali.</p>
<p>The team enriched parasite DNA by removing human white blood cells and uninfected red blood cells before applying PacBio Ultra-Low-Input HiFi long-read sequencing. They combined this approach with Hi-C, a technique that captures interactions between DNA regions to reconstruct chromosome organization.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The researchers ultimately assembled parasite genomes from eight participants, producing high-quality references for <em>P. ovale wallikeri, P. malariae, </em>and <em>P. falciparum.</em></p>
<p>Unlike earlier fragmented references, the new assemblies resolved previously inaccessible regions near chromosome ends, known as subtelomeric regions. These areas contain repetitive DNA and expanded gene families associated with interactions between parasites and their human hosts, enhancing “understanding of parasite persistence, transmission, immune evasion, and comparative evolutionary studies.”</p>
<p>Notably, the researchers identified more than 2,000 genes belonging to the <em>PIR </em>gene family in <em>P. ovale wallkeri, </em>accounting for approximately one-quarter of its genome.</p>
<p>Comparisons among parasites collected from the same geographic region also revealed extensive genetic rearrangements near chromosome ends, highlighting mechanisms that may contribute to antigenic variation and immune invasion.</p>
<p>“Uncovering these full genomes revealed the extent of expansions of gene families sitting at the ends of chromosomes, which regularly shuffle genetic material to adapt and evade the human immune system,” said first author Sunil Dogga, PhD, formerly of the Wellcome Sanger Institute and now at the Swiss Tropical and Public Health Institute.</p>
<p>The findings are particularly relevant as malaria elimination efforts increasingly confront infections caused by non-<em>falciparum </em>species, which can be difficult to diagnose and may persist even where <em>P. falciparum </em>transmission declines.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Beyond improving understanding of parasite biology, the genomic resources could support development of more accurate molecular diagnostics, identification of potential therapeutic targets, and studies investigating how parasite populations respond to treatment and control measures.</p>
<p>“Establishing gold-standard reference genomes for these neglected parasites fills a critical knowledge gap in global malaria research,” said senior author Mara Lawniczak, PhD, group leader at the Wellcome Sanger Institute.</p>
<p>The researchers emphasized that incorporating these overlooked species into genomic surveillance will be important for developing more comprehensive malaria elimination strategies. The authors wrote, “This work provides a critical foundation for including these neglected species in global malaria elimination efforts.”</p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/">Reference Genomes of Malaria-Causing <i>Plasmodium</i> Parasites Completed</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Neuroprotective Protein Atlas Positions the Blood&#45;Brain Barrier as a Selective Checkpoint</title>
<link>https://edusehat.com/en/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint</link>
<guid>https://edusehat.com/en/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint</guid>
<description><![CDATA[ The blood-brain barrier keeps most proteins in the bloodstream out of the brain, but not all. The pathways that import them are damaged early in Alzheimer’s disease models, hinting at new ways to treat the disease.
The post Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2203499176.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 05:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Neuroprotective, Protein, Atlas, Positions, the, Blood-Brain, Barrier, Selective, Checkpoint</media:keywords>
<content:encoded><![CDATA[<p><span>Working in mice, scientists from the Gladstone Institutes, University of California, and elsewhere have created what they claim is the first atlas of neuroprotective proteins that are transported across the blood-brain barrier and into the brain. According to the scientists, the atlas contains 92 proteins so far and their analysis points to potential strategies for treating neurodegenerative conditions. Details are provided in a new </span><i><span>Cell </span></i><span>paper titled “</span><a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01326-7" target="_blank" rel="noopener"><span>The blood-brain barrier imports diverse neuroprotective proteins through pathways impaired early in Alzheimer’s disease models</span></a><span>.”</span></p>
<p><span>The study suggests that the blood-brain barrier is much more than a physical boundary intended solely to protect the brain from toxins. As Andrew Yang, PhD, a Gladstone investigator and one of the authors on the study put it, “we’re finding that it’s an intelligent interface that plucks the right proteins in the blood, often from distant parts of the body and delivers them to the right cell types in the brain.” Importantly, as the paper’s title suggests, the proteins included in the atlas make their way into the brain through pathways that are impaired early on in the development of diseases like Alzheimer’s.</span></p>
<p><span>To generate the atlas, Yang and his colleagues developed a method of tracking the specific blood plasma proteins that crossed into the brains of mice. They used protein-labeling chemistry to track proteins from multiple organs such as the liver and kidney without disrupting their biology. Specifically, they developed “a bioorthogonal proteomics strategy, an <em>in vivo</em> click-enrichment screen of labeled plasma proteins entering the brain” and used it to systematically map the blood-brain barrier “transportome,” according to the paper. The approach was benchmarked against a commonly used biotin labeling approach and was shown to consistently produce “stronger signals in plasma and brain vessels” as well as to enable “robust detection of plasma proteins in neurons, astrocytes, and microglia.” </span></p>
<p><span>The scientists used the method to tag various mouse blood proteins before injecting them back into the bloodstream. They examined brain tissue to see which labeled proteins successfully crossed the barrier. Of the 861 proteins that the scientists tracked in this way, they found that 92 crossed into the brain. Most were proteins produced primarily in the liver but also in adipose tissue and the intestine. Once there, the proteins were directed to specific types of brain cells to perform specialized functions. </span></p>
<p><span>An example is the liver protein apolipoprotein AI or (APOA1) that once in the brain activates a pathway needed to maintain healthy astrocyte connections. Studies link its absence to a greater risk of developing Alzheimer’s disease. “We think of blood proteins as messengers carrying signals from distant body parts, and the cells of the blood-brain barrier import only the ones the brain really needs,” said Haoyue Zhou, PhD, a postdoctoral scholar in Yang’s lab and first author of the paper.</span></p>
<p><span>A key part of the study was exploring what happens to protein delivery in Alzheimer’s. As the disease progresses, the blood-brain barrier breaks down allowing harmful proteins to leak into the brain. Using their protein-labeling method, Yang’s team discovered another problem. They found that even before the barrier breaks down, it stops importing protective proteins like APOA1 into the brain. Loss of the protein erodes neuronal connections, which contributes to behavioral changes and other early signs of the disease. </span></p>
<p><span>Conceivably, increasing the supply of APOA1 to the brain could help counter the emergence of Alzheimer’s symptoms. To discover whether this might be possible, the scientists tracked proteins in mouse models engineered to produce extra APOA1 in the liver. And indeed they found that as more APOA1 entered the brain, the mice showed fewer signs of the disease. These findings suggest that “Alzheimer’s disease may not start entirely inside the brain” but “when the brain’s supply line from the body is severed,” Yang noted. “If that’s right, we may be able to fight this disease from outside the brain, by restoring what the brain has lost.”</span></p>
<p><span>Boosting production of beneficial proteins like APOA1 to ensure the brain has a sufficient supply is one possible treatment strategy. Another option is harnessing the brain’s natural “ZIP code” system to deliver therapies directly to specific types of brain cells. A third option that Yang and his colleagues are currently exploring is harnessing the blood-brain barrier’s transport machinery to help drugs reach the brain more efficiently. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint/">Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>High Frequency of Drug&#45;Impacting Gene Variants Found in All of Us Cohort</title>
<link>https://edusehat.com/en/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort</link>
<guid>https://edusehat.com/en/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort</guid>
<description><![CDATA[ A study finds that everyone in a diverse, nearly 100,000-person sample carried at least one genetic variant that affects how their body processes medications, and a quarter of those people had been prescribed a medication that is known to be impacted by the variant they carried.
The post High Frequency of Drug-Impacting Gene Variants Found in All of Us Cohort appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177211585.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 13 Nov 2026 05:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>High, Frequency, Drug-Impacting, Gene, Variants, Found, All, Cohort</media:keywords>
<content:encoded><![CDATA[<p>A study headed by researchers at the University of Pittsburgh has found that everyone in a diverse, nearly 100,000-person sample from the National Institutes of Health’s <em>All of Us</em> Research Program (All of Us) carried at least one genetic variant that affects how their body processes medications. The results also showed that a quarter of those people had been prescribed a drug that is known to be impacted by the variant they carried.</p>
<p>The researchers say the discovery highlights the value of genetic testing for some medications and that electronic health record alerts could be helpful when a clinician prescribes one of these drugs. Such an alert would allow the clinician to consider prescribing an alternate medication or adjusting the dosage, if appropriate.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Many people have experience with taking a medication that is not working well for them or that has a side effect,” said Philip E. Empey, PharmD, PhD, associate professor in Pitt’s School of Pharmacy and associate director for pharmacogenomics at the Institute for Precision Medicine at Pitt and UPMC. “While many things impact how a patient responds to medication, our research tells us that genetics could be [a] factor for a large proportion of patients and it points to the value of precision medicine in prescribing.”</p>
<p>Empey is senior author of the researchers’ published paper in <em>Science Translational Medicine</em>, titled “<a href="http://dx.doi.org/10.1126/scitranslmed.adt8040" target="_blank" rel="noopener">Frequency of pharmacogenomic variation and medication exposures among <em>All of Us</em> Participants</a>.”</p>
<p>Pharmacogenomics (PGx) promises improved outcomes through individualized prescribing, the authors wrote in their paper. “PGx can impact drug effectiveness and toxicity. Many commonly prescribed medications have genotype-guided dosing or drug selection recommendations in their Food and Drug Administration (FDA) approved labeling or in guidelines developed by the Clinical Pharmacogenetics Implementation Consortium (CPIC).”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>More than 300 medications have information on their labels about genetic variant interactions, where genetic testing may be of value to guide prescribing, Empey said. One example is a chemotherapy drug used for colon cancer that could have serious toxicity in up to 8% of patients who carry these genetic variants, so those patients are proactively tested before treatment. However, the authors noted, “Despite the strong evidence supporting the use of PGx data in clinical practice, broader implementation is limited in part by the relative paucity of data on the frequency of variants, alleles, and predicted phenotypes across diverse biogeographical groups.”</p>
<p>For their reported study the research team used data from the National Institutes of Health (NIH) <a href="https://www.nih.gov/allofus" target="_blank" rel="noopener"><em>All of Us</em> Research Program</a>, an initiative that aims to gather data from one million people across the U.S. to help better understand how lifestyle, environment, and genes influence health and disease. Pitt is a key partner in the program, launching All of Us Pennsylvania in 2018. “This study represents one of the largest and the most diverse PGx datasets with linked medication exposures events to date,” the team noted. “<em>All of Us</em> has particular value in identifying and understanding the frequency of both previously unknown and rare variants because of the size of the cohort, comprehensiveness in genotyping approach, and the genetic diversity.”</p>
<p>The team evaluated the frequency of 16 genetic variants known to impact the effectiveness or toxicity of various medications among nearly 100,000 <em>All of Us</em> participants. The results showed that everyone in the study was found to carry at least one such variant with a median of nine variants. “We found 100% of participants carried at least one known PGx variant and nearly all (99.49%) had a predicted phenotype for a gene which has a CPIC or FDA recommendation for a change in prescribing,” they stated. “Among nearly 100k participants in <em>All of Us</em> Research Program, pharmacogenomic variants and actionable results are common and the diversity of the cohort provided for identification of novel variants and population frequencies.”</p>
<p>By then matching the genetic data to the participants’ medical records, the research team also found that more than 24% of participants had been prescribed at least one medication known to interact with a variant they carried. “Clinical impact was high with 24.38% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance,” they wrote. The most common medications identified in the review were ondansetron (anti-nausea), ibuprofen (anti-inflammatory), omeprazole and pantoprazole (both treat acid reflux and heartburn), and atorvastatin (lowers cholesterol).</p>
<p>The team also identified over 17,000 novel variants and reported the frequency of known medication-linked genetic variants across multiple ancestry groups, including in populations where these frequencies were not previously estimated. “Importantly, we report thousands of novel variants as well as hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, especially within Americas and African ancestry groups.” they wrote in summary.</p>
<p>“The limited diversity of racial and ethnic groups in early studies is a challenge in genetic research and skews risk estimates,” Empey said. “That’s part of the beauty of the <em>All of Us</em> Research Program—it was intentionally designed to help close these gaps by including people from a wide range of age groups, backgrounds, and life experiences. It also underscores the value of having a large precision medicine dataset where whole genome testing data can be studied along with clinical data.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Empey said it will be up to policy makers and health insurers to weigh the benefits of widespread genetic screening for variants that interact with medications against the cost, and that this is a very active area of research. He said it makes sense to screen patients with a panel test that can look for common variants that are known to affect many medications and have these results in their medical record, much like a test for kidney function. This approach is also being applied in situations where patients are on many medications at the same time or in patients starting certain medications known to be impacted by genetics, such as clopidogrel, a medication used after cardiac stenting.</p>
<p>People who have already undergone pharmacogenomic testing should be sure to share their results with their pharmacists and prescribers so that it is integrated with their electronic health record, said Empey, who is leading efforts at UPMC to make it easy for clinicians to see if a patient carries variants that may affect a medication that they’re prescribing and recommend changes when needed.</p>
<p>“Just like with any new technology, it comes down to responsible implementation,” Empey said. “Costs are coming down and the data is increasing, so it is important for patients and clinicians to be aware that the use of precision medicine in prescribing is becoming commonplace.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort/">High Frequency of Drug-Impacting Gene Variants Found in <i>All of Us</i> Cohort</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From recommendation to reality: Why newborn screening needs funding now</title>
<link>https://edusehat.com/en/from-recommendation-to-reality-why-newborn-screening-needs-funding-now</link>
<guid>https://edusehat.com/en/from-recommendation-to-reality-why-newborn-screening-needs-funding-now</guid>
<description><![CDATA[ For the Sereno family, time has always been important. And for Lina Sereno, trusting her gut made all of the difference when it came […]
The post From recommendation to reality: Why newborn screening needs funding now appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/sereno-family2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 12 Nov 2026 04:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, recommendation, reality:, Why, newborn, screening, needs, funding, now</media:keywords>
<content:encoded><![CDATA[<p><span>For the Sereno family, time has always been important.</span></p>
<p><span>And for Lina Sereno, trusting her gut made all of the difference when it came to her two sons: Salvatore and Giovanni.</span></p>
<p><span>“</span><span>My older son, Salvatore, was diagnosed with metachromatic leukodystrophy (MLD) in October of 2009,” explains Sereno, “but it took approximately seven months to find out what was happening to him. I took him to six different doctors, and each one suggested that he had ADHD. I agreed to medication for two months. Instead of improving, he became worse.”</span></p>
<p><span>It was during this time that Sereno recalls the night her son Salvatore became dazed and unresponsive. “I notified his doctor, and that finally prompted the MRI that got us the MLD diagnosis,” she says. “All these years later, I believe he may have experienced a seizure.”</span></p>
<p><span>Shortly thereafter, Sereno got her younger son Giovanni tested as well and found that he too had MLD. His early diagnosis gave him access to early treatments that Salvatore never had the opportunity to get. “I know with all my heart that Giovanni is thriving today because of that early diagnosis and treatment,” says Sereno.</span></p>
<p><span>“The journey felt incredibly long and lonely,” Sereno recalls. “No parent should have to fight so hard to get answers while their child is losing precious time.”</span></p>
<p><span>As such, the Surge to Save Newborns Act (H.R. 10571), a bipartisan bill introduced in September has been introduced with the aim to close critical gaps in state-level infant health screenings so families like the Serenos don’t lose precious time. </span></p>
<p><span>To discuss both the Sereno family’s own personal journey, as well as the importance of passing H.R. 10571, Bio.News sat down with Lina Sereno.</span></p>
<h3>Newborn screening for rare disease is hope for families</h3>
<p><span>“The fact that a disease is rare makes </span><a href="https://bio.news/latest-news/advocate-explains-why-we-need-newborn-screening-advisory-committee/"><span>newborn screening</span></a><span> even more important,” explains Sereno. “Most parents have never heard of MLD until it affects their own family. By the time symptoms appear, it may be too late to prevent irreversible damage.”</span></p>
<p><span>It was 17 years ago when Salvatore and Giovanni were diagnosed, and the Sereno’s story shows just how impactful time (both gained and lost), and healthcare innovation have been to their family</span></p>
<p><span>“At that time, the only treatment option available to us was a bone marrow transplant,” Sereno says. “My husband and I made the best decisions we could for both of our sons based on the medical knowledge and treatment options available.”</span></p>
<p><span>Today, much more is understood about MLD—especially the importance of early intervention. While a new gene therapy has been approved for MLD the risk remains for children diagnosed after symptoms begin as some of the damage may already be irreversible. </span></p>
<p><span>“I wish I had known how drastically our lives would change,” Sereno says. “Raising two boys with MLD has been incredibly difficult, but it has also shown me the extraordinary strength of our family and the power of love. There have been challenges I never could have imagined, but there has also been so much joy and beauty.”</span></p>
<p><span>Following his bone marrow transplant, Giovanni has remained almost symptom-free for 17 years. “He goes to school, plays video games, has friends and experiences most of what other kids his age do,” Sereno says. </span></p>
<p><span>Unfortunately, for Salvatore, the delay in his diagnosis has had distinct effects.</span></p>
<p><span>“Salvatore’s disease progressed rapidly during his bone marrow transplant,” says Sereno. “He walked into the hospital and left fully disabled and dependent on a G-tube for nutrition.”</span></p>
<p><span>Today, Salvatore is dependent on his family for care. </span></p>
<p><span>“His story is why I want other families to have the opportunity that came too late for him,” says Sereno. “Even if newborn screening identifies just one child a year who can benefit from early treatment, it is worth it. That is one child, one family and an entire lifetime that could be changed.”</span></p>
<p><span>Rarity should never determine whether a child gets that chance, she says. Newborn screenings mean hope for families.</span></p>
<p><span>“Instead of constantly worrying about the unknowns of this disease, parents could have information, access to specialists and the opportunity to act early,” she continues. “Every family deserves that chance. No parent should have to learn that their child has a devastating disease only after symptoms appear and precious treatment time has been lost, when the possibility of treatment is either gone or would not be as beneficial.”</span></p>
<h3>From the RUSP decision to real-world screening</h3>
<p><span>MLD and Duchenne muscular dystrophy were added to the Recommended Uniform Screening Panel (RUSP) on December 16, 2025—a major milestone for families and advocates. However, a federal recommendation does not automatically provide states with the resources to implement it.</span></p>
<p><span>“Rather,” Sereno explains, “each state must take the necessary steps to add MLD to its newborn screening panel. That process may require legislative or regulatory action, laboratory validation, specialized equipment, staff training, clinical follow-up systems and additional funding.”</span></p>
<p><span>While the federal recommendation by RUSP is an important first step to resolving this issue, it is not enough if states cannot implement said recommendations in a timely and efficient manner.</span></p>
<p><span>“Scientific advances and new treatments are creating opportunities to identify and treat babies earlier than ever before,” explains Sereno. “But without adequate funding, states may not have the resources to implement these screenings in a timely manner.”</span></p>
<p><span>It doesn’t matter how many healthcare advancements are made if families can’t (or don’t know to) access them.</span></p>
<p><span>“For families who have spent years advocating for newborn screening, this decision to include MLD and Duchenne muscular dystrophy to the RUSP represents hope,” Sereno reminds. “It acknowledged that early detection matters and that babies should have the opportunity to be identified before symptoms appear.”</span></p>
<p><span>Historically, implementation of a newly recommended condition can take five to six years in many states, and in some cases, considerably longer, which ultimately translates to missed opportunities for early diagnosis and treatment.</span></p>
<p><span>“State laboratories may lack the funding, equipment, facilities or trained personnel needed to establish a new screening test,” she continues. “They must also develop testing protocols, validate results, coordinate confirmatory testing and establish pathways for referring affected newborns to specialists.”</span></p>
<p><span>This has translated to the inclusion of MLD and Duchenne muscular dystrophy varying from state-to-state, creating what caregivers refer to as the “birth lottery,” where two babies with the same condition can have very different opportunities simply because they were born in different states.</span></p>
<p><span>“The state-by-state approach is profoundly unfair,” says Sereno. “It is heartbreaking to know that the state in which a baby is born can determine whether a potentially devastating disease is detected early enough for treatment to make a difference.”</span></p>
<p><span>Newborn screening should not depend on a family’s ZIP code, financial resources or ability to advocate for their child. </span></p>
<p><span>“These are essential steps, but states should not have to face these challenges alone. Without dedicated resources and coordinated support, even a strong commitment to newborn screening can be delayed by financial and operational barriers,” Sereno adds. “Every newborn deserves equitable access to screening for conditions on the RUSP, and every state needs the resources to make that possible.”</span></p>
<p><span>“Our work is not finished,” explains Sereno. “We must now ensure that states move forward with implementation so that this recommendation translates into real access to screening for newborns across the country.”</span></p>
<h3>Surge to Save Newborns bill: Turning a federal recommendation into action</h3>
<p><span>The Surge to Save Newborns bill would allow the progress made through the RUSP to go beyond just the recommendation of addition of new diseases by requesting</span><span> $35 million a year for 5 years to ensure every state is screening for the 40 conditions on the RUSP plus 2 additional conditions not yet nominated.</span></p>
<p><span>“We need to have a coordinated national effort that brings together families, patient advocacy organizations, clinicians, laboratories, policymakers and other stakeholders to ensure that states have the support necessary to put recommended screenings into practice,” Sereno argues. “That means investing in laboratory capacity, testing technology, personnel, training and the infrastructure needed to identify affected newborns and connect them to timely follow-up care.”</span></p>
<p><span>Federal funding is a critical part of this solution and could help states move more quickly while promoting a more consistent and equitable approach to implementation nationwide, she says. </span></p>
<p><span>States should not have to choose between competing public health priorities or delay implementation because they cannot afford the necessary resources. </span></p>
<p><span>“Dedicated federal support could help accelerate implementation and reduce the disparities that currently exist across state lines,” Sereno explains. “This is an investment in prevention, early diagnosis and the future of our children. The cost of implementation must be weighed against the potentially devastating human and financial consequences of a missed or delayed diagnosis.”</span></p>
<h3>Congress must act</h3>
<p><span>When asked what she would say to congress regarding H.R. 10571 Sereno says she would implore them to think about the families behind these decisions. </span></p>
<p><span>“Think about the parents who spend months visiting doctor after doctor, desperately searching for answers,” she asserts. “Think about the children who could have received treatment before symptoms began but were not identified in time.”</span></p>
<p><span>Adding a condition to the RUSP is the beginning of the promise, Sereno says, not the fulfillment of it. Without funding, that promise may remain out of reach for the very babies who need it most.</span></p>
<p><span>The Surge to Save Newborns is about turning that promise into action.</span></p>
<p><span>“I urge policymakers to support the Surge to Save Newborns initiative and the legislation needed to provide states with dedicated implementation funding,” Sereno implores. “We have the knowledge. We have the treatments. We have the federal recommendation. Now we need the funding and the national commitment to make newborn screening a reality for every baby, in every state.”</span></p>
<p> </p>
<p><i><span>Please act now and reach out to your congressman to support the Surge to Save Newborns </span></i><a href="https://surgetosave.org/act-now/"><i><span>https://surgetosave.org/act-now/</span></i></a></p>
<p><i><span>To get more involved and join our coalition, you can reach out to: Elisa Seeger  elisa@aldalliance.org</span></i></p>
<p>The post <a href="https://bio.news/latest-news/from-recommendation-to-reality-why-newborn-screening-needs-funding-now/">From recommendation to reality: Why newborn screening needs funding now</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Argenx Expands Immunology Capabilities with Up&#45;to&#45;$1.15B UNP Acquisition</title>
<link>https://edusehat.com/en/argenx-expands-immunology-capabilities-with-up-to-115b-unp-acquisition</link>
<guid>https://edusehat.com/en/argenx-expands-immunology-capabilities-with-up-to-115b-unp-acquisition</guid>
<description><![CDATA[ The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases.
The post Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Argenx-research-lab-shot__Screenshot-2026-11-10-110538-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Argenx, Expands, Immunology, Capabilities, with, Up-to-1.15B, UNP, Acquisition</media:keywords>
<content:encoded><![CDATA[<p>More than a year after they began partnering to develop oral macrocyclic peptides against multiple historically “undruggable” targets, Argenx has agreed to acquire Unnatural Products (UNP) for up to $1.15 billion, the companies said.</p>
<p>The deal—Argenx’s second planned acquisition announced in nearly four months—is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases. The buyout would transform Argenx from a minority stakeholder in privately held UNP to the sole owner of its shares.</p>
<p>Argenx is looking to diversify its pipeline beyond its antibody-based portfolio, which is led by the blockbuster franchise consisting of marketed drugs Vyvgart<sup>®</sup> (efgartigimod alfa-fcab) injection, indicated to treat adults with generalized myasthenia gravis (gMG); and Vyvgart Hytrulo<sup>®</sup> (efgartigimod alfa and hyaluronidase-qvfc), a subcutaneous treatment combination of the neonatal Fc receptor inhibitor (FcRn) and endoglycosidase that is indicated for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).</p>
<p>The Vygart/Vyvgart Hytrulo franchise generated $4.534 billion in net product sales during the first nine months of 2026—up 58% from $2.866 billion in January-September a year ago. During the third quarter, Argenx racked up $1.721 billion, up 53% from $1.127 billion in Q3 2025.</p>
<p>“Our ambition is to be the leading immunology innovation company, and as Argenx builds its next chapter, we are investing with discipline where it will count the most for patients,” Argenx CEO Karen Massey said in a statement.</p>
<h4><strong>‘Shots on goal’</strong></h4>
<p>Argenx’s acquisition of UNC builds on a <a href="https://www.genengnews.com/topics/drug-discovery/unnatural-products-argenx-partner-on-macrocyclic-peptides-for-immune-disease/" target="_blank" rel="noopener">collaboration launched in July 2025</a> to develop immunology drugs: “What the platform’s about is being able to take smart shots on goal” in order to “find a successful hypothesis to weave your way through that chemical landscape to a development candidate,” Cameron Pye, PhD, UNP’s CEO and co-founder, told <em>GEN</em>.</p>
<p>The partners agreed to apply UNP’s drug discovery platform, which combines AI-guided compound design, massively parallel synthesis, and direct-to-biology screening capabilities. UNP agreed to conduct research and development until IND-enabling studies, with Argenx having the exclusive option to develop and commercialize products against these targets across multiple indications.</p>
<p>The companies have not disclosed details of their progress toward developing new candidates. Argenx is among UNP’s biopharma giant collaboration partners, along with:</p>
<ul>
<li><strong>BridgeBio Pharma</strong>—Undisclosed value, launched in 2024 to develop macrocyclic peptides for rare diseases and oncology.</li>
<li><strong>Novartis</strong>—Up to $1.8 billion of which $100 million was paid upfront, launched in February to develop an undisclosed cardiovascular disease program.</li>
<li><strong>Merck & Co</strong>.—Undisclosed upfront payment up to $220 million in milestone payments, launched in 2024 to develop macrocyclic candidates against an oncology therapeutic target.</li>
</ul>
<p>“After working together for more than two years, we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients,” Massey added. “We want to preserve what has made UNP successful while bringing the strengths of both teams together.”</p>
<p>Argenx shares traded on Euronext Brussels rose modestly on news of the deal, climbing nearly 5% Monday from €815.80 ($906.11) to €853.80 ($948.23). The company’s American depositary shares (ADSs) traded on the Nasdaq Global Select Market rose nearly 4% from $927.21 to $962.27.</p>
<p>On Tuesday, Argenx’ Euronext Brussels shares inched up another 1% to €863.40 ($958.89) as of 11:01 am ET, while its ADSs barely rose 0.21% to $964.27 in morning trading as of 11:15 am ET.</p>
<h4><strong>Skittishness and support</strong></h4>
<p>The modest stock bounce appeared to reflect lingering skittishness by investors following a pair of setbacks over the past month.</p>
<p>Argenx shares fell more than 10% on October 8 after it announced it was ending the Phase III UNITY trial (<a href="https://clinicaltrials.gov/study/NCT06684847" target="_blank" rel="noopener">NCT06684847</a>)  assessing efgartigimod subcutaneous (SC) in adults with moderate-to-severe Sjögren’s disease. Argenx followed the recommendation of UNITY’s Independent Data Monitoring Committee (IDMC) to stop the trial for futility after concluding that the study would be unable to meet its primary endpoint.</p>
<p>Then on October 23, the FDA jolted Argenx by requesting the company carry out an additional confirmatory registrational trial evaluating efgartigimod SC in dermatomyositis (DM). The agency reasoned that while Argenx showed positive overall results in the Phase II/III ALKIVIA trial (<a href="https://clinicaltrials.gov/study/NCT05523167" target="_blank" rel="noopener">NCT05523167</a>)  assessing the drug in DM, the subgroup of DM patients was too small for the results to achieve statistical significance.</p>
<p>In contrast to the investor reaction, Thomas J. Smith, senior managing director, immunology and metabolism, and a senior research analyst with Leerink Partners, voiced support for the planned acquisition.</p>
<p>“We like this deal for ARGX as it brings engineering and design capabilities to generate macrocyclic peptides (i.e., oral, long-acting, etc.), signaling confidence in oral FcRn potential and expanding on the company’s early-stage pipeline with potential for further modalities beyond specialized antibodies,” Smith wrote Monday in a research note.</p>
<p>“We believe the deal represents potential for longer-term strategic value given both I&I and large pharma’s focus on oral and long-acting therapeutics capable of driving enhanced efficacy with improved convenience vs. conventional biologics,” Smith added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Pye and Joshua Schwochert, PhD, co-founded UNP in 2016, launching the company in a garage on the west side of Santa Cruz, CA, during their final year of doctoral research in the <a href="https://lokey.chemistry.ucsc.edu/members/slokey_picture/" target="_blank" rel="noopener">lab of Scott Lokey, PhD, at the University of California, Santa Cruz</a>. Lokey’s research group focuses on understanding the relationship of stereochemistry and N-Methylation patterns pertaining to cell permeability, as well as applying the relationship to create diverse and permeable drug scaffolds with exquisite selectivity that constrained peptides can offer.</p>
<p>UNP raised $32 million in a Series A financing completed in 2023 and led by Merck Global Health Innovation Fund and TechBio-focused ARTIS Ventures.</p>
<h4><strong>Second acquisition</strong></h4>
<p>If the deal is completed as planned, UNC would be Argenx’s second acquisition this year. The first is Forte Biosciences, a developer of targeted immunotherapies for autoimmune and autoimmune-related diseases. Argenx on August 27 completed its <a href="https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-portfolio-with-2-2b-buyout-of-forte-biosciences/" target="_blank" rel="noopener">up to $2.2 billion acquisition of Forte</a>, in a deal also intended to expand the buyer’s immunology portfolio with a pipeline led by FB102, a first-in-class anti-CD122 monoclonal antibody that has shown promising early clinical stage data.</p>
<p>Argenx agreed to acquire UNP for $550 million in upfront cash, plus up to $595 million in payments tied to achieving specified development and regulatory milestones.</p>
<p>The boards of both companies have approved the transaction, which is expected to be completed by year’s end subject to customary closing conditions.</p>
<p>Following closing of the deal, UNP’s staff and leadership will continue to operate from its Santa Cruz, CA, site, which will serve as Argenx’s hub for peptide discovery. UNP will continue to lead its discovery work within a strategic framework agreed upon with Argenx, which will bring clinical development and commercialization capabilities to advance peptide treatments to patients.</p>
<p>“Today is a tremendous milestone for UNP and a testament to the exceptional work of our scientists, employees, collaborators and supporters,” CEO Pye stated. “From the earliest days, we believed our platform had the potential to redefine what is possible in the discovery and design of new medicines. I am so proud of what our team has accomplished and believe Argenx provides the ideal environment to accelerate and amplify that vision to bring innovative therapies to patients.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/">Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Automation a Path to Lower Cell Therapy Costs</title>
<link>https://edusehat.com/en/automation-a-path-to-lower-cell-therapy-costs</link>
<guid>https://edusehat.com/en/automation-a-path-to-lower-cell-therapy-costs</guid>
<description><![CDATA[ Australian developer Currus Bio predicts that automating the production of its candidate cancer cell therapy, CUR-001, using the Cocoon platform will reduce costs and enhance its ability to scale production as the product moves through trials.
The post Automation a Path to Lower Cell Therapy Costs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/08/GettyImages-1320590180small-1024x738.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Automation, Path, Lower, Cell, Therapy, Costs</media:keywords>
<content:encoded><![CDATA[<p>Australian developer Currus Biologics says automating the production process for CUR-001, a candidate cell therapy for solid tumors, has significantly reduced the amount of viral vector required to make the product.</p>
<p>CEO Sam Cobb shared <a href="https://finance.yahoo.com/healthcare/articles/octane-biotech-currus-biologics-automate-210000192.html" target="_blank" rel="noopener">details</a> of the project this week, telling <em>GEN</em> that, in a bid to minimize manual handling requirements, the firm transferred the existing CUR-001 manufacturing process to the Cocoon automated production platform.</p>
<p>“This involved optimizing several key manufacturing parameters, including the amount of lentiviral vector required for transduction, cell densities during seeding and transduction, and the use of different starting materials.</p>
<p>“Importantly,” she continues, “this optimization enabled us to reduce the amount of lentiviral vector required for manufacturing, which has the potential to significantly reduce manufacturing costs.</p>
<p>“The objective was not to change the fundamental biology of CUR-001, but to establish a more consistent, reproducible, and efficient manufacturing process that can support future clinical and commercial development.”</p>
<p>The optimized process has now been transferred to Melbourne-based contract manufacturer, Cell Therapies (CTPL), which will produce CUR-001 for Currus’ planned Phase I clinical trial program.</p>
<p>The process automation project was supported by Swiss CDMO Lonza, which until recently owned a controlling stake in the Cocoon platform, and Octane Biotech, the original developer that re-acquired the technology in March.</p>
<h4><strong>Scale-up benefits</strong></h4>
<p>Automating the CUR-001 production process is also likely to aid Currus and its manufacturing partners as the cell therapy moves through clinical development toward commercial launch, Cobb says.</p>
<p>“One of the advantages of the Cocoon platform is its modular design, which allows manufacturing capacity to be expanded by adding additional units rather than fundamentally changing the manufacturing process.</p>
<p>“A final decision on commercial manufacturing will depend on clinical outcomes, regulatory requirements, anticipated patient demand, manufacturing capacity, and commercial economics,” she says.</p>
<h4><strong>Automation advantages</strong></h4>
<p>Process automation is likely to become more common in CAR T cell therapy manufacturing, but the widespread use of fully autonomous processes is unlikely, according to Cobb.</p>
<p>“One of the major barriers to broader adoption of autologous CAR T cell therapies is the complexity and cost of manufacturing individual patient batches. Automation provides a way to address both challenges while improving process standardization.”</p>
<p>Some core parts of cell therapy production can already be automated, with things like cell selection, activation, genetic modification, expansion, and harvest being the obvious examples.</p>
<p>However, other aspects of production—material collection, sampling quality control, batch review and release, cryopreservation, and distribution—may prove harder to automate, Cobb says.</p>
<p>“Some of these activities may also become increasingly automated, but I do not think fully autonomous manufacturing is a prerequisite for achieving meaningful improvements in efficiency,” she adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/automation-a-path-to-lower-cell-therapy-costs/">Automation a Path to Lower Cell Therapy Costs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Extracellular Vesicle Product Developer Creates Potency Assay</title>
<link>https://edusehat.com/en/extracellular-vesicle-product-developer-creates-potency-assay</link>
<guid>https://edusehat.com/en/extracellular-vesicle-product-developer-creates-potency-assay</guid>
<description><![CDATA[ A company developing extracellular vesicle-based products has developed a potency assay for quality control. They hope to adapt it for future products and scale it to commercial manufacturing.
The post Extracellular Vesicle Product Developer Creates Potency Assay appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Vivienne-Evox-Neurons-and-EVs-image.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Extracellular, Vesicle, Product, Developer, Creates, Potency, Assay</media:keywords>
<content:encoded><![CDATA[<p>Developing potency assays for complex new biologics, such as extracellular vesicle (EV)-based products, can be a challenge, with some manufacturers putting it off until regulators ask hard questions. That’s the view of Evox Therapeutics, who say they’ve succeeded in developing a potency assay that can be hopefully adapted to multiple future products in their pipeline.</p>
<p>According to Rebecca Gavin, PhD, chemistry, manufacturing, and controls (CMC) director at Evox, the assay has already been pre-qualified and transferred into a quality control (QC) laboratory.</p>
<p>The company hopes it can be fully qualified during a planned first-in-human study next year and, in the future, be used for batch QC during commercial production of their products.</p>
<p>“Our product is quite complex, and that’s why people often struggle to develop a potency assay,” Gavin says.</p>
<p>“Sometimes CMC can get kicked down the road a little, with people thinking they’ll worry about it later when they have more funding, so [the fact] that we’ve developed one already is something we’re really proud of.”</p>
<p>Evox’s product encapsulates a ribonucleoprotein (RNP) within an EV that is used as the delivery mechanism. The RNP is coupled to a guide RNA, which targets a specific gene with the aim of reducing protein production, Gavin explains.</p>
<p>Although this could spur lots of complex questions, such as whether the EV is taken up by the cell and whether the editing machinery makes it to the nucleus, she says that this can lead to over-characterization and over-testing.</p>
<p>“You don’t want to have a batch release assay panel that’s 50 assays long, where you’re having to measure and quantify every aspect of a complex product, and need to dedicate 50% of your batch to testing, especially in the gene therapy field where batch yields are already tricky,” she explains.</p>
<p>To get around this, the company developed an assay that simply measures potency, thereby demonstrating that the product is being successfully assembled and delivered to a cell.</p>
<p>The assay doses EV products at different concentrations onto an immortalized adherent cell line, she says. The cells are allowed to grow for a while, and then the cell lysates are tested on a Jess Simple Western system.</p>
<p>“We get a very specific quantitative readout, and that allows us to determine a dose-response curve, which shows how active our product is at reducing our protein of interest,” she explains.</p>
<p>Going forward, the company hopes this simple potency assay can be fully qualified for commercial production and adapted for multiple products in their pipeline.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/extracellular-vesicle-product-developer-creates-potency-assay/">Extracellular Vesicle Product Developer Creates Potency Assay</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hybrid Model Captures Lactate Run&#45;Away and Back&#45;Metabolism</title>
<link>https://edusehat.com/en/hybrid-model-captures-lactate-run-away-and-back-metabolism</link>
<guid>https://edusehat.com/en/hybrid-model-captures-lactate-run-away-and-back-metabolism</guid>
<description><![CDATA[ A hybrid model provides hard-to-achieve insights into lactate performance during bioprocessing, creating conditions for more accurate predictions to better manage key batch parameters and variability.
The post Hybrid Model Captures Lactate Run-Away and Back-Metabolism appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Gemini_Generated_Image_xq337mxq337mxq33.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hybrid, Model, Captures, Lactate, Run-Away, and, Back-Metabolism</media:keywords>
<content:encoded><![CDATA[<p>A new hybrid mechanistic-data-driven model of lactate consumption and production for mammalian cell cultures captures both lactate back-metabolism and lactate run-away. It also provides accurate real-time predictions of viable cell density, monoclonal antibody, glucose, and lactate concentrations during bioprocessing, according to researchers from University College London and AstraZeneca.</p>
<p>For biopharmaceutical manufacturers, this model, outlined in a recent <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bit.70417" target="_blank" rel="noopener">paper</a>, provides another tool to accurately predict batch-to-batch variability and failing runs early in the process, according to a team led by principal investigator Li Qin, PhD, postdoctoral research fellow, and senior researcher Stephen Goldrick, PhD, associate professor, digital bioprocess engineering, both at University College London.</p>
<p>By fine-tuning the initial model, the team improved upon the original 88% accuracy rate, reducing the root mean squared error by about 50% for glucose and by about 30% for lactate.</p>
<p>“This model addresses a key industrial challenge,” Goldrick tells <em>GEN</em>. “In fed-batch CHO cultures, cells normally switch from lactate production to lactate back-metabolism. If they do not, the culture goes into lactate run-away, which can cause batch failure or a significantly lower titer. This switch is poorly understood and rarely controlled.”</p>
<p>Therefore, a lactate switch detection algorithm is one of the key features of this model. As Goldrick explains, “Our model uses pH as a soft sensor to detect early, at around day 5, whether the cells will undergo lactate back-metabolism. This information could be built into the control strategy, so the process can be adjusted to avoid lactate run-away.”</p>
<h4><strong>Stratifying parameters</strong></h4>
<p>The novelty of this approach is three-fold, they say, encompassing “new kinetic equations to accurately describe Chinese hamster ovary cell growth and death dynamics…new equations for lactate production and consumption…to better capture metabolic transitions under varying process conditions…and adaptive kinetic updating integrated with a lactate-switch detection algorithm to incorporate online and offline measurements into the model dynamically.”</p>
<p>The model was trained with online data such as pH values, glucose flow rates, and other nutrient feeds combined with historical data such as concentrations of glucose, lactate, and mAb concentrations as well as cell densities accumulated from random runs. The team trained the model on five runs that switched from producing lactate to consuming it (called back-metabolism), three to evaluate predictive performance, one that exhibited lactate run-away (in which the cell culture continued producing lactate), and one external lactate run-away scenario.</p>
<p>That combination helped the researchers determine which parameters could be predicted accurately with online data and which highly variable parameters needed to be fine-tuned using a combination of real-time and historic data. “This targeted strategy significantly reduces model update time compared to full recalibration, while maintaining predictive accuracy,” they note.</p>
<p>Ten is a relatively small number of training runs, the scientists admit, but the values predicted by the model in those runs closely matched those of actual measured values, suggesting this model can make a real contribution to the industry. Further work will extend the measured production values to include amino acid consumption, ammonia accumulation, osmolality dynamics, and product quality attributes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/hybrid-model-captures-lactate-run-away-and-back-metabolism/">Hybrid Model Captures Lactate Run-Away and Back-Metabolism</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Farm Waste to Medical Nanoparticles</title>
<link>https://edusehat.com/en/from-farm-waste-to-medical-nanoparticles</link>
<guid>https://edusehat.com/en/from-farm-waste-to-medical-nanoparticles</guid>
<description><![CDATA[ Fruit peels, rice husks, and other crop leftovers can yield biomedical nanoparticles, but variable feedstocks, scale-up hurdles, and thin safety data still stand between lab promise and reliable commercial bioprocessing.
The post From Farm Waste to Medical Nanoparticles appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-Pandey-bionanomaterials_GBPN_IMAGE_12NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Farm, Waste, Medical, Nanoparticles</media:keywords>
<content:encoded><![CDATA[<p>The world’s farms produce a mountain of leftovers every year—more than six billion tons of crop residues in 2020 alone, by one estimate. Much of it is burned or buried. A new review argues that a good share could instead become raw material for biomedical nanoparticles.</p>
<p>Writing in <a href="https://doi.org/10.3389/fbiom.2026.1831334" target="_blank" rel="noopener"><em>Frontiers in Biomaterials Science</em></a>, a team led by Sadanand Pandey, PhD, professor in the School of Bioengineering and Food Technology at Shoolini University in Solan, India, surveyed research from 2015 to 2026 on turning agricultural waste into metallic, polymeric, and carbon-based nanostructures. The picture is promising but unfinished.</p>
<p>The appeal rests on the chemistry the plants have already done. Peels, husks, seeds, and pomace are packed with polyphenols, flavonoids, and polysaccharides that can reduce metal ions and coat the resulting particles, replacing harsh chemical reagents. Silica-rich rice and wheat husks are favored sources of silica nanoparticles, while sugarcane bagasse supplies abundant cellulose.</p>
<p>The studies the authors compiled point to a range of uses. Silver nanoparticles made with pomegranate peel extract inhibited <em>E. coli</em> at 16 µg/mL. Zinc oxide particles produced with banana peels broke down 90% of a test dye within two hours and fought <em>Staphylococcus aureus</em> biofilms. Carbon dots made from fruit and vegetable scraps glow brightly enough for imaging and appear far less toxic than conventional semiconductor quantum dots.</p>
<p>The process economics look attractive too. One study cited in the review reported that biologically mediated synthesis cut energy use by 30% and costs by 40% while raising output by 50% compared with conventional methods.</p>
<p>But the authors are frank about what stands in the way, and much of it is a familiar bioprocessing problem: raw-material variability. A banana peel’s chemistry depends on the variety, growing conditions, harvest date, and how the waste was handled. Those differences carry through to particle size, shape, surface charge, and stability, making batch-to-batch consistency hard to guarantee.</p>
<p>Scale-up adds more friction. Green reactions tend to run slower than chemical ones, and lignocellulosic feedstocks often need pretreatment, which can erode cost savings. Without standard protocols for synthesis, purification, and characterization, regulators have little to benchmark against. Long-term <em>in vivo</em> safety data are also thin, and risks such as oxidative stress and bioaccumulation need systematic study before any clinical use.</p>
<p>To close those gaps, the team calls for standardized methods, scalable biorefinery models, and tools such as AI-assisted metabolomic analysis to fine-tune the process. If those pieces fall into place, today’s crop waste could become a dependable supply chain for tomorrow’s nanomedicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/from-farm-waste-to-medical-nanoparticles/">From Farm Waste to Medical Nanoparticles</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</title>
<link>https://edusehat.com/en/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years</link>
<guid>https://edusehat.com/en/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years</guid>
<description><![CDATA[ Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes. 
The post How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/09/Sep29_2020_Getty_1181263174_DoctorAndPatient-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 11 Nov 2026 02:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Breast, Cancer, Chemotherapy, May, Impact, Biological, Aging, and, Loss, Healthy, Life, Years</media:keywords>
<content:encoded><![CDATA[<p>Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes.  The study, by researchers at Georgetown University’s Lombardi Comprehensive Cancer Center and colleagues, is the first to estimate the lifetime balance of the benefits of curing breast cancer versus possible acceleration of biological aging using population-based simulation modeling. The findings point to a need to explore whether interventions to slow or reverse biological aging could improve long-term health for breast cancer survivors.</p>
<p>“Female breast cancer survivors comprise the single largest segment of the 18.6 million cancer survivors in the United States, said Jeanne Mandelblatt, MD, MPH, director of the Georgetown Lombardi’s Institute for Cancer and Aging Research (I-CARE). “However, some forms of chemotherapy that extend survival have triggered a secondary crisis: treatment-induced molecular damage to the body’s cells and organs, causing acceleration of biological age.” Mandelblatt notes that this accelerated biological aging can result in loss of healthy life years due to earlier onset of aging diseases and conditions like frailty and cognitive problems. “Chemotherapy-induced biologic aging can persist for years, and the effects of this acceleration are not visible for many years.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Senior author Mandelblatt, together with first and corresponding author Swarnavo Sarkar, PhD, a member of I-CARE at Lombardi, and colleagues reported their findings in <em>JAMA Open Network</em>, titled “<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856363?resultClick=3" target="_blank" rel="noopener">Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors</a>.” In their report the investigators concluded “These findings suggest that integrating knowledge about biological aging into survivorship care may help identify opportunities to deploy pharmaceutical and behavioral interventions that target aging-related processes.”</p>
<p>While breast cancer survival rates have been steadily increasing over time due to advances in screening and therapeutics, growing evidence also suggests that some breast cancer survivors may experience long-term toxic effects of chemotherapy, including accelerated aging (biological age in excess of chronological age), the authors wrote. This may be associated with the development of chronic aging-related diseases such as cardiovascular disease and diabetes.</p>
<p>“One mechanism by which chemotherapy accelerates aging is through increases in the accumulation of senescent cells, defined as cells that have stopped dividing but are resistant to cell death,” the team continued. “These cells promote further aging through changes in tissue modeling and inflammation, contributing to excess non–breast cancer morbidity and mortality.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To investigate the potential long-term effect of cancer therapy on the biological aging of breast cancer survivors the team carried out a comparative effectiveness study that used an established population-level simulation model, and current data on chemotherapy’s effects on cellular senescence. “This comparative effectiveness study used an established Cancer Intervention and Surveillance Modeling Network breast cancer model integrating biological aging with breast cancer epidemiology,” they wrote.</p>
<p>The investigators used data about the relationships between chemotherapy and blood levels of the <em>p16 </em>protein, a common biomarker of senescence, to estimate the biological age of breast cancer survivors over their remaining lives. “Biological aging was modeled using data on distributions of post-chemotherapy senescence measured by <em>p16<sup>INK4a</sup></em> levels, and the model assumed chemotherapy-induced senescence only affected non–breast cancer mortality,” they explained. The <em>p16</em> protein levels were used for this study because there is good data from published research and there is evidence from the lab that clearing <em>p16</em>-rich cells could increase their lifespan. There are also evolving studies of other biological aging markers that could be used in future studies.</p>
<p>The population simulation model the researchers developed was based on women who were 30 to 79 years of age; the model compared the effects of types of chemotherapy that caused more vs. less cellular damage (i.e., cytotoxic) and biological age acceleration. Breast cancer survivors who received the most cytotoxic anthracycline regimens were estimated to have lost 9.4 remaining life years on average due to earlier onset of aging-related diseases. “Survivors diagnosed at early ages and/or treated with the most cytotoxic regimens were projected to have the greatest biological age acceleration, with increased risk of death from non–breast cancer causes at earlier chronological ages than expected in general populations,” the researchers stated.</p>
<p>Sarkar added. “The key to our methodology is accounting for the fact that while chemotherapy improves breast cancer survival, treatment can also increase damage to normal tissues. This affects many aging systems, including increasing the number of senescent cells, which are damaged cells that have stopped dividing and are also resistant to cell death. Senescent cells secrete biological molecules that cause several aging-related diseases through added tissue damage and inflammation.”</p>
<p>The data analysis was possible because both Mandelblatt and Sarkar are members of CISNET (Cancer Intervention and Surveillance Modeling Network), a 25-year-old consortium of National Cancer Institute-sponsored investigators who use simulation modeling to improve the understanding of cancer prevention, screening, and treatment and their effects on population trends in incidence and mortality.</p>
<p>While treatment choices will always be based on the potential to cure, Mandelblatt hopes that the model results can be used to guide future studies evaluating the benefits of testing biological age after treatment ends. “Since the goal of treatment is to improve breast cancer survival, oncologists should not modify treatment decisions based on potential for accelerated aging, but our results suggest the need for awareness of possible age acceleration,” the researchers pointed out.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The goal would be to provide personalized survivorship care to mitigate any aging effects of therapy and improve quality of life and health over a survivor’s lifetime. This is particularly salient now, Mandelblatt noted, since physical activity and medications being used for other purposes show promise in slowing accelerated aging in breast and other cancer survivors, which may recoup the loss of life years estimated in this study.</p>
<p>And as the authors also stated, more research is needed to test the impact of biological age assessment and management of biological age acceleration on survivorship outcomes. “Knowledge about the risks of accelerated aging among women exposed to chemotherapy may help motivate lifestyle changes,” they stated. “Further, as evidence on the safety and utility of senolytic and other anti-aging drugs evolves, modeling may help identify populations of survivors at risk for age acceleration who might benefit from pharmacologic intervention.”</p>
<p>Sarkar added, “There are two next steps we are planning, the first being expanding the scope of this methodology for other types of breast cancer treatments, such as radiotherapy, immunotherapies, targeted therapies and hormonal treatments, which also appear to speed up aging, with effects potentially lasting for many years after treatment. We also plan to include information about survivor characteristics to help guide future conversations about individual outcomes.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years/">How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BioAdvance: BIO releases national action plan to strengthen US biotech leadership</title>
<link>https://edusehat.com/en/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership</link>
<guid>https://edusehat.com/en/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership</guid>
<description><![CDATA[ A new seven-point plan to strengthen America’s biotechnology leadership amid intensifying global competition from China was released by the Biotechnology Innovation Organization (BIO) on […]
The post BioAdvance: BIO releases national action plan to strengthen US biotech leadership appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/BioAdvance-cover.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 19:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BioAdvance:, BIO, releases, national, action, plan, strengthen, biotech, leadership</media:keywords>
<content:encoded><![CDATA[<p><span>A new seven-point plan to strengthen America’s biotechnology leadership amid intensifying global competition from China was released by the Biotechnology Innovation Organization (BIO) on Nov. 10.</span></p>
<p><a href="http://bio.org/bioadvance" target="_blank" rel="noopener"><span>BioAdvance: Securing America’s Biotech Century</span></a><span>, calls for a bold, coordinated national strategy and targeted policy reforms to accelerate medical breakthroughs, strengthen America’s innovation ecosystem, and ensure the next generation of lifesaving medicines is developed and manufactured in the U.S.</span></p>
<p><span>America built the  biotechnology industry, notes BIO President & CEO John F. Crowley.</span></p>
<p><span>“For decades, American biotechnology innovators have turned scientific discovery into hope for patients and families, building an industry that saves lives, drives economic growth, and strengthens our nation’s security and competitiveness,” Crowley says.</span></p>
<p><span>By 2025, the U.S. bioscience industry employed more than 2.3 million Americans across more than 156,000 business establishments and generated nearly $3.2 trillion in total economic output,</span><a href="https://bio.news/state-policy/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem/" target="_blank" rel="noopener"><span> according to </span><span>the BIO/CSBA/TEConomy 2026 report</span></a><span>.</span></p>
<p><span>“America’s biotechnology innovators have built one of our nation’s greatest strategic assets,” Crowley says. “But our leadership is not guaranteed. We must invest, innovate, and act with urgency.”</span></p>
<p><span>As <a href="https://www.bio.org/sites/default/files/2026-11/bio-advance_executivesummary_digital_11042026.pdf" target="_blank" rel="noopener">the Executive Summary explains</a>, China is competing to take over as the world leader in  biotech, posing challenges to our health, economy, and national security.</span></p>
<p><span>“China has steadily elevated biotechnology as a strategic priority, directing massive state resources toward the sector in every new five-year plan,” the Executive Summary says. “Between 2016 and 2021, the value of China’s biotechnology industry grew more than 100-fold.”</span></p>
<h2>The action plan</h2>
<p><span>BioAdvance plan outlines how Congress and the administration can respond to the challenge with actions tailored to America’s strengths. The plan addresses seven actionable priorities across three areas:</span></p>
<p><b>Coordinate: Establish a clear national strategy for U.S. biotech leadership</b></p>
<ul>
<li aria-level="1"><span>Establish a White House Office of Biotechnology.</span></li>
</ul>
<p><b>Accelerate: Bring lifesaving discoveries to patients faster</b></p>
<ul>
<li aria-level="1"><span>Speed up the path to first-in-human clinical studies.</span></li>
<li aria-level="1"><span>Modernize and streamline drug development.</span></li>
<li aria-level="1"><span>Improve patient access to clinical trials.</span></li>
</ul>
<p><b>Build: Strengthen the foundations of American biotechnology</b></p>
<ul>
<li aria-level="1"><span>Sustain support for biomedical research.</span></li>
<li aria-level="1"><span>Expand U.S. biomanufacturing capacity and expertise.</span></li>
<li aria-level="1"><span>Strengthen intellectual property protections and access to capital.</span></li>
</ul>
<p><span>“This moment demands the ambition and determination that catalyzed the biotechnology revolution and made America the definitive global leader,” Crowley states. “BIO stands ready to work with the administration, Congress, and the entire biotechnology ecosystem to accelerate the next generation of lifesaving breakthroughs, and ensure the United States leads the biotech century.”</span></p>
<p><a href="http://bio.org/bioadvance" target="_blank" rel="noopener"><b>Learn more and download the full action plan at bio.org/bioadvance.</b></a></p>
<p><strong>Read more: <a href="https://www.statnews.com/2026/11/10/china-biotech-bio-plan-space-race/" target="_blank" rel="noopener">BIO CEO: American biotech needs a coordinated plan to beat China — now</a></strong></p>
<p>The post <a href="https://bio.news/bios-view/bioadvance-bio-releases-national-action-plan-to-strengthen-us-biotech-leadership/">BioAdvance: BIO releases national action plan to strengthen US biotech leadership</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research</title>
<link>https://edusehat.com/en/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research</link>
<guid>https://edusehat.com/en/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research</guid>
<description><![CDATA[ Illumina has announced an early access program to a duplex sequencing workflow that reads both DNA strands to detect trace ctDNA in molecular residual disease and tumor evolution studies. Kits are expected in early 2027.
The post Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/GettyImages-1325872227.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 08:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Illumina, Offers, Early, Access, Duplex, Sequencing, for, MRD, Tumor, Evolution, Research</media:keywords>
<content:encoded><![CDATA[<p>Spotting a handful of tumor DNA fragments among one million total DNA fragments may be the kind of sensitivity researchers need when studying molecular residual disease (MRD), the small amount of cancer that can remain after treatment. Illumina has opened an early access program for a sequencing workflow to support research in that range.</p>
<p>Announced this week, the research-use-only workflow is designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples and to support longitudinal, whole-genome studies of MRD and tumor evolution. Kits are expected to ship in the first quarter of 2027.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The workflow relies on duplex chemistry, which confirms each base call using both complementary strands of the original DNA molecule. Seeing the same change on both strands increases confidence that it is biological rather than an error introduced during library preparation or sequencing, according to the Illumina press release.</p>
<p>On the hardware and software side, the workflow combines the NovaSeq X sequencing platform with DRAGEN bioinformatics software. Illumina said that pairing NovaSeq X sequencing with duplex chemistry yields quality scores above Q65. DRAGEN then generates duplex consensus reads, optimizes quality scores, and interrogates thousands of tumor-specific variants across the genome, combining evidence from the few that may be present in plasma. The workflow supports 5–10 ng of cell-free DNA (cfDNA) input.</p>
<p>In representative studies, the workflow reproducibly detected ctDNA at 2.5 parts per million.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Researchers need effective ways to find the faintest traces of tumor DNA—signals that can be especially difficult to detect in early-stage, low-shedding, or low-mutation-burden tumors,” said Cande Rogert, vice president, global head of advanced science at Illumina, in a press release. “This early access technology is an important step toward helping researchers explore those challenging settings with greater sensitivity and generate evidence that can advance MRD research.”</p>
<p>The duplex workflow adds to Illumina’s MRD research portfolio and complements Illumina WGS Oncology Prep, which supports tumor fingerprinting and longitudinal ctDNA monitoring in a standardized whole-genome workflow.</p>
<p>NYU Langone Health is among the early access users and is applying the approach to MRD research. “MRD research is moving fast, and new tools are making it possible to bring ultrasensitive, tumor-informed analysis in-house,” said Matija Snuderl, MD, director of molecular pathology at NYU Langone Health. He added that the team looks forward to “generating evidence with a non-bespoke approach that can help advance our understanding of disease recurrence.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/illumina-offers-early-access-to-duplex-sequencing-for-mrd-tumor-evolution-research/">Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Cancer&#45;Associated Gene Triggers Cell Division Without Unpacking the Genome</title>
<link>https://edusehat.com/en/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome</link>
<guid>https://edusehat.com/en/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome</guid>
<description><![CDATA[ A study showed how E2F1 can trigger cell division without having to unpack the cell’s genetic material. Instead, it takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell.
The post How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/GettyImages-2152737017.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 10 Nov 2026 05:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Cancer-Associated, Gene, Triggers, Cell, Division, Without, Unpacking, the, Genome</media:keywords>
<content:encoded><![CDATA[<p>Living cells are one of the few materials that can replicate themselves, and this is crucial for tissue development and recovering from injury or illness. But making sure cell division only happens at the right time is essential, otherwise unregulated replication can lead to problems like cancer.</p>
<p>The results of a study headed by researchers at the University of California, Santa Cruz, have now shown that a cancer-related gene known as <em>E2F1</em> can cause cells to divide without having to abide by the normal rules of cell division. Their research found that instead of having to unpack the genetic material inside the cell, E2F1 takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell. The discovery helps to further illuminate the processes that drive cell proliferation and may influence cancer growth and could provide insight that will help in the future design of more precise and targeted treatments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Cancers may overcome the typical checks and balances that our cells are using to maintain a dormant state, dysregulating and increasing the level of E2F1 to find a shortcut back to the cell cycle,” said Ali Shariati, PhD, Associate Professor of Biomolecular Engineering at the Baskin School of Engineering. Shariati, and Professor Chemistry & Biochemistry Seth Rubin, PhD, are co-senior and co-corresponding authors of the researchers published paper in <em>The EMBO Journal</em>, titled “<a href="https://doi.org/10.1038/s44318-026-00936-4" target="_blank" rel="noopener">E2F1 induces a G0-G1 reentry transcriptional program without changing chromatin accessibility</a>.” In their paper the researchers concluded, “Our work redefines the relationship between transcription factor and chromatin dynamics during fate transitions and establishes E2F1 as a potent regulator capable of inducing cell-cycle reentry without changing chromatin accessibility.”</p>
<p>Nearly all cells have the ability to divide, but the majority don’t, instead waiting in a state similar to hibernation. And this hibernation doesn’t happen automatically—the body must constantly send signals to prevent cell division. Otherwise, any body part could grow bigger than its proper size, or grow tumors. “Many cells in the human body reside in a reversible nondividing quiescent state termed G0,” the authors explained. “Quiescent cells repress cell-cycle genes via chromatin-based mechanisms to maintain a non-dividing state, yet remain poised to reenter the cell cycle upon stimulation.”</p>
<p>The UCSC researchers are studying how cells know when and how to divide, and the influence on these processes of genes known to be important in cancer. Rubin’s lab focuses on the biochemistry and gene expression of cell division, while Ali Shariati’s lab studies how cells translate input from the body in order to decide whether or not to divide. “Cells can’t just rely on the assumption that they will stop dividing,” Shariati said. “The cells need to actively say, ‘this is the liver, it should be this large, and after we reach this critical size, let’s just stop dividing,’ That’s called homeostatic behavior, and that’s not a trivial task for the body. It’s a state where the cells are ready to be activated, but normally aren’t, unless there is an external requirement. It’s a delicate balance to maintain.” The authors further explained, “Cells enter quiescence when they do not receive the required signaling cues for cell-cycle progression such as growth factors.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To recover from injuries or illness, the body can send a signal to cells to leave hibernation and divide. To do so, it must instruct cells to physically unpack the DNA that is tightly wrapped around proteins inside its nucleus. To recreate this process in the lab, scientists typically add nutrients and growth signals to dormant cells, which cause them to divide.</p>
<p>The UC Santa Cruz researchers studied an important gene called <em>E2F1</em>, which is central for cell division and malfunctions in many cancers. “E2F1 is known to be a transcriptional activator that binds to and induces expression of cell-cycle genes such as those encoding cyclins, cyclin-dependent kinases, and DNA replication machinery,” the team noted. Other scientists have found that the activation of this gene can cause cells to divide without growth signals, and the UCSC scholars further confirmed this finding.</p>
<figure aria-describedby="caption-attachment-340488" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-340488" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1-300x119.jpg" alt="On the left, dormant cells (turquoise) lie in wait for biological signals. On the right, cells are awakened by E2F1 (magenta) and begin to divide. " width="300" height="119" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1-300x119.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_PressRelease-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">On the left, dormant cells (turquoise) lie in wait for biological signals. On the right, cells are awakened by E2F1 (magenta) and begin to divide. [Ali Shariati / UC Santa Cruz]</figcaption></figure>
<p>The team further discovered that E2F1 appears to be taking a shortcut method to cause division. Using a very limited amount of physical space in the genome, the E2F1 protein can bind directly to the genome in order to switch on the genes related to cell division. “… quiescent cells can reenter the cell-cycle and complete their division without global changes in chromatin accessibility when induced by expression of a single transcription factor; E2F1,” they wrote. “Our results show that E2F1 is able to rapidly promote quiescence exit by activating an accelerated gene expression program without global changes in chromatin accessibility.”</p>
<p>Shariati further commented, “The surprising part is, unlike the typical process, E2F1 is able to activate the cell cycle genes without physically unpacking the genome much or at all. That means this is a new way of transcription factors being able to activate genes and let the cells completely change their fate and go on to divide.” And while DNA binding is essential to the ability of E2F1 to trigger cell division, “… deletion of the DNA binding domain in E2F1 led to a complete loss of cell cycle reentry,” the investigators noted, “The precise mechanisms underlying the transcriptional activation of cell-cycle genes by E2F1 without significant changes in chromatin accessibility remain unknown and merits further investigation.”</p>
<p>The ability to activate cell division makes E2F1 similar to a special category of genes that scientists call “pioneer factors,” which can unlock tightly packed DNA to fundamentally reprogram cells. This special status indicates that cells must maintain a precise level of E2F1 to maintain proper cell division. Indeed, the UC Santa Cruz researchers found that cells can sense a specific threshold of E2F1: once levels cross that line, dormant cells begin to divide.</p>
<p>E2F1’s shortcut method of division has its own limitations. The scientists found that cells can only divide at most three times without any additional growth signals. To study cell division over time, the researchers used live single-cell imaging techniques developed in the Shariati lab, including their in-house <a href="https://doi.org/10.1016/j.crmeth.2023.100500" target="_blank" rel="noopener">DeepSea software</a>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Nonetheless, the shortcut method to cell division that E2F1 uses happens much faster than the typical process with nutrients. Researchers suspect cancer cells may exploit this E2F1 activity, although more research will be needed to better understand how this mechanism works.</p>
<p>Shariati plans to further study how exactly E2F1 activates the genes after it binds to the genome. This could help to find a more precise and targeted approach for interfering with this pathway in the context of cancer. He also wants to study the eight genes in the same family as <em>E2F1</em>, some of which cause cells to become dormant, and their role in cancer.</p>
<p>Rubin is also interested in whether E2F1 can be targeted in cancers. “There has been much effort in the field to target E2F1’s role in cell division by inhibiting upstream proteins that control E2F1 activity,” Rubin said. “We have been wondering whether there are ways to target E2F1 itself to stop cancer cells from proliferating. The first steps are figuring out what specific cancers would benefit from blocking E2F1 activity, and then finding molecules that bind and prevent E2F1 from activating cell cycle gene expression.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-cancer-associated-gene-triggers-cell-division-without-unpacking-the-genome/">How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cancer drug study puts numbers to the cost of IRA’s pill penalty</title>
<link>https://edusehat.com/en/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty</link>
<guid>https://edusehat.com/en/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty</guid>
<description><![CDATA[ The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and disincentives for follow-on research is a reduction in new cancer treatments, […]
The post Cancer drug study puts numbers to the cost of IRA’s pill penalty appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/towfiqu-barbhuiya-uM5mnbNm8eA-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cancer, drug, study, puts, numbers, the, cost, IRA’s, pill, penalty</media:keywords>
<content:encoded><![CDATA[<p><span>The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and disincentives for follow-on research is a reduction in new cancer treatments, a study finds.</span></p>
<p><span>The introduction of the IRA is associated with a 37% decline in follow-on small-molecule oncology studies and a 27% decline in lead-indication small molecule approvals, according to</span><a href="https://link.springer.com/article/10.1007/s43441-026-01061-4"> <span>research by Vital Transformation</span></a><span>. It also showed a 14% decline in the share of orphan oncology studies.</span></p>
<p><span>The research, published Oct. 20,</span> <span>analyzed 1,148 secondary clinical trials associated with 364 medicines approved by the Food and Drug Administration (FDA) from 175 companies between 2018 and 2025. Researchers used statistical modeling to compare post-approval drug development and research activity across disease areas before and after the IRA’s introduction.</span></p>
<p><span>“The findings indicate that the effects of the legislation on late-stage pharmaceutical research may warrant greater attention from policymakers, particularly in oncology, where continued clinical development can expand treatment options for patients with serious and difficult-to-treat cancers,”</span><a href="https://vitaltransformation.com/wp-content/uploads/2026/11/IRA_Press_Release_2NOV-final.pdf"> <span>according to Vital Transformation</span></a><span>.</span></p>
<h2>Why small molecules and follow-up matter</h2>
<p><span>The IRA allows the Centers for Medicare & Medicaid Services (CMS) to control the price of medications by making drug makers engage in “negotiations” or face steep penalties. Biologic medicines are exempted from these price controls for as long as 13 years, but small molecule drugs, which are often prepared as pills and comprise</span><a href="https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2023.1314077/full"> <span>about 90% of prescription drugs</span></a><span>, only receive a maximum of nine years of protection.</span></p>
<p><span>This “pill penalty” creates a disincentive to invest in small molecule drugs, which has been</span><a href="https://bio.news/health/capitol-hill-september-2024-pprv-pediatric-rare-disease-voucher-inflation-reduction-act-price-controls/#:~:text=%E2%80%98A%20classic%20issue,the%20Manhattan%20Institute."> <span>noted by policymakers</span></a><span> and others.</span></p>
<p><span>Follow-up studies investigate whether a drug approved for one condition is useful for another indication. This approach can speed access to new drugs for patients, especially oncology drugs, for which approximately 60-75% of marketed medications have more than one indication,</span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13297679/"> <span>according to research</span></a><span>.</span></p>
<p><span>The IRA discourages follow-up studies because drugs approved for an additional indication do not get additional protection from CMS price “negotiations.”</span></p>
<p><span>The Vital Transformation research puts actual numbers to the pill penalty in cancer research, identifying the 27% reduction in studies for new small molecule cancer drugs. It also shows that barriers to developing drugs for second indications puts an even greater damper on research—causing a decline of nearly 40% in follow-up studies for oncology drugs.</span></p>
<h2>Policy corrections</h2>
<p><span>There is bipartisan </span><span>legislation to correct the pill penalty, entitled the</span><a href="https://www.congress.gov/bill/119th-congress/house-bill/1492"> <span>Ensuring Pathways to Innovative Cures (EPIC) Act</span></a><span>. It would give small molecule drugs the same protection from price negotiations that biologics receive.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) praised the EPIC act when it was introduced.</span></p>
<p><span>“For decades small molecule medicines that come in a pill or tablet have been recognized for improving patient adherence, being easier to take, and more broadly accessible to those who need them. As a result, hundreds of such therapies have been developed,” said</span><a href="https://www.bio.org/press-release/bio-applauds-introduction-bipartisan-bill-eliminate-pill-penalty"> <span>BIO President & CEO John F. Crowley</span></a><span>, explaining the importance of the EPIC Act. “Today, instead of building on years of biomedical progress, some innovator companies and investors are now being forced to pull away.”</span></p>
<p><span>The data indicates a need for policy solutions, according to the Vital Transformation study.</span></p>
<p><span>“We hope this study reinvigorates debate” about the IRA’s “unintended consequences and encourages thoughtful policy solutions,” says the study. “The IRA manifestly creates disincentives that negatively impact patients seeking treatments in areas of high unmet medical need, particularly those requiring cures addressing metastatic late-stage cancers.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/cancer-drug-study-puts-numbers-to-the-cost-of-iras-pill-penalty/">Cancer drug study puts numbers to the cost of IRA’s pill penalty</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Formulation Development Roundup</title>
<link>https://edusehat.com/en/formulation-development-roundup</link>
<guid>https://edusehat.com/en/formulation-development-roundup</guid>
<description><![CDATA[ What leaders suggest are the key considerations for developing robust formulations.
The post Formulation Development Roundup appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_GettyImages-2224940107.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Formulation, Development, Roundup</media:keywords>
<content:encoded><![CDATA[<p>Formulation development is a critical step in the production of a drug to ensure that it is safe, effective, stable, and suitable for administration. Companies that provide formulation development services are experts in applying best practices to achieve optimal results. <em>GEN</em> sought the perspectives of experts from four leading companies to describe the considerations they make when working with customers on developing new formulations.</p>
<p><em>GEN</em> asked two questions: How would you approach formulation development for a customer’s specific molecule, and what key risks would you evaluate first? How do you determine that you have found a robust formulation rather than just the best-performing formulation under your initial test conditions?</p>
<p> </p>
<h4><strong>Abzena</strong></h4>
<p>Initially, we would perform a developability assessment to understand how the molecule behaves under platform manufacturing stresses, including low pH, freeze-thaw, shear, and hold conditions. This establishes the early-risk profile, including aggregation, fragmentation, oxidation, and deamidation risks, and identifies any molecule-specific liabilities before formulation screening begins.</p>
<figure aria-describedby="caption-attachment-340462" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340462" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-300x300.jpg" alt="Gary Watt" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Abzena-Gary-Watts.jpg 1304w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gary Watt, PhD<br>Head of Formulation</figcaption></figure>
<p>We would then align with the customer on the target product profile (TPP), including intended dose, concentration, route of administration, and presentation requirements, so the formulation strategy is driven by clinical and product needs rather than screening performance alone.</p>
<p>Once the TPP is agreed, we would confirm compatibility with platform analytical methods and run focused formulation screens assessing pH, ionic strength, excipient compatibility, and thermal stability. For subcutaneous products, we would also evaluate high-concentration feasibility, including solubility, viscosity, and aggregation risk.</p>
<p>Lead formulations would then be challenged through thermal and freeze/thaw stability studies using orthogonal analytical methods. Robustness is demonstrated when the selected formulation performs consistently across relevant stresses, analytical readouts, and small variations in formulation or process conditions, rather than simply being the best performer in the initial screen.</p>
<p>For Phase I/first-in-human (FIH) supply, the final formulation should provide an acceptable stability margin, support scale-up and manufacturing, and generate data suitable for Investigational New Drug (IND) filing.</p>
<p>Good Manufacturing Practices (GMP) batches would be placed on International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)-compliant stability studies, typically for up to four years, to confirm long-term performance and further justify the formulation selection.</p>
<p> </p>
<h4><strong>BioAgilytix</strong></h4>
<p>When approaching formulation development, I would start by understanding the molecule itself: what makes it unstable, which quality attributes matter most, and what conditions are most likely to cause problems. That means looking at physical and chemical stability, aggregation or particle formation, potency and purity, as well as sensitivity to things like pH, temperature, oxidation, agitation, and freeze-thaw. I would also look closely at the excipients, because stabilizers and other formulation components can affect both the molecule and its degradation pathways.</p>
<figure aria-describedby="caption-attachment-340463" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340463" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-300x300.jpg" alt="Jessica Weaver" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-BioAgilytix-Jessica-Weaver-e1794230452134.jpg 900w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Jessica Weaver<br>Scientific Officer</figcaption></figure>
<p>From the analytical side, an important question is whether we have the right assays to detect those changes. A formulation may alter how a drug degrades, and an assay that works well for the drug substance may not tell the whole story once that molecule is in its final formulation. We need stability-indicating methods that can distinguish the intact drug from degradation products and detect meaningful changes in the critical quality attributes without interference from the formulation itself.</p>
<p>The bigger question then becomes more than which formulation performs best in an initial screen. We need to understand why it performs well and whether it continues to perform when challenged.</p>
<p>For me, that is the difference between a formulation that looks good and one that is truly robust. It should tolerate normal variability in formulation parameters, manufacturing, handling, and storage. If performance falls off as soon as you move away from the exact conditions used in the initial study, you probably haven’t found a robust formulation yet. Confidence comes from analytical and stability data showing that the formulation continues to protect the molecule under the conditions it is likely to encounter.</p>
<p> </p>
<p><strong>Curia Global</strong></p>
<figure aria-describedby="caption-attachment-340464" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340464" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-300x300.jpg" alt="Tyler Jones" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Curia-TylerJones-e1794230551980.jpg 899w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Tyler Jones, PhD<br>Director of Formulation R&D</figcaption></figure>
<p>We take a bespoke approach to formulation development, where we don’t make assumptions on behavior based on the type of molecule, but rather we use a process to efficiently and pragmatically identify critical quality attributes and understand why a molecule behaves the way it does. First, the Curia team would characterize the molecule across a wide formulation space, systematically mapping pH vs. ionic strength, the two parameters that most strongly influence how molecules present themselves to their environment. This broad physicochemical space allows us to force a molecule down the various degradation pathways it could encounter, and doing this across a range of temperatures allows us to understand the temperature-dependency of these pathways. Many biologics do not follow Arrhenius-type kinetics with regard to degradation activation energies, so understanding which degradation pathways are most relevant at the intended storage temperatures is critical in weighting formulation space performance.</p>
<p>Once this baseline understanding of molecule behavior is established, we can then pointedly mitigate remaining issues. For example, if we achieve good physical stability but are still encountering some chemical degradation such as oxidation, we can then screen antioxidants and have the background data to justify why we are adding such excipients.</p>
<p>Eventually, with enough stability data to have confidence in a final formulation space, we would utilize DOE studies to refine each variable in the formulation. The gold standard for us is long-term stability, so to definitively show the formulation is robust, we run long-term stability studies on a small selection of bracketed formulations around our sweet spot.</p>
<p> </p>
<p><strong>Quotient Sciences</strong></p>
<p>Formulation development should start with the target product profile and the molecule itself, including the required dose and exposure, route of administration, dosage form, and the API’s physicochemical, solid-state, and biopharmaceutic properties. The first priority is to identify the risks most likely to compromise clinical performance or create downstream development barriers. Depending on the molecule, these may include solubility and dissolution relative to dose, permeability, solid-form and chemical stability, excipient compatibility, dose feasibility, and manufacturability.</p>
<figure aria-describedby="caption-attachment-340461" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340461" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-300x300.jpg" alt="Asma Patel" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/RoundUp-Quotient-AsmaPatel.jpg 900w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Asma Patel, PhD<br>Vice President, Global Commercial and Scientific Consulting, Drug Product</figcaption></figure>
<p>The objective is not to select the most sophisticated technology, but rather the simplest formulation capable of delivering the required clinical performance while remaining viable through scale-up, transfer, and later-stage manufacture.</p>
<p>A robust formulation should be understood, not simply selected. Critical material attributes and process parameters should be challenged across justified ranges, including relevant interactions and boundary conditions, to determine where performance is maintained and where it begins to fail. The formulation choice should then be confirmed through reproducibility across batches, stability over time, performance on representative equipment, clinically relevant<em> in vitro</em> testing, and, where appropriate, human data.</p>
<p>A formulation is robust when normal variability is understood, controlled, and does not materially affect product quality or intended clinical performance.</p>
<p> </p>
<p> </p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/formulation-development-roundup/">Formulation Development Roundup</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Therapeutic Immune Manipulation</title>
<link>https://edusehat.com/en/therapeutic-immune-manipulation</link>
<guid>https://edusehat.com/en/therapeutic-immune-manipulation</guid>
<description><![CDATA[ Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces.
The post Therapeutic Immune Manipulation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Amgen_Lab-Shot_CAR-T-Alternatives.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Therapeutic, Immune, Manipulation</media:keywords>
<content:encoded><![CDATA[<p>Chimeric antigen receptor (CAR) T-cell therapy was a major breakthrough in immunotherapy. To date, according to the Alliance for Cancer Gene Therapy, seven therapies have been approved for blood cancers such as Kymriah<sup>®</sup> and Yescarta<sup>®</sup>. As extraordinary as these CAR T-cell therapies are, the approach struggles with solid tumors, as well as adverse side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) resulting from <em>in vivo</em> T cell expansion. Complex manufacturing for autologous therapies and resultant costs limit the number of patients that can be treated.</p>
<p>Alternative approaches to engaging the immune system have been explored for decades, for instance, bispecific T-cell engager (BiTE) technology pioneered by Amgen. Companies like Artiva Biotherapeutics and Dragonfly Therapeutics are exploring the benefits that natural killer (NK) cells can bring, especially in B cell driven autoimmune diseases. Additionally, rare T cell populations such as invariant natural killer T (iNKT) cells are being harnessed to perform beyond their normal capabilities. Scientists also continue to innovate to try and bring solid cancers with edgy antigens under clinical control.</p>
<p>Importantly, autologous CAR T-cell therapy illustrated that the immune system can be exploited to combat disease as well as the challenges that need to be addressed when doing so. The next generation of immunotherapies is beginning to progress through clinical trials, and a new class of drugs could potentially be introduced for autoimmune diseases as well as oncology indications.</p>
<h4><strong>Harnessing the immune system</strong></h4>
<p>“BiTE<sup>®</sup> technology was developed to address an important unmet need in cancer care,” said Jean-Charles Soria, MD, PhD, senior vice president, global oncology development at Amgen. “For 30 years, we have built on this science, first in blood cancers and more recently in solid tumors.”</p>
<p>While the immune system has a natural ability to recognize and kill cancer cells, tumors can develop ways to evade that response. BiTE therapies bring T cells into direct contact with tumor cells by binding both CD3 on the T cell and a specific antigen on the tumor cell, activating T-cell-mediated killing.</p>
<p>BiTE and CAR T-cell therapies are distinct, complementary approaches that harness the immune system to fight cancer, according to Soria. BiTE “off-the-shelf” therapies are designed to redirect a patient’s own T cells to recognize and eliminate tumor cells expressing a selected target. This can enable treatment without the individualized cell collection and manufacturing process required for CAR T therapy.</p>
<p>Both platforms have demonstrated meaningful clinical benefits in appropriate settings. The optimal approach depends on the disease, the target biology, the patient’s condition, practical treatment considerations, and the totality of clinical evidence. “BiTE therapies may be particularly well suited to cancers with targets that are frequently and consistently expressed on tumor cells, with limited expression in healthy tissues,” said Soria.</p>
<p>Amgen continues to explore the impact of existing BiTE therapies, including the potential to address needs earlier in the small cell lung cancer treatment journey, and the potential to combine BiTE therapies with other innovative mechanisms of action. “We are also investigating new assets across additional tumor types. This includes xaluritamig, an investigational STEAP1-targeted BiTE in advanced clinical development for prostate cancer, where immunotherapy has historically had limited success,” Soria elaborated.</p>
<p>As the understanding of cancer biology grows, immunotherapy will become increasingly precise. Amgen’s focus is to translate deep insights in human genetics and disease biology into the right targets and therapeutic approaches to provide meaningful new options. The company brought to market the first globally approved BiTE molecule in hematologic malignancies, and the first FDA-approved BiTE therapy for a common solid tumor, small cell lung cancer.</p>
<h4><strong>Bumping up defenses</strong></h4>
<p>“The role of any cell therapy is to very potently kill the pathogenic B cells. We use non-genetically modified NK cells in combination with monoclonal antibodies (mAbs) such as Rituxan<sup>®</sup> for targeting the antigen on the B cell,” said Fred Aslan, MD, CEO at Artiva Biotherapeutics.</p>
<p>The Fab region of the mAb binds to the antigen on the B cell while the Fc portion binds to CD16 on the NK cell surface. This three-way binding activates the NK cell to kill the B cell. Given alone, Rituxan relies on endogenous NK cells that can be lowered or have low activity in patients with B cell cancers or autoimmune diseases. Dosing billions of NK cells simultaneously with the mAb positions the mAb to do more.</p>
<figure aria-describedby="caption-attachment-340469" class="wp-caption alignright"><img decoding="async" class="wp-image-340469 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-300x195.jpg" alt="Artiva_ MOA CAR T Alternatives" width="300" height="195" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-300x195.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-1024x665.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399-768x499.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Artiva_MOA_CAR-T-Alternatives-e1794231580399.jpg 1398w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">AlloNK is Artiva Biotherapeutics’ lead molecule. The high affinity CD16 NK cell is used in combination with Rituxan (rituximab). The Fab region of the mAb binds to the antigen on the B cell while the Fc portion binds to CD16 on the NK cell surface. This 3-way binding activates the NK cell to kill the B cell. This image was generated using artificial intelligence. [Artiva Biotherapeutics]</figcaption></figure>
<p>Importantly, since NK cells do not expand <em>in vivo,</em> serious side effects that result from T-cell expansion, CRS and ICANS, are avoided allowing therapeutic infusions outside of large hospital settings. However, the high dosages necessitate a robust manufacturing process.</p>
<p>A spin-off of Korea-based GC Cell, Artiva Biotherapeutics’ largest differentiation is its scalable process to manufacture NK cells. Umbilical cord units are selected from individuals with high affinity CD16 on the NK cells. Each umbilical cord creates about 50 intermediates that, in turn, each produce about 80 billion cells. “At a dose of eight billion cells, we can treat about 500 patients with a single umbilical unit. The COGS is a magnitude less than autologous CAR T-cell therapy,” said Aslan.</p>
<p>The company tested the NK cells with multiple targeting mAbs in two oncology and five autoimmune indications, close to 150 patients to date, to generate comparison data between the mAb and the combination therapy.</p>
<p>For example, using Rituxan alone, the average patient had an incomplete depletion; one B cell/ mL remained in the blood. In the combination therapy, no B cells were evident across all indications. In studies with aggressive non-Hodgkin lymphoma and Hodgkin lymphoma using a CD40 antibody, the complete response rate and durability were in line with autologous CAR T-cell therapy. Initial results with autoimmune disease also demonstrated results in line with autologous CAR T-cell therapy.</p>
<p>Artiva Biotherapeutics’ lead indication is refractory rheumatoid arthritis. They are initiating a Phase III trial with data expected by 2028.</p>
<h4><strong>Matching depletion to disease</strong></h4>
<p>The platform approach of Dragonfly Therapeutics for autoimmune disease spans CCR6, CD19, BAFFR, FAP, CD52 and BCMA, each aimed at a different pathogenic population and a different set of diseases, from lupus nephritis to fibrosis to amyloidosis.</p>
<p>The novel immune engagers include both first-in-class mAbs and trispecific immune cell engagers (TriNKETs). TriNKETs are antibody-like molecules with three binding arms: one for an antigen, one for NKG2D, and one for CD16. Both NKG2D and CD16 are activating receptors on NK cells.</p>
<figure aria-describedby="caption-attachment-340470" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-340470" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-300x169.jpg" alt="Dragonfly Lab" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_Dragonfly_Lab-shot_CAR-T-Alternatives.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The novel immune engagers developed by the Dragonfly Therapeutics team include both first-in-class mAbs and TriNKETs (trispecific immune cell engagers), antibody-like molecules with three binding arms: one for an antigen, one for NKG2D, and one for CD16. [Dragonfly Therapeutics]</figcaption></figure>
<p>In autoimmune disease, CAR T cells and Dragonfly Therapeutics’ biologically native immune engagers both aim for deep depletion of pathogenic B cells and an immune reset, but employ different routes. Not only do NK cells not require the same massive clonal expansion as T cells, but, additionally, NKG2D activation is already tuned by the body to respond to stressed cells. These facets can give a wider window between a depleting versus a harmful dose, sidestepping CAR T toxicity emerging in autoimmune disease.</p>
<p>Recruiting the patient’s existing cells means no expansion phase, no lymphodepletion, no gene modification of a living cell, and, therefore, no secondary malignancy risk from the product itself. A half-life measured in days makes the effect dose-controllable and reversible.</p>
<p>The company’s most clinically advanced autoimmune program, DF5112, a CCR6-targeting mAb, offers a multimodal approach. Overall, DF5112 is designed to deplete pathogenic CCR6+ cells and inhibit chemotaxis, minimizing tissue inflammation, providing benefit across several autoimmune diseases, including psoriatic arthritis, rheumatoid arthritis, lupus, hidradenitis suppurativa, and others.</p>
<p>Near completion of Phase I, the DF5112 CCR6 mAb sits on the specific cells that drive tissue inflammation in many autoimmune diseases, Th17 cells and a subset of memory B cells, while sparing the bulk of the immune system. It is the first molecule to deplete both at once. Early data are on track to be shared end of 2026.</p>
<p>According to Dragonfly Therapeutics, the next generation of immunotherapy is about depleting exactly the right cells. As different autoimmune diseases are driven by different cells, the company is building a toolkit that can match the depleted cell to the disease biology.</p>
<h4><strong>Utilizing distinct T cells </strong></h4>
<p>Another approach is utilizing iNKT cells. iNKT cells are a distinct T cell population with an internal targeting and homing device (iTCR) and modulate both arms of immunity, innate and adaptive. They naturally hone to tissues, promote tumor killing, viral clearance, suppress inflammatory cytokines and GvHD.</p>
<p>MiNK Therapeutics believes that due to iNKT cell biology these cells may represent a foundational approach to immune restoration applicable across a broad range of conditions. iNKTs have shown benefit in treating solid tumor cancers in their native form and MiNK Therapeutics has demonstrated that these cells can be engineered or edited for super-targeting. Clinical data show no neurotoxicity or CRS at 1 billion cells/ dose.</p>
<p>The company’s lead program, agenT-797, an allogeneic, off-the-shelf iNKT-cell therapy, is being evaluated in virally induced acute respiratory distress syndrome (ARDS), where a favorable safety profile, increased survival rate, and decreased secondary infection rates have been observed.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<h4><strong>Reprogramming tumors</strong></h4>
<p>CAR T cells struggle with solid tumors. Almost no antigens are found solely on tumor cells, plus the antigens that exist are patchy, and get lost over time. According to a USC research team one fix is to install an antigen, but only if the installation stays inside the tumor.<sup>1</sup> The concept is turning a signal the tumor controls into one the physician controls in a safe manner.</p>
<p>Tumor hallmarks like hypoxia are a reasonable biological address, but not a safe one to use alone since brain, liver, bone marrow and gut are also low in oxygen. Focused ultrasound (FUS) gives a precise physical address, but heat-shock-driven expression is a brief spike that fades before T cells can do much.</p>
<p>Therefore, the research team combined inputs to develop SHIFTERS (solid-tumor hallmark inducible, focused-ultrasound triggered enhanced reprogramming system), a two-key AND gated circuit that rewires tumor hallmarks into the clinically-validated antigen CD19 under FUS control. Hypoxia turns on one half of a split Gal4-VP64 transcription factor; FUS heating turns on the other half. Both need to be present for the halves to assemble and switch on CD19.</p>
<figure aria-describedby="caption-attachment-340471" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340471" src="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-1024x439.jpg" alt="USC Shifters schematic CAR T Alternatives" width="696" height="298" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-1024x439.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-300x129.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives-768x329.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Labant_USC_Shifters-schematic_CAR-T-Alternatives.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">SHIFTERS combines tumor hypoxia and FUS to induce CD19 in genetically engineered tumor cells. CD19 activates synNotch receptors on engineered T cells, inducing EGFR-directed CAR expression. Primed T cells can then attack EGFR-positive tumor cells, including neighboring cells without induced CD19. Not-to-scale conceptual illustration of a preclinical system; generated by AI. [Wang Lab, USC]</figcaption></figure>
<p>To test the hypothesis, the circuit was pre-installed in tumor cell lines then CD19 synNotch/estimated glomerular filtration rate (EGFR) CAR T cells were infused into 3D spheroids and <em>in vivo</em> immunodeficient mice models. The cells get “primed” by the induced CD19, and then kill surrounding tumor cells via EGFR. Killing stays localized; priming wears off quickly once T cells leave the area.</p>
<p>Testing across different oxygen levels showed the switch only fired at tumor-like one percent, ignoring normal low-oxygen tissue. SHIFTERS holds 60-80% expression through 72 hours, then returns to baseline by about day six; durable enough to work, reversible enough to be safe. With only 25% of tumor cells induced, more than half the entire population was killed.</p>
<p>SHIFTERS is modular. Swapping hypoxia for a liver-cancer-specific promoter reproduced the process in liver cancer cells only, with near-zero activity in other cell types. Next steps include adding ultrasound-gated cytokines (IL-2, IL-18, interferon-γ) to counter tumor immunosuppression without systemic toxicity; building a library of other tumor-hallmark promoters for other cancers; and working out the right FUS dosing schedule and behavior in immunocompetent models.</p>
<p> </p>
<p><em>References</em></p>
<p>1. Guo T, Zhu Z, Qu Y et al. Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. <em>Sci Adv</em>. 2026 Jun 12;12(24):eaed0666. doi: 10.1126/sciadv.aed0666.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/therapeutic-immune-manipulation/">Therapeutic Immune Manipulation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New AI Models Are Turbo&#45;Charging Protein Design</title>
<link>https://edusehat.com/en/new-ai-models-are-turbo-charging-protein-design</link>
<guid>https://edusehat.com/en/new-ai-models-are-turbo-charging-protein-design</guid>
<description><![CDATA[ Computer-designed protein therapeutics move from proof-of-concept to wet-lab validation and even clinical trials as the field heats up.
The post New AI Models Are Turbo-Charging Protein Design appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_2026_GettyImages-2172899400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Models, Are, Turbo-Charging, Protein, Design</media:keywords>
<content:encoded><![CDATA[<p>Getting a new biologic to market is laborious, expensive, and time-consuming, and one of the biggest drains on resources is watching promising candidates fail in preclinical or clinical testing. AI models that can design new proteins may be the ticket to optimizing drug development and providing companies better shots on goal. Companies are taking different approaches to the <em>de novo</em> design, but all share a common need: copious amounts of training data to level up their models. Will it eventually lead to fully autonomous <em>de novo</em> drug design?</p>
<h4><strong>Optimizing multispecifics development</strong></h4>
<p>Sanofi is moving AI-based protein design from proof-of-concept toward real-world drug discovery. Norbert Furtmann, PhD, head of biologics AI and design at Sanofi, says his team’s program is three-pronged: foundational models; property prediction and virtual screening; and <em>de novo </em>design.</p>
<p>The foundational models team develops sequence- and structure based models, analogous to large-language models but trained to “speak the language of proteins,” Furtmann says. These models have been built using a combination of public and in-house data. The property prediction and virtual screening team builds models to predict properties essential for function and developability, including stability, solubility, affinity, and so on. They run large <em>in silico</em> screens on hundreds of thousands of sequences, identifying which designs will move on to lab testing.</p>
<p>This is particularly valuable for multispecifics, where the enormous combinatorial design space makes comprehensive lab testing impossible. “If we have optimized monospecific antibody or nanobody building blocks, let’s say against target A, against target B, and against target C, and we want to plug them together, then we are facing enormous design spaces,” says Furtmann. “That could easily go into the hundreds of thousands of molecules, and you could not test all of them in a lab.”</p>
<p>The <em>de novo</em> design team starts with a target antigen structure and then has the AI model help design antibodies or nanobodies against it. Furtmann says the company’s first proof-of-concept studies on therapeutically relevant targets have been so successful that they are now looking to scale up the program. “We had a target where traditional discovery approaches faced challenges,” he says. Using their <em>de novo</em> design platform, the scientists successfully created functional binders, which Furtmann says are now moving forward into multispecifics.</p>
<p>When designing the binders, Furtmann says, it’s important to look beyond basic characteristics. “We try to think end-to-end and to understand what the monovalent building blocks need to look like to become successful, developable molecules in a multispecific format,” Furtmann says. “If you have a monospecific molecule, and then you plug five of them together for a multispecific, and they don’t behave well anymore, you need to start optimization again.”</p>
<p>The “lab-in-the-loop” workflow is key to this strategy, Furtmann says. This means taking the AI-generated designs, synthesizing them in the lab, and then feeding that data back into the model to fine-tune its designs. To achieve this, the company invests heavily in automation to achieve rapid, reproducible measurements and reliable data. “We aim for integration of the AI with the wet lab to get to fast feedback loops,” he says. “Yes, for monospecific optimization, but also specifically for the more complex multispecific molecules.”</p>
<h4><strong>A whole new type of antibody</strong></h4>
<p>Biolojic Design, based in Ness Ziona, Israel and Washington, DC, is using AI to build “multibodies,” standard human antibodies engineered to bind two or more targets. Unlike bispecific antibodies, which are built from fragments of two different antibodies, multibodies retain the familiar structure of a conventional human IgG antibody. This approach benefits from the established manufacturing, regulatory, pharmacokinetic, and safety advantages of ordinary antibodies, while enabling multiple therapeutic effects from a single drug.</p>
<p>Antibody structure typically includes quite a bit of “unused” space. Antibodies recognize their targets through six complementarity-determining regions (CDRs), but only a small fraction of that surface area is needed for antigen binding. “If you look at known antibody-antigen pairs, most of the CDRs are not involved in binding,” says Yanay Ofran, PhD, founder and CEO of Biolojic. “Each antibody has a lot of ‘free real estate.’ Our models allow us to precisely identify the free real estate and ‘develop’ it to accommodate additional binding.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The AI model redesigns this part of the molecule, allowing it to recognize additional epitopes without compromising specificity. Each arm of a multibody conditionally binds only one target at a time, but the drug binds differently depending on the tumor, tissue, or patient. This adaptability could help address tumor heterogeneity while limiting off-target interactions.</p>
<p>To build their multibodies, Biolojic fine-tunes temporary, highly specialized models for each project, Ofran says. “This is not a general solution intended to solve all the problems,” he says. “It’s a concentrated effort of a couple of months to build a dedicated model that will make one drug that no other technology can make and then will be retired.” First, existing models propose roughly a billion antibodies, each predicted to possess some desired property, such as binding a particular target or having a good developability profile. Researchers synthesize and test the variants and feed measurements of binding affinity, expression, specificity, and stability back into the model to refine it. That model proposes candidates combining all the required characteristics, which are subsequently evaluated in the lab.</p>
<p>One Biolojic product, a conditional agonist/antagonist, has already entered Phase II trials. The antibody binds the cytokine IL-2 in a context-dependent fashion, enabling it to stimulate T cells that attack the tumor while blocking T cells that protect it. This asset is being developed by Biolojic’s spinout company, Aulos Bioscience. So far, safety and efficacy data are encouraging, Ofran says.</p>
<p>Ofran points out that Biolojic’s approach goes beyond simply speeding up drug discovery. “We want to be fast, we want to be inexpensive, but what we want to do most is to come up with molecules that we are unlikely to find in traditional discovery,” he says. “Not to accelerate the time for getting the same type of molecules that you will get otherwise, but to get molecules that do things that traditionally discovered molecules cannot do.”</p>
<h4><strong>Evolving methods need new benchmarks</strong></h4>
<p>It can be difficult to objectively compare models when proof-of-concept results rely on different targets, assays and metrics, and that’s where Seattle-based A-Alpha Bio comes in. “We are particularly interested in answering this question earnestly: what is the kind of data that helps build better models?” says Natasha Murakowska, PhD, director of applied machine learning at A-Alpha. “What will it require to do this sort of <em>de novo</em> design perfectly every time?”</p>
<figure aria-describedby="caption-attachment-340478" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340478" src="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-300x187.jpg" alt="AI protein design models" width="300" height="187" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-300x187.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-1024x638.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure-768x478.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-DND-figure.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">As AI protein design models proliferate, it’s important to be able to compare different systems against one another using an objective standard benchmark, and to generate large amounts of data for training and improving the models. A-Alpha Bio’s large VHH de novo design benchmark tests models against the same panel of 28 antigens spanning three tiers of difficulty. [A-Alpha Bio]</figcaption></figure>
<p>To that end, A-Alpha is running a large VHH <em>de novo</em> design benchmark. They have invited about a dozen groups to each submit 10,000 designed antibody sequences, which A-Alpha will synthesize and test against a panel of 10 targets, yielding some 110,000 VHHs. Their aim is to build the largest apples-to-apples benchmark of <em>de novo</em>-designed antibodies, evaluating not just whether antibodies bind, but how strongly and how specifically, and what sequence or structural features distinguish the winners.</p>
<p>Central to this effort is AlphaSeq, A-Alpha’s library-on-library yeast display assay. One library encodes the antibodies, the other encodes the targets; when combined, AlphaSeq effectively measures all pairwise interactions. This generates, on the scale of one million quantitative protein-protein interaction data points per experiment, Murakowska explains, revealing information about not only target binding affinity but also off-target effects.</p>
<p>The benchmark’s target panel is stratified into three tiers of difficulty. In Tier 1, a known antibody–antigen crystal structure is provided, and the models must design novel variants that improve binding. Tier 2 provides a crystal structure of the antigen alone, challenging models to choose a bindable epitope and design a complementary interface.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Tier 3 is what Murakowska calls the “holy grail”: targets where no structural information is provided, requiring the model to infer the antigen’s structure, pick a druggable region, and then design an antibody to bind it. “It stacks complexity, and it tasks model makers in multiple ways,” she says. “If you want to earnestly solve this problem, teams need to think about the holistic problem of representing the right protein, representing the right epitope, which is that surface that the antibody binds, and then also designing for that surface.”</p>
<p>Leveling up AI-assisted drug design requires vast amounts of high-quality data that doesn’t currently exist. A-Alpha recently launched the Atlas Consortium, a collaborative model where companies of very different sizes jointly generate new, shared AlphaSeq datasets under a common experimental framework. One of the key selling points of the Atlas Consortium is that every member, large or small, increases the value of participation for the other members by contributing datasets.</p>
<figure aria-describedby="caption-attachment-340477" class="wp-caption aligncenter"><img decoding="async" class="wp-image-340477" src="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-1024x470.jpg" alt="consortium members" width="696" height="319" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-1024x470.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-300x138.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369-768x352.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Seydel-GroupPhoto_A-AlphaBio_2026July-e1794232462369.jpg 1400w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">A new collaborative initiative, the Atlas Consortium, seeks to increase the available body of data to address major objectives for AI-driven protein design. Each quarter, A-Alpha Bio generates datasets using the AlphaSeq platform for training and benchmarking models. These datasets are then pooled and shared with consortium members. [A-Alpha Bio]</figcaption></figure>
<h4><strong>Human out of the loop?</strong></h4>
<p>Anthropic has published results showing that its Claude models can design miniprotein binders with essentially no human involvement. The models designed binders against 15 protein targets and sent the designs to Adaptyv Bio and Twist Bioscience for synthesis and evaluation. Testing confirmed that the Claude-designed minibinders were successful for 14 of the 15 targets.</p>
<p>To achieve this, Claude drew on existing open-source software, including backbone generators like RFdiffusion3; sequence-design tools such as ProteinMPNN; and structure predictors used to screen candidates before synthesis. Within that framework, Claude selected which surface of each target to bind, chose and combined design tools, filtered candidates, and delivered 30 ranked designs per target after 24- to 48-hour autonomous runs. Human involvement was limited to selecting targets, granting permissions, and ensuring the infrastructure was running properly.</p>
<p>Among 1,320 designs, 354 bound their targets, giving an overall hit rate of 27%, although results varied widely depending on the target. Claude was not able to come up with a binder for maltose-binding protein, for instance, although it did produce several binders against TNFα, a therapeutically relevant target that has stumped other AI design efforts.</p>
<p>The designs were evaluated solely for binding affinity, not for activity, and none of the designs were solved structurally. Anthropic describes the result as foundational, a step toward the goal of AI systems autonomously handling drug-discovery from end to end.</p>
<p>“Minibinders are not meant to be drugs,” says Emily Leproust, PhD, CEO of Twist Bioscience. Designing therapeutics will require the model to advance to larger, more complex models, which will require more data points to train them. “That’s why we are adding more and more capacity, so that people can build more data points with us at a lower cost and at speed.”</p>
<p>“What we like about AI is you can do co-optimization of binding and developability at the same time,” Leproust adds. Traditional drug screening involves first optimizing for binding and then engineering in developability after the fact, which can be frustrating and inefficient. Using AI to optimize for both in parallel can boost success rates. “That can significantly, I think, increase the probability that an antibody is going to behave well in the clinic, because you don’t engineer developability after the fact,” she says. “It’s a subtle thing, but it really makes a big impact.”</p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/new-ai-models-are-turbo-charging-protein-design/">New AI Models Are Turbo-Charging Protein Design</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests</title>
<link>https://edusehat.com/en/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests</link>
<guid>https://edusehat.com/en/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests</guid>
<description><![CDATA[ Childhood cancers may not always need extra mutations to spread, a new review study indicates. Instead, developmental plasticity may let tumor cells shape-shift into states that help them grow, resist treatment, and ultimately metastasize.
The post Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/GettyImages-2204955763.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 22:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Childhood, Cancers, May, Not, Always, Need, Extra, Mutations, Spread, Study, Suggests</media:keywords>
<content:encoded><![CDATA[<p><span>Data from a new study from scientists at the University of East Anglia and Liverpool John Moores University could help explain why some childhood tumors spread aggressively despite having relatively few genetic mutations. The findings, which are published in a new </span><i><span>Trends Open </span></i><span>review paper,</span><span> indicate that childhood cancers may not always need to develop extra mutations to spread. Some cells may be able to switch into different cellular states between behaviors that help them grow, survive treatment, and ultimately spread. </span></p>
<p><span>Furthermore, in the paper, titled “Developmental plasticity as a framework for paediatric cancer metastasis,” the scientists write that the process may be reversible. “Many childhood cancers arise from cells that are still closely linked to developmental programs used during early life,” and these programs “normally allow cells to move around the developing body, adapt to changing environments, and become different tissue types,”  said Darrell Green, PhD, an assistant professor and scientific group leader for RNA research at Norwich Medical School at University of East Anglia and one of the authors on the paper. “We think that cancer cells in children may exploit this natural flexibility of young, developing cells in order to spread.” </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>To reach their conclusions, the scientists reviewed evidence from various childhood cancers, including neuroblastoma, Ewing sarcoma, osteosarcoma, medulloblastoma, and rhabdomyosarcoma. According to the paper, they integrated “genomic, epigenomic, developmental and single-cell evidence to examine how oncogenic lesions and developmental origins define accessible cellular states, while epigenetic, metabolic, and microenvironmental signals regulate transitions between them.”</span></p>
<p><span>Based on their analysis, the scientists propose that genetic changes determine which cellular identities cancer cells can adopt, while reversible changes in gene activity seem to dictate whether those cells become aggressive, resistant to treatment or capable of forming metastatic tumors. </span></p>
<p><span>This suggests that “rather than needing to acquire new mutations before they can spread, childhood cancer cells may already possess the ability to become metastatic,” Green explained. “The new, key question is not just what mutations they carry, but which cellular state they are in at a particular moment.” It is a point that “challenges the long-held assumption that cancers must acquire new mutations before they can metastasize.” </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The scientists hope that their work could ultimately lead to new types of treatments or at least point to ways to modify existing treatments. This means, for example, that instead of focusing solely on killing tumor cells or targeting mutated genes, future therapies might aim to stop cancer cells entering the states that make them dangerous in the first place. In fact, “it may eventually become possible to predict when cancers are preparing to spread,” Green said. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/childhood-cancers-may-not-always-need-extra-mutations-to-spread-study-suggests/">Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate</title>
<link>https://edusehat.com/en/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate</link>
<guid>https://edusehat.com/en/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate</guid>
<description><![CDATA[ Sanofi halted development of an oral STAT6 degrader that had been under study in a Phase I first-in-human trial in Europe. STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, launched in 2020. 
The post StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/nurix-scientist.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 09 Nov 2026 11:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Nurix, Nosedives, Sanofi, Halts, Phase, Immunology, Candidate</media:keywords>
<content:encoded><![CDATA[<p><strong>Nurix Therapeutics (Nasdaq: NRIX)</strong> suffered its worst one-day loss as a public company Wednesday when <strong>Sanofi (Euronext Paris: SAN and Nasdaq: SNY)</strong> terminated development of the Phase I immunology candidate SAR448272 (NX-3911)—a key program of the companies’ nearly seven-year, up to $ 2.5 billion collaboration to discover, develop, and commercialize protein degradation drugs for “challenging” diseases.</p>
<p>The rest of the collaboration continues despite Sanofi pulling the plug on SAR448272 (NX-3911), an oral signal transducer and activator of transcription 6 (STAT6) degrader that had been under study in a Phase I first-in-human trial in Europe (European Union Clinical Trials Register number <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Feuclinicaltrials.eu%2Fctis-public%2Fview%2F2026-526014-87-00&data=05%7C02%7Calex.philippidis%40sagepub.com%7Cc95c54bf0ac44b176ea408df3b6c9722%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639295012066774767%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FBy14hQz1TcP2YE%2BGi9ZXifh%2BnNO7%2FFCA%2F2kR9qSDo8%3D&reserved=0">2026-526014-87-00</a>). The trial began recruiting patients in Germany in July and had planned to expand recruitment into the Czech Republic, France, Italy, and Spain, a milestone that triggered a $10 million payment from Sanofi to Nurix in August.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, which took effect in January 2020 when Sanofi paid Nurix $55 million upfront. At the time, Sanofi committed to paying Nurix up to $2.5 billion in total payments, most of that tied to achieving research, preclinical, clinical, regulatory, and sales milestones.</p>
<p>As of August 31, Sanofi had paid Nurix a total $129 million—the $55 million upfront; $22 million in 2021 when Sanofi exercised an option to expand from three to five targets; $22 million for achieving research milestones; and $30 million for license extension fees—according to Nurix’s <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fir.nurixtx.com%2Fstatic-files%2Fc8ca0871-108d-480d-9f6b-080ac39488ff&data=05%7C02%7Calex.philippidis%40sagepub.com%7Cc95c54bf0ac44b176ea408df3b6c9722%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639295012066792878%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=JZEd8DtVNcs5ZdwuUcpKAULtGF3YcMalBSJBOsZRQ%2FQ%3D&reserved=0">Form 10-Q quarterly report for the third quarter</a>, filed October 13.</p>
<p>Nurix insisted that its recent cash runway guidance would not be affected by Sanofi’s halting development of SAR448272. Nurix said it had enough cash to fund operations into the second half of 2029 based on its $1.1 billion of cash, cash equivalents, and marketable securities as of August 31.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>Reassurance and rejection</strong></h4>
<p>“While [Tuesday]’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline,” Arthur T. Sands, MD, PhD, Nurix president and CEO, stated Tuesday after the close of markets.</p>
<p>The following day, investors appeared to reject that reassurance, selling off enough shares for Nurix stock to <span><strong>nosedive 38%</strong></span> from $25.82 to $15.95. Shares <span><strong>fell another 7%</strong> </span>to $14.84 Thursday on a day the Nasdaq market had its worst one-day performance in the past 19 months—but the stock <span><strong>bounced back 3%</strong></span> Friday, finishing the week at $15.30 and a <span><strong>nearly 43% five-day decline</strong></span>.</p>
<p>“While we can understand the market’s knee-jerk disappointment following the news (STAT6 is regarded as a high-value target), we continue to view Nurix as a differentiated name within the emerging oral protein degrader space,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, wrote in a research note.</p>
<p>The reason why, Romero explained, is Nurix’s ongoing up-to-$2.3 billion global collaboration with <strong>Roche (SIX Swiss: RO and ROP)</strong> to develop bexobrutideg (“bexdeg” or “bexo”; NX-5948), a clinical-phase oral brain-penetrant Bruton’s tyrosine kinase (BTK) degrader.</p>
<p>In addition to the dollars, Romero said, that partnership is also attractive for Nurix because bexdeg can potentially be developed for numerous other therapeutic areas with diseases driven by BTK; the collaboration stretches across malignant hematology, immunology, and neurology.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Another reason why the Roche-Nurix partnership is attractive, the J.P. Morgan analyst added, is because Roche shoulders 60% of global development costs (with Nurix chipping in the other 40%) while the companies have agreed to split 50-50 both the U.S. commercialization responsibility (Roche holds sole ex-U.S. commercialization rights), as well as the resulting profits and losses from U.S. commercialization.</p>
<h4><strong>$48B market opportunity</strong></h4>
<p>“Historical stock moves around NRIX/STAT6 suggest the program carried some value, but was not the primary driver of NRIX’s value, with the much larger strategic inflection tied to the Roche/bexo partnership,” commented Roger Song, MD, equity analyst with Jefferies, in a research note.</p>
<p>In a June 8 <a href="https://ir.nurixtx.com/static-files/7ab7c64e-19dd-4242-bf61-420c9dfba537#page=15">investor presentation</a>, Nurix quantified the size of that potential inflection as a $48 billion addressable market opportunity across five diseases: chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), chronic spontaneous urticaria (CSU), and multiple sclerosis (MS).</p>
<p>CLL and small lymphocytic lymphoma (SLL) are the two diseases where bex-deg development is furthest along; the drug is under study in the Phase III DAYBreak trial (CLL-306, <a href="https://clinicaltrials.gov/study/NCT07516093">NCT07516093</a>), which is recruiting patients toward an estimated enrollment of 620, and carries an estimated primary completion date of October 2029. Last month, the first patient was enrolled in a Phase I/II combination trial (NX-5948-203; <a href="https://clinicaltrials.gov/study/NCT07520006">NCT07520006</a>) evaluating the combination of bex-deg and venetoclax, a standard-of-care BCL2 inhibitor, in patients with relapsed/refractory CLL, with planned expansion to first-line therapy.</p>
<p>“We see opportunity for upside from bex-deg expansion into inflammatory/autoimmune and neurological indications,” Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer, wrote in a research note. “We see CSU as [a] particularly attractive indication given derisking of BTK-targeting by [Novartis’ <strong>(SIX Swiss: NOVN and NYSE: NVS)</strong> BTKi (BTK inhibitor)] remibrulnib and higher bex-deg potency on mast cell degranulation assay without bleeding risk.</p>
<h4><strong>Sanofi’s decision</strong></h4>
<p>So why did Sanofi terminate development of SAR448272?</p>
<p>Nurix offered no reason in its press release, and company executives told Song of Jefferies it was not told in advance of the decision.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“The decision was due to emerging nonclinical findings that precluded Sanofi from bringing it forward in atopic dermatitis,” Sanofi indicated to Nurix during a quick catch up conversation, according to Romero, who cautioned: “Nurix has <em>not </em>reviewed any data and therefore could not confirm the issues Sanofi saw. Nurix is also unclear whether Sanofi’s broader portfolio strategy played a role in the decision.”</p>
<p>Biliouris offered a possible portfolio explanation for Sanofi’s decision: “It may be driven by robust/convincing (HV) data from other SNY [Sanofi] collaboration (STAT6i), STAT6 degrader safety signals, or SNY strategic prioritization following [<strong>Regeneron Pharmaceuticals (Nasdaq: REGN)</strong>]’s partnership around long-acting IL-13/IL-13 x IL-14,” Biliouris wrote.</p>
<p>Sanofi is partnering with privately held <strong>Recludix Pharma</strong> to develop an oral STAT6 inhibitor or “STAT6i” called REX-8756 (also known as SAR448755). REX-8756 is a first-in-class, reversible orthosteric inhibitor of the STAT6 SH2 domain that targets Type 2 inflammatory pathways (IL-4 and IL-13), and which according to the companies is designed to be highly potent, selective, and durable.</p>
<p>The companies have advanced REX-8756 to a Phase I trial designed to assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics, with single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The blinded, placebo-controlled trial expects to enroll approximately 100 healthy volunteers.</p>
<p>Recludix presented positive preclinical model data for REX-856 at the Revolutionizing Atopic Dermatitis (RAD) Congress, held June 17-19 in Nashville, TN. Sanofi and Recludix launched their collaboration in 2023. It includes $125 million in “near-term” payments; up to $1.2 billion-plus in development, regulatory and sales milestones; as well as up to double-digit royalties on product sales.</p>
<p>More recently last month, Sanofi and Regeneron expanded their 23-year-old partnership—whose most successful product is the multi-indication blockbuster Dupixent<sup>®</sup> (dupilumab)—by adding multiple next-generation, long-acting antibodies to their alliance. Sanofi agreed to pay Regeneron $1 billion upfront, and up to an additional $7 billion tied to achieving development, regulatory, and commercial milestones.</p>
<p>Under the expanded license and collaboration agreement, Sanofi and Regeneron agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4), and interleukin-4 receptor alpha (IL-4Rα). The IL-13 antibody, REGN20423, is now being evaluated in the Phase I AURA-AD trial (<a href="https://clinicaltrials.gov/study/NCT07527923">NCT07527923</a>) in atopic dermatitis, while the other three antibodies are expected to enter the clinic in 2027.</p>
<p> </p>
<h2><strong>Leaders and laggards</strong></h2>
<p><strong>Karyopharm Therapeutics (KPTI)</strong> shares <span><strong>skidded 21%</strong></span> Tuesday, from 11 cents to 9 cents, after the Newton, MA-based developer of nuclear export inhibitors designed to treat cancer said it filed for protection from creditors under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. Karyopharm said it entered into a Restructuring Support Agreement with its lenders, noteholders, and other key stakeholders, under which the company, once reorganized, plans to merge with privately held, London-based <strong>Ayrmid</strong>—which has agreed to serve as lead bidder in a court-supervised sale process intended to maximize value for all stakeholders. Karyopharm said it has secured commitments for up to $55 million in debtor-in-possession (DIP) financing from its existing secured lenders. Upon court approval, the DIP financing plus cash from ongoing operations is expected to support Karyopharm operations during the Chapter 11 process and meet the company’s financial obligations.</p>
<p><strong>Rhythm Pharmaceuticals (NASDAQ: RYTM)</strong> shares <span><strong>surged 28%</strong></span> from $86.44 to $110.68 Wednesday after <em>The Wall Street Journal</em> reported that <strong>AstraZeneca (LSE, NYSE, and Nasdaq Stockholm: AZN)</strong> made a roughly $10 billion offer to buy the rare disease drug developer, citing unnamed sources. AstraZeneca offered to pay $124 a share for the biotech last month, the Journal reported—a 35% premium over Rhythm’s closing share price Tuesday. AstraZeneca raised its bid to $134 a share, according to Reuters. Rhythm has declined comment while AstraZeneca has not commented on the reported offers. Shares <span><strong>slid 5%</strong></span> to $105.02 Thursday before <span><strong>rising again 7%</strong></span> to $112.28 Friday, after the merger-and-acquisition blog Betaville posted speculation from traders that a second potential global pharma giant may have made a counteroffer for Rhythm.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nurix-nosedives-as-sanofi-halts-phase-i-immunology-candidate/">StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Aging Proteome: Clocks, Cohorts, and Clinical Trials</title>
<link>https://edusehat.com/en/the-aging-proteome-clocks-cohorts-and-clinical-trials</link>
<guid>https://edusehat.com/en/the-aging-proteome-clocks-cohorts-and-clinical-trials</guid>
<description><![CDATA[ In this GEN webinar, two experts will show how ultra-sensitive, multiplexed proteomics can measure both the pace of aging and the effects of interventions designed to change it. 
The post The Aging Proteome: Clocks, Cohorts, and Clinical Trials appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_460712007_DNA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Aging, Proteome:, Clocks, Cohorts, and, Clinical, Trials</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/XiaoJunMa_headshot.jpg" class="h-full w-full object-cover" alt="Image of Xiao-Jun Ma, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Xiao-Jun Ma, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Chief Technology Officer<br>Alamar Biosciences</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/XiaoJunMa_headshot.jpg" alt="Image of Xiao-Jun Ma, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Xiao-Jun Ma, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Xiao-Jun Ma, PhD, joined Alamar Biosciences in June of 2021 as chief technology officer. Xiao-Jun is a successful R&D leader with more than 20 years of experience in the life sciences and molecular diagnostics industries. Most recently he served as vice president and chief scientific officer in the Genomics Division of Bio-Techne. During his 11-year tenure at ACD, Ma led the development of a portfolio of<em> in situ</em> RNA and DNA detection solutions for research and clinical diagnostics markets. Prior to joining ACD, he was vice president of R&D/biostatistics at bioTheranostics. Before bioTheranostics, Ma held senior bioinformatics positions at Johnson & Johnson and Monsanto/Searle (Pfizer), where he applied his multi-disciplinary knowledge in molecular biology and bioinformatics to discover novel drug targets and biomarkers. He received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/MichaelCorley_headshot.jpg" class="h-full w-full object-cover" alt="Image of Michael J. Corley, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Michael J. Corley, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]">Tenured Assoc. Professor of Medicine<br>University of California, San Diego</h3>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/MichaelCorley_headshot.jpg" alt="Image of Michael J. Corley, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Michael J. Corley, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Michael J. Corley, PhD, is an associate professor in medicine within the Division of Geriatrics, Gerontology, & Palliative Care and The Stein Institute for Research on Aging. He received his undergraduate degree from UCSD, an MA and PhD in behavioral neuroscience from the University of Hawaii, and completed postdoctoral training at the John A. Burns School of Medicine in epigenetics, immunology, and infectious diseases. Corley leads a global epigenetics research program focusing on understanding the interplay between the immune system, viruses, and aging. His laboratory is at the forefront of generating critical data to advance the development, validation, and implementation of novel biomarkers and therapeutics aimed at promoting longevity.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, December 1, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-01T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Geroscience proposes that slowing the biology of aging could delay many chronic diseases at once. Testing that idea requires biomarkers that are precise, reproducible, and responsive to intervention.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, two experts will show how ultra-sensitive, multiplexed proteomics can measure both the pace of aging and the effects of interventions designed to change it. In his talk, Michael Corley, PhD, will explain why the aging field is limited less by ideas than by evidence, and how completed clinical trials with banked samples can be used to screen candidate interventions quickly. He will share proteomic and epigenetic findings from a randomized trial of semaglutide, including cardiometabolic and inflammatory protein changes during treatment and after the drug is stopped. He will also describe XPRIZE Healthspan, a global competition whose central biorepository will hold samples from 20 intervention trials.</p>


<p class="wp-block-paragraph">Then Xiao-Jun Ma, PhD, will present a data-driven proteomic module identified across three cohorts that tracks biological aging. He will show how a clock built from this module relates to mortality, cognition, and comorbidity burden, how it compares with DNA methylation clocks, and what it reveals about when proteomic aging accelerates. Key takeaways include:</p>


<ul class="wp-block-list">
<li>Why evidence, not ideas, is the bottleneck in geroscience, and how completed trials can help close the gap</li>



<li>How proteomic measurements capture intervention effects that epigenetic clocks may miss</li>



<li>How an intrinsic, unsupervised protein module can serve as a portable measure of biological aging</li>



<li>What large, harmonized trial biorepositories mean for biomarker discovery in aging research</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://alamarbio.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="80" src="https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c-300x80.jpg" alt="Alamar Biosciences Logo" class="wp-image-302414" srcset="https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c-300x80.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/10/AlamarDropLogo_4c.jpg 379w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/the-aging-proteome-clocks-cohorts-and-clinical-trials/">The Aging Proteome: Clocks, Cohorts, and Clinical Trials</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ER&#45;Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals</title>
<link>https://edusehat.com/en/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals</link>
<guid>https://edusehat.com/en/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals</guid>
<description><![CDATA[ The results of a study found that women with higher blood levels of two common PFAS were more likely to develop estrogen receptor-negative breast cancer, saying their results have important public health implications.
The post ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/09/Nov19_2020_Getty_1201440632_CancerCell-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 01:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ER-Negative, Breast, Cancer, Risk, Linked, with, Blood, Levels, Two, PFAS, Forever, Chemicals</media:keywords>
<content:encoded><![CDATA[<p>Per- and polyfluoroalkyl substances (PFAS) are a large group of chemicals used in common consumer products. Often referred to as “forever chemicals,” PFAS do not break down easily in the environment and can remain in the body for years.</p>
<p>The results of a study carried out by National Institutes of Health researchers has now found that women with higher blood levels of two common PFAS, perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), were more likely to develop estrogen receptor-negative (ER-negative) breast cancer. ER-negative tumors lack receptors that allow the hormone estrogen to help cancer cells grow. There was no clear association observed between the two chemicals and breast cancer risk overall.</p>
<p>“Our findings, which we confirmed using a meta-analysis of prior research, indicate that certain legacy PFAS, including PFOA and PFOS, are associated with a higher risk of ER-negative breast cancer, a more aggressive tumor type with few known risk factors,” said NIH Stadtman Investigator Alexandra White, PhD, who led the study. Although PFOA and PFOS compounds have been largely phased out and replaced with new PFAS compounds, most individuals have measurable levels of PFOA and PFOS in their bodies.</p>
<p>White is senior and corresponding author of the researchers’ published paper in <em>Journal of Clinical Oncology</em>, titled “<a href="https://doi.org/10.1200/JCO-26-00318" target="_blank" rel="noopener">Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study</a>,” in which they concluded “Given the widespread exposure to PFAS and limited established risk factors for ER-negative tumors, these results have important public health implications.”</p>
<p>Breast cancer is the most common cancer among women, and incidence rates are rising in the U.S. and worldwide, the authors stated. Established breast cancer risk factors, such as reproductive history, exogenous hormone use and lifestyle factors, have been more strongly linked with hormone receptor–positive than with hormone receptor–negative tumors.</p>
<p>Scientists know less about what raises the risk of ER-negative breast cancer. “Evidence suggests that hormone receptor–negative tumors might have distinct etiologies, yet their risk factors remain largely unknown,” the researchers wrote. “This knowledge gap is concerning as hormone receptor–negative tumors are more aggressive with poorer clinical outcomes.”</p>
<p>The newly reported research drew on the <a href="https://www.niehs.nih.gov/research/atniehs/labs/epi/resources/data-sharing/sister" target="_blank" rel="noopener">Sister Study</a>, which is led by NIH’s National Institute of Environmental Health Sciences (NIEHS). This larger study enrolled 50,884 women ages 35–74 in the U.S. and Puerto Rico from 2003 to 2009. None had breast cancer when they joined the Sister Study, but each had a full or half-sister who had been previously diagnosed with breast cancer.</p>
<p>For their PFAS study White and team included 1,609 women who developed breast cancer and a comparison sample of 2,269 women. “We oversampled estrogen receptor (ER)–negative cases (324 ER-negative, 1,120 ER-positive) to improve statistical power,” they explained in their paper. “To our knowledge, this is the largest study to date of PFAS exposure and breast cancer incidence, particularly for ER–tumors.”</p>
<p>The investigators measured 17 PFAS in blood, collected years before women were diagnosed with cancer. “Seventeen PFASs were quantified in prediagnostic plasma using liquid chromatography-high-resolution mass spectrometry,” they noted. The results of their studies showed that women in the group with the highest PFOA levels had a 67% higher rate of ER-negative breast cancer than those in the lowest group. For PFOS, the rate was 93% higher—nearly twice as high. These numbers describe relative differences between groups, not an individual woman’s chance of getting breast cancer.</p>
<p>The team also carried out meta-analyses, including the current and prior prospective studies, which showed consistent positive associations of PFOA and PFOS with ER-negative breast cancer. “Our meta-analyses of studies with prediagnostic blood measurements further support a positive association between PFOA and ER-tumors, with suggestive evidence for PFOS and ER-tumors,” they stated.</p>
<p>“These findings matter for women’s health broadly,” said first author Che-Jung Chang, PhD, a former research fellow at NIH and a current researcher at DLH, a scientific research organization. “Although PFAS are persistent in the environment and in our bodies, exposure to them is still potentially modifiable, meaning people can take steps to reduce their exposure, and these findings could open new avenues for prevention.”</p>
<p>Because the strongest associations involved tumors without hormone receptors, the authors suggest that PFAS may affect cancer risk through other non-hormonal biologic pathways. Possible pathways include changes in gene activity or immune system. The reported study did not test those potential explanations.</p>
<p>The authors say future studies should evaluate people with higher PFAS exposure and in groups more affected by ER-negative breast cancer. “More research is needed, particularly evaluating the risk of breast cancer associated with newer replacement PFAS chemicals,” White added.</p>
<p>In their paper the authors concluded, “Future studies should prioritize investigating these associations in populations with higher PFAS exposure and a greater burden of hormone receptor–negative breast cancer to better inform targeted prevention efforts. Research is also needed to assess the carcinogenic potential of newer PFAS replacement chemicals, which remain poorly characterized.”</p>
<p>Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., commented, “Women deserve clear answers about how chemicals in their environment may affect their health. This NIH study links two forever chemicals to a higher risk of ER-negative breast cancer and demands further investigation. Under President Trump’s leadership, we will pursue the evidence, confront environmental health risks, and give women the information they need to protect their health.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/er-negative-breast-cancer-risk-linked-with-blood-levels-of-two-pfas-forever-chemicals/">ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma</title>
<link>https://edusehat.com/en/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma</link>
<guid>https://edusehat.com/en/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma</guid>
<description><![CDATA[ &quot;Two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement.
The post Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Dec14_2020_Getty_904268264_XYChromosomes1-1024x683-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 07 Nov 2026 01:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Novartis, Confirms, Nine, Cases, Tumors, Children, Treated, with, Gene, Therapy, Zolgensma</media:keywords>
<content:encoded><![CDATA[<p>Novartis has confirmed nine reports—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma<sup>®</sup> (onasemnogene abeparvovec-xioi).</p>
<p>“Of those, two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement furnished to <em>GEN</em> and other news outlets.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Patient safety is our priority. In each case, we timely and appropriately notified health authorities and will continue to work with them on next steps,” the pharma giant added.</p>
<p>To date, Novartis stated, Zolgensma has been used to treat more than 6,000 patients worldwide across clinical trials, managed access programs, and commercial treatment.</p>
<p>The statement added: “The potential risk of tumors due to vector integration is currently included in the Zolgensma prescribing information.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Zolgensma is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (<em>SMN1</em>) gene.</p>
<p>Zolgensma is designed to address the genetic root cause of SMA by replacing the function of the missing or nonworking <em>SMN1</em> with a new working copy of the gene delivered into a patient’s cells. The gene therapy consists of a recombinant, non-replicating AAV serotype 9 (AAV9) vector whose DNA persists largely in episomal form, according to the therapy’s prescribing information label.</p>
<p>Random integration of recombinant AAV vector DNA into human DNA has been reported with Zolgensma and in published studies about other AAV gene therapies, Novartis has acknowledged.</p>
<p>“The clinical relevance of individual integration events is unknown, but it is acknowledged that individual integration events could potentially contribute to a risk of tumorigenicity. Cases of tumor have been reported in patients who received Zolgensma post-approval,” the label added.</p>
<h4><strong>‘Theoretical risk’</strong></h4>
<p>Zolgensma’s <a href="https://www.novartis.com/us-en/sites/novartis_us/files/zolgensma.pdf" target="_blank" rel="noopener">prescribing label </a>includes a section titled “AAV Vector Integration and Risk of Tumorigenicity.” That section, however, states: “There is a theoretical risk of tumorigenicity due to integration of AAV [adeno-associated virus] vector DNA into the genome.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The label urges prescribers to report cases of tumors in patients who received Zolgensma to Novartis.</p>
<p>Novartis’ statement followed a statement issued Thursday by the Muscular Dystrophy Association (MDA). In the MDA statement, the association acknowledged awareness of reports about tumors developing in Zolgensma patients.</p>
<p>MDA stated that it “understand[s] that this raises questions and concerns for families, particularly those who have made important treatment decisions for themselves or their children. We take these reports seriously and believe families deserve transparent, timely, and science-based information as more is learned.”</p>
<p>“MDA is seeking additional information, reviewing the available scientific and safety data with clinical and research experts, and has reached out to Novartis,” the association added. “We recognize the sense of urgency from families to access additional information about these reports in order to make informed treatment and monitoring decisions. MDA is working to learn more as soon as possible.”</p>
<h4><strong>‘Confidential channels’</strong></h4>
<p>SMA Europe, an umbrella organization for SMA patient groups across the continent, issued its own <a href="https://www.sma-europe.eu/news/information-regarding-recent-zolgensma-safety-concerns?ref=/news" target="_blank" rel="noopener">statement</a> Thursday saying it was informed about the tumor cases “through confidential channels, and have made clear to Novartis that the SMA community now needs timely public communication.”</p>
<p>“We have strongly urged the company to provide clear information on what is currently known, what remains uncertain, what this may mean for people who have already received treatment, and whether any additional monitoring or action is recommended,” SMA Europe added.</p>
<p>SMA Europe and MDA spoke out after a hospice chaplain <a href="https://www.linkedin.com/posts/rev-carolyn-philstrom-a022aa254_im-deeply-disturbed-to-hear-this-news-that-share-7523572705716273152-Yypr/?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAIZI_4BqbJMjmmSJ_keDePIgmaFCPQ_iaY" target="_blank" rel="noopener">shared on LinkedIn </a> the post of a private Facebook group in which the parent of a child with SMA wrote of being informed by his neurologist that Novartis was withholding information about some of the tumor cases and opting instead for a “tiered rollout” of data.</p>
<p>“I am also sending this screenshot to reporters. I strongly encourage you to abandon any belief that Novartis can control this narrative, and to do something radical for your company: tell the truth,” Rev. Carolyn Philstrom urged.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>During the first three quarters of this year, Novartis’ Zolgensma Group—consisting of the namesake IV-formulation gene therapy and an intrathecal formulation approved last year and marketed as Itvisma<sup>®</sup> (onasemnogene abeparvovec-brve)—generated $1.071 billion in net sales, up 16% from $925 million in January–September 2025. Of that total, $404 million was generated during the third quarter, up 34% from $301 million in Q3 2025.</p>
<p>Zolgensma Group finished last year with $1.232 billion in net sales, up 1.5% from $1.214 billion in 2024. Zolgensma is one of Novartis’ top 20 brands.</p>
<p>Novartis shares traded on the SIX Swiss exchange barely budged, dipping 0.1% to CHF 134.12 ($163.25) on Thursday. Novartis’ American Depositary Receipts, traded on the New York Stock Exchange, slid 1.85% to $161.93.</p>
<h4><strong>Past safety issues</strong></h4>
<p>The nine acknowledged tumors are not the first instances of safety issues tied to Zolgensma.</p>
<p>In 2022, Novartis acknowledged that two patients <a href="https://www.genengnews.com/topics/genome-editing/novartis-confirms-deaths-of-two-patients-treated-with-gene-therapy-zolgensma/" target="_blank" rel="noopener">died of acute liver failure following treatment with Zolgensma</a>. Both cases occurred at approximately five to six weeks post Zolgensma infusion, and approximately 1-10 days following the initiation of corticosteroid taper, Novartis stated at the time.</p>
<p>In response, Novartis revised Zolgensma’s label to specify that fatal acute liver failure had been reported. That marked a change from the previous wording of the gene therapy’s “black box” warning, which previously included acute liver failure as a known side effect that has been reported following treatment.</p>
<p>Zolgensma was developed by AveXis, a gene therapy developer that was <a href="https://www.genengnews.com/news/novartis-to-acquire-gene-therapy-developer-avexis-for-8-7b/" target="_blank" rel="noopener">acquired by Novartis for $8.7 billion</a> in a deal completed in 2018.</p>
<p>A year later, the FDA approved Zolgensma for the treatment of SMA in children under age two with SMA with bi-allelic mutations in the <em>SMN1</em> gene. Zolgensma was the second gene therapy authorized by the FDA for an inherited disease.</p>
<p>Later in 2019, the FDA announced AveXis’ acknowledgement that the accuracy of data from product testing performed in animals submitted in its Biologics License Application (BLA) for Zolgensma had been <a href="https://www.genengnews.com/topics/genome-editing/fda-places-partial-clinical-hold-on-some-trials-of-novartis-gene-therapy/" target="_blank" rel="noopener">impacted by an unspecified manipulation of data</a> intended to support the development of its production process for the gene therapy. AveXis replaced its two top scientific executives, one of whom publicly denied wrongdoing.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>A <a href="https://www.jpeds.com/article/S0022-3476(20)30682-X/fulltext" target="_blank" rel="noopener">2020 paper</a> published in <em>The Journal of Pediatrics</em> detailed two cases of transient, drug-induced subacute liver failure following treatment with Zolgensma.</p>
<p>And a <a href="https://www.nature.com/articles/s41434-021-00273-7.pdf?proof=t" target="_blank" rel="noopener">2021 study in <em>Nature</em>-published <em>Gene Therapy</em></a> showed that of nine children treated with the gene therapy in Qatar, none experienced failure—but all patients experienced elevated levels of the liver enzymes aspartate aminotransferase (AST) or alanine transaminase (ALT), two experienced high prothrombin time, and one experienced elevated bilirubin. One patient experienced vomiting after infusion.</p>
<h4><strong>Beyond Zolgensma</strong></h4>
<p>Zolgensma isn’t the only gene therapy linked to tumors this year.</p>
<p>In January, Regenxbio announced that the FDA placed a clinical hold on its AAV9 gene therapy candidate RGX-111 for the treatment of mucopolysaccharidosis type I (MPS I or Hurler syndrome) after a single case where an intraventricular CNS tumor developed in a 5-year-old boy treated in its Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT03580083" target="_blank" rel="noopener">NCT03580083</a>). The FDA also placed a clinical hold on a similar gene therapy RGX-121 for the treatment of MPS II (Hunter Syndrome), citing the similarities in products, study populations, and shared risk between the clinical studies. The clinical holds remain in effect.</p>
<p>“The tumor was successfully resected, and the patient remains in neurologically stable condition with advanced cognitive function at five years of age—an outcome that is inconsistent with the natural history of severe MPSI,” the study’s corresponding author, Lindsey A. George, MD, of the Perelman Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in May in </a><em><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">The New England Journal of Medicine (NEJM)</a></em>.</p>
<p>“Data from three decades of experience with more than 6000 patients have shown that AAV gene therapy is associated with a favorable safety profile<sup><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608#core-collateral-r1" target="_blank" rel="noopener"><strong>1</strong></a></sup> and clinical benefits among diverse patient populations,” George and colleagues commented. “That said, our findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which emphasizes the need to optimize gene delivery methods and monitor transduced tissues after treatment.”</p>
<p>And in October, Michigan-based researchers led by Arul M. Chinnaiyan, MD, PhD, of the Michigan Center for Translational Pathology <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in <em>The New England Journal of Medicine</em></a> a case of paraspinal neoplasm in a 3-year-old boy with infantile-onset Krabbe disease (with biallelic <em>GALC</em> variants p.Arg220Ter and p.Tyr319Cys) following treatment with Forbes biologics’ AAV gene therapy FBX-101.</p>
<p>“At the time of the last follow-up, the patient remained asymptomatic,” Chinnaiyan and colleagues wrote. “These findings emphasize the need for cassette designs without splice donors, as well as attention to vector purity and extended genomic surveillance after AAV gene therapy.”</p>
<p>And in October, Michigan-based researchers led by Arul M. Chinnaiyan, MD, PhD, of the Michigan Center for Translational Pathology <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2601608" target="_blank" rel="noopener">reported in <em>The New England Journal of Medicine</em></a> a case of paraspinal neoplasm in a 3-year-old boy with infantile-onset Krabbe disease (with biallelic <em>GALC</em> variants p.Arg220Ter and p.Tyr319Cys) following treatment with Forbes biologics’ AAV gene therapy FBX-101.</p>
<p>“At the time of the last follow-up, the patient remained asymptomatic,” Chinnaiyan and colleagues wrote. “These findings emphasize the need for cassette designs without splice donors, as well as attention to vector purity and extended genomic surveillance after AAV gene therapy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma/">Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics</title>
<link>https://edusehat.com/en/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics</link>
<guid>https://edusehat.com/en/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics</guid>
<description><![CDATA[ A priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.
The post Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-200554028-001.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 22:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, Glycosylation, Control, Longer, Secondary, Concern, the, Development, Complex, Biologics</media:keywords>
<content:encoded><![CDATA[<p>In developing traditional monoclonal antibodies (mAbs), drug manufacturers have often postponed addressing glycosylation issues until downstream processing.</p>
<p>The new generation of antibody therapeutics, however, offers no such leeway.</p>
<figure aria-describedby="caption-attachment-340114" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340114" src="https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee-225x300.jpg" alt="" width="225" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee-225x300.jpg 225w, https://www.genengnews.com/wp-content/uploads/2026/11/Sojeong-Lee.jpg 756w" sizes="(max-width: 225px) 100vw, 225px"><figcaption class="wp-caption-text">Sojeong Lee, PhD, Director of upstream development at Samsung Biologics</figcaption></figure>
<p>Compared with conventional mAbs, newer antibody therapeutics such as bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), Fc-fusion proteins, and advanced immunotherapies are far more sensitive to glycan heterogeneity. Even subtle variations in glycosylation can directly influence therapeutic efficacy and batch-to-batch consistency.</p>
<p>For these newer therapeutics, glycosylation must therefore be considered from the earliest stages of cell line and process development.</p>
<p>This priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><strong>Early glycosylation control drivers</strong></p>
<p>The growing emphasis on upstream glycosylation control is primarily a consequence of increasing biologic complexity. Traditional mAbs are significantly more predictable in behavior, typically displaying stable glycosylation profiles in later clinical phases that pose minimal threat to efficacy or safety.</p>
<p>Modern biologics present a markedly different challenge:</p>
<ul>
<li>BsAbs rely upon highly precise structural configurations to facilitate simultaneous engagement of multiple targets. As a result, even relatively minor glycan asymmetry may impair target binding or compromise functional activity.</li>
<li>ADCs introduce further complexity, with glycosylation influencing drug-antibody ratio (DAR) stability, payload retention, and overall molecular integrity.</li>
<li>Fc-fusion proteins and immunotherapies frequently depend upon tightly controlled glycan profiles to achieve appropriate pharmacokinetic behavior and immune system engagement.</li>
</ul>
<p>Historically, downstream processing provided manufacturers with opportunities to compensate for variability introduced upstream. Adjustments during purification or process optimization frequently proved sufficient to address modest glycosylation inconsistencies associated with conventional antibody therapeutics.</p>
<p>However, this approach is increasingly inadequate for modern biologics. In certain cases, even a minor shift in specific glycan variants can critically compromise the drug’s pharmacokinetic profile, therapeutic efficacy, or safety. Many of these glycosylation-related challenges originate at the cellular and metabolic level during biosynthesis. Once heterogeneous glycan populations have been established, downstream interventions are inherently limited in their ability to fully correct structural inconsistencies.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Consequently, the industry is transitioning away from reactive correction models toward proactive upstream quality engineering.</p>
<h4><strong>Mitigating regulatory and commercial risk</strong></h4>
<p>Integrating quality considerations earlier in development offers significant regulatory and commercial advantages. If glycosylation inconsistencies emerge during scale-up or commercial manufacturing, the consequences may include batch rejection, additional comparability studies, regulatory delays, or disruptions to clinical programs.</p>
<p>Regulatory frameworks, including ICH Q8, Q9, and Q11, require manufacturers to identify critical quality attributes (CQAs), understand sources of process variability, and establish scientifically justified control strategies. For biologics, glycosylation has long been recognized as an important quality attribute linked to safety, efficacy, and immunogenicity. However, the increasing complexity of newer modalities has intensified expectations around early process understanding and glycan control.</p>
<p>Consequently, proactive upstream glycosylation control helps manufacturers meet these expectations by improving process consistency throughout development and scale-up. It also strengthens regulatory submissions by demonstrating that glycan heterogeneity is understood, monitored, and appropriately controlled across the manufacturing process.</p>
<h4><strong>Clone selection is critical to consistency</strong></h4>
<p>When implementing proactive control of glycosylation upstream, manufacturers must recognize that glycan variability is highly clone-dependent.</p>
<p>A substantial proportion of glycosylation variability, around 80%, originates from the intrinsic characteristics of the production clone itself. Even minor differences in genes such as <em>MGAT1</em> and <em>FUT8 </em>in a clone can alter the clone’s Golgi enzyme expression, which in turn can affect the branching/ fucosylation of subsequent antibodies, thereby affecting antibody-dependent cellular cytotoxicity (ADCC). A single glycan variant can therefore destroy a therapeutic’s mechanism of action.</p>
<p>Consider an Fc-fusion immunotherapy targeting the interleukin-6 receptor. If produced from a clone with high mannose levels, the eventual therapeutic’s half-life could drop from an expected 21 days to three days. Failure to eliminate unsuitable clones during early development may therefore result in otherwise promising candidates exhibiting unacceptable clinical characteristics during later stages.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>For this reason, developers must increasingly assess glycan quality attributes in addition to productivity and titer in early screening activities as part of their clone selection strategies.</p>
<p>Glycosylation-related quality attributes should be assessed in the context of the molecule’s intended mechanism of action and functional requirements. Examples include:</p>
<ul>
<li>Fucosylation levels: As an influencing factor in ADCC activity, fucosylation levels are particularly important for oncology therapeutics and immune-engaging molecules.</li>
<li>Galactosylation patterns: These patterns are significant where complement-dependent cytotoxicity (CDC) activity is required, as increased galactosylation may enhance C1q binding.</li>
<li>Sialic acid linkage profiles: Different sialylation patterns may influence inflammatory responses and pharmacokinetic performance in distinct ways, requiring careful evaluation. Also, sialic acids have a direct, strong correlation with the charge variant profiles, especially with the acidic variants, which can affect the binding affinity, immunogenicity, and other critical attributes.</li>
</ul>
<ul>
<li>High mannose content: As high mannose content can influence clearance rates and immunogenicity risk, it is an increasingly important quality consideration.</li>
</ul>
<h4><strong>High-throughput analytics are transforming cell line development</strong></h4>
<p>To evaluate glycosylation-related attributes effectively during early-stage development, drug developers and CDMOs are increasingly utilizing advanced analytical technologies, including HILIC-UPLC, LC-MS glycopeptide mapping, HPLC, and capillary electrophoresis. By integrating these high-throughput methodologies directly into early screening workflows, these organizations can simultaneously assess productivity and glycan quality, thereby reducing the likelihood that unsuitable clones progress through development.</p>
<p>Importantly, the objective is not necessarily to identify clones exhibiting a perfect glycan profile but rather to identify clones that naturally align as closely as possible with the target profile from the outset, thereby minimizing the extent of subsequent optimization required.</p>
<h4><strong>Structured experimental design</strong></h4>
<p>As biologic systems become increasingly complex, intuition-based optimization approaches are becoming insufficient.</p>
<p>Numerous upstream variables, including temperature, pH, substrate composition, oxygen transfer, amino acid availability, and lipid concentrations, may influence glycosylation pathways within the Golgi apparatus. Even relatively minor variations in culture conditions may alter branching patterns, fucosylation levels, or sialylation outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Managing this complexity requires structured and statistically robust methodologies.</p>
<p>Design of experiments (DoE) approaches are therefore becoming essential for identifying critical process parameters while minimizing experimental burden. Screening DoEs allow developers to evaluate which parameters most significantly affect glycosylation outcomes, while optimization DoEs facilitate refinement of process conditions to balance productivity with quality objectives.</p>
<p>These methodologies also support broader QbD principles increasingly emphasized by regulators, including the establishment of process design spaces and robust monitoring strategies under frameworks such as ICH Q8 and Q11.</p>
<h4><strong>The role of automation, analytics, and data integration </strong></h4>
<p>Looking ahead, the continued evolution of upstream glycosylation control is likely to be driven by advances in automation and data analytics.</p>
<p>Many organizations have already begun integrating online monitoring technologies and automated feedback systems into bioprocessing workflows. Over time, these systems are expected to become increasingly sophisticated, enabling more dynamic adjustment of bioreactor conditions in response to real-time glycan analytics.</p>
<p>Artificial intelligence (AI) and machine learning are also expected to play increasingly important roles. As larger multi-batch datasets become available, AI-driven models may help predict relationships between process parameters and glycosylation outcomes with greater speed and accuracy than traditional analytical approaches alone.</p>
<p>However, realizing these capabilities will require substantial investment in organizational infrastructure.</p>
<h4><strong>Glycosylation in the years to come</strong></h4>
<p>No longer a downstream consideration, glycosylation control is set to play an increasingly important role in biologics development and manufacturing strategies.</p>
<p>For biopharma companies and CDMOs, this change will require stronger, AI-enabled technical capabilities to integrate volumes of analytical and manufacturing data effectively at speed, so operators can better understand how upstream conditions may influence glycan outcomes throughout scale-up and commercial production.</p>
<p>Timely insights such as these will only become more vital as the range of biologic modalities continues to diversify and as regulatory expectations surrounding consistency continue to evolve.</p>
<p>Going forward, organizations that integrate these considerations from the outset will be better positioned to support consistent therapeutic performance, reduce late-stage risk, and meet the growing demands associated with next-generation biologics.</p>
<p> </p>
<p><em>Sojeong Lee, PhD, is director of upstream development at Samsung Biologics</em></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/why-glycosylation-control-is-no-longer-a-secondary-concern-in-the-development-of-complex-biologics/">Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors</title>
<link>https://edusehat.com/en/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors</link>
<guid>https://edusehat.com/en/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors</guid>
<description><![CDATA[ NYU Grossman School of Medicine researchers found that DNA-copying problems at a small set of chromosome sites can determine how cancer cells respond to PARP inhibitors, pointing to possible biomarkers of drug sensitivity. 
The post Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/08/Aug3_2020_GettyImages_696241690_DNAandCanceCell-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 15:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Where, DNA, Copying, Fails, Can, Decide, How, Cancer, Cells, Respond, PARP, Inhibitors</media:keywords>
<content:encoded><![CDATA[<p>Not all DNA damage is equal. Every time a cell divides, it has to copy its DNA, and some stretches of the genome are harder to copy than others. Cancer cells depend on a protective response to get past those failures. A new study pinpoints where on chromosomes the problems arise and shows that blocking that response with PARP inhibitors lets damage build up at those sites, compromising the cancer cells’ survival.</p>
<p>The work, led by researchers at NYU Langone Health’s Perlmutter Cancer Center, was published in <em>Nature Cell Biology</em> under the title “<a href="https://www.nature.com/articles/s41556-026-02126-0" target="_blank" rel="noopener">Positional replication fork instability drives PARP inhibitor cytotoxicity</a>.” Eli Rothenberg, PhD, a professor of biochemistry and molecular pharmacology at NYU Grossman School of Medicine, and Dipika Gupta, PhD, a postdoctoral scholar in his lab, are co-corresponding authors.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The team began with CRISPR screens in breast and small cell lung cancer models. The screens flagged ESCO2, a protein that helps hold newly copied chromosomes together, as a strong determinant of sensitivity to PARP inhibitors. Even partial loss of ESCO2 increased sensitivity in colorectal, ovarian, and lung cancer cells. The ESCO2-depleted cells kept the tested homologous recombination response. That DNA repair pathway is impaired in the BRCA-mutated cancers for which PARP inhibitors are typically used.</p>
<p>To find out why the cells were sensitive, the researchers turned to quantitative single-molecule imaging, an ultrasensitive microscopy approach developed in Rothenberg’s laboratory. It let them distinguish subtypes of replication-associated damage sites that other methods cannot readily separate, according to Rothenberg. Reducing ESCO2 increased G-quadruplexes, or G4s, which are folded DNA structures that can obstruct copying. The increase was concentrated at a small subset of replication sites, particularly in repetitive pericentromeric regions next to centromeres.</p>
<p>“The imaging enabled us to move beyond measuring damage across an entire cell,” Gupta said. “We could detect subtle replication problems, distinguish the sites involved, and identify the protective response that the cells relied on.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>That response depended on PARP1 activity and involved two other proteins. TIMELESS helps protect DNA replication, and DDX11 is an enzyme that can unwind G4 structures. PARP inhibition disrupted the response in ESCO2-depleted cells. G4s built up further, DNA synthesis declined, and damage increased near centromeres, which helps explain the cells’ sensitivity to the drugs.</p>
<p>“We often think of DNA damage in terms of quantity: More damage means a greater chance of killing a cancer cell,” Rothenberg said. The findings point instead to location as a factor in treatment response.</p>
<p>The authors said the results provide a foundation for developing biomarkers of cancer drug sensitivity. They also raise the possibility that other DNA-damaging treatments work partly because they are more likely to hit these sensitive genomic sites. Whether that holds in other genetic contexts and with other treatments remains to be tested.</p>
<p>Rothenberg is working with clinicians to apply the imaging approaches to patient-derived cancer cells. The goal is to identify patterns of replication stress and DNA damage that could help predict who responds to treatment. The study was conducted in cancer cell models, so further preclinical and clinical research is needed to establish whether these features can guide treatment decisions.</p>
<p>“Our work reveals a genomic Achilles’ heel—a small subset of sites where replication problems can have disproportionately severe consequences. Identifying those sites helps explain what cancer cells depend on to survive and why a particular treatment can be so effective,” added Rothenberg.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors/">Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Boehringer Ingelheim Inks Up&#45;to&#45;$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical</title>
<link>https://edusehat.com/en/boehringer-ingelheim-inks-up-to-74b-cancer-drug-collaboration-with-sino-biopharmaceutical</link>
<guid>https://edusehat.com/en/boehringer-ingelheim-inks-up-to-74b-cancer-drug-collaboration-with-sino-biopharmaceutical</guid>
<description><![CDATA[ The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical. 
The post Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/03-0178_Boehringer_Workplace_Laboratory_Research_RGB.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 07:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Boehringer, Ingelheim, Inks, Up-to-7.4B, Cancer, Drug, Collaboration, with, Sino, Biopharmaceutical</media:keywords>
<content:encoded><![CDATA[<p>Boehringer Ingelheim has launched an up-to-$7.358 billion-plus second collaboration with Sino Biopharmaceutical (SBP Group) to develop next-generation cancer therapies based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.</p>
<p>The companies have signed a strategic multi-program option and license agreement designed to deepen their existing partnership in oncology, which encompasses three Boehringer-developed cancer treatments and was launched in 2024.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The latest collaboration will encompass six biologic preclinical programs. Five programs focus on treatments originating with a wholly owned SBP Group subsidiary, LaNova Medicines. The sixth comes from another SBP Group subsidiary, Beijing Tide Pharmaceutical.</p>
<p>The collaboration is intended to marry SBP Group’s platforms and early-development capabilities with Boehringer Ingelheim’s global oncology.</p>
<p>“Our partnership with SBP Group brings together complementary science to broaden our development portfolio of antibody-drug conjugates and T-cell engagers. It puts our China strategy into action by connecting innovation from China with our global research and development capabilities,” Paola Casarosa, Member of the Board of Managing Directors and Head of the Innovation Unit at Boehringer Ingelheim, said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Under the agreement, SBP Group has agreed to oversee early development. After unspecified clinical milestones are reached, Boehringer Ingelheim may exercise options for exclusive development, manufacturing, and commercialization rights. Those rights may be exercised outside China, Hong Kong, and Macau for four of the programs, and worldwide for the remaining two.</p>
<p>Boehringer Ingelheim has agreed to pay SBP Group upfront and near-term payments totaling $358 million, and up to $7 billion tied to achieving option-exercise, development, regulatory, and commercial milestones of US$7 billion. Boehringer Ingelheim also agreed to pay SBP Group tiered royalties on potential future product sales.</p>
<p>Boehringer Ingelheim said the collaboration added to its efforts intended to build a broad and differentiated oncology portfolio spanning cancer cell-directed therapies and immuno-oncology. The companies reason that their latest partnership will offer opportunities to further the ADC and T-cell engager portfolio through multiple programs and technology approaches.</p>
<p>Investors sent SBP Group shares on the Hong Kong Stock Exchange rising 5% on the news, from HKD 4.885 (61 cents) to HKD 5.15 (65 cents). Boehringer Ingelheim is privately held.</p>
<h4><strong>Commitment to China</strong></h4>
<p>For Boehringer Ingelheim, the latest partnership with SBP Group underscores what it said was a strengthened commitment to China’s growing innovation ecosystem. In October, Boehringer Ingelheim <a href="https://english.shanghai.gov.cn/en-Latest-WhatsNew/20261015/f763213f079843ffa3d2e3c6c390596d.html" target="_blank" rel="noopener">opened its China R&D Center in Zhangjiang, Shanghai</a> designed to expand its early clinical development and external innovation capabilities by connecting its global R&D network with innovation in China.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Boehringer Ingelheim and China-based SBP Group launched their first cancer-focused collaboration in April 2024, when SBP agreed to develop three oncology drugs originating with the Germany-based Boehringer:</p>
<ul>
<li><strong>Brigimadlin (BI 907828)</strong>—A mouse double minute 2 (MDM2)-p53 antagonist whose development was halted by Boehringer Ingelheim in all indications last year after the drug failed the 400-patient Phase II/III Brightline-1 trial (<a href="https://clinicaltrials.gov/study/NCT05218499" target="_blank" rel="noopener">NCT05218499</a>). Brigimadlin missed its primary endpoint of progression-free survival (PFS) in the trial, which compared the drug to doxorubicin in dedifferentiated liposarcoma.</li>
<li><strong>Obrixtamig (BI 764532)</strong>—A delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) bispecific T-cell engager. Obrixtamig is under study in the Phase II DAREON<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">-5 trial (<a href="https://clinicaltrials.gov/study/NCT05882058" target="_blank" rel="noopener">NCT05882058</a>), a dose selection and expansion trial designed to assess the drug in relapsed/refractory small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (epNEC), and large cell neuroendocrine carcinoma of the lung (LCNEC-L). Last month at the European Society for Medical Oncology (ESMO) Congress in Madrid, Boehringer Ingelheim shared positive data from the Phase Ib DAREON<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">-9 trial (<a href="https://clinicaltrials.gov/study/NCT05990738" target="_blank" rel="noopener">NCT05990738</a>) evaluating obrixtamig plus chemo drug topotecan in adults with extensive stage small cell lung cancer.</li>
</ul>
<ul>
<li><strong>Zongertinib</strong>—A selective human epidermal growth factor receptor 2 (HER2) inhibitor that covalently binds to the tyrosine kinase domain (TKD) of both wild type and mutated HER2 receptors, including those with an exon 20 mutation. Boehringer reasons that improved selectivity of a HER2 tyrosine kinase inhibitor (TKI) may yield improved tolerability and efficacy. Zongertinib is under study in the Phase III Beamion LUNG-3 trial (<a href="https://clinicaltrials.gov/study/NCT07195695" target="_blank" rel="noopener">NCT07195695</a>) comparing the drug to standard adjuvant treatment in adults with completely resected Stage II-IIIB NSCLC whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations.</li>
</ul>
<p>“Our second partnership with Boehringer Ingelheim marks an important milestone in SBP Group’s international innovation strategy and further validates our scientific capabilities in next-generation oncology,” stated Theresa Tse, Chairwoman of SBP Group. “By combining our innovative platforms and early-development capabilities with Boehringer Ingelheim’s global oncology expertise, we aim to maximize the potential of these programs and bring innovative treatment options to patients worldwide.”</p>
<p>“We will continue to expand our global partner network and contribute high-quality innovation from China to global healthcare,” Tse added.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/boehringer-ingelheim-inks-up-to-7-4b-cancer-drug-collaboration-with-sino-biopharmaceutical/">Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patient Advocacy Coffee Chat: Basic steps to being a good advocate</title>
<link>https://edusehat.com/en/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate</link>
<guid>https://edusehat.com/en/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate</guid>
<description><![CDATA[ “What does good advocacy look like? Why do we advocate? And what are some tips and tricks for effective advocacy?” asked Karin Hoelzer, Senior […]
The post Patient Advocacy Coffee Chat: Basic steps to being a good advocate appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/BIO_CoffeeChat_10_2026b.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:25:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patient, Advocacy, Coffee, Chat:, Basic, steps, being, good, advocate</media:keywords>
<content:encoded><![CDATA[<p><span>“What does good advocacy look like? Why do we advocate? And what are some tips and tricks for effective advocacy?” asked Karin Hoelzer, Senior Director of Patient Advocacy at the Biotechnology Innovation Organization (BIO). </span></p>
<p><span>Her questions kicked off BIO’s October Coffee Chat, Advocacy in Action, which welcomed patient advocates from across the healthcare community. While BIO’s Coffee Chats are a monthly occurrence, this month’s chat buttressed BIO’s </span><a href="https://pace.bio.org/"><span>Patient Advocacy Changemakers Event (PACE)</span></a><span>, which took place on October 22 and 23 in Washington, DC. </span></p>
<p><span>The event brought together patient advocates from across the country and across therapeutic areas, providing a forum to share insights, exchange information, and make new connections in the pursuit of better access to and affordability of therapies for patients.</span></p>
<h3>What makes an effective patient advocate?</h3>
<p><span>Every advocate’s story is different. Every advocate comes to patient advocacy with a unique drive behind why they do what they do—some coming from the patient perspective, some from the caregiver perspective, some from a community health perspective. Yet, not matter the background or policy issue at hand, advocacy is empowering—one of the many things effective advocates have in common. </span></p>
<p><span>“Advocacy is an opportunity we have in our country we all need to take advantage of and help folks develop those skills not only in our own community but in other communities because it really does matter,” said Jenny Luray, Senior Vice President of Strategy and Public Engagement, Research!America, “So many Americans think that they don’t have as much power as they do.”</span></p>
<p><span>Amanda Krzepicki, MPH, Policy Director at the Autoimmune Association, agreed. She found her start as an AmeriCorps Community Health Corps member at a federally qualified health center just across the river in Alexandria. </span></p>
<p><span>“While I was there, I saw the stark inequities that impact this region, as well as across the country, and how people rely on community health centers and what a robust resource they are for communities,” she recalled. “So that really made me want to jump into the state policy space.” </span></p>
<p><span>And that motivation has remained a driving force for Krzepicki. “Watching that shift in lawmakers when they realize someone is so passionate about an issue has always been, I think, really fulfilling, and even more so watching bills get introduced because of it.”</span></p>
<p><span>Advocacy provides agency and the power to change the </span><i><span>status quo</span></i><span>. </span></p>
<p><span>“I think it’s so important to be able to tie real patient stories to topics that can be quite complex at times. An area that I have worked on for quite some time is patient access, especially the issue of copay accumulators, copay maximizers, and alternative funding programs, and that certainly is a slow and drawn-out process,” said Brian DuVal, MPH, Director of Patient Advocacy at BIO. “But there have been wins, especially at the state level, and I’ve been pleased to have been part of some of those. So, in general, being able to bring patients together to help demystify some of these complex issues has been very fulfilling.”</span></p>
<p><span>But, breaking such complex issues down and demystifying health policy in ways that are compelling to decisionmakers is not always easy. So how are DuVal, Krzepicki, and Luray training the new class of patient advocates? And what have been some of the biggest lessons learned while working on the Hill?</span></p>
<h3>Paying it forward: Training the new class of patient advocates</h3>
<p><span>Having a hands-on approach to bill making, Krzepicki said, has been one of the most effective motivators for new advocates. </span></p>
<p><span>“Watching a patient react to a bill getting introduced, an office agreeing to get a co-sponsorship on, and the feeling of hope that it elicits is very impactful. I think sometimes we can become quite jaded,” Krzepicki said, “but watching the patients experience success and feel so hopeful can remind us all to be hopeful, and then we ultimately get the result.”</span></p>
<p><span>And patient advocates have been able to advance key legislation to improve patient access. But not every win results in a bill passing the House and Senate—or even just getting introduced. And not every step needs to be made at the federal level.</span></p>
<p><span>“The small wins definitely count,” reminded DuVal. “Keeping advocates motivated between these really big legislative pushes, especially when things may feel slow at times, it is very important to celebrate the small wins and also really understand all the different forms that advocacy can take.”</span></p>
<p><span>Many issues at play today—prescription drug affordability boards, vaccine access and more—are happening at the state level, making advocacy more of a two-hander than a straightforward process. </span></p>
<p><span>Luray echoed her position, saying: “I’d like to see more patient advocacy groups in districts because that’s where you’re most likely to get more of the members’ attention. Forming events with a local healthcare provider, the Lions Club or women’s organizations, whatever works in terms of your disease area, creating those opportunities, all of it is really important. When that member meets you on the ground, they don’t forget it.”</span></p>
<h3>United front: Hill days and fly-ins</h3>
<p><span>Another element of patient advocacy that the speakers discussed was Hill days and fly-ins, which can help policymakers see just how big an issue is through the sheer number of advocates that are at their door. </span></p>
<p><span>And in today’s world, that can happen both physically and virtually, increasing both access and affordability in the very functioning of advocacy itself. </span></p>
<p><span>“We have done a virtual fly-in in the past,” Krzepicki said. “If you have advocates spread out across the country, and you’re maybe a smaller organization, the cost to do a virtual fly-in is much more reasonable than bringing people out and accommodating travel.” Though in-person is still best practice, Krzepicki said. </span></p>
<p><span>“When I was in the consulting space, it was incredible to bring patients to the Hill and to tell their stories, to connect with lawmakers, and I think even more importantly, to connect with staffers,” Krzepicki said. “People are often quite focused on the lawmaker, but a lot of the time, if you can relate to the staff and they have a personal tie, they can use their personal connection with the lawmaker to also sway an issue area.”</span></p>
<p><span>This focus on Hill staffers was echoed throughout the panel, especially considering the fact that staffers often long outlast the legislators themselves. So the trick, the panelists explained, was to be a resource to these staffers even outside of your policy focus. </span></p>
<p><span>“When I was on the Hill, the advocates that I relied on were those that always came in with a lot of information,” Luray recalled. “I never felt they were like gaslighting me, and they were willing to answer questions and be a resource on things that might not be on their top list, but they were able to be helpful.”</span></p>
<h3>Information: An advocate’s greatest asset</h3>
<p><span>Advocates and volunteers have to stay informed, both about which legislators have strong ties and interests in which issues, as well as about the policy issue itself, and adjacent policy concerns—which is a never-ending process, in particular in today’s environment where so many patient access issues are interconnected. </span></p>
<p><span>“It’s keeping advocates really informed and giving them information along the way so they’re learning as time goes on, and developing expertise,” Luray said. “I think it’s very satisfying to people as they get more experienced and comfortable with advocacy than they were maybe three years ago. But it’s a constant effort. You constantly have to be in touch with people.”</span></p>
<p><span>That is even more important this year with the midterms on the horizon. The congressional landscape is changing, and advocates need to be ready. </span></p>
<p><span>“As the new Congress comes in, there’s going to be a lot of new staff,” Krzepicki said. “So I do think at the beginning of next year we’ll be doing a little bit of education around our issue areas and things like that.”</span></p>
<p><span>One way that advocates can prepare themselves is to come to BIO’s monthly coffee chats, where they can talk about the healthcare policies that are impacting patients the most and connect with fellow advocates to learn and plan for future work. </span></p>
<p>The post <a href="https://bio.news/latest-news/patient-advocacy-coffee-chat-basic-steps-to-being-a-good-advocate/">Patient Advocacy Coffee Chat: Basic steps to being a good advocate</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives</title>
<link>https://edusehat.com/en/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives</link>
<guid>https://edusehat.com/en/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives</guid>
<description><![CDATA[ Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not […]
The post BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/07/sangharsh-lohakare-Iy7QyzOs1bo-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, responds, Health, Affairs, Analysis, highlighting, the, importance, orphan, drug, incentives</media:keywords>
<content:encoded><![CDATA[<p>Orphan drug development is one of the more fraught undertakings in biomedical research. Targeting rare diseases often requires cutting-edge science, but science is not always enough. The economics of treating small populations can make it difficult to secure the financial support needed to make it through clinical trials and onto the market.</p>
<p>To ensure that promising ideas aren’t abandoned in the face of those challenges, Congress has provided a number of incentives for orphan drug development, including provisions that exempt orphan drugs from government price controls under the Inflation Reduction Act.</p>
<p>But those incentives often come under attack. Recently, <a href="https://www.healthaffairs.org/doi/10.1377/hlthaff.2026.00209">a Health Affairs article</a> suggested that the IRA-related protections weren’t needed, given that some orphan medicines are commercially successful.</p>
<p>That analysis, however, is built on the flawed premise that just because a sliver of orphan drugs earn back development costs, orphan medicines, as a class, don’t face unique and daunting obstacles throughout the R&D process.</p>
<p>BIO believes that kind of thinking is wrongheaded, and <a href="https://www.healthaffairs.org/doi/10.1377/hlthaff.2026.01330">Health Affairs this month published a rebuttal</a> from BIO’s Vice President of Healthcare Policy & Research, Crystal Kuntz.</p>
<p>BIO argued that orphan drugs carry unique scientific challenges, uncertainties in development, and commercial obstacles that would discourage innovation without additional supports.</p>
<p>“Incentives to develop orphan drugs have been critical in encouraging research, and eroding such policies risks starving some of the best ideas in medicine of resources at the exact wrong time for patients waiting to benefit from today’s groundbreaking science,” Kuntz wrote.</p>
<p>BIO noted that the existence of these incentives has led to a “golden age” in orphan drug development, but that much work remains to be done. Thousands of rare diseases still lack a treatment, an indication of the need to not roll back the very policies that are making an impact.</p>
<p>The post <a href="https://bio.news/bios-view/bio-responds-to-health-affairs-analysis-highlighting-the-importance-of-orphan-drug-incentives/">BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Modernizing the Western Blot for the 21st Century: More Than Just Automation</title>
<link>https://edusehat.com/en/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation</link>
<guid>https://edusehat.com/en/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation</guid>
<description><![CDATA[ Traditional Western blotting can confirm whether a protein is present, but it is often treated as semi-quantitative. It can be difficult to determine how much protein is present, compare results across experiments, or distinguish a true biological difference from technical errors. The case for automation becomes stronger when paired with performance data.
The post Modernizing the Western Blot for the 21st Century: More Than Just Automation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Modernizing, the, Western, Blot, for, the, 21st, Century:, More, Than, Just, Automation</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.rndsystems.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-338704 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002-300x111.jpg" alt="R&D Systems logo" width="300" height="111" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002-300x111.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/RnD-Systems_primary-logo_color-1-002.jpg 755w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>In the 1980s, Western blotting was revolutionary. For the first time, scientists could identify a protein of interest within a complex sample with a high degree of certainty. Decades later, the technique remains a cornerstone of protein analysis. But like most technologies, both inside and outside the lab, it is not without limitations. What once felt fit for purpose now has to keep up with the demands of 21st-century biopharma: vast sample sets, aggressive competition, and, most importantly, the ticking clock for individuals waiting for life-saving therapies.</p>
<p>Traditional Western blotting can confirm whether a protein is present, but it is often treated as semi-quantitative. It can be difficult to determine how much protein is present, compare results across experiments, or distinguish a true biological difference from technical errors. The predominantly manual process also makes user-to-user variability difficult to avoid. As a result, time that could be spent moving a program forward is often spent repeating experiments, troubleshooting, or adding orthogonal techniques to gain confidence in the result.</p>
<p><figure aria-describedby="caption-attachment-340263" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340263" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-1024x731.jpg" alt="Western Blotting with Antibodies" width="696" height="497" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-1024x731.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-300x214.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies-768x549.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-Western-Blotting-with-Antibodies.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Credit: Bio-Techne</figcaption></figure></p>
<p>That delay matters. Therapeutic efficacy, time to market, and a manufacturer’s reputation are all influenced by one common factor: data quality. In another era, prolonged timelines may have been expected and even accounted for. Today, laboratories across the globe are investing in instrumentation that accelerates development pipelines while improving the quality of the data used to make decisions. The data should speak for itself: either the sample is good to go or it is not.</p>
<p>Evolution is natural for almost all forms of technology, and the Western blot is no exception. In the early 2010s, Simple Western<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> technology entered the fray, bringing automation to many steps of the Western blot workflow that otherwise introduce variability. Simple Western, as the name suggests, simplifies the Western blot. The underlying principle remains familiar: proteins are separated and then probed using target-specific antibodies. The difference is that protein separation, immunodetection, and analysis occur in an automated, capillary-based system. The workflow reduces manual intervention and condenses a process that can take at least six hours, and sometimes days, into an approximately three-hour run with minimal hands-on time.</p>
<p>The case for automation becomes stronger when paired with performance data. In one internal reproducibility study, four users ran the same ERK1 Simple Western assay on separate days using HeLa lysates. Across all ERK1 data points collected over four days, the coefficient of variation was below 10%, illustrating how an automated workflow can support consistency across users and experiments<sup>1</sup>.</p>
<p><figure aria-describedby="caption-attachment-340262" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340262 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-1024x426.jpg" alt="" width="1024" height="426" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-1024x426.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-300x125.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated-768x320.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems-GEN-Article_SW_Figure_1_hz-updated.jpg 1400w" sizes="auto, (max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 1: Dystrophin protein expression was assessed using two different methods: traditional Western blot (A) and Simple Western (B). In the traditional Western blot analysis, 20 μg of protein was loaded per sample lane. For the Simple Western analysis, 1.25 μg of protein was loaded per sample lane for DMD samples and 0.25 μg for healthy controls. [Bio-Techne]</figcaption></figure></p>
<p>Sensitivity is another practical advantage, particularly when sample is limited or the target is low abundance. In a comparison using HEK293 lysates, Simple Western detected GSK3α over more than four logs of dynamic range, while traditional chemiluminescent Western blotting covered approximately 2.5 logs. A dystrophin analysis in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) samples further showed why this matters: traditional Western blotting used 20 μg of protein per lane, whereas Simple Western analysis used 1.25 μg for DMD samples and 0.25 μg for healthy controls while still supporting clearer measurement of dystrophin expression (<em>Figure 1</em>).</p>
<p>These are just a handful of examples that demonstrate the significant shifts that Simple Western brings to protein analysis. None of this means that traditional Western blotting no longer has value. Its principles remain sound, and its familiarity is part of its staying power. But the demands of contemporary research and development have changed. When decisions depend on speed, reproducibility, sensitivity, and quantitative confidence, a manual workflow can become the bottleneck. Simple Western does not abandon what made Western blotting useful. It brings the technique into a format better suited to the pace and expectations of modern biopharma.</p>
<p> </p>
<p><em><img loading="lazy" decoding="async" class="alignleft wp-image-340264 size-thumbnail" src="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode-150x150.jpg" alt="R&D Bio-Techne Sponsored Content QR Code" width="150" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/ProteinSimple-RD-Systems_QRCode.jpg 298w" sizes="auto, (max-width: 150px) 100vw, 150px"></em></p>
<p> </p>
<p><em>Learn More r<a href="https://www.rndsystems.com/instruments/simple-western" target="_blank" rel="noopener">ndsystems.com/simplewestern</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/modernizing-the-western-blot-for-the-21st-century-more-than-just-automation/">Modernizing the Western Blot for the 21st Century: More Than Just Automation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What Biotech Licensing Really Buys</title>
<link>https://edusehat.com/en/what-biotech-licensing-really-buys</link>
<guid>https://edusehat.com/en/what-biotech-licensing-really-buys</guid>
<description><![CDATA[ In this Point of View Sun Chau Siu, PhD, and Kaisong Zhou, PhD, give insights on the hidden challenges of transferring intellectual property.
The post What Biotech Licensing Really Buys appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Hero-Image-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, Biotech, Licensing, Really, Buys</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-340279" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340279" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-300x300.jpg" alt="Sun Chau Siu" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Dr.-Sun-Chau-Siu-e1793893626383.jpg 1045w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Sun Chau Siu, PhD <br>Executive Director,<br>Head of Regulatory Affairs<br>and Project Management<br>Altruist Biologics</figcaption></figure></p>
<p>Biotech licensing is often framed as a transaction around intellectual property. The molecule still comes first: if the biology is weak, the target is undifferentiated, or the clinical rationale is unconvincing, no amount of technical discipline will rescue the program.</p>
<p>What it tends to underestimate is a related question: once the rights change hands, how much of an asset’s apparent value will survive not only clinical development but the transfer itself? In biologics, the asset is never just the molecule. It also includes the development system built around it: cell line history, process development logic, analytical methods, comparability strategy, manufacturing experience, documentation discipline, and the technical judgment accumulated over time. A licensing agreement can specify rights to those assets and the obligations surrounding their transfer. It cannot guarantee that the development system behind it will remain reproducible when another organization takes over. Yet licensing diligence does not always treat the transferability of that development system as a distinct attribute of the asset being acquired.</p>
<p>At signing, a biologics asset can appear meaningfully de-risked. The target may be compelling, the early package persuasive, and the market opportunity attractive. Even so, the asset can carry technical liabilities that emerge only when transfer, scale-up, validation, or regulatory review exposes the gap between a promising molecule and a reproducible development system.</p>
<p><figure aria-describedby="caption-attachment-340276" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340276" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-300x300.jpg" alt="Kaisong Zhou" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-Altruist-Portrait-Kaisong-Zhou-e1793893794694.jpg 1225w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Kaisong Zhou, PhD<br>Chairman and CEO<br>Altruist Biologic</figcaption></figure></p>
<p>Those liabilities rarely present themselves as a single obvious flaw. More often, they emerge in forms that are easy to dismiss during the optimism of dealmaking. Consider a potency assay that performs consistently in the originating laboratory. The method transfers on paper, the procedure is followed, and the initial results appear acceptable. Months later, however, differences in reference standards, laboratory conditions, or system suitability behavior begin to create unexplained variability. What looked like an analytical transfer becomes a development problem because the originating team’s tacit understanding of the assay never truly transferred. A comparability strategy may exist on paper, but not at the level required once process changes begin to accumulate. A program can transfer successfully at pilot scale and still require substantial redevelopment before Process Performance Qualification (PPQ) or commercial readiness because the development rationale was never designed to travel.</p>
<p>That is why these issues are dangerous. Scientific risk can reveal itself at multiple stages, including in the clinic. Transfer risk often does not. It can remain buried until another organization has to reproduce the process, defend the analytics, explain the development history, and carry the program forward under different operating conditions.</p>
<p>What makes this dynamic harder to manage is a structural incentive problem. After signing, organizational incentives can make transfer problems surprisingly easy to defer. The seller has closed the deal, while the technical teams on both sides may still be working through how knowledge, responsibilities, and decisions will transfer. Problems that might be correctable early can instead compound quietly, becoming harder and more expensive to address by the time they are visible. In practice, transfer risk begins as soon as the transaction is signed.</p>
<p>This is why the language of licensing can be misleading in biologics. Intellectual property can be assigned precisely, but process knowledge, development judgment, and technical context do not transfer as neatly. A contract can define rights, territories, and economics, but it cannot guarantee that tacit knowledge reflected in assay behavior, deviation history, control strategy logic, and the many small decisions behind them will be understood and reproduced by the receiving organization.</p>
<p>The industry’s response to transfer failures can sometimes focus too heavily on additional documentation. Documentation is not the same as understanding. In many biologics programs, the critical knowledge that determines whether a process is reproducible is held by a small number of people: the scientist who characterized the founding cell line, the process development lead who resolved the early instability, the analyst who knows why the potency assay behaves differently after a weekend shutdown. That knowledge is rarely captured in a batch record. When those individuals are engaged in the transfer, problems can surface earlier. When the transfer relies heavily on documentation alone, they may be hidden until much later, often when they are more difficult and expensive to address. The critical question is therefore not how much documentation exists, but how much of the knowledge required to interpret that documentation can actually travel. Some biologics programs are reproducible in the hands of the originating team without being equally transferable to a new organization. They are reproducible performances, held together in part by the people who run them. Licensing moves the rights. It does not move the cast.</p>
<p>The deeper issue is structural. The industry has sophisticated tools for evaluating scientific risk: target biology, mechanism of action, probability of clinical success, and competitive differentiation. Chemistry, Manufacturing, and Controls (CMC) diligence can assess regulatory compliance, batch history, manufacturing experience, process understanding, and analytical readiness. The gap is that these assessments do not necessarily answer a distinct licensing question: whether the underlying development rationale can be reproduced by a new organization.</p>
<p>That is why transfer-readiness should be treated as a distinct diligence dimension, alongside scientific, commercial, and regulatory assessment. The key question is not only whether an asset is scientifically attractive, but whether another organization can inherit it without materially relearning it. Four questions provide a practical test: Is the process sufficiently understood, rather than merely functional? Are the analytical methods reproducible across laboratories, rather than demonstrated only within a single one? Can the comparability strategy withstand expected process evolution? And does critical institutional knowledge live in the system, or primarily in the people who built it? In practice, these questions should be part of technical diligence before a deal is signed, because what appears to be a manageable transfer issue can become a material driver of cost, timeline, and post-deal execution.</p>
<p>Not every transaction is built on a fully mature development system; some deals are option bets, acceleration strategies, or pipeline-replenishment moves. But those motives do not change the nature of the risk. A buyer is not only acquiring scientific potential, but also inheriting the consequences of how that potential was developed.</p>
<p>This becomes even more consequential for complex modalities such as antibody-drug conjugates (ADCs), where development depends on tightly linked knowledge across the antibody, linker and payload, conjugation process, analytical methods, raw materials, and multiple internal or external suppliers. A transfer may therefore require reconstructing a network of technical relationships and control strategies, not simply reproducing a process.</p>
<p>Transfer-readiness should not be confused with development maturity. An early-stage asset can be intentionally immature yet highly transferable if its critical knowledge, assumptions, and decision logic are well understood and captured. Conversely, a more advanced asset can carry significant transfer risk if too much development knowledge remains tacit or organization-specific.</p>
<p>That distinction has economic consequences. An asset requiring substantial process redevelopment, analytical remediation, or knowledge reconstruction after licensing may still be attractive to acquire, but its timeline, resourcing requirements, and risk profile are different from those of an asset that can be transferred with minimal relearning. Transfer-readiness therefore has implications not only for technical execution, but for how an asset is valued, resourced, and integrated after the deal.</p>
<p>Biotech licensing starts with differentiated molecules. But in biologics, value is not created by discovery alone. The question is whether the knowledge system that made the asset valuable can move with it.</p>
<p> </p>
<p><em>Sun Chau Siu, PhD, is executive director, head of regulatory affairs and project management at Altruist Biologics. Kaisong Zhou, PhD, is chairman and CEO, Altruist Biologics (an Innovent CDMO).</em></p>
<p>The post <a href="https://www.genengnews.com/insights/what-biotech-licensing-really-buys/">What Biotech Licensing Really Buys</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Revealing the Chemistry Around Us Through Mass Spectrometry</title>
<link>https://edusehat.com/en/revealing-the-chemistry-around-us-through-mass-spectrometry</link>
<guid>https://edusehat.com/en/revealing-the-chemistry-around-us-through-mass-spectrometry</guid>
<description><![CDATA[ Mass spectrometry-based exposomics could be a powerful approach to measuring and understanding environmental impact on health.
The post Revealing the Chemistry Around Us Through Mass Spectrometry appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GEN_NOV_2026_GettyImages-1390096829.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Revealing, the, Chemistry, Around, Through, Mass, Spectrometry</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-340303" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340303" src="https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-300x300.jpg" alt="Matthew Lewis" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/TL-Bruker-Dr.-Matthew-Lewis-headshot-e1793898683528.jpg 1170w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Matthew Lewis, PhD<br>Vice President of Metabolomics and Lipidomics<br>Bruker Daltonics</figcaption></figure></p>
<p>Health is increasingly viewed through the lens of family history and genetics, nutrition and fitness, and, for many, medications and treatments for various conditions. However, public perception is waking up to another factor: the chemistry of our environment.</p>
<p>From air quality and drinking water to clothing and cookware, there is growing skepticism surrounding the multitude of synthetic materials that coat and comprise our environment. This realization that the world around us has an impact on our growth, development, and well-being follows a century of industrial expansion in which the chemistry of the world changed far faster than the means to measure or understand its impacts. A scientific field concerned with this frontier of research has been quietly maturing for twenty years. It is called exposomics.</p>
<p>Exposomics, a modern omics approach to understanding environmental impact, is still an emerging science, but it is already changing how we think about the relationship between the environment and our health. This article explores how researchers can now study the chemistry of the world around us and the body’s response to it with unprecedented breadth, increasingly bringing both into a common analytical framework. The growing attention to the chemistry around us is well founded. It is also now matched by the means to investigate it.</p>
<h4><strong>What is the exposome?</strong></h4>
<p>The exposome as a term was introduced in 2005 as a deliberate complement to the genome. It refers to external factors that have an impact on an organism’s biology (in our case, on human health). Across a person’s lifetime, these will include environmental, lifestyle, occupational, dietary, biological and social influences, each capable of imparting (alone or together via complex interactions) measurable molecular signatures and provoking equally measurable biological responses. Exposomics is the science of measuring it and its impacts.</p>
<p>Today, scientists are gaining a clearer understanding of how much the exposome matters. Working with UK Biobank data, researchers compared what genetic risk scores and environmental exposures each contribute to ageing and early death. Set against age and sex alone, polygenic risk scores across 22 major diseases added less than two percentage points to the explained variation in mortality. The exposome added seventeen.<sup>1 </sup>The two are not rivals, however. Inherited risk still explained more for dementias and for breast, prostate, and colorectal cancers, while environment explained more for diseases of the lung, heart, and liver.<sup>1</sup> The difference is that while genomics is a mature science, exposomics remains emergent, operating across a much broader chemical landscape.</p>
<h4><strong>Technology for exposomics research</strong></h4>
<p>For most of the twentieth century, environmental health science was concerned with identifying potential health concerns, testing them, and regulating them if needed, one at a time. This approach shaped our view on the dangers of lead, asbestos, and tobacco, slowly over decades. However, exposures are not always singular concerns. The chemical world around us is complex, with a stunning diversity of components interacting with biology and each other in ways that isolated testing cannot capture or represent. Even modern environmental monitoring only concentrates on a short list of regulated pollutants, despite inhalation exposure spanning thousands of organic compounds, numerous inorganic substances, and a large biological component.<sup>2</sup> Exposomics takes a different approach. As a modern “omics” science, it measures molecular signals broadly rather than selectively (both the exposures themselves and the body’s biochemical responses) and relies on data-driven statistical analysis to find the patterns that matter.</p>
<p>Here, high-resolution mass spectrometry is a key enabling technology. It separates and detects molecules according to their mass with enough precision and selectivity to distinguish compounds that differ only slightly and, critically, without being told in advance what to look for. And importantly, the same technology is as applicable to studying the chemistry of living systems (e.g. biofluids and tissues) as it is to environmental samples (e.g. air, water, dust, soil, food and consumer products). Using mass spectrometry, a single analysis of blood or urine can measure hundreds or thousands of signals at once, including those from pollutants, drugs, dietary compounds, molecules produced by gut bacteria, and the body’s own metabolic responses to all of it. When applied to air analysis, measurements of diverse and unexpected components can be made continuously and in real time, capturing short-lived compounds and brief exposure events that a filter sample collected over hours would average away.</p>
<h4><strong>Enabling understanding and action</strong></h4>
<p>Measuring the chemistry around us is valuable, but measurement alone does not explain how an exposure influences health. These measurements become most useful when they can be connected. The objective of exposomics is to link the source of an exposure, the amount that enters the body, the biological responses it provokes, and ultimately any impact on health.</p>
<p>Completing that chain remains difficult, and the field is clear-eyed about where the challenges lie. Detecting a signal in a mass spectrometer is not the same as knowing what chemical produced it, and many of the signals detected remain unannotated, collectively constituting what researchers often refer to as the dark matter of the chemical exposome.<sup>3</sup> Their identification depends on reference libraries that are still underdeveloped for environmental chemicals, and workflows vary enough between laboratories that studies can be difficult to compare.<sup>3</sup> However, progress is being made, for example, in artificial intelligence methods that predict chemical behavior to improve confidence in identification,<sup>4</sup> and in the prioritization of harmonized workflows throughout the field.<sup>3</sup> Still, for today, mass spectrometry-based exposomics is a powerful approach that can see more than it can readily interpret. And therein lies its promise as a tool for novel discovery.</p>
<p>The challenges extend beyond identifying individual chemicals. Researchers must also account for the sheer scale of environmental exposure and how sharply it can vary among places and people. The World Health Organization reports that 99% of the world’s population breathes air exceeding its guideline limits.<sup>5</sup> At the same time, we know that the exposome is geospatially linked, with recent mobile monitoring studies showing that pollutant concentrations can vary dramatically over surprisingly short distances.<sup>6</sup> Finally, it has been suggested that exposure profiles can differ markedly even between neighbors in the same building,<sup>2</sup> together making the exposome an individual and community matter as much as a population one. As a result, exposomics research is increasingly being pursued across all three scales through multidisciplinary collaborations that combine environmental science, analytical chemistry, epidemiology and clinical research.</p>
<p> </p>
<p><em>Matthew Lewis, PhD, is vice president of metabolomics and lipidomics at Bruker Daltonics.</em></p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Argentieri MA, Amin N, Nevado-Holgado AJ, et al. Integrating the environmental and genetic architectures of aging and mortality. <em>Nature Medicine</em>. 2025;31(3):1016-1025. doi:10.1038/s41591-024-03483-9.</li>
<li>Gao P. The human airborne exposome. <em>Nature Health</em>. 2026;1:26-34. doi:10.1038/s44360-025-00026-5.</li>
<li>Talavera Andújar B, Schymanski EL. High Resolution Mass Spectrometry To Investigate the Human Exposome: Where Are We? <em>Exposome</em>. 2025. doi:10.1093/exposome/osaf017.</li>
<li>Sillé FCM, Prasse C, Luechtefeld T, Hartung T. AI redefines mass spectrometry chemicals identification: retention time prediction in metabolomics and for a Human Exposome Project. <em>Frontiers in Public Health</em>. 2025;13:1687056. doi:10.3389/fpubh.2025.1687056.</li>
<li>World Health Organization. <a href="https://www.who.int/health-topics/air-pollution#tab=tab_1" target="_blank" rel="noopener">Air Pollution</a>. Accessed 7 May 2026.<u></u></li>
<li>Robinson ES, Tehrani MW, Yassine A, et al. Ethylene Oxide in Southeastern Louisiana’s Petrochemical Corridor: High Spatial Resolution Mobile Monitoring during HAP-MAP. <em>Environmental Science & Technology</em>. 2024;58(25):11084–11095. doi:10.1021/acs.est.3c10579.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/omics/revealing-the-chemistry-around-us-through-mass-spectrometry/">Revealing the Chemistry Around Us Through Mass Spectrometry</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond the Payload</title>
<link>https://edusehat.com/en/beyond-the-payload</link>
<guid>https://edusehat.com/en/beyond-the-payload</guid>
<description><![CDATA[ In this Point of View Anthony Blaszczyk, PhD, principal scientist at USP provides insights on how delivery technologies will shape the future of cell and gene therapy.
The post Beyond the Payload appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-GTG_16x9-Virtual-background.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, the, Payload</media:keywords>
<content:encoded><![CDATA[<p>Over the last decade, cell and gene therapies (CGTs) have shown the ability to modify disease-inducing biological pathways, restore missing cellular functions, and achieve long-term therapeutic benefit following a single administration. However, even with significant design and development advancements, efficient on-target delivery remains challenging. The ability to safely, efficiently, and repeatedly deliver the correct genetic cargo to the right cell is one of the most critical determinants of clinical success.</p>
<p><figure aria-describedby="caption-attachment-340314" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340314" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-300x300.jpg" alt="Anthony Blaszczyk" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-AJB-Headshot.jpg 1244w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Anthony Blaszczyk, PhD<br>Principal Scientist, USP</figcaption></figure></p>
<p>While payload design will remain a primary focus, the next era of innovation in CGT may ultimately be driven by the delivery vehicle itself. In many cases, therapeutic efficacy, safety, and manufacturability are directly influenced by delivery performance. As payload technologies continue to advance, delivery may emerge as the key factor separating scientific possibility from clinical reality.</p>
<p>As a follow-up to last month’s article, “For mRNA, Delivery Is the New Standard,” which explored the future of mRNA delivery, this article examines the landscape of CGT delivery technologies. Specifically, we examine the strengths, challenges, and future directions of several leading platforms that are poised to play key roles in the future of advanced therapeutics.</p>
<p>Adeno-associated viral vectors (AAVs), lentiviral vectors (LVVs), and lipid nanoparticles (LNPs) have emerged as leading delivery platforms, each offering unique advantages and limitations. While AAV has largely dominated <em>in vivo</em> gene therapy, LVV has emerged as a viable <em>in vivo</em> delivery approach, in addition to its predominant use for <em>ex vivo</em> cell engineering applications, such as CAR T therapy. LNPs gained global recognition through their deployment in mRNA vaccines during the COVID-19 pandemic and have become a leading non-viral delivery technology. Because each platform employs a fundamentally different approach for transporting genetic material, complementary roles exist within the CGT landscape. Nevertheless, future advances for each platform will likely depend less on the genetic payload and more on improving delivery efficiency, target specificity, and safety.</p>
<h4><strong>Understanding the various delivery approaches</strong></h4>
<p>AAV is a small, non-enveloped viral vector that is approximately 20–25 nm in diameter. Although the overall structure between serotypes is similar, they vary significantly in receptor and surface proteins, which impact tissue targeting and immune recognition. Encapsulated within the capsid is a single-stranded DNA (ssDNA) genome containing the gene of interest (GOI). AAV does have a relatively limited packing capacity of around 4.7 kb, restricting the size of transgenes that can be delivered. Following cellular uptake and nuclear entry, the AAV genomic DNA is converted to double-stranded DNA and expressed by host-cell machinery to produce therapeutic proteins.</p>
<p>LVV contains a lipid envelope that mediates cell entry and encloses an RNA genome along with the viral enzymes required for genomic integration. Compared with AAVs, LVVs possess a larger packaging capacity and can typically accommodate genetic payloads of approximately 8–10 kb, enabling delivery of larger or more complex transgene constructs. Following cellular entry, the RNA genome is reverse transcribed into DNA and transported to the nucleus, where it integrates into the host genome. This permanent integration supports long-term transgene expression, which is unique to LVV as compared to the other delivery systems.</p>
<p>LNPs are synthetic, non-viral delivery systems that are typically 50–150 nm in diameter. These particles contain a dense core of ionizable lipids, phospholipids, cholesterol, and PEG-lipids that encapsulate a genetic payload, such as mRNA or siRNA. LNPs offer the greatest payload flexibility among the three platforms and can accommodate large mRNA molecules, combinations of nucleic acids, and gene-editing cargoes that may exceed the packaging limitations of viral vectors. Unlike viral vectors, an LNP does not deliver its genomic payload to the nucleus. Following cellular uptake and endosomal escape, the released mRNA is translated directly in the cytoplasm to the therapeutic protein.</p>
<p><figure aria-describedby="caption-attachment-340313" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340313" src="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-993x1024.jpg" alt="Delivery systems AAV, LVV, LNP" width="696" height="718" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-993x1024.jpg 993w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-291x300.jpg 291w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05-768x792.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/POV-USP-Delivery-systems-AAV-LVV-LNP-v05.jpg 1358w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Delivery mechanisms for LVV, AAV, and LNP. [USP]</figcaption></figure></p>
<h4><strong>Target specificity</strong></h4>
<p>Target specificity is becoming an increasingly important consideration as CGT payloads grow more powerful and complex. Emerging technologies, such as CRISPR, base editing, and prime editing, introduce new challenges due to their size, complexity, and heightened safety risks. As a result, the future success of many advanced therapies may depend not only on what they deliver, but how precisely they can deliver the cargo.</p>
<p>For <em>in vivo</em> delivery, AAV offers the highest degree of target specificity and can effectively target many different cell types. Different serotypes naturally exhibit different tissue tropisms, and capsid engineering efforts have further enhanced the ability to selectively target specific tissues. AAV vectors are widely regarded as the most mature platform for targeted <em>in vivo</em> gene delivery. As regulatory expectations continue to emphasize safety, the ability to precisely direct therapeutic payloads may become even more valuable.</p>
<p>While LVVs generally contain moderate target specificity <em>in vivo</em>, they have demonstrated extraordinary success in <em>ex vivo</em> applications, in which target cells are isolated, genetically modified, and returned to the patient. The success of <em>in vivo</em> LVV therapy will likely depend on continued improvements in targeting technologies, including custom envelope engineering, which may require a shift away from the frequently used VSV-G glycoprotein.</p>
<p>When compared with AAV and LVV, LNP generally has the lowest intrinsic target specificity and the highest degree of off-target delivery. Following systemic administration, LNPs have displayed a tendency to accumulate in the liver, limiting their ability to selectively target other tissues. However, advances in lipid chemistry and targeting strategies have shown promise for improving tissue specificity.</p>
<h4><strong>Safety</strong></h4>
<p>Improved targeting and delivery efficiency can be directly linked to improved safety. In many advanced therapies, high doses are required to achieve sufficient therapeutic activity. However, these elevated doses increase off-target risks, toxicity, and unintended immune responses. Because of this, improved delivery efficiency can improve safety by lowering dose requirements.</p>
<p>AAV vectors are generally well tolerated and have become the leading platform for <em>in vivo</em> gene therapies. Pre-existing immunity against naturally occurring AAV serotypes, however, can reduce efficacy and complicate (re)dosing strategies. High dosing requirements have been linked with serious adverse events, including hepatotoxicity, thrombotic microangiopathy, cytokine-mediated toxicity, and sensory neuron toxicity.<sup>1</sup> These findings have increased regulatory focus on dose optimization, patient selection, and immune monitoring.</p>
<p>LVV is often preferred because its ability to integrate into the host genome can provide durable gene expression, even as treated cells divide and pass the therapeutic sequence to daughter cells. This long-term persistence can be particularly advantageous in therapies targeting proliferating cell populations. However, permanent integration also introduces safety concerns, including the risk of insertional mutagenesis, that do not apply in the same way to non-integrating CGT platforms. Modern self-inactivating LVVs have substantially reduced this concern, yet long-term monitoring remains important.<sup>2</sup></p>
<p>LNPs avoid the genomic integration risks associated with viral vectors and provide only transient expression of their RNA cargo. Although LNPs contain no viral proteins, both the lipid components and the RNA payload can stimulate innate immune responses that contribute to vaccine efficacy and common side effects. LNPs also have relatively high off-target delivery rates, particularly to the liver, that carry additional safety risks. Although uncommon, other risks associated with LNPs are PEG-associated immunogenicity and lipid-associated toxicity.<sup>3</sup>  Some of these risks are amplified in applications requiring repeat dosing, which is increasingly common for RNA-based therapies.</p>
<h4><strong>Future directions</strong></h4>
<p>The future of CGT is expected to see continued advancements in the coming years. Some of the most transformative developments may come from improvements in delivery technology. These innovations may come in the form of enhanced target specificity and expanded delivery of sophisticated payloads, such as CRISPR, base editing, prime editing, and other emerging technologies. Successful progression will rely on the development of delivery systems capable of precisely transporting these payloads to the appropriate cells while minimizing safety risks.</p>
<p>For AAV, future innovation will likely focus on engineered capsids with improved transduction efficiency, enhanced tissue specificity, and reduced susceptibility to pre-existing immunity. These advancements could support lower dosing strategies, which are generally associated with increased safety and decreased manufacturing demands, while also expanding the range of treatable diseases. AAV is also being pursued as a delivery system for gene editing technologies, such as CRISPR. While the high specificity makes AAV a valuable option, the payload limitations introduce challenges. Researchers are working on new ways to overcome this hurdle, such as engineering variants that yield smaller machinery proteins or using dual-AAV systems that split large transgenes into separate vectors.</p>
<p>For LVVs, the future will likely involve continued dominance in <em>ex vivo</em> applications while further expanding into <em>in vivo</em> gene delivery. Achieving that transition will require new envelope designs and targeting approaches capable of delivering genetic payloads with greater precision. If custom-engineered envelopes can develop LVVs that preferentially target specific cells at a high rate, the large payload capacity of LVVs would make them prime candidates for delivering gene editing tools.</p>
<p>For LNPs, advances in lipid chemistry and surface engineering may unlock applications far beyond the liver. If LNPs can be designed to effectively achieve this extrahepatic delivery, a plethora of new uses would potentially be unlocked. Because of their flexibility, scalability, and compatibility with gene-editing systems, LNPs are particularly well positioned to support future generations of RNA and genome-editing therapies. Lastly, innovations can be made to enhance LNP efficiency by improving the endosomal escape issue that plagues these delivery systems.</p>
<p>AAV, LVV, and LNP delivery platforms are all expected to remain central to the future of CGT. AAV remains the leading platform for targeted <em>in vivo</em> delivery, LVV offers unique advantages through its payload capacity and durable expression, and LNPs provide unmatched flexibility and scalability. Rather than a single dominant technology emerging, future success will depend on selecting the most appropriate platform for specific therapeutic objectives. As delivery systems continue to mature, ensuring consistent product quality and analytical characterization will become increasingly important for their successful development and adoption.</p>
<p>Whether utilizing AAV vectors, LVVs, or LNPs, future innovations will require equally sophisticated analytical tools to evaluate quality attributes. To support emerging technologies and new modalities, USP actively engages with stakeholders from across industry, academia, and regulatory communities to identify key challenges and areas where standards can best support adoption and improve consistency. Reference standards can help laboratories develop methods and monitor performance. USP has already developed a portfolio of AAV reference materials that support a wide range of analytical workflows and has recently expanded into LVV reference materials, with additional LVV- and LNP-related standards under development. As the field continues to advance, these standards can help ensure consistent and accurate characterization needed to support development and improve confidence in product quality.</p>
<h4><strong>Conclusion</strong></h4>
<p>As gene therapies become more sophisticated, including the incorporation of gene- and base-editing technologies, efficient and precise delivery will remain a key determinant of clinical success. Continued advances in targeting, payload delivery, manufacturability, and safety are expected to expand the capabilities of AAV, LVV, and LNP platforms. Rather than competing technologies, these delivery systems are likely to serve complementary roles, each offering distinct advantages for specific therapeutic applications. Ultimately, the next generation of transformative medicines may be defined not only by the genetic payloads they carry, but by the ability to safely, efficiently, and precisely deliver those payloads to the right cells at the right dose.</p>
<p> </p>
<p><em>Anthony Blaszcyk, PhD, is principal scientist in the Global Biologics Department at USP.</em></p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Ertl HCJ. Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression. <em>Drugs</em>. 2023;83(4):287-298. doi:10.1007/s40265-023-01836-1.</li>
<li>Schlimgen R, Howard J, Wooley D, et al. Risks Associated with Lentiviral Vector Exposures and Prevention Strategies. <em>J Occup Environ Med</em>. 2016;58(12):1159-1166. doi:10.1097/JOM.0000000000000879.</li>
<li>Kim S, Park C, Lee Y, et al. Inflammatory and immune-mediated toxicity of lipid nanoparticles. <em>Biomed Pharmacother</em>. 2026;199:119385. doi:10.1016/j.biopha.2026.119385.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/beyond-the-payload/">Beyond the Payload</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Conventional CRISPR</title>
<link>https://edusehat.com/en/beyond-conventional-crispr</link>
<guid>https://edusehat.com/en/beyond-conventional-crispr</guid>
<description><![CDATA[ Genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies—eGenesis, Epicrispr, KOMO Biosciences, and Sumitomo Pharma America—discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.
The post Beyond Conventional CRISPR appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-4_Sumitomo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Conventional, CRISPR</media:keywords>
<content:encoded><![CDATA[<p>In December 2023, the FDA approved the first CRISPR-based treatment in the United States for sickle cell disease.<sup>1</sup> Despite this advance, conventional CRISPR-Cas9 systems may introduce potentially harmful DNA breaks and cannot easily be delivered to muscle and brain cells. Moreover, genome editing is not designed to replace neurons or retinal cells that have already been lost. In this article, experts from four companies discuss how they are moving beyond conventional CRISPR to develop novel approaches for treating disease.</p>
<h4><strong>Pig organs save lives</strong></h4>
<p>Xenotransplantation involves transplanting an organ from one species into another, explains Mike Curtis, CEO of eGenesis.</p>
<p>“There are just not enough human organs to satisfy the human need for kidneys, livers, lungs, and hearts,” he notes. “Xenotransplantation opens up a new supply of animal organs.”</p>
<p>Curtis explains how the first animal organs were transplanted into people more than 60 years ago. However, these organs were rejected within minutes to hours because of immune compatibility challenges.</p>
<p>Curtis emphasizes how advances in gene editing over the past 15 years have enabled xenotransplantation. “CRISPR really opened the door to precise gene editing, which has given us the ability to engineer pig organs that are more compatible with the human body,” he says.</p>
<p>The company has made three classes of CRISPR-based gene edits to modify its pig organs for human use. First, it inactivated genes encoding for human-incompatible carbohydrates on the surface of pig organs. “In our studies, a pig kidney modified in this way has been able to function in a human for several days to weeks without hyperacute rejection,” says Curtis.</p>
<figure aria-describedby="caption-attachment-340338" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340338" src="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-1024x463.jpg" alt="three classes of gene edits" width="696" height="315" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-1024x463.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-300x136.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis-768x347.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-1_eGenesis.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">The three classes of gene edits performed by eGenesis on the pig genome. [eGenesis]</figcaption></figure>
<p>The second class of edits introduced human genes into the pig genome to improve the human immune response to the animal organ. Finally, the third class of edits inactivated endogenous retroviruses in the pig genome, alleviating concerns that infectious diseases could cross over from pigs to people.</p>
<p>eGenesis’s most advanced program is for the kidney. The company’s recent publication in <em>The Lancet</em> describes the first few transplants of pig kidneys into people.<sup>2</sup></p>
<p>Curtis recalls one patient in the study. “This gentleman was doing poorly and had a very high risk of dying on dialysis. He was on the pig kidney for nine months, which improved his condition. He was then able to receive a human kidney transplant and is doing great eight months later.” The company is embarking on its Phase I/II/III RESTORE kidney trial, expected to initiate in the first quarter of 2027.</p>
<p>eGenesis’s second program involves the liver. The patient’s blood is perfused through a pig liver located outside of the body. This procedure provides life support and allows the person’s liver to recover while a human liver becomes available.</p>
<p>Finally, eGenesis is hoping to tackle end-stage heart failure. For the past couple of years, the company has been studying the long-term effects of pig heart transplants in baboons. Its first pig-to-human heart transplant is expected in 2027.</p>
<p>Is eGenesis finished with its gene edits? “One of our ultimate goals is to produce animal organs that require no immunosuppression,” says Curtis. “The only way to achieve that goal is iterative gene editing based on our first generation of organs. If we have our way, it should only get better from here.”</p>
<p>Although most of eGenesis’s edits have used CRISPR technology, the company is agnostic about the specific gene-editing tool. “Our goal is to improve the compatibility of pig organs for human recipients. The specific tool we use, whether it is Cas9, base editing, or prime editing, matters less to us than the outcome,” Curtis notes.</p>
<h4><strong>Epigenetic editing</strong></h4>
<p>While DNA contains the instructions for gene expression, epigenetic tags—such as DNA methylation and histone acetylation—act like switches that turn genes on and off. Epigenetic modifications help explain why people with the same genetic mutation may experience very different outcomes.</p>
<p>“We are leveraging the power of the epigenome to create new therapeutic possibilities,” explains Amber Salzman, PhD, CEO of Epicrispr. She notes how the first generation of CRISPR technology was designed to cut DNA and remove faulty genes.</p>
<p>“In contrast, we bind to the gene with CRISPR-Cas technology and tell the DNA what to do. Should the gene be expressed more, less, or not at all? All without cutting the DNA strands.”</p>
<p>Instead of the Cas9 nuclease used in first-generation CRISPR technologies, Epicrispr’s platform utilizes a much smaller molecule called CasONYX, which is deactivated and unable to cut DNA.</p>
<p>The platform fuses what it calls a modulator to each deactivated Cas nuclease. “These molecules will methylate DNA or put on histone modifications,” notes Salzman. Studies suggest that these modifications can potentially last indefinitely. And because Epicrispr’s Cas molecules and modulators are so small, they can fit into adeno-associated viruses (AAVs), which can access the muscles, eyes, and brain.</p>
<p>The company’s lead indication is facioscapulohumeral muscular dystrophy (FSHD). “We are the only company going after the root cause in FSHD, which is fundamentally a disease of reduced methylation,” Salzman notes.</p>
<figure aria-describedby="caption-attachment-340339" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340339" src="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-1024x579.jpg" alt="Epicrispr’s CasMINI" width="696" height="394" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-1024x579.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-300x170.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr-768x434.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Yesavage_Figure-2_epiCrispr.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Epicrispr’s CasMINI uses a guide RNA to bind to the DNA sequence of interest. A fused modulator molecule can then methylate the DNA. [Epicrispr]</figcaption></figure>
<p>More specifically, FSHD is associated with fewer repeats in the <em>D4Z4</em> region of the genome and a looser chromatin architecture. This structure allows for the expression of the toxic DUX4 protein, which kills muscle cells.</p>
<p>Epicrispr’s FSDH machinery is delivered to the muscle with an AAV. The region is then remethylated to suppress the genes responsible for DUX4 expression. “In patients with less-advanced disease, we can correct enough cells to stop DUX4 production and see a gain in lean muscle volume,” says Salzman.</p>
<p>The company also has early preclinical data on Duchenne muscular dystrophy. A major challenge in treating this condition is that the faulty dystrophin protein is too large to fit into AAVs. However, a protein called utrophin can compensate for a lack of dystrophin.</p>
<p>“We deliver a construct to the muscle cells with an AAV vector that instructs utrophin to be expressed at high levels and make up for the lack of dystrophin,” she notes.</p>
<p>Epicrispr has generated <em>in vitro</em> data for Alzheimer’s disease showing the activation of the <em>SORL1</em> gene in neuronal cells. This gene has been shown to be neuroprotective in the disease. It also has promising preclinical results for retinitis pigmentosa, an eye disease caused by a faulty protein called rhodopsin.</p>
<p>Finally, Salzman argues that Epicrispr’s strategy may be safer than traditional CRISPR. “When you are cutting, you can have genomic instability. Instead, we just make epigenetic marks,” she adds.</p>
<h4><strong>Inserting large genes</strong></h4>
<p>“I think the next phase of genome engineering will be less about changing one letter at a time and more about installing complete genetic programs,” predicts Jesse B. Owens, PhD, assistant professor at the University of Hawaii at Manoa and chief scientific advisor of KOMO Biosciences.</p>
<p>While conventional CRISPR-Cas9 technology is excellent for small edits, the insertion of large amounts of DNA is far less efficient, he notes. Furthermore, CRISPR generates exposed DNA breaks that can cause unwanted deletions or rearrangements.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Integrases fill a different niche. They actively install gene-sized DNA at a defined site without leaving an exposed double-strand break. “An integrase is like a molecular paste function,” adds Owens. “It recognizes relatively long DNA addresses in the genome and actively inserts large fragments of DNA.”</p>
<p>“Integrases have been known for some time,” he continues. “The key difference is that our enzymes have been engineered with laboratory-directed evolution to be highly effective.” For instance, Owens’s recent publications demonstrate that evolved integrases can insert DNA into the desired genomic destination 80% of the time.</p>
<p>Owens stresses that the biggest remaining bottleneck for many therapeutic applications involves delivering the genetic editing machinery to the right cells. “A hyperactive integrase changes that equation,” he says. “When delivery is scarce, a much more efficient enzyme gives the DNA that reaches a cell a better chance of becoming a correct insertion.”</p>
<p>The company’s partners are currently interested in CAR T and other engineered immune-cell therapies. Such therapies often require large DNA insertions to fit multiple components for cancer therapy—including multiple receptors, persistence factors, and a safety switch within a single genetic cassette.</p>
<p>Beyond therapeutics, integrase technology has many applications in cell-line development and biomanufacturing. For instance, a highly efficient integrase-based system could create a more predictable starting cell-line population and compress development timelines.</p>
<p>“KOMO’s capacity for full gene replacement allows one product to address many different mutations in the same gene, rather than designing a separate editor for every patient’s mutation,” notes Owens.</p>
<h4><strong>Stem cell approval</strong></h4>
<p>“In advanced degenerative neurologic and eye conditions, critical target cells have already degenerated and died,” explains Alex Solyom, MD, vice president and head of clinical research, rare disease and biopharma at Sumitomo Pharma America. Interventions like CRISPR are not targeted to regenerate tissue structures that no longer exist in the patient.</p>
<p>Induced pluripotent stem cells (iPSCs) provide a supply of healthy cells to potentially replace or functionally restore damaged tissue. Researchers can generate them by reprogramming mature cells (such as skin or blood cells) back into an embryonic-like state. Importantly, iPSCs avoid ethical concerns associated with embryonic stem cells derived from fertilized eggs.</p>
<p>iPSCs provide a convenient basis for developing potential therapies. They can replicate endlessly in culture following reprogramming. They are also pluripotent, meaning that they can mature into virtually any specialized cell type.</p>
<p>“With iPSC-derived regenerative therapies, we aim to reestablish functional cells and tissue regardless of the underlying genetic mutation. This can be particularly important for diseases driven by mutations across multiple genes,” Solyom notes.</p>
<p>He highlights Sumitomo’s DSP-3077, an investigational iPSC therapy being developed as an off-the-shelf cell therapy for patients with retinitis pigmentosa, a progressive genetic eye disorder in which retinal photoreceptors degenerate.</p>
<p>Currently in Phase I/IIa trials, DSP-3077 consists of an iPSC-derived retinal sheet produced from a three-dimensional retinal organoid. This organoid is formed during a proprietary self-organizing process in which required cell types are differentiated from the iPSCs.</p>
<p>A single subretinal injection inserts the sheets into the patient’s eye. The injected sheets are designed to physically engraft into the patient’s retinal tissue. “We believe this will support natural retinal tissue architecture and replace degenerated photoreceptors, potentially helping to restore visual function,” Solyom says. In March of 2026, the investigational therapy received an FDA Orphan Drug Designation.</p>
<p>Meanwhile, Sumitomo’s raguneprocel, a dopaminergic neural cell product, is the world’s first approved iPSC-derived medicine. In March 2026, it received conditional, time-limited approval as AMCHEPRY<sup>®</sup> in Japan to improve motor symptoms in Parkinson’s disease.</p>
<p>“Being able to deliver to patients functional tissue made up of a complex structure and multiple cell types—and derived from the same stem cell line—is a worthwhile challenge and a great accomplishment drawing on decades of research,” concludes Solyom.</p>
<p> </p>
<p><em>References</em></p>
<p>1. Singh A, Irfan H, Fatima E, et al. Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease. <em>Ann Med Surg</em> (Lond). 2024;86(8):4555-4559. doi: 10.1097/MS9.0000000000002146.</p>
<p>2. Riella LV, Borges TJ, Rosales IA, et al. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study. <em>Lancet</em>. 2026;408(10559):1029-1040. doi: 10.1016/S0140-6736(26)01295-X.</p>
<p>The post <a href="https://www.genengnews.com/insights/beyond-conventional-crispr/">Beyond Conventional CRISPR</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Oral Sleep Apnea Therapy Poised to Expand Treatment Options</title>
<link>https://edusehat.com/en/oral-sleep-apnea-therapy-poised-to-expand-treatment-options</link>
<guid>https://edusehat.com/en/oral-sleep-apnea-therapy-poised-to-expand-treatment-options</guid>
<description><![CDATA[ An oral obstructive sleep apnea therapy targeting multiple pathways is poised to improve patient compliance and, possibly, outcomes.
The post Oral Sleep Apnea Therapy Poised to Expand Treatment Options appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_1361394553_SleepApnea.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Oral, Sleep, Apnea, Therapy, Poised, Expand, Treatment, Options</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Right now, there is no pharmaceutical treatment for obstructive sleep apnea, a condition that is estimated to affect more than one billion people globally and approximately 30 million Americans. Multiple studies (notably in 2010<sup>1</sup> and 2017<sup>2</sup>) report that as many of half those prescribed continuous positive airway pressure (CPAP)—the gold standard apnea therapy—reject it outright, and between 12% and 25% of those who begin those treatments abandon CPAP within three years.</p>


<p class="wp-block-paragraph">The reason for such high non-compliance is that CPAP is uncomfortable and socially awkward, Joel Latham, president and CEO, Incannex Healthcare, says. His company aims to be the first to potentially market an oral pharmaceutical therapy for obstructive sleep apnea.</p>


<p class="wp-block-paragraph">Latham says Incannex Healthcare’s mission is “targeting indications that have limited or no treatment options available.” So, while a therapy for obstructive sleep apnea, known as IHL-42X, is its lead therapeutic, the company’s pipeline also includes therapeutics based on distinctly different therapeutic platform to treat generalized anxiety disorder and rheumatoid arthritis.</p>


<h4 class="wp-block-heading"><strong>Oral apnea therapy</strong></h4>


<p class="wp-block-paragraph">Regarding obstructive sleep apnea, “We are targeting multiple pathways, and [the condition’s] underlying, fundamental causes,” he tells <em>GEN</em>. Just as importantly, the therapeutic (code-named IHL-42X) is oral, which should significantly improve compliance and potentially make more people amenable to therapy. It has received Fast Track designation from the U.S. Food and Drug Administration (FDA).</p>


<p class="wp-block-paragraph">The Phase II RePOSA trial showed that IHL-42X significantly reduced the frequency of breathing disruptions during sleep compared with placebo, with individual reductions of up to 83%. Reductions exceeding 30% were achieved by 33.3% of patients receiving the low dose and 41.2% receiving the high dose. A subsequent dose-optimization study, DReAMzz, began patient dosing in August 2026, supported by 14 clinical sites across the U.S. “We expect to have the data from that trial in the first half of 2027,” Latham says.</p>


<figure class="wp-block-image alignright size-medium is-resized"><img loading="lazy" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-300x300.jpg" alt="Joel Latham" class="wp-image-340328" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/OYR-Joel-Latham-Headshot-e1793902112442.jpg 1260w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption">Joel Latham<br>President and CEO<br>Incannex Healthcare</figcaption></figure>


<p class="wp-block-paragraph">“IHL-42X is an oral, fixed-dose combination of acetazolamide and dronabinol,” he continues. “Acetazolamide [a carbonic anhydrase inhibitor used for altitude sickness and glaucoma] induces metabolic acidosis, which signals…there is excess CO<sub>2</sub> in the blood, and thereby causes people to take a breath. Dronabinol [a synthetic tetrahydrocannabinol used to control nausea and stimulate appetites] simultaneously dilates the airways. So, by inducing the taking of a breath and dilating the airways simultaneously, we’re able to reduce the number of apnea episodes that patients experience during the evening.”</p>


<p class="wp-block-paragraph">Because this approach pairs two already-approved drugs, risks are reduced, the development pathway is streamlined, and costs are lowered.</p>


<h4 class="wp-block-heading"><strong>Anxiety and arthritis</strong></h4>


<p class="wp-block-paragraph">To treat generalized anxiety disorder, Incannex Healthcare is developing PSX-001, a psilocybin-based therapy designed to be used with cognitive behavioral therapy. The Phase II trials that completed in 2025 showed a 50% reduction in anxiety in 44% of patients.</p>


<p class="wp-block-paragraph">Generalized anxiety disorder affects approximately three percent of the U.S. population. First-line treatments are selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, both administered with cognitive behavioral therapy.</p>


<p class="wp-block-paragraph">“The current standard of care has an extremely high non-compliance rate,” Latham says. Medical literature cites non-compliance rates between 40% to 60% within six months. Given PSX-001’s apparent efficacy in Phase II studies, “This is a market where we firmly believe we can make significant impacts for patients suffering from debilitating anxiety disorders.”</p>


<p class="wp-block-paragraph">Its third pipeline therapeutic—for rheumatoid arthritis—is on the back burner for now. “It’s been de-risked, but we truly have our hands full with the two lead assets,” Latham admits. IHL-675A, as this therapeutic is known, has completed “a plethora of preclinical and Phase I and II clinical studies, and the data’s been pleasing…but we’re focusing our resources on those [other] two assets.”</p>


<h4 class="wp-block-heading"><strong>From Aus to the UAE</strong></h4>


<p class="wp-block-paragraph">Incannex Healthcare has changed substantially since being founded in Australia in 2014. When it went public in 2016 on both the Australian Stock Exchange (ASX) and the NASDAQ, Latham—an early investor—joined the company as general manager. “After two years, I was elevated to CEO,” he says.</p>


<p class="wp-block-paragraph">“Then, in 2023, we decided to delist from the ASX and purely focus on the NASDAQ because we firmly believe that’s where our true peers were. Shifting its ASX shares to the NASDAQ made it easier for U.S. brokers to trade Incannex Healthcare stock and for Incannex Healthcare to leverage U.S. investors’ knowledge around the cannabinoid and psychedelic sectors, as well as access more potential investors.</p>


<p class="wp-block-paragraph">Recently, Incannex Healthcare moved its executive headquarters from Melbourne to Dubai, while retaining offices in Melbourne—“where the vast majority of our research team is located”—and New York. “Being in the UAE allows me to efficiently manage the two vastly different time zones that we deal with,” he says.</p>


<p class="wp-block-paragraph">“Abu Dhabi,” he continues, “is quite a biotech hub. That’s one of the leading reasons for me moving here and setting up offices.” The United Arab Emirates is considered an emerging, fast-growing regional biopharma center with very fast regulatory approvals and a strong desire to enlarge its biopharma manufacturing base.</p>


<p class="wp-block-paragraph">“We’re developing relationships, and we’re working with sovereign funds and with the government in relation to potential grants,” Latham says. That funding—an influx of nearly $60 million in the past year, which brought its cash balance to more than $74 million—provides “ample runway to see assets through to potential completion of Phase III,” he adds.</p>


<h4 class="wp-block-heading"><strong>Maturity brings changes</strong></h4>


<p class="wp-block-paragraph">Being president and CEO, he says “has been quite a unique experience,” given the multiple capital markets Incannex Healthcare has competed in, the multiple clinical assets it has developed, and clinical trials it has completed.</p>


<p class="wp-block-paragraph">“Very early on,” Latham recalls, “we were entrenched in preclinical studies. We were able to move quickly, generating data, creating new assays and studies, filing provisional patents, and derisking assets.” Now the operational scale is much larger and, he points out, “We’re at a later stage of development, so things move slower.” Examples of current challenges include onboarding trial sites, ensuring adequate patient recruitment levels, maintaining productive FDA interactions, and managing the permits and licensing necessary to import trial products into the U.S. For Incannex Healthcare’s pipeline, that includes working with the Drug Enforcement Agency.</p>


<p class="wp-block-paragraph">One thing has remained constant, however. From the very beginning, Latham says, “Everything’s been developed completely in-house in collaboration with our chief scientific officer, chief medical officer, and the expert leading advisory boards we’ve established for each of our assets.”</p>


<h4 class="wp-block-heading"><strong>Next milestones</strong></h4>


<p class="wp-block-paragraph">Completing the IHL-42X obstructive sleep apnea study, which dosed its first patient in August, is the company’s next milestone, Latham says. “We’re hyper-focused on getting those results out in 2027.”</p>


<p class="wp-block-paragraph">Meanwhile, Incannex Healthcare continues developing PSX-001 to treat generalized anxiety. “Various potential collaboration discussions are underway as well, so we expect to be able to deliver a few key milestones and updates to the market in the coming months,” he says.</p>


<p class="wp-block-paragraph"><em> </em></p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sidebar is-layout-flow wp-block-column-is-layout-flow">
<h3 class="wp-block-heading"><strong><strong>Incannex Healthcare</strong></strong></h3>


<p class="wp-block-paragraph"><strong>Location:</strong> Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000, Australia</p>


<p class="wp-block-paragraph"><strong>Phone:</strong> 61 (409) 840-786</p>


<p class="wp-block-paragraph"><strong>Website:</strong> <a href="https://incannex.com/" target="_blank" rel="noreferrer noopener">incannex.com</a></p>


<p class="wp-block-paragraph"><strong>Principal:</strong> Joel Latham, president and CEO</p>


<p class="wp-block-paragraph"><strong>Number of Employees:</strong> 30</p>


<p class="wp-block-paragraph"><strong>Focus:</strong> Incannex Healthcare is a clinical-stage company developing therapeutics for unmet needs. Its lead programs are an oral therapy for obstructive sleep apnea and a combination psilocybin/psychotherapy approach to treating generalized anxiety disorder.</p>
</div>
</div>


<p class="wp-block-paragraph"></p>


<p class="wp-block-paragraph"><em>References</em></p>


<ol class="wp-block-list">
<li>Catcheside, Peter G, Predictors of continuous positive airway pressure adherence. <em>F1000 Medicine Reports</em>. September 2010; 2:70 (<a href="https://s3-eu-west-1.amazonaws.com/science-now.reports/f1000reports/files/9008/2/70/article.pdf">doi:10.3410/M2-70</a>)</li>



<li>Jacobsen AR, Eriksen F, Hansen RW, et al. <a href="https://doi.org/10.1371/journal.pone.0189614" target="_blank" rel="noopener">Determinants for adherence to continuous positive airway pressure therapy in obstructive sleep apnea</a>. <em>PLOS ONE</em>. 2017; 12(12): e0189614.</li>
</ol>


<p class="wp-block-paragraph"></p>

<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/oral-sleep-apnea-therapy-poised-to-expand-treatment-options/">Oral Sleep Apnea Therapy Poised to Expand Treatment Options</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tissue Engineering Takes Shape</title>
<link>https://edusehat.com/en/tissue-engineering-takes-shape</link>
<guid>https://edusehat.com/en/tissue-engineering-takes-shape</guid>
<description><![CDATA[ Personalized grafts, bioinks, and off-the-shelf tissues are advancing regenerative medicine toward broader clinical use.
The post Tissue Engineering Takes Shape appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Fig-2-Humacyte.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tissue, Engineering, Takes, Shape</media:keywords>
<content:encoded><![CDATA[<p>Tissue engineering is on the move from an ambitious idea toward everyday clinical reality. At the interface of biology, materials science, and engineering, the field seeks to repair or replace damaged human tissues and organs. Some approaches embrace personalized medicine, creating tissues and treatments from a patient’s own cells and materials. Others are developing off-the-shelf engineered products for broad availability. We spoke to experts in the field about the latest developments pushing both strategies forward. Technologies range from heart patches and spinal cord repair to bone, cartilage and vascular grafts, and beyond.</p>
<h4><strong>Living cardiac band-aid </strong></h4>
<figure aria-describedby="caption-attachment-340294" class="wp-caption alignright"><img decoding="async" class="wp-image-340294" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-300x300.jpg" alt="Jordan Lancaster" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Jordan-Lancaster-e1793897464951.jpg 933w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Jordan Lancaster, PhD<br>CEO, Avery Therapeutics</figcaption></figure>
<p>“The concept of making functional tissue to replace damaged tissues and organs has captured the imagination of many for a long time,” says Jordan Lancaster, PhD, CEO of Avery Therapeutics. Case in point: heart failure. Lancaster elaborates, “Today, we manage cardiac diseases like heart failure by administering drugs that help reduce symptoms of the disease. And while the current armament of drugs for heart failure does slow progression of disease, the prognosis remains grim, and the disease continues to advance. There are no therapies today that get to the root cause of heart failure, which is loss of functioning cardiomyocytes (heart muscle cells) and fibrosis. We want to change this. We want to develop novel therapies that address the root cause of disease, and reverse disease in ways that are currently unobtainable.”</p>
<p>According to Lancaster, the company is pursuing an immunomodulatory approach coupled with tissue engineering to essentially create a “living band-aid, of sorts.” Their preclinical collaborative studies employed an allogeneic cardiac patch composed of a proprietary mix of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes and fibroblasts embedded in a bioresorbable matrix. Lancaster explains, “This biologic product is placed on damaged tissue and creates a localized immunomodulatory response that drives disease repair. Our immunomodulatory platform is built utilizing cellular material, a proprietary combination of cells produced via a multi-day manufacturing process. The biologic engages the immune system and recruits immune precursor cells, which drive repair.”</p>
<p>Developing the approach also required overcoming key hurdles such as manufacturing at scale, handleability, and shelf stability (cryopreservation). Additionally, Lancaster says the company has learned a lot about the immune system and its ability to serve as a conserved therapeutic target for diseases of inflammation and fibrosis. “We are exploring and have established deep mechanistic insight into how to redirect the immune system into pro-reparative pathways, which we have validated in highly translatable preclinical models of heart failure. We are keen to advance these insights into novel therapies.”</p>
<p>As a late-stage preclinical company, Avery will initially focus on heart failure of ischemic etiology with plans to advance the technology toward clinical testing.</p>
<h4><strong>Bioinks for 3D bioprinting </strong></h4>
<figure aria-describedby="caption-attachment-340290" class="wp-caption alignright"><img decoding="async" class="wp-image-340290" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--300x300.jpg" alt="Yehiel Tal" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal--768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Yehiel-Tal-.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Yehiel Tal<br>CEO, CollPlant Biotechnologies</figcaption></figure>
<p>While tissue engineering has made remarkable progress, fundamental barriers remain, according to Yehiel Tal, CEO of CollPlant Biotechnologies, including “access to safe and reproducible biomaterials, recreation of the complex biological and mechanical environment of human tissue, vascularization, and scalable manufacturing.” Bioinks, specialized cell-laden gel-based biomaterials, are a critical aspect. He elaborates, “Bioinks must support cell viability while providing the printability, structural stability, degradation profile, and mechanical properties required for functional tissue formation.”</p>
<p>The company is addressing these challenges through its proprietary plant-derived recombinant human type 1 collagen (rhCollagen) platform. Tal reports, “Because our collagen is bioidentical to human collagen and produced without animal or human tissue, it offers a consistent, scalable, animal-free building block for regenerative medicine. Our bioink portfolio combines rhCollagen with complementary biomaterials and photoactive components to tailor mechanical strength, degradation kinetics, and printing performance for different tissues and printing technologies.”</p>
<figure aria-describedby="caption-attachment-340291" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-340291 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-300x252.jpg" alt="3D-bioprinted regenerative breast implants" width="300" height="252" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-300x252.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-1024x860.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant-768x645.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-CollPlant-Regenerative-breast-Implant.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">3D-bioprinted regenerative breast implants, composed of rhCollagen and biodegradable biopolymers, are designed to provide structural support, promote vascularization and tissue ingrowth, and gradually degrade as the patient’s own tissue replaces the implant. CollPlant Biotechnologies’ regenerative implants are currently in preclinical development. [CollPlant Biotechnologies]</figcaption></figure>
<p>One example from this portfolio is BioFlex<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup>, a ready-to-print kit for high-resolution digital light processing (DLP) bioprinting. DLP bioprinting projects a digital image of each layer of a desired 3D structure onto light-sensitive bioink, selectively solidifying the material to build the structure layer by layer. Tal explains, “BioFlex combines Collink.3D<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup> 50 with a biodegradable polymer and proprietary photoactive agents, simplifying formulation while retaining the flexibility to create complex, biologically relevant structures. It is intended for advanced tissue models, drug discovery, engineered tissues, and ultimately transplantable organs.”</p>
<p>The company is also applying tissue engineering to medical aesthetics. Tal says, “We have advanced commercial-size, 3D-bioprinted regenerative breast implants through large-animal preclinical studies. These implants are designed to gradually degrade while supporting vascularization and regeneration of the patient’s own tissue.”</p>
<p>Tal believes progress in the field will depend on integrating biomaterials, cells, vascular networks, bioreactors, automation, and computational design into scalable manufacturing platforms. “We see major opportunities in human tissue models, regenerative soft-tissue products, and organ manufacturing, enabled by biomaterials that are both biologically relevant and industrially reproducible.”</p>
<h4><strong>Personalized spinal cord repair </strong></h4>
<p>More than 18,000 people sustain traumatic spinal cord injuries in the U.S. annually, with approximately 310,000 patients living with the condition. The injured spinal cord has little regenerative capacity and develops a cellular and extracellular environment that inhibits neural regrowth.</p>
<figure aria-describedby="caption-attachment-340293" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340293" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-246x300.jpg" alt="Gil Hakim" width="200" height="244" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-246x300.jpg 246w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662-768x937.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Gil-Hakim-e1793897765662.jpg 782w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gil Hakim<br>CEO, Matricelf</figcaption></figure>
<p>Gil Hakim, CEO of Matricelf<strong>,</strong> reports, “Chronic spinal cord injury is characterized by tissue cavities and scarring that interrupt neural pathways. Regeneration requires addressing inflammation, restoring extracellular-matrix cues, and enabling transplanted cells to survive, organize, extend axons, form functional synapses, and integrate with spinal cord circuitry.”</p>
<p>Matricelf is developing NewRal, a 3D neural-tissue transplant composed of patient blood-derived iPSCs as well as an extracellular-matrix hydrogel derived from the patient’s omental tissue. Before transplantation, the cells differentiate and assemble into 3D neural tissue spheroid constructs containing electrically active neural cells, designed to replace damaged neural tissue and support new neural connections.</p>
<p>“The dual-autologous design may reduce immune mismatch and the need for immunosuppression,” says Hakim. “Compared with transplants using donor cells or synthetic, animal-derived, or standardized scaffolds, NewRal combines patient-specific cells, biological matrix, and preassembled neural tissue.”</p>
<p>Matricelf is addressing manufacturing complexity and patient variability through standardized Good Manufacturing Practices (GMP) processes and optimization via closed-system automation. Hakim indicates that pilot efficacy studies in chronic spinal cord injury animal models have shown improvement in functional recovery and tissue regeneration in 80% of treated animals. The company completed Good Laboratory Practice (GLP) safety studies, advanced GMP manufacturing and clinical site preparations, initiated patient identification activities, and received FDA feedback on elements of the proposed first-in-human clinical program planned for 2027.</p>
<figure aria-describedby="caption-attachment-340296" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-340296 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-1024x403.jpg" alt="Matricelf’s NewRal technology illustration" width="1024" height="403" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-1024x403.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-300x118.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution-768x302.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Matricelf_NewRal_high_resolution.jpg 1400w" sizes="auto, (max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">To treat spinal cord injuries, patient-derived cells and an autologous hydrogel are combined to create personalized 3D neural tissue for transplantation at the site of spinal cord injury. Illustrated is Matricelf’s NewRal technology. [Matricelf]</figcaption></figure>
<h4><strong>Living bone and cartilage grafts </strong></h4>
<figure aria-describedby="caption-attachment-340297" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340297" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-300x300.jpg" alt="Nina Tandon" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Nina-Tandony-e1793898011794.jpg 770w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nina Tandon, PhD<br>CEO, EpiBone</figcaption></figure>
<p>Tissue engineering is also making strides in the repair of bone and cartilage. According to Nina Tandon, PhD, CEO of EpiBone, “The gold standard treatments for skeletal defects are unfortunately riddled with compromises to meet the standard of ‘replacing like with like.’ Craniofacial bone loss after trauma or tumor surgery, and damaged joint cartilage, are the big ones. What happens today? A surgeon can harvest bone from your hip or leg, so now you have two wounds and real donor-site pain. They can use cadaver tissue, which the body often resorbs. Or they can bolt in metal or plastic that never becomes bone and, sooner or later, needs revising.”</p>
<p>EpiBone aims to shift from replacing tissue to regrowing it using stem cells to create personalized bone and cartilage products. Tandon explains, “Depending on the case, we can shape a graft to a patient’s exact anatomy before it reaches the operating room, or supply it off the shelf, ready when the surgeon needs it. Either way, it is living tissue on a natural bone matrix, so it is designed to integrate and remodel the way native tissue does rather than be tolerated as a foreign object.”</p>
<p>The process begins with adult stem cells seeded onto a natural bone matrix and matured in a bioreactor. Tandon elaborates, “I describe the bioreactor as diet and exercise: it feeds the tissue and puts it through the mechanical loading it will see in the body (going jogging a couple miles a day, roughly). Out comes living, 3D bone or cartilage. Honestly, the biology is the fun part. The moat is manufacturing. Making living tissue reproducibly, at the right size and shape and at clinical grade, is the hard problem, and it is the one we have spent more than a decade on.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>The company has advanced its bone and cartilage programs into human trials. Tandon reports, “In our first-in-human bone trial, we treated six patients with zero product-related adverse events. Those six jaws are the thing I am proudest of.” EpiBone has also tested an injectable cartilage therapy for osteoarthritis in dogs and horses, reporting improvements over standard-of-care treatment.</p>
<p>Looking ahead, Tandon sees the next decade focusing on scale and broader availability of custom and off-the-shelf living grafts.</p>
<h4><strong>Off-the-shelf vascular grafts </strong></h4>
<p>When a patient suffers a severe injury or chronic vascular disease, surgeons may need to replace or repair an artery. Current options include using a patient’s own vein, synthetic grafts, or an animal-derived allograft.</p>
<figure aria-describedby="caption-attachment-340295" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-340295" src="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-266x300.jpg" alt="Laura Niklason" width="200" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-266x300.jpg 266w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-909x1024.jpg 909w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400-768x865.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Liszewski-Laura-Niklason-e1793897920400.jpg 1183w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Laura Niklason, MD, PhD<br>President and CEO, Humacyte</figcaption></figure>
<p>“Harvesting a vein can be especially dangerous in urgent cases, taking more time in the OR, adding increased risk for infection, and resulting in a second surgical wound with the potential for post-operative pain,” says Laura Niklason, MD, PhD, president and CEO of Humacyte. She also notes some synthetic grafts are prone to infection while animal-derived allografts carry other issues. What is needed is a readily available conduit that behaves like living tissue but resists infection, maintains patency, and integrates seamlessly with the body.</p>
<p>Humacyte has developed acellular tissue-engineered vessels (ATEVs) as off-the-shelf, universally implantable vascular grafts. Niklason explains, “We begin with human vascular smooth muscle cells seeded onto a biodegradable scaffold, which gradually dissolves as the tissue forms.” Pulsatile, artery-like conditioning then prompts the cells to build a strong matrix of human collagen and other extracellular matrix proteins. After the vessel matures, the cells used to grow it are removed while the extracellular matrix and structural proteins remain. The resulting bioengineered vessel can be stored until needed. After implantation, the patient’s own cells gradually repopulate and remodel the vessel, transforming it into living tissue.</p>
<p>The company’s lead product, Symvess<sup>®</sup>, was approved by the FDA in December 2024 as a vascular conduit for adults with extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible. In September 2026, the FDA approved extending its shelf life from 18–36 months. Humacyte is also planning submission of a supplemental Biologics License Application in the second half of 2026 for hemodialysis applications.</p>
<p>Niklason believes tissue engineering is at an important inflection point. “What’s changing now is the shift toward manufactured, off-the-shelf regenerative products that have the potential to reach a large scale of patients. The opportunity ahead is to make engineered human tissue a routine part of surgical and medical care for the benefit of the patients who need it.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/tissue-engineering-takes-shape/">Tissue Engineering Takes Shape</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Orphan Therapeutics Accelerator In&#45;Licenses Its First Gene Therapy, Eyes Pipeline Expansion</title>
<link>https://edusehat.com/en/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion</link>
<guid>https://edusehat.com/en/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion</guid>
<description><![CDATA[ The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources.
The post Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/10/Getty_2235763333_GeneTherapy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Orphan, Therapeutics, Accelerator, In-Licenses, Its, First, Gene, Therapy, Eyes, Pipeline, Expansion</media:keywords>
<content:encoded><![CDATA[<p><span>Recently, the Orphan Therapeutics Accelerator (OTXL) announced an agreement with UCL Ventures, </span><span>the commercialization company of University College London (UCL), </span><span>and Children’s Medical Research Institute (CMRI) to in-license an investigational therapy program for ornithine transcarbamylase deficiency (OTCD), a rare, X-linked metabolic disorder. The drug candidate in question, now dubbed OTXL-101, was formally known as AAVLK03hOTC. It was developed through a collaboration between Paul Gissen, MBCHB, PhD, and the OTCD project team at University College London, and Ian Alexander, MBBS, PhD, and his team at CMRI. </span></p>
<p><span>This marks the first therapy in-licensed by OTXL, a nonprofit biotech set up specifically to utilize tax and other incentives to “liberate and reininitiate development of shelved therapies for rare and ultra rare conditions” that have been shelved in recent years for various reasons, according to Craig Martin, OTXL’s CEO and co-founder. </span></p>
<p><span>The nonprofit biotech is one part of a four-pronged approach targeting shelved cell and gene therapies. The other parts include the Orphan ClinDevNet, a network of affiliated contract development and manufacturing organizations, contract research organizations, and other partners who have agreed to work under reduced-cost, success-based agreements. </span></p>
<p><span>Approved products can be commercialized through Orphan Therapies, OTXL’s commercial subsidiary, which was established a year ago, or outlicensed to biotech or biopharma partners. Recently, Orphan Therapies established commercial availability for an <em>ex vivo</em> cell therapy for patients with Wiskott-Aldrich syndrome. </span></p>
<p><span>Finally, support for </span><span>OTXL and </span><span>other programs in need of financing or partners can be accelerated and facilitated through CGTxchange, an artificial intelligence-enabled marketplace, diligence, and deal-making platform established through a </span><a href="https://www.genengnews.com/topics/genome-editing/asgct-president-terry-flotte-touts-rare-disease-initiatives-as-his-term-ends/" target="_blank" rel="noopener"><span>joint venture between OTXL and the American Society of Gene & Cell Therapy (ASGCT)</span></a><span>. It serves as a marketplace for shelved therapies with potential that could be picked up by both traditional and non-traditional kinds of investors or funders.</span></p>
<p><span>In fact, OTXL-101 was initially identified with the help of the platform that now underlies CGTxchange, according to Martin. He told</span><i><span> GEN</span></i><span> that prior to in-licensing OTXL-101, the OTXL team looked at more than 80 different therapeutic programs. “We first started looking at it almost two years ago,” he said. At the time, OTXL-101 was outlicensed to Bloomsbury Genetic Therapies, which had initiated a Phase I/II study dubbed the Halting Ornithine transcarbamylase deficiency with Recombinant AAV in Children or HORACE trial. </span></p>
<p><span>The first patient, a 10-year-old male with late-onset OTCD, was treated at Great Ormond Street Hospital in December 2023. The plan was to run a 12-patient trial, however when the Bloomsbury Genetic Therapies shut down in 2025, the program was returned to UCL and CMRI. Preliminary results from the first patient were presented at the 2025 ASGCT annual meeting.</span></p>
<p><span>OTXL had moved on to other candidates at the time, Martin said, but when the initial plans for the treatment fell through, and the therapy was returned to UCL and CMRI, they reconsidered. “We started negotiating with them and found everybody was really feeling like this was a therapy that needed to get to patients. And we were able to structure the deal in such a way that it really fit our model and provided a more viable path forward for the therapy,” he said. </span></p>
<h4><b>A rare disease therapy gets a new life</b></h4>
<p><span>Ornithine transcarbamylase deficiency or OTCD is caused by mutations in the OTC gene that reduce or eliminate ornithine transcarbamylase activity. This enzyme is essential to the liver’s urea cycle, which converts toxic ammonia from protein metabolism into urea for elimination. When ammonia builds up in the blood, it can cause hyperammonemic decompensations, brain injury, and coma. </span></p>
<p><span>The condition is currently managed medically by protein restriction, nitrogen-scavenging medicines, and amino acid supplements. But patients remain at risk for elevated blood ammonia and serious complications. Another option is liver transplantation which can restore metabolic control but carries surgical risks and requires lifelong immunosuppression. Estimates from Orphanet indicate that its birth frequency ranges from approximately one in 56,500 to one in 113,000 live births. </span></p>
<p><span>If it passes further testing and is approved, OTXL-101 could be an important treatment tool. To treat OTCD, OTXL-101 uses a liver-targeted adeno-associated virus vector to deliver a functional OTC gene and restore urea cycle activity. The gene therapy is intended to treat children and adolescents with OTCD and has received U.S. and EU orphan drug designations as well as a U.S. rare pediatric disease designation. </span></p>
<p><span>This initial clinical evidence of the efficacy of OTXL-101, which now spans more than two and a half years, “gives us a sense of its potential to benefit patients,” Martin said. In his conversation with </span><i><span>GEN</span></i><span>, he explained: The data showed that following treatment with the gene therapy, the patient had successfully been taken off Ravicti, a prescription nitrogen-binding medicine for long-term management of high ammonia levels, as well as off of a restricted diet. And they have continued to do well. </span></p>
<p><span>The type of evidence that OTXL will consider for future in-licensed candidates and therapies that are included in the CGTxchange will vary, Martin said. For one thing, not all rare disease therapies will have years of post-treatment data on patients as that will depend on factors such as when the trials were stopped or suspended and their specific endpoints. In general, “the criteria that are most important to us are ‘is this an area of high unmet medical need? Is it a therapeutic approach that we have a good understanding of and based on evidence from clinical trials, wherever they are in that process?’” he said. Other pertinent questions focus on who the partners involved are and whether they can work with OTXL. </span></p>
<p><span>In terms of OTXL-101, “we are going through the process of doing stability and potency testing on the material that had been manufactured for the trial,” Martin said. Also, “we’ve done some other things related to extending patents in a number of countries so that we know we’ve got the ability to provide access in a variety of places.” Finally, the therapy will be listed on the CGTxchange. “We have some of the funds required to continue to move it forward, but we’d like to be able to have a set of funding that would allow us to extend ideally past the next inflection point,” Martin explained. </span></p>
<p><span>Meanwhile, OTXL is exploring other candidates for potential in-licensing deals. “We’re actually in some conversations now and not just around the clinical stage, but also other commercial-stage or commercial products that we might be able to help move forward,” Martin said. It is important to note here that OTXL is modality agnostic and is willing to consider other kinds of treatment approaches beyond cell and gene therapies. Martin pointed to the team’s recent work on the <em>ex vivo</em> cell therapy for patients with Wiskott-Aldrich syndrome. “If there are other therapies like that out there where the traditional commercial model just doesn’t work for big biotechs or biopharma companies, those would be good candidates for us to … put into our existing infrastructure and move forward.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion/">Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests</title>
<link>https://edusehat.com/en/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests</link>
<guid>https://edusehat.com/en/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests</guid>
<description><![CDATA[ Researchers used an AI-guided engineering approach to create a broadly protective bird flu vaccine that is designed to remain effective across a wide range of existing and future H5Nx variants. 
The post Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_4X4A7027-2-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 06 Nov 2026 04:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bird, Flu, Vaccine, Developed, Using, Outperforms, Current, Stockpiled, Vaccines, Preclinical, Tests</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Cambridge and at the University of Cambridge spin-out DIOSynVax reported on the development of a broad-spectrum bird flu vaccine that in animal trials provided complete protection against globally circulating, diverse H5Nx variants of the disease. Current pandemic preparedness relies on stockpiling vaccines against individual virus variants that have already emerged. The Cambridge team’s approach uses AI-guided engineering to create broadly protective vaccines intended to remain effective across a wide range of existing and future variants.</p>
<p>The team’s study, described in <em>Cell Reports Medicine,</em> found the new digitally engineered multi-antigen mRNA vaccine to be superior to bird flu vaccines currently stockpiled by many governments for use in the event of a human outbreak. Their preclinical trial results showed that the existing vaccines tested protected only around 50% of animals exposed to multiple H5N1 bird flu variants, compared with complete protection achieved by the team’s new vaccine, DVX-panH5Nx.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The results demonstrate the potential of AI-guided vaccine design in developing broad protective population immunity ahead of evolving biological threats. The researchers say the vaccine represents the third success with their AI-guided technique for designing vaccines against highly infectious viruses that threaten animal and human health. The new study in addition demonstrates that the team’s ‘plug and play’ approach can be used to create safe, highly effective vaccines for a plethora of infectious diseases threatening animal and human health globally.</p>
<p>“Rather than providing immunity to a single variant of bird flu, our new broad-spectrum vaccine is protective against a huge range of variants,” said Professor Jonathan Heeney, PhD, in the Lab of Viral Zoonotics, University of Cambridge’s Department of Veterinary Medicine. “It’s designed to anticipate viral evolution, rather than reacting to it … These new-generation vaccines are a game changer for national biosecurity and more resilient public health. They mean we can be prepared to respond immediately to virus epidemics and pandemics, rather than the current scenario of always being on the back foot and responding with a strain which will have changed.”</p>
<p>In their paper, titled “<a href="http://dx.doi.org/10.1016/j.xcrm.2026.103131" target="_blank" rel="noopener">Broad vaccine protection against globally diverse influenza A H5Nx viruses</a>,” senior and corresponding author Heeney and colleagues stated, “Compared to WHO candidate vaccine viruses (CVVs), DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Bird flu is an RNA vaccine (as are the coronaviruses that cause COVID-19) that is spreading in animals around the world and is currently considered a significant threat to global public health, the authors noted. “Influenza A H5Nx viruses continue to diversify and undergo gene reassortment as they infect avian and mammalian hosts worldwide,” they wrote. RNA viruses represent a particular threat to human health because they can mutate rapidly into new strains that can jump from animals to humans and evade our immune systems—and our existing vaccines.</p>
<figure aria-describedby="caption-attachment-340287" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340287" src="https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-211x300.jpg" alt="Professor Jonathan Heeney." width="211" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-211x300.jpg 211w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-720x1024.jpg 720w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-768x1092.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000-1080x1536.jpg 1080w, https://www.genengnews.com/wp-content/uploads/2026/11/4X4A7000.jpg 1242w" sizes="(max-width: 211px) 100vw, 211px"><figcaption class="wp-caption-text">Professor Jonathan Heeney [J.Garget/University of Cambridge]</figcaption></figure>
<p>“It’s when bird flu adapts to live in the airways of mammals that we start to get really nervous,” said Heeney, “not only because of the impact on animal health but because of the threat to humans. If we can make better animal vaccines, then we can better protect human health as well.”</p>
<p>The decades-old approach to vaccine design has been largely reactive, responding to pathogens after they have emerged. The team’s goal is to create broadly protective vaccines for both animals and humans, helping reduce opportunities for pathogens to emerge, adapt, and spread. Their new class of universal vaccines is future proofed. The vaccines not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans.</p>
<p>To design the new bird flu vaccine, Heeney and team collected the genetic sequence data of all the bird flu viruses logged by surveillance programs around the world, which take virus samples from wildlife, livestock, and humans infected with bird flu. They built an AI tool to integrate the huge amount of genetic data and use it to design a range of “super-antigens” which contain the antigen features common to this whole group of viruses. These were screened in cells to select the best one for the vaccine, which was then tested in animal trials.</p>
<p>“… we engineered a broadly protective, multi-antigen panH5Nx vaccine using computational and structure-guided HA, NA, and M2 antigens, capturing global H5Nx diversity,” the team noted. Heeney added, “Using AI vastly speeds up the process of vaccine design, and then we can test the vaccine candidates in the lab to make sure they’re robust and safe.”</p>
<p><em>In vivo</em> tests showed that the new DVX-panH5Nx vaccine completely protected mice and ferrets against a range of genetically distinct H1N1 variants—all of which have caused human infections and represent potential pandemic threats. “By integrating HA, NA, and M2 antigens representing global H5Nx diversity, we demonstrated that broad, cross-clade protection could be achieved using a single vaccine formulation,” the researchers commented. “… the broad immunogenicity of DVX-panH5Nx translated into complete protection against lethal heterologous challenges in mice and superior survival in ferrets.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In comparison, only half the animals survived these same viruses when immunized with the World Health Organization’s existing bird flu vaccine. The bird flu vaccine stockpiled by governments is based on representative virus isolates identified through the World Health Organization’s pandemic influenza preparedness program. It was designed to protect against one specific strain of the disease, but the study found it provides minimal protection against other strains in circulation.</p>
<p>“Here, we present a mechanistically informed, digitally engineered mRNA vaccine, DVX-panH5Nx, designed to anticipate viral evolution rather than reacting to it with single isolate-based vaccines,” the investigators reported. They suggest that their collective data “… support a shift in pandemic influenza preparedness toward broadly protective, digitally designed, multi-antigen vaccines that reflect global viral diversity.”</p>
<p>The next step is to test the new bird flu vaccine in human clinical trials, so that it can be ready to be given to humans immediately, when needed. The team is also working on a seasonal flu vaccine that would provide broad-spectrum protection over several flu seasons. Preliminary results show that the vaccine antigen they designed in 2018 is still effective after seven years.</p>
<p>Earlier this year the team announced that their <a href="https://doi.org/10.1016/j.jinf.2026.106759" target="_blank" rel="noopener">broad-spectrum coronavirus vaccine</a> had proved safe in human trials, and published results showing their <a href="https://pubmed.ncbi.nlm.nih.gov/42836655/" target="_blank" rel="noopener">broad-spectrum influenza vaccine</a> protects against both human and swine flu viruses.</p>
<p>In their newly released paper the team concluded, “Leveraging genomic surveillance data from animal reservoirs and human spillover events, with structural insights and immune correlates, offers a powerful framework not only for next-generation pre-pandemic H5Nx vaccines but also for improving seasonal influenza vaccines and developing more effective broadly protective vaccines against other rapidly evolving RNA viruses.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests/">Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rethinking the Clone&#45;First Paradigm for First&#45;in&#45;Human Biologics</title>
<link>https://edusehat.com/en/rethinking-the-clone-first-paradigm-for-first-in-human-biologics</link>
<guid>https://edusehat.com/en/rethinking-the-clone-first-paradigm-for-first-in-human-biologics</guid>
<description><![CDATA[ A stable-pool strategy can move cell line development off the critical path to Phase I while preserving a path to a conventional clonal cell line as a program matures.
The post Rethinking the Clone-First Paradigm for First-in-Human Biologics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-200554028-001.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rethinking, the, Clone-First, Paradigm, for, First-in-Human, Biologics</media:keywords>
<content:encoded><![CDATA[<p>For decades, biologics development has followed a familiar sequence: create an expression construct, transfect host cells, isolate single cells, screen hundreds or thousands of clones, select a lead clone, establish a cell bank, develop the process, and then manufacture clinical material.</p>
<p>It is a proven model. But there is an increasingly important question for early-stage drug development: Does every molecule need to complete that entire sequence before investigators can answer the first clinical question?</p>
<p>For many first-in-human programs, the immediate objective is not commercial manufacturing. It is to produce a relatively small quantity of well-characterized material, establish appropriate controls and determine whether a therapeutic candidate demonstrates sufficient clinical promise to justify further investment.</p>
<p>That changes how developers can think about cell line development.</p>
<figure aria-describedby="caption-attachment-340043" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-340043" src="https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-281x300.jpg" alt="" width="281" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-281x300.jpg 281w, https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool-768x819.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Jesse-McCool.jpg 847w" sizes="auto, (max-width: 281px) 100vw, 281px"><figcaption class="wp-caption-text">Jesse McCool, PhD [GBI Biomanufacturing]</figcaption></figure>
<h4><strong>Moving cloning off the critical path</strong></h4>
<p>One approach is to manufacture initial clinical material from a characterized stable cell pool, while single-cell cloning is deferred or proceeds in parallel.</p>
<p>This is fundamentally different from using a transient expression system. A stable pool consists of cells in which the expression construct has been integrated into the host-cell genome. The challenge is controlling the heterogeneity within that population.</p>
<p>With conventional random integration, cells can differ substantially in transgene copy number, insert integrity and integration location. Those differences can translate into variability in growth, productivity, stability and product quality. Single-cell cloning solves this problem by searching a heterogeneous population for an individual clone with the desired characteristics. An alternative is to reduce heterogeneity earlier.</p>
<p>Transposase-based cell line development systems, such as the Leap-In Transposase platform used in our work, employ a cut-and-paste mechanism for genomic integration. By creating a more controlled integration process, these systems can generate stable pools with a narrower distribution of cellular characteristics than conventional random integration.</p>
<p>The distinction is important. The pool does not become clonal. It becomes more predictable.</p>
<p>That predictability creates the possibility of using the stable pool itself as the manufacturing substrate for an early clinical program.</p>
<h4><strong>What does the data need to show?</strong></h4>
<p>Deferred cloning should not be interpreted as deferred characterization.</p>
<p>A stable pool intended for GMP manufacturing still requires an appropriate control strategy, including assessment of identity, purity and adventitious agents, along with limits on population doublings and evidence that the cell population remains suitable throughout the intended manufacturing window.</p>
<p>The resulting protein also needs to be characterized. The relevant question is whether material produced by the pool has appropriate identity, purity, potency and product-quality attributes for the intended clinical study.</p>
<p>Published experience with transposon-generated stable pools provides an important proof-of-concept. Stable pools have been used for GMP manufacturing at substantial scale, with later clone-derived processes demonstrating comparable process performance and product-quality profiles.</p>
<p>In these studies, viable cell concentration, viability, antibody titer and cell-specific productivity tracked similarly between pool- and clone-derived manufacturing. Product-quality measurements, including purity, charge variants and glycosylation, also fell within comparable ranges.</p>
<p>That does not mean a pool and its derivative clone will be identical across every analytical measurement. Nor does historical experience eliminate the need for molecule-specific assessment.</p>
<p>It demonstrates something more useful: The relationship between pool-derived and later clone-derived material can be characterized and managed.</p>
<h4><strong>Right-sizing the manufacturing process</strong></h4>
<p>Changing the cell line development strategy also creates an opportunity to reconsider scale.</p>
<p>Early clinical studies may require only modest quantities of a biologic, particularly for potent antibodies and other protein therapeutics. Yet sponsors frequently manufacture those first batches using infrastructure designed for much larger material requirements.</p>
<p>A small-scale, closed upstream process can better match manufacturing capacity to the clinical question.</p>
<p>In the SmartScale GMP platform developed at GBI Biomanufacturing, for example, stable-pool development is connected to a shake-flask-based upstream process using OptimumGrowth flasks, progressing from seed culture through a 7-liter production scale. The upstream process is then integrated with downstream purification, drug substance manufacturing and fill-finish.</p>
<p>The principle is more important than the particular vessel: Use the smallest robust GMP process capable of producing the amount of material the clinical program actually requires.</p>
<p>Importantly, starting small should not strand a successful molecule at small scale. A development strategy should anticipate movement into larger single-use bioreactors, fed-batch or perfusion processes if clinical demand increases.</p>
<h4><strong>Sequence the risk rather than eliminate the work</strong></h4>
<p>This approach reflects a broader change occurring in early biologics development.</p>
<p>Historically, developers have often tried to resolve risks associated with later-stage development before administering the first clinical dose. That can make sense when the probability of technical or clinical success is high. For novel therapeutics, however, it can commit substantial time and capital before the most fundamental uncertainty has been resolved: Does the drug work in patients?</p>
<p>A phase-appropriate CMC strategy does not eliminate necessary development activities. It sequences them.</p>
<p>For a suitable molecule, a sponsor can generate a controlled stable pool, characterize that population, manufacture a small GMP batch and establish the CMC package necessary to support the initial clinical investigation. Meanwhile, single-cell cloning can continue in parallel or begin after the program has generated evidence supporting further investment.</p>
<p>If the clinical signal is positive, a derivative clone can be selected, banked and advanced toward the more extensive process characterization expected later in development. Comparability between pool- and clone-derived material then becomes a defined development activity rather than an assumed outcome.</p>
<p>Not every biologic will be a good candidate. Molecules with difficult product-quality profiles, unstable expression, unusual safety considerations or large initial material requirements may favor a conventional clone-first strategy.</p>
<p>But single-cell cloning should no longer be treated automatically as the starting line for every first-in-human biologic.</p>
<p>For appropriate molecules, stable-pool manufacturing provides another option: characterize what matters, manufacture at the scale the study requires and move the first clinical question forward while conventional cell line development continues in parallel.</p>
<p>For drug developers facing increasingly constrained capital and intense pressure to reach meaningful clinical milestones, the question may no longer be, “How quickly can we select the final clone.” It may now be: “Can stable pools move biologics to first-in-human studies faster?”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/rethinking-the-clone-first-paradigm-for-first-in-human-biologics/">Rethinking the Clone-First Paradigm for First-in-Human Biologics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace</title>
<link>https://edusehat.com/en/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace</link>
<guid>https://edusehat.com/en/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace</guid>
<description><![CDATA[ The boundaries of what’s considered “druggable” are shifting as advances in cell and gene therapies expand the possibilities for cancer treatment. Expanded insights can open new avenues for biomarker research and therapeutic discovery.
The post As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Sampled_AdobeStock_NongEngEng_2030363578.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Therapeutic, Modalities, Expand, Genomic, Profiling, Must, Keep, Pace</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="http://sampled.com/gen" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-309223 size-medium" src="https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo-300x76.jpg" alt="Sampled logo" width="300" height="76" srcset="https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo-300x76.jpg 300w, https://www.genengnews.com/wp-content/uploads/2025/02/Sampled_logo.jpg 600w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>The boundaries of what’s considered “druggable” are shifting as advances in cell and gene therapies expand the possibilities for cancer treatment. For drug developers, this evolving therapeutic landscape creates new reasons to revisit challenging targets and explore genomic alterations that may have been overlooked when fewer treatment approaches were available.</p>
<h4><strong>A broader therapeutic toolbox opens new possibilities</strong></h4>
<p>For many decades, much of drug discovery was focused on finding a small molecule capable of binding a specific target. While this approach remains important, an expanded therapeutic toolkit now allows developers to target a wider range of biological mechanisms. The maturation of cell and gene therapies, RNA therapeutics, targeted protein degradation approaches, antibody-drug conjugates, and other modalities expand the range of biological targets that may be therapeutically tractable. In this way, disease mechanisms and targets that may once have been considered “undruggable” now warrant closer attention, as they can provide an opportunity for development teams to tackle more ambitious projects.</p>
<h4><strong>Improved genomic profiling means greater opportunity</strong></h4>
<p>Drug developers have often prioritized indications with a substantial unmet need and well-characterized driver genes supported by a strong biological rationale for therapeutic targeting. However, the landscape of cancer-associated variants is diverse and remains incompletely understood, even in well-studied forms of the disease. This creates a growing opportunity for researchers to identify and investigate a broader range of potentially relevant genomic alterations, both in indications already served by targeted therapies and in historically underexplored cancer types with substantial unmet need. One promising approach is to focus on a specific cohort with substantial unmet need while casting a wider net for variant discovery. Gaining broader genomic insights early in development can create more opportunities for discovery, biomarker development, and the identification of potentially transformative therapies.</p>
<h4><strong>Why genomic testing will remain essential</strong></h4>
<p>Many precision therapies rely on genomic information for patient selection, while drug discovery teams use genomic evidence to identify and prioritize targets for therapy development. Diseases such as cancer can be driven by both well-characterized and less common genetic alterations, making a comprehensive, reliable, and rapidly available view of an individual patient’s genomic landscape essential across the personalized medicine continuum, from target discovery through patient selection. While multiomics approaches provide important context for understanding disease biology, researchers must continue to examine genomic variation more broadly and in greater depth for personalized medicine to reach its full potential.</p>
<h4><strong>Closing the gap from sample to hypothesis </strong></h4>
<p>Realizing the potential of broader genomic insights to support therapy development across multiple emerging modalities presents several challenges. Translating samples into usable data at scale requires infrastructure that supports efficient, consistent processing across large cohorts and extended study timelines.</p>
<p>One component of closing this gap is comprehensive genomic profiling (CGP), which brings a wider range of cancer-associated genomic alterations into focus. By assessing single nucleotide variants, insertions and deletions, copy number variants, and select gene fusions, CGP allows researchers to look beyond familiar markers and investigate a broader genomic landscape. These expanded insights can open new avenues for biomarker research and therapeutic discovery.</p>
<h4><strong>Integrating sample stewardship, CGP, and analysis</strong></h4>
<p>Sampled is an integrated analytical laboratory and biorepository offering custom sample collection kitting, secure sample storage, end-to-end sample processing, genomic profiling, and data analysis to support oncology research. Visit sampled.com to explore our comprehensive genomic profiling capabilities and learn how we can support your next research project.</p>
<p> </p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-340228 size-thumbnail" src="https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-150x150.jpg" alt="Sampled QR Code November 2026" width="150" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-298x300.jpg 298w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-1016x1024.jpg 1016w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK-768x774.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/sam270_qr-gen_v1_CMYK.jpg 1389w" sizes="auto, (max-width: 150px) 100vw, 150px"></p>
<p> </p>
<p>Visit <a href="http://sampled.com/gen" target="_blank" rel="noopener">sampled.com/gen</a>.</p>
<p>The post <a href="https://www.genengnews.com/sponsored/as-therapeutic-modalities-expand-genomic-profiling-must-keep-pace/">As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gene That Preserves Bone Stem Cell Supply Throughout Life Identified</title>
<link>https://edusehat.com/en/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified</link>
<guid>https://edusehat.com/en/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified</guid>
<description><![CDATA[ Researchers found that the HOXA10 gene preserves bone stem cell supply throughout life, and say the discovery advances understanding of stem cell biology and could indicate potential therapeutic approaches to improve bone healing and regeneration in aging and disease. 
The post Gene That Preserves Bone Stem Cell Supply Throughout Life Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/GettyImages-1459917555.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gene, That, Preserves, Bone, Stem, Cell, Supply, Throughout, Life, Identified</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at NYU Langone Health have found that the action of a key gene is required to maintain a lifelong supply of stem cells that make bone healing possible. Working with genetically engineered mice, the team identified the gene <em>HOXA10</em> as a lifelong protector of the stem cell supplies, keeping them from maturing into bone-building cells called osteoblasts until needed for healing.</p>
<p>“Our study shows that<em> HOXA10</em> protects healing capacity normally by acting as a brake on premature maturation,” said Philipp Leucht, MD, PhD, the Jyoti Menon Associate Professor of Orthopedic Surgery in the Department of Orthopedic Surgery at NYU Grossman School of Medicine. “To our knowledge, this study is the first to assign a definitive role for HOX genes in the active maintenance of adult skeletal stem cells.” The findings suggest that HOX genes may represent potential therapeutic targets for boosting bone regeneration.</p>
<p>Leucht, who is also the vice chair for research in the Department of Orthopedic Surgery, is senior and co-corresponding author of the researchers’ published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aeg2088" target="_blank" rel="noopener"><em>Hoxa10</em> governs lifelong skeletal stem cell maintenance and bone repair</a>,” in which they reported, “Together, these findings define a conserved Hox-dependent program that preserves skeletal stem cell identity and regenerative competence, revealing how developmental transcription factors are repurposed to sustain the adult skeleton across the life span.”</p>
<p>Skeletal stem and progenitor cells (SSPCs) sustain bone homeostasis and regeneration throughout life, the authors explained, but the transcriptional programs that preserve their identity aren’t well understood. Accumulating evidence suggests Hox genes may play critical roles in maintaining tissue-resident stem cells throughout the lifespan, “… serving as molecular determinants that preserve stem cell identity and function in adult tissues across different species,” the team continued. However, there are “critical gaps” in understanding of how Hox genes may regulate bona fide skeletal stem cells (SSCs) and their progeny. “This has profound implications for understanding skeletal aging, fracture healing, and potential therapeutic interventions.”</p>
<p>For their newly reported study the authors examined the state of bone stem cells in mice for 15 months after they deleted<em> HOXA10</em> in 6-day-old pups. They found that by the end of that period, 90% of the stem cells and descendants that should have been present were gone due to a loss of self-renewal. “Most bone research asks how stem cells become bone,” said Leucht. “We asked how they remain as stem cell replacements in the first place. Without the study gene, bone burns through its reserves too early, which is what we see in aging bone.”</p>
<p>The researchers in addition found that mice engineered to lack <em>HOXA10</em> action could not heal properly after breaking a bone. The proportion of stem cell progenitors in the callus—the temporary tissue bridge spanning a break as it begins to heal—was only 48% for the engineered mice, compared with 76% for control mice with the functional gene.</p>
<p>Other experiments confirmed that deleting <em>HOXA10</em> causes collagen proteins that lay the early framework for rebuilding bone to become disorderly. This is a problem because the rope-like scaffold at a break site must be arranged in neat lines, rather than as a tangled mesh, for new bone to harden with calcium. “Our <em>in vivo</em> genetic studies demonstrate that HoxA genes are not merely correlated with skeletal stemness but are functionally necessary for maintaining this state,” the team noted. “Loss of Hox activity results in depletion of SSC pools, defective matrix organization, impaired repair after serial injuries, and compromised skeletal morphology with age.”</p>
<p>The researchers also obtained bone biopsies from human patients and silenced three related HOX genes at once. The human cells responded like mouse cells, only with more dramatic reductions in stem cell numbers. The human cells also began to die, with apoptosis (programmed self-destruction) up by 50%. This suggests that human stem cells may depend even more on HOX genes for long-term self-renewal, Leucht said. Commenting on their studies in human SSPCs, the authors noted, “Together, these findings demonstrate that distal Hox genes are essential for preserving the core properties of human SSPCs—including proliferation, survival, self-renewal, and inhibition of premature differentiation—thereby supporting their role in maintaining SSC pools in adult human bone.”</p>
<p>To carry out the study the research team genetically engineered mice to have their<em> HOXA10</em>-expressing stem cells tagged with a fluorescent green marker, as well as to have built-in mechanisms that the team could use to switch the genes off on command. This let them accurately track the status of the cells at all stages of life in the study mice.</p>
<p>The investigators learned that <em>HOXA10</em>-positive cells outperform other stem cells in the periosteum, the membrane that covers the surface of most bones, at colony-forming. This test, in which a single cell is prompted to generate a colony of cells by dividing and multiplying continually, is considered a standard readout of self-renewal capacity.</p>
<p>HOX genes have been shown by past studies to control periosteal stem and progenitor cells, or PSPCs, which play a key role in bone healing. HOX genes are known to encode proteins that act like the body’s “zip code,” specifying the position of limbs in the womb. The new study builds on another led by Leucht and <a href="https://doi.org/10.1242/dev.201391" target="_blank" rel="noopener">published in 2023</a>, which showed that increasing the activity of the <em>HOXA10</em> gene could improve fracture healing in older mice.</p>
<p>“Our study identifies <em>HOXA10</em> as a preserver of skeletal stem cell pools over time by promoting self-renewal, suppressing premature maturation, and lining up the protein fibers in a break so that the two ends of broken bone can knit,” said Leucht. “The findings establish HOX genes as potential therapeutic targets for enhancing bone regeneration.”</p>
<p>In their paper the authors concluded, “By illuminating how a single transcriptional regulator coordinates the complex behaviors necessary to maintain SSC across the life span, this work advances our understanding of stem cell biology and provides a foundation for therapeutic  approaches to improve bone healing in aging and disease.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gene-that-preserves-bone-stem-cell-supply-throughout-life-identified/">Gene That Preserves Bone Stem Cell Supply Throughout Life Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches</title>
<link>https://edusehat.com/en/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches</link>
<guid>https://edusehat.com/en/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches</guid>
<description><![CDATA[ Researchers mapped more than a million cells across glioblastoma tumors, categorizing cancer cells at different stages of their journey within the different environments in glioblastoma tumors, and showing that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients. 
The post Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/07/Jul15_2020_Getty_1128676746_BrainCancer-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomic, Human, Glioblastoma, Cell, Atlas, Could, Act, Compass, Guide, Future, Treatment, Approaches</media:keywords>
<content:encoded><![CDATA[<p>Aggressive glioblastoma (GB) brain tumors follow predictable rules, not chaotic randomness, according to new research reported by scientists at the Wellcome Sanger Institute, the European Molecular Biology Laboratory (EMBL), the German Cancer Research Center (DKFZ), the Cancer Research UK Cambridge Institute, and their collaborators.</p>
<p>For their study, reported in <em>Nature</em> (“<a href="https://www.nature.com/articles/s41586-026-11234-8" target="_blank" rel="noopener">A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity</a>,”) co-senior author Omer Bayraktar, PhD, at the Wellcome Sanger Institute and Professor at the UCL Cancer Institute, and colleagues mapped over one million cells across glioblastoma tumors, categorizing cancer cells at different stages of their journey within the different environments in glioblastoma tumors. They looked at different time stages and used lab-grown mini tumors to mimic this development. The study findings showed that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients.</p>
<p>Along with challenging previously held beliefs about brain tumors, the newly discovered roadmap opens new paths for developing targeted treatments. As the cancer cells move along in a predictable way during tumor progression, future drugs could specifically target the early developmental-like cells before they transform into harder-to-reach, resistant states.</p>
<p>The reported work has built a new foundational resource for studies to explore the mechanisms and biology of cancerous brain cells. The researchers have made the resulting <a href="https://www.gbmspace.org/" target="_blank" rel="noopener">GBM-Space atlas</a> is freely accessible.</p>
<p>Using the same single-cell multiomic data, investigators also decoded the gene regulators that drive and restrict glioblastoma cell state transitions, highlighting potential targets that could help avoid treatment resistance. The team stated, “In a companion study, we leveraged the joint transcriptomic and epigenetic data generated here to define and perturb gene regulatory networks controlling GB plasticity. Beyond identifying master regulators of GB states, this orthogonal approach suggested hierarchical transitions across GB cancer states and recapitulated the GB trajectory identified here.” These results are published by co-senior author Bayraktar, and colleagues in their companion paper in <em>Nature, titled “</em><a href="https://doi.org/10.1038/s41586-026-11177-0" target="_blank" rel="noopener">Decoding the regulatory programs governing glioblastoma plasticity</a>.” Together the two papers unify understanding of the architecture of glioblastomas with insights about cancer cell plasticity, giving a holistic view of this cancer type.</p>
<p>Bayraktar said, “Glioblastoma has evaded understanding for years, despite being one of the most studied types of cancer tumor. By building the largest, multi-modal atlas of these tumors to date, we have shown that these tumors are not as chaotic as previously accepted. Instead, they follow a set of rules that can be used to rewrite our understanding of glioblastoma and act as a compass to guide much needed new treatments in the future.”</p>
<p>Glioblastoma is an aggressive form of brain cancer, and the most common type of brain cancer in adults, with an average survival time of 12 to 18 months. The most common glioblastoma treatment, when possible, is surgery followed by a combination of chemotherapy and radiotherapy. But as the authors pointed out, “The extensive tumor heterogeneity of glioblastoma (GB), an incurable adult brain cancer, presents a major obstacle to treatment.”</p>
<p>These tumors are difficult to treat due to their location, and as many tumors invade multiple parts of the brain, which can make surgery difficult or impossible in some cases. The tumors are also made up of multiple, highly dynamic cancer cell states that had previously not seemed to follow any consistent rules or pattern. This means that treatment might not destroy every cell, leading to drug resistance and cancer re-emergence.</p>
<p>“Nearly two decades of molecular profiling has found that malignant cells exist across a spectrum of cellular states within each tumor, resembling developmental neural progenitors as well as mesenchymal-like and injury response states,” the authors noted. “… we still do not understand how cancer cells diversify into distinct states and give rise to GB heterogeneity. In particular, whether malignant cells follow stereotyped or variable cellular trajectories across GB tumors is unknown.”</p>
<p>For their newly reported study the Sanger Institute researchers and their collaborators used state of the art multiomic technologies and tailored machine learning computational tools to map multiple sections of brain tumor samples from 12 glioblastoma patients<sup>. </sup>combining single-cell and spatial atlasing, imaging, and whole-genome sequencing data. “Here we applied a holistic multimodal mapping approach to jointly characterize the genetic, cellular and tissue architecture of GB tumors,” they wrote.</p>
<p>The range of information generated offers up a complete understanding of each cancer cell’s molecular state, where it is in the tumor, how it is likely to change over time, how it interacts with the environment around it, and its genetic information. Additionally, the team used samples from multiple regions of the brain tumors, to give a full picture of the cells in each tumor section and how they related to each other.</p>
<p>This allowed the team to see that glioblastoma cells move through the same structural pattern across each patient, following the same rules as the tumor grows. “We identify that glioblastoma heterogeneity is driven by spatially patterned transitions of cancer cells from developmental-like states towards those defined by a glial injury response and hypoxia,” they wrote. The results found that cancer cells in early stages resemble brain stem cells. These developmental-like cells are found at the outer, leading edge of the tumor, where the glioblastoma cells start to invade the surrounding healthy brain tissue. These cells act as a pool giving rise to other cancer cell states.</p>
<p>Then, as the tumor expands, these cells transform into injury response cell states, mimicking cell pathways that are involved in brain tissue repair and wound healing. These injury response cells create an inner structural layer in the tumors. And in the later stages of brain tumor development the core of the tumor is cut off from oxygen, meaning that all cell types transition from injury response into severely hypoxic (oxygen deprived) states.</p>
<p>As well as mapping brain tumor samples, the team developed brain organoids to validate the tumor roadmap. This research also showed that each cancer cell progression stage requires specific immune microenvironments in the tumors.</p>
<p>“This cellular trajectory regionalizes tumors into distinct tissue microenvironments and manifests in a molecularly conserved manner across tumors as well as genetically distinct tumor subclones,” they stated in their paper. “Our findings define a stereotyped trajectory of cancer cells in glioblastoma and unify glioblastoma tumor heterogeneity into a tractable cellular and tissue framework.”</p>
<p>The team suggests that finding ways to interrupt or disrupt these environments could lead to new ways to treat aggressive brain tumors. In the future, new therapeutics could also focus on the gene regulation networks, potentially stopping cell progression, or target the early developmental cells that cannot be easily removed by surgery and often lead to cancer recurrence.</p>
<p>Richard Mair, MBBS, PhD, FRCS (SN), co-author at the Cancer Research UK Cambridge Institute and Cambridge University Hospitals NHS Foundation Trust, said: “For too long, we have approached glioblastoma treatment knowing that each patient’s tumor contains a complex mixture of cancer cells, but without a clear understanding of how best to target them all. This research gives us an opportunity to think differently. If we can anticipate the different biological states a tumor is likely to adopt, we can begin to develop treatments that target multiple aspects of the disease from the very beginning. This could fundamentally change how we design new therapies for glioblastoma, moving towards treatments that are informed not just by what a tumor looks like today, but by what it is likely to become.”</p>
<p>Oliver Stegle, PhD, co-senior author of both studies at the European Molecular Biology Laboratory (EMBL) and the German Cancer Research Center (DKFZ), added, “Combining unbiased single-cell and multiomics techniques with tailored computational tools allowed us to go back to the drawing board and challenge long-held assumptions about glioblastoma. We demonstrate that complex but predictable molecular networks govern cancer cell development. This work shows how computational biology can turn massive datasets into meaningful discoveries for patient care.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/multiomic-human-glioblastoma-cell-atlas-could-act-as-compass-to-guide-future-treatment-approaches/">Multiomic Human Glioblastoma Cell Atlas Could Act as Compass to Guide Future Treatment Approaches</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites</title>
<link>https://edusehat.com/en/lonza-expanding-us-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites</link>
<guid>https://edusehat.com/en/lonza-expanding-us-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites</guid>
<description><![CDATA[ The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees. 
The post Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/b94fd657006030de0f418450a7f34f41-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lonza, Expanding, U.S., CDMO, Footprint, with, Purchase, Five, Merck, KGaA, Sites</media:keywords>
<content:encoded><![CDATA[<p>Lonza plans to more than double its U.S. footprint of contract development and manufacturing organization (CDMO) sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would only say was valued “in the low- to mid-triple-digit millions Swiss francs.”</p>
<p>At between CHF 100 million and CHF 500 million, the transaction would amount to between $121.6 million to $608.2 million.</p>
<p>The deal would expand Lonza’s U.S. CDMO network from four to nine sites and grow the company’s U.S. workforce nearly 25% by adding approximately 1,100 employees, resulting in a combined headcount of more than 6,000 employees.</p>
<p>The expansion would also add end-to-end development and manufacturing capabilities in the U.S., with the aim of supporting customers from clinical through commercial phases in growth areas that include antibody-drug conjugates (ADCs) and other bioconjugates, viral vectors for cell and gene therapies, as well as advanced drug-delivery technologies.</p>
<p>The deal with German Merck marks a continuing expansion by Lonza of its U.S. CDMO operations. In 2024, Lonza <a href="https://www.genengnews.com/topics/bioprocessing/lonza-completes-acquisition-of-vacaville-ca-site-from-roche/" target="_blank" rel="noopener">acquired for $1.2 billion the large-scale biologics manufacturing site in Vacaville, CA</a> built by the seller’s Genentech subsidiary. More recently in September, Lonza announced plans to construct a large-scale commercial spray-drying facility in Bend, OR, a project intended to establish Lonza as the leading CDMO provider of commercial-scale spray-drying PSD-4 capacity in the U.S.</p>
<p>Lonza topped <em>GEN</em>’s most recent annual A-List of <a href="https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/" target="_blank" rel="noopener">Top 10 Contract Development and Manufacturing Organizations</a>, published in September, based on its 2025 revenues of CHF 6.531 billion ($8.053 billion at the time; $7.944 billion now).</p>
<h4><strong>‘Strong fit’</strong></h4>
<p>“This acquisition is a strong fit with our One Lonza strategy and reflects our disciplined approach to capital allocation, investing in opportunities that will drive long-term, profitable growth and deliver attractive returns,” Lonza CEO Wolfgang Wienand said in a statement.</p>
<p>“<a href="https://www.lonza.com/about-us/strategy" target="_blank" rel="noopener">One Lonza</a>” is Lonza’s approach to growth. Using the metaphor of an engine, Lonza has articulated a set of five core competencies designed to work together to generate long-term value. The five consist of high-performance teams; a leading scientific, technological, digital ecosystem; unparalleled customer partnerships; end-to-end execution excellence; and plug-and-play investment and integration capabilities.</p>
<p>“It will significantly expand our U.S. presence, bringing us even closer to our customers, while increasing the resilience of our global manufacturing network. With high demand for bioconjugates and viral vectors, the acquired sites will strengthen our ability to support customers from innovation to launch and commercial supply,” Wienand added.</p>
<p>Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, stated that the transaction with Lonza represented “another important step in advancing our mid- to long-term strategic agenda.”</p>
<p>In May Merck KGaA articulated a four-prong strategy for “<a href="https://www.emdgroup.com/investors/reports-and-financials/earnings-materials/2026-q1/us/Strategic%20Update%20May%2013,%202026%20NA.pdf" target="_blank" rel="noopener">creating sustainable value and growth</a>,” based on combining biology, chemistry, physics, with data and artificial intelligence (AI), and enabled by “enhanced company integration for speed and scale”—a challenge given the company’s heritage of businesses with their own distinct brands, such as EMD Serono, MilliporeSigma, and Sigma-Aldrich.</p>
<p><strong>‘Strong foundation’</strong></p>
<p>“A more concentrated Life Science portfolio will allow us to focus our investments on building our scientific leadership and make us an even stronger partner for our customers,” Beckmann said. “Our CDMO teams have built a strong foundation through their expertise and commitment. We believe Lonza is well positioned to build on that foundation and support the business’s next phase of growth.”</p>
<p>Merck KGaA reasons that the divestment to Lonza will sharpen the focus of its Life Science business sector while providing the CDMO business with a strong platform for its next phase of development.</p>
<p>The Life Science sector consists of a broad portfolio of consumables, technologies, and services that the company said will continue to serve pharmaceutical, biotechnology and CDMO customers from discovery through manufacturing.  During the first half of 2026, the Life Science sector reported net sales of €4.677 billion ($5.236 billion), up 4.3% from €4.485 billion ($5.022 billion) in January-June 2025. During the second quarter, Life Science racked up €2.412 billion ($2.701 billion), up 6.4% from €2.267 billion ($2.538 billion) in Q2 2025.</p>
<p>Merck KGaA is set to report third-quarter results on November 12—while Lonza last month said Q3 results were in line with its expectations, without quantifying its results. Lonza also reiterated its full-year 2026 outlook, which it upgraded over the summer, of 11–12% constant exchange rate sales growth and a CORE EBITDA margin of 33–34%. The company also reiterated its expectation of a negative foreign exchange impact of approximately 2% to 3% on 2026 sales growth.</p>
<p>Lonza said the U.S. CDMO facilities it has agreed to acquire from Merck KGaA include sites in:</p>
<ul>
<li><strong>St. Louis, MO: </strong>Bioconjugates</li>
<li><strong>Madison and Verona, WI:</strong> High-potency payload-linkers</li>
<li><strong>Carlsbad, CA:</strong> End-to-end viral vector solutions, including aseptic fill-finish capabilities</li>
<li><strong>Indianapolis:</strong> Lipid nanoparticle, liposome, and PEGylated protein solutions, including aseptic fill-finish capabilities</li>
</ul>
<p>The four sites are expected, Lonza said, to generate a combined approximately CHF 250 million ($304 million) in sales at a margin of core earnings before interest, taxes, depreciation, and amortization (EBITDA) that is below Lonza’s, with an “insignificant” impact on the group.</p>
<p>Once integrated into Lonza, the buyer said, the four sites are expected to deliver “significant, profitable” growth over time, using existing available capacities and additional expansion space. Lonza expects the sites will benefit from Lonza’s sole or “pure-play” focus on CDMO activity, with further investments in the sites to align with evolving market demand.</p>
<h4><strong>Peak sales forecast</strong></h4>
<p>“Lonza anticipates the business to reach peak sales at Lonza’s future group margin level by mid-2030s,” the company predicted.</p>
<p>Last month Lonza ramped up its growth projections following completion of its transformation into a pure-play CDMO. The company upgraded its Organic Growth Model, consisting of organic sales growth at constant exchange rates (CER) from the low-teens (10%-13%), and core earnings before interest, taxes, depreciation, and amortization (EBITDA) growth that surpasses sales growth—and articulated an upgraded ambition to:</p>
<ul>
<li>Reach core EBITDA margin “in the high thirties in the mid-term”</li>
<li>Drive return on invested capital (ROIC) up to two to three times weighted average cost of capital as of 2026, and</li>
<li>Improve free cash flow conversion on average over time</li>
</ul>
<p>Lonza said it will fund its acquisition of the Merck KGaA U.S. CDMO sites and with cash at hand and its existing credit facilities, maintaining the company’s BBB+ rating.</p>
<p>The deal is expected to close in mid-2027 subject to customary closing conditions. Lonza said the transaction will not affect its previously announced share buyback following its planned divestment of its Capsules & Health Ingredients (CHI) business. Lonza in March announced plans to sell CHI to Lone Star Funds for CHF 2.3 billion ($2.797 billion), in a deal set to close by year’s end.</p>
<p>“I am particularly excited to welcome the highly experienced teams at these sites to One Lonza,” Wienand said. “It takes great people with deep scientific expertise and excellence in development and manufacturing to reliably translate breakthrough innovation into viable therapies for patients. Together, we will build an even stronger offering for our customers.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/lonza-expanding-u-s-cdmo-footprint-with-purchase-of-five-merck-kgaa-sites/">Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Beyond Outsourcing: Building Better CDMO Partnerships</title>
<link>https://edusehat.com/en/beyond-outsourcing-building-better-cdmo-partnerships</link>
<guid>https://edusehat.com/en/beyond-outsourcing-building-better-cdmo-partnerships</guid>
<description><![CDATA[ Rose BioSolutions CEO David Enloe argues that advanced therapies demand deeper scientific collaboration, earlier problem-solving, and shared accountability
The post Beyond Outsourcing: Building Better CDMO Partnerships appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 06:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Beyond, Outsourcing:, Building, Better, CDMO, Partnerships</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="http://www.rosebiosolutions.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-340233 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-300x108.jpeg" alt="Rose Biosolutions logo" width="300" height="108" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-300x108.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-1024x369.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-768x276.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions.jpeg 1200w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>For decades, biopharma outsourcing often followed a relatively simple script: a sponsor developed a process, handed it to a contract manufacturer, and expected the work to be carried out to specification. David Enloe, CEO of Rose BioSolutions, believes that model is becoming obsolete—especially for complex cell and gene therapies.</p>
<figure aria-describedby="caption-attachment-340232" class="wp-caption alignright"><img decoding="async" class="wp-image-340232" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-300x300.jpg" alt="David Enloe" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions-David-Enloe-1.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">David Enloe<br>CEO, Rose BioSolutions</figcaption></figure>
<p>As Enloe takes the helm at Rose, he is pushing for a relationship in which the contract development and manufacturing organization (CDMO) functions less like a vendor and more like an extension of the sponsor’s team. “We’re in the promise-making business,” he said, describing commitments that extend beyond clients to patients and their families.</p>
<p>That mindset changes what a CDMO must bring to the table. Manufacturing capacity still matters, but scientific leadership, regulatory expertise, quality knowledge, and program management increasingly help determine whether a program can move efficiently toward the clinic. Enloe sees this as part of a broader evolution in outsourcing, with development and manufacturing becoming more tightly intertwined.</p>
<p>That is particularly true in advanced therapies, where one program can differ dramatically from the next. Enloe contrasts the emerging model with an earlier era in which manufacturers were often expected primarily to execute a sponsor’s established process. For technically demanding programs, simply following a transferred procedure is no longer enough. Sponsors and CDMOs need to examine risks together, challenge assumptions, and make decisions with the full development path in view.</p>
<p>The value of that collaboration can be greatest early, before a seemingly small decision becomes an expensive obstacle. Rose is investing in scientific, regulatory, quality, and project-management expertise at the front end of client programs. Because a CDMO works across multiple projects, it can bring lessons from prior successes—and failures—to a sponsor that may be advancing only one critical asset.</p>
<figure aria-describedby="caption-attachment-340237" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340237" src="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-300x201.jpg" alt="Rose BioSolutions Lab" width="300" height="201" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-300x201.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-1024x686.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility-768x515.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Rose-BioSolutions_CDMO-Facility.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Rose BioSolutions</figcaption></figure>
<p>“It’s always painful to see an innovator make a process change that ultimately requires substantial rework,” Enloe says. Investing more time—and, in some cases, more money—upfront to identify manufacturing and regulatory risks can help avoid costly delays and rework later.</p>
<p>This early involvement also reflects a shift in how drug developers think about manufacturability. Scientists creating a new therapy are rightly focused on whether it can improve patients’ lives, Enloe says. But development teams increasingly need confidence that the therapy can also be made robustly, reproducibly, and at scale. Manufacturing challenges can no longer be kicked down the road.</p>
<p>For Rose, that means giving clients direct access to technical leaders and encouraging unusually open communication. Enloe describes the desired relationship with a simple image: “We’re just 872 miles down the hallway.” Distance should not determine how closely teams work together.</p>
<p>Trust is central to making that model function. Enloe says sponsors today are more willing to share their concerns, constraints, and objectives than they were earlier in his career. That transparency lets both sides hold each other accountable for decisions and timelines—and improves the chances of solving problems before they threaten a program.</p>
<p>Enloe brings personal perspective to that argument. He spent about 15 years on the sponsor side before moving into CDMO leadership. “I’ve been you as long as I’ve been me,” he tells clients. That experience, he adds, makes his “empathy gene overexpress” when he considers the pressures developers face.</p>
<p>Ultimately, the partnership model is meant to serve a larger purpose. A CDMO might work on rare diseases, cancer, migraine, or mental-health treatments in the same span of time. For Enloe, that breadth is a reminder that manufacturing is not simply an operational service. It is part of the path between an idea and a patient—and the strongest partnerships are built around getting that path right together.</p>
<p> </p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-340236 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/11/RoseBioSolutions_QRCode.jpg" alt="Rose BioSolutions QR Code " width="138" height="144"></p>
<p> </p>
<p>To learn more, visit <a href="https://www.rosebiosolutions.com/" target="_blank" rel="noopener">www.rosebiosolutions.com</a>.</p>
<p>The post <a href="https://www.genengnews.com/sponsored/beyond-outsourcing-building-better-cdmo-partnerships/">Beyond Outsourcing: Building Better CDMO Partnerships</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roundtables: Inside the Quest for Cognitive Immortality</title>
<link>https://edusehat.com/en/roundtables-inside-the-quest-for-cognitive-immortality</link>
<guid>https://edusehat.com/en/roundtables-inside-the-quest-for-cognitive-immortality</guid>
<description><![CDATA[ Tuesday, November 17, 2026 In an effort to reach an elusive continuity of the self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Join science editor Mary Beth Griggs and senior editor for biomedicine Antonio Regalado for a conversation exploring possible paths to keep your mind going, including gradual… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/11/MITTR-Roundtables-Nov26-With-border.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roundtables:, Inside, the, Quest, for, Cognitive, Immortality</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph"><strong>Tuesday, November 17, 2026</strong></p>



<p class="wp-block-paragraph">In an effort to reach an elusive continuity of the self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Join science editor Mary Beth Griggs and senior editor for biomedicine Antonio Regalado for a conversation exploring possible paths to keep your mind going, including gradual brain replacement and uploading our memories to the cloud.</p>



<p class="wp-block-paragraph"><strong>Going live at 17:00 GMT / 12pm EST / 9am PST</strong></p>



<div class="wp-block-buttons is-content-justification-left is-layout-flex wp-container-core-buttons-is-layout-b192c3d7 wp-block-buttons-is-layout-flex">
<div class="wp-block-button is-style-fill is-style-fill--1"><a class="wp-block-button__link has-black-color has-text-color has-background has-custom-font-size wp-element-button" href="https://events.zoom.us/ev/AqvDmLgUpSLmnGlDBRTVInfuLpbEbkP7nLjovCVsGoSC1i2jsj-x~Aq6BnlbSSzgL8vA66X1w-QGbSPL3EetZLv_MxsmrmoxewbW5YdRLHn0YhlobWLoVAAXaP5HsL41fSqS6q7rEvOEDSg">Register Now</a></div>
</div>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Related Story</strong>:</p>



<ul class="wp-block-list">
<li><a href="https://www.technologyreview.com/2026/10/15/1145819/six-wild-ideas-perpetuating-your-mind-cognitive-immortality/"><strong>Six wild ideas for perpetuating your mind</strong></a></li>
</ul>



<p class="wp-block-paragraph"><strong>Speakers:</strong></p>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-full is-resized is-style-default wp-duotone-333-ffffff-2"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png" alt="" class="wp-image-1114149" srcset="https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png 300w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Antonio-Regalado.png?resize=150,150 150w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption"><strong><a href="https://www.technologyreview.com/author/antonio-regalado/" target="_blank" rel="noreferrer noopener">Antonio Regalado</a></strong><br>Senior Editor, Biomedicine</figcaption></figure>
</div>



<div class="wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow">
<figure class="wp-block-image aligncenter size-full is-resized is-style-default wp-duotone-333-ffffff-3"><img decoding="async" width="1080" height="1080" src="https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png" alt="" class="wp-image-1125906" srcset="https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png 1080w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2024/01/Mary-Beth-Griggs.png?resize=768,768 768w" sizes="(max-width: 1080px) 100vw, 1080px"><figcaption class="wp-element-caption"><strong>Mary Beth Griggs</strong><br>Science Editor</figcaption></figure>
</div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>]]> </content:encoded>
</item>

<item>
<title>Greener Biomanufacturing Starts Beyond the Bioreactor</title>
<link>https://edusehat.com/en/greener-biomanufacturing-starts-beyond-the-bioreactor</link>
<guid>https://edusehat.com/en/greener-biomanufacturing-starts-beyond-the-bioreactor</guid>
<description><![CDATA[ A new modeling study finds that buildings, not bioreactors, dominate energy consumption in antibody manufacturing. Continuous processing and smarter facility design could reduce emissions, but water and disposable materials complicate sustainability decisions for manufacturers worldwide.
The post Greener Biomanufacturing Starts Beyond the Bioreactor appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Mike-mAb-bioprocess-modeling_GBPN_IMAGE_04NOV26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Greener, Biomanufacturing, Starts, Beyond, the, Bioreactor</media:keywords>
<content:encoded><![CDATA[<p>When it comes to making monoclonal antibodies greener, the biggest energy drain might not be the bioreactor. It might be the building around it.</p>
<p>A new modeling study found that approximately 85% of energy demand in antibody manufacturing came from facility infrastructure, including heating, ventilation, and air conditioning (HVAC), lighting, and utilities. Electricity for HVAC alone accounted for 46% of energy use, while lighting added another 21%. Published in <a href="https://doi.org/10.1016/j.nbt.2026.10.002" target="_blank" rel="noopener"><em>New Biotechnology</em></a>, the findings suggest that improving a plant’s layout and operations could be as important as upgrading its production technology.</p>
<p>Benjamin Smith, PhD, a principal data scientist at Amgen, and his colleagues from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Process Intensification Sustainability Workgroup modeled three manufacturing scenarios: stainless-steel fed-batch, single-use fed-batch, and end-to-end single-use continuous processing. Using BioSolve Process software, the researchers compared water and materials consumption, energy demand, and greenhouse-gas emissions for facilities producing roughly 120 kg of antibody annually.</p>
<p>The fed-batch scenarios relied on 2,000-L bioreactors, while continuous processing used a 500-L bioreactor over a longer production run. Despite its smaller vessel, the continuous system delivered comparable annual output with less infrastructure. Its modeled facility occupied 12,387 cubic meters, versus 14,089 for single-use fed-batch and 14,937 for stainless-steel fed-batch.</p>
<p>That smaller footprint translated into lower energy intensity: 13,239 kilowatt-hours per kilogram of antibody for continuous manufacturing, compared with 17,017 and 19,120 kilowatt-hours for the two fed-batch approaches, respectively. The researchers concluded that, at equivalent output, “facility footprint—not process type—is the main determinant of energy intensity.”</p>
<p>Yet continuous processing was not automatically greener on every measure. Stainless-steel systems consumed considerably more cleaning water but required substantially fewer disposable consumables. Single-use fed-batch had the highest consumables intensity. Continuous processing required more culture medium and certain buffers, demonstrating why sustainability decisions involve competing demands.</p>
<h4><strong>Making the facility work smarter</strong></h4>
<p>The researchers also modeled a more efficient continuous process incorporating a 50% increase in antibody titer, two flow-through polishing steps, fivefold concentrated medium, and reuse of media and buffer bags. Compared with baseline continuous processing, this combination cut water use per kilogram of product by 26% and consumables intensity by 58%. Modeled carbon dioxide-equivalent emissions fell by 66% to 78% relative to the baseline continuous and stainless-steel fed-batch scenarios, respectively.</p>
<p>Building improvements offered another opportunity. Reducing cleanroom classifications where appropriate, optimizing airflow and lighting, increasing equipment density, and improving utilities could together lower modeled facility energy consumption and emissions by up to approximately 35%. Climate also mattered: temperate locations generally required less heating or dehumidification than colder or humid sites.</p>
<p>The findings come with qualifications. The models considered hypothetical single-bioreactor plants, not larger commercial facilities with multiple production trains. The assessment also excluded some lifecycle impacts, including raw-material production and transportation. The workgroup plans to extend the analysis through lifecycle assessment and test-bed data.</p>
<p>For bioprocess developers, the implication is that boosting productivity and shrinking the space needed to achieve it might deliver sustainability gains beyond those available from individual equipment upgrades. Greener antibody manufacturing could begin with rethinking the factory itself.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/greener-biomanufacturing-starts-beyond-the-bioreactor/">Greener Biomanufacturing Starts Beyond the Bioreactor</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Suspended Vials Help Optimize Continuous Freeze&#45;Drying</title>
<link>https://edusehat.com/en/suspended-vials-help-optimize-continuous-freeze-drying</link>
<guid>https://edusehat.com/en/suspended-vials-help-optimize-continuous-freeze-drying</guid>
<description><![CDATA[ Researchers have developed a process with suspended vials accompanied by a digital twin for optimized continuous and autonomous freeze-drying. It offers more uniform and better-quality products, and higher yields.
The post Suspended Vials Help Optimize Continuous Freeze-Drying appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/GettyImages-1289557906.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Suspended, Vials, Help, Optimize, Continuous, Freeze-Drying</media:keywords>
<content:encoded><![CDATA[<p>U.S. researchers have suspended vials to enable autonomous continuous freeze-drying and have developed a digital twin to help optimize the new process.</p>
<p>The team, from the Massachusetts Institute of Technology (MIT), has found that suspending vials on a wire during freeze-drying, a process called lyophilization, gives a more uniform drying process to produce a more consistent product.</p>
<p>The new process also provides all the existing benefits of continuous processing, such as higher production capacity and improved quality control.</p>
<p>“Because this is a continuous lyophilization technology, you get all the benefits of continuous versus batch manufacturing,” explains Prakitr Srisuma, PhD, formerly a researcher at MIT’s Argonne National Laboratory.</p>
<p>“But we have the unique benefit with the suspended wire technology of [more] uniformity of the [final] product.”</p>
<p>Traditionally, vials are dried in a cupboard where they may be occasionally moved around, disturbing their contents, Srisuma explains. By contrast, suspending the vials on wires moved by magnets means they receive the same exposure to different conditions during drying, and their passage through the drying process is very smooth, he says.</p>
<p>“If a vial has been sitting on a shelf and you try to move it, there’s going to be friction, which will generate small particles but, with suspended vials, we avoid those issues,” he explains.</p>
<p>The team had previously spoken to <em>GEN</em> about <a href="https://www.genengnews.com/topics/bioprocessing/continuous-manufacturing-making-freeze-drying-a-hot-topic/" target="_blank" rel="noopener">modeling lyophilization processes</a>. Since then, they have developed a digital twin of the continuous lyophilizer, which they can use to help optimize the process.</p>
<p>Going forward, the team aims to use the digital twin to develop advanced predictive control and optimization strategies. In addition, Srisuma says, the researchers may explore using microwave lyophilization.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/suspended-vials-help-optimize-continuous-freeze-drying/">Suspended Vials Help Optimize Continuous Freeze-Drying</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Small Bioprocess Monitoring Hits the Goldilocks Zone</title>
<link>https://edusehat.com/en/small-bioprocess-monitoring-hits-the-goldilocks-zone</link>
<guid>https://edusehat.com/en/small-bioprocess-monitoring-hits-the-goldilocks-zone</guid>
<description><![CDATA[ A viable-cell-density-on-a-chip monitor offers hope for more fully functional, PAT-compliant in-line monitoring for small bioprocesses, filling a current instrumentation gap. The catch? It’s still in early development.
The post Small Bioprocess Monitoring Hits the Goldilocks Zone appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/12/Oct1_2024_GettyImages_1397353290_MotherboardMainMicrochip_RESIZE4014-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Small, Bioprocess, Monitoring, Hits, the, Goldilocks, Zone</media:keywords>
<content:encoded><![CDATA[<p>Process analytical technology (PAT) bioprocess monitoring instruments generally are designed for large-scale processes, which leaves small-scale bioprocessing at a decided disadvantage. In the days of blockbuster therapeutics, that wouldn’t have mattered much. Today, however, process intensification and increasingly personalized therapies are decreasing batch sizes, so the lack of real-time PAT monitoring options for small-scale manufacturing is a growing concern.</p>
<p>That limitation is felt particularly in the paucity of in-line instrumentation to measure viable cell density, where biocapacitance probes are too large. Alternative, offline viable cell counting methods such as the trypan blue exclusion method limit real-time monitoring in small vessels and, according to a team of Swiss scientists, are impractical for small-scale bioprocessing.</p>
<p>The team led by Yves Mermoud, PhD, research scientist, Eastern Switzerland University of Applied Sciences (OST), and colleagues from OST and Zurich University of Applied Sciences is showing progress in remedying that situation with a viable cell density that appears to be neither too big nor too cumbersome but, as Goldilocks said, just right.</p>
<p>They recently <a href="https://www.researchgate.net/profile/Samuel-Huber-3/publication/415249643_625_-_Bioimpedance_Microsensor_for_Cell-Density_Monitoring_in_Small-Scale_Bioprocessing/links/6ac4f5865770bb0daeda65c0/625-Bioimpedance-Microsensor-for-Cell-Density-Monitoring-in-Small-Scale-Bioprocessing.pdf" target="_blank" rel="noopener">reported</a> on a proof-of-concept, miniature, viable cell density sensor that they tested against concentrations of Chinese hamster ovary (CHO) cells. This work is admittedly in its early stages, but it promises a PAT-compliant sensor for small volumes that currently lack good measurement options.</p>
<p>The miniature bioimpedance sensor they are developing has a 1 x 10 mm footprint at a 25 µL working volume. “Performance [is] close to conventional probes,” Mermoud and colleagues report.</p>
<figure aria-describedby="caption-attachment-340171" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class=" wp-image-340171" src="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-300x114.jpg" alt="" width="374" height="142" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-300x114.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-1024x388.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-768x291.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1-1536x582.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/11/Dutton-Picture1.jpg 1637w" sizes="(max-width: 374px) 100vw, 374px"><figcaption class="wp-caption-text">The miniature, proof-of-concept, bioimpedance sensor has a 1 x 10 mm footprint at a 25 µL working volume. [Yves Mermoud, PhD, research scientist, Eastern Switzerland University of Applied Sciences]</figcaption></figure>
<h4><strong>A good starting point</strong></h4>
<p>The team measured electrical impedance from 10 kHz to 5 MHz, with an amplitude of 200 mV. The detection limit was approximately 0.5 × 10<sup>6</sup> cells mL⁻¹. Deviations at the upper and lower limits were comparable to those of commercial probes, according to data the team presented at the recent Eurosensors 2026 meeting.</p>
<p>There, they reported a linear correlation when measuring the viable density of CHO cells and closely—but not perfectly—tracked reference cell counts. More specifically, Mermoud tells <em>GEN</em>, “Their measurements showed strong correlation with the reference cell counts (R² = 0.92), indicating that a linear relationship explained 92% of the observed variation.”</p>
<p>To create these miniaturized sensors, the researchers fabricated evaporated platinum thin-film electrodes onto a 100 mm fused silica wafer by photolithography. The wafer was cut into 15 x15 mm microchips that were connected to an impedance analyzer. Each chip features two microfluidic channels.</p>
<p>“The PAT microchip cell density sensor has already demonstrated continuous at-line monitoring in representative 14-day CHO fed-batch cultivations,” Mermoud says. “In these studies, cell suspension was circulated through an external demonstrator module housing the PAT microchip. Our focus now is on improving signal analysis to account for process-related changes in the culture medium over time.</p>
<p>“Going forward, we will package the PAT microchip as a standard insertion probe for direct inline deployment in the bioreactor and expand the data analytics with multivariate models that leverage the microchip’s multiple sensing modalities,” Mermoud elaborates.</p>
<p>“We are currently seeking industrial partners to support and accelerate this final translation into a commercial process sensor.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/small-bioprocess-monitoring-hits-the-goldilocks-zone/">Small Bioprocess Monitoring Hits the Goldilocks Zone</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Standardized Apheresis Processes Would Help Cell Therapy Sector</title>
<link>https://edusehat.com/en/standardized-apheresis-processes-would-help-cell-therapy-sector</link>
<guid>https://edusehat.com/en/standardized-apheresis-processes-would-help-cell-therapy-sector</guid>
<description><![CDATA[ Variation in collection practices, or apheresis, and handling procedures is a source of cell therapy starting material variability and a major headache for manufacturers, suggesting a degree of standardization would help the industry.
The post Standardized Apheresis Processes Would Help Cell Therapy Sector appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/12/Nov1_2018_GettyImages_998855520_InsertingSyringePatientArm.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Standardized, Apheresis, Processes, Would, Help, Cell, Therapy, Sector</media:keywords>
<content:encoded><![CDATA[<p>Variability in collection practices at sampling sites has an impact on the quality of cell therapy starting materials, say the authors of new <a href="https://www.sciencedirect.com/science/article/abs/pii/S1465324926009667" target="_blank" rel="noopener">analysis</a>, who suggest that a degree of standardization would aid industry.</p>
<p>Biological factors, such as age, disease status, treatment regimen, and donation history, impact the quality of cells harvested at collection sites, which is a challenge for cell therapy developers trying to turn these variable materials into consistent products.</p>
<p>But biology is not the only source of variability, according to Christina Celluzzi, PhD, from the Association for the Advancement of Blood & Biotherapies, who says firms should not underestimate the role cell collection practices play in determining quality.</p>
<p>“Variability at the apheresis stage complicates comparability assessments when manufacturers change processes, transfer technology, or add capacity. It also limits how efficiently sponsors can use comparability protocols and post-approval change strategies,” she tells <em>GEN</em>.</p>
<h4><strong>Standardization</strong></h4>
<p>Celluzzi and colleagues looked at the impact of variation in apheresis and handling protocols in a recent <a href="https://www.sciencedirect.com/science/article/abs/pii/S1465324926009667" target="_blank" rel="noopener">study</a>, concluding that standardizing parts of these processes would aid cell and gene therapy developers.</p>
<p>“Not every area needs the same degree of standardization,” she says, adding, “for example, there will always need to be flexibility with regard to device selection and vascular access techniques.”</p>
<p>“In contrast, the elements of apheresis that support comparability and traceability would benefit most from tight standardization. These include minimum donor eligibility data elements, definitions of quality attributes, and product identification and labeling,” Celluzzi says.</p>
<p>She cites existing standards—such as <a href="https://www.isbtweb.org/resource/in-015-an-introduction-to-isbt-128---english-v6-pdf.html" target="_blank" rel="noopener">ISBT 128</a>, which covers terminology, labeling, and chain of identity—as an ideal starting point for industry efforts to standardize cell collection practices.</p>
<p>“Adoption of such standards should be paired with implementation support, so that standardization doesn’t widen capability gaps between collection sites.</p>
<p>“We believe the technical content of best practices is best developed by stakeholders, for example through consensus efforts led by organizations such as PDA and ASTCT. Regulators would then recognize or incorporate those standards rather than author them from scratch,” she continues.</p>
<p>That said, the clarification of existing regulations covering cell therapy starting materials would also help industry, according to Celluzzi.</p>
<p>“We’re also asking FDA to clarify several points: how it distinguishes investigational from commercial starting materials, its expectations for collections made outside the United States, and how consensus standards can support regulatory submissions.”</p>
<p>Harmonizing material receipt procedures at cell therapy production facilities would help too, Celluzzi says, citing strictly defined temperature limits and cryopreservation media specifications as examples.</p>
<p>“Common templates for leukapheresis manuals, SOPs, and chain-of-custody and chain-of-identity records would be beneficial,” Celluzzi says, adding, “Risk-based site qualification would let manufacturers focus audits on product-specific risks instead of repeatedly reassessing established quality systems.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/standardized-apheresis-processes-would-help-cell-therapy-sector/">Standardized Apheresis Processes Would Help Cell Therapy Sector</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building Custom DNA without Bacterial Constraints</title>
<link>https://edusehat.com/en/building-custom-dna-without-bacterial-constraints</link>
<guid>https://edusehat.com/en/building-custom-dna-without-bacterial-constraints</guid>
<description><![CDATA[ Moving high-fidelity DNA assembly from the production queue to the lab bench and the science can start sooner.
The post Building Custom DNA without Bacterial Constraints appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/RibbonBio_DNA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, Custom, DNA, without, Bacterial, Constraints</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://ribbonbio.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-336834 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-300x97.jpg" alt="Ribbon Bio logo" width="300" height="97" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-300x97.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1024x330.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-768x247.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1536x495.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1303x420.jpg 1303w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-696x224.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1392x449.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1068x344.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB.jpg 1921w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>The standard way to build custom DNA still runs through a living cell: assemble the sequence, push it into bacteria, grow overnight, extract, clean up. Molecular biologists have leaned on this for half a century, and for most constructs it works. But it is slow to schedule, demands culturing and biosafety infrastructure, and quietly fails on the sequences researchers care about most.</p>
<p>Those failures were the starting point for Ribbon Bio. “Sometimes the sequence we want to study is precisely the sequence that bacteria do not want to maintain,” said Divya Vijay Pratheek, the company’s vice president of product, in a recent GEN webinar. Toxic elements and secondary structures can collapse a clone, costing days or weeks of troubleshooting. Outsourcing relieves the bottleneck but puts proprietary sequences in someone else’s hands.</p>
<h4><strong>Taking out the host</strong></h4>
<p>Ribbon Bio’s cell-free assembly technology removes bacteria from the equation entirely thus eliminating several practical burdens. Without a host, Pratheek explained, there is no endotoxin or residual genomic DNA to carry into downstream assays, contamination that matters most for therapeutic and patient-facing work. Since sequences no longer have to survive inside a living host, toxic or unstable designs become workable, and the failure points of transformation, colony selection, and plasmid prep fall away.</p>
<p>The workflow opens with software. Ribbon Bio’s proprietary algorithm reads target sequences for trouble spots such as GC content, repeats, homopolymers, and secondary structure, then lays out oligo pools with boundaries chosen to sidestep them. Ribbon’s proprietary enzymes stitch the oligos into fragments, checked before assembly into the finished molecule. The design is tuned most to catch most complexities, before they lead to failed reactions.</p>
<h4><strong>From service to bench</strong></h4>
<p>The company first sold this as a synthesis service, MiroSynth<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, which it still runs for extremely complex molecules. These days, the MiroMine<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> kit puts the method directly in customers’ hands enabling them to build complex DNA in house. The early-access version builds molecules up to roughly 7 kilobases, needs only standard lab hardware, and runs manually or using automation, with platform scripts in progress.</p>
<p>The figures came from Ribbon Bio’s own runs. Molecules near 3.4 and 6.8 kb returned 100% sequence-perfect reads, and a roughly 4 kb construct came in at 88%, shown openly against the company’s 90% accuracy floor. Fragments ranging from 30%–70% global and 20%–82% local GC content, plus repeats and homopolymers, cleared the same four-hour workflow. Endotoxin levels sat at or below 0.1 units per microgram, with no detectable bacterial genomic DNA.</p>
<h4><strong>A library builder’s test</strong></h4>
<p>Flock Bio, a company that assembles pooled custom DNA libraries, is an early user of Ribbon Bio’s kit.  In one internal study, the company’s scientists ran 12 fragments through MiroMine and got all 12, roughly half of them high-complexity, cleanly assembled.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The payoff was speed. With MiroMine, Flock ran fragment assembly, cleanup, checks, and pooled ligation inside one working day; with cloning adding three to four days, a full library can land in a week. “If we get that oligo pool on Monday, we’re shipping by Friday,” said Matthew D. Youngblut, PhD, Flock Bio’s co-founder and chief scientific officer, who pointed to value of fast-turn work for things like antibody discovery, binder design, and more.</p>
<h4><strong>The takeaway</strong></h4>
<p>For over fifty years, traditional DNA assembly has relied on bacterial propagation, a process that introduces labor intensive processes, sequence constraints, contamination risks, and extended production cycles. In this webinar, Ribbon Bio and Flock Bio lay out a case for retiring that requirement: purer starting material, access to sequences bacteria reject, and a turnaround counted in days instead of weeks. For scientists working in therapeutic development, endotoxin-free production addresses regulatory and safety concerns that currently require additional purification steps. The technology also enables iteration cycles that match the pace of modern screening technologies, particularly in competitive areas like antibody discovery.  While the program is young and not every use case is proven, the direction is clear: pull the build onto the bench, and the science can start sooner.</p>
<p> </p>
<p><em><img decoding="async" class="alignleft wp-image-340203 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/11/RibbonBio_QRCode.jpg" alt="Ribbon Bio QR Code" width="146" height="151"></em></p>
<p> </p>
<p><em>Try MiroMine<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> in your lab today at <a href="https://ribbonbio.com/miromine/" target="_blank" rel="noopener">www.ribbonbio.com/miromine</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/building-custom-dna-without-bacterial-constraints/">Building Custom DNA without Bacterial Constraints</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HIV&#45;Blocking Antibody Shows Promise, but Resistant Strains Break Through</title>
<link>https://edusehat.com/en/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through</link>
<guid>https://edusehat.com/en/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through</guid>
<description><![CDATA[ A new study finds that the VRC01 antibody initially protects against HIV infection, but resistant strains can cause breakthrough infections as antibody levels decline, highlighting the need for multiple antibodies.
The post HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2204954260.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 05 Nov 2026 03:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HIV-Blocking, Antibody, Shows, Promise, but, Resistant, Strains, Break, Through</media:keywords>
<content:encoded><![CDATA[<p>One of the mechanisms being developed to help combat HIV is to prevent HIV-negative individuals, who are at risk of acquiring HIV-1, from becoming infected. One form of this preventative strategy is using broadly neutralizing antibodies (bnAbs)—administered intravenously—that could protect individuals from acquiring HIV-1. This could be most relevant for people with partners living with HIV, people at increased risk of HIV exposure (including individuals with ongoing sexual exposure risk), people who cannot or prefer not to use conventional PrEP, and among populations with high HIV incidence—for example, communities in regions of sub-Saharan Africa with substantial HIV transmission.</p>
<p>The antibody-mediated prevention (AMP) clinical trials were landmark trials in this area—the first to investigate whether intravenous infusion of a bnAb could prevent HIV-1 acquisition. The trials focused on the bnAb VRC01, which targets the CD4-binding site on the HIV-1 envelope (Env) glycoprotein. By binding to this region, VRC01 can neutralize susceptible HIV-1 strains and potentially prevent the virus from infecting host cells.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The broadly neutralizing antibody VRC01 has been thoroughly vetted as a potential prophylactic that could prevent people from becoming infected with HIV. Now, a new analysis of data from two clinical trials in the Americas and sub-Saharan Africa shows that the antibody initially provides strong protection, but that some strains of the virus can still cause breakthrough infections after treatment has stopped. The findings point to the importance of combining multiple types of antibodies to suppress HIV completely and to prevent breakthrough infections in vulnerable people.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “Extended <em>in vivo</em> activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections.”</p>
<p>Antibodies such as VRC01 are designed to halt the virus’ ability to infect its host initially through common sites of exposure. VRC01 has recently progressed to large-scale clinical trials, but scientists must test whether it can provide meaningful, real-world protection against the ever-evolving myriad strains of HIV.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In this new report, researchers parsed data from HVTN 704 and HPTN 085, two clinical trials where participants received infusions of VRC01 for 80 weeks. The two parallel antibody-mediated prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition.</p>
<p>The researchers focused their attention on the period after the treatment ended, from weeks 80 to 104. More specifically, they analyzed HIV-1 acquisition in AMP through the week 104 final study visit.</p>
<p>The researchers showed that VRC01 initially protected against HIV strains that were considered highly sensitive to the antibody, achieving a prevention efficacy of 66.3%. They write that against viruses considered highly sensitive to VRC01, “VRC01 prophylaxis maintained cumulative prevention efficacy of 66.3%, suggesting that the antibody successfully blocked or cleared these infections.”</p>
<p>As VRC01 concentration waned, suppressed viruses—often evolving greater resistance because of selective pressure—emerged as detectable infections. After week 80, some of the participants were still diagnosed with HIV that was considered more resistant to the antibody, and diagnoses were higher compared with the placebo group. They write, “In the post–week 80 period (after the final dose at week 72), HIV diagnosis and resistance to VRC01 were more frequent and greater in the VRC01 groups versus placebo.”</p>
<p>The findings, the authors explain, suggest that, “whereas single antibodies can block sensitive strains, multiple antibodies are likely required to prevent both viral escape and breakthrough infections.” The authors write that their results carry implications for the design and analysis of future trials of HIV-1 broadly neutralizing antibodies, such as the importance of testing for the virus far after infusions have ended.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/hiv-blocking-antibody-shows-promise-but-resistant-strains-break-through/">HIV-Blocking Antibody Shows Promise, but Resistant Strains Break Through</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Epigenomics Is Transforming Drug Discovery and Development</title>
<link>https://edusehat.com/en/how-epigenomics-is-transforming-drug-discovery-and-development</link>
<guid>https://edusehat.com/en/how-epigenomics-is-transforming-drug-discovery-and-development</guid>
<description><![CDATA[ In this GEN eBook readers will discover how epigenomic insights are improving every stage of the drug discovery pipeline, from target identification and validation to mechanism-of-action studies and therapeutic optimization.
The post How Epigenomics Is Transforming Drug Discovery and Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_CoverImage_Nov2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Epigenomics, Transforming, Drug, Discovery, and, Development</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<p class="wp-block-paragraph">Understanding gene regulation has become essential to modern drug discovery. While DNA sequence and RNA expression provide valuable information, they reveal only part of the story. Epigenomic technologies, particularly chromatin mapping assays like CUT&RUN, are enabling researchers to investigate the regulatory mechanisms that control gene expression, offering a level of insight that transcriptional profiling alone cannot provide.</p>


<figure class="wp-block-image alignright size-medium"><img decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-232x300.jpg" alt="Epicypher eBook Cover, How Epigenomics Is Transforming Drug Discovery and Development" class="wp-image-340189" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/11/Epicypher_eBookCover_Nov2026.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<h4 class="wp-block-heading"><strong>Introduction</strong></h4>


<p class="wp-block-paragraph">In this <em>GEN</em> eBook, <em>How Epigenomics is Transforming Drug Discovery and Development</em>, readers will discover how epigenomic insights are improving every stage of the drug discovery pipeline, from target identification and validation to mechanism-of-action studies and therapeutic optimization.</p>


<h4 class="wp-block-heading"><strong>Read this eBook to learn:</strong></h4>


<ul class="wp-block-list">
<li>Why understanding gene regulation matters in drug discovery and development</li>



<li>How epigenomic profiling is being used to identify novel therapeutic targets, elucidate drug mechanisms of action, investigate treatment resistance, and support development of emerging modalities such as targeted protein degraders (e.g. PROTACs, molecular glues)</li>



<li>How next-generation technologies, including CUT&RUN, are providing unprecedented insights into gene regulation</li>
</ul>


<p class="wp-block-paragraph">Through expert perspectives and real-world case studies, this eBook demonstrates how researchers are applying epigenomic approaches to answer critical biological questions, characterize therapeutic responses, and make more informed decisions throughout drug development.</p>


<p class="wp-block-paragraph">Whether you’re working in target discovery, translational research, or therapeutic development, this eBook provides a practical overview of the technologies and strategies that are reshaping modern drug discovery.</p>


<p class="wp-block-paragraph">Read this eBook to learn how CUT&RUN and related epigenomic tools are helping pharmaceutical and biotechnology researchers uncover disease mechanisms, identify high-confidence drug targets, and accelerate the development of more effective therapies.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/how-epigenomics-is-transforming-drug-discovery-and-development/">How Epigenomics Is Transforming Drug Discovery and Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting</title>
<link>https://edusehat.com/en/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting</link>
<guid>https://edusehat.com/en/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting</guid>
<description><![CDATA[ The findings, part of a trove of abstracts that will be presented at next month’s American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult hemoglobin (HbA).
The post Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/06/June04_2021_Stocktrek-Images-Getty-Images_Sickle-Cell-Disease-e1622842099798.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 23:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kamau, Therapeutics, Releases, Encouraging, Sickle, Cell, Clinical, Data, Ahead, ASH, Meeting</media:keywords>
<content:encoded><![CDATA[<p>Kamau Therapeutics, a California biotech company co-founded by Stanford University physician-scientist Matthew Porteus, MD, PhD, has emerged from stealth with the release of preliminary clinical data on its first cohort of gene-edited patients with sickle cell disease (SCD).</p>
<p>The findings, part of a trove of abstracts that will be presented at next month’s American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three SCD patients as well as restored expression of adult hemoglobin (HbA). In contrast to FDA-approved Casgevy, which overcomes the SCD mutation by switching up expression of fetal hemoglobin (HbF), Kamau is employing a direct replacement of the SCD mutation using homology-directed repair (HDR) of the β-globin gene.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>All three patients are currently transfusion-independent and have not experienced any pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). In addition to the predominant HbA profile being restored, Kamau reports that the sickle hemoglobin (HbS) level fell below 20% of total hemoglobin in the two patients who have reached the 6-month post-infusion mark.</p>
<figure aria-describedby="caption-attachment-297262" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-297262 size-medium" src="https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-243x300.jpg" alt="Matthew Porteus" width="243" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-243x300.jpg 243w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-828x1024.jpg 828w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-768x950.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1242x1536.jpg 1242w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1657x2048.jpg 1657w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-340x420.jpg 340w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-679x840.jpg 679w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-324x400.jpg 324w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-648x800.jpg 648w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-696x860.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1392x1721.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1068x1320.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2024/06/MatthewPorteus_Headshot-1920x2374.jpg 1920w" sizes="(max-width: 243px) 100vw, 243px"><figcaption class="wp-caption-text">Matthew Porteus, MD, PhD,<br>Co-Founder, Kamau Therapeutics<br>Associate Professor of Pediatrics, Stanford University</figcaption></figure>
<p>Porteus told <em>GEN </em>he was “very encouraged” by this early readout of Kamau’s RESTORE trial. “These were the target results that we were expecting once we got HDR to work in engraftable HSCs,” Porteus said. “We are now full speed ahead on enrolling more patients and moving to talk to the FDA about the registration trial design.” The Phase I/II RESTORE trial is enrolling some 15 participants.</p>
<p>Between the abstract submission and next month’s presentation at ASH, Porteus said Kamau has “further data that gives us confidence in the safety, efficacy and sustainability of the approach.” Porteus says that the updated data will be included in the ASH talk, which will be given by John DiPersio, MD, Director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine, on December 14 in New Orleans.</p>
<p>“Achieving hemoglobin levels above 10 g/dL, with sickle hemoglobin below 20% and adult hemoglobin predominant, in patients who also remain free of vaso-occlusive events, is an encouraging early signal,” DiPersio said in a press release. “Seeing that profile alongside stable engraftment of corrected cells is what we would hope to see from a durable correction of the underlying mutation.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Vali Barsan, MD, co-founder and CEO of Kamau Therapeutics, said his team applies “process engineering to HDR, nature’s own high-fidelity repair pathway.” The HDR pathway “can implement corrections we design directly into a patient’s own stem cells,” Barsan continued. “That has been the promise of gene editing from the beginning, and these data are early clinical evidence that it can be realized.”</p>
<h4><strong>Direct deposit</strong></h4>
<p>Porteus, who is head of R&D of Kamau, has been <a href="https://www.genengnews.com/topics/genome-editing/a-story-of-perseverance-an-interview-with-matthew-porteus/" target="_blank" rel="noopener">steadfast in his determination</a> to translate some of the basic insights he helped define regarding DNA repair and recombination into the clinic, especially for the benefit of patients with SCD. He said his new company adopts a twin-stranded approach: reduce production of pathogenic HbS and restore the body’s own production of normal HbA. Kamau’s gene replacement strategy is a 1:1 exchange of the faulty HbS allele with a healthy HbA copy, rather than a gene addition strategy.</p>
<p>“We developed nula-cel to work in a patient’s own stem cells, enabling those cells to produce adult hemoglobin under the body’s normal regulation,” Porteus said. The nula-cel therapy directly corrects the SCD mutation in the β-globin gene. That is in contrast to the HbF switching approach taken in Casgevy, the gene editing therapy sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics, approved in late 2023.</p>
<p>A major question is whether Kamau’s HDR strategy will offer any long-term clinical advantages compared to Casgevy. Porteus believes it might. “Since we see a greater reduction in HbS than the HbF [switching] approaches, we think that it will prove better at preventing the myriad of multi-organ damage that the disease causes,” Porteus told <em>GEN</em>. For example, “it has been shown that exchange transfusion, in which the target is to keep HbS below 30%, is better at preventing stroke or recurrent stroke than upregulation of HbF.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In addition, Porteus said, “evolution has selected a tunable HbA as the solution to oxygen delivery to tissues under various conditions, whereas HbF is not tunable in its oxygen unloading. This may result in better long-term organ health.”</p>
<p>Of course, Kamau still faces some very stiff headwinds en route to commercial viability. In December 2024, Editas Medicine suspended its own gene editing asset for SCD after it was unable to find a pharma partner to move the therapy to approval despite strong clinical data.</p>
<p>Porteus notes that in his reading of Editas’ published data, “it did not appear the clinical results were improved over Casgevy.” Moreover, there are encouraging signs that the gene therapy approaches approved in 2023 are beginning to reach patients. “That Lyfgenia is, and Casgevy will soon be, profitable as patient infusions logarithmically increase quarter-over-quarter, while only addressing a tiny portion of the [SCD] patient population, gives us conviction on the commercial upside,” Porteus told <em>GEN</em>.</p>
<p>“The demand is there and we will be part of the solution to meet that demand,” Porteus insists. And as the CAR T commercial market demonstrates, “being first to market helps but the ultimate winner is best in indication.”</p>
<h4><strong>ASH anticipation</strong></h4>
<p>DiPersio’s presentation at ASH next month will be entitled: “First Clinical Results of Precise HBB Gene Correction by Homology Directed Repair in Patients with Severe Sickle Cell Disease: Safety and Efficacy from Phase 1A of the RESTORE Study” (NCT04819841). He will present results on three SCD patients treated with Kamau’s revised manufacturing process (V2.0) for nula-cel, along with continued follow-up of the first patient ever treated with nula-cel four years ago, under the auspices of Graphite Bio, Porteus’ previous company. <a href="https://www.genengnews.com/topics/genome-editing/a-sickle-sequel-matthew-porteus-launches-kamau-with-positive-nula-cell-patient-zero-results/" target="_blank" rel="noopener">Graphite Bio halted its SCD clinical trial in late 2022</a> and subsequently disbanded.</p>
<p>The ASH data “provide early clinical evidence that precise HDR-mediated correction of the native HBB gene is feasible,” Porteus said. “We look forward to learning more as the RESTORE trial progresses.”</p>
<p>All three V2.0 treated patients achieved transfusion independence before they were released from hospital, achieving neutrophil engraftment at a median of 21 days. In the two patients with more than six months of follow-up, total hemoglobin exceeded 10 g/dL, with relatively low levels of HbS (17.6% at 12 months and 19.1% at 8 months) and high HbA (77% at 12 months and 67% at 8 months).</p>
<p>Bone marrow HDR allele frequencies stabilized at approximately 20%, consistent with durable engraftment of gene-corrected HSCs. Single-cell analyses showed more than 90% of circulating red blood cells contained protective levels of HbA. There were no serious adverse events related to nula-cel or the multistep gene-editing process V2.0-treated patients, but some consistent with the busulfan conditioning and stem-cell transplantation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Off-target gene editing remained low and unchanged, Kamau said. HDR allele frequencies exceeded the 20% target in all three patients (32–38%). HSC mobilization required a median of just 1.3 apheresis cycles to reach target cell dose.</p>
<p>Nula-cel, which has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), is an <em>ex vivo</em> approach. Kamau engineers a patient’s own stem cells outside the body, verifying each cell product’s quality, potency, and safety, before reinfusing the HSCs into the patient. Kamau claims this offers a measure of control that would not be possible using an <em>in vivo </em>gene editing approach.</p>
<p>Kamau is funded by a group of investors including Khosla Ventures, Cormorant Asset Management, NEVA SGR, Draper VC, Modi Ventures, and Regeneron Ventures. The company’s leadership team also includes chief technology officer Ramji Krishnan, PhD, who brings experience in CMC leadership at BMS/Celgene, and autologous HSC gene therapy experience at Rocket; chief medical officer Jacob Garcia, MD, previously at Juno/BMS; and chief business officer Reza Afkhami, formerly with Global Blood Therapeutics, where he helped manage <a href="https://www.genengnews.com/topics/drug-discovery/pfizer-to-acquire-gbt-for-5-4b-adding-sickle-cell-disease-drug-and-pipeline/" target="_blank" rel="noopener">the company’s 2022 acquisition by Pfizer</a>.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/kamau-therapeutics-releases-encouraging-sickle-cell-clinical-data-ahead-of-ash-meeting/">Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE panel notes challenges IRA poses for patients</title>
<link>https://edusehat.com/en/pace-panel-notes-challenges-ira-poses-for-patients</link>
<guid>https://edusehat.com/en/pace-panel-notes-challenges-ira-poses-for-patients</guid>
<description><![CDATA[ Changes brought on by the Inflation Reduction Act (IRA) often increase patient costs and reduce access, while also harming the innovation that brings new […]
The post PACE panel notes challenges IRA poses for patients appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/JDR_4635-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 20:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panel, notes, challenges, IRA, poses, for, patients</media:keywords>
<content:encoded><![CDATA[<p><span>Changes brought on by the Inflation Reduction Act (IRA) often increase patient costs and reduce access, while also harming the innovation that brings new treatments, according to patient advocates.</span></p>
<p><span>Correcting the situation requires raising the patient voice and telling patient stories, said panelists at BIO’s Patient Advocacy Changemakers Event (PACE), in Washington DC, Oct. 22-23. PACE has been held annually for 15 years and provides a unique opportunity for patient advocates, the biotech industry, and other stakeholders to promote the development of new treatments.</span></p>
<p><span>“The Inflation Reduction Act was signed into law about four years ago now. Are patients better off?” asked</span><a href="https://pace.bio.org/2026-program/cui-bono-benefits-price-controls-1"> <span>panel</span></a><span> moderator</span><a href="https://pace.bio.org/speakers/karin-hoelzer"> <span>Karin Hoelzer, BIO Senior Director of Patient Advocacy</span></a><span>.</span></p>
<p><span>On balance, panelists maintained, patients are not better off. IRA price controls clearly create a barrier to access by discouraging investment in innovative new drugs, but there are many other more direct, negative impacts on patients, the panelists said.</span></p>
<h2>The out-of-pocket cap and Medicare Part D</h2>
<p><span>If there is good news out of IRA it is the out-of-pocket cap on annual payments by patients whose prescriptions are covered by Medicare Part D, said the panelists,</span><a href="https://pace.bio.org/speakers/jennifer-snow"> <span>Jennifer Snow, Founder and Managing Director – Apteka</span></a><span>, and</span><a href="https://pace.bio.org/speakers/patrick-wildman"> <span>Patrick Wildman, SVP of Advocacy & Government Relations – Lupus Foundation of America</span></a><span>.</span></p>
<p><span>Both cautioned that the Part D redesign that brought about the cap also brings in some challenges.</span></p>
<p><span>“For people who have high costs to address their medical needs, the cap would be really important for them,” said Wildman. “But for people who don’t hit the cap, their costs may actually have gone up as a result of the IRA. And that’s simply because there’s been a shift from co-pays to cost share.”</span></p>
<p><span>Both he and Snow also expressed concern about what the IRA would mean for future changes in Part D.</span></p>
<p><span>“I worry about the long-term kind of return on investment of the Inflation Reduction Act when we’re looking ahead to the Part D redesign,” said Snow. “From a beneficiary perspective, I think we’re in for a huge, huge shift in terms of Part D. The benefit is just not stable right now, and I think longer term, we’re going to be looking for solutions on how to ensure that Part D can stay at least as great as it is now.”</span></p>
<p><span>One immediate challenge brought about by the cap has been an escalation of insurance companies’ utilization management practices, which create barriers to accessing drugs, according to Wildman.</span></p>
<p><span>Snow agreed: “We’re up to like 50% of branded drugs requiring prior authorization in Part D,” she said. “It’s just under 10% for step therapy.”</span></p>
<h2>Part B and other price controls</h2>
<p><span>Another area where future changes could cause problems is in Medicare Part B, which covers drugs that are administered by a professional provider. Under IRA, these drugs will be subject to price controls in 2028, and the result will likely be new challenges to access, the panelists said.</span></p>
<p><span>“We don’t know what reimbursement mechanism they’re going to use for providers, and the providers may be underwater,” Snow said. “If providers can no longer afford to provide those negotiated drugs, what happens to access?”</span></p>
<p><span>“There are real impacts on patients. And I think our role is to show what those impacts are,” Wildman said. “In the case of a low reimbursement for administering a price-negotiated drug, the downstream impacts are the patient doesn’t get that drug or they have to change providers.”</span></p>
<p><span>Along with the IRA, the panel also looked at other mechanisms to control prices, including Prescription Drug Affordability Boards (PDABs), which are being used by several states to control or cap the reimbursement insurers, state Medicaid programs, and public entities pay for prescription drugs.</span></p>
<p><span>“Much like the Inflation Reduction Act, PDABs look at drug pricing and affordability,” but from a state perspective, Snow said. “Is it affordable to the state who’s trying to set it up or affordable for the patient? Those two cannot be reconciled. And I think we see that on the federal level, too. Drug pricing is not about affordability. From a patient advocacy perspective, the more we push back on that notion, I think, the stronger the affordability story becomes.”</span></p>
<h2>Patient stories</h2>
<p><span>Wildman agreed that the approach states take with PDABs tends to ignore the patient’s perspective, and said that federal efforts at drug price control are similarly challenged. He said patient advocates are trying to make the Centers for Medicare & Medicaid Services (CMS) take patients into account when deciding on their actions.</span></p>
<p><span>“I think that is part of the solution, making sure that CMS is fully engaged with the patient community and is looking at us not only as a partner in ensuring the stability of the program but also the future of the program,” he said.</span></p>
<p><span>Snow reached out to the audience of patients and patient advocates at PACE, asking for their help by sharing their stories.</span></p>
<p><span>“Those who are patient advocates, your experiences, the experiences of the people you represent, are critical to helping inform our white papers, or issue briefs, or comment letters. Or you can go to CMS yourself and share your experience,” Snow said.</span></p>
<p><span>She added that CMS used to listen to taxpayers who fund them and patients who used their services, but that has changed.</span></p>
<p><span>“Over time, it has felt more like there are other stakeholders who are getting the voice. And I think it’s time to wrench that back and make sure that the patient voice is heard. For that, we’ll need your stories,” Snow said.</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panel-notes-challenges-ira-poses-for-patients/">PACE panel notes challenges IRA poses for patients</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study</title>
<link>https://edusehat.com/en/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study</link>
<guid>https://edusehat.com/en/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study</guid>
<description><![CDATA[ Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration.
The post Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1869420709.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 09:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alamar, Nightingale, Health, Team, Biobank, Neurodegeneration, Protein, Study</media:keywords>
<content:encoded><![CDATA[<p>Many of the blood proteins that could flag <a href="https://www.genengnews.com/?s=neurodegeneration&filter=&page=null" target="_blank" rel="noopener">neurodegeneration</a> are so scarce that standard assays barely register them. A new UK Biobank study will test whether an ultrasensitive platform can pick them up across 80,000 blood samples, potentially years before symptoms appear.</p>
<p>Alamar Biosciences and Nightingale Health announced the UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study on November 2, 2026. Nightingale will run the measurements in its own laboratories using Alamar’s NULISA platform, quantifying hundreds of circulating proteins in samples from UK Biobank participants. The Michael J. Fox Foundation for Parkinson’s Research, Alzheimer’s Research UK, and LifeArc are funding the work, which is expected to be completed by the end of 2027.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>NULISA, short for NUcleic acid Linked Immuno-Sandwich Assay, pairs antibodies tagged with DNA oligonucleotides to capture a target protein. A capture-and-release process washes away background signal, and the DNA reporters are then read out by next-generation sequencing.</p>
<p>The timing reflects a growing view that the biology behind Alzheimer’s and Parkinson’s disease begins years before diagnosis. The companies noted that Alzheimer’s and other dementias affect more than 55 million people worldwide and Parkinson’s affects more than 12 million, with both projected to rise sharply by 2050.</p>
<p>“Working with Nightingale and UK Biobank, we can now measure those signals across tens of thousands of people, years before symptoms appear, and give researchers everywhere a new way to ask when and why these diseases begin,” said Yuling Luo, PhD, Alamar’s founder, CEO, and chair.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>UK Biobank’s deputy chief scientist, Adam Lewandowski, PhD, said proteins help repair tissue, regulate inflammation, and support countless bodily functions, “yet we still know relatively little about how they work together to influence brain health.”</p>
<p>Samantha Hutten, PhD, principal biomarker scientist, translational research at the Michael J. Fox Foundation, said the data could help “evaluate potential biomarkers and inform future therapeutic research.” LifeArc CEO Sam Barrell said the resource could also help lay “the groundwork for more accurate diagnosis” of rare dementias, which can be difficult to diagnose because their symptoms overlap with other conditions.</p>
<p>After the study is completed, the full dataset will be made available to approved researchers worldwide through the UK Biobank Research Analysis Platform.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/alamar-nightingale-health-team-up-on-uk-biobank-neurodegeneration-protein-study/">Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data</title>
<link>https://edusehat.com/en/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data</link>
<guid>https://edusehat.com/en/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data</guid>
<description><![CDATA[ Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. 
The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/recursion-pharma-1024x576-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 05:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Recursion, Eyes, 2027, Pivotal, Trial, for, Lead, Candidate, After, Positive, Phase, FAP, Data</media:keywords>
<content:encoded><![CDATA[<p>Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous polyposis (FAP) therapy generated positive mid-stage clinical data.</p>
<p>Most patients treated with REC-4881 showed reductions in both the number of larger, higher-risk polyps and in lower GI polyp burden, according to updated data from the Phase Ib/II TUPELO trial (<a href="https://clinicaltrials.gov/study/NCT05552755" target="_blank" rel="noopener">NCT05552755</a>). That data was presented by Lisa Boardman, MD, a gastroenterologist and Professor of Medicine at Mayo Clinic, at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting, being held through Wednesday in Denver.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“REC-4881 is reducing the larger polyps that often drive much of the surgery for these [FAP] patients, across the GI tract from a single oral therapy,” Najat Khan, PhD, Recursion’s president and CEO, said in a statement. “This is a lifelong disease with no approved pharmacologic therapies, and REC-4881 is the clearest proof point yet of what we built Recursion to do.”</p>
<p>Recursion said its anticipated second half 2027 timing for a registrational trial will depend on its talks with the FDA, with additional details set to be provided later this year.</p>
<p>Recursion announced the REC-4881 data after the close of markets on Monday. The news appeared to make little impression on investors, as Recursion shares stayed all but flat Tuesday as of 12:55 pm ET, inching up 0.1% to $3.84, a penny above yesterday’s closing price.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>Licensed from Takeda</strong></h4>
<p>REC-4881 is a first-in-class, oral allosteric inhibitor of MEK1 and MEK2 that Recursion is developing through a global licensing agreement with Takeda Pharmaceutical signed in 2020 and covering FAP and related areas of oncology. Recursion agreed to pay Takeda $1.5 million upfront, up to $39.5 million in payments tied to achieving development and regulatory milestones, plus low-to-mid single-digit royalties on net sales of products containing the drug by Recursion, its affiliates, or sublicensees.</p>
<p>Takeda initially developed the drug as TAK-733 and used Recursion’s artificial intelligence (AI) platform to uncover targeted areas of oncology where the drug could be effective.</p>
<p>For FAP, a rare genetic disorder, the standard of care has long consisted of lifelong active endoscopic surveillance and eventual prophylactic surgical removal of the colon.</p>
<p>“People have been doing research in the chemoprevention space in FAP for decades, and at least in the United States, we still don’t have an agent that is FDA approved,” stated Bryson Katona, MD, PhD, TUPELO study investigator and director of the GI Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine. “We’re still having to send FAP patients for major surgeries and we’re still doing frequent scopes on these patients. The need for effective chemoprevention in FAP is very large, and it’s only going to increase over time as the number of FAP patients continues to increase.”</p>
<p>Estimates of prevalence FAP vary widely. While Recursion has counted >50,000 FAP patients in the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom), other institutions have shared figures showing FAP to affect <a href="https://www.jax.org/education-and-learning/clinical-and-continuing-education/clinical-topics/cancer-resources/fap-and-afap" target="_blank" rel="noopener">approximately one in 6,800 to 31,000 individuals worldwide</a>, including <a href="https://rarediseases.org/rare-diseases/familial-adenomatous-polyposis/" target="_blank" rel="noopener">about one in 5,000 to 10,000 Americans</a>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Recursion is among biopharmas working to develop treatments for FAP.</p>
<p>One FAP treatment is already in Phase III study—eRapa<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, which since 2024 has been developed by Biodexa Pharmaceuticals under an exclusive global license from Emtora Biosciences, which licensed eRapa from the University of Texas (UT) Health San Antonio in 2012, when Emtora was known as Rapamycin Holdings.</p>
<p>eRapa is an oral tablet formulation of the mTOR inhibitor rapamycin (sirolimus), sold in generic versions; Pfizer ceased selling the branded version, Rapamune<sup>®</sup>, in 2023. Last month, Biodexa said it had enrolled 100 patients in its registrational Phase III Seranta trial (<a href="https://clinicaltrials.gov/study/NCT06950385" target="_blank" rel="noopener">NCT06950385</a>) of eRapa, which has an estimated primary completion date of July 2030.</p>
<p>Also in clinical trials for FAP is Tempest Therapeutics’ TPST-1495, a first-in-class oral small molecule selective dual EP2 and EP4 prostaglandin receptor antagonist targeting prostaglandin E2 (PGE2) signaling in the tumor microenvironment. In March, Tempest launched a Phase II open label trial (<a href="https://clinicaltrials.gov/study/NCT06557733" target="_blank" rel="noopener">NCT06557733</a>) designed to assess how well TPST-1495 reduces the number of polyps in the small bowel and colon in patients with FAP. The study’s estimated enrollment is 38 patients with primary completion expected June 30, 2027.</p>
<p>Recursion’s TUPELO trial was designed to study polyp burden reduction after 12 weeks on REC-4881 (4mg once daily) and again after 12 weeks off-treatment. Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden after 12 weeks of treatment, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%.</p>
<p>Since the initial November 2025 data cut, all four patients added to the study showed a reduction in total polyp burden, including two patients with 89% and 98% reduction, respectively. At Week 25, after 12 weeks off treatment, 85% of patients (11 of 13) remained below baseline.</p>
<p>Recursion reasons that the persistence of polyp burden reduction below baseline in most patients studied may allow for dosing flexibility.</p>
<h4><strong>‘Certainly encouraging’</strong></h4>
<p>“Seeing durability over a twelve-week course is certainly encouraging. In longer trials we’ll see exactly how long that durability lasts, but I think it is a very encouraging first sign for this drug,” Katona said.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Within the upper GI tract, 92% of patients (12 of 13) had reductions in polyp burden after 12 weeks of treatment, with a 55% median reduction. Nearly half (six of 13) achieved reductions of ≥65%, more than one in three achieved ≥75%, and two patients achieved reductions of ≥98%. Half (six of 12) improved by at least one Spigelman stage at Week 13, while 92% (11 of 12) remained below baseline at Week 25, after 12 weeks off-treatment, and six of 11 had equal or greater reductions during the off-treatment period than during treatment.</p>
<p>Within the lower GI tract, nine of 11 patients (82%) with measurable polyp burden at baseline had reductions after 12 weeks of treatment, with a 50% median reduction, and four of 11 achieved reductions of 65% or more. At Week 25, after 12 weeks off-treatment, seven of 10 patients remained below baseline.</p>
<p>Six of eight patients that showed polyps greater than 5 mm at baseline had reductions in the number of these polyps after 12 weeks of treatment. Four achieved reductions of ≥80%, including two whose larger-polyp counts fell from more than 90 polyps to one. In both of those patients, all of the larger polyps were in the upper GI tract.</p>
<h4><strong>One patient, 98% reduction</strong></h4>
<p>The highest responder was a patient who went from 1,344 mm of total polyp burden to 32 mm, a 98% reduction, and from 96 upper GI polyps >5 mm to one. Recursion cautioned that the patient was not representative of the overall population.</p>
<p>The company also cautioned that the study collected its polyp counts using >5 mm as the largest size category; separate counts for polyps >10 mm were not collected.</p>
<p>Six of the eight patients assessed at Week 25 were below their baseline count after 12 weeks off treatment. Most of the larger polyps at baseline were in the upper GI, Recursion said.</p>
<p>No new safety signals were observed as of the data cutoff in the expanded patient population, which includes patients 18 and older. Most treatment-related adverse events (TRAE), according to recursion, were Grade 1 or 2 (21 of 26 patients, 80.8%). The highest-grade TRAE was Grade 3 in four patients (15.4%), and there were no Grade 4 or 5 TRAEs.</p>
<p>The most common TRAEs were consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Adverse events were manageable, and most resolved within 12 weeks off treatment. Four patients were discontinued for Grade 1 or 2 TRAEs, with no discontinuations for a Grade 3 event.</p>
<p>Recursion announced the clinical data along with third quarter earnings that showed a reduced quarterly net loss year over year. Recursion ended the third quarter with a net loss of $119.036 million, compared to a net loss of $162.253 million for Q3 2025, on revenue that tripled to $18.552 million from $5.175 million. For Q1-Q3 2026, Recursion cut its net loss to $367.545 million from $536.637 million a year ago.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/recursion-eyes-h2-2027-pivotal-trial-for-lead-candidate-after-positive-phase-ii-fap-data/">Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Precision Automation Meets Biology</title>
<link>https://edusehat.com/en/precision-automation-meets-biology</link>
<guid>https://edusehat.com/en/precision-automation-meets-biology</guid>
<description><![CDATA[ In this GEN podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and expertise can support it. The conversation covers where variability creeps into cell-based work, how automation can take over routine tasks, and how instruments, software, and scientific expertise can work together. It also considers how a lab’s needs shift as their work matures, and what that means for choosing the right tools at each step.
The post Precision Automation Meets Biology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Getty_1435758706_LabEquipment.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 05:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Precision, Automation, Meets, Biology</media:keywords>
<content:encoded><![CDATA[<p></p>

<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">For laboratories running cell-based research, automation can mean high-throughput work, but its real value is in reducing repetitive work, controlling variability between experiments, and boosting consistency while still supporting flexible processes. Small manual inconsistencies can have an outsized impact, and the tools that are meant to help can sometimes get in the way. Precision automation ensures that the technology serves the question being asked.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> podcast, a cellular workflow automation specialist from Molecular Devices explores what precision automation means for working biologists and how purpose-built instruments, software, and expertise can support it. The conversation covers where variability creeps into cell-based work, how automation can take over routine tasks, and how instruments, software, and scientific expertise can work together. It also considers how a lab’s needs shift as their work matures, and what that means for choosing the right tools at each step.</p>


<p class="wp-block-paragraph"></p>
</div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading has-text-align-center"><strong>Podcast Guest: </strong></h4>


<figure class="wp-block-image aligncenter size-full is-resized webinar-pic-caption td-caption-align-center"><img fetchpriority="high" decoding="async" width="1400" height="1400" src="https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot.jpg" alt="Matt Stoltz" class="wp-image-340164" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot.jpg 1400w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/11/MattStoltz-_Headshot-768x768.jpg 768w" sizes="(max-width: 1400px) 100vw, 1400px"><figcaption class="wp-element-caption"><strong>Matt Stoltz</strong><br>Sr. Cellular Workflow Automation Specialist<br>Molecular Devices</figcaption></figure>
</div>
</div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sponsor-box is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph"><strong>Sponsored by</strong></p>


<figure class="wp-block-image size-medium is-resized"><a href="https://www.moleculardevices.com/" target="_blank" rel="noreferrer noopener"><img decoding="async" width="300" height="68" src="https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-300x68.png" alt="Molecular Devices logo" class="wp-image-221725" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-300x68.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1024x232.png 1024w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-768x174.png 768w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1536x348.png 1536w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-2048x464.png 2048w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-696x158.png 696w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1392x315.png 1392w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1068x242.png 1068w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1920x435.png 1920w, https://www.genengnews.com/wp-content/uploads/2023/03/Molecular-Devices_Logo_Color-1853x420.png 1853w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/topics/omics/precision-automation-meets-biology/">Precision Automation Meets Biology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lost and Found: Neural Pathway for Forgetting Found in C. elegans</title>
<link>https://edusehat.com/en/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans</link>
<guid>https://edusehat.com/en/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans</guid>
<description><![CDATA[ Researchers identified the key molecular and neural pathways that cause the nematode Caenorhabditis elegans to actively forget a specific odor it previously remembered, providing a framework for understanding how specific memories are differentially eliminated.
The post Lost and Found: Neural Pathway for Forgetting Found in C. elegans appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/05/GettyImages-1128676754-e1765821893874.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 04 Nov 2026 02:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lost, and, Found:, Neural, Pathway, for, Forgetting, Found, elegans</media:keywords>
<content:encoded><![CDATA[<p>For as long as human inquiry has existed, people have tried to understand how and why we remember and forget. As we have begun to understand how the brain works, researchers have slowly uncovered the biological mechanisms underlying memory. Researchers from Kyushu University have now found the key molecular and neural pathways that cause the nematode worm <em>Caenorhabditis elegans</em> to actively forget a specific odor it previously remembered.</p>
<p>Through extensive studies of the <em>C. elegans</em> nervous system, the team discovered that a peptide called NLP-47 triggers this process of active forgetting. NLP-47 is received by a different neuron further along the circuit, which in turn sends a signal to the neuron storing the memory of the odor, leading to its erasure. Most strikingly, when <em>C. elegans</em> memorized two different odors simultaneously, this circuit erased the memory of only one odor while leaving the other intact.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“There are many diseases that involve memory loss,” said research lead Professor Takeshi Ishihara, PhD, at Kyushu University Faculty of Science. “But before we can understand what goes wrong, we need to understand how forgetting works in the brain, and I hope this research will lead to a better understanding of such brain functions.”</p>
<p>Ishihara is senior and corresponding author of the researchers’ published paper in <em>Current Biology</em>, titled “<a href="http://dx.doi.org/10.1016/j.cub.2026.10.015" target="_blank" rel="noopener">Neuropeptidergic-glutamatergic circuit regulates selective forgetting of olfactory learning</a>.” In their paper the authors concluded that their findings may “… offer insights into disorders associated with dysregulated forgetting, including dementia and PTSD.”</p>
<p>Forgetting specific memories is “… as essential as forming them,” the authors wrote. “…  animals must selectively discard irrelevant experiences while preserving others to adapt to constantly changing environments.” But as they further noted, “Despite proposals of selective forgetting in psychological frameworks, the molecular and neuronal mechanisms underlying this selectivity remain largely unexplored.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Ishihara commented, “Research on memory has focused on how it is formed and maintained. How memories are lost has received less attention. We usually think of forgetting as a failure of memory. But forgetting is just as essential for adaptation and survival. This raises a question: How does the brain decide which memories to erase?”</p>
<p>To uncover the mechanism of active forgetting, the team has been studying the model organism <em>C. elegans, </em>a nematode with only 302 neurons. Because each neuron has been identified, it is possible to trace a memory and its erasure to specific neurons. <em>C. elegans</em> are blind but have an exceptional sense of smell. <a href="https://doi.org/10.1016/j.celrep.2013.02.019" target="_blank" rel="noopener">In 2013,</a> Ishihara’s team used <em>C. elegans</em> to identify the neurons that cause the active forgetting of a specific odor memory housed in another neuron.</p>
<p>However, at that time, the team could not identify the molecules that activate this pathway. For their newly reported study first author and PhD candidate Yuuki Onishi, and colleagues set out to identify the responsible molecules. The researchers trained <em>C. elegans</em> to learn a specific smell, diacetyl. “<em>C. elegans</em> exhibits chemoattraction to various odorants, including diacetyl …” they explained. After about four hours—the time it usually takes for the organism to forget a smell—diacetyl was administered again. If the <em>C. elegans</em> moved toward the diacetyl smell, it meant that it had forgotten the memory, if not, the memory had been retained.</p>
<p>The <em>C. elegans</em> olfactory system comprises two pairs of sensory neurons, AWA and AWC, which receive volatile attractive odorants. In a previous study, Ishihara’s team identified that AWA neurons store the memory of the odor, and that memory was erased by signals from AWC neurons. Experiments aiming to identify the “forgetting” signal released by AWC identified the neuropeptide NLP-47 and its receptor GNRR-1. When the team then investigated which neural circuits these two factors affected, they discovered that AIZ neurons, which are located between AWC and AWA, were involved. “Neuropeptide NLP-47, secreted from AWC neurons, regulates forgetting of the olfactory memory through its receptor GNRR-1, an orthologue of the human GnRH receptor, in AIZ interneurons,” the scientists wrote.</p>
<figure aria-describedby="caption-attachment-340135" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340135" src="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1-300x169.jpg" alt="When C. elegans learns two odors at the same time, the two memories do not share the same fate. Four hours later, the memory of diacetyl has faded while the memory of isoamyl alcohol remains. The researchers identified the neuropeptide and the neural circuit that direct this selective forgetting. [Takeshi Ishihara/Kyushu University] " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Ishihara-release-figure-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">When <em>C. elegans</em> learns two odors at the same time, the two memories do not share the same fate. Four hours later, the memory of diacetyl has faded while the memory of isoamyl alcohol remains. The researchers identified the neuropeptide and the neural circuit that direct this selective forgetting. [Takeshi Ishihara/Kyushu University]</figcaption></figure>
<p>Ishihara further explained, “First, AWC releases NLP-47 and activates the GNRR-1 receptor on the AIZ neurons. The AIZ neurons would then release glutamate, another neurotransmitter. The glutamate then acts on the GLR-4 receptor on the AWA neurons that house the memory of the scent, leading to active forgetting. When we used optogenetics to suppress the activity of the AWC and AIZ neurons, we found that the nematodes were more resilient to forgetting.”</p>
<p>Follow-up experiments revealed that this active forgetting was highly specific. When nematodes were trained to remember two odors—diacetyl and isoamyl alcohol—simultaneously, the NLP-47/GNRR-1 pathway only forgot the diacetyl smell. “Simultaneous conditioning with two odorants revealed that neuropeptidergic-glutamatergic signaling selectively promotes forgetting of diacetyl memory without affecting isoamyl alcohol memory … indicating that forgetting can be regulated in a memory-specific manner,” the investigators stated.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p><em>C. elegans</em> in which NLP-47/GNRR-1 or glutamate did not function were more resistant to forgetting the smells. “Discovering that this forgetting system is not indiscriminate and can target a specific memory is fascinating,” Onishi said. “At first, I was not expecting to find such a concrete mechanism of active forgetting with a remarkable specificity. I hope this research will lead to a deeper understanding of forgetting and eventually to more insights on conditions and pathologies involving memory.”</p>
<p>Commented Ishihara, “Interestingly, receptors like GNRR-1 are found in other organisms, including humans. In rodents, these receptors are found in the hippocampus, the brain’s center for memory, although their role there is not yet known. Our findings may also lead to an understanding of the mechanisms by which mammals forget specific memories.”</p>
<p>In their paper the authors concluded, “Our findings provide a framework for understanding how specific memories are differentially eliminated and suggest that such mechanisms extend to other species.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/lost-and-found-neural-pathway-for-forgetting-found-in-c-elegans/">Lost and Found: Neural Pathway for Forgetting Found in <i>C. elegans</i></a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE panel lays out patient input possibilities in PDUFA VIII</title>
<link>https://edusehat.com/en/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii</link>
<guid>https://edusehat.com/en/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii</guid>
<description><![CDATA[ The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process. Stakeholders […]
The post PACE panel lays out patient input possibilities in PDUFA VIII appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/11/960px-US_Food_and_Drug_Administration_lapel_pin.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panel, lays, out, patient, input, possibilities, PDUFA, VIII</media:keywords>
<content:encoded><![CDATA[<p><span>The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process.</span></p>
<p><span>Stakeholders discussed their latest opportunity to impact the Prescription Drug User Fee Act (PDUFA), which regulates America’s gold-standard drug approval process, at BIO’s Patient Advocacy Changemakers Event (PACE) in Washington, DC, on Oct. 22-23.</span></p>
<p><span>PDUFA has roots in the 1980s, when ACT UP activists fought for AIDS patients, according to Steve Berman, VP for Science and Regulatory Affairs Strategy at the Biotechnology Innovation Organization (BIO), who led the PDUFA discussion at PACE.</span></p>
<p><span>“At that time, drug development in the U.S. was very different than it is today. Seventy percent of all new medicines were available outside the U.S. before they were available here,” and drug review often took three years, Berman said. “At the height of the AIDS crisis, patients couldn’t get drugs to save their lives. Patient advocates said this was unacceptable.”</span></p>
<p><span>Congress responded with PDUFA. First passed in 1992 and reauthorized every five years, PDUFA requires drug makers to pay fees to help fund the Food and Drug Administration (FDA). In return, FDA is required to provide a professional, efficient approval process. Before the act, FDA drug review averaged close to 29 months, and today the average is down to 10 months,</span><a href="https://www.pharmacytimes.com/view/understanding-the-fda-approval-process-and-pdufa-dates"> <span>according to a report</span></a><span>.</span></p>
<p><span>“It is absolutely critical to have a functional FDA, to have a well-funded FDA, to have an FDA that has processes and the infrastructure allowing for more regulatory certainty,” said panelist Adora Ndu, Chief Regulatory Officer and EVP of Portfolio Strategy at BridgeBio Pharma. Along with Berman, Ndu represented the biotech industry during recent negotiations with FDA to create</span><a href="https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/"> <span>a proposal for the contents of PDUFA VIII</span></a><span>.</span></p>
<h2>Why PDUFA reauthorization matters to patients</h2>
<p><span>The reauthorization process, which provides an excellent opportunity for patient input into FDA operations, is currently underway.</span></p>
<p><span>The process began with a public meeting, including many speakers from the patient advocacy community. This transitioned to the biopharma industry, represented by BIO and others, negotiating with FDA officials about the fees industry will pay and the services and initiatives the agency will provide in return. The six-month-long negotiations ended in August with the</span><a href="https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/"> <span>PDUFA VIII commitment letter</span></a><span>.</span></p>
<p><span>Throughout negotiations, FDA had monthly check-ins with stakeholder groups consisting of 50-60 patient advocates. That input was crucial, according to Ndu.</span></p>
<p><span>“[FDA] would pull from the stakeholder meetings to say, ‘This is what we’re hearing, how does it inform the direction that we should take?’ ” she said.</span></p>
<p><span>Patient input continues as Congress uses the commitment letter’s proposals to create PDUFA legislation, which must be reauthorized by September 2027.</span></p>
<p><span>“Patient advocacy groups play an important role in helping educate Congress members about the importance of user fees overall and the details of this particular agreement, and also in shaping any policies that may come along as riders,” said Berman.</span></p>
<p><span>As panelist Jeff Allen, President and CEO of Friends of Cancer Research, told the session at PACE, PDUFA updates are essential.</span></p>
<p><span>“Science and technology are evolving rapidly,” Allen said. “This five-year process gives us all the opportunity to check in and make sure policies are in place to keep pace with the science.”</span></p>
<p><span>Along with adding necessary updates, Congress members often use the “must-pass” nature of the act to add riders that are not central to PDUFA’s mission. As Congress increasingly delays “must-pass” legislation, that strategy is risky, Allen said.</span></p>
<p><span>“I’m sure we will see some good ideas from various policy proposals that could appropriately ride along this PDUFA package,” Allen said. “But I think we have to keep this relatively narrow, in order to make sure that we don’t inadvertently derail an important process.”</span></p>
<h2>Increasing patient voice in drug development<b> </b></h2>
<p><span>The proposal in the commitment letter aimed at achieving the basic, but challenging, goal of ensuring FDA operates efficiently, according to Ndu. This resulted in a PDUFA VIII commitment letter that contains improvements to increase patient participation, she said.</span></p>
<p><span>Ndu highlighted some provisions benefiting the rare disease community, including continuing the successful</span><a href="https://www.fda.gov/industry/fda-rare-disease-innovation-hub/rare-disease-innovation-science-and-exploration-rise-workshop-series"> <span>Rare Disease Innovation, Science, and Exploration (RISE) workshop series</span></a><span>. The PDUFA VIII commitment letter envisions 10 RISE workshops.</span></p>
<p><span>RISE workshops “enable a discussion around the barriers in drug development, bringing all the stakeholders together to ensure conversation can happen and can actually translate into enabling more treatments,” Ndu said.</span></p>
<p><span>The entire patient community can benefit from “continuation of patient-focused drug development activities from prior PDUFAs,” proposed in PDUFA VIII, according to Berman.</span></p>
<p><span>“FDA would be required to hold multiple public meetings talking about how they consider patient-focused drug development and patient preferences in their regulatory decision making,” he said.</span></p>
<p><span>Ideally, FDA should include data from patient experiences in their drug labelling, and this is a step in that direction, Ndu said, noting that “FDA will share some of the case studies of how they have considered patient experience data.”</span></p>
<p><span>Berman maintained that PDUFA VIII’s improved patient engagement opportunities will result in better drug development.</span></p>
<p><span>“One of the reasons why drug development is so slow and expensive is that science is challenging,” he explained. “And the best way to address scientific challenges is as a community.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panel-lays-out-patient-input-possibilities-in-pdufa-viii/">PACE panel lays out patient input possibilities in PDUFA VIII</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline</title>
<link>https://edusehat.com/en/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline</link>
<guid>https://edusehat.com/en/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline</guid>
<description><![CDATA[ A study investigating the observed connection between pulmonary hypertension and cognitive decline symptoms has linked brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive disease in the lungs and heart. 
The post Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/low-res-1-e1793639966551.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:25:18 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inflammatory, Process, Identified, Link, Between, Pulmonary, Hypertension, and, Cognitive, Decline</media:keywords>
<content:encoded><![CDATA[<p>A study by University of Pittsburgh and UPMC researcher-clinicians has uncovered why many pulmonary hypertension (PH) patients report symptoms of cognitive decline.</p>
<p>The team carried out a multimodal investigation involving brain MRI studies, blood-based molecular profiling, and functional studies in mouse models, and linked specific brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive the disease in the lungs and heart. The findings suggest that cognitive decline may be present in other vascular and inflammatory conditions beyond pulmonary hypertension. The results also point to neural targets that may be relevant for future diagnostic, prognostic, and therapeutic approaches.</p>
<p>“Patients often assume memory issues or trouble concentrating are unrelated to their pulmonary hypertension,” said research lead Stephen Chan, MD, PhD, Vitalant Chair in Vascular Medicine and director of the Vascular Medicine Institute and Center for Pulmonary Vascular Biology and Medicine at the Pitt School of Medicine and UPMC. “Our findings suggest those symptoms are a central part of the disease process and deserve attention.”</p>
<p>Chan is senior author of the researchers’ published paper in <em>Journal of Clinical Investigation</em>, titled “<a href="https://doi.org/10.1172/JCI195110" target="_blank" rel="noopener">Cerebellar and frontal lobe alterations in pulmonary hypertension implicate an inflammatory lung vascular/brain axis</a>.”</p>
<p>Millions of people are affected by pulmonary hypertension, which causes high blood pressure in the blood vessels of the lungs. Common symptoms include shortness of breath, chest pain, and feeling lightheaded. More recently scientists have linked pulmonary hypertension with cognitive issues such as impaired executive function and memory problems. “Cognitive impairment is increasingly recognized in pulmonary hypertension (PH), a disease traditionally viewed as limited to the heart and lungs,” the authors wrote. “Given that inflammation is shared by PH and neurodegenerative diseases, we investigated its role in driving brain and cognitive deficits in PH.”</p>
<p>Recent research by Chan identified a genetic variant in a gene called NCOA7, which produces a protein of the same name. In a quarter of pulmonary hypertension patients, this variant drives inflammatory responses and worsens the odds of survival. Chan hypothesized that the same variant might be connected to brain inflammation that leads to cognitive impairment in people with pulmonary hypertension.</p>
<p>To test that theory, Chan and colleagues used brain MRI scans and blood tests to look for brain changes that were unique to pulmonary hypertension. They first compared the brain scans of people with pulmonary hypertension against those without, using data from a large public health database and a smaller group of UPMC patients to test and confirm their hypothesis.</p>
<p>Patients with pulmonary hypertension in both test groups had a consistent and substantial loss of brain tissue and weakened communication between two brain regions involved in memory, attention and planning—the cerebellum, at the base of the brain, and the frontal lobe, just behind the forehead. Notably, the same brain changes were absent in people with other heart, lung, and psychiatric conditions. “Using structural and functional MRI data from UK Biobank (N = 248 PH) and a prospective validation cohort, we identified reduced cerebellar white matter volume, thinner frontal gyri, and weakened cerebellar-frontal connectivity in patients with PH but not in other heart or lung diseases,” the team reported. These changes were accompanied by worsened executive function and processing speed.”</p>
<p>The brain differences could not be explained by low blood oxygen, poor heart function, or the medications used to treat the disease—evidence that the changes are specific to pulmonary hypertension, rather than a side effect of the disease’s effects on the heart and lungs.</p>
<p>By analyzing genetic data from both groups of patients and conducting additional laboratory studies, the team found that the NCOA7 variant already linked to blood vessel inflammation in pulmonary hypertension is also connected to inflammation in the cerebellum of these patients.</p>
<p>Examining cerebellum tissue from patients and mice with pulmonary hypertension, they saw signs that brain immune cells—microglia—had become overactive, and evidence that neurons were changing in response. Mice that both developed the disease and lacked the NCOA7 gene had more severe cerebellar damage than mice with pulmonary hypertension alone, establishing that the gene plays a causal role in regulating brain inflammation in this disease. “Postmortem analysis and PH mouse models showed cerebellar microglial activation and structural deficits worsened by NCOA7 deficiency,” the investigators wrote in summary. “Collectively, these findings support PH-associated cerebellar–frontal brain deficiencies linked to chronic neuroinflammation and NCOA7 dysfunction.”</p>
<p>Chan suspects that this mechanism is active in other diseases beyond pulmonary hypertension. “I believe that NCOA7 deficiency may underlie a spectrum of inflammatory conditions—including those that may contribute to dementia and aging,” Chan said. “If so, these findings could introduce new diagnostic and therapeutic avenues for preserving brain function in a much broader group of people.” The authors added: “From a translational perspective, the association of inflammatory plasma biomarkers with structural and functional brain alterations may inform new diagnostic and prognostic strategies … Our findings also open avenues for testing whether PH-associated neuroinflammatory changes are therapeutically reversible.”</p>
<p>Current guidelines for managing pulmonary hypertension do not include cognitive screening, and no biological marker exists to predict or track how much the disease affects the brain. This study points to a potential marker and identifies inflammation as a potential therapeutic target for preserving brain function and quality of life.</p>
<p>“This changes the way we look at a disease like pulmonary hypertension,” said Chan. “In medicine, we typically treat the symptoms of one organ system; but the reality is that our bodies are very complex, and disease processes may be affecting multiple parts of the body in a variety of ways.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/inflammatory-process-identified-as-link-between-pulmonary-hypertension-and-cognitive-decline/">Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy</title>
<link>https://edusehat.com/en/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy</link>
<guid>https://edusehat.com/en/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy</guid>
<description><![CDATA[ uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) at 36 months serving as the primary endpoint. 
The post FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/uniQURE-EXTERIOR_1583081674129-EDITED-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 04:25:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Sets, May, PDUFA, Action, Date, for, uniQure’s, Huntington’s, Disease, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<p>The FDA has set a May 1 target action date under the Prescription Drug User Fee Act (PDUFA) for uniQure’s Huntington’s disease gene therapy candidate ifezuntirgene inilparvovec—which, if approved, would be the first treatment shown to modify the fatal, inherited neurodegenerative disorder—after accepting the company’s Biologics License Application (BLA) under Priority Review.</p>
<p>The action by the FDA, announced Monday, marks a complete reversal of agency opposition that surfaced last year and hardened earlier this year.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The FDA did caution uniQure, however, that it was tentatively planning to discuss the BLA at a future advisory committee meeting, most likely the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC). No date for such a meeting had been set at deadline, though uniQure said it was told it would be notified by the agency when that happens.</p>
<p>uniQure submitted its BLA to the FDA in September, as well as a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).</p>
<p>“The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease,” uniQure CEO Matt Kapusta said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>One analyst offered another reason for the significance of the FDA action: “We see the acceptance of the BLA as an important milestone for ifezuntirgene inilparvovec as it further removes regulatory risk,” Lachlan Hanbury-Brown, research analyst, healthcare with William Blair, wrote in a research note.</p>
<h4><strong>Investor caution</strong></h4>
<p>However, investors appeared more cautious, as uniQure shares dipped 3% to $24.03 as of 10:56 am. ET from $24.83 at Friday’s close despite the positive news. Chatter on investor websites suggested several possible reasons why investors were reluctant to buy uniQure stock:</p>
<ul>
<li>The PDUFA target action date was later than expected.</li>
<li>Four-year data for the gene therapy showed lower slowing of disease progression than earlier three-year data.</li>
<li>Continuing concerns about risk in the ongoing trials.</li>
</ul>
<p>Ifezuntirgene inilparvovec uses the company’s gene-silencing miQURE<sup>®</sup> platform and incorporates a microRNA designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).</p>
<p>uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) at 36 months serving as the primary endpoint.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>uniQure said it plans to begin patient screening in the United States by the end of 2026.</p>
<p>In addition to Priority Review, uniQure’s BLA for ifezuntirgene inilparvovec has been granted the FDA’s Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations.</p>
<p>The FDA reversal follows a change in leadership at the Center for Biologics Evaluation and Research (CBER) as Vinayak (Vinay) Prasad, MD, who opposed uniQure’s BLA, resigned for the second time in March, effective April 30. Prasad relinquished his roles as CBER director and FDA chief medical and scientific officer under Martin A. Makary, MD, who resigned effective May 12.</p>
<h4><strong>FDA stunner</strong></h4>
<p>Under Prasad, the FDA <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fgenome-editing%2Funiqure-staggers-as-fda-questions-data-for-huntingtons-gene-therapy-candidate%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353474402%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=zbb16UnyYtcIzvKJGmCgGhleaCrz7ncpqJsnuw8swco%3D&reserved=0">stunned uniQure in November 2025</a> when it told the company that what it had called “game-changing” data in September, showing <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fgenome-editing%2Fgene-therapy-significantly-slows-huntington-disease-progression%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353487080%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=F%2FolhGKO8AE54WlV%2Fc6TJjlvmFLZggg9Q1UPJRElcU4%3D&reserved=0">significant slowing of HD progression</a> in patients treated with the gene therapy candidate, may not be enough to secure FDA approval. The data prompted one analyst to predict ifezuntirgene inilparvovec (then known as AMT-130) would <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Ftranslational-medicine%2Fstockwatch-uniqure-shares-reach-five-year-high-on-game-changing-huntingtons-data%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C7d6a4029d2a441dd46ed08de7c76c9f6%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639085047353516935%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=7dQJW8yAGUGNEDXNL%2FkI%2FRDGud7CWET2H02EuVJtU7E%3D&reserved=0">generate $4 billion peak worldwide annual sales by 2032</a>, though a consensus of other analysts forecasted just $1.7 billion in peak sales.</p>
<p>Key among uniQure’s Phase I/II results was the statistically significant 75% slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months in patients treated with the high dose of 6×10<sup>13</sup> gc/subject of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database. That more than met the primary endpoint of the Phase I/II study, which consisted of trials in the United States (<a href="https://clinicaltrials.gov/study/NCT04120493">NCT04120493</a>) and Europe (<a href="https://clinicaltrials.gov/study/NCT05243017">NCT05243017</a>).</p>
<p>The FDA stepped up its public criticism against uniQure on March 2, when it issued what the company termed a “strong” recommendation to conduct a prospective, randomized, double-blind, sham surgery-controlled study to support a future marketing application for AMT-130. The FDA concluded that data from uniQure’s earlier Phase I/II study, which compared ifezuntirgene inilparvovec to an external control, were not sufficient to provide the primary evidence of effectiveness needed for the agency to approve the gene therapy candidate.</p>
<p>UniQure stock responded to the FDA jawboning by plummeting 42% on March 2 and 3, then flattening in the middle of that week, before rebounding 58% by March 6. The <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-under-fire-from-fda-uniqure-stock-roller-coasters/">stock gyrations followed Prasad announcing his resignation plans</a>.</p>
<p>In June, with Karim Mikhail then serving as acting CBER director, the FDA reversed itself and <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-positive-phase-iii-data-sells-investors-on-intellia/">accepted the three-year analysis</a> from the two Phase I/II trials as the primary basis of a Biologics License Application (BLA) for accelerated approval of ifezuntirgene inilparvovec. Mikhail has since been appointed permanent CBER director.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<h4><strong>Four-year data</strong></h4>
<p>Last month, uniQure reported positive four-year data for ifezuntirgene inilparvovec showing a continued slowing of disease progression based on the two ongoing Phase I/II studies. At 48 months TFC, the primary measure of uniQure’s confirmatory study, showed consistent slowing of functional decline, with absolute treatment benefit maintained in Month 48. Differences seen between the high and low doses on both composite cUHDRS and TFC were consistent with a dose-dependent treatment effect, uniQure said.</p>
<p>The primary endpoint of cUHDRS showed a 44% slowing of disease progression (non-significant p=0.144) while TFC showed a 61% slowing of disease progression (nominal p=0.008), according to uniQure.</p>
<p>“While efficacy in the high-dose group as measured by the cUHDRS softened from year 3 to year 4 and thus could point to a weakening of treatment effect, we see concerns from this endpoint as overdone given several caveats in the analysis, and the fact that it is not the primary endpoint of the confirmatory study or the basis for the current BLA,” Hanbury-Brown commented.</p>
<p>“We believe the additional 48-month results from the ongoing Phase I/II study of AMT-130 in HD continue to show a positive clinical benefit, especially around the more important regulatory endpoint of TFC, which increased separation from the external control group from 3 to 4 years following treatment,” Hanbury-Brown added.</p>
<p>In its announcement Monday, uniQure said the two trials have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients, of which six received a low dose of ifezuntirgene inilparvovec, 10 a high dose, and 10 a sham procedure. Four control patients subsequently crossed over to treatment after approximately 12 months.</p>
<p>The European open-label study enrolled 13 patients—six receiving low-dose ifezuntirgene inilparvovec and seven, the high dose. A third cohort of 12 patients explored both doses in combination with immunosuppression, while and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/fda-sets-may-1-pdufa-action-date-for-uniqures-huntingtons-disease-gene-therapy/">FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD</title>
<link>https://edusehat.com/en/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd</link>
<guid>https://edusehat.com/en/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd</guid>
<description><![CDATA[ The FDA has delayed a decision on Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) seeking additional approval for mitapivat in sickle cell disease (SCD) until next year. 
The post FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/Aug16_2016_Getty_481945753_SickleCellRedCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Delays, PDUFA, Action, Agios’, Mitapivat, sNDA, for, SCD</media:keywords>
<content:encoded><![CDATA[<p>The FDA has delayed a decision on Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) seeking additional approval for mitapivat in sickle cell disease (SCD) until next year. The FDA has extended its target action date under the Prescription Drug User Fee Act (PDUFA) by three months, from the originally scheduled November 1, 2026, to February 1, 2027, Agios acknowledged in a statement.</p>
<p>Investors punished Agios with a stock selloff that sent the company’s share price slumping nearly 18% from $37.23 to $30.55 on Friday.</p>
<p>The three-month extension was triggered by what the FDA deemed a major amendment to the sNDA—namely the submission, at the agency’s request, of additional information to assess whether a Risk Evaluation and Mitigation Strategy (REMS) would be necessary for mitapivat in SCD.</p>
<p>Agios responded to the FDA on October 19 by submitting approximately nine months of updated safety data through October 9 from the ongoing open-label extension periods of the Phase II/III RISE UP trial (<a href="https://clinicaltrials.gov/study/NCT05031780">NCT05031780</a>).</p>
<p>According to <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01480-7/fulltext">data published October 24 in <em>The Lancet</em></a>, 56 (41%) of 138 patients in the mitapivat group showed a hemoglobin response, compared with two (3%) of 69 patients on placebo (95% CI; two-sided p<0·0001). The annualized rate (95% CI) of sickle cell pain crises was 2.6 for mitapivat compared with 3.1 for placebo (two-sided p=0.1213). Serious adverse events were reported in 28 (20%) patients on mitapivat vs. 20 (29%) patients on placebo; one mitapivat patient’s event was deemed treatment related.</p>
<p>Mitapivat, an oral pyruvate kinase activator, “has the potential to be an effective and convenient disease-modifying treatment for people with sickle cell disease, researchers concluded in the study.</p>
<p>The new data, Agios said, continued to show no cases of hepatocellular injury (HCI) among patients with SCD treated with mitapivat who showed a pattern and severity similar to those observed trials for mitapivat in adults with thalassemia, Agios stated, adding that the risk-benefit profile of mitapivat in SCD remained unchanged.</p>
<h4><strong>“More cautious stance”</strong></h4>
<p>“Based on our recent conversations/inbounds, investors were focused on the potential for a REMS in SCD and how the FDA might be considering safety in this patient population, and we see the news being perceived by the market as signaling a more cautious stance from the FDA overall,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, wrote in a research note.</p>
<p>Romero added that the delay “also seems to be surprising the market,” as Agios investors are concerned the agency’s action narrows mitapivat’s potential first-to-market advantage relative to Novo Nordisk’s SCD candidate etavopivat, which Novo has told investors it would advance to a first regulatory filing in the fourth quarter of this year.</p>
<p>Agios has, since January, marketed mitapivat as a treatment for thalassemia, under the name Aqvesme®. Mitapivat is also marketed for hemolytic anemia under the name Pyrukynd®. Both mitapivat drugs combined have generated $65.491 million in net product revenue during the first half of this year, more than triple (209% above) the $21.181 million racked up during January–June 2025.</p>
<p>The company plans to report third quarter results on Thursday.</p>
<p>“Even if a REMS is necessary, management expects no additional delays and is launch ready. While the extension could delay the commercial launch by ~3 months, management does not believe it changes the commercial opportunity,” Andrew Berens, MD, senior managing director, targeted oncology and a senior research analyst with Leerink Partners, wrote in a research note.</p>
<p>Berens projected in April that mitapivat in SCD had a 60% chance of reaching the market, with peak sales of about $550 million in the United States.</p>
<h4><strong>“Interesting period”</strong></h4>
<p>“We believe Agios is navigating an interesting period, with the Aqvesme launch in thalassemia underway,” Romero commented. “That said, we struggle to see meaningful near-term upside for the stock and think it may take some time for investors to gain conviction in the launch trajectory of mitapivat in SCD, if/when approved.”</p>
<p>Agios said it will continue its labeling discussions with the FDA, including elements of a potential REMS, and will keep working closely with the agency to bring mitapivat to the market as soon as possible.</p>
<p>“We have strong conviction in mitapivat’s potential to transform care for people living with sickle cell disease, grounded in the comprehensive data from the RISE UP clinical program and further supported by the additional data we submitted in response to the FDA’s recent request,” Agios CEO Brian Goff said in a statement.</p>
<p>Agios’ sNDA was submitted under the FDA’s accelerated approval pathway, and has been granted Priority Review. The accelerated approval requires a confirmatory clinical trial—a condition Agios is satisfying through the Phase III REIGNITE trial (<a href="https://clinicaltrials.gov/study/NCT07656415">NCT07656415</a>), which dosed its first patient in July. The trial is designed to demonstrate the clinical benefit of mitapivat on reducing transfusion burden in patients aged 12 years and older with sickle cell disease.</p>
<p>“We are launch-ready, building on our commercial infrastructure and the strong relationships we have established over several years with hematologists, sickle cell centers, and patients,” Goff added. “We will continue to work expeditiously with the goal of bringing mitapivat to patients with sickle cell disease as soon as possible.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/fda-delays-pdufa-action-on-agios-mitapivat-snda-for-scd/">FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform</title>
<link>https://edusehat.com/en/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform</link>
<guid>https://edusehat.com/en/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform</guid>
<description><![CDATA[ 10x Genomics launches Sentira, an Anthropic Claude-powered AI platform designed to accelerate single-cell data analysis, broaden research access, and streamline workflows while raising questions about expertise and AI reliability.
The post Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/11/GettyImages-2253444748.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 03 Nov 2026 00:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sentira, Brings, Claude’s, 10x, Genomics’, Chromium, Platform</media:keywords>
<content:encoded><![CDATA[<p>Ask any single cell researcher for their biggest experimental bottlenecks, and they will say data analysis. Going back to the beginning of the field, there has always been a “last mile problem,” notes Michael Schnall-Levin, PhD, CTO of 10x Genomics. Why? Because researchers have unique experimental methods and questions, each of which involves some level of writing their own analysis code. It has been “not scalable to write software that can do everything for everyone.”</p>
<p>But now, with advances in LLMs, researchers can use tools to answer questions without needing to be bioinformaticians. Today, 10x is launching Sentira Single Cell, a cloud-based agentic analysis powered by Anthropic’s Claude models as an application for Chromium users.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Schnall-Levin thinks that this will be “massively accelerating” for users. How much faster? “What might have taken someone weeks before could take hours,” he says. And that speed will not only help individual researchers but ultimately, he notes, be beneficial to the pace of scientific research and progress. It is not just about speed, however. Schnall-Levin says that there will like be other benefits. For example, it may reveal results in data that people are not currently seeing.  In addition, the company hopes that Sentira will broaden the group of people who can ask questions of single-cell data directly.</p>
<p>Sentira is, for the company, an umbrella of software capabilities. Sentira spatial was launched a few weeks ago; today’s announcement is specific to single-cell analysis. Sentira is not locked to any model: it can use different LLMs but the Anthropic models are working well, Schnall-Levin reports. And the project follows with Anthropic’s general push into the life science industry.</p>
<p><strong>From virtual lab to AI-powered single-cell analysis</strong></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The idea for the Sentira project started at the beginning of 2026, with some work 10x Genomics was doing together with James Zou, PhD, associate professor, Department of Biomedical Data Science at Stanford University. Zou’s name has become infamous with the concept of the “Virtual Lab” which he explains as a laboratory made of algorithms. The idea was first introduced in the 2025 <em>Nature </em>paper, “<a href="https://www.nature.com/articles/s41586-025-09442-9" target="_blank" rel="noopener">The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies.</a>”</p>
<p>Built on 10x Cloud, Sentira Single Cell provides the computing power needed to analyze Chromium data and run multiple analyses in parallel without requiring researchers to configure or manage their own infrastructure. The customer will interact with a chat interface which will help them go through and dynamically ask questions in the data that involves (on the back end) scripting and writing different analysis code.</p>
<p>10x is not training its own LLM model. Rather, it relies on models from Claude. The company will use researchers’ data to understand how the application is performing and to make improvements. But there is no flow back into the models themselves, the company asserts.</p>
<p><strong>The extra cost of going agentic</strong></p>
<p>The company reports that the cost will be an added “modest” cost. More specifically, the company notes that Sentira pricing is credit-based, through 10x Cloud Credit packs. The rough estimate is that each agentic session costs ~12 credits, with complete analysis through to experimental conclusions requiring around 60 credits. At launch, all users will receive 100 promotional credits for the first Chromium dataset uploaded to Sentira Single Cell, enough for users to become familiar with the platform and get to experimental conclusions. Credit packs are available in a range of sizes, with volume discounts that lower the price per credit as pack size increases. (See below for more specific pricing information.)</p>
<p><strong>The promise and peril of AI-driven analysis</strong></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>When asked about potential concerns about using AI in this way, Schnall-Levin notes (chuckling) that generally speaking he is “far more nervous about AI risks outside of this.”</p>
<p>One point that they discuss within the company, however, is how—as these tools get more powerful—people may have a tendency to rely on them without thinking. And although 10x does believe that the Sentira tools are accurate, he asserts that they are not perfect. “We don’t want someone to just start putting stuff out in a publication with no additional review. We think that this is a really good way to generate initial analysis and exploration, but people are still on the hook and responsible for it.” People need to understand the power and also the limitations, he notes.</p>
<p>Social media is ripe with discussion on the role of AI in single-cell analysis. Luciano Martelotto, PhD, director of global market development for single cell at Waters Biosciences, has expressed opinions—not about Sentira, specifically—but about using AI to analyze single cell data, in general. He notes one worry which is that “nothing in an AI-generated analysis looks broken. The code runs, the plots are pretty, the story makes sense. The mistakes that matter are the silent ones.”</p>
<p>None of the mistakes are “AI being dumb,” he continues. “It does what it’s asked. What it doesn’t do is get that uneasy feeling when a result looks too good. That feeling comes from having watched data go wrong, and I don’t think it can be prompted or coded into existence… not yet, at least.”</p>
<p>And when data analysis becomes increasingly automated and outsourced, will researchers lose the ability to analyze single cell data on their own?  Schnall-Levin sees this as an age old question about technological progress. He points to how few people today can navigate our location by the stars, because modern technology means that we do not need to. But it is a double-edge sword: expertise may be inevitably be lost as people are empowered to accomplish tasks without having to learn the details. Still, the benefits of these new technologies are very likely to outweigh the downside. Either way, this is the direction the world is moving in, and now the single cell field has another tool to move with it.</p>
<p> </p>
<p><strong>Pricing Information:</strong></p>
<table>
<tbody>
<tr>
<td><strong>Credit Packs</strong></td>
<td><strong>Pack Price</strong></td>
<td><strong>Price per Credit</strong></td>
</tr>
<tr>
<td>10x Cloud Credits – 100 Pack</td>
<td>$120</td>
<td>$1.20</td>
</tr>
<tr>
<td>10x Cloud Credits – 1,000 Pack</td>
<td>$1,150</td>
<td>$1.15</td>
</tr>
<tr>
<td>10x Cloud Credits – 2,000 Pack</td>
<td>$2,200</td>
<td>$1.10</td>
</tr>
<tr>
<td>10x Cloud Credits – 10,000 Pack</td>
<td>$10,500</td>
<td>$1.05</td>
</tr>
<tr>
<td>10x Cloud Credits – 25,000 Pack</td>
<td>$25,000</td>
<td>$1.00</td>
</tr>
</tbody>
</table>
<p>The post <a href="https://www.genengnews.com/topics/omics/sentira-brings-claudes-ai-to-10x-genomics-chromium-platform/">Sentira Brings Claude’s AI to 10x Genomics’ Chromium Platform</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance</title>
<link>https://edusehat.com/en/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance</link>
<guid>https://edusehat.com/en/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance</guid>
<description><![CDATA[ Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the FDA&#039;s new draft guidance for personalized gene therapies.
The post StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1407334381-1068x748-1-1024x717-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 02 Nov 2026 03:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Gene, Editing, Shares, Jump, ESGCT, Data, FDA, Draft, Guidance</media:keywords>
<content:encoded><![CDATA[<p>Shares of gene editing therapy companies mostly surged by double digits this past week on two growth catalysts. One catalyst was expected: The European Society of Gene and Cell Therapy’s <a href="https://www.genengnews.com/topics/genome-editing/hamburg-hosts-2026-european-gene-therapy-conference/">33rd ESGCT Annual Congress</a>, which finished Friday in Hamburg, Germany, brought forth the usual flurry of data presentations, including many positive readouts by developers of new editing-based therapies.</p>
<figure aria-describedby="caption-attachment-340047" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340047" src="https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag-253x300.jpg" alt="" width="253" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag-253x300.jpg 253w, https://www.genengnews.com/wp-content/uploads/2026/10/Diamantas_Kyle_900-x-900_Flag.jpg 370w" sizes="(max-width: 253px) 100vw, 253px"><figcaption class="wp-caption-text">Kyle Diamantas, FDA acting commissioner</figcaption></figure>
<p>The other catalyst happened October 27 when the FDA issued draft guidance (<a href="https://www.regulations.gov/docket/FDA-2026-D-11783">FDA-2026-D-11783</a>) intended to help sponsors develop and pursue approvals for personalized gene therapies designed to treat patients with rare genetic diseases. The guidance, <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval"><em>Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management</em></a>, offers a regulatory framework for submitting and managing Biologics License Applications (BLAs) for individualized genome editing products.</p>
<p>“For patients with rare genetic diseases, a one-size-fits-all approach to treatment simply does not work and neither should a one size fits all approach to regulation,” FDA acting commissioner Kyle Diamantas, said in a statement.</p>
<p>Maury Raycroft, PhD, equity analyst at Jefferies, viewed the draft guidance positively in a Friday note: “Gene editing cos have underperformed the past yr, but we anticipate a range of de-risking data & reg catalysts ahead; recent constructiveness from FDA/gov should keep momentum going.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The draft guidance introduces to the FDA the concept of the Individualized Feature Space (IFS), a set of pre-defined limits describing allowable limits of variation for genome edited (GE) components of an individualized GE product, so such therapies can vary from patient to patient without needing to perform additional clinical trials, while remaining within the scope of a single BLA.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“For a GE product whose only variable feature is a gRNA spacer sequence, the IFS should describe which types of spacer sequences are allowable in the BLA—such as any spacer sequence that targets a defined class of pathogenic gene variants in a specified gene and results in the same editing outcome (e.g., correcting the gene so that it encodes the wild-type protein),” the draft guidance explains.</p>
<p>The FDA is soliciting public comment through November 27, both <a href="https://www.regulations.gov/docket/FDA-2026-D-11783">online</a> and via <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval">mail</a>.</p>
<h4><strong>Mostly positive impact</strong></h4>
<p>Since the draft guidance was issued after the close of markets, investors had to wait until Wednesday to see the impact of the proposed rules plus ESGCT data on gene editing stocks. That impact turned out to be mostly positive, with shares of four gene editing therapy developers <span><strong>rising between 4% and 29%</strong></span>. Even higher gains earlier in the week were dampened by a <span><strong>nearly 3% drop</strong></span> in the Nasdaq Composite on Friday, sparked by disappointing third-quarter earnings reported by tech and artificial intelligence (AI) companies.</p>
<p>The biggest gainer this past week was <strong>Prime Medicine (Nasdaq: PRME)</strong>, whose shares enjoyed a <span><strong>five-day leap of 29%</strong></span> from $3.67 to $4.72—a <span><strong>20% falloff</strong> </span>from the 52-week high Prime reached on Thursday, when its share peaked at $5.91 at 9:57 a.m. ET.</p>
<p>The draft guidance continued a month-long <span><strong>53% surge</strong></span> sparked by a pair of positive clinical developments: Last month Prime received FDA clearance allowing the launch of a planned Phase I/II trial for its <em>in vivo</em> Prime Editor PM647 in alpha-1 antitrypsin deficiency (AATD).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>And on October 5, Prime dosed the first patient in a Phase I/II open-label trial (<a href="https://clinicaltrials.gov/study/NCT07748403">NCT07748403</a>) assessing its <em>in vivo</em> Prime Editor PM577a in adults and teens as a treatment for H1069Q-mutated Wilson disease, the first reported instance of prime editing being used to edit DNA directly in a person. Prime says initial data from the trial is expected in 2027.</p>
<p>“Overall, we see promise over the long-term for the pipeline and could consider becoming more constructive on the stock as we move closer to value-creating milestones (initial clinical data) in 2027,” Tessa T. Romero, a senior analyst focused on biotechnology equity research with J.P. Morgan, commented in a June 18 research note that followed clinical trial clearance for PM577a in New Zealand.</p>
<p>Second highest among editing stocks this week with a <span><strong>13% jump</strong></span> is <strong>Beam Therapeutics (Nasdaq: BEAM)</strong>. The developer of CRISPR base editing therapies saw its shares climb from $24.05 on October 23 to $27.23 Friday, driven in part by positive initial data from its Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT06735755">NCT06735755</a>) showing clinical proof of concept for BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa).</p>
<p>BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, which is associated with the most severe form of GSDIa.</p>
<h4><strong>Maximum outcomes</strong></h4>
<p>As of data cutoff August 17, two of three patients in the trial’s 40 mg cohort achieved the trial protocol’s maximum 15-hour controlled fasting duration—a result consistent with restored endogenous glucose production, Beam said. The two also saw 100% reduction in daily starch requirements, no longer requiring starch supplementation, and improved glucose control with more time spent in the euglycemic range and less in the hyperglycemic range.</p>
<p>“BEAM-301 appears impressive at first clinical data look,” Myles R. Minter, PhD, a partner and biotechnology analyst with William Blair, wrote in a research note. Minter has estimated that BEAM-301 will generate peak annual sales of $475 million.</p>
<p>That would be 31% above the $362 million in peak sales modeled by Minter’s colleague at William Blair, Sami Corwin, PhD, a biotechnology-focused healthcare analyst, for Genglycos® (pariglasgene brecaparvovec-opnr), which won FDA approval in August as the first-ever drug authorized to treat GSDIa in adults and children ages 8 and older. Genglycos is marketed by <strong>Ultragenyx Pharmaceutical (Nasdaq: RARE)</strong>.</p>
<p>The third 40 mg patient showed no time to fasting hypoglycemia (TTH) increase, potentially due to high body mass index (BMI) and heterozygosity for the R83C mutation, according to Beam.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“This could be solved with moving to the higher 60 mg dose or could warrant a BMI restriction in future cohort or even evaluation of potential weight-based dosing,” Minter added.</p>
<p>Based on the data, Beam is advancing BEAM-301 to a 60 mg cohort, where it has begun enrollment, and plans to engage with the FDA about a potential approval path.</p>
<p>Beam and Prime are likely to benefit from the FDA’s framework for genome editing drugs, Jefferies analyst Raycroft said: “We believe the framework could support/accelerate [Beam’s] PKU program entering the clin YE26/early’27 by leveraging data across 3 mut[ation]-specific PAH base editors.”</p>
<p>As for Prime, Raycroft noted that the company has FDA alignment to develop additional mutations under the same IND using most of the H1069Q package: “Follow-on editors may need only mut[ation]-specific off-target work and limited clin data for pot’l licensure.”</p>
<h4><strong>Data presented and awaited</strong></h4>
<p><strong>Editas Medicine (Nasdaq: EDIT) </strong>saw its shares <span><strong>rise 11%</strong></span> this past week, from $2.40 October 23 to $2.67 Friday. The company presented two posters at ESGCT: One detailed a <a href="https://www.editasmedicine.com/wp-content/uploads/2026/10/ESGCT-2026-Poster-P0781_tLNP-Platform-Process_FINAL.pdf">configurable, GMP-ready manufacturing platform for targeted LNP therapeutics</a> shown to enable rapid evaluation of novel binders and cargos while maintaining consistent T-cell targeted LNP (tLNP) quality across scales, binders, and batches.</p>
<p>The other showed robust <em>in vivo</em> delivery of mRNA to targeted T cells using its <a href="https://www.editasmedicine.com/wp-content/uploads/2026/10/ESGCT-2026_poster-P0361_RTO_FINAL.pdf">scalable tLNP platform</a>, which allowed for transient expression of CAR in targeted T cells, resulting in deep B-cell depletion in the blood within 24 hours post-dose. Researchers also reported seeing therapeutically relevant B-cell depletion in lymphoid tissues, “creating the potential for clinically meaningful immune reset for autoimmune therapy.”</p>
<p><strong>Intellia Therapeutics (Nasdaq: NTLA)</strong> shares also <span><strong>grew 11%</strong></span> week-over-week, from $11.21 to $12.47. Intellia investors are also waiting for clinical data on lonvoguran ziclumeran (Lonvo-z), a one-time CRISPR/Cas9 gene-editing therapy being developed to treat hereditary angioedema (HAE). Those results are to be presented in two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, set for November 12–16 in Phoenix. The presentations include four-year follow-up data from patients who received a one-time 50 mg dose of lonvo-z.</p>
<p>On November 12, Intellia executives and HAE key opinion leaders plan to discuss the company’s preparations for the commercial launch of lonvo-z during a conference call with analysts.</p>
<p><strong>CRISPR Therapeutics (Nasdaq: CRSP)</strong> shares <span><strong>rose 4%</strong></span> this past week from $49.39 to $51.42 Friday as investors await third-quarter results set to be released this month, and clinical data updates such as a planned readout from the Phase Ib trial (<a href="https://clinicaltrials.gov/study/NCT07491172">NCT07491172</a>) of CTX310<sup>®</sup>, a CRISPR/Cas9 <em>in vivo</em> gene editing therapy candidate targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia. That data will be presented at the American Heart Association (AHA) Scientific Sessions 2026, set for November 6–9.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Not all editing therapy stocks reaped the fruits of the FDA guidance and ESGCT data announcements. Shares of <strong>Caribou Biosciences (Nasdaq: CRBU)</strong>, a CRISPR therapeutics developer whose co-founders include Jennifer Doudna, PhD, <span><strong>dropped nearly 21%</strong></span> from 53 cents on October 23 to 42 cents Friday. Caribou thus continued a slide triggered by its <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives/">review of strategic alternatives</a> and plans to reduce a “substantial” portion of its workforce—a decline that has caused the company’s stock to <span><strong>plunge 66%</strong></span> over the past month from $1.27 on September 30.</p>
<h4><strong>Anthropic details acquisition, partnerships</strong></h4>
<p>Anthropic used a <a href="https://www.anthropic.com/research/early-progress-drug-development">press release</a> rather than the <a href="https://www.sec.gov/Archives/edgar/data/2130357/000162828026067168/anthropicpbc-sx1.htm">Form S-1 Registration Statement</a> disclosing its initial public offering (IPO) plans to flesh out its progress and plans in the drug development space it has targeted as one key area of future growth.</p>
<p>The AI giant—which <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-ipo-discloses-plans-for-life-sciences-growth/">filed for its long-awaited IPO </a> on October 26—acknowledged pursuing its own drug discovery efforts and disclosed that in August, it acquired Mithril Medicine, a developer of treatments for two rare forms of muscular dystrophy staffed by a single person, founder Cody Tranbarger, a biotech entrepreneur and investor. Tranberger used Claude to organize contracts, logistics, and experiments with 11 external labs, as well as to delegate “many other aspects of Mithril’s operations.” Mithril has advanced within 18 months a therapy for one form of muscular dystrophy from an idea to positive results in mice.</p>
<p>“If his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028,” Anthropic predicted.</p>
<h4><strong>“Deep research partnerships”</strong></h4>
<p>Anthropic also listed a series of six “deep research partnerships” with drug developers. Two of the six are public companies, <strong>Bristol Myers Squibb (BMS; NYSE: BMY)</strong> and <strong>Generate: Biomedicines (Nasdaq: GENB)</strong>, which in February <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-ai-drug-developer-generates-400m-ipo/">carried out its own $400 million IPO</a> (of which $369.3 million was net proceeds). The other four partners are private companies: <strong>BigHat Biosciences</strong>, <strong>Divergence Labs</strong>, <strong>Enveda</strong>, and <strong>The Column Group (TCG)</strong>.</p>
<p>Anthopic’s release also offered some details of its work with collaboration partners:</p>
<ul>
<li><strong>BMS:</strong> The pharma giant used Anthropic’s Claude family of large-language models to estimate the likelihood of success for planned clinical trials of an unidentified early-stage drug. “Together, we plan to expand this work in 2027 to understand its potential for increasing the probability of success in early development,” Anthropic said.</li>
<li><strong>Generate:</strong> Six Generate scientists used Claude Code to propose new designs for part of a chimeric antigen receptor T cell (CAR T) therapy’s genetic instructions, creating room for additional instructions addressing other types of cancer. One design “about 70%” shorter showed greater effectiveness than the standard version in lab tests: “Compact ICDs [intracellular domains] may lower the dose needed to generate CAR T cells <em>in vivo</em> and enable more complex CAR therapies, such as CAR cocktails,” <a href="https://generatebiomedicines.com/wp-content/uploads/2026/10/refactored-intracellular-domains-enhance-car-expression-and-function.pdf">Generate concluded</a>.</li>
<li><strong>BigHat:</strong> Researchers from the protein and antibody drug developer joined Anthropic in applying Claude to <a href="https://cdn.prod.website-files.com/64ff35ef45fc1e4545e5ffa1/6ae0ea8e28d4a390cbe66b52_bighat_pilot_retro_final_v2.pdf#navpanes=0">improve binding, stability, and anti-clumping properties</a> of two antibody fragments that could become parts of future drugs: one designed to target cancer cells, and one designed to keep a drug in the body longer.</li>
<li><strong>Enveda:</strong> The developer of molecules based on living organisms “reduced human review time by 89%, from over 25 hours to less than three, by linking its manufacturing documents to Claude. After reviewing 1,061 pages of documentation, Anthropic Claude caught all 11 issues that human reviewers had spotted and flagged seven they missed: “A promising development for future use cases in decreasing the time, cost, and error rates in drug development,” <a href="https://enveda.com/CMC-Document-Processor/">Enveda concluded</a>.</li>
<li><strong>TCG:</strong> A spinout of the venture capital firm, called Pleiades, will use Claude to reduce scientific, operational, and administrative overhead as it runs more, and more complex, drug development programs “than is usual for a small team,” Anthropic said, adding: “The savings will enable previously untenable risks on a larger array of challenging and innovative projects.”</li>
<li><strong>Divergence:</strong> Using Claude, the food allergy drug developer generated “roughly 35,000” antibody designs in about a month for testing. Divergence found three design arms designed to bind tightly to IgE, and 20 that could help dislodge IgE from the immune cell (three of which dislodged more IgE than standard medication). Divergence plans to build a drug that combines the two types of arms, <a href="https://divergencelabs.com/publications/ige-preprint.pdf">stating in a study</a>: “We expect biparatopic construction … to provide a significant boost to potency and disruptive efficacy.”</li>
</ul>
<p>In a <a href="https://www.linkedin.com/feed/update/urn:li:activity:7521638389297618945/">LinkedIn post</a>, however, Geoff Harris, PhD, CSO and co-founder of Excellergy—an indirect, wholly owned subsidiary of <strong>Novartis (SIX Swiss: NOVN and NYSE: NVS) </strong>acquired for up to $2 billion in June—said Divergence Labs’ study “doesn’t describe a drug, but the components of what might be a drug someday, maybe, which is years behind the competition.”</p>
<p>“A monoclonal antibody drug that is exceptional at disarming the IgE axis already exists and is in the clinic today,” Harris added, namely Excellergy’s lead candidate EXL-111, a trifunctional allergic effector cell response inhibitor designed to treat allergic diseases by targeting the IgE axis. EXL-111 is in a Phase I trial (<a href="https://clinicaltrials.gov/study/NCT07356713">NCT07356713</a>) with an estimated primary completion date of December 7.</p>
<p>Anthropic says it envisions Divergence and its other partners applying Claude to ultimately bring their candidates into the clinic as well: “We plan to continue extending Claude’s role into clinical trials as these drug programs advance, and as we partner with more organizations whose drug development programs are already at the clinical stage.”</p>
<h4><strong>Leaders and laggards</strong></h4>
<p><strong>Acumen Pharmaceuticals (Nasdaq: ABOS)</strong> shares <span><strong>cratered 91%</strong> </span>from $2.29 to just 21 cents Friday after the developer of Alzheimer’s disease (AD) drugs targeting amyloid beta oligomers announced that it was ceasing development of its lead pipeline candidate sabirnetug (ACU193) and evaluate its strategic options after the humanized monoclonal antibody failed the Phase II ALTITUDE-AD trial (<a href="https://clinicaltrials.gov/study/NCT06335173">NCT06335173</a>) in participants with early AD. Sabirnetug missed its primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months vs. placebo at either the 35 mg/kg or the 50 mg/kg dose. Sabirnetug also failed to achieve statistical significance on key secondary efficacy endpoints, including the Clinical Dementia Rating–Sum of Boxes (CDR-SB), and did not show any meaningful difference between the sabirnetug and placebo treatment arms. Acumen said it plans to take steps to carry out cash conservation measures and explore strategic options.</p>
<p><strong>Aspen Neuroscience (ASPE) </strong>shares <span><strong>dipped 0.7%</strong></span> from its initial public offering (IPO) price of $15 a share to $14.89 Friday as the developer of autologous induced-pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases began its first full day of trading. Shares began the day at $14.70, below the IPO price—the low end of its $15-$17 price range when it priced 9.375 million shares, raising $140.625 million in gross proceeds. Proceeds are intended to fund clinical trials for its lead candidate, the Parkinson’s disease therapy sasineprocel, now in the Phase I/IIa ASPIRO open-label dose escalation study (<a href="https://clinicaltrials.gov/study/NCT06344026">NCT06344026</a>), as well as development of the company’s microglia programs, including initiating IND-enabling studies.</p>
<p><strong>Genmab (Nasdaq: GMAB) </strong>shares <span><strong>jumped 28% </strong></span>from $44.67 to $57.29 Wednesday after the antibody drug developer announced data from the global Phase III LiGeR-HN1 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06525220&data=05%7C02%7Calex.philippidis%40sagepub.com%7C131a0ad3a85b4a2196a708df362706b1%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639289213847837766%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=F7Z5EC0YjX9EddbZXCq2F5TVWspvkNjDkg%2FKyTmFnZ0%3D&reserved=0">NCT06525220</a>) assessing petosemtamab in combination with pembrolizumab, the cancer immunotherapy blockbuster marketed by <strong>Merck & Co. (NYSE: MRK)</strong> as Keytruda®, vs. pembrolizumab alone in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Based on the first interim analysis assessed by an independent data monitoring committee, treatment with the petosemtamab combination showed a “statistically significant and clinically meaningful” improvement in overall survival (OS), reducing the risk of death by 50%, and objective response rate (ORR) vs. pembrolizumab [OS hazard ratio 0.50, p<0.0001; ORR odds ratio 3.17 p<0.0001), meeting the trial’s dual primary endpoints regardless of HPV status.</p>
<p><strong>Iovance Biotherapeutics (Nasdaq: IOVA)</strong> shares <span><strong>tumbled 35%</strong></span> from $14.81 to $9.56 Thursday after the tumor infiltrating lymphocyte (TIL) cell therapy developer announced data from Cohorts 1 and 2 of its Phase II IOV-LUN-202 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04614103&data=05%7C02%7Calex.philippidis%40sagepub.com%7C131a0ad3a85b4a2196a708df362706b1%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639289213847909389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=c5nxp6oOYcCUls%2Fe3WaUlxpyB%2F75klzTvl85Ch11Smo%3D&reserved=0">NCT04614103</a>) evaluating lifileucel in previously treated metastatic non-small cell lung cancer. As of the October 14 data cutoff 17 of 69 patients responded, an ORR of 24.6%, consistent with the 25.6% ORR previously reported in 39 patients but less than what investors expected. Iovance said a retrospective analysis found a biomarker-enriched subgroup defined by Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>) wild-type status, human epidermal growth factor receptor 2 (<em>HER2</em>) wild-type status, and current or former smoking.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance/">StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>100 Million&#45;Cell AI&#45;Ready Dataset with Single&#45;Cell and Proteomic Data Created by Parse and Nomic</title>
<link>https://edusehat.com/en/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic</link>
<guid>https://edusehat.com/en/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic</guid>
<description><![CDATA[ Parse Biosciences and Nomic Bio are partnering to create Cascade, a 100-million-cell multimodal dataset combining single-cell and proteomic data to advance AI-driven immune modeling, drug discovery, and therapeutic target identification.
The post 100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2242943155.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 04:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>100, Million-Cell, AI-Ready, Dataset, with, Single-Cell, and, Proteomic, Data, Created, Parse, and, Nomic</media:keywords>
<content:encoded><![CDATA[<p>Parse Biosciences, a QIAGEN company and a provider of scalable and accessible single-cell sequencing, and Nomic Bio, focused on high-throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset’s scale and depth will offer pharma partners cellular- and protein-level insight into immune biology, with the goal to accelerate their ability to identify and validate new drug targets.</p>
<p>Cascade is a multimodal, perturbation dataset that captures how immune cells respond to treatment across multiple timepoints. The dataset will combine 100 million single-cell RNA-seq profiles with more than 11,000 proteomic secretome profiles, capturing how different immune cell types respond to over 150,000 individual and combinatorial cytokine and drug perturbation conditions. By pairing transcriptomic and proteomic readouts of the same immune responses over time, Cascade will provide researchers a view into the mechanisms driving human immune signaling, filling a critical data gap for building predictive, virtual cell models.</p>
<p>Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug discovery.</p>
<p>The single-cell RNA-seq data generation will be performed in Parse’s GigaLab, a high throughput service lab capable of profiling billions of cells a year. These data will be paired with proteomic secretome data that will be generated through Nomic’s Omini 1000 platform, which will measure more than 1,000 secreted proteins across all samples.</p>
<p>“Biological AI modeling has hit a data bottleneck. Despite their central role in drug discovery, there is a surprisingly small amount of available data measuring the human’s immune response to key perturbations like cytokines and other drugs,” notes Charlie Roco, PhD, co-founder and chief technology officer at Parse Biosciences. “Cascade is a critical step to revealing these interactions, and we expect to dramatically improve the predictive power of our partner’s AI models as a result.”</p>
<p>
</p><p>The post <a href="https://www.genengnews.com/topics/omics/100-million-cell-ai-ready-dataset-with-single-cell-and-proteomic-data-created-by-parse-and-nomic/">100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure</title>
<link>https://edusehat.com/en/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure</link>
<guid>https://edusehat.com/en/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure</guid>
<description><![CDATA[ According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI and robotics systems.
The post Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/Trends-Automation-GettyImages-2210278635.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 04:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Opentrons, Raises, 40M, Series, Expand, Its, Robotics, Software, Data, Infrastructure</media:keywords>
<content:encoded><![CDATA[<p><span>Opentrons Labworks has raised $40 million from a Series E financing round led by healthcare investor Avego, with additional investment from BroadOak Capital Partners. The company has said that it plans to use the capital to scale its robotics, software, and data infrastructure tools.</span></p>
<p><span>Specifically, the funds will support the company’s efforts to design artificial intelligence and robotics systems that work together to design, execute, and learn from scientific experiments. This includes investing in AI-driven experimental execution, extending its automation capabilities, and expanding into new markets and geographies. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>Additionally, the funds will allow Opentrons to enable faster protocol development through its software and AI, expand capabilities across its robots and instruments, and provide deeper integration of its tools into the broader lab automation ecosystem. </span></p>
<p><span>“Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data,” said James Flexner, managing partner at Avego. “We see a significant opportunity for autonomous science to converge around Opentrons’ platform.” James Atwood, PhD, Opentrons’ CEO, added “we made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardizing on Opentrons.”</span></p>
<p><span>Opentrons reports that to date, it has deployed over 11,000 robots to laboratories in over 80 countries. Its customer base includes academic groups, diagnostic labs, and global pharmaceutical companies, Earlier this year, the company announced that it is using <a href="https://www.genengnews.com/topics/drug-discovery/opentrons-uses-nvidia-tech-to-build-training-data-that-powers-physical-ai-in-the-lab/" target="_blank" rel="noopener">Nvidia’s Isaac and Cosmos AI platforms</a> to generate training data needed to develop and deploy physical AI-enabled laboratory robotics.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/opentrons-raises-40m-in-series-e-to-expand-its-robotics-software-data-infrastructure/">Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>No Nonsense: David Liu Lauds Progress in Disease&#45;Agnostic Gene Editing at ESGCT</title>
<link>https://edusehat.com/en/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct</link>
<guid>https://edusehat.com/en/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct</guid>
<description><![CDATA[ Liu ensured that his return visit to ESGCT (having spoken at the congress in Barcelona in 2019) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”
The post No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 01:10:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nonsense:, David, Liu, Lauds, Progress, Disease-Agnostic, Gene, Editing, ESGCT</media:keywords>
<content:encoded><![CDATA[<p><strong>HAMBURG</strong>—The distinguished researcher who had the dubious honor of speaking before David Liu, PhD, in a plenary session at the European Society of Gene & Cell Therapy (ESGCT)—2018 Kavli Award winner Virginijus Siksnys, PhD—opened his talk with a bashful admission: “I’m just the warm up for David,” the Lithuanian chuckled.</p>
<figure aria-describedby="caption-attachment-340012" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-340012 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-300x189.jpg" alt="" width="300" height="189" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-300x189.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-1024x645.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited-768x484.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCTPodium_edited.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">David Liu, PhD, speaking at ESGCT 2026, Germany. [K. Davies]</figcaption></figure>
<p>Liu ensured that his return visit to ESGCT (having spoken at the congress in <a href="https://www.genengnews.com/topics/genome-editing/promising-results-reported-in-tay-sachs-gene-therapy-trial/" target="_blank" rel="noopener">Barcelona in 2019</a>) would be one of the highlights of the conference. The “meta lesson” of the past few years in therapeutic genome editing, Liu began, is that different scientific approaches and applications can synergize with regulatory, manufacturing, and economic advances “to achieve the mission we’re on.”</p>
<p>That mission is already confronting the immense challenge of expanding the early clinical promise of genome editing beyond the vanishingly long tail of genetic diseases. There are more than 200,000 known mutations responsible for some 8,000 known genetic diseases, affecting roughly 400 million families.</p>
<p>Liu’s journey into precision genome editing kicked off ten years ago with the publication of the first landmark base editing report. Prime editing (PE) was described three years later. The two technologies, both building off the CRISPR-Cas chassis, provide a vast repertoire of potential gene edits encompassing single-base substitutions and are being commercially driven by two biotech companies co-founded by Liu—Beam Therapeutics and Prime Medicine.</p>
<h4><strong>AI and PE </strong></h4>
<p>Liu gave two examples of how his lab is integrating artificial intelligence (AI) into the development of enhanced prime editing technology.</p>
<p>In the first example, <a href="https://www.nature.com/articles/s41586-026-10820-0" target="_blank" rel="noopener">published a few months ago in <em>Nature Biotechnology</em></a>, Liu’s lab used an AI tool called ProteinMPNN to improve the overall attributes of prime editors. In 2023, Liu’s lab used phage-assisted continuous evolution (PACE) to evolve prime editors in the lab. Although these evolved PE6 prime editors had higher activity, they tended to exhibit lower stability and expression levels.</p>
<p>ProteinMPNN, Liu said, excels at the inverse protein folding problem: generating sequences that can fold stably into a given structure. By allowing ProteinMPNN to redesign as many as 25 percent of the reverse transcriptase amino acids, the researchers were able to remedy stability deficits. The new PE8 variants show stronger expression and editing efficiencies in various cell types.</p>
<p>Another recent paper describes <a href="https://www.nature.com/articles/s41587-026-03261-7" target="_blank" rel="noopener">the development of a free machine learning tool called OptiPrime</a> to predict prime editing outcomes. “We can’t call it Optimus Prime or Hasbro would sue us,” Liu joked.</p>
<p>Each pegRNA contains multiple regions that are subject to variability that can significantly impact PE efficiency. OptiPrime helps simplify the search through potentially hundreds of potential pegRNA variants that can all in principle engineer the same edit. Researchers can use the <a href="https://optipri.me/" target="_blank" rel="noopener">OptiPri.me website</a> to generate a rank-ordered list of the top pegRNA candidates. The relevant information can be copied and pasted into the online order forms for a researcher’s favorite gene synthesis service.</p>
<figure aria-describedby="caption-attachment-340008" class="wp-caption aligncenter"><img decoding="async" class="wp-image-340008" src="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-1024x758.jpg" alt="David Liu, PhD, speaking in a plenary session at ESGCT 2026" width="500" height="370" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-1024x758.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-300x222.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage-768x569.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/KevinDavies_DavidLIu_ESGCT_stage.jpg 1400w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">David Liu, PhD, speaking in a plenary session at ESGCT 2026 in Hamburg, Germany. [K. Davies]</figcaption></figure>
<h4><strong>Ten years after </strong></h4>
<p>By any measure, the pace of uptake and clinical potential of base and prime editing has been remarkable. Liu counted nine examples—representing he estimated one person-century of work—of precision genome editing rescuing disease phenotypes in animal models, including progeria, sickle cell disease, cystic fibrosis, phenylketonuria, and spinal muscular atrophy.</p>
<p>Several programs have progressed to IND-enabled studies and encouraging clinical results. In March 2025, Beam Therapeutics reported the first clinical correction of a human pathogenic mutation, a subject with alpha-1 antitrypsin deficiency (BEAM-302). Around the same time, <a href="https://www.genengnews.com/topics/genome-editing/asgct-2025-worlds-first-patient-treated-with-personalized-crispr-therapy/?_gl=1*z8smdu*_up*MQ..*_ga*NDA0NjcwOTU3LjE3OTMyOTE3NDY.*_ga_F1EYPPYL3X*czE3OTMyOTE3NDYkbzEkZzAkdDE3OTMyOTE3NDYkajYwJGwwJGg5NzcwODI2OTA." target="_blank" rel="noopener">the Baby KJ story</a>, which revolved around bespoke base editing, captured the world’s attention, revealing that even babies aren’t prisoners to the mutations in their DNA.</p>
<p>Liu also pointed to clinical progress in prime editing. In April 2025, the first <em>ex vivo</em> prime editing patient—57-year-old Tracy Atteberry—was dosed (<a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2509807" target="_blank" rel="noopener">reported at the end of 2025</a> by Jennifer Gori, PhD, and colleagues). The 57-year-old Atteberry, from Nebraska, received prime-edited stem cells engineered to repair the two-base gene deletion. And in October, the first patient was dosed in an <em>in vivo </em>prime editing trial for Wilson disease (PM577a).</p>
<p>Liu said he was feeling optimistic because regulators in the U.S., U.K. and elsewhere in general “are not standing in the way.” There seems to be “a liberalization of policies around initiation and BLAs for drug approval.” Indeed, the day before Liu’s lecture, the U.S. Food and Drug Administration issued a well-received draft guidance, “<a href="https://www.fda.gov/media/195887/download" target="_blank" rel="noopener">Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management</a>.”</p>
<h4><strong>Disease agnostic approach</strong></h4>
<p>Liu closed by focusing on his group’s work in developing a multi-disease therapeutic approach using only a single treatment, which would benefit more patients than just those with a very rare mutation. Around 30 percent of genetic diseases feature at least one premature stop codon. As was <a href="https://www.genengnews.com/topics/genome-editing/single-prime-editing-platform-shows-potential-vs-multiple-diseases/" target="_blank" rel="noopener">reported last year</a>, Liu’s team has pursued the idea of using suppressor tRNAs, which can read through the stop (or nonsense) codon, thereby restoring production of a full-length protein.</p>
<p>“A tRNA approach enables far fewer drugs to target a larger number of mutations/diseases,” Liu said.</p>
<p>There are 418 tRNA genes in the human genome, signaling considerable redundancy in translation as there are only 61 coding triplets. “You don’t need 418 tRNA genes,” he said. Many humans are lacking at least one of these tRNA genes, showing that humans can tolerate tRNA mutations. Liu’s idea was to “convert a dispensable tRNA into a permanent tRNA suppressor,” a method called prime editing-mediated readthrough of premature termination codons (PERT), which could be used as a one-time treatment for multiple genetic diseases that shared the same premature stop codon.</p>
<p>Led by postdoc Sarah Pierce, PhD, Liu’s lab used prime editing to convert each of the 418 human tRNAs into a suppressor tRNA, engineering each anticodon to the three triplets (CUA, UCA, and UUA) that recognize the three stop codons. As described in the 2025 paper, Liu’s team chose to focus on a leu tRNA, which exhibited the highest suppression activity. This was converted into an optimized suppressor.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“We’re not over-expressing this optimized suppressor tRNA,” Liu said. By only making about 40% of the tRNA that was replaced, Liu said he was “optimistic we can achieve suppression without over expression.” The most promising data so far comes from the use of PERT to treat a mouse model of Hurler syndrome. PERT treatment led to the expression of about seven percent of the wild-type enzyme activity, which Liu suggested “can rescue the disease.”</p>
<p>Although it is early days, Liu closed by saying he was “very hopeful that various therapeutic approaches… will help increase the applicability of gene editing to more and more patients.” However, “until regulatory streamlining and clinical derisking continues to drive the risk and cost lower and lower, the vast majority of genetic disease remain too rare to be pursued by industry.”</p>
<p>In one new effort to tackle rare diseases, researchers at the Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory have partnered to establish a non-profit collaboration called the <a href="https://www.jax.org/news-and-insights/2026/july/jax-launches-the-center-for-therapeutic-genetics" target="_blank" rel="noopener">Center for Therapeutic Genetics</a> (CTG) that, Liu said, “we hope is mimicked everywhere… to connect patients with rare diseases.”</p>
<p>The project has received initial commercial support from several companies, including Apertura and Viralgen, as well as Liu’s gene editing companies, Beam Therapeutics and Prime Medicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/no-nonsense-david-liu-lauds-progress-in-disease-agnostic-gene-editing-at-esgct/">No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice</title>
<link>https://edusehat.com/en/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice</link>
<guid>https://edusehat.com/en/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice</guid>
<description><![CDATA[ Scientists identified a potential therapeutic target for pancreatic ductal cell adenocarcinoma, discovering that the protein ANO6 is involved in a process helping pancreatic cancer cells obtain nutrients from surrounding cells, while suppressing the immune system’s ability to fight tumors. 
The post Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_nature-cancer-cover-art.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 31 Oct 2026 01:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Blocking, Protein, Slows, Pancreatic, Tumor, Growth, and, Reduces, Immune, Suppression, Mice</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at Fox Chase Cancer Center have identified a protein called anoctamin 6 (ANO6) as potential therapeutic target for pancreatic ductal cell adenocarcinoma (PDAC), the most common form of pancreatic cancer. The team’s research discovered that ANO6 helps pancreatic cancer cells obtain nutrients from surrounding cells while suppressing the immune system’s ability to fight tumors. In particular, ANO6 enables cancer-associated fibroblasts (CAFs)—cells that make up much of the dense tissue surrounding pancreatic tumors—to transfer cholesterol and other lipids to cancer cells.</p>
<p>In preclinical tests the scientists demonstrated that blocking ANO6 slowed tumor growth and reduced immune suppression. “These findings help explain how pancreatic cancer cells obtain essential nutrients despite the unusual structure of the pancreatic tumor microenvironment,” said Igor Astsaturov, MD, PhD, a professor at Fox Chase. “Cancer-associated fibroblasts are not passive bystanders. They actively support tumor growth by transferring lipids to cancer cells.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Astsaturov is co-senior author of the researchers’ published paper in <em>Nature Cancer</em>, titled “<a href="https://doi.org/10.1038/s43018-026-01265-5" target="_blank" rel="noopener">ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression</a>,” in which they reported “Blockade of ANO6 antagonizes tumor growth, partly by disrupting cholesterol delivery to cancer cells, and attenuates immune suppression, identifying ANO6 as a candidate therapeutic target in PDAC.”</p>
<p>Pancreatic ductal adenocarcinoma is surrounded by dense connective tissue and has relatively few functional blood vessels as these collapse due to the expansion of CAFs and their self-generated collagenous fibers acting as a functional unit. How cancer cells obtain nutrients such as cholesterol in this environment isn’t well understood. “How PDAC cells obtain membranous lipids such as cholesterol has, therefore, remained unclear and resolving this could reveal a therapeutic strategy,” the authors wrote.</p>
<p>“We found that CAFs can act as a source of these nutrients,” said co-senior author Edna Cukierman, PhD, professor and co-leader of the Cancer Signaling and Microenvironment Program at Fox Chase. “Using laboratory and animal models, we discovered that CAF units acquire cholesterol from the bloodstream and transfer it to nearby pancreatic cancer cells through a process called trogocytosis.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The study showed that during trogocytosis, cancer cells take small pieces of the CAF cell membranes, allowing them to acquire cholesterol and other lipids needed for survival and growth. In their paper the authors further explained, “… we show that CAFs transfer exogenous cholesterol and other nutrients through contact-dependent transfer of plasma membrane (PM) fragments, a process known as trogocytosis (trogo, ‘to gnaw’), whereby PDAC cells nibble CAF membranes.”</p>
<p>The process depends on ANO6, which helps prepare the CAF membrane for transfer. When researchers reduced or eliminated ANO6 in CAFs, the cells were less able to support pancreatic cancer cell survival as effectively. In mouse models, tumors supported by ANO6-positive CAFs grew substantially faster than those without functional ANO6.</p>
<p>The study also showed that the same process can interfere with the immune response. CAFs form direct contacts with cytotoxic T lymphocytes (CTLs), immune cells that can recognize and kill cancer cells. During these interactions, the T cells can acquire CAF membrane material, including cholesterol. Excess cholesterol in the tumor environment can contribute to T-cell exhaustion, making the immune cells less effective.</p>
<p>“CAFs also inhibit T cell activity in pancreatic tumors, a major barrier to immunotherapy in this cancer type,” the investigators noted. “We link this immunosuppression to trogocytosis of the CAF membrane by cytotoxic T lymphocytes (CTLs), which causes CTL exhaustion, and show that ANO6 inhibition in CAFs attenuates it.”</p>
<p>Astsaturov further commented, “With Serge Fuchs, professor at the University of Pennsylvania and co-author on the paper, we were surprised to find that the same cellular mechanism can benefit the tumor in two ways—by supplying cancer cells with lipids while also weakening cancer-fighting T cells. Targeting ANO6 could potentially disrupt both of these tumor-supporting functions at the same time.”</p>
<p>The team’s studies in mouse models showed that blocking ANO6 reduced cholesterol accumulation in tumor-infiltrating T cells and improved markers of T-cell activity. Laboratory experiments also showed that T cells exposed to CAFs with reduced ANO6 had greater cancer-killing activity. Cukierman commented “Excitingly, reducing ANO6 expression also disrupted the stromal synapse-mimicry circuit we previously identified, which coordinates tumor nutritional support, CAF-unit metabolism, and immune suppression. These findings position ANO6 as the missing mechanistic link that unifies nearly a decade of discoveries by our team.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The researchers tested whether disrupting ANO6 could slow pancreatic cancer growth. In mouse models, treatment with the niclosamide or clofazimine—drugs that inhibited ANO6-dependent activity in the study—significantly reduced tumor weight. Niclosamide also reduced the delivery of cholesterol to pancreatic cancer cells.</p>
<p>The researchers noted that trogocytosis is one of several ways pancreatic cancer cells may obtain lipids, and that further research is needed to determine whether selectively targeting ANO6 could be an effective treatment strategy. The ANO6-targeting drugs used in the study may also be deployed to treat other recalcitrant cancers beyond pancreatic adenocarcinoma. And as the team further noted, “Both agents may inhibit targets unrelated to ANO6 and there remains a possibility that their antitumor activity is not exerted solely through trogocytosis.”  Still, they stated, “With that caveat, these well-tolerated and inexpensive compounds provide a tractable pharmacological entry point for testing ANO6 blockade and support the development of selective ANO6 inhibitors for CAF-rich desmoplastic tumors such as pancreatic cancer.”</p>
<p>Astsaturov added, “We believe our findings identify ANO6 as a potential therapeutic target that could simultaneously disrupt the nutrient supply supporting pancreatic cancer cells and reduce the immune-suppressive effects of the tumor microenvironment.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/blocking-protein-slows-pancreatic-tumor-growth-and-reduces-immune-suppression-in-mice/">Blocking Protein Slows Pancreatic Tumor Growth and Reduces Immune Suppression in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Eating disorders are on the rise. GLP&#45;1s could make things worse.</title>
<link>https://edusehat.com/en/eating-disorders-are-on-the-rise-glp-1s-could-make-things-worse</link>
<guid>https://edusehat.com/en/eating-disorders-are-on-the-rise-glp-1s-could-make-things-worse</guid>
<description><![CDATA[ GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/261028_GLP1EatingDisorder.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 18:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Eating, disorders, are, the, rise., GLP-1s, could, make, things, worse.</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Eating disorders are surging globally:</strong> A new study in JAMA Psychiatry found anorexia and bulimia rose 71% between 1990 and 2023, affecting an estimated 18.1 million people—and experts say the true number affected by eating disorders is likely three times higher.</li><br><li><strong>Social media is fueling the crisis:</strong> TikTok's algorithm served users with eating disorders 4,343% more harmful content than those without—and clinicians say "thinspiration" trends can trigger new cases.</li><br><li><strong>GLP-1 drugs are making things worse:</strong> Experts are already seeing patients—some as young as 11—misusing weight-loss drugs</li></ul>" data-chronoton-post-id="1147838" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders.</p>



<p class="wp-block-paragraph">A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023, there were an estimated 18.1 million people living with one of these two disorders.</p>





<p class="wp-block-paragraph">What’s worse is that the number is likely to be much higher than that once we factor in other eating disorders. And, disturbingly, those in the field are already starting to see GLP-1 weight-loss drugs exacerbating the issue.</p>



<p class="wp-block-paragraph">Cheri Levinson is a clinical psychologist at the University of Louisville in Kentucky who has specialized in eating disorders for almost 20 years. She says she’s now seeing more patients with more severe symptoms than at any other time in her career, and that many of them are misusing GLP-1s. “This is the worst I’ve seen things,” she says.</p>



<p class="wp-block-paragraph">Eating disorders are mental health conditions in which people’s eating behaviors impact their health. They include anorexia nervosa (defined by a fear of weight gain), bulimia nervosa (in which people binge and purge), binge eating disorder, and others.</p>



<p class="wp-block-paragraph">It’s thought that some people have a genetic predisposition to certain eating disorders, but that some external factor is what triggers their onset. That might be stress, or social pressure to be skinny. Often, simply restricting food intake can trigger an eating disorder, says Levinson.</p>



<p class="wp-block-paragraph">Eating disorders—along with the pressure to look thin—were already prevalent in the 1990s (the <a href="https://www.cosmopolitan.com/lifestyle/a73344972/fashion-week-smoking-skinny-heroin-chic/">heroin chic</a> era springs to mind). To find out how things might have changed since then, Ruhai Bai at the Children’s Hospital of Nanjing Medical University in China and his colleagues pulled together data from studies and surveys conducted on populations around the world. The team used statistical models to fill in any data gaps.</p>



<p class="wp-block-paragraph">That research allowed the researchers to estimate the annual incidence of two eating disorders—anorexia nervosa and bulimia nervosa—for each of 204 countries and territories between 1990 and 2023. They also estimated the impact those disorders had on global health by calculating their disability-adjusted life years (one <a href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/global-health-estimates-leading-causes-of-dalys/">DALY</a> represents a year of healthy life lost).</p>



<p class="wp-block-paragraph">The findings, <a href="https://media.jamanetwork.com/media-releases/10.1001/jamapsychiatry.2026.3457">published in <em>JAMA Psychiatry</em></a> on Wednesday, are unsettling. Between 1990 and 2023, there was a 71% increase in the incidence of those two eating disorders, the team found. Those conditions had a huge impact on global health, too. In 2023, they “cost the world the equivalent of about 3.83 million years of healthy life,” says Bai.</p>





<p class="wp-block-paragraph">Bai and his colleagues expect these figures to continue to rise. In 2023, an estimated 18.1 million people had either anorexia nervosa or bulimia nervosa; by 2050, the team predict, the two conditions could affect 21.8 million people.</p>



<p class="wp-block-paragraph">It gets worse. Those two conditions represent less than half of all eating disorders, says Levinson, who was not involved in Bai’s study. The true impact of these disorders is “probably three times the rate that they’re reporting,” she says.</p>



<p class="wp-block-paragraph">Bai and his colleagues didn’t explore the reasons for this rise (although Bai points out that it can’t be entirely explained by population growth). So how did we get here?</p>



<p class="wp-block-paragraph"><strong>Social media may have played a role.</strong> “Social media comparisons, influencers, challenges, diet trends can all be precipitating … events for an eating disorder,” says Cynthia Bulik, a clinical psychologist at the University of North Carolina, who was not involved in the new study. Bulik has been studying and treating eating disorders since the early 1980s. “Between 1990 and 2023 there has clearly been an upsurge of those types of environmental exposures,” she says.</p>



<p class="wp-block-paragraph">Many social media users are exposed to filtered and modified images of skinny influencers who may have undergone cosmetic surgery or extreme dieting and who are promoting “thinspiration” or “fitspiration” content. But users with eating disorders appear to be more likely to engage with this content—and to be fed more of it as a result.</p>



<p class="wp-block-paragraph">When researchers at the University of Melbourne <a href="https://www.sciencedirect.com/science/article/pii/S1740144524001293">investigated this phenomenon</a> a couple of years ago, they found that the algorithms of TikTok users with eating disorders delivered 4343% more “toxic eating disorder videos” than those of users who didn’t have the disorders. They also got more content focused on dieting or exercising. Many were fed over 1000 problematic videos per month. Bulik describes social media as “quicksand” for people with, or at risk of, eating disorders.</p>



<p class="wp-block-paragraph">The covid-19 pandemic—and the social isolation that accompanied lockdowns—also appears to have contributed to the rise in eating disorders. Research conducted in 2021 found that the number of people hospitalized with eating disorders in the US <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786185"><em>doubled</em> between 2018 and 2020</a>.</p>





<p class="wp-block-paragraph">Researchers don’t yet have good data on how trends in eating disorders might have progressed since 2023. But anecdotally, things seem to be getting even worse. “There are more eating disorders, more severe eating disorders… and we’re seeing earlier ages of onset,” says Levinson. “We’re seeing eight- and nine-year-olds with eating disorders.”</p>



<p class="wp-block-paragraph"><strong>“From what I’m hearing and seeing, I am not going to be surprised if that number isn’t at least doubling again,” she adds.</strong></p>



<p class="wp-block-paragraph">Levinson particularly worries about the impact of GLP-1 weight-loss drugs, which have exploded in popularity in recent years. A <a href="https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx">Gallup survey</a> conducted earlier this year suggested that 15% of Americans had used one of these drugs for weight loss. And they’re becoming more accessible—drug companies are working on new formulations that are both easier to take and more effective, and many people can buy versions of these drugs from compound pharmacies or dubious online sources.</p>



<p class="wp-block-paragraph">In <a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2850584">a small study</a> published earlier this year, Levinson and her colleagues found that 30% of people with eating disorders had used GLP-1 drugs. The drugs might benefit some of those people. But 10% appeared to have misused the drugs. And Levinson thinks that figure is also an underestimate.</p>



<p class="wp-block-paragraph">Levinson says she and her colleagues have seen children develop eating disorders after being prescribed GLP-1s for medical reasons. They’ve seen others—even children as young as 11—buy versions of these drugs over TikTok.</p>



<p class="wp-block-paragraph"><strong>“We’re very concerned that GLPs will lead to even faster and more extreme weight loss</strong> in people with anorexia nervosa, and that patients will come to us in even more advanced stages of illness that become difficult to reverse,” says Bulik.</p>



<p class="wp-block-paragraph">Both Bulik and Levinson are continuing to study the impacts of these drugs in eating disorders. In the meantime, both urge medical professionals to consider the risks GLP-1s might pose to people with those disorders. Bulik contributed to a set of <a href="https://onlinelibrary.wiley.com/doi/10.1002/wps.70096">research and clinical guidelines</a>, published earlier this month, that recommends doctors screen for eating disorders before prescribing the drugs, for example. The guidelines also recommend more patient education and more robust monitoring of people who take GLP-1s.</p>



<p class="wp-block-paragraph"><em>If you think you or someone you know might have an eating disorder, you can find information and support at</em> <a href="https://www.nationaleatingdisorders.org/"><em>the National Eating Disorders Association</em></a><em>.</em></p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>



<p class="wp-block-paragraph"><br></p>]]> </content:encoded>
</item>

<item>
<title>IP: American as apple pie and essential for biotech</title>
<link>https://edusehat.com/en/ip-american-as-apple-pie-and-essential-for-biotech</link>
<guid>https://edusehat.com/en/ip-american-as-apple-pie-and-essential-for-biotech</guid>
<description><![CDATA[ The United States leads the world in biotech innovation, and a major driver is its strong intellectual property (IP) system. In fact, IP rights […]
The post IP: American as apple pie and essential for biotech appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/smithsonian-8OIVMGwvS7E-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>IP:, American, apple, pie, and, essential, for, biotech</media:keywords>
<content:encoded><![CDATA[<p><span>The United States leads the world in biotech innovation, and a major driver is its strong intellectual property (IP) system.</span></p>
<p><span>In fact, IP rights are as American as apple pie. President George Washington not only talked about the importance of intellectual property protection in his first State of the Union address, but American IP rights were codified in the Patent Act in April of 1790—only 14 years into the country’s founding.</span></p>
<p><span>“That’s because the Founders, in creating our country and looking at the model of what was working and not working in England, saw that economic protection for scientific discoveries and innovations was critical to grow, support and nurture the economic success of a new country,” said Coke Morgan Stewart, the President and CEO of the Council for Innovation Promotion (C4IP), and former Deputy Undersecretary of Commerce for Intellectual Property and Deputy Director of the U.S. Patent and Trademark Office (USPTO) during</span><a href="https://ipprotectionmatters.org/episodes/30d15670-12ac-4c15-8f37-3e9b03f3ff26:ip-protections-for-scientific-discoveries-and-innovations-critical-for-americas-economic-success/"> <span>a conversation she had with the Center For Individual Freedom</span></a><span>.</span></p>
<p><span>For</span><a href="https://www.usipalliance.org/october-ip-month"> <span>IP Awareness Month this October</span></a><span>, Bio.News looks at how IP has helped facilitate decades of innovation in biotech, helping patients lead better, healthier, and long lives. </span></p>
<h3>The circle of biotech innovation</h3>
<p><span>It all starts with the spark of an idea. </span></p>
<p><span>A scientist in a lab makes a discovery and recognizes its potential to fill an unmet medical need: a treatment, therapy, or even a cure. So the scientist’s institution or company files a patent on their discovery. But why?</span></p>
<p><span>The biotech industry is one of the most research-intensive industries operating today, requiring often over a decade of work and billions of dollars to get a drug, treatment, or cure to market. </span></p>
<p><span>And IP protections, in many ways, act as the armor around an idea or invention, allow for:</span></p>
<ul>
<li aria-level="1"><span>The incentivization of innovation, allowing inventors to recover their research and development costs and profit from their hard work;</span></li>
<li aria-level="1"><span>Prevention of counterfeiting, which doesn’t just prevent theft of an idea, but also the ability to profit from its introduction to the market, allowing inventors to keep developing new ideas; and</span></li>
<li aria-level="1"><span>Attraction of investment, building economic value for both individual companies, as well as the economy as a whole.</span></li>
</ul>
<p><span>Any biotech, big, small, or in between, needs IP protections to keep the circle of innovation turning, but when it comes to small biotechs, the stakes are much higher, making these protections even more imperative—and protecting them is good for patients too.</span></p>
<p><a href="https://bio.news/bio-convention/ahead-of-bio-ip-conference-research-highlights-why-biotech-needs-strong-patents/"><span>As Bio.News reported</span></a><span>: “By most estimates, small and medium-sized biotech firms are behind the majority of new drugs. One study shows 55% of drugs gaining Food and Drug Administration (FDA) approval between 2011-2022 were developed by companies with less than $500 million in revenue.”</span></p>
<p><span>“There’s a lot of people who believe that patents stifle competition,” said panelist Dede Willis, CEO of Orbit Geonomics</span><a href="https://bio.news/bio-convention/bio-2026-biotech-threatened-by-pressures-on-patent-protection/"> <span>during the 2026 International BIO Convention</span></a><span>. “I would actually argue the opposite, for life sciences in particular, especially biotech, where the timelines to get to market and the cost to develop a product are extremely high. The patents are actually increasing competition because they’re enabling new technologies to be funded and commercialized.”</span></p>
<h3>Completing the cycle</h3>
<p><span>Let’s look at the end of a development cycle: the R&D was successful, the clinical trials are complete, and the FDA is on board. The drug is going to market and the investors are making a return on their investment. What do they do? Say </span><i><span>Thanks, that was fun, but I am moving on</span></i><span>. Well, as it would turn out, not really.</span></p>
<p><a href="https://www.bio.org/toolkit/intellectual-property/circle-biotech-innovation"><span>As BIO has found</span></a><span>, “Revenue from product sales helps fund future research. U.S. biopharma firms reinvest about 34% of their revenue into R&D, more than almost every other industry.”</span></p>
<p><span>And the numbers behind that 34% are huge. As the study, “</span><a href="https://www.nature.com/articles/d41573-024-00131-2"><span>Comprehensive measurement of biopharmaceutical R&D investment</span></a><span>” found, “global biopharmaceutical R&D investment totaled $276 billion across 4,191 global companies in 2021.”</span></p>
<p><span>And these numbers have been holding steady and even gaining momentum.</span></p>
<p><a href="https://bio.news/bio-convention/big-summit-experts-see-signs-of-ma-momentum-in-2026/"><span>As Bio.News reported in February</span></a><span>: “both licensing and M&A in biopharma, saw over 4,000 deals and more than $600 billion in headline value—and 2026 seems to be keeping up this momentum.”</span></p>
<p><span>Continuing, “there were a total of 4,341 deals in 2025, compared to 3,883 in 2024, and the $606 billion in total deal value was higher than the $421 billion in 2024. The $291 billion in upfront cash and equity of 2025 was an improvement over the $191 billion in 2024. Notably, large cap biopharmas signed fewer, higher-value deals, with 255 in 2025, compared to 294 in 2024.”</span></p>
<p><span>And thus the cycle continues, and even powers itself.</span></p>
<p><span>As a last example, a</span><a href="https://www.uschamber.com/assets/documents/GIPC_IPIndex2026_Annex_v3.pdf"> <span>2026 study</span></a><span> published by the U.S. Chamber of Commerce Global Innovation Policy Center found that the U.S.’s strong IP safeguards not only make it more competitive today, but also ensure competitiveness for the future.</span></p>
<p><span>“Economies with robust IP environments are 97% more likely to be prepared for the future of growth,” the study observed. Continuing, “economies with strong IP systems are 59% more likely to be able to transform their economies using sophisticated, state-of-the-art technologies compared with economies whose IP systems require improvement.”</span></p>
<p><span>And so, IP proves itself time and time again to be a key element of innovation, progress, and competitiveness.</span></p>
<p>The post <a href="https://bio.news/federal-policy/ip-american-as-apple-pie-and-essential-for-biotech/">IP: American as apple pie and essential for biotech</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO supports FDA’s new Fit&#45;for&#45;Purpose Rare Disease Framework Initiative</title>
<link>https://edusehat.com/en/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative</link>
<guid>https://edusehat.com/en/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative</guid>
<description><![CDATA[ BIO praised a Food and Drug Administration (FDA) initiative targeting more tailored, patient-centered, and predictable development of rare disease drugs, while recommending ways to […]
The post BIO supports FDA’s new Fit-for-Purpose Rare Disease Framework Initiative appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/wikimedia-david-richfield.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, supports, FDA’s, new, Fit-for-Purpose, Rare, Disease, Framework, Initiative</media:keywords>
<content:encoded><![CDATA[<p>BIO praised a Food and Drug Administration (FDA) initiative targeting more tailored, patient-centered, and predictable development of rare disease drugs, while recommending ways to make it happen, at an Oct. 28 public meeting.</p>
<p>The<a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease"> FDA’s Fit-for-Purpose Rare Disease Framework Initiative</a> seeks to accommodate the unique challenges of developing and reviewing drugs for rare diseases.</p>
<p>Compared to other conditions, rare diseases have small patient populations, limited natural history data, and disease heterogeneity, and they pose challenges in generating conventional clinical evidence. Attracting investment for rare disease drug development can be difficult due to the constraints of small patient populations and certain regulatory challenges.</p>
<p>For all these reasons, <a href="https://pubmed.ncbi.nlm.nih.gov/37353796/">95% of rare disease patients still lack an approved treatment,</a> though rare disease impacts over <a href="https://www.fda.gov/patients/rare-diseases-fda">30 million Americans</a>, making efforts to ease drug development both welcome and urgently needed.</p>
<p>“We strongly support FDA’s effort today,” E’Lissa Flores, Senior Director, Science and Regulatory Affairs at the Biotechnology Innovation Organization (BIO), told the public meeting. “BIO sees this Framework as an opportunity to translate fit-for-purpose principles into consistent practice, with greater predictability, early alignment, patient input, and appropriate consideration of uncertainty, while maintaining scientific rigor and FDA standards.”</p>
<p>Led by FDA’s Rare Disease Innovation Hub—in partnership with the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Office of the Commissioner—the <a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease">initiative was announced</a> Oct. 14, and<a href="https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fda-rare-disease-framework-initiative-public-meeting-10282026"> the public meeting</a> was called as the first major step in its development.</p>
<p>“BIO’s members appreciate that FDA is seeking input before moving forward and welcome the opportunity to provide feedback through this public meeting and through written comments until Dec. 11,” Flores said.</p>
<h2>FDA’s basic principles for the initiative</h2>
<p><a href="https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease">FDA said the following principles</a> would be instrumental in developing the Fit-for-Purpose Rare Disease Framework Initiative:</p>
<ul>
<li>“Providing greater clarity, consistency, and predictability in regulatory decision-making through tailored guidance and transparent communication.”</li>
<li>“Embedding the patient’s voice both early, and at clearly defined milestones, in the drug development and review process.”</li>
<li>“Further leveraging external expertise to support customization of regulatory review.”</li>
<li>“Building shared resources, robust training, and institutional knowledge on rare disease drug development and review.”</li>
<li>“Applying risk-based approaches, particularly to chemistry, manufacturing, and controls review and pre-approval inspections.”</li>
<li>“Championing the use of cutting-edge science, novel methods and innovative statistical approaches in rare disease drug development.”</li>
</ul>
<h2>BIO’s initial recommendations</h2>
<p>In her comments at the public meeting, Flores highlighted some emerging themes for consideration when implementing the initiative:</p>
<ul>
<li>“BIO encourages FDA to apply fit-for-purpose evidentiary approaches that maintain scientific rigor while reflecting the realities of rare disease,” Flores said. To do this, FDA should consider all available evidence—such as natural history, biomarker, and real-world evidence—and apply it consistently across all FDA centers and review teams.</li>
<li>The fit-for-purpose principles should extend to the Chemistry, Manufacturing and Controls (CMC) portion of an investigational new drug (IND) application, as this component is also different for rare diseases. “BIO supports risk-based approaches to the timing and generation of CMC evidence that recognize the realities of rare disease development while maintaining appropriate product-quality standards,” Flores said.</li>
<li>The Framework presents an opportunity to move innovation into regulatory practice. FDA should seek to advance methods from pilots and workshops into routine regulatory use and for updating guidance.</li>
<li>Early and ongoing FDA-sponsor alignment is essential, through early conversations about expectations that take place before an IND. “That includes early dialogue around endpoints, evidence-generation strategies, trial design, preclinical and CMC expectations, and acceptable uncertainty,” according to Flores.</li>
<li>“Patient input should be embedded throughout the development lifecycle,” Flores emphasized. This means FDA should clarify when patient input should be provided, how it will be considered, “and how patient engagement, patient experience data, and patient preference information can appropriately inform regulatory decision-making.”</li>
<li>Consistent implementation across review divisions and FDA centers is essential. “The Rare Disease Innovation Hub can help by integrating expertise across the Agency, sharing successful approaches and best practices, and facilitating external expertise to support reviewer education and ensure decisions reflect the latest science,” Flores said.</li>
</ul>
<p>“BIO looks forward to continuing its engagement with the FDA to advance fit-for-purpose regulatory approaches that maintain scientific rigor while supporting the timely development of safe and effective treatments for patients with rare diseases,” Flores concluded. BIO plans to work closely with its members to submit detailed comments and key recommendations to docket in support of FDA’s development and implementation of the Framework.</p>
<p>FDA has issued a Request For Information on the initiative and is accepting written<a href="https://www.federalregister.gov/documents/2026/10/16/2026-21142/fit-for-purpose-rare-disease-framework-initiative-public-meeting-request-for-information-and"> comments through the Federal Register until Dec. 11</a>.</p>
<hr>
<p><em>(Photo by David Richfield, Wikimedia Commons.)</em></p>
<p>The post <a href="https://bio.news/federal-policy/bio-supports-fdas-new-fit-for-purpose-rare-disease-framework-initiative/">BIO supports FDA’s new Fit-for-Purpose Rare Disease Framework Initiative</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDC report details impact of AMR pathogens</title>
<link>https://edusehat.com/en/cdc-report-details-impact-of-amr-pathogens</link>
<guid>https://edusehat.com/en/cdc-report-details-impact-of-amr-pathogens</guid>
<description><![CDATA[ The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says […]
The post CDC report details impact of AMR pathogens appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/cdc-iwkcspbMWx8-unsplash-e1793305581228.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDC, report, details, impact, AMR, pathogens</media:keywords>
<content:encoded><![CDATA[<p><span>The most dangerous antimicrobial-resistant (AMR) pathogens in America are causing an estimated 9.7 million infections and 50,800 deaths in the U.S. each year, says the Centers for Disease Control and Prevention (CDC).</span></p>
<p><span>Released Oct. 27, CDC’s</span><a href="https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats"> <span>latest report</span></a><span> on AMR pathogens identifies 19 bacteria and fungi that pose urgent, serious, or concerning threats to human health.</span></p>
<p><span>“The most comprehensive estimate to date of the impact of drug-resistant pathogens on human health in the United States …</span><a href="https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats"> <span>the AR Threats Report</span></a><span> provides critical data that can help guide policy, investments, and interventions to protect Americans from drug resistance,” according to CDC.</span></p>
<p><span>These dangerous pathogens have mutated to the point where existing antimicrobial drugs are no longer able to contain them. Germs that were once mostly considered threats to hospitalized patients are also causing infections in people who receive care outside of hospitals.</span></p>
<p><span>Combatting these new superbugs requires new antimicrobials, but there are few such drugs in development because the market for antimicrobial innovation is fundamentally broken.</span></p>
<p><span>“This latest report shows more detail on the enormous threat of AMR, which we know has the potential to cause</span><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext"> <span>nearly 170 million deaths worldwide by 2050</span></a><span>,” says Emily Wheeler, Vice President of Infectious Disease Policy at the Biotechnology Innovation Organization (BIO). “We need new antimicrobials for the most critical infections, and the only way to get that is with policy solutions that encourage development and innovation, such as the PASTEUR Act.”</span></p>
<h2>A policy solution for market dysfunction</h2>
<p><span>Unfortunately, the market for developing new antimicrobials is broken.</span></p>
<p><span>The need to use antimicrobials judiciously makes it</span><a href="https://workingtofightamr.org/wp-content/uploads/2026/07/The-Toll-of-the-Broken-Antimicrobial-Market-2026.pdf"> <span>nearly impossible for biotechs</span></a><span> developing these innovative drugs to recoup their investment. In recent years, the FDA has approved a few new antimicrobials from small companies, but today, nearly every company behind those innovations “have either gone into bankruptcy or the economic equivalent. Their R&D investors are completely wiped out,”</span><a href="https://bio.news/biosecurity/pasteur-act-amr-antimicrobial-resistance-barda-carb-x-2023-bio-international-convention/#:~:text=Furthermore%2C%C2%A0when%20we%20develop%20new%20antibiotics%2C%20%E2%80%9Cas%20soon%20as%20we%20start%20using%20them%2C%20the%20bacteria%20respond%2C%E2%80%9D%20said%20Kevin%20Outterson%2C%20Executive%20Director%20of%20CARB-X%2C%20in%20an%20interview%20during%20the%202023%20Biotechnology%20Innovation%20Organization%20(BIO)%20International%20Convention."> <span>Kevin Outterson</span></a><span>, whose organization CARB-X leads a public-private partnership to fund new antimicrobials,</span><a href="https://bio.news/federal-policy/senators-seek-solutions-for-amr-maintaining-us-biotech-leadership/"> <span>told an Aug. 7 Senate hearing</span></a><span>.</span></p>
<p><span>One policy proposal to address the problem is</span><a href="https://www.bennet.senate.gov/2026/06/24/bennet-young-colleagues-reintroduce-bipartisan-pasteur-act-to-fight-antimicrobial-resistance/"> <span>the PASTEUR Act</span></a><span>, which would encourage development of new, innovative antimicrobials for the most critical infections.</span></p>
<p><span>Instead of a model based on volume, PASTEUR would implement a new contracting model that provides predictable support for qualifying new antimicrobials, ensuring health care providers have the tools they need to treat superbugs.</span></p>
<p><span>Government incentives for new AMR treatments would save lives, and money, Outterson said. “This would be a remarkably great value for the U.S. taxpayers,” he maintained. “A Center for Global Development study found a 28-to-1 return.”</span></p>
<p><span>The price of inaction is steep, and not only in lives.</span></p>
<p><span>“Seven bacterial threats included in the report that are commonly associated with health care caused more than 42,000 deaths in 2023 and resulted in nearly $12 billion dollars in healthcare costs,” </span><a href="https://www.cdc.gov/antimicrobial-resistance/programs/AR-investments.html"><span>CDC said</span></a><span>. </span></p>
<p><span>Given AMR’s costs in lives, health, and money, BIO supports the PASTEUR Act. The “legislation would help to repair the broken marketplace for antimicrobials by enabling a business model centered around the appropriate use of new and novel treatments,” said</span><a href="https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=16321#:~:text=%22The%20introduction%20of,need%20them%20most.%22"><span> BIO President & CEO John F. Crowley, when the bill was reintroduced</span></a><span> in Congress earlier this year.</span></p>
<p><span>BIO has called attention to patient challenges with AMR, including by sharing the story of patient advocate</span><a href="https://fightofourlives.com/stories/katy/"> <span>Katy Grainger in “The Fight of Our Lives.”</span></a><span> BIO also has more</span><a href="https://www.bio.org/policy/human-health/antimicrobial-resistance"> <span>resources on AMR here.</span></a></p>
<h2>CDC’s list of the 19 most-dangerous pathogens</h2>
<p><b>Urgent Threats</b></p>
<p><span>These pathogens are public health threats that require urgent and aggressive action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/cauris"><i><span>Candida auris</span></i><span> (</span><i><span>C. auris</span></i><span>)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/acinetobacter"><span>Carbapenem-resistant </span><i><span>Acinetobacter</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/CRE"><span>Carbapenem-resistant Enterobacterales (CRE)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/gonorrhea"><span>Drug-resistant </span><i><span>Neisseria gonorrhoeae</span></i></a></li>
</ul>
<p><b>Serious Threats</b></p>
<p><span>These pathogens are public health threats that require prompt and sustained action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/cdiff"><i><span>Clostridioides difficile</span></i><span> (</span><i><span>C. diff</span></i><span>)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/campylobacter"><span>Drug-resistant </span><i><span>Campylobacter</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/candida"><span>Drug-resistant </span><i><span>Candida</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/TB"><span>Drug-resistant </span><i><span>Mycobacterium tuberculosis</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/nmeningitidis"><span>Drug-resistant </span><i><span>Neisseria meningitidis</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/salmonella"><span>Drug-resistant nontyphoidal </span><i><span>Salmonella</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/typhi"><span>Drug-resistant </span><i><span>Salmonella</span></i><span> Typhi</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/shigella"><span>Drug-resistant </span><i><span>Shigella</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/spneumoniae"><span>Drug-resistant </span><i><span>Streptococcus pneumoniae</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/ESCRE"><span>Extended-spectrum cephalosporin-resistant Enterobacterales (ESC-RE)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/MRSA"><span>Methicillin-resistant </span><i><span>Staphylococcus aureus</span></i><span> (MRSA)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/paeruginosa"><span>Multidrug-resistant </span><i><span>Pseudomonas aeruginosa</span></i></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/VRE"><span>Vancomycin-resistant </span><i><span>Enterococcus</span></i><span> (VRE)</span></a></li>
</ul>
<p><b>Concerning Threats</b></p>
<p><span>These pathogens are public health threats that require careful monitoring and prevention action.</span></p>
<ul>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/GBS"><span>Clindamycin-resistant group B </span><i><span>Streptococcus</span></i><span> (GBS)</span></a></li>
<li aria-level="1"><a href="https://arpsp.cdc.gov/artr/GAS"><span>Drug-resistant group A </span><i><span>Streptococcus</span></i><span> (GAS)</span></a></li>
</ul>
<p>The post <a href="https://bio.news/health/cdc-report-details-impact-of-amr-pathogens/">CDC report details impact of AMR pathogens</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Building the Future of AAV Gene Therapy</title>
<link>https://edusehat.com/en/building-the-future-of-aav-gene-therapy</link>
<guid>https://edusehat.com/en/building-the-future-of-aav-gene-therapy</guid>
<description><![CDATA[ This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-generation innovations are helping overcome long-standing manufacturing bottlenecks.
The post Building the Future of AAV Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Catalent_AAVGeneTherapyEbook.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Building, the, Future, AAV, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<p class="wp-block-paragraph">Adeno-associated virus (AAV) gene therapies have transformed the treatment landscape for rare and genetic diseases, delivering potentially life-changing outcomes for patients and validating the promise of genetic medicine. As the field continues to mature, however, the challenges facing developers are evolving. The question is no longer simply whether an AAV therapy can demonstrate clinical efficacy. Increasingly, success depends on whether organizations can reliably develop, manufacture, scale, and deliver these therapies in a commercially sustainable way.</p>


<figure class="wp-block-image alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-232x300.jpg" alt="Building the Future of AAV Gene Therapy: Strategies for Scalable Development, Manufacturing, and Commercialization Catalent eBook" class="wp-image-339984" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-1583x2048.jpg 1583w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Catalent_Cover-scaled.jpg 1978w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Today, gene therapy developers must navigate a complex environment characterized by rising demand, manufacturing capacity constraints, global supply chain considerations, and increasing expectations for commercial readiness. Traditional approaches that worked during early clinical development may not be sufficient as programs advance toward registration, launch, and long-term commercial supply. As a result, the industry is placing greater emphasis on platform technologies, integrated development strategies, resilient supply chains, and manufacturing innovations that can accelerate timelines while improving scalability and consistency.</p>


<p class="wp-block-paragraph">This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-generation innovations are helping overcome long-standing manufacturing bottlenecks. It also examines the growing importance of supply chain orchestration and case management in ensuring therapies reach patients safely, efficiently, and on time.</p>


<p class="wp-block-paragraph">As the number of AAV-based therapies advances through clinical development and toward commercialization, organizations that successfully integrate manufacturing strategy, supply chain planning, and technological innovation will be best positioned to deliver therapies at scale. The lessons and insights presented in these articles highlight practical approaches for addressing today’s challenges while preparing for the future of gene therapy. Together, they provide a roadmap for developers seeking to accelerate development, optimize manufacturing performance, strengthen supply resilience, and ultimately improve patient access to transformative AAV-based medicines.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/building-the-future-of-aav-gene-therapy/">Building the Future of AAV Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>First Whole&#45;Body Single&#45;Cell Atlas of Adult Vertebrate Generated in Danionella cerebrum</title>
<link>https://edusehat.com/en/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum</link>
<guid>https://edusehat.com/en/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum</guid>
<description><![CDATA[ Researchers created the first comprehensive whole-body single-cell atlas of an adult vertebrate, the tiny, transparent fish Danionella cerebrum, offering a new resource for studying brain regeneration, cellular diversity, and investigating how different tissues function together.
The post First Whole-Body Single-Cell Atlas of Adult Vertebrate Generated in Danionella cerebrum appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>First, Whole-Body, Single-Cell, Atlas, Adult, Vertebrate, Generated, Danionella, cerebrum</media:keywords>
<content:encoded><![CDATA[<p>Whitehead Institute researchers have created the first comprehensive whole-body single-cell atlas of an adult vertebrate, the tiny, transparent teleost fish <em>Danionella cerebrum</em>.</p>
<p>The team profiled more than 600,000 cells from across the fish to build the whole-body single-cell transcriptome atlas of which genes are active in which cell. A cell’s transcriptome is the full set of RNA molecules it has made from its DNA at a given time, providing a snapshot of which genes the cell is using.</p>
<p>Together, the data provide a molecular reference for the cell types found throughout <em>Danionella</em>, the patterns of gene activity that distinguish them, and where many of them are located. Offering a new resource for studying brain regeneration, cellular diversity, and investigating how different tissues function together, the atlas gives researchers a baseline for exploring how injury, aging, drugs, or other changes affect cells across the whole animal.</p>
<p>The team has made the atlas publicly available through <a href="https://digifish.wi.mit.edu/" target="_blank" rel="noopener">DigiFish</a>, an interactive resource for exploring cell types and gene activity throughout the animal. Paired with <em>Danionella</em>’s transparency and growing experimental toolkit, the atlas can help researchers identify specific cells and genes to study or manipulate and then follow their activity in the animal.</p>
<p>“Once you have a spatially resolved atlas, you know what cell types exist, but you also know the neighbors of those cell types in this context,” said Kutay Deniz Atabay, PhD, who led the work as a postdoctoral researcher in the lab of Whitehead Institute Member Peter Reddien, PhD. “This gives you access at multiple different levels of complexity, from molecular to cellular to systems.”</p>
<p>Atabay is first author, and Reddien senior and corresponding author of the researchers’ published paper in <em>Science</em>, titled “<a href="https://www.science.org/doi/10.1126/science.aeg1125" target="_blank" rel="noopener">Whole-body single-cell atlas of an adult vertebrate, <em>Danionella cerebrum</em>,</a>” in which they stated, “This whole-vertebrate transcriptome atlas yields a comprehensive resource for myriad questions in biology and neuroscience.”</p>
<p><em>Danionella cerebrum</em> is one of the world’s smallest vertebrates (∼12 mm in length), and has the smallest vertebrate brain on record, containing ∼650,000 neurons within 0.6 mm<sup>3</sup>, the authors wrote. This is approximately four times the size of the Drosophila brain, but with all the major vertebrate brain regions. Viewed from above, <em>Danionella cerebrum</em> offers a rare sight in a vertebrate, in that its brain is visible through the top of its head. “Thanks to its optical transparency, <em>D. cerebrum</em> is arguably unparalleled for noninvasive live whole-brain and whole-body imaging at single-cell resolution in an adult vertebrate …” the team noted.</p>
<p>Since the species was adopted for neuroscience research in 2018 and formally described in 2021, the tiny, transparent fish has drawn rapidly growing interest for its unique biology.</p>
<p>Whitehead Institute researchers recognized that the tiny fish brought whole-animal single-cell profiling within reach, allowing the team to create the first comprehensive map of cell types and gene activity across an adult vertebrate. That perspective could help reveal how cells in different tissues coordinate their responses—and how changes in one part of the body influence others.</p>
<p>Cell atlases have become increasingly detailed, but extending them across a whole adult vertebrate has been difficult for the basic reason of size. Profiling the cellular diversity of larger animals comprehensively is technically demanding and expensive. “The molecular mapping of cell transcriptomes across the entire animal anatomy of an adult vertebrate has not been achieved, largely because most vertebrates are too large for comprehensive molecular access to their cellular and molecular complexity, the investigators pointed out. <em>Danionella</em>—at barely one centimeter long—makes the experiment possible, while its close relationship to zebrafish allows researchers to draw on genetic tools developed for one of biology’s most widely used model organisms. “We reasoned that the extreme miniaturization of <em>Danionella</em> could enable organism-wide cell type profiling and facilitate high-throughput molecular studies,” they continued. “<em>D. cerebrum</em> is also closely related to zebrafish, which allows for the transfer and use of an expansive molecular toolkit, and its genome, similar to many other teleosts, is approximately half the size of the zebrafish genome.“</p>
<p>Atabay first became interested in <em>Danionella</em> in early 2019, while searching for a small, transparent animal in which he could watch the nervous system regenerate. Its miniature size and accessible brain made it especially promising for that work, and the researchers found that the fish has broad regenerative capacity, including in the brain and fins. Reddien’s lab, meanwhile, had already seen the value of a comprehensive whole-animal cell atlas through work on planarians, regenerative flatworms whose small size had made such an atlas possible. Together, those interests led to a larger question.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Deniz and I had the thought: Would it be possible to get a cell-type transcriptome atlas for a complete vertebrate?” said Reddien, who is also a professor of biology at Massachusetts Institute of Technology and an Investigator with the Howard Hughes Medical Institute. “Here’s an animal where we’d have a chance.”</p>
<p>To build the atlas, the researchers used single-cell RNA sequencing to measure gene activity in individual cells collected from across the brain, spinal cord, eyes, internal organs, fins, head, and trunk. They paired those data with spatial methods that mapped cell types and patterns of gene activity back to their locations in tissues. In their paper the team explained, “We combined regionally stratified single-cell RNA sequencing (scRNA-seq) with whole-animal spatial transcriptomics [multiplexed high-throughput fluorescent <em>in situ</em> hybridization (MERFISH) and hybridization chain reaction fluorescent in situ hybridization (HCR-FISH)] to build, validate, and explore a body-wide single-cell transcriptome atlas.”</p>
<p>The resulting atlas was extensive enough to capture even exceptionally rare cell populations. Looking across the animal revealed patterns that can be difficult to see when tissues are studied separately. In the nervous system, neurons from the same region often had more similar patterns of gene activity, even when they used different neurotransmitters—the chemicals neurons use to communicate—than when compared with neurons using the same neurotransmitter in different regions. Similar patterns have been observed in other vertebrates, including mammals, suggesting that regional and developmental identity may be an important organizing feature of vertebrate nervous systems.</p>
<p>The atlas also revealed signs that adult cells retain a molecular memory of where they belong in the body. The researchers found that fibroblasts, a type of connective tissue cell, maintained region-specific activity of genes best known for establishing different parts of the body during development. Cells in the pectoral and pelvic fins, for example, retained gene programs associated with forelimb and hindlimb development in other vertebrates. What these persistent signals do in adult <em>Danionella</em> remains unknown, but they may help tissues maintain or rebuild the appropriate structures. In planarians, positional information provides molecular guidance that helps regenerating tissues rebuild the correct structures.</p>
<p>The team also used the atlas as a reference for studying <em>Danionella</em>’s remarkable regenerative abilities. After injuring the telencephalon, a region of the forebrain, the missing neurons regenerated and the researchers were able to trace a progression from an early wound and immune response to neural stem-cell activity and the production and maturation of new neurons. “… profiling telencephalon regeneration revealed a temporally ordered molecular cascade, involving signatures of wound response and immune cell recruitment, radial glia proliferation, neurogenesis, and neuronal maturation …” they stated.</p>
<p>For Reddien, the advance presents numerous, diverse opportunities for new science. “There’s been this era of genome sequencing, where you get the complete list of all the genes that it takes to make an organism,” he says. “The transcriptomes of cells tell you how that genome is being utilized in the different cell types. To have the transcriptome of every cell type seems like a big turning point in how one would investigate the biology of an organism.”</p>
<p>In their paper the authors concluded “These findings and resources position <em>D. cerebrum</em> as a powerful model for systems neuroscience, stem cell biology and regeneration, biomechanics and collective behavior, and evolutionary biology.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/first-whole-body-single-cell-atlas-of-adult-vertebrate-generated-in-danionella-cerebrum/">First Whole-Body Single-Cell Atlas of Adult Vertebrate Generated in <i>Danionella cerebrum</i></a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development</title>
<link>https://edusehat.com/en/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development</link>
<guid>https://edusehat.com/en/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development</guid>
<description><![CDATA[ In developing fetuses, the human brain generates an excess of neurons, most of which are eliminated around when the baby is born. New research suggests that this is an important quality-control mechanism.
The post Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/10/Getty_183878409_FetusWithDNAUmbilicalCord-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 03:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Brain, Quality, Control, Selectively, Eliminates, Neurons, with, Abnormal, Variants, Development</media:keywords>
<content:encoded><![CDATA[<p><span>By analyzing genomic data from neurons, scientists from Harvard Medical School (HMS), Boston Children’s Hospital, and their collaborators have gained insights into a critical quality-control mechanism that takes place in the developing fetal brain. </span></p>
<p><span>During development, the human brain generates an excess of neurons, most of which are eliminated around when the baby is born. According to a study published this week in </span><i><span>Nature</span></i><span>, scientists report that neurons with multiple copy number variants, including DNA  duplications or deletions, are widespread in the developing brain. However they are selectively eliminated shortly before or after birth likely because the genomic alterations disrupt their ability to form synapses. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>Full details are provided in a paper titled “</span><a href="https://www.nature.com/articles/s41586-026-11190-3#author-information" target="_blank" rel="noopener"><span>Perinatal elimination of genetically aberrant human cortical neuron</span></a><span>.” The findings reported there are significant because copy number variants can impact brain function and may contribute to neuropsychiatric conditions, including autism, schizophrenia, epilepsy, and intellectual disability. A better understanding of the pruning process in the developing brain could improve how autism and other disorders in which neural development goes awry are treated. </span></p>
<p><span>As Diane Shao, MD, PhD, HMS instructor of neurology at Boston Children’s and a co-first author on the study noted, “If that quality control system can be disrupted, that could be part of what goes wrong in neurodevelopmental disorders like autism. Understanding the mechanism could eventually point us toward what to look for, and maybe what to protect.”</span></p>
<p><span>One of the first steps in the study was exploring the prevalence of copy number variants in developing human brains. To do that, the scientists designed single-cell whole genome sequencing approaches that allowed them to lightly sequence the genomes of single neurons. They used this method to sequence over 1,500 neurons from 16 individuals. They then validated the results with deeper sequencing of over 800 neurons from 12 individuals. They then used various computational methods to identify copy number variants in each sequenced genome. With their approach, it was possible to see the genomic changes “one neuron at a time, map where in the genome they occur, and compare how common they are from before birth to old age,” explained Peter Park, PhD, co-senior author on the paper and professor of biomedical informatics at HMS.</span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>The data showed that an average of nearly 26 percent of neurons in the prenatal cortex had widespread copy number variants, but this rapidly decreased to an average of 6.2 percent after birth. </span><span>Specifically, “neurons with widespread CNVs were mainly eliminated perinatally, timed roughly parallel to periods of programmed cell death, whereas neurons with smaller CNV burdens declined slowly in frequency with postnatal age,” the scientists wrote. </span></p>
<p><span> “We were totally unprepared for how common these were in early development,” said Christopher Walsh, MD, PhD, a co-senior author on the paper and professor of pediatrics and neurology at Boston Children’s Hospital. “But it makes sense in the context of what we know about the formation of excess neurons and in the context of the IVF literature.” </span></p>
<p><span>Next, the team explored the pathways through which the abnormal neurons are eliminated. By sequencing and analyzing DNA and RNA from over 44,000 individual cells, they found that neurons with widespread copy number variants also had abnormal expression of the genes involved in the creation and maintenance of neural synapses. It suggests that unlike healthy brain cells, these abnormal neurons fail to make critical connections during fetal development which causes them to die off. </span></p>
<p><span>“This competition for synapses has been described for years, but without the benefit of a genomic understanding,” Walsh noted. We didn’t realize that this struggle for survival—this Darwinian competition—was nature’s quality control mechanism in the brain.”</span></p>
<p><span>As part of the study, the team also confirmed some earlier findings that flawed neurons continue to be eliminated throughout adulthood, albeit at a much slower rate. Currently, they are looking into whether this neural elimination process is different in developing brains of people with autism and other neurodevelopmental disorders. They are also exploring whether this process plays a role in development of adult-onset neurodegenerative disorders like Alzheimer’s disease. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/brain-quality-control-selectively-eliminates-neurons-with-abnormal-variants-in-development/">Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hamburg Hosts 2026 European Gene Therapy Conference</title>
<link>https://edusehat.com/en/hamburg-hosts-2026-european-gene-therapy-conference</link>
<guid>https://edusehat.com/en/hamburg-hosts-2026-european-gene-therapy-conference</guid>
<description><![CDATA[ GEN&#039;s Kevin Davies, PhD, reports from ESGCT where patient safety, expanding access to gene therapy, and progress towards an HIV vaccine were prominent themes among the early talks at ESGCT 2026.
The post Hamburg Hosts 2026 European Gene Therapy Conference appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ESGTIllustration-scaled-e1793274396802.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 30 Oct 2026 00:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hamburg, Hosts, 2026, European, Gene, Therapy, Conference</media:keywords>
<content:encoded><![CDATA[<p><strong>HAMBURG</strong>—The historic German port city of Hamburg is playing host to the European Society of Gene & Cell Therapy (ESGCT) conference this week.</p>
<p>As noted in the opening session, the Port of Hamburg was established more than 800 years ago. It is also a proud center of editing—newspapers rather than genes—as the site of the headquarters of <em>Der Speigel</em> and <em>Die Zeit</em>. And of course, Hamburg famously helped forge the sound and legend of the “Fab Four”—the Beatles played numerous gigs between 1960-62 in the central St. Pauli district. It was also where Ringo Starr met his future bandmates in 1960.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Patient safety, expanding access to gene therapy, and progress towards an HIV vaccine were prominent themes among the early talks at ESGCT 2026. In the opening plenary session, Dimitrios Mougiakakos, MHBA, discussed his group’s research on CAR T therapy for lupus, noting progress but some patient deaths. “Lower risk does not mean no risk,” he said, pointing to the rapid production of CAR T cells as a potential risk factor. A “Volkswagen approach” might be better than a “Ferrari approach,” he concluded.</p>
<p>Italian professor Giuliana Ferrari, PhD, discussed her team’s research on beta-thalassemia, one of the “less rare of the rare diseases,” characterized by more than 400 different globin gene mutations. Ferrari noted that some of the patients in the <em>ex vivo </em>TIGET-BTHAL Phase I/II trial, which began in 2015, had restarted blood transfusions, while others remained transfusion-independent after nine years, producing respectable levels of hemoglobin.</p>
<p>Ferarri’s team has spent several years optimizing manufacturing protocols to launch a new trial, Bthal FT007-01. The first two patients have been enrolled in this Phase IIb trial, an academic initiative between Italian groups designed to provide affordable access to gene therapy. Refinements include the implementation of a shorter 40-hour cell culture and gene transduction protocol (down from 60 hours) and a change in conditioning regimen.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>HIV hope</strong></h4>
<p>In addition to his academic position at Scripps Research Institute, Bill Schief, PhD, is also the vice president of protein design at Moderna. Although he acknowledged he was a slightly unusual choice for a plenary speaker, as his work was not technically gene therapy, he relished the chance to present his team’s promising work on the quest to engineer a specific immune response and to develop a functional HIV vaccine.</p>
<p>The statistics remain sobering: More than 40 million people live with HIV, but more than 20 percent do not receive antiretroviral therapy. There are 1.2 million new HIV infections and 570,000 deaths per year. All told, 44 million people have died of AIDS, and global funding for AIDS research is going down. “We need a vaccine,” Schief emphasized.</p>
<p>Schief and colleagues are designing vaccines to guide the immune system toward antibodies that target conserved, vulnerable regions of the HIV envelope protein. Hope resides in the development of broadly effective Abs (bnAbs). A successful HIV vaccine will need to induce multiple classes of bnAbs, Schief said.</p>
<p>Schief reviewed research to deliver a sequence of immunogens, using priming, “shepherding,” and “polishing,” with the goal of producing bnAbs and long-lived plasma cells to sustain production. The strategy is “very complicated but not crazy,” Schief said, citing the need for serum bnAbs to have breadth, potency, and durability.</p>
<p>Over the past two years, researchers have reported clinical results and animal studies that represent significant advances towards their goal. In 2025, <a href="https://www.science.org/doi/10.1126/science.adr8382" target="_blank" rel="noopener">Schief’s team reported promising Phase I results in <em>Science</em></a>. IAVI G002, conducted in the U.S., tested an mRNA vaccine designed to activate the desired antibody precursors, followed by a different mRNA vaccine intended to advance their development. IAVI G003 was conducted in Rwanda and South Africa, testing the initial vaccine approach in African populations.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Let’s make sure the strategy works there [in Africa],” Schief said. The findings provided proof of concept but stopped short of a full vaccine. Earlier this year, Schief and colleagues published in <a href="https://www.nature.com/articles/s41586-026-10837-5" target="_blank" rel="noopener"><em>Nature</em></a> results showing that <a href="https://www.genengnews.com/topics/infectious-diseases/germline-targeting-hiv-vaccine-generates-broadly-neutralizing-antibodies-in-primates/" target="_blank" rel="noopener">germline-targeting vaccines can induce pre-specific bnAbs</a> in memory B cells and serum in non-human primates.</p>
<h4><strong>CAR T promise</strong></h4>
<p>Michel Sadelain, MD, PhD, presented a compelling overview of the promise of CAR T therapy in oncology and other therapeutic areas. Of the seven CAR T therapies approved in the U.S. to date, five target CD19. In oncology, survival duration has quadrupled from about six months to more than 25 months. Sadelain said there was promising data in other fields, including rheumatology (lupus, arthritis, and scleroderma), as well as preliminary results in neurology (myasthenia gravis). This progress has all been achieved with the original two molecular designs that yielded Yescarta and Kymriah: CD28z CAR and 4-1BBz CAR.</p>
<p>But progress in tackling solid tumors with CAR therapy has not kept pace with hematological malignancies, Sadelain said. He listed five primary challenges in this regard:</p>
<ul>
<li>The need to increase functional persistence of T cells</li>
<li>Potency</li>
<li>Sensitivity</li>
<li>The need to understand and prevent toxicity</li>
<li>New targets</li>
</ul>
<p>In one line of research, Sadelain’s team revisited signaling strength, with a view to tempering it. In 2025, the group showed that by switching from three ITAMs to a single ITAM, they could create a strong effector function with much greater persistence. This “1XX” signaling module was <a href="https://ascopubs.org/doi/abs/10.1200/JCO-24-02424" target="_blank" rel="noopener">taken to the clinic in B-cell lymphoma</a>, with excellent responses seen administering as few as 25 million cells—a tenth of the regular dose (100-400 million cells).</p>
<p>In another approach, Sadelain’s team has used CRISPR to develop a new CAR—<a href="https://www.nature.com/articles/s41591-021-01621-1" target="_blank" rel="noopener">the HLA-independent T cell (HIT) receptor</a>—that is at least 10-fold more sensitive. The characterization of this CAR in solid tumors such as renal cell carcinomas in immunodeficient mice continues.</p>
<p> </p>
<p><em>*ESGCT 2026; Hamburg, Germany; October 27-30, 2026.</em> <strong></strong></p>
<p></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/hamburg-hosts-2026-european-gene-therapy-conference/">Hamburg Hosts 2026 European Gene Therapy Conference</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Three&#45;Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain</title>
<link>https://edusehat.com/en/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain</link>
<guid>https://edusehat.com/en/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain</guid>
<description><![CDATA[ By optimizing laser, optical, and acquisition parameters, The Rockefeller University researchers developed a three-photon microscopy platform that captures deep-brain neural activity in living mice at single-cell resolution without surgically removing the overlying cortex.
The post Three-Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GettyImages-827580658.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 09:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Three-Photon, Microscopy, Reveals, Neural, Activity, Deep, the, Mouse, Brain</media:keywords>
<content:encoded><![CDATA[<p>Watching neurons deep inside the brain usually means contending with scattered light—or removing tissue to get a clearer view. Now, researchers at The Rockefeller University have redesigned a three-photon microscopy platform to record neuronal activity in deep brain regions of living mice without surgically removing the overlying cortex.</p>
<p>Led by Alipasha Vaziri, PhD, head of Rockefeller’s Laboratory of Neurotechnology and Biophysics, the team developed Three-photon Ultra-Deep Imaging (TrUDI). Their study, “<a href="https://www.nature.com/articles/s41592-026-03251-2">Cellular-resolution three-photon ultra-deep imaging (TrUDI) of neuronal population activity at 2-mm depth in the mammalian brain,</a>” was published in <em>Nature Methods</em>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>TrUDI generated approximately 250 times more detected fluorescence photons at the same laser power as previous approaches, enabling single-cell-resolution recordings of neuronal population activity at depths of approximately 2 mm.</p>
<p>“Often in technology, people stick with a certain laser or parameter for historical reasons, and everyone just accepts those limitations,” Vaziri said. “We wanted to take a clean slate approach.”</p>
<p>As light penetrates brain tissue, scattering makes it increasingly difficult to distinguish fluorescent signals from background. Three-photon microscopy produces less background fluorescence than two-photon microscopy, potentially allowing deeper imaging. However, generating sufficient signal requires energetic laser pulses, and increasing average laser power risks heating and damaging tissue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Previous three-photon functional recordings had reached approximately 1.2 mm, short of the technique’s theoretical depth limit of more than 2 mm.</p>
<p>The researchers used computer models to guide coordinated changes to the laser and optics. The authors wrote, “TrUDI matches the parameters of the excitation laser, the optical system, and the acquisition to linear and nonlinear limits for safe laser exposure while satisfying the spatiotemporal requirements of single-cell resolution calcium (Ca<sup>2+</sup>) imaging.”</p>
<figure aria-describedby="caption-attachment-339959" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339959" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO-300x200.jpg" alt="TrUDI" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Vaziri_101926_HERO.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A volumetric rendering of stacked images taken with the Vaziri lab’s new platform TrUDI. [Laboratory of Neurotechnology and Biophysics at The Rockefeller University]</figcaption></figure>
<p>The team also developed a neuron-targeted excitation scheme that switches on the laser only as it scans identified cells. “The way we did this was through a series of very systematic, principled, and ground-up optimizations,” Vaziri said.</p>
<p>Together, these changes increased the fluorescence signal available for recording transient activity in individual neurons. The platform was tested in mice, and the paper reports recordings over fields of view approximately 230 by 230 µm<sup>2</sup> at 8.6 Hz, reaching approximately 2 mm into the mouse cortex and hippocampus.</p>
<p>The advance expands access to circuits that previously required removal of overlying tissue for optical imaging, potentially helping researchers investigate how neuronal populations across deep brain regions coordinate their activity. It does not, however, make every deep structure accessible.</p>
<p>“There are regions of the striatum that are inaccessible, and there are still a number of deep brain nuclei which are much deeper that still require invasive approaches,” Vaziri added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>For now, the work demonstrates how coordinated optimization can bring three-photon imaging closer to its fundamental depth limit while preserving the tissue above the regions being studied.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/three-photon-microscopy-reveals-neural-activity-deep-in-the-mouse-brain/">Three-Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How the Heart Stays Strong with MCT1&#45;Dependent Mitochondrial Lactate Import</title>
<link>https://edusehat.com/en/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import</link>
<guid>https://edusehat.com/en/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import</guid>
<description><![CDATA[ Preclinical study results suggest how the heart can keep itself well-fueled even under times of stress, by burning glucose in the cell cytosol while burning lactate in the mitochondria.
The post How the Heart Stays Strong with MCT1-Dependent Mitochondrial Lactate Import appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GeneTherapy_GettyImages_2101175464_HolographicHumanHeart.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 05:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, the, Heart, Stays, Strong, with, MCT1-Dependent, Mitochondrial, Lactate, Import</media:keywords>
<content:encoded><![CDATA[<p>Maintaining energy flow to the heart is a complex process which can break down during common but severe cardiovascular disease conditions such as heart failure. Researchers previously knew that heart muscle seems to do an unusual metabolic trick to always get enough energy, which is using two carbohydrate energy sources—glucose and lactate—at the same time.</p>
<p>In most human tissues, using more glucose makes it harder to use lactate, and vice versa, but the heart is different. Working with experimental mice, scientists headed by a team at the University of Utah have now found a unique cell-level difference that helps keep heart muscle fueled up, which is the ability to burn glucose in the cell cytosol while burning lactate in the mitochondria. This spatial separation allows both energy-generating reactions to happen simultaneously, helping keep the heart fueled up no matter the energy source.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>While mostly dispensable to daily life, this process is crucial to preventing heart failure when the heart is stressed. “This appears to be a critical backup system for heart function,” says Gregory Ducker, PhD, assistant professor of biochemistry at University of Utah Health. “In an emergency, we would really, really rely on this.”</p>
<p>The findings could point to new potential therapeutic strategies for some serious heart disorders. Ducker is senior author of the researchers’ published paper in <em>Nature</em>, titled “<a href="http://dx.doi.org/10.1038/s41586-026-11182-3" target="_blank" rel="noopener">MCT1-dependent mitochondrial lactate import sustains cardiac metabolism</a>,” in which they stated, “Thus, the existence of a parallel lactate-based pathway for carbohydrate oxidation can sustain cardiac energetics and maintain myocardial structure and function under diverse stress conditions.”</p>
<p>The heart is the hardest-working muscle in the body, beating constantly no matter what the body’s energy reserves look like. The heart’s energy demands can be met through the use of both glucose and lactate as fuel. “The heart possesses a dynamic capacity to oxidize a variety of fuels, including glucose and lactate, to meet its energetic demands under diverse dietary, exertion, and injury stressors,” the authors wrote.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Laboratory work and experiments in mice reported by Ducker and colleagues now suggest how the heart can use both fuel sources at the same time. Their research found that the separation between glucose and lactate metabolism depends on a molecule called MCT1, which moves lactate to the inside of the mitochondria. “We further observe that MCT1, traditionally localized to the plasma membrane, also resides in the inner mitochondrial membrane of mouse and human cardiomyocytes,” they wrote. Genetic mutations in MCT1 prevent lactate from entering the mitochondria and disrupt the heart’s energy balance, leading to heart failure when stressed. “Genetic ablation of MCT1 abolishes mitochondrial lactate oxidation, disrupts adaptation to neurohormonal, hemodynamic or ischemic stress and accelerates the development of heart failure with enhanced mortality,” the investigators further stated.</p>
<p>These results uncover a new requirement for lactate to fuel the injured heart and suggest new therapeutic targets to re-energize the heart during heart failure. “Our findings help point to new areas in which we could target the heart muscle to benefit and repair itself by allowing it to use lactate better,” Ducker said. “That’s the long-term goal: to help the heart muscle heal.”</p>
<p>The discovery of a new pathway through which the heart muscle can use lactate to generate energy opens promising opportunities for developing new treatments for serious heart conditions, including heart failure and heart attacks.</p>
<p>“Rather than simply releasing lactate into the bloodstream as a waste product, we may be able to enhance the heart’s ability to use it as a valuable source of energy,” says Stavros Drakos, MD, PhD, Professor of Medicine at University of Utah Health and co-senior author of the study. “By optimizing this process, we could potentially improve heart muscle function in patients suffering from heart failure or heart attacks.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/how-the-heart-stays-strong-with-mct1-dependent-mitochondrial-lactate-import/">How the Heart Stays Strong with MCT1-Dependent Mitochondrial Lactate Import</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026 report on biotech’s economic impact portrays a vast ecosystem</title>
<link>https://edusehat.com/en/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem</link>
<guid>https://edusehat.com/en/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem</guid>
<description><![CDATA[ The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of […]
The post 2026 report on biotech’s economic impact portrays a vast ecosystem appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/BIOR_GSD_TEConomy-Report_3Stat_102226.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 02:00:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026, report, biotech’s, economic, impact, portrays, vast, ecosystem</media:keywords>
<content:encoded><![CDATA[<p><span>The latest portrait of America’s biotech industry describes a growing economic force responsible for $3.19 trillion in total U.S. economic output and employment of 2.31 million workers.</span></p>
<p><span>But the BIO/CSBA/TEConomy 2026 report, released Oct. 28, also details important, perhaps less-noticed trends. For example: Biomanufacturing employment grew at nearly 16% nationwide in 2021-25, with 26 states adding jobs and 16 of them growing by more than 20%. The report also includes eye-opening data on the broad geographic expansion of the clinical trial subsector, vital for innovators and patients.</span></p>
<p><span>This is the 12</span><span>th</span><span> edition of this overview of the biotech industry on the national, state and local levels. Produced every two years since 2004 by TEConomy Partners for the Biotechnology Innovation Organization (BIO), the BIO/CSBA/TEConomy report includes individual reports for 50 states, Puerto Rico and the District of Columbia.</span></p>
<p><span>The new report indicates biotech remains strong in the U.S., says Peter Pellerito, a Senior policy Advisor for BIO who has worked on the reports since the beginning.</span></p>
<p><span>“U.S. industry continues to be the leader in global biotechnology competitiveness and biosecurity because of a strategic history of sustained cutting-edge, biology-based research and workforce development partnerships at all levels of industry activity,” he says.</span></p>
<p><span>“Just as drug and pharmaceutical basic and applied research efforts have identified new therapies for patients, so too has the economic impact footprint of our industry grown,” says Pellerito. “While innovation and capacity in biomanufacturing remain substantial in national hubs like California and Massachusetts, the industry continues to expand across all 50 states, Puerto Rico, and the District of Columbia, helping diversify local economies through the creation of quality jobs.”</span></p>
<h2>Employment: Booming growth plateaus</h2>
<p><span>The report shows rapid expansion in biotech from 2021 through 2025: employment in the industry grew 7% and the number of biotech business establishments reached 156,000 by</span> <span>2025. But the strong growth occurred in the post-pandemic years of 2022 and 2023 and has eventually slowed and leveled off in the last two years.</span></p>
<p><span>“The overall employment gain masks two distinct periods. Industry employment rose 5.7 percent in 2022 and increased another 1.2 percent in 2023 before declining 0.3 percent in 2024 and growing just 0.4 percent in 2025. Employment in 2025 was essentially unchanged from its 2023 level,” according to the report.</span></p>
<p><span>“The hiring slowdown warrants attention,” because biotech job growth has generally outpaced private job growth for the past 25 years, the report notes. Still, the healthy growth in 2021-25 touched much of the country.</span></p>
<p><span>“Forty-one states, the District of Columbia, and Puerto Rico experienced net bioscience employment growth over the period,” the report says. “The leading states by absolute job gains were Texas, Florida, Massachusetts, Illinois, North Carolina, Pennsylvania, New York, Ohio, and New Jersey.”</span></p>
<h2>A massive clinical trial ecosystem</h2>
<p><span>The report features a special focus on clinical trials, noting the efforts states make to attract this patient-centered business activity.</span></p>
<p><span>“The special analysis conducted for this report identified 63,468 distinct clinical studies active in the United States or Puerto Rico during 2021–25,” the report says. “Universities, hospitals, research institutes, and other research organizations sponsored 66 percent of these studies, while industry sponsored an additional 29 percent.”</span></p>
<p><span>Ryan Helwig, TEConomy Principal and Senior Director, who’s worked on 11 reports, explains the importance of the report’s analysis of clinical trials.</span></p>
<p><span>“BIO really understood that we need to help industry stakeholders and ordinary Americans get their arms around  the vast footprint of these trials,” he says. “This robust clinical research complex is essential to our national competitiveness and a key piece of advancing real innovations into the clinic and ultimately to commercialization for the benefit of patients.”</span></p>
<p><span>States with larger populations have an advantage in attracting clinical trials, which is why larger states were in the top five hosting clinical trials in 2021-25: California (16,738), Texas (13,742), New York (12,695), Florida (11,686), and Pennsylvania (9,395), according to the report.</span></p>
<p><span>Still, “the subsector is spread across the country,” with trials hosted in every state, the District of Columbia and Puerto Rico, Helwig says.</span></p>
<p><span>The wide availability of clinical trials is good news for patients who are eager to participate and gain early access to cutting-edge medicines. Yet, as the report notes, clinical trial opportunities still could be more widely distributed.</span></p>
<p><span>“A strong national clinical research enterprise is most effective when the right studies are accessible to the patients and communities that need them, underscoring the importance of continued investment in clinical research capacity, diverse participant recruitment, and regional site networks,” the report says.</span></p>
<h2>Biomanufacturing booms</h2>
<p><span>The report also has an expanded section on biomanufacturing, focused specifically on the production of biologic medicines and therapies .</span></p>
<p><span>“Biological product manufacturing has been an important growth segment within the U.S. bioscience industry and the pharmaceuticals subsector. In 2025, the industry employed 46,936 workers, an increase of 15.8 percent from 2021,” the report notes.</span></p>
<p><span>The trend toward reshoring is helping drive the growth in biomanufacturing, and states are competing to benefit from the extensive investment in infrastructure and workforce development that’s involved in establishing new biomanufacturing facilities.</span></p>
<p><span>“There are three main pillars of support that states use to attract this segment of our industry,” according to Pellerito: Enabling infrastructure development; encouraging workforce development; and creating a business-friendly environment through measures such as targeted tax incentives.</span></p>
<p><span>States who succeed in attracting biomanufacturing can hope for big rewards. As the report notes, the last couple of years have seen U.S. and international companies commit to projects totaling hundreds of billions of dollars in value with a projected tens of thousands of  generated jobs.</span></p>
<p><span>“Many of these are just at the investment and early building phases,” Helwig says. “Just imagine what that does for the bioscience industry and ecosystem when those facilities start to fully come on line.”</span></p>
<p><a href="http://www.bio.org/jobs"><b>Read the report here.</b></a></p>
<p>The post <a href="https://bio.news/state-policy/2026-report-on-biotechs-economic-impact-portrays-a-vast-ecosystem/">2026 report on biotech’s economic impact portrays a vast ecosystem</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Collaboration and Roadmaps Key to Capsid Accessibility</title>
<link>https://edusehat.com/en/collaboration-and-roadmaps-key-to-capsid-accessibility</link>
<guid>https://edusehat.com/en/collaboration-and-roadmaps-key-to-capsid-accessibility</guid>
<description><![CDATA[ Apertura says widening access to its TfR1 CapX capsid is a core philosophy, and that includes inviting a wide range of collaborations and supporting collaborators through advice and preclinical roadmaps. 
The post Collaboration and Roadmaps Key to Capsid Accessibility appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/AGTX001-Img-1_2x-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Collaboration, and, Roadmaps, Key, Capsid, Accessibility</media:keywords>
<content:encoded><![CDATA[<p>Providing manufacturing and preclinical development advice, as well as forging a broad range of collaborations, is important to increasing access to capsids and their associated plasmids. That’s according to a gene therapy company focused on engineering adeno-associated virus (AAV) capsids and payloads.</p>
<p>For Jorge Santiago-Ortiz, PhD, vice president, CMC & regulatory affairs at Apertura Gene Therapy, the development and manufacturing story of the company’s own lead capsid, TfR1 CapX, is reassuringly uneventful. This is why he focused his talk at the Bioprocessing Summit in Boston on sharing knowledge about engineered capsids and their manufacturability.</p>
<p>“Giving access to capsids is in everyone’s best interests to advance the field,” Santiago-Ortiz says. “And we have already formed a number of partnerships with different types of institutions, for example, foundations, academic institutions, and for-profit organizations too.”</p>
<p>According to Santiago-Ortiz, Apertura Gene Therapy believes its TfR1 CapX is a best-in-class novel AAV capsid for highly efficient delivery to the central nervous system, even at low doses. Manufacturing the capsid itself involves standard unit operations and commercially available reagents, and has taken place internally and at contract manufacturer and other partner facilities in clinical batches of up to 500 L.</p>
<p>Santiago-Ortiz says the company’s success is down to having considered manufacturability early alongside any modifications groups might need to make to standard analytics techniques for the analysis of bespoke capsids.</p>
<p>However, he says, what resonated most with the Bioprocessing Summit audience was the company’s focus on widening access to its capsid technology. This includes, for example, he says, Material Transfer Agreements (MTAs) for academic researchers and even for-profit companies to evaluate their transfer.</p>
<p>In addition to providing access to the capsid and its associated plasmid, he says, they also provide advice on manufacturing, nonclinical development, and regulatory strategies, alongside analytical development guidance.</p>
<p>“As soon as a partnership is announced, we’re as proactive as possible in providing advice and guidance,” he says. “We want to be open and reachable and answer the questions partners might have.”</p>
<p>In addition, Apertura Gene Therapy helps link up partners who might want to manufacture with the aid of a contract manufacturer.</p>
<p>“We connect different parties who have developed different experience and, hopefully, this list of partners will grow as more people adopt this technology and establish their capability to manufacture this virus,” he adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/collaboration-and-roadmaps-key-to-capsid-accessibility/">Collaboration and Roadmaps Key to Capsid Accessibility</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Microbial Dark Matter Could Revive Antibiotics</title>
<link>https://edusehat.com/en/microbial-dark-matter-could-revive-antibiotics</link>
<guid>https://edusehat.com/en/microbial-dark-matter-could-revive-antibiotics</guid>
<description><![CDATA[ Most microbes remain out of reach, and many antibiotic-producing genes stay silent. A new review argues that combining genomics, innovative cultivation, and scalable manufacturing could turn this hidden chemistry into desperately needed new antibiotic treatments.
The post Microbial Dark Matter Could Revive Antibiotics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-Dark-Matter_GBPN_IMAGE_22OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microbial, Dark, Matter, Could, Revive, Antibiotics</media:keywords>
<content:encoded><![CDATA[<p>The world’s microbes have not run out of ways to fight bacteria. Antibiotic hunters may simply have been searching the same familiar territory—and overlooking what happens after a promising molecule is found. That is the central message of a <a href="https://www.sciencedirect.com/science/article/pii/S0734975026002600" target="_blank" rel="noopener">review</a> by Ahmed Hamed, PhD, and Zeinab Khalil, PhD, both at the University of Queensland. The researchers describe “microbial dark matter” as organisms that resist conventional cultivation, along with silent biosynthetic pathways in familiar microbes that could encode undiscovered natural products.</p>
<p>The stakes are considerable. Antimicrobial resistance directly caused an estimated 1.27 million deaths worldwide in 2019, according to figures cited in the review. Yet traditional screening has repeatedly mined the same microorganisms, particularly <em>Streptomyces</em>, often rediscovering known compounds rather than uncovering new antibiotic structures.</p>
<p>Genome-mining tools now identify biosynthetic gene clusters (BGCs)—groups of genes responsible for producing specialized molecules—even when those products never appear in laboratory cultures. Metagenomics extends the search to microbes that scientists cannot grow, while devices that recreate natural environments can bring some previously inaccessible organisms into cultivation.</p>
<p>Consider teixobactin, an antibiotic discovered from <em>Eleftheria terrae</em>, a soil bacterium recovered using an iChip device that cultivates microbes in their native environment. Although teixobactin shows activity against several Gram-positive pathogens, its producer remains difficult to grow conventionally. The review highlights the ongoing reliance on chemical synthesis to supply the compound.</p>
<p>“Detection, however, is not production,” the researchers write. An analysis of 50 studies cited by the authors found that large-scale attempts to express natural-product pathways in alternative microbial hosts produced detectable compounds only 11–32% of the time. Missing genes, inadequate precursor supply, product toxicity, and poor fermentation performance can all stall development.</p>
<p>The review makes bioprocess engineering central to the solution. In one cited study, adding talc microparticles to an engineered <em>Streptomyces</em> culture increased production of pamamycin nearly threefold, from 18 to 50 mg/L. Reworking pathway regulation, engineering microbial production hosts, and optimizing culture conditions offer other routes to better yields.</p>
<p>Artificial intelligence could help researchers choose which clusters deserve attention by connecting genomic and molecular features to predicted biological activity. But predictions still require experimental confirmation, and abundant material is needed to study a promising compound’s mechanism and development potential.</p>
<p>Rather than bet on any single platform, Hamed and Khalil envision an iterative workflow linking ecological sampling, genome and metabolome analysis, activity testing, target identification, and scalable production. The next antibiotic breakthrough, their review suggests, will depend as much on making a molecule as on finding it.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/microbial-dark-matter-could-revive-antibiotics/">Microbial Dark Matter Could Revive Antibiotics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors</title>
<link>https://edusehat.com/en/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors</link>
<guid>https://edusehat.com/en/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors</guid>
<description><![CDATA[ CDMOs already play a critical role in the cell and gene therapy development and manufacturing space, says Rose Biosolutions. Emerging bioprocessing technologies, production methods, and strategies are creating even more opportunities for contractors.
The post Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-2199680273.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Decentralization, AI, and, Gene, Editing, Are, Opportunities, for, CGT, Contractors</media:keywords>
<content:encoded><![CDATA[<p>Decentralization, artificial intelligence (AI) process modeling, and advances in gene editing are expanding the cell and gene therapy (CGT) production toolkit and creating opportunities for third-party contractors.</p>
<p>The CGT industry makes extensive use of CDMOs, with—depending on who you ask—anywhere between <a href="https://www.grandviewresearch.com/industry-analysis/cell-gene-therapy-manufacturing-market" target="_blank" rel="noopener">66%</a> and <a href="https://www.deloitte.com/content/dam/assets-zone3/us/en/docs/industries/life-sciences-health-care/2024/us-lshc-advanced-therapy-2024.pdf" target="_blank" rel="noopener">90%</a> of CGT production being outsourced to an external manufacturer.</p>
<p>Contractors play a pivotal role, in part, because they have the real-world production expertise that therapy developers lack, says Alan Smith, PhD, global head of innovation at <a href="https://www.prnewswire.com/news-releases/gi-partners-completes-acquisition-of-the-cdmo-and-cell-solutions-businesses-from-charles-river-laboratories-and-forms-rose-biosolutions-302765625.html" target="_blank" rel="noopener">recently founded</a> CDMO, Rose Biosolutions.</p>
<p>“Highly experienced CDMOs offer broad experience and capability, along with mastery of the activities required for a successful manufacturing, quality, and regulatory strategy needed to realize the partner developer’s vision.</p>
<p>“Good CDMOs build relationships; great CDMOs build relationships on trust, defined by competency and intimacy with their partners. The relationship has evolved with the needs of partner developers and grown to include expertise, experience, and trust,” he tells <em>GEN</em>.</p>
<p>Quality control expertise is a major outsourcing driver, according to Smith, who adds, “Strong quality systems employed by CDMO partners limit risk to product quality attributes that are of key concern in the logistics chain.</p>
<p>“A thorough understanding of key product quality attributes and appropriate product characterization lead to development of control strategies that ensure product consistency and meet the requirements of logistics chain,” he says.</p>
<h4><strong>Decentralization</strong></h4>
<p>In recent years, decentralized CGT manufacturing models, where patient-specific therapies are produced local to the intended recipients, have emerged as a way of minimizing transportation requirements.</p>
<p>And this is creating opportunities, says Jeff Mocny, PhD, vice president of scientific leadership at Rose, who tells <em>GEN</em>, “CDMOs can be uniquely positioned to accommodate the manufacturing needs of decentralized paradigms. Drawing on the expertise in product manufacture, required quality elements and expedited release strategies, they can enable high-quality, safe and effective delivery preparations to enable bedside production.”</p>
<h4><strong>Early adoption</strong></h4>
<p>According to <a href="https://www.simon-kucher.com/en/insights/cdmo-growth-report-2026" target="_blank" rel="noopener">analysis</a>, the CDMO space is competitive with most contractors seeking to differentiate themselves based on price and capabilities.</p>
<p>As a result, contractors tend to be well informed about potential market-reshaping advances in technology, Mocny says, citing systems that have recently emerged in the CGT space by way of example.</p>
<p>“There are many new gene editing strategies and gene delivery strategies which are likely to have a significant impact on the CGT space. Additionally, <em>in vivo</em> gene editing and gene delivery are showing promise in early studies and will likely have an impact on the direction that the industry is going.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/decentralization-ai-and-gene-editing-are-opportunities-for-cgt-contractors/">Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Crossing the Digital Validation Chasm</title>
<link>https://edusehat.com/en/crossing-the-digital-validation-chasm</link>
<guid>https://edusehat.com/en/crossing-the-digital-validation-chasm</guid>
<description><![CDATA[ An iterative, risk-based, model-driven digital validation strategy enables rapid responses to process changes and innovative technological implementations that would be slow to validate using traditional processes.
The post Crossing the Digital Validation Chasm appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-1357100011-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Crossing, the, Digital, Validation, Chasm</media:keywords>
<content:encoded><![CDATA[<p>A digital validation chasm exists between good manufacturing practices and the adoption of advanced control strategies, according to researchers at the Pharmaceutical Manufacturing Technology Center, University of Limerick. They <a href="https://link.springer.com/article/10.1007/s12247-026-11080-1" target="_blank" rel="noopener">propose</a> bridging that gap with a unified, risk-based digital validation workflow that combines process understanding and model-based design with accepted quality risk management and lifecycle-oriented validation principles.</p>
<p>The chasm between traditional validation processes and digital technologies isn’t a regulatory issue, one of the researchers, Dermot McMorrow, PDEng, assistant professor, digital manufacturing, tells <em>GEN</em>. “Increasingly…it’s more about translating risk-based, lifecycle validation principles into day-to-day engineering practice,” he adds.</p>
<p>“Guidance supports the use of automation, iterative development, digital tools, and critical thinking…but validation is still often implemented through sequential, document-centric qualification activities that are fragmented from engineering development,” McMorrow elaborates. “The challenge, therefore, is organizational and methodological—how to integrate process understanding, risk assessment, engineering development, verification, and evidence generation into a coherent lifecycle.”</p>
<p>The model predictive controller the team developed for pH regulation used a data-driven Hammerstein-Wiener model to help tune the controller and “a process and control focused analysis…to identify and prioritize relevant failure modes and to inform requirements and verification scope,” according to the researchers, who were led by Damian McCarthy, PhD, staff robotics test engineer, and senior author Eoin Hinchy, PhD, associate professor, automated manufacturing.</p>
<p>“The main benefit,” McMorrow says, “is that the workflow connects process understanding, quality risk management, controller development, requirements, verification, and deployment within the same engineering lifecycle. Rather than treating validation-related verification as something performed after engineering is complete, evidence can be generated as the system is developed.</p>
<p>“The approach also creates explicit traceability from identified risks through functional requirements and acceptance criteria to verification activities and resulting evidence,” he adds.</p>
<p>Consequently, verification efforts can focus on the most relevant risks, thus supporting both automated repeatable testing and physical challenge testing. Because process changes can be validated relatively easily, one practical barrier to continuous system enhancements may be overcome.</p>
<p>The team also demonstrated in a real-world setting “that the controller developed and verified within the model-based environment can be deployed within an industry programmable logic controller environment,” McMorrow says. “Using the standard IEC 61131-3 structured text format also provides an industrially recognized representation of the controller implementation and supports traceability within the wider model-based workflow.”</p>
<h4><strong>Iterative imperative</strong></h4>
<p>Implementing such a workflow change, particularly in a highly regulated environment, should be done iteratively, with ample testing and user feedback.</p>
<p>Key implementation points, the researchers note, include assessing the maturity of the innovation to be implemented and the organization’s level of readiness for that advancement. The team’s prior work provides structured tools, such as an innovation maturity rubric, to guide those assessments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>They found that model-based design-driven digital validation processes mitigated digital validation challenges. Specifically, they “streamlined compliance tasks, reduced resource burdens, and enhanced traceability, demonstrating the framework’s practicality in real-world settings,” according to McMorrow, in his earlier doctoral <a href="https://researchrepository.ul.ie/entities/publication/15208a65-ee25-4c78-8e73-dd34a5dacd7d" target="_blank" rel="noopener">research</a>.</p>
<p>The team’s proposed workflow “has the potential to reduce reliance on repeated manual testing and documentation,” McMorrow says, and thus support the real-time reconfigurations needed in modern production environments.</p>
<p>But, McMorrow cautions, “Any industrial implementation would still need to be incorporated into the organization’s own quality system, validation strategy, and regulatory context. The study…is a practical proof-of-concept…rather than a pre-validation solution ready for direct deployment.” Related work by this team has also applied model-based validation approaches to new and existing equipment, including legacy programmable logic controller systems.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/crossing-the-digital-validation-chasm/">Crossing the Digital Validation Chasm</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections</title>
<link>https://edusehat.com/en/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections</link>
<guid>https://edusehat.com/en/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections</guid>
<description><![CDATA[ A controlled human trial reveals how preexisting antibodies influence dengue virus replication and immune responses, offering insights to develop safer, more broadly protective vaccines against all four dengue strains.
The post Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-1572391417-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 29 Oct 2026 01:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, Dengue, Study, Reveals, How, Preexisting, Immunity, Shapes, Secondary, Infections</media:keywords>
<content:encoded><![CDATA[<p>Roughly half of the world’s population is now at risk of dengue, with an estimated 100–400 million infections occurring each year. The viral infection (also known as break-bone fever) is more common in tropical and subtropical areas of the world. Currently, prevention relies on control of the mosquito vector that transmits the virus.</p>
<p>Dengue virus has a particularly unique challenges, and is especially pernicious compared with many other viruses, as secondary infections can be worse than the first. Now, a new Phase I trial involving controlled infections in human volunteers provides new details about how preexisting immunity and anti-dengue antibodies affect the nature of secondary infections with dengue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The work is published in <em>Science Translational Medicine</em> in the paper, “Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses.”</p>
<p>The findings are among the first to glean insights using a large controlled human challenge, and could inform future therapeutics and the design of more broadly protective vaccines.</p>
<p>Secondary infections with dengue are often the most severe ones because preexisting antibodies can boost viral counts and raise the risk of severe symptoms. This has frustrated the development of badly needed vaccines for dengue. Furthermore, it’s been challenging to understand how pre-infection affects dengue outcomes, as animal models have many limitations and patients usually don’t present until after viral counts have peaked.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>In this study, researchers recruited 45 healthy adults who had either zero, one, or more than one prior infection with any of the four strains of dengue virus (DENV1-DENV4). The volunteers received injections of a live, weakened strain of DENV3 in a challenge study, allowing the researchers to fully interrogate dengue immunity dynamics in humans in a safe and controlled setting.</p>
<p>The findings led to various conclusions: for example, people whose antibodies boosted the replication of the virus had the highest viral counts and waning of CD8-bearing T cells and antibodies. Additionally, people who had higher amounts of antibodies against the viral nonstructural protein 1 displayed more balanced immune responses and lower viral counts.</p>
<p>More specifically, the authors write, “Viremia was associated with more, but still mild, clinical signs and symptoms, and secondary infection resulted in greater viremia, neutralizing antibodies, and protective T cell responses. However, those whose baseline antibodies most efficiently increased dengue virus replication in an <em>in vitro</em> assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies. In contrast, higher baseline antibodies against the nonstructural protein 1 of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells, revealing how vaccines can induce broad, long-­lasting protection.”</p>
<p>“Collectively, this work confirms multiple hypotheses generated by natural history studies and reveals the optimal conditions for inducing potent and persistent immunity against DENV1 to DENV4,” they note.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/human-dengue-study-reveals-how-preexisting-immunity-shapes-secondary-infections/">Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE panels tackle challenges to access and barriers to coverage</title>
<link>https://edusehat.com/en/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage</link>
<guid>https://edusehat.com/en/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage</guid>
<description><![CDATA[ Breakthrough therapies can change the lives of patients who previously had few or no treatments for their conditions, but only if the patients can […]
The post PACE panels tackle challenges to access and barriers to coverage appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Death-by-1000-cuts.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 18:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE, panels, tackle, challenges, access, and, barriers, coverage</media:keywords>
<content:encoded><![CDATA[<p><span>Breakthrough therapies can change the lives of patients who previously had few or no treatments for their conditions, but only if the patients can break through the barriers to accessing those drugs.</span></p>
<p><span>Challenges to access were a primary focus of BIO’s 15</span><span>th</span><span> annual Patient Advocacy Changemakers Event, the premier gathering of patients, advocates, drugmakers, and policymakers, held Oct. 22-23 in Washington, DC. There were several expert panels specifically exploring the challenges of overcoming barriers to coverage for drugs patients need.</span></p>
<p><span>Below are some of the lessons offered.</span></p>
<h2>Death by a thousand cuts: Utilization management</h2>
<p><span>During </span><a href="https://pace.bio.org/2026-program/death-thousand-cuts-1"><span>a session on interconnected challenges </span></a><span>restricting patient access, one utilization management approach panelists discussed was step therapy, which asks patients to fail first on a cheaper drug before getting the drug their doctor prescribed. Panelists said patients feel trapped and frightened when told they can’t get the medicine their doctor recommends.</span></p>
<p><span>The social workers at CancerCare can receive a thousand calls a week from such patients, said Kim Czubaruk, VP of Policy at CancerCare.</span></p>
<p><span>“But behind each call is a patient or a caregiver that really is probably in the toughest moment of their life,” she added.</span></p>
<p><span>The number of people who need help is more than any patient group can handle, said panelist Brian Connell, VP of Federal Affairs at Blood Cancer United. “There are folks who fall through the cracks and don’t get the right treatment. I think that points to the need for broader systemic reform.”</span></p>
<h2>Enabling coverage of new drugs</h2>
<p><a href="https://pace.bio.org/2026-program/getting-runaround-games-payers-play--1"><span>Another session </span></a><span>explored best practices for patient groups seeking to engage payers to ensure coverage for new breakthrough therapies.</span></p>
<p><span>Mike Graglia, CEO of Cure SYNGAP1, said the rare neurodevelopmental disease SYNGAP1 has many symptoms—like seizures and disturbed sleep—that can be treated with other drugs, and other symptoms unaddressed by existing treatments—including a tendency to violence. There are genetic treatments for SYNGAP1 in the pipeline, and Graglia’s group wants to make sure they will be covered by insurance.</span></p>
<p><span>“We’re going to survey our own community and try to measure the impact—the lost earnings, the divorces, the mental health burden, the burden on siblings, all the things that are really easy to talk about, but really actually hard to measure,” he explained.</span></p>
<p><span>When an insurer does not agree to put a new drug in its formulary, patients and their advocates can appeal the decision, sometimes with good effect, panelists said.</span></p>
<p><span>“My message for everyone here is, number one: Always appeal, and tell your whole community, always appeal, especially in the age of AI, where we know 80% of these denials are overturned on appeal,” said Melanie Lendnal, SVP of Policy & Advocacy at ALS Association.</span></p>
<p><span>“In urgent situations, you can ask for an expedited appeal, and get an answer within 72 hours,” added Monica Bryant, Co-Founder of Triage Cancer. She said few in the patient community are aware of this possibility, and even healthcare professionals are surprised to hear it.</span></p>
<h2>From clinical guidelines to access in the clinic</h2>
<p><span>One tool patients and health care professionals can use as evidence in promoting coverage for a new drug is </span><a href="https://pace.bio.org/2026-program/clinical-guidelines-access"><span>through clinical guidelines, according to a session</span></a><span> moderated by Lenja Wiehe, Director, Global Patient Advocacy Lead at Alexion.</span></p>
<p><span>“We all share a responsibility to make sure that scientific progress translates into better care for patients,” Wiehe said. “And clinical guidelines can help us to get there. They turn evolving evidence into recommendations for care; they support patient-clinician conversations; and they provide an important reference point for decisions about care.”</span></p>
<p><span>Unfortunately, many rare disease drugs lack clinical guidelines, which generally need to be developed by government agencies and expert panels, said Jamie Sullivan, SVP of Policy and Advocacy at RARE Foundation.</span></p>
<p><span>According to one study, “Over 60% of the orphan drugs lacked a clinical guideline to begin with,” Sullivan said. “And so it’s just a lack of another input that payers can use” to improve coverage. </span></p>
<h2>By the numbers</h2>
<p><span>Meaningful data can be used to reduce barriers and advance policy that increases access, according to a session on </span><a href="https://pace.bio.org/2026-program/-stories-statistics-shape-smart-policy"><span>telling stories with statistics</span></a><span>.</span></p>
<p><span>Patient surveys can provide the data that helps make meaningful arguments, said Lynn Albizo, Chief Public Policy Officer of the Immune Deficiency Foundation.</span></p>
<p><span>“We use those surveys to get our statistics, particularly for our rare disease community. We can get down to specifically how many people with primary immunodeficiency on IG therapy are on Medicare,” she said. “I have tables of those statistics that I use to be able to share data with legislators.”</span></p>
<p><span>A compendium of annually updated data from peer-reviewed literature can make a high-impact handout said Robert Egge, Chief Public Policy Officer of the Alzheimer’s Association.</span></p>
<p><span>But there are times when numbers can work against you, warned Jennifer Dexter, SVP of Policy and External Affairs at the National Health Council. For example, when seeking Medicare Part D coverage for a rare disease drug, her group sometimes hears that only a small group of people will be served.</span></p>
<p><span>“We have to be there saying ‘It’s our people, it’s the people we’re representing who make up that small number.’ And we really have to put a face to it to overcome the small numbers,” she said.</span></p>
<p>The post <a href="https://bio.news/federal-policy/pace-panels-tackle-challenges-to-access-and-barriers-to-coverage/">PACE panels tackle challenges to access and barriers to coverage</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bonjour Genomics: A Video from ASHG</title>
<link>https://edusehat.com/en/bonjour-genomics-a-video-from-ashg</link>
<guid>https://edusehat.com/en/bonjour-genomics-a-video-from-ashg</guid>
<description><![CDATA[ GEN editors Uduak Thomas and Julianna LeMieux, PhD, recap ASHG, highlighting key sessions, Ultima Genomics’ user group meeting, Illumina news, and insights from PacBio’s new CEO Mark Van Oene.
The post Bonjour Genomics: A Video from ASHG appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1177333932.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bonjour, Genomics:, Video, from, ASHG</media:keywords>
<content:encoded><![CDATA[<p>Uduak Thomas, Senior Editor at <em>GEN</em>, took a minute away from the talks, posters, and expo hall to join Julianna LeMieux, PhD, <em>GEN’</em>s Deputy Editor in Chief, to talk about the meeting, the sessions they attended, and the trends that they are noticing.</p>
<p>Although they had only been at the meeting for a day, there was plenty to discuss: Ultima Genomics’ user group meeting, the opening Presidential address given by ASHG President Susan Slaugenhaupt, PhD, Illumina’s news, and an interview with PacBio’s new CEO Mark Van Oene. PhD.</p>
<p> </p>
<div>
<div><br>
</div>
</div>
<p>The post <a href="https://www.genengnews.com/topics/omics/bonjour-genomics-a-video-from-ashg/">Bonjour Genomics: A Video from ASHG</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial</title>
<link>https://edusehat.com/en/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial</link>
<guid>https://edusehat.com/en/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial</guid>
<description><![CDATA[ Researchers found that the vitamin B5 derivative pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine in combination with topical calcipotriol/betamethasone dipropionate helped to alleviate symptoms. 
The post Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/11/Getty_872062320_Psoriasis.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Vitamin, Derivative, Pantethine, Alleviates, Psoriasis, Symptoms, Small, Human, Trial</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at State Key Laboratory of Biomedical Analysis (SKLBA) (formerly known as National Center of Biomedical Analysis) in Beijing have discovered that the vitamin B5 derivative pantethine limits the activity of dendritic cells (DCs), which are immune cells that are key contributors to autoimmune diseases such as psoriasis. The newly reported study showed that pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine in combination with topical calcipotriol/betamethasone dipropionate helped to alleviate symptoms.</p>
<p>In their published study in <em>Journal of Experimental Medicine</em> (<em>JEM</em>) (“<a href="http://dx.doi.org/10.1084/jem.20252558" target="_blank" rel="noopener">Vanin-pantethine metabolic axis shapes dendritic cell function and affects inflammatory disorder progression</a>,”) senior author Wei-Na Zhang, PhD, a researcher at the State Key Laboratory of Biomedical Analysis, and colleagues, suggested that their findings point to “… a potentially viable metabolic strategy for DC-centered intervention in AIDs [autoimmune diseases].” Zhang co-led the new <em>JEM</em> study with Qing Xia PhD, Ai-Ling Li, PhD, and Tao Zhou, PhD, also from the State Key Laboratory of Biomedical Analysis, and Cheng-Xin Li, PhD, from The First Medical Center of Chinese PLA General Hospital in Beijing.</p>
<p>Dendritic cells are specialized immune cells that help to coordinate the different parts of the immune system. They can engulf and present foreign antigens to activate highly specific T cells, as well as secrete a variety of immune signaling molecules to recruit other types of immune cells and promote inflammation. Because of this central role in directing immune responses, abnormal activation of dendritic cells is thought to underlie a variety of autoimmune diseases, including psoriasis. “Aberrant activation of dendritic cells (DCs) is intricately associated with inflammatory diseases, rendering DCs an appealing therapeutic target,” the authors wrote. “Metabolites are emerging as crucial regulators of DCs, yet therapeutic strategies targeting DC metabolism for inflammatory diseases remain underexplored.”</p>
<p>Zhang further added, “Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression. But therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored.”</p>
<p>Through their study the team found that levels of metabolic enzymes known as Vanins are elevated in the dendritic cells of patients with psoriasis and several other autoimmune diseases. Vanin enzymes convert the metabolite pantethine into vitamin B5, an essential nutrient required for cellular energy production. Pantethine itself is a widely available nutritional supplement often used to lower blood cholesterol levels due to its ability to inhibit cholesterol synthesis. Intriguingly, cholesterol can promote the activation of dendritic cells, and high blood cholesterol is a major risk factor for the development of psoriasis.</p>
<p>Through their study the team showed that depleting these enzymes inhibited dendritic cell activation and limited their ability to activate T cells. Moreover, treating mice with a drug that inhibits Vanins prevented the animals from developing psoriasis.</p>
<p>Zhang and colleagues determined that increased Vanin activity in dendritic cells reduces panthetine levels, leading to increased cholesterol synthesis and dendritic cell hyperactivation. Replenishing pantethine levels reversed this process, lowering the accumulation of cholesterol and suppressing dendritic cell activation. “Pantethine supplementation or pharmacologically induced Vanin inhibition reduces cholesterol overload, impedes DC activation, and mitigates psoriasiform inflammation,” they wrote.</p>
<figure aria-describedby="caption-attachment-339879" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339879" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al-300x165.jpg" alt="Psoriasis patients prescribed pantethine capsules in addition to topical ointments show a marked improvement in symptoms after 3 months of treatment (bottom). [© 2026 Cao et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20252558]" width="300" height="165" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al-300x165.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Cao_et_al.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Psoriasis patients prescribed pantethine capsules in addition to topical ointments show a marked improvement in symptoms after three months of treatment (bottom). [© 2026 Cao et al. Originally published in <a href="https://doi.org/10.1084/jem.20252558" target="_blank" rel="noopener"><em>Journal of Experimental Medicine</em></a>]</figcaption></figure>
<p>“We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the upregulation of Vanins,” Zhang noted.</p>
<p>To investigate further the researchers initiated a small-scale trial of pantethine supplementation in 24 human psoriasis patients. Every patient was treated with topical calcipotriene/betamethasone ointment, but half of the patients also received oral pantethine. Over the course of 12 weeks, patients given the additional pantethine treatment showed improved symptoms, particularly if they had elevated blood cholesterol levels at the start of the trial. “Importantly, our clinical trial revealed that pantethine combination therapy significantly decelerates the progression of psoriasis in patients,” they reported.</p>
<p>Zhang commented, “Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation. Overall, our study uncovers the Vanin-pantethine-cholesterol axis as a key metabolic pathway governing dendritic cell activation and provides a foundation for therapeutic strategies targeting several dendritic cell–mediated autoimmune diseases.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/vitamin-derivative-pantethine-alleviates-psoriasis-symptoms-in-small-human-trial/">Vitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die</title>
<link>https://edusehat.com/en/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die</link>
<guid>https://edusehat.com/en/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die</guid>
<description><![CDATA[ In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy while the second experienced sudden death.
The post Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Artiva_Facilties_Exterior_Updated-RESIZE1220.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 28 Oct 2026 04:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Artiva, Axes, 94, Workforce, Weighs, Strategic, Alternatives, After, Two, Patients, Phase, IIa, Trial, Die</media:keywords>
<content:encoded><![CDATA[<p>Artiva Biotherapeutics said it will eviscerate its workforce 94% and evaluate strategic options after two patients treated with its lead candidate in a Phase IIa trial died—though one death was unrelated to the treatment.</p>
<p>Artiva has ended development of the lead candidate, a non-genetically modified, allogeneic, cryopreserved NK cell therapy called AlloNK<sup>®</sup> and also called AB-101. AlloNK had been evaluated in a Phase IIa “basket” trial (<a href="https://clinicaltrials.gov/study/NCT06991114" target="_blank" rel="noopener">NCT06991114</a>) assessing the candidate in rheumatoid arthritis (RA), Sjögren’s Disease, idiopathic inflammatory myopathies, and systemic sclerosis in combination with rituximab—the monoclonal antibody treatment for arthritis and several forms of cancer marketed by Roche’s Genentech subsidiary and Biogen as Rituxan<sup>®</sup>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety events. One patient succumbed to leukoencephalopathy, a fatal neurological event, following treatment, which included protocol-specified lymphodepletion with cyclophosphamide and fludarabine.</p>
<p>“The investigator and an independent safety review assessed the event as likely related to fludarabine-associated neurotoxicity,” Artiva said in a statement. “Given the widespread use of fludarabine-containing lymphodepletion regimens in cell therapy development, Artiva intends to share additional details of this case in a scientific publication.”</p>
<p>After reporting the event to the FDA and the trial’s data safety monitoring board (DSMB), the agency requested that Artiva pause enrollment and dosing in the Phase IIa study, Artiva said. The company also paused its plans to begin enrollment and dosing in a Phase III trial of AlloNK.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The second patient experienced sudden death approximately two months after beginning study treatment. “The investigator assessed this event as unrelated to AlloNK or any other component of the study treatment regimen, and the cause of death has not been determined,” Artiva stated, adding that the second death was also reported to the FDA and DSMB.</p>
<h4><strong>‘Deeply saddened’</strong></h4>
<p>“Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority. We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families,” Artiva CEO Fred Aslan, MD, stated. “We plan to provide findings from the first case, which was assessed as likely related to fludarabine toxicity, given its widespread use in cell therapy conditioning regimens.”</p>
<p>In halting development of AlloNK, Artiva also cited uneven clinical data as well as an assessment of the therapy’s risks and benefits, the likelihood of future enrollment delays, and the overall development and potential commercial outlook.</p>
<p>According to the company, the data “continued to demonstrate deep B cell depletion and clinical activity consistent with the Company’s previously reported findings.”</p>
<p>“However, longer-term follow-up did not reflect the level of durability of clinical response the Company believes is needed to support continued development,” Artiva added. “The Company will work closely with the FDA, investigators, and institutional review boards to ensure an appropriate and orderly close-out of its clinical development program, including continued safety monitoring and reporting as required.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>As a result, Artiva has canceled a presentation of AlloNK clinical data at the upcoming ACR Convergence 2026 conference, to be held November 6-11 in Orlando, FL. The company is also canceling an investor webcast it had scheduled for November 9.</p>
<p>“Updated clinical data may be presented at future scientific meetings depending on the outcome of the strategic alternatives process,” Artiva added.</p>
<p>Investors responded to Artiva’s announcement with a stock selloff that sent shares tumbling 30.5% on Tuesday, from $6.16 to $4.27 as of 2:04 p.m. ET.</p>
<h4><strong>Analyst downgrades</strong></h4>
<p>Several investment firms downgraded their ratings of Artiva stock, including Cantor Fitzgerald, TD Cowen, Needham & Co., H.C. Wainwright, and Wedbush—where David Nierengarten, PhD, managing director and a senior analyst covering small-mid cap biotech stocks, cut his firm’s rating from “Outperform” to “Neutral” and slashed its 12-month price target 90% from $40 to $4.</p>
<p>Artiva also retained Leerink Partners to assist in the company’s strategic review, which will entail evaluating internal options and potential strategic alternatives intended to maximize stockholder value.</p>
<p>Among options under review, Artiva said, include a merger, business combination, sale or licensing of assets, dissolution, and liquidation. Artiva does not plan to offer updates on the review “unless and until the Board of Directors has approved a specific course of action, the process has concluded, or the Company determines that further disclosure is appropriate or required by law.”</p>
<p>Artiva will also carry out a reduction of its workforce by approximately 94%. That would amount to roughly 98 of the 104 full-time employees that Artiva employed as of June 30, according to the company’s <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001817241/0c3c7f0b-10f5-4c7b-b009-26e549fa823a.pdf" target="_blank" rel="noopener">Form 10-Q quarterly report for the second quarter</a>, filed August 6 with the U.S. Securities and Exchange Commission.</p>
<p>As of September 30, 2026, Artiva said in its statement, it had approximately $319.1 million in cash, cash equivalents and investments—a preliminary and unaudited figure, the company cautioned. The announcement did not quantify how much Artiva expects to spend on its planned workforce reduction.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Complete quarterly results will be included in Artiva’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/artiva-axes-94-of-workforce-weighs-strategic-alternatives-after-two-patients-in-phase-iia-trial-die/">Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers</title>
<link>https://edusehat.com/en/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers</link>
<guid>https://edusehat.com/en/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers</guid>
<description><![CDATA[ Blood cancers carry complex genomic rearrangements that no single assay fully captures. At ASHG 2026 in Montréal, Nabsys presented early data comparing its Electronic Genome Mapping technology with established cytogenetic methods and previewed new analysis software for hematologic malignancies.
The post ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/Getty_1441707827_leukemiaWhiteBloodCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Nabsys, Links, Cytogenetics, and, Genomics, Map, Hematologic, Cancers</media:keywords>
<content:encoded><![CDATA[<p>Blood cancers are often driven by large-scale genomic rearrangements, including translocations, deletions, duplications, and other structural and copy number changes, that no single assay captures well. In practice, characterizing a hematologic malignancy can mean piecing together results from karyotyping, fluorescence <em>in situ</em> hybridization (FISH), chromosomal microarray, and sequencing, each with its own resolution limits and blind spots.</p>
<p>Nabsys is positioning its Electronic Genome Mapping (EGM) technology as one way to close some of those gaps. At the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20–24 in Montréal, the Providence, RI-based company shared preliminary data on EGM in hematologic malignancies and previewed analysis software built for that application.</p>
<h4><strong>Bridging two disciplines</strong></h4>
<p>In a Nabsys-sponsored CoLab session on October 22, Alka Chaubey, PhD, FACMG, the company’s chief medical and genomics officer, presented “Electronic Genome Mapping in Hematologic Malignancies: Bridging Cytogenetics and Molecular Genomics” on behalf of Brynn Levy, MSc(Med), PhD, FACMG, of Columbia University. The talk covered early findings on how well EGM detects structural and copy number variants, including how its results compared with established cytogenetic methods.</p>
<p>The work builds on OhmX Platform installations at Columbia University Medical Center, awarded through the RAMP UP Program from Hitachi High-Tech America and Nabsys. Running on OhmX, EGM is designed to give a high-resolution, genome-wide view of structural and copy number variation. Nabsys frames the technology as a complement to existing tools rather than a replacement.</p>
<p>“Researchers need a more complete view of the complex genomic changes in hematologic cancers,” said Barrett Bready, MD, Nabsys’s founder and CEO. “These preliminary findings highlight EGM’s potential to complement established methods.”</p>
<h4><strong>Software shaped by users</strong></h4>
<p>Alongside the data, Nabsys demonstrated Nabsys Navigator<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, its cloud-based platform for EGM analysis and visualization. Navigator includes two pipelines: SV-Discover<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, for genome-wide structural variant analysis, and SV-Verify<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, for confirming structural variants flagged by other technologies. Booth visitors could also preview the company’s forthcoming hematologic malignancy analysis software, the same tool used to analyze samples in Chaubey’s presentation, and weigh in on its development. Bready said the company is “pairing that work with software development shaped directly by the researchers who will use it.” The OhmX Platform is for research use only and is not intended for diagnostic procedures.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-nabsys-links-cytogenetics-and-genomics-to-map-hematologic-cancers/">ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis</title>
<link>https://edusehat.com/en/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis</link>
<guid>https://edusehat.com/en/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis</guid>
<description><![CDATA[ In this GEN webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states. 
The post Single-Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2135397939_ColonCancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 21:10:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Cell, Multiomics:, Phenotypic, Plasticity, Colorectal, Cancer, Metastasis</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/MirjanaEfremova_headshot.jpg" class="h-full w-full object-cover" alt="Image of Mirjana Efremova, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Mirjana Efremova, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Senior Lecturer<br>Queen Mary University of London</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/MirjanaEfremova_headshot.jpg" alt="Image of Mirjana Efremova, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Mirjana Efremova, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Mirjana Efremova earned a PhD in computational biology at the Medical University of Innsbruck, Austria, where she investigated the process of clonal evolution of cancer under immunosurveillance and how the immune system shapes tumor progression. She did her post-doctoral work at the Teichmann Lab, Wellcome Sanger Institute, where she co-led the development of the first human atlas of the maternal-fetal interface in early pregnancy using single cell transcriptomics. She also developed a cell-cell communication statistical framework CellPhoneDB (www.cellphonedb.org) for predicting enriched receptor-ligand pairs between the different cell types and inference of cellular communication networks.  In May 2020, she started a lab at Barts Cancer Institute, Queen Mary University of London (U.K.) within the Centre for Cancer Evolution. Her lab is focused on investigating the non-genetic mechanisms driving cancer initiation, metastasis, and therapy resistance.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 19, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-19T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Phenotypic plasticity—the ability of tumor cells to switch states in response to their environment—drives colorectal cancer (CRC) progression, metastasis, and therapy resistance, but what controls it has been unclear. The application of single-cell multiomics and spatial transcriptomics in primary and metastatic tumor samples can reveal regenerative and inflammatory cancer cell states.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states. These regenerative and inflammatory cancer cell states resemble metastasis-initiating cells in mouse models, are regulated by the transcription factors AP-1 and NF-κB, and sit at the invasive edge in an immunosuppressive niche. Improved understanding of these microenvironment-driven states and their regulators offers researchers new ways to target metastasis.</p>


<p class="wp-block-paragraph">Webinar attendees will learn more about:</p>


<ul class="wp-block-list">
<li>The regenerative and inflammatory cancer cell states found in primary and metastatic CRC, including a hybrid regenerative/stem state, and how liver metastases re-establish the primary tumor’s heterogeneity;</li>



<li>Transcriptional regulation of these states as well as signals from fibroblasts, macrophages, and T cells, and where the states sit in the tumor; and</li>



<li>How to apply single-cell multiomics and spatial transcriptomics to link cell state, regulation, and tissue location, and identify candidate targets to limit plasticity and metastasis.</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.10xgenomics.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="77" src="https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-300x77.jpg" alt="10x Genomics logo" class="wp-image-129310" srcset="https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-300x77.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-768x197.jpg 768w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1024x263.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-696x178.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1392x359.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo-1068x274.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2019/10/10x_Logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/single-cell-multiomics-phenotypic-plasticity-in-colorectal-cancer-metastasis/">Single-Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spatial Proteomics for Precision Oncology</title>
<link>https://edusehat.com/en/spatial-proteomics-for-precision-oncology</link>
<guid>https://edusehat.com/en/spatial-proteomics-for-precision-oncology</guid>
<description><![CDATA[ In this GEN webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples. 
The post Spatial Proteomics for Precision Oncology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_1786420513_StomachCancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spatial, Proteomics, for, Precision, Oncology</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/BerndBodenmiller_headshot.jpg" class="h-full w-full object-cover" alt="Image of Bernd Bodenmiller, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Bernd Bodenmiller, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Associate Professor<br>Dept. of Quantitative Biomedicine<br>University of Zürich<br>ETH Zürich, Switzerland</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/BerndBodenmiller_headshot.jpg" alt="Image of Bernd Bodenmiller, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Bernd Bodenmiller, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Bernd Bodenmiller, PhD, is a quantitative biologist who develops novel experimental and computational approaches for the quantitative analysis of tumor ecosystems to improve our understanding of the mechanisms of tumor development. He is the founding director of the Department of Quantitative Biomedicine (DQBM) at the University of Zürich, which fosters research and education at the interface of biomedical research, biotechnology, and computational biology to guide development of next-generation precision medicine. His group has pioneered the development of imaging mass cytometry, which enables the simultaneous imaging of dozens of proteins and transcripts in tumor tissues and the histoCAT software toolbox. His group applies these methods to unravel how cells in the tumor ecosystem drive cancer development to identify mechanisms that might be exploited for therapeutic targeting.</p>
<p>Bodenmiller obtained his PhD in the group of Ruedi Aebersold, PhD, at ETH Zürich. For his postdoctoral training, he joined the laboratory of Garry Nolan, PhD, at Stanford University. In 2012, he became a group leader and in 2013 an SNF/ERC assistant professor at the University of Zürich. In 2019, he was tenured and became the founding director of the DQBM. In October 2020, Bodenmiller was appointed as Dual Professor for Quantitative Biomedicine at UZH and ETH Zürich.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Monday, November 16, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-16T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Tumors are complex cellular ecosystems in which cancer cell phenotypes, their spatial organization, and their interactions with immune and stromal compartments determine disease progression and therapy response. To resolve this complexity, the use of highly multiplexed Imaging Mass Cytometry<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (IMC<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">) together with multiomic profiling and artificial intelligence (AI) can identify clinically relevant features of the tumor microenvironment, providing a rich framework for patient stratification and targeted therapy in precision oncology.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples. In a study of 323 epithelial ovarian cancers, tumors with more diverse cell phenotypes and spatial organization recurred faster. His lab also identified a therapy-resistant tumor cell phenotype (TUBB3+/pRB+) associated with recurrence and poor response to standard therapy. Spatial transcriptomics and <em>ex vivo</em> drug screening of 3D sphere models and patient samples showed that these cells resist standard-of-care agents but are sensitive to specific inhibitors. In 498 clear cell renal cell carcinomas, the use of AI revealed three survival ecotypes that predict survival better than basic clinical data and molecular stratification models. Each ecotype has its own genomic and metabolic features and is predictive of treatment outcome. Deep learning predicted the ecotypes directly from routine H&E slides, and the findings were validated across five cohorts comprising more than 2,500 patients.</p>


<p class="wp-block-paragraph">Webinar attendees will learn how integrating spatial single-cell proteomics by IMC with multiomics and AI identifies therapy-resistant cell populations and prognostic tumor ecosystems. This approach provides a detailed framework for patient stratification and targeted therapy in precision oncology.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://standardbio.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="214" src="https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-300x214.png" alt="Standard Biotools logo" class="wp-image-221017" srcset="https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-300x214.png 300w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-768x549.png 768w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-696x497.png 696w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-588x420.png 588w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo-100x70.png 100w, https://www.genengnews.com/wp-content/uploads/2023/02/standardbio_logo.png 785w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/spatial-proteomics-for-precision-oncology/">Spatial Proteomics for Precision Oncology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anthropic IPO Discloses Plans for Life Sciences Growth</title>
<link>https://edusehat.com/en/anthropic-ipo-discloses-plans-for-life-sciences-growth</link>
<guid>https://edusehat.com/en/anthropic-ipo-discloses-plans-for-life-sciences-growth</guid>
<description><![CDATA[ Anthropic’s Form S-1 Registration Statement did not reveal what research areas it is pursuing through the molecular biology lab it disclosed last month, and what if any new therapies it is seeking to discover and develop. But the IPO filing said that Anthropic is creating AI agents based on its Claude family of large language models that focus beyond accelerating drug discovery and development, toward handling many of the physical tasks associated with creating new therapies. 
The post Anthropic IPO Discloses Plans for Life Sciences Growth appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ANTHROPIC-LAB-IMAGE-ORIGINAL-CROP11111-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anthropic, IPO, Discloses, Plans, for, Life, Sciences, Growth</media:keywords>
<content:encoded><![CDATA[<p>Anthropic plans to expand its growing presence in life sciences by investing further in knowledge, talent, partnerships, and additional acquisitions, the artificial intelligence (AI) giant disclosed in its long-awaited initial public offering (IPO) filing.</p>
<p>Anthropic’s <a href="https://www.sec.gov/Archives/edgar/data/2130357/000162828026067168/anthropicpbc-sx1.htm" target="_blank" rel="noopener">Form S-1 Registration Statement</a>, filed Monday with the U.S. Securities and Exchange Commission, did not reveal key details such as what research areas it is pursuing through the molecular biology lab it disclosed last month, and what if any new therapies it is seeking to discover and develop. Nor did it quantify Anthropic’s total spending on life science activity.</p>
<p>The IPO filing also did not say how much money Anthropic seeks to raise on Wall Street—how many shares at what price—though news reports have had the company pursuing an eye-popping valuation of $2 trillion, 13% above the $1.77 trillion valuation of Elon Musk’s SpaceX when it went public in June. Anthropic plans to begin trading public shares on the Nasdaq Global Select Market under the ticker symbol ANT.</p>
<p>However, the filing said that Anthropic is creating AI agents based on its Claude family of large language models that focus beyond accelerating drug discovery and development, toward handling many of the physical tasks associated with creating new therapies.</p>
<p>“Claude is used in drug discovery and development by our customers, our biotechnology partners, and our own researchers. We are building AI agents that support scientists at each stage of that process,” Anthropic stated.</p>
<p>“Beyond knowledge work, we believe frontier AI has the power to transform physical work. Advances in Claude’s general capabilities, together with our Model Hardware Standard, now allow it to operate lab and manufacturing equipment such as microscopes, liquid handlers, and off-the-shelf robotic arms.”</p>
<p>In August, Anthropic publicly <a href="https://www.anthropic.com/news/model-hardware-standard-research-preview" target="_blank" rel="noopener">previewed</a> its Model Hardware Standard (MHS), which began as a collaboration between Anthropic and Howard Hughes Medical Institute (HHMI) Janelia Research Campus. Anthropic described HMS as “a shared specification for AI agents to safely operate physical devices, to a first group of scientific research labs and advanced manufacturers.”</p>
<p>“Currently in research preview, our Model Hardware Standard enables AI agents to find, understand, and safely operate lab and manufacturing equipment such as microscopes, liquid handlers, and off-the-shelf robotic arms,” Anthropic explained in its IPO filing. “Our Model Hardware Standard is model-agnostic and lets any agent harness reach devices with a programmable interface through standard protocols such as MCP.”</p>
<h4><strong>AI workbench</strong></h4>
<p>And in June, Anthropic <a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">released Claude Science</a>, an AI workbench for scientists that consolidates fragmented research tools, including more than 60 scientific databases and connectors pre-configured for genomics, proteomics, structural biology, and more, into a single reasoning layer. One Anthropic partner, Basecamp Research, has made available through Claude Science its antibiotic design and vaccine target prediction <a href="https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1" target="_blank" rel="noopener">EDEN models</a> for global public health research.</p>
<p>In the IPO filing, Anthropic also summarized many—though not all—of its recent life-sci activities: “To build the best tools for the industry, we have invested in deep life sciences expertise of our own, hiring industry experts, building a molecular biology lab, acquiring Coefficient Bio, and partnering with industry leaders.”</p>
<p>Those efforts have paid off, the company said: As of September 30, 2026, Anthropic included among its customers “nine of the 10 largest” pharmaceutical companies, without disclosing their names. Those 10 are among the over 50% of the Fortune 500 that Anthropic counts among its customers with $100,000 or more of revenue on a TTM [trailing 12 months] basis. Anthropic added that every company in the Fortune 10, and more than 30% of the Forbes Global 2000 were also among its customers with $100,000+ revenue TTM.</p>
<p>Anthropic is carrying out life sciences research through a molecular biology lab and a research group <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit/" target="_blank" rel="noopener">formed earlier this year</a> “to see whether general AI models can systematize and accelerate discoveries capable of revolutionizing biology and medicine,” the company stated last month. “Our focus is on fundamental biology research using Claude: exploring datasets of DNA to identify uncharacterized protein families, generating hypotheses at scale, and testing them through experiments in the lab.”</p>
<p>The IPO filing offered no details about how many researchers are based at the lab, and how much R&D spend the lab accounts for of Anthropic’s total research and development expense. That expense jumped more than quintupled during the first six months of this year, to $9.741 billion from $1.85 billion in January-June 2025. For all of last year, Anthropic spent a total $6.338 billion on R&D, according to the Form S-1.</p>
<p>The research lab generated worldwide headlines last month when Anthropic <a href="https://www.anthropic.com/research/claude-discovers-novel-enzyme-system" target="_blank" rel="noopener">announced</a> that its Claude large-language model “discovered a novel enzyme system with properties reminiscent of CRISPR, with only high-level direction from our scientists.”</p>
<p><a href="https://x.com/DarioAmodei/status/2102831170299834652?s=43" target="_blank" rel="noopener">Elaborating further in a post on X</a>, Anthropic CEO Dario Amodei described the novel enzyme system as “a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student.”</p>
<h4><strong>‘Something interesting’</strong></h4>
<p>“The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out,” Amodei added.</p>
<p>In April, tech news outlets <em>The Information</em> and the Substack-based <em>Newcomber</em> newsletter founded by Eric Newcomber first reported that Anthropic acquired the stealth AI biotech startup Coefficient Bio for about $400 million in stock. Anthropic confirmed the acquisition though not the price in its IPO, saying it bought the company “to accelerate our research in the life sciences.”</p>
<p>Founded last year, Coefficient has developed an AI platform for purposes that include planning drug research and development, managing clinical regulatory strategy, and identifying new drug opportunities, <em>OncoDaily</em> reported. Coefficient was established by co-founders that include Nathan Frey, PhD, and Samuel Stanton, PhD, both previously with Genentech’s Prescient Design computational drug discovery unit. Another co-founder, Aris Theologis, serves as CEO and was previously chief business officer at Evozyne and a vice president at Paragon Biosciences.</p>
<p>According to the IPO filing, Anthropic finished January-June 2026 with a staggering net loss of $80.748 billion, up more than six-fold from the $12.969 billion net loss the company reported for the first six months of 2025. However, revenue leaped 14-fold to $16.286 billion in the first half of this year, from $1.163 billion in January-June 2025.</p>
<p>And Anthropic’s operating loss, defined as operating expenses exceeding revenue from core business operations, actually shrunk during the first half of 2026 to $693 million from $2.135 billion a year earlier.</p>
<p>For all of 2025, Anthropic reported a net loss of $41.965 billion, up five-fold from the $8.309 billion net loss of 2024, itself more than five times the $1.531 billion net loss of 2023.</p>
<p>Goldman Sachs and Morgan Stanley are co-leading the IPO, with participation by 20 other banks and other investment institutions.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-ipo-discloses-plans-for-life-sciences-growth/">Anthropic IPO Discloses Plans for Life Sciences Growth</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>World HUPO 2026: Asia&#45;Pacific Ambition and the Road to Predictive Biology</title>
<link>https://edusehat.com/en/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology</link>
<guid>https://edusehat.com/en/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology</guid>
<description><![CDATA[ Conversations at HUPO 2026 revolved around questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can help us decide which experiment to run next.
The post World HUPO 2026: Asia-Pacific Ambition and the Road to Predictive Biology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-2-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 06:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>World, HUPO, 2026:, Asia-Pacific, Ambition, and, the, Road, Predictive, Biology</media:keywords>
<content:encoded><![CDATA[<p>By the time the Singapore Human Proteome Organization (HUPO) congress began, streets were being closed ahead of the Formula One Grand Prix. The humidity was a considerable change from the snow outside last year’s meeting in Toronto.</p>
<p>HUPO assembled 1,428 delegates from 45 countries under the theme “Proteomics Plus: Transforming Lives.” Across the September 27–October 1 program, conversations kept returning to questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can help us decide which experiment to run next.</p>
<figure aria-describedby="caption-attachment-339629" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class=" wp-image-339629" src="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-300x225.jpg" alt="" width="448" height="336" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-3-1.jpg 1400w" sizes="(max-width: 448px) 100vw, 448px"><figcaption class="wp-caption-text">Credit: Gustav Ceder</figcaption></figure>
<p>The program itself reflected a field broadening its reach. Alongside the main scientific sessions were pre-congress workshops and training courses, short flash talks linked to poster sessions, and mentoring and networking for early-career researchers. The Early Career Researcher (ECR) program also featured manuscript, poster and three-minute thesis competitions. HUPO continued its interactive Bioinformatics Hub format, with 11 sessions spanning AI, multiomics and reproducibility. One, led by the Human Protein Atlas, explored integrating multiomics data and AI tools into its resources.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The exhibition hall and industry-supported seminars added another dimension. Thermo Fisher Scientific and Olink shared a booth for the first time, while Illumina showcased proteomics approaches for population-scale studies. Both hosted scientific seminars. Their presence underscored how technology development, data analysis and clinical research are increasingly part of the same conversation.</p>
<h4>An invitation from China</h4>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Fuchu He, PhD, chairman of the National Center for Protein Sciences in Beijing, set out an ambitious direction in the opening keynote. He leads the China-initiated Proteomic Navigator of the Human Body, or π-HuB, whose published roadmap envisages investment running into billions of renminbi over three decades.</p>
<p>Jing Yang, PhD, π-HuB’s secretary-general and a researcher at Guangzhou National Laboratory, described an effort to profile organs, tissues, cell types, and individuals, building a reference for how human biology changes over a lifetime.</p>
<p>The ambition is to “predict the proteomic states of each person across their lifetime,” he explained, accounting for influences including the microbiome, immune system, environment, and lifestyle. Reliable individual predictions remain a research goal.</p>
<p>“We really want to collaborate with HUPO,” Yang told <em>GEN</em>, describing discussions about extending cooperation beyond conferences and communication into science and funding.</p>
<h4>Building a cell, together</h4>
<p>Tiannan Guo, PhD, a professor at Westlake University, connected spatial proteomics and temporal perturbation proteomics with the development of AI-based virtual cell modeling. His presentation described proteomic work spanning 58 major tissue types, 251 more finely defined tissue types, and 25 carcinoma types, as well as a perturbation proteomics-based virtual cell model for triple-negative breast cancer with potential clinical benefits.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Guo’s virtual-cell framework brings together existing biological knowledge, cellular architecture, and dynamic measurements of responses to perturbations. Models would guide experiments, and the resulting measurements would test and refine their predictions.</p>
<p>The Westlake AI Virtual Cell–Yeast, or WAY, project divides that challenge into interconnected cellular functions, including metabolism, membrane systems, and stress responses. Task-specific AI agents would work together.</p>
<p>Contributors to the published framework include researchers affiliated with ETH Zurich, Stanford University, and the University of Toronto, among others.<strong><sup> </sup></strong></p>
<h4>Cells have to cope with lunch</h4>
<p>Florian Rosenberger, PhD, a SciLifeLab fellow and assistant professor at Karolinska Institutet, gave an example of what a real cell must handle.</p>
<p>“Life is all about being able to deal with the little fluctuations,” he told <em>GEN</em>, including “being able to deal with lunch without dying instantly.”</p>
<p>His single-cell deep visual proteomics work investigates mitochondrial disease while preserving tissue context. Access to oxygen and nutrients varies between neighboring cells, as can the accumulation of mutations. Rosenberger compared the patchwork of cellular states to a Portuguese tile floor.</p>
<p>By isolating cells in different functional states and arranging them in an inferred sequence, or pseudotime, his group can investigate proteomic changes associated with deterioration. This reconstructs a possible progression rather than following the same cell through time. The aim is to distinguish responses associated with failure from those that might support resilience. Rosenberger stressed that this is early work, but understanding those responses could eventually inform research in other diseases involving mitochondrial dysfunction.</p>
<p>“What is the normal working range that a cell can have, and when does it tip over into disease?” he asked.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>Fabian Coscia, PhD, head of the spatial proteomics group at the Max Delbrück Center in Berlin, described how cancer cells can differ in their response to treatment. Rare cell populations may carry protein states associated with resistance before treatment begins; others adapt during treatment. Comparing pretreatment and post-treatment samples helps investigate both possibilities.</p>
<p>In Alzheimer’s brain tissue, his group found that neurons with visible tau pathology and neighboring cells without it did not separate neatly into affected and unaffected categories. Proteomic measurements revealed intermediate states.</p>
<p>“You have an entire trajectory of states,” Coscia said. These are precisely the distinctions a predictive model will need to capture.</p>
<h4>From tissue to accessible samples</h4>
<p>Birgit Schilling, PhD, a professor at the Buck Institute for Research on Aging, spoke with<em> GEN</em> in Toronto the previous year. This year in Singapore, she described how her laboratory was now using spatial mass spectrometry to investigate human osteoarthritis, finding localized changes in bone that bulk analysis could obscure.</p>
<p>“What I’m particularly excited about is that we took that to then bring that back to a biomarker fluid,” she said. The team is following tissue-level discoveries with biomarker work in synovial fluid, the fluid within the joint.</p>
<p>Mitchell Lai, PhD, a senior lecturer in pharmacology at the National University of Singapore, examines Alzheimer’s biomarkers in an Asian cohort with substantial cerebrovascular disease, testing their usefulness beyond the Western populations that dominated earlier studies.</p>
<p>“Now we are more interested in prognostic biomarkers,” Lai said. He wants measurements that help anticipate future dementia and cognitive impairment.</p>
<p>His work with the NULISA technology, explores brain-derived phosphorylated tau. The assays recognize both a phosphorylation site and a brain-associated splice variant, distinguishing a more specific signal within circulating tau.</p>
<p>Lai emphasized that longitudinal research requires comparable assays even when samples are collected years apart.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Jochen Schwenk, PhD, who chaired HUPO’s Plasma Proteome Project over the past decade, noted a substantial increase in abstracts describing studies of human biofluids in large cohorts. He welcomed the trend but cautioned against drawing conclusions too early without considering findings from similar studies. He also highlighted growing interest in microsampling, which could make sample collection easier and broaden the role of proteomics in precision medicine.</p>
<p>Gabriel Mazzucchelli, PhD, head of the omics group in the University of Liège’s mass spectrometry laboratory, is exploring a different sample: sweat. His team has developed a spectral library containing around 4,000 proteins and conducted pilot work on treatment monitoring. An overnight collection patch under development could make repeated sampling possible without hospital visits.</p>
<h4>Mapping protein forms and functions</h4>
<p>The separate, closed Day of the Research Initiatives brought π-HuB, the Human Proteome Project, and the Human Proteoform Project together to discuss the field’s future.</p>
<figure aria-describedby="caption-attachment-339630" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339630" src="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-300x225.jpg" alt="" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/HUPO-image-1-1.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Gustav Ceder</figcaption></figure>
<p>Neil Kelleher, PhD, director of Northwestern University’s Chemistry of Life Processes Institute, described the Human Proteoform Project’s ambition as having “the genome project moment for proteins.” Representing the Consortium for Top-Down Proteomics, he proposed a reference set of intact molecular forms of proteins across human cell types and body fluids, estimating 50–100 million distinct proteoforms.</p>
<p>His presentation argued that distinguishing those forms could improve biomarker selection, patient stratification, and drug-target decisions. “It is a structural project more than a functional one.”</p>
<p>The proposed reference would require roughly 10 years and $300 million–$500 million annually, he estimated.</p>
<p>Cecilia Lindskog, PhD, an associate professor at Uppsala University and chair of HUPO’s Human Proteome Project, described the complementary challenge.</p>
<p>“We want to determine the function of every human protein,” she said, noting that fewer than a third have well-characterized, experimentally validated functions. She wants shared standards, complementary methods, and potentially shared samples and joint pilot studies to help close that gap.</p>
<p>The Human Protein Atlasintroduced a helpdesk at the congress alongside a Bioinformatics Hub session on integrating multi-omics data and AI tools.</p>
<p>Coscia described workshops bringing imaging researchers, the Human Protein Atlas, and the mass spectrometry community together around data formats and integration. He called for better protocols, interlaboratory comparisons, and metadata that make experiments reproducible. He also cautioned that exploratory spatial proteomics remains largely a discovery technology; some findings may reach clinical practice through established methods such as immunohistochemistry.</p>
<h4>Beyond the congress</h4>
<p>At the gala dinner in the Flower Dome at Gardens by the Bay, there was plenty to discuss. Singapore’s population studies, China’s international initiatives, and the clinical questions running through the conversations gave “Proteomics Plus” substance: more ways to measure biology, more people contributing, and more demanding questions about what the results mean.</p>
<p>By the next HUPO, it would be great to hear how those models performed on new data and whether candidate biomarkers held up in larger, more diverse patient cohorts. The next step is to show not just what proteomics can measure, but which experiments and clinical decisions those measurements can improve.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/world-hupo-2026-asia-pacific-ambition-and-the-road-to-predictive-biology/">World HUPO 2026: Asia-Pacific Ambition and the Road to Predictive Biology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Predicting Leukemia Survival May Be Aided by Six Gene Scoring System</title>
<link>https://edusehat.com/en/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system</link>
<guid>https://edusehat.com/en/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system</guid>
<description><![CDATA[ Researchers studying mice and human data identified a six gene signature, and developed a scorings system, that could help forecast acute myeloid leukemia patient survival, and potentially point to new therapeutic targets. 
The post Predicting Leukemia Survival May Be Aided by Six Gene Scoring System appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/05/GettyImages-1632999309.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Predicting, Leukemia, Survival, May, Aided, Six, Gene, Scoring, System</media:keywords>
<content:encoded><![CDATA[<p>A study by researchers at the Centre for Genomic Regulation (CRG) has identified six different genes that can help forecast survival of patients with acute myeloid leukemia (AML), a type of cancer that has very variable outcomes between patients.</p>
<p>Headed by ICREA Research Professor Luciano Di Croce, PhD, a researcher at the CRG, the team created a scoring system by moving repeatedly between laboratory experiments with mice and patient records, crossing the two to look for genes that behaved consistently in both.</p>
<p>The investigators had initially focused on a gene called <em>PHF19</em>, which the Di Croce lab has studied for more than a decade and is thought to suppress blood cancer formation. PHF19 belongs to a family of genes that keep other genes switched off, a system that cells use as they progress along the differentiation process from immature to mature cells.</p>
<p>Through their research the team found six genes that reliably predict AML patient survival. Some genes—<em>CARMIL1, HOPX,</em> and <em>ALDH1A1</em>—were more active in patients with poor outcomes while others—<em>CALR, STAR,</em> and <em>PHF19</em>—were less active. The collective activity of all six genes, which the researchers called the PHFScore, divided patients into groups with sharply different survival prospects.</p>
<p>Findings from the study could point to new ways of helping to predict outcomes in patients with this type of blood cancer, contributing to the development of future prognostic tests, and may suggest new therapeutic targets. Patients suspected of having AML already give a bone marrow sample for laboratory analysis, and measuring six genes is simpler and cheaper than reading a broader genetic profile.</p>
<p>“<em>PHF19</em> on its own already tells us something about how patients will fare, but combining it with five other genes is a dramatic improvement which gives us more accurate information for AML prognosis,” said Di Croce.</p>
<p>Gianni Gamarra Figueroa, PhD, added, “Some of the genes have never been linked to blood cancer before and could also be potential new therapeutic targets. These genes haven’t been described in leukemia or even in how blood forms. We don’t yet know what they are doing there, which is exactly what makes them worth exploring.”</p>
<p>Di Croce is senior author and Gamarra Figueroa is first author of the team’s published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aed6757" target="_blank" rel="noopener">Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival</a>.” In their paper the authors concluded “By integrating our <em>in vitro</em> multiomic data with the molecular and clinical data from various AML datasets, we successfully identified a molecular signature—the PHFScore—to identify patient prognosis.”</p>
<p>Acute myeloid leukemia is “… a heterogeneous malignancy characterized by diverse genetic and epigenetic alterations,” the authors wrote.  Earlier work in the Di Croce’s lab showed that mice lacking the <em>PHF19</em> gene manifest a condition resembling myelodysplastic syndrome (MDS), where blood cells fail to mature properly and build up in the body without yet becoming cancerous. “We previously showed that the Polycomb-associated factor Phf19 is required for hematopoietic stem cell (HSC) maintenance and state control in mice and that its loss (Phf19<sup>KO</sup>) impairs HSC function,” the team continued.</p>
<p>“Leukemia develops in stages, as a cell gradually accumulates defects,” explained Gianni Gamarra, PhD, “Losing <em>PHF19</em> doesn’t cause leukemia on its own, but it is already a push down that road.”</p>
<p>The new study asked what happens when leukemia originates in cells that have similar starting conditions—not cancerous, but not quite healthy either. The researchers introduced a leukemia-causing gene into mouse blood cells with and without <em>PHF19</em>. Cells lacking the gene formed more colonies in the lab and, when transplanted into mice, took hold more easily. They also stayed locked in an immature, stem-cell-like state.</p>
<p>“Blood cells form a hierarchy,” added Gamarra Figueroa. “At the top are stem cells, which are still plastic and could become almost anything. As they move down, they mature and take on a fixed identity. The more a cancer holds on to that plasticity, the more malignant it tends to be.”</p>
<figure aria-describedby="caption-attachment-339826" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339826" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right-300x238.jpg" alt="Spleen tissue from a mouse without PHF19 (left) and a mouse with normal PHF19 function (right). Dense clusters of immune cells sit within blood-rich regions in pink. Without PHF19, cells are altered in their differentiation process " width="300" height="238" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right-300x238.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Ph19-normal-left-vs-KO-right.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Spleen tissue from a mouse without PHF19 (left) and a mouse with normal PHF19 function (right). Dense clusters of immune cells sit within blood-rich regions in pink. Without PHF19, cells are altered in their differentiation process [Gianni Gamarra/Centro de Regulación Genómica]</figcaption></figure>
<p>The plasticity made the cells harder to treat. Cells without <em>PHF19</em> largely ignored the effects of chemotherapeutic drugs which are commonly used to push leukemia cells into a mature state, one of the strategies doctors use against a disease in which cells become stuck partway through development and multiply unchecked. “<em>Phf19</em> deletion promoted acquisition of stemlike features and reduced responsiveness to differentiation-inducing AML therapies,” the team stated.</p>
<p>To check whether their mouse model reflected human disease, the researchers compared which genes were switched on and off in both the mouse cells and from data generated in human studies. The same pattern appeared in patient datasets. “Molecular and functional consequences of Phf19 loss paralleled those observed in the datasets of patients with AML,” they further noted. “Patient data from different AML datasets allowed us to determine that patients with low levels of PHF19 expression had a stemlike transcriptomic profile, which, according to the literature, is linked to more chemoresistant leukemias.”</p>
<p>Among younger adults treated for AML, those with the lowest levels of <em>PHF19</em> survived for less time than those with the highest. they were also less likely to go into remission after standard chemotherapy. Fewer than half did so, compared with up to 85% of patients with the highest levels.</p>
<p>“The patients have advanced leukemia, so we are comparing mice and humans at very different stages of the disease, yet the molecular data point in the same direction, which gives our model a great deal of strength,” said Gamarra Figueroa.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/predicting-leukemia-survival-may-be-aided-by-six-gene-scoring-system/">Predicting Leukemia Survival May Be Aided by Six Gene Scoring System</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution</title>
<link>https://edusehat.com/en/overcoming-bottlenecks-biopharmas-big-challenge-is-execution</link>
<guid>https://edusehat.com/en/overcoming-bottlenecks-biopharmas-big-challenge-is-execution</guid>
<description><![CDATA[ The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution. Closing this gap is one of the greatest opportunities biopharma has today to enhance resilience and unlock the full value of its science.
The post Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/07/GettyImages-1460261281.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Overcoming, Bottlenecks:, Biopharma’s, Big, Challenge, Execution</media:keywords>
<content:encoded><![CDATA[<p>The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution.</p>
<p>That’s the opinion of Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva. Major scientific advances have enabled the development of truly amazing therapeutics such as RNA technologies and cell and gene interventions, yet manufacturing innovation hasn’t kept pace. “Our ability to manufacture these therapies reliably, repeatedly, and at scale remains a major constraint,” Pivet tells <em>GEN</em>.</p>
<figure aria-describedby="caption-attachment-339781" class="wp-caption alignright"><img decoding="async" class="size-full wp-image-339781" src="https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot.jpg" alt="" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot.jpg 200w, https://www.genengnews.com/wp-content/uploads/2026/10/Nicolas-Pivet-Headshot-150x150.jpg 150w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva. [Cytiva]</figcaption></figure>
<p>“The industry often focuses on symptoms [of biomanufacturing bottlenecks] such as paper batch records, disconnected laboratory information management systems, fragmented automation architectures, isolated enterprise resource planning deployments, or data silos. Those challenges are real, but they are not the root cause,” Pivet stresses.</p>
<p>“The deeper issue,” he says, “is that many manufacturing environments evolved over decades and were never designed as connected systems. Digital capabilities were often layered on to solve local problems rather than integrated around end-to-end manufacturing performance. The result is an environment that is increasingly data-rich but…insight-poor.”</p>
<p>In that environment, organizations can’t extract actionable insights early enough to affect outcomes. They have a visibility problem.</p>
<h4><strong>Focus on observability</strong></h4>
<p>The first step in resolving the bottlenecks is to solve specific problems.</p>
<p>“You cannot control what you cannot see,” Pivet says. He advises industry to focus first on improving observability. Gaining insights into process deviations early enables earlier intervention, which creates better decisions and improves confidence in those decisions, he explains. This is the foundation of advanced manufacturing.</p>
<p>“Then connect the data, workflows, and decisions required to improve the outcome,” Pivet advises. “Biopharma does not lack information. It lacks accessible, contextualized, and trusted information,” he says. “Connecting process, equipment, analytical, and workflow data establishes the foundation required for predictive analytics, advanced automation, digital twins, and AI.”</p>
<p>“Only after that [has occurred] should advanced control or AI-enabled decision-making become part of the discussion.”</p>
<p>Therefore, rather than starting with AI use cases—as many try—organizations should first focus on observability, and then address interconnectivity, data integrity, and maintaining operational context for those data flows. When those are resolved, AI can be added to the mix. “AI does not fix weak foundations,” he says. “It exposes them.”</p>
<h4><strong>Face organizational barriers</strong></h4>
<p>The barriers to digital transformation are more often organizational than technical. That’s because biomanufacturers consider change riskier than maintaining current practices. In 2025, “more than a third of biopharma companies were still in early exploration or had not started their digital transformation journey,” he says, underscoring his point.</p>
<p>Trust is typically the rate-limiting step, and that is established only by reliable performance. Therefore, “the organizations moving fastest are those demonstrating value on real manufacturing problems, validating outcomes, and gradually scaling successful approaches rather than attempting sweeping transformations,” Pivet observes.</p>
<p>Manufacturing equipment in the future will not just be smarter; it will be designed from the outset as elements of connected, interoperable systems that provide early visibility and easy integration into automated and connected workflows.</p>
<h4><strong>Prepare the workforce</strong></h4>
<p>“The conversation around AI often focuses on technology. The more important conversation is about people,” Pivet emphasizes.</p>
<p>Automation, agentic and generative AI, and other smart manufacturing technologies are changing roles throughout the workforce at, seemingly, warp speed. Everyone, from equipment operators, process engineers, data scientists, and quality professionals up through the executive suite, is coming to grips with new ways of working that require new skills and new ways of thinking.</p>
<p>“Data literacy, systems thinking, automation fluency, model interpretation, and cross-functional collaboration are becoming increasingly important,” Pivet points out. Consequently, people are spending less time collecting information and reacting to events, and more time interpreting data and optimizing processes.</p>
<p>The workforce, however, is still in transition. “The Global Biopharma Index reported that 29% of organizations experience severe shortages in digital and AI-related skills,” he says.</p>
<p>“Workforce readiness is one of the defining challenges of this decade,” Pivet continues. “The most successful manufacturers I encounter are not necessarily the ones deploying the most advanced technologies. They are the organizations creating confidence around new ways of working.”</p>
<p>Within five years, he predicts a plethora of hybrid roles that blend both process and digital expertise. Future titles may include digital process engineer, manufacturing data scientist, process intelligence specialist, and manufacturing systems architect, he adds.</p>
<p>Filling those new roles means preparing the workforce today. He advocates upskilling individuals enterprise-wide, ensuring the various functional teams learn together, rather than treating digital transformation as the purview of any particular group.</p>
<p>Even today, across industries, traditional learning programs are being complemented by immersive learning experiences. Biopharma will be no different, especially given its growing complexity and limited opportunities for hands-on learning in the face of good manufacturing requirements, production schedules, and equipment availability.</p>
<p>Immersive learning experiences involving mixed reality and augmented reality “allow operators, technicians, and engineers to interact with equipment and workflows, and troubleshooting scenarios in highly realistic digital environments,” he says. By accelerating learning, enhancing retention, and building confidence, workers are better prepared when they enter live manufacturing environments.</p>
<p>Eventually, Pivet says, “Immersive learning may become as important to workforce development as flight simulators became to aviation training.”</p>
<h4><strong>Ease tech transfer</strong></h4>
<p>The tech transfer process also has a major bottleneck, but it has nothing to do with technology or human factors.</p>
<p>“The most common reason transfers fail is not because process instructions are missing,” he says. “It is because process understanding fails to transfer with them. Receiving organizations often inherit process descriptions, specifications, and operating procedures, but not the context explaining why those parameters matter or how the process behaves under changing conditions.”</p>
<p>Those gaps are becoming ever more important as therapies become increasingly complex. Successful tech transfer, therefore, includes transferring process understanding. Digital twins help minimize the gap between process instructions and process understanding by enabling teams “to test assumptions virtually before testing them physically,” Pivet says, thus enhancing success. In this way, “…uncertainty is removed rather than relocated.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<h4><strong>Lead with digital change</strong></h4>
<p>If you can prioritize only one area for improvement, Pivet advises choosing digital infrastructure because, he explains, “people and processes increasingly depend on information. Digital infrastructure creates the conditions for successful technology transfer, effective workforce development, predictive analytics, process understanding, and operational improvement. Without trusted information flows, organizations struggle to scale knowledge, replicate success, or improve decision quality.”</p>
<p>High-quality information flows, he predicts, will be a major determinant of manufacturing competitiveness in the coming decade. “The companies best positioned to lead the next era of biomanufacturing will be those that combine AI initiatives with strong connected-data and observability foundations,” he suggests. By doing so, they will be better able to translate scientific innovation into predictable, scalable, operational performance.</p>
<p>“Biopharma does not have an imagination problem,” Pivet reiterates. “It has an execution problem. Closing that execution gap is one of the greatest opportunities our industry has to accelerate patient access, improve resilience, and unlock the full value of the science being developed today.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/overcoming-bottlenecks-biopharmas-big-challenge-is-execution/">Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>South African Labs Strive for Africa’s Biopharma Sovereignty</title>
<link>https://edusehat.com/en/south-african-labs-strive-for-africas-biopharma-sovereignty</link>
<guid>https://edusehat.com/en/south-african-labs-strive-for-africas-biopharma-sovereignty</guid>
<description><![CDATA[ Africa still imports 99% of its routine vaccines and 70–90% of its biopharmaceuticals. The Africa CDC warns this vulnerability could cost the continent up to $1.1 trillion in skills and jobs through 2050. 
The post South African Labs Strive for Africa’s Biopharma Sovereignty appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/a-petri-dish-for-growing-micro-o.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 27 Oct 2026 03:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>South, African, Labs, Strive, for, Africa’s, Biopharma, Sovereignty</media:keywords>
<content:encoded><![CDATA[<p>Africa still imports 99% of its <a href="https://jogh-ep.org/article/154008-strategic-pathways-to-pharmaceutical-self-reliance-in-africa-lessons-enablers-and-opportunities" target="_blank" rel="noopener">routine vaccines</a> and 70–90% of its biopharmaceuticals. The <a href="https://africacdc.org/investment-in-health-research-and-development/#prId=372147" target="_blank" rel="noopener">Africa CDC </a> warns this vulnerability could cost the continent up to $1.1 trillion in skills and jobs through 2050.</p>
<p>This is motivating a biotech revolution building up in South Africa—the continent’s most industrialized nation where startups are confronting <a href="https://espace.enap.ca/id/eprint/423/" target="_blank" rel="noopener">“pharmaceuticals apartheid”</a>—tinkering with low-cost, decentralized biotech R&D and manufacturing prototypes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>So much is at stake and urgent, said Nick Enslin, co-founder and COO of Immobazyme, one of the flagship South African startups that specializes in advanced biomanufacturing and precision fermentation with the goal of making affordable, high-value recombinant proteins, enzymes, and growth factors to help slash Africa’s biopharma import bill.</p>
<p>“One of the biggest things we realized as a country, but also as Africa, is that we’re importing 99% of our biologics and drugs. For the COVID-19 vaccine, we were the last group of people to get this vaccine,” he lamented. A cursory look at the South African Clinical Research Association, the equivalent of the FDA, shows they still follow the 2014 FDA guidelines, he said. “And that’s quite old,” he told <em>GEN</em>.</p>
<p>As a result, they would need to update their regulations to understand the science better, what biosimilars are, what mRNA vaccines are, and why the science is moving so fast that regulators are struggling to keep up.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Africa has “many opportunities” to domesticate its medical biologics supply chains, but reality is daunting, said Enslin, citing a recent <a href="https://www.bloomberg.com/news/articles/2026-06-19/aspen-disruption-triggers-south-africa-contraceptive-shortage" target="_blank" rel="noopener">“disruption</a>” at Aspen—Africa’s largest generic drugs maker—which threatens an oral contraceptives shortage in South Africa.</p>
<p>Part of the reason is that GMP manufacturers of biosimilars, specifically, are far and few between on the African continent.</p>
<p>“In South Africa, we’ve only got a handful, and most of them are looking at small molecules, chemicals, and stuff like that, necessarily creating bio-biologics,” said Enslin.</p>
<h4><strong>The mission</strong></h4>
<p>The mission is clear for Immobazyme, which recently captured the limelight after raising $1.45 million in venture funding (bringing the total the company has raised to $2.9 million), which is modest by Silicon Valley standards but significant in South Africa’s limited venture finance ecosystem.</p>
<p>“Having our own GMP facility, manufacturing biosimilars for the African continent, that’s where we want to be by the end of the 2030s,” said Enslin, who is talking about “lower hanging fruit” for Africa’s biotech innovators to grab and accelerate through development and into the market.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>He added that he is referring to “nutraceuticals, cosmetics, food and beverages, and agribiotech, which are subject to lower regulation and certification than drugs and other medicines. But it’s still the same premise that the African continent is struggling with these kinds of novel products.”</p>
<p>His first patent came about when he was a student at South Africa’s Stellenbosch University, the premier South African and African research corridor in the Western Cape Province, where billionaires live adjacent to bubbling ideas in biotech, banking, and software.</p>
<p>“We realize that these enzymes, whether it’s in an industrial application or mRNA manufacturing, are relatively expensive. And you use them once, and then you can’t recover them. You can’t reuse them again even though they’re perfectly fine to reuse,” he said.</p>
<p>So, they developed a method to immobilize enzymes on a solid metal matrix, allowing substrates to pass through and undergo enzymatic reactions while the enzymes remain in place for repeated use, he explains, giving an example of lactose-free myelin oligodendrocyte glycoprotein (MOG).</p>
<p>“What they do is they immobilize lactase, which is an enzyme that breaks it down into simpler sugars. And they passed the milk over and got lactose-free milk. But the current enzyme immobilization technologies that were out there at the time were either quite expensive or they weren’t optimized for multiple different kinds of applications. So, this is where PepTrap came in,” Enslin said, referring to the proprietary, synthetic cellulose-based enzyme immobilization technology developed by Immobazyme that traps and stabilizes enzymes, allowing them to be reused cost-effectively across multiple industries.</p>
<p>Getting the science right was the easier part for Enslin and his two co-founders. Scaling the science into any kind of business “is just really tough, but scaling a biotechnology company in South Africa is even tougher. It’s capex heavy. It’s infrastructure heavy. And then every time you 10x your manufacturing capability, you have to basically buy a completely new production pipeline to meet that scale,” he said.</p>
<h4><strong>The hub</strong></h4>
<p>For decades, South African universities have been excellent at generating world-class research papers, but much of that IP stays stuck in academic journals. LaunchLab CERIBIO is a 300 m<sup>2</sup> biotechnology laboratory and business incubator at Stellenbosch University and looks to actively disrupt this “<a href="https://council.science/blog/publish-or-perish-mentality/" target="_blank" rel="noopener">publish or perish</a>” culture in South Africa. Enslin’s Immobazyme startup is one of the most successful spinouts from this incubator.</p>
<p>“It is very challenging to do commercial work in a university laboratory,” said Anita Nel, chief director of innovation and commercialization at Stellenbosch University. Hence, they have created this space to ensure that the university’s biotech spinout companies have a dedicated, shared space. They actively encourage their researchers to publish their results once CERIBIO has the opportunity to protect their inventions, as publications also bring credibility to their research. “It is more a case of patent before you publish than preventing publication at all,” she added.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>When a university researcher comes to LaunchLab CERIBIO with a breakthrough, there is a filtering method to ensure the presentation can translate into commercial success. “We perform due diligence on every new invention that is disclosed to us to make very sure that there is commercial potential, that it is novel, and to determine what the best route to market is—either a license to a company with an existing market or a new spinout company with the support of the university,” she told <em>GEN</em>.</p>
<p>The spinouts from LaunchLab CERIBIO are also supported to de-risk the ventures further and are connected to both local and global investors who can provide funding to help them progress faster. “These investors understand the deep-tech and biotech space and feel comfortable investing in this sector, without expecting the fast progress that you typically see in fintech,” she added.</p>
<h4><strong>Nod of approval</strong></h4>
<p>Immobazyne’s recent venture financing success is a riposte to critics who for a long time have argued that Africa’s biotech can’t attract this kind of liquidity. It’s a massive nod of approval, Enslin explained. “I think that’s a testament to the kinds of companies that are coming out of the African continent and that resilience and the determination. There have been some amazing success stories coming out of South Africa,” he said, pointing to South Africa’s Kapa Biosystems, which was acquired for a record $445M by Roche in 2015.</p>
<p>“It’s an affirmation that we can actually build something incredible here. I think it’s heating the ecosystem here on the ground in the Western Cape specifically. I mean, they’re calling us the Silicon Valley or the Cape Silicon Valley,” he said with humor.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/south-african-labs-strive-for-africas-biopharma-sovereignty/">South African Labs Strive for Africa’s Biopharma Sovereignty</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Investment Banker Talks U.S.&#45;Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital</title>
<link>https://edusehat.com/en/stockwatch-investment-banker-talks-us-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital</link>
<guid>https://edusehat.com/en/stockwatch-investment-banker-talks-us-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital</guid>
<description><![CDATA[ Geoff Meyerson addressed the growth of U.S.-Chinese licensing/collaboration deals, the recent growth of IPOs, and the still-chilly climate for startups seeking financing in a recent interview with GEN Edge.
The post StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/A-List_GettyImages2-1401171512-1024x682-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 26 Oct 2026 08:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Investment, Banker, Talks, U.S.-Chinese, Deals, IPOs, and, Tough, Climate, for, Startups, Seeking, Capital</media:keywords>
<content:encoded><![CDATA[<p>Barring something cataclysmic over the next two months, it’s fair to say 2026 has been the year biotech stocks have shaken off the post-COVID doldrums. The largest electronic transfer fund by total assets, the $11 billion <strong>iShares Biotechnology ETF (Nasdaq: IBB)</strong> <span><strong>soared 34%</strong></span> over the 12 months ending Friday, from $154.58 to $207.74, while the second-largest ETF, the $10.6 billion <strong>State Street SPDR S&P Biotech ETF (NYSE Arca: XBI), <span>leaped 39%</span></strong> from $107.56 to $149.54.</p>
<p>That bounceback helps explain the surge in initial public offerings (IPOs) this year vs. 2025–27 offerings totaling $7.776 billion, up a sizzling 573% from $1.155 billion in 11 offerings in all of 2025. During the third quarter, nine IPOs totaling $2.4 billion reached Wall Street, the largest number in five years, according to investment bank Locust Walk.</p>
<figure aria-describedby="caption-attachment-339794" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339794" src="https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-300x277.jpg" alt="" width="300" height="277" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-300x277.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-1024x945.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-768x708.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-1536x1417.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Geoff-Meyerson-Locust-Walk-And-Banyan-BioInnovations-CROP11111-RESIZE3663-2048x1889.jpg 2048w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Geoff Meyerson is CEO and co-founder of the investment bank Locust Walk. He is also co-founder and CEO of investment firm Banyan BioInnovations.</figcaption></figure>
<p>“Yes, we’ve absolutely had a comeback year,” declared Geoff Meyerson, CEO and co-founder of the investment bank Locust Walk. He is also co-founder and CEO of Banyan BioInnovations, an investment firm launched in May to nurture startups by identifying best-in-class or first-in-class clinical-stage assets, forming new companies, or “NewCos,” around them, then providing experienced, centralized support to help them accelerate drug development.</p>
<p>In its recently released 2026 Q3 Market Conditions Report, Locust Walk tracked measures showing growing strength yet continuing challenges for biotech companies during the third quarter:</p>
<ul>
<li><strong>Global licensing deals</strong> fell to a two-year low of about $48 billion in 41 transactions, from $71.5 billion in 43 transactions during Q2, with the average deal declining to $1.171 billion from $1.662 billion as deals focused more on clinical-stage assets than milestone-heavy discovery/preclinical assets.</li>
<li><strong>China leads in licensing, </strong>accounting for 58% of 2026 value through Q3, up from 48% a year ago, while the United States placed second at 26%. Europe and the United Kingdom slipped to 8%.</li>
<li><strong>Mergers and acquisitions (M&A) </strong>totaled $42.1 billion in 30 transactions, down from a three-year high of $80.7 billion in 35 transactions during Q2. However, total M&A value of $173 billion during Q1–Q3 2026 is already larger than all of 2025.</li>
<li><strong>PIPE (private investment in public equity)</strong> activity grew to $3.808 billion across 14 deals, well over the $603 million of Q2 and $1.151 billion of Q3 2025.</li>
</ul>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Meyerson addressed the growth of U.S.-Chinese licensing/collaboration deals, the recent growth of IPOs, and the still-chilly climate for startups seeking financing in a recent interview with <em>GEN Edge </em>(edited for length and clarity).</p>
<p><strong><span><em>GEN</em> <em>Edge</em>:</span> Public stock markets and private VC markets have shown strength this year, yet we’re seeing plenty of companies avoid them through licensing and collaboration deals, many reaching multiple billions of dollars. Why have licensing-collaboration deals continued to grow despite improving markets?</strong></p>
<p><strong>Geoff Meyerson:</strong> It’s a good question. It’s a complicated answer. In the United States, most licensing deals are early-stage discovery and preclinical. It’s rare to do a clinical stage license in the United States, because typically, if you want to get access to U.S. rights as a pharma company, you have to buy the company. In the United States, companies won’t do a license unless it’s a non-core asset. That’s why the M&A statistics show that 91% of total deal value was for U.S.-headquartered companies. The difference, though, is where global licensing deals are derived from: 58% of the total value is coming from China, compared to 26% from the United States.</p>
<p><strong><span><em>GEN Edge:</em></span> Why?</strong></p>
<p><strong>Meyerson:</strong> Because for Chinese companies, the Hong Kong markets have effectively shut down. That was a very popular route last year to raise capital. Now, because of red chip and other policies, it’s becoming significantly harder to raise capital in Hong Kong, and a lot of Chinese companies are in line, and the government makes the decision as to whether or not a company can go public.</p>
<p>If you also look at the M&A statistics out of China, approximately 1% of the total deal value is from M&A. If you can’t get liquidity as an investor via going public, and you can’t get an exit via M&A, how else can you either support your company or potentially return capital to the shareholders? The only other option that I’m aware of is licensing. The licensing deals have become the lifeblood and the source of revenue or capital for Chinese companies. That’s why that trend is so material.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>In many cases, you can even return the capital to your investors from a license, which in the United States would be double taxed, highly inefficient; that’s why you don’t see a lot of that happening in the United States. The difference also is that the upfronts in China are typically lower as a percentage of the total deal value compared to the United States, because in China, optics matter more. In the United States, the share of the expected net present value matters more. The Chinese companies don’t value the royalties as much. They value very large milestones that in many cases will never be achieved, so that inflates the total deal value number, and that’s one of the reasons why the number is so skewed in China’s favor.</p>
<p><strong><span><em>GEN Edge:</em></span> How concerned are you about Washington, both the Trump administration and Congress, tightening the rules for U.S.-Chinese collaborations?</strong></p>
<p><strong>Meyerson:</strong> It’s an interesting question and interesting timing for it, because [on October 16], the Chinese government made a major proclamation about <a href="https://www.jdsupra.com/legalnews/china-proposes-new-restrictions-on-5034995/">not being able to transfer certain technology platforms outside of China</a>. There’s just as much, if not more, risk in the actions of the Chinese government compared to the U.S. government. In China, one-party rule can make a decision, and it happens. In the United States, you need Congress, you need legislation. Yes, there could be executive orders, but it’s not the same force and permanence. So, there’s definitely geopolitical risk.</p>
<p>My instinct is that it’s not going to be something that is going to be shut down, ever. There will always be a way around it. I’m not going to cover that here, but all kinds of strategies can be deployed to minimize some of the regulatory barriers. Undoubtedly, it’s going to get harder before it gets easier, and it’s going to be driven by both governments, not just the United States.</p>
<p><strong><em><span>GEN Edge:</span> </em>What effect has the growth in U.S.-Chinese licensing collaborations had on the market and public company stocks?</strong></p>
<p><strong>Meyerson:</strong> I think the U.S. companies that don’t know their competitive set out of China run the risk of having their technology being surpassed from a data perspective. And what’s changed is a lot of U.S. companies have decided not to publish their early-stage pipeline, they’re not publishing patents early. They’re waiting till the last minute, because as soon as that patent is filed, 18 months later it publishes. And the second it publishes, tons of AI bots are circling, figuring that out, and within a week or two, you can design chemical matter or biology around it.</p>
<p>I’m not so sure that market capitalization of the companies is being impacted, but I do think that whenever there’s positive data in the United States, that spurs lots of Chinese companies to push harder. If there’s positive data in China, and that can be read through to the United States, it’s just like any competitor announcing data can impact the stock price of your drug if it’s in the same class, if you haven’t fully differentiated from everyone else. Is it a class effect? Or is it something that is unique to a specific drug? I don’t know if there are direct impacts of all this competition, other than data emerging that, just like any other data coming out in a class and having an impact.</p>
<p><strong><span><em>GEN Edge:</em></span> This year has seen one pause in biotech IPO activity just after the Iran war started, after Generate Biomedicines went public. The markets heated up again in the spring through summer, but have held back in recent weeks. How much of that is investors and others waiting to see what Anthropic does with their IPO, or are there other reasons for the pause lately?</strong></p>
<p><strong>Meyerson:</strong> My guess is that the recent swoon with the specialists has really caused an issue. That’s number one. And number two, with the inflation print and the increase in rates on long-dated treasuries, that has a real negative impact on biotech. My instinct is, the markets will recover for the specialists. Who knows how long the rates will be higher on the long-dated bonds, but I think it will be coming back. I don’t think the cycle is over.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p><strong><span><em>GEN Edge:</em></span> What effect is Anthropic’s IPO having on AI-focused biotech IPOs?</strong></p>
<p><strong>Meyerson:</strong> I’m not so sure AI biotech IPOs are actually meaningful, because at the end of the day most drugs—probably more than half of the drugs now were discovered using AI. And 99.5% of all drug spend happens after you have a lead candidate. AI has an impact, but not nearly as much of an impact at that point compared to the early discovery. You’ve still got to put a drug in a human and test it, and that’s not something AI can accelerate. I think AI’s impact on biotech will be certainly felt, but not nearly as much as, obviously, an AI company that’s been transformational.</p>
<p>As it relates to Anthropic, I don’t think that people are in biotech are really focused on that, to be honest. If anything, once Anthropic and OpenAI get public, that will be a lot of capital unlocked at LPs [limited partnerships] that could potentially recycle that into other funds. If anything, I think it’s going to be a huge boon to tech and biotech to have huge values  of money, or quantums of capital, being recycled in the ecosystem.</p>
<p><strong><span><em>GEN Edge:</em></span> Is that because Anthropic has made moves in recent months to position itself as a life-sci research and development company? </strong></p>
<p><strong>Meyerson:</strong> Yes, they’re going to dabble. But at the end of the day, it’s just like Google, when they started playing life sciences. They’ve got to either be selling tools to those that are developing, or they’ve got to be developing [drugs] themselves. There’s no way around it. You’re doing one or the other. If they’re just selling technology to other people, that’s fine, that’s a SaaS [software-as-a-service] model. If they’re actually developing drugs and putting molecules in patients, they’re not going to have an advantage from an AI perspective. Maybe they can recruit patients a little faster, maybe they can streamline some of the results.</p>
<p>But the reality is, you still need to wait for disease course to play out, and you have to have patients and doctors, and all these things that they have zero experience with. So, they’re going to have to build a pharma company if that’s what they really want to do. I’m not convinced Anthropic or any of these AI companies are going to build pharmas. And if they do, they’ll probably spin it off into a separate company, because it’s not going to grow nearly as fast, it’ll be a drag on their growth. My guess is they’re going to be a drug discovery engine, and they’ll license stuff out, which is fine, but that’s still relatively low value.</p>
<p><strong><span><em>GEN Edge:</em></span> What has been driving PIPE activity, and what companies are more likely to go that route for going public?</strong></p>
<p><strong>Meyerson:</strong> The rationale for a PIPE is manyfold. One, there’s been many more reverse mergers that have taken place as a viable normalized way of getting public. If, let’s say, there were 20 IPOs at one point this year, there were 20 reverses, which means, really, 40 companies got public, not 20, but those 20 that got public via reverse all needed a PIPE to complete that. A lot of the PIPEs are from reverse mergers. With quality investors, the aftermarket performance of PIPEs has actually also outperformed that of the IPOs. So, there’s a feeling that you can get a better deal in a PIPE than an IPO or a secondary [offering], and as a result that’s driving people to want to participate.</p>
<p>Then the question is, which companies would want to do a PIPE if you can get a better deal as a secondary? The answer is nobody. Why would you want to do a pipe at a lower price if you can get a better deal as a secondary offering? I think the difference is, for companies where it’s not clear how their data is going to be reacted to by the market, you can lock in the money and not take the price action risk, versus someone who is confident the market’s gonna love the data, you can probably roll the dice, release your data, and then, then do the secondary on the heels of that data release.</p>
<p>We’ve seen times where people came out with data that they thought would be great, and the market hated it, and the stock went down, and then they couldn’t raise capital. So, there is some certainty and some value in doing a PIPE to have the certainty of raising the money, even if it’s potentially at a lower price than you’d have been able to get if you released the data first.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p><strong><span><em>GEN Edge:</em></span> The report also tracked 46 venture financing deals in North America during the third quarter, down from 55 in Q2 but above the 38 of Q3 2025. The average deal size has grown to $96 million from $83 million in Q2 and $75 million in Q3 2025, with most deals concentrated in Series B, rounds. Doesn’t this confirm what startups have long been complaining about, that they find it hard to raise capital for Series A in earlier rounds?</strong></p>
<p><strong>Meyerson:</strong> Yes. I tend to differentiate between Series A, Series B, versus stage of development, because Banyan Bio is starting companies that are Phase II companies through a Series A round. I would think about it’s probably more driven by stage of development than round of financing. Raising money for discovery slash preclinical drugs, drug companies, is really hard. And most of it is going to clinical stage and beyond, which is really saying the market has changed, fundamentally, from 2020, 2021, where if you had a clinical stage drug, you were probably not gonna raise money, because everyone was focused on high-science white space platforms, really sexy iPSCs, and all the different, technologies.</p>
<p>I think what people are saying is that a startup needs to be incubated longer in academia and only spin it out when you have a full development candidate, or later, if not already an IND on file. One of the reasons you’re seeing a lot of NewCos out of China with clinical or late preclinical assets is, you’re able to in-license it for cheaper than what you would have done to develop it yourself on your own. I think that’s the arbitrage out of China that a lot of these investors are seeing. So, yes, it’s a tale of two cities. If you’re doing early discovery high science it’s a very tough spot in the market.</p>
<p><strong><span><em>GEN Edge:</em></span> Will that, in turn, compel some of these companies to try going public instead?</strong></p>
<p><strong>Meyerson:</strong> Yes, but the public market wants clinical data also. It doesn’t value preclinical companies very highly, so you can do it, but you’d better be a really great team, with great investors, and a highly promising story in a very interesting area. Ordinarily, that’s going to be very hard to do.</p>
<p><strong><span><em>GEN Edge:</em> </span>Where are startups looking as alternatives to traditional VC, as a result?</strong></p>
<p><strong>Meyerson:</strong> Family offices have been a big ask, but they’re not stupid either. The more a family office looks like an institutional investor, the more the answer’s going to look like it. So, disease foundations or families that have family members with a particular disease is generally an interesting way of attracting capital. The challenge is, without having them raise their hands, that they have a kid, or a family member, or a parent with that disease, it’s very hard to find them.</p>
<p>That’s where the disease foundations often do a very nice job, and if you partner with them, that can be an interesting approach. Some of the universities are actually investing in their own spinoffs to get to a point where they can create more value. But candidly, we used to play in that space, and we don’t anymore because of the challenge of getting funding.</p>
<p><strong><span><em>GEN Edge:</em></span> On the VC side, biologics’ share of financing value has continued to grow. What biologics are investors drawing toward, and what indications? Is it still cancer, maybe immunology, or has recent success brought neuro on the map?</strong></p>
<p><strong>Meyerson:</strong> Cancer and immunology are always going to be the two biggest, as a general rule, but, CNS is definitely doing okay. They’re the big three. I’m kind of surprised that rare disease has not had the same receptivity that it used to have. I think people are focused on larger markets, larger opportunities, because that’s where pharma is focused. I would say probably the most value to be found is in rare disease or smaller opportunities that could still be meaningful, just not mega-blockbuster.</p>
<p><strong><span><em>GEN Edge:</em></span> Looking ahead, what does the fourth quarter hold? Can you offer a preliminary look at what 2027 will hold for the markets?</strong></p>
<p><strong>Meyerson:</strong> Obviously, people are on hold until the midterm elections. I think once there’s clarity around what the balance of power is going to be, I think that will help. The hope is that there’ll be some bipartisan legislation aimed at improving the efficiency of the American drug development system. That’s something that I’m certainly supportive of and a champion of.</p>
<p>I’m not someone who’s going to tear down China to build up the United States. I think the United States should compete with China; I think that’s the right approach. I think that there will be, hopefully, some optimism to get some stuff done in ‘27. If that happens, I think the markets will continue apace.</p>
<p>It’s hard to tell: Does the interest rate continue to go up? If it goes up, I think we’re going to see a more challenging biotech ecosystem. Pharma has not gotten out from their patent cliffs. In fact, that’s a feature, not a bug. Every pharma, by definition, has a patent cliff they have to go through. The question is when and how much. So, there’s a built-in buying mechanism.</p>
<p>China’s not going away. There’s risk there with regulation on both sides, but fundamentally, I’m an optimist. I’m bullish on the industry, mid- to long-term. It’s very hard to predict one quarter to the next, for sure. But I don’t think the cycle has already played out. We only really started in earnest doing well a year ago. So, after four years of painful time, I don’t believe that we’re only going to have one year of a window, and then it shuts down again. I think the industry’s too large and too robust for that to happen.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-investment-banker-talks-u-s-chinese-deals-ipos-and-a-tough-climate-for-startups-seeking-capital/">StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities</title>
<link>https://edusehat.com/en/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities</link>
<guid>https://edusehat.com/en/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities</guid>
<description><![CDATA[ Researchers analyzed mulitomic and clinical data from 2000 colorectal cancer samples and used an AI tool, iPhenMap, to help identify cancer cell vulnerabilities and drug combinations that could be used to treat MSS CRC.
The post Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/09/GettyImages-683401718.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 02:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomic, Study, MSS, CRC, Identifies, Vulnerabilities, Pointing, Therapeutic, Possibilities</media:keywords>
<content:encoded><![CDATA[<p>An international study headed by scientists at RCSI University of Medicine and Health Sciences, and The Institute of Cancer Research, London, has identified potential new ways to treat microsatellite stable (MSS) colorectal cancer (CRC). The team integrated multiomic, single-cell, and clinical data from around 2,000 CRC tumors and developed an AI tool, iPhenMap, to create biological tumor maps.</p>
<p>The study uncovered vulnerabilities in these tumors and identified the drug combinations—including drugs already approved to treat other tumor types—that <em>in vivo</em> experiments in models indicated could be used to target CRC, potentially enabling more effective treatments. The researchers suggest that their results provide a clear roadmap for repurposing existing drugs and for new drug development to create more effective, personalized treatments for patients who currently have limited options.</p>
<p>Research co-lead Professor Annette Byrne, PhD, head of the RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, said “Patients with MSS RAS-mutant metastatic colorectal cancer urgently need better treatment options, particularly when their disease no longer responds to standard therapy. While these findings remain preclinical, they highlight promising therapeutic opportunities and provide a strong foundation for further development. The next step will be to identify the biological features that predict response and determine how these approaches can be advanced safely towards clinical evaluation.”</p>
<p>Professor Byrne is co-senior and co-corresponding author of the team’s published paper in <em>Cancer Cell</em>, titled “<a href="http://dx.doi.org/10.1016/j.ccell.2026.09.014" target="_blank" rel="noopener">Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities</a>.” In their report the researchers concluded, “Collectively, the results present a rich resource for the CRC research community and provide evidence for combinatorial treatment approaches with translational potential.”</p>
<p>Microsatellite stable colorectal cancer accounts for 80-85% of the 2,500 new bowel cancer cases diagnosed annually in Ireland, but remains challenging to treat, with limited response to many newer therapies. “Between 40% and 50% of these cases harbor mutations in the retrovirus-associated sequences (RAS) gene superfamily, 8–10 with RAS-mutant (RAS-mt) patients consistently displaying inferior outcomes compared with their RAS-wild-type (RAS-wt) counterparts,” the authors wrote.</p>
<p>Trials combining chemotherapy with newer targeted drugs or immunotherapies have delivered only modest improvements over current standard treatments. As the authors further pointed out, “As MSS CRC patient survival in particular has not significantly improved in recent decades, a concerted effort to unravel disease complexity is warranted.” And integrated analyses of multiomics datasets could provide key insights, they suggested.</p>
<p>Using 2,000 patient tumor samples—including more than 300 MSS CRCs that had not previously been profiled—the researchers analyzed genetic, metabolic protein, and clinical data with the help of artificial intelligence (AI) tools, revealing previously unrecognized ways in which the cancer cells divide, grow, adapt and interact with their environment. “To our knowledge, no study to date has presented a global integration of bulk genomics, epigenomics, proteomics, and metabolomics with single-nucleus/single-cell RNA sequencing (sn/scRNA-seq) and clinical parameters (phenome) in the MSS CRC setting,” they stated in their paper.</p>
<p>To do this the team developed a machine-learning AI tool called iPhenMap, which can create a biological map of the tumor. Using this map, they were able to spot connections between the different elements of the tumor—such as the genetic and metabolic features—that have been missed in previous studies that looked at the data in isolation.</p>
<p>Importantly, they found previously unidentified vulnerabilities in the tumors. They then tested these vulnerabilities in laboratory models and showed that certain drug combinations could work well to target them and treat the cancer. For example, the targeted drug trametinib—approved to treat various cancers including melanoma, lung cancer, and thyroid cancer, with a specific mutation—was shown to significantly reduce tumor growth and extend survival in the laboratory models when combined with other drugs.</p>
<p>The researchers hope this work will accelerate the path to clinical testing of new treatment strategies for colorectal cancer using drugs which have already been developed and approved. In addition, the team believe their AI approach could be used to identify more effective drugs for other tumor types.</p>
<p>In their paper the investigators wrote, “In conclusion, the in-depth molecular characterization of MSS CRC has revealed biological insights and promising therapeutic opportunities. By seamlessly integrating genomic, epigenomic, proteomic, metabolomic, and snRNA-seq/scRNA-seq expression analyses, we have substantially advanced understanding of the disease’s complex and heterogeneous biology and in parallel have identified promising new contexts of vulnerabilities with further translational potential.” Given what the team describes as “… the dearth of available effective treatments for MSS CRC patients …” the newly identified vulnerabilities may represent “the foundation for precision oncology treatment frameworks aimed at improving outcomes in this intractable disease setting.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Research co-lead and co-senior author Professor Anguraj Sadanandam, PhD, group leader, Systems and Precision Cancer Medicine Group, The Institute of Cancer Research, London, said, “A major strength of this research is the scale and diversity of the dataset, which was only possible through collaboration with European partners. By bringing together data from patients across multiple countries and integrating DNA, RNA, epigenetic, protein, metabolic, single-cell and clinical data at this scale, we were able to expose connections between tumor biology and therapeutic dependency that would otherwise be missed. AI and machine learning will increasingly help cancer researchers to bring these complex data together, not just to classify tumors, but to understand how they behave, identify their vulnerabilities and guide the development and repurposing of treatments, so that patients can live longer and healthier lives.”</p>
<p>Rodrigo Dienstmann, PhD, Vall d’Hebron Institute of Oncology, Barcelona and University of Vic–Central University of Catalonia was co-senior author of the study.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/multiomic-study-of-mss-crc-identifies-vulnerabilities-pointing-to-therapeutic-possibilities/">Multiomic Study of MSS CRC Identifies Vulnerabilities Pointing to Therapeutic Possibilities</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Wirelessly Powered Electronic Implant, ECHO, Enables Drug&#45;Free Management of ‘Diabesity’</title>
<link>https://edusehat.com/en/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity</link>
<guid>https://edusehat.com/en/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity</guid>
<description><![CDATA[ Researchers developed an implantable, wirelessly powered electronic device, ECHO, that uses electrocatalysis to remove excess glucose from the bloodstream on demand, and could offer a drug-free approach to managing obesity and type 2 diabetes (T2D). 
The post Wirelessly Powered Electronic Implant, ECHO, Enables Drug-Free Management of ‘Diabesity’ appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/GettyImages-2174865889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 24 Oct 2026 02:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Wirelessly, Powered, Electronic, Implant, ECHO, Enables, Drug-Free, Management, ‘Diabesity’</media:keywords>
<content:encoded><![CDATA[<p>Researchers at ETH Zürich, the University of Lyon, and the University of Basel have developed an implantable, wirelessly powered electronic device, known as ECHO, (electrocatalytic closed-loop health optimization)  that could offer a drug-free approach to managing obesity and type 2 diabetes (T2D). These two interlinked metabolic disorders often coexist—as “diabesity”—affecting billions of people worldwide.</p>
<p>The team’s implantable device uses electrocatalysis to remove excess glucose from the bloodstream on demand. Tested in a diabesity mouse model, the device was coupled to a continuous glucose monitor (CGM) via a smartphone, enabling autonomous closed-loop metabolic control, such that the electrocatalyst was only activated when glucose levels exceeded a predefined threshold. The results showed that the device rapidly restored elevated blood glucose level to the normal range, with repeated treatments maintaining glucose control for weeks, without any drug use. Lowering glucose also shifted whole-body metabolism toward the use of stored fat, so treated mice also demonstrated reduced body weight.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead Martin Fussenegger, PhD, a professor at the Department of Biosystems Science and Engineering, ETH Zürich, is senior and corresponding author of the team’s published paper in <em>Science Advances</em>, titled “<a href="https://doi.org/10.1126/science.ady8560" target="_blank" rel="noopener">Wireless electrocatalytic closed-loop system for drug-free management of diabesity</a>.” In their report the team wrote in summary, “We believe that closed-loop electrocatalytic devices could establish a platform concept for regulating disease-relevant metabolites, offering a potential route toward drug-sparing, dynamically controlled metabolic interventions.”</p>
<p>Obesity and diabetes are closely interconnected metabolic disorders that reinforce one another through complex hormonal, inflammatory, and energy-regulation processes, together contributing to the global rise of diabesity. “The physiological relationship between obesity and diabetes is bidirectional and self-reinforcing, involving a complex interplay of metabolic, hormonal, and inflammatory changes,” the authors explained. Existing treatments rely heavily on long-term medication and lifestyle changes, while current glucose-monitoring and insulin-delivery systems face limitations in accuracy, reliability, personalization, and cost. “Current treatments rely largely on drugs that lower blood glucose or body weight, but these therapies can produce side effects, require lifelong administration, and may lose effectiveness over time,” the authors continued.</p>
<p>Emerging approaches, including engineered therapeutic cells and drugs that target both weight and blood glucose, offer promise but remain constrained by concerns of side effects, safety, and affordability. Another emerging strategy involves electrocatalysis, which uses electrode surfaces to drive chemical reactions that convert glucose into other compounds. “A subcutaneous implant containing a solid electrocatalyst that directly removes excess glucose from the bloodstream at an electrically adjustable rate could provide a dose-controllable, drug-free therapeutic alternative.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Using electrocatalysis, Debasis Maity and colleagues developed the implantable ECHO device. The wirelessly powered device uses a platinum (Pt)-decorated gold (Au) nanoclusters embedded in a porous, conductive graphite felt (GF) matrix. The electrocatalyst converts circulating glucose into gluconate, which can be excreted through the kidneys.</p>
<p>Connected via smartphone to a continuous glucose monitor, ECHO automatically activates when blood sugar exceeds a predetermined threshold, enabling targeted glucose removal without the need for external insulin or medication.</p>
<p>In a proof-of-concept study in obese mice with type 2 diabetes, the authors showed that wireless activation of the device at low power (0.75 volts and 10 milliamperes) restored normal blood glucose levels within an hour, and shifted the body’s energy use from glucose toward fat. Over six weeks of treatment the mice experienced reductions in body weight and triglyceride levels, alongside increases in circulating free fatty acids and ketone bodies. These changes occurred without detectable episodes of low blood sugar or adverse effects on physiological function, inflammation, or behavior.</p>
<p>“The CGM system tracked glucose concentrations and transmitted the data to a smartphone, which processed the data and sent instructions back to the ECHO device, which in turn rapidly adjusted glucose concentrations to maintain homeostasis in response—achieving this without hypoglycemic episodes or the need for small-molecule drugs or biopharmaceuticals,” the authors wrote.</p>
<p>In a related <a href="https://doi.org/10.1126/science.aem0762" target="_blank" rel="noopener">perspective</a>, William Bentley, PhD, and Gregory Payne, PhD, at the Fischell Department of Bioengineering, University of Maryland, wrote, “Existing bioelectronics devices provide notable access to the nervous and neuromuscular systems … future electronic intervention devices might help to manage diseases other than diabetes, modulate human-microbiome interactions, or maintain redox homeostasis in stress conditions, among many other applications.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/wirelessly-powered-electronic-implant-echo-enables-drug-free-management-of-diabesity/">Wirelessly Powered Electronic Implant, ECHO, Enables Drug-Free Management of ‘Diabesity’</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: Patient featured in ‘Fight of Our Lives’ shares her story</title>
<link>https://edusehat.com/en/pace-patient-featured-in-fight-of-our-lives-shares-her-story</link>
<guid>https://edusehat.com/en/pace-patient-featured-in-fight-of-our-lives-shares-her-story</guid>
<description><![CDATA[ Seven fingertips and both lower legs. For Katy Grainger, that was the toll sepsis took—and the beginning of a second career spent making sure […]
The post PACE: Patient featured in ‘Fight of Our Lives’ shares her story appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/fight-of-our-lives.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 22:50:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, Patient, featured, ‘Fight, Our, Lives’, shares, her, story</media:keywords>
<content:encoded><![CDATA[<p><span>Seven fingertips and both lower legs. For Katy Grainger, that was the toll sepsis took—and the beginning of a second career spent making sure others recognize it sooner.</span></p>
<p><span>Grainger, a member of the board of directors at the Sepsis Alliance and author who now speaks nationally on sepsis awareness, opened the second day of the Biotechnology Innovation Organization’s (BIO) Oct. 22-23 Patient Advocacy Changemakers Event (PACE) in Washington, D.C. For a room full of patient advocates, her session was less a personal account than a demonstration of what a well-told story can do—the skill at the center of nearly everything else on this year’s program.</span></p>
<p><span>“I think most of the people in this room have seen a TV show where they have heard the term </span><i><span>sepsis</span></i><span>, and usually it happens in a really excited situation: you’ve got a patient in a bed; they’re getting sicker and sicker; they don’t know what’s going on, and someone says, </span><i><span>Oh my gosh, we have to do something,</span></i><span>” began Grainger. “But the reality with sepsis is that 80–90% of it actually happens out in the community. Meaning that you start getting sepsis when you’re at home, and it’s up to you to get yourself to that hospital to save your own life.”</span></p>
<p><span>Today, Grainger commits her time to raising awareness about the risk of sepsis, and the importance of the patient voice. She is featured in “</span><a href="https://fightofourlives.com/stories/katy/"><span>Fight of Our Lives</span></a><span>” BIO’s storytelling campaign.</span></p>
<h3>It could happen to anyone</h3>
<p><span>“I had a small infection on my thumb that was no bigger than a mosquito bite, but there was something about it that told me that something was wrong,” Grainger recalled.</span></p>
<p><span>It was a sunny afternoon in Hawaii, just days after Grainger had taken a vacation with her children that a perfect storm of events led her to the hospital with severe sepsis. </span></p>
<p><span>“I noticed that I had a bump on my thumb. It was pretty small, but it was a weird color, kind of purplish and it had this white haze,” said Grainger. “It just looked unusual, and my gut really told me that something wasn’t right.”</span></p>
<p><span>As so, Grainger did the right thing; she took herself to the hospital. There, doctors gave her antibiotics, took a sample to test and sent her home. But there were a few other issues at play.</span></p>
<p><span>First, her local town was dealing with a higher risk of infections due to past flooding. And second, Grainger was home alone, as her husband was out on a fishing trip for the weekend. Unfortunately for Grainger, while home by herself, her symptoms started coming on fast. </span></p>
<p><span>“I don’t really remember what happened that weekend,” she said. “I can only guess based on text messages.”</span></p>
<p><span>She continues, “I sent my husband a text and I said, ‘</span><i><span>Hey, I threw up, but don’t worry, I’m fine. It was just because of the antibiotic that I took on an empty stomach,’</span></i><span> which also tells me I wasn’t eating. I had these little clues that I just was not generally well all weekend, but I was dismissing it—and that’s really common.”</span></p>
<p><span>Her next text to her husband said goodnight, and that she was going to bed early. </span></p>
<p><span>“That could have been my last text ever to my husband,” Grainger said. “But luckily, I woke up the next morning.”</span></p>
<p><span>Even in her confused state, Grainger was able to call a friend, saying something was wrong and she needed to go to the hospital immediately. Upon arrival, Grainger’s blood pressure was 50/30.</span></p>
<p><span>“I have since been told that that can be called 50/dead,” Grainger said.</span></p>
<h3>Road to recovery</h3>
<p><span>What followed was an emergency sepsis protocol by the hospital, a week in an induced coma, the loss of her lower legs and parts of her fingers—she praised the doctors for saving her thumbs—and a long road to recovery. </span></p>
<p><span>“They extubated me in the hospital, and when they did that, I also was awakened,” Grainger remembered. “The first thing I saw was my missing fingertips, and I immediately went into a very deep depression. We spent three weeks trying to save my hands and feet, and amazingly, we were able to save my hands.”</span></p>
<p><span>But even throughout her hardship, Grainger found hope. And with her new lease on life, albeit a very different life, Grainger has committed herself to helping patients and spreading awareness. </span></p>
<p><span>“Because of the incredible medical care I got, I’m here today, and I can speak to you about the power of the patient voice,” she concluded. “If there’s one thing I’ve learned through all of this, it’s that there is nothing that can replace the story that a person tells about what they have been through. That speaks to people like yourselves in this room; it speaks to government officials; it speaks to people doing the testing and designing the products for patients; and it makes such a difference.”</span></p>
<p>The post <a href="https://bio.news/latest-news/pace-patient-featured-in-fight-of-our-lives-shares-her-story/">PACE: Patient featured in ‘Fight of Our Lives’ shares her story</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In the biotech world, you can’t see everything</title>
<link>https://edusehat.com/en/in-the-biotech-world-you-cant-see-everything</link>
<guid>https://edusehat.com/en/in-the-biotech-world-you-cant-see-everything</guid>
<description><![CDATA[ Earlier this week, I attended a screening of You Can See Everything, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes.  I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/YCSE_NP_1_1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 19:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>the, biotech, world, you, can’t, see, everything</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Holmes's charm is still unsettling on screen:</strong> Even knowing the full Theranos story, the documentary captures how effectively Holmes plants seeds of doubt—journalists who interviewed her in her prime later admitted she had fooled them completely.</li><br><li><strong>Peer review isn't a perfect safety net:</strong> Science's built-in fact-checking system has real cracks—10,000 papers were retracted in 2023 alone, and preprint servers, press releases, and social media now routinely bypass it.</li><br><li><strong>Reporters face the same vulnerability as investors:</strong> Even seasoned science journalists rely on trust and expert opinion to vet claims, raising an uncomfortable question: how confident can anyone really be that they wouldn't have fallen for it too</li></ul>" data-chronoton-post-id="1147610" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Earlier this week, I attended a screening of <em>You Can See Everything</em>, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes. </p>



<p class="wp-block-paragraph">I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given how familiar many of us are with the Theranos story thanks to years of media coverage, the best-selling book <em>Bad Blood</em>, and the Hulu series <em>The Dropout</em>, starring Amanda Seyfried.</p>



<p class="wp-block-paragraph">Like many others who have seen the film, I came away feeling unsettled. But not just about Holmes’s fraud and the somewhat disturbing interactions between the subjects. The film reignited a concern I’ve had about covering science for most of my career: Despite our best efforts, we never can actually <em>see everything</em>.</p>





<p class="wp-block-paragraph">In case you’re rusty on the details, Elizabeth Holmes dropped out of Stanford University in 2003 to run Theranos, a diagnostics company she founded, when she was just 19. She went on to claim that her company had invented a way to run over 100 diagnostic tests on just a few drops of blood.</p>



<p class="wp-block-paragraph">Holmes raised hundreds of millions of dollars for Theranos, which was valued at $9 billion in 2014. <em>Forbes</em> named her the youngest self-made female billionaire—she was <a href="https://www.forbes.com/profile/elizabeth-holmes/">worth $4.5 billion</a> when she was just 30 years old.</p>



<p class="wp-block-paragraph">Things started to unravel in 2015, when <a href="https://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901">an investigation by the <em>Wall Street Journal</em></a> raised concerns by former Theranos employees that the tests didn’t work. Some also said that the company’s device had not been tested properly, and that blood samples had been analyzed on machines from other companies instead. <em>MIT Technology Review</em> named it one of the <a href="https://www.technologyreview.com/2015/12/31/164066/the-6-biggest-technology-failures-of-2015/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">biggest technology failures of 2015</a>.</p>



<p class="wp-block-paragraph"><em>Forbes</em> had revised Holmes’s worth to $0 by 2016. That year, a damning government report said that <a href="https://www.technologyreview.com/2016/04/01/161208/theranos-promised-a-revolution-but-delivered-dangerous-errors/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">the company’s lab was struggling with basic procedures</a> and gave patients results even when they knew they could be wrong.</p>



<p class="wp-block-paragraph">In 2018, Theranos, Holmes, and former company president Ramesh Balwani were <a href="https://www.technologyreview.com/2018/03/14/241044/sec-charges-theranos-founder-elizabeth-holmes-with-massive-fraud/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">charged with “massive fraud.”</a> In 2022, she was sentenced to a little over 11 years in prison for defrauding investors. She began serving her sentence in May 2023.</p>



<p class="wp-block-paragraph">It was around a month before this that filmmakers Nathan Fielder, Lance Oppenheim, and their colleagues began documenting Holmes and her partner, Billy Evans, at home with their two young children. I’m not giving anything away when I say it’s an extremely intimate portrayal—at least of how the two adults interact with Fielder, who is also a central character in the film.</p>



<p class="wp-block-paragraph">As you might know if you’ve seen <a href="https://www.youtube.com/watch?v=HvW_N5p1q44">the trailer</a>, there are plenty of super close-ups. I felt as if I spent most of the film staring straight into the faces of those people. And almost the whole way through, they all seemed to be trying to figure each other out. Holmes is known for her dishonesty, but she invited cameras into her home in an apparent bid to reframe the narrative and position herself as an honest person with an unusual mind. Will anyone believe her?</p>





<p class="wp-block-paragraph">I couldn’t help feeling some empathy for Holmes, a mother we see preparing to leave her two kids for a lengthy prison sentence. And even though I have long known the facts, Holmes is clearly an effective manipulator. You can see her plant the seeds of doubt in Fielder’s mind. At times, I felt she was convincing me, sitting in my cinema seat. Maybe she really didn’t <em>mean</em> to lie?</p>



<p class="wp-block-paragraph">But then I remembered how other journalists felt after being taken in by her claims. “I blew it,” <em>Fortune</em>’s Roger Parloff <a href="https://fortune.com/2015/12/17/how-theranos-misled-me-elizabeth-holmes/">reflected</a> in 2015, a year after profiling Holmes and her company. “I’m pretty sure she lied to me,” <em>STAT</em>’s Matthew Herper <a href="https://www.statnews.com/2026/10/20/elizabeth-holmes-superpower-authenticity-vs-truth-matt-herper-take/">wrote</a> recently, having interviewed Holmes in 2015. Even the former employee turned whistleblower Tyler Shultz, who <em>knew</em> the product didn’t work, said that he could “have a five-minute conversation with her and walk away feeling like my work was changing the world,” he <a href="https://www.statnews.com/2022/06/01/theranos-whistleblower-tyler-shultz-lessons-learned/">said in 2022</a>.</p>



<p class="wp-block-paragraph">I didn’t cover Theranos in the 2010s. If I’d interviewed Holmes, would I have fallen for it all?</p>



<p class="wp-block-paragraph">One of the early red flags in the Theranos case was the lack of published, peer-reviewed data. Much of the company’s work was classified as a “trade secret.” Scientists tend to publish their work in journals—a slow process that involves having the work evaluated by often anonymous experts in the field, who provide feedback, highlight questionable conclusions, and often ask for clarification. Peer review is meant to add rigor to the publication process. You should be able to trust published scientific papers.</p>



<p class="wp-block-paragraph">Except that sometimes you can’t.</p>



<p class="wp-block-paragraph">Scientists aren’t perfect. Some will exaggerate their results or inflate their importance. Some manipulate data to serve a hypothesis. Sometimes these infractions are caught during peer review, but not always. There are plenty of examples of scientific findings that could never be replicated by other labs and ended up collapsing under the weight of real evidence. Many papers ultimately end up with corrections. Some are withdrawn—<a href="https://www.nature.com/articles/d41586-023-03974-8">10,000 research papers were retracted in 2023</a>.</p>



<p class="wp-block-paragraph">At any rate, there’s been a shift to sharing research in other ways. Today, many scientists opt to publish their work at preprint servers like arXiv, medRxiv, and bioRxiv before they submit them to established journals. Those outlets bypass peer review. So do company press releases, social media posts, and many conference presentations. And I get a lot of my stories from conversations and interviews.</p>



<p class="wp-block-paragraph">I’ll admit I’ve looked at a scientific finding and thought: A scientist has just said they’ve done that. <em>How can I be sure they really have?</em></p>



<p class="wp-block-paragraph">I like to think that I hold myself to high journalistic standards here, as does everyone at <em>MIT Technology Review</em>. I would never publish a story about some new scientific development without doing my own form of peer review, and asking scientists—ideally people I know and trust—what they think of a new claim. </p>



<p class="wp-block-paragraph">But the film is a stark reminder of how easy it can be to fall for an appealing narrative. While most scientists are, I hope, pretty honest, and Holmes is certainly an outlier, we should all continue to interrogate the claims being fed to us. If you’ve seen the film, let me know what you think!</p>



<p class="wp-block-paragraph"><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cryo&#45;EM and AI&#45;Designed Scaffold Reveal How Andes Hantavirus Binds Cells</title>
<link>https://edusehat.com/en/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells</link>
<guid>https://edusehat.com/en/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells</guid>
<description><![CDATA[ Using cryo-EM and an AI-designed scaffold, researchers mapped how Andes hantavirus engages a receptor on human cells. The findings explain how antibodies block attachment and may highlight a potential target for antiviral development.
The post Cryo-EM and AI-Designed Scaffold Reveal How Andes Hantavirus Binds Cells appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/GettyImages-2186951140.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 12:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cryo-EM, and, AI-Designed, Scaffold, Reveal, How, Andes, Hantavirus, Binds, Cells</media:keywords>
<content:encoded><![CDATA[<p>Hantaviruses can turn exposure to infected rodents into a life-threatening illness, including a pulmonary syndrome that can progress rapidly to respiratory failure. Andes virus adds another concern: unlike other hantaviruses known to cause human disease, it can also spread between people. Understanding how it first attaches to human cells could help researchers identify ways to interrupt infection.</p>
<p>Researchers at Albert Einstein College of Medicine in New York, Institut Pasteur in Paris, and LSU Health Shreveport have now resolved that interaction in near-atomic detail. Combining cryo-electron microscopy (cryo-EM) and functional experiments, they showed how the Andes virus spike captures a human receptor—and how antibodies interfere.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The study, published in <em>Nature</em>, is titled “<a href="https://www.nature.com/articles/s41586-026-11184-1" target="_blank" rel="noopener">Structural basis for protocadherin-1 recognition by New World hantaviruses</a>.”</p>
<p>Previous research established that Andes virus and other New World hantaviruses use the cell-surface protein protocadherin-1 (PCDH1) to enter host cells. What remained unclear was how the viral spike recognized this receptor. An isolated spike subunit could not bind PCDH1; the interaction required the assembled, four-part structure.</p>
<p>To examine that assembly, the team engineered a soluble Andes virus spike using methods that included an artificial intelligence–designed scaffold. The scaffold helped stabilize the square-shaped complex outside the virus, allowing the researchers to combine it with PCDH1 and analyze the resulting structure using cryo-EM.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<figure aria-describedby="caption-attachment-339755" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339755" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-300x300.jpg" alt="PCDH1" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_ANDVgreen_PCDH1pink-1-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">rVSV-ANDV infected cells (green) and PCDH1 bound to them (pink) [Albert Einstein College of Medicine]</figcaption></figure>
<p>The images revealed that PCDH1 binds asymmetrically within a deep central pocket formed by four copies of the viral Gn glycoprotein. Rather than presenting a receptor-binding site on an individual subunit, the spike builds one through the arrangement of its components.</p>
<p>Mutagenesis experiments identified three Gn loops that help shape the binding site. Changes involving these loops also enabled the researchers to transfer PCDH1-binding ability from New World to Old World hantavirus glycoproteins, according to the paper.</p>
<p>The team also investigated four neutralizing antibodies. Structural and functional analyses showed that the antibodies prevented receptor binding through two mechanisms: obstructing access to the PCDH1-binding site or creating a physical barrier that prevented receptor engagement.</p>
<p>“The depth of this pocket also helps explain how the virus limits antibody access. What’s striking is how the same pocket can accommodate the receptor while restricting antibody access. PCDH1’s long, slender shape lets it reach deep inside, but most antibodies are too bulky to follow,” said Rohit Jangra, PhD, assistant professor of microbiology and immunology at LSU Health Shreveport.</p>
<p>That distinction suggests a direction for therapeutic development. According to the researchers, engineered molecules with a narrow, elongated shape might reach farther into the pocket and block attachment. The team intends to explore this vulnerability as a basis for antiviral strategies against Andes virus and potentially related pathogens, including Sin Nombre virus.</p>
<p>The authors wrote, “Together, these findings define the structural determinants of hantavirus–receptor recognition, reveal how a virus can mask its receptor-binding site by recessing it in a surface depression and how antibodies can counter this strategy, and provide a framework for the design of antiviral therapeutics targeting the hantavirus spike.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/cryo-em-and-ai-designed-scaffold-reveal-how-andes-hantavirus-binds-cells/">Cryo-EM and AI-Designed Scaffold Reveal How Andes Hantavirus Binds Cells</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery</title>
<link>https://edusehat.com/en/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery</link>
<guid>https://edusehat.com/en/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery</guid>
<description><![CDATA[ A year-long collaboration involving scientists at PerturbAI, OpenAI, and their other institutions yielded an AI reasoning framework that turns datasets into testable hypotheses, with thousands of agents analyzing whole-brain genomic data in minutes instead of months.
The post PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/GettyImages-2224152938.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PerturbAI, and, OpenAI, Launch, Reasoning, Agents, for, Biomedical, Discovery</media:keywords>
<content:encoded><![CDATA[<p><span>This week, PerturbAI, OpenAI, and their collaborators shared results from a year-long effort aimed at developing an artificial intelligence (AI) reasoning framework that helps scientists interpret large experimental datasets, connect results with existing research, and generate testable hypotheses. Details are provided in a new bioAxriv preprint titled “</span><a href="https://www.biorxiv.org/content/10.64898/2026.10.15.759436v1" target="_blank" rel="noopener"><span>Distributed AI agents enable comprehensive discovery of biological insights at scale</span></a><span>.” </span></p>
<p><span>Besides the scientists at PerturbAI and OpenAI, other authors listed on the paper are scientists affiliated with Scripps Research Institute, University of California, San Diego, and Howard Hughes Medical Institute. In the paper, they explained the results of applying the AI framework to data from </span><a href="https://www.biorxiv.org/content/10.64898/2026.03.16.711480v1" target="_blank" rel="noopener"><span>PerturbAI’s whole-brain atlas</span></a><span>, published earlier this year. Specifically, the team developed thousands of agents to analyze cellular responses, search the scientific literature, and connect experimental results with existing biological knowledge. The system then synthesized the findings into a reasoning atlas that linked genes, cell responses, details from existing literature, and possible biological mechanisms. </span></p>
<p><span>When applied to the whole-brain atlas, “thousands of parallel agents thoroughly examined the dataset in minutes” and without access to the source manuscript “recovered its conclusions, predicted held-out perturbation effects, and identified perturbation relationships with shared or opposing outcomes across effect strengths,” the scientists wrote. In fact, the system completed the analysis in 32 minutes. Furthermore, “distributed agents scaled literature coverage with workload, retrieving 100s times more references than [a] single-agent mode.” </span><span> </span></p>
<p><span>To evaluate the quality of the agents’ interpretations, biologists reviewed their reports for novelty, evidential support, follow-up priority, and confidence level. According to numbers reported in the preprint, in blinded comparisons against reports generated by single AI agents, human experts preferred the reasoning-agents’ interpretations 75% of the time or 45 of 60 judgements. Single agent interpretations were preferred in 10 or 16.7%, and five were ties (8.3%).  </span></p>
<p><span>The work builds on a year-long collaboration that is now expanding into joint drug-target discovery that will leverage PerturbAI’s proprietary causal biological data. Using PerturbAI’s causal<em> in vivo</em> data, PerturbAI and OpenAI will now apply their AI reasoning frameworks to discover new drug targets. “Biomedical experiments are generating data faster than scientists can interpret it, meaning promising new discoveries are likely to remain hidden,” said Grace Zheng, PhD, CEO and co-founder of PerturbAI. “By combining large-scale causal data generated directly in living systems with frontier AI, our partnership with OpenAI is making it possible to investigate more biological data, faster and with greater depth, and to make target discovery more systematic.”</span></p>
<p><span>“By combining PerturbAI’s experimental data with OpenAI’s reasoning capabilities, we can help scientists uncover new biological insights and identify promising leads for drug discovery,” added Joy Jiao, head of life sciences at OpenAI. “The scale, quality, and speed of PerturbAI’s discovery engine make them an ideal partner, and this is just the beginning of what we can achieve together. Running nearly 2,000 agents in parallel shows how we can scale biological interpretation alongside high-throughput experimentation, helping researchers turn those findings into better medicines.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/perturbai-and-openai-launch-ai-reasoning-agents-for-biomedical-discovery/">PerturbAI and OpenAI Launch AI Reasoning Agents for Biomedical Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nvidia, UW Institute for Protein Design Unveil Open&#45;Source Protein Design AI Model</title>
<link>https://edusehat.com/en/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model</link>
<guid>https://edusehat.com/en/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model</guid>
<description><![CDATA[ RFD4-Proteina is an open model based on Nvidia’s NVIDIA BioNeMo™ artificial intelligence (AI) platform for chemistry and biology that combines programmable protein design with search capabilities. RFD4-Proteina generates targeted protein designs, enabling scientists and agents to search and refine those designs using molecular inputs, constraints, and scoring objectives. 
The post Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages_1402266486_proteins-1024x538-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nvidia, Institute, for, Protein, Design, Unveil, Open-Source, Protein, Design, Model</media:keywords>
<content:encoded><![CDATA[<figure aria-describedby="caption-attachment-339716" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-339716 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-200x300.jpeg" alt="" width="200" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-200x300.jpeg 200w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-683x1024.jpeg 683w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-768x1151.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web-1025x1536.jpeg 1025w, https://www.genengnews.com/wp-content/uploads/2026/10/David-Baker-493455cCPMichel1212026-web.jpeg 1281w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nobel laureate David Baker, PhD, IPD’s director and a professor of biochemistry at UW Medicine [UW Medicine Institute for Protein Design]</figcaption></figure>
<p>The University of Washington (UW) School of Medicine <a href="https://www.ipd.uw.edu/" target="_blank" rel="noopener">Institute for Protein Design</a> (IPD) has partnered with Nvidia to develop an open, generative model that uses biomolecular reasoning designed to improve how well researchers can design new proteins with specific functions.</p>
<p>RFD4-Proteina is an open model based on Nvidia’s <a href="https://github.com/NVIDIA-BioNeMo" target="_blank" rel="noopener">NVIDIA BioNeMo<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> artificial intelligence (AI) platform</a> for chemistry and biology that combines programmable protein design with search capabilities. According to its developers, RFD4-Proteina generates targeted protein designs, enabling scientists and agents to search and refine those designs using molecular inputs, constraints, and scoring objectives. Potential applications include designing proteins to interrupt disease processes or detect signs of disease in diagnostic tests.</p>
<p>RFD4-Proteina concurrently refines a protein’s sequence and structure alongside the structures of interacting molecules, so that a change in one effortlessly leads to changes in the others. RFD4-Proteina has achieved five-fold to 10-fold higher design success rates while generating protein candidates five to 10 times faster than previous models, the developers said.</p>
<p>Lab bench tests showed that RFD4-Proteina achieved higher computational design success rates and generation throughput than the evaluated baselines across four benchmark suites: protein binding, small-molecule binding, enzyme scaffolding, and DNA binding, Nvidia said.</p>
<p>The model helps researchers explore and prioritize candidates for laboratory testing. And by remaining open, UW and Nvidia added, RFD4-Proteina will enable investigators to build on its capabilities by exploring more potential protein designs and advancing promising drug candidates into lab testing faster.</p>
<p>“We are moving from an era of discovering the proteins nature has made to one in which we can design entirely new ones,” Nobel laureate David Baker, PhD, IPD’s director and a professor of biochemistry at UW Medicine, said in a statement. “RFD4-Proteina expands what scientists can create, from proteins that could advance drug discovery to enzymes that break down pesticides.”</p>
<h4><strong>‘New solutions’</strong></h4>
<p>“RFD4-Proteina will open the door to new solutions in medicine, sustainability, materials and biotechnology,” Baker added. “I think with these improved generative AI methods, we’ll see better medicines … and applications more broadly outside of medicine and sustainability, new ways of breaking down polymers, new ways of making bioplastics.”</p>
<figure aria-describedby="caption-attachment-339714" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339714" src="https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA-300x202.jpg" alt="" width="300" height="202" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA-300x202.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/UW-IPD-dry-lab-RFD4-PROTEINA.jpg 640w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Members of the RDF4 modeling team run tests at the Institute for Protein Design. [Sierra Adler / UW Medicine Institute for Protein Design]</figcaption></figure>
<p>RFD4-Proteina derives its name from the IPD’s <a href="https://www.bakerlab.org/2023/07/11/diffusion-model-for-protein-design/" target="_blank" rel="noopener">RosettaFold Diffusion</a>, a guided diffusion model for generating new proteins, and Nvidia’s <a href="https://research.nvidia.com/labs/genair/proteina/" target="_blank" rel="noopener">Proteina-Complexa</a>, a generative model for protein binder design for protein and small molecule targets. Proteina-Complexa combines inference-time optimization with a pretrained flow-based generative model built on Nvidia’s La-Proteina AI model developed for atomistic protein design.</p>
<p>RFD4-Proteina is available through partners that include Amazon Bio Discovery, Anthropic’s Claude Science, Benchling, Databricks, Google Cloud, Hugging Face, Nebius, OpenAI, and Tamarind Bio. The partners enable researchers and developers to integrate the open protein design model into agent, cloud, and scientific computing workflows.</p>
<p>At IPD, researchers who have applied the model to their novel protein design challenges reported that RFD4-Proteina represented an improvement over past methods’ efficacy and speed.</p>
<p>“We were able to precisely control what types of glycans (sugars important for immune-system recognition) are attached to proteins in ways past models haven’t been able to achieve, and to do so in under just a week rather than months,” said Meg Lunn-Halbert, a UW PhD candidate in biochemistry and in biological physics, structure and design.</p>
<h4><strong>From months to days</strong></h4>
<p>Added Seth Woodbury, a UW bioengineering predoctoral candidate and National Science Foundation fellow: “In just a few days we designed a pesticide-degrading enzyme that performs many fold better than my previous best, which took months to design.”</p>
<p>RFD4-Proteina arose from a collaboration between IPD and Nvidia researchers and is immediately available for use as an open-source resource hosted through Berkeley Software Distribution (BSD-3).</p>
<p>IPD leaders of the project were three UW PhD students—Nathaniel Corley, Maxwell Kazman, and Rafi Brent—as well as Kieran Didi, a visiting student from the University of Oxford.</p>
<p>The development of RFD4-Proteina was funded by the Howard Hughes Medical Institute, Gates Foundation (INV-092109), Grantham Foundation, Fund for Science and Technology, Schmidt Sciences, OpenFold consortium (part of OMSF), Rosetta Commons, and additional supporters of the IPD. According to its website, the Gates Foundation <a href="https://www.gatesfoundation.org/about/committed-grants/2025/12/inv-092109" target="_blank" rel="noopener">committed $25,748,619</a> through a grant dated November 2025.</p>
<p>The Jen-Hsun and Lori Huang Foundation provided a computational grant that was critical to RFD4-Proteina’s development, UW stated in announcing the introduction of RFD4-Proteina.</p>
<p>Baker is a Howard Hughes Medical Institute Investigator and one of three winners of the 2024 Nobel Prize in Chemistry “for computational protein design,” along with Sir Demis Hassabis, PhD, and John Jumper, PhD.</p>
<p>Hassabis is a co-founder of Google DeepMind who is now chief scientist of Google parent Alphabet and the founder/CEO of Google-co-owned Isomorphic Labs. Jumper announced plans in June to leave Google DeepMind for Anthropic, the AI giant that has filed for an initial public offering (IPO) that would value the company at an eye-popping $2 trillion.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/nvidia-uw-institute-for-protein-design-unveil-open-source-protein-design-ai-model/">Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private</title>
<link>https://edusehat.com/en/eqt-to-acquire-qiagen-for-121b-plans-to-take-tools-diagnostics-provider-private</link>
<guid>https://edusehat.com/en/eqt-to-acquire-qiagen-for-121b-plans-to-take-tools-diagnostics-provider-private</guid>
<description><![CDATA[ EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns. 
The post EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/S_1191_0_CC_GEN_QIAGEN_Employee_0267-16x9-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>EQT, Acquire, Qiagen, for, 12.1B, Plans, Take, Tools, Diagnostics, Provider, Private</media:keywords>
<content:encoded><![CDATA[<p>An entity of Swedish private equity firm EQT has agreed to acquire Qiagen for €10.8 billion (about $12.1 billion) cash, both said today, in a deal that would take private the global life-sciences tools, diagnostics, and workflow solutions provider following on-and-off takeover attempts over nearly seven years.</p>
<p>The buyer is EQT Private Equity, a holding company indirectly controlled by the firm’s EQT XI fund and managed and controlled by affiliates of EQT. Within EQT Private Equity, “indirect participations” or stakes are held by co-investors Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority; and CPP Investment Board Europe, a wholly-owned subsidiary of Canada Pension Plan Investment Board or CPP Investments.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>EQT’s takeover offer followed what Qiagen called a comprehensive review by its Supervisory Board and Managing Board evaluating the company’s strategic prospects through discussions with strategic and financial parties.</p>
<p>Qiagen said that its boards concluded that a buyout by EQT would offer the best prospects for the company’s next growth phase by giving it greater flexibility to invest longer term under a private owner while providing shareholders with attractive and certain cash value.</p>
<p>“After considering Qiagen’s stand-alone strategic prospects and the alternatives available through discussions with strategic and financial parties, we unanimously concluded that this is the best path forward for Qiagen, its shareholders, and other stakeholders,” Stephen H. Rusckowski, chairman of Qiagen’s Supervisory Board, said in a statement.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<h4><strong>‘Compelling value’</strong></h4>
<p>“This transaction offers shareholders compelling value while positioning Qiagen for its next phase of development under private ownership,” Rusckowski added.</p>
<p>News of Qiagen’s strategic review emerged in January through a <em>Bloomberg News</em> report that said the company was weighing a potential sale, attributed to unnamed sources, amid fresh interest from would-be buyers in acquiring the company.</p>
<p>Investors reacted to news of the strategic review with a <a href="https://www.genengnews.com/topics/bioprocessing/stockwatch-qiagen-shares-rebound-on-report-it-is-assessing-strategic-options/" target="_blank" rel="noopener">buying surge</a> that sent Qiagen shares to their highest levels since February 2023, a 17% one-week gain that saw its New York Stock Exchange shares rise from $47.57 on January 16 to $55.62 on January 23. Qiagen’s European shares, traded on the Frankfurt Stock Exchange’s XETRA market, rose 12.5% from €40.99 ($45.55) to €46.13 ($51.46).</p>
<p>Qiagen shares slipped since then as investors questioned whether the company would reach agreement with a buyer, and as the company lowered its full-year guidance to investors. In April, Qiagen cut its net sales growth forecast from 5% down to 1–2%, while lowering its adjusted diluted EPS forecast from $2.50 to $2.43. The reductions followed weaker than anticipated sales—a year-over-year 5% drop at constant exchange rates—of Qiagen’s QuantiFERON blood test kit due to reduced demand for immigration-related tuberculosis testing in the U.S. and Middle East.</p>
<p>Qiagen shares reached a 52-week low of €27.56 ($30.62) May 12 on XETRA and $32.13 the following day on NYSE before climbing back to the low €40s on XETRA and mid-$40s on NYSE.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<h4><strong>Cautious investor reaction</strong></h4>
<p>On Thursday, investors appeared to react cautiously to the deal. Shares on XETRA rose 5% from €42.82 ($47.77) to € 44.94 ($50.13). On NYSE, shares barely rose 0.4%, from an even $50 to $50.22. Qiagen has suspended its full-year guidance for this year due to the planned acquisition.</p>
<p>At €46.50 ($51.88) per share, EQT Equity Partners’ offer for Qiagen represents an 8.6% premium above Qiagen’s closing stock price Wednesday—but a premium of 40.3% to the XETRA closing price of €33.15 ($36.84) on July 8, the last trading day before news reports about private equity firms being interested in acquiring Qiagen. The premium climbs to 46.9% when compared to the three-month volume-weighted average price (VWAP) on XETRA of €31.66 ($35.18) per Qiagen share up to and including July 8.</p>
<p>The €10.8 billion ($12.1 billion) enterprise value of the deal includes approximately $1.1 billion of net debt, Qiagen said.</p>
<p>“Qiagen’s management team and employees have built an exceptional company with a portfolio of highly attractive products and respected brands, strong market positions and considerable technical expertise,” stated Matteo Thun-Hohenstein, Partner at EQT. “EQT brings deep sector experience, a global network and operational capabilities, and we are proud to partner with Qiagen’s highly talented and capable employees to further invest in Qiagen’s continued product innovation and growth.”</p>
<h4><strong>Track record</strong></h4>
<p>EQT has €354 billion in assets under management and a three-decade track record of acquiring, developing, and sometimes selling companies that include life sciences tools/tech concerns.</p>
<p>In 2019, EQT <a href="https://www.genengnews.com/topics/bioprocessing/eqt-agrees-to-acquire-majority-interest-in-cdmo-aldevron/" target="_blank" rel="noopener">acquired a majority interest in Aldevron</a>, which it sold two years later to Danaher for approximately $9.6 billion. Also in 2021, EQT joined the private equity business of Goldman Sachs to <a href="https://www.genengnews.com/topics/drug-discovery/goldman-sachs-eqt-to-buy-parexel-for-8-5b-continuing-cro-consolidation/" target="_blank" rel="noopener">acquire contract research organization Parexel for $8.5 billion</a>. In 2023, EQT co-led a €129 million ($138 million at the time; $144 million today) <a href="https://www.genengnews.com/topics/translational-medicine/going-dutch-vectorys-138m-series-a-to-advance-vectorized-antibody-programs-for-neurodegenerative-diseases/">Series A financing of Amsterdam biotech VectorY</a>, with proceeds intended toward advancing its vectorized antibodies for neurodegenerative disease treatment. Other current and former portfolio companies of EQT include SPT Labtech, Galderma, Dako and HemoCue.</p>
<p>EQT says its healthcare and life sciences experience includes around 100 investment professionals across 15 countries, with over €30 billion (about $33.6 billion) invested across more than 210 companies in healthcare globally.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>EQT Private Equity said it had obtained enough committed equity and debt financing to fund the offer and related transaction costs. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole, and UniCredit are acting as bookrunners and mandated lead arrangers for the committed debt financing.</p>
<p>Both EQT and Qiagen stressed the prospective buyer’s plan for long-term ownership of the tools/diagnostics giant. Under the Business Combination Agreement signed by both, EQT Private Equity agreed to support Qiagen’s long-term development through “commitments relating to Qiagen’s strategy, business, key brands, operational footprint, R&D activities, employee arrangements, prudent financing, and culture of excellence.”</p>
<h4><strong>Mid-2027 close expected</strong></h4>
<p>Upon completion of the transaction, which is expected to close in mid-2027, Qiagen said it will continue to operate under its own name and brand. If closing has not occurred within 10 months of October 21 (August 21, 2027) because required regulatory approvals remain pending, Qiagen may opt to pay shareholders an interim dividend of up to $0.47 per share. Any interim dividend would not be deducted from the offer price.</p>
<p>Qiagen said its boards will recommend that the company’s shareholders tender their shares into the takeover offer and vote in favor of the deal in a position statement to be published after EQT publishes the offer document detailing the transaction. The Takeover Offer will be subject to a minimum acceptance threshold of 50% of Qiagen’s outstanding share capital plus one share, approval of post-closing measures and a decision to adopt them by Qiagen’s boards, merger control and foreign investment clearances, and additional conditions.</p>
<p>Qiagen shareholders who do not accept the Takeover Offer will receive a cash distribution in an amount per share equal to the Offer Price less applicable withholding taxes—which Qiagen said may result in a lower net amount being received than if the shareholders had accepted the Takeover Offer.</p>
<p>If the deal goes through, EQT’s planned purchase would end nearly seven years or on-and-off merger-and-acquisition activity surrounding Qiagen. In March 2020, Thermo Fisher Scientific <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fcoronavirus%2Fthermo-fisher-to-expand-coronavirus-infectious-disease-dx-with-planned-11-5b-qiagen-acquisition%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C28b88f85661e4c341de808de59e20c86%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639047025085584898%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Rmudj4AreTISalol8OzJBF%2BKvc%2FBEflHXO3VafkxDxc%3D&reserved=0" target="_blank" rel="noopener">offered to acquire Qiagen for approximately $11.5 billion</a> in a deal driven by the COVID-19 pandemic. Thermo Fisher explained at the time that it sought to purchase Qiagen in order to expand its molecular diagnostics portfolio with a SARS-CoV-2 coronavirus test and other infectious disease tests.</p>
<p>However, Thermo Fisher <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fcoronavirus%2Fthermo-fisher-qiagen-part-ways-as-covid-19-fuels-collapse-of-12-5b-deal%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C28b88f85661e4c341de808de59e20c86%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639047025085609061%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=74Y6gYE7f9KBZz2HGpCBxudVZy9NZtgjMN%2FXaRY93b4%3D&reserved=0" target="_blank" rel="noopener">terminated its buyout offer five months later</a> when it failed to win support from two-thirds (66.67%) of investors, with only 47% of holders of outstanding Qiagen shares agreeing to tender their shares. Key to the deal falling through was vocal opposition from the hedge fund Davidson Kempner, an activist investor that raised its stake in Qiagen from 3.6% to 8%. The deal collapsed despite Thermo Fisher sweetening its offer to $12.5 billion by raising its per-share offering price from €39 ($43.34) to €43 ($47.98).</p>
<p>Two years later, in 2022, <em>The Wall Street Journal</em> reported that Bio-Rad Laboratories was in talks with Qiagen on a merger deal valued at more than $10 billion, a deal that neither company confirmed at the time.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/eqt-to-acquire-qiagen-for-12-1b-plans-to-take-tools-diagnostics-provider-private/">EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer</title>
<link>https://edusehat.com/en/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer</link>
<guid>https://edusehat.com/en/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer</guid>
<description><![CDATA[ The results of a large prospective proteomic study have associated proteins linked with the immune system, cell adhesion, blood vessel formation, and known prostate cancer genes, to future risk of developing prostate cancer, including aggressive disease. 
The post Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/07/Jul14_2020_Getty_1178748795_ProstateCancerCells-scaled-e1627958312296.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 04:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proteins, Circulating, Blood, Linked, Future, Risk, Prostate, Cancer</media:keywords>
<content:encoded><![CDATA[<p>The results of a large prospective proteomic study, headed by Oxford Population Health, have linked proteins associated with the immune system, cell adhesion, blood vessel formation, and known prostate cancer genes, with the future risk of developing prostate cancer (PCa), including aggressive disease.</p>
<p>Findings from the study, involving more than 2,500 men, revealed biological differences between those who later developed prostate cancer, and those who did not. The results may may help guide future studies aimed at identifying men at greater risk of the disease.</p>
<p>Professor Karl Smith-Byrne, MPhil, DPhil, at Oxford Population Health, said, “Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease. Together with existing and future genetic evidence, these findings may help us identify biological pathways that could be targeted to prevent aggressive prostate cancer.”</p>
<p>The study, “<a href="http://dx.doi.org/10.1016/j.eururo.2026.08.014" target="_blank" rel="noopener">Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10yr</a>,” is published in <em>European Urology</em>, and was presented at the American Society of Human Genetics (ASHG) Annual Meeting. In their paper co-senior author Smith-Byrne and colleagues, concluded, “These findings identify candidate protein risk factors for overall and clinically significant PCa, and warrant further validation and mechanistic evaluation.”</p>
<p>Prostate cancer is the most commonly diagnosed cancer in men worldwide, but relatively little is known about why some men develop the disease or why some cancers become aggressive. Most established risk factors, such as age and genetics, cannot be changed. “Identifying individuals at future risk of clinically significant prostate cancer remains challenging because of the limited number of established predictors,” the researchers noted. Their previous research had identified potential protein risk factors for prostate cancer, “… suggesting that broader proteomic investigation may provide further insights into the mechanisms underlying PCa development.” This is particularly important, they noted, given the lack of preventive strategies.</p>
<p>High-throughput proteomic technologies allow large-scale evaluation of potential protein-disease associations. For their newly reported study, which was part funded by Cancer Research UK, the investigators analyzed blood samples from 982 men who subsequently developed prostate cancer and a randomly selected sample of 1,573 men from the European Prospective Investigation into Cancer and Nutrition (EPIC). They measured more than 6,000 proteins in the blood and looked for differences linked to the later development of prostate cancer, particularly aggressive disease. Participants were followed for around 16 years. “This study is the largest population-based investigation of proteomic risk factors for PCa to date, with comprehensive protein profiling and a case-cohort design enabling robust risk estimation,” the investigators stated.</p>
<p>Their analyses identified circulating proteins associated with future PCa risk, including proteins related to immune, adhesion, angiogenesis, and PCa driver-gene pathways. “Notably, these protein differences were detectable in the blood long before a man’s diagnosis with PCa, and many were associated with clinically significant disease,” they commented.</p>
<p>Twelve proteins were linked to prostate cancer diagnosed more than 15 years after the blood sample was collected. These included GZMK, a protein produced by immune cells involved in recognizing and destroying abnormal cells, suggesting that immune processes may help keep prostate cancer in check long before it is diagnosed.</p>
<p>The researchers also identified seven proteins linked to aggressive prostate cancer. “The long follow-up and detailed characterization of clinically relevant subtypes allowed the identification of proteins associated with aggressive disease,” they stated. One protein, ANKRD1, was consistently linked to several serious forms of the disease, including cancers that had spread or were ultimately fatal. Other findings pointed to processes involved in how cancer cells interact with surrounding tissue and how new blood vessels form.</p>
<p>First author Zhe Huang, PhD, a postdoctoral epidemiologist at Oxford Population Health, said, “Prostate cancer is not one disease. Many prostate cancers grow slowly and may never cause harm, while others are aggressive and can be life-threatening. By measuring thousands of proteins in blood collected years before diagnosis, we can begin to investigate how men who later develop aggressive prostate cancer may differ from men who do not. Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future.”</p>
<p>The study also found links with blood levels of proteins produced by genes already known to be important in prostate cancer, including <em>ERBB3, KRAS,</em> and <em>NRAS</em>. These proteins were particularly linked to aggressive prostate cancer diagnosed around a decade later. This does not mean cancer was already present when the blood was collected, but the findings may provide clues to biological changes associated with the future development of the disease.</p>
<p>The researchers compared their results with other large population studies and genetic evidence to test the robustness of their findings. Several findings were supported by these additional analyses, although not all could be confirmed. The proteins identified are not yet suitable for use as clinical tests; most associations were modest and further studies are needed to establish whether they could improve prediction of clinically significant prostate cancer. “Studies integrating tumor genomics and circulating proteomics will be required to clarify the relationship among circulating protein levels, genomic alterations, and disease development, and dedicated prediction studies are warranted to support their potential utility for biologically informed risk stratification,” the researchers concluded.</p>
<p>Future research through the Prostate Cancer Aetiology and Prevention Programme (PCAP), funded by Cancer Research UK, will investigate whether these findings could ultimately contribute to better ways of predicting or preventing prostate cancer.</p>
<p>Professor Ruth Travis, DPhil, at Oxford Population Health, and one of the PCAP programme leads, said,” For the first time, technologies that allow us to measure thousands of proteins simultaneously are giving us unprecedented insight into the earliest stages of prostate cancer development. Combined with large, long-term population studies, they allow us to look back many years before diagnosis and investigate the biological changes associated with future cancer risk. Understanding these processes is a critical step towards developing new strategies to prevent prostate cancer.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/proteins-circulating-in-blood-linked-to-future-risk-of-prostate-cancer/">Proteins Circulating in Blood Linked to Future Risk of Prostate Cancer</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patient advocates launch PACE by reviewing their big hits in 2026</title>
<link>https://edusehat.com/en/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026</link>
<guid>https://edusehat.com/en/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026</guid>
<description><![CDATA[ Patient advocacy is often a long game, so it is important to remember (and celebrate) the home runs as the hits come—and keep on […]
The post Patient advocates launch PACE by reviewing their big hits in 2026 appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Patient-Advocates-B-roll-Scratch.00_08_00_13-Still002.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:15:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patient, advocates, launch, PACE, reviewing, their, big, hits, 2026</media:keywords>
<content:encoded><![CDATA[<p><span>Patient advocacy is often a long game, so it is important to remember (and celebrate) the home runs as the hits come—and keep on coming. </span></p>
<p><span>The Biotechnology Innovation Organization (BIO) launched their 15th annual Patient Advocacy Changemakers Event (PACE) in Washington DC on Oct. 22 with a celebration of some of advocacy’s biggest recent wins during their </span><a href="https://pace.bio.org/2026-program/patient-advocates-leading-way-1?&filters.date=22-Oct-2026%2C23-Oct-2026%2C&sortby=customfield_6234%20asc&searchgroup=libraryentry-2026-program"><span>Home Run! Patient Advocates Leading the Way</span></a><span> panel. </span></p>
<p><span>Michele Oshman, BIO Chief Patient Advocate and SVP, Patient Advocacy Center of Excellence, asked a panel of patient advocates about 2026’s banner achievements.</span></p>
<h3>Hitting it out of the park in 2026</h3>
<p><span>One big area that advocates got a few good hits in was the vaccine space. This is especially important in the wake of the COVID pandemic, which saw some states restricting vaccine access in ways that surprised many public health professionals. </span></p>
<p><span>Sue Peschin, MHS, President and CEO at the Alliance for Aging Research explained how, even though her organization works primarily with older populations, when it came to vaccine legislation, partnering with pediatric and chronic disease advocates got policies to home base faster.</span></p>
<p><span>“We started something called the Our Best Shot Network to really bring the different coalition leaders together,” Peschin said, “so that folks could coordinate and amplify each other’s opportunities.”</span></p>
<p><span>As a result, advocates have been able to co-lead a number of sign-on letters to the Food and Drug Administration (FDA) to highlight issues that would not have otherwise gotten as much attention, particularly when it comes to the Advisory Committee on Immunization Practices (ACIP). The network has also brought in center-right politicians to help sway their colleagues when problematic vaccine policy arises.</span></p>
<p><span>“There was an initiative to require prescriptions in order to get a COVID vaccine that was almost up for a vote at ACIP,” said Peschin, “and because of connections that we had made with conservative friends, they contacted ACIP and pulled back on that vote and made sure that that didn’t come up. No matter what you think about COVID vaccines, that would have set a horrible precedent for vaccines overall. So that was a big deal.”</span></p>
<p><span>There were wins in the Alzheimer’s community as well. </span></p>
<p><span>“We have new blood tests, blood-based biomarker tests,” recalled Erika Sward, Chief Advocacy Officer for the UsAgainstAlzheimer’s. “There are two pieces of legislation that are advancing through the House and the Senate called the </span><a href="https://www.congress.gov/bill/119th-congress/house-bill/6130/text"><span>ASAP Act</span></a><span> and the </span><a href="https://www.congress.gov/bill/118th-congress/senate-bill/2379/text"><span>CHANGE Act</span></a><span>, both of which are basic common sense laws that will make sure that people have access to cognitive testing tests and also these blood-based biomarkers for screening once they have been approved by FDA.”</span></p>
<p><span>Another example Sward gave started in 2025.</span></p>
<p><span>“For fiscal year 2026, the president’s budget proposed a 40% cut to the National Institutes of Health (NIH),” Sward explained. “By the time they finally finished the budget in March of this year, we had a $415 million increase to the NIH, and that is because we all worked together.”</span></p>
<p><span>There have also been some groundbreaking wins that were a long time coming, as Annie Kennedy, Chief Mission Officer at the RARE Foundation explained.</span></p>
<p><span>“We, as an organization, worked for a number of years with our patient advocacy coalitions and our industry coalitions and crafted what was called the Speeding Therapy Access Today (STAT), which would have established a rare disease center of excellence at the FDA,” Kennedy recalled. “And while that momentum and those hundreds of advocates that were repeatedly going to the Hill for a number of years didn’t yield a center of excellence, it did yield the Rare Disease Innovation Hub at FDA.”</span></p>
<p><span>Kennedy continued: “We’ve had wonderful acceptance and championship from both Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) when that hub was first established. That has remained. Despite all of the changes and shifts in the different individuals who’ve been leading the agency, there has been unwavering and unflagging support for the hub.”</span></p>
<h3>Moving forward together</h3>
<p><span>So how do advocates reach these wins and then keep on going? Panelists emphasized collaboration.</span></p>
<p><span>“The secret sauce for all of us has been in the collaborations that we form,” said Kennedy. “The strength has been in the coming together and understanding where the opportunities are to lean in and where the opportunities are to pivot from what we thought we would be working on this year.”</span></p>
<p><span>“While you are at PACE, make a point to meet people that you’ve never met before and get their contact information so that you can follow up with them,” said Sward. “Figure out how you can create new networks that may help you move forward. Find other organizations with whom to lock arms—and ask questions.”</span></p>
<p><span>“Don’t be afraid to stop a speaker and say, </span><i><span>What the heck does that mean?</span></i><span> That’s important,” said Peschin. “That is a great way to both learn more and make deeper connections.”</span></p>
<p>The post <a href="https://bio.news/federal-policy/patient-advocates-launch-pace-by-reviewing-their-big-hits-in-2026/">Patient advocates launch PACE by reviewing their big hits in 2026</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: Pushing past the pain to achieve access for the 21st Century</title>
<link>https://edusehat.com/en/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century</link>
<guid>https://edusehat.com/en/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century</guid>
<description><![CDATA[ Patient advocates are no strangers to the sometimes painful challenges of promoting access to medicines and treatments. The key, they say, is staying two […]
The post PACE: Pushing past the pain to achieve access for the 21st Century appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/21st-century-pain-points.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, Pushing, past, the, pain, achieve, access, for, the, 21st, Century</media:keywords>
<content:encoded><![CDATA[<p><span>Patient advocates are no strangers to the sometimes painful challenges of promoting access to medicines and treatments. The key, they say, is staying two steps ahead.</span></p>
<p><span>“We’ve all experienced decades of incredible innovation as it relates to the biopharmaceutical community,” Kate Mevis, Associate VP of U.S. Federal Policy at Merck told an Oct. 22 session of the BIO Patient Advocacy Changemakers Event (PACE) in Washington, DC. “But we really need to make sure that access, coverage, cost, and the policies that govern those, keep pace with this innovation.”</span></p>
<p><span>Mevis moderated the PACE panel called </span><a href="https://pace.bio.org/2026-program/21st-century-access-pain-points-patients--1?&filters.date=22-Oct-2026%2C23-Oct-2026%2C&sortby=customfield_6234%20asc&searchgroup=libraryentry-2026-program"><span>21st Century Access: Pain Points for Patients</span></a><span>, which investigated barriers to patient access.</span></p>
<div class="ast-oembed-container "></div>
<p><span><br>
So what have been patient’s biggest pain points in recent years? And what are advocates doing to relieve the pressure?</span></p>
<h3>Utilization management remains a major pain point</h3>
<p><span>“Eighty percent of people living with psoriasis or psoriatic arthritis report that they have been subjected to some sort of utilization management,” said Leah Howard, President and CEO of the National Psoriasis Foundation. “That statistic is even higher in Medicare. About 90% of patients accessing therapies through Medicare experience utilization management.”</span></p>
<p><span>Howard said she’ll often ask a gathering how many audience members have experienced step therapy, prior authorization challenges or other forms of utilization management. “Literally, every single hand in the room goes up,” she said.</span></p>
<p><span>These utilization management challenges are compounded by insurers using copay accumulators and maximizers, said Carl Schmid, Executive Director at the HIV+Hepatitis Policy Institute. </span></p>
<p><span>“Patients rely on copay assistance for over $20 billion to help us pay for our drugs. That’s a lot of money,” Shmid said. “But unfortunately, pharmacy benefit managers (PBMs) and insurers are stealing around $7 billion of that through copay accumulators and maximizers.”</span></p>
<p><span>And these two pain points together are often even more magnified by the fact that patients are rarely dealing with just one disease.</span></p>
<p><span>“Most people have multiple diseases,” said Pam Traxel, SVP, Alliance Development and Philanthropy at the American Cancer Society Cancer Action Network. “So one of the things that’s so important about resolving utilization management is it is not just that a patient is studying one time to get access to one medicine. If you have a chronic disease, you are doing this throughout your entire life in many different areas.”</span></p>
<h3>Pain points in the real world</h3>
<p><span>And these issues are not just hypothetical, they are happening in real ways. </span></p>
<p><span>“Earlier this year, one health insurance company came out with their policy for 2026 that took a treatment that was approved nine years ago for psoriasis and psoriatic arthritis, and said that for a patient on their formulary to access that treatment, they would have to go through 14 other therapies, over 42 months to get to that one that their clinician wanted them to use,” explained Howard. “And this wasn’t because this was some brand new therapy that had just been approved.”</span></p>
<p><span>Luckily, the National Psoriasis Foundation and their partner groups in Pennsylvania, where this plan was located, succeeded in getting the insurer to reduce the list to five alternative therapies and 15 months, a noted improvement on the original plan.</span></p>
<p><span>But as Shmid pointed out, there is still work to be done on many advocacy fronts. </span></p>
<p><span>Shmid’s organization, the HIV+Hepatitis Policy Institute, filed a discrimination lawsuit three years ago after finding that some insurers were not covering the HIV drugs people needed, or were placing all HIV drugs on the highest formulary tier—a clear violation of the Affordable Care Act, </span><a href="https://bio.news/health/how-to-break-down-barriers-in-hiv-care/"><span>as Bio.News reported.</span></a></p>
<p><span>The HIV+Hepatitis Policy Institute won their suit, but the problem now is that the ruling is not being enforced. </span></p>
<p><span>“I get a lot of calls from people who are faced with these thousands and thousands of dollars in charges, and they say, ‘</span><i><span>Wait, I’m looking at the literature. You won. Why am I being charged this?’</span></i><span> And they’re angry,” Shmid said. </span></p>
<p><span>“It’s hard enough to pay their premiums, and now they’re being stuck with thousands of dollars of bills that they didn’t expect,” he continued. “We cannot give up on this issue. We have to hold the federal government accountable. We have to hold the insurers and PBMs accountable for what they’re getting away with right now.”</span></p>
<h3>Pushing back against the pain</h3>
<p><span>But advocates see reasons for hope.</span></p>
<p><span>“I think the American people have reached the boiling point on this issue,” said Shmid. “It’s not just the patients. It’s not just the caregivers, our families. It’s not just the providers. It’s members of Congress. Everyone is experiencing this prioritization or step therapy.”</span></p>
<p><span>The challenge of advocacy, however, is the ability to maintain momentum on established issues, while also anticipating new ones.</span></p>
<p><span>“There needs to be an urgency around our desire to remove these barriers because as we are fighting the original issue, the insurers are onto something totally different,” said Traxel.</span></p>
<p><span>At its core, the driver of patient advocacy is to ensure that biotech innovation can actually serve the common good it is intended for. </span></p>
<p><span>“When people talk about the promise of drug discovery and the great developments that happen, the fact that those treatments are sitting on the shelf and the patient can’t access them makes it feels like this whole process is for naught,” said Howard. “We can’t let that happen.”</span></p>
<p>The post <a href="https://bio.news/latest-news/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century/">PACE: Pushing past the pain to achieve access for the 21st Century</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science</title>
<link>https://edusehat.com/en/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science</link>
<guid>https://edusehat.com/en/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science</guid>
<description><![CDATA[ ASHG President Susan Slaugenhaupt, PhD, opened the society’s Montreal meeting with a heartfelt address emphasizing hope, leadership, and the importance of communication amid the challenges facing science today. 
The post ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ASHG_Susan-Slaugenhaupt_rectangle.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 23 Oct 2026 01:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG, President, Susan, Slaugenhaupt, Calls, for, Hope, Leadership, and, Communication, Science</media:keywords>
<content:encoded><![CDATA[<p>The American Society of Human Genetics (ASHG) meeting, being held in Montreal this week, kicked off with the Presidential address given by Susan Slaugenhaupt, PhD, Professor of Neurology at Harvard Medical School and ASHG President.</p>
<p>Slaugenhaupt opened the speech noting that “it’s really hard to know what to say in a presidential address” and that one of her friends told her that, “right now, people just need a message of hope.” And another said, “You always speak from the heart, so just do that.” Slaugenhaupt proceeded to deliver her heartfelt address—emphasizing hope, leadership, and the importance of communication amid the challenges facing science today. Some of the highlights are here.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“Persistence is not simply how we survive difficult periods in science. It is how we protect our passion, strengthen our teams, and turn discovery into a better future,” she asserted. “I know I’m not alone in feeling anger and frustration about what has happened to science in the United States, how it is reviewed, funded, and perceived by the public. The very idea of education is under attack. Scientific priorities are increasingly shaped by political forces rather than rigorous peer review. We see people rejecting vaccines, distrusting physicians, and dismissing decades of evidence-based progress. As scientists, our instinct is to respond with data. We want to explain the evidence. We want to demonstrate what the science shows, that the data alone are not bridging the divide. Whatever our individual political beliefs are, politics should not determine the value of scientific discovery. So what do we do? We act, we persist, we communicate. The most successful people I know are not people who never encounter barriers. They are people who meet those barriers with persistence and determination and keep going.”</p>
<p>Slaugenhaupt told the story of the quote below being taped to her office door by a team member after a particularly hard day in the lab. The piece of paper has remained tacked above her desk for nearly 30 years.</p>
<figure aria-describedby="caption-attachment-339692" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-339692" src="https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-1024x768.jpeg" alt="Susan Slaugenhaupt quote" width="696" height="522" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-1024x768.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-300x225.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1-768x576.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Unknown-1.jpeg 1440w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">The quote referred to by Susan Slaugenhaupt, PhD, in her ASHG presidential address [Julianna LeMieux]</figcaption></figure>
<p>The message that stayed with Slaugenhaupt from that quote is that persistence and determination are what carry us through when everything else has been exhausted. “That lesson helped shape me as a scientist and later as a leader,” she noted.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Recounting this story brings me to an important lesson beyond persistence and determination, and that is the importance of building a cohesive team that has your back. Always pay attention to your team and treat them well. It doesn’t matter if this is your lab team or your leadership team. Those people make you better every single day. Give credit generously. Ask people what they need to succeed. Notice the quiet members of your team. Make it safe to admit mistakes and create opportunities for people to grow in their roles. At some point in your career, success becomes less about advancing yourself and more about helping others advance. When that shift happens, embrace it.”</p>
<p>“This career is not easy, but your work is absolutely essential. Never forget that. If there is one quality that defines scientists, it’s passion. We don’t do this job because it pays particularly well or because there isn’t anything else we’re interested in. We do it because we can’t imagine doing anything else. Most of us caught the bug early. Curiosity became fascination, fascination became purpose, and eventually science became part of who we are. No matter how challenging the current environment is, I still see this passion in people every day and all of you. Most importantly, I see it in young people.”</p>
<p>“For the past 15 years, I’ve run an undergraduate summer student program. Every summer, those students arrive at the lab and they bring something remarkable with them. They bring optimism, energy, possibility. They are completely convinced that they will make discoveries that will change lives. And honestly, some of them probably will. Whenever I begin to think about the future, I think about those students, and that is why I remain hopeful. Hundreds of millions of people worldwide live with a genetic disease. They often face diagnostic odysseys only to learn that their disease has no treatment. Those of you who work with families know that there is nothing more powerful than a parent’s determination to help their child. They do not stop. They do not quit. They do not lose hope. They embody persistence.”</p>
<p>She also emphasized the importance of communicating science and designed the Presidential Symposium to focus on exploring the barriers that limit meaningful public engagement and discuss what scientists can do to help bridge these gaps. Because, she said, “speaking out is not optional anymore. It is part of our responsibility. Protesting might not be for everyone, but communicating must be. We must all be more vocal about the critical role in science and more specifically human genetics and genetics plays in improving the health of people around the world.”</p>
<p>“Over the past 18 months, we have witnessed an unprecedented challenge to science in the U.S. Actions that undermine scientific integrity, public trust, and research funding have affected all of us. Sadly, I suspect we’re not simply waiting for a return to the way things used to be. We are being asked to help shape what comes next. So when the path forward feels uncertain, remember this, your work matters. Build teams that support one another and celebrate one another’s success. Tell people outside this room what you do and why it matters. Protect the passion that brought you to science in the first place and above all, persist. Persist for the students who are just beginning their journeys. Persist for the patients and families who are waiting for answers. Persist for one another and persist because the future of human health depends on what we discover together. I am absolutely convinced that human genetics and genomics will continue to transform medicine and improve lives around the world.”</p>
<p>“Every person in this room is part of that future. The world needs your science. The world needs your voice and now more than ever, the world needs you to persist. Thank you.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-president-susan-slaugenhaupt-calls-for-hope-leadership-and-communication-in-science/">ASHG President Susan Slaugenhaupt Calls for Hope, Leadership, and Communication in Science</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC&#45;Derived 3D Models</title>
<link>https://edusehat.com/en/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models</link>
<guid>https://edusehat.com/en/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Arati Naveen, PhD, will trace the foundational discoveries that shaped organoid technology as a new approach methodology (NAM), while highlighting pioneering contributions and contemporary advances.
The post The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC-Derived 3D Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_1435534172_StemCell.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Organoid, Odyssey:, Glimpse, Into, the, Past, Present, and, Future, hPSC-Derived, Models</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/AratiNaveen_3-e1792592201588.jpeg" class="h-full w-full object-cover" alt="Image of Arati Naveen, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Arati Naveen, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">CIRM Postdoctoral Scholar<br>Cedars-Sinai Medical Center</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/AratiNaveen_3-e1792592201588.jpeg" alt="Image of Arati Naveen, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Arati Naveen, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Arati Naveen, PhD, graduated with her bachelor’s in biomedical engineering from the University of Buffalo. She then moved to L.A. to pursue her master’s in stem cell biology and regenerative medicine at the University of Southern California (USC). She received her PhD in biomedical and translational sciences at Cedars-Sinai in the Jefferies Lab, where her dissertation project explored the interplay between heart disease and immunometabolism. In the Sharma Lab, her work focuses on using cardiac organoids to study autoimmune mediated heart disease and for predictive modeling of drug cardiotoxicity.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, December 3, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-12-03T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Human induced pluripotent stem cell (iPSC)-derived organoids combine the ability to generate diverse cell types with the retention of parental genetic backgrounds, providing opportunities to investigate human development, disease mechanisms, and individual differences in therapeutic responses. These models capture aspects of complex tissue architecture and multicellular interactions within a more physiologically relevant spatial environment. Over the past two decades, advances in stem cell reprogramming, directed differentiation, and three-dimensional culturing techniques have enabled the development of organoid models for the brain, retina, heart, lung, intestine, liver, pancreas, kidney, and many more.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker, Arati Naveen, PhD, will trace the foundational discoveries that shaped organoid technology as a new approach methodology (NAM), while highlighting pioneering contributions and contemporary advances. This webinar will examine the ways in which the challenges of tissue maturation, vascularization, reproducibility, and scalability, are being addressed. One example explored is harnessing microgravity to strengthen organoid performance and support the broader adoption as NAMs.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you the chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-full is-resized"><a href="https://www.corning.com/" target="_blank" rel=" noopener"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo.jpg" alt="Corning Logo" class="wp-image-277211" srcset="https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo.jpg 300w, https://www.genengnews.com/wp-content/uploads/2023/11/Corning_Logo-150x150.jpg 150w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/the-organoid-odyssey-a-glimpse-into-the-past-present-and-future-of-hpsc-derived-3d-models/">The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC-Derived 3D Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Raman+NIR Spectra Improves Glucose Soft Sensing</title>
<link>https://edusehat.com/en/ramannir-spectra-improves-glucose-soft-sensing</link>
<guid>https://edusehat.com/en/ramannir-spectra-improves-glucose-soft-sensing</guid>
<description><![CDATA[ Combining Raman and NIR spectroscopy into a single framework creates a multi-modal soft-sensing option that is effective for fed-batch, online, and in-line glucose sensing, preparing the way for hybrid/continuous processing.  
The post Raman+NIR Spectra Improves Glucose Soft Sensing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/08/Aug7_2020_Getty_626533919_FemaleScientistUsingFTIRSpectrophotometer-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>RamanNIR, Spectra, Improves, Glucose, Soft, Sensing</media:keywords>
<content:encoded><![CDATA[<p>Accurate glucose monitoring has been a bottleneck in fed-batch fermentation for years, and is especially critical as biopharmaceutical manufacturers transition toward hybrid and continuous bioprocessing for advanced therapeutics.</p>
<p>Fusing Raman and near-infrared (NIR) spectroscopy into a multimodal soft-sensing framework appears, however, to remove that bottleneck. This new framework provides high-frequency, low-latency measurements that aren’t typically available with existing commercial, off-line sensors. Its developers say it provides “accurate, online-compatible glucose soft sensing,” and that it is also amenable for in-line applications.</p>
<p>More specifically, Raman spectroscopy offers crisp, highly specific chemical fingerprints, while NIR offers broad, information-laden spectral coverage. Realizing this, a team including senior authors Xiwei Tian, DEng, of East China University of Science and Technology in Shanghai and Yinlan Ruan, PhD, of Guilin University of Electronic Technology, encoded each modality separately and then merged them using dual-stream, cross-attention transformer architecture (DS-CAT).</p>
<p>The team tested their system using 142 preprocessed, synchronized Raman-NIR records.</p>
<p>Writing in <em>Bioprocess and Biosystems Engineering</em>, they <a href="https://link.springer.com/article/10.1007/s00449-026-03437-0" target="_blank" rel="noopener">report</a> that their model explained 99% of the variation in true glucose concentration. Anything above 95% is considered good. Likewise, the root mean square error of 1.09 g/L was well within the level needed to ensure effective feed control. Furthermore, the mean absolute error of 0.89 g/L achieved by this model suggests it is consistently accurate. Such consistency is particularly important for real-time processing controls, where outliers could negatively affect feeding strategies. Results remained similar throughout five-fold validation, the scientists report.</p>
<p>Additionally, “Prediction-based perturbation…revealed strong dependence on Raman information, while Raman-block sensitivity analysis identified 1122−1335 cm<sup>-1 </sup>[which is associated with carbohydrate vibrational modes] as the interval showing the strongest prediction sensitivity,” Tien, Ruan, and colleagues point out. Those findings are comparable to other literature reports, while demonstrating the enhanced sensitivity, reduced noise, and reduced drift of this new framework.</p>
<p>Notably, the researchers note that the DS-CAT framework “outperform[ed] partial least squares regression, gradient boosting regression trees, convolutional neural networks, and temporal convolutional networks under the same evaluation protocol.” By performing better than these four industry-standard modeling approaches, DS-CAT has the potential to substantially improve soft-sensor capabilities for real-time glucose monitoring.</p>
<p>These findings suggest the DS-CAT approach to glucose sensing may enable reliable insights that lead to better control of a critical parameter in closed-loop mammalian and microbial fermentation. If so, the high-frequency and low-latency data measurements this method delivers may become a key element in a rational transition from fed-batch fermentation toward continuous manufacturing.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ramannir-spectra-improves-glucose-soft-sensing/">Raman+NIR Spectra Improves Glucose Soft Sensing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Patients Should Be Considered When Choosing a Vector Production Method</title>
<link>https://edusehat.com/en/patients-should-be-considered-when-choosing-a-vector-production-method</link>
<guid>https://edusehat.com/en/patients-should-be-considered-when-choosing-a-vector-production-method</guid>
<description><![CDATA[ Vector production costs have a disproportionate influence on gene therapy prices, according to researchers who say that, given this, choosing the vector manufacturing method that best suits the intended use of the product is vital.
The post Patients Should Be Considered When Choosing a Vector Production Method appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_1211253347_AsepticVirusLab-scaled-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Patients, Should, Considered, When, Choosing, Vector, Production, Method</media:keywords>
<content:encoded><![CDATA[<p>Viral vector production costs have a disproportionate influence on gene therapy prices, so choosing the virus manufacturing method that fits the product and its intended patient population is critical.</p>
<p>That is the view of researchers at Thermo Fisher Scientific, who examined the economics of gene therapy production in a <a href="https://www.nature.com/articles/s41434-026-00631-3#Sec21" target="_blank" rel="noopener">study</a> and concluded that choosing the right vector manufacturing platform is challenging.</p>
<p>“Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” study author Seyed Pouria Motevalian, PhD, writes.</p>
<p>Motevalian and co-authors compared three recombinant adeno-associated virus (rAAV) manufacturing methods—transient transfection, producer cell line approaches (PCLs), and baculovirus-based production—and found that the cost drivers for each differ markedly.</p>
<p>“On a per-batch basis, baculovirus infection is the most cost-efficient platform, followed by transient transfection and PCLs. However, when costs are normalized to vector titer, the ranking shifts, with transient transfection becoming the lowest-cost platform.</p>
<p>“Each platform has a distinct economic fingerprint: transient transfection is dominated by plasmids, transfection reagent, media, and endonuclease; PCL perfusion processes are driven by media and perfusion-related single-use hardware; and the baculovirus platform shifts a greater share of cost into downstream operations, particularly affinity capture,” Motevalian says.</p>
<h4><strong>Patient focus</strong></h4>
<p>With all this in mind, Motevalian and co-authors argue that, rather than focusing on material and reagent costs, developers must also factor in the needs of the target patient population when choosing how to produce viral vectors.</p>
<p>“Our analyses suggest there is no universally ‘best’ rAAV platform. Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” they say.</p>
<p>For example, for products intended for smaller populations, transient transfection, in which vector genes are introduced into producer cell lines, may be the best approach, despite the high cost of the DNA plasmids required.</p>
<p>In contrast, for mass market gene therapies, baculovirus infection or PCL-based vector manufacturing methods are a more cost-effective option, particularly in combination with optimized upstream and downstream processes.</p>
<p>Understanding these dynamics is critical for developers, according to the authors, who say gene therapy firms must factor them into process development as early as possible.</p>
<p>“Integrating quantitative cost modeling into platform selection and process development decisions early in program design will be essential for making rAAV therapies economically sustainable and expanding global patient access,” they say.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/patients-should-be-considered-when-choosing-a-vector-production-method/">Patients Should Be Considered When Choosing a Vector Production Method</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>iPSC Manufacturing Starts with the Source</title>
<link>https://edusehat.com/en/ipsc-manufacturing-starts-with-the-source</link>
<guid>https://edusehat.com/en/ipsc-manufacturing-starts-with-the-source</guid>
<description><![CDATA[ For iPSC developers, scalable manufacturing begins long before the bioreactor. Pluristyx leaders explain why starting material, process discipline, automation, and shared data will help therapies reach patients reliably and affordably.
The post iPSC Manufacturing Starts with the Source appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-iPSCs_GBPN_IMAGE_15OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>iPSC, Manufacturing, Starts, with, the, Source</media:keywords>
<content:encoded><![CDATA[<p>For developers of induced pluripotent stem cells (iPSCs), the path to commercial-scale manufacturing can be derailed long before cells reach a production bioreactor. According to two leaders at Pluristyx, one of the field’s most persistent problems is surprisingly basic: many programs begin with cell lines that were never intended for clinical manufacturing.</p>
<p>“It is difficult to find the right cell line,” said Benjamin Fryer, PhD, CEO and cofounder of Pluristyx. Researchers often build promising processes around readily available lines, only to discover later that the material lacks the provenance, consent, or good manufacturing practice (GMP) pedigree needed for human use. By then, Fryer said, teams may have invested years in process development, animal studies, and publications—only to restart with a new line.</p>
<p>Clinical readiness also depends on whether donor consents support the intended use, said Priya Baraniak, PhD, chief commercial and development officer at Pluristyx. Beyond that, developers face the familiar manufacturing demands of robustness, reproducibility, and scale at a cost that is “clinically and commercially feasible,” she noted.</p>
<p>That makes the choice of starting material a bioprocessing decision, not merely a research decision. As developers move from milliliter-scale work toward liters or tens to hundreds of liters, Fryer said, “the manufacturing process has to be somewhat similar.” Passage number and population doublings should be controlled so cells at small and large scale are effectively the same biological age. Production format matters, too. “You need to make sure that the cells are available in the process format you’re going to use,” Fryer said. A therapy intended for suspension culture, for example, should move toward suspension early rather than undergo a disruptive conversion late in development.</p>
<p>Baraniak put the principle simply: “Standardizing your input is really important.” Even high-quality cells can introduce variability if their passage history, characterization, or biological state changes from run to run.</p>
<p>That issue is especially important for iPSCs because their expansion potential can create a false sense of security. “We often fall into a false narrative that these cells can be expanded forever and they’re an evergreen source,” Baraniak said. “They accumulate genetic mutations and aberrations as you expand them,” potentially leaving developers with a process built around cells that no longer behave as intended.</p>
<p>The challenge extends beyond raw material into process design. Baraniak said cell manufacturing still relies too heavily on “golden hands”—highly skilled operators whose tacit knowledge can be difficult to reproduce across people, sites, and scales. “You can’t rely on just golden hands,” she said. Processes must instead be engineered to minimize operator-dependent decisions and tolerate normal manufacturing variation.</p>
<p>That transition also changes the role of automation. Fryer cautioned that simply replacing a human hand with a robotic one does not solve a poorly understood process. Manufacturers first need to understand why cells respond to particular media, handling steps, environmental conditions, and culture parameters. That mechanistic knowledge can guide smarter automation, closed systems, and process analytics rather than locking fragile procedures into hardware.</p>
<p>The same manufacturing discipline could expand the usefulness of iPSCs in new approach methodologies (NAMs), including drug screening, toxicology, disease modeling, and engineered tissues. Unlike limited primary tissues, well-controlled iPSC banks can provide renewable human material representing different donors, disease states, and genetically engineered variants. But those models only become useful at industrial scale if they can be manufactured, distributed, and reproduced consistently.</p>
<p>For Baraniak, that need for reproducibility reflects how far the field has come. “We’ve moved past the point of proving that these therapies have viability, that iPSCs work,” she said. “So now it’s how do we make them work over and over and over.”</p>
<p>That shift—from demonstrating biological possibility to engineering repeatable manufacturing—might define the next phase of iPSC commercialization. Better starting materials, deeper process understanding, automation, and more open sharing of manufacturing experience will not eliminate biological complexity. But they could keep that complexity from becoming the bottleneck that prevents promising iPSC technologies from reaching patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ipsc-manufacturing-starts-with-the-source/">iPSC Manufacturing Starts with the Source</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Researchers Validate Buoyant Mass for Cell Health Testing</title>
<link>https://edusehat.com/en/researchers-validate-buoyant-mass-for-cell-health-testing</link>
<guid>https://edusehat.com/en/researchers-validate-buoyant-mass-for-cell-health-testing</guid>
<description><![CDATA[ Scientists have used measurement of buoyant mass by suspended microchannel resonator (SMR) technology to assess the immune fitness of T cells and predict patient response to immune checkpoint blockade (ICB).
The post Researchers Validate Buoyant Mass for Cell Health Testing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2279568676-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Researchers, Validate, Buoyant, Mass, for, Cell, Health, Testing</media:keywords>
<content:encoded><![CDATA[<p>U.S. scientists have shown that measuring the buoyant mass of T cells can help predict patient response to immune checkpoint blockade (ICB) immunotherapy.</p>
<p>The team from the Massachusetts Institute of Technology (MIT) showed that measuring the buoyant mass of T cells predicted patient response more accurately than a traditional tumor mutational burden (TMB) approach.</p>
<p>According to the researchers, the new technique could be used not only to predict cancer cell sensitivity to treatment, but also to address the productivity of cell cultures used in gene therapy manufacturing.</p>
<p>“We’ve wanted to show people this is a new physical marker that predicts the fate of the T cells,” explains Jiaquan Yu, PhD, a research scientist working in microfluidic engineering and cancer immunology at MIT.</p>
<p>“By fate, we mean we measure the naïve state of the T cells and get an indication of how they will behave after activation.”</p>
<p>The team used suspended microchannel resonator (SMR) technology, a specialized instrument that uses a vibrating sensor containing a microfluidic channel to measure buoyant mass, Yu says.</p>
<p>The buoyant mass of the T cells is measured relative to water and from the buoyant mass, they were able to calculate the immune fitness of the cells, Yu continues. And, thus, whether they were likely to activate to fight cancer as part of treatment with ICB immunotherapy.</p>
<p>“For T cells, being in the heavier group suggests you’re better equipped to produce proteins,” Yu says. “And that capacity gives us an indication of the fitness of the cells and their ability to respond after activation.”</p>
<p>The team was able to test the performance of the technique in a clinical study of 28 patients with melanoma receiving ICB, Yu explains. And, in that study, they were able to prove that measuring buoyant mass was more effective than TMB at predicting treatment response.</p>
<p>“People are underestimating simple non-molecular signatures, such as mass, volume, and density, as we’re all focused on biomarkers focused on genes and RNA,” Yu says.</p>
<p>“What we’re showing here is that mass gives a result that integrates a lot of information.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/researchers-validate-buoyant-mass-for-cell-health-testing/">Researchers Validate Buoyant Mass for Cell Health Testing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Using AI Agents and Bio&#45;Foundation Models to Automate Vector Design for Cell Line Development</title>
<link>https://edusehat.com/en/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development</link>
<guid>https://edusehat.com/en/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development</guid>
<description><![CDATA[ In this GEN webinar, Asimov’s VP of Business Development and Commercial Strategy Jamie Freeman, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to tailor expression vector design for each molecule. 
The post Using AI Agents and Bio-Foundation Models to Automate Vector Design for Cell Line Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/09/GettyImages-1150965935-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Using, Agents, and, Bio-Foundation, Models, Automate, Vector, Design, for, Cell, Line, Development</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/JamieFreeman_headshot.jpg" class="h-full w-full object-cover" alt="Image of Jamie Freeman, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Jamie Freeman, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">VP of Business Development and Commercial Strategy<br>Asimov</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/JamieFreeman_headshot.jpg" alt="Image of Jamie Freeman, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Jamie Freeman, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Jamie Freeman, PhD, is VP of Business Development and Commercial Strategy at Asimov, where he works with partners to improve the design and manufacturing of novel biological therapeutics. Prior to joining Asimov, Jamie was responsible for the development and initial commercialization of Horizon Discovery’s CHO Source platform. Jamie earned a PhD in cell and molecular biology from Cardiff University, followed by a postdoc at the MRC Laboratory of Molecular Cell Biology.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 12, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-12T19:00:00.000Z">11:00 PST, 14:00 EST, 19:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Protein foundation models have transformed binder design, but turning those binders into drugs remains an empirical, trial-and-error process. Lead optimization, cell line development, and process development each still rely on screening large numbers of candidates, clones, or conditions, with little ability to predict which will succeed.  As pipelines shift toward bispecifics and other complex formats, that approach is getting harder to sustain.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Asimov’s VP of Business Development and Commercial Strategy Jamie Freeman, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to tailor expression vector design for each molecule. He will highlight how scientists use Kernel, Asimov’s computer-aided genetic design software, to automate the design of optimized expression vectors, and how AI agents can take on custom genetic designs for uncommon requirements. </p>


<p class="wp-block-paragraph">Through a series of case studies, he will also share how AI-designed vectors outperformed Asimov’s own previous best designs, how rapid stable pool data changed which multispecific lead a partner advanced, and how a model predicted chain ratios to improve correct pairing without reducing titer. Key takeaways from the webinar include:</p>


<ul class="wp-block-list">
<li>How exploring genetic design space, rather than relying on off-the-shelf vectors, can improve titer and product quality for both standard and complex formats</li>



<li>How AI models trained on measurements from inside the cell can learn the mechanisms of expression and apply them to design better expression vectors</li>



<li>How model-guided workflows and stable pools bring better-informed decisions to vector design and lead selection</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.asimov.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="53" src="https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-300x53.jpg" alt="asimov logo" class="wp-image-216608" srcset="https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-300x53.jpg 300w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1024x181.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-768x136.jpg 768w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-696x123.jpg 696w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1392x248.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo-1068x189.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2023/01/asimov_logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/using-ai-agents-and-bio-foundation-models-to-automate-vector-design-for-cell-line-development/">Using AI Agents and Bio-Foundation Models to Automate Vector Design for Cell Line Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bridging the Translational Gap in Pancreatic Cancer Through Biology&#45;First Modeling</title>
<link>https://edusehat.com/en/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling</link>
<guid>https://edusehat.com/en/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity.
The post Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2190808113_PancreaticCancerCells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bridging, the, Translational, Gap, Pancreatic, Cancer, Through, Biology-First, Modeling</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Josh_Wheeler_headshot_2000px-e1792604937405.jpg" class="h-full w-full object-cover" alt="Image of Josh Wheeler, MD, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Josh Wheeler, MD, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Vice President, Research and Development<br>Genialis</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Josh_Wheeler_headshot_2000px-e1792604937405.jpg" alt="Image of Josh Wheeler, MD, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Josh Wheeler, MD, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Josh Wheeler, MD, PhD, is the vice president of Research and Development at Genialis with more than 15 years of experience spanning academic research, computational biology, and biotechnology. His work sits at the intersection of clinical development, translational medicine, AI and machine learning, diagnostics, and precision oncology. At Genialis, he leads clinical and research innovation strategy, biomarker and diagnostic development, clinical trial assay and regulatory strategy, and biopharma partnerships. Josh previously trained and practiced at Stanford across anatomic pathology, neuropathology, molecular diagnostics, and computational biology. He earned his MD from the University of Colorado Anschutz Medical Campus through the NIH-funded Medical Scientist Training Program and his PhD in biochemistry from the University of Colorado Boulder.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Matthieu-Spriet.jpg" class="h-full w-full object-cover" alt="Image of Matthieu Spriet, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Matthieu Spriet, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Technical Specialist<br>Inventia Life Science</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Matthieu-Spriet.jpg" alt="Image of Matthieu Spriet, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Matthieu Spriet, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Matthieu Spriet, PhD, is a technical sales specialist at Inventia Life Science with expertise in 3D biology, biochemistry, cell signaling, oncology, and assay development. He earned his PhD in biochemistry and molecular biology from the University of Nebraska Medical Center. His thesis focused on profiling and understanding RNA expression in cholangiocarcinoma.</p>
<p>After graduating, Matthieu spent many years working in early-stage drug discovery, developing cell-based assays across multiple disease models, including oncology, immunology, cardiology, hepatology, and regenerative medicine. Matthieu is passionate about scientific communication and collaboration, with a focus on advancing biomedical research through advanced 3D cell models and drug discovery innovation.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, November 18, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-18T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Pancreatic cancer is experiencing a renaissance in therapeutic options and improvements in patient outcomes. Accelerating therapeutic advances demands a more robust translational pipeline linking patient biology to preclinical model systems. The tumor microenvironment shapes both prognosis and therapeutic vulnerabilities, making its representation in preclinical models critical for translation.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity. During the webinar, he will present Genialis Supermodel, an interpretable AI foundation model that translates tumor RNA-seq into biological states that can be compared across patients, experimental models, and Inventia’s RASTRUM platform, which enables bioprinted PDAC models with increasing microenvironmental complexity through the addition of cancer-associated fibroblasts (CAFs) and T cells.</p>


<p class="wp-block-paragraph">Using pancreatic cancer as a case study, he will demonstrate how increasing microenvironmental complexity moved the bioprinted models toward distinct biological states observed in patients. You will learn how CAFs drove EMT and TGF-beta/SMAD activity with loss of classical epithelial identity, while adding immune cells produced inflammatory and interferon programs. These changes also exposed therapeutic biology not apparent in monoculture, including altered RAS/MAPK, EGFR, beta-catenin, and YAP/TEAD signaling. Key takeaways include:</p>


<ul class="wp-block-list">
<li>How technologies from Genialis and Inventia provide a framework to connect patient tumor biology with experimentally tractable model systems</li>



<li>How patient-centered models generate therapeutic hypotheses that monoculture may miss</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://inventialifescience.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="82" src="https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-300x82.png" alt="Inventia Life Science Logo" class="wp-image-339662" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-300x82.png 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-1024x279.png 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-768x210.png 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-1536x419.png 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Inventia-Life-Science_Logo_HighRes_Pink-2048x559.png 2048w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/bridging-the-translational-gap-in-pancreatic-cancer-through-biology-first-modeling/">Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI</title>
<link>https://edusehat.com/en/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi</link>
<guid>https://edusehat.com/en/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi</guid>
<description><![CDATA[ Researchers also developed a clinical obesity polygenic score that combined information from numerous genetic variants, a score that was shown to be significantly associated with BMI, body fat percentage, and waist circumference. 
The post ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2158974218.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Signals, Based, Clinical, Obesity, Show, Stronger, Links, Cardiovascular, Health, than, Those, Linked, BMI</media:keywords>
<content:encoded><![CDATA[<p>Conducting the first genome-wide association study and analysis based on a new definition of clinical obesity, a research team has identified genetic signals that differed substantially from those associated with body mass index (BMI)—yet showed stronger connections to cardiovascular health.</p>
<p>The researchers—nine from Johns Hopkins University, one from The Ohio State University—analyzed 151,642 people with clinical obesity and 128,874 controls without obesity spanning five ancestry groups, using data from the UK Biobank and <em>All of Us</em> Research Program. The biobank says it possesses the world’s most comprehensive dataset of biological health and lifestyle data gathered from a half million participants, while <em>All of Us</em> is the NIH initiative designed to advance precision medicine by collecting and study data from 1 million or more people living in the United States.</p>
<p>Researchers identified 127 independent genetic loci associated with clinical obesity. Of these, 63 had no significant association with BMI. The most discordant variant, researchers reported, was rs15285, a single-nucleotide polymorphism (SNP) located within the 3′-untranslated region (3′UTR) of the <em>LPL</em> gene that encodes lipoprotein lipase. That variant was colocalized to expression quantitative trait loci (eQTLs) for lipoprotein lipase, and associated with elevated triglyceride levels.</p>
<p>The team also developed a clinical obesity polygenic score that combined information from numerous genetic variants, a score that was shown to be significantly associated with BMI, body fat percentage, and waist circumference. Compared to a BMI polygenic score, the clinical obesity polygenic score developed by the researchers showed improved association with cardiovascular risk factors and proteomic markers of inflammation—such as interleukin-6, fibroblast growth factor 21, and hepatic growth factor—as well as markers of insulin resistance, including adiponectin, resistin, leptin, and leptin receptor.</p>
<p>The clinical obesity polygenic score improved risk discrimination over a BMI polygenic score for myocardial infarction (heart attack), heart failure, and stroke, the research team added.</p>
<p>Researchers then validated the improvement across four additional long-running U.S. public health studies:</p>
<ul>
<li><strong>Atherosclerosis Risk in Communities (ARIC)</strong>, a study of the NIH’s National Heart, Lung, and Blood Institute whose focus has widened from identifying risk factors for subclinical atherosclerosis to risk factors for heart diseases including heart attack, coronary heart disease, stroke, and heart failure. About 16,000 U.S. adults have been enrolled.</li>
<li><strong>Multi-Ethnic Study of Atherosclerosis (MESA)</strong>, an NHLBI-sponsored study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA enrolled 6,814 adults during its baseline period between 2000-2002.</li>
<li><strong>Framingham Heart Study</strong>, under NHLBI direction, was launched in 1948 to identify common factors or characteristics that contribute to cardiovascular disease. Since 1971, the Boston University School of Medicine has served as NHLBI’s contractor and academic partner for the study. More than 15,400 across multiple cohorts have been enrolled.</li>
<li><strong>Women’s Health Initiative</strong>, which first won funding in 1992 and is also NHLBI-sponsored, focuses on strategies for preventing heart disease, breast and colorectal cancer, and osteoporosis in postmenopausal women. 161,808 women have been enrolled.</li>
</ul>
<h4><strong>‘Biologically and clinically relevant’</strong></h4>
<p>“These findings demonstrate that clinical obesity captures genetic loci distinct from BMI that are biologically and clinically relevant to cardiovascular health,” the researchers concluded.</p>
<p>Findings were reported in “<a href="https://content-cdn.sessionboard.com/content/ir9aMTzTJWbLVh1FTe9F_SohailZahid_ASHG2026_poster.pdf" target="_blank" rel="noopener">Genome-wide analysis and polygenic prediction of clinical obesity</a>,” a poster study presented during the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20-24 in Montreal. Co-corresponding authors were Sohail Zahid, MD, PhD, an investigator at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease; and Alexis Battle, PhD, director of the Malone Center for Engineering in Healthcare and director of the Research, Strategy, and Partnerships, Data Science and Artificial Intelligence Institute at Johns Hopkins.</p>
<p>The research team posted a <a href="https://www.medrxiv.org/content/10.64898/2026.05.20.26353665v1" target="_blank" rel="noopener">preprint version of their study on medRxiv</a> on May 22.</p>
<p>“Stratifying individuals into low, intermediate, and high inherited obesity risk groups, we found that clinical obesity polygenic risk reclassified 35% of individuals compared to BMI polygenic risk,” researchers reported in the preprint. “Unlike rare variant panel testing which already guides targeted therapy in monogenic obesity, further work is needed to determine the incremental benefit of clinical obesity polygenic scores for diagnosis, risk stratification, or management beyond BMI-based assessment.”</p>
<p>The new clinical obesity definition used by researchers was <a href="https://www.thelancet.com/commissions-do/clinical-obesity" target="_blank" rel="noopener">introduced last year by <em>The Lancet</em> Diabetes & Endocrinology Commission</a>.  The 58-member Commission set out to establish objective criteria for disease diagnosis, aid clinical decision making, and prioritize therapeutic interventions and public health strategies, by characterizing excess body fat and dysfunctional adiposity beyond BMI.</p>
<p>“We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health,” the Commission stated last year. “Excess adiposity should be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (e.g., waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, gender, and ethnicity.”</p>
<p>In people with very high BMI (i.e., >40 kg/m<sup>2</sup>), the Commission continued, excess adiposity can pragmatically be assumed without further confirmation: “We also recommend that people with confirmed obesity status (i.e., excess adiposity with or without abnormal organ or tissue function) should be assessed for clinical obesity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/ashg-signals-based-on-clinical-obesity-show-stronger-links-to-cardiovascular-health-than-those-linked-to-bmi/">ASHG: Signals Based on Clinical Obesity Show Stronger Links to Cardiovascular Health than Those Linked to BMI</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BCG Vaccine&#45;Induced Trained Immunity May Help Protect Against Dementia</title>
<link>https://edusehat.com/en/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia</link>
<guid>https://edusehat.com/en/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia</guid>
<description><![CDATA[ The results of a preclinical study suggest that the BCG vaccine, which is widely used to prevent tuberculosis and treat bladder cancer, may also have properties that reduce the risk for dementia by inducing trained immunity.
The post BCG Vaccine-Induced Trained Immunity May Help Protect Against Dementia appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/02/GettyImages-1440168032-e1707342315623.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 22 Oct 2026 03:55:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BCG, Vaccine-Induced, Trained, Immunity, May, Help, Protect, Against, Dementia</media:keywords>
<content:encoded><![CDATA[<p>The results of a preclinical study headed by researchers at Johns Hopkins University School of Medicine suggest that the Bacillus Calmette-Guerin (BCG) vaccine, which is widely used to prevent tuberculosis and treat bladder cancer, may also have properties that reduce the risk for dementia. BCG is a live, weakened vaccine made from an altered strain of the bacterium <em>Mycobacterium bovis</em>.</p>
<p>The team found that in mice genetically engineered to develop biological symptoms of dementia (PS19 mice), those animals that received the BCG vaccine were less likely to show hallmark signs of the disease, such as neurofibrillary (tau) tangles (NFTs) in the brain, sustained immune cell activation, and memory loss compared to mice that received no vaccine. BCG-treated mice performed better in a novel object recognition test, and showed improved maintenance of body-weight and survival.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead William Bishai, MD, PhD, co-director of the Johns Hopkins Center for Tuberculosis Research, believes that myeloid cells in the central nervous system and brain are using information from BCG to recognize and help the body respond to the formation of plaques and tangles characteristic of Alzheimer’s disease and related dementias. Bishai said, “We’re hard at work trying to understand the detailed mechanism for how it works, but this research points to early clues that aspects of trained immunity are likely driving this response.”</p>
<p>Trained immunity refers to the ability, in mammals, of innate immune system cells to take on an expanded role. Following an initial stimulus, innate immune cells, including monocytes and macrophages, may learn how to identify and respond to future threats that are different from the first. Typically, other immune system cells, such as T cells, take on this type of adaptive and learned response.</p>
<p>Bishai is senior and corresponding author of the team’s published paper in <em>Science Advances</em>, titled “<a href="https://doi.org/10.1126/sciadv.aej4603" target="_blank" rel="noopener">BCG vaccination mitigates tau pathology and restores cognitive functions in PS19 mice</a>,” in which the authors concluded “Our study strongly suggests that dementia protection by BCG is a credible observation that merits future basic research and large-scale prospective clinical trials to provide definitive answers.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>Observational studies in humans—those not designed to show cause and effect—have linked off-target effects of vaccines to a reduced incidence of dementia. “There is a growing appreciation that vaccines may have beneficial off-target effects such as reducing the risk of dementia,” the authors wrote. The shingles vaccine has been <a href="https://www.nature.com/articles/s41586-025-08800-x" target="_blank" rel="noopener">linked</a> to a 20% reduced incidence of dementia, while several previous studies cited by the researchers found that BCG used as an immunotherapy for non-muscle invasive bladder cancer was linked to a 12% to 78% reduced risk of dementia throughout a three- to 15-year period.</p>
<p>“While less publicized, there is also considerable evidence that Bacille Calmette-Guérin or BCG, the live attenuated vaccine to prevent tuberculosis (TB) and treat bladder cancer, may also have dementia-preventive properties,” the team continued.</p>
<p>It’s been postulated that trained immunity is a mechanism by which BCG could protect against dementia, they noted. “Upon exposure to a first antigen such as BCG, innate immune cells, typically myeloid cells, have been shown to undergo epigenetic and metabolomic reprogramming such that upon exposure to a second, unrelated antigen, their immune response is greater than it was to the first,” they explained.</p>
<p>To test directly whether BCG could represent a preventive therapy for Alzheimer’s disease, the team turned to the PS19 (P301S) mouse model, which develops symptoms of dementia, specifically marked by tau pathology or a clumping of tau proteins in the brain representing late stages of the disease. ‘The overexpression of P301S tau is associated with AD-relevant pathological and functional features, including neuronal loss, microgliosis, neurofibrillary tangles (NFT) deposition, and cognitive impairment,” they wrote.</p>
<p>The team divided mice into cohorts that received the BCG vaccine and those that received a saline injection. An additional comparison group included age-matched mice that did not have dementia and that also received the saline injection. Mice in the BCG treatment group received the vaccine at three months of age. Multiple assessments, based on brain imaging, memory recall (through an object recognition test) and indicators of disease, including neuroinflammation and the expression of genes linked to Alzheimer’s disease, were conducted eight to nine months later.</p>
<p>The researchers found that those mice that received BCG were about five times more likely to have signs of reduced tau deposits in their brain. They were also four times less likely to have markers of sustained inflammation, signaling that their immune cells had already likely responded to tau by clearing out some of the tangles, and had created a stable or protective immune response.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The untreated mice showed activation of 716 genes connected to Alzheimer’s disease, cell death, and neuroinflammation. BCG administration normalized all but nine of these. Compared to untreated mice, the mice who received BCG were less likely to have signs of brain atrophy and also more likely to live longer and perform better on tasks related to remembering and identifying objects.</p>
<p>“BCG seems to be reducing the degree of hyperinflammation in the brain—which is a good thing—and it may be doing it through a trained immune cell mechanism,” said Bishai. “There are a number of other characteristics of trained immunity that we are studying in the lab now.”</p>
<p>In their paper the team wrote in summary, “We found that early BCG administration starting at three months of age reduced brain atrophy, p-tau levels, and neuronal loss measured at the later time point of eight to nine months. Simultaneously, BCG therapy restored glutamate levels <em>in vivo</em> and improved recognition-memory performance, body weight, and survival of PS19 mice, suggesting key disease modifying effects.”</p>
<p>This research, Bishai says, is believed to be the first to study BCG and dementia in mouse models with tau pathology (specifically showing how immune cells may play a role in clearing neurofibrillary tangles). “Mechanistically, our study identified BCG-induced trained immunity properties as playing key roles in the clearance of tau NFTs,” they stated. Others have found similar findings with BCG and improved cognition in amyloid mouse models—which represent earlier stages of the disease marked by plaque formation.</p>
<p>“This is a great example of translational science working in reverse—starting with an intriguing observation in people and then going back to the laboratory to understand why it might be happening,” commented co-author Barbara Slusher, PhD, professor of neurology at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Drug Discovery program.</p>
<p>Slusher cautions that researchers still need to understand more of the underlying biology before they can say who might benefit, when treatment would need to be given and whether the effect can be safely reproduced in people at risk for dementia. “If we can identify the specific immune changes that are protective, we may be able to develop even more targeted approaches for the prevention of Alzheimer’s disease.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/bcg-vaccine-induced-trained-immunity-may-help-protect-against-dementia/">BCG Vaccine-Induced Trained Immunity May Help Protect Against Dementia</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exercise in a pill</title>
<link>https://edusehat.com/en/exercise-in-a-pill</link>
<guid>https://edusehat.com/en/exercise-in-a-pill</guid>
<description><![CDATA[ We all know exercise is good for us. It builds muscle, strengthens bones, lowers blood pressure, and boosts mood. By deciphering how movement benefits the body, researchers hope to develop medicines that can offer some of the same perks—without the workout. The idea isn’t to replace exercise but to bring its upsides to people who… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/Excercise-Final-v.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 17:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exercise, pill</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">We all know exercise is good for us. It builds muscle, strengthens bones, lowers blood pressure, and boosts mood. By deciphering how movement benefits the body, researchers hope to develop medicines that can offer some of the same perks—without the workout. The idea isn’t to replace exercise but to bring its upsides to people who struggle with frailty, disability, or chronic illness. </p>



<h3 class="wp-block-heading">The sticking points</h3>



<p class="wp-block-paragraph">It will take a lot of experimentation to untangle the myriad pathways by which exercise promotes health. But IDing the cascade of hormones, enzymes, and other molecules related to physical activity is just the first step. Scientists need to figure out how to turn that knowledge into safe and effective drugs. That’s a tall order: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/">More than 90%</a> of treatments that enter human studies fail.</p>



<p class="wp-block-paragraph">There are regulatory hurdles too. The FDA approves medications to treat diseases, not to enhance wellness, says Thomas Burris, a pharmacologist at the University of Florida whose work focuses on diseases that respond to exercise, like obesity, type 2 diabetes, and dementia.</p>



<h3 class="wp-block-heading">The progress</h3>



<p class="wp-block-paragraph">There may never be a pill that delivers all the benefits of exercise, but research could lead to new medicines that mimic some aspects of working out. Scientists have already identified many important exercise-related signals and have even developed compounds to regulate them. (Some preliminary results have been so promising that doping authorities have proactively banned the compounds.) </p>



<p class="wp-block-paragraph">Burris and his colleagues are focused on a receptor that’s always switched on, even without exercise. Working out appears to boost that receptor in muscle cells, which in turn helps bolster endurance over time. Burris’s lab has spent years <a href="https://news.ufl.edu/2023/09/exercise-mimicking-drug/">designing a drug</a> that cranks up the receptor’s activity directly, and mice treated with the drug ran longer and farther than mice that weren’t. They “become marathon mice without having to do any type of exercise,” Burris says. There are even indications—also in mice—that the compound mimics some of the cognitive benefits of exercise and could help treat heart failure. Burris founded a company called Pelagos to carry the work forward into a clinical trial.</p>



<p class="wp-block-paragraph">Other workout-mimicking drugs have already entered human studies. In June, the biotech firm Cambrian Bio <a href="https://www.cambrianbio.com/news-and-publications/cambrian-bio-presents-positive-human-translational-data-for-atx-304-the-first-ampk-network-activator-at-the-american-diabetes-associations-86th-scientific-sessions">reported</a> that its experimental drug ATX-304 boosted metabolism and reduced liver and belly fat in people with obesity and prediabetes<em>. </em>It activates a metabolic switch that helps cells sense when energy supplies dip and coordinates the production of more fuel—the same switch that helps us sustain long sessions jumping rope or swimming laps. Cambrian hopes it will help people lose weight without losing muscle, a common concern with GLP-1 medicines.  </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<h3 class="wp-block-heading">Progress meter ………… 5</h3>



<figure class="wp-block-image size-full is-resized"><img decoding="async" width="387" height="48" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/purple-20.svg" alt="" class="wp-image-1147277"></figure>



<p class="wp-block-paragraph"><strong>Our understanding of how exercise benefits the body is still coming into focus, and drug development is prone to failure.</strong></p>]]> </content:encoded>
</item>

<item>
<title>Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows</title>
<link>https://edusehat.com/en/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows</link>
<guid>https://edusehat.com/en/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows</guid>
<description><![CDATA[ The partners are targeting NGS core labs with a combined offering that automates next-generation sequencing library prep workflows using kits from Takara Bio and SPT Labtech’s firefly instrument. They are starting with RNA-seq with plans to expand. 
The post Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/12/GettyImages-1481209562.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Takara, Bio, USA, SPT, Labtech, Team, Automate, NGS, Library, Prep, Workflows</media:keywords>
<content:encoded><![CDATA[<p>Takara Bio USA and SPT Labtech have inked an agreement that will allow them to provide automated library preparation workflows that pair Takara Bio’s next-generation sequencing library prep chemistries with SPT Labtech’s firefly liquid handling platform. Under the terms of the partnership agreement, the companies will first optimize select SMART-seq<sup>®</sup> RNA-seq library prep workflows, a new offering from Takara Bio, on SPT Labtech’s firefly with plans to ultimately expand to a growing menu of new RNA-seq, DNA-seq, and immune profiling kits.</p>
<p>The target customer base for the combined offering is NGS core labs and customers who prepare NGS libraries from a high volume of samples and need to expand their current capabilities. With the new offering, the company claims that these customers will have access to automation scripts to easily deploy workflows that can generate high-quality, reproducible sequencing data and that are easy to integrate into labs’ existing processes. The partners also note that SPT Labtech’s firefly does not require a large footprint, making it suitable for labs constrained by staffing, space, and cost.</p>
<p>Both partners will discuss the collaboration during this year’s annual meeting of the American Society of Human Genetics.</p>
<p>For Takara Bio, the partnership fits into a bigger picture. The company is incorporating automation as an integral part of an NGS technology launch package. The company plans to start shipping its SMART-Seq mRNA long read extended kit in January 2027. This will be the first product launched with an optimized workflow for the firefly instrument. Takara Bio claims that the combined products will help labs standardize long-read transcriptomics at scale while benefitting from greater input flexibility, better recovery of full-length transcripts, and greater quantification confidence among other benefits. Automation scripts are already available for download on the SPT cloud portal for two existing kits, SMART-Seq mRNA LP and SMART-Seq Total RNA Library Prep with ZapR<sup>®</sup> Depletion with unique molecular identifiers.</p>
<p>Commenting on the partnership, Andrew Farmer, DPhil, president and CEO of Takara Bio USA, noted that the company is committed to making its NGS chemistries easier to implement at scale. “Through our collaboration with SPT Labtech, automation is becoming a foundational element of how we bring NGS products to market. As we introduce new library preparation technologies, customers can expect automated workflows to be built into the product experience from the start,” he said.</p>
<p>Paul Lomax, head of genomics at SPT Labtech, noted that by combining their products, both companies aim to help “more laboratories access the benefits of automated library preparation without the infrastructure requirements often associated with larger automation platforms.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/takara-bio-usa-spt-labtech-team-up-to-automate-ngs-library-prep-workflows/">Takara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roche, Hansoh Launch Up&#45;to&#45;$15B+ Cancer ADC Collaboration</title>
<link>https://edusehat.com/en/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration</link>
<guid>https://edusehat.com/en/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration</guid>
<description><![CDATA[ The companies&#039; strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC technology platform.
The post Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2179548801_AntibodyDrugConjugate.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roche, Hansoh, Launch, Up-to-15B, Cancer, ADC, Collaboration</media:keywords>
<content:encoded><![CDATA[<p>Roche and Hansoh Pharmaceutical Group have launched their second collaboration focused on developing cancer-fighting antibody-drug conjugates (ADCs), a partnership that could generate more than $15 billion for the Shanghai-based drug developer.</p>
<p>Roche and Hansoh have agreed to develop an unspecified number of ADCs “across multiple cancer types,” without disclosing the cancer types and targets they plan to focus on. The companies did say, however, that their strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC technology platform.</p>
<p>“Expanding our strategic collaboration with Hansoh marks an important step in advancing our ADC vision,” Boris L. Zaïtra, head of Corporate Business Development at Roche, said in a statement. “Exploring next generation ADCs is one of the most compelling frontiers in oncology today, offering the opportunity to address critical unmet needs and accelerate potential therapies for patients worldwide.”</p>
<p>Roche’s latest Hansoh partnership was announced October 19, a year and two days after the pharma giant was granted an exclusive global license (excluding China, Hong Kong, Macau and Taiwan) by Hansoh to develop its HS-20110, an ADC being developed to treat colorectal cancer and other solid tumors. HS-20110 consists of a humanized anti-CDH17 monoclonal antibody covalently conjugated to topoisomerase inhibitor (TOPOi) payload.</p>
<p>At the time, Roche agreed to pay Hansoh $80 million upfront and up to $1.45 billion in potential development, regulatory approval, and commercialization milestone payments, plus royalties, toward developing HS-20110. The drug is under study in advanced colorectal cancer in a global Phase I/II trial (<a title="Original URL: https://clinicaltrials.gov/study/NCT07283367. Click or tap if you trust this link." href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07283367&data=05%7C02%7CSavannah.Wiegel%40sagepub.com%7C457be5dcfb8f4fe223d708df2ec75245%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639281105751915276%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=YPNLp%2B1eB6Uvla0qKAAhjIbrqPgWLHKJmdmRyyva3Xc%3D&reserved=0" target="_blank" rel="noopener" data-auth="NotApplicable" data-linkindex="0">NCT07283367</a>) in China whose primary completion date is December 31, 2029; as well as in advanced solid tumors in a global Phase I trial (<a title="Original URL: https://clinicaltrials.gov/study/NCT06892379. Click or tap if you trust this link." href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06892379&data=05%7C02%7CSavannah.Wiegel%40sagepub.com%7C457be5dcfb8f4fe223d708df2ec75245%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639281105751944126%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=iosS%2FLGC1HyYtPliI45Dz9PnvZXIAZtYaBhi8VfQNxc%3D&reserved=0" target="_blank" rel="noopener" data-auth="NotApplicable" data-linkindex="1">NCT06892379</a>) in the U.S. and China whose primary completion date is December 31.</p>
<p>“Building on the ADC partnership we announced last year, we are delighted to further strengthen our collaboration with Roche,” stated Eliza Sun, executive director of Hansoh’s board. “This new agreement reflects our shared commitment to advancing ADC innovation and underscores our strategy of leveraging our deep expertise to accelerate the development of transformative therapies for cancer patients globally.”</p>
<p class="x_MsoNormal" data-olk-copy-source="MessageBody">Investors sent Hansoh shares on the Hong Kong Stock Exchange rising nearly 10% over two days, from HKD 31.38 ($3.94) at the start of Monday trading to HKD 34.38 ($4.31) at Tuesday’s close. Roche’s two classes of stock traded on the SIX Swiss Exchange each climbed roughly 3% during the period: RO bearer shares rose from CHF 384.60 ($463.21) to CHF 395.60 ($476.46), while ROP participation certificates went from CHF 379.20 ($456.67) to CHF 389.90 ($469.56).</p>
<h4><strong>Four ADCs disclosed in pipeline</strong></h4>
<p>HS-20110—identified with the placeholder name “CHU”—is one of four cancer-fighting ADCs disclosed online in <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.roche.com%2Fsolutions%2Fpipeline&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782719394%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=dMePOleHd17aiLs3XzYg04uQ8qh4N1ZUoHO9ufJGzgw%3D&reserved=0" target="_blank" rel="noopener">Roche’s pipeline</a>, last updated July 23. The other three are:</p>
<ul>
<li><strong>RG6648</strong>, a c-Mesenchymal-epithelial transition factor (cMET)-targeting ADC whose active antitumor payload is the antibody YL0010014. When released, YL0010014 is designed to arrest the cell cycle of tumor cells, leading to tumor cell apoptosis. MediLink licensed the ADC, which it called YL211, in 2024 for up to nearly $1 billion, including $50 million in upfront and near-term milestone payments.</li>
<li><strong>RG6810</strong>, a DLL3-targeted ADC with a topoisomerase I (Topo1) isomerase payload, being developed to treat small cell lung cancer (SCLC). Roche licensed the ADC, which it called IBI3009, from San Francisco and Suzhou-based Innovent Biologics last year for $80 million upfront and up to $1 billion in development and commercial milestone payments, plus tiered royalties on net sales.</li>
<li><strong>Tam-Peli (tambotatug pelitecan or RG6919)</strong>, a B7H3-targeting ADC for solid tumors licensed worldwide except China, Hong Kong, and Macau in January from Suzhou, China-based MediLink, which called the candidate YL201. The ADC was developed using MediLink’s Tumor Microenvironment-Activatable LINker-payload (TMALIN<sup>®</sup>) platform.</li>
</ul>
<p>Last month, MediLink released positive interim data from the Phase III TAISHAN-302 trial (<a href="https://clinicaltrials.gov/study/NCT06612151" target="_blank" rel="noopener">NCT06612151</a>) assessing Tam-Peli vs. standard-of-care topotecan in Chinese patients with relapsed SCLC who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor. TAISHAN-302 met its primary endpoint of overall survival (OS) with Tam-Peli demonstrating a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 54% (median OS 13.3 vs. 9.4 months; stratified HR=0.46; p<0.0001).</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Tam-Peli also showed robust efficacy across secondary endpoints, significantly extending progression-free survival (PFS) (median PFS 7.4 vs. 2.8 months) and response rates (59.1% vs. 9.7%) vs. topotecan. The Tam-Peli data was presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul with simultaneous <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2610229%3Faf%3DR%26rss%3DcurrentIssue%26referrer%3Dhttps%253A%252F%252Fwww.google.com%252F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782749883%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=OeWCYKS3VJxKecK82rPuRQMiW8s%2FHDlAg4cSveQXuEA%3D&reserved=0" target="_blank" rel="noopener">publication in <em>The New England Journal of Medicine</em></a>.</p>
<h4><strong>Ongoing ADC collaborations</strong></h4>
<p>Roche has several other ongoing discovery and development collaborations with Chinese partners focused on ADCs.</p>
<p>In August, Roche’s Genentech subsidiary agreed to license ADCs it plans to develop with Shanghai-based DualityBio based on its DualityBio Unique Payload Antibody Conjugate (DUPAC) platform. The ADCs would be developed against Genentech-defined oncology targets using payloads from DUPAC. Roche agreed to pay DualityBio $45 million upfront and more than $1 billion in development, regulatory, and commercial milestone payments, plus tiered royalties.</p>
<p>Through its latest partnership with Hansoh, Roche aims to multiply the number of ADCs in its development pipeline and product portfolio. Roche now markets two ADCs. One is Kadcyla<sup>®</sup> (ado-trastuzumab emtansine / RG3502), a HER2-targeted antibody and microtubule inhibitor conjugate approved to treat HER2-positive breast cancer. Kadcyla is under study in combination with Roche’s Tecentriq<sup>®</sup> (atezolizumab) in the Phase III ASTEFANIA trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04873362&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782767152%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=tqWwZVSif8QrDwiGxFVZ5N9wyXSgA8O3rt1iX17UE%2B4%3D&reserved=0" target="_blank" rel="noopener">NCT04873362</a>) for high-risk early breast cancer.</p>
<p>The other marketed Roche ADC is Polivy<sup>®</sup> (polatuzumab vedotin), which is approved for specific types of lymphoma.  While a consensus of analysts expects Kadcyla and Polivy to rack up a combined CHF 3.5 billion ($4.3 billion) this year, according to LSEG data cited by Reuters.</p>
<p>Hansoh has agreed to lead early development of the programs through the completion of global Phase Ia clinical trials. After that, Roche agreed to oversee further development of the programs worldwide except China, Hong Kong, Macau, and Taiwan—where Hansoh will retain all rights to develop, register and commercialize the programs.</p>
<p>Also outside China, Hong Kong, Macau, and Taiwan, Hansoh has the option to select up to two programs and contribute to their development. In return, Roche will pay Hansoh unspecified “incremental upside” payments stemming from their commercialization in the United States.</p>
<p>Roche has agreed to pay Hansoh $400 million upfront, an additional $110 million to be paid next year on the first anniversary of the collaboration, and more than $15 billion in payments tied to achieving development, regulatory, and commercialization milestones associated with the programs. Hansoh could also gain from Roche tiered royalties on potential future product sales.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<h4><strong>Patent cliff pressure</strong></h4>
<p>The partnership is one of several collaborations through which Swiss-based Roche hopes to recoup sales it expects to lose as its aging blockbusters lose patent exclusivity. The best-selling of these drugs is its Genentech-marketed multiple sclerosis drug Ocrevus<sup>®</sup> (ocrelizumab), which <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Ftop-20-drugs-heading-for-the-patent-cliff-2026-2029%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782782029%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=RHVVkDomkTBk8KTqPamt%2B9hVynu2PkIAs3QfinxBAFI%3D&reserved=0" target="_blank" rel="noopener">heads for the proverbial “patent cliff” in 2027</a>. Ocrevus generated CHF 3.47 billion ($4.192 billion) in sales during January-June and CHF 7.01 billion ($8.467 billion) in 2025.</p>
<p>That sales pressure has prompted Roche to launch numerous collaborations: In addition to the Hansoh and DualityBio collaborations, Roche has partnered since August alone with:</p>
<ul>
<li><strong>Rona Therapeutics</strong>, another Chinese biotech, on an agreement to license its RNA interference (RNAi) obesity and metabolic disease candidate targeting activin receptor-like kinase 7 (ALK7), announced October 13 and valued at up-to-$1.16 billion ($100 million upfront and near-term).</li>
<li><strong>Defand Therapeutics, </strong>a Chinese startup, on a drug discovery partnership of undisclosed value (though <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fendpoints.news%2Froche-does-fourth-china-deal-since-august-teaming-with-defand-on-degraders%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782794666%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=3wwi8ubmEbjcOqrkDg3pFV6Y8090aBKnNQ9IfT9pvTM%3D&reserved=0" target="_blank" rel="noopener">reportedly</a> up to about $1 billion, up to $10 million of that upfront) to discover and develop molecular glue therapies for multiple cancer and immunology targets, announced October 7.</li>
<li><strong>Ataviastik Bio, </strong>a Cambridge, MA hematology drug developer, on a partnership to discover and develop small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases, valued at up to $1.9 billion ($70 million upfront), announced September 24.</li>
<li><strong>Earendil Labs</strong>, a Wilmington, DE, biologics developer, on a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology, valued at up to $1.15 billion ($55 million upfront), announced September 24.</li>
</ul>
<p>At up-to-$15.5 billion, the latest Roche-Hansoh collaboration is among the largest but not the largest partnership between a Western pharma and a Chinese biotech. That distinction belongs to AstraZeneca’s up-to-$18.5 billion collaboration ($1.2 billion upfront) with CSPC Pharmaceutical Group to develop “multiple” injectable next-generation therapies for obesity and type 2 diabetes across eight programs announced in January. That does not include a separate up-to-$1.77 billion ($30 million upfront) partnership by the companies to develop small interfering RNA (siRNA) therapies for kidney diseases, launched in July.</p>
<p>In May, Bristol Myers Squibb (BMS) <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Fbms-hengrui-pharma-partner-on-13-programs-in-up-to-15-2b-collaboration%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782815248%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=6dXHP%2BUSMzcHBa3SrGlzm5IsfPgBo1fJp%2Bo%2FvYo96As%3D&reserved=0" target="_blank" rel="noopener">launched an up-to-$15.2 billion partnership</a> with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, and immunology. The 13 consist of four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five “innovative” assets to be jointly discovered and developed by both companies. Also in May, Pfizer <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fdrug-discovery%2Fpfizer-innovent-ink-up-to-10-5b-cancer-treatment-collaboration%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C5aa2b45fbc2a4779ff2508df2e1f490f%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639280384782826682%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=gps5ijxT%2BVzbPbuATAcMdIKK01rJbBMjQ4N%2FKrpK3lU%3D&reserved=0" target="_blank" rel="noopener">inked an up to $10.5 billion oncology alliance</a> with Innovent Biologics to develop 12 early-stage and <em>de novo</em> antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/roche-hansoh-launch-up-to-15b-cancer-adc-collaboration/">Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Catalytic Reactive&#45;Hydrogen Membranes Capture and Break Down PFAS</title>
<link>https://edusehat.com/en/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas</link>
<guid>https://edusehat.com/en/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas</guid>
<description><![CDATA[ Newly developed palladium-coated membranes capture PFAS and use reactive hydrogen to break their carbon–fluorine bonds. During 58 days of continuous operation, the system achieved up to 96% removal and 83% defluorination.
The post New Catalytic Reactive-Hydrogen Membranes Capture and Break Down PFAS appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/GettyImages-2149301660.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Catalytic, Reactive-Hydrogen, Membranes, Capture, and, Break, Down, PFAS</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Arizona State University (ASU) and collaborating institutions have developed catalytic reactive-hydrogen membranes that capture and chemically break down six per- and polyfluoroalkyl substances (PFAS) in water. The approach couples contaminant removal with carbon–fluorine bond cleavage, addressing a limitation of conventional treatments that separate “forever chemicals” from water but leave contaminated waste requiring further handling.</p>
<p>The study, led by Bruce Rittmann, PhD, director of ASU’s Biodesign Swette Center for Environmental Biotechnology, involved collaborators at Rice University, Tongji University, the National University of Singapore, and Nanjing University. Published in <em>Proceedings of the National Academy of Sciences</em>, the paper is titled “<a href="https://www.pnas.org/doi/10.1073/pnas.2613985123" target="_blank" rel="noopener">Catalytic Reactive-Hydrogen Membranes for Rapid Capture and Hydrodefluorination of Six PFAS of Regulatory Concern</a>.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>“PFAS are hard to break down, and normal processes that we use don’t work,” Rittmann said.</p>
<p>That persistence stems from the compounds’ strong carbon–fluorine bonds. Activated carbon, ion exchange, and membrane filtration can remove PFAS from water, but do not themselves resolve the challenge of destroying the captured contaminants. The new system instead brings PFAS and reactive hydrogen together on palladium-coated membrane fibers under ambient conditions.</p>
<figure aria-describedby="caption-attachment-339638" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339638" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination-300x169.jpg" alt="" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_rittmann-defluorination.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A palladium-coated membrane uses hydrogen to help break down PFAS “forever chemicals.” [Jason Drees]</figcaption></figure>
<p>Hydrogen gas travels through the fibers to the palladium catalyst, where it generates two forms of active hydrogen with complementary functions. Surface hydrogen supports PFAS capture, while subsurface hydrogen stored as beta-phase palladium hydride supplies the driving force for hydrodefluorination.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“The palladium attracts the PFAS molecule, and the palladium attracts the hydrogen and puts them together,” Rittmann added.</p>
<p>Solid-state analyses identified formation of the palladium hydride and associated lattice expansion. In the paper, the researchers described their findings as “a mechanistic framework for how active hydrogen is generated, stored, and deployed in catalytic membranes.”</p>
<p>The team tested PFOA, PFOS, PFNA, PFHxS, PFBS, and GenX. During 58 days of continuous operation, the system achieved up to 96% removal and 83% defluorination.</p>
<p>Performance also varied by compound. Long-chain PFAS were removed and defluorinated faster than short-chain analogs. GenX was more resistant, which the authors attributed to its ether linkage, weaker adsorption, and higher average carbon–fluorine bond dissociation energy. Nevertheless, the membrane enabled GenX removal and defluorination, producing 2-propoxypropanoic acid.</p>
<p>Practical deployment will require further engineering, including reducing palladium use. “Palladium is expensive,” Rittmann said. One potential application is treating concentrated waste streams generated by existing PFAS-removal systems, rather than replacing those systems outright. The researchers are also developing related hybrid membranes combining palladium with pollutant-degrading bacteria, although the current study’s catalytic system uses palladium rather than microbes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/new-catalytic-reactive-hydrogen-membranes-capture-and-break-down-pfas/">New Catalytic Reactive-Hydrogen Membranes Capture and Break Down PFAS</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Immune Pathway Contributing to Radiation Therapy&#45;Related Lung Damage Identified in Mice</title>
<link>https://edusehat.com/en/immune-pathway-contributing-to-radiation-therapy-related-lung-damage-identified-in-mice</link>
<guid>https://edusehat.com/en/immune-pathway-contributing-to-radiation-therapy-related-lung-damage-identified-in-mice</guid>
<description><![CDATA[ Working with a mouse model of radiation-induced lung injury, researchers uncovered an immune pathway that may contribute to radiation-related lung damage and, suggest their results may point to a potential preventive strategy.
The post Immune Pathway Contributing to Radiation Therapy-Related Lung Damage Identified in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_High-Quality-WomenCenter_031221_-175.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 21 Oct 2026 02:40:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Pathway, Contributing, Radiation, Therapy-Related, Lung, Damage, Identified, Mice</media:keywords>
<content:encoded><![CDATA[<p>More than 70% of people diagnosed with lung cancer will undergo radiation therapy (RT) at some point in their treatment, but while such therapy is often lifesaving, it can permanently damage healthy lung tissue and limit future cancer treatment options.</p>
<p>Working with a mouse model of radiation-induced lung injury (RILI) researchers headed by a team at City of Hope have uncovered an immune pathway that may contribute to radiation-related lung damage, which may point to a potential preventive strategy. The researchers suggest that insights from their preclinical study could lead to new treatments that prevent radiation therapy from harming healthy lung tissue and so improve patients’ quality of life.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Research lead Heather McGee, MD, PhD, an assistant professor in the departments of radiation oncology and immuno-oncology at City of Hope, said, “Many researchers in our field study how radiation activates well-known immune cells such as T cells to fight cancer. We are the first group to show that radiation also reprograms rare immune cells called innate lymphoid cells, and that these cells play a key role in driving damage to healthy lung tissue.” McGee is corresponding author of the team’s published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-77637-3" target="_blank" rel="noopener">Type I IFN promotes ILC2-to-ILC1 plasticity in pre-clinical radiation-induced lung injury</a>.”</p>
<p>Lung cancer is one of the leading causes of cancer-related mortality worldwide, accounting for about 18% of all cancer-related deaths, the authors wrote, and radiation therapy (RT) plays a critical role in the treatment of patients with lung cancer. However, they noted, “Although RT can cure patients with lung cancer, it can also lead to severe complications, such as radiation-induced lung injury (RILI), pneumonitis, and radiation-induced lung fibrosis (RILF).”</p>
<p>When healthy lung tissue is damaged, the effects can be severe and long-lasting. Up to 20% of patients struggle with debilitating breathing difficulties and reduced quality of life, leaving some patients tethered to heavy oxygen tanks. “RILI can significantly impair lung function, often leading to supplemental oxygen dependence,” the team added. McGee leads a team of scientists investigating the role that innate lymphoid cells play in the response to radiation.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>To better understand how radiation damages healthy lung tissue the researchers developed a mouse model of radiation-induced lung injury and focused their studies on the potential role of innate lymphoid cells (ILCs). “While ILCs have been implicated in the pathogenesis of various lung diseases, their contribution to RILI has not been investigated,” they noted in their report. “In this study, we evaluate how high-dose, restricted field radiation therapy affects lung ILC function and plasticity in the context of RILI.”</p>
<p>The team used a number of techniques to track radiation’s impact on the immune system. “Using a mouse model of localized lung irradiation, we combine flow cytometric characterization of ILC subsets and cytokine production with single-cell transcriptomic and pseudotime analyses to define radiation associated changes in ILC phenotype and function, they explained. “We further use adoptive transfer experiments to determine whether ILC2s acquire ILC1-like features after irradiation<em> in vivo</em>.”</p>
<p>Their results showed that radiation provoked a dramatic transformation of ILCs causing them to adopt different identities and altering their functions. One type of ILC, called ILC2s, helps protect the lungs from damage. Radiation transformed these cells into another type, ILC1s, which promote inflammation that damages healthy lung tissue.</p>
<p>The researchers also discovered what drives this transformation, showing that radiation increased levels of the signaling protein interferon-beta (IFN-β), which acted as the switch that pushed protective ILC2 cells to become inflammatory ILC1 cells. Tests on human ILCs showed similar biological changes. “These findings identify radiation-induced type I interferon-mediated ILC plasticity as a mechanism underlying the pathogenesis of RILI,” the investigators noted.</p>
<p>McGee said, “Much like a player switching teams, radiation-induced IFN-β can shift these immune cells from a protective role to one that promotes inflammation. Our findings shed light on a previously unknown mechanism that leads to radiation-induced lung damage.”</p>
<p>The investigators in addition tested whether blocking the IFN-β signaling pathway during radiation could stop the harmful immune cell transformation. The found that in mice, disrupting this pathway reduced inflammation, limited lung injury, and decreased the fibrosis that can permanently scar healthy lung tissue.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Our findings suggest that high levels of IFN-beta contribute to the development of lung damage during radiation and that blocking this signaling pathway could offer a potential treatment to reduce this debilitating side effect,” said first author Jaeho Kim, MD, PhD, a radiation oncology postdoctoral fellow at City of Hope.</p>
<p>If the team’s approach proves effective in people it could protect patients from long-term lung damage, expand radiation options for individuals with chronic lung conditions such as chronic obstructive pulmonary disease (COPD), and enable more aggressive radiation treatment when needed. In their paper the team stated, “In conclusion, our study identifies an immune regulatory mechanism whereby type I IFN-induced ILC2-to-ILC1 plasticity contributes to the pathogenesis of RILI,” they concluded. “We also demonstrate that inhibiting this plasticity by blocking IFNAR1 signaling can alleviate lung damage in mouse models, offering a potential therapeutic strategy to minimize the side effects of radiation therapy in patients.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/immune-pathway-contributing-to-radiation-therapy-related-lung-damage-identified-in-mice/">Immune Pathway Contributing to Radiation Therapy-Related Lung Damage Identified in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Canada’s Arctic Research Could Help Discover Next&#45;Gen Therapeutics</title>
<link>https://edusehat.com/en/canadas-arctic-research-could-help-discover-next-gen-therapeutics</link>
<guid>https://edusehat.com/en/canadas-arctic-research-could-help-discover-next-gen-therapeutics</guid>
<description><![CDATA[ Unlocking the Arctic’s subterranean DNA must ensure a delicate balance between scientific rigor and ethical stewardship. Synthetic biology and chemistry could help discovery of new life-saving therapeutics. 
The post Canada’s Arctic Research Could Help Discover Next-Gen Therapeutics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-and-team-out-in-the-field-credit-Athabasca-University-free-to-use-cc.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 23:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Canada’s, Arctic, Research, Could, Help, Discover, Next-Gen, Therapeutics</media:keywords>
<content:encoded><![CDATA[<p>Buried under the permanently frozen soils of Canada’s Arctic is a biological trove not tapped by modern medicine.</p>
<p>Canadian scientists, fascinated by the extreme Arctic tundra, are tinkering with sophisticated genomic toolkits, digging subterranean material. There is hope that their bioprospecting could also be latched on by biotech innovators aid discovery of next-generation drug therapeutics.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Labs work to biosynthesize complex bioproducts in scalable fermenters hoping to never need to grow the Arctics sensitive native organisms.</p>
<p>Canada’s Arctic permafrost and ancient boric soils contain huge amounts rich DNA that has degraded over thousands of years, says Srijak Bhatnagar, PhD, who leads the Enviromics Group, a computational biology and environmental microbiology research lab at Canada’s Athabasca University. He and his team have spent years gathering environmental DNA from Canada’s Arctic waters.</p>
<figure aria-describedby="caption-attachment-339556" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339556" src="https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-300x169.jpg" alt="Srijak Bhatnagar, PhD, at work in his laboratory at Athabasca University" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons-1536x864.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Bhatnagar-at-work-credit-Athabasca-Univeristy-free-to-use-creative-commons.jpg 1920w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Srijak Bhatnagar, PhD, at work in his laboratory at Athabasca University. [Athabasca University]</figcaption></figure>
<p>“Permafrost is revealing frozen organisms that are a historical record from tens of thousands of years ago. They could be cold-adapted, ancient, or new in the sense that humanity has not seen them in a while,” he tells <em>GEN</em>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The motivation for various biotech innovators bioprospecting the Arctic for biosynthetic gene clusters is not only academic but commercial, he says.</p>
<p>There is a hope that aids for making novel antibiotics could someday emerge from such bioprospecting, and “antibiotics are a billion-dollar industry globally” he says.</p>
<h4><strong>Cultivating new microbes</strong></h4>
<p>In the past, nearly 99% of environmental microbes could not be cultivated under conventional laboratory settings—and this left big biochemical pathways hidden, says Justin Nodwell, PhD, a biochemistry professor at the University of Toronto. His lab specializes in taking streptomycete biosynthetic gene clusters (BGCs)—genes identified in unculturable environmental microbes that remain silent in standard conditions—and using synthetic biology to express them in <em>Streptomyces</em> to produce new antibiotics and natural products.</p>
<figure aria-describedby="caption-attachment-339557" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-339557" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-300x213.jpg" alt="Justin Nodwell, PhD, in his lab with a colleague at University of Toronto." width="300" height="213" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-300x213.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-1024x726.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-768x545.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use-1536x1090.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Dr-Nodwell-in-his-lab-credit-Nodwell-Lab-cc-free-to-use.jpg 1800w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Justin Nodwell, PhD, in his lab with a colleague at University of Toronto. [Justin Nodwell, PhD, Nodwell Lab]</figcaption></figure>
<p>So it seems, local labs in Canada are overcoming this hurdle through <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4324309/" target="_blank" rel="noopener">high-throughput metagenomics</a> and single-cell DNA sequencing.</p>
<p>“When we obtain total genomic material directly from permafrost cores, bioinformaticians can build complete genomes of unculturable organisms, and this shows cryptic BGCs,” Nodwell says.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>It is true that specialized metabolism from more conventional environments has been mined extensively not just for antibiotics, he says, but also, chemotherapeutic drugs. Nodwell shared the example of doxorubicin, a frontline chemotherapeutic, rapamycin and others, pointing out a phenomenon known as the <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/dereplication" target="_blank" rel="noopener">dereplication</a> problem. Dereplication involves the process of identifying interfering substances in samples.</p>
<p>“You tend to rediscover things that are known. And that certainly is something we’ve encountered in this lab. In terms of whether going to Arctic environments is going to lead to new metabolites, I think scientifically that very interesting though the jury isn’t entirely in,” he says.</p>
<p>On the importance of prospecting extremophile microorganisms, he brings the example of Hazel Barton, PhD, a microbiologist and ecologist at the University of Alabama. She studies cave microbiomes, often cave exploring ancient caves, including a cave in New Mexico called the Lechuguilla Cave, which has not been accessed from the surface of the earth for around 4 million years.</p>
<p>Microbiologists like Nodwell are curious to know if “there is new stuff down there, stuff that hadn’t been sampled before. At the very least, there should be stuff that hasn’t been exposed to antibiotics used in medicine”.</p>
<h4><strong>Expensive synthetic biology </strong></h4>
<p>In Canada, researchers studying the Arctic permafrost, including Nodwell, are energized to find new microbes stuff there—though he cautions against wild expectations.</p>
<p>“I guess we’ll also find some things that we’ve seen before—but whether if that can be turned that into distributable medicinal products—it’s still it’s impossible to say,” he says.</p>
<p>From the perspective of the synthetic biology that he studies, the main obstacle occurs when taking a streptococcal BGC, identified from a non-culturable cord adapted environment, and trying to refactor it for expression in a standard warm-adapted host platform, such as <em>Streptomyces.</em></p>
<p>Some of the biosynthetic gene clusters are enormous, up to 100,000 base pairs, which is a lot of synthetic DNA to make, he says of the technical challenges Canadian researchers face.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“[If] you’re going to do it synthetically, and it’s very expensive. If you’re going to do it by PCR, that’s a lot of reactions. It’s a major undertaking to build something like that. But it is doable,” he says.</p>
<p>“But whereas there’s good algorithms for finding the biosynthetic genes for compounds, the boundaries are often somewhat mysterious. Like you’ll find a string of, let’s say, 15 genes that are clearly involved in making a molecule. And then there’ll be a few on either end that it’s like maybe they’re involved, maybe they’re not. And so, if you don’t know the biochemical pathway that makes the molecule, it’s very hard to say what genes you need and where to do that cutoff. There are ways around that now, but there still is often a sort of a judgment call you have to make”.</p>
<h4><strong>Blind curve</strong></h4>
<p>In the endeavor to bioprospect Canada’s Arctic—Bhatnagar warns of a “blind curve”. Canadian researchers and biotech innovators can sequence the data and make it publicly available in places like GenBank or SRA.</p>
<p>But because of the financial hefty and mismatches, “a company elsewhere, most likely [in the] US, is going to mine it, create a product that could, for all we know, be a billion-dollar product,” Bhatnagar says.</p>
<p>Crucially, Canada is not a signatory of the UN <a href="https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=XXVII-8-b&chapter=27&clang=_en" target="_blank" rel="noopener">Nagoya Protocol on Access to Genetic Resources</a>. For indigenous populations who live in the Canadian Arctic, discussion on biopiracy and ownership of genetic materials is critically important.</p>
<p>“Canada is not a signatory of Nagoya Protocol, so we do not protect biocultural property. [For indigenous populations] that genetic knowledge is coming from what was their biocultural property, and they would as: What’s our benefit?”</p>
<p>This is a very important question to consider since what has traditionally happened is outsiders go to indigenous peoples, gather existing knowledge, listen to traditional knowledge, learn about traditional medicine, to see that knowledge used for developing patents without consideration of the indigenous people providing the original knowledge.</p>
<p>“I come from India (originally), and I distinctly remember in my childhood reading articles about how some of the traditional plants and medicines that we had been using; a western company basically isolated the chemical and patented it, and I’m like how can you patent it when we have been using it for like thousands of years?”</p>
<p>Overall, unlocking the Arctic’s subterranean DNA must ensure a delicate balance between scientific rigor and ethical stewardship. Yes—synthetic biology and chemistry could help discovery of new life-saving therapeutics, but Canadian researchers must establish build solid frameworks to protect Indigenous biocultural rights thus making local bioprospecting a mutually beneficial public good.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/canadas-arctic-research-could-help-discover-next-gen-therapeutics/">Canada’s Arctic Research Could Help Discover Next-Gen Therapeutics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG 2026: Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</title>
<link>https://edusehat.com/en/ashg-2026-landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</link>
<guid>https://edusehat.com/en/ashg-2026-landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</guid>
<description><![CDATA[ IMU Biosciences and UK Biobank will profile 80,000 blood samples using technologies from Waters and Ultima Genomics, creating a high-resolution immune dataset to advance AI-driven biomedical research and disease prediction.
The post ASHG 2026: Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2242943155.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 12:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG, 2026:, Landmark, Biobank, IMU, Immune, Profiling, Initiative, Taps, Ultima, and, Waters</media:keywords>
<content:encoded><![CDATA[<p>London-based IMU Biosciences, together with the UK Biobank, has announced a collaboration to generate the world’s most detailed, large-scale picture of the human immune system. By integrating high-dimensional immune-cell profiling, transcriptomic analysis, and AI-based computational methods, the study aims to reveal the human immune system in unprecedented detail and scale.</p>
<p>The project will add a high-resolution immune data layer and a foundational dataset to UK Biobank by generating more than 100 million immune data points from each of tens of thousands of samples to create the largest, most detailed immune dataset assembled to date. In order to do so, the project has selected the technology of both Waters and Ultima Genomics.</p>
<p>The project will use IMU’s HD Immunology platform in conjunction with Waters Corporation’s flow cytometry and multiomic instrumentation (BD FACSDiscover Cell Analyzer platform and BD Rhapsody single-cell multiomics platform) as part of their strategic partnership announced in June. Ultima’s recently launched UG200 Sequencing Platform will produce the project’s readouts and support large scale data generation. Taken together, the project will profile blood samples from an initial cohort of 80,000 blood samples from UK Biobank participants with the hope to expand across the full UK Biobank cohort of 500,000 participants.</p>
<p>“We are proud to be selected alongside the BD platforms from Waters to power foundational dataset generation and enable a new layer of single-cell immune-profiling data,” said Gilad Almogy, PhD, CEO of Ultima Genomics. “Building on our ongoing work with the 600,000-sample UK Biobank Pharma Proteomics Project, this demonstrates the platform’s suitability for large-scale omics data generation from large, deeply characterized biobank cohorts.”</p>
<p>The project will begin this year and will add a new immune profiling data layer on top of UK Biobank’s existing de-identified genomic, imaging, clinical and lifestyle data. Over time, the resulting data will be returned to UK Biobank and made available to approved researchers studying how immune variation relates to disease risk, progression, treatment response, and long-term health outcomes.</p>
<p>As part of the selection process, Ultima’s UG200 Sequencing Platform was validated on its performance with the BD Rhapsody platform and to work together to enable the large-scale project. The UG200 Sequencing Platform was launched in February 2026 and is now shipping.</p>
<p>Uniting UK Biobank’s population-scale samples with single-cell immune profiling, the collaboration is designed to generate immune data at the scale, reproducibility, and resolution needed for both broad biomedical research and future immune-prediction studies.</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“This new dataset,” notes Naomi Allen, DPhil, chief scientist at UK Biobank, “will provide our global research community with a valuable insight into how the immune system changes with aging. Scientists will be able to study which specific immune cell changes contribute to the future risk of conditions like cancer, diabetes, and dementia, paving the way for earlier disease detection and more accurate diagnosis.”</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“Blood samples from UK Biobank’s generous participants,” Allen continues, “have already been turned into genetic, proteomic, and metabolomic data. When complete, this detailed map of the immune system will in turn fuel the detection of new drug targets and help clinicians to understand who might respond best to a particular treatment.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters/">ASHG 2026: Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG: Long&#45;Read Genomics Meets Clinical Data in PacBio, Verily Health AI Deal</title>
<link>https://edusehat.com/en/ashg-long-read-genomics-meets-clinical-data-in-pacbio-verily-health-ai-deal</link>
<guid>https://edusehat.com/en/ashg-long-read-genomics-meets-clinical-data-in-pacbio-verily-health-ai-deal</guid>
<description><![CDATA[ A multi-year collaboration will connect PacBio&#039;s HiFi sequencing with Verily Pre, combining long-read genomic and clinical data for biomedical research and AI model development.
The post ASHG: Long-Read Genomics Meets Clinical Data in PacBio, Verily Health AI Deal appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/12/Aug2023_GettyImages_1444892930_DNAMolecularStructure-resize-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 08:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG:, Long-Read, Genomics, Meets, Clinical, Data, PacBio, Verily, Health, Deal</media:keywords>
<content:encoded><![CDATA[<p>PacBio and Verily Health have entered a multi-year collaboration to combine PacBio’s HiFi long-read sequencing with Verily’s clinical data and cloud-based analysis. The companies said the arrangement is intended to produce clinico-genomic datasets that can be used in biomedical research and in the training and deployment of artificial intelligence models.</p>
<p>Under the agreement, PacBio sequencing workflows will be connected with Verily Pre, a platform for governing, analyzing, and using health data. Verily will configure the platform’s Workbench research environment to aggregate, analyze, and curate HiFi genomic datasets alongside real-world clinical information. The companies also plan to use Verily Pre’s trusted agentic environment for AI model training and inference.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Long-read sequencing can capture structural variants, methylation patterns, and full-length RNA transcripts that may be difficult to resolve with short-read methods. Integrating those data with clinical records, however, can require separate tools and customized workflows. The collaboration will focus on connecting these steps and supporting larger long-read studies across research organizations, biopharma companies, clinical institutions, and population genomics programs.</p>
<p>PacBio develops sequencing systems for life science and clinical research. Its HiFi technology generates long reads and is used in areas including human genetics, oncology, infectious disease, and agricultural research. The company said its whole-genome sequencing workflows already operate within the Verily Pre environment, providing a technical starting point for the expanded work.</p>
<p>Verily Health is a healthcare data intelligence company whose technology is designed to help organizations manage and analyze protected health information. Verily Pre, its primary data platform, includes governance, modeling, and secure research tools.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>“Working with PacBio, we hope to deliver a meaningful impact to researchers and innovators working to find new answers for neurology, oncology, rare disease, and other areas of critical unmet need,” said Stephen Gillett, chairman and CEO of Verily Health.</p>
<p>PacBio president and CEO Mark Van Oene said the companies aim to create a path for turning complex biological information into data that can be used at scale in AI workflows. The announcement did not disclose financial terms, specific customers, or a timetable for broader deployment. Over the course of the collaboration, the companies plan to extend the integration to larger and more complex long-read programs.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-long-read-genomics-meets-clinical-data-in-pacbio-verily-health-ai-deal/">ASHG: Long-Read Genomics Meets Clinical Data in PacBio, Verily Health AI Deal</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Psychological Stress Triggers Arthritis Flares in Mice via IL&#45;6&#45;Dependent Pathway</title>
<link>https://edusehat.com/en/psychological-stress-triggers-arthritis-flares-in-mice-via-il-6-dependent-pathway</link>
<guid>https://edusehat.com/en/psychological-stress-triggers-arthritis-flares-in-mice-via-il-6-dependent-pathway</guid>
<description><![CDATA[ A study in mice offers up a biological explanation for how psychological stress can contribute to arthritis flares, and identifies a stress-responsive pathway that could be explored as a potential therapeutic target. 
The post Psychological Stress Triggers Arthritis Flares in Mice via IL-6-Dependent Pathway appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2182156911.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 05:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Psychological, Stress, Triggers, Arthritis, Flares, Mice, via, IL-6-Dependent, Pathway</media:keywords>
<content:encoded><![CDATA[<p>Psychological stress has long been associated with worsening symptoms in rheumatoid arthritis (RA). However, the underlying mechanism connecting psychological stress to the occurrence of joint inflammation has remained poorly understood. Headed by a team at Chiba University, a study in mice suggests that arthritis may retain a form of tissue inflammatory memory that can be reactivated by stress. The study results offer up a biological explanation for how psychological stress can contribute to arthritis flares, and identify a stress-responsive pathway that could be explored as a potential therapeutic target.</p>
<p>Better understanding of this pathway in the future could help guide the development of strategies to improve disease management and the quality of life of people living with RA.</p>
<p>“Our findings suggest that targeting the stress-responsive pathways may offer a future therapeutic strategy that acts without broadly suppressing the immune system,” noted research co-lead professor Hiroshi Nakajima, MD, PhD, at the Graduate school of Medicine.</p>
<p>Nakajima is senior and co-corresponding author of the researchers’ published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.aec9257" target="_blank" rel="noopener">Fibroblast-like synoviocytes exacerbate autoimmune arthritis upon psychological stress in an IL-6–dependent manner</a>.”</p>
<p>Psychological stress affects a variety of biological processes, including the immune system, the authors wrote. “It is well documented that acute psychological stress exacerbates inflammatory diseases.” However, while psychological stress can exacerbate autoimmune diseases such as rheumatoid arthritis (RA), the underlying biological mechanisms aren’t aren’t well understood. “The relationship between psychological stress and the exacerbation of RA has been recognized over the past few decades, but the underlying molecular mechanisms have remained unclear,” the team continued. In particular, how psychological stress can trigger inflammation in joints that were previously affected, even after the disease has gone into remission, remains an important unanswered question. “… the mechanisms underlying tissue inflammation during remission remain unclear,” they noted.</p>
<p>To answer this, the Chiba University team, in collaboration with researchers at Asahi General Hospital, and International University of Health and Welfare Narita Hospital, investigated how psychological stress can reactivate arthritis, examining stress-induced flares in a mouse model.</p>
<p>For their study the researchers used an antigen-induced arthritis (AIA) mouse model in which arthritis was allowed to enter a remission-like state before the animals were exposed to restraint stress. Their experiments indicated that exposure psychological stress reactivated inflammation in the joints. Using tissue analysis, immune-cell profiling and molecular measurements, the researchers traced the inflammatory signals activated by stress, finding that stress activated the sympathetic nervous system and brown adipose tissues (BAT), a type of body fat involved in producing heat. Stress activation caused BAT to release interleukin-6 (IL-6), an inflammatory signaling protein.</p>
<p>“Our findings suggest that the effects of psychological stress on arthritis extend beyond the immune cells traditionally associated with autoimmune disease. Instead, stress can activate processes within other tissues that contribute to the return of joint inflammation,” said study co-lead assistant professor Shigeru Tanaka, at Chiba University Graduate School of Medicine.</p>
<p>The researchers further identified which cells within the joint respond to this circulating IL-6. Their findings pointed to fibroblast-like synoviocytes (FLS), specialized cells found in the synovial tissue surrounding the joints. IL-6 stimulates these cells to produce CXCL1, a chemokine (immune-signaling protein) that attracts neutrophils, a type of white blood cell involved in inflammation. The resulting recruitment of neutrophils contributes to the reactivation of joint inflammation. Blocking the CXCR2 receptor, which responds to CXCL1, significantly reduced stress-triggered arthritis in the mouse model.</p>
<p>“In the RA joint, various cells, including macrophages and FLS, produce IL-6, creating an inflammatory network through their interactions,” the investigators explained. “Our study demonstrated a phenomenon in which IL-6 originates from outside the joint and stimulates FLS, leading to the recurrence of arthritis.”</p>
<p>The researchers further tested the pathway by blocking key receptors and monitoring changes in inflammatory markers, joint swelling, and immune-cell accumulation. When the mice were treated with a β3-adrenergic receptor antagonist, the researchers observed a reduction in plasma IL-6 levels, joint swelling, CXCL1 expression, and the accumulation of neutrophils in the joints.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>“Our current research revealed that β3-adrenergic receptor blockade successfully suppresses stress-induced arthritis flares,” they wrote. “This finding suggests a possible therapeutic strategy targeting the sympathetic nervous system.”</p>
<p>Nakajima added, “Our findings suggest that targeting the stress-responsive pathways may offer a future therapeutic strategy that acts without broadly suppressing the immune system.”</p>
<p>The researchers in addition examined whether this stress-related pathway was reflected in people with RA. They found that patients with Trp64Arg, a specific variant of the <em>ADRB3</em> gene, which makes cells less responsive to stress-related hormones, showed a weaker link between perceived stress and arthritis activity when compared to patients without the variant. However, because this analysis was observational, the findings do not prove that stress directly caused changes in disease activity.</p>
<p>Overall, the findings suggest that arthritis may retain a form of tissue inflammatory memory that can be reactivated by stress independently of lymphocytes. “These findings identify a BAT–IL-6–fibroblast axis that reactivates inflammatory memory in arthritis and suggest that targeting stress-responsive pathways may provide a complementary therapeutic strategy alongside current RA treatments without broadly suppressing systemic immunity,” the team concluded.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/psychological-stress-triggers-arthritis-flares-in-mice-via-il-6-dependent-pathway/">Psychological Stress Triggers Arthritis Flares in Mice via IL-6-Dependent Pathway</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</title>
<link>https://edusehat.com/en/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</link>
<guid>https://edusehat.com/en/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters</guid>
<description><![CDATA[ IMU Biosciences and UK Biobank will profile 80,000 blood samples using technologies from Waters and Ultima Genomics, creating a high-resolution immune dataset to advance AI-driven biomedical research and disease prediction.
The post Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2242943155.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 05:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Landmark, Biobank, IMU, Immune, Profiling, Initiative, Taps, Ultima, and, Waters</media:keywords>
<content:encoded><![CDATA[<p>London-based IMU Biosciences, together with the UK Biobank, has announced a collaboration to generate the world’s most detailed, large-scale picture of the human immune system. By integrating high-dimensional immune-cell profiling, transcriptomic analysis, and AI-based computational methods, the study aims to reveal the human immune system in unprecedented detail and scale.</p>
<p>The project will add a high-resolution immune data layer and a foundational dataset to UK Biobank by generating more than 100 million immune data points from each of tens of thousands of samples to create the largest, most detailed immune dataset assembled to date. In order to do so, the project has selected the technology of both Waters and Ultima Genomics.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>The project will use IMU’s HD Immunology platform in conjunction with Waters Corporation’s flow cytometry and multiomic instrumentation (BD FACSDiscover Cell Analyzer platform and BD Rhapsody single-cell multiomics platform) as part of their strategic partnership announced in June. Ultima’s recently launched UG200 Sequencing Platform will produce the project’s readouts and support large scale data generation. Taken together, the project will profile blood samples from an initial cohort of 80,000 blood samples from UK Biobank participants with the hope to expand across the full UK Biobank cohort of 500,000 participants.</p>
<p>“We are proud to be selected alongside the BD platforms from Waters to power foundational dataset generation and enable a new layer of single-cell immune-profiling data,” said Gilad Almogy, PhD, CEO of Ultima Genomics. “Building on our ongoing work with the 600,000-sample UK Biobank Pharma Proteomics Project, this demonstrates the platform’s suitability for large-scale omics data generation from large, deeply characterized biobank cohorts.”</p>
<p>The project will begin this year and will add a new immune profiling data layer on top of UK Biobank’s existing de-identified genomic, imaging, clinical and lifestyle data. Over time, the resulting data will be returned to UK Biobank and made available to approved researchers studying how immune variation relates to disease risk, progression, treatment response, and long-term health outcomes.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>As part of the selection process, Ultima’s UG200 Sequencing Platform was validated on its performance with the BD Rhapsody platform and to work together to enable the large-scale project. The UG200 Sequencing Platform was launched in February 2026 and is now shipping.</p>
<p>Uniting UK Biobank’s population-scale samples with single-cell immune profiling, the collaboration is designed to generate immune data at the scale, reproducibility, and resolution needed for both broad biomedical research and future immune-prediction studies.</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“This new dataset,” notes Naomi Allen, DPhil, chief scientist at UK Biobank, “will provide our global research community with a valuable insight into how the immune system changes with aging. Scientists will be able to study which specific immune cell changes contribute to the future risk of conditions like cancer, diabetes, and dementia, paving the way for earlier disease detection and more accurate diagnosis.”</p>
<p class="framer-text framer-styles-preset-1v5ef23" dir="ltr">“Blood samples from UK Biobank’s generous participants,” Allen continues, “have already been turned into genetic, proteomic, and metabolomic data. When complete, this detailed map of the immune system will in turn fuel the detection of new drug targets and help clinicians to understand who might respond best to a particular treatment.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/landmark-uk-biobank-imu-immune-profiling-initiative-taps-ultima-and-waters/">Landmark UK Biobank, IMU Immune Profiling Initiative Taps Ultima and Waters</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ADC Development from Concept to Clinic</title>
<link>https://edusehat.com/en/adc-development-from-concept-to-clinic</link>
<guid>https://edusehat.com/en/adc-development-from-concept-to-clinic</guid>
<description><![CDATA[ This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics.
The post ADC Development from Concept to Clinic appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Cover-Image_ADCs-8-x-11-scaled-e1792182648204.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 20 Oct 2026 01:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ADC, Development, from, Concept, Clinic</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<figure class="wp-block-image alignright size-medium"><img decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg" alt="Eurofins eBook Cover" class="wp-image-339513" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery while minimizing off-target effects. Their potential in areas such as targeted cancer cell killing and targeted protein degradation has fueled significant growth, resulting in numerous FDA approvals and more than 100 ADCs currently in clinical development. However, ADC development remains complex and highly empirical, requiring careful optimization of linker chemistry, payload selection, bioconjugation strategies, drug-to-antibody ratio (DAR), stability, and overall antibody integrity.</p>


<p class="wp-block-paragraph">The ADC journey begins with linker-payload synthesis and bioconjugation. Eurofins Discovery offers extensive expertise in the design and synthesis of linker technologies, including protease-sensitive, glycosidase-sensitive, pH-sensitive, PEGylated, branched, and shielding linkers. Payloads are manufactured in specialized high-containment facilities to ensure the safe handling of highly potent compounds. Multiple conjugation options are available, providing flexibility to explore different designs and generate ADCs with customized pharmacokinetic profiles, improved stability, and controlled DAR distributions.</p>


<p class="wp-block-paragraph">Once conjugation is complete, ADCs undergo purification using a range of chromatography techniques. These methods remove unconjugated antibodies, excess linker-payload materials, and aggregates to produce highly pure ADC preparations. This is essential for more reliable downstream analyses and ensures more accurate assessment of ADC performance.</p>


<p class="wp-block-paragraph">DAR analysis is then conducted using high-resolution liquid chromatography-mass spectrometry (LC-MS). This approach confirms linker-payload incorporation, identifies individual DAR species, and provides detailed insights into ADC homogeneity. Such information is critical for optimizing product consistency, efficacy, safety, and manufacturability.</p>


<p class="wp-block-paragraph">Finally, a comprehensive suite of biochemical, functional, and cytotoxicity assays is essential to characterize ADC candidates. Data-driven assessment of binding, biological function, and therapeutic potential, through both <em>in vitro</em> and <em>in vivo</em> studies, helps identify the most promising candidates for further advancement and development.</p>


<p class="wp-block-paragraph">Eurofins Discovery provides a fully integrated ADC development platform spanning every stage of the workflow, from linker-payload design through analytical characterization and functional assessment. By leveraging deep expertise in chemistry, biochemistry, and antibody optimization and characterization, Eurofins Discovery scientists help mitigate development risks and shorten timelines while optimizing ADC safety, efficacy, and manufacturability.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/adc-developmentfrom-concept-to-clinic/">ADC Development from Concept to Clinic</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PACE: BIO’s 15th annual patient advocacy event focuses on access</title>
<link>https://edusehat.com/en/pace-bios-15th-annual-patient-advocacy-event-focuses-on-access</link>
<guid>https://edusehat.com/en/pace-bios-15th-annual-patient-advocacy-event-focuses-on-access</guid>
<description><![CDATA[ America’s biotech industry has facilitated 50 years of innovative breakthroughs that have changed the landscape of healthcare as we know it—offering the promise of […]
The post PACE: BIO’s 15th annual patient advocacy event focuses on access appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/michelde-and-John-at-PACE-2025.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 18:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PACE:, BIO’s, 15th, annual, patient, advocacy, event, focuses, access</media:keywords>
<content:encoded><![CDATA[<p><span>America’s biotech industry has facilitated 50 years of innovative breakthroughs that have changed the landscape of healthcare as we know it—offering the promise of giving people more time with the people they love.</span></p>
<p><span>But none of these breakthroughs mean anything if they can’t get into the hands of patients. That is why the patient voice is so important to biotech and the policy around it.</span></p>
<p><span>To amplify the voice of patients and their advocates, the</span><a href="https://pace.bio.org/"> <span>Biotechnology Innovation Organization’s (BIO) 15th annual Patient Advocacy Changemakers Event (PACE)</span></a><span> will convene October 22–23 in Washington DC. PACE is an opportunity for patient advocates to build community, connect with fellow patient groups and BIO members, and discuss policy issues that impact patient access, affordability, and the promise of future innovation.</span></p>
<p><span>“PACE is a unique event among all the gatherings of patients and caregivers and advocates in our community,” says John F. Crowley, president and CEO of BIO. “It’s the one chance we have to bring together people living with disease, people who care for those living with disease, researchers, government policymakers, and industry leaders to come together in a forum to discuss all the different ways in which we can partner, share ideas, and advance therapies for everybody in need.”</span></p>
<p><span>“Getting 21st Century medicines to patients requires a 21st century approach to affordability and access, and PACE brings patients, advocates, and BIO members together to shape access today and deliver hope for tomorrow,” says Michele Oshman Chief Patient Advocate and Senior Vice President, Patient Advocacy Center of Excellence.</span></p>
<p><span>So what can participants expect from the event, and what is BIO working to facilitate?</span></p>
<h3>Some changes for 2026</h3>
<p><span>This year’s PACE makes some additions, focusing on specialized breakout sessions, new keynote speakers, and timely policy issues (like access and affordability) that are affecting patients immediately.</span></p>
<p><span>“We have multiple specialized breakout sessions for folks who are truly DC experts and who work on policy every day, as well as breakouts for organizations that may be building that capability,” explains Oshman. </span></p>
<p><span>“This year’s PACE program goes a little bit deeper into policy than perhaps in past years. And there are a couple of reasons for that,” Oshman says. “One is that we’re gearing up for PDUFA VIII (the Prescription Drug User Fee Act reauthorization), and we want to make sure that patient advocates share their voice as part of that process. We’re also at a unique time in terms of patient access to therapies. We recognize the affordability and access challenges patients are facing, and now is the time to prepare for the next congressional session and bring your voice to the Hill.”</span></p>
<p><span>Additionally, BIO is welcoming baseball’s all-time Iron Man,</span><a href="https://pace.bio.org/speakers/cal-ripken-jr?&azletter=R&searchgroup=libraryentry-speakers"> <span>Cal Ripken Jr.</span></a><span> as the keynote speaker to the event. He will talk about his career and philanthropic work, and how his own patient journey shaped his work, in a conversation with Crowley.</span></p>
<p><span>“I used to say that I have two hats,” recalls Crowley, “on one hand, I was the entrepreneur, the CEO, the drug developer. On the other hand, I was the father of two children with a very rare disease. I came to realize that it really is just one hat with one aligned mission.”</span></p>
<p><span>It was that spirit of storytelling that helped Crowley, and patient advocates like him, understand that advocacy is a holistic endeavor, not a mission of parts.</span></p>
<p><span>“I think early on there was a view that people living with diseases or their loved ones weren’t sophisticated enough or weren’t objective enough,” he explains. “The opposite is actually true. We are the ones oftentimes who care the most, who know the best, and who have the unique ability to convene everybody who may bring any value toward advancing therapies that might alleviate suffering, and extend and enhance life. So that patient perspective I’ve come to learn is not only </span><i><span>one</span></i><span> important part, it is </span><i><span>the most</span></i><span> important part of everything we do in biomedical research.”</span></p>
<p><span>Patient advocates are the keystone when it comes to driving innovative medicines into the hands of patients, and events like PACE provide the ideal space for these conversations.</span></p>
<p><span>“If we simply innovate and we don’t ensure access for everybody in need, we will have failed,” says Crowley. “And that’s why this conference is so important: to not only talk about what it takes to advance what we call the virtuous circle of innovation, but how we actually then make sure that everybody has access to that medicine.”</span></p>
<p><span>These conversations and more will permeate the week’s event, not only helping keep advocates more informed, but connecting them to colleagues that can collaboratively help them reach their goals.</span></p>
<p><span>“My hope for PACE this year is that it’s the beginning of a conversation, not the culmination of one,” says Oshman.</span></p>
<p><a href="https://pace.bio.org/"><b>Find out more and register for PACE.</b></a></p>
<p>The post <a href="https://bio.news/health/pace-bios-15th-annual-patient-advocacy-event-focuses-on-access/">PACE: BIO’s 15th annual patient advocacy event focuses on access</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Diasome’s HDV&#45;Insulin for T1D Finalizing Phase III Plans After Promising Data</title>
<link>https://edusehat.com/en/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data</link>
<guid>https://edusehat.com/en/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data</guid>
<description><![CDATA[ HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells.
The post Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/HDV-Diasome-3-rendering-JPEG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 03:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Diasome’s, HDV-Insulin, for, T1D, Finalizing, Phase, III, Plans, After, Promising, Data</media:keywords>
<content:encoded><![CDATA[<p>Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster drugs, which have generated billions for their developers, are indicated for type 1 diabetes (T1D)—though six professional groups earlier this year published a <a href="https://journals.sagepub.com/doi/10.1177/15209156261449879">consensus statement</a> designed to facilitate their safe use in managing T1D.</p>
<p>New Orleans-based Diasome says T1D treatment represents an unmet need that it is looking to address through its next-generation formulation of insulin targeting hepatocytes—which regulate how the body stores nutrients and controls whole-body blood glucose and fat metabolism—by using and clearing insulin, GLP-1, and serotonin as they enter the liver through the portal vein.</p>
<p>Diasome’s formulation comes from its own hepatocyte-directed vesicle (HDV<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">) lipid nanoparticle platform, designed to deliver peptides, proteins, and hormones—including insulin—to the portal-hepatic region with precision.</p>
<p>HDV is a phospholipid bilayer bicelle that is designed to bind standard insulin lispro and preferentially direct it to hepatocyte receptors, enhancing cellular uptake and bioavailability by mimicking natural cell membranes. Its net negative surface charge enables electrostatic binding with positively charged proteins and peptides.</p>
<p>Biotin-PE is embedded in HDV’s surface membrane, enabling what Diasome says is efficient targeting to hepatocytes, where the sodium-dependent multivitamin transporter is most highly expressed, facilitating selective hepatic uptake.</p>
<p>In binding up to 100 proteins and peptides onto each disc, concentrating and directing biologics and drug therapies through the portal-hepatic highway, HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells.</p>
<figure aria-describedby="caption-attachment-339531" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339531" src="https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-291x300.jpg" alt="" width="291" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-291x300.jpg 291w, https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-994x1024.jpg 994w, https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG-768x791.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Diasome-Bobs-Headshot-in-Color-NEAR-SQUARE-JPEG.jpg 1024w" sizes="(max-width: 291px) 100vw, 291px"><figcaption class="wp-caption-text">Robert Geho, Diasome’s co-founder and CEO</figcaption></figure>
<p>“Either subcutaneously or via oral administration, we’re able to preferentially deliver enough of those payloads into the liver and the portal vein that feeds the liver to basically mimic the endogenous release of those materials,” Robert Geho, Diasome’s co-founder and CEO, told <em>GEN</em>.</p>
<p>“Diasome is taking these commonly used APIs [active pharmaceutical ingredients] and adding very elegant chemistry to them in kind of an API-agnostic fashion and changing the biodistribution in an important way to enable the liver, especially, to just basically turn back on in response to those targeted molecules.”</p>
<h4><strong>Pivotal studies</strong></h4>
<p>Diasome is preparing to advance its HDV-insulin formulation into pivotal studies after generating positive Phase IIb data earlier this year and presenting it at two conferences earlier this fall.</p>
<p>“We’re working hard right now to finalize our Phase III planning. It’s a combination of finalizing the protocol, doing the power calculations, figuring out how many studies need to be run, choosing the insulin that we’re going to use, and then at some point fairly soon, get in front of the FDA and have a discussion about our pivotal program. We are very much dialed in on all of that Phase III preparation,” said Geho, himself a T1D patient.</p>
<p>Diasome is far from alone in developing treatments for T1D, an historically tough-to-drug indication; the primary treatment remains insulin, along with daily management (checking blood sugar and counting carbohydrates), and adjunctive therapies.</p>
<p>By year’s end, Lexicon Pharmaceuticals hopes to resubmit a new drug application (NDA) for sotagliflozin in T1D, depending on positive data from the Phase III STENO1 trial (<a href="https://clinicaltrials.gov/study/NCT06082063">NCT06082063</a>) sponsored by the Steno Diabetes Center Copenhagen.</p>
<p>Sotagliflozin is an oral inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2) marketed for heart failure as Inpefa®. Lexicon’s effort to expand the label to T1D (under the name Zynquista) was stymied in 2024 when the FDA rejected the company’s NDA for the drug as an add-on therapy to insulin for adults with T1D and chronic kidney disease (CKD). Lexicon responded by launching STENO1 and two other investigator-initiated trials, SUGARNSALT (Joslin Diabetes Center; <a href="https://clinicaltrials.gov/study/NCT06217302">NCT06217302</a>) and SOPHIST (University of Dundee, <a href="https://clinicaltrials.gov/study/NCT06435156">NCT06435156</a>).</p>
<p>Another SGLT2 inhibitor, dapagliflozin, was rejected by the FDA in 2019 as an adjunct treatment to insulin in adults with T1D. Since then, researchers have studied it in combinations for T1D, such as with pioglitazone, marketed by Takeda Pharmaceutical as Actos<sup>®</sup> (<a href="https://clinicaltrials.gov/study/NCT03878459">NCT03878459</a>) and in combination with insulin and Novo Nordisk’s semaglutide marketed for obesity as Wegovy<sup>®</sup> and for T2D as Ozempic<sup>®</sup> (<a href="https://clinicaltrials.gov/study/NCT03899402">NCT03899402</a>). Dapagliflozin is marketed by AstraZeneca as Farxiga<sup>®</sup> for T2D and specific forms of heart and kidney disease.</p>
<h4><strong>Expanding landscape</strong></h4>
<p>This year has seen better news for T1D drugs: The T1D landscape expanded in June when the FDA approved a broader label for Sanofi’s Tzield<sup>®</sup> (teplizumab) widening use of the CD3-directed monoclonal antibody to children aged 1 year and older with Stage 2 T1D. Tzield was initially approved in 2022 for children ages 8 and older, as the first disease-modifying therapy in autoimmune T1D. A year later, Sanofi inherited Tzield by acquiring its original developer Provention Bio for $2.9 billion.</p>
<p>Another T1D candidate fared worse in July when Roche ended development of acmopatide (CT-868), a once-daily dual GLP-1/GIP receptor agonist for T1D with obesity—despite generating positive Phase II data a month earlier showing the drug improved blood glucose management and reduced body weight. Roche instead opted to focus its T1D development effort on enicepatide (CT-388), a once-weekly subcutaneous injectable which CEO Thomas Schinecker told analysts held greater potential for development in multiple indications.</p>
<p>Roche inherited both drugs when it <a href="https://www.genengnews.com/topics/drug-discovery/roche-to-acquire-carmot-therapeutics-for-up-to-3-1b/">acquired Carmot Therapeutics for up-to-$3.1 billion</a> in a deal completed in 2024.</p>
<p>The T1D treatment landscape may be shaken as early as November, when Eli Lilly—whose GIP/GLP-1 receptor agonist tirzepatide is marketed for diabetes as Mounjaro®—is expected to read out data from two Phase III trials comparing the drug to placebo in adults with T1D and obesity or overweight—the 49-week, 905-patient SURPASS-T1D-1 trial (<a href="https://clinicaltrials.gov/study/NCT06914895">NCT06914895</a>), and the 20-month, 465-patient SURPASS-T1D-2 trial (<a href="https://clinicaltrials.gov/study/NCT06962280">NCT06962280</a>).</p>
<p>A T1D indication would likely add billions in new sales to Mounjaro, which racked up $18.605 billion in revenue during the first half of 2026—up more than double (106%) from $9.041 billion a year earlier. Lilly is set to report Q3 results on October 29.</p>
<h4><strong>Positive case</strong></h4>
<p>Researchers from Diasome and partners have made a positive case for HDV-insulin in recent weeks, presenting data from the Phase IIb OPTI-2 trial (<a href="https://clinicaltrials.gov/study/NCT06238778">NCT06238778</a>) at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held September 28–October 2, 2026, in Milan.</p>
<p>During OPTI-2, a 25-week double-blind trial, 226 adults with T1D treated with multiple daily injections were randomized 1:1 to bolus insulin with insulin lispro (sold under several generic versions and marketed by Eli Lilly as Humalog®) or Diasome’s hepatic-directed insulin lispro (HDV-L) with continuous glucose monitoring (CGM) for 12 weeks of optimization followed by13 weeks of maintenance therapy.</p>
<p>The data, initially published in June, showed that HDV-L was non-inferior to insulin lispro in reducing A1C. HDV-L was also associated with reductions in clinically meaningful hypoglycemia, including severe hypoglycemia, while preserving glycemic control in people with T1D using multiple daily injections.</p>
<p>“These data support advancement into Phase [III] studies,” the researchers concluded.</p>
<p>Five insulin lispro-treated subjects had severe hypoglycemic events compared to zero with HDV-L (p = 0.0598). And while treatment emergent adverse events (TEAE) were similar between groups, but only one person randomized to HDV-L had serious TEAEs, compared with eight insulin lispro patients. There were no deaths or cases of diabetic ketoacidosis.</p>
<p>A week later at the inaugural Breakthrough T1D Clinical & Research Congress held October 9-11 in Philadelphia, researchers presented both previously published findings from OPTI-2 as well as new data from the trial showing that compared to insulin lispro, HDV-L was associated with a lower exposure-adjusted incidence rate (EAIR) per person-year for level 1 or 2 hypoglycemia, level 2 hypoglycemia, and level 1 hypoglycemia.</p>
<h4><strong>“Breakthrough in insulin therapy”</strong></h4>
<p>“We reduced hypoglycemia risk substantially in a six-month double-blinded trial versus insulin lispro. We think it’s a breakthrough in insulin therapy,” Geho said. “Hypoglycemia risk is the single biggest rate-limiting challenge to achieving glycemic control in people with insulin-deficient diabetes. If you can fix that, you can actually enable people to take more insulin safely, which will have a big impact on their A1C control.”</p>
<p>Even with advanced pump technologies and CGM technologies, he added, the unmet clinical need on hypoglycemia is substantial.</p>
<p>“If we look at GLP-1, we’re really focused on the data that’s coming out that some 50% of new GLP-1 users discontinue within one year, 85% discontinue within two years. And why is that? The two big issues are cost and side effects,” Geho said.</p>
<p>Both percentages were reported among overweight or obese patients taking GLP-1s. The roughly 50% one-year discontinuation percentage appears in a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/">2025 study</a> by researchers at the University of Pennsylvania’s Perelman School of Medicine and health data and analytics company Truveta: 46.5% of T2D patients and 64.8% without T2D stopped within a year—though 47.3% of T2D patients and 36.3% of patients without T2D resumed use of GLP-1s within that year.</p>
<p>The 85% percentage comes from an analysis of real-world integrated pharmacy and medical claims data from 16 million commercially insured members that was posted in July 2024 by Prime Therapeutics, a pharmacy benefit manager.</p>
<p>Three months later, Prime spelled out its <a href="https://www.primetherapeutics.com/documents/d/primetherapeutics/glp-1-year-2-cost-effectiveness-study-abstract-10-24-24">methodology</a>: 3,046 GLP-1 using members were matched to three control members for a total of 8,343 unique control members identified (306 control members matched to more than one GLP-1 user). The mean age of individuals identified was 46 years, 81% were women and 14% had a prediabetes diagnosis.</p>
<h4><strong>“Competitive advantage”</strong></h4>
<p>“So, we think that offering a technology that is more physiologic—in other words, we’re changing where these molecules work enough that the body essentially reaches a better balance, settles down from a GI tolerability point of view—that would be a big competitive advantage,” Geho added.</p>
<p>Geho established Diasome in 2005 with his father W. Blair Geho, MD, PhD. The elder Geho pursued his PhD in pharmacology under the tutelage of Earl W. Sutherland, Jr., a Case Western Reserve University researcher who won the 1971 Nobel Prize in Physiology or Medicine “for his discoveries concerning the mechanisms of the action of hormones.”</p>
<p>Specifically, Sutherland demonstrated how signals from one cell to another are conveyed by a messenger, the hormone, while signals within cells are conveyed by other messengers. Around 1960 he showed how cyclic adenosine monophosphate (cAMP) serves as the secondary messenger within the cell.</p>
<p>To date, Diasome has raised approximately $85 million, attracting capital from investors that have included Eli Lilly and the JDRF T1D Fund (since renamed T1D Fund, A Breakthrough T1D Venture<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, following the rebranding in 2024 of JDRF, which was founded in 1970 as the Juvenile Diabetes Research Foundation). The company’s last announced financing was the first closing of its Series C round in December 2023; its amount has not been announced but has been <a href="https://www.crainscleveland.com/health-care/diasome-pharmaceuticals-announces-95-million-first-close-series-c-financing-round/">reported to be $9.5 million</a>.</p>
<p>“We’re anticipating a Series D financing, so that work is underway,” Robert Geho said. “That’s an active part of our work right now.”</p>
<p>Since its founding, Diasome has grown its workforce to between 20-25, counting both full-time employees and significant consultants.</p>
<p>“In terms of full-time headcount, I am anticipating increasing that by probably 25 or 30% over the next several months,” Geho estimated.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data/">Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics</title>
<link>https://edusehat.com/en/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united-therapeutics</link>
<guid>https://edusehat.com/en/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united-therapeutics</guid>
<description><![CDATA[ Two weeks after its stock lost more than half its value following a setback in a seven-year legal wrangle, Liquidia shares finally began bouncing back thanks to a settlement with United Therapeutics that drew mixed conclusions from four analysts about which company won out long-term.
The post StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Oct26_2020_Getty_545863899_Lung-1068x894-1-1003x840-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 19 Oct 2026 03:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Liquidia, Rebounds, After, Settling, Legal, Wrangle, with, United, Therapeutics</media:keywords>
<content:encoded><![CDATA[<p>Two weeks after its stock lost more than half its value following a setback in a seven-year legal wrangle, <strong>Liquidia (Nasdaq: LQDA)</strong> shares finally began bouncing back this past week thanks to a settlement with <strong>United Therapeutics (Nasdaq: UTHR)</strong> that drew mixed conclusions from four analysts about which company won out long-term.</p>
<p>The settlement ended six lawsuits that encompassed patent infringement, trade secret, and antitrust claims between the companies. Short-term, Liquidia agreed to pay $380.7 million to United Therapeutics and parties to settle antitrust litigation launched in 2019. Back then, <strong>Sandoz Group (SIX Swiss: SDZ)</strong> and its marketing partner RareGen (since merged into Liquidia) accused United Therapeutics of carrying out anticompetitive actions by blocking the launch of a generic version of United’s injectable treprostinil, which first won FDA approval in 2002 and is marketed as Remodulin<sup>®</sup>.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Liquidia also agreed to remove pulmonary hypertension associated with interstitial lung disease (PH-ILD) as an indication from the label of its sole commercial product Yutrepia<sup>®</sup> (treprostinil) inhaled powder and no longer promote the prostacyclin mimetic for PH-ILD to new patients. In doing so, Liquidia opted not to challenge a U.S. District Court for the District of Delaware decision finding the company to have infringed claims 1 and 14 of U.S. Patent No. 11,826,327, which is owned by United. That decision sent Liquidia shares <span><strong>plummeting 57%</strong></span> from $70.69 to $30.26 on September 30.</p>
<p>The settlement allows Liquidia to continue selling Yutrepia for pulmonary arterial hypertension (PAH) while continuing other ongoing development programs for the drug outside of PH-ILD. That includes Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP). The FDA last month granted its Fast Track designation to Yutrepia in SSc-RP, a disease for which no therapy is currently approved by the agency.</p>
<p>Also, the settlement allows Liquidia to continue developing L606 (liposomal treprostinil inhalation suspension), an extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. Liquidia is partnering with Pharmosa Biopharm to develop L606 in PH-ILD as well as PAH.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><strong>“Very favorable outcome” for Liquidia</strong></p>
<p>“We view this as a very favorable outcome for LQDA and broadly in line w/ the base case we previously outlined,” Manoj Eradath, PhD, a senior biotechnology equity researcher with Jefferies, wrote in a research note.</p>
<p>Eradath wrote that investors were concerned about a potential interruption in Yutrepia sales following the decision by District Court Judge Richard G. Andrews, who was appointed in 2011 by President Barack Obama: “The settlement removes that overhang.” Eradath added that the decision also created uncertainty around the PH-ILD development pathway for L606 that is resolved by the settlement.</p>
<p>“Overall, w/ the legal overhang removed, we now view LQDA primarily as a Yutrepia growth story in PAH w/ upside from label expansion + significant pipeline opportunities from L606,” Eradath commented. He raised Jefferies’ 12-month price target on Liquidia stock 22%, from $45 to $55.</p>
<p>Also agreeing that Liquidia won out through the settlement was Serge Belanger, a senior analyst covering the biotechnology sector for Needham & Co.: “The agreement removes legal overhangs around Yutrepia and allows LQDA to build the [drug’s] blockbuster presence in PAH,” Belanger wrote in a research note, as reported by <em>Investor’s Business Daily</em>.</p>
<h4><strong>25% stock surge</strong></h4>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>Investors appeared to side with Belanger and Eradath, as news of the settlement sparked a <span><strong>25% five-day surge</strong></span> in Liquidia’s share price. On Wednesday, the first trading day after the settlement was announced, Liquidia shares <span><strong>soared nearly 27%</strong></span> from $26.81 to $33.94. Shares <span><strong>climbed another 2.5%</strong></span> Thursday, reaching $34.78 before <span><strong>dipping 1% </strong></span>Friday to $34.35.</p>
<p>United Therapeutics shares, in contrast, <span><strong>slipped 0.6%</strong> </span>Wednesday from $543.40 to $540.03, but <span><strong>inched up 0.3%</strong></span> Thursday to $541.51. United’s shares <span><strong>dipped nearly 2%</strong></span> Friday, finishing the week at $533.12 and a <span><strong>3% decline</strong></span> for the week.</p>
<p>Yutrepia finished the first six months of this year with $300.263 million in net product sales, multiples above the $6.517 million reported for January–June 2025. That is because Yutrepia reached the U.S. market on June 2, 2025, following final FDA approval on May 23 of last year.</p>
<p>During a conference call with analysts, Liquidia CEO Roger Jeffs, PhD, and Michael Kaseta, COO and CFO, disclosed that Yutrepia racked up unaudited Q3 net product sales of $222.7 million—a 31% or roughly $52 million leap above second quarter net product sales of $170.382 million, a jump the company attributed primarily to PAH prescriptions. Those sales, according to Liquidia, contributed to the company’s total cash and cash equivalents of $396.1 million as of September 30.</p>
<p>The Liquidia executives said Yutrepia’s sales were split 60/40 between PAH and PH-ILD, with PAH sales trending toward 70%. That trend, Eradath observed, “suggest[s] the commercial impact from removal of PH-ILD may be lower than initially expected.”</p>
<p>By 2028, Liquidia expects Yutrepia to reach blockbuster status with more than $1 billion in annual sales.</p>
<p>Close to blockbuster status is United Therapeutics’ two inhalable forms of treprostinil called Tyvaso<sup>®, </sup>which generated generated a combined $910.1 million in January–June 2026, with Tyvaso DPI the top-seller at $656.9 million<sup>. </sup>The company has marketed an oral inhalation solution of Tyvaso for PAH since initial FDA approval in 2009. The agency approved a nebulizer for the drug in 2017,  an additional indication of PH-ILD in 2021, followed a year later by approval of <span class="iNqyIf" data-sfc-cp="" data-sfc-root="ep" data-epip="">Tyvaso DPI<sup>®</sup><!--TgQPHd|||[]--></span> inhalation powder for PAH and PH-ILD.</p>
<p><strong>“Clearcut win” for United Therapeutics</strong></p>
<p>Two other analysts, however, pegged United Therapeutics as the winner in the litigation with Liquidia. Jessica Fye, a managing director and senior equity research analyst with J.P. Morgan, observed that United stands to gain significant sales as people with PH-ILD shift to its Tyvaso from Liquidia’s Yutrepia.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>
<p>“We see a framework in place that should allow for a substantial proportion of current PH-ILD patients on Yutrepia to transition to Tyvaso, and we think much of this process could occur over the next two quarters (i.e., 4Q and 1Q),” Fye wrote in a research note.</p>
<p>Fye added that the increased sales offer a timely lift to Tyvaso’s sales as United Therapeutics awaits FDA review on a new indication for Tyvason, idiopathic pulmonary fibrosis (IPF). The company has said it expects the FDA to complete its review on the IPF indication in late April.</p>
<p>“We continue to see Tyvaso’s IPF launch making UTHR a stock to own as we see a very large market opportunity in that setting,” Fye concluded, without quantifying that opportunity.</p>
<p>And unlike his colleague Eradath, Jefferies equity analyst Roger Song, MD, declared the settlement a “clearcut win for near-/mid-term” and a “decisive win” for United Therapeutics, since United preserved its exclusivity in treating PH-ILD through treprostinil, and “extracted meaningful economics from LQDA.”</p>
<p>“We view the outcome as a clear win for UTHR: Protecting the PH-ILD franchise and avoiding the delays and uncertainty associated with a multi-year appellate process,” Song wrote in a research note. “Importantly, the settlement should improve visibility into future Tyvaso growth in PH-ILD while allowing investors to refocus on continued PH-ILD/ DPI ramp, emerging IPF/ ralinepag opportunity, and broader pipeline development.”</p>
<p>Ralinepag is a once-daily oral prostacyclin (IP) receptor agonist being developed by United Therapeutics for PAH and under FDA review with a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027.</p>
<h4><strong>$175M due by October 30</strong></h4>
<p>United Therapeutics will see the bulk of the settlement money, starting with $175 million that Liquidia agreed to pay the biotech giant by October 30, though that date can be extended up to six 30-day periods according to a <a href="https://www.liquidia.com/static-files/12a07a5c-31f6-4fef-92f1-82b3d7f61416">regulatory filing</a>. The payment is intended to resolve United’s antitrust litigation against Liquidia tied to treprostinil injection.</p>
<p>Liquidia also agreed to pay United Therapeutics $145.4 million in two equal installments of $72.7 million due on or before January 31, 2027, and April 30, 2027. In addition, Liquidia agreed to shell out another $60.3 million this month to parties with interests in the treprostinil injection antitrust lawsuit, including United and ICU Medical, which acquired cartridge manufacturer Smiths Medical ASD in 2022.</p>
<p>At the same time, Liquidia terminated its promotional agreement tied to treprostinil Injection and will no longer commercially support the product.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="7"></span></aside>
<p>Despite the millions it stands to receive from Liquidia through the settlement, United Therapeutics shied away from declaring outright victory in its statement about the end of litigation—though it sought to offer an explanation for why it challenged Liquidia in court, stating that Liquidia used United’s clinical trial data for Tyvaso in PH-ILD to build its development case for Yutrepia.</p>
<p>“We are grateful that our significant investments in research and development brought nebulized Tyvaso® and Tyvaso DPI® to people living with PH-ILD after previous therapies failed to effectively treat this challenging disease. The U.S. Patent and Trademark Office awarded us a patent for our innovative PH-ILD treatment in November 2023,” United Therapeutics stated. “Liquidia disregarded our patent and the pending patent litigation and began marketing Yutrepia for PH-ILD in 2025, knowing that a ruling like the federal court’s recent decision could require it to remove the PH-ILD indication from its approved product label.”</p>
<p>United Therapeutics also stated that before the September federal district court ruling, it offered Liquidia a settlement that would have kept Yutrepia available for PAH and PH-ILD patients: “Liquidia chose not to accept our proposal and instead let the court proceedings play out.”</p>
<p>The company also cited its history; it was founded in 1996 as LungRx by chairperson and CEO Martine Rothblatt, PhD, with the aim of discovering a cure for her daughter’s PAH: “Our deep connection to patients and families desperate for life-saving treatment drives our longstanding commitment to ensuring that they receive them.”</p>
<h2>Leaders and laggards</h2>
<ul>
<li><strong>Generate: Biomedicines (Nasdaq: GENB) </strong>shares <span><strong>tumbled 11%</strong></span> from $13.84 to $12.26 Wednesday after the artificial intelligence (AI)-based drug developer launched an up-to-$1.265 billion collaboration with <strong>Zealand Pharma (Nasdaq: ZEAL)</strong>. The companies agreed to design and develop multi-specific protein therapeutics for obesity and other metabolic diseases using Generate’s platform, which integrates generative AI with high-throughput experimental validation. The collaboration aims to combine Zealand’s expertise in metabolic health with Generate’s ability to engineer proteins with AI and refine those designs using experimental data toward desired biological functions. Generate agreed to lead research through lead-candidate selection, after which Zealand agreed to oversee subsequent clinical development, regulatory submissions, and worldwide commercialization. Zealand agreed to pay Generate $30 million upfront and up to $35 million in early preclinical milestones for two initial programs (a third may also be developed), plus up to nearly $1.2 billion tied to achieving development, regulatory, and commercial milestones, plus tiered royalties on worldwide net sales of any commercialized products resulting from the collaboration.</li>
</ul>
<ul>
<li><strong>Recursion (Nasdaq: RXRX)</strong> shares<span> <strong>jumped 11%</strong></span> from $3.74 to $4.16 Thursday on two announcements: <strong>Sanofi (Euronext Paris: SAN) </strong>optioned the first development candidate from the companies’ multi-program research collaboration, a dual-targeting inflammatory disease candidate expected to enter Phase I trials in 2027. The decision triggered a $10 million milestone payment to Recursion, bringing to $144 million the total upfront and milestone payments Sanofi has paid the AI-based drug developer since the companies launched their partnership in 2022. Recursion is eligible for $300 million-plus in additional milestones plus double-digit royalties on net sales of approved products. Recursion also priced a $200 million stock offering: 61.54 million shares of its Class A common stock at $3.25 per share. The offering was expected to close on or about Friday. Investors participating in the financing included Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management, and “other prominent healthcare specialists and mutual funds.”</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united-therapeutics/">StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ADC Developmentfrom Concept to Clinic</title>
<link>https://edusehat.com/en/adc-developmentfrom-concept-to-clinic</link>
<guid>https://edusehat.com/en/adc-developmentfrom-concept-to-clinic</guid>
<description><![CDATA[ This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics.
The post ADC Developmentfrom Concept to Clinic appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Cover-Image_ADCs-8-x-11-scaled-e1792182648204.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 05:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ADC, Developmentfrom, Concept, Clinic</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>


<figure class="wp-block-image alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg" alt="Eurofins eBook Cover" class="wp-image-339513" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Eurofins_eBookCover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery while minimizing off-target effects. Their potential in areas such as targeted cancer cell killing and targeted protein degradation has fueled significant growth, resulting in numerous FDA approvals and more than 100 ADCs currently in clinical development. However, ADC development remains complex and highly empirical, requiring careful optimization of linker chemistry, payload selection, bioconjugation strategies, drug-to-antibody ratio (DAR), stability, and overall antibody integrity.</p>


<p class="wp-block-paragraph">The ADC journey begins with linker-payload synthesis and bioconjugation. Eurofins Discovery offers extensive expertise in the design and synthesis of linker technologies, including protease-sensitive, glycosidase-sensitive, pH-sensitive, PEGylated, branched, and shielding linkers. Payloads are manufactured in specialized high-containment facilities to ensure the safe handling of highly potent compounds. Multiple conjugation options are available, providing flexibility to explore different designs and generate ADCs with customized pharmacokinetic profiles, improved stability, and controlled DAR distributions.</p>


<p class="wp-block-paragraph">Once conjugation is complete, ADCs undergo purification using a range of chromatography techniques. These methods remove unconjugated antibodies, excess linker-payload materials, and aggregates to produce highly pure ADC preparations. This is essential for more reliable downstream analyses and ensures more accurate assessment of ADC performance.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>


<p class="wp-block-paragraph">DAR analysis is then conducted using high-resolution liquid chromatography-mass spectrometry (LC-MS). This approach confirms linker-payload incorporation, identifies individual DAR species, and provides detailed insights into ADC homogeneity. Such information is critical for optimizing product consistency, efficacy, safety, and manufacturability.</p>


<p class="wp-block-paragraph">Finally, a comprehensive suite of biochemical, functional, and cytotoxicity assays is essential to characterize ADC candidates. Data-driven assessment of binding, biological function, and therapeutic potential, through both <em>in vitro</em> and <em>in vivo</em> studies, helps identify the most promising candidates for further advancement and development.</p>


<p class="wp-block-paragraph">Eurofins Discovery provides a fully integrated ADC development platform spanning every stage of the workflow, from linker-payload design through analytical characterization and functional assessment. By leveraging deep expertise in chemistry, biochemistry, and antibody optimization and characterization, Eurofins Discovery scientists help mitigate development risks and shorten timelines while optimizing ADC safety, efficacy, and manufacturability.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/adc-developmentfrom-concept-to-clinic/">ADC Developmentfrom Concept to Clinic</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science</title>
<link>https://edusehat.com/en/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science</link>
<guid>https://edusehat.com/en/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science</guid>
<description><![CDATA[ Danaher and Nvidia are collaborating to advance autonomous science, combining lab instrumentation, automation, and software with accelerated computing and AI so that experiments inform models and models help design better experiments.
The post Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/Sampled_AdobeStock_1313726087_Charoen.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 05:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Danaher, Nvidia, Combine, Lab, Instrumentation, and, Advance, Autonomous, Science</media:keywords>
<content:encoded><![CDATA[<p><span>Recently, Danaher announced a collaboration with Nvidia that the company says is aimed at advancing autonomous science to support new discoveries. The company described the partnership as part of broader efforts to help shape the future artificial intelligence-enabled science. </span></p>
<p><span>Under the terms of the agreement, the companies are working to combine Danaher’s scientific instrumentation, automation technologies, laboratory workflow software, and domain expertise with Nvidia’s accelerated computing and AI technologies. According to the company, the combined tools will help scientists move faster from prediction to experimental evidence by creating a learning cycle where experiments inform models and models help design better experiments.</span></p>
<p><span>Currently, Danaher and Nvidia are working to integrate AI into scientific instruments through edge computing like NVIDIA DGX Spark, accelerated analytics and data processing with RAPIDS, as well as real-time inference, scientific reasoning and foundation model technologies, including BioNeMo Open Models. Initial efforts are focused on a select group of priority instruments, with the potential to expand across a broader portfolio over time. </span></p>
<p><span>“We are collaborating around a shared vision for more connected, adaptive and accessible innovation, helping researchers solve consequential challenges and translate discovery into human impact,” said Julie Sawyer Montgomery, Danaher’s president and CEO. </span></p>
<p><span>In her comments, Kimberly Powell, vice president of healthcare at Nvidia noted that the partnership is “bringing accelerated computing and physical AI into the lab— connecting models with instruments and real experimental data, where experiments improve models and models design better experiments, helping researchers compress years of discovery into months.” </span></p>
<p><span>Earlier this month, Danaher announced plans to launch its first AI-powered autonomous lab, which is designed to help scientists develop custom antibodies and other molecular tools faster and more efficiently. The company said at the time that the planned lab will combine AI, robotics, and technologies from several Danaher operating companies in one connected workflow. Danaher also said at the time that the lab is part of a broader internal program to build a fleet of smart instruments that among other things are easy to integrate and control programmatically and include agentic systems designed to simplify operations, improve data quality, and generate deeper insights. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science/">Danaher, Nvidia Combine Lab Instrumentation and AI to Advance Autonomous Science</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ASHG 2026 Awards Honor Achievements in Research, Education, and More</title>
<link>https://edusehat.com/en/ashg-2026-awards-honor-achievements-in-research-education-and-more</link>
<guid>https://edusehat.com/en/ashg-2026-awards-honor-achievements-in-research-education-and-more</guid>
<description><![CDATA[ ASHG will honor seven recipients with its 2026 Professional Awards, recognizing outstanding contributions to human genetics and genomics research, education, mentorship, and public service at ceremonies this week.
The post ASHG 2026 Awards Honor Achievements in Research, Education, and More appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2235551856.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 01:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ASHG, 2026, Awards, Honor, Achievements, Research, Education, and, More</media:keywords>
<content:encoded><![CDATA[<p>One of the highlights of the annual American Society of Human Genetics (ASHG) meeting are the awards. Indeed, last year, Julianna LeMieux, PhD, <em>GEN</em>‘s Deputy Editor in Chief, covered the <a href="https://www.genengnews.com/topics/omics/eric-green-receives-ashg-leadership-award-to-standing-ovation/" target="_blank" rel="noopener">award ceremony and acceptance speech</a> by Eric Green, MD, PhD, for the Leadership Award, that brought the house down.</p>
<p>This year, ASHG is pleased to recognize seven recipients of its 2026 Professional Awards for their outstanding achievements in human genetics and genomics research, education, mentorship, and public service. Award winners will be recognized during ceremonies at the meeting later this week.</p>
<p>“ASHG is honored to recognize this exceptional group of awardees, whose work demonstrates the many ways human genetics and genomics can advance science and serve society,” said Susan A. Slaugenhaupt, PhD, ASHG President. “Each honoree has helped shape a stronger, more collaborative, and more impactful field. Their achievements inspire our community and reflect the promise of genetics to improve lives around the world.”</p>
<p><strong>ASHG Lifetime Achievement Award</strong></p>
<p>Yusuke Nakamura, MD, PhD: The ASHG Lifetime Achievement Award recognizes substantial and far-reaching scientific contributions to human genetics. Nakamura is the President of the National Institutes of Biomedical Innovation, Health and Nutrition in Japan. His career reflects the extraordinary power of sustained scientific inquiry to transform a field. From pioneering highly polymorphic Variable Number Tandem Repeat (VNTR) markers that helped launch the positional cloning era, to identifying disease genes and illuminating the genetic foundations of cancer, Nakamura has repeatedly expanded what is possible in human genetics, immunogenomics, and genomics research. His landmark contributions to <em>APC</em> and colorectal cancer genetics helped shape modern molecular oncology, while his work on inherited disorders and complex traits broadened understanding of how genetic variation influences human health. Through leadership in the International HapMap Project, early genome-wide association studies, and the creation of BioBank Japan, he helped build the global infrastructure for precision medicine. As a scientist, mentor, and visionary leader, Nakamura’s legacy continues to inspire discovery and improve human health worldwide.</p>
<p><strong>ASHG Leadership Award</strong></p>
<p>Aravinda Chakravarti, PhD: The ASHG Leadership Award recognizes leadership and vision in advancing the ASHG mission through promotion of genetics and genomics knowledge into the broader scientific community. Chakravarti is the Director of the Center for Human Genetics and Genomics, Professor of Medicine, and the Muriel G. & George W. Singer Professor of Neuroscience at the New York University Grossman School of Medicine in New York. Chakravarti has profoundly shaped modern human genetics through foundational contributions to population genetics, statistical genetics, linkage disequilibrium mapping, and the study of complex disease. His work helped identify the genetic mutation involved in cystic fibrosis, advanced understanding of Hirschsprung disease as a model for complex disease, and demonstrated the importance of non-coding genetic variation in human disorders. As a former ASHG president, founding editor of leading genomics publications, and leader in major international initiatives including the Human Genome Project, HapMap, and 1000 Genomes Project, Chakravarti has helped build the knowledge, methods, and collaborations that continue to move genetics and genomics forward.</p>
<p><strong>ASHG Scientific Achievement Award</strong></p>
<p>Wendy Chung, MD, PhD: The ASHG Scientific Achievement Award recognizes remarkable contributions to human genetics and genomics research over the last decade. Chung is Chief of Pediatrics at Boston Children’s Hospital and the Mary Ellen Avery Professor of Pediatrics at Harvard Medical School in Boston. An internationally recognized leader in genomic medicine, she has made discoveries that span congenital anomalies, autism and other neurodevelopmental disorders, cardiopulmonary conditions, metabolic disease, obesity, diabetes, and rare Mendelian disorders. She has helped identify more than 60 new genes for human disease and has led major collaborative efforts that bring together clinicians, researchers, patients, and families to answer urgent scientific and clinical questions. Her work has moved gene discovery from the laboratory into clinical care, shaping genetic diagnosis, population-based screening, newborn sequencing, and emerging therapeutic approaches. Through scientific breadth, translational vision, and patient-centered leadership, Chung has profoundly advanced the field of human genetics.</p>
<p><strong>ASHG Early Career Award</strong></p>
<p>Rebecca Ahrens-Nicklas, MD, PhD: The ASHG Early Career Award recognizes early career independent investigators whose work has had a significant impact on the field of human genetics. Ahrens-Nicklas is an Associate Professor of Pediatrics in the Division of Human Genetics and Metabolism at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania and directs the Gene Therapy for Inherited Metabolic Diseases Program at CHOP in Philadelphia. She is leading a new era of precision medicine, advancing a future where a rare disease diagnosis could lead to a treatment path. Her work to develop and deliver the world’s first personalized <em>in vivo</em> CRISPR therapy for an infant with a severe, ultra-rare disease demonstrated the power of collaboration and the extraordinary potential of individualized genetic medicines. Today, she continues to develop custom therapies for patients with rare diseases, redefining what precision genomic medicine can achieve.</p>
<p><strong>ASHG Advocacy Award</strong></p>
<p>Roxanne Khamsi: The ASHG Advocacy Award honors excellence and achievement in promoting the science of human genetics and its application to the common good. Roxanne Khamsi is a contributing writer at <em>The Atlantic.</em> She has spent more than two decades illuminating the intersection of genetics, medicine, and human experience as a reporter, editor, and science journalist whose work has appeared in <em>WIRED</em> magazine, <em>Scientific American</em>, and <em>The New York Times</em>. She brings clarity, curiosity, and compassion to some of the most complex stories in science, including the diagnosis and treatment odyssey for patients with rare diseases, breaking stories on the genetic mechanisms of COVID, and challenging outdated classifications and models in medical genetics. Her new book, <em>Beyond Inheritance</em>, challenges reductive views of genetic mutations as purely harmful. With the rigor of a journalist and the humanity of a storyteller, she makes science accessible without flattening its nuance.</p>
<p><strong>ASHG Education Award</strong></p>
<p>Robbee Wedow, PhD: The ASHG Education Award recognizes outstanding contributions to human genetics education. Wedow is an Assistant Professor of Sociology and Data Science at Purdue University in West Lafayette, Ind. He is recognized for helping students see genetics—and one another—with greater clarity, curiosity, and care. As co-investigator and instructor of the <a href="https://www.wedowlab.com/humane-genetics-curriculum-hgc" target="_blank" rel="noopener">Humane Genetics Curriculum</a> (HGC), he has shaped a powerful learning experience that helps students understand human genetic variation, the complex roots of human traits, and the difference between what genetic evidence can—and cannot—support. Together with Brian Donovan, PhD, the developer of HGC, they have reached thousands of students in hundreds of classrooms nationwide, from middle school through undergraduate education. HGC gives educators a practical, scientifically precise framework for discussing race, ancestry, and genetics in today’s world. Grounded in discussion, critical inquiry, and mutual respect, Wedow’s teaching has prepared future leaders in his classrooms in medicine, law, public policy, and beyond to use genetics knowledge with both scientific rigor and social responsibility.</p>
<p><strong>ASHG Mentorship Award</strong></p>
<p>Nancy B. Spinner, PhD: The ASHG Mentorship Award recognizes ASHG members who have shown a sustained pattern of exemplary mentorship at the graduate student, postdoctoral, residency, or fellowship level. Spinner recently joined Northwell Health in New York as Associate Chair of Genomic Strategy and Faculty Development in the Department of Pathology. Her move to Northwell follows a 35-year career at the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania in Philadelphia where she is now Emeritus Professor of Pathology. She has built a career defined not only by scientific excellence, but by the people she has helped succeed. Spinner was often ahead of the trends in her approach to mentorship, educating her trainees in translational science, and pairing rigorous training with thoughtful, individualized career development. She has trained more than 23 laboratory directors and scientists, all still active in the field, along with fellows, graduate students, undergraduates, and high school students, many of whom have advanced to faculty roles. Through association mentorship programs, service on committees, lectures, and career panels, Spinner creates the kind of collegial, generous environment where people stay, grow, and lead. Her gift is seeing each mentee clearly—and guiding them toward work aligned with their talents, accomplishments, and long-term best interests.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ashg-2026-awards-honor-achievements-in-research-education-and-more/">ASHG 2026 Awards Honor Achievements in Research, Education, and More</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exposure to Common Endocrine&#45;Disrupting Chemicals May Alter Normal Breast Development</title>
<link>https://edusehat.com/en/exposure-to-common-endocrine-disrupting-chemicals-may-alter-normal-breast-development</link>
<guid>https://edusehat.com/en/exposure-to-common-endocrine-disrupting-chemicals-may-alter-normal-breast-development</guid>
<description><![CDATA[ A study in human breast organoids has found that exposure to some common endocrine-disrupting chemicals may lead to molecular changes in breast tissue that could influence susceptibility to breast cancer later in life. 
The post Exposure to Common Endocrine-Disrupting Chemicals May Alter Normal Breast Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_261012_organoid.jpg.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 01:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exposure, Common, Endocrine-Disrupting, Chemicals, May, Alter, Normal, Breast, Development</media:keywords>
<content:encoded><![CDATA[<p>The results of a preclinical study by researchers at Tufts University School of Medicine and at Boston University suggest that exposure to some common chemicals—particularly multiple bisphenols at once—may alter how normal human breast tissue develops. Findings from the study using human breast organoids suggest that such exposures may lead to molecular changes in breast tissue that could influence susceptibility to breast disease later in life.</p>
<p>The results lay the groundwork for scientists to investigate whether these molecular changes persist in human tissues, contribute to disease later in life, and could yield biomarkers to help assess breast cancer risk. “If these results are validated by additional studies, they could change how we think about cancer prevention,” said Charlotte Kuperwasser, PhD, a professor of developmental, molecular, and chemical biology at Tufts University School of Medicine. Kuperwasser is senior corresponding author of the team’s published paper in <em>PNAS</em>, titled “<a href="http://dx.doi.org/10.1073/pnas.2613054123" target="_blank" rel="noopener">Environmental chemical mixtures reprogram mammary epithelial development to epigenetic states associated with breast cancer</a>.” The study’s co-first authors are Meadow Parrish and Meloryn Seraj, both PhD students in genetics, molecular, and cellular biology at Tufts Graduate School of Biomedical Sciences.</p>
<p>A growing body of research has raised questions about whether exposure to endocrine-disrupting chemicals—substances that can interfere with the body’s hormones—may contribute to breast cancer risk. “Endocrine-disrupting chemicals (EDCs) are pervasive contaminants in air, water, food, and consumer products, and human exposure to these agents begins in utero and continues throughout life,” the authors wrote. “A growing body of epidemiologic and experimental evidence suggests that developmental exposure to EDCs may contribute to the rising incidence of hormone-sensitive cancers, including breast cancer, in young women.” However, much of what scientists know about how chemicals affect breast tissue comes from animal models or laboratory-grown cells that cannot fully reproduce the complexity of human tissue.</p>
<p>“The breast also is unusual in that it undergoes major developmental changes well after birth, including during puberty and pregnancy,” said Kuperwasser. “And the concern is that breast tissue cells may be highly sensitive to environmental cues, such as chemical exposure, during critical windows of mammary gland development.”</p>
<p>To better capture this complexity, the researchers used three-dimensional breast organoids, grown from breast tissue donated by 13 healthy young women. The organoids contain multiple types of breast cells and can reproduce some aspects of how human breast tissue actually develops.</p>
<p>As the organoids developed over about three weeks, the researchers exposed them to a panel of individual chemicals and mixtures, including endocrine-disrupting chemicals, chemicals that affect metabolism, and known or suspected carcinogens. They then analyzed molecular changes, including changes in gene activity and DNA modifications. “… we developed an AI-assisted 3D human breast organoid high-content screening (3D-HCS) platform capable of quantitatively measuring developmental disruption and morphogenetic alterations across organoids exposed to chemicals,” they explained.</p>
<p>The results indicated that different chemicals affected tissue development in different ways, but the most striking finding involved three common bisphenols: BPA, BPS, and BPF. Individually, the chemicals produced relatively few changes in the organoids. But when combined at very low concentrations—comparable to levels detected in human blood and urine—the mixture of BPA, PBS and BPF disrupted normal breast development in organoids from most of the donors.</p>
<p>“Focusing on bisphenols, we show that a low-dose mixture (BPA, BPS, and BPF; 3BPX) disrupts organoid development and induces transcriptional programs characterized by extracellular matrix remodeling, epithelial plasticity, and partial epithelial–mesenchymal transition, accompanied by widespread DNA methylation remodeling.”</p>
<p>Kuperwasser added, “We intentionally used concentrations of chemicals that were relevant to real-world exposure rather than the very high doses sometimes used in toxicology studies. We also tested a mixture of these because people are typically exposed to multiple chemicals at the same time.”</p>
<p>The team then compared the molecular changes associated with the bisphenol mixture with molecular data from human breast cancers. The exposure-associated pattern was most strongly represented in data from patients with invasive lobular carcinoma—a type of breast cancer that may not cause a detectable lump and can be difficult to detect with a mammogram. “We identify conserved, exposure-induced transcriptional signatures as well as DNA methylation fingerprints that mirror patterns detectable in human breast cancers, suggesting that developmental exposures may leave durable molecular fingerprints that create cancer-relevant tissue states,” they concluded.</p>
<p>The finding does not establish that the chemicals cause cancer or show how the observed molecular changes might contribute to breast disease. Instead, the researchers say the work demonstrates a new way to study how environmental exposures may affect normal human tissue before cancer develops.</p>
<p>“Historically, we have thought about cancer risk largely in terms of inherited mutations, lifestyle factors, and exposures that directly damage DNA,” said Kuperwasser. “These findings raise another possibility: Environmental exposures may subtly alter how normal tissues develop, leaving behind molecular changes that do not cause cancer by themselves but may make the tissue more permissive to cancer many years later.”</p>
<p>She noted that such persistent molecular changes could eventually serve as a kind of biological record—like a “scar” of past exposure. If validated in people, such a marker could potentially help identify individuals at higher risk and inform earlier or more targeted screening.</p>
<p>Future studies involving larger and more diverse groups of donors, as well as a broader range of chemicals and mixtures, are needed to determine how widely the findings apply and if molecular changes observed in organoids are associated with breast disease in people.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/exposure-to-common-endocrine-disrupting-chemicals-may-alter-normal-breast-development/">Exposure to Common Endocrine-Disrupting Chemicals May Alter Normal Breast Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Designing the Ecosystem for CGT Success</title>
<link>https://edusehat.com/en/designing-the-ecosystem-for-cgt-success</link>
<guid>https://edusehat.com/en/designing-the-ecosystem-for-cgt-success</guid>
<description><![CDATA[ This proceedings eBook, developed in partnership with GEN and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures perspectives and lessons from The Cell Summit ’26 and extends the conversation beyond the meeting itself.
The post Designing the Ecosystem for CGT Success appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/BioLife-Cover-Art.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 17 Oct 2026 01:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Designing, the, Ecosystem, for, CGT, Success</media:keywords>
<content:encoded><![CDATA[<div aria-hidden="true" class="wp-block-spacer"></div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>


<h3 class="wp-block-heading"><strong>Preserving the Promise: Insights from The Cell Summit ’26</strong></h3>


<p class="wp-block-paragraph">In July 2026, BioLife Solutions welcomed leaders from across the cell and gene therapy (CGT) space to Cincinnati, Ohio for the second annual Cell Summit. Once again, our goal was simple: bring together people with different perspectives, from across the CGT ecosystem, to create an environment where we could speak openly about the challenges standing between scientific innovation and successful patient treatment. </p>


<p class="wp-block-paragraph">Cell and gene therapy has already demonstrated what is scientifically possible. CAR T therapies, gene therapies, and other advanced medicines have delivered outcomes that would have been unimaginable only a generation ago. </p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>


<h4 class="wp-block-heading"><strong>The next challenge is scale.</strong> </h4>


<figure class="wp-block-image alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-232x300.jpg" alt="BioLife October 2026 eBook Cover" class="wp-image-339381" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_Biolife_Cover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">Mature healthcare industries demonstrate what coordinated scale can look like. Vaccines can be manufactured and distributed globally at enormous volumes. Insulin is produced continuously and reliably for millions of patients. These industries did not reach that scale through manufacturing capacity alone. They developed interconnected systems of production, supply, distribution, clinical delivery, reimbursement, infrastructure, standards, and oversight that work together repeatedly and predictably. </p>


<h4 class="wp-block-heading"><strong>CGT is still building that system.</strong></h4>


<p class="wp-block-paragraph">As Steven Thompson challenged attendees with his welcome address at The Cell Summit, the question is no longer simply whether these therapies can work. The question is whether the industry can build a system that reliably converts scientific proof into patient access, delivered doses, durable outcomes, and ultimately a sustainable commercial model. </p>


<p class="wp-block-paragraph">That question became the foundation for the conversations that followed. </p>


<p class="wp-block-paragraph">Scientists, therapy developers, clinicians, treatment centers, technology providers, manufacturing experts, and other industry leaders examined the CGT pathway from multiple angles. On the second day of the meeting, eight roundtable groups explored real-world challenges spanning scale-up, scale-out, logistics, manufacturing readiness, CDMO partnerships, commercialization strategy, rare disease reimbursement, and public perception. </p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>


<p class="wp-block-paragraph">Although each group approached their problems from different perspectives, the discussion repeatedly arrived at the same conclusion: scale is an operating system, not a single workstream. </p>


<p class="wp-block-paragraph">Manufacturing, reimbursement, care delivery, logistics, partnerships, data, governance, evidence, and trust are interdependent. An eligible patient must be identified and referred. A product must be collected or manufactured. A dose must reach the treatment center at the right time and in the right condition. The patient must be able to receive treatment. The therapy must deliver the intended outcome. And the economics must support doing it again for the next patient. </p>


<h4 class="wp-block-heading"><strong>If one link breaks, patients wait and the commercial model weakens.</strong> </h4>


<p class="wp-block-paragraph">A manufacturer may successfully release a product, but if the treatment center is not ready, the patient still waits. A treatment center may be prepared, but if reimbursement is unresolved, treatment may not proceed. A therapy may demonstrate remarkable clinical benefit, but if manufacturing, logistics, infrastructure, or economics cannot support repeatable delivery, that scientific success will struggle to reach its full potential. </p>


<p class="wp-block-paragraph">The opposite is equally true. </p>


<h4 class="wp-block-heading"><strong>When the links connect, more appropriate patients can receive treatment, delivery becomes more predictable, resources are used more efficiently, and the commercial model becomes sustainable.</strong> </h4>


<p class="wp-block-paragraph">This is the opportunity in front of CGT: not simply to optimize each individual function, but to design the interfaces between them. </p>


<p class="wp-block-paragraph">This proceedings eBook, developed in partnership with GEN (Genetic Engineering & Biotechnology News) and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures perspectives and lessons from The Cell Summit ’26 and extends the conversation beyond the meeting itself. It brings together scientific, clinical, manufacturing, and operational viewpoints around a common question: What must be true for CGT to move from scientific possibility to repeatable, sustainable delivery? </p>


<p class="wp-block-paragraph">The first Cell Summit (in 2025) asked how we could work together to improve the development and delivery of cell therapies. This year reinforced that collaboration is not simply beneficial to CGT advancement; it is fundamental to it. </p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="6"></span></aside>


<h4 class="wp-block-heading"><em><strong>A therapy is not successful when it leaves the manufacturing site. It is successful when it reaches and helps the patient, as intended.</strong> </em></h4>


<p class="wp-block-paragraph">We hope these proceedings encourage continued discussion, challenge conventional thinking, and help our community design the CGT ecosystem as deliberately as we design the therapies themselves. </p>


<p class="wp-block-paragraph">Thank you to our speakers, roundtable leads, attendees, and partners who shared their expertise, challenged assumptions, and made The Cell Summit ’26 possible. </p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/designing-the-ecosystem-for-cgt-success/">Designing the Ecosystem for CGT Success</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Floridians and health advocates rally to oppose school, daycare vaccine changes</title>
<link>https://edusehat.com/en/floridians-and-health-advocates-rally-to-oppose-school-daycare-vaccine-changes</link>
<guid>https://edusehat.com/en/floridians-and-health-advocates-rally-to-oppose-school-daycare-vaccine-changes</guid>
<description><![CDATA[ BIO voices concerns in statement for hearing about potential rule change. Reducing the number of vaccines required for school children risks the spread of […]
The post Floridians and health advocates rally to oppose school, daycare vaccine changes appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/mother-at-fla-hearing-sharpen.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 21:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Floridians, and, health, advocates, rally, oppose, school, daycare, vaccine, changes</media:keywords>
<content:encoded><![CDATA[<h4>BIO voices concerns in statement for hearing about potential rule change.</h4>
<p><span>Reducing the number of vaccines required for school children risks the spread of dangerous, preventable diseases, concerned Floridians and public health advocates told a Florida Department of Health (FDOH) panel hearing on Oct. 8.</span></p>
<p><span>The </span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"><span>hearing</span></a><span> allowed public input into FDOH’s proposed rule change to eliminate requirements for four of the current 11 vaccines students need to enter public schools and daycare.</span></p>
<p><span>The new rule would mean the hepatitis B, varicella (chickenpox), haemophilus influenzae type b (Hib), and pneumococcal conjugate vaccines would no longer be required for students entering public school or child care programs,</span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"> <span>FDOH explains.</span></a><span> Immunization for polio, diphtheria, measles, rubella, pertussis, mumps, and tetanus would still be required.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) provided written comments to the hearing urging FDOH to maintain its current vaccine requirements.</span></p>
<p><span>“We are deeply concerned that the proposed changes, if enacted, will decrease immunization coverage in Florida and leave many vulnerable to preventable infectious diseases,” BIO wrote. “Vaccination requirements have been instrumental in reducing, and in some cases eliminating deadly diseases. Removing these requirements would reverse decades of scientific and public health progress without evidence-based justification.”</span></p>
<p><span>While the hearing featured many speakers against the proposal and many in favor of it, the overall majority of Floridians oppose the proposed rule and want to keep vaccine requirements as they are,</span><a href="https://www.flfamiliesforvaccines.org/polling"> <span>according to a poll commissioned by Florida Families for Vaccines</span></a><span>. Of the 1,000 likely voters polled by McLaughlin & Associates, 79%—including 71% of registered Republicans—support Florida’s long-standing school entry vaccine requirements.</span></p>
<h2>What they said at the hearing</h2>
<p><span>Speakers who urged against changing the vaccine schedule represented a wide range of viewpoints.</span></p>
<p><span>Evelyn, a 7-year-old cancer survivor, described the importance of her classmates being vaccinated.</span></p>
<p><span>“The chemo broke my immune system. I had to stay away from sick people because their germs could hurt me really bad. I was so happy to go back to school. I missed my friends,” Evelyn said. “Mommy and Daddy knew I would be safe because everybody got their vaccine shots when I couldn’t.”</span></p>
<p><span>Evelyn’s father, Kyle Huneycutt, said his daughter’s diagnosis changed how his family saw the world. “The health of the community around your child matters in a way you may have never considered before,” he explained.</span></p>
<p><span>The patient’s family view was also represented by Donielle Deitz, a caregiver and a volunteer for the American Cancer Society’s Cancer Action Network (ACS CAN), who urged maintaining “evidence-based school immunization requirements.”</span></p>
<p><span>“Childhood vaccines protect people with cancer,” she said, noting that the hepatitis B vaccine FDOH would remove from the requirements “is a powerful cancer prevention tool” against liver cancer.</span></p>
<p><span>Medical professionals also spoke of the risks of changing the vaccination schedule, which may give the impression that some vaccines are less important.</span></p>
<p><span>Angela Moore, a registered nurse, said she had witnessed what can happen when families decide against protecting their children.</span></p>
<p><span>“We have seen children whose parents have denied them safe and effective vaccines be afflicted by diseases that my generation and the generation before me had the luxury of protection from, due to herd immunity,” she said.</span></p>
<p><span>Donald Neel, MD, a pediatrician, recalled the times before the four vaccines were available. “I spent many hours of my life and parents’ lives, holding their hands and praying for their child, who was critically ill with either pneumococcal pneumonia or the various types of meningitis,” he said.</span></p>
<p><span>Many speakers represented the parents’ perspective in opposing the proposed rule.</span></p>
<p><span>“We want to send our children to schools and daycare and not have to worry about preventable diseases,” said Cass Miller of</span><a href="https://www.flfamiliesforvaccines.org/"> <span>Florida Families for Vaccines</span></a><span>. “For families, an outbreak is not just a statistic; it means missing childcare, a parent missing work, or staying away from grandparents because someone has been exposed.”</span></p>
<p><span>Shelly Pedraza, President Elect of</span><a href="https://www.floridapta.org/"> <span>the Florida PTA</span></a><span>, which includes about 200,000 parents, said “Florida PTA opposes the removal of these vaccine requirements,” because parents are concerned about the health risks.</span></p>
<p><span>Those representing teachers said they and their families would be put at risk if vaccination rates drop at their workplace.</span></p>
<p><span>Giving the business perspective, Karen van Caulil, president and CEO of the</span><a href="https://flhealthvalue.org/"> <span>Florida Alliance for Healthcare Value</span></a><span>, noted that employers pay for many health insurance plans, and also suffer when parents are absent for child care.</span></p>
<p><span>“When preventable illness leads to additional doctor visits, emergency care or hospitalization, those costs are felt by families and employers alike,” she said. “That is why employers have a direct and practical interest in policies that help keep children and communities healthy.”</span></p>
<h2>The ‘parents rights’ argument</h2>
<p><span>Those speaking in favor of the rule mostly spoke of the right for parents to make their own decisions, vaccine-related injuries (which occur rarely but are eligible to submit federal remuneration through the Vaccine Injury Compensation Program (VICP)), and unscientific theories on vaccine safety.</span></p>
<p><span>Florida Surgeon General Joseph Ladapo, MD, who has championed the rule change and led the hearing, stressed that there were no questions about the safety and effectiveness of the four vaccines that his new rule would eliminate. Ladapo repeatedly explained that the only reason for the rule change was to increase parents’ right to choose for their children.</span></p>
<p><span>BIO and others noted that Florida already allows for religious and medical exemptions to school vaccine requirements.</span></p>
<p><span>“Current standards ensure that individual choice is protected while maintaining the greatest access to vaccines for those who wish to take them,” said BIO’s letter. “Further loosening the requirements does not impact an individual’s right to choose vaccination or not, it jeopardizes broader immunity levels and increases the likelihood of outbreaks.”</span></p>
<p><span>Ladapo also said other states do not require school children to have some of the vaccines that Florida would cancel. But no state excludes all four vaccines.</span></p>
<p><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hepb-child-school-2026/"><span>Every state except for Alabama</span></a><span> requires hepatitis B vaccines, and</span><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hib-childcare-2026/"> <span>West Virginia is the only state</span></a><span> that doesn’t mandate a Hib vaccine, according to</span><a href="https://www.immunize.org/"> <span>immunize.org</span></a><span>. Seven states do not require a</span><a href="https://www.immunize.org/wp-content/uploads/laws/pcv-cc-rqt-map-2026.pdf"> <span>pneumococcal vaccine</span></a><span>.</span></p>
<p><span>As of now, all states require children entering public school and daycare to have the chickenpox vaccine, which also helps protect against meningitis, and</span><a href="https://www.epicresearch.org/articles/first-birth-cohort-eligible-for-chickenpox-vaccine-had-a-sharp-drop-in-shingles-cases/"> <span>according to a new study</span></a><span>, prevents later episodes of shingles.</span></p>
<p><i><span>FDOH is accepting comments on the rule proposal by email at </span></i><a href="mailto:vaccinerule@flhealth.gov"><i><span>vaccinerule@flhealth.gov</span></i></a><i><span> until 5 pm on Oct. 19.</span></i></p>
<p>The post <a href="https://bio.news/state-policy/floridians-health-care-advocates-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements/">Floridians and health advocates rally to oppose school, daycare vaccine changes</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tigerlily Foundation joining conversation at PACE</title>
<link>https://edusehat.com/en/tigerlily-foundation-joining-conversation-at-pace</link>
<guid>https://edusehat.com/en/tigerlily-foundation-joining-conversation-at-pace</guid>
<description><![CDATA[ The Tigerlily Foundation was born from a promise made in a moment of profound vulnerability.  In 2006, Maimah Karmo was a 32-year-old mother to […]
The post Tigerlily Foundation joining conversation at PACE appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/angiola-harry-SJCalEw-1LM-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tigerlily, Foundation, joining, conversation, PACE</media:keywords>
<content:encoded><![CDATA[<p><span>The </span><a href="https://tigerlilyfoundation.org/"><span>Tigerlily Foundation</span></a><span> was born from a promise made in a moment of profound vulnerability. </span></p>
<p><span>In 2006, Maimah Karmo was a 32-year-old mother to an infant daughter, Noelle, when she was diagnosed with an aggressive form of breast cancer. While undergoing chemotherapy, she made a promise: if she survived, she would create a world where no young woman would face that journey alone. </span></p>
<p><span>This year marks Tigerlily’s 20th anniversary. </span></p>
<p><span>While their legacy and heart remain in breast cancer, their scope now addresses broader health disparities. Tigerlily now focuses on women’s health and oncology. The impact of this evolution is tangible. </span></p>
<p><span>Over the past 19 years, their network of ANGEL Advocates has expanded to all 50 states and across three continents, training hundreds of women in advocacy, clinical trial literacy, and policy. In the past two years alone, they’ve reached more than 7 million Black and Brown patients nationwide, ensuring their voices and lived experiences are not afterthoughts but central to how we define and achieve equitable care. </span></p>
<p><span>In the lead up to the Biotechnology Innovation Organization’s (BIO) </span><a href="https://pace.bio.org/"><span>Patient Advocacy Changemakers Event (PACE)</span></a><span>, taking place on October 22–23, Bio.News sat down with Maimah Karmo to talk about Tigerlily’s work. Karmo will participate in PACE’s panel, </span><a href="https://pace.bio.org/program"><span>In the Wrong Ballpark: Why PDABs Don’t Work</span></a><span> on Oct. 22.</span></p>
<h3>Bio.News: Patient access to treatments is deeply personal to the organization. How does this translate into your work?</h3>
<p><span>For Tigerlily, access isn’t an abstract policy concept; it’s the difference between life and death, and it is deeply personal. When I was diagnosed, I was dismissed multiple times because of my age. I had to fight to get a mammogram, fight to get a biopsy, and fight to be taken seriously. That experience shaped everything we do. Our work, from the exam room to Capitol Hill, is informed by patients and designed for patients.</span></p>
<p><span>We believe that true access is about more than just a price tag. As I often say, what is the point of a drug that I can afford financially if I can’t even get it in the first place? Our policy work, therefore, is dedicated to redefining “affordability” to include timely access. Through our HEAL Policy Center of Excellence, we equip patients with the tools to speak directly to power. Whether it’s fighting for coverage of biomarker testing or ensuring insurance doesn’t delay care through prior authorization or step therapy, our goal is to remove the barriers that stand between a patient and their prescribed treatment.</span></p>
<h3>Bio.News: Tigerlily has been a champion for patient access in state legislatures. <a href="https://bio.news/latest-news/patient-groups-praise-virginia-pdab-veto/">Your work in Virginia</a> was highlighted in Bio.News earlier this year. Can you tell us more about the impact you have had across the country this year?</h3>
<p><span>Our work on Prescription Drug Affordability Boards (PDABs) is a perfect example of how we translate patient concern into policy advocacy. We’ve been deeply engaged in states across the country on this issue because PDABs are often sold as a silver bullet for high drug costs, but the reality for patients is far different.</span></p>
<p><span>First, almost no one outside of the policy world knows these boards exist, especially the communities most impacted. Second, the discussions around them are often misleading. They are framed as a lever to make drugs more affordable for patients, but in reality, they are designed to save money for the state, and there is zero evidence of patient cost savings. Recent studies confirmed that upper payment limits set by PDABs have not delivered a single dollar in savings to patients.</span></p>
<p><span>For Tigerlily, this is unacceptable. We are not saying we don’t want more affordable drugs; we absolutely do! But we want them without creating new access barriers. Our efforts have been focused on educating our community to serve as a catalyst, amplifying their voices to ensure they can engage in these conversations and share their personal stories. We were proud that our work in Virginia resulted in a veto of harmful PDAB legislation, and we will continue to fight to ensure that patient concerns are heard and that affordability policies actually prioritize patient access.</span></p>
<h3>Bio.News: What other policies are a priority for Tigerlily?</h3>
<p><span>Our policy priorities are patient-centered and cover a broad range of issues at both the federal and state levels.</span></p>
<p><span>On drug pricing, beyond PDABs, we are advocating for 340B program reform to ensure that discounts go to supporting vulnerable patients as intended, and we are engaging on Medicare Drug Price Negotiation Program (MDPNP) implementation to ensure that efforts to lower prices don’t inadvertently slow innovation or create new barriers to access for patients.</span></p>
<p><span>We are also prioritizing utilization management reform, including prior authorization and step therapy. These “fail first” protocols delay patients from accessing the treatments their providers prescribe, and we support the Safe Step Act as a crucial interim fix. We are also engaging in policies to ensure access to diverse clinical trials for all, including the Clinical Trial Modernization Act to allow trial sponsors to cover costs like travel and childcare, which are major barriers for underrepresented groups. And with access to clinical trials for innovative therapies as well as already-existing therapies, biomarker testing is a high priority to ensure every patient has access to the current gold standards to receive the best treatment for them and their specific disease markers.</span></p>
<p><span>While our mission has expanded, we remain steadfast in our legacy breast cancer priorities. We continue to support and engage in reauthorization for the SCREENS for Cancer Act to protect funding for safety-net screening programs, the Access to Breast Cancer Diagnosis Act to ensure coverage for diagnostic tests, and the EARLY Act to educate young women and their doctors about breast cancer risks.</span></p>
<h3>Bio.News: Your fourth annual BEACON Symposium takes place this October. What themes will be explored? What does this milestone mean to the organization?</h3>
<p><a href="https://tigerlilyfoundation.org/event/tigerlilys-4th-annual-beacon-symposium/"><span>The BEACON Symposium</span></a><span> has become a cornerstone of our work because it’s where we shift from dialogue to action. This year’s theme is “From Access to Action: Scaling Patient-Led Solutions for an Equitable Future”. It perfectly captures the moment we are in as an organization and as a community.</span></p>
<p><span>The panels will tackle some of the most critical issues facing patients today. One panel, “Bridging the Trial Gap: From Equitable Access to Community-Centered Trials,” will explore how we move beyond simply enrolling more diverse patients to designing trials that are truly centered on community needs. </span></p>
<p><span>The second panel, “The Cost Conundrum: When Drug Pricing Policies Create More Problems Than Solutions,” will dig into drug pricing policy issues and how well-intentioned policies can sometimes backfire and create new hurdles for the very people they aim to help. And most importantly, how advocates can engage and amplify the patient voice to ensure good policies are made that actually lower prices for patients.</span></p>
<p><span>For us, the Fourth Annual BEACON Symposium is a milestone that reflects how much this movement has grown. It’s no longer just Tigerlily’s event; it’s a gathering place for the entire patient advocacy community to co-create solutions. It’s where we, together, become the beacon of hope and light that drives us forward to health equity.</span></p>
<h3>Bio.News: Maimah will be speaking on behalf of Tigerlily Foundation later this month at PACE. What are you most excited to share with the patient advocacy community?</h3>
<p><span>I am most excited to share that Tigerlily’s patient advocacy is not standing still but rather is expanding in new and powerful ways. I’ll be sharing how we are building a bigger table and bringing more voices into the conversation.</span></p>
<p><span>I’ll be highlighting our new programs, which embody this growth. EmPOWER Her is our peer navigation program that connects newly diagnosed patients with trained survivor navigators, providing the compassionate, one-on-one support that I wish I had when I was diagnosed. SheLEADS is a community-led initiative piloting in North Carolina designed to transform the systems of care for Black women by combining peer navigation with provider engagement and policy change. Our BLISS Brunch series is creating joyful, culturally responsive spaces for education and connection, bringing clinical trial literacy directly into trusted community settings. And our newly created IGNITE Center of Excellence is turning community engagement from simple outreach into an evidence-based discipline, ensuring that the trust we build translates into measurable health outcomes.</span></p>
<p><span>What I’m most excited to share is that after 20 years, our commitment to our work is the same: to lead with love, legacy, and unstoppable faith. But our reach and our impact are greater than ever. We are proving that when you center patients and give them the power to lead, you don’t just create change, you build a movement.</span></p>
<p><i><span>You can still register for PACE! Visit </span></i><a href="https://pace.bio.org/registration"><i><span>https://pace.bio.org/registration</span></i></a><i><span> </span></i></p>
<p>The post <a href="https://bio.news/health/tigerlily-foundation-joining-conversation-at-pace/">Tigerlily Foundation joining conversation at PACE</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genentech documentary celebrates 50th anniversary of biotech</title>
<link>https://edusehat.com/en/genentech-documentary-celebrates-50th-anniversary-of-biotech</link>
<guid>https://edusehat.com/en/genentech-documentary-celebrates-50th-anniversary-of-biotech</guid>
<description><![CDATA[ A scientist and a financier walk into a bar…  It sounds like the setup to a joke, but in the case of molecular biologist […]
The post Genentech documentary celebrates 50th anniversary of biotech appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/genentech-documentary-JPG.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genentech, documentary, celebrates, 50th, anniversary, biotech</media:keywords>
<content:encoded><![CDATA[<p><span>A scientist and a financier walk into a bar… </span></p>
<p><span>It sounds like the setup to a joke, but in the case of molecular biologist Herbert Boyer, Ph.D., and venture capitalist Robert Swanson, it was the setup for an entirely new industry: biotechnology. </span></p>
<p><span>The two founded Genentech, considered the “original biotech” company, which is celebrating its 50th year. And the biotech industry as a whole is looking back on its last half-century and reflecting on the breakthroughs that have saved and improved the lives of patients worldwide. To mark the moment, the documentary </span><a href="https://www.nytimes.com/paidpost/genentech/the-impossible-bet.html"><span>“The Impossible Bet”</span></a><span> was produced in collaboration with The New York Times’ </span><a href="https://advertising.nytimes.com/custom-content/"><span>T Brand Studio</span></a><span> to explore Genentech’s growth and impact and reflect on the role patients have played in the industry’s development. </span></p>
<h3>From the first human insulin to a breast cancer breakthrough</h3>
<p><span>Boyer and Swanson’s first conversation ultimately led to the creation and commercialization of recombinant DNA (rDNA) technology to engineer bacteria to produce vital human proteins. That was a game-changer for diabetes patients.</span></p>
<p><span>“At the time, there was a really urgent patient need. Insulin was derived from animal pancreases, and there wasn’t enough that could be produced to serve all the diabetic patients around the world,” Ashley Magargee, CEO of Genentech, explained in the documentary. </span></p>
<p><span>But thanks to Boyer’s groundbreaking work researching recombinant DNA, and Swanson’s ability to fund and commercialize it, Genentech was able to use recombinant DNA technology to clone and synthesize human insulin and the E. coli gene.</span></p>
<p><span>“For the first time, we had human insulin,” Magargee continued. “Diabetic patients were able to get a sustainable supply of the medicine that they would need. It was such a watershed moment because it proved that Genentech could exist, and that started, really, this wonderful industry of biotech.”</span></p>
<p><span>The insulin breakthrough was followed by the development of a drug to treat breast cancer: Herceptin. </span></p>
<p><span>HER2-positive breast cancers—accounting for 20% of breast cancers—were once a death sentence: “more aggressive, more likely to spread, more likely to recur,” explained Levi Garraway, Executive Vice President, Head of Global Product Development and Chief Medical Officer at Genentech.. </span></p>
<p><span>Heceptin changed that, and is still used today. </span></p>
<p><span>This paved the path toward targeted therapy, which has been one of the most important innovations in rare disease.</span></p>
<p><span>“The most important implication of targeted cancer treatments was that if we can understand the biology of a disease at a detailed molecular level, that understanding can unlock an entirely new era of transformative medicines,” said Garraway.</span></p>
<h3>Compassionate Use and the importance of the patient voice</h3>
<p><span>During the clinical trial stage of Heceptin’s development, the scientists at Genentech looked out their window and saw protestors. They were all breast cancer patients. </span></p>
<p><span>“Really, they were saying, </span><i><span>We need to live.</span></i><span> They were pleading to live. </span><i><span>Why can’t you just give me the drug? I will take all the risk</span></i><span>,” explained Magargee.</span></p>
<p><span>Genentech invited them in.</span></p>
<p><span>“We brought them in and started talking to them about how we could develop a lottery system for compassionate use,” Margaree recalled. </span><i><span>Compassionate Use</span></i><span> allows patients who have life-threatening diseases, and no other options, to receive an investigational medicine before it comes on the market.</span></p>
<p><span>“The outcome of that was a recognition on the part of Genentech that these patient voices are, in fact, incredibly important,” said Margaree. “We’ve come a long way in bringing patients into our research early on to make sure that as we’re working in the drug discovery, drug development phases, we actually are bringing the voice of the patient into everything we do.”</span></p>
<p><span>This patient-informed mindset has shaped decades of work since—whether designing and conducting clinical trials, speaking to the Centers for Disease Control and Prevention, or organizing Hill Day in Washington</span><span>,</span><span> DC, where patients can speak directly to policymakers about their needs. </span></p>
<h3>AI as biotech’s next frontier</h3>
<p><span>As the documentary explains, the road to biotech innovation has never been easy.</span></p>
<p><span>“You have to follow the science wherever it may lead you, in order to make the next leap and get to the next right answer,” said Aviv Regev, Head of Research and Early Development at Genentech. </span></p>
<p><span>While the biotech industry has completely changed the landscape of healthcare on the planet and continues to move at lightspeed, innovation is nonetheless an uphill battle.</span></p>
<p><span>“We still have 90% of all molecules that enter clinical studies fail, and that’s an incredible failure rate,” said Magargee on the </span><a href="https://bio.news/health/ai-drug-discovery-biotech-nvidia-genentech-anniversary-bio-international-convention-2026/"><span>BIO Mainstage at the 2026 International Convention</span></a><span>. “And it’s because drug discovery is very, very difficult – every aspect of it is very difficult.”</span></p>
<p><span>As the biotech industry reflects on the past 50 years, it is also looking ahead to what comes next, particularly to artificial intelligence (AI)—not to replace scientists, but to assist them.</span></p>
<p><span>“We need more scientists than we ever have before, because when they’re equipped and empowered with these tools, they’re asking bigger and more important questions than have ever been able to ask before,” said Magargee.</span></p>
<p><span>“It’s going to be not just faster computers or better algorithms or more interesting science,” concluded Magargee to applause, “it’s going to be so many more birthdays for people, it’s going to be so many more memories, and so much more time with your loved ones, and that’s going to be the impact that we’re going to have together.”</span></p>
<p>The post <a href="https://bio.news/health/genentech-documentary-celebrates-50th-anniversary-of-biotech/">Genentech documentary celebrates 50th anniversary of biotech</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Floridians turn out to oppose changing school and daycare vaccine requirements</title>
<link>https://edusehat.com/en/floridians-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements</link>
<guid>https://edusehat.com/en/floridians-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements</guid>
<description><![CDATA[ BIO voices concerns in statement for hearing about potential rule change. Reducing the number of vaccines required for school children risks the spread of […]
The post Floridians turn out to oppose changing school and daycare vaccine requirements appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/mother-at-fla-hearing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Floridians, turn, out, oppose, changing, school, and, daycare, vaccine, requirements</media:keywords>
<content:encoded><![CDATA[<h4>BIO voices concerns in statement for hearing about potential rule change.</h4>
<p><span>Reducing the number of vaccines required for school children risks the spread of dangerous, preventable diseases, concerned Floridians and public health advocates told a Florida Department of Health (FDOH) panel hearing on Oct. 8.</span></p>
<p><span>The </span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"><span>hearing</span></a><span> allowed public input into FDOH’s proposed rule change to eliminate requirements for four of the current 11 vaccines students need to enter public schools and daycare.</span></p>
<p><span>The new rule would mean the hepatitis B, varicella (chickenpox), haemophilus influenzae type b (Hib), and pneumococcal conjugate vaccines would no longer be required for students entering public school or child care programs,</span><a href="https://www.floridahealth.gov/2026/10/08/florida-department-of-health-holds-public-hearing-on-proposed-revisions-to-school-immunization-rule/"> <span>FDOH explains.</span></a><span> Immunization for polio, diphtheria, measles, rubella, pertussis, mumps, and tetanus would still be required.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) provided written comments to the hearing urging FDOH to maintain its current vaccine requirements.</span></p>
<p><span>“We are deeply concerned that the proposed changes, if enacted, will decrease immunization coverage in Florida and leave many vulnerable to preventable infectious diseases,” BIO wrote. “Vaccination requirements have been instrumental in reducing, and in some cases eliminating deadly diseases. Removing these requirements would reverse decades of scientific and public health progress without evidence-based justification.”</span></p>
<p><span>While the hearing featured many speakers against the proposal and many in favor of it, the overall majority of Floridians oppose the proposed rule and want to keep vaccine requirements as they are,</span><a href="https://www.flfamiliesforvaccines.org/polling"> <span>according to a poll commissioned by Florida Families for Vaccines</span></a><span>. Of the 1,000 likely voters polled by McLaughlin & Associates, 79%—including 71% of registered Republicans—support Florida’s long-standing school entry vaccine requirements.</span></p>
<h2>What they said at the hearing</h2>
<p><span>Speakers who urged against changing the vaccine schedule represented a wide range of viewpoints.</span></p>
<p><span>Evelyn, a 7-year-old cancer survivor, described the importance of her classmates being vaccinated.</span></p>
<p><span>“The chemo broke my immune system. I had to stay away from sick people because their germs could hurt me really bad. I was so happy to go back to school. I missed my friends,” Evelyn said. “Mommy and Daddy knew I would be safe because everybody got their vaccine shots when I couldn’t.”</span></p>
<p><span>Evelyn’s father, Kyle Huneycutt, said his daughter’s diagnosis changed how his family saw the world. “The health of the community around your child matters in a way you may have never considered before,” he explained.</span></p>
<p><span>The patient’s family view was also represented by Donielle Deitz, a caregiver and a volunteer for the American Cancer Society’s Cancer Action Network (ACS CAN), who urged maintaining “evidence-based school immunization requirements.”</span></p>
<p><span>“Childhood vaccines protect people with cancer,” she said, noting that the hepatitis B vaccine FDOH would remove from the requirements “is a powerful cancer prevention tool” against liver cancer.</span></p>
<p><span>Medical professionals also spoke of the risks of changing the vaccination schedule, which may give the impression that some vaccines are less important.</span></p>
<p><span>Angela Moore, a registered nurse, said she had witnessed what can happen when families decide against protecting their children.</span></p>
<p><span>“We have seen children whose parents have denied them safe and effective vaccines be afflicted by diseases that my generation and the generation before me had the luxury of protection from, due to herd immunity,” she said.</span></p>
<p><span>Donald Neel, MD, a pediatrician, recalled the times before the four vaccines were available. “I spent many hours of my life and parents’ lives, holding their hands and praying for their child, who was critically ill with either pneumococcal pneumonia or the various types of meningitis,” he said.</span></p>
<p><span>Many speakers represented the parents’ perspective in opposing the proposed rule.</span></p>
<p><span>“We want to send our children to schools and daycare and not have to worry about preventable diseases,” said Cass Miller of</span><a href="https://www.flfamiliesforvaccines.org/"> <span>Florida Families for Vaccines</span></a><span>. “For families, an outbreak is not just a statistic; it means missing childcare, a parent missing work, or staying away from grandparents because someone has been exposed.”</span></p>
<p><span>Shelly Pedraza, President Elect of</span><a href="https://www.floridapta.org/"> <span>the Florida PTA</span></a><span>, which includes about 200,000 parents, said “Florida PTA opposes the removal of these vaccine requirements,” because parents are concerned about the health risks.</span></p>
<p><span>Those representing teachers said they and their families would be put at risk if vaccination rates drop at their workplace.</span></p>
<p><span>Giving the business perspective, Karen van Caulil, president and CEO of the</span><a href="https://flhealthvalue.org/"> <span>Florida Alliance for Healthcare Value</span></a><span>, noted that employers pay for many health insurance plans, and also suffer when parents are absent for child care.</span></p>
<p><span>“When preventable illness leads to additional doctor visits, emergency care or hospitalization, those costs are felt by families and employers alike,” she said. “That is why employers have a direct and practical interest in policies that help keep children and communities healthy.”</span></p>
<h2>The ‘parents rights’ argument</h2>
<p><span>Those speaking in favor of the rule mostly spoke of the right for parents to make their own decisions, vaccine-related injuries (which occur rarely but are eligible to submit federal remuneration through the Vaccine Injury Compensation Program (VICP)), and unscientific theories on vaccine safety.</span></p>
<p><span>Florida Surgeon General Joseph Ladapo, MD, who has championed the rule change and led the hearing, stressed that there were no questions about the safety and effectiveness of the four vaccines that his new rule would eliminate. Ladapo repeatedly explained that the only reason for the rule change was to increase parents’ right to choose for their children.</span></p>
<p><span>BIO and others noted that Florida already allows for religious and medical exemptions to school vaccine requirements.</span></p>
<p><span>“Current standards ensure that individual choice is protected while maintaining the greatest access to vaccines for those who wish to take them,” said BIO’s letter. “Further loosening the requirements does not impact an individual’s right to choose vaccination or not, it jeopardizes broader immunity levels and increases the likelihood of outbreaks.”</span></p>
<p><span>Ladapo also said other states do not require school children to have some of the vaccines that Florida would cancel. But no state excludes all four vaccines.</span></p>
<p><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hepb-child-school-2026/"><span>Every state except for Alabama</span></a><span> requires hepatitis B vaccines, and</span><a href="https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hib-childcare-2026/"> <span>West Virginia is the only state</span></a><span> that doesn’t mandate a Hib vaccine, according to</span><a href="https://www.immunize.org/"> <span>immunize.org</span></a><span>. Seven states do not require a</span><a href="https://www.immunize.org/wp-content/uploads/laws/pcv-cc-rqt-map-2026.pdf"> <span>pneumococcal vaccine</span></a><span>.</span></p>
<p><span>As of now, all states require children entering public school and daycare to have the chickenpox vaccine, which also helps protect against meningitis, and</span><a href="https://www.epicresearch.org/articles/first-birth-cohort-eligible-for-chickenpox-vaccine-had-a-sharp-drop-in-shingles-cases/"> <span>according to a new study</span></a><span>, prevents later episodes of shingles.</span></p>
<p><i><span>FDOH is accepting comments on the rule proposal by email at </span></i><a href="mailto:vaccinerule@flhealth.gov"><i><span>vaccinerule@flhealth.gov</span></i></a><i><span> until 5 pm on Oct. 19.</span></i></p>
<p>The post <a href="https://bio.news/state-policy/floridians-turn-out-to-oppose-changing-school-and-daycare-vaccine-requirements/">Floridians turn out to oppose changing school and daycare vaccine requirements</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Can’t bear to say goodbye to your pet? Biotech’s got you covered.</title>
<link>https://edusehat.com/en/cant-bear-to-say-goodbye-to-your-pet-biotechs-got-you-covered</link>
<guid>https://edusehat.com/en/cant-bear-to-say-goodbye-to-your-pet-biotechs-got-you-covered</guid>
<description><![CDATA[ I don’t remember much about Peppy, my first and only pet cat. I can conjure the sensation of stroking her while she purred, recall how she used to get stuck in trees (just like in cartoons!), and chuckle about the time she pooed in my baby sister’s cot. That’s about it. What I do vividly… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/AdobeStock_551902166.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Can’t, bear, say, goodbye, your, pet, Biotech’s, got, you, covered.</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Pet longevity is a growing area of research:</strong> Companies like Loyal are trialing drugs in over 1,300 dogs to combat aging, metabolic disease, and conditions like arthritis — and there's even a longevity medicine company focused entirely on cats.</li><br><li><strong>Cloning offers grieving owners "a way to hold on":</strong> For $50,000, US company Viagen Pets will create a genetic twin of your dog or cat — not an exact replica, but close enough that some experts see it as a legitimate response to pet loss.</li><br><li><strong>Cryonics promises revival, but delivers almost nothing:</strong> A handful of companies will freeze your dead pet indefinitely, banking on future technology to bring them back — even those in the field admit reanimation is currently impossible.</li></ul>" data-chronoton-post-id="1146766" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">I don’t remember much about Peppy, my first and only pet cat. I can conjure the sensation of stroking her while she purred, recall how she used to get stuck in trees (just like in cartoons!), and chuckle about the time she pooed in my baby sister’s cot. That’s about it.</p>



<p class="wp-block-paragraph">What I do vividly remember, though, is the day she went missing. I was 10 years old, and I searched everywhere for her, scouting nearby fields and woods until sunset. I made posters. We never found her. I was devastated.</p>



<p class="wp-block-paragraph">There was no way to get more time with Peppy, but almost 30 years later, pet owners are being offered an ever-expanding set of options to potentially prolong their years with their furry companions. The possibilities include drugs, cloning, and even cryonics. But is that a good thing?</p>





<p class="wp-block-paragraph">There’s certainly a market for pet preservation. And a growing number of biotech companies have their sights set on pet longevity. Loyal, a company that is currently working on three potential longevity drugs for dogs, is <a href="https://loyal.com/clinical-trials">trialing</a> one designed to improve metabolic health in around 1,300 pet dogs across the US. Others are <a href="http://google.com/url?q=https://animalbioscience.com/for-vets/&sa=D&source=docs&ust=1789052975323016&usg=AOvVaw17YrZEtPUxIc3YvqYS9m2e">testing dog drugs</a> that aim to combat both age-related diseases, including conditions like <a href="https://rejuvenatebio.com/pipeline">obesity and osteoarthritis</a>, and aging itself. There’s even a company focused on <a href="https://thecathealth.com/">longevity medicines for</a> domesticated cats.</p>



<p class="wp-block-paragraph">I don’t know how or when Peppy died. But if there had been a drug that might have protected her from diabetes or arthritis, there’s no doubt I would have tried to get my hands on it.</p>



<p class="wp-block-paragraph">That’s about where my enthusiasm for pet life extension ends, though.</p>



<p class="wp-block-paragraph">I’m far less interested in cloning, a relatively new option for people mourning a pet and seeking a replacement. In most cases, this technology involves taking the DNA of a pet, putting it into an egg cell from another animal of the same species, and growing the resulting embryo in a surrogate animal. It worked for Dolly the sheep, who was born the year before Peppy went missing. It has since worked for other mammals, including cattle, horses, and ferrets—and cats and dogs. In the US, a company called Viagen Pets offers to clone cats and dogs for $50,000 a go. This doesn’t result in an exact replica of the animal but a genetic twin.</p>



<p class="wp-block-paragraph">Still, there are lots of reasons why a person might want to clone a pet. On its website, Viagen explicitly offers customers “a way to hold on.” Lori Kogan, a professor of clinical sciences at Colorado State University who has studied human-animal relationships for decades, doesn’t have a problem with the practice. She points out that while we have well-established rituals for coping with the loss of a person—such as funeral services, time off work, and memorial gifts—we don’t really have the same for pets. As a result, pet owners can experience what is sometimes called “disenfranchised grief,” she says. Having their feelings go unrecognized can feel isolating. If cloning a pet brings a person peace, she says, “who are we to judge?”</p>





<p class="wp-block-paragraph">Fair enough. But I can’t help thinking that pet loss in childhood might be different. It’s often the first time a child confronts death. Losing Peppy was a formative experience, and distressing though it was, I like to think it helped prepare me for losses I experienced in adulthood. I wouldn’t want my own children to think that death is not final, and that individuals can be replicated or replaced.</p>



<p class="wp-block-paragraph">Or, for that matter, revived, which is the promise behind pet cryonics. For a fee, a handful of companies offer to cool dead pets to extremely low temperatures and store them for long periods of time—even indefinitely. The idea is that at some point in the future, we’ll have invented incredible technologies that will not only bring your pet back to life but also cure whatever it died of. <a href="https://www.alcor.org/about/">Alcor</a>, a cryonics facility in Arizona, is currently storing the remains of hundreds of pets as well as people. It even recently announced it had cooled a small marsupial—its first pet sugar glider.</p>



<p class="wp-block-paragraph">With cryonics, the chances of being reunited with your pet are bordering on zero. Even those who work in the field acknowledge that the stored people and animals are unlikely to be reanimated. As things stand, there is no way to really and truly bring any animal “back.”</p>



<p class="wp-block-paragraph">I miss Peppy. But given the chance, would I stick her in a vat of liquid nitrogen? Or get another cat to give birth to a genetically identical animal? No, I would not.</p>



<p class="wp-block-paragraph">RIP to the one and only Peppy.</p>]]> </content:encoded>
</item>

<item>
<title>This implant can restore sight for patients with macular degeneration</title>
<link>https://edusehat.com/en/this-implant-can-restore-sight-for-patients-with-macular-degeneration</link>
<guid>https://edusehat.com/en/this-implant-can-restore-sight-for-patients-with-macular-degeneration</guid>
<description><![CDATA[ Age-related macular degeneration (AMD) affects more than 5 million people around the world. And until now, no treatment could restore their vision. The Prima system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that. It combines a retinal implant with camera-­equipped eyeglasses to improve sight in patients… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/prima-implant-2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 18:10:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>This, implant, can, restore, sight, for, patients, with, macular, degeneration</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Age-related macular degeneration (AMD) affects more than 5 million people around the world. And until now, no treatment could restore their vision. The Prima system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that. It combines a retinal implant with camera-­equipped eyeglasses to improve sight in patients who develop a blind spot in the middle of their vision due to advanced AMD. After training sessions, more than 80% of recipients were able to read, do crosswords, and use their phones.</p>


<div class="wp-block-image">
<figure class="wp-block-image alignright size-large is-resized"><img fetchpriority="high" decoding="async" width="1045" height="1292" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png?w=840" alt='""' class="wp-image-1146408" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png 1045w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png?resize=243,300 243w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped.png?resize=768,950 768w" sizes="(max-width: 1045px) 100vw, 1045px"><figcaption class="wp-element-caption"><strong>The retina processes light in three layers of cells: Photoreceptors</strong> convert light into electricity, <strong>bipolar cells</strong> process that signal, and <strong>ganglion cells</strong> transmit the signal to the optic nerve and the brain. Prima replaces the photoreceptors.</figcaption><div class="image-credit">BROWN BIRD DESIGN</div>
</figure>
</div>


<p class="wp-block-paragraph">Developed by the California-based Science Corporation, the system takes advantage of the fact that AMD doesn’t damage all retinal circuitry; only photoreceptors—the cells that convert light into an electrical signal—die off. Prima’s implant mimics those cells and transmits visual information directly to healthy eye circuitry and on to the brain. “We’re leveraging all of the body’s own natural functions to process and transmit the information,” says Frank Brodie, an ophthalmologist at the University of California, San Francisco, and medical director for Prima. </p>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="3115" height="2905" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png" alt="" class="wp-image-1146409" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png 3115w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=300,280 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=768,716 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=1536,1432 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped1.png?resize=2048,1910 2048w" sizes="(max-width: 3115px) 100vw, 3115px"><div class="image-credit">BROWN BIRD DESIGN</div>
</figure>
</div>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">CAPTURE</h4>



<p class="wp-block-paragraph">Glasses outfitted with a miniature front-facing <strong>camera </strong>capture what someone is seeing in real time. The video feed is roughly five megapixels running at 30 frames per second, which is similar to TV. The raw video is transmitted to a connected processor via a <strong>fiber-optic cable</strong>.</p>
</div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">CONVERT</h4>



<p class="wp-block-paragraph">A small, handheld processor, which can be set on a table or tucked in a pocket, converts the video feed into infrared light signals that route back to the glasses. The device also includes physical buttons that let the wearer adjust contrast, brightness, and zoom.</p>
</div>
</div>



<p class="imageSet__caption wp-block-paragraph"></p>



<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="3115" height="1185" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png" alt="" class="wp-image-1146410" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png 3115w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=300,114 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=768,292 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=1536,584 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/ND26-dl_mapped2.png?resize=2048,779 2048w" sizes="(max-width: 3115px) 100vw, 3115px"><div class="image-credit">BROWN BIRD DESIGN</div>
</figure>
</div>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">DISPLAY</h4>



<p class="wp-block-paragraph">A laser <strong>projector </strong>on the glasses faces the wearer and shines pulses of <strong>near-infrared light</strong> directly at the eye at 880 nanometers—an invisible wavelength. This signal passes through the <strong>pupil </strong>and on to the <strong>retinal implant</strong> in the back of the eye.</p>
</div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<h4 class="wp-block-heading">SEE</h4>



<p class="wp-block-paragraph">The implant is made up of 378 pixels, each with an <strong>electrode </strong>and two <strong>photovoltaic cells</strong>, which do double duty. They convert the light into a current that healthy bipolar and ganglion cells pass on to the brain. They also act as solar cells to power the chip, eliminating the need for a battery.</p>
</div>
</div>



<p class="imageSet__caption wp-block-paragraph"></p>




<p class="wp-block-paragraph"><em>Linda Marsa is a former </em>Los Angeles Times<em> reporter and an author who covers medicine, health, science, and the environment. </em></p>]]> </content:encoded>
</item>

<item>
<title>Proteomics Reveals Ovarian Remodeling Decades After Menopause</title>
<link>https://edusehat.com/en/proteomics-reveals-ovarian-remodeling-decades-after-menopause</link>
<guid>https://edusehat.com/en/proteomics-reveals-ovarian-remodeling-decades-after-menopause</guid>
<description><![CDATA[ 5,812 protein groups were quantified in postmenopausal ovaries, uncovering molecular shifts associated with inflammation, immunity, and extracellular matrix remodeling.
The post Proteomics Reveals Ovarian Remodeling Decades After Menopause appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2282334711.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 07:20:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proteomics, Reveals, Ovarian, Remodeling, Decades, After, Menopause</media:keywords>
<content:encoded><![CDATA[<p>For decades, the postmenopausal ovary has been cast as a retired organ—a fibrotic remnant that stops releasing eggs and then largely sits idle. But a deep look at its proteins tells a different story. Using high-resolution proteomics, researchers found that the ovary continues to reorganize its structure, metabolism, and immune activity for decades after reproduction ends.</p>
<p>Scientists at Northwestern University and the Buck Institute for Research on Aging conducted the study, which analyzed healthy ovarian tissue from 28 postmenopausal women ages 50 to 75. The paper, “<a href="https://onlinelibrary.wiley.com/doi/10.1111/acel.70714" target="_blank" rel="noopener">The Human Ovary Exhibits Dynamic Molecular Remodeling in the Decades Post-Menopause</a>,” was published in <em>Aging Cell</em>. “I would venture to say most people assume those ovaries are just sitting there doing nothing, similar to the appendix,” said co-corresponding author Francesca Duncan, PhD, an associate professor of reproductive science in medicine at Northwestern University Feinberg School of Medicine. “But that’s what makes this study very different.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p>Rather than focusing only on hormones, the team measured the tissue’s proteome. They analyzed the samples using data-independent acquisition mass spectrometry coupled with parallel accumulation–serial fragmentation, or diaPASEF. The approach systematically captured peptide signals across samples, allowing the team to quantify 5,812 protein groups. Differential-abundance testing, multivariate modeling, continuous-age regression, and pathway analyses were then used to identify changes shared across age groups and those that progressed with age.</p>
<p>The analyses converged on a shift from cellular maintenance toward active remodeling. Ovaries from women in their 50s contained more proteins linked to RNA processing, gene regulation, proteostasis, and tissue structure. Ovaries from women 70 and older showed stronger signatures of lipid metabolism and innate immunity. The researchers integrated recurring signals into Buck Postmenopausal Ovary Molecular Signature (BuckPOMS), “a 26-protein consensus molecular signature marked by loss of structural and epithelial-associated programs and gain of extracellular matrix remodeling, inflammatory signaling, and complement activation,” the authors wrote. They also validated two extracellular proteins, WNT4 and fibromodulin, by immunohistochemistry. “What became clear across all these methodologies is that the ovary was not stagnant,” said co-corresponding author Birgit Schilling, PhD, professor and director of the Buck Institute’s Mass Spectrometry Center.</p>
<p>“The ovary is not just a reproductive organ,” added Schilling. “It really influences how somebody ages because it speaks to all these other organs, such as the brain, and also to the bone, and women after menopause experience often a lot of bone problems. So, we think there is a connection between all these organs.”</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p>The study advances a field that has largely concentrated on fertility loss, the menopausal transition, or comparisons spanning the entire lifespan. By narrowing the analysis to the decades after menopause, the researchers produced a reference map of continued ovarian aging. Histologically normal ovaries also showed overlap with senescence-associated programs and proteins previously linked to ovarian cancer, particularly among women in their 60s. The authors stress that this is not evidence of malignancy; instead, healthy aging and cancer may share inflammatory and matrix-remodeling biology. That distinction matters as women routinely live decades after menopause and researchers consider how the ovary may influence bone, brain, cardiovascular, and broader systemic aging.</p>
<p>“This ongoing molecular remodeling that occurs in the postmenopausal ovary challenges the notion that the ovary is an innocent bystander in the post-reproductive period and instead suggests a potentially more active role in systemic aging and chronic disease risk in women,” the authors wrote.</p>
<p>Future prospective studies will need documented age at menopause, hormone-therapy history, larger and more diverse cohorts, and longitudinal health outcomes to distinguish chronological aging from time since menopause and treatment effects. “We do not yet know if there’s ever a point in a woman’s life when this organ is no longer beneficial and it’s actually harmful,” said Duncan. “These results really point to the need to ask this question.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/proteomics-reveals-ovarian-remodeling-decades-after-menopause/">Proteomics Reveals Ovarian Remodeling Decades After Menopause</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Illumina Combines Multiomics Informatics Applications in New BioInsight Platform</title>
<link>https://edusehat.com/en/illumina-combines-multiomics-informatics-applications-in-new-bioinsight-platform</link>
<guid>https://edusehat.com/en/illumina-combines-multiomics-informatics-applications-in-new-bioinsight-platform</guid>
<description><![CDATA[ Illumina is bringing its software, AI, and data offerings together in the new BioInsight platform, designed to help scientists analyze genomic and multiomic datasets. It will be showcased at ASHG in Montreal.
The post Illumina Combines Multiomics Informatics Applications in New BioInsight Platform appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/TL_GettyImages-1284442152-lo.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:45:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Illumina, Combines, Multiomics, Informatics, Applications, New, BioInsight, Platform</media:keywords>
<content:encoded><![CDATA[<p><span>Ahead of the 2026 meeting of the American Society of Human Genetics (ASHG), Illumina announced the launch of the BioInsight platform, a new unified software environment that provides tools to help scientists extract insights from multiomics datasets. According to the company, the platform provides scientists with seamless access to Illumina’s analysis applications, artificial intelligence tools, and curated data resources in a single environment. </span></p>
<p><span>The company plans to showcase the BioInsight Platform during the annual ASHG meeting being held in Montreal, Canada this year.  </span></p>
<p><span>Illumina’s BioInsight business unit was created a year ago to address what the company perceived to be a gap in analysis capabilities for handling the scale and complexity of multiomics datasets. “With the BioInsight Platform, we are bringing customers one simple place to access the full breadth of our offerings across software, AI, and data,” said Rami Mehio, senior vice president and general manager of the BioInsight business. Moving forward, “customers that use the BioInsight platform will also have access to new capabilities in the future, empowering them to drive the next wave of biological insights for our industry.”  </span></p>
<p><span>The list of tools available on the platform includes SpliceA12, a new genomic AI model that Illumina unveiled last week that is designed to identify disease-relevant splice variants. Being able to predict splice effects is key to resolving variants of uncertain significance in rare disease research, hereditary cancer testing research, and drug discovery. To date, its predecessor, SpliceA1, has been cited in over 3,400 publications and is incorporated into guidelines from ClinGen. </span></p>
<p><span>Details of SpliceA12’s framework, its training, and how it stacks up against other tools are provided in a </span><a href="https://assets.illumina.com/content/dam/illumina-marketing/images/genomics-research/articles/spliceai2/SpliceAI2.pdf" target="_blank" rel="noopener"><span>pre-print</span></a><span> published by scientists from Illumina, University of Oxford, University of California, San Francisco, and the New York Genome Center. According to the article, the tool “reconstructs complete transcripts directly from genomic sequence and considerably improves identification of splice-altering variants and quantification of their effects in diverse benchmarks spanning cryptic splicing, splicing quantitative trait loci, and massively parallel reporter assays.”</span></p>
<p><span>The data shared in the paper includes results from comparing SpliceA12’s to alternative splice prediction models on matched DNA and disease phenotype data from Genomics England cohorts. The findings show that SpliceA12 identified 17% more disease-relevant splice variants than other models. Furthermore, analysis of matched whole genome and RNA sequencing data from the National Institutes of Health’s Genotype-Tissue Expression portal showed that SpliceA12 improved quantification of splice site usage by 34% compared to the next best model. </span></p>
<p><span>Other findings indicate that SpliceA12’s results align more closely with downstream protein effects seen in the UK Biobank proteomic datasets. It also better captured the effects of splice variants across multiple population genomics datasets, according to data shared in the preprint. </span></p>
<p><span>Other applications included in the BioInsight platform include a new version of Illumina’s DRAGEN software solution. Version 4.6 expands where and how scientists can use the secondary analysis software and offers new deployment options including the DRAGEN software mode, which lets scientists run the tool across supported cloud and standard CPU environments. </span></p>
<p><span>Also available are Illumina’s BaseSpace and Connected Multiomics among other applications. Customers will also have access to the BioInsight AI lab, the research arm of BioInsight, which applies multiomic data and AI for tasks like variant prediction and training foundation models.  The platform also features curated datasets for research spanning oncology, rare disease, population health, and multiomics.</span></p>
<p><span>Access is available via a credits-based system in lieu of a more traditional annual subscription. This gives scientists the flexibility to use the capabilities they need while freeing them to explore and adopt new technologies as needed. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/omics/illumina-combines-multiomics-informatics-applications-in-new-bioinsight-platform/">Illumina Combines Multiomics Informatics Applications in New BioInsight Platform</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Alzheimer’s Risk Gene APOE4 Disrupts Myelination</title>
<link>https://edusehat.com/en/how-alzheimers-risk-gene-apoe4-disrupts-myelination</link>
<guid>https://edusehat.com/en/how-alzheimers-risk-gene-apoe4-disrupts-myelination</guid>
<description><![CDATA[ Study linked the APOE4 gene with suppression of Wnt signaling in the oligodendrocyte cells that provide neurons with their fatty myelin insulation, and also demonstrated a potential approach to preventing disruption of myelination. 
The post How Alzheimer’s Risk Gene APOE4 Disrupts Myelination appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/12/Dec12_2023_Ralwel-GettyImages-610655320-e1670883749182-1068x467-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Alzheimer’s, Risk, Gene, APOE4, Disrupts, Myelination</media:keywords>
<content:encoded><![CDATA[<p>One of the main ways that the <em>APOE4</em> gene variant—the biggest genetic risk factor for late onset Alzheimer’s disease—undermines brain circuit function is by disrupting myelination, the process of insulating neurons with a fatty sheath that optimizes their electrical transmission. Studies headed by neuroscientists at The Picower Institute for Learning and Memory at MIT have now provided several lines of evidence to implicate a specific molecular pathway in that disruption.</p>
<p>Headed by Picower Professor Li-Huei Tsai, PhD, and Leyla Akay, PhD, a former graduate student in Tsai’s lab, the researchers showed that APOE4 leads to a suppression of Wnt signaling in the oligodendrocyte cells that provide neurons with fatty myelin insulation. The results indicated that when Wnt signaling is deficient the cells accumulate droplets of lipids rather than deploying fats to properly myelinate the neurons’ axon branches.</p>
<p>The team discovered a key role for Wnt using multiple methods, including a screen in which they used CRISPR gene editing to systematically knock out each protein-coding gene in the genome, one by one, in cultures of human APOE4-carrying oligodendrocytes. The screen showed that when genes promoting Wnt activity in oligodendrocytes were lacking, lipid droplets accumulated, and that when genes suppressing Wnt were lacking, lipid droplets were, too.</p>
<p>Experiments in both human cell cultures and in mice modeling Alzheimer’s disease showed that when Wnt signaling in APOE4-carrying oligodendrocytes was restored, myelination rebounded. “This proof of principle of doing CRISPR screens for genetic modifiers of APOE4-associated lipid accumulation in a central nervous system cell type is very exciting,” said Tsai, who also directs MIT’s Aging Brain Initiative. “I think this type of screen not only provides new insights into cellular pathways contributing to lipid metabolism defects, but really also has the potential to provide new targets for drug development.”</p>
<p>Tsai is co-senior author, and Akay is first author of the researchers’ published paper in <em>Cell Stem Cell</em>, titled “<a href="https://doi.org/10.1016/j.stem.2026.09.012" target="_blank" rel="noopener">Genome-wide CRISPR screen reveals Wnt signaling as a potential therapeutic target for lipid accumulation and impaired myelination in APOE4 oligodendrocytes</a>.”</p>
<p>In 2022, Tsai’s Lab led by Akay, together with co-author Joel Blanchard, PhD, and colleagues, <a href="https://doi.org/10.1038/s41586-022-05439-w" target="_blank" rel="noopener">showed</a> that APOE4 caused lipid droplet accumulation in oligodendrocytes and upset myelination. But, Akay said, that droplet accumulation could happen for many reasons. In their newly reported study, which sought to dig deeper into the underlying molecular mechanisms, the team noted, “We previously found that APOE4 expression causes lipid droplet accumulation in oligodendrocytes, reducing myelination, but the underlying mechanisms were unknown.”</p>
<p>For the study now reported in <em>Cell Stem Cell</em>, the team performed a genome-wide CRISPR knockout screen in induced pluripotent stem cell (iPSC)-derived oligodendrocytes. “We used a well-characterized human iPSC line, homozygous for the APOE4 allele, to generate oligodendrocytes, as previously described,” they explained. “This CRISPR screen allowed us an unbiased way to test every single possibility,” Akay said. “What kind of lipid enzymes are involved in this process? And what are upstream pathways that could be targeted?”</p>
<p>In parallel with the CRISPR screen, the team also analyzed the chromatin accessibility of the DNA in human oligodendrocyte cell cultures and in postmortem human brain samples, in each case comparing APOE4-carrying samples to ones carrying the neutral APOE3 variant. “To further understand how APOE4 perturbs the epigenome of oligodendrocytes and to identify putative master regulators of APOE4’s effects on lipid accumulation, we next used assay for transposase-accessible chromatin using sequencing (ATAC-seq) to compare  transposase-accessible regions of the genome between iPSC-derived oligodendrocytes, isogenic except for APOE genotype,” they continued.</p>
<p>This analysis of ATAC-seq data allowed the investigators to assess which genes were most accessible for expression, versus which ones were locked down from transcription. The chromatin analysis showed that genes promoting Wnt signaling were less accessible in APOE4 carriers. “There was a striking overlap between ATAC-seq and CRISPR screen results,” Tsai said. “Both pointed to a dysregulation of the Wnt signaling pathway.”</p>
<figure aria-describedby="caption-attachment-339392" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339392" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Figure3B-wnt-akay-upscale-300x186.jpg" alt="An enlarged figure from the paper shows that untreated APOE4 oligodendrocytes (left) accumulate lipid droplets (yellow), but are rescued by Gsk3b inhibition (right). [Tsai Lab/MIT PIcower Institute] " width="300" height="186" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Figure3B-wnt-akay-upscale-300x186.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Figure3B-wnt-akay-upscale.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">An enlarged figure from the paper shows that untreated APOE4 oligodendrocytes (left) accumulate lipid droplets (yellow), but are rescued by Gsk3b inhibition (right). [Tsai Lab/MIT Picower Institute]</figcaption></figure>
<p>Further analysis, including direct observations in cells at the lab bench, revealed how Wnt signaling became depressed in cultured APOE4 oligodendrocytes. Two proteins, beta-catenin and GSK3b, each compete to regulate Wnt. Beta-catenin promotes Wnt and GSK3b suppresses it. The team found that in APOE4 oligodendrocytes compared to APOE3 oligodendrocytes, there was reduced beta-catenin expression and excessive GSK3b expression.</p>
<p>The team then tested interventions that manipulate GSK3b activity. In human APOE3 oligodendrocyte cultures they showed that increasing GSK3b with a chemical called Dif3 increased lipid droplets. In APOE4 oligodendrocytes, they showed that inhibiting GSK3b with a chemical called CHIR99021 reduced droplets. In more complex “organoid” cultures combining APOE4 oligodendrocytes with neurons, they found that inhibiting GSK3b increased myelination and promoted the growth of neural axons.</p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="5"></span></aside>
<p>The tests suggested that GSK3b inhibition could be a proof-of-concept therapeutic strategy for restoring Wnt signaling and myelination. As a final test, they treated mice carrying APOE4 and genetically modeling Alzheimer’s tau pathology with doses of CHIR99021. The treated mice exhibited a reduction in lipid droplets in the hippocampus of the brain and showed increased myelination, when compared to untreated controls.</p>
<p>“Our results suggest that inhibition of GSK3B could reduce lipid droplet burden in APOE4 oligodendrocytes through increasing mitochondrial us age of stored lipids, or potentially by upregulating lipophagic mechanisms,” the team wrote in summary.</p>
<p>In addition to highlighting suppression of Wnt signaling, the CRISPR screen and chromatin analysis provided key clues about the molecular mechanisms by which loss of Wnt alters how oligodendrocytes metabolize lipids. Akay and Tsai said they are eager to follow up on those clues. They are also interested in investigating GSK3b’s linkage to tau phosphorylation, a major feature of Alzheimer’s pathology. “Given GSK3B’s established role as a major tau phosphorylating kinase, our work draws an interesting potential parallel between oligodendrocyte lipid accumulation and neuronal tau pathology,” the authors noted in their report.</p>
<p>Raw data from the study is available on the <a href="https://osf.io/m4ekt/overview?view_only=6385445b378c42a981aa3e1a50918605" target="_blank" rel="noopener">Open Science Framework</a>. Akay and Tsai have applied for a patent on the CRISPR screen results.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/how-alzheimers-risk-gene-apoe4-disrupts-myelination/">How Alzheimer’s Risk Gene <i>APOE4</i> Disrupts Myelination</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots</title>
<link>https://edusehat.com/en/newly-identified-microexons-offer-clues-to-autism-spectrum-disorders-genetic-roots</link>
<guid>https://edusehat.com/en/newly-identified-microexons-offer-clues-to-autism-spectrum-disorders-genetic-roots</guid>
<description><![CDATA[ Hundreds of newly identified microexons seem to matter for autism and other neurological conditions, according to a Nature study. A machine learning model of their regulatory code also pinpoints variants predicted to disrupt their splicing in autistic individuals.
The post Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/Fotolia_30836005_JigsawPuzzleBrain.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 03:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Newly, Identified, Microexons, Offer, Clues, Autism, Spectrum, Disorder’s, Genetic, Roots</media:keywords>
<content:encoded><![CDATA[<p><span>Scientists from the University of Toronto, the Sloan Kettering Institute, King’s College London, and the Francis Crick Institute have published data that points to a role for several new microexons in the development of autism spectrum disorder (ASD). According to the findings, published today in </span><i><span>Nature</span></i><span>, the scientists identified hundreds of new microexons that appear to be involved in ASD and other neurological conditions, and developed a machine learning approach to predict the impact of ASD-associated genetic variants on how these segments are regulated. </span></p>
<p><span>Full details are available in a paper titled “</span><a href="https://www.nature.com/articles/s41586-026-11119-w" target="_blank" rel="noopener"><span>A microexon regulatory code reveals autism-linked genetic variation</span></a><span>.” In it, the scientists described how they used a computational tool dubbed MicroExonator to analyze over 100 terabytes of publicly available RNA sequencing data. The tool was developed by Guillermo Parada, PhD, the study’s co-lead author and a postdoctoral fellow in the laboratory of Benjamin Blencowe, PhD,  at King’s and the Crick. Using the tool, he identified more than 1,500 new microexons, of which nearly 300 appeared to be specifically spliced in the brain. Furthermore, many are concentrated in genes associated with critical brain-specific processes, supporting a potential link to neurological health. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="3"></span></aside>
<p><span>The scientists also explored whether DNA variants found in people with autism might preferentially impact the expanded repertoire of microexons. Specifically they built and applied a machine learning model designed to identify the key regulatory features governing whether a microexon is spliced in or out of messenger RNAs. “What surprised me was that the sequences the model identified as important closely matched those conserved throughout vertebrate evolution,” says Parada.</span></p>
<p><span>Next, the scientists applied the model to whole-genome sequence data from thousands of people with autism and neurotypical sibling pairs. Specifically, they analyzed the predicted impact of ASD-associated genetic variants on the microexon regulatory code. “We were able to show that rare genetic variants generally have the largest predicted effects on the splicing of neuronal microexons,” says Blencowe, one of the study’s senior authors and a professor of molecular genetics at University of Toronto. The model further pinpointed a subset of rare variants predicted to alter microexon splicing that are associated with autism.</span></p>
<p><span>Additionally, the team found that the variants predicted to affect microexons are predominantly detected among the 85% of autistic individuals that previously lacked a genetic link to autism. This is an important point because “hundreds of genomic variants have been associated with autism, and these deliver a genetic diagnosis in 15 percent of autistic individuals,” says Blencowe, who is also a part-time professor at King’s and the Crick. That means that for 85 percent of people with an ASD diagnosis, the genetic explanation for their condition remains unknown. The findings from this study could provide some answers. </span></p>
<aside class="my-8" aria-label="Advertisement"><span data-render-ad="4"></span></aside>
<p><span>“In terms of future work, it will be important to understand how disrupted microexons affect interactions between proteins that are important for nervous system development and function,” Blencowe adds. One of the research programs in his lab is also exploring new therapeutic approaches to target microexon dysregulation.</span></p>
<p><span>Furthermore, the scientists believe that the machine learning model they developed can be used to characterize other newly discovered genetic variants and their effects in neurological conditions like schizophrenia and epilepsy where microexons are believed to play a role.</span></p>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/omics/newly-identified-microexons-offer-clues-to-autism-spectrum-disorders-genetic-roots/">Newly Identified Microexons Offer Clues to Autism Spectrum Disorder’s Genetic Roots</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Thirty Million Compartments: Testing Single&#45;Molecule PCR’s Potential</title>
<link>https://edusehat.com/en/thirty-million-compartments-testing-single-molecule-pcrs-potential</link>
<guid>https://edusehat.com/en/thirty-million-compartments-testing-single-molecule-pcrs-potential</guid>
<description><![CDATA[ Countable Labs has named Fred Hutchinson its first certified service provider, currently serving researchers across the Seattle region. And the company is continuing to build its list of service providers.
The post Thirty Million Compartments: Testing Single-Molecule PCR’s Potential appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 16 Oct 2026 00:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Thirty, Million, Compartments:, Testing, Single-Molecule, PCR’s, Potential</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://countablelabs.com/" target="_blank" rel="noopener"><img decoding="async" class="wp-image-331996 size-medium alignnone" src="https://www.genengnews.com/wp-content/uploads/2026/05/CountableLabs_logo-300x67.jpg" alt="Countable Labs logo" width="300" height="67" srcset="https://www.genengnews.com/wp-content/uploads/2026/05/CountableLabs_logo-300x67.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/05/CountableLabs_logo.jpg 475w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<figure aria-describedby="caption-attachment-332024" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-332024" src="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-300x170.jpg" alt="Cancer cells" width="300" height="170" srcset="https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-300x170.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-1024x580.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-768x435.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-741x420.jpg 741w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-696x394.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-1392x788.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer-1068x605.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/05/Getty_2273179177_Cancer.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: anusorn nakdee / iStock / Getty Images Plus</figcaption></figure>
<p>Digital PCR (dPCR) earned its reputation by solving a real problem: it let researchers count nucleic acid molecules directly, without leaning on a standard curve. But the method works by assuming something it cannot verify—that each of a limiting number of droplets holds no more than one target molecule. At low concentrations, that assumption mostly holds. Push the input higher, or add a few more targets to the same reaction, and multiple target molecules start sharing individual partitions. At that point, the instrument is no longer counting and is instead estimating using Poisson statistics.</p>
<p>The gap between what dPCR promises and what it can reliably deliver as target input and multiplexing needs surpass dPCR thresholds, is directly addressed by Countable Labs, whose single molecule counting PCR platform was the subject of a recent <em>GEN </em><a href="https://www.genengnews.com/multimedia/webinars/digital-pcr-playbook-applications-and-challenges-across-research-and-clinical-labs/" target="_blank" rel="noopener">webinar</a>. Rather than relying on statistical inference, the company’s technology partitions a sample into a gel-like matrix having approximately 30 million discrete compartments, physically separating individual molecules for direct counting, across the widest-available dynamic range.</p>
<p>Testing this claim under real lab conditions fell to Alex Zevin, PhD, director of the Genomics Shared Resource at Fred Hutchinson Cancer Center. His core facility, which supports more than 100 investigators and processes more than 10,000 samples a year, has spent the past decade layering on quantification technologies: The Nanostring nCounter<sup>®</sup> technology in 2014, ABI QuantStudio<sup>TM</sup> 5 instruments in 2017, the BioRad QX200<sup>TM</sup> digital droplet PCR system in 2024, and, since mid-2025, a Countable Labs demo unit that has successfully processed hundreds of samples across nine labs.</p>
<h4><strong>Counting instead of correcting</strong></h4>
<p>The mechanics matter here. Standard qPCR analyzes a sample in bulk and needs a standard curve to translate a threshold cycle into a quantity. Droplet dPCR and dPCR systems distribute samples across a relatively low number of partitions, subjecting these techniques to sensitivity issues outside of a limited dynamic range. Countable PCR partitions samples at a level that is orders of magnitude greater than that of dPCR by isolating single molecules in a proprietary matrix and performing readouts for direct counting of positive partitions, using 3D light-sheet imaging. It also uses a proprietary universal multiplexing chemistry that sidesteps design constraints of multiplexed assays available on other platforms.</p>
<h4><strong>Putting it to work</strong></h4>
<p>Zevin highlights early results that instilled confidence in the Countable Labs platform. One example he shared involved an Illumina library quantification assay, built simply by tagging existing P5 and P7 primers with the platform’s adapter sequence. It produced a linear response against commercial standards and tracked closely with results from the KAPA Library Quantification Kit, the method his lab already trusted. “What this told me is that we could easily switch our quantification from qPCR to a Countable PCR-based readout,” Zevin said.</p>
<figure aria-describedby="caption-attachment-339368" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339368" src="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-300x254.jpg" alt="Figure 1. Results from GAPDH transcript quantification" width="300" height="254" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-300x254.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-1024x866.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs-768x649.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-1_Countable-Labs.jpg 1100w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 1. Results from GAPDH transcript quantification using cDNA from two cell lines. Both samples demonstrated highly linear response (r2>0.999) over three orders of magnitude suggesting improved sensitivity compared to standard qPCR.</figcaption></figure>
<p>Similar patterns turned up elsewhere. Working with primers and cDNA from the lab of Steve Henikoff, PhD, at Fred Hutchinson Center, Zevin’s team saw improved sensitivity quantifying GAPDH transcripts in comparison to their existing qPCR approach (Figure 1). A 16S ribosomal RNA assay, built with primers from the lab of David Fredericks, MD, also at Fred Hutchinson, held a linear response across six orders of magnitude down to roughly 10 input copies (Figure 2). It also successfully processed microbiome samples from the lab of Neelendu Dey, MD, another Fred Hutchinson collaborator.</p>
<p>The most clinically weighted example involved <em>BCR-ABL/ABL1</em> fusion detection, which is central to acute myeloid leukemia. Using an off-the-shelf Countable Labs assay, the lab accurately detected positive signals from as little as 55 picograms of input RNA. That work has since grown into another collaboration at Fred Hutchinson, this time with the lab of Jerald Radich, MD,  to compare the assay against validated clinical assays and evaluate its precision across multiple sites.</p>
<p>In her portion of the presentation, Rachel Kane, Countable Lab’s director of business development, discussed a JAK2 V617F example that detected 31 mutant alleles against roughly 773,000 wild-type copies, a sensitivity she put at ten times that of digital PCR. She also described a design in which isolating molecules before amplification means a four-target multiplexed reaction returns the same counts as four separate single-target reactions, avoiding probe competition factors that erode precision on other platforms, as multiplexing increases.</p>
<figure aria-describedby="caption-attachment-339367" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-339367" src="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-1024x391.jpg" alt="Figure 2. Results from 16s quantification" width="600" height="229" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-1024x391.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-300x115.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs-768x293.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/WebinarArticle_Figure-2_Countable-Labs.jpg 1400w" sizes="auto, (max-width: 600px) 100vw, 600px"><figcaption class="wp-caption-text">Figure 2. Results from 16s quantification using 338F and 806R primer sequences and control. Serial dilution of control showed highly linear response (r2 > 0.99) over six orders of magnitude. Countable Labs PCR system shows superior sensitivity compared to standard qPCR.</figcaption></figure>
<h4><strong>What comes next</strong></h4>
<p>Where Countable Labs sees the platform heading matters as much as where it has already been. For Zevin, the more immediate future applications are close to home: HIV reservoir detection, where a shrinking reservoir under treatment demands ever more sensitive assays, alongside pharmacogenomic SNP panels and mycoplasma contamination screening. Countable Labs, for its part, has named Fred Hutchinson its first certified service provider, currently serving researchers across the Seattle region. And the company is continuing to build its list of service providers.</p>
<p>Absolute counting quietly becomes statistical correction once concentration or multiplexing climbs. That’s the exact problem a design built around physical isolation is meant to resolve. Whether it holds up at scale and across sites is still being tested. But as Kane put it, “Digital PCR changed what was quantifiable. Single molecule counting changes what’s measurable.”</p>
<p>The post <a href="https://www.genengnews.com/sponsored/thirty-million-compartments-testing-single-molecule-pcrs-potential/">Thirty Million Compartments: Testing Single-Molecule PCR’s Potential</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Six wild ideas for perpetuating your mind</title>
<link>https://edusehat.com/en/six-wild-ideas-for-perpetuating-your-mind</link>
<guid>https://edusehat.com/en/six-wild-ideas-for-perpetuating-your-mind</guid>
<description><![CDATA[ Have you ever thought about what makes you you? Science assures us it has everything to do with the three-pound organ between our ears, with its billions of neurons and trillions of delicate connections. But it’s a lot trickier to explain why we have a sense of self-awareness or to pin down precisely where that… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/eye-brains.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Six, wild, ideas, for, perpetuating, your, mind</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">Have you ever thought about what makes you <em>you</em>? Science assures us it has everything to do with the three-pound organ between our ears, with its billions of neurons and trillions of delicate connections. But it’s a lot trickier to explain why we have a sense of self-awareness or to pin down precisely where that first memory of Mommy actually resides. As we age, we forget most of what we’ve experienced, yet there’s still undeniable continuity: At 30, or 50, or 70, you will still be you.</p>



<p class="wp-block-paragraph">To preserve that elusive continuity of self, some far-thinking technologists are working on ways to keep your brain going—even beyond death. Let’s call them the “mind savers.” They’re exploring everything from freezing brains in liquid nitrogen to augmenting living ones to uploading our memories to the cloud. Here, we look at six possible paths for keeping your mind going, how feasible they’d be, and what benefits the ­present-day research might bring—even if cognitive immortality doesn’t pan out.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-large"><img fetchpriority="high" decoding="async" width="2383" height="1342" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?w=840" alt='""' class="wp-image-1146281" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg 2383w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=300,169 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=768,433 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=1536,865 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-1.jpg?resize=2048,1153 2048w" sizes="(max-width: 2383px) 100vw, 2383px"><div class="image-credit">EDDIE GUY</div>
</figure>
</div>


<h3 class="wp-block-heading">Head transplant</h3>







<p class="wp-block-paragraph">White’s experiments have been a source of grim fascination ever since. But to a few neuroscientists they’re inspiration, suggesting that one day a human head transplant—or, as some call it, a body transplant—could succeed. </p>



<p class="wp-block-paragraph">The idea’s main proponent is Sergio Canavero, a controversial Italian surgeon who, 10 years ago, even claimed he’d found a volunteer in Valery Spiridinov, a computer programmer suffering from a degenerative muscle disease. Spiridinov initially agreed to have his head transferred to the body of a brain-dead donor in China, but he later bowed out of the plan and <a href="https://nypost.com/2018/12/18/disabled-man-changes-mind-about-head-transplant/">instead</a> got married. And that might be just as well. Critics say the procedure would be more like murder than medicine. Or, best-case scenario: Volunteers would be left paralyzed and in need of a ventilator for life. </p>





<p class="wp-block-paragraph">Canavero says that’s not necessarily true. He claims people’s views on the operation will change once they accept that reconnecting severed spinal cords is already possible. He pointed <em>MIT Technology Review</em> to a research article from this past summer that he coauthored with surgeons at Moscow’s Sklifosovsky Research and Clinical Institute for Emergency Medicine. The team cut through the spinal cords of three pigs at a point midway along their backs and then tested whether the severed nerve bodies could be fused back together using a surgical sealant. According to that paper, which appeared <a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0349579">in the journal <em>PLOS One</em></a>, all the pigs regained the ability to stand and even walk unsteadily.</p>



<p class="wp-block-paragraph">Does that mean a head could be attached to a new body and then actually control it? Mainstream researchers aren’t convinced. Grégoire Courtine, a spinal rehabilitation specialist at the École Polytechnique Fédérale de Lausanne in Switzerland, says he’s been following Canavero’s claims “with little respect” and thinks that we should “pay zero attention.”</p>



<p class="wp-block-paragraph">“There is no technology … capable of such a crazy idea,” Courtine wrote in an email.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<figure class="wp-block-image alignright size-full is-resized"><img decoding="async" width="1000" height="1000" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png" alt="" class="wp-image-1146279" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png 1000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-laptop.png?resize=768,768 768w" sizes="(max-width: 1000px) 100vw, 1000px"></figure>



<h3 class="wp-block-heading">Mindclones</h3>







<p class="wp-block-paragraph">Just 12 years after the book came out, artificial-intelligence technology has already brought some of her predictions to “life,” so to speak. Services such as StoryFile, Afterlife AI, and Synthesia allow users to upload their personal information and likeness in order to produce either conversational bots that share their memories or video talking heads that sound (and look) exactly like them. Influencers now let their “AI clones” do their work on TikTok, and some people are even building <a href="https://www.technologyreview.com/2022/10/18/1061320/digital-clones-of-dead-people/">avatars of their aging parents</a> in order to preserve their personalities.</p>





<p class="wp-block-paragraph">While this mimicry can produce comical results, unhealthy attachments, or uncanny vibes, the increasing realism of generative AI invites people to emotionally accept the avatars as real beings. That was the case when Rothblatt appeared as a digital avatar during a 2025 event held by the UCLA Department of Communication called “The Bridge to Humanizing AI.”</p>



<p class="wp-block-paragraph">Her copy, named Marvatar, was projected on a screen, led the discussions, and talked with the meatspace Rothblatt as an equal, at one point saying, “The dance isn’t about who leads, but how we move together.” According to the university, attendees were “visibly moved” and wept “with wonder” at Rothblatt’s vision of digital equality.</p>



<p class="wp-block-paragraph">What’s still missing from Rothblatt’s mindclone prediction is evidence that these avatars have—or ever will have—any kind of true self-awareness. (We asked ChatGPT if it’s conscious, and <a href="https://chatgpt.com/share/6a8363b3-2560-83ea-92ed-c298b6ef4ef4">it answered</a>, “Probably not.”) But all that remains a gray zone. Neuroscientists don’t have a clear definition of consciousness, much less <a href="https://www.nature.com/articles/s41599-024-03553-w">a diagnostic test</a> they could apply to an avatar. </p>



<p class="wp-block-paragraph">Instead, what if the final determination is in the eye of the beholder? Your digital clone might not<em> be</em> you. But at some point it might be good enough for me. </p>



<div aria-hidden="true" class="wp-block-spacer"></div>



<figure class="wp-block-image alignright size-large is-resized"><img decoding="async" width="1000" height="1000" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?w=840" alt="" class="wp-image-1146278" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png 1000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-jar.png?resize=768,768 768w" sizes="(max-width: 1000px) 100vw, 1000px"></figure>



<h3 class="wp-block-heading">Brain in a jar</h3>







<p class="wp-block-paragraph">So, campy sci-fi film lovers that we are, it got our attention last year when a company called Bexorg started showing journalists <em>actual</em> human brains in vats, which it has been acquiring from organ donors soon after death and then “rebooting” by infusing them with oxygen-rich artificial blood.</p>



<p class="wp-block-paragraph">The company claims these “physiologically intact human brains” will be more useful than animals for drug testing and safer than trying experiments on living volunteers. Add an Alzheimer’s compound to one of these disembodied brains and researchers can then measure exactly what the drug does inside the organ.</p>



<p class="wp-block-paragraph">Bexorg’s CEO, Zvonimir Vrselja, is “sure” that some people would like to restore consciousness to out-of-body brains, but he’s tried to douse such speculation. While they are metabolically active, the company says, the brains have lost all coordinated electrical activity. That means they aren’t conscious—although, just to make sure, the neuroscientists running the experiments add the strong anesthetic propofol to the tissues. </p>



<p class="wp-block-paragraph">What’s more, right now a brain can be kept “alive” outside the body for only about 24 hours. That wouldn’t be much of a second life. Still, efforts are underway to improve the life-support systems. Bexorg says it hopes to eventually keep its brains going for two weeks.</p>



<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img loading="lazy" decoding="async" width="2378" height="1343" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg" alt="" class="wp-image-1146282" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg 2378w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=300,169 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=768,434 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=1536,867 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-2.jpg?resize=2048,1157 2048w" sizes="auto, (max-width: 2378px) 100vw, 2378px"><div class="image-credit">EDDIE GUY</div>
</figure>
</div>


<h3 class="wp-block-heading">Gradual brain replacement</h3>







<p class="wp-block-paragraph">On paper, the goal is to manufacture tissue to graft into the brains of stroke victims, reversing damage and restoring function. Less officially, the project’s existence is a surprise coup for an extreme plan to defeat aging advanced by Jean Hébert, the neuroscientist leading the program, who argued in his 2020 book,<em> Replacing Aging</em>, that we can live longer by replacing our aging brain cells with young ones.</p>





<p class="wp-block-paragraph">We don’t want to lose our identities. That’s why—according to Hébert—it would have to happen gradually, in small chunks, so our brains would have time to adapt to the new tissue.</p>



<p class="wp-block-paragraph">Scientists who applied for the program say Hébert insisted on a very specific technological approach. While most researchers engineer individual cell types, ARPA-H asked for complex chunks of young, functional cortex—more or less like what you’d find in a developing fetus. “He wanted to create essentially an embryonic form of cortex that he thought you could somehow graft into an adult brain,” says Marius Wernig, a Stanford University stem-cell researcher who applied.</p>



<p class="wp-block-paragraph">Skeptics say it’s unknown whether replacement brain chunks will ever properly function as part of your brain—say, by taking over memories. What’s more, it’s still unclear how to manufacture youthful cortex, or what ARPA-H calls “neocortical precursor tissue,” in the lab. One idea is to employ the latest advances in brain organoids. Imagine, if you will, a human cortex grown in a lab dish without a body. </p>



<p class="wp-block-paragraph">We know that the agency has an aggressive timeline: Over the course of five years, it wants researchers to lay the foundation for the first human tests of replacement cortex. The aim, it says, is to “take the ‘permanent’ out of brain damage.” And maybe out of old age, too. </p>



<figure class="wp-block-image alignright size-large is-resized"><img loading="lazy" decoding="async" width="1000" height="1000" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?w=840" alt="" class="wp-image-1146277" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png 1000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/BRAIN-alsobrain.png?resize=768,768 768w" sizes="auto, (max-width: 1000px) 100vw, 1000px"></figure>



<div aria-hidden="true" class="wp-block-spacer"></div>



<h3 class="wp-block-heading">Brain upload</h3>







<p class="wp-block-paragraph">Scientists are already mapping this wiring in simpler animals. Two years ago, Seung took part in analyzing a fly brain that had been cut into paper-thin sheets and imaged with an electron microscope. Then he and his colleagues used image-analysis software to trace 139,255 neurons and about 55 million synapses. The fly map could lead to energy-efficient software that computes the way real brains do, Seung says. </p>



<p class="wp-block-paragraph"> Others believe the ultimate outcome of “connectomics” research  will be what’s called “whole-brain emulation,” or sometimes just “uploading.” It’s the idea, popular in some quarters of Silicon Valley, that a simulation created from a sliced-up brain could become so detailed that it would reproduce not only a generic intelligence but a particular one, like yours—complete with memories and opinions, and able to live again in a data server somewhere. </p>



<p class="wp-block-paragraph">Setting aside the question of whether a simulation would really be you, everyone agrees that this technology isn’t coming in time for those of us alive today. A <a href="https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0326920">survey</a> of 312 neuroscientists, published in 2025 in <em>PLOS One</em>, estimated that human whole-brain emulation wouldn’t happen before 2125.</p>



<p class="wp-block-paragraph">That long and unpredictable tech horizon helps explain why two US companies, Nectome and Sparks Brain Preservation, are offering to preserve human brains (or bodies) today by infusing them with the same potent chemicals used to “fix” the brains of fruit flies for connectome mapping. The idea: If the fine details of a brain’s structure can be preserved, one day in the far future it might be reanimated. </p>



<p class="wp-block-paragraph">But there’s a startling twist. Because brain tissue needs to be preserved quickly after a person’s death, both companies say they want to work with people taking advantage of medical aid in dying, now legal in 13 states and Washington, DC. In that procedure, doctors supply a lethal dose of drugs, but it’s the patient—someone with a terminal prognosis—who pushes the plunger. For a fee, the companies say, they can have a preservation team at the ready. So far, the service is not popular. The companies each say they are still awaiting their first aid-in-dying customer. </p>



<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img loading="lazy" decoding="async" width="2410" height="1353" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg" alt="" class="wp-image-1146283" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg 2410w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=300,168 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=768,431 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=1536,862 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/Unknown-3.jpg?resize=2048,1150 2048w" sizes="auto, (max-width: 2410px) 100vw, 2410px"><div class="image-credit">EDDIE GUY</div>
</figure>
</div>


<h3 class="wp-block-heading">Synthetic neocortex</h3>







<p class="wp-block-paragraph">That’s right: an extra brain.</p>



<p class="wp-block-paragraph">Recently, we’ve seen inklings of how this might come to pass. In 2024, Science Corporation, in California, unveiled a “biohybrid” brain-computer interface featuring nerve cells grown on a digital chip. Placed on an animal’s brain, these cells sent out long, thin axons that integrated with the animal’s own neurons. The result: two-way communication from computer to brain, in the brain’s language.</p>





<p class="wp-block-paragraph">The technology could permit new types of medicine, like an implant that directs brain cells to produce dopamine and thereby treat Parkinson’s. But Max Hodak, the company’s CEO, says it also might count as a new brain part, which he likens to a “big, externalized cranial nerve.” </p>



<p class="wp-block-paragraph">Such a device could serve as the connector to Kurzweil’s computerized neocortex in the cloud, giving a living person unlimited extra processing power. Still other entrepreneurs believe if you kept adding biohybrid components to a brain, eventually you could morph it into an immortal machine. </p>



<p class="wp-block-paragraph">Daniel Burger, founder of the venture-­funded stealth startup Eightsix Science (its name refers to the 86 billion neurons in a human brain), says this dream could require mixing several of the brain-saving techniques on this list. He thinks we might need brains in vats, affording neuro-­engineers easy access, so they can gradually replace brain parts with biohybrid neural grafts. </p>



<p class="wp-block-paragraph">The ultimate goal is to migrate your mind into your extra, engineered brain, without ever breaking the continuity of self. “It’s not the typical ‘scan, store, simulate,’” says Burger. “I don’t think simulations will be conscious.” He adds, “We’re saying it’s going to be way more complicated, and it’s probably going to look like gradual brain replacement into a hardware brain.”</p>



<p class="wp-block-paragraph">Once your mind is hardware, you won’t need a biological body. Instead, you could take up residence in a data center somewhere and perhaps even have backups distributed around the globe. “From that point on,” Burger acknowledges, “stuff becomes really crazy.”</p>]]> </content:encoded>
</item>

<item>
<title>Pig kidneys that were “frozen” for a year have been brought back to life</title>
<link>https://edusehat.com/en/pig-kidneys-that-were-frozen-for-a-year-have-been-brought-back-to-life</link>
<guid>https://edusehat.com/en/pig-kidneys-that-were-frozen-for-a-year-have-been-brought-back-to-life</guid>
<description><![CDATA[ Pig kidneys that were cooled to -150 °C and stored in a freezer for months have been successfully rewarmed and shown to work again for the first time, say scientists. They hope to replicate the findings with human organs. The kidneys—which are similar in size to human ones—were left in a glass-like state, in one… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/pig-freeze.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 19:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pig, kidneys, that, were, “frozen”, for, year, have, been, brought, back, life</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Frozen kidneys brought back to life:</strong> Scientists have successfully vitrified pig kidneys—cooling them to -150°C—and rewarmed them after up to a year in storage. The kidneys regained color and produced urine, key signs they were working.</li><br><li><strong>Nanoparticles are the secret ingredient:</strong> Iron oxide nanoparticles infused into the organs allow for rapid, even rewarming when activated by an electromagnetic field—solving one of cryobiology's longest-standing technical headaches.</li><br><li><strong>A revolution for transplantation:</strong> Long-term organ banking could mean organs wait for patients, not the other way around—giving doctors time to better match donors and recipients and potentially reduce the need for lifelong immune-suppressing drugs.</li><br><li><strong>Still not ready for prime time:</strong> The rewarmed kidneys showed signs of injury, likely from toxic cryoprotectant chemicals, and produced less urine than expected.</li></ul>" data-chronoton-post-id="1146091" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p class="wp-block-paragraph">Pig kidneys that were cooled to -150 °C and stored in a freezer for months have been successfully rewarmed and shown to work again for the first time, say scientists. They hope to replicate the findings with human organs.</p>



<p class="wp-block-paragraph">The kidneys—which are similar in size to human ones—were left in a glass-like state, in one case for over a year. Once they had been rewarmed, tested in machines, and transplanted into pigs, the kidneys regained their color and made urine—key signs they were working.</p>





<p class="wp-block-paragraph">“Ten years ago … I wouldn’t say I had high hopes it was actually going to work,” says Erik Finger, a transplant surgeon at the University of Minnesota who co-led the work. “After we did the last transplant, I walked out of the room and said, ‘This is a big deal.’” The research was shared at the preprint server <a href="https://www.biorxiv.org/content/10.64898/2026.10.07.756990v1">bioRxiv</a> and has not yet been peer-reviewed.</p>



<p class="wp-block-paragraph">The kidneys aren’t perfect, and the researchers have yet to demonstrate that they can sustain life over the long term. But the results represent a milestone achievement, say others in the field.</p>



<p class="wp-block-paragraph">“Thank God that someone’s actually managed to do it in one organ and prove that it works,” says Peter Kilbride, a cryobiologist and cofounder of Kyros Kairos, a company focused on improving funding for cryopreservation research, who was not involved in the research. “For years, people have been trying and failing to get to this step. Finally, we’ve got this breakthrough.”</p>



<p class="wp-block-paragraph">“Their work is amazing and will enable us to truly, indefinitely bank organs,” says Korkut Uygun, a biomedical engineer and professor of surgery at Harvard Medical School, who was also not involved in the research. “It is a revolutionary time for transplantation.”</p>



<h3 class="wp-block-heading">Buying time</h3>



<p class="wp-block-paragraph">Every year, tens of thousands of organ transplants take place in the US alone. These procedures are thought to have <a href="https://jamanetwork.com/journals/jamasurgery/fullarticle/2100153">saved 2 million years of life in the last 25 years</a>. But there’s plenty of room for improvement.</p>



<p class="wp-block-paragraph">One major challenge is the lack of available organs. Even when an organ becomes available, it can be difficult to get it to the right recipient within 24 to 36 hours, which is the current limit for preserving human organs.</p>



<p class="wp-block-paragraph">People who receive organ transplants must also take drugs that suppress their immune systems for the rest of their lives. These drugs are meant to stop their bodies from rejecting the new organs. But they come with side effects and increase the risk of infections and cancer.</p>



<p class="wp-block-paragraph">The ability to bank organs for long periods of time holds the promise to address all these challenges. Doctors would have more time to match organs to recipients. They’d be able to limit the risk of organ rejection, too—potentially by preparing recipients, and their immune systems, beforehand.</p>



<p class="wp-block-paragraph">“With real organ banking … instead of the patients waiting for the organ, it’s the organs that are waiting for the patients,” says Finger.</p>





<p class="wp-block-paragraph">Scientists have been able to cool cells to ultra-low temperatures through a process called vitrification, which essentially turns them to something like glass. This procedure is already used to store eggs, sperm, and embryos. Vitrifying whole organs is much harder.</p>



<p class="wp-block-paragraph">Some problems can be avoided with cryoprotectants—chemicals that work like antifreeze and prevent damaging ice crystals from forming. But these chemicals tend to be incredibly toxic. It’s also difficult to rapidly and uniformly cool large tissues, and just as hard to evenly rewarm an organ all the way through.</p>



<p class="wp-block-paragraph">Working with John Bischof, a bioengineer at the University of Minnesota, Finger and colleagues have come up with a solution. Once an organ has been loaded with a cryoprotectant, they infuse it with iron oxide nanoparticles. These nanoparticles don’t do anything to the cells. But when it’s time to rewarm the organ, they can be activated with an electromagnetic field. </p>



<p class="wp-block-paragraph">When the radiofrequency of that field switches between two states, the particles also flip, realigning themselves with the field. That causes them to release heat throughout the organ. Adjusting the power of the field allows the team to control the rate of heating so that it gets faster once the organ reaches -120°C. </p>



<p class="wp-block-paragraph">The researchers successfully vitrified rat kidneys using this approach in <a href="https://www.nature.com/articles/s41467-023-38824-8">work published in 2023</a>. Back then, they were able to rewarm kidneys that had been kept in a freezer for up to 100 days before transplanting them into rats.</p>



<p class="wp-block-paragraph">Since then, the team has been trying to achieve the same success with bigger organs. Pig kidneys are thought to be a good model for human ones—they’re about the same size and look similar. Rat kidneys weigh around one gram; pig kidneys are around 100.</p>



<p class="wp-block-paragraph">It hasn’t been easy. The cryoprotectant used for vitrifying rat kidneys didn’t work as well in the pig organs. “We had to rediscover and modify the cocktail,” says Bischof. “That’s why it’s taken us three years.”</p>



<h3 class="wp-block-heading">Deep-freezing kidneys</h3>



<p class="wp-block-paragraph">The first step in the procedure is to remove a kidney from a donor pig. Once it’s out, the kidney is flushed with a commonly used organ preservation solution to remove the blood, bagged, and temporarily laid on a bed of ice in a cooler so it can be taken over to the engineering lab.</p>





<p class="wp-block-paragraph">There, team members unpack the kidney and hook it up to a device they’ve designed to control the organ’s temperature and pressure. Then they start to load it up with the cocktail of cryoprotectants, slowly enough to ensure an even spread through the organ but quickly enough to minimize any toxic effects. It takes around two hours.</p>



<p class="wp-block-paragraph">The next step is to infuse the organ with the iron oxide nanoparticles, which are pumped through the organ for around seven to eight minutes, says Finger. Then it’s time to cool the organ by pumping cold nitrogen vapor into a chamber housing it.</p>



<p class="wp-block-paragraph">It’s a delicate process, and the team must ensure that the organ is cooling all the way through. At the same time, they must lower the kidney’s temperature as quickly as possible to prevent ice from forming. “Oftentimes there are multiple people doing different things to make sure that things don’t go awry,” says Bischof.</p>



<p class="wp-block-paragraph">Once the organ reaches the vitrified state at around -120 °C, it “behaves like a glass,” says Finger. “At that point, you can stay stable for long periods of time—we think indefinitely.” The team then pauses the cooling process to ensure that the organ is glassy throughout. Otherwise, it could crack.</p>



<p class="wp-block-paragraph">After the pause, if everything goes well, the kidney is ultimately cooled to -150 °C. Once it’s in the freezer, it can stay there for days, weeks, or even months. The team has kept a small number of kidneys banked for over a year.</p>



<h3 class="wp-block-heading">Pink right up</h3>



<p class="wp-block-paragraph">The real test of these kidneys comes when they’re taken out of the freezer, rewarmed, and flushed of their chemicals and nanoparticles. Can they support life? So far, the team has tested some of them in a couple of different ways.</p>



<p class="wp-block-paragraph">In one set of experiments, the researchers put rewarmed kidneys on <a href="https://www.technologyreview.com/2026/07/24/1140790/the-quest-to-keep-organs-alive-outside-the-body/">perfusion devices</a>—systems that are already used in transplant surgeries both to provide organs with nutrients and to help doctors assess them while they’re out of the body.</p>



<p class="wp-block-paragraph">In another set of experiments, Finger and his colleagues transplanted rewarmed kidneys into pigs and monitored them for two hours. In both experiments, the rewarmed kidneys seemed to recover, says Finger. “They pink right up,” he says. </p>



<figure class="wp-block-video"><video height="1080" width="1920" controls src="https://wp.technologyreview.com/wp-content/uploads/2026/10/Suppl-video-2-acute-transplant.m4v" preload="none"></video><figcaption class="wp-element-caption">The team see blood flow into the rewarmed, transplanted kidney, allowing it to “pink up.”</figcaption><div class="video-credit">COURTESY OF THE RESEARCHERS</div>
</figure>



<p class="wp-block-paragraph">There are lots of ways to measure the function of a kidney, but one key test is whether or not the organ can make urine. By this measure, the rewarmed kidneys did well, although they produced around two-thirds of the amount that would normally be expected. “They produce urine … within a minute or so,” says Finger. “We know that they work.” </p>



<p class="wp-block-paragraph">Most of the rewarmed kidneys had been banked for days or weeks. But one had been in the freezer for just over a year. When Finger and his colleagues rewarmed it and put it on a perfusion machine, they found that it produced urine “immediately.” “It actually looked better than many of the [other] kidneys,” says Finger. “We’re comfortable now saying we can store them for a year and rewarm them with excellent function.”</p>



<p class="wp-block-paragraph">“It’s a very big deal to go a year,” says Kevin Myer, president and CEO of <a href="https://www.lifegift.org/">LifeGift</a>, an organ procurement organization based in Texas. Being able to store organs for that length of time would transform organ transplantation. He envisions banks of organs that could be used on demand in emergency cases where people can’t wait, such as for some drug overdoses or gunshot wounds.</p>



<h3 class="wp-block-heading"><strong>Final hurdles</strong></h3>



<p class="wp-block-paragraph">But the procedure isn’t ready for prime time just yet. As well as producing less urine than expected, the rewarmed kidneys also showed signs of injury. The damage seems to be caused by the cryoprotectant chemicals, say the researchers.</p>





<p class="wp-block-paragraph">“This is one big breakthrough that solves half the problem,” as Kilbride puts it.</p>



<p class="wp-block-paragraph">The team has shown that the rewarmed kidneys can regain blood flow, which is “very important,” says Greg Fahy, a cryobiologist who is considered a pioneer in the field. But he’s worried about the extent of the damage to the organs. “We can’t tell from these experiments whether these kidneys might have supported life or not.”</p>



<p class="wp-block-paragraph">But Fahy, who is chief scientific officer at the biotech companies Intervene Immune and 21st Century Medicine (where he is also executive director), acknowledges that it’s not clear how these kidneys might fare once they’re inside a living animal for the long term. </p>



<p class="wp-block-paragraph">Finger also hopes to find ways to repair the damage seen in the kidneys. Other research has shown that the health of transplant organs <a href="https://www.technologyreview.com/2026/09/14/1144010/donated-livers-can-be-made-biologically-younger/">can improve while they’re on perfusion machines</a>. And damaged kidneys might undergo some level of self-repair once they’re in a body. At any rate, human kidneys may cope better with the process than pig kidneys, says Finger.</p>



<p class="wp-block-paragraph">The next step will be to test the kidneys in pigs over longer periods of time. The team, along with many other researchers in the field, will continue the search for less toxic cryoprotectants, too. Finger, Bischof, and their colleagues are also planning experiments with human kidneys.</p>



<p class="wp-block-paragraph">Finger is optimistic. “We’re going to see that there’s injury, and it’s not perfect … but now we’ve got to the point where it works,” he says. “These are big, historic milestones in our field, and we’re excited about it.”</p>]]> </content:encoded>
</item>

<item>
<title>Alzheimer’s Small&#45;Molecule Therapy Shows Promise in Mice and Early Human Trial</title>
<link>https://edusehat.com/en/alzheimers-small-molecule-therapy-shows-promise-in-mice-and-early-human-trial</link>
<guid>https://edusehat.com/en/alzheimers-small-molecule-therapy-shows-promise-in-mice-and-early-human-trial</guid>
<description><![CDATA[ A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies for Alzheimer&#039;s disease and was well tolerated in a Phase I trial.
The post Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1490968075.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 05:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Alzheimer’s, Small-Molecule, Therapy, Shows, Promise, Mice, and, Early, Human, Trial</media:keywords>
<content:encoded><![CDATA[<p>One of the hallmarks of Alzheimer’s disease is the extracellular deposition of amyloid-β (Aβ) plaques. Current treatments for Alzheimer’s disease include anti-Aβ therapeutics that have demonstrated proof-of-concept disease modification; however they have yielded only modest clinical benefits. Because of this, researchers aim to identify other targets and have recently focused on microglia—the brain’s resident innate immune cells whose duties include maintaining neural networks and clearing cellular debris.</p>
<p>Now, a small molecule therapy for Alzheimer’s disease that targets the brain’s microglia cells protected neurons in a mouse model and was found to be safe in humans, according to new research that includes results from a Phase I trial involving 115 participants and patients. More specifically the new work reports on “VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist that engages the transmembrane domains of TREM2 and its adaptor DAP12 to promote higher-order receptor complex formation and downstream signaling.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease.” The therapy stands at the leading edge of a new class of experimental drugs that target microglia through small molecules rather than antibodies, the latter of which have faced various obstacles to translation.</p>
<p>Microglia contain the transmembrane receptor TREM2, which supports the cells’ ability to respond to signs of disease and to break down amyloid-beta. Genetic studies have identified multiple rare coding variants of TREM2—such as p.R47H (Arg47→His)—which impair TREM2 signaling and correlate with a higher risk of late-onset Alzheimer’s disease.</p>
<p>Here, a large collaboration across multiple research teams engineered two small molecules that activate human TREM2: VG-3927 and VG-3909. The compounds reduced markers of neuronal damage and inflammatory signaling when given to cultured neurons and microglia and boosted microglia’s ability to break down amyloid-beta in a mouse model.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>More specifically, the authors note, “In human iPSC-derived neuron-microglia-astrocyte cultures, VG-3927 reduced inflammatory cytokines and markers of neuronal damage. In 5xFAD amyloidosis mice expressing the common variant of hTREM2 (5xFAD;hTREM2CV), VG-3909 induced neuroprotective transcriptional reprogramming of microglia, particularly in the plaque niche; enhanced Aβ phagocytosis; and boosted brain glucose metabolism.”</p>
<p>The team then tested ascending doses of the small molecules in a Phase I trial. In the first-in-human, randomized, double-blind, placebo-Phase I trial (NCT06343636), VG—3927 was well tolerated across single and multiple ascending doses of up to 140 milligrams and penetrated the central nervous system. It also reduced levels of a marker of TREM2 in the cerebrospinal fluid in patients with Alzheimer’s disease—a promising finding in the nascent field of TREM2-targeted therapies.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/alzheimers-small-molecule-therapy-shows-promise-in-mice-and-early-human-trial/">Alzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Contracting Expansion: A Path to Better CAR T&#45;Cell Therapy Production</title>
<link>https://edusehat.com/en/contracting-expansion-a-path-to-better-car-t-cell-therapy-production</link>
<guid>https://edusehat.com/en/contracting-expansion-a-path-to-better-car-t-cell-therapy-production</guid>
<description><![CDATA[ Shorter cell expansion steps could significantly accelerate CAR T-cell therapy production processes, according to researchers, who cite microfluidic culture systems, real-time PAT tools, and AI-enabled predictive models as key enablers of this new rapid manufacturing paradigm.
The post Contracting Expansion: A Path to Better CAR T-Cell Therapy Production appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2189264798-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Contracting, Expansion:, Path, Better, CAR, T-Cell, Therapy, Production</media:keywords>
<content:encoded><![CDATA[<p>Shortening the time allotted to cell expansion in CAR T-cell therapy production could yield more effective, lower-dose products that get to patients sooner than those made using current methods.</p>
<p>The steps involved in making a CAR T-cell therapy—separation, enrichment, activation, modification, expansion, harvest, and cryopreservation—do not actually take a long time—usually between 10 and 21 days.</p>
<p>Yet, for the seriously ill patients who need them, the wait can still be too long. Analysis in <a href="https://www.tandfonline.com/doi/full/10.1080/14796694.2024.2393566" target="_blank" rel="noopener">2024</a> suggested that some 30% of therapies made each year go unused, because the intended recipient’s health deteriorates while the product is being made.</p>
<p>As a result, reducing “vein-to-vein time”—the time required to turn patient-derived material into a therapy and administer it—has become a goal for the CAR T industry, with most efforts focusing on process efficiency or decentralized production.</p>
<h4><strong>Contracting expansion</strong></h4>
<p>Another way of reducing vein-to-vein times would be to shorten <em>ex vivo</em> expansion, <a href="https://link.springer.com/article/10.1186/s13036-026-00666-5#Sec22" target="_blank" rel="noopener">according</a> to Marta Costa, PhD, and colleagues at Portugal’s iBET, who say a “rapid manufacturing” approach would yield more effective, more consistent therapies.</p>
<p>“Rapid manufacturing changes the manufacturing goal as, instead of maximizing the number of cells produced outside the body, it aims to make fewer but fitter cells, by limiting expansion to three days or less.</p>
<p>“This preserves naïve and stem cell-like memory T cells, which proliferate and persist much better once infused, and this can, ultimately, result in lower CAR T cell doses,” she tells <em>GEN</em>.</p>
<h4><strong>Fitter cells</strong></h4>
<p>Under the current manufacturing paradigm, expansion processes run for as long as it takes the culture to achieve a desired density—often in the order of 10⁸ cells. The problem is that, after this period, the cells are often fully differentiated and exhausted.</p>
<p>Limiting expansion would increase the proportion of “fitter” naïve T cells harvested and, according to Costa and colleagues, produce therapies as effective as those made from fully differentiated cells, but at a much lower dose.</p>
<p>Achieving such precise control over shortened production processes will require innovative digital technologies, Costa says.</p>
<p>“Automation is what makes speed safe and allows for reproducibility. It also makes decentralized and point-of-care manufacturing realistic, allowing CAR T cell manufacturing to run at many hospitals supported by a closed, standardized and sensor-equipped system that is essential to ensure product quality.”</p>
<p>Costa cites the CliniMACS Prodigy and Lonza’s Cocoon as technologies that could facilitate the approach, adding, “They are being explored for rapid CAR T cell production as they integrate the steps from leukapheresis to final product in one closed system.</p>
<p>“Besides,” she continues, “to truly allow CAR T-cell therapies to rely on rapid manufacturing processes, faster analytics for product release are needed as several assays still take a week or more to assess product safety and potency.”</p>
<p>AI modeling also has a potential role to play, according to Costa.</p>
<p>“At the moment, most CAR T cell manufacturing processes follow a fixed recipe that is applied regardless of how patients’ cells respond. AI and data-driven approaches have the potential to shift this paradigm by predicting how cells will grow and differentiate, while enabling continuous, online monitoring of cell state.</p>
<p>“These insights can then be used to dynamically adjust process parameters and steer cells toward a desired quality phenotype. Ultimately, this could enable more adaptive manufacturing strategies, including selecting the optimal harvest timepoint based on the evolving state of the cells rather than a predefined culture duration,” she says.</p>
<p>“The evidence increasingly shows that cell quality matters more than cell quantity. Shorter processes produce fitter cells, cost less, increase capacity, and help patients who cannot wait weeks. That combination is hard to argue against, and it is also one of the reasons <em>in vivo</em> CAR T cell strategies, which remove <em>ex vivo</em> manufacturing altogether, are rapidly gaining momentum. We will see what the future holds.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/contracting-expansion-a-path-to-better-car-t-cell-therapy-production/">Contracting Expansion: A Path to Better CAR T-Cell Therapy Production</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Turning Process Understanding Into Control of Lipid Nanoparticles</title>
<link>https://edusehat.com/en/turning-process-understanding-into-control-of-lipid-nanoparticles</link>
<guid>https://edusehat.com/en/turning-process-understanding-into-control-of-lipid-nanoparticles</guid>
<description><![CDATA[ Splitting lipid nanoparticle manufacturing into multiple mixing steps can help better control the size, shape, and stability of particles, with the aim of improving product quality during commercial-scale production.
The post Turning Process Understanding Into Control of Lipid Nanoparticles appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1441708537-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Turning, Process, Understanding, Into, Control, Lipid, Nanoparticles</media:keywords>
<content:encoded><![CDATA[<p>A new academic spin-off company aims to help manufacturers of lipid nanoparticles (LNP) produce products that are of consistent quality when produced at scale.</p>
<p>Bizon Labs, a spin-out of the Massachusetts Institute of Technology (MIT), is named after bison who run toward storms, as an indicator of how the company tackles head-on the challenges of improving LNP formulations.</p>
<p>According to Cedric Devos, PhD, a postdoctoral associate in the Department of Chemical Engineering at MIT, their work aims to physically optimize LNP delivery through adapting processes, rather than focusing on optimizing via chemistry alone.</p>
<p>“Our goal is specifically to reach a level of control over particle attributes that will enable novel biological applications,” he explains.</p>
<p>“One key example, often given in the field, is that you need extremely specific particle features to target specific organs, and these can’t be achieved yet with what’s out there in process work.”</p>
<p>The process innovations that the team behind Bizon have pioneered, Devos says, are in achieving control over LNP size and morphology that’s extremely difficult with conventional techniques.</p>
<p>This allows, he says, processes to be better understood and, thus, replicated at a variety of production scales.</p>
<p>To achieve this, the team split traditional mixing processes that produce LNPs in a single step into multiple steps to give better control over their attributes. For example, this allows them to tweak LNP shape to enable better product stability for long-term storage, he says.</p>
<p>In addition, he adds, breaking up the mixing process into multiple smaller steps allows companies to develop more complex models and simulations, which should, in turn, help them to understand their processes better.</p>
<p>But among the critical pillars they’re looking at for the future are optimizing the therapeutic cargo, better mechanistic understanding of the LNP process, and improving downstream processing, including purification.</p>
<p>“We’re still doing research,” he says. “There’s much more to control.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/turning-process-understanding-into-control-of-lipid-nanoparticles/">Turning Process Understanding Into Control of Lipid Nanoparticles</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>For Biocatalysis, Solvents Are a Key Bioprocessing Parameter</title>
<link>https://edusehat.com/en/for-biocatalysis-solvents-are-a-key-bioprocessing-parameter</link>
<guid>https://edusehat.com/en/for-biocatalysis-solvents-are-a-key-bioprocessing-parameter</guid>
<description><![CDATA[ Deep eutectic solvents can modulate multiple biocatalysis process parameters, thus minimizing or eliminating the need for bioengineering in certain enzymes while enhancing productivity and product quality.
The post For Biocatalysis, Solvents Are a Key Bioprocessing Parameter appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_1939530453_PharmaceuticalLab.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>For, Biocatalysis, Solvents, Are, Key, Bioprocessing, Parameter</media:keywords>
<content:encoded><![CDATA[<p>As biomanufacturers slowly transition from aqueous to non-aqueous solvents for biocatalysis, deep eutectic solvents (DES) are getting more attention as sustainable, tunable options. Their primary uses in biocatalysis are to enhance substrate solubility and enzyme activity, modulate enzyme stability, and tune stereo- and regioselectivity.</p>
<p>Furthermore, research shows DES can increase titer and productivity compared to traditional catalysts, and enzymes catalyzed in DES are thermally stable without the need for protein engineering.</p>
<p>But the choice of solvent isn’t a straightforward decision. Scientists are learning that the solvent itself is a key process parameter with spillover effects that can even affect stereochemistry.</p>
<p>The choice of solvent can have profound effects on product quality, according to a recent <a href="https://www.sciencedirect.com/science/article/pii/S2693125726000397#sec5" target="_blank" rel="noopener">literature review</a> by Xiamen University scientists Yuxuan Hou, a student, and professors Jinyu Meng, PhD; Binghui Chen, PhD; Jifeng Yuan, PhD; and Shizhen Wang, PhD.</p>
<p>“DES composition and water content shape the enzyme-specific microenvironment and thereby affect catalytic performance,” they note. Changing it affects the DES hydrogen- bond network, viscosity, diffusivity, polarity, and solvent distribution around the protein surface.</p>
<p>They cited studies in which the residual activity of cellulase and pectinase rose and then fell as water quantities increased, and a hydrogenase/TiO<sub>2</sub> photocatalytic system in which increasing the solvent quantity reduced dioxygen transport, and increasing the water content increased activity.</p>
<p>Additionally, they write, “Accumulating evidence indicates that DES can enhance enzyme thermostability while preserving catalytic activity.” The choice of hydrogen bond donors and acceptors was a key determinant.</p>
<p>For example, in the case of <em>Candida rugosa</em> lipase, the hydrogen bond donor enabled the enzyme’s half-life to increase from one hour to more than nine hours using DES. For <em>Humicola insolens</em> cutinase, the hydrogen bond acceptor was the key determinant, increasing half-life from 22 minutes to 62. The benefit is that modulating thermostability through the solvent rather than through bioengineering is faster and more cost-effective.</p>
<p>“In addition, the aqueous fraction can affect the interactions between DES components and proteins, and alter hydration, thereby further modulating enzyme thermostability,” the scientists point out.</p>
<p>Changing the solvent can also affect the stereoselectivity and regioselectivity of an enzyme<em>. </em>Hou and colleagues cite <a href="https://doi.org/10.1002/adsc.201601064" target="_blank" rel="noopener">one study</a> in which baker’s yeast was used to convert arylpropanones [high value intermediates used to manufacture some active pharmaceutical ingredients]. With water as a solvent, the arylpropanones were largely converted to the “S” version, but when DES was used, the conversion was predominantly to the “R” version.</p>
<p>This solvent-modulated selectivity significantly enhances flexibility, but it also means quality must be finely controlled to ensure the choice of solvent doesn’t negatively affect the product.</p>
<p>Clearly, the choice of solvent has serious consequences for product quality that biomanufacturers may not fully appreciate. The challenge is a lack of data regarding enzyme behavior in various solvents.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/for-biocatalysis-solvents-are-a-key-bioprocessing-parameter/">For Biocatalysis, Solvents Are a Key Bioprocessing Parameter</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cell Therapy Manufacturing Takes Shape Across Asia&#45;Pacific</title>
<link>https://edusehat.com/en/cell-therapy-manufacturing-takes-shape-across-asia-pacific</link>
<guid>https://edusehat.com/en/cell-therapy-manufacturing-takes-shape-across-asia-pacific</guid>
<description><![CDATA[ Cell and gene therapy is accelerating across Asia-Pacific, but manufacturing remains fragmented. Strategic automation, adaptable bioprocessing platforms, stronger supply chains, and workforce development could help therapies scale across diverse markets.
The post Cell Therapy Manufacturing Takes Shape Across Asia-Pacific appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Mike-APAC-CGT_GBPN_IMAGE_08OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cell, Therapy, Manufacturing, Takes, Shape, Across, Asia-Pacific</media:keywords>
<content:encoded><![CDATA[<p>Cell and gene therapy (CGT) is gathering momentum across the Asia-Pacific region (APAC), but translating that growth into scalable manufacturing will require more than simply moving established processes into new markets. The challenge is that the region cannot be treated as a single manufacturing environment.</p>
<p>“APAC is better viewed as a collection of complementary ecosystems rather than one uniform market,” says Jerry Huang, APAC marketing manager, cell therapy technologies for Terumo Blood and Cell Technologies. China has a fast-growing CGT innovation and commercialization ecosystem, while Japan brings particular strength in induced pluripotent stem cells and regenerative medicine. Korea combines strong biologics and contract development and manufacturing organization capabilities, and Australia offers an established clinical-trial infrastructure.</p>
<p>Those strengths are accompanied by significant manufacturing differences. “Each country can have different regulatory requirements, import rules, manufacturing capabilities, and reimbursement environments,” Huang says. As a result, he adds, developers “cannot assume that a single, centralized manufacturing site will efficiently serve every Asian market.”</p>
<p>For bioprocessing teams, those differences quickly become practical concerns. CGT manufacturing can involve many individual operations and transfers between systems, creating more opportunities for manual intervention and variability. Media and reagents may also differ in availability and regulatory acceptability from one country to another, complicating technology transfer and localization.</p>
<p>Supply chains can compound the problem. According to feedback from customers in Thailand, Huang says, “some imported materials can take up to three months to arrive,” which makes inventory planning and supplier agreements part of good manufacturing practice (GMP) operations. Fresh-cell logistics can be equally demanding. He points to an example of shipping from Taiwan to U.S. clinical sites, where “flight schedules and even typhoon risk need to be factored into manufacturing planning.”</p>
<p>Workforce constraints add another layer of complexity. In some organizations, CGT manufacturing personnel can require six to nine months of training for required proficiency, while turnover among skilled operators and senior GMP managers can introduce additional operational risk.</p>
<p>Automation could reduce some of those vulnerabilities, but Huang argues that it should follow process understanding, not substitute for it. Here, Huang points out that the most crucial issue is “simplifying and integrating fragmented workflows, while using automation where it adds value and balancing a standardized core workflow with modularity and adaptability for different pipelines, process needs, and local requirements.”</p>
<p>In China, for example, Terumo Blood and Cell Technologies is working with local partners to build a more simplified, integrated, and fit-for-purpose chimeric antigen receptor (CAR) T-cell manufacturing workflow. “The idea is not to replace local technologies,” Huang says, “but to bring together each partner’s strengths with our global manufacturing experience and quality standards.” The goal, he adds, is to “simplify the workflow, reduce manual steps and operational complexity, and improve batch economics” while maintaining the consistency and scalability required for clinical and commercial manufacturing.</p>
<p>Ultimately, Huang sees regional scale depending on manufacturing approaches “designed for the region’s diversity rather than attempting a single model and trying to make it work everywhere.” Standardized manufacturing cores, more integrated workflows, digital traceability, resilient supply chains, qualified material alternatives, and a larger GMP-trained workforce could all help turn Asia-Pacific’s diverse CGT ecosystems into a more connected manufacturing landscape.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cell-therapy-manufacturing-takes-shape-across-asia-pacific/">Cell Therapy Manufacturing Takes Shape Across Asia-Pacific</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Preterm Birth for Some Women Linked to Specific Autoantibodies</title>
<link>https://edusehat.com/en/preterm-birth-for-some-women-linked-to-specific-autoantibodies</link>
<guid>https://edusehat.com/en/preterm-birth-for-some-women-linked-to-specific-autoantibodies</guid>
<description><![CDATA[ By analyzing maternal sera from term and preterm pregnancies, in combination with studies in live mice and in human placental tissues, researchers identified antibodies that play a role in triggering early labor.
The post Preterm Birth for Some Women Linked to Specific Autoantibodies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/Getty_2147604693_bioprocessing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 15 Oct 2026 01:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Preterm, Birth, for, Some, Women, Linked, Specific, Autoantibodies</media:keywords>
<content:encoded><![CDATA[<p>A typical pregnancy lasts 40 weeks, but for about one in 10 pregnant women labor begins too soon, and premature or preterm birth is the leading cause of newborn deaths worldwide. Doctors have struggled to understand why preterm birth occurs—or how to predict which pregnancies are at highest risk.</p>
<p>By analyzing maternal sera from term and preterm pregnancies, in combination with studies in live mice and in human placental tissues, researchers at University of California, San Francisco (UCSF) identified antibodies that play a role in triggering early labor. The antibodies were present in higher levels and appeared earlier during pregnancy in women who went on to give birth to their babies before 37 weeks’ gestation, compared to women who delivered their babies at term.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>For their study the researchers used a new immune profiling tool built at UCSF, which they suggest could lead to new ways of screening for preterm birth risk and to new preventive interventions. “We built our tool to find exactly these kinds of hidden immune signals,” said Joe DeRisi, PhD, the Gordon M. Tomkins Professor of Biochemistry and Biophysics. “The fact that it’s pointing us toward why some pregnancies go wrong is an exciting result.”</p>
<p>The results also hint that an existing drug used to treat certain inflammatory conditions might feasibly represent a potential candidate for preventing preterm birth. DeRisi is senior author of the scientists’ published paper in <em>Nature Immunology</em>, titled “<a href="https://www.nature.com/articles/s41590-026-02689-y" target="_blank" rel="noopener">Evidence for maternal autoantibodies in the pathogenesis of preterm birth</a>.”</p>
<p>Every pregnancy presents a puzzle for the human immune system. A fetus is not genetically identical to a mother, yet her body must not reject it. “The maternal immune system is reprogrammed during pregnancy to tolerate a semi-allogeneic fetus, yet the mechanisms by which immune tolerance is established and maintained in normal human pregnancy remain incompletely understood,” the authors noted.  In most cases the immune system knows not to attack. However, as the authors pointed out, “Failure to establish or maintain maternal–fetal immune tolerance is associated with preterm birth, and complications of prematurity remain the leading cause of death in children under five worldwide.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>To investigate whether the immune system could be triggering some cases of preterm births research lead and first author Elze Rackaityte, PhD, formerly a postdoctoral researcher in the DeRisi lab and now an assistant professor at UCSF, recruited volunteers who were being seen at UCSF’s fertility clinic. The team collected initial blood samples and then tracked a handful of women after they became pregnant from frozen embryo transfers.</p>
<p>“We wanted to capture the immune system before pregnancy, and then measure what changed,” Rackaityte said. “This patient population was particularly well suited to answering that question, because the timing of pregnancy following a frozen embryo transfer could be closely tracked.”</p>
<p>The researchers used a technology called phage immunoprecipitation (IP) sequencing (PhIP-seq), which the DeRisi lab has substantially refined and advanced. PhIP-Seq allows researchers to take a broad look at the antibodies in a person’s blood and determine which proteins they recognize—including, in this case, whether any are reacting to the body’s own proteins.</p>
<p>For their reported study the team used the approach to identify a set of antibodies that appeared consistently once pregnancy began. With that baseline established, the team then turned to a much larger dataset: blood samples from more than 2,000 pregnant women across eight cohorts, including samples collected by California’s statewide prenatal screening program at 15 weeks of gestation. This could show whether any antibodies were specifically associated with preterm birth, not just with pregnancy itself.</p>
<p>The data showed that women who went on to deliver prematurely experienced broader antibody changes earlier than those who delivered at term. Within the broader antibody signature seen in women with preterm deliveries, one antibody that reacted against a protein called IL1RA—which is known to control inflammation in the body— stood out.</p>
<p>IL1RA works by blocking a molecule called IL1β, which drives a kind of inflammation known to trigger uterine contractions. IL1RA is the body’s natural brake to keep IL-1β in check. An antibody that neutralizes IL1RA removes that brake, allowing IL1β and the inflammation it causes to rise unchecked. This could explain why some women with the antibody go into labor too early.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>To confirm the significance, Rackaityte injected the IL1RA antibodies into pregnant mice. IL1β levels rose in the mothers’ blood, and their placentas showed signs of damage—something also seen in human preterm deliveries. “Consistent with our hypothesis, anti-IL1RA injected dams also exhibited profound reproductive defects,” the team wrote.</p>
<p>Wondering how the immune molecule was linked to placental health, Rackaityte next examined human placental tissue to find where IL-1RA was normally located. She found it accumulated in the junctions between cells lining placental blood vessels where nutrients and oxygen cross from mother to fetus. “The placenta is basically stocking up on this inhibitor to protect the pregnancy, and it’s deposited in these strings that go along with the flow of blood,” Rackaityte said. “The first time I looked under the microscope, I thought something went wrong because I had never seen a protein organized like this before.”</p>
<p>The researchers caution that the anti-IL1RA antibodies were seen in only a fraction of preterm births, so there are likely many other causes. They also don’t yet know whether the antibodies were already present before pregnancy—triggered by previous infection or immune disease—or appeared after conception, since the women who carried the antibody signature were only followed after they conceived.</p>
<p>Anakinra, a synthetic form of the IL1RA molecule, has already been used for nearly two decades to treat inflammatory diseases including rheumatoid arthritis. The new results suggest that the already-approved drug could be worth investigating as a potential way to prevent preterm births, by putting the brakes back on IL-1, preventing inflammation and preterm uterine contractions. “Just the fact that this drug has been around for a while, and that we have decades of safety data on it, is very compelling for use in pregnancy,” Rackaityte said.</p>
<p>In her new lab, Rackaityte plans to continue studying anti-IL1RA antibodies as well as follow up on other antibodies that were found in the preterm-birth-associated immune signature. In their paper the authors concluded, “Beyond an individual protein, these collective proteome-wide data, representing thousands of individuals, reveals that pregnancy itself elicits a broad and shared program of humoral autoreactivity, and that preterm birth is distinguished by a markedly expanded signature targeting proteins essential for placental function, vascular remodeling and immune regulation.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/preterm-birth-for-some-women-linked-to-specific-autoantibodies/">Preterm Birth for Some Women Linked to Specific Autoantibodies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The US military’s race to make fake blood</title>
<link>https://edusehat.com/en/the-us-militarys-race-to-make-fake-blood</link>
<guid>https://edusehat.com/en/the-us-militarys-race-to-make-fake-blood</guid>
<description><![CDATA[ Its call sign was Morphine 1-2.   In February 2007, the hulking dual-­rotor casualty evacuation helicopter had just flown three wounded soldiers to a field hospital in Balad, north of Baghdad, when another call came: an emergency mission to fly through an insurgent-controlled area in broad daylight. Typically, helicopters would be in a spot like… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/260917-KaloCyte-044-thumb.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 17:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, military’s, race, make, fake, blood</media:keywords>
<content:encoded><![CDATA[<p>Its call sign was Morphine 1-2.  </p>



<p>In February 2007, the hulking dual-­rotor casualty evacuation helicopter had just flown three wounded soldiers to a field hospital in Balad, north of Baghdad, when another call came: an emergency mission to fly through an insurgent-controlled area in broad daylight. Typically, helicopters would be in a spot like this only at night, and with all lights turned off. </p>



<p>As it passed near the city of Karmah, in the eastern side of Al-Anbar province, an insurgent fired a portable missile launcher. The tail gunner, who likely saw the shot roaring in, yelled for the pilot to make an evasive move. But the missile had already locked on, and the ensuing blast started a fire on board. After the pilot battled the failing machine for 58 agonizing seconds, Morphine 1-2 plunged to the ground. All seven crew members were killed.  </p>





<p>Why was the helo there in daylight? “It was getting blood and bringing it back. It was [on] what we call a ‘blood run,’ and [it’s] the highest of priorities besides casualty evacuation,” explains Lieutenant Commander Robert Murray, a Navy officer and program manager at DARPA, the Defense Advanced Research Projects Agency, who studied this incident as an intelligence officer.</p>



<p>Today, a <a href="https://www.who.int/news/item/12-06-2026-safe-blood-supply-improves-as-voluntary-donations-exceed-85---but-many-people-still-lack-access">chronic shortage of blood</a> in both the <a href="https://www.army.mil/article/270961/the_army_is_planning_for_a_conflict_with_china_including_shoring_up_blood_supply">military</a> and <a href="https://www.theguardian.com/us-news/2026/jul/30/american-red-cross-blood-supply-crisis">civilian worlds</a> is fueling a race to develop synthetic alternatives. About <a href="https://jts.health.mil/assets/docs/cpgs/Frozen_Deglycerolized_Red-Blood_Cells_05_Aug_2024_ID26_v1.2.pdf">90% of preventable battlefield deaths</a> are due to hemorrhage—bleeding that happens when a blood vessel ruptures—and it’s <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12584296/">the leading cause</a> of maternal deaths worldwide. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12035996/">study published in <em>Transfusion</em> in 2025 found that of 1.2 million trauma patients</a> in the United States who potentially needed blood before reaching a hospital, just 1% received it. The shortage results in about <a href="https://www.facs.org/media-center/press-releases/2024/surgeons-address-the-urgent-need-to-eliminate-blood-deserts/">10,000 preventable deaths each year</a> in the US, according to the American College of Surgeons. Globally, that figure <a href="https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2024/february-2024-volume-109-issue-2/viewpoint-blood-deserts-face-the-burden-of-global-blood-deficits/">is likely in the millions</a>. </p>



<p>One reason for the shortfall is that blood has a storage problem. Whole blood lasts only 35 days when refrigerated, so banks separate out components to stretch the timeline. But that’s an imperfect solution. The platelets that help wounds clot are typically stored at room temperature and last for a week or less. Hospitals and the military freeze the red blood cells that carry oxygen, as well as the protein-rich plasma that restores volume and aids coagulation. Once thawed, though, both will spoil within days. “What happens if I don’t know when I’m going to be attacked? Well, thaw it and you let it expire, right?” Murray says. </p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><strong>A <em>JAMA</em> study of combat injuries in Afghanistan suggests a magic number for someone who needs a transfusion: You have 36 minutes to get started.</strong></p>
</blockquote>



<p>That’s why Murray—who, in addition to his military experience, has a PhD in physiology—is leading a DARPA effort to address blood’s battlefield problems. He’s in charge of a new $73 million dollar program called RAPIID (for “resuscitation and prevention of ischemia-induced dysfunction”). Its goal is to create shelf-stable versions of the three major transfusion constituents: plasma, platelets, and red blood cells. As it gets underway late this year, RAPIID picks up on decades of work to synthesize blood or help it last longer. Most recently, that includes a prior $47.5 million DARPA project called FSHARP (for “fieldable solutions for hemorrhage with bio-artificial resuscitation products”), in which researchers have demonstrated promising results in animals. </p>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img fetchpriority="high" decoding="async" width="3000" height="1791" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg" alt="a machine on a workbench with tubes and jars" class="wp-image-1146257" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg 3000w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=300,179 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=768,458 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=1536,917 1536w, https://wp.technologyreview.com/wp-content/uploads/2026/10/240611-KaloCyte-synthetic-blood-181.jpg?resize=2048,1223 2048w" sizes="(max-width: 3000px) 100vw, 3000px"><figcaption class="wp-element-caption">KaloCyte techs use a device called a tangential flow filtration machine<br>to process unencapsulated hemoglobin.</figcaption><div class="image-credit">MATT ROTH</div>
</figure>
</div>

<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="933" height="933" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg" alt="gloved hand pouring clumps of red powder from a vial onto a petri dish" class="wp-image-1146256" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg 933w, https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/20240705_nf_blood_powder1_1400px.jpg?resize=768,768 768w" sizes="(max-width: 933px) 100vw, 933px"><figcaption class="wp-element-caption">After processing, the hemoglobin is concentrated and then freeze-dried to make it shelf-stable.</figcaption><div class="image-credit">MATT ROTH</div>
</figure>
</div>


<p>With RAPIID trials for the different components occurring in parallel, the goal is to have bags of dried blood products deployed in the field by 2029. That puts Murray in the position of a conductor coordinating an orchestra of clinical trials with the FDA, while also sourcing the paraphernalia that goes along with transfusions—everything from combat-durable storage bags to tests that could check how much artificial blood a patient already has. </p>



<p>Getting it all done will be tough, but the military is feeling the pressure to address its shortage. Blood drives may not deliver in time after a mass-casualty event, and a <a href="https://jamanetwork.com/journals/jama/fullarticle/2658323"><em>JAMA</em> study of combat injuries in Afghanistan</a> suggests that if the injured person needs a transfusion, the magic number is 36 minutes. “If something is survivable—and generally we classify most all hemorrhage as survivable—[you’re] almost guaranteed to survive if you get the blood before that 36-minute mark,” Murray says. After that, the chance of survival “starts to drop precipitously.”  </p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<p>In the mission to make portable,<strong> </strong>shelf-stable blood components, plasma is the low-hanging fruit. Researchers have known how to isolate and freeze-dry plasma, the yellowish liquid that makes up 55% of whole human blood, since the late 1930s. On the battlefields of World War II, its mix of water, salts, and thousands of types of proteins helped restore blood volume in wounded soldiers—and to some degree controlled bleeding. In the 1960s, the US abandoned freeze-dried plasma because it carried a risk of transmitting hepatitis to recipients from infected donors. But screening, testing, and drying techniques improved, and starting in 2010, the US military launched a yearslong effort to rebuild its capacity for producing these products. Over the past two years, the FDA has allowed two types of freeze-dried plasma to be used in emergencies by the US military—and one can even be used by civilians. </p>



<p>As for platelets, efforts at <a href="https://www.tandfonline.com/doi/10.1080/10731190600974962?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed#d1e104">extending their life</a> date back to the 1950s, but they haven’t seen a ton of success. Bioengineers have, for example, attempted to attach the membranes of <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13197205/">platelets</a> to synthetic particles. The most successful project comes from a company called Cellphire, which freeze-dries <em>actual</em> human platelets. The product has <a href="https://www.cellphire.com/news/announces-cryptics-phase-2-3-clinical-study-final-topline-results">shown safety and efficacy</a> in humans in clinical trials, but its dependence on donors means it’s unclear whether this approach can scale.</p>



<p>Red blood cells have been similarly tough to preserve or mimic. Their most critical component is hemoglobin, which carries oxygen and comes encased in a cell membrane. For more than a century, researchers have been looking for ways to deliver hemoglobin without the immunological challenges created by this exterior, including the fact that donors’ and recipients’ blood types need to be compatible. Evolutionary pressure developed that wrapper for very good reason, though: “Naked” hemoglobin tends to break down quickly in the bloodstream, and that can <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8526348/">cause organ damage</a>. It also scavenges nitric oxide, our body’s natural mechanism for opening up blood vessels, and causes those channels to constrict.</p>





<p>This problem became all too clear in the 1980s and 1990s, when fears that transfusions could transmit HIV sparked interest in a class of membrane-free delivery mechanisms called hemoglobin-based oxygen carriers (HBOCs). One, named HemAssist, consisted of hemoglobin subunits linked together to avoid the rapid-breakdown problem. It had the added benefit of lasting roughly a year in cold storage (red blood cells last about 40 days)—but it didn’t solve the nitric oxide problem, so it constricted blood vessels. In a clinical trial, 24 of the 52 people who <a href="https://www.wsj.com/articles/SB891369100869844000">received HemAssist</a> died, compared with eight out of 46 in the control group. The parent company terminated trials in 1998. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2364833/pdf/bmj-336-7651-news-00977.pdf">review of clinical studies</a> published in <em>JAMA</em> in 2008 further solidified HBOCs’ fate, finding that they generally triple patients’ chances of heart attack and increase the risk of death by 30%.</p>



<p>More recently, researchers have tried to grow red blood cells in a lab using a technology called “blood pharming,” which involves making them from progenitors known as induced pluripotent stem cells. The stumbling blocks? Cost and yield. DARPA launched a <a href="https://www.darpa.mil/news/2013/on-demand-blood-transfusions">pharming initiative</a> in 2008, using stem cells from discarded umbilical-cord blood, but was unable to get the cost below tens of thousands of dollars per unit of red blood cells. They pulled the plug and offloaded the research to the <a href="https://www.usuhs.edu/4D-Bio3/research#odbprog">Uniformed Services University</a>. Even if the cost were lower, though, pharmed blood can’t be stored in a backpack. “These are still cells—they still require a refrigerator, they still require special handling,” Murray says. </p>



<p>It won’t be easy to solve all these challenges at once. “Each one of those projects individually is a massive undertaking,” says John Holcomb, a surgery professor at the <a href="https://www.uab.edu/medicine/surgery/trauma/faculty/holcomb#:~:text=Holcomb%20has%20served%20in%20multiple,and%20film%20Black%20Hawk%20Down.">University of Alabama at Birmingham</a>, who was a combat surgeon in Mogadishu, Somalia, during the battle that inspired <em>Black Hawk Down</em>. “I think that they will probably be successful individually. How we use those individual products, or combine those products together, I think remains to be seen.”</p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<p>Several years after DARPA gave<strong> </strong>up on lab-grown blood, Murray was stationed at a base on Okinawa, an island 400 miles southwest of the Japanese mainland, where he witnessed the vulnerability of the blood supply firsthand. The site houses a blood bank that serves the roughly 27,000 Marines commanded from the island—plus thousands more military personnel on the base and deployed within a 100-million-square-mile stretch of the Pacific called <a href="https://www.militarytimes.com/news/pentagon-congress/2026/06/17/fair-winds-indopacom-pentagon-returns-command-name-to-us-pacific-command/">USPACOM</a>, which ranges from western India to Hawaii and from Antarctica to the Arctic. “The blood center is right next to the hospital, which is about 200 meters from all of the satellite communications on that island,” Murray told me. A missile strike could take out all three.</p>



<p>Murray wondered: Is there a way to produce synthetic blood that could last longer? As he completed his PhD in physiology in 2018, the military was also awakening to the vulnerability of the Okinawa facility. The <a href="https://media.defense.gov/2020/May/18/2002302061/-1/-1/1/2018-NATIONAL-DEFENSE-STRATEGY-SUMMARY.PDF">2018 National Defense Strategy</a>, which shifted military focus from terrorism to a potential ground war with China or Russia, showed war planners the risks of relying on a single site for blood runs covering all of USPACOM. DARPA then got serious once again about making fake blood and kicked off the FSHARP program in 2023. <a href="https://www.darpa.mil/about/people/robert-murray">Murray came aboard</a> as a deputy program manager in DARPA’s Biological Technologies Office in 2024 and was named a program manager in 2026, just a few months before RAPIID <a href="https://www.darpa.mil/news/2026/rapiidly-transitioning-shelf-stable-blood-substitutes-battlefield">put out its call for proposals</a> this past May. </p>


<div class="wp-block-image">
<figure class="wp-block-image alignwide size-full"><img decoding="async" width="1916" height="1916" src="https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg" alt="TEM image of platelets" class="wp-image-1146264" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg 1916w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=150,150 150w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=300,300 300w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=768,768 768w, https://wp.technologyreview.com/wp-content/uploads/2026/10/SynthoPlate-cryoTEM.jpg?resize=1536,1536 1536w" sizes="(max-width: 1916px) 100vw, 1916px"><figcaption class="wp-element-caption">SynthoPlate, seen here under a microscope, is a synthetic platelet carrying peptides that help it mimic the work of natural platelets, including sticking to broken blood vessels and to one another.</figcaption><div class="image-credit">COURTESY OF SEN GUPTA</div>
</figure>
</div>


<p>Before he took the helm, related work had been underway for years. Aided by FSHARP funding, researchers at a company called KaloCyte continued testing a technique—originally developed by doctors who are now at the University of Maryland, Penn State, and the University of Pittsburgh—that “upcycles” hemoglobin from expiring donor blood. “We take that hemoglobin and then we package it in a lipid nanoparticle that functions like an artificial cell membrane,” explains CEO Elaine Haynes. </p>



<p>The product, called ErythroMer, is essentially a new kind of HBOC. The membrane prevents breakdown, limits dangerous scavenging of nitric oxide, and also helps the hemoglobin take up and release oxygen. Each ErythroMer cell includes a lipid called KC-1003, which acts like a sentry: In response to high pH in the lungs, it signals another small molecule within ErythroMer to move away, allowing oxygen in. Then, in tired tissue, where pH is lower, KC-1003 brings the small molecule back, releasing the oxygen.  </p>



<p>Using a well-understood process called lyophilization, similar to one that World War II–era scientists used with plasma, the team freeze-dries its product to store at room temperature, where it can remain stable for two years. In a 2016 study of mice and rats with up to <a href="https://www.sciencedirect.com/science/article/pii/S0006497119310286">70% of their blood removed</a>, ErythroMer stabilized blood pressure and oxygen delivery—without the devastating constriction of blood vessels that sank HemAssist. FSHARP furthered that work, helping fund studies on how the HBOC interacted with plasma and platelets.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><strong>Much like the handle of a Swiss Army knife, the synthetic platelet has specialized attachments—peptides that serve as the biological equivalents of a corkscrew or a nail file.</strong></p>
</blockquote>



<p>KaloCyte, though, still has plenty to figure out. Haynes says the company can source only about 1,000 to 2,000 units of expiring hemoglobin a month. So it has licensed a yeast strain that it aims to use to create its own hemoglobin in the lab.</p>



<div class="wp-block-group is-layout-constrained wp-block-group-is-layout-constrained">
<p>Over a video call from her desk, Haynes showed me a sample of ready-to-use ErythroMer. It was encased in a heavy-duty storage bag with two chambers. One was full of scarlet powder—the hemoglobin product—and the other of sterile water to rapidly rehydrate it in the field. Eventually, she explained, under Murray’s master plan, “you’ll have another container with the synthetic platelet, and then a third container with the plasma.” </p>



<p>But achieving that vision depends on finding a synthetic platelet that works.</p>
</div>



<p>To do that, DARPA has turned to Anirban Sen Gupta, a bioengineering professor at Case Western Reserve University. “Traditionally platelets were thought of [as] blood cement, but it’s not that simple,” he explains. “They are, in my opinion, like drones, surveilling the blood vessel wall continuously, looking for signs of injury.” Sen Gupta’s team, which also includes collaborators at the University of Pittsburgh, used FSHARP funding to continue work on a product called SynthoPlate. Fabricated from a lipid nanoparticle that he likens to the handle of a Swiss Army knife, it has specialized peptide attachments—the biological equivalents of a corkscrew or a nail file. The first version has three: One binds to a chemical called von Willebrand factor, which helps platelets stick to the walls of injured blood vessels; another attaches to collagen, which acts as a scaffold for regrowing cells; and the third mimics a blood protein called fibrinogen, which acts like a Lego connector that allows the synthetic platelets to stick to real ones near a wound. Like ErythroMer, the product is freeze-dried and can be reconstituted with sterile water. It keeps for over a year at room temperature and at least three months at a desertlike 122 °F.</p>



<p>In a 2026 paper in <em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13335430/">Advanced Science</a></em>, the researchers showed that SynthoPlate cut bleeding time and blood loss by more than half in mice with low platelet counts. In a <a href="https://www.sciencedirect.com/science/article/pii/S1538783625008311">separate study</a>, they also safely injected the faux platelets into rats’ bone marrow—a more useful delivery site, given that a bleeding patient might not have an available vein. Sen Gupta and a colleague have spun this work out into a company called Haima Therapeutics. </p>



<p>The good news, as he sees it, is that the pharmaceutical industry excels at mass-­producing millions of billions of lipid nanoparticles—witness Operation Warp Speed, in which these blobs of fat held delicate snippets of mRNA in covid shots. “The magic of the artificial platelet is in all those peptides that are decorating the surface of the particle, but the scalability of the platform is very well established,” he says.</p>



<hr class="wp-block-separator has-alpha-channel-opacity">



<p>Around the world, prospective<strong> </strong>blood alternatives abound. Researchers at Cambridge University in the UK are trying to <a href="https://www.nhsbt.nhs.uk/news/the-nhsbt-led-restore-trial-into-growing-blood-featured-in-the-new-yorker/">pharm red blood cells</a> for people with rare blood types or blood disorders like sickle cell anemia, and other researchers have also <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7804213/">cultured platelets</a> and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10959681/">red blood cells</a>. Japanese scientists are already <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12829376/">testing their own version</a> of encapsulated human hemoglobin in human subjects.</p>





<p>Over the course of the next three years, RAPIID will move DARPA’s efforts closer to real life. In addition to ErythroMer and SynthoPlate, the agency in early October announced funding of blood components for five other companies. Among them is a firm called Abioremedi that eschews hemoglobin for synthetic versions of other oxygen-carrying proteins such as cytoglobin, neuroglobin, and myoglobin encased in albumin—the most-abundant protein in human plasma. Octapharma USA won the sole contract to supply plasma to RAPIID, and will also be competing in platelets with an FDA-approved pair of clotting proteins it affixes to a disc-shaped nanoparticle.</p>



<p>With those players in place, the agency will focus the next year on getting technologies through large FDA-regulated animal studies. Murray has set up a bit of a Hunger Games scenario: Each contractee working on blood components only has one year of guaranteed funding. He says he’s taking advantage of advancements in the field since FSHARP launched, but is also hedging against any manufacturing or regulatory setbacks ahead of his 2029 deadline. Getting cut doesn’t mean the product is bad, just that the time frame was too demanding. </p>



<p>The second and third years will focus on human trials, overseen by the University of Colorado Anschutz Medical Campus. That will include using the products in situations where the risk of side effects is outweighed by the danger of doing nothing, such as with severely injured people in ambulances.</p>



<p>The possibility of fatal outcomes has invited second-guessing about DARPA’s choices. For Shibani Pati, who directs the Center for Research in Transfusion Medicine and Cell Therapies at the University of California, San Francisco, Murray could be making things too “DARPA hard” on himself by backing products like SynthoPlate and ErythroMer, which are previously untested in humans. “They need to make a very concerted effort to take what they’ve already developed and push it through to approval through the FDA,” she says. “Not start with moonshot projects that will take forever to get through.” For platelets, Pati thinks the RAPIID program would have done better to tap Cellphire, since its products have already received millions from the Pentagon and shown safety and efficacy in humans. (Murray notes that he can only select companies that apply, and Cellphire did not.)</p>



<p>She has similar qualms about ErythroMer. A different HBOC that sources hemoglobin from cattle, called Hemopure, has been approved for use since 2001 in South Africa, she notes. And though it hasn’t been approved by the FDA—it was part of the fateful 2008 <em>JAMA </em>study—US doctors are cleared to use it for patients who have bad immune responses or religious objections to conventional transfusions. </p>



<p>Holcomb, the surgery professor, worries the effort will run into issues with interactions between the products. He notes that individual blood components have more than one role: Red blood cells also help with clotting, platelets also are anti-inflammatory, and plasma helps tune coagulation. There’s no guarantee that the versions RAPIID helps develop will work in the same ways.  </p>



<p>Murray says that FSHARP’s animal studies tested all the products together, using whole blood as a baseline, precisely because of such possible interactions. The cocktail met its program metrics in all but one area: The clotting was not quite as good, perhaps because negative charges in some molecules repel one another. </p>



<p>“I do not think they will replicate all the functions that whole blood does in our body,” Holcomb says. But, he admits, “you may not need to, right? When you get seriously injured and you lose 50% of your intravascular volume, you’re dead, right? So if you lose 30% and maybe you’re hanging on to life just barely, maybe you show up with all these different products, and you have enough whole blood left in you to do these other functions.” </p>



<p>Murray is determined to complete trials so that shelf-stable blood can be delivered in 2029. In addition to the storage bags, he’s already sourcing finger sticks for in-field blood testing and a battery-powered device to heat up the blood components.</p>



<p>The danger of blood runs—and, by extension, the vulnerability of millions in combat zones, maternity wards, and ambulances—drives his scientific daring. Knowing the stakes, he told his boss in 2024 that even if FSHARP failed, “we should invest 50 million more dollars in it and do it again.”</p>



<p><em>Andrew Rosenblum is a technology journalist and the author of the techno-thriller </em>Stretch Goals.</p>]]> </content:encoded>
</item>

<item>
<title>The Top 10 Questions Shaping the Future of Optogenetic Biomanufacturing</title>
<link>https://edusehat.com/en/the-top-10-questions-shaping-the-future-of-optogenetic-biomanufacturing</link>
<guid>https://edusehat.com/en/the-top-10-questions-shaping-the-future-of-optogenetic-biomanufacturing</guid>
<description><![CDATA[ This article explores the ten most important questions facing optogenetic biomanufacturing as it moves from proof‑of‑concept demonstrations toward mainstream adoption in modern bioprocessing.
The post The Top 10 Questions Shaping the Future of Optogenetic Biomanufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/240516_Prolific0454-2.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Top, Questions, Shaping, the, Future, Optogenetic, Biomanufacturing</media:keywords>
<content:encoded><![CDATA[<figure aria-describedby="caption-attachment-339161" class="wp-caption alignright"><img decoding="async" class="wp-image-339161" src="https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-300x300.jpg" alt="Maximilian Hoerner" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/240516_Max_Horner_0524-1-scaled-e1791910673532.jpg 1617w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Maximilian Hoerner, PhD</figcaption></figure>
<p>The emergence of increasingly complex biologics such as multi‑specific antibodies, cytokines, fusion proteins, and other structurally demanding modalities has exposed the limits of conventional bioprocessing. Many of these molecules are difficult to express at commercially viable yields, and their quality attributes can be highly sensitive to the cellular environment. As a result, productivity, consistency, and cost remain major constraints across the industry.</p>
<p>Traditional cell line development (CLD) relies on constitutive promoters that drive static expression throughout development and production. Because production is always on, cells must divide and manufacture protein simultaneously, even when the product is burdensome or toxic. While this model worked relatively well for easy-to-express monoclonal antibodies, it does not work well for next-generation biologics, where the inherent trade-off between higher specific productivity and rapid cell growth, both competing for the same cellular resources, is increased. Light‑controlled gene expression using optogenetics is emerging as a credible alternative.</p>
<p>This article explores the ten most important questions facing optogenetic biomanufacturing as it moves from proof‑of‑concept demonstrations toward mainstream adoption in modern bioprocessing.</p>
<p><strong>1. What is optogenetics, and why is it relevant to biologics manufacturing?</strong></p>
<p>Optogenetics uses light‑responsive proteins to control specific cellular functions. In biomanufacturing, the key application is regulating gene expression with light instead of relying on constitutive promoters or chemical inducers. When light‑controlled gene expression systems are engineered into production cell lines, illumination at defined wavelengths can switch expression on, off, or to intermediate levels.</p>
<p>This is important because it introduces a fundamentally different control modality. Conventional systems provide static expression, whereas optogenetics enables dynamic, reversible, and tunable control. As biologics become more complex and more sensitive to expression conditions, having a way to precisely modulate transcription directly, rather than perturbing the entire cell by modulating process parameters such as temperature, will become increasingly valuable.</p>
<p><strong>2. What core limitation in biologics manufacturing does light</strong><strong>‑</strong><strong>based control address?</strong></p>
<p>The main limitation is the inherent competition between cell growth and protein production. In constitutive systems, cells must divide and manufacture protein at the same time, drawing on the same finite pool of metabolic resources. This creates a structural trade‑off: clones that produce strongly have a slow doubling time and/or do not grow to viable densities, while clones that grow well often produce only modest titers. This trade‑off becomes much more pronounced for challenging molecules such as multi‑specific antibodies, cytokines, and fusion proteins that are aggregation‑prone or place a significant burden on the host cell.</p>
<p>Optogenetics addresses this by separating the growth and production phases. Cells can grow in an uninduced, low-burden state and then transition into a productive state upon illumination. As light acts directly on transcriptional regulators in a dose-dependent manner, expression can be tuned precisely rather than modulated indirectly through temperature shifts or coarsely and irreversibly by chemical induction. Chemical inducers can also negatively affect cell performance through off-target effects and are difficult to remove during downstream processing, which has limited their adoption in mammalian biomanufacturing. The direct, tunable control by light also enables more deliberate modulation of pathways that influence critical quality attributes such as post-translational modifications (PTMs), which is increasingly important for complex biologics and biosimilars.</p>
<p><strong>3. How does optogenetic light exposure work, and is it safe for cells and media?</strong></p>
<p>Optogenetics uses light as an informational cue rather than an energy source. Because photoreceptors respond to brief, low-intensity pulses and stay “on” for a tunable period of time before reverting to the off state, optogenetic systems can maintain precise control without continuous or high-power illumination.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The wavelengths used in bioprocessing are in the visible range and non-ionizing, operating well under established phototoxicity thresholds. At these levels, light does not harm cells or DNA, nor does it disrupt cellular physiology. Although certain media components are known to be light-sensitive, the illumination used for optogenetic induction has not shown detrimental effects on cellular performance.</p>
<p><strong>4. What is the impact of optogenetics on lab operations?</strong></p>
<p>Optogenetic workflows use standard lab equipment with the addition of illumination devices compatible with existing infrastructure, such as plates, shake flasks, or bioreactors. The main operational difference occurs during pool generation and single-cell cloning, where cells must remain uninduced. This is achieved by working under “safe light” conditions, visible wavelengths that do not activate the specific optogenetic system but allow the operator to handle the cell culture. Only small areas of the lab need to be adapted for this purpose. For all other operations, including biomanufacturing, local interventions to shield cells from room light are typically sufficient.</p>
<p><strong>5. How many cellular functions can be controlled with light in a single cell line?</strong></p>
<p>Current systems can independently regulate cellular functions using two or three different wavelengths. For example, one color may control production while another modulates a critical quality‑related pathway. Functions that require coordinated timing can be linked to the same wavelength. As genetic circuit design advances, the number of independently controllable functions is expected to increase.</p>
<p><strong>6. When might optogenetically manufactured biologics reach clinical and commercial stages?</strong></p>
<p>Optogenetic cell line development is already being explored for multiple programs. Regulatory agencies have established pathways for evaluating emerging bioprocess technologies, and optogenetic systems are beginning to move through these mechanisms. If early development proceeds as expected, optogenetically controlled processes could support clinical filings in the next two years, with commercial adoption following thereafter.</p>
<p><strong>7. Can optogenetics be integrated into existing facilities?</strong></p>
<p>Yes. Optogenetic manufacturing does not require new bioreactor designs; illumination hardware can be added to standard single‑use or stainless‑steel systems. For single‑use bags, light is delivered externally through the bag without breaching the sterility barrier; for stainless‑steel tanks, cultures can be circulated through illuminated loops. No cleanroom redesign is required.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p><strong>8. How does optogenetic manufacturing scale to larger bioreactors?</strong></p>
<p>Scaling optogenetic systems depends on three factors: the sensitivity of the photoreceptors, the lifetime of their activated state in the dark, and the mixing and light-scattering characteristics of the bioreactor. Modern optogenetic systems for biomanufacturing are designed to respond to very low light intensities, and once activated, they gradually return to the off state in the dark at a characteristic rate, typically over tens of minutes.</p>
<p>Since stirred-tank bioreactors mix continuously and scatter light throughout the vessel, cells receive sufficient illumination over the photoreceptor’s characteristic activation lifetime even at large volumes. Simulation studies and early pilot-scale experiments up to the 200 L scale suggest that optogenetic activation can be achieved at commercially relevant scales, including stainless steel and single-use systems.</p>
<p><strong>9. What has convinced established players to evaluate this technology?</strong></p>
<p>Biologics development and manufacturing are intentionally conservative, with new technologies adopted only when they demonstrate clear, reproducible benefits and maintain patient safety. For any emerging bioprocess platform, the threshold for evaluation is data showing that it can deliver meaningful improvements without introducing new risks or operational complexity.</p>
<p>In comparative studies, optogenetic induction has produced more than two‑fold increases in titer for standard monoclonal antibodies as well as for more difficult‑to‑express therapeutic proteins. These gains have been achieved while maintaining or improving critical quality attributes, including those influenced by folding, assembly, and post‑translational modification.</p>
<p>As the next generation of therapeutics become increasingly complex, leading biopharma and CDMO players see the need for novel biomanufacturing platforms capable of meeting that complexity without compromising titers, and for that reason several key players are actively evaluating optogenetic technology for potential integration.</p>
<p><strong>10. Where is optogenetic biomanufacturing headed in the next decade?</strong></p>
<p>If current trends continue, optogenetic control may become a standard tool for managing expression, quality, and other cellular functions in biologics manufacturing. The ability to modulate gene expression dynamically opens possibilities for more efficient production of complex therapeutics, more predictable quality profiles, and more flexible facility design. As the technology matures, it is likely to be adopted across CDMOs, biotech, and biopharma companies seeking greater control over their manufacturing processes.</p>
<p><em>Maximilian Hoerner, PhD, is the head of optogenetics at Prolific Machines</em></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/the-top-10-questions-shaping-the-future-of-optogenetic-biomanufacturing/">The Top 10 Questions Shaping the Future of Optogenetic Biomanufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Enodia Therapeutics Inks Pfizer Deal to Develop Sec61&#45;Targeting Small Molecules</title>
<link>https://edusehat.com/en/enodia-therapeutics-inks-pfizer-deal-to-develop-sec61-targeting-small-molecules</link>
<guid>https://edusehat.com/en/enodia-therapeutics-inks-pfizer-deal-to-develop-sec61-targeting-small-molecules</guid>
<description><![CDATA[ Backed by multiple Sec61 inhibitor families, proteomics and cryo-EM datasets, and machine learning-driven design, Enodia Therapeutics’ platform is the foundation of a new research collaboration and license agreement with Pfizer. 
The post Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/11/GettyImages-1405788998-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Enodia, Therapeutics, Inks, Pfizer, Deal, Develop, Sec61-Targeting, Small, Molecules</media:keywords>
<content:encoded><![CDATA[<p><span>Biotechnology firm Enodia Therapeutics has announced a research collaboration and licensing agreement with pharma giant Pfizer to discover and develop small molecule inhibitors of Sec61, using Enodia’s proprietary platform. </span></p>
<p><span>Under the terms of the agreement, Enodia will perform discovery activities to screen, optimize, and develop Sec61 inhibitor candidates against multiple collaboration targets. Following the collaboration term, Pfizer will be responsible for all clinical, manufacturing, regulatory, and commercial activities. Furthermore, Enodia will receive an upfront payment and is eligible for future research, development, and sales milestone payments, as well as tiered royalties on net sales, bringing the total potential value to more than $500 million.</span></p>
<p><span>Enodia develops novel small-molecule therapies for targeted protein degradation using its platform, which is designed to identify small molecules that enable selective Sec61 translocon modulation, a novel approach to inhibit disease-driving proteins when they are synthesized and before pathological effects occur. To date, the company has built a broad chemical space that spans multiple Sec61 inhibitor families and is supported by biological datasets including proteomics and cryo-EM data as well as tailored cell-line libraries. </span></p>
<p><span>“Enodia has built a broad platform that enables selective Sec61 translocon modulation, a novel approach to inhibit disease-driving proteins while preserving essential physiological functions,” said Yves Ribeill, PhD, Enodia’s CEO. “We look forward to collaborating with Pfizer, combining their deep expertise and clinical resources with our approach for precisely targeting pathological proteins to bring forth potential new medicines.”</span></p>
<p><span>Earlier this year, Enodia announced that it had </span><a href="https://www.genengnews.com/topics/genome-editing/targeted-protein-degradation-drives-deal-between-enodia-therapeutics-and-kezar-life-sciences/"><span>purchased assets from Kezar Life Sciences’</span></a><span> Sec61-based discovery and development program. At the time, Enodia said that the acquisition helped advance its understanding of Sec61 selectivity mechanisms. The company also said that insights from Kezar’s programs would further strengthen Enodia’s core focus on Sec61-driven selectivity for targeted protein degradation. Under the terms of the purchase agreement, Kezar received an initial upfront payment totaling $1 million, and was expected to receive future payments upon achievement of certain development, regulatory and commercialization milestones. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/enodia-therapeutics-inks-pfizer-deal-to-develop-sec61-targeting-small-molecules/">Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>X&#45;Chromosome Gene Linked to Increased Autism Diagnosis in Males</title>
<link>https://edusehat.com/en/x-chromosome-gene-linked-to-increased-autism-diagnosis-in-males</link>
<guid>https://edusehat.com/en/x-chromosome-gene-linked-to-increased-autism-diagnosis-in-males</guid>
<description><![CDATA[ New research suggests that variants in the MECP2 gene on the X chromosome might help partly explain why autism is diagnosed about four times more often in males than it is in females. 
The post X-Chromosome Gene Linked to Increased Autism Diagnosis in Males appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/05/Getty_1015900158_AutismBrain-1024x683.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 14 Oct 2026 06:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>X-Chromosome, Gene, Linked, Increased, Autism, Diagnosis, Males</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital, and collaborating institutions have identified new genetic candidates that help explain why autism is diagnosed about four times more often in boys than it is in girls. The study, involving tests in induced pluripotent stem cell (iPSC)-derived neurons (iNeurons), revealed that small changes in the gene <em>MECP2</em> on the X chromosome might help explain part of this difference.</p>
<p>Huda Zoghbi, MD, Distinguished Service Professor at Baylor, director of Duncan NRI, and a Howard Hughes Medical Institute investigator, is senior and corresponding author of the team’s published paper in <em>The American Journal of Human Genetics</em>, titled “<a href="https://doi.org/10.1016/j.ajhg.2026.09.011" target="_blank" rel="noopener">A massively parallel reporter assay of <em>MECP2</em> cis-regulatory elements reveals genetic candidates for male-biased autism</a>.” In their paper, the team concluded, “These findings suggest noncoding <em>MECP2</em> variants can cause idiopathic, male-biased autism and provide a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Autism is a common, heritable neurodevelopmental trait that affects how a person communicates, interacts with others, and experiences the world, and is characterized by altered social interactions and restricted, repetitive behaviors or interests,” Zoghbi explained. “It is diagnosed about four times more in male individuals than in female individuals, suggesting sex-specific factors may increase male vulnerability,” the researchers added in their paper.</p>
<p>In the current study, the researchers drew from their long experience with gene <em>MECP2</em>, which is on the X chromosome and has been associated with neurodevelopmental conditions, including autism. “We tested the idea that the predominance of autism in males could be explained in part by mild mutations in an X chromosome gene’s regulatory regions,” commented Rebecca Meyer-Schuman, PhD, a postdoctoral associate in the Zoghbi lab. “Females might be protected from such a mild mutation because of their second X chromosome, but males, who have only one copy, would be more vulnerable. The regulatory regions are like dials that control whether a gene will be expressed and by how much. And what better place to start looking at these regulatory regions than the gene <em>MECP2</em>, where brain health depends on how much of the gene is expressed, and where mutations can cause neurodevelopmental disorders that include autism.”</p>
<p>Previous murine studies by Zoghbi lab and others have taught researchers that <em>MECP2 </em>produces a Goldilocks protein, meaning that it must maintain a “just right” concentration or activity level for a healthy brain. Having too little—about 50% or less of the normal levels—leads to Rett syndrome, and having twice the normal levels causes a different neurodevelopmental condition called <em>MECP2</em> duplication syndrome. “Both loss-of-function and gain-of-function variants lead to severe neurodevelopmental conditions—Rett syndrome (MIM: 312750) and <em>MECP2 </em>duplication syndrome (MDS; MIM: 300260[intellectual developmental disorder, X-linked, syndromic, Lubs type (MRXSL)]), respectively,” the authors commented. “Because <em>MECP2</em> is on the X chromosome, hemizygous male individuals have a more severe phenotype than heterozygous female carriers with the same variant.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Meyer-Schuman also noted, “Previous studies in mice also showed us that milder changes in <em>MECP2</em> levels, for instance reducing the expression by 30% or increasing it by 50%, do not cause the more severe features of Rett syndrome or <em>MECP2</em> duplication syndrome like seizures or motor problems, but lead to autism-like behaviors.”</p>
<p>For their current study the team used a massively parallel reporter assay (MPRA) to screen the regulatory regions of the <em>MECP2 </em>gene in induced pluripotent stem-cell (iPC)-derived neurons. “This allowed us to identify and manipulate the regulatory regions and determine what kinds of changes would alter their function,” Meyer-Schuman said. The researchers also screened <em>MECP2 </em>regulatory regions in autistic individuals and tested the genetic variants they identified using the MPRA assays.</p>
<p>“We identified two regulatory regions where male autistic individuals inherited a variant from their unaffected mother that altered regulatory activity,” Meyer-Schuman said. “One of these variants reduced <em>MECP2 </em>expression by approximately 30% in human neurons, a magnitude that produces social deficits, hyperactivity and anxiety-like characteristics in mice. As predicted by the mouse model, this individual was diagnosed with autism and ADHD but had none of the defining characteristics of Rett syndrome.”</p>
<p>In their paper, the authors commented that their work supports a broader hypothesis that altered dosage or expression of sex chromosome genes are a major source of the male bias observed in autism. Zoghbi added, “These findings, a result of integrating human and animal studies, suggest that <em>MECP2 </em>regulatory variants can contribute to male-biased autism and reveal just the tip of the iceberg, providing a framework for uncovering regulatory variants in other X chromosome neurodevelopmental genes that may contribute to autism’s missing heritability.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/x-chromosome-gene-linked-to-increased-autism-diagnosis-in-males/">X-Chromosome Gene Linked to Increased Autism Diagnosis in Males</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spatial Biology Moves Toward Translation</title>
<link>https://edusehat.com/en/spatial-biology-moves-toward-translation</link>
<guid>https://edusehat.com/en/spatial-biology-moves-toward-translation</guid>
<description><![CDATA[ Spatial technologies preserve tissue context to guide therapeutic development and translate molecular insights into clinically actionable information.
The post Spatial Biology Moves Toward Translation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_10x-Genomics-Figure-1_Atera_stage-III-B-cervical-cancer-tissue-section-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spatial, Biology, Moves, Toward, Translation</media:keywords>
<content:encoded><![CDATA[<p>If “Spatial Biology” conjures images of a science conducted in zero gravity aboard the International Space Station, think again. As one of the most rapidly advancing areas in biomedical research and precision medicine, spatial biology probes the inner landscape of intact cells and tissues down to single-molecule resolution. By preserving location and organization, instead of dissociating tissue into component parts, this discipline maps fine architecture, cellular neighborhoods, and individual molecules.</p>
<p>Maintaining that context is driving new ways of characterizing disease progression, identifying biomarkers, advancing therapeutics, and monitoring treatment responses. Fueling these advances is an expanding toolbox that encompasses high-plex imaging, spatial transcriptomics and proteomics, multiomic profiling, and increasingly sophisticated computational analyses. We consulted industry leaders about how the field is progressing, barriers that remain, and their vision for what is needed to propel spatial biology into its next phase.</p>
<h4><strong>Scaling spatial discovery </strong></h4>
<p>While genomics and single-cell sequencing profile molecular features and cellular states, spatial biology answers questions that neither can address, such as where those features and cells are located and how they are organized.</p>
<figure aria-describedby="caption-attachment-339238" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-339238" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534-300x300.jpg" alt="Kamila Belhocine" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Kamila-Belhocine-PhD-Copy-e1791901844534.jpg 368w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Kamila Belhocine, PhD<br>Senior Director<br>10x Genomics</figcaption></figure>
<p>“When you dissociate a tissue into individual cells, you lose something fundamental: where those cells were and how they were organized relative to one another,” observes Kamila Belhocine, PhD, senior director of spatial biology at 10x Genomics. She continues: “Spatial biology puts that context back. In cancer, for example, knowing that a particular immune cell population is present within a tumor sample is useful. But knowing whether those cells have infiltrated the tumor core, are sitting at its margin, or are excluded from it altogether can tell you something very different about the biology, and potentially, about response to treatment. The same principle applies to understanding tissue architecture in cases like development and cell differentiation, and disease progression.”</p>
<p>Several barriers have prevented spatial biology from going mainstream in the biopharma/biotech industry. Belhocine says, “I think about four things: speed, reliability, cost, and interpretability. Spatial needs to be fast enough to fit into routine research workflows, robust enough to generate consistent results at scale, affordable enough to use across large studies and, ultimately, straightforward enough to turn the resulting data into biological insight. The first three are fundamentally technology and engineering challenges. Interpretability is harder because it also requires accumulating evidence and validating which spatial signatures are truly meaningful and actionable.”</p>
<p>However, according to Belhocine, single-cell technologies had to address similar issues. “A decade ago, single-cell analysis was largely a specialized technique. Continued innovation made it easier, more scalable, more robust, and dramatically more cost-effective, opening it to a much broader community and enabling much larger studies. We think spatial is following a similar trajectory.”</p>
<figure aria-describedby="caption-attachment-339235" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-339235" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-300x300.jpg" alt="Gary Latham" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Gary-J-Latham-PhD-Copy-e1791901959881.jpg 1200w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Gary Latham, PhD<br>Chief Technology Officer<br>Bio-Techne</figcaption></figure>
<p>Belhocine says the company’s newest spatial instrument, Atera, which will be shipping in the second half of the year, is an important step in that progression. “This technology combines whole-transcriptome spatial profiling with single-cell sensitivity and subcellular resolution at a massive scale designed for much larger studies.”</p>
<p>Looking ahead, Belhocine predicts, “As spatial technologies become more scalable, robust and cost-effective, researchers can apply them across much larger patient cohorts to identify biomarkers and signatures of treatment response. Additionally, AI will undoubtedly accelerate that trajectory even further.”</p>
<h4><strong>Spatial multiomics </strong></h4>
<p>Gary Latham, PhD, CTO, Bio-Techne, provides another perspective on the role of integrating protein analysis and gene expression in spatial biology. “A fuller understanding of tissue biology requires seeing where proteins and genes are expressed, how they relate, and how they interact within the tissue architecture.”</p>
<figure aria-describedby="caption-attachment-339240" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-339240" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-1-Copy-297x300.jpg" alt="Human breast cancer" width="297" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-1-Copy-297x300.jpg 297w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-1-Copy.jpg 342w" sizes="auto, (max-width: 297px) 100vw, 297px"><figcaption class="wp-caption-text">Automated spatial biology systems enable high-throughput, hyperplexed analysis of tissue samples. Human breast cancer sample stained with 105-plex multiomics panel on COMET. The image shows a HER2+ tumor with HER+ cells and immune infiltrates. Markers shown: HER2 (white), collagen I (teal), CD45 (red), and CD38 (yellow). [Bio-Techne]</figcaption></figure>
<p>This molecular multiplexing can provide a more complete view of tissue biology. “Spatial biology is unique from other technologies because it takes us from seeing what is there to understanding <em>what is where</em>,” says Latham. He continues, “This is critical because biology can’t be understood as a parts list. Instead, it is a dynamic system of interactions and networks where location defines meaning. While single-cell sequencing can tell you which cell types exist and their molecular states, spatial biology tells you how those cells are organized, how they may be interacting, and how these relationships may influence disease biology and clinical outcomes.”</p>
<p>Latham indicates that the field is working to overcome several challenges. “There is a need for reproducible, standardized automation for today’s biomarkers and tomorrow’s multiomic precision medicine. Many spatial biology workflows remain exploratory and manual during early discovery phases. As programs move toward translational research, the focus shifts to robustness, reproducibility, and standardized, validated workflows. Ultimately, clinical adoption requires validated panels, automation, and throughput suited to routine testing.”</p>
<figure aria-describedby="caption-attachment-339239" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-339239" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-2-Copy-300x280.jpg" alt="Human prostate cancer" width="300" height="280" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-2-Copy-300x280.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Bio-Techne-Fig-2-Copy.jpg 368w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Automated spatial biology systems enable high-throughput, hyperplexed analysis of tissue samples. Human prostate cancer sample stained with a 105-plex multiomics panel on COMET. The image shows tissue fibrosis associated with cancer-associated fibroblasts (CAFs). Markers shown: COL1A1 RNA (yellow), E-Cadherin (white), alpha-SMA (blue), and FAP (magenta). [Bio-Techne]</figcaption></figure>
<p>According to Latham, Bio-Techne is helping address these barriers in several ways. Its COMET Suite provides an end-to-end automated platform for hyperplex immunofluorescence and multiomics staining, imaging, and analysis of tissue samples. Additionally, its RNAscope portfolio enables same-section multiomics, with 80,000 RNA probes spanning 450 species and compatibility with multiple automated staining instruments.</p>
<p>Latham believes the spatial multiomics approach can connect gene and protein expression with tissue architecture within the same cells and microenvironment, revealing biological relationships and linking state to function that no single modality can uncover.</p>
<p>He says several areas are seeing the fastest adoption of spatial biology. “Oncology and immuno-oncology continue to dominate spatial biology applications, while immunology and neuroscience represent the next-most prominent areas of focus. Biodistribution of gene therapies is an especially high-impact application: spatial multiomics can localize an AAV vector, transgene mRNA, or oligonucleotide therapeutics such as ASOs and siRNAs to specific cells, then measure changes in the target or downstream gene expression and the associated protein phenotype.”</p>
<h4><strong>Integrated discovery & translation</strong></h4>
<p>Spatial biology is increasingly moving beyond simply identifying where cells are located to understanding how cellular neighborhoods, cell–cell interactions, and biological pathways shape disease biology. As Thomas Campbell, PhD, senior director of product management for Bruker Spatial Biology, explains, “Biology is inherently multi-dimensional, and no single spatial technology can or will capture every aspect of that complexity. The field needs multiple fit-for-purpose approaches that allow researchers to ask different questions and connect insights across DNA, RNA, proteins, and cellular function.” This ability to examine biology from complementary perspectives is becoming increasingly important as spatial research moves from discovery toward translation.</p>
<p>According to Campbell, understanding these context-dependent differences is driving the field. “The next phase of spatial biology will be about using high-plex discovery to develop focused, quantitative assays that can be deployed across large cohorts. One of the biggest challenges in translational biopharma is the discovery-to-translation gap. A study may identify dozens or hundreds of potentially relevant biomarkers, but a translational or clinically deployable assay demands a much smaller, highly reproducible panel.”</p>
<p>Thus, defining a clinically relevant spatial signature requires insights across the genome, transcriptome, and proteome. Campbell says Bruker Spatial Biology’s portfolio comprises platforms spanning multiple omic layers—including DNA, RNA, proteins, post-translational modifications, miRNA and live cell function—“because we recognize that no single modality can fully resolve the biological complexity that drives disease.”</p>
<figure aria-describedby="caption-attachment-339237" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-339237" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy-300x300.jpg" alt="Thomas Campbell" width="200" height="199" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Thomas-Campbell-PhDr-Copy.jpg 368w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Thomas Campbell, PhD<br>Senior Director<br>Bruker Spatial</figcaption></figure>
<p>That integrated approach is reflected in several of the company’s platforms. CosMx<sup>®</sup> Spatial Molecular Imager (SMI) provides a view of the whole transcriptome at subcellular resolution, while enabling the simultaneous measurement of RNA and protein within the same tissue section. The CellScape<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup> XR platform provides quantitative spatial proteomics using flexible assay chemistry. Meanwhile, the GeoMx<sup>®</sup> Digital Spatial Profiler (DSP) profiles the whole transcriptome and more than 1,200 proteins from distinct tissue compartments. Campbell says that, together, these three platforms “provide complementary views of biology and, when used together, enable a more complete understanding of cellular function across multiple omic layers.”</p>
<p>Campbell sees this transition from discovery to translation as one of the most important opportunities for spatial biology. “Whether it’s in oncology, immunology, or neuroscience applications, the future of spatial biology is not simply just about generating more data; it’s translating increasingly sophisticated spatial discoveries into assays that can answer focused biological and clinical questions across large numbers of samples,” he says. “That requires a portfolio of complementary technologies. High-plex discovery platforms can reveal the complexity and heterogeneity of disease, while more focused and quantitative approaches can translate those findings into reproducible biomarkers and clinically relevant assays. Ultimately, the value of spatial biology will be measured by how effectively we can connect discovery to clinically actionable insights.”</p>
<h4><strong>From plex to precision </strong></h4>
<p>“Historically, spatial biology involved a fundamental tradeoff between plex, sensitivity, and resolution—researchers had to sacrifice one to gain another,” suggests Mike Miller, PhD, CTO and CPO at Quanterix. He says that is now shifting. “With today’s tools, those tradeoffs have narrowed considerably. The current challenge becomes building a platform that delivers reproducibility, rigor, and clinical-grade integrity at scale.”</p>
<p>The company is addressing those needs in several ways. Miller reports: “Our Akoya PhenoCycler-Fusion platform enables researchers to visualize and quantify 100+ proteins in a single tissue section at single-cell resolution.” The platform uses molecular barcoding chemistry. Miller elaborates: “Molecular barcoding is a way of identifying and measuring multiple proteins in a tissue while avoiding many of the limitations of traditional immunohistochemistry and conventional multiplexing approaches.”</p>
<figure aria-describedby="caption-attachment-339236" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-339236" src="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-300x300.jpg" alt="Mike Miller, PhD" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Liszewski_Mike-Miller-PhD-Copy-e1791902140174.jpg 1800w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Mike Miller, PhD<br>Chief Technology Officer<br>Quanterix</figcaption></figure>
<p>This approach combines three main components: an antibody that recognizes the target of interest; a unique molecular barcode, consisting of a short oligonucleotide sequence attached to the antibody; and a complementary oligonucleotide carrying a fluorescent reporter that binds to the barcode, enabling target visualization and quantification. “The key advantage is that the fluorescent reporter can be reversibly hybridized and removed without removing the antibody or repeatedly staining and stripping the tissue. This enables a cyclical imaging workflow.”</p>
<p>The company also recently introduced its PhenoCode2.0 chemistry as part of its new molecular barcoding kit, “which lets researchers reliably barcode virtually any antibody of their choice.” Miller continues: “This means researchers can easily expand and customize their biomarker panels to address new hypotheses, incorporate emerging biomarkers, and scale between unbiased discovery and targeted validation, accelerating the path to new insights.”</p>
<p>Beyond expanding what can be measured, Miller believes the next phase of spatial biology will focus on translating high-plex discoveries into larger, clinically relevant studies. “That’s ultimately what will separate platforms going forward, bridging the gap between generating a striking image in discovery and generating a measurement that holds up in a clinical trial or diagnostic setting.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/spatial-biology-moves-toward-translation/">Spatial Biology Moves Toward Translation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How COVID, Characterization, and Commerce Are Driving an RNA Revolution</title>
<link>https://edusehat.com/en/how-covid-characterization-and-commerce-are-driving-an-rna-revolution</link>
<guid>https://edusehat.com/en/how-covid-characterization-and-commerce-are-driving-an-rna-revolution</guid>
<description><![CDATA[ COVID-19 accelerated efforts to develop faster, more efficient ways of manufacturing high-quality RNA sequences.
The post How COVID, Characterization, and Commerce Are Driving an RNA Revolution appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-1215274453-Copy-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, COVID, Characterization, and, Commerce, Are, Driving, RNA, Revolution</media:keywords>
<content:encoded><![CDATA[<p>The technology underpinning RNA <u><a href="https://publichealth.jhu.edu/2021/the-long-history-of-mrna-vaccines" target="_blank" rel="noopener">vaccines</a></u><sup>1</sup> and therapeutics<sup>2</sup> has been around for decades. However, until recently, only a handful of products were on the market.</p>
<p>Everything changed in 2020 when mRNA vaccines proved<sup>3</sup> to be effective against SARS-CoV-2, the virus that causes COVID-19. In the years since, many more RNA products entered the clinic as developers recognized both their therapeutic and commercial potential.</p>
<p>The pandemic also kick-started efforts to optimize RNA manufacturing that will likely shape the sector for decades to come, according to David Sokolowski, global workflow manager for nucleic acid therapeutics at Cytiva.</p>
<p>“The COVID vaccines heralded the rapid industrialization of RNA and LNP [lipid nanoparticle] technologies, and due to the nature of a pandemic, large amounts of vaccine safety data were generated. However, it remains a nascent industry with limited applications commercially available, and this space is where developers are rushing to build.</p>
<p>“Manufacturing good quality RNA and LNP became easier with the proliferation of high-quality reports from successful studies, trials, and campaigns occurring all over the world.</p>
<p>“Now, we’re supporting the development of therapeutics with even grander aspirations and increasingly exotic biology—whether they are encoding and producing mAb via RNA, or enabling next-generation <em>in vivo</em> cell therapy, LNP-mediated therapeutics have no shortage of potential advances ahead,” he continued.</p>
<h4><strong>Manufacturability</strong></h4>
<p>The key to developing any RNA-based product—be it a vaccine or a therapeutic—is to ensure it can be produced in bulk in a cost-effective and efficient manner, says Luis Avila, PhD, a scientist at services firm Novoprotein Scientific.</p>
<p>“RNA design fundamentally determines both manufacturability and biological performance, but optimizing for one often comes at the expense of the other.” The best approach is to design for manufacturability from the start,” he says, adding “the right template architecture can contribute with optimized promoter design, transcription initiation sequences, encoded polyA tails, transcript boundaries, and sequence composition to improve IVT [<em>in vitro </em>transcription] performance while minimizing problematic secondary structures.”</p>
<p>“Combined with other factors, such as engineered RNA polymerases, optimized reaction chemistries and advanced capping technologies, these design strategies will improve RNA yield, integrity, and translational performance all while reducing the generation of dsRNA,” he tells <em>GEN</em>.</p>
<p>The type of RNA being made should be the key consideration in any assessment of manufacturability, according to Avila, who cites the differences between messenger RNA and self-amplifying RNA to illustrate the point.</p>
<p>“For mRNA, coding-sequence composition, transcript length, GC content, and secondary structure strongly influence IVT efficiency. Whereas optimized UTRs [untranslated regions], cap structures, and poly(A) tails primarily govern RNA stability and translational efficiency.</p>
<p>“For saRNA, the incorporation of the large alphavirus replicase cassette substantially increases transcript length and structural complexity, thus making IVT more challenging while enabling intracellular RNA amplification that dramatically lowers the therapeutic dose required,” he says.</p>
<p>Producing circular RNA—a covalently closed-loop structure that is stable and resistant to exonuclease degradation—can be even harder, according to Avila.</p>
<p>“circRNA presents an even greater manufacturing challenge because linear IVT is followed by an additional circularization step whose efficiency remains a major bottleneck. Following circularization, translation relies on efficient cap-independent initiation through optimized IRES [internal ribosome entry site] elements and RNA architecture.”</p>
<h4><strong>Characterization</strong></h4>
<p>So, designing an RNA therapeutic or vaccine with manufacturing in mind is critical. However, the ability to realize that optimized blueprint on the factory floor is entirely dependent on being able to characterize the product in real-time, as it is being made.</p>
<p>And, unfortunately for the industry, RNA characterization is a complex challenge, says Matthew Ranaghan, PhD, applications scientist at analysis technology firm Refeyn.</p>
<figure aria-describedby="caption-attachment-339229" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-339229" src="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-with-model-Copy-300x169.jpg" alt="TwoMP with model" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-with-model-Copy-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-with-model-Copy.jpg 420w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Analyzing multiple RNA molecules in a single pass reduces the experimentation burden on RNA developers. Being able to visualize characteristics within minutes—as shown here—would benefit any developer, says Refeyn. [Refeyn]</figcaption></figure>
<p>“Thorough Characterization of RNA is critical to ensuring the safety, stability, and efficacy of next-generation RNA therapeutics, yet it remains a significant analytical bottleneck.”</p>
<p>“Current methods are limited to various types of chromatography, which struggle with poor resolution for large RNAs, or mass spectrometry, which requires digesting samples into smaller oligos with RNases. While both have advantages, they demand extensive and time-consuming method development.”</p>
<p>Traditional RNA analysis usually consists of separate assays looking at specific characteristics. For example, size exclusion chromatography is used to assess aggregation while enzyme-linked immunosorbent assays are used to check for trace amounts of double-stranded RNA.</p>
<p>One promising alternative is mass photometry (MP), a technique that can analyze RNA molecules within minutes based on only nanograms of material within minutes in a single experiment. There are multiple potential advantages according to Ranaghan.</p>
<p>“A single readout replaces the need for multiple instruments, drastically reducing hands-on time, reagent costs, and the need for extensive method development across different platforms. A single readout also enables at-line process monitoring, allowing for immediate go/no-go decisions during bioprocessing and purification.”</p>
<p>“We envision the faster speed and higher resolution of MP to enable its use as a multi-attribute tool for at-line assessment of the various critical quality attributes (CQAs) of RNA therapeutics,” he says.</p>
<p>“We have already demonstrated how MP can rapidly assess integrity, fragments, multimer, and purity in a single measurement. We are also actively building out more applications,” Ranaghan adds.</p>
<h4><strong>Commercial concerns</strong></h4>
<p>Manufacturers of RNA products also need to develop commercialization plans as early as possible—in parallel with process development—to ensure they reach the patients who need them and garner the revenues needed to fund future research.</p>
<figure aria-describedby="caption-attachment-339227" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-339227" src="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-300x300.jpeg" alt="Rajiv Gangurde" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-300x300.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-1024x1024.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-150x150.jpeg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy-768x768.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_Rajiv_Gangurd-Copy.jpeg 1200w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Rajiv Gangurde, PhD<br>Vice President<br>Parexel International</figcaption></figure>
<p>And, for some firms, developing such plans can be a steep learning curve, says Rajiv Gangurde, PhD, vice president of chemistry, manufacturing, and controls (CMC) for cell and gene therapies at contract research organization Parexel International.</p>
<p>“Like many newer modalities, RNA-based therapies typically emerge out of academia or start-up biotech, and transitioning from academia to industry can be challenging due to differences in objectives, differences in expertise, fundraising, etc.”</p>
<p>“In addition, newer modalities require heavier than usual investment in CMC activities to establish proof-of-concept as well as manufacturability. There is heavy reliance on external partners, creating capability and capacity constraints.</p>
<p>“Most importantly,” Gangurde continued, “a phase-appropriate CMC strategy aimed at global approvals can significantly derisk development and help minimize costs and timelines.”</p>
<p>Yet preparing a CMC strategy that will win approval in multiple markets is no small undertaking, particularly, as Gangurde points out, because regulatory guidelines for RNA-based therapies are still evolving.</p>
<p>Another challenge is the lack of consistency. For instance, the U.S. Food and Drug Administration (FDA) and EU EMA use different definitions and guidelines for CMC.</p>
<p>Gangurde told us, “Harmonization of guidelines and expectations across the two agencies will be hugely beneficial to developers of RNA therapies. For example, while both agencies recognize potency/efficacy assessment as a critical quality attribute (CQA), there are some differences in method validation requirements, timing, and regulatory expectations across clinical phases.”</p>
<p>“While the FDA accepts real-world experience and surrogate endpoints, particularly for rare or life-threatening diseases, EMA requires more comprehensive clinical data and demonstration of long-term efficacy for approval. The EMA also mandates an appropriate degree of method validation at each stage of development, whereas the FDA does not expect validation of the potency assays during Phase I,” he added.</p>
<p>The product component designations used by regulatory agencies can also differ. For example, the lipid nanoparticle for the COVID-19 vaccine, Spikevax, consists of four lipids: SM-102, PEG2000-DMG, DSPC, and cholesterol.</p>
<p>The FDA designates each of these components as a “drug substance,” whereas the EMA designates them as “novel excipients”—each designation has differing data submission requirements.</p>
<h4><strong>Continuous process</strong></h4>
<p>In the future, RNA manufacturing methods are likely to keep improving, according to Novoprotein’s Avila, who says continuous production processes are likely to have a major impact.</p>
<p>“One of the most exciting developments is the emergence of continuous or flow-based IVT manufacturing. This has the potential to improve productivity, reduce costs, and enable more consistent large-scale RNA production through continuous enzyme utilization and process integration.”</p>
<p>“As equally transformative are advances in engineered low-dsRNA T7 RNA polymerases, improved co-transcriptional capping chemistries, and integrated continuous purification. All of which will enable improvements in RNA quality, simplify downstream processing, and accelerate GMP manufacturing,” he added.</p>
<figure aria-describedby="caption-attachment-339230" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-339230 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-Auto-with-model-Copy-300x214.jpg" alt="TwoMP- Auto with model" width="300" height="214" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-Auto-with-model-Copy-300x214.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Gareth_TwoMP-Auto-with-model-Copy.jpg 724w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">RNA characterization is a challenge using current technologies. Refeyn claims its mass photometry system—seen here at lab in Waltham, Massachusetts—reduces the number of assays required. [Refeyn]</figcaption></figure>
<p>This view is shared by Ranaghan from Refeyn, who cites the shift toward continuous flow manufacturing as one of the most exciting advances in the field.</p>
<p>“Moving away from traditional batch processing to a continuous flow model is highly logical because it minimizes the time that the fragile mRNA product spends exposed to active reaction components that drive fragmentation and aggregation. This shift not only improves overall yield and intactness, especially for massive transcripts like saRNA, but it also creates a mandate for faster, real-time analytics.”</p>
<p>For Parexel’s Gangurde, efforts to make production more efficient and sustainable will drive innovation, with the WHO’s recently launched <u><a href="https://www.who.int/news/item/13-06-2025-mrna-technology-transfer-programme-s-phase-2.0-discussed-with-partners-on-the-sidelines-of-g20-summit" target="_blank" rel="noopener">mRNA Technology Transfer Programme Phase 2.0</a></u><sup>4</sup> being a case in point.</p>
<p>“This is a major global initiative aimed at scaling up commercially viable mRNA-based vaccine and therapeutic production in low- and middle-income countries—where the need for these therapies is most critical.”</p>
<p>Launched in 2021 in collaboration with the Medicines Patent Pool (MPP), the initiative has enabled 15 partners across Latin America, Africa, Eastern Europe, and Asia to receive foundational mRNA technology.</p>
<p>Phase 2.0 focuses on building local manufacturing capacity so countries can make mRNA vaccines and therapeutics for future outbreaks and diseases like influenza, TB, HIV, malaria, dengue, and leishmaniasis, as well as oncology drugs and mAbs.</p>
<p>Gangurde says, “By decentralizing production, the program reduces reliance on a few high-income countries for mRNA supply, supporting global access for mRNA-based therapies.”</p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Beyrer C. <a href="https://publichealth.jhu.edu/2021/the-long-history-of-mrna-vaccines" target="_blank" rel="noopener"><em>The Long History of mRNA Vaccines</em></a>. Johns Hopkins Bloomberg School of Public Health; 2021. Accessed August 12, 2026.</li>
<li>Chatterjee S, Bhattacharya M, Lee SS, Chakraborty C. An insight of different classes of RNA-based therapeutic, nanodelivery and clinical status: Current landscape. <em>Current Research in Biotechnology </em>2023;6:100150-100150. doi:10.1016/j.crbiot.2023.100150</li>
<li>Parvin N, Mandal TK, Joo SW. The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems, Systems. <em>Pharmaceutics</em> 2024; 16(11): 1366. Doi: 10.3390/pharmaceutics16111366</li>
<li>World Health Organization: <a href="https://www.who.int/news/item/13-06-2025-mrna-technology-transfer-programme-s-phase-2.0-discussed-with-partners-on-the-sidelines-of-g20-summit">WHO. mRNA Technology Transfer Programme’s Phase 2.0 discussed with partners on the sidelines of G20 Summit</a>. Who. June 13, 2025. Accessed August 12, 2026.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/how-covid-characterization-and-commerce-are-driving-an-rna-revolution/">How COVID, Characterization, and Commerce Are Driving an RNA Revolution</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia</title>
<link>https://edusehat.com/en/ucb-dedicates-future-us-biologics-manufacturing-campus-in-georgia</link>
<guid>https://edusehat.com/en/ucb-dedicates-future-us-biologics-manufacturing-campus-in-georgia</guid>
<description><![CDATA[ Some 330 permanent jobs are expected to be based at the approximately 460,000-square-foot campus, which will occupy 79 acres within the Rowen innovation district in Georgia’s Gwinnett County. 
The post UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/be461031910_ucb_stillcam01_fr001_nopeople2_2_1_1_0.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 23:05:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>UCB, Dedicates, Future, U.S., Biologics, Manufacturing, Campus, Georgia</media:keywords>
<content:encoded><![CDATA[<p>UCB has dedicated the Rowen, GA, site where it plans to build a $2 billion biologics manufacturing campus that is set to open as the Belgian-based drug developer’s first U.S. manufacturing site.</p>
<p>When completed in 2032 or 2033, the campus is expected to support commercial production of recently approved and future biologic medicines, applying artificial intelligence, automation, and advanced manufacturing technologies. The campus is intended to further integrate UCB’s U.S. patient value chain from research and development through manufacturing and delivery.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Some 330 permanent jobs are expected to be based at the approximately 460,000-square-foot campus, which will occupy 79 acres within the Rowen innovation district in Georgia’s Gwinnett County. UCB bought the 79 acres from the Rowen Foundation, which is developing a 1,900-acre campus on Highway 316, launched in 2020 as a “knowledge” community for biopharma and other innovation-based fields.</p>
<p>In its announcement of the campus site dedication, UCB said it chose to build its first U.S. manufacturing campus in Georgia because of what it called the Peach State’s strong life sciences ecosystem, highly skilled workforce, robust infrastructure, and access to leading academic and research institutions.</p>
<p>Another factor in the decision: Gwinnett County has committed $174 million in incentives and infrastructure investments to support UCB’s project.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>UCB’s project is the brightest recent success of Georgia life sciences leaders, who worked through industry group Georgia Life Sciences to lay out a 10-year “Roadmap” last year with the aim of “positioning Georgia as the scale-up manufacturing hub of the Southeast.” The UCB project, announced in March, helped place Georgia among the “Next 5 States” within <em>GEN</em>’s <a href="https://www.genengnews.com/topics/drug-discovery/next-10-u-s-biopharma-clusters/">Next 10 U.S. Biopharma Clusters</a> A-List.</p>
<p><strong>“Long-term commitment”</strong></p>
<p>“Our manufacturing investment in the United States reflects our long-term commitment to patients, strengthening our ability to serve them while contributing to scientific innovation, highly skilled jobs, and economic growth in Georgia,” UCB CEO Jean-Christophe Tellier said in a statement.</p>
<figure aria-describedby="caption-attachment-339205" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339205" src="https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-300x200.jpg" alt="" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-1024x683.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/assets_MS2006199_000001_UCB-Dedication-3-RESIZE-1500.jpg 1500w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">UCB executives and dignitaries cut a ceremonial ribbon to mark the dedication of UCB’s future biologics manufacturing campus in Rowen, GA. Jeffrey Kessler, U.S. Department of Commerce Under Secretary for Industry and Security, stands at left. At the center are Georgia Gov. Brian Kemp (R); UCB CEO Jean-Christophe Tellier; Katherine Raeymaekers, Consul General of Belgium in Atlanta; and Nicole Love Hendrickson (D), Chairwoman of the Gwinnett County Board of Commissioners. [UCB]</figcaption></figure>
<p>Tellier and other UCB leaders were joined at a dedication ceremony by dignitaries that included Georgia Gov. Brian Kemp (R); Jeffrey Kessler, U.S. Department of Commerce Under Secretary for Industry and Security; Nicole Love Hendrickson (D), Chairwoman of the Gwinnett County Board of Commissioners; and Katherine Raeymaekers, Consul General of Belgium in Atlanta.</p>
<p>During the ceremony, the dignitaries joined top UCB executives in unveiling the Emmanuel Janssen Circle, a commemorative stonework installation just completed within the roundabout to the entrance of the future campus. Janssen (1879-1955) was a Belgian businessman who founded Union Chimique Belge (UCB) on January 18, 1928. The company initially focused on industrial chemicals before evolving into a developer of biologics for indications in neurology and immunology.</p>
<p>“UCB’s new biomanufacturing campus builds on the entrepreneurial legacy of Baron Emmanuel Janssen, founder of UCB, while strengthening the transatlantic collaboration that drives economic growth, scientific innovation, and improving people’s lives,” Raeymaekers stated. “Today’s site dedication reflects the strength of the partnership between Belgium, the United States, and the State of Georgia—and our shared commitment to enduring progress, innovation, and opportunity.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>UCB worked with numerous public and private partners to locate its biologics manufacturing campus in Rowen—including the Metro Atlanta Chamber; Georgia Quick Start, which provides customized workforce training through the Technical College System of Georgia; Gwinnett County Government; Georgia Power Company; the public-private economic development initiative Partnership Gwinnett; and the Georgia Department of Economic Development.</p>
<p>Headquartered in Brussels, UCB employs more than 10,000 people in nearly 40 countries—including the United States, where the company employs more than 2,000 people in research, development, manufacturing, commercial operations, and corporate functions.</p>
<p>UCB has maintained a U.S. presence for nearly a century. The company now employs more than 400 people in Georgia, where it established its Stateside headquarters in Atlanta in 1993.</p>
<p>More than 1,000 construction jobs are expected to be created in connection with the campus during the six- to seven-year projected timeframe for design and construction.</p>
<p>“At UCB, our purpose is to create value for people living with severe diseases, and that purpose guides the science we pursue, where we invest, and the choices we make for the long term,” Tellier added.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ucb-dedicates-future-u-s-biologics-manufacturing-campus-in-georgia/">UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO supports retaining current vaccine recommendation categories</title>
<link>https://edusehat.com/en/bio-supports-retaining-current-vaccine-recommendation-categories</link>
<guid>https://edusehat.com/en/bio-supports-retaining-current-vaccine-recommendation-categories</guid>
<description><![CDATA[ BIO’s comments advise strengthening communication and clarity of recommendations, and maintaining access. The Advisory Committee on Immunization Practices (ACIP) should remain the body responsible […]
The post BIO supports retaining current vaccine recommendation categories appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/04/vaccine-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 19:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, supports, retaining, current, vaccine, recommendation, categories</media:keywords>
<content:encoded><![CDATA[<h4>BIO’s comments advise strengthening communication and clarity of recommendations, and maintaining access.</h4>
<p><span>The Advisory Committee on Immunization Practices (ACIP) should remain the body responsible for making vaccine recommendations, and ACIP’s recommendation categories do not need to be changed, BIO tells the Department of Health and Human Services (HHS).</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) made these comments in its Sept. 20 response to a HHS</span><a href="https://www.federalregister.gov/documents/2026/08/24/2026-17250/request-for-information-categories-used-in-federal-vaccine-recommendations-and-the-role-of-shared"> <span>request for information (RFI)</span></a><span> that asks “whether the categories currently used in Federal vaccine recommendations are adequate.” The RFI contained a proposal on restructuring ACIP’s established vaccine categories, which currently include: routine (universal) recommendations, risk-based recommendations, and recommendations based on shared clinical decision-making.</span></p>
<p><span>“The current vaccine recommendation categories were developed to translate ACIP’s scientific assessment into clear clinical guidance about which populations could be considered for a vaccine and under what circumstances, while supporting consistent implementation, coverage, and access,” say BIO’s comments, prepared by Phyllis Arthur, BIO EVP and Chief of Global Health. “The categories were not intended to signal different standards of evidence or different levels of confidence in vaccine safety and effectiveness.”</span></p>
<p><span>Some of BIO’s specific recommendations include:</span></p>
<h3>Maintain ACIP’s authority</h3>
<p><span>“All policymaking should reflect that ACIP is tasked with making vaccine recommendations, while other entities are tasked with different and specific areas of vaccine policy,” BIO comments say. “Grounded in its statutory role, decades of experience rigorously evaluating vaccine evidence through a transparent and deliberative process, and its critical ties to vaccine coverage, access, and the broader public health system, ACIP remains the appropriate federal entity for developing vaccine recommendations, consistent with the distinct responsibilities established by Congress.”</span></p>
<p><span>The comments also note that the well-established complementary roles of ACIP—through the Centers for Disease Control and Prevention—the Food and Drug Administration (FDA), and other agencies have historically delivered an effective federal vaccine system.</span></p>
<h3>Existing categories work and should be explained</h3>
<p><span>“Changes to the recommendation categories are not needed; if any change is made, it should be led by ACIP and include opportunity for meaningful public comment,” according to BIO’s input. “BIO believes the current recommendation categories provide an appropriate framework to support vaccination decisions.”</span></p>
<p><span>BIO underlines the importance of making it clear that the Shared Clinical Decision-Making (SCDM) category does not mean a vaccine is less important than others. An SCDM recommendation simply indicates a healthcare provider and patient should discuss whether to administer the vaccine because the expected benefit may depend on an individual’s specific circumstances.</span></p>
<p><span>“Importantly, the use of SCDM should not diminish vaccine confidence or create the perception that these vaccines are less valuable or less appropriate for patients who may benefit from them,” the comments say.</span></p>
<h3>Avoid threats to patient access</h3>
<p><span>Because federal and state vaccine schedules are defined by ACIP, changes to the meaning or status of an ACIP category could have consequences beyond clinical guidance.</span></p>
<p><span>BIO therefore wants HHS to make it clear that routine, risk-based, and SCDM vaccines all remain ACIP-recommended vaccines, so that patients maintain their insurance coverage. This extends to other access programs as well, including: the Vaccines for Children program, state pharmacist scope-of-practice laws, and hospital/facility vaccination requirements, among others.</span></p>
<p><span>“Americans who want to receive vaccines should be able to do so without cost-sharing, regardless of how a vaccine recommendation is categorized,” writes BIO.</span></p>
<p><a href="https://www.bio.org/letters-testimony-comments/bios-response-hhs-request-information-categories-used-federal-vaccine"><b>Read BIO’s full comments.</b></a></p>
<p>The post <a href="https://bio.news/federal-policy/bio-supports-retaining-current-vaccine-recommendation-categories/">BIO supports retaining current vaccine recommendation categories</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Caribou Plunges as It Pursues Strategic Alternatives</title>
<link>https://edusehat.com/en/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives</link>
<guid>https://edusehat.com/en/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives</guid>
<description><![CDATA[ Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory B cell non-Hodgkin lymphoma; and of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma.
The post StockWatch: Caribou Plunges as It Pursues Strategic Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Caribou-lab-shot-1024x546-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 13 Oct 2026 05:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Caribou, Plunges, Pursues, Strategic, Alternatives</media:keywords>
<content:encoded><![CDATA[<p><strong>Caribou Biosciences (Nasdaq: CRBU)</strong>, whose co-founders include Jennifer Doudna, PhD, capped a <span><strong>one-year 83% freefall</strong> </span>of its stock after announcing plans to evaluate strategic alternatives, as investors responded with a selloff that sent shares of the CRISPR genome-editing cell therapy developer<span><strong> plunging 62%</strong> <strong>this past week</strong></span>.</p>
<p>Caribou announced plans to carry out an unspecified “substantial” reduction of its workforce—which numbered 97 people as of February 27, according to its most recent Form 10-K Annual report, filed March 5—as well as a halt to trials of its two clinical-phase pipeline candidates, both allogeneic chimeric antigen receptor (CAR) T-cell therapy programs, and other cost reduction measures also yet to be specified.</p>
<figure aria-describedby="caption-attachment-339164" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-full wp-image-339164" src="https://www.genengnews.com/wp-content/uploads/2026/10/Rachel-Haurwitz-PhD__696x464-SQUARE-696-CROP.jpeg" alt="" width="296" height="296" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Rachel-Haurwitz-PhD__696x464-SQUARE-696-CROP.jpeg 296w, https://www.genengnews.com/wp-content/uploads/2026/10/Rachel-Haurwitz-PhD__696x464-SQUARE-696-CROP-150x150.jpeg 150w" sizes="(max-width: 296px) 100vw, 296px"><figcaption class="wp-caption-text">Rachel Haurwitz, PhD, Caribou Biosciences co-founder, president, and CEO</figcaption></figure>
<p>“Caribou’s story has taken a heartbreaking turn,” co-founder, president, and CEO Rachel Haurwitz, PhD, <a href="https://www.linkedin.com/feed/update/urn:li:activity:7513328985603264513/">posted on LinkedIn</a>, announcing the company’s strategic review. “This decision is not a loss of belief in our science, our clinical data, or what these programs could mean for patients. It reflects the difficult reality that the current financing environment for allogeneic CAR T-cell therapies has made it impossible to secure the capital required to responsibly advance them.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Haurwitz co-established Caribou in 2011 along with Doudna and two other co-founders: Martin Jínek, PhD, a former postdoctoral fellow in Doudna’s lab, now at the University of Zurich, who led the seminal 2012 study leading to the Nobel Prize; and James Berger, PhD, professor in the department of biophysics and biophysical chemistry at Johns Hopkins University School of Medicine.</p>
<p>Caribou became operational in 2012, which would make it the oldest CRISPR therapeutics company as far as Haurwitz could recall in a 2021 interview. That year, Caribou went public through an upsized initial public offering (IPO) that raised $321 million in aggregate net proceeds after deducting underwriting discounts and commissions and other offering expenses. Caribou sold 21.85 million shares at an IPO price of $16 a share, up from <a href="https://www.genengnews.com/topics/genome-editing/ipo-raises-304m-for-caribou-developer-of-gene-edited-cell-therapies/">earlier plans to sell 13.5 million shares</a>.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Two years later, Haurwitz <a href="https://www.genengnews.com/gen-edge/force-of-nature-caribou-biosciences-hits-clinical-runway-with-crispr-based-cancer-therapeutics/">shared with <em>GEN</em></a> her journey from graduate student in Doudna’s lab to launching a biotech start-up: “This is the only job I’ve ever had!”</p>
<h4><strong>Trials halted</strong></h4>
<p>As a result of the strategic review, Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory (r/r) B cell non-Hodgkin lymphoma. Caribou has said vispa-cel is the first allogeneic CAR T-cell therapy “to our knowledge” that has reached the clinic with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR T-cell exhaustion.</p>
<p>To manufacture vispa-cel, Caribou applies Cas9 hybrid RNA-DNA guide or “chardonnay” (chRDNA) to make three edits: A knockout of the <em>TRAC</em> gene to remove the T cell receptor; a site-specific insertion of an anti-CD19 CAR into the <em>TRAC</em> gene; and a knockout of PD-1.</p>
<p>Also halted were clinical studies of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma (RRMM). To manufacture CB-011, Caribou uses Cas12a chRDNAs designed to direct precise genome editing, in order to make four edits:</p>
<ul>
<div class="my-8"><span data-render-ad="5"></span></div>
<li>A knockout of the <em>TRAC</em> gene to remove the T-cell receptor</li>
<li>A site-specific insertion of a humanized anti-BCMA CAR into the <em>TRAC</em> gene</li>
<li>A site-specific insertion of a gene encoding a B2M–HLA-E-peptide fusion into the <em>B2M</em> gene</li>
<li>The resulting knockout of the endogenous <em>B2M</em></li>
</ul>
<p>“This method simultaneously eliminates endogenous HLA class I presentation on the surface of the CAR T cells and expresses HLA-E, a minor HLA class I antigen, to blunt both T and NK cell-mediated rejection of the CAR T-cell therapy by the patient’s immune system,” Caribou explained on its website.</p>
<h4><strong>Strategic pivot</strong></h4>
<p>The development of CB-011 and vispa-cel followed a strategic pivot by Caribou from a platform company for biopharma partners applying genome editing in research or product development, to a developer of genome-edited therapies based on its own next-generation CRISPR technology.</p>
<p>While that pivot has generated positive data readouts, it has not shielded Caribou from the financial challenges faced by numerous gene-edited therapy developers. In April 2025, Caribou chopped its workforce by 32% and pruned its pipeline by ending all preclinical research, the Phase I GALLOP trial (<a href="https://clinicaltrials.gov/study/NCT06752876">NCT06752876</a>) of vispa-cel in lupus (before the first patient could be dosed), and development of CB-012, including the Phase I AMpLify trial (<a href="https://clinicaltrials.gov/study/NCT06128044">NCT06128044</a>) assessing the candidate in relapsed or refractory acute myeloid leukemia (AML).</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>“It was really about right sizing the organization relative to our focused priorities,” Haurwitz explained last year in an interview. Asked how hopeful she was about an improving economic environment over the next 12 months, she replied: “I remain a believer and I remain an optimist. I’d probably be in the wrong job in the wrong line of work if I weren’t.”</p>
<p>“I certainly think for the work that we are doing, I continue to fully believe that doing right by patients is the North Star, because business success falls out from that in terms of nearer term clinical catalysts and opportunities that come from doing right by patients. And longer-term commercial opportunity also comes from doing right by patients,” Haurwitz added.</p>
<p>Caribou has retained Wedbush Securities as its exclusive financial advisor to assist in evaluating strategic options.</p>
<p>Caribou announced its pursuit of strategic alternatives after the closure of financial markets on October 6. The following day, Caribou shares began three days of stock declines, <span><strong>nosediving 46%</strong></span> from $1.14 to 62 cents. Those shares <span><strong>tumbled another 22%</strong></span> Thursday to 48 cents, but closed Friday with another <strong><span>4% decline</span></strong>, finishing the week at 46 cents.</p>
<p><strong>Cash crunch</strong></p>
<p>Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst with Leerink Partners, reported in a research note that Caribou was facing an increasingly pressing cash crunch at a time when the company needed significant capital to fund its planned Phase III ANTLER-3 trial, designed to assess vispa-cel in second-line auto-CAR T ineligible diffuse large B-cell lymphoma (DLBCL).</p>
<p>Caribou never enrolled patients in the pivotal study, though it reached agreement with the FDA in May on a design for the trial, which was expected to be a randomized, controlled clinical study enrolling approximately 250 CD19-naïve second line (2L) large B cell lymphoma patients ineligible for transplant and not candidates or not eligible for autologous CAR T-cell therapy.</p>
<p>“We are sympathetic to management’s stated rationale for exploring strategic alternatives,” Graybosch commented. “Evidently, investors were unwilling to fund the trial on what would have been highly dilutive terms, especially in the context of lingering clinical risk and uncertainty around the strength of vispa-cel’s Ph[ase I/II] outcomes and partial HLA-matching strategy, as well as substantial in- and out-of-class competition.”</p>
<p>That competition, she wrote, included epcoritamab, a bispecific T-cell engager (BiTE) therapy already marketed as Epkinly® by <strong>Genmab (Nasdaq Copenhagen and Nasdaq: GMAB)</strong> and <strong>AbbVie (NYSE: ABBV)</strong>.</p>
<p>On October 5—the day before Caribou’s strategic alternatives announcement—Genmab and AbbVie reported positive topline data from the Phase III EPCORE DLBCL-2 trial (<a href="https://clinicaltrials.gov/study/NCT05578976">NCT05578976</a>) showing that the combination of epcoritamab, rituximab, the corticosteroid prednisone, and three chemotherapy drugs showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed DLBCL patients.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>The combination therapy, nicknamed R-CHOP, consists of rituximab—the CD20-directed cytolytic antibody marketed by <strong>Genentech</strong>, a member of the <strong>Roche Group (SIX Swiss: RO and ROP)</strong> and <strong>Biogen (Nasdaq: BIIB)</strong> as Rituxan®—plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone. In DLBCL patients with an International Prognostic Index (IPI) score of 2 to 5, R-CHOP reduced the risk of disease progression or death by 51% (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001).</p>
<h4><strong>“Interesting” timing</strong></h4>
<p>“The timing of [Caribou’s] initiative is interesting,” Graybosch observed. “We believe there is enhanced strategic value and clinical rationale for allogeneic cell therapies in a world where TCEs [T-cell engagers] become entrenched in the 1L [first-line] setting.”</p>
<p>As for CB-011, it began development much earlier than vispa-cel, “with an appreciably more challenging competitive setup in RRMM, where we saw elevated clinical risk for its post-BCMA therapy development path due to potential efficacy-compromising loss-of-antigen,” the Leerink Partners analyst added.</p>
<p>Single target allogeneic BCMA CAR-T treatments have posed a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10657357/">potential risk of RRMM relapse through antigen loss</a> as myeloma cells mutate or downregulate BCMA to evade the CAR T cells. To minimize that risk, Caribou designed its Phase I CaMMouflage trial (<a href="https://clinicaltrials.gov/study/NCT05722418">NCT05722418</a>) to limit the therapy dosing to BCMA-naïve patients—an approach that proved successful when the company last year announced positive data from a 12-patient, BCMA-naïve cohort showing a 92% overall response rate (11/12 patients), a 75% or greater complete response rate (9/12), and 91% minimal residual disease (MRD) negativity (10/11 evaluable patients).</p>
<p>To avoid the risk of antigen loss, several developers of allogeneic BCMA CAR-Ts have designed dual targeting CAR Ts. For example, <strong>Allogene Therapeutics (Nasdaq: ALLO) </strong>is developing ALLO-329, which targets CD19 on B cells and CD70 on activated T cells. ALLO-329 generated positive preclinical data in April, with a data update from the Phase I RESOLUTION trial (<a href="https://clinicaltrials.gov/study/NCT07085104">NCT07085104</a>) expected later in Q4.</p>
<p>Another challenge to CB-011 and other allogenic therapies for RRMM: The multiple myeloma space has been reshaped by autologous BCMA CAR-T therapies that have won approval by demonstrating safety and effectiveness—including Carvykti<sup>®</sup> (ciltacabtagene autoleucel), co-marketed by <strong>Legend Biotech (Nasdaq: LEGN) </strong>and <strong>Johnson & Johnson (NYSE: JNJ)</strong>; and Abecma<sup>®</sup> (idecabtagene vicleucel), marketed by <strong>Bristol Myers Squibb (NYSE: BMY)</strong>.</p>
<h4><strong>Souring on the stock</strong></h4>
<p>Graybosch downgraded Caribou’s rating from “Outperform” to “Market Perform” and chopped the firm’s 12-month price target 75%, from $4 to $1. Graybosch was among several Wall Street analysts who responded to Caribou’s news by souring on the company’s stock, downgrading their ratings:</p>
<ul>
<li><strong>Brookline Capital Markets (Leah Ruch Cann)</strong>—From “Buy” to “Hold,” no price target.</li>
<li><strong>H.C. Wainwright (Robert Burns)</strong>—From “Buy” to “Neutral,” no price target.</li>
<li><strong>RBC Capital Markets (Luca Issi, PhD)</strong>—From “Outperform” to “Sector Perform,” price target slashed 90% from $10 to $1.</li>
</ul>
<p>Caribou reported $113.8 million in cash, cash equivalents, and marketable securities as of the end of the second quarter on June 30—a <span><strong>4% dip</strong></span> from the $118.6 million reported at the end of Q1, but a <span><strong>20% drop</strong></span> from the $142.8 million Caribou had as of December 31, 2025, and a <span><strong>38% slide </strong></span>from the $183.9 million reported June 30, 2025.</p>
<p>“We expect that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operations for at least the next 12 months from the date this Form 10-Q is filed with the SEC [U.S. Securities and Exchange Commission],” Caribou stated in its most recent Form 10-Q quarterly report detailing second-quarter results, filed August 13.</p>
<h2><strong>Leaders and laggards</strong></h2>
<ul>
<li><strong>Arrivent BioPharma (Nasdaq: AVBP)</strong> shares <span><strong>plummeted 47%</strong></span> October 6 from $28.46 to $15.09 after the cancer drug developer announced that its lead pipeline candidate firmonertinib failed the Phase III FURVENT trial (<a href="https://clinicaltrials.gov/study/NCT05607550">NCT05607550)</a> designed to assess the oral, mutation-selective epidermal growth factor receptor (EGFR) inhibitor in previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Firmonertinib did not meet its primary endpoint of meaningful progression free survival (PFS) compared to chemotherapy as evaluated by blinded independent central review (BICR). Arrivent said that clinical benefit was seen in secondary endpoints such as PFS by investigator’s assessment and confirmed objective response rate by BICR. A trend toward improved overall survival was also seen, the company added.</li>
<li><strong>Pacira BioSciences (Nasdaq: PCRX)</strong> shares <span><strong>soared 44%</strong> </span>Thursday from $25.20 to $36.39 after <strong>Viatris (Nasdaq: VTRS)</strong> agreed to acquire the non-opioid pain drug developer for $1.65 billion. The deal adds to Pacira’s portfolio with two marketed drugs—the postsurgical pain relief therapy Exparel® (bupivacaine liposome injectable suspension), and the osteoarthritis knee pain treatment Zilretta® (triamcinolone acetonide extended-release injectable suspension). Viatris said it plans to apply its intellectual property expertise and ability to extend product lifecycles and sustain meaningful sales post-competition “to maximize the long-term value of the Pacira portfolio” and expects to expand its reach across select markets. Pacira generated approximately $746 million in revenue and approximately $177 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) during the 12 months ending June 30. Viatris plans to commence a tender offer for all outstanding Pacira common stock shares for $36.50 per share cash. The deal is set to close by year’s end.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/stockwatch-caribou-plunges-as-it-pursues-strategic-alternatives/">StockWatch: Caribou Plunges as It Pursues Strategic Alternatives</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sickle Cell Trait Linked to Distinct Malaria Parasite Variants</title>
<link>https://edusehat.com/en/sickle-cell-trait-linked-to-distinct-malaria-parasite-variants</link>
<guid>https://edusehat.com/en/sickle-cell-trait-linked-to-distinct-malaria-parasite-variants</guid>
<description><![CDATA[ A study in Cameroon found that sickle cell trait is associated with distinct malaria parasite genotypes, potentially explaining reduced disease risk despite similar infection rates.
The post Sickle Cell Trait Linked to Distinct Malaria Parasite Variants appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_IMG_1436_084226.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 04:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sickle, Cell, Trait, Linked, Distinct, Malaria, Parasite, Variants</media:keywords>
<content:encoded><![CDATA[<p>Malaria is one of the deadliest infectious diseases on the planet, afflicting people for the entirety of recorded history. In places where malaria is most common, it’s shaped human evolution by driving higher rates of a protective genetic change. Two copies of the genetic change cause sickle cell disease, but one copy helps protect people from malaria. More specifically, sickle cell hemoglobin (HbS) confers protection against symptomatic malaria caused by <em>Plasmodium falciparum.</em></p>
<p>Now, a new study has found that people with the sickle cell variant are almost exclusively infected by a distinct variety of malaria parasites, which might contribute to their lower rates of disease.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Sickle cell trait may protect against malaria, not only by changing how the human host responds to infection, but also by shaping which parasites are able to survive and establish infection,” says Sandrine Nsango, PhD, associate professor of molecular biology at the University of Douala and researcher at the Centre Pasteur du Cameroun, Head of the Department of Biomedical Sciences, Faculty of Science, University of Bertoua.</p>
<p>This work is published in <em>Nature Microbiology</em> in the paper, “<a href="https://www.nature.com/articles/s41564-026-02502-4" target="_blank" rel="noopener">Sickle cell haemoglobin status shapes malaria parasite genotype in asymptomatic infections.</a>”</p>
<p>Previous work had discovered the unusual strain of malaria by investigating the rare cases where people with the sickle cell variant develop disease symptoms. The new research extends these findings to asymptomatic infections, in which people are infected by the parasite but don’t get sick. While less visible than the disease itself, asymptomatic infections were extremely common, affecting three-quarters of the healthy study population.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>HbS carriers with symptomatic malaria harbor parasites enriched for <em>P. falciparum</em> sickle-associated alleles (Pfsa+). While these may partially overcome HbS-mediated protection, their role in asymptomatic infections is unclear. Researchers analyzed the genetics of over 2,246 healthy schoolchildren in a region of high malaria transmission in Mfou, Cameroon, as well as the malaria parasites infecting them. The team found that people with and without the sickle cell variant tend to be infected by genetically different varieties of malaria parasites.</p>
<p>In addition, specific varieties of the parasite infect people with and without the sickle cell variant at similar overall rates<em>.</em> They write, “analyzing the parasite Pfsa and the human HbS genotypes for 1,701 asymptomatic <em>P. falciparum</em> infections confirmed that heterozygous HbS (HbAS) and homozygous non-HbS (HbAA) genotypes have similar rates of asymptomatic infection.” However, despite being infected at similar rates, people carrying the sickle cell variant are much less likely to develop symptomatic malaria.</p>
<p>The researchers found that which parasites are present in an asymptomatic infection differs based on if the infected person has the sickle cell variant. They write, “the HbS genotype is strongly associated with parasites carrying the Pfsa+ alleles at the Pfsa1 and Pfsa3 loci, indicating a selective advantage for these alleles in HbS carriers.” These findings suggest that the sickle cell variant influences which parasites can infect a person, whether or not they develop disease symptoms.</p>
<p>People with the sickle cell variant are just as likely to become infected—albeit with a different variety of the parasite—but they’re a tenth as likely to develop harmful disease. These observations suggest that the biological characteristics of this parasite variety may contribute, at least in part, to the protection against disease conferred by the sickle cell trait.</p>
<p>To understand why people with sickle cell don’t get disease as often—and use that knowledge to develop better therapies—researchers should not only look at the biology of the sickle cell variant but also investigate the differences in the malaria parasite.</p>
<p>Nsango says that their findings emphasize that malaria is an example of a continued evolutionary interaction between humans and the parasite. “The sickle cell mutation is one of the clearest examples of how infectious diseases can shape human evolution, but our findings suggest that humans also shape the evolution of the parasite in return,” Nsango says. “Understanding these interactions may help us anticipate how malaria parasites adapt in the future and design more effective strategies for malaria control.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/sickle-cell-trait-linked-to-distinct-malaria-parasite-variants/">Sickle Cell Trait Linked to Distinct Malaria Parasite Variants</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multiomics in 2026 and Beyond</title>
<link>https://edusehat.com/en/multiomics-in-2026-and-beyond</link>
<guid>https://edusehat.com/en/multiomics-in-2026-and-beyond</guid>
<description><![CDATA[ Multiomics analysis combines data from two or more omics layers—such as genomics, transcriptomics, proteomics, and epigenomics. However, published criticisms of multiomics approaches have highlighted concerns about data integration and a tendency toward […]
The post Multiomics in 2026 and Beyond appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-2204954826-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 00:25:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multiomics, 2026, and, Beyond</media:keywords>
<content:encoded><![CDATA[<p>Multiomics analysis combines data from two or more omics layers—such as genomics, transcriptomics, proteomics, and epigenomics. However, published criticisms of multiomics approaches have highlighted concerns about data integration and a tendency toward false-positive findings.<sup>1–3</sup></p>
<p>What additional roadblocks might accompany ambitious multiomics projects in 2026? Could any bottlenecks emerge in cost, sample preparation, data integration, or AI implementation? We recently interviewed experts from five companies to gain their perspectives. Here is what they had to say.</p>
<h4><strong>Sample preparation</strong></h4>
<p>“I sound like a broken record because I can’t stop talking about the importance of sample prep in multiomics work,” says Michael Easterling, PhD, vice president of MALDI/Imaging at Bruker Daltonics.</p>
<p>Easterling stresses challenges such as section-to-section variability, internal standards, FFPE samples, and long sample runs that complicate downstream algorithms. “For multiomics imaging, these issues are not as well defined as some of the bulk methods that have been around much longer,” he notes.</p>
<p>Scott Jelinsky, PhD, senior director of R&D at Thermo Fisher Scientific, agrees. “Different molecular classes have different requirements for sample collection, storage, and preparation,” he says. “Therefore, careful experimental design and standardization are essential.”</p>
<p>Easterling mentions the consequences of inadequate freezing during biopsies, which can disrupt cell structures and lead to ice crystal artifacts. “It is important to really make sure that you have a solid workflow to correctly harvest tissue and provide a good chain of custody from the point that it’s harvested all the way to the analyzer.”</p>
<p>What are some tips for multiomics researchers hoping to prepare their samples in an optimal way? “Community networking is key here,” argues Easterling. “I would say get involved with the overall spatial imaging community and network and find out exactly how to do these things.”</p>
<p>Another practical consideration, according to Jelinsky, is planning the workflow from the beginning so that sample collection, aliquoting, storage, and analytical requirements are compatible across different assays. “Decisions made early in the study can have a significant impact on what can be measured and how confidently the different datasets can be interpreted together,” he notes.</p>
<h4><strong>Data integration and analysis</strong></h4>
<p>Multiomics technologies generate vast amounts of high-resolution data across modalities that often behave differently from a statistical perspective, notes Najiba Mammadova, PhD, associate director of product management at 10x Genomics. “Multiomics assays have advanced incredibly quickly, and now the analysis and interpretation tools need to keep pace,” she notes.</p>
<p>Mammadova specifically highlights the challenges of computationally aligning multiple omics from different cells or tissues. After all, how can researchers be certain that they are measuring the same cells and biological features?</p>
<figure aria-describedby="caption-attachment-339145" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-339145 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-300x300.jpg" alt="10x Genomics MultiPro Human Discovery Panel" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy-768x767.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_10x-Genomics_Figure-2-Copy.jpg 788w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The 10x Genomics MultiPro Human Discovery Panel, which integrates into existing Flex scRNA-seq workflows, is the largest antibody-based, single-cell protein panel, enabling integrated analysis of 326 protein targets. [10x Genomics]</figcaption></figure>
<p>“That’s why I think measuring multiple modalities from the same cell or tissue is so important,” she adds. “It reduces the need to reconstruct the biology after the fact and gives researchers a more direct view of what’s happening in the sample.”</p>
<p>Vanee Pho-Conners, PhD, vice president of global marketing at Mission Bio, agrees that data integration is often a major hurdle with multiomics work. “Each omics layer has its own data structure, distributions, and variabilities, so combining them isn’t plug-and-play,” she explains. Multiomics analysis also often requires cross-disciplinary expertise in biostatistics, machine learning, and biology—capabilities many labs lack in-house.</p>
<p>“It’s important to ask how you can combine these data sets in a clean way where you preserve all the information, reduce the noise, and start to make biological inferences,” adds Easterling. “It’s not something that’s routine today, but the situation is changing rapidly, and new ways to integrate these datasets of varying dimensionality are starting to appear.”</p>
<p>Timing is yet another important consideration, notes Jelinsky. Proteins, RNA, and metabolites may exhibit different kinetics and respond on different timescales, so measurements collected at the same time may not always align. “Understanding those temporal relationships is essential when integrating and interpreting the results,” he says.</p>
<figure aria-describedby="caption-attachment-339148" class="wp-caption aligncenter"><img decoding="async" class="wp-image-339148" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-1024x626.jpg" alt="Thermo Fisher’s multiomics solutions illustration" width="500" height="306" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-1024x626.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-300x183.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-768x470.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1-1536x939.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Thermo-Fisher_Figure-1.jpg 1814w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Thermo Fisher’s multiomics solutions include services as well as products for sample preparation, separation, acquisition, and analysis. [Thermo Fisher]</figcaption></figure>
<h4><strong>AI and multiomics</strong></h4>
<p>“I think the rate-limiting multiomics questions are shifting from ‘Can we measure this?’ to ‘Can we <em>interpret it</em>?’ And that’s where AI has enormous potential,” notes Mammadova. “We’re generating increasingly rich, high-dimensional datasets, and AI can help researchers identify patterns, interpret those data more quickly, and ultimately build models that can predict things like disease progression or treatment response.”</p>
<p>However, Easterling warns that even the most advanced AI technologies often cannot overcome challenges associated with inadequate sample preparation. “Unfortunately, if a model’s trained on an inconsistently prepared section, it’ll give you a confident biological story that’s completely wrong. And the reader of this data may have no way to tell.”</p>
<figure aria-describedby="caption-attachment-339149" class="wp-caption aligncenter"><img decoding="async" class="wp-image-339149" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-1024x379.jpg" alt="DNA, RNA, and protein workflow " width="500" height="185" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-1024x379.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-300x111.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-768x284.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-1536x568.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mission-Bio_Figure-3-2048x757.jpg 2048w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">The DNA, RNA, and protein workflow on Tapestri’s single-cell platform. Each cell is encapsulated in its own droplet, and a unique molecular barcode (specific to each cell) gets attached to each DNA, RNA, and protein molecule. [Mission Bio]</figcaption></figure>
<p>As an example of recent AI advances, Easterling highlights multiomic workflows pioneered at the Medical University of South Carolina for single-cell analysis. The group has developed an AI algorithm that assists lasers in targeting individual cells rather than clusters of cells.<sup>4</sup> Pho-Conners also emphasizes how Mission Bio is using machine learning to jointly cluster DNA, RNA, and protein—referred to as triomics—from the same cell. “We are using a combination of triomics and AI-driven integration to establish disease resistance. This really goes beyond correlations using a single omics layer,” she says.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Although Jelinsky is generally optimistic about AI advances in multiomics, he foresees fundamental limitations. “I see AI as a tool that can help researchers navigate complexity and generate better hypotheses rather than as a replacement for scientific judgment. AI does not remove the need for rigorous experimental design or biological validation,” he stresses.</p>
<h4><strong>Challenges with extracellular vesicles</strong></h4>
<p>Distinct multiomics challenges also exist in analyzing extracellular vesicles (EVs), small membrane spheres released by cells that contain multiple omics (DNA, RNA, protein, metabolites, and lipids).</p>
<p>“EVs are how cells talk to each other, and a living cell sends up to ten thousand a day. This makes them good biomarkers,” says Pierre Arsène, founder and CEO of Mursla Bio.</p>
<p>However, with traditional EV analysis, each potential omics layer is measured from EVs derived from an unknown blend of cells. There is usually no way to know whether a protein signal and an RNA signal came from the same tissue, for instance.</p>
<figure aria-describedby="caption-attachment-339151" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-339151" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-1024x338.jpg" alt="Mursla’s biomarker discovery workflow" width="500" height="165" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-1024x338.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-300x99.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-768x254.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-1536x507.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Mursla-Bio_Figure-4-2048x676.jpg 2048w" sizes="auto, (max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Mursla’s biomarker discovery workflow for tissue-specific extracellular vesicles. Antibody-coated magnetic beads capture hepatocyte-derived vesicles from under two milliliters of plasma, leaving behind extracellular vesicles from other tissues. [Mursla Bio]</figcaption></figure>
<p>“Tissue-specific extracellular vesicles (TS-EVs) are how we recover that record,” explains Arsène. Mursla’s technology begins with a blood draw. Liver-specific EVs are then captured using antibodies against proprietary surface markers (more specifically, hepatocyte-EV markers). Finally, proteomics and RNA sequencing are performed on two milliliters of plasma for biomarker discovery.</p>
<p>“The great thing about TS-EVs is that they arrive addressed, carrying surface proteins specific to the sending cell and sealed behind a membrane that shields proteins and RNA from the enzymes that would destroy them in blood.”</p>
<p>EvoLiver, Mursla’s blood test for liver cancer surveillance in cirrhotic patients, holds an FDA Breakthrough Device Designation. It analyzes three proteins and five microRNAs derived from hepatocytes. Proteins provide information about tumor surface phenotype and metabolic reprogramming, while microRNAs reveal the regulatory programs driving that phenotype.</p>
<p>As with so many other multiomics platforms, Arsène stresses the importance of TS-EV sample preparation. “Blood handling standards for EVs lag well behind standard liquid biopsy, so our clinical work relied mostly on prospective collection under a common protocol rather than using legacy biobanks.”</p>
<h4><strong>The future of multiomics</strong></h4>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Mammadova highlights the potential for cost-related challenges in multiomics, particularly as the field moves toward larger studies. “Making these technologies more scalable and cost-effective will be critical to expanding their use across research,” she adds.</p>
<p>“However, I see more overall challenges than roadblocks in multiomics work,” she concludes. “They’re the kind of problems the field works through as technologies mature.”</p>
<figure aria-describedby="caption-attachment-339031" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-339031" src="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Bruker-_Figure-5-Copy-300x159.jpg" alt=">19,000 genes and the 64-plex CosMx Human Immuno-Oncology Protein panel" width="300" height="159" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Bruker-_Figure-5-Copy-300x159.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Yesavage_Bruker-_Figure-5-Copy.jpg 656w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Detection of the whole transcriptome along with over 64 proteins in a human breast cancer FFPE tissue section using Bruker’s CosMx spatial molecular imager. [Bruker Spatial Biology]</figcaption></figure>
<p>Spatial multiomic layers will also become increasingly critical for decoding the complexity of disease biology, predicts Prajan Divakar, PhD, Bruker Spatial Biology vice president of product management. “Investigators continue to demonstrate the need for more complete spatial datasets, and we are seeing clear applications and momentum for clinical translation,” he says. Divakar highlights Bruker’s CosMx<sup>®</sup> spatial molecular imager, which measures the whole transcriptome and over 64 proteins.</p>
<p>Finally, Arsène argues that simply adding more layers of analysis without biological resolution is unlikely to advance multiomics research in the future. For instance, in the largest study of a blood-based cancer test ever run (involving around 50,000 participants), incorporating an additional protein layer in advanced adenoma increased the sensitivity only modestly—from about 15% to 16%.<sup>5</sup> “More and more layers allow you to gain dimensions, but you end up losing coherence. And no cohort in the world is large enough to train that coherence back computationally.”</p>
<p>Jelinsky agrees that the value of multiomics will lie not in generating more data, but in selecting complementary measurements that address a specific biological question. “I think the future of multiomics will be less about generating the largest possible number of measurements and more about determining which combination of measurements provides the most meaningful biological insight,” he says.</p>
<p> </p>
<p><em>References </em></p>
<ol>
<li>Behrens LMP, Fernandes GDS, Gonçalves GF, et al. Limitations and opportunities in multi-omics integration for neurodevelopmental, neurodegenerative and psychiatric disorders: A systematic review. <em>Neuroscience</em>. 2026;599:76-93. doi: 10.1016/j.neuroscience.2026.01.019.</li>
<li>Hayes CN, Nakahara H, Ono A, Tsuge M, Oka S. <em>Genes (Basel)</em>. From Omics to Multi-Omics: A Review of Advantages and Tradeoffs. 2024;15(12):1551. doi: 10.3390/genes15121551.</li>
<li>Baião AR, Cai Z, Poulos RC, et al. A technical review of multi-omics data integration methods: from classical statistical to deep generative approaches. <em>Brief Bioinform</em>. 2025;26(4):bbaf355. doi: 10.1093/bib/bbaf355.</li>
<li>Dressman JW, Bayram MF, Angel PM, Drake RR, Mehta AS. Single-Cell Multiomic MALDI-MSI Analysis of Lipids and N-Glycans through Affinity Array Capture. <em>Anal Chem</em>. 2025;97(24):12493-12502. doi: 10.1021/acs.analchem.4c06233.</li>
<li>Shaukat A, Burke CA, Chan AT, et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. <em>JAMA</em>. 2025;334(1):56-63. doi: 10.1001/jama.2025.7515.</li>
</ol>
<p>The post <a href="https://www.genengnews.com/topics/omics/multiomics-in-2026-and-beyond/">Multiomics in 2026 and Beyond</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>‘Molecular Movie’ of Penicillin Synthesis Could Inform Future Antibiotic Development</title>
<link>https://edusehat.com/en/molecular-movie-of-penicillin-synthesis-could-inform-future-antibiotic-development</link>
<guid>https://edusehat.com/en/molecular-movie-of-penicillin-synthesis-could-inform-future-antibiotic-development</guid>
<description><![CDATA[ An international research team have revealed previously unseen rapid chemical stages in the formation of β-lactam antibiotics such as penicillin, offering insights that could help to support future antibiotic development. 
The post ‘Molecular Movie’ of Penicillin Synthesis Could Inform Future Antibiotic Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Penicillin-biosynthesis-image.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 00:25:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘Molecular, Movie’, Penicillin, Synthesis, Could, Inform, Future, Antibiotic, Development</media:keywords>
<content:encoded><![CDATA[<p>Researchers from the University of Oxford and international collaborators have revealed previously unseen rapid chemical stages in the formation of β-lactam antibiotics such as penicillin, offering insights that could help to support future antibiotic development.</p>
<p>Rather than relying on static X-ray crystallographic structures of the enzyme, the Oxford University team, collaborating with partners from Diamond Light Source, Lawrence Berkeley National Laboratory, PAL-XFEL, and SLAC National Accelerator Laboratory, followed the reaction in real time. To do this they used X-ray free-electron lasers (XFEL) to observe the enzyme isopenicillin N synthase, (IPNS) as it converts its linear peptide substrate into the β-lactam ring system of penicillin.</p>
<p>The study brought together expertise in structural biology, spectroscopy, chemistry, computation and enzyme engineering. The approach, they say, provides a powerful way to study fleeting chemical intermediates that have previously been inaccessible, both in antibiotic biosynthesis and in other biologically important enzyme reactions.</p>
<p>The team captured several rapid stages in the reaction. These included a thioaldehyde intermediate formed just before the β-lactam ring is created, and a monocyclic β-lactam intermediate, representing the first ring-shaped structure on the way to forming the complete penicillin scaffold. These steps provide the clearest picture yet of how the IPNS enzyme assembles the penicillin scaffold. Subtle movements throughout the enzyme help guide these chemical steps, showing that both the enzyme’s shape and its chemistry work together to control penicillin formation.</p>
<p>The results show, in unprecedented detail, how the enzyme IPNS achieves an exceptionally complex transformation in a single step. Christopher Schofield, PhD, Professor of Chemistry, University of Oxford, said, “Penicillin has shaped modern medicine, but there is still much to learn about how nature builds this important antibiotic structure. By capturing these fleeting steps, we can better understand how enzymes control complex chemistry with remarkable precision … As rates of antimicrobial resistance continue to rise, understanding this process will ultimately help us make existing antibiotics more efficient and design new antibiotic structures.”</p>
<p>Allen M Orville, PhD, group leader of the XFEL Hub, further commented, “The XFEL Hub at Diamond brought specialist expertise in time-resolved X-ray methods and XFEL-based structural biology to this study. Working closely with our colleagues in Oxford and at partner facilities, we helped bring together the experimental approaches needed to capture these fleeting stages of enzyme catalysis. The results show the power of combining complementary expertise and X-ray techniques to move beyond static structures and reveal how enzymes work in real time. It is a great example of how time-resolved structural biology can uncover new principles of enzyme function and, ultimately, inform the design of new catalysts and therapeutics.”</p>
<p>Schofield is co-senior author of the researchers’ published paper in <em>Nature Catalysis</em>, titled “<a href="https://doi.org/10.1038/s41929-026-01618-4" target="_blank" rel="noopener">Unanticipated intermediates during isopenicillin N synthase catalysis identified by time-resolved X-ray free-electron laser studies</a>.”</p>
<p>Ever since penicillin was developed into a working drug at the University of Oxford in the early 1940s, β-lactam antibiotics have been among the most important medicines for treating bacterial infections. Their activity depends on a special ring—the β-lactam ring—a highly strained chemical ring system that interferes with bacterial cell wall synthesis, ultimately causing the cell wall to fail and the bacteria to die. “Isopenicillin N synthase (IPNS) catalyses the biosynthesis of isopenicillin N (IPN), forming the fused four-membered β-lactam and five-membered thiazolidine ring system that is characteristic of the penicillins,” the authors explained.</p>
<p>Rising rates of antimicrobial resistance are undermining the effectiveness of existing antibiotics. Today, <a href="https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide" target="_blank" rel="noopener">one in six bacterial infections</a> is resistant to antibiotics, the authors noted, citing WHO figures. With too few new antibiotics in development, understanding how nature builds these molecules is an important step towards replenishing the antibiotic pipeline.</p>
<p>Scientists have been studying how nature constructs this β-lactam ring for decades, but the key fleeting reaction intermediates have been too difficult to observe directly.</p>
<p>To capture the reaction in real time, the researchers used a system in which thousands of tiny droplets containing anaerobic enzyme microcrystals were deposited onto a moving 2 mm wide tape. As the tape entered an oxygen filled chamber, oxygen rapidly diffused into the crystals and initiated the reaction simultaneously across the sample. By precisely controlling the speed of the tape, the researchers could determine how long each crystal reacted before reaching the X-ray interaction point, where an ultrafast XFEL pulse recorded an atomic resolution snapshot.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Combining thousands of these snapshots allowed the team to build a frame-by-frame “molecular movie” of penicillin biosynthesis. This method allows individual reaction intermediates that exist only for tiny fractions of a second to be observed at atomic resolution, and under physiological temperature and pressure, before they disappear.</p>
<p>The newly reported findings help to resolve a long-standing mechanistic question that has remained unanswered for more than four decades. The work also showed that water molecules inside the enzyme play a key role in guiding the reaction. The combined results of their studies, they noted, “… reveal unexpected insight into the IPNS reaction mechanism including the vital roles of active-site water molecules.”</p>
<p>The study ultimately builds on the work of Nobel prize-winning Oxford chemist Dorothy Hodgkin, PhD, who first solved the structure of penicillin in 1945 using X-ray crystallography.</p>
<p>Beyond penicillin, IPNS belongs to a large family of iron-dependent oxygenase enzymes involved in human biology, including those that enable us to sense and respond to changes in oxygen availability. The mechanistic insights from this work could therefore have implications beyond antibiotics, offering new principles for enzyme engineering and catalyst design.</p>
<p>“These findings provide structural insight into IPNS catalysis, inform on the wider Fe(II) oxygenase superfamily and highlight the power of X-ray free-electron laser methods for resolving transient enzymatic intermediates,” the team stated in their paper. First author Patrick Rabe, PhD, Wellcome Career Development Award Investigator, University of Oxford, said, “These insights matter because they can inform how we think about antibiotic biosynthesis and future strategies for developing antibacterial medicines. The ability to capture structural snapshots over milliseconds to seconds of reaction time allows us to connect enzyme motion, iron chemistry and water-mediated proton transfer. This gives us a much richer view of how IPNS controls a difficult chemical transformation. By understanding this process in atomic detail, we can begin to think about engineering these enzymes to produce new or improved antibiotic scaffolds.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/molecular-movie-of-penicillin-synthesis-could-inform-future-antibiotic-development/">‘Molecular Movie’ of Penicillin Synthesis Could Inform Future Antibiotic Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Immune Cell Atlas Charts How People’s Aging Paths Diverge</title>
<link>https://edusehat.com/en/immune-cell-atlas-charts-how-peoples-aging-paths-diverge</link>
<guid>https://edusehat.com/en/immune-cell-atlas-charts-how-peoples-aging-paths-diverge</guid>
<description><![CDATA[ Two people born on the same day can have immune systems that age differently. An immune cell atlas shows that a ratio between two cell types can reveal who is on a healthy or unhealthy path.
The post Immune Cell Atlas Charts How People’s Aging Paths Diverge appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2019/08/Aug26_2019_Getty_1148114678_WhiteAndRedBloodCells_1400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 10 Oct 2026 00:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Cell, Atlas, Charts, How, People’s, Aging, Paths, Diverge</media:keywords>
<content:encoded><![CDATA[<p><span>Studies of the immune system show that two people born on the same day can have immune systems that age differently, leaving some older adults with resilient defense systems and others with dysfunctional ones that put them at increased risk for age-related diseases. Now a new study led by scientists at Washington University School of Medicine in St Louis, Nationwide Children’s Hospital in Ohio, and King’s College London provides a map of human immune aging that could help explain these different trajectories. Details are published in a new </span><i><span>Immunity </span></i><span>paper titled “</span><a href="https://dx.doi.org/10.1016/j.immuni.2026.09.012" target="_blank" rel="noopener"><span>Single-cell analyses of global cohorts outline determinants of immune aging and link the ratio of GZMK⁺ to GZMB⁺ Tem cells to health trajectories</span></a><span>.”</span></p>
<p><span>According to the paper, a ratio between two immune cell types can reveal whether someone stays healthy or may face risk of future disease. To get to this insight, the scientists first analyzed approximately 12.4 million individual immune cells from the blood of over 2,600 mainly healthy adults ages 20 to 90-plus across eight cohorts in North America, the United Kingdom, Asia, and Australia. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Their analysis showed that while the blood of younger people was uniformly enriched with naive immune cells that had not been exposed to specific pathogens and remained adaptable to new infections or vaccines, older immune systems were more diverse. Specifically, some older participants had a greater abundance of immune cells that reflect inflammation.</span></p>
<p><span>To map this shift, the researchers placed each participant on a spectrum based on the ratio between two types of white blood cells: specifically, granzyme B-producing cells and granzyme K-producing cells. Some white blood cells, known as effector memory CD8 T cells, use granzymes to destroy target cells or coordinate immune responses. While granzyme B-producing cells serve as direct destroyers of diseased cells, granzyme K-producing cells have been less studied and may play a role in boosting immune responses. </span></p>
<p><span>Next, the researchers evaluated whether participants’ positions on the spectrum, which corresponds to a specific type of CD8 T cell, could dictate their risk of getting sick. In other words, they looked at whether having more of one type of CD8 T cell has an impact on the person’s health as they age. To answer that question, the scientists turned to the UK Biobank. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>While that dataset includes protein information from the participants, it lacks counts of CD8 T cells. To get around this hurdle, the scientists used a smaller dataset of seemingly healthy adults that included data on CD8 T cell counts and blood proteins to create a computer model to map out the protein tracks left behind when either granzyme B-producing or granzyme K-producing cells dominated. They then applied this model to the baseline blood protein samples of 50,000 participants from the UK Biobank, calculating their position on the immune cell spectrum.</span></p>
<p><span>Using this approach, the scientists were able to draw out some useful insights for their work. Specifically, they found that healthy adults whose immune system leaned heavily toward granzyme B cells at baseline tipped the scale toward a higher risk of death a decade later compared to those with more granzyme K cells. The granzyme B-dominant group also was more likely to develop chronic conditions, including Type 2 diabetes, hypertension, liver disease, and renal failure, among others, over the following decade.</span></p>
<p><span>“A higher level of granzyme B cells in a healthy state means the immune system might be already reacting to something,” said Marina Terekhova, MD, a professor in pathology & immunology at WashU Medicine and one of the co-authors on the paper. “It isn’t a formal disease diagnosis, but it may indicate the body is off track.”</span></p>
<p><span>A healthy immune system gradually shifts toward granzyme K cells over time, while an immune system that leans toward granzyme B cells signals unhealthy aging. Because individuals can reach this granzyme B state much earlier in life, their immune systems age on different trajectories, explaining why two people born in the exact same year can face different risks for chronic disease and death decades later.</span></p>
<p><span>These findings point to “clues in the blood that can tell us whether someone is on a healthy or unhealthy aging trajectory,” said Maxim Artyomov, PhD, the alumni endowed professor of pathology and immunology at WashU Medicine and one of the corresponding authors on the paper. Artyomov and his lab are now adapting their research into a simple blood test that can be processed using standard equipment. “Identifying specific biological red flags in the immune system could pave the way for early-warning tests that spot disease risks years before a clinical diagnosis.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/immune-cell-atlas-charts-how-peoples-aging-paths-diverge/">Immune Cell Atlas Charts How People’s Aging Paths Diverge</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>We’re still figuring out the side effects of GLP&#45;1 weight&#45;loss drugs</title>
<link>https://edusehat.com/en/were-still-figuring-out-the-side-effects-of-glp-1-weight-loss-drugs</link>
<guid>https://edusehat.com/en/were-still-figuring-out-the-side-effects-of-glp-1-weight-loss-drugs</guid>
<description><![CDATA[ This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age. Overweight and diabetic people who take GLP-1s have a biological age around two to three years younger than similar… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/GettyImages-2292410673.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 17:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>We’re, still, figuring, out, the, side, effects, GLP-1, weight-loss, drugs</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>GLP-1 drugs may slow biological aging:</strong> New research from Eli Lilly and Novo Nordisk suggests overweight and diabetic people on GLP-1s have a biological age two to three years younger than those on a placebo.</li><br><li><strong>Side effects range from mundane to alarming:</strong> Beyond common gastrointestinal issues, the drugs have been linked to pancreatitis, gallstones, and dozens of lawsuits alleging sudden vision loss—though both companies dispute the claims.</li><br><li><strong>Hair and nails may also be affected:</strong> A large study found increased hair loss among GLP-1 users, and a smaller study found 66% reported nail disorders—though researchers stop short of saying the drugs are to blame.</li><br><li><strong>Children are a growing concern:</strong> GLP-1 prescriptions for kids aged eight to eleven rose 310-fold between 2019 and 2026, yet the World Health Organization explicitly advises against drug treatment for children under 10, citing a lack of safety evidence.</li><br></ul>" data-chronoton-post-id="1146094" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of <a href="https://www.technologyreview.com/2026/10/02/1145610/younger-contest-race-to-biological-youth/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">biological age</a>.</p>



<p>Overweight and diabetic people who take GLP-1s <a href="https://www.technologyreview.com/2026/10/06/1145836/weight-loss-drugs-glp1-lilly-novo-aging-clocks/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">have a biological age around two to three years younger</a> than similar individuals who take a placebo, according to findings from Eli Lilly and Novo Nordisk, two pharmaceutical companies that make the drugs.</p>



<p>I’ve heard people in the aging field describe GLP-1s as longevity drugs for a while now (even if they only benefit people who are overweight or diabetic in the first place). This latest announcement comes after we’ve seen a raft of other benefits associated with taking these drugs. But there are also some weird side effects.</p>



<p>So far, GLP-1 agonist drugs—which repress hunger—have been approved for treating diabetes, chronic kidney disease, and obesity, and they can also be prescribed for some people who are overweight or at risk of certain cardiovascular diseases. But there is research to suggest they might also help people with substance-use disorders, and they’ve been investigated for potential benefits <a href="https://www.technologyreview.com/2025/11/28/1128511/what-we-still-dont-know-about-weight-loss-drugs/">in neurodegenerative disease and cancer</a>.</p>



<p>And a <em>lot</em> of people are taking them. According to <a href="https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx">a recent Gallup poll</a>, 11% of Americans are taking a GLP-1 drug for weight loss, up from 3% in 2024. And 15% of Americans say they’ve used one for weight loss at some point.</p>



<p>They can be incredibly effective. But, like any drug, they can come with side effects. And we’re still figuring out exactly what those might be, and how widespread they are.</p>



<p>The most common side effects are gastrointestinal—nausea, vomiting, diarrhea, and constipation. The drugs have also been linked to <a href="https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse">pancreatitis and gallstone disease</a>. </p>



<p>Some claim that, in rare cases, the drugs might cause damage to nerves behind the eye. Dozens of people are <a href="https://www.wsj.com/health/pharma/patients-sue-glp-1-drugmakers-over-risk-of-sudden-vision-loss-f60d7acb">suing Novo and Eli Lilly after developing a condition that can lead to sudden vision loss</a>. They’re claiming that their symptoms were brought on by the GLP-1 drugs that these companies manufacture. Both companies dispute the claims. Research into the link is mixed.</p>



<p>We’re still getting to grips with the effects of weight-loss drugs on hair and nails, too. When Savanna Vidal at the George Washington University School of Medicine and Health Sciences in Washington, DC, and colleagues assessed electronic health data from 67 US health-care organizations, they found that <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12997224/">GLP-1 use was associated with an increased risk of hair loss</a>. It’s still not thought to be common, however.</p>



<p>And at a conference in Austria last week, another group presented <a href="https://eadv.org/wp-content/uploads/2026/09/EADV_2026_Bruno_GLP1_Press_Release_01_10.pdf">the results of a smaller study</a> suggesting that 66% of GLP-1 users reported at least one nail disorder—in some cases involving nail detachment. Nail conditions were also fairly common among people who didn’t take the drugs, though. The authors don’t claim that the drugs are causing nails to fall out (as I’m sure 11% of the American population will be relieved to hear).</p>



<p>The side effects might look different in children, but there’s not much data on those at the moment. Still, pediatric side effects will be something to watch given that, between 2019 and 2026, there was <a href="https://nyulangone.org/news/glp-1-use-among-young-children-obesity-us-remains-rare-rising-rapidly">a 310-fold increase in GLP-1 prescriptions for eight- to 11-year-old children</a> with obesity in the US. Child prescriptions are still rare, but they’ve been rising.</p>



<p>On Wednesday, the World Health Organization released <a href="https://www.who.int/news/item/07-10-2026-who-issues-first-global-guidelines-on-child-and-adolescent-obesity">its first guidelines on managing obesity in children and adolescents</a>. Despite the scale of the issue—the WHO estimates that 70 million children aged five to nine were living with obesity in 2024—the organization explicitly says it does <em>not</em> recommend pharmacological treatment for kids under 10.</p>



<p>“This recommendation accounts for the lack of evidence on both benefits and the potential adverse events and consequences of the different medications and/or their active ingredients on normal growth, development, physiological parameters, and mental health,” the <a href="https://iris.who.int/server/api/core/bitstreams/be4ad6b0-4a33-488c-a062-b9a57d068c2d/content">guidelines</a> state.</p>



<p>I get press releases about GLP-1s on an almost daily basis. There’s been a ton of research into these drugs, and there are probably hundreds of other studies underway. There will likely be plenty more on this from The Checkup as the evidence evolves.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Preclinical Manufacturing Can De&#45;Risk the Path to GMP&#45;Ready Viral Vector Programs</title>
<link>https://edusehat.com/en/how-preclinical-manufacturing-can-de-risk-the-path-to-gmp-ready-viral-vector-programs</link>
<guid>https://edusehat.com/en/how-preclinical-manufacturing-can-de-risk-the-path-to-gmp-ready-viral-vector-programs</guid>
<description><![CDATA[ In this GEN webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production. 
The post How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2282040515_AAV-e1791478774265.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 10:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Preclinical, Manufacturing, Can, De-Risk, the, Path, GMP-Ready, Viral, Vector, Programs</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/7_27_21_DL-13_ChrisNieder-scaled-e1791478062758.jpg" class="h-full w-full object-cover" alt="Image of Chris Nieder">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Chris Nieder</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Senior Director and Head of Technical Development<br>SK pharmteco</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/7_27_21_DL-13_ChrisNieder-scaled-e1791478062758.jpg" alt="Image of Chris Nieder">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Chris Nieder</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Christopher Nieder is senior director and head of technical development at SK pharmteco, where he has spent more than five years supporting the development and scale-up of advanced therapies. He leads Technical Development across upstream, downstream, drug product, and analytical development and has supported a broad range of AAV, LVV, adenovirus, and HSV vector programs. Chris brings almost 20 years of industry experience spanning process development, scale-up, tech transfer, and GMP manufacturing.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, November 17, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-17T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">To move viral vector programs from early research toward the clinic, sponsors have to generate the right material and data during development. Non-GMP production of adeno-associated virus (AAV), lentiviral, and adenoviral vectors can support applications ranging from R&D and animal studies to assay development, toxicology planning, and early manufacturability assessments. But to be successful, sponsors have to align production scale, analytical testing, documentation, and material use with the specific questions their studies aim to answer.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production. He will discuss topics such as how to select from among shake flasks, development-scale bioreactors, and pilot-scale approaches; and how to use early process and analytical data to identify yield and scalability challenges. Attendees will also learn how early CDMO engagement can clarify manufacturing scope, timelines, costs, and GMP-readiness without compromising expectations for non-GMP material. Key takeaways from the webinar include:</p>


<ul class="wp-block-list">
<li>How early-stage sponsors can use non-GMP AAV, lentiviral, and adenoviral production to support R&D, animal studies, toxicology planning, assay development, and manufacturability assessment</li>


<li>How process and analytical data generated before GMP can reduce duplicated prep work, lower technical risk, and streamline later scope definition</li>


<li>When shake flasks, development-scale bioreactors, or pilot-scale production can provide the most useful insight for the next development step</li>


<li>How to align material use, analytical testing, documentation, and expectations without over-positioning preclinical material as clinical-grade supply</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.skpharmteco.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="106" src="https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-300x106.jpg" alt="skpharmteco logo" class="wp-image-331275" srcset="https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-300x106.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1024x361.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-768x270.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1193x420.jpg 1193w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-696x245.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1392x493.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1068x376.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/how-preclinical-manufacturing-can-de-risk-the-path-to-gmp-ready-viral-vector-programs/">How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Discovery to Development</title>
<link>https://edusehat.com/en/from-discovery-to-development</link>
<guid>https://edusehat.com/en/from-discovery-to-development</guid>
<description><![CDATA[ The articles in this eBook examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and explore how the next generation of therapies will move from concept to clinic.
The post From Discovery to Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/iStock_2282725115_AntibodiesAndVirus.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 10:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Discovery, Development</media:keywords>
<content:encoded><![CDATA[<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p>


<h4 class="wp-block-heading"><strong>The Era of Modality Convergence: Why Drug Development Is Being Rewritten</strong></h4>


<figure class="wp-block-image alignright is-resized"><img decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-232x300.jpg" alt="From Discovery to Development: Navigating the New Era of Therapeutic Innovation eBook cover" class="wp-image-339116" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/10/GEN_ProBio_cover.jpg 1200w" sizes="(max-width: 232px) 100vw, 232px"></figure>


<p class="wp-block-paragraph">The life sciences industry is entering a new era, defined not by a single breakthrough technology but by the convergence of many. Artificial intelligence is accelerating drug discovery, cell and gene therapies are expanding treatment possibilities, and antibody engineering continues to evolve beyond traditional monoclonal antibodies. Meanwhile, mRNA platforms, viral vectors, antibody-drug conjugates (ADCs), multispecific antibodies, and other advanced therapeutic modalities are transforming how developers approach previously intractable diseases. Taken individually, each of these innovations represents a significant advancement. Together, they are reshaping the drug development landscape.</p>


<p class="wp-block-paragraph">For decades, therapeutic development followed a familiar path: identify a target, optimize a lead candidate, advance through preclinical studies, and move into clinical evaluation. While the science was challenging, the overall framework remained relatively consistent. Today, that framework is evolving rapidly. Developers are no longer limited to choosing between small molecules and conventional biologics. Instead, they have access to a growing toolkit of therapeutic technologies, each with unique advantages, manufacturing requirements, analytical challenges, and regulatory considerations. At the same time, advances in computational biology and AI-driven discovery are generating more candidates than ever before.</p>


<p class="wp-block-paragraph">As a result, the challenge is no longer simply finding promising molecules. Increasingly, success depends on identifying candidates that can be manufactured, scaled, and translated into viable therapies. Decisions once reserved for later stages, including developability, manufacturability, analytical characterization, and clinical strategy, must now be addressed much earlier in the process. Drug development is becoming a continuous, interconnected journey rather than a series of separate steps.</p>


<p class="wp-block-paragraph">The boundaries between traditional disciplines are also beginning to blur. Cell therapies may incorporate viral vectors. Gene therapies may leverage lipid nanoparticles. Antibody programs may evolve into multispecific or conjugated formats. The future of drug development is not defined by any single modality, but by the ability to integrate technologies effectively.</p>


<p class="wp-block-paragraph">Organizations that combine discovery expertise, modality-specific knowledge, CMC capabilities, and manufacturing execution will be best positioned to navigate this increasingly complex environment. The articles that follow examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and explore how the next generation of therapies will move from concept to clinic.</p>

<p>The post <a href="https://www.genengnews.com/resources/ebooks/from-discovery-to-development/">From Discovery to Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DNA Typewriter, PEtracer Map Mouse Development Through Organogenesis</title>
<link>https://edusehat.com/en/dna-typewriter-petracer-map-mouse-development-through-organogenesis</link>
<guid>https://edusehat.com/en/dna-typewriter-petracer-map-mouse-development-through-organogenesis</guid>
<description><![CDATA[ Two DNA-recording systems traced cellular family trees across mouse embryogenesis, offering new insight into how organs form and when developing cells commit to specific fates.
The post DNA Typewriter, PEtracer Map Mouse Development Through Organogenesis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-523740840.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 10:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DNA, Typewriter, PEtracer, Map, Mouse, Development, Through, Organogenesis</media:keywords>
<content:encoded><![CDATA[<p>Researchers have used two DNA-recording systems to reconstruct cellular family trees across mouse embryonic development. The companion studies—“<a href="https://www.science.org/doi/10.1126/science.ael0508" target="_blank" rel="noopener">A DNA typewriter records the cell lineage history of a mouse, from zygote to late organogenesis</a>,” published in <em>Science</em>, and “<a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01196-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426011967%3Fshowall%3Dtrue" target="_blank" rel="noopener">Comprehensive lineage tracing maps the landscape of cell fate decisions in mouse embryogenesis</a>,” published in <em>Cell</em>—offer high-resolution views of mammalian development, which has been difficult to track because embryos develop inside the uterus and cannot be continuously observed.</p>
<p>The team from the <em>Science </em>study was led by co-senior authors Jay Shendure, PhD, professor of genome sciences at the University of Washington School of Medicine and a Howard Hughes Medical Institute investigator, and Chengxiang Qiu, PhD, a molecular and systems biologist at Dartmouth College. Their approach centered on DNA Typewriter, a lineage-tracing technology developed by Shendure and Junhong Choi, PhD, that uses a cell’s DNA as a recording medium.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The researchers redesigned the system’s recording “tape” to make its history easier to recover from individual cells, then inserted it into the genome of a fertilized mouse egg. As cells divided, “a burst of editing unequivocally marks the daughters of the first cleavage, which serve as inline replicates,” the authors wrote in the <em>Science </em>paper. Because daughter cells inherited the marks already written before acquiring new ones, shared patterns revealed common ancestry and the order of developmental branching.</p>
<figure aria-describedby="caption-attachment-339110" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339110" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_DNA-Typewriter-Genome-Sciences-FigS1_injection-3-300x199.jpg" alt="DNA Typewriter is injected into the genetic material of a fertilized mouse egg. This technology taps into the genetic material in the fertilized egg and resulting embryonic cells as a recording device of the cells' histories. It tracks their relationships as the embryo develops." width="300" height="199" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_DNA-Typewriter-Genome-Sciences-FigS1_injection-3-300x199.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_DNA-Typewriter-Genome-Sciences-FigS1_injection-3.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">DNA Typewriter is injected into the genetic material of a fertilized mouse egg. This technology taps into the genetic material in the fertilized egg and resulting embryonic cells as a recording device of the cells’ histories. It tracks their relationships as the embryo develops. [Kyle O’Conner/Seattle Hub for Synthetic Biology]</figcaption></figure>
<p>“Most biological measurements are based on either live imaging, which is limited by the fact that most animal tissues are not transparent, or genomics, which are destructive and only measure a single timepoint,” Shendure said. “Recording techniques like the ones in these studies enable measurements over time including in settings that we can’t directly visualize.”</p>
<p>The experiment was attempted in 100 fertilized eggs and yielded 10 embryos for examination. One embryo carried the most informative record, allowing the team to trace nearly every profiled cell back to one of the first two cells formed after the fertilized egg divided. Although one founding cell produced more descendants, the two branches generated diverse cell types in nearly equal proportions.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The ordered recording also allowed the researchers to estimate when cell types diverged from shared developmental paths. Blood and retinal cells committed relatively early, whereas cells forming the skin’s outer layer committed later. The results indicate that cell identity is not fixed in a single coordinated step; instead, different lineages become restricted on distinct schedules.</p>
<p>Earlier lineage-tracing approaches often relied on DNA-cutting enzymes that could damage cells, erase previous records, exhaust recording capacity, or leave unordered marks whose chronology had to be inferred. “DNA Typewriter avoids all of this,” said co-first author Haedong Kim, PhD, a postdoctoral scientist in genome sciences at UW Medicine. “It writes without fully severing the DNA, keeps recording relatively steadily, and writes everything in strict order, so we can record cell lineages at much higher resolution for a longer time.”</p>
<p>In the <em>Cell</em> paper, Jonathan Weissman, PhD, and colleagues used a prime-editing system called PEtracer to map lineage dynamics across more than 1.4 million cells from 16 mouse embryos. Together with the DNA Typewriter study in <em>Science</em>, the work demonstrates that mammalian cellular family trees can be reconstructed at unprecedented scale. “It’s really proof of principle that we can do what was done with the roundworm in 1983, but for mammals like you and me,” Weissman said.</p>
<p>The work provides a framework for investigating how normal organs form and where development can go awry. More complete lineage records could help researchers study congenital malformations, neurodevelopmental and genetic disorders, and cancer, as well as guide stem cell engineering. As Shendure explained, “Recording techniques like the ones in these studies enable measurements over time including in settings that we can’t directly visualize.” Scaling the methods across additional embryos and experimental conditions could support more quantitative—and eventually predictive—models of mammalian development.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/dna-typewriter-petracer-map-mouse-development-through-organogenesis/">DNA Typewriter, PEtracer Map Mouse Development Through Organogenesis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The State of AI in Drug Discovery</title>
<link>https://edusehat.com/en/the-state-of-ai-in-drug-discovery</link>
<guid>https://edusehat.com/en/the-state-of-ai-in-drug-discovery</guid>
<description><![CDATA[ GEN’s virtual summit returns on November 4 to examine how AI is reshaping R&amp;D timelines and real-world patient translation. From big pharma to AI-natives, this year’s program features the leaders of many of today’s outstanding companies and organizations powering the AI revolution!
The post The State of AI in Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2242544252_DigitalDNAPill.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 02:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, State, Drug, Discovery</media:keywords>
<content:encoded><![CDATA[<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/AlizaApple_headshot.jpg" class="h-full w-full object-cover" alt="Image of Aliza Apple, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Aliza Apple, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Vice President<br>Catalyze360 AI/ML, Eli Lilly</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/AlizaApple_headshot.jpg" alt="Image of Aliza Apple, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Aliza Apple, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Aliza Apple, PhD, is a vice president of Catalyze360 AI/ML at Eli Lilly, where she leads the strategy, build and launch of Lilly’s external-facing AI/ML efforts for drug discovery. She previously served as the COO and head of Lilly Gateway Labs West Coast, where she supported the local biotech ecosystem through early engagement and providing tailored offerings to meet their needs. Prior to Lilly, Aliza served as a co-founder at Santa Ana Bio, a venture-backed precision biologics company focused on autoimmune disease, and as an advisor to the founders of Firefly Biologics. Prior to biotech, Aliza was a partner in McKinsey’s life sciences practice. During her nine years at McKinsey in New York and San Francisco, she collaborated with leaders from more than 20 biopharma companies to develop their corporate and portfolio strategies, evaluate business development opportunities, and improve their organizational effectiveness.</p>
<p>Aliza completed her PhD in bioengineering at UC Berkeley and UCSF and holds a BS in physics from Georgetown University. She completed a postdoctoral fellowship at Cornell Medical College, supported by the NIH Kirschstein National Research Service Award.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Sam-Rodriques.jpeg" class="h-full w-full object-cover" alt="Image of Sam Rodriques, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Sam Rodriques, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Co-Founder, Director, and CEO<br>Edison Scientific and FutureHouse</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Sam-Rodriques.jpeg" alt="Image of Sam Rodriques, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Sam Rodriques, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Physicist and bioengineer Sam Rodriques, PhD, is the co-founder, director, and CEO of Edison Scientific and FutureHouse. Sam has invented technologies for spatial and temporal transcriptomics, brain mapping, gene therapy, and nanofabrication, and briefly ran an academic lab at the Francis Crick Institute in London prior to launching FutureHouse in San Francisco in 2023. FutureHouse is a new research lab focused on building an AI Scientist to accelerate research in biology and other complex sciences. In 2025, Sam launched Edison Scientific to commercialize the agents being built at FutureHouse, with the goal of wanting “science to move faster.”</p>
<p>Sam graduated summa cum laude with highest honors in physics from Haverford College, where he worked on new methods for calculating quantum entanglement in multipartite quantum systems. He holds a PhD in physics from MIT, having worked between the MIT Media Lab, the MIT Department of Brain and Cognitive Sciences, and the Broad Institute. Among his awards and fellowships are the Hertz Foundation Graduate Fellowship, an NSF Graduate Research Fellowship, and a Churchill Scholarship.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Peyton-Greenside-Headshot-2026-e1791476441492.jpg" class="h-full w-full object-cover" alt="Image of Peyton Greenside, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Peyton Greenside, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Co-Founder and CEO<br>BigHat Biosciences</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Peyton-Greenside-Headshot-2026-e1791476441492.jpg" alt="Image of Peyton Greenside, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Peyton Greenside, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Peyton Greenside, PhD, is the co-founder and CEO of BigHat Biosciences, a Bay Area biotechnology company pioneering an ML-driven platform to accelerate the design of next-generation antibodies and other therapeutic proteins.</p>
<p>Peyton holds a BA in applied mathematics from Harvard University, a PhD from Stanford University, and an MPhil in computational biology from the University of Cambridge, U.K.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Tessier-Lavigne-Xaira.jpg" class="h-full w-full object-cover" alt="Image of Marc Tessier-Lavigne, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Marc Tessier-Lavigne, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Co-Founder, Chairman, and CEO<br>Xaira Therapeutics</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Tessier-Lavigne-Xaira.jpg" alt="Image of Marc Tessier-Lavigne, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Marc Tessier-Lavigne, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Marc Tessier-Lavigne, PhD, is the co-founder, chairman, and CEO of Xaira Therapeutics. Previously, he held executive positions in the private sector at Genentech, where he was executive vice president for research and chief scientific officer, and in the academic sector, where he served as president of The Rockefeller University and then for seven years at Stanford University, where he remains a professor of biology (on leave). He also served previously on the faculty of the University of California, San Francisco, and was an investigator with the Howard Hughes Medical Institute. A Rhodes Scholar, Marc has been a leader in understanding mechanisms that direct the wiring of the brain and has helped elucidate mechanisms of neurodegeneration. He is the recipient of numerous scientific awards, including the 2020 Gruber Neuroscience Prize, and has been elected to multiple scientific societies, including the U.S. National Academy of Sciences and U.S. National Academy of Medicine; he is also an officer of the Order of Canada, one of that country’s highest honors. Marc is the co-founder of two neuroscience biotech companies, Renovis and Denali, and has served on the boards of Agios, Regeneron, Pfizer, Juno, and Denali.</p>
<p>Marc holds a BS degree in physics from McGill University in his native Canada. He earned a BA in philosophy and physiology from the University of Oxford as a Rhodes Scholar, and a PhD in physiology from the University of London.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<div class="wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-3e41869c wp-block-buttons-is-layout-flex">
<div class="wp-block-button"><a class="wp-block-button__link wp-element-button" href="https://events.zoom.us/ev/AhU-gkQDgAxdLnotC4XH9bsSU27D7B6VJ9r7cboVW7D-XBlhuQdY~ApctLSdDOQGhoFB6oDQ77y_R7tlH2uiWKtuSw3NzxTFvnxPWyLBVS6lxOudLAszRSm_7K8poqEpmZQQtSUa7tIp3_w" target="_blank" rel="noreferrer noopener">REGISTER NOW</a></div>
</div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, November 4, 2025</time><br><ul><li><strong>Time:</strong> <time datetime="2025-11-04T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<p class="wp-block-paragraph">From billion-dollar funding rounds and waves of IPOs to the first AI-guided molecules entering the clinic, the industry is signaling a clear inflection point: AI is set to fundamentally reshape drug discovery. At the center of this shift are maturing foundation models for molecules and cellular systems that unveil insights into complex biology.</p>


<p class="wp-block-paragraph">Yet the challenge is no longer prediction alone. Building the infrastructure that connects accelerated computing, generative design, and experimental feedback will be critical for transforming AI into a fully integrated engine for therapeutic innovation.</p>


<p class="wp-block-paragraph"><em>GEN</em>’s virtual summit, <strong><em>The State of AI in Drug Discovery</em>,</strong> returns on <strong>November 4</strong> to examine how AI is reshaping R&D timelines and real-world patient translation. From big pharma to AI-natives, this year’s program features the leaders of many of today’s outstanding companies and organizations powering the AI revolution, including Xaira Therapeutics, Edison Scientific, Eli Lilly, Chai Discovery, Lila Sciences, BigHat Biosciences, and more!</p>


<p class="wp-block-paragraph">Among the program highlights during this 4-hour event are:</p>


<ul class="wp-block-list">
<li>Building the AI scientist with <strong>Sam Rodriques, PhD</strong> (Edison Scientific)  </li>


<li>A fireside chat with Xaira Therapeutics CEO <strong>Marc Tessier-Lavigne, PhD</strong> </li>


<li>Powering AI adoption through strategic enterprise partnerships with <strong>Aliza Apple, PhD</strong> (Lilly TuneLab), <strong>Simon Barnett</strong> (Dimension), and <strong>Elliot Hershberg, PhD</strong> (Amplify Ventures)  </li>


<li>The role of agentic workflows in accelerating drug discovery with <strong>Le Cong, PhD</strong> (Stanford and Phylo) and <strong>Andrew Beam, PhD</strong> (Lila Sciences) </li>


<li>The new era of programmable therapeutics with <strong>Josh Meier</strong> (Chai Discovery) and <strong>Peyton Greenside, PhD</strong> (BigHat Biosciences) </li>


<li>And breakout sessions from our four event sponsors: <strong>A-AlphaBio, Benchling,</strong> <strong>LabVantage,</strong> and <strong>Revvity Signals</strong>.</li>
</ul>




<p class="wp-block-paragraph">Don’t miss this exceptional virtual summit, featuring many of the visionaries shaping the future of AI in drug discovery and biotech. Registration, as always, is free.</p>




<p class="has-text-align-center wp-block-paragraph"><u><strong>Guest Speakers Include</strong></u></p>


<figure class="wp-block-image size-full"><img decoding="async" width="2224" height="1072" src="https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image.jpg" alt="The State of AI in Drug Discovery speakers" class="wp-image-339067" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image.jpg 2224w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-300x145.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-1024x494.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-768x370.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-1536x740.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/AIDD-Speaker-Group-Image-2048x987.jpg 2048w" sizes="(max-width: 2224px) 100vw, 2224px"></figure>
</div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">






<p class="has-text-align-center wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image aligncenter size-medium is-resized"><a href="https://www.benchling.com/" target="_blank" rel=" noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="83" src="https://www.genengnews.com/wp-content/uploads/2022/07/Benchling_logo-300x83.jpg" alt="Benchling logo" class="wp-image-203139" srcset="https://www.genengnews.com/wp-content/uploads/2022/07/Benchling_logo-300x83.jpg 300w, https://www.genengnews.com/wp-content/uploads/2022/07/Benchling_logo.jpg 600w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></figure>


<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://www.revvity.com/" target="_blank" rel=" noopener"><img loading="lazy" decoding="async" width="300" height="163" src="https://www.genengnews.com/wp-content/uploads/2025/09/revvitysignals_logo-e1758737697993.jpg" alt="Revvity Signals logo" class="wp-image-321277"></a></figure>


<figure class="wp-block-image aligncenter size-medium is-resized is-style-default"><a href="https://www.labvantage.com/" target="_blank" rel=" noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="57" src="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg" alt="LabVantage logo" class="wp-image-131319" srcset="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-696x132.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-741x142.jpg 741w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo.jpg 750w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></figure>


<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://www.aalphabio.com/" target="_blank" rel=" noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="169" src="https://www.genengnews.com/wp-content/uploads/2026/10/aalphaBio_logo-1.jpg" alt="A-Alpha Bio logo" class="wp-image-339064"></a></figure>
</div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>


<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>



<p>The post <a href="https://www.genengnews.com/multimedia/summits/the-state-of-ai-in-drug-discovery/">The State of AI in Drug Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Epigenetics Underlies Comparatively Accelerated Molecular Aging in Larger and Male Dogs</title>
<link>https://edusehat.com/en/epigenetics-underlies-comparatively-accelerated-molecular-aging-in-larger-and-male-dogs</link>
<guid>https://edusehat.com/en/epigenetics-underlies-comparatively-accelerated-molecular-aging-in-larger-and-male-dogs</guid>
<description><![CDATA[ Large dogs tend to be shorter lived than their smaller counterparts, and a new study found that male and larger dogs undergo accelerated molecular aging, with pronounced DNA methylation changes on the X chromosome and at transposable elements. 
The post Epigenetics Underlies Comparatively Accelerated Molecular Aging in Larger and Male Dogs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-sophiedog.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 02:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Epigenetics, Underlies, Comparatively, Accelerated, Molecular, Aging, Larger, and, Male, Dogs</media:keywords>
<content:encoded><![CDATA[<p>Domestic dogs offer a useful model for understanding the biology of aging because their lifespans vary dramatically with body size. Large dogs tend to be shorter lived than their smaller counterparts, but why? Headed by a team at Arizona State University, a study of nearly 900 dogs now suggests that the answer may be written into the animals’ epigenomes.</p>
<p>Research professor Noah Snyder-Mackler, PhD, at Arizona State University School of Life Sciences, and colleagues developed an epigenetic clock that predicted mortality in dogs and showed that epigenetic aging is fastest early in life. The study results indicated that male dogs and larger dogs undergo accelerated molecular aging, with male dogs exhibiting pronounced DNA methylation (DNAm) changes on the X chromosome, and larger animals exhibiting methylation changes at transposable elements (TEs), stretches of DNA that can influence genome stability and gene regulation.</p>
<p>Snyder-Mackler is senior and corresponding author of the researchers’ published paper in <em>Science</em> (“<a href="http://dx.doi.org/10.1126/science.aeb2986" target="_blank" rel="noopener">Epigenetic aging and transposon dysregulation reflect size-related lifespan compression in dogs</a>,”) in which they concluded, “Our findings broadly establish companion dogs as a translational model for uncovering molecular mechanisms of lifespan variation, epigenomic instability, and age-related disease.”</p>
<figure aria-describedby="caption-attachment-339073" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339073" src="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-3-300x169.jpeg" alt="Genome-wide DNA methylation in 894 dogs from the Dog Aging Project reveals accelerated aging in larger dogs and faster loss of repression of transposable elements. [Blaise Mariner & Brianah McCoy] " width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-3-300x169.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/low-res-3.jpeg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Genome-wide DNA methylation in 894 dogs from the Dog Aging Project reveals accelerated aging in larger dogs and faster loss of repression of transposable elements. [Blaise Mariner & Brianah McCoy]</figcaption></figure>
<p>Aging is a universal process, but its pace and biological mechanisms substantially differ between individuals within even the same species, the authors wrote. “Whether shorter-lived individuals simply die earlier or instead experience accelerated biological aging throughout life remains unclear,” they noted. And while comparative studies across species have identified mechanisms associated with exceptional longevity, they may not be as well suited to identifying the molecular drivers of aging variation. “Domestic dogs provide a model for addressing this challenge because body size strongly predicts lifespan, with larger breeds living substantially shorter lives than smaller breeds despite sharing many physiological and environmental conditions,” the team continued.</p>
<p>In fact, smaller breeds can live nearly twice as long as larger breeds. And companion dogs live in human environments, consume commercial diets, and receive routine medical care, making them a relevant translational model for studying how genetic background and environmental exposures shape aging, the investigators pointed out.</p>
<figure aria-describedby="caption-attachment-339072" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-339072" src="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-4-300x200.jpeg" alt="Study author with dogs" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-4-300x200.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/low-res-4.jpeg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Professor and School of Life Sciences Associate Director Noah Snyder-Mackler poses for portraits with his two dogs, 7-year-old Homer, bottom, and 4-year-old Juno, top, on the steps of Old Main on the ASU Tempe campus on Monday morning, September 28, 2026. Snyder-Mackler’s recent research focuses on dog epigenetics. [Deanna Dent/Arizona State University]</figcaption></figure>
<p>But how intrinsic factors such as size and biological sex influence variation in dog aging and lifespan remains unclear. “It is well established that size and sex influence lifespan in dogs, but it remains unclear whether shorter-lived dogs experience accelerated epigenetic aging,” they stated. Previous research has demonstrated that DNAm is a useful indicator of biological aging, with “epigenetic clocks” offering a way to understand the factors that accelerate or decelerate biological aging. “DNA methylation (DNAm) has emerged as a robust molecular biomarker of age, with ‘epigenetic clocks’ offering a quantitative framework for identifying factors that accelerate or decelerate biological age.”</p>
<p>For their newly reported study Snyder-Mackler, together with first author Blaise Mariner, PhD, and colleagues generated 1,640 methylomes from a cohort of 894 dogs in the Dog Aging Project. They combined the molecular data with detailed genetic and demographic data. The results indicated that molecular aging occurs most rapidly early in a dog’s life. The study also found that larger and male dogs—both of which have shorter lifespans than their respective counterparts—age more quickly at the molecular level.</p>
<p>The authors identified different epigenetic patterns underlying these effects. According to the findings, sex-related changes were concentrated on the X chromosome, while body-size-related changes were especially prominent in TEs. “Thus, size and sex, two axes associated with shorter expected lifespan in dogs, appear to shape aging through partially distinct epigenetic architectures,” they stated. “Larger dogs show greater methylation loss at TEs with age, consistent with increased immune remodeling and genomic instability … These data address a major gap in comparative epigenomics by providing evidence that, within a species, demographic groups with shorter expected lifespans show faster epigenetic aging.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/epigenetics-underlies-comparatively-accelerated-molecular-aging-in-larger-and-male-dogs/">Epigenetics Underlies Comparatively Accelerated Molecular Aging in Larger and Male Dogs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ARPA&#45;H’s BoSS Program Funds Three Teams Tackling Cold Chain Challenges for Cell Therapies</title>
<link>https://edusehat.com/en/arpa-hs-boss-program-funds-three-teams-tackling-cold-chain-challenges-for-cell-therapies</link>
<guid>https://edusehat.com/en/arpa-hs-boss-program-funds-three-teams-tackling-cold-chain-challenges-for-cell-therapies</guid>
<description><![CDATA[ Cell therapies and other biologics depend on ultracold storage and tightly controlled shipping. ARPA-H has funded teams of companies, research agencies, and universities developing alternatives, aiming to widen patient access to these therapies.
The post ARPA-H’s BoSS Program Funds Three Teams Tackling Cold Chain Challenges for Cell Therapies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/Getty_2024513047_PharmaceuticalFactory.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 09 Oct 2026 02:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ARPA-H’s, BoSS, Program, Funds, Three, Teams, Tackling, Cold, Chain, Challenges, for, Cell, Therapies</media:keywords>
<content:encoded><![CDATA[<p><span>The Advanced Research Projects Agency for Health, (ARPA-H), an agency within the United States’ Department of Health and Human Services (HHS), recently announced awards and teams involved in its BioStabilization Systems (BoSS) program, an initiative that aims to develop new methods for producing, storing, and transporting cell-based biologic medicines at room temperature. ARPA-H has committed to provide up to $87 million across the four-year program. This round of funding will support Phase I of the program.</span></p>
<p><span>The teams have been tasked with pursuing new technologies that confer long-term, shelf-life stability to cell-based therapies and biologics making it possible to store and ship them without refrigeration. To accomplish this goal, BoSS teams will work across two technical areas. They will work on interventions to stabilize cells for storage and then reactivate them on demand as well as on creating novel processing systems that ensure these interventions are efficient and scalable for manufacturing. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>This week, members of the Reversible Ambient Temperature (RAB) team said that they have been awarded up to $7.3 million initially from ARPA-H. The RAB team includes representatives from Draper, a non-profit research, development, and manufacturing company, which serves as the administrative lead,and Likarda, a biotechnology company that develops hydrogel technologies for delivering and preserving cell therapies and biologics, which serves as the technical lead for the team. Other members of the team include scientists from CaseBioscience, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and University of Colorado. </span></p>
<p><span>For their part, this team will use AI-assisted design of experiments to optimize formulation, quiescence induction parameters, hydrogel composition, and recovery media as well as freeze-assisted droplet drying to achieve a stable product. Specifically, the RAB team’s biostabilization strategy, led by Likarda, will focus on simultaneous control of cell state, physical environment, and the cellular stress responses activated during freezing, dehydration, storage, and recovery. Meanwhile, the bioprocessing engineering team, led by Draper, will convert the manual steps of biostabilization into an automated, commercially viable workflow and will develop custom instruments to scale up the processes.</span></p>
<p><span>Likarda will contribute its proprietary Core-Shell Spherification hydrogel technology, which is designed to encapsulate and protect living cells while maintaining viability and function. CaseBioscience will provide expertise in clinical media formulation, biopreservation, and cellular metabolism to the development and evaluation of novel approaches for long-term ambient stabilization of therapeutic cells.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>“The RAB team brings together deep expertise in cryoprotection, encapsulation, and cell state, with a focus on protecting cell viability throughout the stabilization and reanimation process, and the team has direct experience bringing products to market,” said Jason Fiering, distinguished technical staff at Draper. “Working in parallel, our interdisciplinary engineering team will develop the customized instruments needed to transfer these processes to clinical manufacturing environments.” </span></p>
<p><span>In his comments, John Baust, PhD, an expert in biopreservation and collaborator on the project with CPSI Biotech noted that “the concept of preserving living cells in a dry state has been pursued for more than two decades, but significant scientific and engineering barriers have yielded limited success.” The BoSS program is an opportunity “to tackle this from multiple scientific and engineering directions simultaneously” that if successful “could represent a paradigm shift in how biologics are preserved, stored, and distributed.”</span></p>
<p><span>Other teams announced by ARPA-H include one led by DesiCorp. This team includes members from the University of Louisville, University of Texas at Austin, Via Therapeutics, VeriSIM Life, and Ossium Health. They will leverage high-throughput screening to identify biocompatible formulations that slow cellular metabolism and AI-assisted process optimization to develop a thin-film freeze-drying (TFFD) system that stabilizes cells at room temperature. </span></p>
<p><span>DesiCorp will lead integration of the overall workflow by using a high-throughput screening platform to rapidly identify biocompatible formulations that enable cells to survive TFFD and resume function after rehydration. Meanwhile, UT Austin researchers will help optimize the TFFD critical process parameters and composition/material attributes, while also contributing expertise in aseptic processing and scaling up the technology. </span></p>
<p><span>A third team is led by the University of California, Davis and includes scientists from Mayo Clinic, Case Western Reserve University, University of Georgia, and Sersense. The team will induce a low metabolic state in cells using light-responsive gels and microfluidic processing techniques to produce cells that are stable at room temperature. </span></p>
<p><span>Recently, that team announced that it had been awarded up to $6 million, initially,  from ARPA-H to fund its project dubbed CYBORGEL. Their efforts will leverage research done in the laboratory of Cheemeng Tan, PhD, a professor of biomedical engineering at UC Davis. Previously, he and his collaborators formed water-rich polymer networks inside living cells to create cell-material hybrids. This process, called intracellular gelation, forms a gel inside the cell and is capable of halting cell division while preserving cellular function. Tan and his team dubbed this cellular product a “cyborg” since the gelation process combines living cells with synthetic materials. </span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>Through CYBORGEL, the collaborators will investigate whether this intracellular gelation process can be extended to reduce the cost and simplify the storage, transportation and delivery of cellular therapies. The researchers will also test whether CYBORGEL cells remain therapeutically useful after being returned to their original state. For instance, one study will test the effectiveness of reanimated CAR T cells for existing clinical trials on cancer immunotherapies. Another will test it on placental mesenchymal stem cells used to treat spina bifida, a medical intervention being developed by UC Davis researchers. </span></p>
<p><span>As part of the initiative, the American Type Culture Collection (ATCC) has been tapped to serve as the IV&V partner. ATCC will provide working cell banks of government-selected cell types that will be used for demonstrations. They will also provide unbiased assessments of both the viability and function of the preserved products and the design features of the preservation systems.  </span></p>
<p><span>The first phase of the BoSS program kicked off in September and is expected to run for 15 months. Over the four-year multi-phase program, the teams’ approaches will be evaluated against increasingly stringent benchmarks for cell viability, production speed, and shelf-life stability. If successful, work under the BoSS program could enable lower costs for cell-based drugs, reduce the risk of therapeutic and pharmaceutical product losses, and enable domestic reserves for public health preparedness. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/arpa-hs-boss-program-funds-three-teams-tackling-cold-chain-challenges-for-cell-therapies/">ARPA-H’s BoSS Program Funds Three Teams Tackling Cold Chain Challenges for Cell Therapies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gut Microbes Trigger Calprotectin to Protect Newborns from Infection</title>
<link>https://edusehat.com/en/gut-microbes-trigger-calprotectin-to-protect-newborns-from-infection</link>
<guid>https://edusehat.com/en/gut-microbes-trigger-calprotectin-to-protect-newborns-from-infection</guid>
<description><![CDATA[ Newborn gut microbes activate epithelial calprotectin production, strengthening early-life immunity and protecting against dangerous infections, potentially offering new strategies to prevent neonatal sepsis.
The post Gut Microbes Trigger Calprotectin to Protect Newborns from Infection appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/06/Microbiome-20-GettyImages-1402265767.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 05:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gut, Microbes, Trigger, Calprotectin, Protect, Newborns, from, Infection</media:keywords>
<content:encoded><![CDATA[<p>The immune systems of newborns are incredibly different from adults, however, the mechanisms that enable early-life immunity remain poorly understood. Because infection is a leading cause of neonatal morbidity and mortality, and infants are particularly vulnerable, understanding the immune mechanisms in early life is of the utmost importance. In addition, despite recognition that acquisition of the microbiota alters early host defense, there is limited understanding of the commensal-induced mechanisms that play a role in the neonate.</p>
<p>Now, a new study shows that the antimicrobial protein calprotectin, found in high concentrations in the guts of newborn mice, is expressed by intestinal epithelial cells in response to commensal bacteria colonizing the gut. More specifically, the healthy newborn mice “express high concentrations of the S100 calcium-binding protein A8/A9 antimicrobial heterodimer calprotectin” and that this early up-regulation in the intestine is driven by initial exposure to commensal bacteria.</p>
<p>They also found that newborn mice with impaired calprotectin expression or poor microbiota colonization were more susceptible to sepsis and death post-infection. However, when the mice were given calprotectin, it rescued the microbiota-depleted pups from infection.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.adx6147" target="_blank" rel="noopener">Early-life microbiota direct an epithelial S100 program required for neonatal immunity.</a>”</p>
<p>The main source of calprotectin in the neonatal intestine was found to be microbiota colonization induced S100A9 expression by intestinal epithelial cells (IECs) and epithelial cells. And neonatal IEC-specific S100A9 knockout pups were highly susceptible to infection.</p>
<p>The study also sheds light on the specific mechanisms that provide early-life immunity against potentially deadly pathogens such as <em>Staphylococcus aureus</em>, <em>Listeria monocytogenes, </em>and <em>Streptococcus pneumoniae</em>, at a crucial time when newborns lack other immune defenses.</p>
<p>In mice and in human intestinal organoids, the researchers demonstrated that commensal microbes such as <em>Lactobacillus </em>produce the metabolite indole-3-lactic acid (ILA), which activates signaling in neonatal epithelial cells to increase the production of intestinal calprotectin.</p>
<p>Together, these findings suggest that microbiota-epithelial dynamics at birth can help program early-life immunity, the researchers write, with potential implications for probiotic approaches that target epithelial cells to prevent neonatal sepsis. This result, plus the authors’ finding that calprotectin is present in the guts of human newborns less than two days old (but not in seven-year-old infants), suggests a similar early-life immune mechanism may be at play in humans.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/gut-microbes-trigger-calprotectin-to-protect-newborns-from-infection/">Gut Microbes Trigger Calprotectin to Protect Newborns from Infection</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Secrets of Oldest Land Animal’s 194&#45;Year Lifespan Revealed with Epigenetics</title>
<link>https://edusehat.com/en/secrets-of-oldest-land-animals-194-year-lifespan-revealed-with-epigenetics</link>
<guid>https://edusehat.com/en/secrets-of-oldest-land-animals-194-year-lifespan-revealed-with-epigenetics</guid>
<description><![CDATA[ Researchers studying a giant tortoise named Jonathan—who is the oldest known living land animal in the world today—say it’s not just good genes, but a lack of genetic wear and tear that may have kept him going for an estimated 194 years.
The post Secrets of Oldest Land Animal’s 194-Year Lifespan Revealed with Epigenetics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/low-res.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 05:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Secrets, Oldest, Land, Animal’s, 194-Year, Lifespan, Revealed, with, Epigenetics</media:keywords>
<content:encoded><![CDATA[<p>Researchers studying a giant tortoise named Jonathan—who at an estimated 194 years of age is the oldest known living land animal in the world today—say it’s not just good genes, but lack of genetic wear and tear that have kept him going for nearly two centuries.</p>
<p>Headed by Stephen Clark MD, PhD, founder of the Kallel Foundation, the team sequenced Jonathan’s genome and identified 287 unique gene variants in this remarkably old Aldabra giant tortoise (<em>Aldabrachelys gigantea</em>) that may reduce the usual effects of aging.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>When comparing Jonathan’s epigenome—the “on/off” switches on his genes—with that of younger giant tortoises of the same species, the team found that switches controlling Jonathan’s DNA repair and metabolism genes were very similar to those in his younger relatives. Usually, the epigenome changes over time, contributing to the aging process. This is a key reason why things start to go wrong in older bodies.</p>
<p>“We found that the gene regulators involved in energy production and DNA repair have remained incredibly stable in Jonathan over almost two centuries,” said Justin Gerlach, PhD, at Peterhouse at the University of Cambridge, who was involved in the study.</p>
<p>The study marks the first time the epigenome of a giant tortoise has been investigated. It was led by researchers at the longevity research non-profit Kallel in the U.S., who say that cracking the genetic code of a multi-century life offers unprecedented insights into extreme lifespan.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Clark is senior and corresponding author of the researchers’ published paper in <em>Science Advances</em>, titled “<a href="http://dx.doi.org/10.1126/sciadv.adw8887" target="_blank" rel="noopener">Epigenetic insights into extreme longevity in the world’s oldest terrestrial animal, Jonathan</a>,” in which they concluded “Our findings support a model for aging wherein the maintenance of low methylation entropy in gene promoters is coupled to efficient mitochondrial energy production, efficient RNA processing, and efficient genomic repair.”</p>
<p>The giant tortoises of the Galapagos and Seychelles islands are the extraordinary last survivors of animals that used to dominate the ecology of many of the world’s islands. Aldabra giant tortoises are exceptionally long-lived, but Jonathan is about 100 years older than most of his species. He’s thought to have hatched in 1832—making him a contemporary of Charles Darwin and Queen Victoria.</p>
<figure aria-describedby="caption-attachment-339001" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-339001" src="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-2-300x230.jpeg" alt="Jonathan arrived in St. Helena as a gift to Sir William Grey-Wilson in 1882, who later became governor of the island. This image was taken around that time - Jonathan is on the left. [A.L. Innes]" width="300" height="230" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/low-res-2-300x230.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/low-res-2.jpeg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Jonathan arrived in St. Helena as a gift to Sir William Grey-Wilson in 1882, who later became governor of the island. This image was taken around that time—Jonathan is on the left. [A.L. Innes]</figcaption></figure>
<p>Jonathan has lived most of his life on the island of St. Helena—a British Overseas Territory in the South Atlantic Ocean—in the grounds of the residence of the governor of St. Helena. Jonathan arrived from the Seychelles 144 years ago, already fully grown, as a gift to the governor.</p>
<p>Gerlach has studied the ecology and conservation of giant tortoises for several decades, but this is the first time he has studied their exceptionally long lives. Gerlach said, “There are few creatures that could tell us more about aging than the giant tortoises of the Galapagos and Seychelles islands. Working with a really old giant tortoise is such a privilege: you get a sense of the tortoise being your collaborator, not your study subject.”</p>
<p>For their study the team extracted Jonathan’s genetic material from cheek scrapings rather than a blood draw (they teased the tortoise with a promise of food until he opened his jaws wide), so that they could compare his genome and methylome with those of four other Aldabras, ranging in age from juveniles to older adults. “Because of concerns for Jonathan’s health and his iconic status on St. Helena, a blood draw for DNA sequencing was not permitted,” the authors explained. “Instead, we collected buccal scrapes and saliva samples for genomic DNA (gDNA) isolation.”</p>
<p>The team’s analyses identified genetic variants associated with several known aging pathways, including DNA repair, telomere maintenance, insulin regulation, mitochondrial function, and cancer. The investigators also analyzed Jonathan’s genome’s methylome—or the total picture of his genome’s methylation, which refers to the addition to DNA of tiny methyl chemical tags that impact gene expression. Methylation entropy, a sign of aging, occurs as random changes in methylation patterns accumulate over time. This analysis showed low entropy within specific gene promoters for mitochondrial function, RNA processing, and genome repair. The regions of low methylation entropy observed in Jonathan “suggest that high-fidelity transcription of genes in these pathways may be crucial for long-lived species,” the researchers noted.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“Nature has already solved the puzzle of aging in remarkable ways, and Jonathan’s genome provides a blueprint for cellular resilience,” said Clark. “Our goal is to take these evolutionary insights and immediately translate them into practical, affordable treatments for everyday people. Aging is the greatest risk factor for nearly every chronic disease we face, and through the generosity of philanthropic partners, we can democratize access to longevity medicine.”</p>
<p>In their paper the authors wrote in summary, “… while we identified many genetic variants in Jonathan associated with known aging pathways, our most notable finding is the low entropy maintained within specific gene promoters. This stability is exceptionally pronounced in promoters of genes involved in mitochondrial function and RNA processing. We hypothesize that maintaining this low-entropy state ensures high-fidelity expression in these critical pathways, partially protecting him from age-related decline.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/secrets-of-oldest-land-animals-194-year-lifespan-revealed-with-epigenetics/">Secrets of Oldest Land Animal’s 194-Year Lifespan Revealed with Epigenetics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Adding Low&#45;Fidelity Data to ML Training Sets Could Yield Better Process Models</title>
<link>https://edusehat.com/en/adding-low-fidelity-data-to-ml-training-sets-could-yield-better-process-models</link>
<guid>https://edusehat.com/en/adding-low-fidelity-data-to-ml-training-sets-could-yield-better-process-models</guid>
<description><![CDATA[ Low-fidelity trend information should be incorporated into the data sets used to train machine learning-based biopharmaceutical process models, according to new analysis, which suggests the approach could also help identify the most manufacturable drug candidates.
The post Adding Low-Fidelity Data to ML Training Sets Could Yield Better Process Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2248132110-small.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Adding, Low-Fidelity, Data, Training, Sets, Could, Yield, Better, Process, Models</media:keywords>
<content:encoded><![CDATA[<p>Combining trend information with high-fidelity experimentally-derived data could improve the accuracy of machine learning-based process models, according to researchers.</p>
<p>Machine learning models have the potential to make biopharmaceutical process development faster and more efficient by, in theory, allowing scientists to predict the impact of changes to parameters ahead of time.</p>
<p>The problem, according to <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bit.70213" target="_blank" rel="noopener">recent research</a>, is that the high-fidelity process information required to train machine learning models is expensive to generate and, as a result, in short supply.</p>
<p>One potential solution would be to include low-fidelity data, which indicate general process trends, in training sets, says lead author Mohammad Golzarijalal, PhD, a research fellow at the University of Melbourne’s digital bioprocess hub.</p>
<p>“The basic idea is that abundant low-fidelity data teach the model the broad global trend of the process, while a smaller amount of high-fidelity data corrects and refines these trends, aligning surrogate model predictions more closely with the available ground truth.</p>
<p>“A model trained only on limited high-fidelity data can overfit and perform poorly outside the conditions it has already observed. By learning useful trends from lower-cost data, a multi-fidelity model can improve predictive accuracy and explore a wider process space without requiring the same number of expensive experiments,” he says.</p>
<p>More accurate models could improve predictions about cell growth, viability, metabolite concentrations, and product titer. They could also guide media optimization, feeding schedules, seeding density, and operating conditions.</p>
<p>“One example discussed in our review is a recent study, which was performed in our own group, that combined 20,000 simulated CHO fed-batch data points with experimental data from 65 bioreactor runs.</p>
<p>“The multi-fidelity Gaussian-process models predicted final monoclonal-antibody titer more accurately than a model trained only on the experimental data,” Golzarijalal says.</p>
<h4><strong>Low-fidelity data </strong></h4>
<p>Low-fidelity process data can be from previous production runs or from cultures grown in bioreactor configurations that differ from those in the process under development. Such data can also be generated using low-cost mechanistic or empirical models.</p>
<p>Drug firms already use low-fidelity data to an extent, although, as Golzarijalal points out, use is usually limited. For example, scientists routinely draw on previous experiments to define parameter ranges, develop design-of-experiments studies, and guide process optimization.</p>
<p>“There is an opportunity to use these data more systematically,” he says, adding, “Multi-fidelity algorithms provide a structured way to determine how much information should be transferred from historical or simulated data to a current problem.</p>
<p>“This can make past experience more useful for prediction and decision-making, rather than treating each new program largely in isolation,” Golzarijalal adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/adding-low-fidelity-data-to-ml-training-sets-could-yield-better-process-models/">Adding Low-Fidelity Data to ML Training Sets Could Yield Better Process Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Big Data Opportunities in Biomanufacturing</title>
<link>https://edusehat.com/en/big-data-opportunities-in-biomanufacturing</link>
<guid>https://edusehat.com/en/big-data-opportunities-in-biomanufacturing</guid>
<description><![CDATA[ Industry-wide standardization and collaboration leverage big data in ways that help companies unleash optimizations enterprise-wide while simultaneously advancing industry knowledge, but succeeding also takes a lot of data prep and security.
The post Big Data Opportunities in Biomanufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/11/GettyImages-122204403-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Big, Data, Opportunities, Biomanufacturing</media:keywords>
<content:encoded><![CDATA[<p>Is your data a predictive asset or something that merely takes up storage space? Odds are good the answer is the latter. Yet, data sets from R&D, tech transfer, facilities operations, supply chain operations, and quality optimization hold details that could be predictive assets for current and future biomanufacturing, product development, and supply chain operations.</p>
<p>Researchers led by Roger Hart, PhD, senior fellow, Big Data Project lead, National Institute for Innovation in Manufacturing Biopharmaceuticals, and senior researcher Kelvin Lee, PhD, professor, University of Delaware, make the case not only for leveraging big data in your own company, but standardizing and sharing key insights industry-wide…without compromising proprietary information.</p>
<p>That opinion is based on results from a big data model developed through the MELLODDY Consortium (Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck KGaA, Novartis, and Servier).</p>
<p>As Hart, Lee, and colleagues report in a <a href="https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1886721/full" target="_blank" rel="noopener">recent paper</a>, the consortium pooled decades of proprietary data—some 2.6 billion data points spanning more than 21 million molecules and more than 40 thousand assays in on-target and secondary pharmacodynamics and pharmacokinetics—using a secure computing platform to jointly train a predictive drug-activity model. That shared quantitative structure-activity relationship model used “the chemical structure of potential drug compounds to predict how they will function,” they note.</p>
<p>Results, they say, significantly outperformed those of any of the individual members. Detailing those results in a separate <a href="https://pubs.acs.org/jcisd8/article-pdf/64/7/2331/10574102/ci3c00799.pdf" target="_blank" rel="noopener">article</a>, Wouter Heyndrickx, PhD, machine learning scientist from consortium lead Janssen Pharmaceuticals, reports benefits in “most of the classification or regression tasks,” writing that the model generally enhanced predictivity, sometimes substantially. Notably, the median Relative Improvement of Proximity to Perfection for conformal efficiency exceeded 12%, with one exceeding 20%.</p>
<h4><strong>Prepping to share</strong></h4>
<p>“Many organizations are already pursuing in-house solutions,” Lee tells <em>GEN</em>. “The benefits are the ability to tailor the solution to one’s specific situation. But by participating in larger-scale efforts, one can benefit from shared learnings and efforts to accelerate the digital transformation. Ecosystem-wide efforts can enable the entire industry to advance digital tools and benefits in ways that might not be apparent to individual organizations.”</p>
<p>Achieving such results takes a lot of data management preparation, the researchers admit. They must:</p>
<ul>
<li>Standardize ontologies, schemas, and holistic data integration and break down data silo enterprise-wide</li>
<li>Enable predictive strategies to optimize processes, such as those supported by digital twins, <em>in silico</em> process design, and hybrid mechanistic/ AI models</li>
<div class="my-8"><span data-render-ad="5"></span></div>
<li>Develop secure, shared datasets that enable data to be pooled while protecting sensitive and proprietary data</li>
<li>Ensure interoperability and real-time data connectivity among sensors from multiple vendors so they can communicate accurately and in real- or near-real time</li>
<li>Industry guidance and buy-in, including regulatory clarity, workforce development, and shared business cases that lower adoption barriers</li>
</ul>
<p>It is, in a word, challenging.</p>
<p>Redesigning legacy data infrastructure is expensive and time-consuming, and multivendor operability is a low priority for equipment developers, Hart says. There are additional barriers, too. Regulators have not yet determined how such models will be evaluated in data submissions. And, finally, workers with combined expertise in biomanufacturing and data science are scarce.</p>
<p>Yet, there are clear advantages to standardizing big data and using it to populate shared models.</p>
<p>“Many organizations face similar challenges and opportunities related to development and manufacturing,” Lee says. “Supporting an industry-wide set of solutions can accelerate the learnings of individual organizations, facilitate tech transfers…foster greater flexibility and interoperability, and support federated learning.”</p>
<p>As the team emphasizes, “Companies that do not adopt these capabilities are competitively disadvantaged from realizing the full benefits of their big data in the biopharmaceutical manufacturing marketplace.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/big-data-opportunities-in-biomanufacturing/">Big Data Opportunities in Biomanufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Hybrid Digital Twins Developed for Future Autonomous Labs</title>
<link>https://edusehat.com/en/hybrid-digital-twins-developed-for-future-autonomous-labs</link>
<guid>https://edusehat.com/en/hybrid-digital-twins-developed-for-future-autonomous-labs</guid>
<description><![CDATA[ An academic laboratory is developing a hybrid digital twin that integrates a mechanistic model with artificial intelligence, with the long-term goal of driving the future of next-generation autonomous robotic laboratories.
The post Hybrid Digital Twins Developed for Future Autonomous Labs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/06/Getty_2147673480_ScientistsInLabDNAOnScreen.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Hybrid, Digital, Twins, Developed, for, Future, Autonomous, Labs</media:keywords>
<content:encoded><![CDATA[<p>Researchers from South Korea are developing a digital twin that combines mechanistic modeling with artificial intelligence. They hope the model will eventually allow them to create a fully autonomous lab, capable of operating with minimal human intervention at academic and on larger scales.</p>
<p>“We’ve been focused on combining this mechanistic model with the data-driven AI model to create a hybridized model,” explains Dong-Yup Lee, PhD, professor and head of the Bioprocess Digital Twin Lab at Sungkyunkwan University.</p>
<p>According to Lee, their digital twin differs from a conventional simulator or standalone model because it’s continuously connected to a multi-sensory modeling system, which collects relevant data from the bioreactor in their lab. The team, he says, has developed mathematical models of mammalian Chinese Hamster Ovary (CHO) cells and uses them to make predictions about how the cells will behave under different bioreactor conditions.</p>
<p>However, he says, predictions from the mechanistic model alone do not always achieve the accuracy or adaptability required for real-time operation. As such, the team has incorporated data-driven AI as a complement to provide more adaptive control of the bioreactor.</p>
<p>“One of the limitations of AI is, if you have lots of data, it’s good for prediction, but it can’t explain why,” he says. “So, we use what is called explainable (XAI).”</p>
<p>XAI can provide information about what input conditions are most strongly affecting process outputs, he says, rather than just providing a prediction. This added interpretability can provide multiple options for improving and controlling bioprocess performance.</p>
<p>According to Lee, the biggest challenge for the team so far has been integrating the mechanistic model with XAI in a way that connects data collection, prediction, and forecasting directly with process control.</p>
<figure aria-describedby="caption-attachment-338956" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338956" src="https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small-300x225.jpg" alt="" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Bioreactor-setup-image-2-small.jpg 900w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Bioprocess Digital Twin Lab’s setup at Sungkyunkwan University. [Sungkyunkwan University]</figcaption></figure>
<p>“We’re probably at 80% on [developing] the hybridized model,” he says. “The remaining 20% is working out how these models can be linked to and interact with the control system and our future robotics.”</p>
<p>Bringing these aspects together, he says, will be a key focus of the team’s future research, with the ultimate aim of moving beyond predictive digital twins toward increasingly autonomous process operation.</p>
<p>Lee is open to industry collaborations, particularly around digital twins, advanced bioprocess monitoring, and autonomous biomanufacturing.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/hybrid-digital-twins-developed-for-future-autonomous-labs/">Hybrid Digital Twins Developed for Future Autonomous Labs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Electrical Signals Sharpen Bioprocess Control</title>
<link>https://edusehat.com/en/electrical-signals-sharpen-bioprocess-control</link>
<guid>https://edusehat.com/en/electrical-signals-sharpen-bioprocess-control</guid>
<description><![CDATA[ Electrical signatures could give bioprocess engineers an earlier view of cell health, detecting apoptosis, refining harvest timing, and moving monitoring from destructive offline assays toward rapid, label-free, potentially automated control of biologics manufacturing operations.
The post Electrical Signals Sharpen Bioprocess Control appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Lapizco-Encinas_GBPN_IMAGE_01OCT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 08 Oct 2026 01:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Electrical, Signals, Sharpen, Bioprocess, Control</media:keywords>
<content:encoded><![CDATA[<p>For bioprocess engineers, knowing when a cell culture is beginning to fail can make the difference between an optimal harvest and a compromised batch. Yet many standard approaches provide only a delayed snapshot of cellular health. A <a href="https://doi.org/10.1002/elps.70146" target="_blank" rel="noopener">review</a> by Alaleh Vaghef-Koodehi, PhD, a postdoctoral researcher at the University of Massachusetts Amherst, and Blanca Lapizco-Encinas, PhD, professor of biomedical engineering at the Rochester Institute of Technology, suggests that cells’ electrical properties could provide a faster window into what is happening inside a bioprocess. Their review traces advances from 2015 through 2026 in using membrane capacitance, cytoplasmic conductivity, polarizability, and surface charge to assess cellular state without labels.</p>
<p>The opportunity is particularly compelling in biologics manufacturing, where the authors call real-time monitoring of cell health a “critical bottleneck.” Conventional apoptosis measurements, including offline fluorescent staining and lactate dehydrogenase release assays, can be destructive and provide limited temporal resolution. Dielectrophoresis (DEP), which exploits how polarizable cells respond to nonuniform electric fields, offers another approach: tracking the changing electrical signature of cells without labeling or destroying them.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Chinese hamster ovary (CHO) cells, which the review calls the “industry workhorse,” provide a striking example. Studies using dual-frequency DEP cytometry followed CHO cells during nutrient-starvation-induced apoptosis and found two distinguishable electrical phases. First came membrane remodeling and a reduction in membrane capacitance. Then cytoplasmic conductivity dropped sharply as ionic homeostasis broke down. In one study, apoptotic populations began appearing between 24 and 36 hours, and cytoplasmic conductivity fell to approximately 0.05 siemens per meter (S/m) compared with about 0.45 S/m in viable cells. A follow-up similarly found membrane capacitance declining gradually before cytoplasmic conductivity plunged to 0.07 S/m in apoptotic cells by 52 hours. Together, the changes provide an electrical timeline of cell death rather than merely an endpoint measurement.</p>
<p>Speed could make those signatures especially valuable on the manufacturing floor. The commercially available 3DEP platform has been used to capture electrical signatures from populations of roughly 20,000 cells within seconds. According to the review, such measurements can reveal emerging apoptotic subpopulations “hours before traditional biochemical markers become detectable.” Earlier warning could allow operators to adjust a process or select a more favorable harvest time before culture performance deteriorates.</p>
<p>The next step might be turning those measurements into automated decisions. The review highlights a 2026 analysis integrating electrical impedance data with supervised machine learning; a tuned random-forest model achieved 90% predictive accuracy and was proposed as a label-free “traffic-light” system for batch monitoring. Combining rapid electrical measurements with computational analysis could ultimately support autonomous intervention and optimized harvesting.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>That vision is not yet routine bioprocess control, but the technology is moving beyond specialized laboratory experiments. Commercial DEP platforms are already increasing accessibility, and the authors see continued integration with computational modeling and machine learning as a route toward real-time automated systems. For biomanufacturing, the electrical life of a cell may become another process signal—one capable of warning that a culture is changing before conventional assays catch up.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/electrical-signals-sharpen-bioprocess-control/">Electrical Signals Sharpen Bioprocess Control</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kagan, Soai Win 2026 Nobel Prize in Chemistry for Discoveries Related to Asymmetric Organic Synthesis</title>
<link>https://edusehat.com/en/kagan-soai-win-2026-nobel-prize-in-chemistry-for-discoveries-related-to-asymmetric-organic-synthesis</link>
<guid>https://edusehat.com/en/kagan-soai-win-2026-nobel-prize-in-chemistry-for-discoveries-related-to-asymmetric-organic-synthesis</guid>
<description><![CDATA[ Henri Kagan, PhD, and Kenso Soai, PhD, shared this year&#039;s award for the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis respectively.
The post Kagan, Soai Win 2026 Nobel Prize in Chemistry for Discoveries Related to Asymmetric Organic Synthesis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Nobel-prize-in-chemistry-2026.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 22:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kagan, Soai, Win, 2026, Nobel, Prize, Chemistry, for, Discoveries, Related, Asymmetric, Organic, Synthesis</media:keywords>
<content:encoded><![CDATA[<p><span>The 2026 Nobel Prize in Chemistry “is about making chemistry choose a mirror image.” With those words, members of the Nobel committee announced that they had awarded the 2026 prize to Henri B. Kagan, PhD, professor emeritus at Université Paris-Sud, and Kenso Soai, PhD, professor emeritus at Tokyo University of Science, for complementary breakthroughs related to the emergence of homochirality. Kagan received the award for his discovery of nonlinear effects in asymmetric organic synthesis, and Soai for the development of autocatalysis in asymmetric organic synthesis.</span></p>
<p><span>The year’s prize recognized foundational discoveries that helped explain a chemical asymmetry observed in living organisms.  Small molecules like amino acids exist as two variants that are mirror images, yet living organisms contain only one of these images while the other is rarely found in nature. Kagan and Soai’s work provided the answer to the question of how homochirality can emerge. Their discoveries have enabled chemists to drive chemical reactions that lead to homochirality, and have been beneficial to scientists that design reactions used in manufacturing to develop new drugs, flavors, scents, and other materials. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Their combined efforts “have provided a solution to a chemical mystery that is over a century old,” said Heiner Linke, PhD, chair of the Nobel Committee for Chemistry. “The chemical reactions they have developed are spectacular.”</span></p>
<p><span>How homochirality emerges is “probably the most fundamental question in life,” explained Peter Somfai, PhD, a professor of organic chemistry at Lund University and a member of the Nobel committee for Chemistry, in an interview. Scientists have long wondered how it happened billions of years ago. “Now we mimicked it in a lab today, not the way it happened four billion years ago, it’s important to stress, but we have for the first time mimicked it.”</span></p>
<h4><b>The core scientific question</b></h4>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>Though chiral molecules exist as non-identical mirror images with potential biological effects, life is homochiral and built exclusively from left-handed amino acids and right-handed sugars. And different enantiomers can have dramatically different properties. “Many molecules occur in two different versions, like my hands. They are one another’s mirror image. They look alike, but they’re not identical,” Linke said. </span></p>
<p><span>When scientists began experimenting with chemical reactions that can form two mirrored molecules, they typically obtained equal proportions of both. But attempts to produce only one of the mirror images, in the context of pharmaceutical development, for example, proved challenging. Some of the earliest discoveries about chirality can be traced back to the mid-19<sup>th</sup> century to Louis Pasteur and his efforts to investigate the behavior of tartaric acid. The field also owes some insights to the work of the chemist Willy Marckwald, who carried out the first successful asymmetric reaction in the early 1900s. He succeeded by using a chiral catalyst which boosted the formation of one mirror image over the other. </span></p>
<p><span>In their respective laboratories, Kagan and Soai made their contributions to the question of how homochirality emerges spontaneously. In 1986, Kagan discovered a new way of manipulating chemical reactions that made it possible to create a larger quantity of one of the images than had previously been thought possible. </span></p>
<p><span>At the time, he and other chemists were working to refine asymmetric reactions with an eye towards producing pure enantiomers. Building on the work done by Marckwald and others, as well as mathematical contributions from Charles Frank, PhD, a theoretical physicist at the University of Bristol, scientists typically used catalysts comprising a metal atom and a chiral substance. They typically used an enantiomer that was as pure as possible the catalyst assuming that combining two mirrored enantiomers would result in a product with equivalent proportions of mirror images. </span></p>
<p><span>Kagan questioned this belief that mixing left- and right-handed catalysts would produce a linear relationship in product chirality, explained Somfai in his remarks during the announcement. “For a long time, it was believed that if we mix a left and right-handed catalyst, the proportion of an ancillary in the product would correlate linearly to that in the catalyst.”</span></p>
<p><span>Kagan’s question led him to test driving a reaction with different combinations of enantiomers in the catalyst. Ultimately, he realized that the relationship to the proportions of enantiomers in the product was not linear as previously thought. One form of the catalyst, the left-right catalyst, drove the chemical reaction in a different way than the two other forms of the catalyst — the right-right or left-left forms. This meant that he had found a way to enhance the formation of one enantiomer over the other. In 1986, he described at least three different asymmetric reactions that displayed what chemists call non-linear effects. </span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>Other scientists were keen to build on Kagan’s discovery, including Soai. While studying an asymmetrical chemical reaction with a non-linear effect, he discovered similarities between the structure of the reaction’s catalyst and the products. That discovery suggested that it may be possible to design a reaction in which the catalyst formed itself in an autocatalytic process. After experimenting with different molecules, Soai published a paper in 1995, where he described finding a chiral substance that could create itself although it did not achieve 100 percent enantiomeric purity. </span></p>
<p><span>Eight years later, in 2003, he was finally able to present a chemical reaction, dubbed the </span><i><span>Soai reaction</span></i><span>,  in which only one of the two possible mirror images was formed. Specifically, the chemical reaction results in an excess of an enantiomer which then forms copies of itself, marking the first time a scientist successfully generated chirality from achiral or racemic conditions outside of nature.  As Somfai put it in his remarks “this is probably the coolest experiment in organic chemistry.”</span></p>
<p><span>Following the award announcement, Soai took questions from the press during which stated that he was out shopping near his home in Hiroshima, Japan when he got the call from the committee letting him know he and Kagan would share this year’s prize. “There are many excellent researchers in this field, so I’m very especially glad to receive this prize” and “to share the prize with Professor Henri Kagan, such a famous organic chemist,” he said. </span></p>
<h4><b>Basic research with a broad impact</b></h4>
<p><span>Though this award recognizes basic organic chemistry research, Kagan and Soai’s work has been hugely impactful in both industrial and pharmaceutical manufacturing. Many active drug molecules are also chiral with only one compound having a desired therapeutic effect. The other might have no therapeutic effect or even be harmful. Given these risks, “we need methods to selectively prepare them, and in developing such methods, the findings of this year’s Nobel laureates are important. They provided powerful tools for this,” Somfai said.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/kagan-soai-win-2026-nobel-prize-in-chemistry-for-discoveries-related-to-asymmetric-organic-synthesis/">Kagan, Soai Win 2026 Nobel Prize in Chemistry for Discoveries Related to Asymmetric Organic Synthesis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Expanding the Possibilities of Next&#45;Generation Sequencing</title>
<link>https://edusehat.com/en/expanding-the-possibilities-of-next-generation-sequencing</link>
<guid>https://edusehat.com/en/expanding-the-possibilities-of-next-generation-sequencing</guid>
<description><![CDATA[ Sequencing by expansion (SBX) and Roche’s AXELIOS 1 platform introduce a new approach to single-molecule sequencing, designed to give researchers flexibility across sequencing workflows.
The post Expanding the Possibilities of Next-Generation Sequencing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Expanding, the, Possibilities, Next-Generation, Sequencing</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://diagnostics.roche.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-57334 " src="https://www.genengnews.com/wp-content/uploads/2018/10/38_roche-logo-300x156.jpg" alt="Roche logo" width="227" height="118" srcset="https://www.genengnews.com/wp-content/uploads/2018/10/38_roche-logo-300x156.jpg 300w, https://www.genengnews.com/wp-content/uploads/2018/10/38_roche-logo.jpg 500w" sizes="auto, (max-width: 227px) 100vw, 227px"></a></p>
<p>As genomic research tackles increasingly complex biological questions, researchers need tools capable of looking beyond the most readily resolved regions of the genome. Repetitive sequences, structural variation, and other complex genomic features can be challenging to resolve with many conventional sequencing workflows. At the same time, laboratories must balance accuracy and speed with practical considerations, including read length, throughput, batch size, and access to data.</p>
<p>Sequencing by expansion (SBX), the technology underlying Roche’s AXELIOS 1 platform, takes a different approach to these challenges by physically expanding the space between encoded bases before detection.</p>
<h4><strong>Creating space for a clearer signal</strong></h4>
<p><figure aria-describedby="caption-attachment-338932" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338932" src="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-300x197.jpg" alt="AXELIOS" width="300" height="197" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-300x197.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-1024x673.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357-768x505.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_10_Team_0400_RGB-1-Copy-e1791316584357.jpg 1083w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Roche</figcaption></figure></p>
<p>SBX leverages a specialized polymerase that converts the sequence of a target DNA or RNA molecule into a measurable surrogate polymer called an Xpandomer, using nucleotide analogs. The resulting Xpandomer is approximately 50 times longer than the original molecule, creating greater physical separation between encoded bases.</p>
<p>The Xpandomer is then measured as it passes through a reusable complementary metal-oxide semiconductor (CMOS) sensor containing millions of nanopores. Its high signal-to-noise reporters are designed to support accurate, ultra-rapid single-molecule sequencing with near real-time base calling and analysis. This architecture may help researchers investigate a range of genomic features, including single nucleotide variants, insertions and deletions, copy-number alterations, repetitive sequences and other complex structures.</p>
<h4><strong>Flexibility beyond chemistry</strong></h4>
<p>The utility of a sequencing technology depends on more than chemistry alone. Research needs can vary substantially from one project to another and even within the same laboratory. AXELIOS 1 pairs SBX chemistry with a sequencing architecture designed to accommodate that variability. The system offers configurable batch sizes, allowing researchers to run smaller batches without waiting to accumulate enough samples for a larger run.</p>
<p>Researchers can also adjust read length according to experimental needs, with reads up to approximately 1,500 base pairs (with a distribution from ~200bp to ~1500 bp) under appropriate sample and library preparation conditions. The platform is capable of end-to-end, same-day whole genome sequencing (WGS) in research workflows, while near real-time base calling and analysis enable access to data as a run progresses.</p>
<p>This flexibility extends across multiple research applications. SBX has been tested in proof-of-principle studies for WGS, RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), spatial analysis, and methylation studies. For each application, the AXELIOS 1 Platform sequences Xpandomer molecules that were created from libraries made with the AXELIOS 1 DNA Library Prep Kit. The data is then analyzed using the no-cost, open-source XOOS bioinformatics analysis suite tailored for SBX. Collaborations also support applications and tools across the sequencing ecosystem, including support for SBX through Google DeepVariant.</p>
<h4><strong>Broadening the genomic picture </strong></h4>
<p><figure aria-describedby="caption-attachment-338931" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338931" src="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_4x3-Copy-300x224.jpg" alt="AXELIOS" width="300" height="224" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_4x3-Copy-300x224.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_AXELIOS_4x3-Copy.jpg 368w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Roche</figcaption></figure></p>
<p>Modern genomics rarely relies on a single experimental approach. Researchers may need to examine genomic variation, gene expression, cellular heterogeneity, or epigenetic changes to build a more complete biological picture. Sequencing platforms that accommodate different applications and project sizes can allow laboratories to design workflows around the scientific question rather than instrument constraints.</p>
<p>By combining a new approach to sequencing chemistry with flexible read lengths, batch sizes, and research applications, AXELIOS 1 is designed to expand the range of genomic questions researchers can pursue. As sequencing continues to evolve, these capabilities could help scientists interrogate previously challenging regions of the genome and build a more complete foundation for biological discovery.</p>
<p><em>For Research Use Only. Not for use in diagnostic procedures. AXELIOS is a trademark of Roche.</em></p>
<p><img loading="lazy" decoding="async" class="alignleft  wp-image-338930" src="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_QR_AXELIOS1article-Copy.jpg" alt="Roche October 2026 sponsored content QR code" width="106" height="106" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Roche_QR_AXELIOS1article-Copy.jpg 210w, https://www.genengnews.com/wp-content/uploads/2026/10/Roche_QR_AXELIOS1article-Copy-150x150.jpg 150w" sizes="auto, (max-width: 106px) 100vw, 106px"></p>
<p>To learn more, visit <a href="https://go.roche.com/AXELIOS1article" target="_blank" rel="noopener">go.roche.com/AXELIOS1article</a></p>
<p>The post <a href="https://www.genengnews.com/sponsored/expanding-the-possibilities-of-next-generation-sequencing/">Expanding the Possibilities of Next-Generation Sequencing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biologics Standards for Innovation, Quality and Access</title>
<link>https://edusehat.com/en/biologics-standards-for-innovation-quality-and-access</link>
<guid>https://edusehat.com/en/biologics-standards-for-innovation-quality-and-access</guid>
<description><![CDATA[ This GEN Spotlight on Biologics Standards for Innovation, Quality and Access brings together experts from across biopharma, standards development, and analytical science to examine the challenges of testing increasingly complex modalities, including monoclonal antibodies, cell and gene therapies, and RNA therapeutics. 
The post Biologics Standards for Innovation, Quality and Access appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Getty_2266921838_Anitbody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biologics, Standards, for, Innovation, Quality, and, Access</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<div class="wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-3e41869c wp-block-buttons-is-layout-flex">
<div class="wp-block-button"><a class="wp-block-button__link wp-element-button" href="https://events.zoom.us/ev/Ai3vvPMJHQoIUrI-pbyGLgZdQhqInEQhYV0XiOKR8M9jabGObaDx~As0uPqNwKJ7MXzWHm-GuyVwmMXwt3jYXihhnkUz8wb4ogwpTrqjzZYt-9Q" target="_blank" rel="noopener">Register Now</a></div>
</div>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/ErinDieveney_headshot.jpg" class="h-full w-full object-cover" alt="Image of Erin Dieveney">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Erin Dieveney</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Vice President, Quality Assurance<br>Aldevron</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/ErinDieveney_headshot.jpg" alt="Image of Erin Dieveney">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Erin Dieveney</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Erin Dieveney leads quality assurance at Aldevron where she helps ensure the quality, compliance, and reliability of products that enable next-generation genomic medicines. Throughout her career, Erin has assumed increasing leadership responsibilities across quality, regulatory affairs, product development, and customer support, developing deep expertise in bringing innovative life sciences technologies to market.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Khaled-Yamout-edit-1.jpg" class="h-full w-full object-cover" alt="Image of Khaled Yamout">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Khaled Yamout</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Founder & CEO<br>Y-Chem Consulting</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Khaled-Yamout-edit-1.jpg" alt="Image of Khaled Yamout">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Khaled Yamout</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Khaled Yamout is a thought leader in analytical sciences, quality and manufacturing. He was previously senior director of analytical services and quality control at TriLink Biotechnologies, where he oversaw the Analytical Sciences Center of Excellence and all analytical aspects of method development and validation to product release and stability, in support of regulatory filings for both small and large molecules. Prior to TriLink, Khaled held various positions in quality control, R&D, and manufacturing where he supported several drug products (small molecules and biologics) from clinical phase to commercial. His experience spans Fortune 500 firms as well as small entrepreneurial businesses in the areas of synthetic, analytical, colloidal, surface modification, protein, and antibody modification and purification.</p>
<p>Khaled holds a BS degree in chemistry from the University of Texas at Arlington.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kok-Seong-Lim-HQ-1.jpg" class="h-full w-full object-cover" alt="Image of Kok-Seong Lim, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Kok-Seong Lim, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Founder and Principal<br>Eight Crest Strategies</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kok-Seong-Lim-HQ-1.jpg" alt="Image of Kok-Seong Lim, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Kok-Seong Lim, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Kok-Seong Lim, PhD, is a pharmaceutical leader with more than 20 years of experience in biological research and development, specializing in analytical sciences, quality control, and CMC strategy for advanced therapy platforms. He has held multiple management roles at Metagenomi, Aura Biosciences, Editas Medicine, and Thermo Fisher Scientific (formerly Brammer Bio), where he contributed to the advancement of more than ten gene therapies and CRISPR-based medicines for rare diseases and oncology indications.</p>
<p>Throughout his career, Kok-Seong has led the buildout of GMP-compliant facilities and analytical infrastructures to support early- and late-stage development. He has managed complex, multimillion-dollar budgets and contributed to regulatory submissions in both the U.S. and EU. Kok-Seong has served on committees such as the USP Biologics Expert Committee for Cell and Gene Therapy and the Standards Coordinating Body, helping to shape best practices and standards for the cell and gene therapy community.</p>
<p>Kok-Seong earned his PhD in biochemistry from the National University of Singapore and holds a BSc in pharmacy from the University of Strathclyde, Scotland.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Michael_Lehmicke.jpg" class="h-full w-full object-cover" alt="Image of Michael Lehmicke">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Michael Lehmicke</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]"> Senior Vice President, Scientific Affairs<br>Alliance for Regenerative Medicine</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Michael_Lehmicke.jpg" alt="Image of Michael Lehmicke">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Michael Lehmicke</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Michael Lehmicke joined the Alliance for Regenerative Medicine in 2019 as its first director of science and industry affairs. Michael has over 20 years of R&D experience in biomaterials, medical devices, and regenerative medicine. He has led product development teams for class II devices, human cell and tissue-based products, and drug/device combination products. He is a creator and an inventor with multiple U.S. patents to his name.</p>
<p>Michael has an MSc in biomedical engineering, with a focus on tissue engineering, from Drexel University. Michael’s areas of expertise include cell-based tissue engineering, bioceramics, biodegradable polymers, project management, strategic pipeline development, and business development.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, October 14, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-14T16:30:00.000Z">09:30 PDT, 12:30 EDT, 16:30 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph"><br>As biologics become more diverse, complex, and faster-moving, how can the biotech and biopharma industry ensure that quality standards keep pace with innovation? We will address this fundamental question in the latest <em>GEN</em> Spotlight <strong></strong>on <strong>Biologics</strong> <strong>Standards for Innovation, Quality and Access</strong>, presented in partnership with USP. This virtual event will explore how evolving standards can provide a stronger foundation for developing and manufacturing next-generation therapeutics.</p>


<p class="wp-block-paragraph">This Spotlight on <strong>Biologics</strong> <strong>Standards for Innovation, Quality and Access</strong> brings together experts from across biopharma, standards development, and analytical science to examine the challenges of testing increasingly complex modalities, including monoclonal antibodies, cell and gene therapies, and RNA therapeutics. Sessions will explore when and how to standardize emerging therapies, a practical layered framework for quality—from raw materials and analytical methods to identity, purity, and potency—and the growing importance of community input in developing standards for new modalities.</p>


<p class="wp-block-paragraph">Session highlights include:</p>


<ul class="wp-block-list">
<li>A roundtable explores layered frameworks to ensure quality in multi-modal therapeutic development featuring Erin Dieveney (Aldevron) and Kok-Seong Lim, PhD (Eight Crest Strategies).</li>


<li>A panel discussion on building standards for a multi-therapeutic modality future, featuring Khaled Yamout (Y-Chem Consulting) and Michael Lehmicke(Alliance for Regenerative Medicine)</li>


<li>And a discussion featuring senior executives from USP on the importance of community input in developing standards for new modalities.</li>
</ul>


<p class="wp-block-paragraph">Join us on <strong>Wednesday, October 14</strong>, to discover how standardization can reduce development risk, support innovation, and help establish a shared foundation for the future of biologics.</p>


<p class="wp-block-paragraph">Registration for this 2.5-hour event is free.</p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.usp.org/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="165" src="https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-300x165.jpg" alt="US Pharmacopeia logo" class="wp-image-329674" srcset="https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-300x165.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-768x421.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-765x420.jpg 765w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo-696x385.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/03/USP_Logo.jpg 800w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>



<p>The post <a href="https://www.genengnews.com/multimedia/biologics-standards-for-innovation-quality-and-access/">Biologics Standards for Innovation, Quality and Access</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition</title>
<link>https://edusehat.com/en/shionogi-grows-rare-disease-portfolio-with-2b-intrabio-acquisition</link>
<guid>https://edusehat.com/en/shionogi-grows-rare-disease-portfolio-with-2b-intrabio-acquisition</guid>
<description><![CDATA[ Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and potential royalties.
The post Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/facilities-collaborations-and-ip-strategy-img-01.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Shionogi, Grows, Rare, Disease, Portfolio, with, 2B, IntraBio, Acquisition</media:keywords>
<content:encoded><![CDATA[<p>Shionogi has agreed to acquire IntraBio for $2 billion, in a deal intended to expand the Japanese pharma’s rare disease portfolio with a drug marketed in the U.S. and European Union for neurological manifestations of Niemann-Pick disease type C (NPC).</p>
<p>The drug, Aqneursa<sup>®</sup> (levacetylleucine), was approved by the FDA in September 2024 for neurological manifestations of Niemann-Pick disease Type C (NPC) in adults and children weighing 15 kg (33 pounds) or more,  and by the European Medicines Agency (EMA) in January.</p>
<p>On September 18, the FDA approved a supplemental New Drug Application expanding the label of Aqneursa to become the first and to date only drug approved for the treatment of ataxia in ataxia-telangiectasia (A-T) patients weighing 15 kg (33 pounds) or more. Aqneursa is now under review by the EMA for adults and children diagnosed with A-T.</p>
<p>“The planned acquisition of IntraBio actively demonstrates Shionogi’s solid commitment to building a leading global rare disease business,” Isao Teshirogi, PhD, Shionogi’s president, CEO, and representative director said Monday in a statement. “Bringing Aqneursa to Shionogi after our acquisition of Radicava<sup>®</sup> will deepen our commitment to rare disease communities, expand our capabilities and strengthen our portfolio as we advance future innovation for patients with significant unmet needs.”</p>
<p>Investors initially appeared less enthusiastic about the IntraBio acquisition, as Shionogi’s shares traded on the Tokyo Stock Exchange fell about 4.5% Monday, from ¥2,786 ($17.61) to ¥2,661 ($16.82)—but the stock bounced back Tuesday, all but recovering with a 3.8% gain that sent shares up to Y2,763 ($17.47).</p>
<p>However, Sumant Kulkarni, a senior analyst covering biotechnology with Canaccord Genuity, viewed the deal more positively.</p>
<p>“In summary, this transaction underscores our view that companies with approved products for rare indications, neuro or otherwise, present significant scarcity value for strategics and investors alike,” Kulkarni wrote Monday in a research note. “We are not entirely surprised by this development, but are encouraged by the upfront consideration.”</p>
<p>Kulkarni added: “In fact, we were surprised that IntraBio had remained independent for the time it did, but the timing makes sense given the recent approval for A-T, which adds another leg to its story.”</p>
<h4><strong>‘Plenty of financial firepower’</strong></h4>
<p>The acquisition of IntraBio comes two months after Teshirogi told <em>Bloomberg News</em> in an interview that Shionogi was “actively pursuing” at least three acquisition opportunities: “From a cash flow perspective, we’ve become a company with plenty of financial firepower. If a good opportunity comes along, there’s absolutely no reason for us to hesitate over any M&A.”</p>
<p>Teshirogi also said Shionogi was looking to expand its U.S. and European manufacturing capacity in order to diversify its production base beyond Japan and thus reduce geopolitical risk over the next decade.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>To that end, Shionogi pursued and won a U.S. government contract in April to establish a Stateside drug product manufacturing site for its Fetroja<sup>®</sup> cefiderocol), a cephalosporin antibacterial indicated to treat adults with complicated urinary tract infections (cUTI) including pyelonephritis; as well as hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).</p>
<p>The contract—awarded through the Biomedical Advanced Research and Development Authority’s (BARDA) Project BioShield—was initially funded at $119 million with multiyear options for a total of up to $482 million.</p>
<p>Shionogi signaled its intent to focus on rare disease drugs in April when it agreed to acquire Radicava (edaravone), a small molecule treatment for amyotrophic lateral sclerosis (ALS), from Tanabe Pharma for $2.5 billion and a potential royalty on future sales. At the time, Shionogi said the deal would benefit it by adding approximately $700 million in annual global sales during the company’s current 2026 fiscal year, which began on April 1.</p>
<h4><strong>59% leap</strong></h4>
<p>That would represent a 59% leap from Shionogi’s entire FY 2025 earnings before interest taxes, depreciation, and amortization (EBITDA) of ¥187.72 billion ($1.187 billion), up 4.7% from ¥179.296 billion ($1.134 billion) in FY 2024.</p>
<p>Radicava generated ¥94.491 billion ($597.582 million) in the 2025 fiscal year that ended on March 31 of this year.</p>
<p>“Through this acquisition, the Company aims to strengthen its business foundation and enhance its corporate value over the medium to long term by maximizing the value of edaravone and expanding its provision of solutions in the rare disease area,” Shionogi explained in reporting fiscal Q1 (April-June) 2026 results in August.</p>
<p>Radicava is marketed under that name as an intravenous (IV) infusion, and as an oral suspension called Radicava ORS. The IV version was approved by the FDA in 2022 and the oral suspension version, two years later.</p>
<p>Based in Austin, TX, IntraBio was established in 2015 to discover, develop, and commercialize therapies for neurodegenerative diseases with high unmet medical need, by commercializing research generated by its scientific co-founders—Professors Grant Churchill, PhD, Antony Gallone, PhD, and Frances Platt, PhD, all of the University of Oxford; and Michael Strupp, MD, of the University of Munich.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Privately held IntraBio finished last year with a $35.8 million net loss on net sales of $67.867 million—all of it generated from sales of Aqneursa—according to data disclosed by Shionogi in its announcement of the acquisition.</p>
<p>Shionogi is expected to close on its acquisition of IntraBio during this quarter, subject to customary closing conditions.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/shionogi-grows-rare-disease-portfolio-with-2b-intrabio-acquisition/">Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lock Down the Critical Factors in Oligo and Oligo&#45;Conjugate Characterization with Stunner and Honeybun</title>
<link>https://edusehat.com/en/lock-down-the-critical-factors-in-oligo-and-oligo-conjugate-characterization-with-stunner-and-honeybun</link>
<guid>https://edusehat.com/en/lock-down-the-critical-factors-in-oligo-and-oligo-conjugate-characterization-with-stunner-and-honeybun</guid>
<description><![CDATA[ This GEN webinar follows oligo quantification from method development through conjugate characterization.
The post Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1826415379-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lock, Down, the, Critical, Factors, Oligo, and, Oligo-Conjugate, Characterization, with, Stunner, and, Honeybun</media:keywords>
<content:encoded><![CDATA[<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kevin_Unchained-Labs_Headshot-scaled.jpg" class="h-full w-full object-cover" alt="Image of Kevin Lance, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Kevin Lance, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Director, Product Management<br>Unchained Labs</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/10/Kevin_Unchained-Labs_Headshot-scaled.jpg" alt="Image of Kevin Lance, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Kevin Lance, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Kevin Lance covers the Stunner portfolio globally at Unchained Labs. His expertise includes biophysical characterization of proteins, ADCs, nucleic acids, viral vectors, and LNPs. Prior to Unchained Labs, his research experience covered the fields of sustained antibody delivery and nanotechnology. He earned his Ph.D. in Bioengineering from the joint UC Berkeley – UCSF Bioengineering Graduate Program.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, November 12, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-11-12T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div>


<div aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<p class="wp-block-paragraph">Oligonucleotide therapeutics, including ASOs, siRNAs, aptamers, and now antibody- and peptide-oligonucleotide conjugates (AOCs and POCs) are gaining momentum fast. But the chemical modifications and conjugations that make them work also make them harder to characterize than classic nucleic acids. Accurate quantification is the foundation of almost every assay and understanding how to arrive at the right concentration factor is the critical first step that echoes through every downstream decision.</p>


<p class="wp-block-paragraph">This webinar follows oligo quantification from method development through conjugate characterization. We’ll cover what to consider when setting concentration factors and how UV-Vis extends to measuring conjugation ratio in AOCs and POCs.</p>


<p class="wp-block-paragraph">We’ll also explore the boundaries of dynamic light scattering in oligo and nucleic acid formulation development. Oligos are flexible and sticky, which makes them hard to characterize by DLS. We’ll show what DLS can and can’t tell you across different lengths of nucleic acid constructs, up through mRNA.</p>


<p class="wp-block-paragraph">Finally, we’ll look at viscosity data for oligonucleotides and nucleic acids to answer in-demand questions on high-concentration formulation and subcutaneous delivery.</p>


<p class="wp-block-paragraph"><strong>Key learning objectives</strong></p>


<ul class="wp-block-list">
<li>Understand the pieces that influence concentration factors for oligonucleotide quantification</li>


<li>Extend UV-Vis quantification to AOC and POC characterization, including conjugation ratio</li>


<li>Set realistic expectations for DLS in nucleotide and nucleic acid characterization</li>


<li>Understand the relationships between viscosity, formulations, and nucleic acids</li>
</ul>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p>


<div aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.unchainedlabs.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="67" src="https://www.genengnews.com/wp-content/uploads/2021/03/UNCHAINED-LABS-Logo_large-300x67.jpg" alt="UNCHAINED LABS Logo" class="wp-image-162665" srcset="https://www.genengnews.com/wp-content/uploads/2021/03/UNCHAINED-LABS-Logo_large-300x67.jpg 300w, https://www.genengnews.com/wp-content/uploads/2021/03/UNCHAINED-LABS-Logo_large.jpg 500w" sizes="(max-width: 300px) 100vw, 300px"></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/lock-down-the-critical-factors-in-oligo-and-oligo-conjugate-characterization-with-stunner-and-honeybun/">Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Calibration Framework Improves Confidence in AI Virtual Cell Models</title>
<link>https://edusehat.com/en/new-calibration-framework-improves-confidence-in-ai-virtual-cell-models</link>
<guid>https://edusehat.com/en/new-calibration-framework-improves-confidence-in-ai-virtual-cell-models</guid>
<description><![CDATA[ Across 14 genetic perturbation datasets and 18 evaluation metrics, commonly used measures such as mean squared error and control-referenced Pearson correlation were often poorly calibrated, particularly in datasets with weaker perturbations. 
The post New Calibration Framework Improves Confidence in AI Virtual Cell Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_2257382308_CellInterior-e1791306952785.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 07:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Calibration, Framework, Improves, Confidence, Virtual, Cell, Models</media:keywords>
<content:encoded><![CDATA[<p>AI virtual cell models may be more capable of predicting cellular responses to genetic perturbations than earlier benchmarks suggested—but only when researchers use evaluation metrics sensitive enough to detect biologically meaningful signals, according to a new study from Shift Bioscience and collaborators.</p>
<p>Published in <em>Nature Biotechnology</em>, the paper, “<a href="https://www.nature.com/articles/s41587-026-03307-w" target="_blank" rel="noopener">Deep Learning Perturbation Models Can Outperform Baselines on Calibrated Metrics</a>,” introduces a positive-control baseline and a framework for testing whether commonly used metrics can distinguish meaningful model predictions from less informative ones.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Genetic perturbation models, a subset of AI virtual cells, predict how activating or inhibiting genes will alter a cell’s transcriptome. If reliable, these models could support scalable <em>in silico</em> screens for therapeutic targets. However, recent studies found that sophisticated deep learning systems often failed to outperform simple baselines, raising doubts about whether the models captured perturbation-specific biology.</p>
<p>The researchers argued that part of the problem lies in the benchmarks themselves. “The promise of <em>in silico</em> perturbation models, or ‘virtual cells,’ is that the same scaling laws will apply, and that providing them with ever-increasing quantities of biological data and compute will improve their prediction of real-world experimental results,” Brendan Swain, PhD, CSO and founder of Shift Bioscience, told <em>GEN</em>. “However, early benchmarks of virtual cell models revealed apparently poor performance, casting doubt on their potential.”</p>
<p>To assess this issue, the team developed an “interpolated duplicate” positive control that combines the average perturbation profile with an independent technical duplicate, weighting each gene by the strength of evidence that it was affected. They then introduced the dynamic range fraction, or DRF, which measures how effectively a metric separates this positive control from a negative control.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Across 14 genetic perturbation datasets and 18 evaluation metrics, commonly used measures such as mean squared error and control-referenced Pearson correlation were often poorly calibrated, particularly in datasets with weaker perturbations. The authors also added that, “In contrast, weighted and rank-based metrics—including WMSE, weighted R<sub>Δ</sub><sup>2</sup>​, and normalized inverse rank (NIR)—consistently exhibited higher calibration across datasets, reflecting their shared design principle of emphasizing perturbation-specific signal.”</p>
<p>Using the better-calibrated measures, the researchers benchmarked nine deep learning models on tasks involving unseen single-gene perturbations and unseen gene combinations. Earlier models, including scGPT and GEARS, often surpassed uninformative baselines once their predictions were evaluated with calibrated metrics. More recent systems, including PRESAGE and scLambda, showed stronger performance, although results varied by dataset and metric.</p>
<p>The analysis also highlighted the importance of dataset design. In Norman19, where the training data covered only 0.63% of possible gene combinations, a simple additive baseline remained difficult to beat. In Wessels23, which covered 10.3% of possible combinations, multiple models surpassed the additive baseline, indicating that deep learning models can outperform additivity when trained on broader portions of the combinatorial landscape.</p>
<p>“Our findings show that by using well-calibrated metrics and the right dataset, virtual cell models can generate biologically meaningful insights,” said Swain. “As a result, we can use them with greater confidence to identify promising new targets that are relevant to aging and disease. We are applying this framework directly in our target identification program, focusing on targets whose inhibition can support both rejuvenation and treatment of age-related disease, giving us a clearly defined route towards clinical development.”</p>
<p>Shift Bioscience, a Cambridge, U.K.–based biotechnology company, plans to apply the framework in large-scale <em>in vitro</em> and <em>in silico</em> screens for inhibition targets relevant to cellular rejuvenation and age-related disease, initially focusing on fibrosis. “Ultimately, we hope these tools will guide researchers as they develop better and better virtual cell models,” Swain told <em>GEN</em>.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/new-calibration-framework-improves-confidence-in-ai-virtual-cell-models/">New Calibration Framework Improves Confidence in AI Virtual Cell Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Weight&#45;loss drugs show signs of slowing biological aging, say drugmakers</title>
<link>https://edusehat.com/en/weight-loss-drugs-show-signs-of-slowing-biological-aging-say-drugmakers</link>
<guid>https://edusehat.com/en/weight-loss-drugs-show-signs-of-slowing-biological-aging-say-drugmakers</guid>
<description><![CDATA[ Popular weight-loss drugs may do more than help people shed pounds. They might also melt away the years. Drug giants Eli Lilly and Novo Nordisk say patients taking their drugs age less quickly, according to readouts from molecular “aging clocks.” Such clocks assess a person’s biological age by looking at changes to DNA that accumulate… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/10/silo-clock2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Weight-loss, drugs, show, signs, slowing, biological, aging, say, drugmakers</media:keywords>
<content:encoded><![CDATA[<p>Popular weight-loss drugs may do more than help people shed pounds. They might also melt away the years.</p>



<p>Drug giants Eli Lilly and Novo Nordisk say patients taking their drugs age less quickly, according to readouts from molecular “aging clocks.”</p>



<p>Such clocks assess a person’s biological age by looking at changes to DNA that accumulate with time, or, in newer versions, by tracking levels of key proteins.</p>



<p>Both companies found that overweight or diabetic patients taking the drugs, called GLP-1s, had reduced biological age compared to those taking a placebo, although the difference varied widely, depending on which type of clock was used, and what organ was tested. </p>



<p>Overall, the difference was around “two to three years,” according to Nikolaj Roed, a global project leader at Novo, who says the company has been seeing “improved biological age in our patients across trials and across different tissues.” </p>



<p>The findings add to wide speculation among scientists that GLP-1 drugs, as they are known, are acting on basic causes of aging and might be a true longevity treatment.</p>





<p>“Two years is a pretty strong effect, in my book,” says Steve Horvath, a professor at the University of California, Los Angeles, who’s credited with<a href="https://www.technologyreview.com/2018/10/19/139463/want-to-know-when-youre-going-to-die/"> inventing aging clocks</a><em>. </em>Horvath says the emerging data could provide “evidence that these GLP-1 drugs are actually what is known as geroprotectors, medications that slow or possibly even reverse biologic aging.”</p>



<p>The companies shared their findings over the weekend during Aging Research & Drug Discovery, a conference devoted to seeking scientific remedies for old age. While that quest has not yet produced any clear-cut success, some scientists now think Novo’s drug semaglutide (sold under the names Ozempic and Wegovy) is coming close.</p>



<p>“In an unhealthy population, I do think it’s an anti-aging drug,” says Vadim Gladyshev, a Harvard biologist who assisted Novo with its molecular measurements. “But in a healthy population, no one knows.”</p>



<p>The drugs cause weight loss by stimulating a receptor, GLP-1, that tells your brain you’re not hungry. Yet real-world studies have shown much wider benefit. The drugs improve kidney function, reduce blood pressure, and even sharply cut the overall chance of death.</p>



<p>“If the question is,‘Can semaglutide reach several diseases relevant to health span and aging?’ we know we can say the answer is yes,” said Alejandro Aguayo-Orozco, a senior scientific director at Novo, the Danish drug giant, during the meeting.</p>



<p>The next question to answer, he said, is whether such effects are accompanied by changes to molecular measures of biological aging: “When you intervene with semaglutide, does it actually move the clocks in any direction? And the answer is yes.” </p>





<p>The company found that, over time, the drugs cause a wide slowdown in aging clocks—as much as 4 years in the case of a clock that looks at heart proteins. “I think it’s pretty clear that the organ age is shifting,” said Aguayo-Orozco.</p>



<p>The studies are also a huge boost for the science of aging clocks. Although these measures reflect a person’s age, it’s been uncertain if they are useful as true biomarkers. Now clock makers have evidence  that their readouts show a drop in age when people take drugs with broad, well-demonstrated benefits.  </p>



<p>“The clock people have been pushing for a decade to get this kind of study done,” says Yuge Ji, a biologist who previously worked in the field and now runs a startup, Reflector Bio. “It’s huge for them.”</p>



<p>As part of its study, Novo took blood draws from 10,052 people, half on the drug and half on a placebo. Their blood, collected at the start of the study as well as months later, was then measured with “proteomic clocks,” which use levels of key proteins to predict a person’s <a href="https://www.nature.com/articles/s41591-024-03164-7">age and risk of dying</a>. </p>



<p>Scientists at Eli Lilly performed similar research on their GLP-1 drug, tirzepatide, using so-called “epigenetic” clocks that assess age by counting accumulated changes to DNA. Lilly’s study was smaller, but also found that for the most part, molecular time moved more slowly for people on the drug.  </p>



<p>“All the clocks are telling a consistent story that we’re seeing a reduction in age,” Kevin Duffin, vice president for aging research at Lilly, said during the conference. “It’s not like we’re going to reverse age by 30 years or something, but it’s a significant reduction.”</p>



<p>The molecules have become the best selling drugs in the world,, with Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, topping the list<a href="https://www.drugdiscoverytrends.com/pharma-50-keytruda-holds-the-top-brand-slot-but-tirzepatide-and-semaglutide-have-already-passed-it-at-the-molecule-level-in-fy2025"> with more than $36 billion in revenue to the company last year</a>. Novo’s semaglutide, also sold under more than one name, was a close second.</p>



<p>Alex Zhavoronkov, the founder of Insilico Medicine, and the organizer of the Boston meeting, says that extending lives by even one year across the world’s population would be equal to tens of millions of lifetimes.  </p>



<p>Last month Zhavoronkov showed that one of his company’s drugs, for a lung disease, also<a href="https://www.wsj.com/tech/biotech/insilicos-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-too-1c5bf5a6"> reversed the signals from aging clocks</a>. That drug is experimental, but Zhavoronkov has sought to promote the idea that humanity is entering a new era of longevity medicines. He also disclosed during the event that he has been “microdosing” the available weight-loss drugs, even though he is not overweight.</p>





<p>“I am on tirzepatide and I am an equal-opportunity injector of semaglutide as well,” Zhavoronkov said.</p>



<p>It was part of an effort to directly raise the question of whether the first mass-market anti-aging remedy is already here.</p>



<p>“Do you think a reasonable person should start taking semaglutide?” he asked Aguayo-Orozco, the Novo scientist, in front of a crowded audience.</p>



<p>“I am not a physician. I cannot answer that question,” Aguayo-Orozco replied.</p>



<p>Several people cautioned that GLP-1 drugs do have side effects, including muscle loss. That is one reason they might not help most people, says Horvath, who says he isn’t ready to take the drugs himself, although he’s thought about it.</p>



<p>“Clearly, the drugs have many benefits in obese people, but I did not yet see sufficient evidence that they will benefit skinny people,” he said. “I guess we will have to wait.”</p>



<p>Answers could start to emerge in a year or two. This past January, a US agency, ARPA-H, put $38 million toward a study in Texas that will attempt to determine whether semaglutide has anti-aging effects in healthy people over 60. That research will look at changes in cognition, mobility, and acuity of the senses.</p>



<p>That project also seeks to help define a regulatory pathway for anti-aging drugs and to “build a new therapeutic industry” around longevity.</p>]]> </content:encoded>
</item>

<item>
<title>Inside All&#45;ScaleFlow: Continuous End&#45;to&#45;End RNA&#45;LNP Manufacturing</title>
<link>https://edusehat.com/en/inside-all-scaleflow-continuous-end-to-end-rna-lnp-manufacturing</link>
<guid>https://edusehat.com/en/inside-all-scaleflow-continuous-end-to-end-rna-lnp-manufacturing</guid>
<description><![CDATA[ Dillico’s GMP-ready Continuous Manufacturing by Engineering, Not Hype
The post Inside All-ScaleFlow: Continuous End-to-End RNA-LNP Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inside, All-ScaleFlow:, Continuous, End-to-End, RNA-LNP, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://dillico.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="alignnone wp-image-338883 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-300x112.jpg" alt="Dillico logo" width="300" height="112" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-300x112.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-1024x383.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo-768x287.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_logo.jpg 1468w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>Messenger RNA (mRNA) is expanding from pandemic-scale vaccines toward a wider therapeutic portfolio. Recent Phase 3 success for an individualized neoantigen therapy from Moderna reinforces the clinical relevance of the lower-volume end of that spectrum, while COVID-19 established the opposite extreme. Clinical success is encouraging emerging and established developers to advance RNA medicines either through CDMOs or by building internal capacities. For increased development and production efficiency, CDMOs and drug developers need fast changeovers and flexibility across sequences and scales. All-ScaleFlow<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> integrates RNA synthesis, purification, buffer exchange, and LNP formation to help democratize development.</p>
<h4><strong>A patented semi-continuous IVT core</strong></h4>
<p><figure aria-describedby="caption-attachment-338880" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338880" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy-300x226.jpg" alt="spiral-shaped semi-continuous reacto" width="300" height="226" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy-300x226.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy-768x579.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_Figure1-Copy-Copy.jpg 900w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 1. Dillico’s spiral-shaped semi-continuous reactor seamlessly handles batch reaction conditions without requiring larger batch vessels. [Dillico]</figcaption></figure></p>
<p>RNA synthesis begins with fixed IVT unit volumes injected into Dillico’s patented, spiral-shaped semi-continuous reactor (<em>Fig 1</em>). The reactor is held in a temperature-controlled environment. Each unitary volume (UnV) advances by one loop periodically and the mature IVT crude UnV exits for optional enzymatic treatment and quenching. This design preserves defined batch reaction conditions without relying on progressively larger batch vessels.</p>
<h4 class="no-clear"><strong>Continuous purification and RNA-LNP formulation</strong></h4>
<p>As illustrated in the process flow diagram (<em>Fig 2</em>), All-ScaleFlow integrates alternating multi-column chromatography (dT Oligo resin or monolith) and multi-stage SPTFF for RNA purification, concentration, and buffer exchange. Surge tanks buffer cyclic chromatography eluate and maintain controlled flow into continuous purification SPTFF and LNP mixing. After encapsulation, a second multi-stage SPTFF step removes ethanol and performs final buffer exchange before in-line dilution or excipient addition and sterile filtration. By coordinating flow rates and interfaces, the platform maintains continuous production from IVT crude to formulated mRNA-LNP while minimizing intermediate holds.</p>
<p><figure aria-describedby="caption-attachment-338881" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-338881" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-1024x359.jpg" alt="ScaleFlowTM" width="796" height="279" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-1024x359.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-300x105.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy-768x269.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Process-Diagram-Copy.jpg 1400w" sizes="auto, (max-width: 796px) 100vw, 796px"><figcaption class="wp-caption-text">Figure 2. Simplified Process Flow Diagram of the All-ScaleFlowTM.</figcaption></figure></p>
<h4><strong>Automated cleaning and sterilization onboard</strong></h4>
<p>To reduce supply chain risks and achieve long-term sustainability, an automated clean-in-place and sterilization-in-place (CIP/SIP) station is integrated on the system. It uses common cleanroom utilities to clean and sanitize the stainless-steel process path. This could save up to 450 kg of single-use plastic (~200 k$) for a large-scale batch IVT production.</p>
<h4><strong>Demonstrated across RNA sequence types</strong></h4>
<p>The synthesis approach has been successfully demonstrated with multiple mRNA and self-amplifying RNA (saRNA) sequences with length ranging from 400 bp to 12,000 bp. Working across different sequences is important for a platform intended to serve diverse vaccines and therapeutics.</p>
<h4><strong>The Process Simulator turns a sequence into a master recipe</strong></h4>
<p><figure aria-describedby="caption-attachment-338877" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-338877 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Equipment-Copy-300x125.jpg" alt="Dillico Equipment" width="300" height="125" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Equipment-Copy-300x125.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico-Equipment-Copy.jpg 525w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Dillico</figcaption></figure></p>
<p>Dillico’s Process Simulator embeds mechanistic process models built from an empirical knowledge base generated through experiments with mainstream, off-the-shelf process components. From product and process requirements, it calculates the global constraints needed to operate the continuous process as a coordinated system and identifies robust conditions that meet quality attributes and throughput targets. This reduces the physical experiments required during process development and supports right-first-time execution, avoiding costly trial-and-error with production materials and analytical testing. Thanks to the Process Simulator, users will be guided through a structured, step-by-step workflow that facilitates technology transfer and lowers the entry barrier for teams new to continuous processing. As part of the digital infrastructure, real process data are contextualized, making them data-lake-ready.</p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-338878" src="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_QRCode-293x300.jpg" alt="Dillico October 2026 QR Code" width="112" height="115" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_QRCode-293x300.jpg 293w, https://www.genengnews.com/wp-content/uploads/2026/10/Dillico_QRCode.jpg 396w" sizes="auto, (max-width: 112px) 100vw, 112px"></p>
<p>Explore All-ScaleFlowTM and request the Evidence Package</p>
<p>The post <a href="https://www.genengnews.com/sponsored/inside-all-scaleflow-continuous-end-to-end-rna-lnp-manufacturing/">Inside All-ScaleFlow: Continuous End-to-End RNA-LNP Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Investigating Prions and Protein Aggregation at High Sensitivity and Throughput</title>
<link>https://edusehat.com/en/investigating-prions-and-protein-aggregation-at-high-sensitivity-and-throughput</link>
<guid>https://edusehat.com/en/investigating-prions-and-protein-aggregation-at-high-sensitivity-and-throughput</guid>
<description><![CDATA[ With no cure available for prion diseases, researchers are striving to improve assay sensitivity and exploit the benefits of real-time monitoring to support the development of better diagnostic and treatment approaches.
The post Investigating Prions and Protein Aggregation at High Sensitivity and Throughput appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AdobeStock_614101305-Copy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Investigating, Prions, and, Protein, Aggregation, High, Sensitivity, and, Throughput</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.bmglabtech.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-76800 size-medium" src="https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-300x128.jpg" alt="BMG Labtech logo" width="300" height="128" srcset="https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-300x128.jpg 300w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-768x327.jpg 768w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-1024x436.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-696x296.jpg 696w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-1068x455.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992-986x420.jpg 986w, https://www.genengnews.com/wp-content/uploads/2018/10/BMG_Logo1371381992.jpg 1249w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<h4><strong>Introduction</strong></h4>
<p>Prions are infectious proteins that cause neurodegenerative diseases in animals including bovine spongiform encephalopathy (cattle), Creutzfeldt-Jakob disease (humans), and chronic wasting disease (deer, elk and other cervids).<sup>1</sup> Prion diseases, also known as transmissible spongiform encephalopathies, result from misfolded proteins that accumulate primarily in the cells of the nervous system including the brains of infected animals. More widely, protein misfolding is linked to diverse neurological and non-neurological diseases and further research is needed in many areas due to the central importance of protein folding and aggregation in biology.</p>
<p>Prions propagate after regularly folded prion proteins (PrP<sup>C</sup>) are converted into misfolded, aggregation-prone PrP<sup>Sc</sup> proteins that build up and yield amyloids. These misfolded proteins and their aggregates damage nerve and other cells and, over time, lead to a decline in brain function and ultimately death.  With no cure available for prion diseases, researchers are striving to improve assay sensitivity and exploit the benefits of real-time monitoring to support the development of better diagnostic and treatment approaches.</p>
<h4><strong>RT-QuIC assays and microplate readers for prion analysis</strong></h4>
<p>Prions typically replicate by a series of sequential, amplifying events. Misfolded PrP<sup>Sc</sup> acts as a point of recruitment of normal PrP<sup>C</sup> cellular prion proteins. This interaction converts the recruited normal protein into the abnormal conformation setting in place a chain reaction where the protein-protein aggregates grow to produce a larger seed of misfolded proteins. As the aggregates grow, they can fragment to produce new nucleation sites. The seeds are eventually transformed into fibers of amyloid-rich assemblies that comprise significant amounts of beta-sheet conformations of the misfolded proteins.</p>
<p><figure aria-describedby="caption-attachment-338896" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-338896" src="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-300x182.jpg" alt="Kinetic RT-QuIC analysis" width="300" height="182" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-300x182.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-1024x621.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-768x465.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-1536x931.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN232-Fig1-Copy-2048x1241.jpg 2048w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 1. Kinetic RT-QuIC analysis of hamster tissue homogenate dilutions using thioflavin T (ThT) assays on a microplate reader.<br>[BMG LABTECH]</figcaption></figure></p>
<p>The most widely used assay for detecting misfolded prions in biological samples is the RT-QuIC (Real-time quaking-induced conversion) assay. RT-QuIC assays are highly sensitive, seeding amplification assays that detect disease-associated prion activity. Formation of amyloid proteins is measured in real time using the fluorescent dye thioflavin T (ThT) whose emission increases significantly upon binding to beta-sheet-rich amyloid structures. Other dyes such as Congo Red are available that bind to amyloid but show reduced specificity for fibril proteins. Cyclic shaking accelerates fragmentation of the growing fibrils and produces a rapid amplification of the original prion seed. In practice, RT-QuIC assays generate characteristic amplification curves (<em>figure 1</em>) that comprise a baseline phase, an exponential increase in fluorescence, and a plateau phase. The lag time, maximum fluorescence, and reaction kinetics can provide quantitative or semi-quantitative measurements of prion seeding activity.</p>
<p>In the experiments shown in figure 1, scrapie brain homogenates were harvested 10 days after inoculation, incubated over time with shaking for the specified serial dilutions of Syrian hamster 263K cells, and ThT fluorescence was measured. The assays were quantified by measuring the loss of seeding activity at the end-point dilution.</p>
<h4><strong>Microplate readers and detection technologies for the investigation of amyloid</strong></h4>
<p>Microplate readers offer a robust platform for performing prion assays and measuring protein misfolding and aggregation. The ability to combine sensitive, high-performance kinetic fluorescence measurements with periodic cycles of rigorous shaking and consistent temperature control makes them the most widely adopted and practicable system for effective RT-QuIC assays.</p>
<p>Originally, the RT-QuIC assay was developed on the FLUOstar<sup>®</sup> Omega microplate reader from BMG LABTECH which quickly became an international standard for prion analysis. BMG LABTECH readers, which continue to lead the way for prion detection and activity measurements, offer a robust platform for shaking for extended periods of time (over multiple days), while periodically reading the fluorescent signal as ThT is incorporated into amyloid aggregates.</p>
<h4><strong>Applications for protein misfolding</strong></h4>
<p>As mentioned earlier, protein misfolding has impact beyond prion disease and is a hallmark of impaired function in a wide range of conditions including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis. The way certain proteins misfold and aggregate is closely tied to how proteins become toxic and cause neurodegenerative diseases.</p>
<p>BMG LABTECH´s application note “Monitoring amyloid-beta aggregation in real-time using a FLUOstar Omega microplate reader<sup>2</sup>” provides one example where the accumulation of misfolded amyloid protein aggregates linked to Alzheimer’s disease is measured using ThT. <em>Figure 2</em> shows some signal curves for samples and controls where ThT incorporation into newly formed amyloid-beta fibrils is measured.</p>
<p><figure aria-describedby="caption-attachment-338895" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-338895" src="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy-300x176.jpg" alt="samples containing either fixed or freshly frozen wild type or APP23 brain homogenates" width="300" height="176" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy-300x176.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy-768x450.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_AN250-Fig2-Copy-Copy.jpg 875w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 2. Signal curves for samples containing either fixed or freshly frozen wild type or APP23 brain homogenates. [BMG LABTECH]</figcaption></figure></p>
<p>In figure 2, error bars represent the deviation of replicate wells within one plate from the mean. All signal curves show a clear increase in fluorescence with time. This increase illustrates the incorporation of ThT into the newly formed amyloid-beta fibrils. After some time, a plateau is reached that is considered as the endpoint of amyloid formation and ThT incorporation process.</p>
<p>Protein misfolding and aggregation are likely to play a critical role in many processes related to aging. Misfolded proteins are also thought to influence different aspects of metabolic dysfunction and amyloid accumulation although the mechanism for most of these effects remains poorly understood. ThT assays thus offer applications across multiple disease areas and research domains.</p>
<h4><strong>Future developments</strong></h4>
<p>RT-QuIC assays have significantly accelerated research and analysis into prions compared with earlier more costly and lengthy bioassays where infected animals were studied over months. RT-QuIC assays also offer potential for disease surveillance in populations of prion-infected animals in the wild that could impact public health. Researchers are also looking at ways to use RT-QuIC-based screening assays to ensure the safety of human food chains. In this context, microplate readers and RT-QuIC assays have been used in experimental settings to characterize prion-seeding activity in samples of tissue from wild and farmed deer that may have been exposed to chronic wasting disease.<sup>3</sup></p>
<p>Beyond surveillance, new drugs are actively being sought for different targets related to protein folding and amyloid accumulation. In clinical trials, translatable biomarkers are needed that track the progression and severity of the neurodegenerative diseases impacted by protein misfolding and aggregation. Progress in artificial intelligence and modeling techniques will enhance studies of protein folding and misfolding which should bring further advances to the drug discovery space.</p>
<p>Demand for ThT assays is poised to increase due to the lack of interventions for neurological and non-neurological diseases caused by protein misfolding and aggregation events and the potential for other high-impact applications.</p>
<p>ThT-related assays are therefore moving away from being a means for a rapid diagnosis towards offering a quantitative tool for disease surveillance, pathogenesis, and therapeutic development across a wide range of disease and fundamental research areas in the life sciences.</p>
<p>BMG LABTECH offers a portfolio of single- to multimode microplate readers ideally suited for studying protein misfolding and aggregation. While the FLUOstar Omega remains the gold standard for RT-QuIC and seeding assays, the PHERAstar<sup>®</sup> FSX was specifically conceived for screening campaigns and is the go-to reader for high-performance high-throughput screening. Both the VANTAstar<sup>®</sup> and CLARIOstar<sup>®</sup> Plus allow for wavelength flexibility and include Enhanced Dynamic Range technology for superior performance and ease of use. Collectively, these multimode readers combine high performance with miniaturized assays and short measurement times, delivering considerable savings on materials and other resources.</p>
<p><em>References</em></p>
<ol>
<li>Dong TT, Satoh K. The Latest Research on RT-QuIC Assays-A Literature Review. <em>Pathogens</em>. 2021 Mar 5;10(3):305. doi: 10.3390/pathogens10030305.</li>
<li>Baumann F. Following Abeta Fibrillization/Aggregation in Real-Time | BMG Labtech. n.d. [Last accessed: 9/14/2026].</li>
<li>Li M et al. RT-QuIC detection of CWD prion seeding activity in white-tailed deer muscle tissues. <em>Sci. Rep</em>. 2021 Aug 18;11(1):16759. doi: 10.1038/s41598-021-96127-8. PMID: 34408204; PMCID: PMC8373970.l</li>
</ol>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-338898" src="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_QRCode-295x300.jpg" alt="BMG Labtech QR Code" width="162" height="165" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_QRCode-295x300.jpg 295w, https://www.genengnews.com/wp-content/uploads/2026/10/BMG_Labtech_QRCode.jpg 307w" sizes="auto, (max-width: 162px) 100vw, 162px"></p>
<p>If you are interested in further details about microplate-based evaluation of prions and protein misfolding, please contact us at <a href="mailto:applications@bmglabtech.com">applications@bmglabtech.com</a> or scan the QR code on the right-hand side</p>
<p>The post <a href="https://www.genengnews.com/sponsored/investigating-prions-and-protein-aggregation-at-high-sensitivity-and-throughput/">Investigating Prions and Protein Aggregation at High Sensitivity and Throughput</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Epitranscriptome Heads Toward Clinical Necessity</title>
<link>https://edusehat.com/en/the-epitranscriptome-heads-toward-clinical-necessity</link>
<guid>https://edusehat.com/en/the-epitranscriptome-heads-toward-clinical-necessity</guid>
<description><![CDATA[ Short-read RNA sequencing reporting the modifications that alter protein output is starting to make epitranscriptomics indispensable for patient selection in precision medicines.
The post The Epitranscriptome Heads Toward Clinical Necessity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GEN_OCT_2026_GettyImages-1541079143-Copy-e1791300669134.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 07 Oct 2026 04:10:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Epitranscriptome, Heads, Toward, Clinical, Necessity</media:keywords>
<content:encoded><![CDATA[<p class="wp-block-paragraph">A deep understanding of epitranscriptomics—RNA modifications—is the missing layer in the quest for more broadly effective precision medicines. That’s the view of Gudrun Stengel, PhD, CEO of Alida Biosciences, and the foundational belief that drives her company to build sequencing tools and scientifically relevant models linking RNA modifications to phenotype.</p>


<p class="wp-block-paragraph">Today, despite the astounding breakthroughs of the past quarter-century, positive responses to advanced therapies such as checkpoint inhibitors and cell and gene therapies are still limited to a relatively small subset of patients. To improve efficacy and understand patient response, Stengel says, “We need to consider all layers of epigenetic regulation to better understand gene regulation and build better models of biology, especially right now, with AI enabling the integration of huge amounts of data.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>


<figure class="wp-block-image alignright size-medium is-resized"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-300x300.jpg" alt="Gudrun Stengel" class="wp-image-338870" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/OYR_Stengel-G-Copy.jpg 1000w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption">Gudrun Stengel, PhD<br>CEO of Alida Biosciences</figcaption></figure>


<p class="wp-block-paragraph">Despite the increasing influx of information, “We still have gaps in our understanding of how information flows from DNA to proteins and ultimately phenotype,” Stengel says. In a multiomics environment, RNA modifications—which she calls “an essential layer of that multiomic stack”—have received relatively little attention because they are considered particularly hard to measure accurately.</p>


<p class="wp-block-paragraph">To help resolve that issue, AlidaBio is focusing on three of the most important RNA modifications as a way to create better and more useful epitranscriptomics models to improve scientists’ understanding of the many layers of epigenetic regulation.</p>
<div class="my-8"><span data-render-ad="4"></span></div>


<h4 class="wp-block-heading"><strong>Why epitranscriptomics</strong></h4>


<p class="wp-block-paragraph">“Epitranscriptomics are a readout of the cell state,” Stengel says. “Single-cell transcriptomics and spatial transcriptomics have shown a huge amount of heterogeneity—similar cell types are characterized by different RNA expression patterns that define what a cell is doing at a given time.” As an example of the timescales of response, she says, “To reset DNA methylation can take up to two weeks. To reset an RNA expression pattern can take a day, and RNA modifications can change RNA expression within a few hours.” Understanding those patterns and their time to action can significantly affect a cell’s response to therapeutics.</p>


<p class="wp-block-paragraph">“RNA modifications don’t change the genetic code, but they change what RNA does,” Stengel emphasizes. “N6-methyladenosine (m6A), the most important mRNA modification, can quickly mark RNA transcripts associated with a previous cell state for degradation and, at the same time, promote the translation of genes that are associated with the future cell state. It is also involved in alternative splicing regulation, which creates more protein diversity.”</p>


<p class="wp-block-paragraph">Epitranscriptomics method development has gained significant momentum in recent years. Current nanopore-based direct RNA sequencing can detect a subset of modifications in native, long RNA molecules. However, the approach currently requires relatively large quantities of high-quality full-length RNA.</p>


<h4 class="wp-block-heading"><strong>Short-read, one-pot detection</strong></h4>


<p class="wp-block-paragraph">Alida Biosciences expanded the industry’s capabilities in 2025 by launching its EpiPlex<sup><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></sup> platform. It was the first commercial solution to analyze sparse and highly-degraded RNA often found in clinical samples and provide simultaneous, one-pot detection, localization, and quantification of three of the best-studied and most frequently occurring mRNA modifications: N6-methyladenosine (m6A), inosine, and pseudouridine, along with gene expression. The company offers kits, analysis software, and services.</p>
<div class="my-8"><span data-render-ad="5"></span></div>


<p class="wp-block-paragraph">“To develop clinical and translational applications, you need to look at clinical samples (fresh-frozen or formalin-fixed paraffin-embedded tissues, and liquid biopsies, for example) that are present at low quantities or that may be highly degraded,” she explains.</p>


<p class="wp-block-paragraph">The long list of potential applications includes patient stratification for specific therapies and response monitoring, as well as therapeutic development of cancer drugs and measuring immune cell fitness. “m6A, the most common modification, plays a huge role in cell differentiation and cell fate,” Stengel says.</p>


<h4 class="wp-block-heading"><strong>Entrepreneurial leanings</strong></h4>


<p class="wp-block-paragraph">Stengel formed the company five years ago, leaving a safe corporate position on the belief that she could create a company that would fill a key knowledge gap.</p>


<p class="wp-block-paragraph">“I had spent a significant number of years in large companies—including Illumina—developing genomics technologies,” she says. Researchers at such companies, however, tend to be involved in either the inception or the development of a product. “I wanted to see things through from the beginning to the end. I thought a smaller company would be the ideal environment to do exactly that. I resigned my job and started putting the pieces together.</p>


<p class="wp-block-paragraph">“When I started the company, many [in the industry] had never heard of epitranscriptomics,” she says. Nonetheless, she secured venture capital funding within six months and built a small, core team.</p>


<p class="wp-block-paragraph">Those early days found her in the lab, working with just a few scientists. “Getting the first, preliminary data was so exhilarating!” she recalls. “It’s a good day when everything works in the lab.”</p>


<p class="wp-block-paragraph">Epitranscriptomics is emerging from a niche discipline, so now most conference attendees, “regardless of the conference,” Stengel adds, are aware of the field. Although, she admits, “not everybody knows why they are important. Yet, that’s a huge step forward.”</p>


<h4 class="wp-block-heading"><strong>Commercial vision</strong></h4>
<div class="my-8"><span data-render-ad="6"></span></div>


<p class="wp-block-paragraph">As scientists increasingly recognize the role RNA modifications play in therapeutic development and outcomes, she can focus on scaling the company and its commercial capabilities. “We started out very R&D heavy,” and now are beginning to earn revenue to fund further innovations. Potential clients include multiomics companies, research hospitals, and “to some extent, diagnostics,” she says.</p>


<p class="wp-block-paragraph">Currently, AlidaBio is working with the oncology company STORM Therapeutics to understand the mechanism of action and to stratify patients for a Phase II drug that acts on methyltransferase-like 3 (Mettl3), the m6A writer enzyme. This is one of a few areas in which RNA modification can make breakthroughs in patient treatment and stratification, she says. “We’re also very interested in predicting response to PD-L1 inhibitors.”</p>


<p class="wp-block-paragraph">For AlidaBio, bioinformatics is an area of continual focus, along with making analysis output more interactive. “We also are applying machine learning models to integrate the amount of information between RNA modifications and gene expression, so there will be significant updates to the EpiScout<sup>®</sup> analysis software,” Stengel says. Other plans remain confidential.</p>


<p class="wp-block-paragraph">For both the company and the industry, “I think the next inflection point is when epitranscriptomics becomes part of mainstream multiomics,” Stengel says. When that happens, researchers will consider RNA expression data incomplete without information about RNA modification.</p>


<p class="wp-block-paragraph">Therefore, eventually, “RNA modifications will become another standard layer that’s integrated into AI models of biology,” she continues. “The real test will be demonstrating that this layer improves patient stratification, predicts treatment response, or identifies new therapeutic opportunities. Once that happens, I think the field will move from being scientifically interesting to clinically indispensable.”</p>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column sidebar is-layout-flow wp-block-column-is-layout-flow">
<h3 class="wp-block-heading"><strong><strong>Alida Biosciences (AlidaBio)</strong></strong></h3>


<p class="wp-block-paragraph"><strong>Location:</strong> 11535 Sorrento Valley Rd, Suite 407, San Diego, CA 92121</p>


<p class="wp-block-paragraph"><strong>Phone:</strong> (858) 922-3299</p>


<p class="wp-block-paragraph"><strong>Website:</strong> <a href="https://www.alidabio.com/">alidabio.com</a></p>


<p class="wp-block-paragraph"><strong>Principal:</strong> Gudrun Stengel, PhD, founder and CEO</p>


<p class="wp-block-paragraph"><strong>Number of Employees:</strong> 20</p>


<p class="wp-block-paragraph"><strong>Focus:</strong> Alida Biosciences developed a technology platform, kits, and services to read and analyze RNA and its modifications by short-read sequencing. The platform provides simultaneous, one-pot detection, localization, quantification, and gene expression information for several of the best-studied and most frequently occurring RNA modifications.</p>
</div>
</div>



<p>The post <a href="https://www.genengnews.com/topics/omics/the-epitranscriptome-heads-toward-clinical-necessity/">The Epitranscriptome Heads Toward Clinical Necessity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sensible Biotechnologies Raises $47M to Expand Next&#45;Generation Platform for mRNA Medicines</title>
<link>https://edusehat.com/en/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines</link>
<guid>https://edusehat.com/en/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines</guid>
<description><![CDATA[ Sensible Biotechnologies raised $47 million to scale VECTOR, its integrated platform pairing AI-enabled mRNA design with manufacturing of naturally modified mRNA in living cells, aiming to develop novel therapeutics beyond vaccines. 
The post Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/AList_GettyImages_1094685558_3DRNAChain-1392x770-1-1519x840-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 20:55:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sensible, Biotechnologies, Raises, 47M, Expand, Next-Generation, Platform, for, mRNA, Medicines</media:keywords>
<content:encoded><![CDATA[<p><span>Sensible Biotechnologies said that it has raised $47 million in financing that it will use to advance and scale its integrated mRNA technology. The financing includes a Series A and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. </span></p>
<p><span>According to the company, the funds will support the development of what it claims is a first-of-its-kind platform for naturally modified mRNA medicines. The so-called Versatile Engine for Cell-based Therapeutic Optimization of RNA (VECTOR) platform integrates computational and artificial intelligence-enabled sequence optimization, high-throughput screening, and proprietary engineered eukaryotic cells to design and manufacture mRNA. Meanwhile, the company’s PromPT technology is designed to capture and protect mRNA inside cells before it is purified for therapeutic use. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Specifically, Sensible will use the funds to expand VECTOR’s AI-enabled mRNA design and automated high-throughput screening capabilities as well as support the development of clinical-grade manufacturing capabilities. Sensible’s platform harnesses the natural machinery of living cells to produce naturally modified mRNA with reduced immunogenicity and high protein expression while avoiding double-stranded RNA contamination. Furthermore, by using engineered living cells, Sensible reduces reliance on specialized raw materials and manufacturing inputs, enabling more scalable production and expanding mRNA into therapeutic applications that require higher or repeated dosing.</span></p>
<p><span>Rather than relying on synthetic manufacturing technology developed more than 40 years ago, “we are taking a fundamentally different approach, using living cells to produce naturally modified mRNA while reducing the cost and supply-chain constraints of conventional production,” said Miroslav Gasparek, Sensible’s co-founder and CEO. “With this financing, we can scale our platform and expand mRNA into therapeutic applications requiring high or repeated dosing that have historically been limited by cost.”</span></p>
<p><span>The Series A includes participation from new investors OTB Ventures and In-Q-Tel, alongside existing investors Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures, and BlueYard Capital, as well as the family office of Christoph Huber, co-founder of BioNTech, and Tim Garnett, former chief medical officer of Eli Lilly, and other individual investors.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>In connection with the financing, Vishal Gulati, MD, FMedSci, managing partner at Recode Ventures, and Joel Schoppig, partner at Oxford Science Enterprises, will join Sensible’s board of directors alongside Miroslav Gasparek and Marian Kupculak, PhD, CSO and co-founder.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/sensible-biotechnologies-raises-47m-to-expand-next-generation-platform-for-mrna-medicines/">Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV</title>
<link>https://edusehat.com/en/in-rare-trials-summit-keynote-bio-expert-highlights-lives-touched-by-pprv</link>
<guid>https://edusehat.com/en/in-rare-trials-summit-keynote-bio-expert-highlights-lives-touched-by-pprv</guid>
<description><![CDATA[ One afternoon in 2024, the BIO Federal Government Affairs team received a call from Hill staff who said, “We just met the most amazing […]
The post In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/Michele-Oshman-and-Dions-keynote-rare-trials-summit.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 13:50:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rare, Trials, Summit, keynote, BIO, expert, highlights, lives, touched, PPRV</media:keywords>
<content:encoded><![CDATA[<p><span>One afternoon in 2024, the BIO Federal Government Affairs team received a call from Hill staff who said, “We just met the </span><a href="https://www.thedionfund.org/thedions"><span>most amazing family</span></a><span>. They came down from Boston. They have a story to share, and we think you guys need to know them.”</span></p>
<p><span>Joe and Courtney Dion came to Washington to share their story: Peter, age 10, and Maggie, age 6, were born with limb-girdle muscular dystrophy (LGMD-R5, formerly known as LGMD-2C), a rare disease that would eventually rob the children of their ability to walk, move independently, and breathe on their own. </span></p>
<p><span>At the time, there was little hope on the horizon.</span></p>
<p><span>“Our first conversation with the Dions was incredibly powerful—it became clear that they had done their homework. They identified a company with a promising gene therapy, but which could not progress to the clinic without significant investment,” explains Michele Oshman, BIO’s Chief Patient Advocate. “They also understood that investment could very well depend on the reauthorization of a little-known, but incredibly powerful federal program called the pediatric priority review voucher (PPRV). … For the cynics out there who think that maybe patient advocacy is not truly organic, they are wrong. It really is.”</span></p>
<p><span>From that day, the Dions made it their mission to get the PPRV reauthorized in time for Peter and Maggie to benefit from gene therapy. </span></p>
<p><span>Oshman, along with Maggie, mom Courtney, and dad Joe Dion, was a keynote speaker at the </span><a href="https://raretrialssummit.com/"><span>Rare Trials Summit</span></a><span>, held in Boston in September. The summit’s aim is to act as a working meeting for those responsible for advancing rare disease clinical programs. </span></p>
<p><span>Oshman and the Dion’s conversation was a perfect example of just how effective patient advocacy can be when patients, innovators, and Congress work together toward solutions.  </span></p>
<h3>What is the PPRV and how does it help patients?</h3>
<p><span>Developing medicines for rare childhood illnesses is very expensive and risky because the market favors medicines that will be used in larger populations. </span></p>
<p><span>Enter the Rare Pediatric Priority Review Voucher program. If a company develops and achieves FDA approval for a rare pediatric disease medicine, the FDA gives them a “voucher”. This voucher acts like a fast-pass ticket. The company can use it to buy time in the form of a 6-month FDA review instead of the standard 10-month review for their next innovation. The voucher is also an extremely high value asset that can be sold to another pharmaceutical company, thus enabling the rare disease innovator to invest tens of millions of dollars back into their R&D efforts.</span></p>
<p><span>The program is something many small, rare-disease-focused companies use to fund their current and future work, and has been a game changer for rare disease patients.</span></p>
<p><span>“Our children Maggie and Peter were diagnosed with limb-girdle muscular dystrophy in 2022,” explained Joe Dion. “At first, we didn’t know what to do. There was no cure. There were no trials. But there was one company that was potentially going to start a trial; it was a waiting game.”</span></p>
<p><span>But not content to just sit and wait, the Dion family got to work. </span></p>
<p><span>“We started advocating and, fast forward to 2025, we got the first ever trial started,” he continued. “At the time, the PPRV program was something that made sense because this is an ultra rare disease. There weren’t enough patients to make it lucrative for investors to come in and invest in the typical pathway to get a drug developed. So the PPRV program was a big, big part of what helped us move things forward.”</span></p>
<p><span>In addition to advocacy, the Dions also hit the fundraising trail to supplement the research and development of treatment—including Joe being on Harpoon Hunters, a Discovery Channel reality TV show, to raise awareness. But an interesting thing to note about the Dion’s story is that their advocacy played a major role in bringing research </span><i><span>into</span></i><span> the United States.</span></p>
<p><span>The company that the Dions were working with was originally based in France and had already compiled pre-clinical data as a foundation for their work. It was the PPRV program that incentivized them to bring their business stateside and break the technology in the American market first. </span></p>
<p><span>“The PPRV program was clutch in getting it to move forward,” said Joe.</span></p>
<p><span>Today, the company is still working to get their treatment to market and the Dions are continuing to ring the bell every step of the way. </span></p>
<h3>Navigating treatment—and recovery</h3>
<p><span>“When we had the chance to be able to get our children treated with gene therapy, we put everything else on hold,” explained Courtney Dion. “We would have moved mountains. We would have gone to France. We would have gone to a third-world country if we had to. We would have sold our house. We would have done anything that we could have to have this opportunity.”</span></p>
<p><span>Luckily, the Dions only had to move to Florida for a short time.</span></p>
<p><span>And so the family moved and worked directly with the team down in Florida to navigate the clinical trial process, as well as see how it affected Maggie and Peter differently. For example, Maggie, who was able to get the treatment at a younger age, had a 92% expression in her recovery—an unprecedentedly successful amount—indicating the importance of getting these treatments out into the world faster and to patients earlier.</span></p>
<p><span>As Oshman pointed out, however, the Dions are in the game for the long run because there are more trials that need to be done, and more children that need to be helped. “These trials aren’t getting stalled because the medicine’s not working,” she reminded. “But because of the financing.” As such, the Dions have prioritized their fundraising efforts so that more children just like theirs can get access to these trials. </span></p>
<p><span>Additionally, because of the work the Dions and advocates like them are doing, the PPRV program was reauthorized in February of 2026—ensuring that doors were opening for rare disease clinical research and development, not closing.</span></p>
<h3>The power of the patient voice</h3>
<p><span>The Dion’s experience is reflective of the power of patient advocacy: patient voices change the world, and their stories can put a human face on complex policy issues.</span></p>
<p><span>Another patient advocate at the event, Effie Parks, host of the</span><a href="https://effieparks.com/about-1"><span> Once Upon a Gene Podcast</span></a><span> and mother to her son Ford, who was diagnosed with CTNNB1 syndrome, opened the event by saying, “When a trial becomes a possibility, we bring our children, our hope, our questions, and our trust. We can want progress with everything we have and still be frightened by what comes next.”</span></p>
<p><span>As Maggie Dion explained, “I love fighting for kids who don’t get a chance to go up and talk.” Not every child has the opportunity to speak as she does, she said; it is not a responsibility she takes lightly. </span></p>
<p>The post <a href="https://bio.news/federal-policy/in-rare-trials-summit-keynote-bio-expert-highlights-lives-touched-by-pprv/">In Rare Trials Summit keynote, BIO expert highlights lives touched by PPRV</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026 Nobel Prize for Physiology or Medicine Goes to Optogenetics, Light&#45;Gated Ion Channels</title>
<link>https://edusehat.com/en/2026-nobel-prize-for-physiology-or-medicine-goes-to-optogenetics-light-gated-ion-channels</link>
<guid>https://edusehat.com/en/2026-nobel-prize-for-physiology-or-medicine-goes-to-optogenetics-light-gated-ion-channels</guid>
<description><![CDATA[ Today, the 2026 Nobel Prize for Physiology and Medicine has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.
The post 2026 Nobel Prize for Physiology or Medicine Goes to Optogenetics, Light-Gated Ion Channels appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2266497868.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 13:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026, Nobel, Prize, for, Physiology, Medicine, Goes, Optogenetics, Light-Gated, Ion, Channels</media:keywords>
<content:encoded><![CDATA[<p>The Nobel Prize in Physiology or Medicine 2026 has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.</p>
<figure aria-describedby="caption-attachment-338818" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-338818 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg" alt="Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD" width="300" height="132" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-768x338.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine.jpg 855w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text"><em>The 2026 Nobel Prize in Physiology or Medicine winners Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD.</em></figcaption></figure>
<p>Deisseroth is a Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University and an HHMI Investigator; Hegemann is the Hertie Senior Research Chair for Neurosciences and a professor of Experimental Biophysics at Humboldt University and Nagel is a professor at the Department for Neurophysiology at the University of Würzburg, in Germany.</p>
<p>“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” says Per Svenningsson, MD, PhD, Chair of the Nobel Committee for Physiology or Medicine.</p>
<p>Although optogenetics is a relatively new technology, the seminal paper from the Deisseroth lab was published in 2005. However, the concept of manipulating specific neuronal cell types within intact circuits on a millisecond timescale was considered long before. Indeed, Francis Crick, PhD, once proposed a method where “all neurons of just one type could be activated or inactivated, leaving the others more or less unaltered.” He speculated that to “turn the firing of one or more types of neurons on and off in the alert animal in a rapid manner … the ideal signal would be light,” acknowledging at the time that his idea was “rather far-fetched.” In addition, scientists have been working on laying the foundation for this technology since the 1970s. For example, when Richard Fork, PhD, at Bell Laboratories in New Jersey at the time, published the stimulation of neurons in<em> Aplysia</em> with laser light in <em>Science</em>.</p>
<p>It was the discovery of the algal protein channelrhodopsin that led the way in making the vision into a reality. Microbial rhodopsins—found across archaea, eubacteria, and eukaryotic microalgae—harness light for cellular bioenergetics. Channelrhodopsin is found on the surface of C<em>hlamydomonas</em>, a single-celled alga with the ability to swim towards a light source. Researchers discovered that the protein can directly convert photon energy into transmembrane ion flux.</p>
<p>The first direct evidence of a light-gated ion channel was named channelrhodopsin-1 (ChR1), discovered and coined by the Hegemann lab. The arguably more consequential breakthrough came just a year later: a collaborative team led by Georg Nagel, demonstrated that a second protein, named channelrhodopsin-2 (ChR2), functioned distinctly from ChR1, and exhibited a blue-shifted activation spectrum and operated as a broad, non-selective cation channel.</p>
<p>Finding a microbial protein that could act as a single unit, simultaneously as a photoreceptor and an ion channel, and the discovery that ChR1 and ChR2 were single-component, light-gated ion channels, provided the precise tools that neuroscientists had been looking for—for fast, genetically targetable optical activation of neurons.</p>
<p>The team in the Deisseroth lab took the baton and performed the first successful demonstration that ChR2 could be expressed in neurons, using a construct provided by Nagel. They introduced the gene for channel-rhodopsin into nerve cells from rats and was able to trigger a nerve signal by illuminating the cells with blue light.</p>
<p>Deisseroth’s lab published this breakthrough in 2005 in the <em>Nature Neuroscience</em> paper, “<a href="https://www.nature.com/articles/nn1525" target="_blank" rel="noopener">Millisecond-timescale, genetically targeted optical control of neural activity</a>.” The study demonstrated that expressing the microbial protein channelrhodopsin-2 (ChR2) from green algae in cultured mammalian neurons allowed precise, millisecond-timescale control of action potentials using flashes of blue light.</p>
<p>The paper’s first author was Ed Boyden, PhD, professor in Neurotechnology at MIT who has been developing the field of optogenetics for the past two decades. Interestingly, CRISPR pioneer Feng Zhang, PhD, is the second author on the 2005 paper. Two years later, Deisseroth’s lab made this light-controlled switch for nerve cells work in the brains of living mice.</p>
<p>Over the past two decades, optogenetics has been used to unpack many biological questions, primarily (but not exclusively) in the field of neuroscience. One early <em>in vivo</em> application of optogenetics probed the causal relationship between the activation of orexin/hypocretin neurons in the lateral hypothalamus and the transitions from sleep to wakefulness. Other notable applications were the search for the memory engram—the physical cellular substrate encoding a specific memory—and unpacking the complexity of dopaminergic neurons in the retina, showing that functionally distinct dopaminergic populations are anatomically intermingled yet strictly segregated by their circuit connectivity.</p>
<p>Optogenetics has also moved into clinical applications, such as the expression of ChR2 in retinal circuitry. In one experiment, intraocular injection of an adeno-associated viral (AAV) vector encoding ChR2 led to expression in retinal ganglion cells in rodents. More specifically, light depolarized the ChR2 expressing retinal ganglion cells, restoring retinal photosensitivity and allowing light signals to reach the visual cortex in a mouse model of retinitis pigmentosa. Expression of ChR2 in surviving retinal neurons could therefore serve as a potential strategy for restoring vision after rod and cone degeneration.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels/">2026 Nobel Prize for Physiology or Medicine Goes to Optogenetics, Light-Gated Ion Channels</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A Method for Assessing Lab&#45;Grown Stem Cell&#45;Derived Embryo Models</title>
<link>https://edusehat.com/en/a-method-for-assessing-lab-grown-stem-cell-derived-embryo-models</link>
<guid>https://edusehat.com/en/a-method-for-assessing-lab-grown-stem-cell-derived-embryo-models</guid>
<description><![CDATA[ Researchers developed a method for testing how closely lab-grown blastoid models resemble real human embryos, finding that while some models perform well, none fully captures the complexity of early human development. 
The post A Method for Assessing Lab-Grown Stem Cell-Derived Embryo Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/GettyImages-2174865889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 10:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Method, for, Assessing, Lab-Grown, Stem, Cell-Derived, Embryo, Models</media:keywords>
<content:encoded><![CDATA[<p>University of Sydney researchers have developed a powerful way to test how closely lab-grown biological models resemble real human embryos, finding that while some models perform well, none yet fully capture the complexity of early human development.</p>
<p>The scientists say the research creates one of the most comprehensive reference maps of early human embryo development, which they used to benchmark the biological accuracy of stem-cell-derived embryo models. They systematically evaluated four leading human blastoid-generation methods and found substantial differences in how faithfully they reproduce the cell types and developmental processes seen in natural human embryos.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Pengyi Yang, PhD, associate professor at the University of Sydney and an ARC Future Fellow in the School of Mathematics and Statistics and Unit Head of Computational Systems Biology at the Children’s Medical Research Institute, said the work gives scientists a more objective way to understand the strengths and limitations of embryo models. “Human embryo models have enormous potential for studying the earliest days of an embryo’s development, but there has been no consistent way to assess how accurately these reflect real human development. Our framework allows researchers to compare these models against a detailed biological reference and determine which cell types and developmental processes are faithfully reproduced, and which are not.”</p>
<p>Yang, who also leads the Trans-Regulatory Biology group at the Charles Perkins Centre, is senior and corresponding author of the team’s published paper in <em>Cell Systems</em>, titled “<a href="https://doi.org/10.1016/j.cels.2026.101738" target="_blank" rel="noopener">Systematic transcriptomic evaluation of blastoid models of early human development</a>.” In their paper the team stated, “The reference map generated from this study enables the benchmarking of blastoids that may guide the optimization of the protocol for the generation of high-fidelity blastoid models that faithfully recapitulate the natural human blastocyst.”</p>
<p>The study of early human embryogenesis from blastocyst formation to gastrulation has been constrained by what the authors describe as “… technical challenges and ethical concerns associated with human embryo research.” But research on blastoid embryo models, which are derived from stem cells, offers scientists a way to study the biological events that underpin fertility, pregnancy success, and early human development without relying on donated human embryos.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<figure aria-describedby="caption-attachment-338825" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338825" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Associate-Professor-Pengyi-Yang-at-desk.-University-of-Sydney-300x200.jpg" alt="Associate Professor Pengyi Yang at his desk. [University of Sydney] " width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Associate-Professor-Pengyi-Yang-at-desk.-University-of-Sydney-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Associate-Professor-Pengyi-Yang-at-desk.-University-of-Sydney.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Associate professor Pengyi Yang, PhD, at his desk. [University of Sydney]</figcaption></figure>
<p>While these research models are not actual human embryos—current models cannot develop into a human embryo—they could help answer questions that have long been difficult to investigate because of technical and ethical constraints. “Recent achievements in generating blastocyst-like structures from stem cells, the blastoids, that are reminiscent of human blastocysts in morphology and cellular composition have opened an avenue to glean knowledge of the biology of early human embryogenesis,” the team continued.</p>
<p>However, just because something looks like an embryo, does that mean it is behaving like one biologically? The University of Sydney team developed a computational framework that helps answer that question. “Establishing a systematic evaluation framework for assessing the fidelity of blastoids in modeling the human blastocyst is critical for enhancing the quality of these stem cell-based embryo models (SCBEMs),” they noted. “… we set out to develop a computational workflow for systematically assessing how closely blastoids generated by current state-of-the-art protocols recapitulate human blastocyst cell states and develop mental features.”</p>
<p>To do this the team combined and harmonized more than 14,000 single-cell transcriptomes—the set of RNA molecules in a cell—from human embryos spanning key stages of their development. This allowed them to create a reference map of how cells normally differentiate and organize themselves during the days immediately before and after implantation.</p>
<p>The investigators then compared that reference against four widely used blastoid-generation protocols developed by international research groups. Rather than assessing whether the models simply resembled embryos under a microscope, the researchers examined their molecular identities, developmental timing, lineage structure, and other biological characteristics.</p>
<p>The results showed that some blastoid models reproduced all three major cell lineages of a natural human blastocyst, or the early embryo, relatively well, while others failed to accurately represent certain cell types or contained large numbers of cells that could not be confidently matched to any known embryonic state. No single model perfectly replicated a natural human blastocyst. “Results of the benchmarking revealed substantial differences between protocols in recapitulating the composition, developmental timing, and coordinated lineage specification of the human blastocyst, highlighting that high-fidelity SCBEMs should reproducibly generate appropriately staged and developmentally coordinated blastocyst cell states,” the authors reported.</p>
<p>Yang said the findings highlight both the promise and current limitations of embryo models. “The encouraging finding is that some models capture important aspects of early embryonic development relatively well, although each model has limitations,” he said. “But our study also shows that current models are not biologically equivalent to real human embryos, and researchers need to be careful about the conclusions they draw from them.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>By providing a standardized benchmark, the researchers hope future models can be improved more rapidly and evaluated more rigorously. “Collectively, our work provides a comprehensive and systematic evaluation of the developmental authenticity of <em>in vitro</em> cultured SCBEMs generated by the state-of-the-art protocols,” they concluded. “Yang added, “If we’re going to use these systems to answer important biological questions, we first need to know what they can reliably tell us. Our work provides a roadmap for improving embryo models and ensuring scientific claims remain grounded in what the models can actually support.”</p>
<p>The researchers have made their reference datasets and benchmarking tools publicly available, enabling scientists worldwide to test new embryo models against the same standards.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/a-method-for-assessing-lab-grown-stem-cell-derived-embryo-models/">A Method for Assessing Lab-Grown Stem Cell-Derived Embryo Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research</title>
<link>https://edusehat.com/en/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert-foundation-symposium-for-hemoglobinopathy-research</link>
<guid>https://edusehat.com/en/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert-foundation-symposium-for-hemoglobinopathy-research</guid>
<description><![CDATA[ Stuart Orkin, MD, and his former trainees Vijay Sankaran, MD, PhD, and Daniel Bauer, PhD, were joined by Swee-Lay Thein, MD, PhD, and John Tisdale, MD, both at the NIH. Their contributions helped to identify BCL11A as a major regulator of the fetal-to-adult hemoglobin switch.
The post Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/IMG_0138.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 06:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Flicking, the, Switch:, Five, Scientists, Honored, 2026, Warren, Alpert, Foundation, Symposium, for, Hemoglobinopathy, Research</media:keywords>
<content:encoded><![CDATA[<p><span data-contrast="auto"><strong>BOSTON</strong>—Four physician scientists and a molecular geneticist from Harvard Medical School (HMS) and the National Institutes of Health (NIH) were honored last week with the 2026 Warren Alpert Foundation prize. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Stuart Orkin, MD, and his former trainees Vijay Sankaran, MD, PhD, and Daniel Bauer, PhD, were joined by Swee-Lay Thein, MD, PhD, and John Tisdale, MD, both at the NIH. Their contributions helped to identify BCL11A as a major regulator of the fetal-to-adult hemoglobin switch, paving the way for the development of the first CRISPR medicine, Casgevy, for sickle cell disease (SCD) and thalassemia.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Opening the symposium, HMS Dean George Daley, MD, paid tribute to Janet Watson, MD, the Brooklyn pediatrician who concluded in 1948 that fetal hemoglobin (HbF) was somehow protective against SCD. “The mechanism behind the switch would remain an enigma for decades,” Daley said. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Each of the five honorees had “distinct and complementary roles” in the effort, Daley said, which culminated in the approval in December 2023 of Casgevy as well as Lyfgenia, a beta-globin gene therapy. Thein and Sankaran identified and characterized BCL11A as a critical regulator of HbF expression. Orkin and Bauer identified the enhancer sequence within </span><i><span data-contrast="auto">BCL11A</span></i><span data-contrast="auto"> that controls erythroid gene expression and would become the specific target for Casgevy to restart HbF production.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“We should hustle to make therapies that are simpler, safer and scalable,” Daley said. Bolstering newborn screening for SCD and expanding global distribution would be major steps to producing a bigger impact, such that “fewer people will have their lives upended by these devastating hemoglobinopathies.”</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Editing out disease</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">The symposium’s keynote speaker—2020 Nobel laureate Jennifer Doudna, PhD—said, “Drug success requires a deep understanding of </span><i><span data-contrast="auto">biology</span></i><span data-contrast="auto">.” Having a functional cure for SCD less than 15 years after her team’s initial development of CRISPR-Cas9 gene editing was “just incredible,” she said.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Doudna paid particular credit to patient volunteers such as Victoria Gray and Jimi Olaghere. “You can’t have success if you don’t have people willing to try it,” she said. According to Doudna, Casgevy is now approved in 39 countries across North America, Europe, and the Middle East. More than 90 percent of SCD patients in the U.S. qualify for reimbursement coverage for Casgevy. And more than 500 patients globally have begun Casgevy treatment. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Naturally, challenges remain. Doudna focused on four: 1) Conditioning toxicity, 2) cost, 3) infrastructure, and 4) expanding global access. “How do we get from one CRISPR therapeutic to CRISPR-for-many? I think it’s achievable,” she said, citing the 2025 Baby KJ story as an example. </span><i><span data-contrast="auto">In vivo</span></i><span data-contrast="auto"> gene editing will be critical in the future, Doudna said, but the toolbox for delivery is growing fast. She noted two recent preprints from her lab advancing novel strategies—</span><a href="https://www.biorxiv.org/content/10.64898/2026.01.13.699115v1" target="_blank" rel="noopener"><span data-contrast="none">NANITE</span></a><span data-contrast="auto"> and </span><a href="https://www.biorxiv.org/content/10.64898/2026.04.26.720920v2" target="_blank" rel="noopener"><span data-contrast="none">JET</span></a><span data-contrast="auto">—as examples of works in progress.</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Beginning with BCL11A</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">The symposium was organized by Ed Benz, MD, a renowned hematologist and President and CEO emeritus of the Dana Farber Cancer Institute. In SCD, the red blood cells (RBCs) become rigid and adhere to blood vessel walls. Tissues become ischemic resulting in pain crises and start to deteriorate. Many patients lose the function of key organs, especially the kidney, heart, and lungs. Life for people with SCD is “constantly dealing with pain, anemia, brain fog, etc. They rarely live a normal lifespan.”</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Orkin noted that this was not his first time winning the Alpert prize. He previously won in 1993 for his research providing a complete molecular genetic description of thalassemia. “A lot has happened in 33 years,” Orkin joked, noting profound changes in presidents, AI, and scientific landmarks. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Orkin’s team has spent years defining the mechanism of BCL11A regulation of globin gene transcription, a process he likened to “going to the thermostat.” He highlighted a key paper along the way led by his former trainee Jian Xu, PhD, now at St. Jude Children’s Research Hospital. In 2011, Xu took an SCD mouse model, knocked out the </span><i><span data-contrast="auto">Bcl11a</span></i><span data-contrast="auto"> gene in the erythroid lineage, and rescued the phenotype of RBCs. This prevented SCD symptoms and validated BCL11A as a therapeutic target in humans. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The Casgevy results, Orkin said, were “spectacular… remarkable, transformative.” Orkin listed several advantages of the HbF reactivation pathway (as opposed to correctional gene therapy), including the validation provided by Casgevy; the balance of globin gene expression, and the fact it offered “one-stop shopping” for all hemoglobinopathies. But this </span><i><span data-contrast="auto">ex vivo</span></i><span data-contrast="auto"> approach cannot reduce the global burden of SCD and thalassemia, Orkin said. Reasons include high cost, the complex nature of the process, and a lack of infrastructure.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Still,</span> <span data-contrast="auto">the clinical success of Casgevy points to a clear target for small molecule drug discovery programs. </span><b><span data-contrast="auto">“</span></b><span data-contrast="auto">I argue that BCL11A is the preferred target,” Orkin continued. The protein acts directly on the gamma-globin promoter and has a steeper dose-response than other regulators, such as LRF. The protein “looks like spaghetti,” based on AlphaFold, Orkin said. It is an obligate multimer, which is critical for gene repression activity. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Although highly stable, BCL11A is degraded in proteasomes as a monomer, raising the possibility that this pathway provides targeting opportunities for small molecules. “The goal should be development of therapies that can be delivered to the majority, if not all, patients with SCD and thalassemia,” Orkin closed.</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Oxford calling</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">The focus of Thein’s research, beginning in Oxford when she joined Sir David Weatherall’s group in 1982, was a tantalizing question: Why are some patients with beta-thalassemia relatively mild and transfusion-independent?</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Thein focused on two large hemoglobinopathy families, finding high levels of HbF reduced the need for blood transfusions. She also found that HbF levels were independent of inherited mutations in the beta-globin gene. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">In 2007, Thein and colleagues performed a groundbreaking genome-wide association study (GWAS), looking at more than 5,000 participants of Northern European descent. Those with extreme phenotypes were genotyped using a panel of 300,000 single nucleotide polymorphisms. One of the three major signals was an unexpected signal that mapped to chromosome 2, which Thein further refined to the second intron of </span><i><span data-contrast="auto">BCL11A</span></i><span data-contrast="auto">. That unexpected signal eventually became a therapeutic target. </span><span data-ccp-props="{}"> </span></p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p><span data-contrast="auto">Sankaran and Orkin independently confirmed Thein’s findings. That study was published in 2008 in </span><i><span data-contrast="auto">Science. </span></i><span data-contrast="auto">But how to go after </span><i><span data-contrast="auto">BCL11A</span></i><span data-contrast="auto">? Ironically, Sankaran observed, the answer was on the next page of the journal: a landmark paper in the early stages of CRISPR research published by Luciano Marraffini, PhD, and Eric Sontheimer, PhD. “I wish I’d paid more attention!” Sankaran quipped.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Sankaran asked: How can we improve available hemoglobinopathy therapies globally? “We need to invest in all of these pathways—</span><i><span data-contrast="auto">ex vivo</span></i><span data-contrast="auto">, </span><i><span data-contrast="auto">in vivo</span></i><span data-contrast="auto">, and small molecules,” he said. With perfect timing, Sankaran’s team had just published an interesting new candidate for an HbF regulator—BACH2, which inhibits binding of NRF2. Although very early days, inhibiting BACH2 offers another intriguing drug target. “Much more biology remains to be understood,” he said.</span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Gene replacement</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">While the other four awardees played a role in characterizing the Casgevy pathway, Tisdale was recognized for his work as the lead clinical site for the Lyfgenia trial, sponsored by Bluebird. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“When I hit the scene in the ‘90s, we had zero drugs to treat [SCD],” he said. The disease produces complications “literally from head to toe,” including strokes in children. The pain is so crippling that patients “can’t plan and can’t hold a job.” Building on the first allogeneic bone marrow transplant in 1996, by Mark Walters, MD, Tisdale’s group looked for less toxic chemotherapy options and established a non-myeloablative approach.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">“Luigi Naldini threw us a lifeline,” Tisdale said,</span> <span data-contrast="auto">with</span> <span data-contrast="auto">a report in </span><i><span data-contrast="auto">Science</span></i><span data-contrast="auto"> in 1996 that lentiviruses could transduce non-dividing cells (like HSCs). Deleting the 3’ LTR reduced the risk of integration turning on adjacent genes. Tisdale’s group partnered with Bluebird for the HBG-206 clinical trial. While initial results were modest, in the Group C cohort, successfully treated patients behaved as if their disease had resolved to sickle cell trait. Lyfgenia was also approved by the FDA in December 2023 and is currently sponsored by Genetix Pharmaceuticals.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Tisdale was asked how he counsels patients interested in signing up for gene therapy. “Most patients don’t understand the options,” he said. The discussion starts with a bone marrow transplant, but many insist they want gene therapy. “The first thing is to optimize hydroxyurea,” which is an inclusion criterion. “Most [patients have failed to try; many can improve that way, especially children.” </span><span data-ccp-props="{}"> </span></p>
<h4><b><span data-contrast="auto">Cognitive dissonance</span></b><span data-ccp-props="{}"> </span></h4>
<p><span data-contrast="auto">“Our field is facing a moment of cognitive dissonance,” said Bauer, in the fifth and final talk from the 2026 laureates. The excitement over gene therapies is balanced, he said, by</span> <span data-contrast="auto">“the frustration that current therapies are too complex to even dent the global burden of disease.”</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Bauer briefly described </span><a href="https://www.genengnews.com/topics/genome-editing/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration/" target="_blank" rel="noopener"><span data-contrast="none">prime assembly</span></a><span data-contrast="auto">, a new technology from his lab led by grad student Sebastian Levesque, which was published in </span><i><span data-contrast="auto">Nature </span></i><span data-contrast="auto">last month. The technology shows similar activity in dividing and non-dividing cells and “raises the prospect of mutation-agnostic gene correction for many diseases.”</span><span data-ccp-props="{}"> </span></p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p><span data-contrast="auto">At the American Society for Hematology conference in 2016, Bauer recalled showing a slide of a mountain with several paths drawn to the top representing different potential approaches for treating SCD. He juxtaposed that slide with a photo of Casgevy trial volunteer Jimi Olaghere proudly standing at the summit of Mt. Kilimanjaro in 2024. </span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">The field has come a very long way, but still has further to travel.</span><span data-ccp-props="{}"> </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert-foundation-symposium-for-hemoglobinopathy-research/">Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anti&#45;Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified</title>
<link>https://edusehat.com/en/anti-inflammatory-drug-target-for-alzheimers-tbi-and-neurodegenerative-disease-identified</link>
<guid>https://edusehat.com/en/anti-inflammatory-drug-target-for-alzheimers-tbi-and-neurodegenerative-disease-identified</guid>
<description><![CDATA[ A study in human monocyte-derived microglia and human brain tissue slices suggests that inflammatory brain conditions, including traumatic brain injury and neurodegenerative diseases such as Alzheimer&#039;s disease, could be treated using an existing drug candidate targeting P2X7R. 
The post Anti-Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1869420709.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anti-Inflammatory, Drug, Target, for, Alzheimer’s, TBI, and, Neurodegenerative, Disease, Identified</media:keywords>
<content:encoded><![CDATA[<p>The results of research headed by a team at the University of Birmingham suggest that inflammatory conditions in the brain, including traumatic brain injury (TBI) and degenerative diseases such as Alzheimer’s disease and Parkinson’s disease, could be targeted with an existing developmental drug.</p>
<p>Using live cultures of human brain cells and slices of brain tissue obtained during neurosurgery, the researchers, headed by Nicholas Barnes, PhD, professor at the University of Birmingham College of Medicine and Health, investigated the role of the P2X7 receptor, which is responsible for triggering inflammatory signaling. Their findings revealed that these P2X7 receptors drive the release of cytokines involved in controlling inflammation. By blocking this receptor with a specific antagonist, the team was able to significantly reduce the inflammatory response in human brain tissue.</p>
<p>The team suggests that their results could open the door to treating a wide spectrum of chronic neurological conditions, including TBI, neurodegenerative diseases, and even psychiatric disorders such as depression and psychosis, which are increasingly understood to have a neuroinflammatory component.</p>
<p>Barnes said, “This exciting discovery marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source. The identification of this receptor could have far-reaching implications for some of the most debilitating and widespread brain disorders such as Alzheimer’s disease, Parkinson’s, and multiple sclerosis, or inflammation-linked psychiatric conditions like schizophrenia and depression.”</p>
<p>Barnes is senior and corresponding author of the team’s published paper in <em>Brain</em>, titled “<a href="https://doi.org/10.1093/brain/awag068" target="_blank" rel="noopener">P2X7 receptor-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics</a>,” in which they concluded “Our findings provide direct relevant evidence for the use of P2X7R antagonism to inhibit human microglia-mediated inflammation, with arising potential benefits for patients with TBI and other neuroinflammatory diseases.”</p>
<p>TBI is a major cause of death globally, and there are currently there are no approved therapeutic drugs to improve clinical outcomes, “… emphasizing the clear unmet substantial clinical need,” the authors wrote.</p>
<p>The mechanical damage associated with TBI drives a neuroinflammatory response. “The purinergic P2X7 receptor (P2X7R) is a key driver of neuroinflammation in a range of animal models of traumatic brain injury,” the team continued. P2X7R is expressed by microglia, the resident immune cells in the CNS that are involved in many developmental, homeostatic and pathological roles. “It is well recognized that microglial activation and the hostile neuroinflammatory response arising after the initial insult provide a therapeutic window for pharmacological intervention,” the investigators further stated.</p>
<p>For their reported study investigating how brain cells respond to and manage inflammation, the team developed a way of turning a type of white blood cell into microglia, replicating a normal cellular transformation that has recently been identified to occur in the brain as a natural part of human aging. These microglia are the central coordinators of the immune system in the brain.</p>
<p>Using readily accessible human peripheral monocytes taken from blood samples, the researchers converted them into microglia-like cells—human monocyte-derived microglia (hMDM)—that were used to see how microglia are likely to respond to the inflammation signals. “This enabled us to demonstrate the ability of clinically relevant P2X7R antagonists, including brain-penetrant molecules, to curtail pro-inflammatory cytokine release,” they wrote.</p>
<p>The team showed that administering a P2X7 receptor antagonist interrupted the triggers that these microglia give off as they are damaged and die. Barnes said, “Studying human microglia has long been a major challenge: once removed from their native brain environment, they rapidly lose their defining characteristics, likely due to the absence of critical regulatory signals. Our approach involved the use of monocyte-derived microglia which provide a powerful, scalable, and virtually unlimited platform for studying human microglial biology with unprecedented precision.”</p>
<p>The team confirmed their results using adult human precision-cut brain slices that had been generated subsequent to neurosurgical resections. “Having identified the response in the human monocyte-derived microglia, this provided the impetus to translate these findings with human brain obtained following neurosurgical procedures, Barnes continued. “This successful translation means the next stage for this research is the development of clinical trials in patients with neurodegenerative conditions and patients with TBI where there are no effective pharmacological treatments to reduce the neuroinflammation and arising damage.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>In their paper the authors concluded, “The present study provides direct translational evidence from human cellular and brain tissue models to support the clinical use of P2X7R antagonists to limit secondary ATP-driven neuroinflammatory events, such as those that occur in TBI, and thus might improve the clinical outcomes for patients.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/anti-inflammatory-drug-target-for-alzheimers-tbi-and-neurodegenerative-disease-identified/">Anti-Inflammatory Drug Target for Alzheimer’s, TBI, and Neurodegenerative Disease Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Phage Proteases Trigger a Conserved Bacterial Antiviral Defense Pathway</title>
<link>https://edusehat.com/en/phage-proteases-trigger-a-conserved-bacterial-antiviral-defense-pathway</link>
<guid>https://edusehat.com/en/phage-proteases-trigger-a-conserved-bacterial-antiviral-defense-pathway</guid>
<description><![CDATA[ Researchers have uncovered how phage proteases activate CBASS antiphage immunity, revealing a novel bacterial virus-sensing mechanism that could inform development of more effective phage therapies.
The post Phage Proteases Trigger a Conserved Bacterial Antiviral Defense Pathway appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Bacteriophage_T4_Infection-e1791216945478.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 06:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Phage, Proteases, Trigger, Conserved, Bacterial, Antiviral, Defense, Pathway</media:keywords>
<content:encoded><![CDATA[<p>Phages continue to garner excitement as potential treatments for bacterial infections, with a particular interest in targeting infections that are growing increasingly more difficult to treat with antibiotics. There are several challenges in that area of development, including that bacteria have their own defense systems against viruses.</p>
<p>Now, new research has revealed that bacteria detect viruses when a viral enzyme cuts an important sensor molecule in the bacterium, kicking off the immune response. Discoveries of bacterial defenses can pave the way for the development of better phage therapies that can evade the bacterial immune system.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The results are published in <em>Science </em>in the paper, “<a href="https://www.science.org/doi/10.1126/science.aeg3949" target="_blank" rel="noopener">Phage proteases activate CBASS antiphage immunity</a>.”</p>
<p> “This is one of the most common forms of bacterial immunity, so when we finally figured it out, it was a total eureka moment,” said Sam Hobbs, PhD, assistant professor of biochemistry at University of Utah Health.</p>
<p>One component of the bacterial immune system is the cyclic oligonucleotide–based antiphage signaling systems (CBASS) which lead to a “last resort” immune response that kills the bacterium before viruses can spread to neighbors.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Precise sensing of the viral trigger is a necessity. In CBASS, cGAS/DncV-like nucleotidyltransferase (CD-NTase) enzymes sense phage infection and synthesize nucleotide signals to initiate antiviral defense. This new work found that the sensing mechanism detects a molecule that the virus needs to survive. More specifically, that phage prohead protease activity is a widespread mechanism of CD-NTase activation.</p>
<p>“We found that the protease from the phage actually acts directly on the host protein, and that is the signal that turns on the whole signaling pathway,” explained Hobbs.</p>
<p>This trigger mechanism is distinct when compared to related antiviral immune pathways, which are activated by the presence of viral genetic material. “This is a totally new mechanism for how these host proteins are activated,” Hobbs said.</p>
<p>Hobbs added that understanding CBASS may advance our knowledge of the human immune system. CBASS is related to a similar immune pathway in humans, indicating that this pathway has persisted at least since bacteria and humans had a common ancestor. And because bacteria have such a rapid life cycle, scientists can use them to very quickly answer questions about how the immune system works, which they can then test in models closer to people.</p>
<p>“The fact that these systems are conserved between bacteria and humans suggests that they’ve been maintained in these different organisms for that entire evolutionary trajectory,” Hobbs said. “The cells are telling us that this is a really important pathway because they’ve maintained it for billions of years. It’s incredibly fascinating, and it’s a cool window into what’s important in maintaining the ability to fight viruses.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/phage-proteases-trigger-a-conserved-bacterial-antiviral-defense-pathway/">Phage Proteases Trigger a Conserved Bacterial Antiviral Defense Pathway</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>HORIBA Expands Customer&#45;Focused Solutions with New East Coast Analytical Solution Plaza</title>
<link>https://edusehat.com/en/horiba-expands-customer-focused-solutions-with-new-east-coast-analytical-solution-plaza</link>
<guid>https://edusehat.com/en/horiba-expands-customer-focused-solutions-with-new-east-coast-analytical-solution-plaza</guid>
<description><![CDATA[ HORIBA recently unveiled an Applications Solutions Plaza (ASP) at its Piscataway, New Jersey facility. The ASP allows customers to bring samples for testing or receive on-site demonstrations using modular, laboratory setups configured around specific pain points.
The post HORIBA Expands Customer-Focused Solutions with New East Coast Analytical Solution Plaza appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/GettyImages-1432981265_2000px.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 06 Oct 2026 03:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>HORIBA, Expands, Customer-Focused, Solutions, with, New, East, Coast, Analytical, Solution, Plaza</media:keywords>
<content:encoded><![CDATA[<p><span>Last week, I drove to HORIBA’s facility in Piscataway, New Jersey to witness the ceremonial grand opening of its Analytical Solution Plaza (ASP), about 15,000 square feet of space within the larger facility that has been transformed into a lab environment focused squarely on working on applications and methods development with customers across multiple industries including materials, semiconductors, energy, life science, and biopharma. Over several hours, company representatives shared details of the company’s history, its current business, and specific plans for the new ASP and how it fits into HORIBA’s broader corporate strategy.</span></p>
<p><span>The New Jersey ASP is the 19<sup>th</sup> to open globally, with the first launching in Japan and then expanding globally to facilities in places like China, the United Kingdom, and now the United States. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>During his opening remarks, Koutara Kato, executive vice president and assistant general manager, commercial operations, at HORIBA Instruments Incorporated, highlighted some of the industries that HORIBA is involved in, such as the semiconductor market, as well as where it plans to concentrate additional resources in future. That list includes energy and environment as well as biopharma and healthcare. Each area the company focuses on “gives us a lot of opportunities and challenges,” he said.</span></p>
<figure aria-describedby="caption-attachment-338814" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338814" src="https://www.genengnews.com/wp-content/uploads/2026/10/HORIBA-US-leadership-300x242.jpg" alt="Some members of the HORIBA team at the event. From L to R: Koutara Kato, executive vice president and assistant general manager, commercial operations; Jeff Julien, PhD, life science applications manager; and Jon Goldey, Manager, Administrative Operations." width="300" height="242" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/HORIBA-US-leadership-300x242.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/HORIBA-US-leadership.jpg 400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Some members of the HORIBA leadership team at the event. From L to R: Koutara Kato, executive vice president and assistant general manager, commercial operations; Jeff Julien, PhD, life science applications manager; and Jon Goldey, administrative operations manager. [GEN]</figcaption></figure>
<p><span>ASPs provide a space for HORIBA to apply its technology and scientific expertise to customers’ challenges and try to find possible solutions. It could especially benefit customers working with tight budgets amidst rising costs for lab equipment, space, and other factors, noted Michael Oweimrin, national sales manager at HORIBA, in his remarks. “We have a plethora of capabilities to address many different markets.” </span></p>
<p><span>Over 280 heads at HORIBA report to the New Jersey facility which is about 130,000 square feet. And roughly 200 people work at the site. Among other features, the ASP features multiple labs, where HORIBA scientists work on customer projects as well as technical rooms for training application scientists. A key part of the ASP is its modularity. Instruments are placed or bolted to tables with wheels making it possible to move them seamlessly between labs as needed. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>A tour of a section of HORIBA’s facility, following the opening remarks and a traditional sake barrel opening ceremony, revealed space for stockrooms, manufacturing, and rooms testing and quality control as well as for training field service engineers. The tour included a look at the ASP labs where scientists leverage HORIBA’s expertise in instruments for modular spectroscopy, particle characterization, and Raman microscopy. Scientists in the ASP labs utilize these technologies to address applications in energy and environment, healthcare, and materials and semiconductors. They utilize HORIBA instruments including LabRAM Odyssey and LabRAM Soleil Raman microscopes as well as the Veloci Biopharma Analyzer, which is designed specifically for biopharma and pharma applications. </span></p>
<p><span>Crucially, the ASP is HORIBA’s answer to an important question, Jeff Julien, PhD, life science applications manager at HORIBA, said in his opening comments. Specifically, “how to leverage what HORIBA does well” to shift the conversation from “what instrument is needed” to “what problem to solve.” Using biopharma as an example, he noted that companies developing therapeutic proteins often rely on input from multiple instruments and techniques during development. These are capabilities that the ASP scientists can provide, he said. </span></p>
<figure aria-describedby="caption-attachment-338816" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-338816" src="https://www.genengnews.com/wp-content/uploads/2026/10/Sake_barrel_HORIBA-300x193.jpg" alt="Members of the HORIBA team at the event participate in a traditional sake barrel opening ceremony as part of the launch [Credit: HORIBA]." width="300" height="193" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Sake_barrel_HORIBA-300x193.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Sake_barrel_HORIBA.jpg 400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Members of the HORIBA leadership team at the event participate in a traditional sake barrel opening ceremony as part of the launch. [HORIBA]</figcaption></figure>
<p><span>As noted earlier, in each ASP lab, instruments sit on modular wheel-based carts and lab benches. This makes it possible to reconfigure the lab space for different customers’ pain points as well as to bring in technologies that  “we think could be applicable to those use cases,” Julien said. “It’s really an exciting time to be a part of HORIBA and doing this ASP development” particularly “as the markets change in terms of requirements and what customers are after,” he added. “It changes the way we think [and] the way we approach all of these problems.”</span></p>
<h4><b>Shifting from sales to solutions</b></h4>
<p><span>HORIBA’s ASPs  reflect a broader corporate strategy to move beyond purely transactional sales towards problem-solving partnerships. In the NJ facility, the focus is specifically in the life science and biopharma sectors. Here, HORIBA is positioning its core technologies as an underutilized set of orthogonal tools for various applications including biotherapeutic characterization.</span></p>
<p><span>To be clear, HORIBA’s primary business is still selling instrumentation, but moving forward, the company wants to do more to help customers utilize its instruments to solve problems, Kato said during a conversation with the press where he discussed some of the thinking behind setting up the ASP. “If a customer [is] facing some issues and difficulties, prior to having those instrumentation, we can address this” through the ASP, he said, by showing them how they can use HORIBA’s instruments and what kinds of outcomes they can expect. In most cases, to use the ASP’s capabilities, customers bring samples in and work with HORIBA scientists and tools. There are some cases where HORIBA can deliver needed instruments to customers’ labs to run their analysis on site.  </span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>The company has no current plans to increase its headcount, rather it is leveraging expertise it already has in house to support customers looking to utilize the ASP’s capabilities. There are a few types of customer profiles that ASP scientists are working with and these typically are people working in research and development with specific pain points that they hope HORIBA’s fluorescence or Raman spectroscopy or its particle characterization capabilities could solve, Julien explained. </span></p>
<p><span>Feasibility testing is a key step, often starting with simplified samples before graduating to real process samples. HORIBA emphasizes rapid pivoting between fluorescence, Raman, and particle characterization depending on what customer samples reveal. </span></p>
<p><span>For example, “perhaps we’re anticipating [doing] a demo with fluorescence and we very quickly learn more about the customer samples or their process and then say … we need to pivot to Raman because that’s actually going to be a better fit for your use case,” he explained. Furthermore, “if we’ve exhausted our options in terms of what we think we can provide as a solution and it’s not meeting customer needs, we then can engage in conversation and … perhaps work together and develop a custom solution or a fit for purpose solution that’s going to meet those particular needs.”</span></p>
<p><span>HORIBA plans to launch additional ASPs in other locations—setups differ across the company’s offices. The strategy is one ASP per country in strategic locations rather than multiple per country, Kato said. This way, rather than having U.S. customers send samples all the way to an ASP in Japan, for example,, they can access a facility closer to them. ASPs are also customized to local industry needs, for example the ASP in Taiwan is semiconductor focused. The U.S. ASP leverages HORIBA’s location in the tri-state biopharma corridor. Conversations with company representatives highlighted HORIBA’s intent to make deeper inroads into the biopharma and life sciences market in particular.  </span></p>
<p><span>One area that the company is interested in broadening its footprint is in the biotherapeutics market. A key solution for the market is the Veloci Biopharma Analyzer which is designed for tasks such as analyzing antibody-drug conjugates, differentiating AAV subtypes, and for analyzing protein stability, among others. “We [are] now in an age where for a lot of therapeutics … [with] some of these stable technologies like near-IR that have been used historically … you’re infringing on the limits of detection for that technology” leading customers to seek out novel orthogonal measurement methods, Julien said. “That’s ultimately where we feel like we can add value.”</span></p>
<p><span>The company is working on some new products but HORIBA representatives declined to provide specific details about what they are. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/horiba-expands-customer-focused-solutions-with-new-east-coast-analytical-solution-plaza/">HORIBA Expands Customer-Focused Solutions with New East Coast Analytical Solution Plaza</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>2026 Nobel Prize for Physiology and Medicine Goes to Optogenetics, Light&#45;Gated Ion Channels</title>
<link>https://edusehat.com/en/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels</link>
<guid>https://edusehat.com/en/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels</guid>
<description><![CDATA[ Today, the 2026 Nobel Prize for Physiology and Medicine has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.
The post 2026 Nobel Prize for Physiology and Medicine Goes to Optogenetics, Light-Gated Ion Channels appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-2266497868.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 23:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>2026, Nobel, Prize, for, Physiology, and, Medicine, Goes, Optogenetics, Light-Gated, Ion, Channels</media:keywords>
<content:encoded><![CDATA[<p>The Nobel Prize in Physiology or Medicine 2026 has been awarded to Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD, for their discoveries of light-gated ion channels and optogenetics.</p>
<figure aria-describedby="caption-attachment-338818" class="wp-caption alignleft"><img decoding="async" class="wp-image-338818 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg" alt="Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD" width="300" height="132" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-300x132.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine-768x338.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/2026NobelPrizePhysiologyMedicine.jpg 855w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text"><em>The 2026 Nobel Prize in Physiology or Medicine winners Karl Deisseroth, MD, PhD, Peter Hegemann, PhD, and Georg Nagel, PhD.</em></figcaption></figure>
<p>Deisseroth is a Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University and an HHMI Investigator; Hegemann is the Hertie Senior Research Chair for Neurosciences and a professor of Experimental Biophysics at Humboldt University and Nagel is a professor at the Department for Neurophysiology at the University of Würzburg, in Germany.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” says Per Svenningsson, MD, PhD, Chair of the Nobel Committee for Physiology or Medicine.</p>
<p>Although optogenetics is a relatively new technology, the seminal paper from the Deisseroth lab was published in 2005. However, the concept of manipulating specific neuronal cell types within intact circuits on a millisecond timescale was considered long before. Indeed, Francis Crick, PhD, once proposed a method where “all neurons of just one type could be activated or inactivated, leaving the others more or less unaltered.” He speculated that to “turn the firing of one or more types of neurons on and off in the alert animal in a rapid manner … the ideal signal would be light,” acknowledging at the time that his idea was “rather far-fetched.” In addition, scientists have been working on laying the foundation for this technology since the 1970s. For example, when Richard Fork, PhD, at Bell Laboratories in New Jersey at the time, published the stimulation of neurons in<em> Aplysia</em> with laser light in <em>Science</em>.</p>
<p>It was the discovery of the algal protein channelrhodopsin that led the way in making the vision into a reality. Microbial rhodopsins—found across archaea, eubacteria, and eukaryotic microalgae—harness light for cellular bioenergetics. Channelrhodopsin is found on the surface of C<em>hlamydomonas</em>, a single-celled alga with the ability to swim towards a light source. Researchers discovered that the protein can directly convert photon energy into transmembrane ion flux.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The first direct evidence of a light-gated ion channel was named channelrhodopsin-1 (ChR1), discovered and coined by the Hegemann lab. The arguably more consequential breakthrough came just a year later: a collaborative team led by Georg Nagel, demonstrated that a second protein, named channelrhodopsin-2 (ChR2), functioned distinctly from ChR1, and exhibited a blue-shifted activation spectrum and operated as a broad, non-selective cation channel.</p>
<p>Finding a microbial protein that could act as a single unit, simultaneously as a photoreceptor and an ion channel, and the discovery that ChR1 and ChR2 were single-component, light-gated ion channels, provided the precise tools that neuroscientists had been looking for—for fast, genetically targetable optical activation of neurons.</p>
<p>The team in the Deisseroth lab took the baton and performed the first successful demonstration that ChR2 could be expressed in neurons, using a construct provided by Nagel. They introduced the gene for channel-rhodopsin into nerve cells from rats and was able to trigger a nerve signal by illuminating the cells with blue light.</p>
<p>Deisseroth’s lab published this breakthrough in 2005 in the <em>Nature Neuroscience</em> paper, “<a href="https://www.nature.com/articles/nn1525" target="_blank" rel="noopener">Millisecond-timescale, genetically targeted optical control of neural activity</a>.” The study demonstrated that expressing the microbial protein channelrhodopsin-2 (ChR2) from green algae in cultured mammalian neurons allowed precise, millisecond-timescale control of action potentials using flashes of blue light.</p>
<p>The paper’s first author was Ed Boyden, PhD, professor in Neurotechnology at MIT who has been developing the field of optogenetics for the past two decades. Interestingly, CRISPR pioneer Feng Zhang, PhD, is the second author on the 2005 paper. Two years later, Deisseroth’s lab made this light-controlled switch for nerve cells work in the brains of living mice.</p>
<p>Over the past two decades, optogenetics has been used to unpack many biological questions, primarily (but not exclusively) in the field of neuroscience. One early <em>in vivo</em> application of optogenetics probed the causal relationship between the activation of orexin/hypocretin neurons in the lateral hypothalamus and the transitions from sleep to wakefulness. Other notable applications were the search for the memory engram—the physical cellular substrate encoding a specific memory—and unpacking the complexity of dopaminergic neurons in the retina, showing that functionally distinct dopaminergic populations are anatomically intermingled yet strictly segregated by their circuit connectivity.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Optogenetics has also moved into clinical applications, such as the expression of ChR2 in retinal circuitry. In one experiment, intraocular injection of an adeno-associated viral (AAV) vector encoding ChR2 led to expression in retinal ganglion cells in rodents. More specifically, light depolarized the ChR2 expressing retinal ganglion cells, restoring retinal photosensitivity and allowing light signals to reach the visual cortex in a mouse model of retinitis pigmentosa. Expression of ChR2 in surviving retinal neurons could therefore serve as a potential strategy for restoring vision after rod and cone degeneration.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/2026-nobel-prize-for-physiology-and-medicine-goes-to-optogenetics-light-gated-ion-channels/">2026 Nobel Prize for Physiology and Medicine Goes to Optogenetics, Light-Gated Ion Channels</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO on the American Road visits pioneering NC biotech hub</title>
<link>https://edusehat.com/en/bio-on-the-american-road-visits-pioneering-nc-biotech-hub</link>
<guid>https://edusehat.com/en/bio-on-the-american-road-visits-pioneering-nc-biotech-hub</guid>
<description><![CDATA[ Research Triangle Park resurgent with billions in investment in biotechnology manufacturing. With a famous biotech cluster in Research Triangle Park (RTP) established almost 70 […]
The post BIO on the American Road visits pioneering NC biotech hub appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/JFC-and-Deborah-Ross.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 16:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, the, American, Road, visits, pioneering, biotech, hub</media:keywords>
<content:encoded><![CDATA[<h4>Research Triangle Park resurgent with billions in investment in biotechnology manufacturing.</h4>
<p><span>With a famous biotech cluster in Research Triangle Park (RTP) established almost 70 years ago, North Carolina is already a powerhouse of pharmaceutical R&D and manufacturing, and recent expansion plans worth billions of dollars will continue growth into the future.</span></p>
<p><span>A delegation from the Biotechnology Innovation Organization (BIO), led by BIO President & CEO John F. Crowley, learned about North Carolina’s biotech industry on an Oct. 2 visit to RTP, a 7,000-acre complex spread across the three cities of Raleigh, Durham, and Chapel Hill, N.C. It was the latest stop of the BIO on the American Road learning and networking tour of America’s biotech ecosystems.</span></p>
<p><span>BIO’s delegation met local members of industry, patient advocates, and Rep. Deborah Ross (D-NC), a champion of IP rights and biotech (<em>pictured at top, with Crowley</em>). The BIO delegation also toured the RTP facilities of Biogen, which are currently undergoing a $2 billion expansion.</span></p>
<p><span>“Companies come to North Carolina and RTP because of the investments, talent, partnerships and strong support from elected leaders, like Rep. Ross, that make innovation possible,” said Crowley. “RTP has built an ecosystem where biotechnology companies can develop medical breakthroughs and manufacture them right here in America. </span><span>The U.S. must continue to lead in biotechnology, and that requires building a stronger American biotech industry. North Carolina and RTP are demonstrating the power of bringing innovation, investment and manufacturing together.”</span></p>
<p><span>Biotech R&D, manufacturing, and distribution are all well represented in North Carolina, where the life sciences employed 103,107 as of 2024, according to a</span><a href="https://www.ncbiotech.org/sites/default/files/2025-01/NCBiotech%202024-TEConomy.pdf"> <span>TEConomy NCBiotech report</span></a><span>. These workers belonged to nearly 6,700 state businesses working in biotech, the report said.</span></p>
<p><span>BIO’s delegation met with several innovation leaders at an industry roundtable hosted at the offices of the North Carolina Biotech Center (NCBiotech). Founded in 1984, NCBiotech was the first state-sponsored initiative of its kind to support the biotech industry. They seek to “create North Carolina’s competitive advantage in the life sciences by engaging partners, maximizing opportunities, and delivering solutions to accelerate innovation, investment, and job creation.”</span></p>
<p><span>BIO also hosted a luncheon with patient advocates from across the state and met with  Rep. Ross, who represents the RTP area, at Biogen’s impressive manufacturing campus, which has roots dating back 30 years in the area.</span></p>
<p><span>Rep. Ross sits on the  House Judiciary Committee and has authored and supported several bills promoting IP and biotech.</span></p>
<p><span>Ross recently cosponsored</span><a href="https://www.biotech.senate.gov/press-releases/bipartisan-senate-and-house-members-introduce-legislation-to-boost-american-biotech-manufacturing-infrastructure-and-innovation/"> <span>H.R. 6089, the Biomanufacturing Excellence Act of 2025</span></a><span> which would establish a public-private partnership to allow innovators to scale their products in the U.S. with smarter, faster, more efficient manufacturing practices. The bill was inspired by recommendations from the National Security Commission on Emerging Biotechnology’s April 2025 Action Plan for Congress.</span></p>
<p><span>“I’m proud to represent North Carolina’s Research Triangle, where universities, startups, and major institutions are constantly pushing the boundaries of what’s possible,” Rep. Ross said. “That’s why I was grateful to visit Biogen’s RTP campus in Morrisville for an important discussion about the future of biomanufacturing in North Carolina. Biomanufacturing is a pillar of our economy and workforce, creating good-paying jobs and attracting some of the brightest minds to our community. It’s more important than ever that we develop new medications here at home that are accessible and affordable.”</span></p>
<h2>‘Bipartisan support for biotech’</h2>
<div class="gs">
<div class=" ">
<div class="ii gt adO">
<div class="a3s aiL ">
<div dir="ltr">
<div>
<p dir="ltr">In her work on IP, Rep. Ross has collaborated with another North Carolina legislator, Sen. Thom Tillis (R-NC), according to Laura Gunter, President of NCLifeSci, BIO’s affiliate in the state.</p>
<p dir="ltr">Gunter praised the pro-biotech work of North Carolina’s federal delegation in general. Reps. Gregory Murphy, M.D. (R-NC), Don Davis (D-NC), and Richard Hudson (R-NC)<a href="https://bio.news/health/epic-act-introduced-to-correct-iras-pill-penalty/" target="_blank" rel="noopener" data-saferedirecturl="https://www.google.com/url?q=https://bio.news/health/epic-act-introduced-to-correct-iras-pill-penalty/&source=gmail&ust=1791210808119000&usg=AOvVaw3B_EJDjUGN6YO4WWqH8u36"> introduced the EPIC Act</a>, designed to give small molecules the same protection from drug price negotiations as biologics. Tillis and Sen. Ted Budd (R-NC) co-sponsored EPIC in the Senate.</p>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span>“Given the high level of biotech employment, the importance of the industry’s supply chain and research activities around the state, we see a lot of good bipartisan support for biotech from our federal delegation,” said Gunter.</span></p>
<p><span>She said NCLifeSci receives assistance and guidance from BIO when addressing federal issues that matter for North Carolina. These include: federal funding for the state’s top-tier research (R1) universities; SBIR federal seed funding for early-stage research; and national security priorities outlined by the NSCEB, Gunter said.</span></p>
<p><span>Founded in the early 1990s, NCLifeSci has focused on state policy affecting biotech.</span></p>
<p><span>“We’ve been able to have a real impact on the industry overall on the state level,” said Gunter. This has included “being one of the first states to really incorporate a matching fund for federal SBIR dollars,” getting state support for workforce development training programs, and tax incentives.</span></p>
<p><span>NCLifeSci was instrumental in establishing the NC Life Sciences Caucus, made up of lawmakers from both parties in both the state House and state Senate. Among its pro-biotech efforts, the Life Sciences Caucus supported the introduction of the first omnibus life sciences appropriation bill for inclusion in the state budget, NCLifeSci helped write the bill.</span></p>
<p><span>“Measures that matter to the industry were grouped in an omnibus package with the goal of saying, here’s a number of areas where the state can contribute to North Carolina’s life sciences,” Gunter said.</span></p>
<p><span>The pro-biotech policy environment and the existence of institutions like NCBiotech help North Carolina build one of the country’s leading biotech ecosystems, according to Gunter. Other attributes of that ecosystem include five R1 research universities, a broad range of small biotechs, a large concentration of clinical research organizations, and manufacturers—from major pharma firms to contract development manufacturing organizations.</span></p>
<p><span>“So we have the full soup-to-nuts of the biotech ecosystem, and it really works well together,” Gunter said.</span></p>
<h2>Biogen’s growth</h2>
<p><span>BIO’s team joined Rep. Ross for a tour of the RTP facilities of BIO member Biogen, a leading biotech company developing innovative treatments in neurology, immunology, and rare diseases. With more than 1,500 manufacturing and technical employees and more than 400 skilled contractors, Biogen is the largest biotech employer in North Carolina, and they’re still growing.</span></p>
<figure aria-describedby="caption-attachment-6498" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-6498 size-medium" src="https://bio.news/wp-content/uploads/2026/10/visit-to-biogen-350x165.jpg" alt="BIO North Carolina" width="350" height="165" srcset="https://bio.news/wp-content/uploads/2026/10/visit-to-biogen-350x165.jpg 350w, https://bio.news/wp-content/uploads/2026/10/visit-to-biogen.jpg 600w" sizes="(max-width: 350px) 100vw, 350px"><figcaption class="wp-caption-text">Visiting Biogen’s facilities.</figcaption></figure>
<p><span>“Biogen announced a $2 billion investment in our existing Research Triangle Park (RTP), North Carolina manufacturing footprint in July 2025, and we’ve continued to progress this multi-project strategic investment plan since our announcement,” said Nicole Murphy, Biogen Executive Vice President and Head of Pharmaceutical Operations and Technology. “This year, Biogen’s facility in RTP has executed approximately $200 million year-to-date, supporting progress across multiple modality expansions, including a new ASO (antisense oligonucleotide) purification factory and additional synthesis capabilities.”</span></p>
<p><span>The expansion will also add new clinical product assembly and packaging capabilities, utility, environmental, and infrastructure improvements, continued digitalization and AI-enabled roadmap deployment, and initial engineering work for future biologics, fill-finish, lyophilization, and oral solid dose capabilities.</span></p>
<p><span>“The work happening here is helping Biogen reliably produce medicines for patients today while also building the capabilities we will need for the future,” Murphy said. “Given recent acquisitions, we are also evaluating additional potential investment opportunities based on our late-stage portfolio.”</span></p>
<p><span>While Biogen is headquartered in Kendall Square in Cambridge, MA, and has a new facility in San Francisco, it mainly conducts its U.S. manufacturing in North Carolina.</span></p>
<p><span>“RTP has become our largest manufacturing footprint because it offers the right environment for advanced biomanufacturing,” Murphy said. “You have leading universities, research institutions, life sciences companies and a deep technical workforce all in one region.”</span></p>
<p><span>Biogen is not just a beneficiary of the biotech expertise in RTP, it is also a major contributor to the ecosystem, Murphy noted.</span></p>
<p><span>“Biogen brings a large, established, and advanced manufacturing presence to RTP, along with continued investment in high-quality jobs, technical capabilities, and infrastructure. Our presence helps strengthen the broader life sciences ecosystem by creating opportunities for collaboration, training, and workforce development,” Murphy said. “We also work with local institutions and programs to help build pathways into biotech manufacturing careers, which is important both for Biogen and for the region’s long-term growth.”</span></p>
<p><span>Biogen’s North Carolina expansion is just one of several announced recently. Others include:</span></p>
<ul>
<li aria-level="1"><span> </span><span>BIO member</span><a href="https://www.gene.com/media/press-releases/15122/2026-08-18/genentech-marks-topping-out-milestone-fo"> <span>Genentech said it is planning to invest $2 billion</span></a><span> in its first East Coast manufacturing facility in Holly Springs, NC.</span></li>
<li aria-level="1"><span>BIO member</span><a href="https://www.novartis.com/news/media-releases/novartis-announces-plans-build-flagship-manufacturing-hub-north-carolina"> <span>Novartis said in November it will build</span></a><span> a flagship manufacturing hub in North Carolina, which will create an additional 700 jobs.</span></li>
<li aria-level="1"><a href="https://news.abbvie.com/2026-04-22-AbbVie-Selects-North-Carolina-for-New-1-4-Billion-Manufacturing-Campus"><span>AbbVie announced plans</span></a><span> for a $1.4 billion manufacturing facility in North Carolina in April.</span></li>
</ul>
<p><span>“North Carolina’s biotech sector is rooted in a long tradition of innovation, and its momentum continues to grow,” Crowley observed.</span></p>
<figure aria-describedby="caption-attachment-6501" class="wp-caption alignnone"><img decoding="async" class="wp-image-6501 size-full" src="https://bio.news/wp-content/uploads/2026/10/patient-luncheon.jpg" alt="NC BIO on the American Road" width="800" height="562" srcset="https://bio.news/wp-content/uploads/2026/10/patient-luncheon.jpg 800w, https://bio.news/wp-content/uploads/2026/10/patient-luncheon-350x246.jpg 350w, https://bio.news/wp-content/uploads/2026/10/patient-luncheon-768x540.jpg 768w" sizes="(max-width: 800px) 100vw, 800px"><figcaption class="wp-caption-text">The luncheon with patient advocates.</figcaption></figure>
<p>The post <a href="https://bio.news/state-policy/bio-on-the-american-road-visits-pioneering-nc-biotech-hub/">BIO on the American Road visits pioneering NC biotech hub</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tariffs’ drag on innovation compounded by lack of guidance, experts say</title>
<link>https://edusehat.com/en/tariffs-drag-on-innovation-compounded-by-lack-of-guidance-experts-say</link>
<guid>https://edusehat.com/en/tariffs-drag-on-innovation-compounded-by-lack-of-guidance-experts-say</guid>
<description><![CDATA[ Continuing confusion about compliance is exacerbating the harms that new pharmaceutical tariffs cause the biotech industry, especially small innovative firms, experts say. Tariffs of […]
The post Tariffs’ drag on innovation compounded by lack of guidance, experts say appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/10/elevate-dI-aXC7DWpQ-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 05 Oct 2026 16:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tariffs’, drag, innovation, compounded, lack, guidance, experts, say</media:keywords>
<content:encoded><![CDATA[<p><span>Continuing confusion about compliance is exacerbating the harms that new pharmaceutical tariffs cause the biotech industry, especially small innovative firms, experts say.</span></p>
<p><span>Tariffs of up to 100% on patented pharmaceuticals and their ingredients that went into effect Sept. 29 are expected to increase costs for innovators, discourage drug development and investment, and potentially reduce patient access to drugs they need. They also weaken U.S. competitiveness at a time when China is seeking to replace America as the world leader in biotech, experts say.</span></p>
<p><span>Meanwhile, the lack of information on how to comply with the Administration’s guidance on tariff implementation is creating chaos that complicates day-to-day operations of drug makers, according to the biotech industry. Innovators of all sizes have questions, ranging from types of patents that will be considered to the process and criteria for seeking an exemption to the tariffs.</span></p>
<p><span>“With these tariffs, the United States has reversed decades of sound trade policy, creating new uncertainty for biotech innovators, and increasing the burden on the small- and mid-sized companies responsible for many of tomorrow’s breakthrough medicines,” according to a statement from the Biotechnology Innovation Organization (BIO).</span></p>
<p><span>As</span><a href="https://www.bio.org/toolkit/human-health/americas-innovation-engine-power-small-and-mid-sized-biotechs"> <span>BIO research shows</span></a><span>, small- to medium-sized biotechs are responsible for 71% of the industry’s output and 54% of the new drug applications. The smaller innovative companies generally have less available capital to adjust to shocks like tariffs or to take moves that could reduce the tariff burden, experts noted.</span></p>
<p><span>The tariffs are being implemented after a Department of Commerce Section 232 investigation determined that global supply chains are risky, and concluded that onshoring drug production bolsters national security. Yet, experts argue that the additional obstacles to global networks posed by the tariffs will weaken the supply chain and reduce our access to medicines we need.</span></p>
<p><span>Companies that agree to move their production to the U.S. can apply for reductions in tariffs, but this relief is out of reach for most small biotechs, which must outsource all of their production. Suddenly shifting their complex manufacturing processes from overseas contractors may be impossible, says Marta Wosińska, a senior fellow at the Brookings Institution, according to Axios.</span></p>
<p><span>These smaller firms also generally lack in-house capacity to adjust to new tariff reporting burdens for compliance, experts say.</span></p>
<h2><b>Insufficient guidance</b></h2>
<p><span>But even those firms seeking to comply do not have adequate guidance to do so, experts say.</span></p>
<p><span>As</span><a href="https://bio.news/federal-policy/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking/"> <span>Bio.News reported on Sept. 14</span></a><span>, with two weeks until implementation, much of the necessary federal guidance was still missing, including information on how to qualify for exemptions based on the type of drug being imported, the country of origin, and engagement in Most Favored Nation (MFN) pricing agreements or onshoring commitments.</span></p>
<p><span>On Sept. 23, days before the tariff went into effect, the Department of Commerce did issue </span><a href="https://www.federalregister.gov/documents/2026/09/23/2026-19498/guidance-and-procedures-for-implementing-tariff-adjustments-for-specialty-pharmaceuticals-and"><span>new guidance</span></a><span>, but “its guidance has created more confusion,” according to a Sept. 27</span><a href="https://www.wsj.com/opinion/the-u-s-tariff-attack-on-u-s-biotech-c3406b92"> <span>Wall Street Journal editorial</span></a><span>.</span></p>
<p><span>“Biotech companies will have to apply for exemptions for each individual product, regardless of whether it meets one of the specified categories, and explain ‘why the import meets an urgent U.S. health need.’ Urgent will be in the eyes of the bureaucrats who rarely act with urgency,” says the editorial.</span></p>
<p><span>Indeed, the Commerce Department’s guidance does not seem to offer hard, fast rules on the definition of “urgent U.S. health need”, nor provide clarity on the criteria that Commerce will use to make case-by-case determinations.</span></p>
<p><span>“The rationale can include information such as the type of disease the product treats and an assessment of alternative therapies or lack of alternative therapies for the type of disease the product treats, the number of U.S. patients that use the product, and whether or not the product is available in other jurisdictions,”</span><a href="https://www.federalregister.gov/d/2026-19498/p-32"> <span>the Commerce department’s guidance says</span></a><span>. While the guidance notes. “Commerce will make an individual, fact-specific, company-specific decision for each request.”</span></p>
<p><span>There is no set time frame for these decisions, and companies still don’t know if those that are ultimately granted exemptions will have to pay full tariffs first and ask for refunds later.</span></p>
<h2><b>The challenge to competition</b></h2>
<p><span>Experts expressed concerns that both tariffs and the cost of compliance will eat away at funding that could be used for research, harming America’s competitiveness and the future of innovative therapies for the American people.</span></p>
<p><span>“One small company says tariff compliance could consume 2% to 4% of its working capital before it commercializes its first medicine,” says The Wall Street Journal’s editorial. “That means less money for research. It’s hard enough developing a new drug. Tariffs add more uncertainty that will discourage investment in U.S. biotech.”</span></p>
<p><span>While the justification given for the tariffs is strengthening national security, experts worry that by harming America’s ability to invest in biotech research, it will have the opposite effect.</span></p>
<p><span>“At a time when the United States should strengthen its biotechnology leadership to compete aggressively with China, these tariffs move us in the wrong direction,” says BIO’s statement.</span></p>
<p>The post <a href="https://bio.news/federal-policy/tariffs-drag-on-innovation-compounded-by-lack-of-guidance-experts-say/">Tariffs’ drag on innovation compounded by lack of guidance, experts say</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates</title>
<link>https://edusehat.com/en/fda-to-highlight-aging-longevity-medicine-in-planned-fars-updates</link>
<guid>https://edusehat.com/en/fda-to-highlight-aging-longevity-medicine-in-planned-fars-updates</guid>
<description><![CDATA[ FDA Chief Scientist Steven Kozlowski, MD, said the updated FARS would come out early in FY 2027 but offered no further specifics on timing.
The post FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/ARDD2026-Zeta-Kozlowski-FDA-Panel-100126-3732-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 03 Oct 2026 05:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>FDA, Highlight, Aging, Longevity, Medicine, Planned, FARS, Updates</media:keywords>
<content:encoded><![CDATA[<p><strong>BOSTON</strong>—The FDA’s top scientific official drew a round of applause by telling a longevity medicine conference here that the agency plans to include aging and longevity among topics it will highlight in the updated Focus Areas of Regulatory Science (FARS) report it plans to issue in the federal fiscal year that began Thursday.</p>
<p>“We all believe that there is a shared risk factor of aging for many, many chronic diseases. But to me, it’s interesting: Is there a way of beginning to start quantifying that, really working a lot on the biological side but also on the clinical side, what that looks like?” FDA Chief Scientist Steven Kozlowski, MD, told attendees at the 13<sup>th</sup> Aging Research & Drug Discovery Meeting (ARDD 2026), held at the David Rubinstein Treehouse at Harvard University.</p>
<p>Kozlowski said the updated FARS would come out early in FY 2027 but offered no further specifics on timing.</p>
<p>“It would be really good to have a shared endpoint [that was] pre-competitive, qualified, and shared broadly so that everybody can use that can serve as a bridge,” Kozlowski elaborated. “Attributes of that endpoint would be regulatory acceptance, right? You buy into that endpoint and it’s really useful, that it allows feasible clinical trial designs that it’s worth doing, that it serves as a standard for all the other novel things that come after it, and that to some extent helps with accessibility [to other researchers].”</p>
<p>Kozlowski spoke during “Matching Clinical Trials of Therapeutics & Regulatory Mandates,” a panel of four current FDA officials.</p>
<p>“Steve and his team have been working really hard to develop these key areas where I’ve been speaking to all of our stakeholders where there is a need for more regulatory science,” said Lowell M. Zeta, JD, Acting Chief of Staff in the FDA’s Office of the Commissioner. “To the extent that we can be and should be evolving our programs to help you all solve the challenges, that’s what we want to hear.”</p>
<p>Zeta called longevity and healthspan—the number of years a person lives free from long-term disease or disability—“an important topic for the agency and HHS [U.S. Department of Health and Human Services].</p>
<h4><strong>‘A defining moment’</strong></h4>
<p>“It’s really a defining moment, an inflection point for the future,” Zeta added. “It’s a test for the future of FDA and how to adapt to the rapidly evolving science in this space.”</p>
<p>Zeta was the highest ranking FDA official on the panel, which included Justin Penzenstadler, PharmD, acting associate director of the FDA’s Office of Cardiology, Hematology, Endocrinology, and Nephrology; and Jeffrey Siegel, MD, director of the FDA’s Office of Drug Evaluation Sciences.</p>
<p>Panel moderator was Andrew Brack, PhD, program manager, proactive health with ARPA-H. Brack oversees <a href="https://arpa-h.gov/explore-funding/programs/prospr" target="_blank" rel="noopener">PROSPR (PROactive Solutions for Prolonging Resilience)</a>, a $144 million research initiative designed to extend American healthspan by redefining how aging and functional decline are measured and treated.</p>
<p>Brack began the panel session by asking a question to the four FDA officials: What do you see as the most realistic regulatory path to date response of trying to develop a therapy that targets aging biology rather than a single disease?</p>
<p>Siegel replied that aging could be considered for approval of new therapies in two ways. One is taking into account that aging increases the prevalence of numerous chronic diseases, including types of cancer, Parkinson’s disease, Alzheimer’s disease, and cardiovascular disease.</p>
<p>“Once you get to two or three that the same mechanism impacts, you begin to think that maybe this general mechanism is having an effect overall on aging-related disorders. And maybe you would be able to generalize from that,” Siegel said</p>
<h4><strong>Impact on people</strong></h4>
<p>But there is another approach, Siegel continued, which entails looking at the ways that aging impacts people, such as increasing the risks of cognitive decline and frailty, and causes loss of senses such as hearing and vision.</p>
<p>“If you have a way to evaluate those general aspects of aging, and you can define a patient population who’s subject to that aging-related deterioration, then you have to make use of a clinical trial that could demonstrate an effect on aging more broadly,” he explained.</p>
<p>The trial would need to measure aging-related domains, showing that the progression of these domains is less in treated patients than in an untreated control group, Siegel said: “That would be an indication that this is impacting the way that patients function and feel and survive, and potentially could be a way towards demonstrating efficacy for a drug impacting aging.”</p>
<p>Basic science research in recent decades has identified general mechanisms that underlie the aging process. Experimental models blocking some of these mechanisms has been demonstrated to increase lifespan, sometimes by as much as 30%, Siegel explained.</p>
<h4><strong>‘Amazing implications’</strong></h4>
<p>Some newer studies, he added, have suggested that treatments that block these aging processes could potentially reverse aging.</p>
<p>“If this can be applied in therapeutics for people, this has amazing implications, potentially increasing lifespan, but also decreasing the adverse effects that aging has on people, including aging-related diseases.”</p>
<p>Officials and researchers have long ascribed economic as well as health benefits to lengthening healthspans: An <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10154220/" target="_blank" rel="noopener">economic analysis published in 2021</a> concluded that a slowdown in aging that increased life expectancy by one year would generate $38 trillion in economic gains—a figure that ballooned to $367 trillion for 10 years of increased life expectancy.</p>
<p>Siegel said earlier trials will look at prevention of age-related comorbidities or mortality as an endpoint, but will also collect measures of clinical outcome assessments. He cited drug development history: The first trial of insulin evaluated a single patient—<a href="https://www.genengnews.com/insights/the-right-protein-to-establish-recombinant-therapeutics/" target="_blank" rel="noopener">a 14-year-old boy with type 1 diabetes</a>—using a single endpoint, mortality.</p>
<p>“I see geroscience following a similar arc, where you start with enriched patients, you’re looking at the hard endpoints, right? And then as the field, the body of evidence builds, you’ll be able to say, hey, here’s some measures that track with mortality. And maybe we ought not run trials as long,” Penzenstadler said. “You might be able to start validating some other endpoints or biomarkers that predict mortality, and that could shorten your trials.”</p>
<p>The FARS focus on aging and longevity sparked a question from a panelist in the panel that followed.</p>
<p>“Let’s say aging will be designated as a disease, how do we define it? And suddenly we come to a decade-long question, what is aging?” asked Steve Horvath, PhD, professor, human genetics and biostatistics at University of California, Los Angeles (UCLA).</p>
<h4><strong>Huge progress</strong></h4>
<p>“I would say we’ve made huge progress in defining that. And in short, it’s complicated, but you will not—in my opinion, you will not be able to get there unless you also have molecular biomarkers of aging,” Horvath asserted. “Assessing function in 10 different ways and disease indication, that’s really easy and very well defined. But what can we, the scientists in the field, contribute to physiologic markers, molecular markers of aging, so that they can be folded into future clinical trials that target aging per se?”</p>
<p>The 2022 FARS report—completed within the tenure of then-FDA commissioner Robert M. Califf, MD, who served under Democratic presidents Joe Biden and Barack Obama—was written with the COVID-19 pandemic still fresh in recent memory. That explains why the first priority highlighted by that report was “Public Health Preparedness and Response.” Also identified were:</p>
<ul>
<li>Increasing Choice and Competition through Innovation.</li>
<li>Understanding the Power of Data.</li>
<li>Empowering Patients and Consumers.</li>
</ul>
<p>The terms “aging research” and “longevity medicine” do not appear in the 2022 FARS.</p>
<p>According to the FDA, a key purpose of FARS reports is to communicate the importance and impact of its ongoing regulatory science research activities that cut across its numerous centers, offices, and laboratories. The FDA defines regulatory science as the science of developing tools, standards and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.</p>
<p>The FDA is now helmed by Acting Commissioner Kyle Diamantas, JD, who previously served as the agency’s deputy commissioner for food. President Donald Trump has nominated Heidi N. Overton, MD, PhD, as permanent commissioner. Overton’s nomination has yet to be voted by the U.S. Senate, whose Committee on Health, Education, Labor, and Pensions <a href="https://www.help.senate.gov/hearings/nomination-of-heidi-overton-to-be-commissioner-of-food-and-drugs" target="_blank" rel="noopener">heard testimony from her</a> on September 24.</p>
<h4><strong>Urging disease prevention</strong></h4>
<p>Before the FDA panel Admiral Brian Christine, MD, HHS assistant secretary for health, urged longevity drug developers and researchers to focus on modifying biological processes associated with aging over time and intervening to prevent disease before it occurs, rather than managing illness once someone gets sick.</p>
<p>Christine—who was appointed by President Donald Trump, confirmed by the U.S. Senate, and serves under HHS Secretary Robert F. Kennedy Jr.—aligned the push toward longevity medicine articulated by panelists at ARDD 2026 with Kennedy’s “Make America Healthy Again” (MAHA) policy framework. Kennedy has led an overhaul of federal policy on nutrition and disease prevention including vaccination schedules, prompting backlash from medical groups and researchers. David Robert Grimes, PhD, a professor of biostatistics at Trinity College Dublin and advocate, last year characterized MAHA as a movement that “<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12678486/" target="_blank" rel="noopener">thrives on science denialism</a>.”</p>
<p>Not so, according to Christine.</p>
<p>“At its core, our MAHA movement is about confronting chronic disease,” Christine contended. “It begins with a very simple question, deceptively simple: Why are so many Americans sick, and what are we willing to do differently about it?”</p>
<p>“For decades, we have too often responded to chronic disease one condition at a time, and frequently, unfortunately, measure the rate and course of the disease,” said Christine, who also leads the U.S. Public Health Service Commissioned Corps, which consists of about 5,300 public health professionals. “Good science must be willing to ask questions even when the answers challenge longstanding assumptions. That matters enormously in healthy aging because patients are already moving faster than many traditional institutions.”</p>
<p>He cited as examples growing interest by women in menopausal hormone replacement therapy, by men in testosterone replacement therapy, and by both in improving their health through peptides, dietary supplements, continuous glucose monitors, wearables, biological AIDS tests, and emerging diagnostic technologies.</p>
<p>“Increasingly, people are learning about these interventions from podcasts, from social media, from wellness clinics, and direct to consumer companies before they ever walk into a physician’s or a nurse’s office,” Christine said.</p>
<p>Christine and the FDA officials spoke during ARDD 2026’s initial series of sessions. Before they spoke, George Q. Daley, MD, PhD, dean of Harvard Medical School, opened the conference with a plea for caution when it comes to promoting the benefits of drugs designed to fight the effects of aging.</p>
<p>“I’m concerned that the optimistic claims being made by some in the aging community far exceed what one can responsibly conclude from our current understanding of the biology,” Daley told ARDD 2026 attendees. “I implore you all to listen attentively to the many compelling presentations scheduled over the next few days, but also skeptically and critically, so that we will emerge with a greater respect for the science, but proper restraint in forward-looking claims of life extension.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/fda-to-highlight-aging-longevity-medicine-in-planned-fars-update/">FDA to Highlight Aging, Longevity Medicine in Planned FARS Updates</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Neurons Involved in Generating Anxiety After Cannabinoid Drug Exposure Identified in Mice</title>
<link>https://edusehat.com/en/neurons-involved-in-generating-anxiety-after-cannabinoid-drug-exposure-identified-in-mice</link>
<guid>https://edusehat.com/en/neurons-involved-in-generating-anxiety-after-cannabinoid-drug-exposure-identified-in-mice</guid>
<description><![CDATA[ Working with mice, scientists have for the first time identified a set of neurons in the brain that play a role in generating anxiety after exposure to cannabinoid drugs, especially under stressful conditions.
The post Neurons Involved in Generating Anxiety After Cannabinoid Drug Exposure Identified in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/GettyImages-170614889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 03 Oct 2026 05:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Neurons, Involved, Generating, Anxiety, After, Cannabinoid, Drug, Exposure, Identified, Mice</media:keywords>
<content:encoded><![CDATA[<p>Working with mice, Northwestern scientists have for the first time identified a set of neurons in the brain that play a role in generating anxiety after exposure to cannabinoid drugs, especially under stressful conditions. Cannabinoids are a class of substances that includes tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis and synthetic analogs.</p>
<p>Scientists exposed mice to a predator odor after giving them a placebo or a cannabinoid drug. Animals given the cannabinoid froze more and spent less time investigating the odor. Using small microscopes, scientists identified neurons activated by the drug that helped drive anxious behaviors. When those neurons were silenced the cannabinoid no longer triggered the same level of anxious behaviors.</p>
<p>The findings could help scientists better understand how cannabis exerts its psychoactive effects, and potentially point to strategies for holding back anxiety in affected individuals. The results could provide insights into strategies for reducing anxiety symptoms in other contexts, outside of cannabis use.</p>
<p>“The results of this study could explain why a good trip can turn bad pretty quickly if people consume too much cannabis or the situation they are in turns stressful or scary,” said Sachin Patel, MD, PhD, chair of psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine.</p>
<p>Patel is senior and corresponding author of the team’s published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-77957-4" target="_blank" rel="noopener">Cannabinoid modulation of central amygdala population dynamics during threat investigation</a>.” In their paper the team concluded that their results “… could ultimately provide important insights into how cannabinoids augment threat reactivity and the interactions between cannabis use and anxiety disorders.”</p>
<p>Plant-derived cannabinoids are widely used for medicinal and recreational purposes, and exert broad-ranging behavioral and physiological effects on mood, anxiety, memory, appetite, and sleep, the authors noted. But they can also precipitate anxiety and panic reactions in people, and increase threat-related defensive responses in rodents. “Specifically, while tension and anxiety relief represent major reasons for cannabis use, paradoxical dose- and context-dependent increases in anxiety and panic are also well-documented, and some studies have suggested associations between cannabis use and the development and worsening of anxiety disorders, especially in heavy cannabis users.” However, they continued, Despite well-established research findings, “… how cannabinoids affect<em> in vivo</em> neural dynamics associated with threat-related behavior has not been examined.”</p>
<p>For their newly reported study the scientists exposed mice to a threatening odor. Before being exposed to the scent, derived from fox urine, the mice either received a placebo or a synthetic cannabinoid drug. Patel and colleagues tested several doses of the synthetic cannabinoid on mice and tracked how much time they spent near the predator odor, and whether they froze or fled from the scent.</p>
<p>To simultaneously record brain activity, the team implanted a small microscope into the mice’s brain. The results showed that mice receiving the cannabinoid drug froze more often and spent less time investigating the predator odor. These anxious behaviors were linked to the drug’s activation of a small group of somatostatin neurons (SOM) in the brain’s central amygdala (CeA), a region that processes fear and stress.</p>
<p>Importantly, when the scientists genetically silenced the somatostatin neurons, mice given the cannabinoid drug did not avoid the predator scent as much. The researchers also conducted brain tissue experiments to analyze how the cannabinoids affected interactions between neurons. They found that the drug weakened the brain’s natural “brake” on the somatostatin neurons, allowing them to become more active. “Our data suggest suppression of GABA release from local afferents onto CeA SOM neurons underlies cannabinoid effects on CeA SOM neurons,” they wrote.</p>
<figure aria-describedby="caption-attachment-338768" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338768" src="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Dr.Patel_50-300x200.jpg" alt="Study authors Drs. Sachin Patel (left) and Farhana Yasmin looking at brain recordings from central amygdala neurons [Gr8y Productions]" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Dr.Patel_50-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Low-Res_Dr.Patel_50.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Study authors Sachin Patel (left) and Farhana Yasmin looking at brain recordings from central amygdala neurons. [Gr8y Productions]</figcaption></figure>
<p>“Higher doses of cannabinoids and environmental stress worked together to synergistically release the ‘brake’ on the central amygdala, which in turn drove excessive anxiety,” Patel noted. “Understanding how cannabis affects brain function to generate its psychoactive effects could ultimately reveal new ways to counteract negative consequences should they arise in some people,” Patel said, also noting that the findings could have implications beyond cannabis. “Suppressing the activity of somatostatin neurons in the central amygdala could represent a final pathway for reducing anxiety symptoms, not just in the context of cannabis side effects,” he explained.</p>
<p>Cannabis use in the U.S. has steadily increased in recent years and so have emergency department visits related to adverse effects from the drug. <a href="https://pubmed.ncbi.nlm.nih.gov/32909828/" target="_blank" rel="noopener">Previous studies</a> have also found an association between cannabis use and increased risk of anxiety in the long term. What’s more, anxiety and mood disorders are also on the rise globally.</p>
<p>Commenting that their newly reported data begin to shed light on neural mechanisms subserving the “dark-side” adverse effects of cannabinoids, the authors concluded, “… we suggest cannabinoids could trigger context-dependent adverse anxiety and panic reactions, in part, via activation of CeA-related circuits and that cannabis-induced long-term adaptations in these circuits could contribute to observed associations between cannabis use and anxiety disorders.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neurons-involved-in-generating-anxiety-after-cannabinoid-drug-exposure-identified-in-mice/">Neurons Involved in Generating Anxiety After Cannabinoid Drug Exposure Identified in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Watching Cancer Proteins in Real Time, with Help from Rare Earth Elements</title>
<link>https://edusehat.com/en/watching-cancer-proteins-in-real-time-with-help-from-rare-earth-elements</link>
<guid>https://edusehat.com/en/watching-cancer-proteins-in-real-time-with-help-from-rare-earth-elements</guid>
<description><![CDATA[ A long-duration single-molecule imaging platform from the Broad Institute and MIT has revealed unexpected stability in homodimers of HER3, one of the most enigmatic members of the ErbB receptor family. 
The post Watching Cancer Proteins in Real Time, with Help from Rare Earth Elements appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_04-small.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 03 Oct 2026 05:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Watching, Cancer, Proteins, Real, Time, with, Help, from, Rare, Earth, Elements</media:keywords>
<content:encoded><![CDATA[<p>A long-duration single-molecule imaging platform from the Broad Institute and MIT has revealed unexpected stability in homodimers of HER3, one of the most enigmatic members of the ErbB receptor family. The research, published in <em>Cell</em>, shows wild-type HER3 forms unexpectedly stable homodimers, and that cancer mutations destabilize these homodimers. The findings could hopefully help shape new cancer therapies. Their paper is entitled, “<a href="https://www.cell.com/cell/fulltext/S0092-8674%2826%2900399-5" target="_blank" rel="noopener">ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging</a>.”</p>
<p>But the tool that delivered it matters just as much: an upconverting nanoparticle (UCNP) probe, doped with heavy rare earth elements, that simply doesn’t photobleach.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>In one corner of Sam Peng’s lab, the imaging rig looks almost improvised. Cameras, lenses, and lasers are bolted directly onto a metal breadboard, like an enormous sheet of Legos built by hand rather than bought off a shelf.</p>
<p>Peng’s team engineered UCNPs doped with ytterbium, erbium, and thulium to track EGFR, HER2, and HER3 at the single-molecule level on live cells simultaneously, in three colors. The new imaging platform holds 100-millisecond resolution and runs for over 16 minutes straight. Conventional dyes lose signal within seconds. These UCNP probes do not photobleach.</p>
<figure aria-describedby="caption-attachment-338779" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class=" wp-image-338779" src="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-300x169.jpg" alt="" width="382" height="215" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_01-small.jpg 1400w" sizes="(max-width: 382px) 100vw, 382px"><figcaption class="wp-caption-text">Researchers in Sam Peng’s lab at the Broad Institute work on the lab’s custom-built imaging rig, where cameras, lenses, and lasers are mounted directly on a metal breadboard. [Broad Institute]</figcaption></figure>
<p>Peng compares short-duration imaging to eavesdropping on a conversation that gets cut short: “If you’re trying to understand a conversation between two people… if all of a sudden I just cut off this conversation, then you have to guess my answer based on our previous two-minute interaction, which is often impossible to do.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The real advantage isn’t a fixed window. Peng said the probe can run for hours. His team stopped at 16 minutes because they’d already captured the long EGFR homodimers they were after.</p>
<h4><strong>HER3’s stable pairing</strong></h4>
<p>The surprising finding was the unexpected stability of HER3 homodimers and the effects of cancer-associated mutations on these pairings.</p>
<p>“The first time we saw HER3 homodimers, we were really puzzled,” Peng told <em>GEN</em>. “We thought that maybe this was some experimental artifact.”</p>
<p>HER3’s kinase domain is too weak to signal on its own, so the prevailing model treated it as a heterodimer partner—something that pairs with other receptors. This does not rule out its forming homodimers. Peng’s team expected HER3 to serve as a negative control for dimer detection. It should have come back empty.</p>
<p>The team reran the experiment with different labels and probes. The result held every time: wild-type HER3 homodimers proved remarkably stable, far outlasting unstimulated EGFR homodimers.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The group’s working model is that these homodimers form a signaling-inactive pool. In this model, they sequester HER3, limiting its availability to pair with other receptors and trigger cancer signaling.</p>
<figure aria-describedby="caption-attachment-338780" class="wp-caption alignright"><img decoding="async" class=" wp-image-338780" src="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-300x169.jpg" alt="" width="350" height="197" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/PengLab_05-small.jpg 1400w" sizes="(max-width: 350px) 100vw, 350px"><figcaption class="wp-caption-text">A researcher points to bright spots on the imaging display. Each spot can mark a single probe, allowing individual receptors to be followed over time. [Broad Institute]</figcaption></figure>
<p>Cancer mutations support the model, but EGFR and HER3 moved in opposite directions. Mutations like the exon-19 deletion make EGFR homodimers more stable, driving signaling that tracks with clinical aggressiveness. The more stable the dimer, Peng said, the more signaling it triggers. The HER3 mutations studied do the opposite, destabilizing the homodimer, potentially freeing HER3 to form signaling-active heterodimers.</p>
<p>HER2 rounds out a third pattern. The HER2 mutations studied only modestly enhance the stability of its homodimers. That tracks with the clinic: HER2 cancers are typically driven by gene amplification.</p>
<h4><strong>Sourcing the materials </strong></h4>
<p>Ytterbium and erbium are heavy rare earth elements. Unlike light rare earth elements such as neodymium, mined at industrial scale for electric vehicle (EV) motors and consumer electronics, heavy rare earth elements are produced in far smaller volumes, for a narrow set of high-performance uses where few substitutes exist. Peng’s imaging platform is one of them.</p>
<p>The supply chain for these materials is highly concentrated. China dominates global rare-earth separation and refining, and its share of the heavy subset is larger still. According to Benchmark Mineral Intelligence, China controlled 85% of total rare earth oxide production in 2025, including an estimated 99% of dysprosium oxide and terbium oxide. That concentration has shown up in prices for those magnet metals: in 2025, dysprosium oxide in North America on average cost 4.4 times the Chinese price.</p>
<p>China introduced export controls on seven rare earth elements in April 2025: samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium. An October 2025 expansion added ytterbium, erbium, holmium, thulium, and europium, including the elements used in Peng’s probes. That expansion is currently suspended under a U.S.–China trade truce.</p>
<p>At bench scale, Peng’s lab works in milligrams to grams, small enough that global supply pressure doesn’t immediately register. His lab buys rare earth salts in vials from a U.S. distributor. “They come in as a form of powder, like salt, just like your kitchen salt,” he said. Erbium salts arrive in pink. “Pretty beautiful,” he noted.</p>
<h4><strong>An expertise gap, not a supply gap</strong></h4>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Heavy rare earth elements aren’t especially scarce in the earth’s crust. They’re just rarely found in concentrations worth mining—and separating them is difficult. While Peng’s lab doesn’t track where the material was mined, it likely comes from China.</p>
<p>Peng’s lab buys these salts the way other labs buy antibodies. Rare earth elements are used in TR-FRET, some forms of NIR-II imaging, mass cytometry, and UCNP tracking, although these methods use different elements and probe chemistries.</p>
<p>As Xi Jinping was recently in Washington for his first state visit in more than a decade, U.S. officials said the two sides had agreed to extend their trade truce, and with it the pause on China’s expanded rare earth controls, from November to January.</p>
<p>Currently, the bottleneck is expertise, not supply. Peng estimates roughly a dozen groups worldwide work at this intersection of UCNP imaging and single-molecule biology. It’s a small overlap, since the work demands nanomaterial chemistry, molecular labeling, advanced optics, and computation, all in one lab. “It’s the integration of this entire pipeline that makes it challenging,” Peng said.</p>
<p>The research of nanoparticle optics has lasted for years. For now, the rare earth salts are the easy part. The optics, and the people who can build them, are what’s scarce.</p>
<p><strong>References</strong></p>
<p>1. Broad Institute. Single-molecule tracker illuminates workings of cancer-related proteins. Broad Institute of MIT and Harvard. Published May 1, 2026. Accessed September 24, 2026. <a href="https://www.broadinstitute.org/news/single-molecule-tracker-illuminates-workings-cancer-related-proteins" target="_blank" rel="noopener">https://www.broadinstitute.org/news/single-molecule-tracker-illuminates-workings-cancer-related-proteins</a></p>
<p>2. Shida JF, Ma K, Toll HW, et al. Multicolor long-term single-particle tracking using 10 nm upconverting nanoparticles. <em>Nano Lett</em>. 2024;24(14):4194-4201. doi:10.1021/acs.nanolett.4c00207</p>
<p>3. Peng Lab, Broad Institute of MIT and Harvard. Accessed September 24, 2026. <a href="https://www.sampenglab.org/publications" target="_blank" rel="noopener">https://www.sampenglab.org/publications</a></p>
<p>4. Ingall G, Mukherjee N. Ex-China rare earths premium to grow, especially for heavies. Benchmark Mineral Intelligence. Published March 24, 2026. Accessed September 24, 2026. <a href="https://source.benchmarkminerals.com/article/ex-china-rare-earths-premium-to-grow-especially-for-heavies" target="_blank" rel="noopener">https://source.benchmarkminerals.com/article/ex-china-rare-earths-premium-to-grow-especially-for-heavies</a></p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>5. Shalal A. US, China agree to extend trade truce by two months, work on bigger deal, Bessent says. <em>Reuters</em>. Published September 23, 2026. Accessed September 24, 2026. <a href="https://www.reuters.com/world/asia-pacific/us-treasurys-bessent-chinas-he-meet-unfinished-business-before-trump-xi-summit-2026-09-23/" target="_blank" rel="noopener">https://www.reuters.com/world/asia-pacific/us-treasurys-bessent-chinas-he-meet-unfinished-business-before-trump-xi-summit-2026-09-23/</a></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/watching-cancer-proteins-in-real-time-with-help-from-rare-earth-elements/">Watching Cancer Proteins in Real Time, with Help from Rare Earth Elements</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A new contest pits competitors against each other in a race to biological youth</title>
<link>https://edusehat.com/en/a-new-contest-pits-competitors-against-each-other-in-a-race-to-biological-youth</link>
<guid>https://edusehat.com/en/a-new-contest-pits-competitors-against-each-other-in-a-race-to-biological-youth</guid>
<description><![CDATA[ This week, I officially signed up for an unusual competition. One that rewards competitors for getting younger. I recently turned 40, and I don’t need reminding that both time and my chronological age only tick forward. But this game is focused on competitors’ biological ages—figures that are meant to provide a better way to measure… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/healthy-habits.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 19:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>new, contest, pits, competitors, against, each, other, race, biological, youth</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Biological age as a competition:</strong> A new six-month contest called pits around 500 participants against each other to reverse their biological age, using tools like epigenetic blood tests, brain scans, face-aging apps, and grip strength measurements.</li><br><li><strong>The science is promising but imperfect:</strong> Over 100 biological "aging clocks" exist, but experts caution they aren't yet reliable enough for individual use—nobody fully understands what each one actually measures.</li><br><li><strong>Data collection is a goal:</strong> Founder Christin Glorioso hopes the contest generates the world's most comprehensive aging-clock dataset, while also giving longevity companies a cheaper alternative to running formal clinical trials.</li><br><li><strong>The leaderboard is shaping up:</strong> One competitor's biological age clocks in nearly 29 years below their chronological age—while another 47-year-old received a biological age of 100 based on how slowly she rises from a chair</li></ul>" data-chronoton-post-id="1145610" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>This week, I officially signed up for an unusual competition. One that rewards competitors for getting <em>younger</em>.</p>



<p>I recently turned 40, and I don’t need reminding that both time and my chronological age only tick forward. But this game is focused on competitors’ <em>biological</em> ages—figures that are meant to provide a better way to measure the age-related health of our organs and bodies.</p>



<p>Over a six-month period, around 500 of us will try to reverse our biological age as measured in a bunch of different ways. There’s even a leaderboard! The winners will include the person who shows the greatest difference between their chronological and biological age, as well as the person who manages to reverse their biological age the most.</p>





<p><strong>The competition is the brainchild of the neuroscientist and physician Christin Glorioso,</strong> who is also founder and CEO of NeuroAge Therapeutics. The company offers tools to track brain health and aging and is <a href="https://www.neuroagetx.com/our-science">running a trial</a> to find out if biological brain age can predict the onset of Alzheimer’s disease.</p>



<p>Glorioso says she has several goals for <a href="https://www.neuroagetx.com/events/younger">the Younger contest</a>. The first, she tells me, is to “explain to the world what <a href="https://www.technologyreview.com/2022/04/15/1050019/aging-clocks/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">aging clocks</a> are.” Regular Checkup readers will be familiar with these tools, but for the uninitiated, they are basically designed to measure biological age.</p>



<p>Many measure chemical signatures that form a layer on top of our DNA and seem to change with age. But others might involve looking at proteins or lipids in blood. Some are designed to measure functional health, while others predict when a person will die. There are more than a hundred clocks out there, and they probably each capture a specific aspect of the biological process of aging.</p>



<p>These clocks are proving <a href="https://www.technologyreview.com/2025/10/14/1124977/aging-clocks-biology-mortality-longevity/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">very useful for scientists</a>, who use them to study aging and development in humans and many other species. But using them to estimate the biological age of an individual person is more controversial. They’re just not good enough for that yet.</p>



<p><strong>Part of the problem is that we don’t really understand what each clock is capturing. </strong>Glorioso hopes that data collected through the Younger contest might help answer that question. She’s hoping to generate “the world’s most comprehensive clock dataset.”</p>



<p>Some <a href="https://www.technologyreview.com/2024/03/18/1089888/the-quest-to-legitimize-longevity-medicine/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">longevity clinics</a> try to get around the limits of biological age testing by using multiple clocks. That’s this competition’s approach too. As a standard competitor, I’ll be sending a blood spot sample to TruDiagnostic, a company that measures epigenetic chemical groups on DNA and offers to reveal an overall biological age as well as a person’s pace of aging and the biological ages of each of 11 organ systems, including the heart and brain.</p>





<p>I’ll get a brain age score from NeuroAge once I complete the cognitive tasks on offer. I’ll also submit some physical measures like grip strength. And I’ll upload a series of selfies to an app developed by a team at Harvard that promises to tell me my face age. That’s exactly what it sounds like—an estimate of how old my face looks.</p>



<p>I’m intrigued to see my scores, even though I know I shouldn’t put too much stock in them. The first time I took a test, four years ago, the company I used <a href="https://www.technologyreview.com/2022/11/18/1063466/i-found-out-biological-age/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">gave me a biological age</a> that matched my chronological age, which was a little disappointing and, if I’m honest, a bit underwhelming. A year later, the same company <a href="https://www.technologyreview.com/2022/11/18/1063466/i-found-out-biological-age/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=10-01-26">told me I had a young heart</a> but a relatively old brain, liver, and hormonal system. My lifestyle hasn’t changed much since then. Will the years have made much difference?</p>



<p>(Ultra competitors—who pay $4,499 rather than the $999 cost of regular entry—are also offered a range of other blood tests and clocks, as well as MRI and DEXA scans. I’ve got complimentary press access to the standard package.)</p>



<p><strong>Glorioso is also hoping to gather information about the effects of some purported longevity approaches. </strong>During the competition, some participants will be offered red-light masks, access to a sauna, or other low-risk offerings that partner companies who are sponsoring the event to varying degrees might want to collect data on. “A lot of these companies just can’t afford to run [clinical] trials,” says Glorioso.</p>



<p>She also sees the event as a public health initiative. A couple of years ago, David Sinclair, who studies aging at Harvard Medical School, and his colleagues estimated that if we could slow down aging in the general population and increase life expectancy by one year, it <a href="https://www.nature.com/articles/s43587-021-00080-0">would save the US economy $38 trillion</a>.</p>



<p>The event officially kicks off in January, but around 120 people have already signed up, says Glorioso. Ultimately, she expects 500 participants. Each person’s six-month run starts as soon as they take their baseline measurements, whenever that may be. A handful of people have already started. “I think the majority of people are going to want to sign up after the holidays,” says Glorioso. “They’re not going to want to be trying to win an aging contest over Christmas and Hanukkah.”</p>





<p>Glorioso took her own baseline measurements back in August. Those initial tests suggested that her biological age was around 10 years below her chronological age. That sounded pretty impressive to me until I looked at the leaderboard and saw that competitor @Fred had a biological age 28.8 years below his chronological age.</p>



<p><strong>The leaderboard is pretty sparse at the moment,</strong> as only seven people have logged their baseline measurements so far. Six of them have biological ages tracking low, but one 47-year-old has been given a biological age of 68.1. She’s competing publicly, so I can see the breakdown of her scores. The worst is for the speed at which she can stand from sitting in a chair—by that measure, she’s been given a biological age of 100.</p>



<p>Hillary Lin, a longevity-focused physician in New York, has just started logging her baseline measurements for the competition. She tells me she’s taken biological age tests in the past and that they’ve tended to give scores below her chronological age, which is currently 37. Last year, the TruDiagnostic test put her pace of aging at 0.75—suggesting she’s only doing nine months’ worth of aging in a typical year. “That’s supposed to be quite good,” she says.</p>



<p>If it had been up to her, Lin says, she would have incorporated more blood tests into the competition, to build a fuller picture of a person’s health. And she’s worried that a six-month period might not be long enough to see changes in biological measures of aging. Still, she’s excited, and is already making plans to improve her sleep, diet, and exercise.</p>



<p>But she already follows a high-protein, low-carb diet and works out at the gym every day. She also visits a sauna every few days (sauna use <a href="https://lifestylemedicine.stanford.edu/sauna-use-as-a-lifestyle-practice/">has been linked to improved heart health</a>). Glorioso’s efforts are impressive too. She tells me she’s started drinking a smoothie made from <a href="https://www.neuroagetx.com/blog/the-duckweed-smoothie-behind-the">a pond plant that has been linked to health improvements</a>, and that she’s cut added sugar and deep-fried foods from her diet. She’s also bought “a bunch of fancy Korean sunscreens” in an attempt to lower her face age.</p>



<p>I haven’t received my kit or logged my baseline measurements yet, and I’ll wait until then to start setting health goals. I don’t fancy my chances against these two competitors. But at the very least, I hope I can stand up faster than a 100-year-old.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Proteomics Maps Eye&#45;Infecting Acanthamoeba Mitochondria Across Oxygen Levels</title>
<link>https://edusehat.com/en/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels</link>
<guid>https://edusehat.com/en/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels</guid>
<description><![CDATA[ A new catalog of 1,122 mitochondrial proteins reveals how Acanthamoeba adapts to oxygen loss—and may highlight possible targets for treating sight-threatening infections.
The post Proteomics Maps Eye-Infecting Acanthamoeba Mitochondria Across Oxygen Levels appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-932734998.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 11:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Proteomics, Maps, Eye-Infecting, Acanthamoeba, Mitochondria, Across, Oxygen, Levels</media:keywords>
<content:encoded><![CDATA[<p>Starve <em>Acanthamoeba</em> of oxygen, and its mitochondria do not simply shut down. Instead, the organelles retool their energy-producing machinery, enabling the amoeba to generate hydrogen gas. <em>Acanthamoeba</em> is a free-living, single-celled organism found in water, soil, and air. Although it rarely causes disease, it can infect the cornea and cause sight-threatening keratitis—and its metabolic flexibility may help it persist there.</p>
<p>That adaptability is one of several defenses that make <em>Acanthamoeba</em> infections difficult to eliminate. The pathogen can also retreat into a drug-resistant cyst, and the treatments available once an infection is diagnosed are limited and may damage human cells. By mapping the organism’s mitochondrial proteins, researchers now have a new way to probe the machinery behind its survival and search for more selective therapeutic targets.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“It’s a big challenge. The lack of readily available diagnostics is a problem, and then even after you finally get to the diagnosis, we don’t have good drugs,” said Jon Stefely, PhD, a metabolism investigator at the Morgridge Institute for Research and assistant professor of biomolecular chemistry at the University of Wisconsin School of Medicine and Public Health. “Our current drugs are untargeted and toxic, and we just need more options for treating these infections.”</p>
<p>To begin expanding those options, Stefely and his colleagues created a high-confidence inventory of the proteins operating inside <em>Acanthamoeba castellanii</em> mitochondria. The experimentally defined mitoproteome reveals the pathogen’s metabolic flexibility while highlighting potential therapeutic vulnerabilities. Their paper, “<a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01067-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426010676%3Fshowall%3Dtrue" target="_blank" rel="noopener">Mitochondrial proteome of <em>Acanthamoeba</em> delineates aerobic and anaerobic pathways dynamically regulated by oxygen</a>,” was published in <em>Cell</em> as part of the <a href="https://sites.broadinstitute.org/mitocarta" target="_blank" rel="noopener">MitoCarta Tree of Life Consortium</a>, along with their other paper published in <em>Cell Press Blue, “<a href="https://www.genengnews.com/topics/omics/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels/Acanthamoeba%20castellanii%20genome%20reannotation%20and%20multi-omic%20encystation%20profiling%20reveals%20cyst%20wall%20proteins%20and%20carbohydrate-active%20enzymes" target="_blank" rel="noopener">Acanthamoeba castellanii </a></em><a href="https://www.genengnews.com/topics/omics/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels/Acanthamoeba%20castellanii%20genome%20reannotation%20and%20multi-omic%20encystation%20profiling%20reveals%20cyst%20wall%20proteins%20and%20carbohydrate-active%20enzymes" target="_blank" rel="noopener">genome reannotation and multiomic encystation profiling reveals cyst wall proteins and carbohydrate-active enzymes</a>.” The consortium was conceived by Vamsi Mootha, MD, of the Broad Institute, Massachusetts General Hospital, Harvard Medical School, and Howard Hughes Medical Institute; Stefely completed the work as a postdoctoral researcher in Mootha’s laboratory.</p>
<p>In their <em>Cell </em>paper, the researchers first improved the organism’s nuclear genome annotation—important because most mitochondrial proteins are encoded in the nucleus—from about 52% accuracy to 98% using long-read RNA sequencing and other empirical methods. “If you imagine a page of words in a book, it would be like all the words were squished together and in a language that you don’t know,” said Stefely. “You would have to ask, ‘Where are the words? How do I separate one word from the next?’ It’s hard to tease apart.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>They then combined mitochondrial immunoprecipitation, density-gradient purification, microscopy, mass spectrometry, and protein-correlation profiling. Proteins that became enriched as mitochondrial samples grew purer were assigned to the organelle. Blue native PAGE–mass spectrometry for complexome profiling further resolved 20 macromolecular assemblies.</p>
<p>The resulting AcMitoCarta catalog contains 1,122 proteins, including 381 without readily identifiable counterparts in human or yeast mitochondria. Just over 300 were described as unique when compared with those organisms. Such divergence could matter for drug discovery: a compound directed at a microbe-specific protein or pathway may be less likely to damage human cells. “What’s been proven historically,” Stefely said, “is that if you have a target protein in a biochemical pathway that’s completely unique to the microbe, it’s a better target than something that has a homolog in humans.”</p>
<p>Proteomic and transcriptomic profiling also showed that oxygen extensively rewires the amoeba’s bioenergetic machinery. Under oxygen-rich conditions, its mitochondria use aerobic pathways; under anoxia, they induce a pyruvate:ferredoxin oxidoreductase-to-hydrogenase pathway. The researchers demonstrated that eye-infection-derived <em>Acanthamoeba</em> cells can produce hydrogen gas without oxygen through a mitochondria-localized, oxygen-sensitive hydrogenase. That metabolic switch may help the organism persist in changing niches, including the cornea.</p>
<p>AcMitoCarta now provides a framework for testing which of these unusual proteins are essential to amoebal survival, cyst formation, or oxygen adaptation. Stefely plans to investigate the candidates and pathways in focused groups, with collaborators contributing expertise in mass spectrometry, RNA sequencing, metabolism, structural biology, and imaging. “A long-term goal is to annotate functions for all of those targets,” he said, “but we’ll take them one small set at a time and there is a lot of potential for new discoveries.”</p>
<p>The catalog does not yet identify a ready-to-use drug, but it narrows the search to experimentally supported mitochondrial components and pathways that differ from those in people. By moving from an incomplete genome annotation to a functional map of oxygen-responsive mitochondrial biology, the work lays a foundation for more selective treatments against an infection whose toughest form can withstand today’s therapies.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/proteomics-maps-eye-infecting-acanthamoeba-mitochondria-across-oxygen-levels/">Proteomics Maps Eye-Infecting <i>Acanthamoeba</i> Mitochondria Across Oxygen Levels</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Talus Bio’s Structure&#45;Free AI Model Targets Unstructured Proteins in Their Native Cellular Context</title>
<link>https://edusehat.com/en/talus-bios-structure-free-ai-model-targets-unstructured-proteins-in-their-native-cellular-context</link>
<guid>https://edusehat.com/en/talus-bios-structure-free-ai-model-targets-unstructured-proteins-in-their-native-cellular-context</guid>
<description><![CDATA[ Intrinsically disordered proteins have resisted structure-based drug discovery because they lack a stable fold to model. Talus Bio&#039;s structure-free AI model sidesteps that limitation, targeting these proteins in their native environment instead of in isolation or from a predicted structure.
The post Talus Bio’s Structure-Free AI Model Targets Unstructured Proteins in Their Native Cellular Context appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/10/GettyImages-1464739073-e1790880191557.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 04:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Talus, Bio’s, Structure-Free, Model, Targets, Unstructured, Proteins, Their, Native, Cellular, Context</media:keywords>
<content:encoded><![CDATA[<p><span>Alex Federation, PhD, has been interested in undruggable targets since his days as a trainee in the laboratory of Jay Bradner, MD, then at Dana-Farber Cancer Institute now at Amgen. At the time, the lab was working on finding molecules that could bind to genomic targets, several of which made it into clinical use. This was also around the time that genome sequencing technologies were becoming more affordable and accessible to scientists. </span></p>
<p><span>“My big excitement when I was starting my independent career was trying to ask the question, ‘could these new technologies actually help us unlock these undruggable targets?’” he told </span><i><span>GEN</span></i><span> in an interview. “There is a lot of interest in this problem” of cracking challenging targets as well as in turning the findings into “something that has an impact in the real world and patients.”</span></p>
<p><span>Those early roots put him on the path that led to co-founding Talus Bioscience, a company that uses artificial intelligence (AI) to enable drug discovery for the disordered proteome, alongside Lindsay Pino, PhD, who also serves as the company’s chief technology officer and leads the development of the company’s screening platform.  In addition to being a co-founder, Federation is also the company’s CEO. He credits Pino with introducing him to proteomics as an effective approach for taking on the undruggable target problem.</span></p>
<p><figure aria-describedby="caption-attachment-338715" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338715" src="https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing-300x218.jpg" alt="An image showing Talus' co-founders, Lindsay Pino, PhD, and Alex Federation, PhD." width="300" height="218" srcset="https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing-300x218.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing-768x559.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/10/Talus-Founders-Standing.jpg 900w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Talus Bio’s two co-founders, Lindsay Pino, PhD, and Alex Federation, PhD [Talus Bio]</figcaption></figure><span>The two founders met in Seattle about 10 years ago and have collaborated on multiple projects in the intervening decade including the technology that now underpins Talus’ platform. The technology measures proteins in their native environment inside cells. To date, the company has generated at least five years of proprietary data that serves as the foundation of the AI models that the company has developed and uses to make predictions. </span></p>
<p><span>This week, Talus released Ptarmigan-1, a solution powered by the company’s MARMOT platform, which it describes as a first-of-its-kind structure-free AI model that accurately predicts small molecule binding sites across the entire human proteome, including proteins that are too unstructured for traditional 3D modeling tools to resolve. MARMOT stands for Measuring Modulation of Transcription and is the underlying experimental assay that captures snapshots of proteins in their cellular environment without removing or tagging them.</span></p>
<p><span>On a separate note, the company’s name and the names of its products are somewhat whimsical as they are drawn from Seattle’s mountains and wildlife. But there is a link to the core challenge that company is taking on. Talus refers to a precarious boulder field requiring careful navigation which is a metaphor for navigating disordered proteins. Marmots and ptarmigans are wildlife that are native to the mountains—a possible reference to Talus’ way of measuring proteins in their native state. </span></p>
<p><span>Talus’ approach focuses on the approximately 40 percent of human proteins in cells that lack stable, defined 3D structures and cannot be studied or targeted using conventional structural biology methods. Outside cells, they fall apart, making them difficult to purify or analyze using standard experimental workflows, Federation noted. Even advanced AI tools like AlphaFold render these proteins as uninterpretable structures. </span></p>
<p><span>“Our platform is essentially a unique way to actually watch what these proteins are doing in the cell in their native state without having to take them out of the cell and letting them fold and function within that native environment where all their partners are,” he explained. “That gives us really for the first time the ability to see them in their native state and find molecules that can interact with these proteins in their native state.” </span></p>
<p><span>Importantly, the company’s technology is label free since adding tags to these proteins changes their dynamics. In a sense, it’s “like we’re taking a cell and taking snapshots of where the proteins are at any given time and what molecules are sticking to those proteins at any given time,” he said. “And we use these new label-free proteomics methods as our camera to take those snapshots. That’s the fundamental measurement that we’re taking.”</span></p>
<p><span>The company has adopted a two-pronged business model. First, they have identified a small number of targets that they are developing molecules for internally. The most advanced molecule in their pipeline targets a rare bone cancer called chordoma. Specifically, they are targeting the brachyury protein, which is encoded by the <em>TBXT</em> gene. This particular protein is typically only expressed in embryonic stem cells; the cancer reactivates it. Simultaneously, the company is open to partnering with other companies to work on targets in a range of disease areas.</span></p>
<p></p><h4><b>Finding molecules for invisible protein pockets</b></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>Ptarmigan-1 is the first version of Talus’ flagship structure-free model, and also a first of its kind AI model, according to its developers. There have been some approaches that have tried to accomplish similar goals, “but this is the first one that will actually tell you if a compound binds and where on the protein it binds,” Federation said.  </span></p>
<p><span>For targeting transcription factors, which Talus is interested in, this is an important capability. Despite clear biological validation of the disease relevance of transcription factors in disease, going after them as potential drug targets has proven to be an intractable challenge. It is “the type of target where the biology is so clear,” he said. “[W]e need molecules that can control these, and this is really the first step to make that possible.”</span></p>
<p><span>Ptarmigan-1 differs from other AI drug discovery tools, which rely on fitting a molecule onto a defined protein pocket. By eliminating the structure requirement entirely, Ptarmigan is designed to target the approximately 40% of the proteome, including many disease-relevant transcription factors and regulatory proteins that are flexible and lack a 3D structure that could be targeted by therapeutics developers. With this release, “we want to get a first tool out there that can really broaden the landscape … beyond just those structure targets,” Federation said. “We are excited for people to be able to take that and apply it broadly to the proteins that they care about.”</span></p>
<p><span>Talus has shared some results from a proof-of-concept study where they used Ptarmigan-1 to evaluate a STAT6 inhibitor series, a validated target for inflammatory disease with a hard-to-model binding site. The results showed that the model outperformed structure-based methods in selecting successful drug candidates even though it had not seen the target or molecules during training. The model also identified small molecules that bound to the flexible pocket on STAT6. These candidates were validated in a third-party lab. </span></p>
<p><span>“The data we’re building at Talus is structure-agnostic, meaning we can measure proteins whether or not they hold a fixed shape,” Pino said. “That means the model can learn just as well from flexible or intrinsically disordered proteins as it does from structured ones, which is what lets it generalize to targets nobody’s had a way to study before.”</span></p>
<p><span>Details of the AI model are provided in </span><a href="https://www.biorxiv.org/content/10.64898/2026.07.28.741295v1" target="_blank" rel="noopener"><span>a preprint </span></a><span>that describes its architecture and the data that went into training it. Rather than forcing proteins into a 3D structural space, Ptarmigan embeds proteins and compounds in a shared high-dimensional mathematical space and then identifies candidate compounds by proximity in that multidimensional space. The model also has a speed advantage over other methods based on internal benchmarks from the company. They claim that since it skips the protein folding process, it runs 5,000 times faster than structure-based methods, and is capable of screening over three billion compounds against the human proteome in a day. </span></p>
<p><span>Ptarmigan-1 is currently free to scientists through a public portal. Users will be able to run a limited number of experiments for free using the platform. But for expanded usage or larger target-specific campaigns that are a heavier lift computationally, Talus is open to direct collaboration for example, partnering with a company that has validated targets and an existing assay but lacks viable molecules. </span></p>
<p><span>Collaborations will make it possible to do “some of these really massive searches that allow us to break into that really novel chemical space” and “search screens on the order of billions of compounds.” Also, “we hope someday when we have the next iterations of these [AI models] to be able to partner on those as well,” Federation said. Oncology is one the company’s primary interests, but the Talus team is also interested in targets in immunology, neurology, and cardiometabolic disease. </span></p>
<p><span>The company is committed to ensure scientists have continued access to the model by maintaining a free-access tier for our Ptarmigan models over the long term.</span> <span>As of today, Talus Bio has announced $28M in venture and non-dilutive funding. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/talus-bios-structure-free-ai-model-targets-unstructured-proteins-in-their-native-cellular-context/">Talus Bio’s Structure-Free AI Model Targets Unstructured Proteins in Their Native Cellular Context</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning</title>
<link>https://edusehat.com/en/mitochondrial-transporter-connects-body-clock-and-diet-to-fat-burning</link>
<guid>https://edusehat.com/en/mitochondrial-transporter-connects-body-clock-and-diet-to-fat-burning</guid>
<description><![CDATA[ Researchers found that SLC25A34, a little-studied protein in the mitochondria of fat cells, acts as a switch that connects the body clock, temperature, and diet to how fat cells store and spend energy. 
The post Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1407267429.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 02 Oct 2026 04:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mitochondrial, Transporter, Connects, Body, Clock, and, Diet, Fat, Burning</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Copenhagen’s NNF Center for Basic Metabolic Research (CBMR) have found that SLC25A34, a little-studied protein in the mitochondria of fat cells, acts as a switch that connects the body clock, temperature, and diet to how fat cells store and spend energy. Headed by associate professor Zach Gerhart-Hines, PhD, the findings could point to new approaches to therapeutically boost energy expenditure in metabolic disease.</p>
<p>“We usually think of the body clock, the response to temperature, and the response to food as separate systems,” said Gerhart-Hines. “A mitochondrial transporter that is tuned by the time of day, the temperature, and what we eat raises the possibility of therapies that shift when and how the body burns fuel. That would be a different kind of lever from today’s obesity and diabetes treatments.” Gerhart-Hines is co-corresponding author of the researchers’ published paper in <em>Science</em>, titled “<a href="https://doi.org/10.1126/science.adz4797" target="_blank" rel="noopener">Mitochondrial carrier SLC25A34 links clock, diet, and temperature control of adipocyte lipid cycling</a>.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“The circadian clock synchronizes physiological processes with environmental cues, integrating signals from sunlight, diet, physical activity, and temperature to optimize metabolic function across tissues,” the authors wrote. Brown adipose tissue (BAT) burns fuel to make heat, and this activity is controlled by the body clock, dropping during sleep and rising before waking. “In mice and humans, BAT metabolic activity begins to increase just before waking, peaks late in the waking period, and then declines to its lowest point during sleep,” the team noted.</p>
<p>However, a cold morning or a skipped meal makes demands the clock never planned for. How the body keeps to a fixed energetic timetable while still improvising has long been a puzzle. “How thermogenic fat can seamlessly achieve both rhythmic continuity and acute responsiveness is a fundamental question of energy homeostasis that has remained unknown,” they continued.</p>
<p>For their reported study to investigate this, the researchers started by searching large datasets for proteins in mouse brown fat that respond to both the clock and the cold. They identified UCP1, the best-known heat-producing protein, and SLC25A34, a related transporter with an as yet unknown job. In mice kept comfortably warm, brown fat contains less SLC25A34 than almost any other organ. But after 24 hours in the cold its levels rose 90-fold, making brown fat the tissue with the most SLC25A34 in the body.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>To work out how the <em>Slc25a34</em> gene is controlled, the team studied mice engineered to lack specific regulatory proteins. They found three separate controls, each answering to a different signal. A clock protein, REV-ERBα, keeps it switched off during sleep and releases it before waking. “During the sleep phase, the adipocyte clock suppresses Slc25a34 expression through the REV-transcriptional repressors,” the authors explained further. “When animals wake and REV-ERB circadian repression is lifted, the peroxisome proliferator–activated receptors α and γ (PPARα and PPARγ) αre able to bind the <em>Slc25a34</em> promoter and restore expression.” Cold also lifts the brake at any hour, overriding the schedule when extra heat is needed. And fat, from the tissue’s own stores or the diet, switches the <em>Slc25a34</em> gene on through another protein, PPARα. “… at any time, when animals are suddenly confronted with an unanticipated need for adipocyte energy expenditure such as exposure to cold temperatures or eating a lipid-rich meal, REV-ERB repression is rapidly overridden and PPARs are activated by lipolytic signals to boost SLC25A34 levels. When the energy demand is met, the REV-ERB–mediated rhythmicity of <em>Slc25a34</em> is reestablished.”</p>
<p>Seemingly paradoxically, both fasting, which promotes using fat, and insulin, the hormone that promotes building fat, increase SLC25A34 levels. This means that signals for burning and storing fat run through the same transporter. However, this is explained by the fact that active brown fat actually builds new fat molecules to then burn, a cycle that generates heat and clears fat and sugar from the blood. SLC25A34 appears to keep the cycle turning by carrying a molecule called oxaloacetate back into the mitochondria. “Our biochemical and metabolic data support a functional model in which SLC25A34 transports oxaloacetate into mitochondria,” the authors noted. Without the transporter, brown fat cells burned less fuel, and in mice the tissue’s fat-burning response was significantly weaker. The team has yet to show directly that the transporter carries oxaloacetate, or what losing it means for long-term health.</p>
<p>The researchers also found that silencing the transporter in brown fat cells from three of four human donors also reduced their fuel burning. Across 24 clinical studies, people with more SLC25A34 in the white fat beneath their skin tended to be leaner and metabolically healthier. This result is an association and does not prove cause, the team points out.</p>
<p>“Many of these mitochondrial transporters still have no known function,” said first author Iuliia Karavaeva, PhD. “This one turned out to be needed both for building fat and for burning it. And we are only scratching the surface: SLC25A34 is also highly expressed in the heart and is implicated in brain and liver metabolism, but what it does in those organs remains a mystery.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/mitochondrial-transporter-connects-body-clock-and-diet-to-fat-burning/">Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>An AI “mind&#45;reading” tool can reconstruct what you’re looking at from a brain scan</title>
<link>https://edusehat.com/en/an-ai-mind-reading-tool-can-reconstruct-what-youre-looking-at-from-a-brain-scan</link>
<guid>https://edusehat.com/en/an-ai-mind-reading-tool-can-reconstruct-what-youre-looking-at-from-a-brain-scan</guid>
<description><![CDATA[ A new AI tool can guess what you’re looking at just by analyzing your brain scans—and re-create that image with remarkable precision. It can go the other way, too, and predict a person’s brain activity based on what they’re looking at.  In the image above, for example, the left-hand image of each pair is what… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/brain-image-output.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 21:30:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>“mind-reading”, tool, can, reconstruct, what, you’re, looking, from, brain, scan</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Mind-reading, but make it science:</strong> Researchers at the Weizmann Institute have built an AI tool that reconstructs images people are looking at—just from their brain scans—with striking accuracy.</li><br><li><strong>A smarter decoder:</strong> The tool uses two AI branches—one tracking image structure, one tracking content—and cleverly trains itself on images never shown to real people, meaning it needs just one hour of brain scan data per person instead of the usual 40.</li><br><li><strong>Big promise, bigger questions:</strong> Scientists are excited about potential uses—helping paralyzed people communicate, decoding dreams, studying PTSD—but warn that as the technology moves toward consumer EEG devices, the risk of extracting someone's thoughts without consent becomes uncomfortably real.</li><br></ul>" data-chronoton-post-id="1145588" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>A new AI tool can guess what you’re looking at just by analyzing your brain scans—and re-create that image with remarkable precision. It can go the other way, too, and predict a person’s brain activity based on what they’re looking at. </p>



<p>In the image above, for example, the left-hand image of each pair is what the user actually saw—and its right-hand counterpart is what the model reconstructed from the brain scan.  </p>



<p>Michal Irani, who developed the tool with her colleagues at the Weizmann Institute of Science in Rehovot, Israel, hopes her “mind-reading” tool will ultimately reveal more about how the brain works, and could perhaps be used to help locked-in people communicate, or allow scientists to re-create the content of dreams. </p>



<p>Judy Illes, a neuroethicist and professor of neurology at the University of British Columbia in Canada, who was not involved in the research, describes the work as “magnificent.” “The idea [of using this approach] to help people with neurologic conditions … therapeutically is tremendously exciting,” she says.</p>



<p>But other scientists warn that a similar approach could be used to reveal people’s inner thoughts and mental imagery, potentially without their consent. “The results seem very impressive,” says Tommy Sprague, a neuroscientist at the University of California, Santa Barbara. “But if there’s a way to surreptitiously extract information about what you’re thinking about, then …1 50 years of sci-fi can come true anytime, and that’s worrisome in a lot of ways.”</p>



<h2 class="wp-block-heading"><strong>Peeking into the brain</strong></h2>



<p>Neuroscientists have been working for years on ways to use functional magnetic resonance imaging (fMRI) to reconstruct what people see and what’s going on in their minds. The first attempts produced images that were blurry and hard to make sense of. Advances in technology—both in the fMRI scans themselves and in the tools used to make sense of the results—have led to improvements over the years.</p>



<p>Irani and her colleagues started by analyzing publicly available brain-scan data. Other researchers had already collected scans from volunteers who were shown hundreds of images while they lay in fMRI scanners.</p>





<p>fMRI uses a giant magnet to track the flow of oxygenated blood through the brain. Brain areas that “light up” on the scans are thought to be those that are particularly active at any given moment. The results are not especially specific—in typical fMRI scanners, each highlighted “voxel” of activity covers around three cubic millimeters,<a href="https://www.nature.com/articles/s41593-024-01688-2"> containing around 16,000 neurons</a>.</p>



<p>But Irani and her colleagues used newer datasets collected using scanners with a higher resolution—each voxel covered around one cubic millimeter of neurons, she says. Those datasets showed what the brain activity of volunteers looked like when they viewed various images.</p>



<p>Other teams have done this too, and<a href="https://arxiv.org/abs/2305.18274"> several</a><a href="https://arxiv.org/abs/2404.07850"> other</a><a href="https://arxiv.org/abs/2403.18211"> tools</a> have been used to re-create images from brain-scan data. But they’re not good enough, says Irani. Say a person saw a banana. These models can generate an image of a banana, but it would look different, she says. “It wouldn’t have the same structure, the same position.”</p>



<h3 class="wp-block-heading"><strong>A better decoder</strong></h3>



<p>The researchers  wanted to more closely re-create the images that had been seen. The first step was to train an AI model on<a href="https://www.nature.com/articles/s41593-021-00962-x"> already available data</a> from eight people who each had been shown around 9,000 images while in a high-resolution fMRI scanner.</p>



<p>Crucially, their “brain decoder” has two branches—one to predict the structure of an image (where the colors are, for instance) and a second to predict its content (for example, a bunch of bananas on a plate). The predictions allow a <a href="https://www.technologyreview.com/2025/09/12/1123562/how-do-ai-models-generate-videos/">diffusion model</a>, a type of AI best known for creating video and images by gradually cleaning up a noisy mess of pixels, to produce a much more accurate representation of what the person saw.</p>



<p>But to improve the models they needed more data—far more than was actually available.  </p>



<p>To get around this problem, Irani and her colleagues trained another model—an <em>encoder</em> that can predict brain activity from an image. The team then used the encoder and decoder together to improve both tools.</p>



<p>It works like this: Start with a new image of, say, a leopard. Then use the encoder to predict what someone’s fMRI brain scan would look like when the person saw that picture. The decoder is then used to reconstruct the image. At first, the reconstruction probably won’t look much like a leopard, says Irani. But repeatedly training the models this way eventually leads to dramatic improvements.</p>



<p>This approach also allows the team to train their models on as many images as they want, even images that have never been shown to a person in an fMRI scanner. Irani says that around 70% of the training data is from images that were not originally paired with fMRI scans.</p>



<p>By combining data from multiple studies, they were also able to identify brain regions that seem to share functions across all individuals. One region seemed to respond to images of food, for example, while another responded to images of sports. Irani, a computer scientist, says she is now working with neuroscientists “to see if we can actually use these tools that we’ve developed to really find out new things about the brain.”</p>



<p>The resulting “universal brain encoder” can work on a scan from a new person with minimal calibration. In other attempts, a tool has typically required about 40 hours of fMRI data on anyone new before it can be used to predict what that person is seeing. Irani’s decoder only needs one hour of data, she says. The finding was presented at <a href="https://2026.ccneuro.org/">the Cognitive Computational Neuroscience conference</a> in New York last month.</p>



<p>That could make it valuable for neuroscientists studying the brain, says Sprague. “None of us can afford 40 hours of imaging for a new subject,” he says. “It’s something like $600 to $1,000 an hour.” Tools like this one could speed up research, he says.</p>



<h3 class="wp-block-heading"><strong>State of the art</strong></h3>



<p>The encoder and decoder aren’t perfect. “Of course we have failures,” says Irani. Over a Zoom call, she pointed out an image of a cake that her tool reconstructed as a pile of three sandwiches, and another of a dog in a bathtub that was reconstructed as a similarly colored goat in a bathtub.</p>



<p>But they represent the state of the art. In a comparison test, the tool was found to be much better than previously described ones. “All in all, really we outperformed the others by a significant margin,” Irani says. “Mind reading” is a “cute, jazzy name” for what they’re doing, she adds.</p>



<p>Irani is now planning to move beyond images to video and audio. She wants to be able to reconstruct what people are thinking about or imagining, and the contents of their dreams. “That’s something we don’t have yet,” she says. “But we’re striving to achieve it.”</p>



<p>Such a tool might enable <a href="https://www.technologyreview.com/2022/03/22/1047664/locked-in-patient-bci-communicate-in-sentences/">people who are “locked in”</a> and completely paralyzed to communicate using their brain activity alone, she says. It could also help scientists unpick some enduring mysteries surrounding the inner workings of our minds, such as what PTSD flashbacks look like.</p>



<p>Advances like this inevitably raise questions about mental privacy. What if some bad actor could reconstruct someone’s thoughts or memories?</p>



<p>“If you’d asked me that 10 years ago, I’d have laughed a lot,” says Sprague. Getting a willing person to lie still in a scanner and actively engage with a research question is hard enough; imagine making someone do it involuntarily. But Irani and other scientists are working on similar approaches to decode brain activity from EEG—electrical brain activity measures collected via a cap of electrodes or <a href="https://www.wired.com/story/this-brain-tracking-device-wants-to-help-you-work-smarter/">even through headphones</a>. </p>



<p>And as models improve, it will become even easier to analyze the brain activity collected this way. “We have to be a little more serious about the ethical considerations,” says Sprague. He thinks Irani’s approach would probably “work quite well” in predicting images that a person is thinking about but not looking at.</p>



<p>The move to EEG would be a “game changer,” says Marcello Ienca, a neuroscientist and philosopher at the Technical University of Munich, Germany. Once an EEG device has been calibrated to a user’s own brain, it could be relatively easy for companies to extract additional information from that person’s brain—potentially without consent. Ienca can also imagine some courts allowing mental image reconstructions as legal evidence.</p>



<p>“I have no doubt that this is, you know, well-intentioned research, but I think it’s also pretty obvious that it could be co-opted for … ethically and societally problematic commercial uses,” he says.</p>



<p>Irani acknowledges the potential for misuse with the use of EEG. But she’s not concerned for now. “I’m trying to think only of good things,” she says.</p>]]> </content:encoded>
</item>

<item>
<title>Designing Peptide Screens to Generate Knowledge, Not Just Hits</title>
<link>https://edusehat.com/en/designing-peptide-screens-to-generate-knowledge-not-just-hits</link>
<guid>https://edusehat.com/en/designing-peptide-screens-to-generate-knowledge-not-just-hits</guid>
<description><![CDATA[ The strongest binder from a primary screen is not necessarily the best drug starting point. Peptide discovery campaigns should capture molecular architecture, biological context, time, and developability from the outset.
The post Designing Peptide Screens to Generate Knowledge, Not Just Hits appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2274968200.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 07:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Designing, Peptide, Screens, Generate, Knowledge, Not, Just, Hits</media:keywords>
<content:encoded><![CDATA[<p>Peptide discovery is entering an era of abundance. Researchers can build larger libraries, incorporate noncanonical residues, constrain backbones in multiple ways, and use increasingly capable computational tools to propose or rank candidates. Yet many programs still organize discovery around a narrow objective: identify the strongest binder.</p>
<p>Affinity is important, but it is not a drug profile. A peptide must also be selective, soluble, synthetically tractable, sufficiently stable, and able to reach the relevant biological compartment. Depending on the program, it may need to cross a membrane, remain extracellular, internalize into a specific cell type, or sustain activity after transient exposure. A screen that reports only binding leaves these questions for later, when changing molecular direction is more expensive.</p>
<p>The next advance will not come from choosing experimental screening over computation, or computation over screening. It will come from designing experiments so that each round produces a more informative map of the chemical and biological landscape.</p>
<p></p><h4><strong>Library is already part of the hypothesis</strong></h4>

<p>A peptide library is never truly unbiased. Its length distribution, residue alphabet, cyclization chemistry, topology, display format, and synthesis method determine which molecules can be produced and which conformations can be explored. These choices also influence stability, solubility, permeability, and presentation of binding groups.</p>
<p>Peptide function is not encoded by sequence alone. Two molecules with similar residue composition can behave differently when one is linear and the other is cyclic, when stereochemistry changes, or when a backbone amide is modified. For constrained peptides, linkage position and ring topology can reorganize the conformational ensemble. A sequence-only analysis may therefore group together molecules that are chemically and pharmacologically distinct.</p>
<p>Recent work illustrates the opportunity. A 2026 <a href="https://www.nature.com/articles/s41589-026-02237-7" target="_blank" rel="noopener">study</a> screened 15,360 fully random, sub-kilodalton cyclic peptides and identified a starting point against the intracellular Keap1–Nrf2 protein–protein interaction. Iterative design, synthesis, and testing produced a membrane-permeable inhibitor active in living cells. The broader lesson is that binding and permeability can be treated as connected design problems rather than sequential hurdles.</p>
<figure aria-describedby="caption-attachment-338658" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-338658 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-1024x474.jpg" alt="Figure 1. Conventional funnel versus information-rich workflow. The revised workflow introduces architecture diversity, counterscreens, functional assays, and property measurements before lead selection. [Sethera Therapeutics]" width="1024" height="474" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-1024x474.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-300x139.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-768x355.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-1536x710.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig1_White-1-2048x947.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text"><em>Figure 1. Conventional funnel versus information-rich workflow. The revised workflow introduces architecture diversity, counterscreens, functional assays, and property measurements before lead selection. [Sethera Therapeutics]</em></figcaption></figure>
<p></p><h4><strong>Screen in biological space, not only against a target</strong></h4>

<p>Purified-protein screens remain useful, particularly when material is limited or throughput is essential. But the assay format can become an unintended selection pressure. Peptides may recognize a purification tag, a surface, an exposed hydrophobic patch, or a conformation poorly represented in the native setting. High apparent affinity can also reflect nonspecific interactions that disappear in another assay.</p>
<p>The solution is not to force every primary screen into a complex cellular system. It is to design a staged assay hierarchy before screening begins. Early counterselections can remove binders to tags, matrices, related proteins, or abundant off-targets. Competition experiments can test dependence on the intended epitope. Homolog counterscreens can reveal selectivity within a target family.</p>
<p>Orthogonal confirmation through kinetic binding, solution-phase competition, biochemical function, or cell-based activity can distinguish reproducible target engagement from assay-specific behavior.</p>
<p>For intracellular programs, permeability and functional activity should enter the workflow as soon as candidate numbers permit. For extracellular targets, serum stability, target turnover, tissue context, and the consequences of sustained versus transient engagement may matter more. The objective is not to measure every property immediately, but to ensure that the screening cascade reflects where the molecule must ultimately work.</p>
<p>Most screening readouts are snapshots. Biology is not. An endpoint measurement can obscure differences in association rate, dissociation rate, target rebinding, internalization, degradation, or intracellular retention. A peptide with modest equilibrium affinity but a slow off-rate may produce stronger functional activity than a tighter binder that dissociates rapidly. Conversely, prolonged engagement may be undesirable when an off-target interaction creates risk.</p>
<p>Time can be incorporated in practical ways. Selection pressure can be increased by extending wash periods or adding soluble competitor. Candidates can be tested after defined exposure to serum, proteases, reducing conditions, or relevant tissue fluids. Cellular assays can separate immediate pathway modulation from activity that persists after washout. Internalization and cytosolic access can be measured at multiple time points rather than inferred from one image.</p>
<p>Round-by-round enrichment also contains temporal information. A sequence that rises steadily may be more credible than one that appears abruptly after a bottleneck. Intermediate sequencing data can reveal early enrichment, late artifacts, and architecture families that respond differently as selection pressure changes.</p>
<p></p><h4><strong>Preserve the reasons molecules fail</strong></h4>

<p>The final hit list is often the least informative version of a screening dataset. It contains the winners but discards much of the evidence needed to understand why they won.</p>
<p>For peptide programs, “inactive” is not a single label. A candidate may fail because it was not produced efficiently, did not display correctly, was not cyclized or otherwise modified, aggregated, degraded, bound nonspecifically, failed to enter cells, or reached the target without changing function. These outcomes should not be collapsed into one negative class. A model trained on them would be asked to learn biology from a mixture of technical and pharmacological failures.</p>
<p>Useful datasets require provenance. Starting-library abundance, enrichment by round, control behavior, counterscreen results, synthesis yield, purity, modification efficiency, assay conditions, batch identity, and detection limits should travel with each sequence. Missing values also need interpretation. “Not detected” can mean below an assay threshold, absent from the starting population, lost during processing, or simply not tested.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p><figure aria-describedby="caption-attachment-338660" class="wp-caption aligncenter"><img decoding="async" class="wp-image-338660 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2-.jpg" alt="Figure 2. Four dimensions of a peptide dataset: sequence and architecture, biological context, time-dependent behavior, and developability. Technical failures remain distinct from biological negatives. [Sethera Therapeutics]" width="1000" height="750" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2-.jpg 1000w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2--300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Sethera_Fig2--768x576.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px"><figcaption class="wp-caption-text"><em>Figure 2. Four dimensions of a peptide dataset: sequence and architecture, biological context, time-dependent behavior, and developability. Technical failures remain distinct from biological negatives. [Sethera Therapeutics]</em></figcaption></figure>This discipline changes what computation can do. Instead of predicting one binding score, models can identify relationships among architecture, affinity, selectivity, stability, permeability, solubility, and synthetic performance. They can also expose uncertainty, which is often more useful for choosing the next experiment than a confident-looking rank order.</p>
<p>Physics-based modeling and machine learning are often presented as competing approaches. In peptide discovery, they are more useful when assigned complementary roles.</p>
<p>Physics-based calculations can examine conformational ensembles, intramolecular hydrogen bonding, solvent exposure, target contacts, and the consequences of a specific substitution. They are especially valuable when experimental data are sparse or a mechanistic explanation is needed. Their limitations include computational cost, sampling challenges, and sensitivity to the underlying model.</p>
<p>Machine learning can recognize relationships across larger datasets, rank candidates, propose combinations a human team might not prioritize, and support multi-parameter optimization. Recent <a href="https://www.nature.com/articles/s42256-026-01237-5" target="_blank" rel="noopener">work</a> has coupled generative models with Bayesian optimization and prospective synthesis and testing to improve peptide scaffolds under experimentally defined constraints. Deep-learning methods are also becoming more capable of cyclic-peptide structure prediction and redesign, although limited training data remain a central challenge.</p>
<p>The most productive workflow uses physical insight to define plausible chemical space, experimental data to anchor predictions, and machine learning to identify the next informative measurements. Optimization should not collapse every objective into one opaque score. Teams should examine trade-offs directly: a modest loss in affinity may be acceptable if it produces a major gain in selectivity, stability, permeability, or manufacturability.</p>
<p></p><h4><strong>Build the learning strategy before the first hit</strong></h4>

<p>An integrated peptide campaign can be organized around five decisions. First, define the intended product profile early. Target compartment, route of administration, dosing expectations, selectivity requirements, and minimum functional effect should shape the screen.</p>
<p>Second, make molecular architecture an explicit variable. Sequence diversity matters, but diversity of constraint, stereochemistry, backbone composition, and topology may reveal different solutions to the same target.</p>
<p>Third, establish the assay hierarchy and controls in advance. Primary enrichment, counterscreens, orthogonal binding, functional activity, and developability measurements should answer distinct questions rather than repeatedly measure the same one.</p>
<p>Fourth, retain complete and interpretable data, including technical failures and uncertain outcomes. Computational methods cannot repair labels that confound failed production with failed biology.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Finally, test models prospectively. A model that explains an existing dataset may still fail on new architecture classes or assay conditions. The meaningful test is whether it selects the next peptides better than established heuristics—and whether those results improve the following round.</p>
<p>The output of a peptide screen should not be viewed only as a ranked list. It should be a calibrated map showing which sequences and architectures succeed under which conditions—and where uncertainty remains.</p>
<p>That map can reveal whether a target favors a particular topology, whether a stability gain repeatedly costs function, whether a permeability strategy generalizes, and which measurements best predict cellular activity. It can also prevent teams from optimizing an impressive binder that was never compatible with the intended medicine.</p>
<p>Peptide discovery will continue to benefit from larger libraries and more capable algorithms. But scale alone does not guarantee learning. The programs that move most efficiently will treat library design, screening, functional biology, physics, and machine learning as parts of one experimental system—built not merely to find a winner, but to understand how to make the next molecule better.</p>
<p class="trimmed"> </p>
<p><em>Karsten Eastman, PhD, is the CEO and co-founder of Sethera Therapeutics.</em></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/designing-peptide-screens-to-generate-knowledge-not-just-hits/">Designing Peptide Screens to Generate Knowledge, Not Just Hits</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Autism Target Discovered in Endothelial Cells in Genetic Deletion Mouse Model</title>
<link>https://edusehat.com/en/autism-target-discovered-in-endothelial-cells-in-genetic-deletion-mouse-model</link>
<guid>https://edusehat.com/en/autism-target-discovered-in-endothelial-cells-in-genetic-deletion-mouse-model</guid>
<description><![CDATA[ Researchers reversed certain behavioral symptoms in a 16p11.2 deletion mouse model of autism spectrum disorder by activating the P2Y2 receptor in endothelial cells of brain blood vessels, which increased blood flow in the brain. 
The post Autism Target Discovered in Endothelial Cells in Genetic Deletion Mouse Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/05/Getty_1015900158_AutismBrain-1024x683.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 07:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Autism, Target, Discovered, Endothelial, Cells, Genetic, Deletion, Mouse, Model</media:keywords>
<content:encoded><![CDATA[<p>Researchers at The Ottawa Hospital and at the University of Ottawa have been able to reverse certain behavioral symptoms in a mouse model of autism by fixing a problem in the endothelial cells (ECs) of brain blood vessels. Building on studies in a 16p11.2 deletion mouse model of ASD that identified brain endothelial cell abnormalities, the team linked 16p11.2 deletion with reduced levels of ATP in endothelial cells. They found that activating P2Y2 receptors rescued the 16p11.2-deletion-associated mouse behaviors.</p>
<p>The results present a promising new treatment target for autism spectrum disorder (ASD) symptoms. “The road from discovery to clinical trials is long, but we’re excited by the possibility that our findings might one day improve the daily lives of people with autism,” said Baptiste Lacoste, PhD, senior scientist at The Ottawa Hospital and professor at the University of Ottawa.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Baptiste is senior author of the team’s published paper in <em>Neuron </em><em>(“</em><a href="https://doi.org/10.1016/j.neuron.2026.09.009" target="_blank" rel="noopener">Purinergic receptor activation rectifies autism-associated endothelial dysfunction</a>”), in which they concluded “These findings suggest that P2Y2 receptor activation represents a promising strategy to rescue brain EC dysfunction and, in turn, improve autism-related behaviors in the 16p11.2 deletion ASD syndrome.”</p>
<p>Autism is a neurodevelopmental condition with widely varying characteristics. Some of the behavioral symptoms can make life more challenging. While many people with autism have found ways to manage these symptoms, no drug treatment exists.</p>
<p>Lacoste’s team <a href="https://doi.org/10.1038/s41593-020-0663-1" target="_blank" rel="noopener">previously discovered</a> that blood vessels in the brain don’t work properly in mouse models with a 16p11.2 deletion, one of the most common genetic mutations seen in autism. They were the first to look at what was happening in the blood vessels of the brain. “Recent evidence in a 16p11.2 deletion mouse model of autism spectrum disorder (ASD) revealed brain endothelial abnormalities postnatally, but the endothelial alterations eliciting these changes remain unknown,” they wrote.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Through their newly reported work the researchers have now found that the problem began in the endothelial cells lining the blood vessels. These cells make sure blood quickly gets to the parts of the brain that are active. This responsive blood supply is needed for proper brain function.</p>
<p>However, the endothelial cells in the 16p11.2 deletion mice don’t respond quickly enough. This happens early in brain development and causes behavioral symptoms later in life, including hyperactivity, repetitive movements, and motor learning impairment.</p>
<p>Headed by former PhD student, Julie Ouellette, PhD, the research team looked at what was wrong with these endothelial cells and whether it could be fixed. They discovered that the cells had half the normal level of ATP. “We demonstrate that 16p11.2 deletion induced EC dysfunction is caused by a bioenergetic failure with reduced intracellular ATP,” they explained. While ATP is usually considered an energy molecule, in this case the cell was missing its target, called a P2Y2 receptor, on its surface. “The identified energetic failure was restricted to ECs, emphasizing these cells as key contributors to ASD pathophysiology,” the investigators added.</p>
<p>By activating this P2Y2 receptor, the researchers were able to restore the cell’s function, increase blood flow in the brain, and reverse the behavioral symptoms in adult mice. This was achieved using a drug known to activate P2Y2 and which is currently approved for humans in Japan and South Korea to treat dry eye syndrome.</p>
<p>“Activation of ATP signaling via endothelial P2-class purinergic receptors, specifically P2Y2, rescued EC dysfunction, restoring angiogenic capacity <em>in vitro</em>, endothelium-dependent cerebrovascular reactivity <em>ex vivo</em>, and activity-dependent cerebral blood flow (CBF) <em>in vivo</em>,” the team stated. “A selective pharmacological P2Y2 agonist also rescued adult 16p11.2-deficient behavioral phenotypes.”</p>
<p>Lacoste said, “It’s as if these cells are asleep, and now we can wake them up. And we may only need to treat them once to wake them up permanently. We will test that further, but it’s an encouraging feature for a future treatment.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>In their paper the authors concluded, “Taken together, this study demonstrates that metabolic reprogramming of brain ECs via purinergic receptor engagement represents a promising therapeutic avenue for ASD.” They also point out that the study only looked at adult mice. This means targeting P2Y2 could reverse behavioral symptoms that were already well established.</p>
<p>Next, the team plans to treat mice earlier in life to see if early treatment has additional benefits. The team has also filed a patent application for using P2Y2 activation in the blood vessels to treat autism symptoms. They are interested in exploring drug development with the aim of eventual clinical trials.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/autism-target-discovered-in-endothelial-cells-in-genetic-deletion-mouse-model/">Autism Target Discovered in Endothelial Cells in Genetic Deletion Mouse Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Microbiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age</title>
<link>https://edusehat.com/en/microbiome-patterns-vary-among-individuals-with-different-cancer-types-and-onset-age</link>
<guid>https://edusehat.com/en/microbiome-patterns-vary-among-individuals-with-different-cancer-types-and-onset-age</guid>
<description><![CDATA[ Researchers analyzing pre-treatment stool samples from 1,364 cancer patients across cancer types, stages, and treatments discovered that adults aged 50 years or younger with colorectal and breast cancers have distinct gut microbiome patterns compared with individuals diagnosed later in life. 
The post Microbiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/03/GettyImages-2151078512.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microbiome, Patterns, Vary, Among, Individuals, with, Different, Cancer, Types, and, Onset, Age</media:keywords>
<content:encoded><![CDATA[<p>Mayo Clinic researchers have discovered that adults aged 50 years or younger with colorectal and breast cancers have distinct gut microbiome patterns compared with individuals diagnosed later in life. The new finding results from the team’s analysis of stool samples from 1,364 cancer patients across cancer types, stages and treatments, enrolled into the Mayo Clinic Cancer Microbiome (MCCM) cohort, a real-world study that recruited cancer patients at Mayo Clinic in Arizona, Florida and Minnesota, representing 40 states. Stool samples were collected before treatment began and linked to detailed clinical data on side effects and outcomes.</p>
<p>Purna Kashyap, MBBS, director of the Mayo Clinic Microbiome Program and Bernard and Edith Waterman Director, Microbiomics Program, Mayo Clinic Center for Individualized Medicine, and Ruben Mars, PhD, a microbiome researcher at Mayo Clinic in Minnesota, are co-corresponding authors of the researchers’ published paper in <em>Cell</em>, titled “<a href="https://doi.org/10.1016/j.cell.2026.09.009" target="_blank" rel="noopener">Microbiome signatures linked to cancer and treatment adverse events in a real-world cohort</a>.”</p>
<p>“The gut microbiome reflects an individual’s environment, lifestyle, diet, and physiological state, making it a sensitive barometer of overall health,” the authors wrote. Increasing evidence is implicating the gut microbiome in cancer biology, pointing to links between composition and function to disease development and treatment outcomes. “As the field shifts from association to causality, a key challenge is prioritizing microbes and pathways most likely to drive specific cancers.”</p>
<p>For their reported study the investigators conducted a real-world study of 1,364 Mayo Clinic Cancer Microbiome cohort patients with different cancer types, before starting a new treatment. “This cohort captures the diversity of cancers and treatments encountered in clinical practice, providing a robust foundation for uncovering microbiome signatures specific to individual cancers,” they wrote.</p>
<p>The investigators compared the cancer patients with 287 people without cancer to identify broad microbiome differences. Comparisons across cancers then revealed more specific signals. After accounting for other health conditions, researchers pinpointed 341 bacterial species associated with five cancer groups.</p>
<p>Among those, neuroendocrine tumors showed a broad loss of common health-associated gut bacteria. Liver and intrahepatic bile duct cancers had higher levels of several bacteria, including <em>Enterococcus faecalis</em>. Esophageal cancer had higher levels of six species, including <em>Streptococcus</em> bacteria. Distinct links were also found in lymphoid leukemia and multiple myeloma and related plasma cell cancers.</p>
<p>“We can now narrow the search to those microbial changes that are most specific to individual cancers,” said Mars. “Those are the signals we need to understand first if we want to determine whether the microbiome plays a causal role in cancer and ultimately develop targeted interventions.”</p>
<p>The study findings indicated that among younger patients, those with colorectal cancer had higher lactate levels and more <em>Veillonella parvula</em>, a gut bacterium that feeds on lactate. Tumors can produce high levels of lactate, which <em>V. parvula</em> uses to grow. Whether that relationship plays a role in early-onset disease is not yet known.</p>
<p>Early-onset (EO) breast cancer showed changes across 64 bacterial species and lower levels of primary bile acids. In breast cancer, one of the 64 species that differed in younger patients was <em>Clostridium scindens</em>, a bacterium involved in bile acid and steroid metabolism.</p>
<p>Colorectal and breast cancer rates are rising among younger adults, the authors stated. Colorectal cancer incidence is increasing about three percent a year among adults ages 20 years to 49 years, while breast cancer incidence is rising 1.4% a year among women younger than 50 years, according to the American Cancer Society. And while the colorectal and breast cancer findings do not establish that these microbial or metabolic differences cause early-onset disease, but they identify links that warrant further study. No comparable age-related microbiome differences were found in brain cancer, the third cancer examined in the early-onset analysis.</p>
<p>Researchers identified gut bacteria associated with survival in colorectal, liver and intrahepatic bile duct, ovarian and prostate cancers, and melanoma. In liver and intrahepatic bile duct cancer, <em>Bifidobacterium longum</em> was associated with longer survival and <em>Blautia A massiliensis</em> with shorter survival.</p>
<p>Researchers also studied whether the gut microbiome before treatment was associated with diarrhea during chemotherapy, a side effect that can make treatment harder to tolerate. Among patients receiving 5-fluorouracil, or 5-FU, a chemotherapy used to treat many types of cancer, those who later developed diarrhea had lower levels of bacterial genes capable of breaking down the drug. Much of that function came from <em>Anaerostipes hadrus</em>, a common gut bacterium. “This example underscores the potential of leveraging our real-world mixed-cancer, mixed-treatment cohort to identify microbiome-driven mechanisms underlying cancer treatment-related adverse effects,” they wrote. The same signal was not linked to diarrhea in patients receiving carboplatin, another chemotherapy drug, suggesting the finding was specific to 5-FU.</p>
<p>“The microbiome is not the sole driver of cancer or treatment outcomes, but it is an underappreciated component that has not traditionally been considered in therapeutic approaches,” said Kashyap. “This gives us a proof of concept that we can begin to understand why some patients experience a particular side effect and identify a target that could potentially be acted upon.”</p>
<p>The researchers next aim to investigate whether cancer-specific microbial signals play a causal role in disease and validate the microbiome’s potential to predict treatment side effects in larger patient groups. In their paper the team concluded, “Our findings illustrate how MCCM, a large, real-world mixed-cancer, mixed-treatment cohort, complements traditional case-control designs by more precisely identifying microbial contributions to cancer pathogenesis, EO cancer, and treatment-related adverse events … These findings demonstrate the strength of our cohort and provide a foundational resource for the discovery of cancer-specific microbiome signatures and predictive biomarkers.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/microbiome-patterns-vary-among-individuals-with-different-cancer-types-and-onset-age/">Microbiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing Brain Organoids from Research Models to Scalable Platforms</title>
<link>https://edusehat.com/en/advancing-brain-organoids-from-research-models-to-scalable-platforms</link>
<guid>https://edusehat.com/en/advancing-brain-organoids-from-research-models-to-scalable-platforms</guid>
<description><![CDATA[ In this GEN webinar, Joseph Shultz (VP of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (VP of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. 
The post Advancing Brain Organoids from Research Models to Scalable Platforms appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2228457143.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, Brain, Organoids, from, Research, Models, Scalable, Platforms</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
        Panelists:
    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/AliStrtak_Headshot.jpg" class="h-full w-full object-cover" alt="Image of Ali Strtak, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Ali Strtak, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Product Manager, Organoids<br>Bio-Techne</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/AliStrtak_Headshot.jpg" alt="Image of Ali Strtak, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Ali Strtak, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Ali Strtak, PhD<strong>, </strong>is product manager for organoids at Bio-Techne. Ali earned her PhD studying the mechanisms of enteric viral infections, using intestinal organoid models to understand how nonstructural viral proteins co-opt host pathways and boost replication, and how that, in turn, translates to the physical manifestations of disease. She published the first functional characterization of a virally encoded calcium ion channel in the <em>Caliciviridae</em> family. Optimizing culture conditions as well as calcium imaging protocols for that work gave her firsthand experience with how culture variability and reagent selection underpin and undermine reproducibility in organoid models. In her current role, she focuses on standardizing organoid culture to make the model more consistent experiment over experiment and more accessible to all researchers interested in getting into organoids, regardless of prior 3D culture expertise.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/Fikri-Birey-headshot-e1790783645613.jpg" class="h-full w-full object-cover" alt="Image of Fikri Birey, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Fikri Birey, PhD</h2>
                <h5 class="mt-0 !text-[15px] !leading-[21px]">Assistant Professor, Department of Human Genetics<br>Emory University School of Medicine</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/Fikri-Birey-headshot-e1790783645613.jpg" alt="Image of Fikri Birey, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Fikri Birey, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Fikri Birey, PhD<strong>,</strong> is an assistant professor in the Department of Human Genetics at Emory University School of Medicine, where he leads a research program focused on uncovering the molecular and cellular mechanisms of human brain development and neurodevelopmental disorders. His lab employs stem cell-derived brain organoids and assembloids to model disease-relevant processes, with particular emphasis on disorders such as autism, epilepsy, and schizophrenia. Birey completed his PhD in genetics at Stony Brook University and postdoctoral research at Stanford University in the laboratory of Sergiu Pasca, MD, where he built the first assembloid platform and applied it to uncover previously inaccessible disease phenotypes and nominate novel therapeutics in Timothy syndrome. He also co-founded the Brain Organoid Hub at Emory, which serves as a central resource for scalable and standardized human brain organoid research. Through this work, Birey aims to bridge basic neurobiology with therapeutic discovery, advancing precision medicine for complex brain disorders.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, October 22, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-22T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present significant challenges for manufacturing teams. Non-standard architectures can often translate to low expression and difficult developability, making cell line development a critical bottleneck between a promising sequence and a viable clinical candidate.</p><p></p><p></p><p class="wp-block-paragraph"><br>In this <em>GEN </em>webinar, Joseph Shultz (vice president of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (vice president of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. Attendees will learn about the unique attributes of Ottimo’s molecule and how a specialist partnership with Asimov accelerated the program. The presenters will also introduce the CHO Edge System, which combines Asimov’s proprietary GS knock-out CHO host, hyperactive transposase, library of characterized genetic elements, and AI-driven genetic design tools to routinely deliver clonal titers of 8-12 g/L.</p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><p><figure class="wp-block-image alignleft size-medium"><a href="https://www.bio-techne.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="56" src="https://www.genengnews.com/wp-content/uploads/2018/10/biotechne_CMYK_logo9124350201-300x56.jpg" alt="biotechne logo" class="wp-image-76009" srcset="https://www.genengnews.com/wp-content/uploads/2018/10/biotechne_CMYK_logo9124350201-300x56.jpg 300w, https://www.genengnews.com/wp-content/uploads/2018/10/biotechne_CMYK_logo9124350201.jpg 500w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/advancing-brain-organoids-from-research-models-to-scalable-platforms/">Advancing Brain Organoids from Research Models to Scalable Platforms</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genome&#45;Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target</title>
<link>https://edusehat.com/en/genome-wide-analysis-identifies-bach2-as-potential-fetal-hemoglobin-activation-target</link>
<guid>https://edusehat.com/en/genome-wide-analysis-identifies-bach2-as-potential-fetal-hemoglobin-activation-target</guid>
<description><![CDATA[ This pathway, which the authors dub the “BACH2-NRF2 axis,” is independent of the well-known BCL11A transcription regulator, the target of the approved cell therapy Casgevy for sickle cell disease (SCD).
The post Genome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_532104607_BloodCells-e1790792336784.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genome-Wide, Analysis, Identifies, BACH2, Potential, Fetal, Hemoglobin, Activation, Target</media:keywords>
<content:encoded><![CDATA[<p>In a major new genome-wide meta-analysis, researchers at Boston Children’s Hospital and the Broad Institute led by Vijay G. Sankaran, MD, PhD, have identified a novel regulatory pathway that activates the expression of fetal hemoglobin (HbF). This pathway, which the authors dub the “BACH2-NRF2 axis,” is independent of the well-known BCL11A transcription regulator, the target of the approved cell therapy Casgevy for sickle cell disease (SCD).</p>
<p>The Boston study raises the interesting prospect of an accessible new target for therapeutic development. The paper, published today in <em>Nature</em>, is entitled: “<a href="https://www.nature.com/articles/s41586-026-11113-2" target="_blank" rel="noopener">Human genetics implicates a BACH2-NRF2 axis in fetal hemoglobin activation</a>.”</p>
<p>These new findings “establish the BACH2–NRF2 axis as a tractable and potentially therapeutically targetable regulatory node involved in HbF activation,” the authors write.</p>
<figure aria-describedby="caption-attachment-338680" class="wp-caption alignleft"><img decoding="async" class="wp-image-338680" src="https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-300x300.jpg" alt="Vijay Sankaran" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/VijaySankaran_headshot.jpg 1400w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Vijay Sankaran, MD, PhD<br>[Boston Children’s Hospital]</figcaption></figure>
<p>For the past few decades, researchers have focused on the fetal-to-adult hemoglobin switch as a potential therapeutic avenue for SCD and thalassemia. Fetal hemoglobin expression declines naturally in the first 6-12 months after birth, replaced by adult hemoglobin. Almost 20 years ago, teams led by Swee-Lay Thein, MD, and, separately, Sankaran and Stuart Orkin, MD, identified BCL11A as a key regulator of that switch. The approval in December 2023 of Casgevy, the gene editing therapy sponsored by Vertex and CRISPR Therapeutics, provided clinical validation of that strategy and has transformed the lives of scores of SCD and thalassemia patients.</p>
<p>In the <em>Nature </em>report, Sankaran’s team analyzed a trove of genome-wide association study (GWAS) data from more than 28,000 individuals spread across European, African, and Asian populations. The study identified 91 discrete genetic associations across 12 genomic regions. One of the strongest signals, albeit weaker than the original GWAS findings two decades ago, highlighted a novel regulatory circuit—the BACH2–NRF2 axis—that directly governs γ-globin gene expression.</p>
<p></p><h4><strong>BACH2 variations </strong></h4>

<p>BACH2 is a known transcription regulator, Sankaran told <em>GEN</em>, but it was not previously suspected as having a role in HbF regulation. Sankaran’s team performed studies to pinpoint the precise genetic variant that contributed to the GWAS signal. The causal variant—rs1010474-C—reduces expression of BACH2 in erythroid progenitor cells. Genetic and biochemical experiments to block BACH2, either using short hairpin RNA knockdown, base editing, or pharmacological inhibition using a small-molecule inhibitor, led to marked elevation of γ-globin transcription (one of the two globin chains that make up HbF) and increased the proportion of HbF-containing red blood cells without disrupting normal erythropoiesis.</p>
<p>Sankaran’s team went on to demonstrate that BACH2 functions as a direct repressor at the γ-globin promoter and locus control region LCR. Under baseline conditions, BACH2 restricts chromatin occupancy of the transcriptional activator, NRF2. But if BACH2 is lost or inhibited, NRF2 binding is able to expand across γ-globin regulatory elements. Loss of BACH2 triggers the formation of discrete nuclear NRF2 foci that specifically colocalize with active sites of γ-globin transcription.</p>
<p>By mapping the transcription factor binding sites, the team identified overlapping consensus motifs for BACH2 (−94 to −106) and NRF2 (−96 to −105) within the upstream γ-globin promoter. Using base editors, the team engineered single-nucleotide substitutions to study the impact of targeted point mutations on gene expression. Promoter variants including −98G>A, −99G>A, and −104G>A—similar to those that might be contemplated in a therapeutic setting—reduced BACH2 binding affinity while enhancing NRF2 binding, resulting in robust HbF expression. Biochemical analysis further confirmed a direct protein interaction between domains of BACH2 and NRF2, indicating that BACH2 physically interacts with NRF2 to mute its transcriptional activity.</p>
<p></p><h4><strong>Parallel pathways </strong></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p>The <em>Nature </em>study from Sankaran’s team also shows that the BACH2–NRF2 axis operates independently of BCL11A. The BACH2–NRF2 promoter motif is sandwiched between two BCL11A binding sites. The researchers found no evidence of direct physical contact between BCL11A and BACH2 or NRF2. Furthermore, simultaneous depletion of both BACH2 and BCL11A yielded additive increases in γ-globin expression, suggesting the potential for multi-target genetic or pharmacological therapies.</p>
<p>Sankaran tells <em>GEN </em>he is excited by the finding that the BACH2 pathway is “completely independent of the BCL11A repressive pathway and is primarily involved in activation of HbF. So, combined editing at the [gamma-globin] promoters,” in addition to what companies like Shanghai-based CorrectSequence Therapeutics is doing at the BCL11A binding site, “could also be beneficial.”</p>
<p>Addressing the translational potential of their work, Sankaran and colleagues emphasize that “the presence of high-confidence human genetic evidence is a more critical predictor of clinical success than the absolute magnitude of the variant effect size.”</p>
<p>Naturally, this report raises the intriguing prospect of new avenues for combining BCL11A-targeted strategies with BACH2/NRF2 modulation for treating SCD and β-thalassemia. “There are already small molecules in development for SCD that we suspect might target BACH2,” Sankaran said. “I think our findings add clarity on the mechanism by which this pathway might modulate HbF.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/genome-wide-analysis-identifies-bach2-as-potential-fetal-hemoglobin-activation-target/">Genome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation Target</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>MRSA Exploits Kidney’s Inner Environment to Persist and Spread</title>
<link>https://edusehat.com/en/mrsa-exploits-kidneys-inner-environment-to-persist-and-spread</link>
<guid>https://edusehat.com/en/mrsa-exploits-kidneys-inner-environment-to-persist-and-spread</guid>
<description><![CDATA[ New research reveals how MRSA exploits the kidney’s hyperosmotic inner medulla to evade immune defenses, establish a persistent reservoir, and spread, while suggesting potential therapeutic strategies to limit infection.
The post MRSA Exploits Kidney’s Inner Environment to Persist and Spread appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-523568832.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 01 Oct 2026 03:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>MRSA, Exploits, Kidney’s, Inner, Environment, Persist, and, Spread</media:keywords>
<content:encoded><![CDATA[<p><span>Methicillin-­resistant <em>Staphylococcus aureus</em> (MRSA) has rapidly risen to become one of the gravest threats to global health, with deaths from <em>Staphylococcus aureus (</em><em>S. aureus)</em><em> </em>having doubled worldwide since 1990. In severe cases, the bacteria invade the bloodstream in life-threatening systemic infections, which have a high risk of kidney injury and failure.</span></p>
<p><span><em>S. aureus </em>is one of the most concerning bacterial pathogens, given that MRSA accounts for the largest increase in the global antimicrobial resistance burden. In addition, deaths attributable to <em>S. aureus</em> infections have doubled since 1990, making it a leading cause of bacterial mortality worldwide. Despite the continued focus on research, tissue reservoirs that permit bacterial persistence remain poorly defined.</span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Now, a new study reveals how MRSA exploits the osmotic environment of the inner kidneys to establish a bacterial reservoir and hide from the immune system. This work suggests that MRSA can establish niches in the kidneys and the findings provide a mechanistic explanation for a longstanding question in the field of MRSA biology, and could inform future strategies aimed at limiting kidney damage from infections.</span></p>
<p><span>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.aed4200" target="_blank" rel="noopener">Hyperosmotic niche adaptation and tissue polyamines underlie MRSA persistence in the kidney</a>.”</span></p>
<p><span>Nobuhiro Kanazawa, PhD, and colleagues used intravenous MRSA infection in mice and combined with multi-plexed imaging, dual-species transcriptomics, host and bacterial genetics, and cell-­based assays, to understand the mechanisms of MRSA persistence in the kidney in a mouse model of systemic infection. The findings reveal the renal inner medulla, the site of urine concentration, as an MRSA reservoir. Here, in this hyperosmotic niche, MRSA evaded immune detection and co-opted tissue polyamines to grow and spread toward the renal cortex.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>MRSA spread to other kidney tissues and grew by co-opting polyamines, which buttressed the bacterial membrane against osmotic stress and boosted the translation of a growth-fueling bacterial enzyme.</span></p>
<p><span>The extreme osmotic environment also shielded MRSA from immune detection and slowed the migration of neutrophils toward the infection site. More specifically, neutrophil recruitment to the inner medulla was delayed.</span></p>
<p><span>The team went on to find that the approved drug furosemide restored neutrophil infiltration and contained MRSA’s spread in the kidneys of mice, hinting that similar “washout” therapies might prove useful. The authors write, “disruption of medullary osmolality with the loop diuretic furosemide accelerated neutrophil infiltration, limited bacterial spread, and improved renal outcomes.”</span></p>
<p><span>The findings, the authors note, revealed the inner medulla as a physiologically immune-­restricted MRSA reservoir and supported “modulation of medullary osmolality and bacterial polyamine metabolism as candidate adjunctive strategies for limiting renal persistence and dissemination during MRSA bacteremia.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/mrsa-exploits-kidneys-inner-environment-to-persist-and-spread/">MRSA Exploits Kidney’s Inner Environment to Persist and Spread</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI and Proteomics Accelerate VAV1 Molecular Glue Discovery</title>
<link>https://edusehat.com/en/ai-and-proteomics-accelerate-vav1-molecular-glue-discovery</link>
<guid>https://edusehat.com/en/ai-and-proteomics-accelerate-vav1-molecular-glue-discovery</guid>
<description><![CDATA[ High-throughput proteomics combined with AI-based structural modeling helped researchers discover molecular glues that degrade VAV1. The approach could support new therapies for blood cancers and autoimmune diseases.
The post AI and Proteomics Accelerate VAV1 Molecular Glue Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/02/GettyImages-1463834926-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 13:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>and, Proteomics, Accelerate, VAV1, Molecular, Glue, Discovery</media:keywords>
<content:encoded><![CDATA[<p>Molecular glues act as matchmakers with a destructive streak: They bring disease-linked proteins into contact with the cell’s disposal machinery, marking them for elimination. Now, researchers have combined high-throughput proteomics with artificial intelligence (AI) to discover and optimize molecular glues that degrade VAV1, an immune-cell signaling protein implicated in blood cancers and autoimmune diseases.</p>
<p>The Baylor College of Medicine-led study, “<a href="https://www.nature.com/articles/s41467-026-77657-z" target="_blank" rel="noopener">Leveraging high-throughput proteomics and AI-based protein folding to accelerate VAV1 molecular glue discovery</a>,” was published in <em>Nature Communications</em>. The team was led by senior and co-corresponding author Jin Wang, PhD, director of Baylor’s Center for NextGen Therapeutics, and first and co-corresponding author Hanfeng Lin, PhD, a postdoctoral researcher in Wang’s laboratory.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Many scientists are increasingly exploring a new way to treat disease: instead of blocking harmful proteins, they aim at eliminating them entirely,” Wang said. Because degradation via molecular glue removes the whole protein rather than inhibiting one of its functions, the strategy could produce a more complete therapeutic effect.</p>
<p>“To find compounds capable of degrading VAV1, we screened a library of molecules using high-throughput proteomics, a technology that can assess thousands of proteins simultaneously. This unbiased analysis revealed a series of compounds, including NGT-201-12, that caused VAV1 levels to drop while affecting relatively few other proteins,” added Lin. Follow-up studies showed that degradation depended on the proteasome and cereblon (CRBN), a component of the cell’s protein-degradation pathway.</p>
<p>The team then developed GluePlex, a computational workflow that integrates AI-based protein-structure prediction with physics-based modeling. Without relying on an experimental structure of the ternary complex, GluePlex modeled how VAV1, CRBN, and the molecular glue assemble. “The model identified a specific region of VAV1, known as the SH3-2 domain, as being essential for degradation. Experimental tests confirmed the prediction and pinpointed the exact spot the glue uses: a small surface loop on VAV1 that acts as a degradation signal, or ‘degron.’ This loop is different from degradation signals commonly associated with cereblon-targeting molecular glues,” Lin said.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“Applying Free Energy Perturbation (FEP) to predicted ternary structures yields cooperativity metrics that correlate with degradation potency, overcoming limitations of standard docking and enabling prospective ranking of analogs—even from weak initial binders,” the authors wrote. Adding halogen substitutions restricted molecular flexibility and improved degradation efficiency, producing NGT-201-18, a more potent degrader that formed a stronger degradation complex. In primary human T cells, NGT-201-18 reduced VAV1 levels and suppressed T-cell activation. Dose-response proteomics identified VAV1 as the principal target but also revealed degradation of LIMD1, an off-target carrying a canonical G-loop degron. The finding shows that one molecular glue can engage structurally distinct degrons and underscores the importance of proteome-wide profiling.</p>
<p>The compounds remain preclinical, and additional studies will be needed to assess their pharmacology, safety, selectivity, and activity in disease models. Still, the work offers both a starting point for therapies aimed at VAV1-driven autoimmune disorders and hematologic malignancies and a broader discovery strategy. “This work introduces a series of VAV1-targeting molecular glues and, just as importantly, shows how artificial intelligence, structural modeling and proteomics can work together at the earliest stage of a project,” Wang said.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/ai-and-proteomics-accelerate-vav1-molecular-glue-discovery/">AI and Proteomics Accelerate VAV1 Molecular Glue Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Merck, SciBrunch Launch Up&#45;to&#45;$2.13B Collaboration to Develop Preclinical KRAS&#45;Inhibiting Molecular Glue</title>
<link>https://edusehat.com/en/merck-scibrunch-launch-up-to-213b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue</link>
<guid>https://edusehat.com/en/merck-scibrunch-launch-up-to-213b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue</guid>
<description><![CDATA[ Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications.
The post Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/SciBrunch-shot-1520.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 05:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Merck, SciBrunch, Launch, Up-to-2.13B, Collaboration, Develop, Preclinical, KRAS-Inhibiting, Molecular, Glue</media:keywords>
<content:encoded><![CDATA[<p>Merck & Co. has acquired exclusive global rights to develop, manufacture, and commercialize SciBrunch Therapeutics’ preclinical oral precision cancer candidate SPR2015, through a licensing and collaboration deal that could generate up to $2.13 billion for the Chinese small molecule oncology drug developer.</p>
<p>SPR2015 is a preclinical molecular glue, more specifically an oral KRAS G12D (ON) inhibitor that SciBrunch is developing for forms of cancer that include colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC)—the most common and aggressive type of pancreatic cancer.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>KRAS G12D is the most common oncogenic RAS mutation in human tumors—with a 38% prevalence in pancreatic cancer, CRC, and NSCLC, according to a <a href="https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e15151">2023 study</a>. The mutation results from a substitution of glycine with aspartate at position 12, a change that leaves KRAS active and continuously signaling for cell proliferation and survival, SciBrunch said.</p>
<p>According to SciBrunch, SPR2015 has shown nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines while maintaining good selectivity over KRAS wildtype cells.</p>
<p>At the 2026 American Association for Cancer Research (AACR) Annual Meeting, a team of SciBrunch researchers that included founder, chairman, and CEO Tao Hu, PhD, presented preclinical data showing SPR2015 to have demonstrated what it termed compelling antitumor efficacy as a monotherapy across multiple <em>in vivo</em> cell-derived and patient-derived xenograft (CDX and PDX) models.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“SPR2015 is a highly potent and selective KRAS G12D (on) inhibitor with nanomolar proliferation inhibitory activities in various KRAS G12D cell lines while with good selectivity over KRAS wild type,” Hu and SciBrunch researcher colleagues reported in a <a href="https://aacrjournals.org/cancerres/article/86/7_Supplement/5978/778768/Abstract-5978-SPR2015-a-highly-potent-and">poster presentation</a> during AACR 2026. They added that PR2015 was expected at the time to human Phase I studies by the end of this year.</p>
<p>In a head-to-head mouse study comparing a single oral once-daily dose at 100 mg/kg of SPR2015 to another unspecified G12D (ON) inhibitor in over 15 CRC CDX or PDX models, SPR2015 showed significantly superior efficacy in the <em>in vivo</em> CRC xenograft models, achieving a 64.7% objective response rate (ORR) and 94.1% disease control rate (DCR) as monotherapy.</p>
<p>“The diligence question is whether those properties survive translation into humans strongly enough to compensate for SPR2015’s later start,” Sreyashi Paul, PhD, business analyst with Lucidquest Ventures, <a href="https://www.lqventures.com/merck-scibrunch-spr2015-deal-diligence-brief/amp/">commented</a> on the firm’s website.</p>
<p>Paul cited the 52% confirmed ORR and 93% disease control rate of Revolution Medicines’ zoldonrasib (RMC-9805) in 27 efficacy-evaluable previously treated KRAS G12D NSCLC patients, <a href="https://aacrjournals.org/cancerres/article/86/8_Supplement/CT021/785173/Abstract-CT021-Preliminary-safety-and-clinical">reported in May</a>, as well as the early human clinical data produced by Verastem’s VS-7375 in the Phase I/II<strong> </strong>TARGET-D 101 dose escalation and dose expansion trial (<a href="https://clinicaltrials.gov/study/NCT07020221">NCT07020221</a>). In June, Verastem reported Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT06162221">NCT06162221</a>) data showing 93% (13/14) of heavily pretreated (second- to fourth-line) patients with metastatic PDAC who received 900 mg once-daily monotherapy achieved greater than 50% reduction in the tumor marker CA19-9.</p>
<p>In their announcement, Merck and SciBrunch did not disclose a current timeframe for taking SPR2015 into Phase I.</p>
<p></p><h4><strong>“Validates R&D strength”</strong></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p>“This agreement with Merck not only validates the R&D strength of our platform but also underscores the potential of SPR2015 in addressing longstanding unmet medical needs in oncology,” Hu said in the companies’ statement. “We are excited that Merck, a global leader in oncology, will take SPR2015 forward.”</p>
<p>Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving development, commercialization, and other milestones across multiple indications.</p>
<p>Merck will record a pre-tax charge of $400 million related to the SciBrunch agreement, or approximately $0.13 per share, to be included in its GAAP and non-GAAP results for the third quarter. The transaction has closed.</p>
<p>“Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth,” stated George Addona, senior vice president, discovery, preclinical development and translational medicine, Merck Research Laboratories. “This agreement complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhibitor for one of the most prevalent mutant forms of KRAS found in human cancers.”</p>
<p>The deal continues the trend of U.S. and other Western pharmas partnering with Chinese biotechs on drug development—and in Merck’s case, a trend of striving to rebuild its cancer pipeline in hopes of recouping sales that it stands to lose when its anchor drug, the multi-indication cancer immunotherapy Keytruda® (pembrolizumab), loses exclusivity for key U.S. patents in 2028.</p>
<p>Keytruda generated $15.81 billion in Q1–Q2 2026 sales in addition to the $31.641 billion it generated last year. Those figures do not include the $590 million racked up by Keytruda Qlex, a subcutaneous injection form of Keytruda that won FDA approval in September 2025. A consensus of Wall Street analysts has forecast peak annual revenue for Keytruda of approximately $33 billion by 2028.</p>
<p></p><h4><strong>$70B potential opportunity</strong></h4>

<p>However, Merck envisions more than making up for the loss of Keytruda, having foreseen more than $70 ​billion of potential ⁠commercial opportunity by the mid-2030s, Louise Chen, a managing director with Scotiabank, told Reuters.</p>
<p>Founded in 2014, Shanghai-based SciBrunch focuses on small molecule oncology therapeutics based on clinically validated targets and differentiated product design strategies. Hu, a serial entrepreneur, founded SciBrunch with medicinal chemist Yang Zhang, PhD, who is the company’s CSO.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>In January, SciBrunch completed an oversubscribed Pre-A round financing of over $35 million, bringing its total capital raised to $65 million over two rounds. Among intended uses for the proceeds, the company announced at the time, was “advancing IND-enabling studies for a new generation of innovative molecular glue RAS inhibitors, exploring their clinical potential in RAS-mutated refractory tumors including colorectal cancer, pancreatic cancer, and non-small cell lung cancer, with the goal of developing preferred therapies for RAS-driven cancers.”</p>
<p>HighLight Capital led the $35 million Pre-A round, with participation from new investor InnoPinnacle Fund and existing shareholders that increased their investments in SciBrunch, including Hankang Capital, BioTrack Capital, LongRiver Investments, and Elikon Venture.</p>
<p>“Since our founding, SciBrunch has remained focused on advancing innovative therapies targeting the RAS pathway and is committed to delivering transformative treatment options for patients with pancreatic, colorectal, lung, and other major malignant tumors,” Hu added.</p>
<p>SPR2015 is not SciBrunch’s lead candidate. That distinction belongs to SPR1020, a brain-penetrant PARP1 selective inhibitor being developed to fight metastatic brain cancer (mBC, with or without brain metastases), ovarian cancer, PDAC, prostate cancer, and glioblastoma. SPR1020 is under study in patients with advanced solid tumors in a Phase I/II open-label, first-in-human trial (<a href="https://clinicaltrials.gov/study/NCT07359066">NCT07359066</a>)  which dosed its first patient on January 8.</p>
<p>“SPR1020 is expected to demonstrate significant efficacy against tumors harboring BRCA mutations or homologous recombination repair (HRR) pathway gene alterations (e.g., breast cancer, prostate cancer),” SciBrunch predicted in the trial’s page on ClinicalTrials,gov.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/merck-scibrunch-launch-up-to-2-13b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue/">Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Current Challenges in CAR T Manufacturing</title>
<link>https://edusehat.com/en/current-challenges-in-car-t-manufacturing</link>
<guid>https://edusehat.com/en/current-challenges-in-car-t-manufacturing</guid>
<description><![CDATA[ Predictive cell intelligence can be used to reveal cellular states and emerging cellular trajectories earlier in the manufacturing process and to support more informed bioprocessing decisions.
The post Current Challenges in CAR T Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2287901746.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 02:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Current, Challenges, CAR, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>CAR T therapy has undergone a remarkable transformation over the past decade, evolving from an experimental treatment into a clinically validated therapeutic platform with seven FDA-approved therapies and a rapidly expanding global market estimated at $6 billion.<sup>1,2</sup></p>
<p>Yet despite its clinical success, manufacturing remains a fundamental bottleneck to broader patient access.</p>
<p>The challenge facing CAR T is no longer clinical validation; it is scalable delivery. Manufacturing remains constrained by donor-to-donor variability, patient-specific production, and complex multi-step workflows operating within tightly controlled GMP environments.<sup>3,4</sup> These factors drive up cost, increase process variability, and limit manufacturing throughput, ultimately restricting patient access to potentially life-saving therapies.</p>
<p>In addition, existing analytical approaches were either never designed to work in real time or have limited capacity to predict manufacturing outcomes. Most inline sensors or probes rely on downstream or metabolite-based measurements that describe what a cell has done, rather than what a cell can become. This limits process visibility and reduces opportunities for informed intervention before failure occurs.<sup>5</sup></p>
<p>As the field moves toward larger patient populations and commercial-scale manufacturing, the industry faces a critical challenge: how do we move from reactive manufacturing to predictive control? Solving this challenge is essential to improve manufacturing robustness, reduce the cost of goods, increase manufacturing capacity, and expand patient access to advanced cell therapies.</p>
<p>Achieving these goals will require more than automation alone. It will need technologies capable of revealing cellular states earlier in the manufacturing process, enabling informed intervention, and a transition from retrospective testing to proactive process control.<sup>5</sup></p>
<p>To address this challenge, Cytomos has developed AuraCyt<sup>®</sup>, a predictive cell intelligence platform designed to reveal cellular states earlier in the manufacturing process and support more informed manufacturing decisions.</p>
<p></p><h4><strong>From dielectric signatures to predictive cell intelligence</strong></h4>

<p>Cells carry rich biophysical information that is not always visible through conventional biological markers. Dielectric spectroscopy accesses this information by measuring the frequency-dependent electrical behavior that arises from a cell’s intrinsic structure.<sup>6-9</sup></p>
<p>Specifically, the cell membrane separates the conductive interior of the cell from its surrounding environment, shaping how the cell responds to an applied electric field. As the frequency increases, the influence of the cell membrane decreases, allowing the electrical response to become progressively more sensitive to intracellular structure and composition as well as membrane properties.<sup>6,8,9</sup> The resulting electrical response reflects the intrinsic physical state of the cell.</p>
<p>AuraCyt captures this response at the single-cell level using ultra-wideband dielectric spectroscopy. By measuring each cell across more than 200 frequencies, the platform generates a high-dimensional digital fingerprint of every cell that reflects the cellular state and captures subtle changes associated with emerging behavior. In the current configuration, this produces 507 parameters per cell, generating biologically grounded, AI-ready digital datasets for cell characterization and predictive analysis.<sup>10</sup></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>This approach represents a paradigm shift in cell analytics: using physics to predict biology. As changes in cellular state often precede measurable biological outcomes, AuraCyt signatures can reveal early signals and emerging cellular trajectories before they are detected by conventional assays. This provides a biophysics-first route to predictive cell intelligence.<sup>5,10</sup></p>
<p></p><h4><strong>Applying predictive cell intelligence to CAR T manufacturing</strong></h4>

<p>To demonstrate how predictive cell intelligence can be applied in a real manufacturing workflow, AuraCyt was evaluated in a CAR T manufacturing case study focused on transduction efficiency and process risk.</p>
<p>Transduction efficiency is a critical determinant of the CAR T manufacturing success, yet current analytical methods typically confirm transduction only after key manufacturing decisions have been made. Cytomos decided to investigate whether predictive cell intelligence could provide earlier insights into manufacturing outcomes.</p>
<p>AuraCyt was evaluated as a rapid, label-free platform for monitoring transduction efficiency and characterizing transduced and non-transduced T-cell populations over an eight-day manufacturing workflow.</p>
<p>Donor-derived T cells were activated with IL-2 and expanded using a standard CAR T manufacturing process. Following activation, the cell population was divided into two arms: one transduced with a CD34-CAR construct and a matched non-transduced control.</p>
<p>AuraCyt analysis was performed on Days 0, 4, 6, and 8. Flow cytometry was performed on Day 6 to confirm CAR-CD34 expression, providing a conventional benchmark for transduction assessment against which earlier AuraCyt measurements could be compared. Cell viability and concentration were monitored throughout the process (<em>Figure 1</em>).</p>
<p><figure aria-describedby="caption-attachment-338539" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-338539 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-1024x204.jpeg" alt="Figure 1. Eight-day CAR-T manufacturing workflow showing activation, transduction, expansion, and analytical assessment timepoints. AuraCyt analysis was performed on Days 0, 4, 6 and 8, while CAR-CD34 expression was confirmed by flow cytometry on Day 6. Non-transduced control cells followed the same process without transduction. [Cytomos]" width="1024" height="204" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-1024x204.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-300x60.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-768x153.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-1536x305.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide1-scaled-e1790612466922-2048x407.jpeg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 1. Eight-day CAR T manufacturing workflow showing activation, transduction, expansion, and analytical assessment timepoints. AuraCyt analysis was performed on Days 0, 4, 6 and 8, while CAR-CD34 expression was confirmed by flow cytometry on Day 6. Non-transduced control cells followed the same process without transduction. [Cytomos]</figcaption></figure>AuraCyt identified distinct dielectric signatures associated with donor T cells (Day 0), T-cell activation, and CAR-CD34 transduction. Flow cytometry confirmed CAR-CD34 expression on Day 6, providing a conventional benchmark for transduction and CAR expression. This aligned with AuraCyt analysis, which showed clear separation between non-transduced, activated, and CAR-CD34⁺ T cell populations using label-free single-cell measurements (<em>Figure 2</em>).</p>
<p><figure aria-describedby="caption-attachment-338540" class="wp-caption aligncenter"><img decoding="async" class="wp-image-338540 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-1024x358.jpeg" alt="Figure 2. (A) Flow cytometry showing CAR-CD34 expression on Day 6 in transduced T cells and (B) flow cytometry of non-transduced control cells; (C) Predictive cell analytics showing clear separation of non-transduced control cells, activated T cells, and CAR-CD34+ T cells at Day 8. [Cytomos]" width="1024" height="358" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-1024x358.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-300x105.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-768x268.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-1536x536.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide2-scaled-e1790612521984-2048x715.jpeg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 2. (A) Flow cytometry showing CAR-CD34 expression on Day 6 in transduced T cells and (B) flow cytometry of non-transduced control cells; (C) Predictive cell analytics showing clear separation of non-transduced control cells, activated T cells, and CAR-CD34+ T cells at Day 8. [Cytomos]</figcaption></figure>Across the eight-day workflow, the AuraCyt Signatures of CAR T cells and non-transduced controls followed distinct trajectories (<em>Figure 3</em>).</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Using Day 0 donor T cells as a reference population, AuraCyt tracked the evolution of both transduced and non-transduced cells over time. Comparison of the resulting dielectric signatures using effect size analysis demonstrated divergence between the two populations by Day 4, prior to conventional confirmation of CAR expression by flow cytometry on Day 6 (<em>Figure 3</em>).</p>
<p><figure aria-describedby="caption-attachment-338542" class="wp-caption aligncenter"><img decoding="async" class="wp-image-338542 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-1024x430.jpeg" alt="Figure 3. AuraCyt reveals progressive divergence between transduced CAR-T cells and non-transduced controls during manufacturing. The effect-size plot quantifies the increasing separation from the baseline donor T-cell state, while the accompanying trajectory plots visualise the emergence of distinct cellular phenotypes over time. Minimal separation is observed at Day 0, with divergence evident by Day 4 and becoming increasingly pronounced through Days 6 and 8. The appearance of distinct cellular trajectories before conventional confirmation of CAR expression suggests that transduction-associated cellular changes are detectable at an earlier stage of the manufacturing process. [Cytomos]" width="1024" height="430" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-1024x430.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-300x126.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-768x322.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-1536x644.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Slide3-1-scaled-e1790612568545-2048x859.jpeg 2048w" sizes="(max-width: 1024px) 100vw, 1024px"><figcaption class="wp-caption-text">Figure 3. AuraCyt reveals progressive divergence between transduced CAR T cells and non-transduced controls during manufacturing. The effect-size plot quantifies the increasing separation from the baseline donor T-cell state, while the accompanying trajectory plots visualize the emergence of distinct cellular phenotypes over time. Minimal separation is observed at Day 0, with divergence evident by Day 4 and becoming increasingly pronounced through Days 6 and 8. The appearance of distinct cellular trajectories before conventional confirmation of CAR expression suggests that transduction-associated cellular changes are detectable at an earlier stage of the manufacturing process. [Cytomos]</figcaption></figure>These findings suggest that AuraCyt can detect transduction-associated changes in cellular states and identify emerging CAR T manufacturing trajectories before conventional transduction assessment. This supports its potential as a rapid, label-free analytical approach for improving process visibility and enabling earlier manufacturing insight.<sup>10</sup></p>
<p></p><h4><strong>Implications for CAR T manufacturing and beyond</strong></h4>

<p>These findings demonstrate how early AuraCyt signatures can reveal CAR T manufacturing trajectories before conventional assessment. By providing earlier insight into cellular states, AuraCyt has the potential to move manufacturing from retrospective quality control towards predictive process control.</p>
<p>Earlier visibility of process trajectory could improve manufacturing consistency, reduce variability, and support more informed decision-making during critical manufacturing windows. In turn, this may help lower the cost and complexity of delivering advanced cell therapies at scale.</p>
<p>Beyond CAR T, the same biophysics-first approach could be applied across cell therapy, biologics, and other advanced manufacturing workflows, providing a foundation for predictive biomanufacturing and AI-enabled process optimization.</p>
<p class="trimmed"> </p>
<p><em>Lindsay Fraser, PhD, is CSO at Cytomos.</em></p>
<p class="trimmed"> </p>
<p><em><strong>References</strong></em></p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>1. U.S. Food and Drug Administration (FDA). <em>Approved Cellular and Gene Therapy Products.</em> Center for Biologics Evaluation and Research, FDA.</p>
<p>2. MarketsandMarkets. <em>CAR T-Cell Therapy Market Report 2026–2031.</em></p>
<p>3. Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. <em>CAR T Cell Manufacturing: Major Process Parameters and Next-Generation Strategies.</em> Journal of Experimental Medicine. 2024.</p>
<p>4. Baguet C, Larghero J, Mebarki M. <em>Early Predictive Factors of Failure in Autologous CAR T-Cell Manufacturing and/or Efficacy in Hematologic Malignancies.</em> Blood Advances. 2024.</p>
<p>5. Mendoza R, Carter K, Peterson S. <em>Early-stage Analytical Development Strategies for Cell Therapy.</em> Cell & Gene Therapy Insights. 2024;10(11):1493–1503.</p>
<p>6. Gawad S, Schild L, Renaud P. <em>Micromachined Impedance Spectroscopy Flow Cytometer for Cell Analysis and Particle Sizing.</em> Lab on a Chip. 2001.</p>
<p>7. Cheung K, Gawad S, Renaud P. <em>Impedance Spectroscopy Flow Cytometry: On-Chip Label-Free Cell Differentiation.</em> Cytometry Part A. 2005.</p>
<p>8. Liang W, Zhao Y, Liu L, et al. <em>Determination of Cell Membrane Capacitance and Conductance via Optically Induced Electrokinetics.</em> Biophysical Journal. 2017.</p>
<p>9. Tehrani FD, O’Toole MD, Collins DJ. <em>Tutorial on Impedance and Dielectric Spectroscopy for Single-Cell Characterisation on Microfluidic Platforms: Theory, Practice, and Recent Advances.</em> Lab on a Chip. 2025.</p>
<p>10. Fraser L, Wright D, Hunter B, Giakoumelou S, Bellot F, et al. <em>Biology Empowering AI: Rethinking Prediction in Biomanufacturing.</em> Poster presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, Dublin, Ireland; 6–9 May 2026. Supported by the attached ISCT poster.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/current-challenges-in-car-t-manufacturing/">Current Challenges in CAR T Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Cells Respond Differently to a Cancer&#45;Causing Gene</title>
<link>https://edusehat.com/en/how-cells-respond-differently-to-a-cancer-causing-gene</link>
<guid>https://edusehat.com/en/how-cells-respond-differently-to-a-cancer-causing-gene</guid>
<description><![CDATA[ Chemotherapies frequently cause cancer cells to enter senescence, but do not fully eliminate these cells. Therefore, it is useful to target these therapy-induced senescent cells with senolytics that eliminate them.
The post How Cells Respond Differently to a Cancer-Causing Gene appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-183281076.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 02:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Cells, Respond, Differently, Cancer-Causing, Gene</media:keywords>
<content:encoded><![CDATA[<p><span>Scientists at NYU Abu Dhabi say they have discovered that a single cancer-causing gene can trigger different responses in cells, with some helping to prevent tumors while others may contribute to their development.</span></p>
<p><span>The study “<a href="https://link.springer.com/article/10.1038/s44319-026-00941-y" target="_blank" rel="noopener">UHRF1 overexpression generates senescent states with different T53 dependencies</a>,” published in <em>EMBO Reports</em>, found that the gene can trigger several forms of cellular senescence, a natural defense in which damaged cells stop dividing to help prevent cancer, a tumor-suppressive function inherent to all cells.</span></p>
<p><span>Using a zebrafish model of liver cancer, the researchers investigated the initial response to a cancer-causing gene and found that some of these precancerous cells are terminally senescent, meaning they cannot generate tumors, while others can regain the ability to divide and potentially contribute to cancer.</span></p>
<p><span>Commonly used chemotherapies frequently cause cancer cells to enter senescence, but do not fully eliminate these cells. Therefore, it is useful to target these therapy-induced senescent cells with senolytics that eliminate them, say the researchers.</span></p>
<p><span>In this study, the team tested a common senolytic to investigate its ability to target senescent cells and found that it was effective against only some of the precancerous cells but not others. The findings suggest that treatments targeting senescent cells may need to account for the different ways these cells behave.</span></p>
<p><span>“Cancer is not simply a matter of whether a cell stops dividing or continues to grow. Our study shows that there are different types of cellular senescence, and depending on the type acquired by a pre-cancerous cell, the outcome can make the difference between turning into a cancer cell or not,” explained Professor of Biology at NYU Abu Dhabi and senior author Kirsten Sadler Edepli, PhD.</span></p>
<p><span>“We also show that these different forms of senescent cells have hugely different responses to treatments, which is important when developing and applying cancer therapies. It is particularly exciting that our undergraduate capstone researchers contributed to this discovery. Their work demonstrates the valuable role students can play in high-impact research when they are given the opportunity to engage directly with important scientific questions and are given dedicated mentors to guide their efforts.”</span></p>
<p><span>The research was conducted by NYU Abu Dhabi researchers in collaboration with the University’s Center for Genomics and Systems Biology. The findings provide new insight into how cells respond when cancer-causing genes are activated and could help researchers better understand how different types of senescent cells should be targeted in cancer treatment, according to the investigators.</span></p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-cells-respond-differently-to-a-cancer-causing-gene/">How Cells Respond Differently to a Cancer-Causing Gene</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium</title>
<link>https://edusehat.com/en/ginkgo-datapoints-apheris-announce-founding-members-of-antibody-developability-consortium</link>
<guid>https://edusehat.com/en/ginkgo-datapoints-apheris-announce-founding-members-of-antibody-developability-consortium</guid>
<description><![CDATA[ The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate selection.
The post Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/Getty_1914734029_Antibody.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 30 Sep 2026 02:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ginkgo, Datapoints, Apheris, Announce, Founding, Members, Antibody, Developability, Consortium</media:keywords>
<content:encoded><![CDATA[<p><span>Ginkgo Datapoints and Apheris have announced the founding members of the Antibody Developability Consortium, a new industry collaboration designed to help pharmaceutical and biotech companies predict antibody manufacturability and developability risks earlier. The consortium aims to do so by building what they claim will be the field’s largest standardized antibody developability dataset. </span></p>
<p><span>The founding members listed in today’s announcement include AbbVie, argenx, Lundbeck, and Takeda, and the consortium remains open to additional pharma and biotech companies interested in joining. Under the terms of the consortium, each founding member will contribute proprietary antibody sequencing with Gingko Datapoints, an offering of Gingko Bioworks, filling any remaining capacity from publicly available sources. The goal is to reach 10,000 antibodies in total.</span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>“This consortium represents an important step forward in building predictive models for antibody developability by creating datasets that are designed for machine learning, addressing limitations associated with convenience datasets,” said Athena Hadjixenofontos, PhD, director of data science, head of AI in biotherapeutics and genetic medicine at AbbVie. “Federated infrastructure enables participants to contribute data while keeping proprietary sequences private. These capabilities could meaningfully accelerate antibody discovery and help advance new medicines for patients.” </span></p>
<p><span>Antibody developability encompasses the biophysical properties that influence whether a candidate antibody can be manufactured, formulated, and successfully advanced into a clinical product. Predicting barriers that could prevent promising antibody candidates from progressing early could support more informed candidate selection and reduce development time and investment.</span></p>
<p><span>This is important, for example, “in complex therapeutic areas such as CNS” where “the ability to select well behaved candidates with superior developability properties is essential,” said Allan Jensen, PhD, vice president, biotherapeutic discovery at Lundbeck. “By bringing together diverse antibody dataset[s], this collaboration has the potential to strengthen predictive approaches.”</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>According to the partners, Gingko Datapoints is leading the scientific design and execution of the consortium. This includes designing the sequence selection approach, overseeing antibody production, and conducting high-throughput wet-lab characterization across core developability endpoints. Gingko is also training a foundation antibody developability model on the dataset in Apheris’ secure environment. </span></p>
<p><span>For its part, Apheris’ federated infrastructure is being used to deliver the foundation model into each participating member’s environment where they can fine-tune it on their proprietary data. Furthermore, members will be able to train, benchmark, and refine their own internal models in Apheris’ environment using the full consortium dataset as well as their own sequence data, without exposing their proprietary information to other members. The consortium has also tapped Charlotte Deane, PhD, professor of structural bioinformatics at the University of Oxford and Peter Tessier, PhD, professor of pharmaceutical sciences and chemical engineering at the University of Michigan, to provide independent scientific oversight.</span></p>
<p><span>Members are expected to have access to the initial dataset by early 2027. There are also plans to explore the addition of more complex antibody formats over time to enable new drug classes and other key properties that help the members predict which drugs will succeed or fail. </span></p>
<p><span>“Pooling standardized developability data across the industry can create stronger predictive models than any one company could build alone,” said Yves Fomekong Nanfack, PhD, head of AI/ML research at Takeda. “As we advance Takeda Research’s ambition to become an AI-native discovery organization, this capability can help identify promising antibody candidates earlier, inform better development decisions, and bring new therapies to patients faster.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/ginkgo-datapoints-apheris-announce-founding-members-of-antibody-developability-consortium/">Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI Tool Helps Link BRSK1 Variants to Neurodevelopmental Disorder</title>
<link>https://edusehat.com/en/ai-tool-helps-link-brsk1-variants-to-neurodevelopmental-disorder</link>
<guid>https://edusehat.com/en/ai-tool-helps-link-brsk1-variants-to-neurodevelopmental-disorder</guid>
<description><![CDATA[ AI-assisted genomic analysis was combined with human genetics and fruit fly experiments to link reduced BRSK1 function to a variable neurodevelopmental disorder. 
The post AI Tool Helps Link BRSK1 Variants to Neurodevelopmental Disorder appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/GettyImages-1702217813.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 07:50:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tool, Helps, Link, BRSK1, Variants, Neurodevelopmental, Disorder</media:keywords>
<content:encoded><![CDATA[<p>For many families affected by rare genetic conditions, genomic testing does not immediately deliver an answer. Now, researchers have combined artificial intelligence, human genetics, and fruit fly experiments to connect variants in <em>BRSK1</em> with a complex neurodevelopmental disorder. The findings provide a potential diagnosis for several previously unexplained cases while offering clues about how reduced activity of the gene may disrupt nervous system development.</p>
<p>The study, “<a href="https://www.cell.com/ajhg/abstract/S0002-9297(26)00346-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0002929726003460%3Fshowall%3Dtrue" target="_blank" rel="noopener">Monoallelic variants in <em>BRSK1</em> are associated with a neurodevelopmental disorder with or without epilepsy</a>,” was led by researchers at Baylor College of Medicine, the Duncan Neurological Research Institute at Texas Children’s Hospital, and the Texome Project, together with collaborating institutions. It was published in the <em>American Journal of Human Genetics</em>.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>According to Hugo Bellen, PhD, who is co-lead author of the study, the work began with a child enrolled in the Texome Project, which provides genetic testing to medically underserved people with rare, undiagnosed conditions in Texas. Standard analysis of the child’s and parent’s genomes had not identified a cause. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11221788/" target="_blank" rel="noopener">AI-MARRVEL</a>, an artificial intelligence–based tool that analyzes genomic and clinical information to prioritize candidate disease variants, highlighted a rare change in <em>BRSK1</em>. Through GeneMatcher, the researchers identified nine additional affected individuals with rare heterozygous variants in the gene, bringing the group to 10 people from seven unrelated families. The team then modeled three patient-derived variants in <em>Drosophila melanogaster</em> to test their effects in a living organism.</p>
<p>The “affected individuals present with developmental delay and variable phenotypes including anxiety, attention-deficit hyperactivity disorder (ADHD), autism, and seizures,” the authors wrote, adding that the severity and symptoms varied. Symptoms differed even among relatives carrying the same variant, suggesting variable expressivity.</p>
<p>“We studied the fly equivalent of <em>BRSK1</em>, called <em>sff</em> (sugar-free frosting), and found that this gene is active primarily in neurons, mirroring the expression pattern seen in humans,” added Mingxi Deng, PhD, who is first author and a postdoctoral fellow in the Bellen lab. “When the fly gene was disabled, the flies developed difficulties moving, showed increased sensitivity to stressors that can trigger seizure-like behavior, became more vulnerable to heat-induced paralysis and lived shorter lives. These findings indicated that the gene is essential for normal nervous system function.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Introducing normal human <em>BRSK1</em> largely corrected the behavioral and neurological defects, whereas three variants (<em>BRSK1<sup>p.Ile202Val</sup></em>, <em>BRSK1<sup>p.Arg237Cys</sup></em>, and <em>BRSK1<sup>p.Thr406Ile</sup></em>) found in affected individuals produced only a partial rescue. The patient variants also failed to normalize neuromuscular junction structure or levels of Futsch, a protein involved in organizing neuronal microtubules. Together, the experiments suggest that the variants partially reduce <em>BRSK1</em> activity rather than eliminating it.</p>
<p>“Microtubule disruption has been linked to several neurodevelopmental and neurological disorders,” Deng said. “Our findings suggest that reduced <em>BRSK1</em> function interferes with the cellular machinery needed for healthy brain development and communication between neurons.”</p>
<p><em>BRSK1</em> encodes a kinase involved in neuronal polarization, synaptic function, and the internal organization of nerve cells. Reduced activity may therefore interfere with the cellular machinery neurons need to develop and communicate. “This work improves our understanding of the genetic causes of neurodevelopmental disorders and highlights the power of combining AI-driven gene discovery with experimental studies in model organisms to uncover new rare diseases and their underlying biology,” Bellen said.</p>
<p>The diagnosis may help participating families understand the source of their condition and could guide recognition of additional cases. Future studies will be needed to determine why the same variant can produce markedly different symptoms and to define more precisely how altered <em>BRSK1</em> activity affects the developing brain.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ai-tool-helps-link-brsk1-variants-to-neurodevelopmental-disorder/">AI Tool Helps Link <i>BRSK1</i> Variants to Neurodevelopmental Disorder</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Antibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice</title>
<link>https://edusehat.com/en/antibody-blocks-t-cell-infiltration-and-limits-neurodegeneration-in-alzheimers-mice</link>
<guid>https://edusehat.com/en/antibody-blocks-t-cell-infiltration-and-limits-neurodegeneration-in-alzheimers-mice</guid>
<description><![CDATA[ Researchers developed a potential antibody-based approach to reducing neurodegeneration in tauopathies, with studies showing that in a mouse Alzheimer’s model anti-CXCR3-treated animals retained more brain tissue and had better memory, even though tau levels stayed the same.
The post Antibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/11/9067712022200.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 04:15:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Antibody, Blocks, Cell, Infiltration, and, Limits, Neurodegeneration, Alzheimer’s, Mice</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Washington University School of Medicine in St. Louis have developed a potential antibody-based approach to reducing neurodegeneration in diseases known as tauopathies, including Alzheimer’s disease. Studying mice with Alzheimer’s-like tau protein accumulation in their brains, the team showed that injecting the animals with an antibody to a protein called CXCR3 over several months blocked the route used by T cells to get into the brain, reducing the number of those cells in the brain by about half.</p>
<p>The treated mice kept roughly 40% more tissue in memory centers of the brain and did better on a memory test compared with untreated mice—even though the levels of tau in their brains didn’t change. “In tauopathies, including Alzheimer’s disease, there’s no treatment right now that actually decreases neurodegeneration,” said David M. Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor in WashU Medicine’s Department of Neurology. “If we can show that we’re really decreasing brain cell death, it’s certainly worth trying to pursue that pathway to prevent the most devastating consequences of these diseases.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Holtzman is senior author of the team’s published paper in <em>Neuron</em>, titled “<a href="https://doi.org/10.1016/j.neuron.2026.08.030" target="_blank" rel="noopener">Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy</a>,” in which they concluded “Our study defines the CXCR3 axis as a critical target that, when blocked, mitigates CD4+ and CD8+ T cell infiltration and confers neuroprotection in a model of tau-mediated neurodegeneration <em>in vivo</em> without influencing levels of soluble or insoluble tau.”</p>
<p>There is no treatment available today to stop the death of brain cells in tauopathies—including Alzheimer’s disease—in which twisted clumps of a protein called tau accumulate in the brain. Cells near those clumps begin to die after tau accumulates, but growing evidence suggests that much of the damage doesn’t come from the protein directly. Instead, it’s the immune system’s response to tau that’s to blame for the damage that eventually robs people of their memory and independence.</p>
<p>The two existing Alzheimer’s drugs on the market—lecanemab and donanemab—target amyloid protein, which forms plaques between brain cells in the early stages of the disease, disrupts cell communication, triggers tau tangles to form inside neurons and eventually leads to cell death. These anti-amyloid medications can slow a person’s decline, but they haven’t been shown to keep brain cells from dying, and they don’t work against primary tauopathies—diseases marked by tau buildup in which amyloid never appears. Alzheimer’s is a secondary tauopathy in which both amyloid and tau proteins accumulate.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Earlier research led by the Holtzman lab raised the possibility that targeting T cells could be an alternative route to treating tauopathies, including Alzheimer’s. In a paper published in 2023 in <a href="https://www.nature.com/articles/s41586-023-05788-0" target="_blank" rel="noopener"><em>Nature</em></a>, Holtzman’s lab showed that in mice with tau buildup, T cells flood into the brain, especially in areas where tau is most abundant, and cause neurodegeneration. In a <a href="https://www.genengnews.com/topics/translational-medicine/immune-cells-driving-alzheimers-like-neurodegeneration-traced-to-lymph-nodes/" target="_blank" rel="noopener">related paper published earlier this month</a> in <em><a href="https://www.nature.com/articles/s41593-026-02427-5" target="_blank" rel="noopener">Nature Neuroscience</a></em>, the team showed that those T cells get their instructions from lymph nodes outside the brain.</p>
<p>In their newly published paper the team noted, “Beyond the roles of reactive microglia and astrocytes, recent work has demonstrated an important role of T cells and adaptive immunity in tau-mediated neurodegeneration, as suggested in human brains with advanced tauopathy and demonstrated in transgenic models.”</p>
<p>How T cells got into the brain once activated remained unknown, however. “The signaling pathways driving brain T cell homing and infiltration in tauopathies remain unknown, and identifying and targeting mechanisms for the prevention of such entry may offer therapeutic potential,” the investigators added.</p>
<p>The cells are known to navigate by following chemical trails called chemokines, and Holtzman’s team had previously found that one chemokine—called CXCL10—was elevated in the tau-mouse model they were utilizing. Other groups had shown that CXCL10 was elevated in Alzheimer’s. Activated T cells carry a protein on their surface, CXCR3, that follows this particular trail. “We hypothesized that the CXCR3 axis is an important chemotactic gradient for brain-infiltrating T cells in tauopathy, thereby linking peripheral immune activation to tau-driven brain injury,” they stated.</p>
<p>For their latest reported study the researchers, including co-senior author Jason Ulrich, PhD, a professor of neurology at WashU Medicine, and first author Joshua T. Emmerson, PhD, a postdoctoral researcher in Holtzman’s lab, examined the brains of mice with tau accumulation, as happens in Alzheimer’s disease. They found that in mice that lacked the CXCL10 chemokine, or the receptor protein CXCR3 on T cells that binds to CXCL10, T cells did not infiltrate the brain, even when researchers deliberately provoked inflammation to elicit an immune response.</p>
<p>The team then injected an antibody that blocked CXCR3 into young mice that had tau buildup in their brains but hadn’t yet had major brain cell loss. Treatment was administered every five days for three and a half months. The results showed that compared with the untreated mice, treated animals had about half as many T cells in their brains at the end of treatment. The treated animals also preserved more brain tissue and exhibited less evidence of nerve cell damage. “In a mouse model of tauopathy and neurodegeneration, chronic systemic anti-CXCR3 treatment markedly reduced parenchymal CD4+ and CD8+ T cell accumulation, attenuated neurodegeneration, and improved aspects of cognition,” they noted.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Yet tau tangles appeared the same in treated and untreated animals. “A key point of interest was the rescue from neurodegeneration but no overt changes to tau pathology,” the researchers added.</p>
<p>Tests by Holtzman’s team also revealed that the antibody traveled to the border of each animal’s brain but not into the brain tissue—an important finding indicating that neurodegeneration can be treated without having to get a therapy into the brain itself.</p>
<p>“Our findings implicate a critical role of CD4+ T cells in accelerating tau-mediated neurodegeneration and suggest that peripheral CXCR3 inhibition could be a therapeutic approach in tauopathies,” the investigators said.</p>
<p>While more research is needed before the approach could be tested in people, Holtzman noted that existing drugs that target T cells—such as some therapies used for multiple sclerosis and other autoimmune disorders that occur when the body’s immune system attacks its own healthy cells—could be evaluated as Alzheimer’s therapies, opening a new therapeutic avenue for the disease.</p>
<p>“Tauopathies aren’t thought of as autoimmune disorders, so they haven’t been treated the same way, but this study shows for the first time in an animal model that these diseases respond to a specific T-cell therapy,” said Holtzman, who also directs WashU’s Hope Center for Neurological Disorders and the Knight Alzheimer Disease Research Center at WashU Medicine. “For this therapeutic approach, if it is safe, you wouldn’t have to design the drug to get into the brain—which is a big deal since most molecules don’t cross the blood-brain barrier well—and you don’t have to get rid of the tau to get this therapeutic effect.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/antibody-blocks-t-cell-infiltration-and-limits-neurodegeneration-in-alzheimers-mice/">Antibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scientists Observe Enzymes Breaking Down DNA in Real Time</title>
<link>https://edusehat.com/en/scientists-observe-enzymes-breaking-down-dna-in-real-time</link>
<guid>https://edusehat.com/en/scientists-observe-enzymes-breaking-down-dna-in-real-time</guid>
<description><![CDATA[ The research may be useful for the development of DNA-based therapeutics and gene-delivery systems. Packaging genetic material into structures that restrict nuclease access could potentially increase its resistance to degradation.
The post Scientists Observe Enzymes Breaking Down DNA in Real Time appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2240900378.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 29 Sep 2026 00:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scientists, Observe, Enzymes, Breaking, Down, DNA, Real, Time</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the Nano Life Science Institute at Kanazawa University in Japan say they have directly visualized how enzymes find and break DNA molecules in real time. Using high-speed atomic force microscopy, the team followed individual enzymes as they moved along DNA and found that they repeatedly returned to vulnerable regions before breaking them apart.</p>
<p>The findings “<a href="https://www.nature.com/articles/s41467-026-77354-x">Shield strike shatter in DNA topology and nuclease interactions</a>,” which were published in <em>Nature Communications</em>, reveal how the structure of DNA influences its vulnerability to enzymatic breakdown.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>According to the scientists, the study provides a dynamic view of a fundamental biological problem: why some DNA is accessible to enzymes while other DNA remains protected.</p>
<p>“Our high-speed AFM imaging allows us to follow the interaction between individual nuclease enzymes and DNA as it happens,” says student Jingge Yang. “We can see that DNA is not simply a passive target. Its local shape and higher-order organization strongly influence where enzymes interact and whether degradation can proceed,” adds Richard Wong, PhD, professor and team leader.</p>
<p></p><h4><strong>Watching DNA degradation molecule by molecule</strong></h4>

<div class="my-8"><span data-render-ad="4"></span></div>
<p>DNA is constantly exposed to processes that can damage or break it. Some enzymes, nucleases, can deliberately break down DNA. They  play important roles in maintaining cells and clearing unwanted DNA.</p>
<p>One of the best-known of these enzymes is DNase I, which helps remove DNA released from damaged or dying cells. Problems with this clearance process have been associated with inflammatory and autoimmune diseases.</p>
<p>Although scientists know a great deal about the chemistry of DNase I, it has been difficult to see exactly how individual enzyme molecules approach DNA, where they remain and what happens immediately before and after the DNA is cut.</p>
<p><figure aria-describedby="caption-attachment-338535" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338535" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1016112584-300x200.jpg" alt="Placing samples into an atomic force microscope, a high-resolution type of scanning probe microscopy with demonstrated resolution on the order of fractions of a nanometer. " width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1016112584-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1016112584.jpg 724w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text"><em>Placing samples into an atomic force microscope, a high-resolution type of scanning probe microscopy with demonstrated resolution on the order of fractions of a nanometer. [Casarsa Guru/Getty Images]</em></figcaption></figure>The Kanazawa scientists researchers addressed this problem using high-speed atomic force microscopy (HS-AFM), a technique that can record nanoscale changes in biological molecules in liquid without requiring them to be fixed, stained, or crystallized. This allowed the researchers to observe in real time how individual nuclease enzymes interacted with and gradually broke apart DNA.</p>
<p>The HS-AFM movies revealed that DNase I did not interact with every part of a DNA molecule in the same way. The enzyme was frequently found near exposed DNA ends and regions where the DNA was curved or locally bent. Individual DNase I molecules could repeatedly return to restricted regions before visible fragmentation occurred.</p>
<p>Longer-lasting interactions were also more common around curved regions where DNA was more likely to be cut. Together, these observations showed that the shape of DNA influenced where the enzymes interacted with it.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Importantly, the HS-AFM cannot directly show the chemical reaction occurring at the enzyme’s active site. The researchers therefore describe the relationship between DNA shape, repeated enzyme engagement, and subsequent cleavage as a spatial and temporal correlation rather than direct observation of the catalytic reaction.</p>
<p></p><h4><strong>Five stages of DNA degradation</strong></h4>

<p><figure aria-describedby="caption-attachment-338533" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338533" src="https://www.genengnews.com/wp-content/uploads/2026/09/884d8ff8057f0bc570d39ea7e6a6fba1-241x300.jpg" alt="Visualizing DNA protection and degradation by high-speed AFM. Higher-order DNA structures protect DNA from nuclease degradation, whereas exposed DNA is bound, cleaved, and progressively fragmented by nucleases. High-speed atomic force microscopy (HS-AFM) enables these dynamic processes of DNA "protection, attack, and destruction" to be visualized at the nanoscale. The AFM tip is illustrated at the upper right. [Richard W. Wong, PhD, Kanazawa University and image created in part using OpenAI's ChatGPT]" width="241" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/884d8ff8057f0bc570d39ea7e6a6fba1-241x300.jpg 241w, https://www.genengnews.com/wp-content/uploads/2026/09/884d8ff8057f0bc570d39ea7e6a6fba1.jpg 500w" sizes="(max-width: 241px) 100vw, 241px"><figcaption class="wp-caption-text">Visualizing DNA protection and degradation by high-speed AFM. Higher-order DNA structures protect DNA from nuclease degradation, whereas exposed DNA is bound, cleaved, and progressively fragmented by nucleases. High-speed atomic force microscopy (HS-AFM) enables these dynamic processes of DNA “protection, attack, and destruction” to be visualized at the nanoscale. The AFM tip is illustrated at the upper right. [Richard W. Wong, PhD / Kanazawa University / Image created in part using OpenAI’s ChatGPT]</figcaption></figure>Based on these recurring patterns of interaction, the researchers developed a conceptual framework that they call STORM: Scan–Target–Occupy–Rupture–Mobilize. In this framework, an enzyme samples the DNA, becomes localized at a particular region, remains associated with it, fragmentation occurs and the resulting pieces are redistributed.</p>
<p>The researchers emphasize that STORM is a framework for describing the interaction patterns revealed by the experiments rather than a fixed sequence through which every enzyme molecule must pass.</p>
<p class="trimmed"> </p>
<p>The team also examined another DNA-cutting enzyme, micrococcal nuclease (MNase). Despite differences between DNase I and MNase, the team observed similar patterns of DNA sampling, localized interaction, repeated association, disruption and fragment redistribution. This suggests that STORM-like behavior may reflect broader physical principles governing how different nucleases interact with DNA.</p>
<p>The experiments also revealed how the physical organization of DNA can protect it from degradation. The researchers examined DNA condensed by protamine, a small protein that binds strongly to DNA. Protamines are particularly important in sperm cells, where they help package the paternal genome into an extremely compact form.</p>
<p>Under the experimental conditions, protamine caused DNA to form mainly two compact structures: elongated rod-like structures and ring-shaped structures called toroids. High-speed microscopy showed that DNase I molecules could gather around these condensed structures without destroying them. The toroidal structures were particularly compact. DNase I rarely penetrated their central regions, and the structures remained intact during continuous observation for more than six minutes despite the presence of the enzyme.</p>
<p>When the condensed structures were partially loosened, however, exposed regions again became susceptible to degradation. The results suggest that protection does not arise simply from the electrical interaction between protamine and DNA. Instead, tightly packing DNA into particular three-dimensional structures creates a physical barrier that limits the enzyme’s access.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>Possible framework for understanding DNA protection and clearance</strong></h4>
<p>The findings could contribute to understanding how compact structures help preserve genetic information, including the exceptionally dense packaging found in sperm cells. They could also be relevant to extracellular DNA released from damaged or dying cells, which can stimulate immune responses if it is not efficiently removed.</p>
<p>The results may additionally be useful for the development of DNA-based therapeutics and gene-delivery systems. Packaging genetic material into structures that restrict nuclease access could potentially increase its resistance to degradation.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/omics/scientists-observe-enzymes-breaking-down-dna-in-real-time/">Scientists Observe Enzymes Breaking Down DNA in Real Time</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bayh&#45;Dole Act’s benefits include $3 trillion in U.S. output, report finds</title>
<link>https://edusehat.com/en/bayh-dole-acts-benefits-include-3-trillion-in-us-output-report-finds</link>
<guid>https://edusehat.com/en/bayh-dole-acts-benefits-include-3-trillion-in-us-output-report-finds</guid>
<description><![CDATA[ It’s been a long day at the university lab, but the researchers, who have been working on a niche bit of molecular biology research, […]
The post Bayh-Dole Act’s benefits include $3 trillion in U.S. output, report finds appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/bayh-dole-report-cover.png" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:30:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bayh-Dole, Act’s, benefits, include, trillion, U.S., output, report, finds</media:keywords>
<content:encoded><![CDATA[<p>It’s been a long day at the university lab, but the researchers, who have been working on a niche bit of molecular biology research, are happy. They have just made a profound discovery that could change the way some cancers are treated, and investors are already lined up to support the work.</p>
<p>Before we know it, they think to themselves, lives will be saved.</p>
<p>In the United States, such technology transfer is often taken for granted—but it hasn’t always been this way. As recently as 45 years ago, if the university researcher had gotten a grant from the federal government, then the federal government took ownership over what was invented.</p>
<p>This system stymied innovation. At the time, the federal government held the patents on roughly 28,000 discoveries, yet licensed fewer than 5% for commercialization. Something had to change.</p>
<p>And so, in 1980 Senator Birch Bayh (D-IN) and Senator Bob Dole (R-KS) drafted the Bayh-Dole Act of 1980 (Patent and Trademark Law Amendments Act, P.L. 96-517) to allow universities, small businesses, and non-profits to retain ownership and patent rights of inventions developed through research supported by federally funding—incentivizing the public-private collaborations required to transform scientific discoveries into new technologies, industries, products and companies.</p>
<p>The results have been a renaissance of innovation and licensing. The legislation’s ongoing success is highlighted in a new report by the Bayh-Dole Coalition, which includes the Biotechnology Innovation Organization (BIO) as a member. The 2026 report, “<a href="https://bayhdolecoalition.org/new-report-shows-3-3-trillion-in-u-s-economic-output-from-bayh-dole-innovation/" target="_blank" rel="noopener">The Economic Impact of the Bayh-Dole Act</a>,” provides impressive statistics.</p>
<h3>Overall economic impact is enormous</h3>
<p>In the last 30 years alone, technology transfer facilitated by the Bayh-Dole Act between federal supported universities and non-profits and the private sector contributed as much as:</p>
<ul>
<li>$3.3 trillion to U.S. gross economic output,</li>
<li>$1.7 trillion to the U.S. GDP, and</li>
<li>6 million job-years of U.S. employment.</li>
</ul>
<p>Since 1980, the annual number of patents on inventions benefiting from government funding has increased more than 70-fold.</p>
<p>And in more recent years, from 2001-2025, technology transfer at academic institutions led to the launch of more than 19,000 startups and the introduction of more than 17,000 new products. It has also seen:</p>
<ul>
<li>$288 billion in GDP,</li>
<li>$577 billion in gross economic output, and</li>
<li>08 million job-years of U.S. employment.</li>
</ul>
<p>In fact, universities and nonprofit research institutions averaged about 19,387 income-generating licenses annually from 2021–2025, that is roughly twice the annual average in 2001–2005.</p>
<p>And furthermore, the report found that there have been:</p>
<ul>
<li>5,972 running-royalty licenses annually from 2021–2025,</li>
<li>$3.2 billion in average annual gross licensing income, and</li>
<li>$1.9 billion in average annual running royalty income.</li>
</ul>
<p>And while that doesn’t necessarily translate one-to-one to on-the-market products, it does reflect the pace at which private-public partnerships are moving and continuing to grow.</p>
<p>Put simply, the legislation did not just spur economic development in the short term, but has continued to generate significant innovation, progress, and economic activity year after year—continuing today.</p>
<p>And the benefits are both micro and macro to economic development.</p>
<h3>A closer look—the regional benefits of Bayh Dole</h3>
<p>This economic impact Bayh-Dole has positively affected every corner of the United States, generating economic activity in every state in the union. The economic development from 2021–2025 alone is notable.</p>
<p>For example, in the South (AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, PR, SC, TN, TX, VA, WV) Bayh-Dole helped facilitate 5,482 startups, and the development of 4,772 products.</p>
<p>Comparatively, in the West (AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY) Bayh-Dole helped facilitate 4,931 startups, and the development of 3,667 products.</p>
<p>And in the Northeast (CT, ME, MA, NH, NJ, NY, PA, RI, VT) Bayh-Dole helped facilitate 4,823 startups, and the development of 2,331 products.</p>
<p>And finally, in the Midwest (IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI) Bayh-Dole helped facilitate 3,791 startups, and the development of 6,482 products.</p>
<p>States like Pennsylvania, Massachusetts, California, and Texas benefited particularly with Pennsylvania seeing $4.49B in gross licensing income and $2.30B in running royalties; Massachusetts seeing $1.98B and $924M; California seeing $1.48B and $578M; and Texas seeing $905M; $876M.</p>
<p>Following up the lead, New York saw $911M in gross licensing income and $517M in running royalties; Georgia saw $655M and $598M; Minnesota saw $733M and $389M; and North Carolina saw $641M and $418M.</p>
<p>And finally, from 2001–2025, Pennsylvania reported the facilitated creation of 1,100 startups, Massachusetts 1,762, California 2,488, and Texas 1,101.</p>
<p>The impact on the growth of the biotechnology industry was especially seen in the Northeast and West regions.</p>
<p>As the report notes, in the Northeast: “Notable innovations benefiting from federal funding emerging from the region’s research institutions include the HIV/AIDS therapy Zerit from Yale University, high-definition video and audio technologies from Columbia University, and mRNA and CAR T-cell technologies from the University of Pennsylvania.”</p>
<p>While in the West: “The University of Arizona has used federal funding to develop…. innovations benefiting from federal funding for the early detection and prevention of osteoporosis began in University of Washington labs.”</p>
<h3>The 2026 Bayh-Dole Report supports BIO’s own research</h3>
<p>The numbers uncovered in the 2026 Bayh-Dole report are supported by BIO’s own commissioned report from AUTM.</p>
<p>When it comes to biotech and life sciences, this report found that biotech and life sciences licensing is especially impactful within the Bayh-Dole landscape. Historically, about 80% of university licensing income and 90% or more of hospital/research-institute licensing income has historically come from life sciences, while 60%–70% of licenses were to small companies or startups.</p>
<p>Ultimately, the picture is clear. The public-private collaboration built by the Bayh-Dole Act has changed the fact of biotech and life sciences innovation and development across the U.S.—and the world. And the lives saved, and improved, are likely incalculable.</p>
<p><a href="https://bayhdolecoalition.org/new-report-shows-3-3-trillion-in-u-s-economic-output-from-bayh-dole-innovation/" target="_blank" rel="noopener"><strong>Read “The Economic Impact of the Bayh-Dole Act.”</strong></a></p>
<p>The post <a href="https://bio.news/federal-policy/bayh-dole-acts-benefits-include-3-trillion-in-u-s-output-report-finds/">Bayh-Dole Act’s benefits include $3 trillion in U.S. output, report finds</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Viral Protein Helps Self&#45;Amplifying RNA Overcome Cellular Defenses</title>
<link>https://edusehat.com/en/viral-protein-helps-self-amplifying-rna-overcome-cellular-defenses</link>
<guid>https://edusehat.com/en/viral-protein-helps-self-amplifying-rna-overcome-cellular-defenses</guid>
<description><![CDATA[ Adding a viral protein, NoV B2, helped self-amplifying RNA overcome cellular defenses and produce more target protein without diminishing immune stimulation, potentially enabling future vaccines to use lower doses.
The post Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/04/GettyImages-1450368712.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 17:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Viral, Protein, Helps, Self-Amplifying, RNA, Overcome, Cellular, Defenses</media:keywords>
<content:encoded><![CDATA[<p><span>A new study led by scientists at Queen Mary University of London describes a way to overcome a cell’s natural defenses against self-amplifying RNA vaccines. According to details provided in a new </span><i><span>Nature Communications </span></i><span>paper, adding a viral protein dubbed NoV B2 helps overcome this issue, while preserving saRNA’s ability to stimulate the immune system. </span></p>
<p><span>According to details provided in the paper, which is titled “</span><a href="https://www.nature.com/articles/s41467-026-77816-2" target="_blank" rel="noopener"><span>Tuning intracellular immunity by Nodamura virus B2 protein enhances self-1 amplifying RNA activity</span></a><span>,” found that adding this protein, which is known to suppress RNA interference, reduced the extent to which the cells restrict saRNA, allowing it to provide far more of the intended protein in both stem cells and regular cells. It addresses a major challenge with saRNA vaccines that hampered their application in gene therapies, cancer immunotherapies, and protein replacement therapies. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Most people are familiar with mRNA-based vaccines because of the Covid-19 pandemic. Since then scientists have worked on developing saRNA which replicates within host cells. The goal is to use the technology to develop vaccines and therapies that provide longer-lasting protection at lower doses that are safe and affordable.</span></p>
<p><span>Specifically, during the self-replicating process, saRNA generates double-stranded RNA which triggers cells’ anti-virus defenses. This makes the saRNA less stable, less able to replicate, and less able to instruct cells to produce the protein that trains the immune system. To date, this has limited the effectiveness of saRNA vaccines. But this development could help scientists develop effective saRNA vaccines that work at lower doses and could be rolled out further and faster than has been possible. </span></p>
<p><span>According to Pierre Maillard, PhD, senior lecturer in antiviral immunity at Queen Mary University of London, and one of the authors on the study, “our findings identify a strategy to overcome a fundamental barrier limiting self-amplifying vaccines” and “if this translates successfully <em>in vivo</em>, it could open new possibilities for vaccine design as well for gene therapies and cancer treatment.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/omics/viral-protein-helps-self-amplifying-rna-overcome-cellular-defenses/">Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit</title>
<link>https://edusehat.com/en/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit</link>
<guid>https://edusehat.com/en/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit</guid>
<description><![CDATA[ This past week, Nektar Therapeutics (Nasdaq: NKTR) offered an uncommon example of victory in court translating into defeat on Wall Street. Nektar’s shares finished Friday flat, dipping 4% from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over Eli Lilly (NYSE: LLY) in a three-year-old legal dispute over the pharma giant’s terminating a collaboration agreement to co-develop Nektar’s lead pipeline candidate rezpegaldesleukin (rezpeg).
The post StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Nektar-Therapeutics-CROPPED11111-JPEG-1024x586-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 28 Sep 2026 06:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Nektar, Shares, Flat, 90M, Jury, Verdict, Less, than, Sought, Lilly, Suit</media:keywords>
<content:encoded><![CDATA[<p>This past week, <strong>Nektar Therapeutics (Nasdaq: NKTR)</strong> offered an uncommon example of victory in court translating into defeat on Wall Street.</p>
<p>Nektar’s shares finished Friday flat, <strong>dipping 4%</strong> from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over <strong>Eli Lilly (NYSE: LLY)</strong> in a three-year-old legal dispute over the pharma giant’s terminating a collaboration agreement to co-develop Nektar’s lead pipeline candidate rezpegaldesleukin (rezpeg).</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>A jury in the Northern District of California awarded Nektar $90 million, plus additional interest to be determined by the court, after agreeing with Nektar that Lilly breached a covenant of good faith and fair dealing implied through the companies’ up-to-$400 million agreement to co-develop rezpeg, initially for autoimmune and other chronic inflammatory conditions.</p>
<p>“We are pleased with the jury’s verdict in Nektar’s favor finding that Lilly breached the implied covenant of good faith and fair dealing in the license agreement,” Nektar said in a statement to <em>GEN</em> and other news outlets.</p>
<p>At deadline, a Lilly spokesperson had not responded to a <em>GEN</em> query seeking comment on the Nektar jury verdict.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The legal victory was ultimately viewed as anything but by investors, since Nektar had sought a verdict of $1 billion against Lilly. True, pre-market investors sparked a mini-buying surge that was enough to send Nektar shares <span><strong>rising ~4.92%</strong></span> early on Friday, Edward Nash, a managing director and senior biotechnology analyst with Canaccord Genuity, reported in a research note.</p>
<p>But when the opening bell sounded, Nektar shares swung back down, <span><strong>slipping 4.6%</strong></span> from an opening price of an even $60 a share the first minute of trading down to $57.22 at 9:48 a.m. That is below expectation based on the 34.14 million outstanding Nektar shares as of Friday morning.</p>
<p>“A judgment of $90M represents $2.64 in cash per share and would imply a 4.4% move upward in the stock compared to [Thursday]’s closing price of $59.38,” Nash explained.</p>
<p></p><h4><strong>Silver lining</strong></h4>

<p>Nash did see a silver lining behind the proverbial cloud of Nektar’s failure to surge on the good legal news.</p>
<p>“While the company was seeking $1B in damages and the $90M falls short of this number, our model does not include any windfall from the case. Importantly, the company also did not require any monies from the case in order to continue developing their pipeline assets,” Nash commented. “Therefore, any sum awarded in the case represents a non-dilutive capital addition to the balance sheet which we have not been factoring into our valuation.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Because the jury’s verdict is still subject to post-trial proceedings and an all-but-expected appeals process, Canaccord Genuity has left out a jury verdict payout from its model for Nektar: “If Lilly appeals the verdict, it could be months or years before Nektar would receive any payment. We will move to include the sum in our model when and if it is paid.”</p>
<p>Nektar said rezpeg is a first-in-class therapeutic designed to target the CD25 sub-receptor in the interleukin-2 (IL-2) receptor complex to stimulate proliferation and growth of regulatory T cells (Tregs). By activating these cells, Nektar reasons, rezpeg could restore balance between Tregs and effector T cells (Teffs) and thus address the underlying immune system imbalance seen in many autoimmune and inflammatory conditions.</p>
<p></p><h4><strong>Dose-dependent AD improvement</strong></h4>

<p>In August, Nektar researchers <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01143-8/abstract">published data in <em>The Lancet</em></a> from the 16-week induction period of the 52-week REZOLVE-AD trial (<a href="https://url.us.m.mimecastprotect.com/s/sYEWCpYWpMszG1RMtPfkIG_9Mw?domain=clinicaltrials.gov">NCT06136741</a>) assessing rezpeg in patients with moderate-to-severe atopic dermatitis (AD). Patients treated with rezpeg showed statistically significant, dose-dependent improvement in mean percent reduction in Eczema Area and Severity Index (EASI) from baseline at Week 16: 61% of patients dosed at the 24 μg/kg once every 2 weeks (q2w) arm; 58% of patients at the 18 μg/kg q2w arm, and 53% of patients dosed at 24 μg/kg once every 4 weeks (p<0.0001, p<0.0001, and p=0.0002, respectively), vs. 31% for placebo.</p>
<p>Nektar shares nearly doubled in February after it announced positive data from the 36-week blinded maintenance period of REZOLVE-AD. Among 55 patients dosed at 24 µg/kg every month, 71% (36) achieved EASI score reductions of at least 75% (EASI-75). Half those patients (18, or 80%) achieved EASI-90. The percentage climbed to 83% among the 56 patients receiving the same dosage of rezpeg every three months. Of those, 63% (21) maintained validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) 0/1 response after quarterly dosing, as did 85% (14) of patients dosed monthly.</p>
<p>Perhaps most encouraging to patients, 75% (25) of patients dosed monthly stopped itching—a percentage that rose to 77% (17) among those who were dosed every quarter.</p>
<p></p><h4><strong>AA durability data</strong></h4>

<p>In its Friday statement, Nektar said it recently advanced rezpeg into pivotal studies in AD and is initiating a pivotal study in alopecia areata (AA), where the company reported positive data in April from a blinded 16-week treatment extension period in its Phase IIb REZOLVE-AA trial (<a href="https://clinicaltrials.gov/study/NCT06340360">NCT06340360</a>).</p>
<p>From week 36 to week 52, 29% of 14 patients at low dose of 18 µg/kg and 31% of 13 patients at high dose of 24 µg/kg achieved new SALT Score ≤20 responses as compared to none in the placebo arm. A SALT Score ≤20 is achieved when a patient has 80% or more of their scalp covered by hair.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>“For me, as a scientist, this is really exciting, because most drugs are inhibitors,” Jonathan Zalevsky, PhD, Nektar’s chief research and development officer, told <em>GEN</em> in June in an interview during the 2026 Biotechnology Innovation Organization (BIO) International Convention, held in San Diego. “Inhibitors work at the beginning, and then they get worse, because it’s just how biology works. We always have escape pathways to any single inhibition. Repression requires workaround; that’s just basic biology. But rezpeg doesn’t work that way. It’s not an inhibitor. It’s healing your immune system, and it’s allowing you to resolve inflammation naturally, the way you’re normally meant to.”</p>
<p>“We think that might be one of the things we’re seeing reflected in the durability of rezpeg. It really seems much more durable than other mechanisms, and it has an activity that really preserves itself, and it long outlasts its own pharmacokinetics. That’s something we’re very excited about,” Zalevsky added.</p>
<p>The company has said it aims to submit a Biologics License Application (BLA) for rezpeg in AD in 2029.</p>
<p>“We remain focused on delivering this important potential new treatment as quickly as possible to patients battling chronic auto-immune conditions,” Nektar stated.</p>
<p></p><h4><strong>Relationship sours</strong></h4>

<p>Nektar’s relationship with Lilly soured in February 2023, soon after rezpeg failed the Phase II ISLAND trial (<a href="https://clinicaltrials.gov/study/NCT04433585">NCT04433585</a>) in its initial development indication of moderately-to-severely active systemic lupus erythematosus (SLE). Lilly halted its collaboration immediately in that indication, followed by the companies determining whether to move forward in AD.</p>
<p>Two months later, Lilly handed back to Nektar all rights to rezpeg (which Lilly labeled LY3471851) in all indications, including AD and psoriasis. That ended a <a href="https://www.genengnews.com/news/lilly-to-co-develop-nektar-autoimmune-candidate-nktr-358/">collaboration launched in 2017</a>, when Lilly agreed to pay Nektar $150 million upfront and up to $250 million tied to achieving development and regulatory milestones toward rezpeg, then called NKTR-358.</p>
<p>Nektar responded to the termination in August 2023 by suing Lilly in U.S. District Court for the Northern District of California in San Francisco, alleging breach of contract and breach of implied covenant of good faith and fair dealing: “This case involves the all-too-familiar story of a large pharmaceutical company elevating profits over all else,” Nektar stated in its initial complaint.</p>
<p>In that complaint, Nektar asserted that Lilly failed to recruit enough patients for the ISLAND trial in lupus, leading to its failure. Nektar also alleged that Lilly incorrectly calculated data from the companies’ AD and psoriasis trials of rezpeg that was presented at the 2022 European Academy of Dermatology and Venereology (EADV) Congress; Lilly has denied the allegations on recruitment failures yet confirmed that the data were incorrectly calculated for both AD and psoriasis trials.</p>
<p></p><h4><strong>Clash over Dermira acquisition</strong></h4>

<div class="my-8"><span data-render-ad="7"></span></div>
<p>Nektar also alleged—and Lilly has strongly denied—that the pharma giant soured, then sought to undermine, their collaboration after Lilly agreed to acquire Dermira for approximately $1.1 billion in 2020. Dermira focused on developing a pipeline of dermatological drugs led by lebrikizumab, a monoclonal antibody designed to bind IL-13 with high affinity. Today Lilly markets that drug under the name Ebglyss® (lebrikizumab-lbkz), following FDA approval in 2024 in moderate-to-severe AD.</p>
<p>Lilly then tried to get Nektar’s lawsuit dismissed—but when it couldn’t do so, it counter-sued, alleging breach of specified confidentiality provisions and defamation–a countersuit the pharma giant was allowed to voluntarily dismiss in October 2025.</p>
<p>A jury trial was initially scheduled to begin on October 27, 2025, was postponed due to the federal government shutdown, and instead began September 8, 2026. The case, Nektar Therapeutics v. Eli Lilly & Co (3:23-cv-03943), was assigned to Judge James Donato, who was appointed by President Barack Obama and confirmed by the U.S. Senate in 2014.</p>
<p>“In May 2023, after rezpeg failed to meet its primary endpoints in two separate Phase II trials, Lilly terminated its collaboration with Nektar and returned the rights to rezpeg at Nektar’s request,” Lilly told <em>GEN</em> in February 2026 through a spokesperson. “Our decision was consistent with Lilly’s normal practices and was made following a review of the compound’s competitive profile, including a high incidence of injection site reactions, which were also reflected in Nektar’s REZOLVE-AD trial.”</p>
<p>“The litigation between Lilly and Nektar remains ongoing, and we stand behind our decision to terminate the collaboration,” Lilly added at the time.</p>
<p></p><h4><strong>Anthropic’s “reminiscent of CRISPR” discovery d</strong><strong>ents gene editing stocks</strong></h4>

<p><strong>Anthropic, </strong>the artificial intelligence (AI) giant that has filed for an initial public offering (IPO) that would value the company at an eye-popping $2 trillion, wreaked some havoc on gene editing stocks this past week after making global headlines with its announcement that its Claude large-language model “discovered a novel enzyme system with properties reminiscent of CRISPR, with only high-level direction from our scientists.”</p>
<p>The discovery emerged from a research group formed earlier this year “to see whether general AI models can systematize and accelerate discoveries capable of revolutionizing biology and medicine,” as Anthropic explained in its <a href="https://www.anthropic.com/news/claude-discovers-novel-enzyme-system">announcement</a>. “Our focus is on fundamental biology research using Claude: exploring datasets of DNA to identify uncharacterized protein families, generating hypotheses at scale, and testing them through experiments in the lab.”</p>
<p>In one of the group’s first research programs, Claude autonomously discovered a novel enzyme system that is associated with an array of DNA repeats—what the company called “a pattern reminiscent of CRISPR.”</p>
<p>“Although we don’t yet know its function, the system that Claude discovered has a set of characteristics that have only ever been found together in a handful of other systems, all of which are programmable and perform operations like cutting, copying, and pasting DNA,” Anthropic explained.</p>
<p>Anthropic CEO Dario Amodei elaborated further <a href="https://x.com/DarioAmodei/status/2102831170299834652?s=43">in a post on X</a>, describing the novel enzyme system as “a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student.”</p>
<p></p><h4><strong>“Mostly” by Claude</strong></h4>

<p>“The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out,” Amodei added.</p>
<p>Anthropic’s statement and Amodei’s elaboration led investors to briefly sell off shares of gene editing company stocks on Wednesday, resulting in declines in high single digit percentages that day. The declines slowed down or turned into single digit gains Thursday, but the stocks all slid again Friday, albeit by low single digits.</p>
<p>Here’s how seven gene editing stocks performed between Tuesday and Friday:</p>
<ul>
<li><strong>Beam Therapeutics (Nasdaq: BEAM)</strong>—<span><strong>Slipping 6%</strong></span> from $25.93 Tuesday to $24.37, finishing the week at $24.27.</li>
<li><strong>CRISPR Therapeutics (Nasdaq: CRSP)—<span>Sliding 8%</span></strong> from $59.03 to $55.76, finishing at $54.23.</li>
<li><strong>Editas Medicine (Nasdaq: EDIT)—<span>Shrinking 12%</span></strong> from $2.92 to $2.69, finishing at $2.58.</li>
<li><strong>Intellia Therapeutics (Nasdaq: NTLA)—<span>Dropping 7%</span></strong> from $12.69 to $12.33, finishing at $11.75.</li>
<li><strong>Lenz Therapeutics (Nasdaq: LENZ)—<span>Dipping 5%</span></strong> from $4.13 to $3.76, finishing at $3.92.</li>
<li><strong>Prime Medicine (Nasdaq: PRME)—<span>Tumbling 18%</span></strong> from $3.54 to $3.13, finishing at $2.90.</li>
<li><strong>Q32 Bio (Nasdaq: QTTB)—<span>Falling 17%</span></strong> from $10.57 to $9.56, finishing at $8.77.</li>
</ul>
<p>Puneet Souda, senior managing director, life science tools and diagnostics and a senior research analyst with Leerink Partners, wrote in a research note that Anthropic’s discoveries along with other biotech-focused AI research would prove beneficial to life sciences tools companies—especially <strong>Twist Biosciences (Nasdaq: TWST)</strong>, citing an earlier July 16 research note reporting that Twist has said its growth ramp of orders for its tools has grown by triple digits.</p>
<p>“We see TWST as the single most important beneficiary today from growing Bio AI efforts but expect all LST [life sciences tools] names to benefit in the long run as the need for automation and large-scale data grows (driven largely by industry funding vs academic),” Souda observed.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit/">StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New CRISPR&#45;Based Tool Enables Genome&#45;Wide Mutagenesis of Bacteriophages</title>
<link>https://edusehat.com/en/new-crispr-based-tool-enables-genome-wide-mutagenesis-of-bacteriophages</link>
<guid>https://edusehat.com/en/new-crispr-based-tool-enables-genome-wide-mutagenesis-of-bacteriophages</guid>
<description><![CDATA[ A CRISPR-based method for disrupting genes across bacteriophage genomes has been developed, creating a faster route to uncover gene functions and engineer phages for potential therapeutic and biotechnology applications.
The post New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/07/GettyImages-1830659494.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, CRISPR-Based, Tool, Enables, Genome-Wide, Mutagenesis, Bacteriophages</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Otago – Ōtākou Whakaihu Waka in New Zealand have developed a CRISPR-based method for systematically disrupting genes across bacteriophage genomes, creating a faster route to uncover gene functions and engineer phages for potential therapeutic and biotechnology applications. The study, titled “<a href="https://dx.doi.org/10.1038/s41564-026-02486-1" target="_blank" rel="noopener">Defining the essential genome of diverse phages with phage Tn-seq</a>,” was published in <em>Nature Microbiology.</em></p>
<p>Bacteriophages, or phages, are viruses that infect bacteria. Their ability to destroy bacterial cells has made them promising candidates for addressing antimicrobial resistance and reducing reliance on agrochemicals. However, many phage genes encode unknown functions, making it difficult to predict how the viruses behave or to modify them reliably.</p>
<p>“Our knowledge of phages is probably like the understanding of antibiotics back in the 1950s,” senior author Peter Fineran, PhD, said. “Many phage genes are currently in the area of microbial dark matter—encoding functions we just don’t understand—which is limiting our ability to use phages in healthcare and biotechnology.”</p>
<p>To address that gap, the team combined transposon insertion sequencing with CRISPR–anti-CRISPR selection. A transposon jumps into a phage genome and disrupts a gene. The selection system then recovers phages carrying those mutations, allowing researchers to determine which genes can be disrupted without preventing the virus from surviving and which are essential for phage function.</p>
<p>After establishing the mutagenesis workflow, the researchers extended it to introduce new genetic cargo. Rather than using the transposon only to disrupt genes, they loaded it with an additional sequence and inserted a fluorescent marker into phage genomes. The approach could also be used to add genes that help phages overcome bacterial defense systems, potentially improving their effectiveness against target pathogens.</p>
<p>“Once we had that established, we thought we could expand the technique and also use it to add genes directly into the phage genomes,” co-lead author Manuela Fuchs, PhD, said.</p>
<p>“This is a systematic, broadly applicable, and cost-effective way to not only investigate gene function, but also rapidly engineer phage genomes,” senior author Leah Smith, PhD, said, in a statement.</p>
<p>The platform could therefore serve two related goals: mapping the largely uncharacterized genetic landscape of phages and building variants with new capabilities. The researchers said the work opens opportunities for fundamental studies as well as future therapeutic development, although engineered phages would still require further testing to establish their safety and effectiveness in specific applications.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/new-crispr-based-tool-enables-genome-wide-mutagenesis-of-bacteriophages/">New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>How Bladder Cells Fight Hidden E. coli: New Insights Into Recurrent UTIs</title>
<link>https://edusehat.com/en/how-bladder-cells-fight-hidden-e-coli-new-insights-into-recurrent-utis</link>
<guid>https://edusehat.com/en/how-bladder-cells-fight-hidden-e-coli-new-insights-into-recurrent-utis</guid>
<description><![CDATA[ A new study finds the drug OM-89 may help bladder cells eliminate hidden E. coli by activating lysosomal pathways and increasing antibiotic uptake, potentially reducing bacterial regrowth in recurrent UTIs.
The post How Bladder Cells Fight Hidden E. coli: New Insights Into Recurrent UTIs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-956351578.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>How, Bladder, Cells, Fight, Hidden, coli:, New, Insights, Into, Recurrent, UTIs</media:keywords>
<content:encoded><![CDATA[<p>Urinary tract infections (UTIs) are among the most common bacterial infections, frequently caused by <em>Escherichia coli. </em>But UTIs are known to be recurrent, even after antibiotic treatment. One reason is that the bacterium can enter the cells of the bladder epithelium to evade both antibiotics and the patient’s immune system, and re-emerge. Researchers have now identified a way to strengthen the bladder cells’ own ability to eliminate these hidden bacteria.</p>
<p>The study, published in<em> PLOS Pathogens</em>, is entitled, “<a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014448" target="_blank" rel="noopener">Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic <em>Escherichia coli</em></a>.”</p>
<p>The findings suggest that the drug OM-89 (marketed as Uro-Vaxom<sup>®</sup>) activates cellular degradation pathways in bladder epithelial cells while also increasing antibiotic uptake. OM-89 has been used for decades to help prevent recurrent UTIs. It is mainly known for stimulating the immune system, but the new study reveals a second mechanism of action: a direct effect on the cells lining the bladder.</p>
<p>The researchers studied mouse and human bladder epithelial cells using organoid models and differentiated cell cultures. They exposed the cells to OM-89, infected them with different strains of <em>E. coli, </em>and treated them with antibiotics. They then tracked bacterial survival, antibiotic uptake, and changes in cellular pathways involved in destroying intracellular material.</p>
<p>The findings show that OM-89 increased lysosomal acidification as well as the activity of lysosomal enzymes. When the researchers blocked lysosomal acidification, OM-89’s protective effect was lost, suggesting that lysosomal activity is directly involved in reducing bacterial regrowth in recurrent UTIs. In addition, OM-89 increased the accumulation of antibiotics inside bladder epithelial cells—an effect that extended across different antibiotic classes and several bacterial strains, including clinical samples from patients.</p>
<p>“We found that OM-89 doesn’t just stimulate the innate immune system as previously assumed,” says Kathrin Tomasek, PhD, project leader at the Laboratory of Microbiology and Microtechnology at EPFL. “It acts directly on bladder cells, strengthening their degradation pathways so they can destroy hidden bacteria more effectively while also helping antibiotics reach those bacteria—together reducing regrowth of the bacteria after treatment ends.”</p>
<p>The findings point toward a host-directed approach to recurrent infection: rather than targeting bacteria alone, treatment could also reinforce the antimicrobial machinery of the infected tissue itself.</p>
<p>More broadly, the study identifies lysosomal pathways in the bladder epithelium as a potential target for future treatment combinations designed to improve antibiotic outcomes.</p>
<p>“While the results come from preclinical models and do not change the approved indication or use of Uro-Vaxom<sup>®</sup>, they deepen our understanding of how OM-89 may help strengthen the bladder’s natural defenses against recurrent infection and reinforce the scientific foundation supporting its use,” adds Christian Pasquali, senior scientific liaison director at OM Pharma and former head of preclinical research.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/how-bladder-cells-fight-hidden-e-coli-new-insights-into-recurrent-utis/">How Bladder Cells Fight Hidden <i>E. coli</i>: New Insights Into Recurrent UTIs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Stroke Remodels Tumor Microenvironment to Promote Glioma Growth</title>
<link>https://edusehat.com/en/stroke-remodels-tumor-microenvironment-to-promote-glioma-growth</link>
<guid>https://edusehat.com/en/stroke-remodels-tumor-microenvironment-to-promote-glioma-growth</guid>
<description><![CDATA[ A study in mouse and human models showed how stroke promotes glioma growth by remodeling the tumor microenvironment, with the emergence of a distinct population of tumor-associated astrocytes with reduced Ca2+ activity, and enrichment of tumor-associated microglia and macrophages (TAMs).
The post Stroke Remodels Tumor Microenvironment to Promote Glioma Growth appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/11/GettyImages-1172511190-e1701113426323.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Stroke, Remodels, Tumor, Microenvironment, Promote, Glioma, Growth</media:keywords>
<content:encoded><![CDATA[<p>The results of a study by researchers at Texas Children’s Duncan Neurological Research Institute (Duncan NRI), at Baylor College of Medicine and collaborating institutions have shown that stroke promotes glioma growth, and point to cellular and molecular mediators involved in the process, linking brain injury to malignant brain tumors.</p>
<p>Working with mouse and human models, the team discovered that stroke induces tumor microenvironment (TME) remodeling, alongside the emergence of a distinct population of tumor-associated astrocytes (TAAs) exhibiting reduced Ca<sup>2+</sup> activity, and enrichment of tumor-associated microglia and macrophages (TAMs). Restoring TAA Ca<sup>2+</sup>  signaling or depleting TAMs, suppressed stroke-induced glioma progression, pointing to the importance of both cell type types in injury response.</p>
<p>Research lead Hyun Kyoung Lee, PhD, principal investigator at the Duncan NRI, and an associate professor of pediatrics – neurology and member of the Dan L Duncan Comprehensive Cancer Center at Baylor, and colleagues reported on their findings in <em>Nature Cancer</em>, in a paper titled “<a href="https://doi.org/10.1038/s43018-026-01238-8" target="_blank" rel="noopener">Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca<sup>2+</sup> activity</a>.” In their paper the investigators concluded, “Collectively, our findings establish stroke-induced remodeling of astrocytic Ca<sup>2+</sup> signaling and TAMs as drivers of glioma progression and link brain injury to malignant disease.”</p>
<p>Glioblastoma (GBM) is the most prevalent and aggressive malignant brain tumor in adults,  and has what the researchers describe as “… a notably dismal 5-year survival rate.”  Research has catalogued a number of genetic mutations associated with GBM, the team pointed out, but the risk factors predisposing individuals to glioma are not well understood. “Recent clinical cohort studies and case reports have identified a correlation between glioma and brain injuries, where ischemic stroke shows significant co-occurrence with brain tumors, including glioma,” they further noted.</p>
<p>Lee added, “Epidemiological and clinical studies suggest that patients with a history of stroke or traumatic brain injury are at increased risk of developing brain tumors.  The risk can be about three-fold to seven-fold, depending on the age and sex of the patient.” However, Lee continued, “Despite these clinical observations, the mechanism that connects brain injury and cancer remains unclear.”</p>
<p>For their newly reported study the researchers, including Qi Ye, PhD, and graduate student Christine Madamba, at the Lee lab, worked with human and mouse models to investigate whether stroke promotes glioma growth and the factors mediating the connection. The team discovered the emergence of a distinct population of brain cells—tumor-associated astrocytes—with distinct physiological and molecular characteristics, including diminished calcium activity. TAAs were accompanied by the accumulation of two other cell types, remodeled tumor-associated microglia and immune cells called macrophages (TAMs). “Mechanistically, we identified SLC4A4 as a key regulator of Ca<sup>2+</sup>  activity in TAAs and CCL2-mediated TAM recruitment,” they reported in their study.</p>
<p>The researchers also showed that restoring TAA calcium signaling or removing TAMs suppressed stroke-induced glioma progression, “… identifying both populations as critical mediators of the stroke response.” The findings suggest that these injury-induced, tumor-promoting pathways are potential therapeutic targets and support continuing research into strategies that could reduce the risk of glioma growth in patients with a history of brain injury.</p>
<p>“We show that stroke promoted tumor infiltration into injured brain regions in human and mouse glioma models, and reduced overall survival,” Lee said. “Looking closer into the cellular and molecular makeup of the tumors, we found that stroke triggers remodeling of the tumor microenvironment.”</p>
<p>The authors stated “In summary, our study reveals that ischemic stroke remodels the TME to promote glioma progression, highlighting injury-induced tumor-promoting pathways as potential therapeutic targets for persons with a history of brain injury … More broadly, our work establishes a framework for investigating TAA-mediated immune regulation, TME remodeling, and the mechanisms linking brain injury to glioma progression and tumorigenesis.”</p>
<p>Lee added, “Our study supports that brain injury can be a risk factor for brain cancer. In addition, our findings contribute to growing evidence pointing at a role of astrocytes in brain tumor growth. Neuron-tumor interactions have been shown to contribute to cancer growth. We show that other brain cells, astrocytes, also seem to communicate with brain cancer cells and influence their behavior. They should be considered when studying cancer mechanisms and therapies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/stroke-remodels-tumor-microenvironment-to-promote-glioma-growth/">Stroke Remodels Tumor Microenvironment to Promote Glioma Growth</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Thar Process Partners with ExtrateX to Bring Prep to Process&#45;Scale SFC to Europe</title>
<link>https://edusehat.com/en/thar-process-partners-with-extratex-to-bring-prep-to-process-scale-sfc-to-europe</link>
<guid>https://edusehat.com/en/thar-process-partners-with-extratex-to-bring-prep-to-process-scale-sfc-to-europe</guid>
<description><![CDATA[ SFC is a platform technology that utilizes upcycled CO2 for the purification of natural and synthetic molecules that is both highly efficient and sustainable at the same time.
The post Thar Process Partners with ExtrateX to Bring Prep to Process-Scale SFC to Europe appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2262544009-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 26 Sep 2026 04:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Thar, Process, Partners, with, ExtrateX, Bring, Prep, Process-Scale, SFC, Europe</media:keywords>
<content:encoded><![CDATA[<p>Thar Process, based in Pittsburgh, PA, a specialist in supercritical CO<sub>2</sub> extraction and purification technology (SFE and SFC), partnered with  ExtrateX, a French expert firm in supercritical fluid systems, to represent and distribute its advanced SFC systems throughout Europe. The deal provides clients with sales and technical support in pharmaceutical, biotech, and specialty chemical labs across the region, according to Todd Palcic, CEO of Thar Process.</p>
<p>“SFC is a platform technology that utilizes upcycled CO<sub>2 </sub>for purification of natural  and synthetic molecules that is both highly efficient and sustainable at the same time,” said Palcic. “ExtrateX’s deep expertise in supercritical CO<sub>2</sub> systems and strong presence across Europe make them the ideal partner.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><figure aria-describedby="caption-attachment-338472" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="wp-image-338472 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1-300x225.jpg" alt="Thar Process's Isolator™ SFC systems are designed for high-resolution separation and purification bioprocessing applications, including  pharmaceutical APIs and excipients, fermented products, peptides (GLP-1s, etc.) and natural products like omega-3s and cannabinoids." width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/13172578-isolator-sfc-10-1.jpg 1024w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Thar Process’s Isolator<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> SFC systems are designed for high-resolution separation and purification bioprocessing, including pharmaceutical APIs and excipients, fermented products, peptides (GLP-1s, etc.) and natural products like omega-3s and cannabinoids. [Thar Process]</figcaption></figure>The technology offers advantages in speed, efficiency, and environmental sustainability compared to conventional separation methods, continued Palcic.</p>
<p>According to Gonzague Choppe, CEO of ExtrateX, “This strategic collaboration brings together the complementary strengths of two companies with extensive expertise in supercritical fluid technologies. Thar Process brings some of the most advanced SFC solutions and deep chromatography expertise, while ExtrateX contributes its extensive experience in supercritical fluid technologies, process expertise, scale-up capabilities and strong European presence.”</p>
<p>The partnership becomes effective on the first day of 2027, with ExtrateX establishing sales and support operations to serve European customers. The company will handle equipment sales, technical installation, maintenance, and customer training.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/thar-process-partners-with-extratex-to-bring-prep-to-process-scale-sfc-to-europe/">Thar Process Partners with ExtrateX to Bring Prep to Process-Scale SFC to Europe</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Young organs may not be a fountain of youth for recipients</title>
<link>https://edusehat.com/en/young-organs-may-not-be-a-fountain-of-youth-for-recipients</link>
<guid>https://edusehat.com/en/young-organs-may-not-be-a-fountain-of-youth-for-recipients</guid>
<description><![CDATA[ Around this time last year I was attending an aging conference in Manchester, listening to a talk about fly aging, when my phone started pinging. News outlets were reporting that a hot mic had caught Russia’s and China’s leaders discussing the possibility of living forever. “With the developments of biotechnology, human organs can be continuously… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/young-old-heart.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 21:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Young, organs, may, not, fountain, youth, for, recipients</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul>
<li><strong>Young hearts don't stay young for long:</strong> New research shows that transplanted hearts quickly take on the biological age of whoever receives them — meaning a 30-year-old heart given to a 70-year-old recipient will soon "act" 70.</li>
<li><strong>The body's environment calls the shots:</strong> Researchers found that neither the recipient's blood nor other organs were meaningfully affected by the donor heart's age, suggesting the body's broader environment overpowers any rejuvenating potential a young organ might carry.</li>
<li><strong>A silver lining for transplant medicine:</strong> The findings could push surgeons to stop discarding older donor hearts, since biological age appears to reset after transplant anyway — potentially expanding a critically short supply of viable organs.</li>
<li><strong>Immortality remains out of reach:</strong> The study underscores just how stubbornly complex aging is — reversing it entirely would require unwinding DNA damage, structural decay, and cellular wear across every tissue simultaneously, which scientists say is an enormous, likely impossible, challenge.</li>
</ul>" data-chronoton-post-id="1145083" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Around this time last year I was attending an aging conference in Manchester, listening to a talk about fly aging, when my phone started pinging. News outlets were reporting that a hot mic had caught Russia’s and China’s leaders <a href="https://www.technologyreview.com/2025/09/05/1123113/putin-organ-transplants-immortality-longevity-replacement/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">discussing the possibility of living forever</a>.</p>



<p>“With the developments of biotechnology, human organs can be continuously transplanted, and people can live younger and younger, and even achieve immortality,” Russia’s Vladimir Putin reportedly told China’s Xi Jinping.</p>



<p>He seems to have been referring to the “replacement” theory of longevity, which has been supported by multiple <strong><a href="https://www.technologyreview.com/2016/11/22/155895/blood-from-old-mice-makes-young-mice-decrepit/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26" target="_blank" rel="noreferrer noopener">experiments</a></strong> that involved physically stitching young mice to old ones. Something about the young blood rejuvenated the old mice. Perhaps young organs could rejuvenate world leaders in their 70s, too.</p>





<p>Unfortunately for Putin, new research pours a little cold water on this idea. Studies on transplanted hearts in both mice and humans suggest that new hearts soon adopt the biological age of the recipient, no matter how young they were to begin with. The finding could be important for transplantation, but it also highlights just how complex aging—and rejuvenation—are.</p>



<p>Jesse Poganik at Brigham and Women’s Hospital in Boston is one of the many scientists trying to understand exactly what it is about the bodies of young mice that rejuvenates old ones. Plenty of research has focused on seeking the secrets of youth in <a href="https://www.technologyreview.com/2026/08/27/1143037/startup-claims-its-found-a-drug-to-make-your-blood-young/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">young blood</a>. But what if it’s something about young organs instead?</p>



<p>To find out, he and his colleagues performed a set of heart transplants in mice. In humans, heart transplants typically involve removing a damaged or injured heart and replacing it with another from a donor who is usually much younger than the recipient. (When Poganik assessed hospital records, he found that most recipients were about 20 years older than their donors.)</p>



<p><strong>The mouse transplants were different:</strong> Mice received a <em>second</em> heart, implanted in the neck—a procedure that’s slightly simpler and allows scientists to compare the new hearts with the existing ones. In some cases, young adult mice were given a heart from a middle-aged donor. In others, middle-aged mice got young hearts.</p>



<p>The team used a trio of <a href="https://www.technologyreview.com/2025/10/14/1124977/aging-clocks-biology-mortality-longevity/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">“aging clocks”</a>—molecular tools used to estimate the biological ages of tissues and whole organisms—to assess whether the additional hearts affected the mice in any way. These clocks were good at predicting the chronological age of mice that didn’t get new hearts.</p>





<p>Poganik says he was expecting to see a reciprocal effect, and that young hearts might benefit older animals, for example. In previous work by other members of his team, young mice that got old hearts experienced a buildup of senescent cells in their other organs. These cells are thought to contribute to the aging process, suggesting that receiving an old organ might prematurely age an animal.</p>



<p><strong>But that’s not what he found.</strong> When he and his colleagues analyzed the transplanted hearts between four and six months after surgery, they found that the hearts seemed to have adopted the biological age of the recipients. Young hearts got older, and old hearts got younger. “The environment of the transplanted organ really dictates how it seems to behave biologically,” he says. The findings were published online at <a href="https://www.biorxiv.org/content/10.64898/2026.09.15.751836v1">bioRxiv</a> last week.</p>



<p>The team also looked at each mouse’s blood and other organs—including its original heart—and were surprised to find that they seemed to be unaffected by the presence of the new heart, despite the age of its donor.</p>



<p><strong>The finding was backed up by data from human heart transplants.</strong> People who receive a donor heart must typically undergo a series of heart biopsies after surgery. The tiny pieces of heart tissue collected from people who had heart transplants at Brigham and Women’s have been stored for decades. And when Poganik and his colleagues tested their biological ages with the aging clocks, they found a similar pattern: No matter the age of the donor, a new heart quickly adopts the biological age of the person who received it.</p>





<p>It’s not clear why this is, but João Pedro de Magalhães, who studies aging at the University of Birmingham in the UK and was not involved in the study, thinks it might have something to do with the recipient’s immune system. Perhaps immune cells circulating in the blood might affect markers of aging in the new organ, he says.</p>



<p>Perhaps the potential rejuvenating effects of a young heart end up being diluted by all the other aged components of an older body, Poganik suggests. Or maybe a single organ just isn’t enough to see an effect.</p>



<p>Poganik hopes his finding will encourage surgeons to consider using hearts from older donors, many of which are discarded on the assumption they won’t function as well. (Machines used to preserve organs before transplantation are changing that already—and Poganik has worked on another study showing that these devices <a href="https://www.technologyreview.com/2026/09/14/1144010/donated-livers-can-be-made-biologically-younger/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-24-26">seem to rejuvenate donor livers</a> to some extent.)</p>



<p><strong>But the study also highlights just how complicated aging is.</strong> If organs seem to be getting older by one measure but not by another, how can we get a full picture of the biological age of an organ, or a person?</p>



<p>This complexity means that scientists are not likely to discover a true way to completely reverse aging, says Poganik. “That would mean that every aspect of aging has to go back in time,” he says. Reversing DNA damage, structural damage, and all the other degradations that are part of the aging package, across all our various cells and tissues, presents an <em>enormous</em> challenge.</p>



<p>“There are aspects of biological age that are probably reversible, and there are aspects that are probably not,” he says. Sorry, Putin.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.<br></p>]]> </content:encoded>
</item>

<item>
<title>Intense Media Pressure an Emerging Challenge in CHO Business</title>
<link>https://edusehat.com/en/intense-media-pressure-an-emerging-challenge-in-cho-business</link>
<guid>https://edusehat.com/en/intense-media-pressure-an-emerging-challenge-in-cho-business</guid>
<description><![CDATA[ Process intensification and the adoption of continuous-mode manufacturing has increased the consumption of culture media. Managing these ever-growing culture volumes in a cost and space efficient manner has become a major challenge for drug manufacturers, says Just – Evotec Biologics.
The post Intense Media Pressure an Emerging Challenge in CHO Business appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-115860608-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Intense, Media, Pressure, Emerging, Challenge, CHO, Business</media:keywords>
<content:encoded><![CDATA[<p>Storing and preparing the culture media required to make protein therapeutics is a major challenge for biopharma, particularly given the growing interest in boosting output through intensification and continuous processing.</p>
<p>So says Guy Rachmuth, from Seattle services firm Just – Evotec Biologics, who told <em>GEN</em>, “Cell culture media requires significant footprint for both batching and storing media, including cold temperature storage for many final liquid media formulations.</p>
<p>“Manufacturers often need tens to hundreds of thousands of liters of media, making storage efficiency an increasingly important consideration. In addition, mixing equipment limitations can necessitate compounding multiple media batches per run and increase operational complexity in manufacturing.”</p>
<p>Rachmuth added, “These challenges become even more pronounced in intensified production processes, where continuous perfusion of bioreactors significantly increases cell culture medium volume requirements.”</p>
<p>With this in mind, Just – Evotec developed J.Media, a concentrated, room-temperature stable powder format that, the firm claims, reduces storage footprint, simplifies logistics and supports more flexible and efficient manufacturing operations.</p>
<p>The product was developed to meet the demands of Just – Evotec’s own manufacturing programs and has since become a core platform technology across the organization supporting nearly 70 projects.</p>
<p>Rachmuth told us, “Given the success we’ve seen internally, we recognized an opportunity to make J.Media available more broadly to the industry. By offering it as a standalone product, we aim to help other organizations benefit from the same combination of productivity, scalability, and cost efficiency.”</p>
<p>In tests, details of which were presented at the <a href="https://www.evotec.com/events/bioprocess-international-us-east-2026" target="_blank" rel="noopener">BPI conference and exhibition in Boston</a>, the media outperformed several commercially available products, exhibiting higher volumetric productivity and cumulative titer.</p>
<p>According to Rachmuth, “The media routinely runs at 80-100 10E6 cells/mL maintaining high viability over a period of 15-25 days, or longer. Our productivity is higher than competitor media.</p>
<p>“In perfusion operations, volumetric productivities of up to 4-5 g/L/day have been achieved, highlighting the platform’s ability to support highly efficient manufacturing processes,” he said.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/intense-media-pressure-an-emerging-challenge-in-cho-business/">Intense Media Pressure an Emerging Challenge in CHO Business</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>JNC Targets Bigger Molecules with Cellufine</title>
<link>https://edusehat.com/en/jnc-targets-bigger-molecules-with-cellufine</link>
<guid>https://edusehat.com/en/jnc-targets-bigger-molecules-with-cellufine</guid>
<description><![CDATA[ JNC is using BioProcess International 2026 to spotlight Cellufine and its emerging MLP chromatography media, developed to address purification challenges posed by viral vectors, vaccines, and other increasingly large and complex biological products.
The post JNC Targets Bigger Molecules with Cellufine appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/JNC-BPI_GBPN_IMAGE-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>JNC, Targets, Bigger, Molecules, with, Cellufine</media:keywords>
<content:encoded><![CDATA[<p>The rapid expansion of viral vectors, vaccines, and other complex biologics is creating a familiar downstream-processing problem in a new form: the molecules and particles that manufacturers need to purify are getting bigger. JNC is addressing that challenge at BioProcess International 2026, where the company is showcasing its Cellufine chromatography portfolio alongside monolith-like particle (MLP) products currently under development.</p>
<p>Cellufine is JNC’s family of cellulose-based chromatography media for biopharmaceutical purification. The company’s newer MLP platform takes that foundation in a different direction by using a large-pore bead architecture intended to improve access for bulky biological targets that can be difficult to accommodate with conventional porous media.</p>
<p>That design was the focus of a presentation by Chigusa Mori, R&D scientist at JNC, titled “Cellufine MLP: Wide Pore Cellulose Base Bead 3D Architecture for Large Biomolecule Chromatography Applications.”</p>
<p>JNC is also highlighting two development-stage MLP products through poster presentations. One examines Cellufine MLP DexQ for separating empty and full adeno-associated virus (AAV) particles, which is a persistent purification challenge in AAV manufacturing. Another explores Cellufine MLP DexS for viral-vector purification.</p>
<p>MLP DexS uses dextran sulfate as a ligand and is being investigated for large-particle applications, including vaccines. Data reported by JNC show that the resin concentrated inactivated influenza virus 13-fold while cutting protein impurities by 90.3%. In testing with human coronavirus OC43, JNC reported a 97.3% reduction in protein impurities together with 91% virus recovery. Those results point to the broader bioprocessing question behind JNC’s showcase: how chromatography can evolve as therapeutic modalities move beyond traditional proteins toward particles and assemblies with very different physical properties.</p>
<p>For downstream developers, pore architecture is becoming more than a resin-design detail. It can determine how effectively large targets enter the bead, interact with ligands, and ultimately separate from process-related impurities.</p>
<p>By bringing its MLP technology to BPI26, JNC is positioning large-pore cellulose chromatography as one approach to extending conventional column purification into areas where the size of the product itself increasingly shapes process performance.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/jnc-targets-bigger-molecules-with-cellufine/">JNC Targets Bigger Molecules with Cellufine</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics</title>
<link>https://edusehat.com/en/muscle-cell-calcium-channel-structure-synchronicity-could-advance-muscle-disease-therapeutics</link>
<guid>https://edusehat.com/en/muscle-cell-calcium-channel-structure-synchronicity-could-advance-muscle-disease-therapeutics</guid>
<description><![CDATA[ Researchers captured the first high-resolution 3D images of the muscle cell calcium channel RyR1 at six stages of opening inside the intact sarcoplasmic reticulum membrane, potentially helping to explain mechanisms behind certain muscle diseases. 
The post Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/Trends-Biotech-GettyImages-1441662854.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Muscle, Cell, Calcium, Channel, Structure, Synchronicity, Could, Advance, Muscle, Disease, Therapeutics</media:keywords>
<content:encoded><![CDATA[<p>Every step we take begins with a burst of calcium inside our muscle cells, causing them to contract. Using cryo-electron microscopy (cryo-EM), researchers at the Max Delbrück Center have revealed how muscle cell calcium channels, known as type-1 ryanodine receptors (RyR1), open synchronously. The team, led by Vasilii Mikirtumov, PhD, a former doctoral student in the <em>in situ</em> structural biology lab of Misha Kudryashev, PhD, suggests that their findings may explain a mechanism behind serious muscle diseases and potentially point to therapeutic targets.</p>
<p>Kudryashev is senior and corresponding author of the scientists’ published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-75504-9" target="_blank" rel="noopener">Ligand-induced activation of RyR1 in native membranes</a>,” in which they conclude that their findings “… explain the mechanism of ligand-gated activation of RyR1 in native membranes and provide structural insights critical for understanding RyR1-associated skeletal muscle diseases and developing targeted therapeutic strategies.”</p>
<p>Skeletal muscle contraction relies on “… a precise interplay between electrical signals and Ca2+ release from internal stores,” the authors explained. Maintaining readiness for contraction, the cells keep calcium locked in this internal compartment, the sarcoplasmic reticulum (SR). Studding its membrane are thousands of RyR1 channels—the largest known ion channels—containing pores that release calcium.</p>
<p>For a muscle to contract properly, RyR1 channels must open synchronously via a mechanism known as “coupled gating.” How they accomplish this has been unclear since it was described almost 30 years ago. “…  the physical mechanism orchestrating this cooperativity has remained unknown,” the authors noted in their paper.</p>
<p>Through their reported studies Mikirtumov, Kudryashev, and colleagues have captured the first high-resolution 3D images of RyR1 at six stages of opening inside the intact sarcoplasmic reticulum membrane. The structure of RyR1 has been described before, but previous studies used channels that had been removed from the membrane. Instead, the Kudryashev lab studied the structure of RyR1 in its natural environment using the advanced imaging techniques of cryo-EM and tomography. “Because RyR1 is a membrane protein, you have to pull it out with detergents to purify it. But that environment can be disruptive to such a sensitive protein,” explained Mikirtumov, who is now a postdoctoral researcher in the lab of Christian Spahn at Charité – Universitätsmedizin Berlin. “We wanted to capture the structure of the channel in its native membrane and find out whether its opening mechanism looks different there.”</p>
<p>The team isolated the SR from rabbit muscle and imaged it at the Core Facility for Cryo-Electron Microscopy, which is run jointly by Charité – Universitätsmedizin Berlin, the Max Delbrück Center, and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP). The Kudryashev lab has specialized expertise in cryo-EM and tomography and the computational tools necessary to analyze the resulting data.</p>
<p>“We shoot electrons through the sample and take thousands of pictures, each with many copies of the same protein,” explained Mikirtumov. “Then we average them all together, and that gives us a high-resolution 3D reconstruction.”</p>
<p>By adding small molecules to initiate channel opening, the researchers caught RyR1 at six stages between fully closed and fully open. “Comparing the structures revealed the full opening motion: The bulky outer part rotates within the plane of the membrane, like turning the ring of a camera lens, while the pore in the channel widens to roughly twice its original width.</p>
<p>The resulting images showed that neighboring channels remain in contact with each other when transitioning from the closed to open states. This contact, or interface, mediates coupled gating: as one channel rotates open, it strains the interface with its neighbor, making it easier for that channel to rotate and open too. “It’s like the cogs in a clock,” said Kudryashev. “Once one cog turns, it primes its neighbors to turn, too.”</p>
<p>In their paper the team wrote in summary, “The RyR1 structures in four distinct as well as two intermediate functional states induced by activating ligands showed that the activation of RyR1 includes a large rotation component in the membrane plane. The structures reveal direct, corner-to-corner physical contacts between receptors, providing a high-resolution view of the interface that mediates coupled gating.”</p>
<p>Using cryo-electron tomography, the team also imaged pairs of neighboring channels at five stages of opening. They found neighboring channels were more likely to be synchronized, and that two interacting closed channels were more stable than two closed channels in isolation. These findings support coupled gating and suggest that channels hold each other shut.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Mutations in the RYR1 gene cause malignant hyperthermia, a life-threatening reaction to some anesthetics, and congenital myopathies that weaken muscles. Many of these mutations alter the channel exactly where it touches its neighbor.</p>
<p>Mikirtumov added, “A lot of these mutations don’t seem to affect how a single channel opens, but rather how channels cooperate with their neighbors. We mapped several of them onto the interface, and we think that in these cases, it’s the cooperation between channels that breaks down.”</p>
<p>The researchers propose that disruption at the interface between channels makes them leaky, releasing calcium when they should retain it. This makes the interface itself a target for therapies. “We propose a mechanism for RyR1 activation, shifting the focus from an individual channel event to a cooperative process orchestrated by a mechanically coupled receptor lattice,” they stated.</p>
<p>The team is already testing the idea. “We need to prevent the channels from opening spontaneously,” said Kudryashev. “Now that we know how the inactive state is organized, we can design biologics or small molecules to stabilize this closed state.” The authors concluded, “These results emphasize the physiological importance of RyR1 arrays as integrated functional units and provide new perspectives on EC-coupling and the development of targeted therapeutics for RyR1-linked channelopathies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/muscle-cell-calcium-channel-structure-synchronicity-could-advance-muscle-disease-therapeutics/">Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s</title>
<link>https://edusehat.com/en/apoe4-linked-to-potentially-reversible-mechanisms-of-brain-blood-vessel-damage-in-alzheimers</link>
<guid>https://edusehat.com/en/apoe4-linked-to-potentially-reversible-mechanisms-of-brain-blood-vessel-damage-in-alzheimers</guid>
<description><![CDATA[ Two studies reveal how APOE4, a major genetic risk factor for Alzheimer’s, disrupts brain blood vessels and promotes abnormal protein accumulation, pointing to potentially reversible disease mechanisms.
The post APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/12/GettyImages-1410984882.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 06:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>APOE4, Linked, Potentially, Reversible, Mechanisms, Brain, Blood, Vessel, Damage, Alzheimer’s</media:keywords>
<content:encoded><![CDATA[<p><span>Data from two studies using models of brain tissue and aged mice help explain how APOE4, a genetic risk factor for Alzheimer’s disease, damages the brain’s blood vessels and promotes the buildup of abnormal protein. The findings are published in two papers in the journals </span><i><span>Cell </span></i><span>and </span><i><span>Cell Stem Cell</span></i><span>. The </span><i><span>Cell</span></i><span> paper is titled “</span><a href="https://www.cell.com/cell/abstract/S0092-8674(26)01069-X" target="_blank" rel="noopener"><span>A pericyte-to-myofibroblast transition links APOE4 to cerebrovascular degeneration</span></a><span>.” The </span><i><span>Cell Stem Cell</span></i><span> paper is titled “</span><a href="https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(26)00302-4" target="_blank" rel="noopener"><span>Cholesterol dysregulation in APOE4 astrocytes promotes α-synuclein pathology in miBrains</span></a><span>.”</span></p>
<p><span>Both studies are led by scientists at the Icahn School of Medicine at Mount Sinai. They help answer questions about the exact mechanism by which blood vessels deteriorate as Alzheimer’s progresses, particularly in people with APOE4. The </span><i><span>Cell</span></i><span> study details how the Mount Sinai researchers combined existing datasets to create a single-cell transcriptomic atlas of the human brain’s vasculature, resulting in a detailed map of gene activity across cells that form and support blood vessels. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>By analyzing the map, they found that APOE4 caused pericytes, which are cells that stabilize small blood vessels and help maintain the blood-brain barrier, to transform into scar-forming myofibroblast-like cells. This change promoted vascular fibrosis and increased amyloid accumulation around the vessels. This created conditions that may compromise blood flow and promote neurodegeneration. Using aged APOE4 mice, the scientists observed the effects of blocking TGF-β signaling, a pathway involved in cellular communication and tissue remodeling. They found that it restored pericyte coverage and reduced both fibrosis and vascular amyloid, effectively demonstrating that it may be possible to reverse APOE4-associated cerebrovascular degeneration therapeutically.</span></p>
<p><span>These results show that “damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible,” said Joel Blanchard, PhD, associate professor of neuroscience, and stem cell biology and regenerative medicine at Mount Sinai and a corresponding author on the study. Furthermore, “ through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain’s circulation in people at high genetic risk for Alzheimer’s disease,” said Braxton Schuldt, MD/PhD candidate in neuroscience and researcher in the Blanchard Laboratory at Mount Sinai. He is also the first author on the paper. </span></p>
<p><span>For the </span><i><span>Cell Stem Cell </span></i><span>study, the Mount Sinai scientists and their collaborators elsewhere used miBrains to investigate how APOE4 promotes abnormal protein build up in diseases like Alzheimer’s and Parkinson’s. Derived from induced pluripotent stem cells, miBrains are three-dimensional human brain tissues developed by the Mount Sinai team to model key features of the human brain and its vascular network. These 3D tissues contain all the major cell types, including neurons, supporting glial cells, myelin-producing cells, and cells that form blood vessels. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>They also mimic the behavior of human brains carrying APOE4. Specifically, miBrains carrying APOE4 accumulate higher levels of abnormal alpha-synuclein, the protein commonly associated with Lewy body dementia and Parkinson’s disease. Experiments reported in the paper showed that APOE4 causes cholesterol to accumulate in astrocytes, and that this excess cholesterol impairs the astrocytes’ lysosomal waste-disposal system, reducing their ability to break down alpha-synuclein. The protein instead aggregates and spreads to neurons, leading to harmful protein deposits. The findings identify cholesterol metabolism in astrocytes and lysosomal function as promising therapeutic targets for Alzheimer’s and Parkinson’s disease.</span></p>
<p><span>“A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved,” said Louise Mesentier-Louro, PhD, assistant professor of neuroscience, and stem cell biology and regenerative medicine at Mount Sinai and first author of the study. “This capability improves reproducibility and scalability of complex disease modeling and supports more efficient drug development and validation.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/apoe4-linked-to-potentially-reversible-mechanisms-of-brain-blood-vessel-damage-in-alzheimers/">APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>National Cancer Institute explainer for CSBA: Why and how to apply for SBIR</title>
<link>https://edusehat.com/en/national-cancer-institute-explainer-for-csba-why-and-how-to-apply-for-sbir</link>
<guid>https://edusehat.com/en/national-cancer-institute-explainer-for-csba-why-and-how-to-apply-for-sbir</guid>
<description><![CDATA[ The SBIR and STTR federal seed funding programs—essential to many biotech start-ups—have been updated with important changes that provide new opportunities to applicants. These […]
The post National Cancer Institute explainer for CSBA: Why and how to apply for SBIR appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/09/towfiqu-barbhuiya-joqWSI9u_XM-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 03:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>National, Cancer, Institute, explainer, for, CSBA:, Why, and, how, apply, for, SBIR</media:keywords>
<content:encoded><![CDATA[<p><span>The SBIR and STTR federal seed funding programs—essential to many biotech start-ups—have been updated with important changes that provide new opportunities to applicants.</span></p>
<p><span>These changes include a new Strategic Breakthrough Program, which can bring up to $30 million to impactful innovations addressing pediatric and rare cancers, experts from the National Cancer Institute (NCI) told a Sept. 17 webinar for the</span><a href="https://www.bio.org/csba"> <span>Council of State Bioscience Associations (CSBA)</span></a><span>.</span></p>
<p><span>Their presentations offer useful information for oncology biotechs, and any biotech needing seed funding to start their work.</span></p>
<p><span>“We tend to be the first source of funds that a company will look for after they’ve raised funds from friends and family,” said Michael Weingarten, Director of NCI’s SBIR Program.</span></p>
<p><span>Organized by the Biotechnology Innovation Organization (BIO) as a service for its state affiliates in the CSBA, the webinar covered National Institutes of Health (NIH) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants—particularly NCI cancer research grants.</span></p>
<h2>About SBIR/STTR</h2>
<p><span>The most recent changes to SBIR and STTR were added in March, when</span><a href="https://bio.news/latest-news/sbir-reauthorization-a-top-bio-priority-is-passed-by-congress/"> <span>the programs were reauthorized by Congress</span></a><span> until September 2031. The next application deadline is Jan. 5, which is why this information matters now, the experts told the webinar.</span></p>
<p><span>Much of the conversation focused on SBIR grants, which individual start-ups can seek by themselves. STTR grants tend to be larger and support technology transfer. Along with a start-up, STTR grants must include an institutional partner, such as a university, that is transferring the technology.</span></p>
<p><span>The impact for start-ups, and American innovation, can be huge. Weingarten cited a 2018 study of Phase II SBIR/STTR grants given out by the NCI for cancer work between 1998-2010. Of those 690 projects, 247 went commercial, achieving over $26 billion in total economic output nationwide and creating over 108,000 jobs with an average salary of $75,000.</span></p>
<p><span>“We invested a total of $787 million in those companies to produce that $26 billion return. So overall return on investment for NCI’s money was about 33-to-1,” he said.</span></p>
<h2>The new Breakthrough Program</h2>
<p><span>One of the changes in the SBIR program that received special focus during the webinar was the new Strategic Breakthrough Award. The program can bring a start-up developing an important innovation for an unmet need as much as $30 million in capital at a critical phase of development, explained Billy Baza, Program Director within the NCI SBI Development Center.</span></p>
<p><span>“It really has to be a significant improvement to existing standard of care,” said Baza, describing the type of innovation targeted by the Breakthrough Award. “It really has to have an impact on the patients.”</span></p>
<p><span>The Strategic Breakthrough Awards differ among the various institutes of the NIH. At the NCI, “our goal is to really fund pivotal clinical studies for pediatric and rare cancers,” Weingarten said.</span></p>
<p><span>Investigation showed that the largest amount of private venture capital for oncology development goes to the most common types of cancer. NCI is hoping this program will encourage private investment in the rarer cancers, Baza said.</span></p>
<p><span>One way the program attracts private capital is through its 1-to-1 matching provision: applicants must use the grant to attract an equal amount of external funding, whether from a private investor, a partner company or another government program.</span></p>
<p><span>“Matching funds need to be secured after the application is submitted, but before the award is made,” Baza said. “That means you’re going to have explain your matching capital fundraising strategy within the commercialization plan.”</span></p>
<p><span>Other requirements, according to Baza:</span></p>
<ul>
<li aria-level="1"><span>“The technology has to be at a clinical stage, with some promising early human clinical data as well.”</span></li>
<li aria-level="1"><span>Patient unmet need has to be clearly demonstrated. “We’re not looking for incremental improvements,” Baza said. “We want innovations that can really impact high-need patient populations.”</span></li>
<li aria-level="1"><span>There must be a credible study plan addressing clinical trial operation and enrollment, and strong interactions with the Food and Drug Administration (FDA).</span></li>
</ul>
<p><span>It can also help to show applicants are receiving FDA support, including Fast Track and orphan designation, or accelerated approval allowing use of surrogate endpoints.</span></p>
<h2>Other procedural and funding changes</h2>
<p><span>Weingarten outlined several changes under the newly reauthorized programs, including a limit of nine applications a year to Health and Human Services SBIR programs. One helpful change allows applicants seeking their first STTR grants to apply for “Direct to Phase II Award,” receiving higher Phase II funding right away without going through Phase I.</span></p>
<p><span>Weingarten also discussed the amounts of the awards available from NCI, including changes in those awards:</span></p>
<ul>
<li aria-level="1"><span>The relatively new Concept Award provides very early-stage SBIR funding for a technology that is still just a concept, without supporting data. “We are looking for out-of-the-box ideas and disruptive technologies in the areas of pediatric or rare cancers,” Weingarten said. Applicants can receive up to $300,000.</span></li>
<li aria-level="1"><span>NCI increased Phase I awards from a maximum of $400,000 to $700,000. “Typically, those are for proof-of-concept studies,” Weingarten said.</span></li>
<li aria-level="1"><span>NCI Phase II awards go up to $2.5 million, usually for 2-3 years. “We tend to think of Phase II as funding IND enabling work,” he said.</span></li>
<li aria-level="1"><span>The Commercialization Readiness Program (CRP), for post Phase II, funds early clinical studies and provides up to $4.2 million.</span></li>
<li aria-level="1"><span>The above-mentioned Strategic Breakthrough Program is capped at $15 million from SBIR, before private matching funds are added.</span></li>
</ul>
<p><span>“If you look across all these different funding streams, companies can access up to $22 million in funding from our program, which is larger than award sizes from any of the other institutes at the NIH,” Weingarten said.</span></p>
<p><b>To learn more:</b></p>
<ul>
<li aria-level="1"><a href="https://sbir.cancer.gov/small-business-funding/application-process/step"><b>Join NCI’s training on how to apply for SBIR/STTR grants.</b></a></li>
<li aria-level="1"><a href="https://sbir.cancer.gov/"><b>NCI SBIR web site.</b></a></li>
</ul>
<p>The post <a href="https://bio.news/federal-policy/national-cancer-institute-explainer-for-csba-why-and-how-to-apply-for-sbir/">National Cancer Institute explainer for CSBA: Why and how to apply for SBIR</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Altruist Biologics’ Suzhou Site Receives EMA GMP Certification</title>
<link>https://edusehat.com/en/altruist-biologics-suzhou-site-receives-ema-gmp-certification</link>
<guid>https://edusehat.com/en/altruist-biologics-suzhou-site-receives-ema-gmp-certification</guid>
<description><![CDATA[ The company’s Quality Risk Management framework enabled proactive identification of compliance risks, reduced uncertainties associated with cross-regional technology transfer, and provided greater predictability as therapies advance toward regulatory submission and commercialization.
The post Altruist Biologics’ Suzhou Site Receives EMA GMP Certification appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/Getty_2024513047_PharmaceuticalFactory.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 25 Sep 2026 03:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Altruist, Biologics’, Suzhou, Site, Receives, EMA, GMP, Certification</media:keywords>
<content:encoded><![CDATA[<p>Altruist Biologics, a CDMO based in China, reports that its Suzhou commercial manufacturing facility has successfully passed a GMP inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the first time the facility has successfully received EMA GMP certification.</p>
<p>The inspection supported the European Union marketing authorization application for a biologics product from a biopharmaceutical client. The EMA inspection involved an assessment covering the full biologics manufacturing lifecycle and a review of the facility’s quality systems and operational performance.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The Suzhou facility’s quality management system, infrastructure, technical capabilities, data integrity controls and organizational management were recognized by the EMA, according to the company. The company’s Quality Risk Management (QRM) framework has enabled proactive identification of compliance risks, reduced uncertainties associated with cross-regional technology transfer, and provided greater predictability as innovative therapies advance toward global regulatory submission and commercialization, stated Kaisong Zhou, PhD, chairman and CEO of Altruist Biologics.</p>
<p>“Quality spans the entire biologics lifecycle, ensuring compliance with rigorous regulatory requirements from development through commercialization,” he said. “The recent EMA GMP certification exemplifies that our robust manufacturing processes, quality systems, talent and world-class facility meet regulatory requirements, and we have the agency’s trust to manufacture and deliver products on behalf of our global partners and the patients they serve.”</p>
<p>Altruist’s Suzhou and Hangzhou sites are designed and operated to meet GMP requirements across multiple regulatory authorities, including the EMA, FDA, the Pharmaceutical and Medical Devices Agency (PMDA) of Japan, and the National Medical Products Administration (NMPA) of China, pointed out Zhou.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Equipped with 60,000 liters of antibody manufacturing capacity and an ADC clinical manufacturing line, the Suzhou facility provides end-to-end services for antibodies, fusion proteins and antibody-drug conjugates, he continued. The Hangzhou site is designed with a total antibody manufacturing capacity of 172,000 liters, with 80,000 liters currently operational across four 20,000-liter stainless steel bioreactors. A 2,000-liter antibody production line is currently under construction and is expected to be operational by mid-2027.</p>
<p>Altruist collectively has 140,000 liters of operational CDMO manufacturing capacity, representing approximately 20% of China’s total capacity, explained Zhou. As additional planned capacity comes online, Altruist’s total manufacturing capacity is expected to reach 232,000 liters.</p>
<p>In addition to the EMA, the Suzhou site has received multiple recognitions from other global regulatory authorities, said Zhou. It has successfully completed remote interactive evaluation by the FDA, and has passed inspections by the NMPA and the Federal Committee for Protection from Sanitary Risks (COFEPRIS) of Mexico, as well as more than 40 quality audits conducted by global clients.</p>
<p>Altruist Biologics, which will be exhibiting at booth 1027 at BPI, is a wholly-owned subsidiary of Innovent Biologics.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/altruist-biologics-suzhou-site-receives-ema-gmp-certification/">Altruist Biologics’ Suzhou Site Receives EMA GMP Certification</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Basecamp Research Raise $140M Series C Financing Toward Advancing AI&#45;Designed Drugs</title>
<link>https://edusehat.com/en/basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</link>
<guid>https://edusehat.com/en/basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</guid>
<description><![CDATA[ According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely. 
The post Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/BASECAMP-RESEARCH-GLENOLLIEBASE-1-696x464-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Basecamp, Research, Raise, 140M, Series, Financing, Toward, Advancing, AI-Designed, Drugs</media:keywords>
<content:encoded><![CDATA[<p>Basecamp Research said today it has completed an oversubscribed $140 million Series C financing whose proceeds are intended to fund the training of next generation EDEN models and apply them toward developing improved <em>in vivo</em> cell therapies for a variety of diseases.</p>
<p>Basecamp, a frontier AI company focused on therapeutic design, focuses on leveraging EDEN (short for “environmentally-derived evolutionary network), its biological foundation model, to develop<em> in vivo</em> cell therapies designed to reprogram a patient’s cells inside the body.</p>
<p>EDEN is Basecamp’s new class of foundation models trained on what the company says is the world’s largest and most diverse evolutionary dataset. According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely.</p>
<p>EDEN-designed cell therapies are also designed to overcome the high manufacturing cost and limited complexity of present-day cell therapies. As a result, Basecamp said in its announcement, its EDEN-designed therapeutics offer the potential to treat complex diseases that include cancer and autoimmune disease, aiming “to underpin the future of cell therapies, making them more sophisticated, more customizable and simpler to administer” than current cell therapies.</p>
<p>“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” Glen Gowers, PhD, Basecamp’s co-founder and CEO, said in the statement. Gowers co-founded Basecamp with Oliver Vince, PhD.</p>
<p>Basecamp says it has shown strong preclinical results across multiple modalities and disease areas. Aiming to expand its partnerships with biopharmas, Basecamp in April appointed Richard Pearce as chief business officer. Pearce previously served as Biogen’s head of business development, strategy, and portfolio management.</p>
<p>“AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most,” Gowers added.</p>
<p></p><h4><strong>Prominent investors</strong></h4>

<p>One prominent investor participating in the financing is Silicon Valley-based VC firm Menlo Ventures, which invested in Basecamp through the Menlo Anthology Fund, a $100 million fund financed by Menlo Ventures and launched in 2024 in partnership with Anthropic, the AI model builder behind the Claude family of large language models. Startups financed by the Menlo Anthology Fund receive access to Anthropic products and research, $25,000 in free credits towards Anthropic’s most advanced models, and what the company calls “best-in-class” venture support from Menlo.</p>
<p>“We’re particularly interested in ventures that leverage AI to enhance human capabilities and productivity in fields such as healthcare, legal services, education, energy, infrastructure, and scientific research,” Daniela Amodei, Anthropic’s co-founder and president, stated in announcing the launch of the Menlo Anthology Fund.</p>
<p>Anthropic’s offerings include Claude Science, the AI research workbench <a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">launched in June</a> and featuring Basecamp’s antibiotic design and vaccine prediction AI models.</p>
<p>Another prominent investor is NVentures, the venture capital arm of Nvidia—the Silicon Valley microprocessing giant<strong> </strong>with which Basecamp has <a href="https://www.genengnews.com/topics/artificial-intelligence/basecamp-research-achieves-programmable-gene-insertion-with-eden-ai-models/" target="_blank" rel="noopener">leveraged AI to unlock programmable gene insertion</a>, which places large therapeutic DNA sequences at precise locations in the human genome.</p>
<p>Researchers from Nvidia joined partners from Basecamp, Microsoft, and two research institutions in detailing EDEN in a <a href="https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1" target="_blank" rel="noopener">preprint posted January 12 on bioRxiv</a>.</p>
<p></p><h4><strong>63% hit rate</strong></h4>

<p>The investigators showed EDEN to achieve an overall functional hit rate of 63.2% across diverse DNA prompts when prompted on only 30bp of DNA from outside the training data. Half (50%) of EDEN-generated LSRs were active in human cells, achieving therapeutically relevant levels of chimeric antigen receptor (CAR) insertion in primary human T cells. Also, an EDEN-generated synthetic microbiome was shown in the preprint to cover 9,067 species with a biome-specific taxonomic accuracy of 99%.</p>
<p>Nvidia and Anthropic were among partners of Basecamp that built its Trillion Gene Atlas, which draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents. The Atlas is at the center of Basecamp’s AI platform, and according to the company is the world’s largest proprietary biological AI training dataset. Pacific Biosciences of California (PacBio) and Ultima Genomics also partnered in building the Atlas.</p>
<p>Trained on data from the Atlas, Basecamp’s EDEN models deliver a universal understanding of how DNA works across all of life. Its capabilities include designing cell and gene therapies, enzymes and peptides.</p>
<p>Unlike AI systems developed for a single scientific task, EDEN models are trained to recognize patterns across biology. As a result, it can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp’s collaboration with Anthropic on Claude Science.</p>
<p>Anthropic and NVentures are among participants in the financing, along with Catalio, European Tech Collective, Firebrand River Capital, King Philanthropies, NATO Innovation Fund, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.</p>
<p></p><h4><strong>‘Next transformation’</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p>Basecamp has garnered additional investment from senior leaders across biopharma and global industry, including André Hoffmann, vice chairman of Roche, a board member of Roche subsidiary Genentech, and co-chair of the World Economic Forum.</p>
<p>“The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalized, AI-designed therapeutics represent the next transformation of that journey,” Hoffmann stated. “Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.”</p>
<p>Basecamp raised $60 million in Series B financing in 2024, and a $20 million Series A round two years earlier.</p>
<p>The Series C financing was led by S32, a Palo Alto, CA-based venture firm. S32 has about $3.5 billion in assets under management after closing earlier this year on a $517 million sixth flagship fund, according to PitchBook.</p>
<p>As a result of the latest financing, Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, will join Basecamp’s board.</p>
<p>“AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people’s lives,” Conrad stated. “Basecamp Research is building an important technology platform at the center of that opportunity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs/">Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models</title>
<link>https://edusehat.com/en/genialis-and-inventia-life-science-collaborate-to-link-patient-biology-with-3d-pancreatic-cancer-models</link>
<guid>https://edusehat.com/en/genialis-and-inventia-life-science-collaborate-to-link-patient-biology-with-3d-pancreatic-cancer-models</guid>
<description><![CDATA[ The collaboration pairs the Genialis Supermodel with Inventia Life Science’s RASTRUM 3D cell model platform to test therapeutic hypotheses in models that mirror the tumor biology of specific patient groups.
The post Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1467893187.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genialis, and, Inventia, Life, Science, Collaborate, Link, Patient, Biology, with, Pancreatic, Cancer, Models</media:keywords>
<content:encoded><![CDATA[<p>Genialis and Inventia Life Sciences agreed to work together to improve how new treatments for pancreatic cancer are tested and matched to the patients most likely to benefit. The companies will combine Genialis’ AI-powered patient insights with Inventia’s RASTRUM 3D cell model platform to build human-relevant models of pancreatic ductal adenocarcinoma (PDAC) that correspond to the tumor biology of identifiable patient populations.</p>
<p>Initial results from this collaboration will be presented this week at the <a href="https://pancan.org/research/community-for-progress/pancan-scientific-summit-2026/" target="_blank" rel="noopener">Pancreatic Cancer Action Network (PanCAN)’s 2026 Scientific Summit</a> in San Diego.</p>
<p>Recent advances in targeted therapies for pancreatic cancer have brought renewed attention to PDAC and underscored the need for better strategies to identify which patients are most likely to benefit from new treatments. <a href="https://inventialifescience.com/platform/rastrum" target="_blank" rel="noopener">Inventia’s RASTRUM</a> platform prints reproducible 3D pancreatic cancer models in which tumor and stromal components can be controlled and perturbed independently.</p>
<p>Genialis characterizes those models with the <a href="https://www.genialis.com/supermodel/">Genialis<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Supermodel</a>—a large molecular model trained on a proprietary harmonized and curated transcriptomics dataset— and connects them to molecular states observed in the clinic. The collaboration also draws on data generated through Genialis’ long standing collaboration with PanCAN.</p>
<p>In the study being presented on Friday, September 25, Genialis identified PDAC patients with poor prognosis based on the composition and activity of the tumor microenvironment across 644 pancreatic cancer patient tumors taken from the <a href="https://pubmed.ncbi.nlm.nih.gov/38166233/">PanCAN SPARK</a> “<a href="https://pancan.org/facing-pancreatic-cancer/patient-services/know-your-tumor/">Know Your Tumor</a>” cohort.</p>
<p><figure aria-describedby="caption-attachment-338142" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class=" td-center wp-image-338142 " src="https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1024x418.jpg" alt="Genialis Supermodel Workflow [Genialis]" width="799" height="326" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1024x418.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-300x122.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-768x313.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1536x627.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-2048x836.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1029x420.jpg 1029w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-696x284.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1392x568.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1068x436.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/2026-Genialis-software-schematic-1920x783.jpg 1920w" sizes="(max-width: 799px) 100vw, 799px"><figcaption class="wp-caption-text">Genialis Supermodel Workflow [Genialis]</figcaption></figure>Genialis then mapped those patient profiles to tumor-fibroblast co-culture models generated on RASTRUM, allowing researchers to investigate the biology associated with poor outcomes and identify potential therapeutic strategies. This gives drug developers a way to test new approaches in models that reflect the biology of the patients they are intended to treat.</p>
<p>“This collaboration closes an important gap in drug discovery by connecting what we learn from patients with what we can test in the lab,” said Cameron Ferris, PhD, CEO and co-founder of Inventia Life Science. “Genialis can identify clinically meaningful biological states in real tumors, while RASTRUM allows us to model and perturb those states at scale. Together, that creates a powerful way to generate and test therapeutic hypotheses that are grounded in the biology of the patients we ultimately want to treat.”</p>
<p>The design closes a loop that translational programs usually leave open: hypotheses are derived from patient data, tested experimentally in human-relevant systems, and returned to the clinical population to determine where they are most likely to apply, noted Ferris.</p>
<p>“Our pharma partners need to make critical decisions about which patients to enroll and which combinations to pursue, yet historically, whether a preclinical result would translate to patients often wasn’t clear until Phase II,” said Rafael Rosenbarten PhD, CEO and co-founder of Genialis. “Inventia gives us a model where we can test those hypotheses experimentally, while the Supermodel helps identify the patients most likely to benefit.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/genialis-and-inventia-life-science-collaborate-to-link-patient-biology-with-3d-pancreatic-cancer-models/">Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Tautomer&#45;Predictor AI Tool Identifies Stable Molecules for Drug Discovery</title>
<link>https://edusehat.com/en/tautomer-predictor-ai-tool-identifies-stable-molecules-for-drug-discovery</link>
<guid>https://edusehat.com/en/tautomer-predictor-ai-tool-identifies-stable-molecules-for-drug-discovery</guid>
<description><![CDATA[ Researchers trained an AI model to learn chemical patterns associated with stability in drug-like molecules and accurately predict where their hydrogen atoms should be positioned.
The post Tautomer-Predictor AI Tool Identifies Stable Molecules for Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1464561575.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Tautomer-Predictor, Tool, Identifies, Stable, Molecules, for, Drug, Discovery</media:keywords>
<content:encoded><![CDATA[<p>New York University (NYU) researchers have trained an AI model to learn chemical patterns associated with stability in drug-like molecules and accurately predict where their hydrogen atoms should be positioned.</p>
<p>The team’s research, headed by Yingkai Zhang, PhD, professor of chemistry at NYU, addresses a longstanding challenge in molecular design and drug discovery, which is how to rapidly and reliably determine the stable form of molecules that share a molecular formula but readily convert into different forms. The researchers have released their method as an open-source tool, <a href="https://github.com/xiaolinpan/Tautomer-Predictor" target="_blank" rel="noopener">Tautomer-Predictor</a>, which can rapidly analyze very large molecular libraries.  Zhang is senior author of the scientists’ published paper in <em>Chemical Science</em> (“<a href="http://dx.doi.org/10.1039/d6sc03714c" target="_blank" rel="noopener">Deep learning of tautomer stability from crystallographic proton positions</a>.”)</p>
<p>Many drug-like molecules can exist in two or more closely related forms called tautomers. A hydrogen atom moves from one site to another, accompanied by a change in the bonding pattern. “Although this may seem like a small change, different tautomers of the same molecule can alter how a molecule interacts with a protein target,” explained Zhang. “Correct tautomer assignment is consequently important for molecular modeling and structure-based drug discovery.”</p>
<p>And as the team noted in their paper, “… incorrect tautomer assignment can compromise molecular docking, free-energy calculations, virtual screening, and other tasks in structure-based drug design.”</p>
<p>However, determining the correct tautomer remains a challenge—akin to finding a needle in a moving haystack. The scientists further commented, “Tautomerism plays a central role in molecular recognition, physicochemical properties, and chemical reactivity, yet rapid identification of stable tautomeric states remains a persistent challenge in molecular design and structure-based drug discovery.”</p>
<p>This challenge exists, in part, because of a scarcity of experimental data that characterizes tautomer structures. For instance, in the Protein Data Bank, a worldwide repository of the 3D structures of large biological molecules that is widely used in biological research, the location of hydrogen atoms that distinguish one tautomer from another are typically not available. The Protein Data Bank contains molecular structures that are largely determined using experimental methods such as X-ray crystallography, but the resolution of macromolecular X-ray structures is generally insufficient to locate the position of hydrogen atoms reliably. As a result, hydrogen positions—and therefore the tautomeric state of a molecule—often have to be inferred by scientists.</p>
<p>Other methods also fall short. Using quantum mechanics to assess tautomers is often too computationally demanding and expensive for screening full libraries, while machine learning is limited by the relatively small datasets of experimentally characterized tautomers in solution, which tend to contain only a few hundred molecules. “A variety of computational methods have been developed to address tautomer prediction, but each faces important trade-offs between accuracy, throughput, and generalizability,” Zhang <em>et al.</em> stated.</p>
<p>In contrast, many high-resolution small-molecule X-ray crystal structures in the Cambridge Structural Database (CSD)—the largest repository of experimental crystal structures in the world—show the position of hydrogen atoms. “Because many CSD structures contain explicitly assigned hydrogen atoms, they offer direct experimental information about tautomeric states in the crystalline environment,” the authors pointed out. “We realized that experimentally resolved hydrogen positions in high-resolution small-molecule crystal structures provide a largely untapped source of experimental information about tautomer stability,” added Zhang, who is also part of the NYU Simons Center for Computational Physical Chemistry.</p>
<p><figure aria-describedby="caption-attachment-338368" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338368" src="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1-300x135.jpg" alt="Two panels depict the same molecule, with the original tautomer on the right and the tautomer predicted by the model on the left. The green region shows where the hydrogen position and bonding pattern change, while the dashed lines show hydrogen-bonding interactions with nearby protein residues. [Image courtesy of study author Xiaolin Pan]" width="300" height="135" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1-300x135.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1-696x314.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_2bpm_tautomer-1.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Two panels depict the same molecule, with the original tautomer on the right and the tautomer predicted by the model on the left. The green region shows where the hydrogen position and bonding pattern change, while the dashed lines show hydrogen-bonding interactions with nearby protein residues. [Xiaolin Pan, PhD]</figcaption></figure>Study first author Xiaolin Pan, PhD, a postdoc in Zhang’s lab, systematically mined the Cambridge Structural Database to construct a dataset containing more than 1.1 million tautomeric states, which is orders of magnitude larger than existing experimental datasets. Pan then trained a graph neural network—a type of artificial intelligence that uses deep learning to find patterns between connected data points—to predict stable tautomers directly from 2D molecular forms, without requiring 3D structures or quantum-mechanical calculations. “The model showed strong performance across crystal-structure, aqueous-solution, and drug-like benchmarks, indicating that transferable and chemically meaningful rules of tautomer stability can be learned from crystallographic proton placements,” the team commented.</p>
<p>When the researchers applied their model to 5,075 PDBbind ligands—biomolecular complexes found in the Protein Data Bank—with multiple possible tautomeric states, they identified 126 cases—approximately 2.5%—in which the assigned ligand tautomer was likely incorrect. In each of these cases, the model reassigned an alternative stable tautomer, which showed improved hydrogen bonding patterns.</p>
<p>“Reassigning these tautomers generally produced more chemically reasonable interactions,” noted Zhang. “This does not mean that the experimentally determined protein structures themselves are incorrect; rather, our results suggest that the previously assigned chemical representation may warrant revision.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>For instance, in one of the molecules in the Protein Data Bank, the AI model predicted a tautomer with a differently positioned hydrogen atom than in the original assignment. As a result of this change, the ligand forms additional hydrogen bonding with nearby protein residues—illustrating how a seemingly small change can alter the molecule’s interactions with its protein environment.</p>
<p>Using this model to more accurately identify a tautomer for drug discovery could not only help determine how it fits into a protein binding site but could also improve subsequent computer simulations. When assessing drug candidates, molecular dynamics simulations follow a molecule and its protein target to see how they interact and move over time.</p>
<p>“These calculations require the molecule’s hydrogen positions and chemical bonding to be correctly assigned, and using the wrong tautomer could alter the predicted interactions and dynamics,” said Zhang.</p>
<p>The team also showed that in one test, their open-source tool <a href="https://github.com/xiaolinpan/Tautomer-Predictor" target="_blank" rel="noopener">Tautomer-Predictor</a>, processed the 4.6 million compound Enamine collection in 3.2 hours on a single GPU-enabled node. “Together, these results establish crystallographic proton placement as a rich and underexploited source of chemical knowledge for learning tautomer stability, and provide a practical route to large-scale tautomer assignment for molecular discovery,” the authors concluded.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/tautomer-predictor-ai-tool-identifies-stable-molecules-for-drug-discovery/">Tautomer-Predictor AI Tool Identifies Stable Molecules for Drug Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Liposome Design Could Provide Effective Slow&#45;Release Drug Delivery System</title>
<link>https://edusehat.com/en/new-liposome-design-could-provide-effective-slow-release-drug-delivery-system</link>
<guid>https://edusehat.com/en/new-liposome-design-could-provide-effective-slow-release-drug-delivery-system</guid>
<description><![CDATA[ A slow-release liposome system delivered local anesthesia for weeks in rats, potentially enabling longer-lasting nerve blocks and new approaches to pain management.
The post New Liposome Design Could Provide Effective Slow-Release Drug Delivery System appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2293154130.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 09:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Liposome, Design, Could, Provide, Effective, Slow-Release, Drug, Delivery, System</media:keywords>
<content:encoded><![CDATA[<p>Drug delivery systems that can carry a large amount of a drug and release it slowly over time are useful for keeping drug levels effective either at a specific site or throughout the body. Extending how long a drug works can reduce how often it needs to be administered, which is especially helpful for injectable treatments that need to be given repeatedly. However, maintaining drug release over very long periods of time is difficult. Indeed, most local anesthetics used in medicine only last eight to 12 hours or a day, at the most.</p>
<p>Now, researchers have formulated a more effective slow-release injectable drug delivery system that achieved pain-numbing anesthetic effects lasting two to three weeks in rats compared to a commercial formulation lasting about four to eight hours. Because nerve blocks in humans tend to work longer than in rats, this advancement could blow the effective time of currently used anesthetics out of the water and have implications for other types of pain.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This work is published in <em>Nature Biomedical Engineering </em>in the paper, “<a href="https://www.nature.com/articles/s41551-026-01793-6" target="_blank" rel="noopener">Ultra-slow release of hydrophilic drugs via multilamellar–multivesicular liposomes formed by unsaturated phospholipids.</a>“</p>
<p>Liposome composition determines how fast drugs leak out, with faster leaking leading to a more potent drug effect over a shorter time period with potentially more toxicity. Up until now, researchers believed that molecules leaked fastest from liposomes made of more “fluid” lipids. However, Yuan Wang, PhD, a research engineer in the laboratory of Daniel Kohane, MD, PhD, challenged this theory by showing that liposomes made of more fluid lipids release drugs that mix well with or dissolve in water, known as “hydrophilic” drugs, extremely slowly. One way to make lipids more fluid is by adding many double chemical bonds to their tails so that the lipids can’t pack together as tightly.</p>
<p>The team demonstrated that the liposomes with many double bonds had a structure with multiple compartments, while those without had a simple spherical structure. As a result, in liposomes with many double bonds, hydrophilic drugs had more lipid barriers to cross leading to slower drug release.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“The more fluid membranes in liposomes with many double bonds may be easier to cross, but the greater number of barriers slow down the drug’s release,” says Wang. “The more fluid liposomes with more double bonds may form concentric spheres that are like onions with many layers or could even potentially be even spheres within spheres.”</p>
<p>Knowing a hydrophilic drug will leak slower from a more fluid liposome, the researchers tested out a proof-of-principle experiment. The team filled their more fluid liposomes with potent tetrodotoxin—a powerful neurotoxin found in pufferfish and blue-ringed octopuses that serves as a powerful numbing agent. When injected near a nerve in the leg of rats, they showed very prolonged local anesthesia, but no toxicity at the injection site or throughout the body. This means the drug released slowly enough to be cleared by the body, but still at high enough levels to be an effective anesthetic. Tetrodotoxin isn’t commercially used in patients yet but could one day be developed as a therapeutic.</p>
<p>“This extended-release combination could be used for longer term perioperative pain instead of opioids, and we are starting to consider using these potentially for chronic pain, as well,” says Kohane, senior associate in pediatric critical care at Boston Children’s and director of Laboratory for Biomaterials and Drug Delivery. “These liposomes can also provide slow release of a wide range of hydrophilic molecules.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/new-liposome-design-could-provide-effective-slow-release-drug-delivery-system/">New Liposome Design Could Provide Effective Slow-Release Drug Delivery System</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Multi&#45;Controller System: Major Boost to Continuous CHO Perfusion</title>
<link>https://edusehat.com/en/multi-controller-system-major-boost-to-continuous-cho-perfusion</link>
<guid>https://edusehat.com/en/multi-controller-system-major-boost-to-continuous-cho-perfusion</guid>
<description><![CDATA[ A novel multi-strategy nonlinear predictive control system maximizes CHO cell perfusion productivity in a continuous bioprocessing environment by optimizing feed, bleed, and harvest flows, and letting biomanufacturers switch seamlessly among controller priorities.
The post Multi-Controller System: Major Boost to Continuous CHO Perfusion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GettyImages-1092323774.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multi-Controller, System:, Major, Boost, Continuous, CHO, Perfusion</media:keywords>
<content:encoded><![CDATA[<p>A nonlinear model predictive control system developed by researchers at Sartorius is making fully-continuous biomanufacturing for Chinese hamster ovary (CHO) cells more productive. By simultaneously controlling feed, bleed, and harvest flows, they increased production by 68% and maintained viable cell density at or above 95%.</p>
<p>This multi-strategy nonlinear model predictive control (NMPC) system allows biomanufacturers to switch seamlessly between such objectives as stable operation and economic optimization, according to Mahshad Valipour, PhD, senior research scientist, and Christopher McCready, head of product innovation, both of Sartorius, writing in a recent <a href="https://link.springer.com/article/10.1007/s12257-026-00318-x" target="_blank" rel="noopener">paper</a>. The control system also accounts for unknown states—many of which are rarely, if ever, measured—through a moving horizontal estimate that considers the process and its constraints.</p>
<p>After the process is stabilized, an economic NMPC (ENMPC) mode further maximizes performance objectives. It does this, Valipour and McCready explain, “by determining optimal operating conditions in real-time… while explicitly enforcing dynamic process feasibility and biological constraints throughout the perfusion run. [It] improves numerical conditioning and avoids instability issues [commonly encountered in standard ENMPC formulations,] eliminating the need for <em>ad hoc</em> damping/terminal functions or frequent weight retuning.”</p>
<p>Combining a multifunction NMPC and an economic mode within one framework enables “seamless transition between operating modes without controller switching or reformulation,” they add. The primary benefit of this approach may be that biomanufacturers can determine maximum feasible operating conditions safely in real time, while accounting for the accumulation of biomaterials that inhibit cell productivity.</p>
<p>The most important step in making this approach work, they indicate, is “capturing the impact of accumulated inhibitory biomaterials on growth and death dynamics.” Conventional models, they point out, do not account for trade-offs among perfusion rate, inhibitor removal, and cell growth. Therefore, conventional models cannot be used to maximize viable cell density.</p>
<p>Experiments using digital twins showed the NMPC transitioned smoothly among process controller strategies while maintaining a healthy cell culture and increasing upstream productivity. Evaluations under realistic real-world conditions showed online and inline measurements of viable cell density and viability matched predictions, as did dead cell density.</p>
<p>Notably, rather than merely maintaining a stable cell culture and viability rate for a prolonged period, this multi-strategy lets biomanufacturers change objectives as the process is running. Even when tested against what they call “a significant plant-model mismatch,” operations, they said, remained stable.</p>
<p>For bioprocessors, this study suggests that advanced automation strategies can resolve the hurdles associated with continuous CHO perfusion, making it more predictable and more efficient.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/multi-controller-system-major-boost-to-continuous-cho-perfusion/">Multi-Controller System: Major Boost to Continuous CHO Perfusion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Media Cleaning Could Help Biopharma Cut Costs and Fully Embrace Perfusion</title>
<link>https://edusehat.com/en/media-cleaning-could-help-biopharma-cut-costs-and-fully-embrace-perfusion</link>
<guid>https://edusehat.com/en/media-cleaning-could-help-biopharma-cut-costs-and-fully-embrace-perfusion</guid>
<description><![CDATA[ A novel media cleaning process could help drug companies significantly reduce production costs, according to MIT researchers, who say the approach could improve the economic case for perfusion bioreactors and continuous manufacturing processes.
The post Media Cleaning Could Help Biopharma Cut Costs and Fully Embrace Perfusion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/GettyImages-542712324.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Media, Cleaning, Could, Help, Biopharma, Cut, Costs, and, Fully, Embrace, Perfusion</media:keywords>
<content:encoded><![CDATA[<p>A novel “electrokinetic cleaning” process could let drug manufacturers recycle a greater proportion of culture media, according to researchers, who predict the approach could make perfusion-based processes more economically viable.</p>
<p>Perfusion bioreactors have been a mainstay of the development lab for decades. However, few firms have embraced them at commercial scale, in part, due to concerns about media costs, says Eric Wynne, PhD, a postdoctoral associate at MIT’s electronics research lab.</p>
<p>“While many factors have constrained adoption of perfusion bioreactors, media cost has often been cited as the main issue,” Wynne tells <em>GEN</em>, adding, “We believe recycling has the potential to lower costs as well as the overall volume of media involved in the manufacturing process.”</p>
<p>The idea, detailed in a new study, is to use a process called electrokinetic waste separation to remove cellular debris, reagents, and other potential contaminants from culture media after cultivation.</p>
<p>The approach uses an electric field to split media into a harvest stream that contains uncharged molecules—primarily the nutrients cells need to grow—and a waste stream in which there is a higher concentration of charged molecules, like ammonia and lactate.</p>
<p>“Electrokinetic waste separation provides a way of cleaning media thoroughly before recycling it. This process is what differentiates our work from previous groups that recycled media directly.</p>
<p>“In this work we improve the yield of this process by taking the ‘waste’ stream and processing it again to harvest additional media,” Wynne says.</p>
<p>The aim is to allow manufacturers to reuse a greater proportion of media—in studies, Wynne and colleagues have recovered 87.5% of spent volume—in subsequent culturing processes.</p>
<p>“The advantage is that, by separating waste, you can replace greater quantities of fresh media with recycled media without significantly impacting cell growth or productivity.</p>
<p>“Companies that use perfusion technologies already recycle media. However, typically the volume of reused media is less than 50%. Also, without a cleaning step, the reused media can negatively impact cellular growth and productivity.</p>
<p>“Electrokinetic waste separation has the potential to both increase the amount recycled and reduce any negative impact on productivity,” he adds.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The approach is still at a pilot stage, but the cost-saving potential is significant, particularly in combination with hybrid and fully continuous-mode manufacturing processes, Wynne says.</p>
<p>“More development is necessary before the technology is ready for adoption, particularly in the area of characterizing how media recycling does or does not affect product quality attributes.</p>
<p>“Adoption would likely require more testing at small scale and pilot scale perfusion bioreactors. Additionally, recycling and waste separation would likely be best suited for a fully continuous mAb production process with continuous chromatography downstream,” he says.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/media-cleaning-could-help-biopharma-cut-costs-and-fully-embrace-perfusion/">Media Cleaning Could Help Biopharma Cut Costs and Fully Embrace Perfusion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CGT Collaboration Moves from Aspirations to Infrastructure</title>
<link>https://edusehat.com/en/cgt-collaboration-moves-from-aspirations-to-infrastructure</link>
<guid>https://edusehat.com/en/cgt-collaboration-moves-from-aspirations-to-infrastructure</guid>
<description><![CDATA[ Act for Hope founder Alexander Seyf says cell and gene therapy’s next challenge is not proving the science, but building a connected ecosystem that can turn breakthrough treatments into reliable, scalable, and equitable patient access.
The post CGT Collaboration Moves from Aspirations to Infrastructure appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Mike-Act-for-Hope_GBPN_IMAGE_24SEPT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CGT, Collaboration, Moves, from, Aspirations, Infrastructure</media:keywords>
<content:encoded><![CDATA[<p>Cell and gene therapy (CGT) has spent much of its young history proving what was once considered improbable: that advanced therapies can tackle diseases previously viewed as untreatable and, in some cases, offer the prospect of a cure. Now, according to Alexander Seyf, CEO and founder of Act for Hope, the sector faces another test—whether the ecosystem surrounding those therapies can work together well enough to deliver them at scale.</p>
<p>“Scientific possibility alone does not create patient access,” Seyf says.</p>
<p>That distinction sits at the heart of Act for Hope, a not-for-profit, member-led initiative created to accelerate growth across the CGT industry through collaboration. Seyf argues that advanced therapies demand a fundamentally different model from conventional pharmaceuticals because their delivery depends on a tightly connected chain of stakeholders.</p>
<p>From patient identification and starting-material collection through manufacturing, testing, release, logistics, treatment, and long-term follow-up, CGT can involve hospitals, manufacturers, contract development and manufacturing organizations, technology suppliers, regulators, payers, academics, and patients.</p>
<p>“No single organization controls that entire journey,” Seyf says. “That makes collaboration not simply desirable, but foundational.”</p>
<p>While the industry frequently discusses expanding manufacturing capacity, Seyf believes another capability must scale alongside it: collaboration. Shared standards, interoperable digital systems, responsible data exchange, and greater alignment between organizations could become increasingly important as more therapies progress toward commercialization and wider patient populations.</p>
<p>“A therapy may be developed by one organization, but access can only be delivered by an ecosystem,” he adds. “Collaboration has to become infrastructure rather than aspiration.”</p>
<p></p><h4><strong>Fragmentation carries a hidden cost</strong></h4>

<p>One obstacle is that CGT’s rapid development has also produced a highly fragmented operating environment. Companies and institutions have built their own processes, terminology, data structures, and technology platforms—often for sound individual reasons. Collectively, however, those differences can create duplicated work, manual handoffs, disconnected systems, and repeated attempts to solve similar problems.</p>
<p>At relatively low treatment volumes, those inefficiencies might be manageable. At global scale, Seyf says, they risk becoming barriers to patient access by increasing cost, complexity, and time.</p>
<p>The challenge is not to standardize the underlying science, he stresses. Rather, the opportunity lies in harmonizing interfaces and processes where differentiation provides little competitive value.</p>
<p>“The industry has historically been exceptionally good at protecting intellectual property and competing on innovation,” Seyf says. “The next phase requires us to become equally good at identifying the areas where we should not compete.”</p>
<p>Act for Hope aims to provide a neutral setting for that work. Its focus includes standardization, digitization, implementation tools, and responsible, permissioned benchmarking, bringing organizations together to address common bottlenecks without compromising proprietary technologies or intellectual property.</p>
<p>“Collaboration should not mean giving away competitive advantage,” Seyf adds. “It should mean collectively removing the inefficiencies that provide no competitive advantage to anyone.”</p>
<p></p><h4><strong>Connecting innovation with patients</strong></h4>

<p>Two planned projects illustrate that approach. Act for Hope is developing a clinical-trial portal intended to make advanced therapy trials easier to discover and navigate. Despite rapid global innovation, Seyf says, connecting potentially eligible patients with trials remains unnecessarily complicated. A second project, the initiatives hub, is a patient-access portal intended to improve connections among stakeholders involved in moving therapies from scientific development to treatment. Both projects reflect a broader premise: increasing manufacturing output alone will not solve CGT’s access challenge.</p>
<p>“The first chapter of CGT was about proving that the science could work,” Seyf says. “The next chapter must be about proving that the ecosystem can work at scale.”</p>
<p>Technology, automation, and artificial intelligence are likely to play major roles in that transition, but Seyf cautions that technology cannot resolve organizational fragmentation by itself.</p>
<p>“Technology can connect systems. Collaboration connects people, organizations, and purpose,” he adds. “We need both.”</p>
<p>For Seyf, the ultimate benchmark is therefore not the number of therapies approved, facilities constructed, or technologies deployed. It is whether the expanding CGT ecosystem can translate those advances into treatment for the patients who need them. That, he argues, will make collaboration not a supporting feature of CGT’s next era, but one of its defining pieces of infrastructure.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cgt-collaboration-moves-from-aspirations-to-infrastructure/">CGT Collaboration Moves from Aspirations to Infrastructure</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Digital Shadows to Aid Complexity in Handling Process Intensification</title>
<link>https://edusehat.com/en/digital-shadows-to-aid-complexity-in-handling-process-intensification</link>
<guid>https://edusehat.com/en/digital-shadows-to-aid-complexity-in-handling-process-intensification</guid>
<description><![CDATA[ AI-augmented digital twins that merely report, rather than control processes, could help biotechnology companies untangle the complexities of analyzing big multidimensional nonlinear datasets to help simplify and improve process intensification.
The post Digital Shadows to Aid Complexity in Handling Process Intensification appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2227991145-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 24 Sep 2026 01:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Digital, Shadows, Aid, Complexity, Handling, Process, Intensification</media:keywords>
<content:encoded><![CDATA[<p><em>In silico</em> AI-augmented models that report on manufacturing processes rather than controlling them offer a convenient way to help companies engage in process intensification without causing regulatory issues. That’s the view of biotechnology expert William Whitford, PhD.</p>
<p>According to Whitford, who is the founder of Oamaru BioSystems, digital shadows are like digital twins in being real-time digital copies of a process or piece of equipment. Unlike them, however, they aren’t designed to actively control a process. Instead, they simply report back on what’s going on.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This makes them easier to set up than digital twins, he says. “They’re not as comprehensive [as a digital twin], but that might be all you need if you don’t want active control for regulatory reasons.”</p>
<p>Nonetheless, he believes digital shadows are valuable for managing the large, complex datasets being generated by today’s bioprocess analytics. “Machine learning can handle the complexity, the amount, the nonlinearity and high dimensionality of the data we’re getting,” he says.</p>
<p>Such data can include time series, imaging and analytical data, as well as historical data collected during process development.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“For example, you might take the outgassing of a [bio]reactor, look at carbon dioxide and oxygen levels and, from there, infer the metabolic activity,” he says. “And [if you add the historical data] you can infer the number of viable cells.”</p>
<p>By contrast, he says, more simple analytics, such as an equation or simple algorithm, can’t digest the variety of data coming in.</p>
<p>The digital shadow, he says, can make inferences or future predictions by simultaneously integrating process measurements, analytical results, biological observations, historical manufacturing data, and contextual production information. This, in turn, can help manufacturers get more product per square foot of plant, per unit of bioreactor volume or time, he says, and thus aid process intensification.</p>
<p>“Once you’ve defined that goal for your process intensification, you want to know what tools are out there and I want people to know about the tools we have,” he says.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/digital-shadows-to-aid-complexity-in-handling-process-intensification/">Digital Shadows to Aid Complexity in Handling Process Intensification</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anthropic&#45;, Nvidia&#45;Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI&#45;Designed Drugs</title>
<link>https://edusehat.com/en/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</link>
<guid>https://edusehat.com/en/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs</guid>
<description><![CDATA[ According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely. 
The post Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/BASECAMP-RESEARCH-GLENOLLIEBASE-1-696x464-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 22:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anthropic-, Nvidia-Backed, Basecamp, Research, Raise, 140M, Series, Financing, Toward, Advancing, AI-Designed, Drugs</media:keywords>
<content:encoded><![CDATA[<p>Basecamp Research said today it has completed an oversubscribed $140 million Series C financing whose proceeds are intended to fund the training of next generation EDEN models and apply them toward developing improved <em>in vivo</em> cell therapies for a variety of diseases.</p>
<p>Basecamp, a frontier AI company focused on therapeutic design, focuses on leveraging EDEN (short for “environmentally-derived evolutionary network), its biological foundation model, to develop<em> in vivo</em> cell therapies designed to reprogram a patient’s cells inside the body.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>EDEN is Basecamp’s new class of foundation models trained on what the company says is the world’s largest and most diverse evolutionary dataset. According to Basecamp, EDEN offers the ability to design long and complex DNA sequences with large serine recombinases capable of delivering those sequences precisely.</p>
<p>EDEN-designed cell therapies are also designed to overcome the high manufacturing cost and limited complexity of present-day cell therapies. As a result, Basecamp said in its announcement, its EDEN-designed therapeutics offer the potential to treat complex diseases that include cancer and autoimmune disease, aiming “to underpin the future of cell therapies, making them more sophisticated, more customizable and simpler to administer” than current cell therapies.</p>
<p>“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” Glen Gowers, PhD, Basecamp’s co-founder and CEO, said in the statement. Gowers co-founded Basecamp with Oliver Vince, PhD.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Basecamp says it has shown strong preclinical results across multiple modalities and disease areas. Aiming to expand its partnerships with biopharmas, Basecamp in April appointed Richard Pearce as chief business officer. Pearce previously served as Biogen’s head of business development, strategy, and portfolio management.</p>
<p>“AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most,” Gowers added.</p>
<p></p><h4><strong>Big-name investors</strong></h4>

<p>One big-name investor participating in the financing is Anthropic—the AI model builder behind the Claude family of large language models. Anthropic invested in Basecamp through its Anthology Fund, a $100 million fund launched in 2024 and financed by Silicon Valley-based VC firm Menlo Ventures. Startups financed by the Anthology Fund receive access to Anthropic products and research, $25,000 in free credits towards Anthropic’s most advanced models, and what the company calls “best-in-class” venture support from Menlo.</p>
<p>“We’re particularly interested in ventures that leverage AI to enhance human capabilities and productivity in fields such as healthcare, legal services, education, energy, infrastructure, and scientific research,” Daniela Amodei, Anthropic’s co-founder and president, stated in announcing the launch of the Anthology Fund.</p>
<p>Anthropic’s offerings include Claude Science, the AI research workbench <a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">launched in June</a> and featuring Basecamp’s antibiotic design and vaccine prediction AI models.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Another name investor is NVentures, the venture capital arm of Nvidia—the Silicon Valley microprocessing giant<strong> </strong>with which Basecamp has <a href="https://www.genengnews.com/topics/artificial-intelligence/basecamp-research-achieves-programmable-gene-insertion-with-eden-ai-models/" target="_blank" rel="noopener">leveraged AI to unlock programmable gene insertion</a>, which places large therapeutic DNA sequences at precise locations in the human genome.</p>
<p>Researchers from Nvidia joined partners from Basecamp, Microsoft, and two research institutions in detailing EDEN in a <a href="https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1" target="_blank" rel="noopener">preprint posted January 12 on bioRxiv</a>.</p>
<p></p><h4><strong>63% hit rate</strong></h4>

<p>The investigators showed EDEN to achieve an overall functional hit rate of 63.2% across diverse DNA prompts when prompted on only 30bp of DNA from outside the training data. Half (50%) of EDEN-generated LSRs were active in human cells, achieving therapeutically relevant levels of chimeric antigen receptor (CAR) insertion in primary human T cells. Also, an EDEN-generated synthetic microbiome was shown in the preprint to cover 9,067 species with a biome-specific taxonomic accuracy of 99%.</p>
<p>Nvidia and Anthropic were among partners of Basecamp that built its Trillion Gene Atlas, which draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents. The Atlas is at the center of Basecamp’s AI platform, and according to the company is the world’s largest proprietary biological AI training dataset. Pacific Biosciences of California (PacBio) and Ultima Genomics also partnered in building the Atlas.</p>
<p>Trained on data from the Atlas, Basecamp’s EDEN models deliver a universal understanding of how DNA works across all of life. Its capabilities include designing cell and gene therapies, enzymes and peptides.</p>
<p>Unlike AI systems developed for a single scientific task, EDEN models are trained to recognize patterns across biology. As a result, it can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp’s collaboration with Anthropic on Claude Science.</p>
<p>Anthropic and NVentures are among participants in the financing, along with Catalio, European Tech Collective, Firebrand River Capital, King Philanthropies, NATO Innovation Fund, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.</p>
<p></p><h4><strong>‘Next transformation’</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p>Basecamp has garnered additional investment from senior leaders across biopharma and global industry, including André Hoffmann, vice chairman of Roche, a board member of Roche subsidiary Genentech, and co-chair of the World Economic Forum.</p>
<p>“The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalized, AI-designed therapeutics represent the next transformation of that journey,” Hoffmann stated. “Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.”</p>
<p>Basecamp raised $60 million in Series B financing in 2024, and a $20 million Series A round two years earlier.</p>
<p>The Series C financing was led by S32, a Palo Alto, CA-based venture firm. S32 has about $3.5 billion in assets under management after closing earlier this year on a $517 million sixth flagship fund, according to PitchBook.</p>
<p>As a result of the latest financing, Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, will join Basecamp’s board.</p>
<p>“AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people’s lives,” Conrad stated. “Basecamp Research is building an important technology platform at the center of that opportunity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/anthropic-nvidia-backed-basecamp-research-raise-140m-series-c-financing-toward-advancing-ai-designed-drugs/">Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery</title>
<link>https://edusehat.com/en/brainstorm-therapeutics-combines-brain-organoids-and-ai-for-cns-drug-discovery</link>
<guid>https://edusehat.com/en/brainstorm-therapeutics-combines-brain-organoids-and-ai-for-cns-drug-discovery</guid>
<description><![CDATA[ BIO 2026 Start-Up Stadium winner generates human data to improve clinical translation. Artificial intelligence is opening new possibilities for drug discovery. But in neuroscience, […]
The post BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/Maya-from-Brainstorm.JPG.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 14:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BrainStorm, Therapeutics, combines, brain, organoids, and, for, CNS, drug, discovery</media:keywords>
<content:encoded><![CDATA[<h4>BIO 2026 Start-Up Stadium winner generates human data to improve clinical translation.</h4>
<p>Artificial intelligence is opening new possibilities for drug discovery. But in neuroscience, AI is only as powerful as the biological data behind it, and BrainStorm Therapeutics believes AI combined with human brain biology can be better.</p>
<p>BrainStorm is generating that biology in the laboratory using patient-derived human brain organoids. These living, three-dimensional models reproduce features of the human brain, generating rich datasets that BrainStorm uses for phenotypic drug discovery and to train AI models.</p>
<p>By combining patient-derived brain organoids with AI, the company aims to uncover disease mechanisms, identify therapeutic targets, screen drug candidates, and determine whether potential treatments can reverse disease-associated dysfunction before they enter clinical trials.</p>
<p>BrainStorm is applying the platform across neurological diseases, with a lead therapeutic program in CDKL5 deficiency disorder, or CDD, and discovery programs in Parkinson’s and Alzheimer’s diseases. The approach also builds on earlier work in Rett syndrome, advancing a repurposed therapeutic candidate from organoid screening to an FDA-cleared Investigational New Drug application for a Phase 2 clinical trial.</p>
<p>The company has attracted attention from the scientific and investment communities, most recently earning the Seed-Stage Start-Up Stadium Award at the 2026 BIO International Convention.</p>
<p>The competition recognizes two companies selected by investor judges from approximately 50 presenting start-ups. BrainStorm received the Seed-Stage Award for companies that had raised less than $1 million, while NF1-focused iNFixion Bioscience received the Emerging Company Award for companies that had raised between $1 million and $10 million.</p>
<h2>The brain power behind the platform</h2>
<p>BrainStorm generates three-dimensional brain organoids from induced pluripotent stem cells derived from patients carrying disease-causing mutations. The cells are differentiated into regionally defined brain organoids containing multiple interacting neural cell types and functional synaptic networks.</p>
<p>Although organoids do not reproduce an entire human brain, they can model selected cellular, molecular, and functional features of specific human brain regions that are difficult to capture in conventional cell cultures or animal models.</p>
<p>“When we measure calcium signaling and electrophysiological activity in these brain organoids, we can detect patterns of neuronal and network dysfunction associated with specific neurological disorders,” said Maya Gosztyla, Ph.D., BrainStorm’s co-founder and chief scientific officer. “These models bring us closer to studying human disease biology in the laboratory and give us a powerful system for evaluating whether a potential therapy can correct that disease biology.”</p>
<p>BrainStorm uses organoid data to investigate disease mechanisms, identify therapeutic targets, screen drug candidates, and determine whether treatments reverse disease-associated phenotypes. Those experiments also generate proprietary, human-relevant datasets to train and refine the company’s AI models.</p>
<p>“This allows us to do two things at once,” Gosztyla said. “We can directly test whether a potential therapy rescues a disease phenotype while generating rich, high-quality human datasets that improve our AI models.”</p>
<p>BrainStorm uses those data to identify disease-associated gene networks and potential therapeutic targets, then brings AI-generated hypotheses back into its organoid platform for experimental testing.</p>
<p>“That creates a closed loop between computation and experiment,” Gosztyla said. “By grounding our AI models in patient-derived human biology and then experimentally testing their predictions, we believe we can improve the likelihood that discoveries made in the laboratory will translate into meaningful benefits for patients.”</p>
<h2>Platform validation in Rett syndrome</h2>
<p>BrainStorm’s strategy builds on work led by founder and CEO Robert T. Fremeau, Jr., Ph.D., while he was chief scientific officer of Vyant Bio. Using patient-derived brain organoids, the Vyant team identified repurposed drug candidates for Rett syndrome and a novel therapeutic target and small-molecule hit scaffold for CDD. Rett syndrome is a rare genetic neurological disorder that primarily affects girls and can cause developmental regression, impaired communication and movement, seizures, and other serious symptoms.</p>
<p>“Our most clinically advanced proof point originated from work I led as chief scientific officer of Vyant Bio,” Fremeau said. “Working with the International Rett Syndrome Foundation, we used patient-derived brain organoids to conduct phenotypic screening and identified donepezil as a potential repurposed therapy for Rett syndrome.”</p>
<p>Donepezil is FDA-approved for Alzheimer’s disease but not for Rett syndrome. The program progressed from organoid screening to submission of a Phase 2 clinical trial application in approximately nine months. The FDA subsequently cleared the Investigational New Drug application, allowing the Phase 2 program to proceed. The translational package included efficacy evidence generated in patient-derived human brain organoids, without requiring new animal efficacy studies for the repurposed drug.</p>
<p>“To our knowledge, donepezil represents the first therapeutic candidate identified through phenotypic screening in a patient-derived brain organoid to progress to an FDA-cleared IND,” Fremeau said. “For us, that provided important translational and regulatory validation of the organoid-based approach demonstrating that human brain organoids can move beyond disease modeling to become a practical drug-discovery platform capable of generating therapeutic hypotheses that advance toward the clinic.”</p>
<h2>The lead program: CDKL5 deficiency disorder</h2>
<p>While the Rett program provided an important example of clinical translation, CDD is now the focus of BrainStorm’s therapeutic development efforts.</p>
<p>CDD is a rare developmental and epileptic encephalopathy caused by pathogenic variants in the CDKL5 gene. It typically presents in early infancy with severe, treatment-resistant seizures and profound developmental, motor, communication, and visual impairments. Existing treatments can reduce seizures in some patients, but no approved therapy addresses the underlying disease biology and neurodevelopmental impairments.</p>
<p>One challenge in developing therapies for CDD is the disorder’s genetic diversity. Different patients carry different pathogenic variants in CDKL5, raising an important question for drug discovery: Can a treatment correct disease biology across multiple genetic backgrounds?</p>
<p>To address that question, BrainStorm is working with the CURE5 Foundation, a patient-led CDD organization, to develop patient-derived brain organoid models representing multiple pathogenic CDKL5 variants.</p>
<p>“We’re growing several new stem-cell-derived brain organoid models from patients with different types of CDKL5 mutations,” Gosztyla said. “These models allow us to ask whether a therapy can work across the genetic diversity of CDD.”</p>
<p>The models provide BrainStorm with a genetically diverse human platform for studying CDD biology and evaluating therapeutic response. They can also support systematic screening of approved drugs to identify potential repurposing opportunities for patients.</p>
<p>At the same time, BrainStorm is advancing its own proprietary therapeutic program for CDD. The program builds on a novel therapeutic target and small-molecule hit scaffold originally identified through phenotypic screening in patient-derived CDD brain organoids.</p>
<p>“Our goal is to develop a first-in-class, disease-modifying therapy that addresses the underlying neuronal dysfunction rather than only treating the symptoms,” Gosztyla said.</p>
<p>CDD organoids exhibit reproducible hyperexcitability that can be measured using high-throughput calcium imaging and electrophysiology. BrainStorm’s hit compound reverses aspects of this disease-associated neuronal dysfunction in CDD organoids while showing little or no effect in healthy controls, suggesting disease-state-selective activity.</p>
<p>The company is now validating the therapeutic response across multiple patient genotypes while advancing the chemistry through hit-to-lead optimization toward selection of a development candidate.</p>
<p>Together, the CURE5 collaboration and BrainStorm’s proprietary program are designed to answer complementary questions: whether existing medicines can be repurposed for genetically diverse CDD patients, and whether a new disease-modifying therapy can be developed specifically to correct the disorder’s underlying neuronal dysfunction.</p>
<h2>Advancing toward a development candidate</h2>
<p>BrainStorm is now raising a seed financing round to advance its CDD program through hit-to-lead optimization toward a development candidate and expand its therapeutic pipeline.</p>
<p>“The main focus of our current fundraising is to bring the CDD program forward toward a development candidate,” Gosztyla said.</p>
<p>The company has attracted more than $1 million in non-dilutive support. A Phase I Small Business Innovation Research award from the National Science Foundation supported development of BrainStorm’s AI foundation-model capabilities and Parkinson’s disease research, including identifying potential disease-modifying targets.</p>
<p>BrainStorm is also collaborating with Novoron Bioscience and Defined Bioscience on a National Institute on Aging Direct-to-Phase II SBIR award. The project uses three-dimensional cortical organoids to model pathological prion-like tau propagation and identify potential treatments for Alzheimer’s disease.</p>
<p>The company has received recognition from organizations including California Life Sciences, NVIDIA, BioMarin, and Servier. BrainStorm has also entered a master collaboration agreement with BioSymetrics, part of Lunai Bioworks (NASDAQ LNAI), to support translational validation.</p>
<p>Its latest recognition, the BIO Start-Up Stadium Award, came after BrainStorm presented at the 2026 BIO International Convention.</p>
<p>Along with exposure to biotechnology investors, the award includes participation in the Science Inc. Accelerator operated by The Innovation Space.</p>
<p>“The accelerator has been extremely valuable in helping us address the practical steps required to move from early therapeutic discovery through development, regulatory strategy, and financing,” Gosztyla said.</p>
<p>The Start-Up Stadium competition also provided BrainStorm with exposure to investors, including members of the judging panel.</p>
<p>“Winning the Seed-Stage Start-Up Stadium Award provides important external validation of our science, our team, and our opportunity to build a differentiated CNS therapeutics company,” Fremeau said. “We are currently raising our seed round to advance our lead CDD program toward a development candidate and demonstrate that patient-derived human brain models can help identify therapies with a greater likelihood of translating into meaningful benefit for patients with devastating neurological diseases.”</p>
<p>After all, developing new neurotherapeutics requires money—and brains.</p>
<p>The post <a href="https://bio.news/bio-convention/brainstorm-therapeutics-combines-brain-organoids-and-ai-for-cns-drug-discovery/">BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas</title>
<link>https://edusehat.com/en/biomimetic-nanoparticles-trigger-light-responses-in-blind-mouse-retinas</link>
<guid>https://edusehat.com/en/biomimetic-nanoparticles-trigger-light-responses-in-blind-mouse-retinas</guid>
<description><![CDATA[ A biomimetic nanoparticle platform inspired by photosynthesis helped activate surviving retinal nerve cells in mice with advanced retinal degeneration.
The post Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/POV-GettyImages-1227553397.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 11:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biomimetic, Nanoparticles, Trigger, Light, Responses, Blind, Mouse, Retinas</media:keywords>
<content:encoded><![CDATA[<p>Even after a retina loses its natural light-sensing cells, some of its nerve circuitry can remain intact. In a new preclinical study, researchers showed that injectable, light-sensitive nanoparticles can lodge near surviving retinal nerve cells and help degenerated mouse retinas respond to illumination.</p>
<p>The work, described in the paper titled “<a href="https://www.nature.com/articles/s41551-026-01773-w" target="_blank" rel="noopener">Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and therapeutic intervention</a>,” was published in <em>Nature Biomedical Engineering</em>. The international team was led by Menglin Chen, PhD, at Aarhus University, with collaborators from the University of Chicago, the University of Eastern Finland, Aarhus University Hospital, and the University of Copenhagen.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The study addresses a central challenge in retinal degeneration: even after light-sensitive photoreceptors are lost, other retinal neurons can persist. The researchers aimed to create a wireless interface between light and those remaining cells without relying on mutation-specific gene therapy, optogenetic modification, or surgically implanted electronics.</p>
<p>“When we started, our fundamental question was whether we could create a material that could act as a wireless interface between light and living cells,” said Chen, who is an associate professor at the Department of Biological and Chemical Engineering. “We can now see that the particles are able to activate nerve cells in blind retinas. That brings us closer to our long-term goal of developing a new type of retinal prosthesis.”</p>
<p><figure aria-describedby="caption-attachment-338351" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338351" src="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-300x200.jpg" alt="" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Menglin-08.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Associate professor Menglin Chen, PhD, studies how the light-sensitive nanoparticles affect living cells. The screen shows calcium being released inside a cell after nanoparticles taken up by the cell are exposed to blue light. Calcium plays an important role in cellular signaling, and the experiment helped the researchers understand how the nanoparticles can translate light into biological activity. [Aarhus University/Johanne Holm Jensen]</figcaption></figure>The nanoparticles are hollow spheres made from graphitic carbon nitride, a light-responsive semiconductor. Inspired in part by chloroplasts, the plant structures that capture sunlight during photosynthesis, the particles convert light into local photoelectrochemical and photothermal effects that can influence cell signaling. In cell experiments, focused laser stimulation induced “inducing calcium-transient release in multiple cells and propagation in primary cardiomyocytes and cardiac fibroblasts,” the authors wrote. At a multicellular scale, light-emitting diode (LED) light helped pace and synchronize beating in cardiomyocytes.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The retinal experiments moved the platform toward a more specific therapeutic application. After the nanoparticles were injected into mouse eyes with advanced retinitis pigmentosa, they accumulated near retinal ganglion cells, which help relay visual information from the eye to the brain. When the eyes were illuminated, the team detected light-induced activity in the visual cortex and observed behavioral responses to light. The researchers also showed that the nanoparticles could activate retinal ganglion cells in isolated porcine retinal tissue under LED photostimulation.</p>
<p>The findings do not show restored normal vision, but they suggest a possible route for restoring light sensitivity in retinas where photoreceptors have degenerated. “Instead of genetically modifying these cells, we use the nanoparticles to create a new connection between light and the nerve cells,” Chen said. “In this way, we are trying to make a blind retina respond to light again.”</p>
<p>The next steps are substantial. The team will need to refine delivery, assess how long the nanoparticles remain functional in the eye, study their long-term safety, and determine whether the light-evoked responses can be strengthened and controlled in ways that are useful for vision restoration.</p>
<p>For now, the work marks an early but notable step: a biomimetic material that can translate light into biological signals across scales, from individual cells to degenerated retinal tissue. Whether that microscopic “solar cell” concept can ultimately help people with vision loss will depend on the next phase of preclinical development.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/biomimetic-nanoparticles-trigger-light-responses-in-blind-mouse-retinas/">Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cell Senescence ‘Barcodes’ Identified with Raman Microscopy and Gene Expression Data</title>
<link>https://edusehat.com/en/cell-senescence-barcodes-identified-with-raman-microscopy-and-gene-expression-data</link>
<guid>https://edusehat.com/en/cell-senescence-barcodes-identified-with-raman-microscopy-and-gene-expression-data</guid>
<description><![CDATA[ Researchers combined Raman microscopy with gene expression data at single-cell resolution from the same cells, and AI, to develop RamanOmics, a noninvasive way to detect biomarkers of cellular senescence as “barcodes.&quot;
The post Cell Senescence ‘Barcodes’ Identified with Raman Microscopy and Gene Expression Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2261205514.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 07:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cell, Senescence, ‘Barcodes’, Identified, with, Raman, Microscopy, and, Gene, Expression, Data</media:keywords>
<content:encoded><![CDATA[<p>As we age, some of the cells in our body enter a state of senescence, in which they stop dividing but do not die. Those senescent cells can contribute to age-related disorders such as cancer, tissue degeneration, and inflammatory diseases.</p>
<p>In an advance that could lead to better ways to diagnose and treat those diseases, MIT researchers have developed a noninvasive way to detect biomarkers of senescence. Their method is based on Raman microscopy, which can reveal the biochemical composition of cells without harming them.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Using the new technique, “RamanOmics”, which combines Raman microscopy with gene expression data at single-cell resolution from the same cells, the researchers were able to identify unique “barcodes” that can be used to quickly identify senescent cells. And while their reported study was carried out in mouse cells, the scientists are now working on adapting it for use with human tissue.</p>
<p>“You can imagine that one day we may develop an endoscope that can look inside your body and identify cellular senescence,” says Jeon Woong Kang, PhD, an MIT research scientist and co-senior author of the team’s published study in <em>Nature Aging</em>, titled “<a href="https://doi.org/10.1038/s43587-026-01219-7" target="_blank" rel="noopener">RamanOmics decodes the spatial vibrational–molecular architecture of senescence in aging and repair</a>,” in which they concluded, “Together, RamanOmics provides a tissue-agnostic framework for scalable, multimodal profiling of cellular states.”</p>
<p>The paper’s co-senior authors are Peter So, PhD, director of the MIT Laser Biomedical Research Center (LBCR) and an MIT professor of biological engineering and mechanical engineering, and Jian Shu, PhD, an assistant professor at Massachusetts General Hospital (MGH) and Harvard Medical School, and an associate member of the Broad Institute and Ragon Institute. The research is part of a National Institutes of Health initiative called the Cellular Senescence Network, which is pursuing a deeper understanding of senescence in hopes of developing therapies that could combat some of the tissue-damaging effects of senescent cells.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Cell senescence is often triggered by DNA damage, which leads to an irreversible arrest of the cell cycle. These cells don’t die, but they undergo significant changes to their shape, metabolic processes, and gene expression profiles.</p>
<p>The immune system is responsible for clearing out these “zombie cells,” but as people age, this clearing process becomes less efficient. When senescent cells accumulate, they may contribute to sagging skin, muscle weakness, and chronic conditions such as osteoarthritis and type 2 diabetes (T2D).</p>
<p>Cellular senescence also has beneficial effects, playing critical roles in embryonic development and tissue regeneration. “Senescence is not just a pathological condition,” So said. “The idea behind the NIH Cellular Senescence Network is to take a very comprehensive approach to understand senescence and identify senescent cells, because it plays a role in so many normal physiological conditions and many pathological conditions.”</p>
<p>Scientists have already identified a few biomarkers for senescence, including two proteins, p16 and p21, which are involved in halting the cell cycle. However, those proteins can only be identified using a process that ends up destroying the cells. “Aging reshapes tissues through the accumulation of senescent cells, yet current definitions of senescence still depend largely on transcriptomic or histological markers that fail to capture its underlying biochemical remodeling,” the team further pointed out.</p>
<p>The MIT team wanted to find a way to noninvasively identify senescent cells using Raman microscopy. Unlike RNA-sequencing, which consumes the cells as it analyzes them, Raman microscopy is a nondestructive technique that reveals the chemical composition of tissues or cells by shining near-infrared or visible light on them.</p>
<p>For their newly reported study the researchers used Raman microscopy in conjunction with spatial RNA sequencing—a technique that reveals where genes are active within a tissue—to identify new markers of senescence. By combining these two techniques the team was able to generate a much broader picture of the distinctive features of senescent cells, including gene expression levels, spatial location, and other biochemical information.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“Our idea was to look at many different features to characterize senescence,” Shu noted. “That’s why we wanted to combine both single-cell gene expression and Raman microscopy, so that we can characterize the senescence from two complementary views.”</p>
<p>Using both methods of analysis, the researchers examined skin and lung tissue from 2-month-old mice and from 26-month-old mice. One of the most dramatic changes seen in both lung and skin cells was an increase in lipid synthesis in older cells, along with accumulation of lipids. How this affects the physiology of the cells is not yet known, the researchers say.</p>
<p>They also found some effects that were specific to each tissue. In senescent skin cells it was discovered that cellular pathways associated with muscle contraction and with remodeling of collagen and the extracellular matrix (ECM) were significantly affected. And in aged lung tissue, there was increased activity of genes involved in immune activation and inflammation. “Together, these results reveal tissue-specific aging patterns: immune activation and vascular remodeling with diminished epithelial renewal in lung, versus metabolic decline and impaired ion homeostasis with partial preservation of epithelial programs in skin,” they stated. In future work, the researchers hope to study further what role these changes play in senescent cells.</p>
<p>Using these data, the researchers were able to identify combinations of Raman peaks that correlate with senescence. These peaks, which represent specific chemical bonds, are linked to the presence of certain lipids, proteins, or other molecules.</p>
<p>“Combining the most important Raman features with the most important gene signatures, we were able to create a barcode that can help us to identify senescent cells in a more unbiased way,” commented Salvatore Sorrentino, PhD, a postdoc at MIT and study co-first author. “Using this barcode, we can focus on a few Raman bands that emerged as the most informative in this work.” Using these bands, it could be possible to identify senescent cells by looking for just those bands of the Raman spectrum. This could help to enable diagnostics that would detect cells that have become senescent.</p>
<p>“Nondestructive Raman features alone could serve as biomarkers of senescence, enabling <em>in vivo</em> monitoring of tissue aging or evaluation of senolytic therapies in humans,” the authors stated. “Coupling biochemical readouts with transcriptomic programs also opens opportunities for high-throughput screening of lipid-pathway modulators and longitudinal tracking of senescence in translational contexts such as skin aging, fibrosis or wound repair.”</p>
<p>To help make that possible, the researchers are now working on a higher-speed version of their Raman imaging system. Currently, it takes about 30 hours to analyze a tissue sample about one square millimeter in size, but they hope to develop a system that can quickly pick out the Raman barcodes they identified from larger samples.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/cell-senescence-barcodes-identified-with-raman-microscopy-and-gene-expression-data/">Cell Senescence ‘Barcodes’ Identified with Raman Microscopy and Gene Expression Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Syngene Expands Integrated Drug Development and Manufacturing Services with BMS</title>
<link>https://edusehat.com/en/syngene-expands-integrated-drug-development-and-manufacturing-services-with-bms</link>
<guid>https://edusehat.com/en/syngene-expands-integrated-drug-development-and-manufacturing-services-with-bms</guid>
<description><![CDATA[ The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center, Syngene&#039;s first dedicated R&amp;D Center.
The post Syngene Expands Integrated Drug Development and Manufacturing Services with BMS appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1368058797.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 03:50:39 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Syngene, Expands, Integrated, Drug, Development, and, Manufacturing, Services, with, BMS</media:keywords>
<content:encoded><![CDATA[<p>CRDMO Syngene International extended its long-standing strategic collaboration with Bristol Myers Squibb (BMS) through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization, according to Syngene officials.</p>
<p>“Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies,” said Peter Bains, managing director and CEO of Syngene.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“The agreement to extend this partnership through 2035 enables us to plan together for the future in terms of building new capabilities and infrastructure with a decade long horizon. Taking a long-term perspective is a key feature of our partnership which adds strategic value to both companies.”</p>
<p>“At Bristol Myers Squibb, everything we do begins with patients. We greatly value our long-standing partnership with Syngene, which has been instrumental in advancing our scientific ambitions,” added Payal Sheth, senior vice president, therapeutic discovery sciences, Bristol Myers Squibb.</p>
<p>“This expanded collaboration reflects our commitment to advancing innovative science by effective integration of our research, development, and manufacturing capabilities to accelerate the delivery of transformative medicines and bring hope to patients around the world who are waiting for new treatment options.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D Center, which was fully commissioned in 2009. Bains noted that the BBRC has evolved into a major strategic R&D site for Bristol Myers Squibb.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/syngene-expands-integrated-drug-development-and-manufacturing-services-with-bms/">Syngene Expands Integrated Drug Development and Manufacturing Services with BMS</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Best Practices for Establishing Data Integrity in Western Blotting</title>
<link>https://edusehat.com/en/best-practices-for-establishing-data-integrity-in-western-blotting</link>
<guid>https://edusehat.com/en/best-practices-for-establishing-data-integrity-in-western-blotting</guid>
<description><![CDATA[ Despite advances in other proteomic methods, including mass spectrometry, western blotting remains one of the most widely-used techniques across life sciences research due to its affordability, specificity, and widespread accessibility.
The post Best Practices for Establishing Data Integrity in Western Blotting appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1433163698.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 00:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Best, Practices, for, Establishing, Data, Integrity, Western, Blotting</media:keywords>
<content:encoded><![CDATA[<p>Western blotting is a fundamental technique, supporting protein detection, identification, quantitation, and providing insight into post-translational modifications. Despite advances in other proteomic methods, including mass spectrometry, western blotting remains one of the most widely used techniques across life sciences research due to its affordability, specificity, and widespread accessibility.</p>
<p>However, the integrity of western blot data has come under scrutiny in recent years following the <a href="https://www.the-scientist.com/data-integrity-in-scientific-research-insights-from-elisabeth-bik-73119" target="_blank" rel="noopener">retraction of a number of papers due to image irregularities</a>. To that end, many major journals, including the <a href="https://www.jbc.org/article/S0021-9258(20)39480-1/fulltext" target="_blank" rel="noopener"><em>Journal of Biological Chemistry</em></a>, <a href="https://www.cell.com/cell/information-for-authors/journal-policies" target="_blank" rel="noopener"><em>Cell</em></a>, and <a href="https://www.nature.com/nature-portfolio/editorial-policies/image-integrity" target="_blank" rel="noopener"><em>Nature</em></a> have specific submission guidelines, with data quality and transparency being top priorities. With this in mind, it is crucial for researchers to understand where to draw the line between improving image presentation and data manipulation when it comes to western blotting.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<h4><strong>Understanding data misrepresentation through image manipulation</strong></h4>
<p>Western blot image integrity can be compromised through undisclosed, seemingly minor adjustments to the contrast, brightness, and exposure through to more deliberate edits, such as cropping out or duplicating bands or lanes, combining lanes from different gels, or rotating bands. While many of these practices can be performed inadvertently, they can mislead data interpretation.</p>
<p>For presentation purposes, non-destructive adjustments, such as image transformation and background subtraction are reasonable and often scientifically necessary depending on sample complexity and signal specificity. However, these adjustments must be made consistently across all lanes being analyzed and must be fully disclosed in figure legends or methods.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><figure aria-describedby="caption-attachment-338264" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338264" src="https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-300x242.jpg" alt="Nikolas Chmiel, PhD [Bio-Rad Labs]" width="300" height="242" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-300x242.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1024x825.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-768x618.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1536x1237.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-2048x1649.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-522x420.jpg 522w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1043x840.jpg 1043w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-696x561.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1392x1121.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1068x860.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Nik_Formal_Headshot10MB-1920x1546.jpg 1920w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Nikolas Chmiel, PhD [Bio-Rad Labs]</figcaption></figure>Thorough documentation of unprocessed image files is the most practical approach to demonstrating image integrity and strengthening the credibility of the research, while expediting the review process, as access to raw images is increasingly demanded during journal submissions. These documents include the original, unprocessed gel image; the processed image submitted for publication, with clear disclosure of adjustments; details of the image detection and processing software, and parameters used; and evidence that identical adjustments were applied to all samples being comparatively analyzed.</p>
<p>There are several image analysis software packages available to researchers to aid gel image analysis and quantitation. These include <a href="https://imagej.net/" target="_blank" rel="noopener">ImageJ</a>, developed by the National Institutes of Health, which is widely accepted by many journals. The software preserves image data and allows creation of macros, enabling identical processing to be applied across multiple images. ImageJ quantifies signal intensity directly, so it’s suitable for a range of workflows including total protein normalization from stain-free approaches or stained images.</p>
<p>As with any densitometry tool, quantitation should be performed on raw images within the linear range of detection, and macros should be validated against a known standard to confirm they produce accurate, reproducible results across all images in a set. <a href="https://fiji.sc/" target="_blank" rel="noopener">Fiji</a> is an image processing package that facilitates analysis in ImageJ, offering integration and comprehensive documentation, and is recommended for first-time users.</p>
<p>Beyond this widely used option, a number of other tools serve more specific purposes, from general image editing to acquisition-integrated workflows. GNU Image Manipulation Program (<a href="https://www.gimp.org/" target="_blank" rel="noopener">GIMP</a>), <a href="https://scikit-image.org/" target="_blank" rel="noopener">Python with scikit-image</a>, <a href="https://bioconductor.org/packages/release/bioc/html/EBImage.html" target="_blank" rel="noopener">EBImage</a>, and <a href="https://www.bio-rad.com/en-uk/product/image-lab-software?ID=KRE6P5E8Z" target="_blank" rel="noopener">Image Lab</a> are also available to researchers and offer various capabilities:</p>
<ul>
<li><strong>GIMP:</strong> GIMP is not designed for scientific quantitation but offers general-purpose image editing for cropping, documentation and annotation.</li>
<div class="my-8"><span data-render-ad="5"></span></div>
<li><strong>Python with scikit-image:</strong> For researchers with programming expertise, Python with scikit-image provides full control over imaging processing pipelines.</li>
<li><strong>EBImage:</strong> Hosted within the Bioconductor Project, EBImage allows seamless integration with downstream statistical analysis using R programming.</li>
<li><strong>Image Lab:</strong> The software preserves the full context of data from acquisition through analysis within a secure traceable environment, enabling documentation and transparency of image generation and processing.</li>
</ul>
<p></p><h4><strong>Choosing the most reliable normalization method</strong></h4>

<p>Alongside the choice of analysis software, reliable protein quantitation also depends on the normalization strategy used to correct for any non-biological differences between test samples prior to comparison, and the choice of method has direct implications for data integrity.</p>
<p><em>Single “Housekeeping” Protein Normalization. </em>Traditionally, western blots have been quantified via normalization against a single loading control, typically housekeeping proteins (HKPs) such as GAPDH, β-actin or β-tubulin, which are ubiquitous, abundant and assumed to be consistently expressed. This approach is widely used, however, HKPs must be validated against positive and negative controls within the researcher’s specific experimental context to <a href="https://www.science.org/doi/10.1126/scisignal.2005966" target="_blank" rel="noopener">confirm consistent expression levels across samples</a>.</p>
<p>As HKP expression is often considerably higher than that of target proteins, rigorous linear range determination must be established to <a href="https://onlinelibrary.wiley.com/doi/10.1155/2014/361590" target="_blank" rel="noopener">avoid oversaturation and loss of quantitative accuracy</a>. This process often requires several rounds of optimization of primary and secondary antibody dilution ratios, which can add significant time and complexity to the experiment.</p>
<p>Despite HKPs’ ubiquitous expression, their expression levels have been shown to fluctuate across different cell types, cell states, and disease states, including in <a href="https://www.oncotarget.com/article/11439/text/" target="_blank" rel="noopener">cancer</a>. Therefore, it is critical for researchers to validate their HKPs for consistent expression across different sample types and experimental conditions.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Normalizing western blots using a single loading control may require stripping and reprobing of the membrane to detect both target and control signals if the proteins run at similar molecular weights. This process can introduce variability and the potential for incomplete stripping or uneven reprobing, increasing the risk of signal variation and reducing result reliability.</p>
<p><em>Total Protein Normalization. </em><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10214384/" target="_blank" rel="noopener">Total protein normalization (TPN)</a> overcomes both the linearity challenges of immunodetection and the reliance on a single control protein to represent the entire protein population (<em>Table 1</em>). Instead, TPN quantifies the total protein loaded in each lane, measured by collecting the signal on the membrane, to produce a normalization factor that is comprehensive and inherently stable. This can be achieved using Stain-Free technology or reversible staining methods such as Ponceau S.</p>
<p>One <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10214384/" target="_blank" rel="noopener">study</a> compared the accuracy and precision of normalization of three HKPs (β-tubulin, actin and GAPDH) against Stain-Free TPN. Although β-tubulin and actin showed accuracy comparable to that of Stain-Free TPN, they exhibited lower precision, potentially reducing the reliability of the measurements. At the same time, GAPDH plateaued rapidly due to oversaturation, resulting in poor accuracy.</p>
<p><a href="https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6360.pdf" target="_blank" rel="noopener">Another study</a> reported similar findings by comparing the linearity of a series of dilutions obtained by Stain-Free TPN measurement as well as HKPs immunodetection, further demonstrating that Stain-Free TPN can serve as a more reliable and accurate loading control than HKPs (<em>Figure 1</em>).</p>
<p><figure aria-describedby="caption-attachment-338261" class="wp-caption alignnone"><img decoding="async" class="wp-image-338261 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1024x641.jpg" alt="Table 1. Comparison between HKP normalization and TPN" width="696" height="436" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1024x641.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-300x188.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-768x481.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1536x962.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-2048x1283.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-671x420.jpg 671w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1341x840.jpg 1341w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-696x436.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1392x872.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1068x669.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Table-1-1920x1203.jpg 1920w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Table 1. Comparison between HKP normalization and TPN</figcaption></figure></p>
<p class="trimmed"> </p>
<p><figure aria-describedby="caption-attachment-338226" class="wp-caption alignnone"><img loading="lazy" decoding="async" class=" td-center wp-image-338226 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1024x576.png" alt="Figure 1. Comparison of Stain-Free total protein measurement and immunodetection of housekeeping proteins in cell lysate. (A) Representative western blot images. (B) Relative intensity of protein bands compared to a predicted quantitative response. Adapted from Hammond et al. 2020." width="696" height="392" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1024x576.png 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-300x169.png 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-768x432.png 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1536x864.png 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-2048x1152.png 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-747x420.png 747w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1493x840.png 1493w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-696x392.png 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1392x783.png 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1068x601.png 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Figure-1_Hammond-et-al_-1920x1080.png 1920w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Figure 1. Comparison of Stain-Free total protein measurement and immunodetection of housekeeping proteins in cell lysate. (A) Representative western blot images. (B) Relative intensity of protein bands compared to a predicted quantitative response. Adapted from Hammond et al. 2020.</figcaption></figure></p>
<p>Stain-Free TPN methods were introduced to address variation in membrane sensitivity, allowing the gel and blot to be visualized through an imaging step that does not interfere with downstream immunodetection. This is particularly useful for enhancing data integrity as Stain-Free approaches provide a true scalar relationship between loading amount and signal intensity, so both target and loading signals can be quantified accurately <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3809032/" target="_blank" rel="noopener">within a linear dynamic range</a> by normalizing each band to the total protein in each lane. This approach improves the reproducibility of TPN, and was recently shown to <a href="https://www.sciencedirect.com/science/article/abs/pii/S0003269722003001" target="_blank" rel="noopener">reduce variability compared to actin or β-tubulin normalization while also reducing the sample size needed for statistical significance by >50%</a>.</p>
<p>However, researchers should be aware that since TPN reflects the whole protein population, it can obscure treatment-induced global shifts in protein expression, so the normalization approach chosen should be matched to the biological context of the experiment.</p>
<p><em>Upholding data integrity. </em>A western blot’s quantitative reliability is dependent on the decisions made at every stage, from image acquisition and processing through to the normalization strategy applied. Rigorous documentation is essential for the transparency and integrity of published data but does not negate the other steps needed to ensure biological validity and quantitative accuracy. Central to this is the normalization method chosen to account for non-biological differences between samples.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Whichever approach is used, it must be reported and accompanied by an explanation of why it was the most suitable choice for the experiment and its biological context. While there are no fixed requirements on which normalization method researchers should follow, many journals now strongly recommend the use of TPN and stress that HKPs should only be used where there is strong evidence that their expression is unaffected by the experimental conditions.</p>
<p>Together, transparent audit-ready documentation, careful tool selection and a well-justified normalization strategy form the foundation of credible, reproducible western blot data, and meet the growing expectations of journals and the wider research community.</p>
<p class="trimmed"> </p>
<p><em>Nikolas Chmiel, PhD, is associate director R&D, life science group, Bio-Rad Laboratories.</em></p>
<p><em> </em></p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/best-practices-for-establishing-data-integrity-in-western-blotting/">Best Practices for Establishing Data Integrity in Western Blotting</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing AAV Development: From Production to Performance</title>
<link>https://edusehat.com/en/advancing-aav-development-from-production-to-performance</link>
<guid>https://edusehat.com/en/advancing-aav-development-from-production-to-performance</guid>
<description><![CDATA[ In this GEN Learning Lab, our expert panelists Guangping Gao, PhD, and Thomas Quinn will explore critical steps in the AAV workflow that influence vector quality and downstream experimental success.
The post Advancing AAV Development: From Production to Performance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_2282040570_AdenoAssociatedVirusVirions-e1790089840193.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 23 Sep 2026 00:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, AAV, Development:, From, Production, Performance</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/headshot.jpg" class="h-full w-full object-cover" alt="Image of Thomas Quinn">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Thomas Quinn</h2>
                <h5 class="mt-0 !text-[15px]">R&D Group Leader<br>Takara Bio USA</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/headshot.jpg" alt="Image of Thomas Quinn">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Thomas Quinn</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Thomas Quinn earned a BS in zoology (genetics) from Michigan State University and an MS in molecular medicine and genetics from Wayne State University, where his thesis involved viral vector development for CAR T therapies targeting melanoma and lung cancers. Since 1998, he has led the viral delivery R&D group at Takara Bio USA, focusing on high-efficiency viral delivery systems (adenoviral, retroviral, lentiviral, and AAV) and CRISPR/Cas9 genome editing products.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/GuangpingGao_Headshot.jpg" class="h-full w-full object-cover" alt="Image of Guangping Gao, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Guangping Gao, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Professor and Chair<br>Dept. of Genetic and Cellular Medicine<br>UMass Chan Medical School</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/GuangpingGao_Headshot.jpg" alt="Image of Guangping Gao, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Guangping Gao, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Guangping Gao, PhD, is an internationally recognized gene therapy researcher who played a key role in the discovery and characterization of a new family of adeno-associated virus (AAV) serotypes, which was instrumental in reviving the gene therapy field. His scientific research career has primarily focused on molecular genetics and viral vector gene therapy of rare genetic diseases, encompassing disease gene cloning, causative mutation identification, pathomechanism investigation, animal modeling, novel viral vector discovery, and engineering for <em>in vivo</em> gene delivery, vector biology, preclinical and clinical gene therapy product development, viral vector manufacturing for preclinical and clinical gene therapy applications as well as technology platforms development as novel approaches for human gene therapy. He has also co-founded several gene therapy companies.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, October 21, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-21T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Technologies for adeno-associated virus (AAV) development are advancing rapidly, driven by innovations in vector engineering and production. New insights into vector quality and performance are supporting the development of new strategies and tools for AAV workflows. These include advances in capsid engineering and workflow standardization—which are accelerating the development of more effective gene therapies.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN Learning Lab</em>, our expert panelists Guangping Gao, PhD, and Thomas Quinn will explore critical steps in the AAV workflow that influence vector quality and downstream experimental success. The discussion will highlight advances in purification and recovery strategies, followed by approaches for accurate AAV titration and vector characterization to support reproducible research and scalable AAV production. The panelists will also discuss innovations in next-generation AAV designs that are empowering researchers to improve gene delivery performance and expand the potential of gene therapies.</p><p></p><p></p><p class="wp-block-paragraph">Key takeaways include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>Practical approaches to overcoming challenges in AAV purification, titration, and downstream analysis</li><p></p><p></p><p></p><li>Best practices for AAV production and workflow standardization</li><p></p><p></p><p></p><li>Emerging technologies that support reproducible and scalable AAV production workflows</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.takarabio.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="104" src="https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-300x104.jpg" alt="Takara logo" class="wp-image-303591" srcset="https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-300x104.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1024x354.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-768x266.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1215x420.jpg 1215w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-696x241.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1392x484.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo-1068x369.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2024/10/Takara_logo.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/advancing-aav-development-from-production-to-performance/">Advancing AAV Development: From Production to Performance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>iNFixion seeks NF1 treatment by enhancing what the body is doing right</title>
<link>https://edusehat.com/en/infixion-seeks-nf1-treatment-by-enhancing-what-the-body-is-doing-right</link>
<guid>https://edusehat.com/en/infixion-seeks-nf1-treatment-by-enhancing-what-the-body-is-doing-right</guid>
<description><![CDATA[ The BIO 2026 Start-up Stadium winner targets a rare disease. As Herb Sarnoff sits in the hospital, waiting for a pain specialist to see […]
The post iNFixion seeks NF1 treatment by enhancing what the body is doing right appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/herb-sarnoff-4.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 16:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>iNFixion, seeks, NF1, treatment, enhancing, what, the, body, doing, right</media:keywords>
<content:encoded><![CDATA[<h4>The BIO 2026 Start-up Stadium winner targets a rare disease.</h4>
<p>As Herb Sarnoff sits in the hospital, waiting for a pain specialist to see his daughter, he describes how a mutation on just one side of the NF1 gene causes neurofibromatosis type 1 (NF1).</p>
<p>“You have one good NF1 gene producing the neurofibromin protein your body needs, and one missing or mutant allele that isn’t, so every cell is not getting enough normal NF1 protein,” he explains. The result is a wide range of difficult symptoms, including painful tumors, bone conditions like scoliosis and osteoporosis, high rates of cancer, and neurocognitive manifestations such as learning disabilities, autism and sleep dysregulation.</p>
<p>Since discovering his daughter’sNF1, a rare disease impacting 1 in 3000 people, nearly 25 years ago, Sarnoff has slowly transformed himself from a tech entrepreneur with limited knowledge of biology to leading iNFixion Bioscience, a biotech developing treatments for NF1. Infixion’s novel NF1 approach aims to supercharge the function of the one good allele rather than trying to fix the mutant one. And the judges were impressed enough to award Infixion a Start-Up Stadium top prize at the 2026 BIO International Convention.</p>
<p>The award recognizes just two start-ups—from among 50 presenting—that investor judges deem to be most promising. iNFixion Bioscience won the Emerging Company Category (between $1 million-$10 million raised). The Seed-Stage winner, with less than $1 million raised, is BrainStorm Therapeutics.</p>
<h2>iNFixion’s innovation</h2>
<p>Gene therapies often seek to correct mutations, but as Sarnoff explains, “fixing” mutant NF1 genes is difficult. “The gene itself is extremely large: 320,000 base pairs of DNA,” he says, adding that sequencing has identified over 5,000 unique NF1 gene mutations, with no hotspots. “So gene therapy for NF1 is really, really challenging.”</p>
<p>Instead, iNFixion is targeting the healthy allele, increasing the amount of NF1 protein it can produce by blocking microRNAs that modulate protein expression.</p>
<p>“MicroRNAs are basically a feedback loop regulating protein in the body by putting a brake on protein production when necessary,” Sarnoff explains. “If you can block the right microRNAs, you’re essentially taking the brake off. But microRNAs are not specific to one gene. So if you take out a microRNA, you’ll likely have off-target effects.”</p>
<p>Instead of completely blocking the targeted microRNA, iNFixion seeks to block its function exclusively in the NF1 gene.</p>
<p>“The approach being pursued utilizes antisense oligonucleotides (ASOs) that block microRNA binding only on NF1 mRNA. This prevents that microRNA from putting a brake on NF1 protein production,” Sarnoff explains. “But that microRNA is still free to work on other genes, thus limiting potential off-target effects.”</p>
<p>iNFixion has shown in early cellular <em>in vitro</em> experiments that its ASO can boost NF1 protein expression by up to 70-80%. They have also adapted their ASO from the human version to a mouse version and shown they can boost NF1 protein expression in the brains of mice. The next step is to optimize for safety and efficacy in both human NF1 organoids and NF1 animal models.</p>
<h2>The drive for funding</h2>
<p>As with all start-ups, iNFixion is constantly seeking funding to continue its work. Thus far, most of the work has been funded by the National Institutes of Health (NIH), Department of Defense (DoD), and foundation grants, Sarnoff says.</p>
<p>“We’ve also been fortunate to get lab space at J&J’s San Diego incubator called JLABS,” he says. “It’s a prestigious and collaborative environment for drug discovery start-ups.”</p>
<p>As he seeks future funding, Sarnoff is hopeful of attracting investor interest. One advantage: Even though NF1 is a rare disease it is not that rare, affecting 125,000 Americans and 2.5 million worldwide.</p>
<p>“So it’s a bit of a sweet spot,” he explains. “We get all the benefits of orphan disease, including special treatment at the FDA, access to priority review vouchers and R&D tax incentives, but it’s a big enough market that there’s definitely interest from pharma.”</p>
<p>Sarnoff says iNFixion is in discussions with pharmaceutical companies interested in iNFixion. As for venture capital, Sarnoff notes that few VC’s provide early-stage funding for orphan disease, although a handful of professional investors are showing interest.</p>
<h2>Personal motivation</h2>
<p>Having explained the disease and Infixion’s approach, Sarnoff begins to grow impatient waiting for his daughter’s pain specialist. Managing pain is a big part of NF1, according to Sarnoff, who says his daughter has had chronic pain for over 10 years related to tumors and bone issues.</p>
<p>His daughter has had 10 major surgeries for scoliosis and tumor removal, and lives with neurocognitive “executive functioning issues,” Sarnoff says. “She’s certainly had her challenges along the way.”</p>
<p>Sarnoff isn’t the only one in his company with personal motivation. Of the seven members in iNFixion’s core team, Sarnoff and three others are NF1 parents, including a pathologist and PhD scientist.</p>
<p>“I made a commitment back in 2017. I said, ‘I’m going to do this.’, and I’ve been working full time on it since,” he says.</p>
<p>An inventor with several patents and previous CEO experience launching a (retail/tech) start-up, Sarnoff is comfortable in the start-up world, but biotech was new.</p>
<p>“I’ve had to start a new career, learning biology and drug discovery, which were completely foreign,” he explains. “I just started gathering resources like any start-up. You begin with an idea and limited resources, and you start building pieces.”</p>
<p>iNFixion is now winning prizes and impressing investors, and Sarnoff clearly seems dedicated to building the other pieces needed for Infixion’s success—and his daughter’s health.</p>
<p>The post <a href="https://bio.news/bio-convention/infixion-seeks-nf1-treatment-by-enhancing-what-the-body-is-doing-right/">iNFixion seeks NF1 treatment by enhancing what the body is doing right</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SARS&#45;CoV&#45;2 Protein Fuels Lung Inflammation by Hijacking Macrophages</title>
<link>https://edusehat.com/en/sars-cov-2-protein-fuels-lung-inflammation-by-hijacking-macrophages</link>
<guid>https://edusehat.com/en/sars-cov-2-protein-fuels-lung-inflammation-by-hijacking-macrophages</guid>
<description><![CDATA[ The SARS-CoV-2 protein ORF8 reprograms macrophages to promote viral replication and lung inflammation. Blocking the ORF8-linked receptor IL-17RA reduced inflammation and fibrosis in mice, pointing to a potential therapeutic target.
The post SARS-CoV-2 Protein Fuels Lung Inflammation by Hijacking Macrophages appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/12/GettyImages-1354651238-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 13:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SARS-CoV-2, Protein, Fuels, Lung, Inflammation, Hijacking, Macrophages</media:keywords>
<content:encoded><![CDATA[<p>Even now, scientists are still untangling how the SARS-CoV-2 virus can leave such lasting damage in the lungs. Severe COVID-19 is not simply a matter of infected airway cells. In the sickest patients, the virus can help set off a destructive inflammatory loop, in which immune cells that should be fighting infection instead become part of the problem.</p>
<p>A new study from researchers at Gladstone Institutes and the University of California, San Francisco (UCSF), identifies one viral protein, ORF8, as a key driver of that process. The paper, “<a href="https://www.science.org/doi/10.1126/sciadv.aee5421" target="_blank" rel="noopener">Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells</a>,” was published in <em>Science Advances</em>.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The work builds on earlier efforts by Gladstone and UCSF scientists to map interactions between SARS-CoV-2 proteins and human proteins in search of viral vulnerabilities that could be targeted with drugs. ORF8 had emerged as an intriguing but puzzling candidate. In isolated lung cells, ORF8 appeared to limit viral replication, yet SARS-CoV-2 variants lacking ORF8 have tended to cause milder disease.</p>
<p>To resolve that contradiction, Melanie Ott, MD, PhD, director of the Gladstone Infectious Disease Institute, and colleagues focused on macrophages, immune cells that help shape the body’s response to infection and inflammation. The team exposed macrophages to ORF8, studied how the cells responded to SARS-CoV-2 infection, and then tested how those immune-cell changes affected nearby alveolar type II lung epithelial cells. They also evaluated ORF8’s effects in mice infected with SARS-CoV-2.</p>
<p>The researchers found that ORF8 increased macrophage expression of angiotensin converting enzyme 2, or ACE2, the receptor SARS-CoV-2 uses to enter cells, making the immune cells more permissive to infection. Once infected, ORF8-exposed macrophages were more likely to lose antiviral function, undergo inflammatory cell death, and release signals that promoted lung inflammation and made surrounding lung epithelial cells more vulnerable to viral replication.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“We were surprised to see how effectively ORF8 turns our own immune defenses against us,” said first author Yusuke Matsui, MD, PhD, a staff research scientist in Ott’s lab. “ORF8 is hijacking macrophages to enhance infection of the surrounding tissue.”</p>
<p>In co-culture experiments, the presence of macrophages changed ORF8’s effect on infection. As the authors wrote in the paper, macrophage co-culture “overrides ORF8’s previously reported inhibition of AT2 [human alveolar type II] infection, restoring infectious viral production.” In mice, SARS-CoV-2 carrying ORF8 caused greater lung inflammation, viral burden, and scarring than virus lacking the protein, supporting the idea that ORF8 helps create a feedforward circuit linking immune-cell infection to lung pathology.</p>
<p>The work also highlights a potential therapeutic target. Researchers tested brodalumab, an antibody already FDA-approved for psoriasis that blocks IL-17RA, the receptor previously linked to ORF8. In mice, IL-17RA blockade countered “ORF8 activity, lowering viral burden and attenuating pulmonary inflammation and fibrosis,” the authors wrote. Ott said the findings could support more targeted treatments for severe COVID-19. “By showing that this single viral protein is the main bridge between viral growth and tissue damage, we’ve found a clear target for new treatments,” she added.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/sars-cov-2-protein-fuels-lung-inflammation-by-hijacking-macrophages/">SARS-CoV-2 Protein Fuels Lung Inflammation by Hijacking Macrophages</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genes Involved in Flatworm Brain Regeneration Identified</title>
<link>https://edusehat.com/en/genes-involved-in-flatworm-brain-regeneration-identified</link>
<guid>https://edusehat.com/en/genes-involved-in-flatworm-brain-regeneration-identified</guid>
<description><![CDATA[ Researchers identified genes that enable the regeneration of dopamine-producing neurons in planarians. This provides a roadmap for investigating whether similar pathways can be activated in humans and potentially leveraged to treat traumatic brain injuries and neurodegenerative diseases.
The post Genes Involved in Flatworm Brain Regeneration Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/09/Getty_170025445_NNehring_Flatworm_grey.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genes, Involved, Flatworm, Brain, Regeneration, Identified</media:keywords>
<content:encoded><![CDATA[<p>The human brain is terrible at healing itself from injury or disease. But some animals can harness their own cellular abilities to not only repair injuries but also to regrow their brains entirely. Researchers from the University of Georgia have now pinpointed several of the genes that make brain regeneration possible in planarians, a type of flatworm that exhibits what the team describes in their newly published report in <em>Nature Communications</em>, as “extraordinary capacity for brain regeneration.”</p>
<p>Both flatworm and human brains are made up of networks of neurons that communicate with each other by sending electrical or chemical signals. Some neurons react to stimuli, such as light or touch, while others control movement. Flatworms can use stem cells to replace neurons after injury. But while humans also have stem cells, they are unable to transform into new neurons effectively enough to heal injury.</p>
<p>The new study sheds light on how shared genes work in flatworms and lays the groundwork for researchers to investigate similar pathways that might be activated in humans to design better therapies for traumatic brain injuries or diseases.</p>
<p>Rachel Roberts-Galbraith, PhD, associate professor in UGA’s Franklin College of Arts and Sciences, said, “Big picture: We would like to come up with ideas for how to better empower the human brain to regenerate itself. The understanding of brain regeneration that we can develop using simple animals gives us a reason to be optimistic. It’s not an inherent property of brains that makes them bad at regeneration. It’s something specific to humans.”</p>
<p>Roberts-Galbraith is senior and corresponding author, and Kendall Clay, PhD, and Taylor Medlock-Lanier, PhD, are co-first authors of the team’s study, titled “<a href="http://dx.doi.org/10.1038/s41467-026-76397-4" target="_blank" rel="noopener">Combinatorial mechanisms specify cellular location and neurotransmitter identity during planarian neurogenesis</a>.” In their paper the team concluded “Our work suggests that combinatorial instruction of cell type and spatial identity could improve exogenous stem cell therapies aimed at precisely replacing neurons after localized injuries.”</p>
<p>Planarians can be found in freshwater, salt water, and even on land. They don’t have circulatory or respiratory systems. But they do have stem cells that can differentiate into whatever their body needs at a given time. Using stem cells, planarians can regrow their entire body from just a sliver of a body fragment. They can rebuild tissues, muscles, and even their brain. Planarian flatworms are known for their regenerative abilities, including<em> de novo</em> brain regrowth after nearly any injury,” the authors wrote. “Critically, neurons are produced in the correct numbers, diversity, pattern, and connectivity to restore function … In addition to regenerative capacity, the planarian nervous system has spatial and cell type complexity, making it suitable for study.”</p>
<p>But how do these tiny creatures know what type of cell to make and where to send it? “… the full pathway from pluripotent stem cell to mature neuron has not been determined for any cell type in the planarian nervous system,” the authors stated. “To better understand how regenerative neurogenesis proceeds in planarians, we focused on a single, conserved cell type: dopaminergic neurons.”</p>
<p>Known as the “feel good” chemical, dopamine is more than just the brain’s reward and pleasure chemical. It also acts as a signal to help neurons communicate with one another and plays a key role in controlling movement. People with Parkinson’s disease, for example, experience tremors and stiffness due to low levels of dopamine.</p>
<p>Through their study the researchers identified almost a dozen genes responsible for instructing stem cells to turn into dopamine-producing neurons and directing those new neurons to the right locations in the worm’s body. “Altogether, we identified ten genes and characterized six genes critical for specifying mature dopaminergic neurons throughout the planarian nervous system, identifying factors that regulate both neurotransmitter identity and cellular location,” they wrote. “Our results demonstrate that planarian neurogenesis requires coordination of factors that initiate neurotransmitter choice and regional location.”</p>
<p>When the researchers knocked out some of the genes discovered in this study, they found the planarians struggled to make new dopamine-producing neurons and also experienced slow movement, similar to the effects of low dopamine in people and other mammals.</p>
<p>Currently, healthcare providers don’t have many options to treat conditions like Parkinson’s, Alzheimer’s or traumatic brain injuries. Harnessing the body’s own cells in the same way planarians do to heal wounds would be a game changer. “The ability to create new neurons in predictable types, numbers, and locations for a given injury or disease would revolutionize treatments of neurodegenerative diseases and other brain injuries,” the researchers noted in their paper. “Our work aims to leverage highly regenerative animals to understand principles of successful neuron replacement.”</p>
<p>Roberts-Galbraith  added, “We figured out the genetic recipe for making these cell types in planarians. We’re hoping this work helps others figure out how to create dopamine-producing neurons from stem cells that can be more effectively transplanted into patients.”</p>
<p>The Roberts-Galbraith lab in the department of cellular biology is part of UGA’s Regenerative Bioscience Center, an interdisciplinary research hub focused on the potential of regenerative medicine.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/genes-involved-in-flatworm-brain-regeneration-identified/">Genes Involved in Flatworm Brain Regeneration Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day</title>
<link>https://edusehat.com/en/stockwatch-novos-2030-strategy-underwhelms-investors-at-capital-markets-day</link>
<guid>https://edusehat.com/en/stockwatch-novos-2030-strategy-underwhelms-investors-at-capital-markets-day</guid>
<description><![CDATA[ Novo said it planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030, and generate more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035.
The post StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/NovoNordisk-Bagsvaerd-HQ-JPEG-drone-1280px-contact-us.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Novo’s, 2030, Strategy, Underwhelms, Investors, Capital, Markets, Day</media:keywords>
<content:encoded><![CDATA[<p>A week after loosening up its branding to “Novo,” <strong>Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO)</strong> laid out a strategy for 2030 that underwhelmed investors of the Danish metabolic biotech giant.</p>
<p>Addressing investors at its 2026 Capital Markets Day, Novo CEO Maziar (Mike) Doustdar and other company executives laid out a series of initiatives aimed at restoring its edge in metabolic and other drugs by growing and diversifying its pipeline, as well as driving sustainable growth, and delivering attractive returns.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>To that end, Doustdar and colleagues said Novo planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030. Those five are expected to emerge from more than five Phase III programs in obesity and diabetes, and another 5+ Phase III programs in other therapeutic areas.</p>
<p>Doustdar also committed Novo to generating more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035, a figure that includes current pipeline assets. Novo plans to combine internal pipeline growth with external growth through merger-and-acquisition (M&A) activity.</p>
<p>“Novo is targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors,” cautioned Evan David Seigerman, a managing director and head of healthcare research at BMO Capital Markets, in a research note.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Seigerman cited a consensus of analysts that estimates a 3.53% compound annual growth rate (CAGR) for Novo, vs. ~3.65% CAGR for its pharma peers. However, he added, “Novo’s outlined growth expectation appears already priced in to [Wall] Street estimates, reading negatively to shares.”</p>
<p>Key to Novo’s new strategy, Doustdar said, was planning for the eventual loss of U.S. patent exclusivity in 2032 for its best-selling drug semaglutide, the glucagon-like peptide-1 (GLP-1) drug marketed as Ozempic<sup class="wp-sup-text">®</sup> for type 2 diabetes in adults and as Wegovy<sup class="wp-sup-text">®</sup> for obesity/weight control—what the CEO called “the elephant in the room.”</p>
<p>“We plan to come on the other side of the LOE [loss of exclusivity] as a bigger company than we are today and a much more diversified version of it,” Doustdar said. “We created an incredibly attractive market, and now almost every other single pharma company, big or small, is trying to come and compete with us. We need to be ready for that.”</p>
<p></p><h4><strong>‘Not seeing concrete news’</strong></h4>

<p>Those and other priorities laid out at the annual capital markets event failed to reassure Novo investors. The company’s primary shares on Nasdaq Copenhagen <span><strong>slumped nearly 8%</strong></span> this morning from DKK 281.55 ($43.19) to an even DKK 260.00 ($39.89). On the New York Stock Exchange, Novo’s American depositary receipts (ADRs) also <span><strong>tumbled</strong> <strong>8%</strong></span> from $43.24 to $39.81.</p>
<p>“Investors are selling the shares because they are not seeing concrete news that could drive the stock higher,” Per Hansen, investment economist at Nordnet, wrote in a research note, as reported by Bloomberg News.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Speaking on CNBC, Hansen elaborated: “Investors hoped for a project ‘miracle’ that could turn the momentum around short term. For obvious reasons that miracle does not exist.”</p>
<p>Markus Manns, a portfolio manager ​at Union Investment, told Reuters he was less than impressed by Novo’s projections of 2030 sales and a “broadly stable” operating margin.</p>
<p>“They (also) did not say much in terms of ‌how to ⁠tackle the semaglutide patent expiration in 2032,” said Manns, who added that he thought Novo made a credible case for pursuing next-generation obesity drugs and a broader early-stage pipeline.</p>
<p>In its presentation, Novo detailed the drugs it expects to launch each year through 2030—starting with next year, when the company plans to launch once-weekly CagriSema (cagrilintide and semaglutide), a diabetes and obesity drug which combines the long-acting amylin receptor agonist with the GLP-1 receptor agonist. Cagrilintide and a high-dose version of CagriSema are scheduled for a 2028 launch, while 2029 is expected to deliver launches of high-dose cagrilintide; zenagamtide, a multi-receptor peptide agonist targeting GLP-1, amylin, and calcitonin receptors; an oral form of zenagamtide; and a next-generation GLP-1.</p>
<p>In 2030, Novo’s launch calendar includes a monthly-dose or “QM” GLP-1; a thermostable GLP-1; an oral high-yield GLP-1; Amylin 355 and an oral version, both long-acting amylin analogues; an oral ACSL5 inhibitor LX9851, co-developed with Lexicon Pharmaceuticals; and UBT251, a long-acting synthetic peptide triple agonist that targets GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors and is being co-developed by Novo with Chinese-owned United Biotechnology.</p>
<p>Monday’s selloff of Novo shares and ADRs lowered the company’s one-year stock performance to a <span><strong>33% decline</strong> </span>year over year on Nasdaq Copenhagen and a <span><strong>35% drop</strong></span> on the NYSE.</p>
<p>By contrast, shares of Novo’s archrival in obesity and diabetes drug development, <strong>Eli Lilly (NYSE: LLY), </strong>have <span><strong>soared 55% </strong></span>year over year, from $754.95 on September 22, 2025 (September 21 was a Sunday) to $1,164.66, <span><strong>up 1%</strong></span> from Friday’s close of $1,152.93.</p>
<p>While Bagsvaerd, Denmark-based Novo Nordisk was first to market with a GLP-1 drug when Ozempic became commercially available in February 2018, Indianapolis-based Lilly has grown to a majority share of GLP-1 drug sales—though Lilly’s blockbuster tirzepatide, marketed for diabetes as Mounjaro<sup class="wp-sup-text">®</sup> and for obesity as Zepbound<sup class="wp-sup-text">®</sup>, are dual-agonists of GLP-1 and GIP receptors.</p>
<p></p><h4><strong>2-to-1 sales edge</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p>Lilly has grown its GLP-1-based drug sales so far this year to a nearly 2-to-1 edge over Novo. The two Lilly drugs have racked up a combined $27.6 billion-plus in revenue—$18.605 billion for Mounjaro, $9.088 billion for Zepbound—accounting for about 65% of Lilly’s total $42.773 billion in revenue between January and June 2026.</p>
<p>By contrast, Novo’s GLP-1 blockbusters have racked up a combined DKK 102.393 billion ($15.715 billion) in sales in the first half of 2026, accounting for about 69% of the company’s total DKK 148.551 billion ($22.798 billion) in adjusted sales.</p>
<p>Ozempic garnered DKK 59.2 billion ($9.085 billion), down 8% from DKK 64.52 billion ($9.902 billion) year over year, while its injectable Wegovy generated sales of DKK 37.719 billion ($5.789 billion), up 2% from DKK 36.888 billion ($5.661 billion) in Q1-Q2 2025. The company also made DKK 5.474 billion ($840 million) in sales from oral Wegovy, which reached the U.S. market on January 5.</p>
<p>Lilly’s competing oral obesity drug Foundayo<sup>®</sup> (orforglipron), a small molecule GLP-1 receptor agonist, generated $98 million in its first quarter on the market, having won FDA approval on April 1.</p>
<p>Doustdar took Novo’s helm in August 2025, intent on regaining the company’s competitive edge in GLP-1 based obesity and diabetes drugs after Lilly’s sales successes with Mounjaro and Zepbound. A year ago this month, Doustdar led the company’s deepest personnel reduction, which <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-analysts-see-pain-and-necessity-in-novo-nordisks-9000-layoffs/" target="_blank" rel="noopener">eliminated about 9,000 jobs</a>.</p>
<p>In addition to those initial layoffs, Novo said Monday that 4,000 additional staffers exited the company, resulting in 13,000 fewer employees than a year ago, bringing the company’s workforce down to approximately 66,000 employees.</p>
<p>Novo said its restructuring generated more than DKK 10 billion ($1.534 billion) in savings that is being allocated to its R&D operations, commercial growth brands, and manufacturing right-sizing efforts. The company also said it reduced its spending on external services by ~30% year-to-date and has renegotiated agreements with suppliers to squeeze out further savings.</p>
<p></p><h4><strong>Flurry of announcements</strong></h4>

<p>In the week leading to and including Monday’s Capital Markets Day, Novo issued a flurry of announcements—including a poke at Lilly by highlighting during the event positive topline results from the Phase III REIMAGINE 5 trial (<a href="https://clinicaltrials.gov/study/NCT06534411" target="_blank" rel="noopener">NCT06534411</a>) and REDEFINE 9 trial (<a href="https://clinicaltrials.gov/study/NCT06388187" target="_blank" rel="noopener">NCT06388187</a>) assessing CagriSema, which the company trumpeted as “Novo’s next innovation in weight management and type 2 diabetes.”</p>
<p>In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg showed superiority to tirzepatide 5 mg for weight loss, achieving an estimated average weight loss of 12.4%, compared with 9.1% for the Lilly drug. CagriSema also confirmed a non-inferior reduction in HbA<sub>1c</sub> of 1.71% vs. 1.67% for tirzepatide.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>In REDEFINE 9, CagriSema 1.0 mg/1.0 mg showed a dramatic weight reduction of 21.0% vs. 2.0% for placebo, meeting that study’s primary superiority endpoint. CagriSema also showed greater improvements than placebo across prespecified endpoints that included systolic blood pressure, waist-to-height ratio, and fasting lipid profile.</p>
<p>The rush of announcements started September 14 with a rebrand that shortened the company’s name in marketing materials to “Novo,” accompanies by an updated Apis bull logo, while keeping “Novo Nordisk” as its legal name.  The company also unveiled a new slogan, “Lasting Health Starts Now.”</p>
<p>“The rebrand is designed to be more memorable and relevant to the way people engage with their health today,” Novo stated in a press release announcing the rebrand. “It also reflects the company’s ambition to bring breakthrough science closer to people’s daily lives and to strengthen recognition and trust as Novo reaches more people in more ways.”</p>
<p></p><h4><strong>Anthropic, Orbis partnerships</strong></h4>

<p>Novo also announced a collaboration of undisclosed value with <strong>Anthropic</strong> (draft Form S-1 Registration Statement filed June 1) to bolster artificial intelligence (AI)-based drug development. Novo agreed to use Anthropic models and Claude Science to advance scientific reasoning for R&D and agentic software engineering, with the aim of helping Novo discover and develop new treatments faster.</p>
<p><a href="https://www.genengnews.com/topics/artificial-intelligence/claude-science-is-here-antibiotics-designed-by-text-prompt-among-applications/" target="_blank" rel="noopener">Launched in June</a>, Claude Science is an AI workbench for scientists that consolidates fragmented research tools, including more than 60 scientific databases and connectors pre-configured for genomics, proteomics, structural biology, and more, into a single reasoning layer.</p>
<p>On Thursday, privately held <strong>Orbis Medicines</strong> announced an up-to-$1.4 billion strategic collaboration and license agreement with Novo, bringing together the two Danish-based drug developers to discover and develop an undisclosed number of next-generation oral macrocycle therapeutics for unspecified cardiometabolic diseases.</p>
<p>The potential $1.4 billion reflects an upfront payment and payments tied to achieving development and commercial milestone payments. Copenhagen-based Orbis will also gain a strategic investment of undisclosed amount from Novo, and potentially gain tiered royalties on future product sales.</p>
<p>Novo plans to apply Orbis’ lab-in-the-loop <sup>n</sup>Gen platform which integrates generative AI and high-throughput synthesis, using a multi-parameter optimization (MPO) engine to design <sup>n</sup>Cycles with desirable properties—detailed in a <a href="https://www.nature.com/articles/s41589-023-01496-y" target="_blank" rel="noopener">2023 <em>Nature Chemical Biology</em> paper</a> as including target biding and other key properties for oral availability, such as proteolytic stability, membrane permeability and metabolic stability. Orbis says it continuously improves its <sup>n</sup>Cycles through one of the industry’s largest experimental macrocycle datasets, which the company generates in real time via its platform.</p>
<p>Novo’s interest in macrocycles appears to reflect a desire to overcome limitations associated with traditional oral peptide treatments, such as low digestive absorption. The 2023 paper showed Orbis’ macrocycles to have an oral bioavailability of up to 18% in rats: “This method for generating orally available peptides is general and provides a promising push toward unlocking the full potential of peptides as therapeutics.”</p>
<p>Other announcements:</p>
<ul>
<li><strong>Frehemgo<sup class="wp-sup-text">®</sup> (denecmig)</strong> won a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending approval for the next-generation factor VIIIa mimetic bispecific antibody to treat hemophilia A, with or without inhibitors, in adults and children.</li>
<li><strong>Denecimig</strong> generated positive results in the Phase III FRONTIER5 trial (<a href="https://clinicaltrials.gov/study/NCT05878938" target="_blank" rel="noopener">NCT05878938</a>), showing that a direct switch to a subcutaneous denecimig pen injector from a vial and syringe injection system for a current Hemophilia A treatment emicizumab, marketed by Genentech as Hemlibra<sup class="wp-sup-text">®</sup>, was well tolerated with no unforeseen safety concerns in adolescents and adults with hemophilia A.</li>
<li><strong>Sogroya<sup class="wp-sup-text">®</sup> (somapacitan) </strong>also won a positive CHMP opinion for the human growth hormone analogue as a once-weekly treatment for children with idiopathic short stature (ISS) with persistent growth disturbance. The drug won FDA approval in 2020.</li>
</ul>
<p class="trimmed"> </p>
<p></p><h2><strong>Leaders & Laggards</strong></h2>

<ul>
<li><strong>BlossomHill Therapeutics (Nasdaq: BLSM)</strong> shares <span><strong>jumped 21%</strong></span> over two days, from $22.17 Tuesday to $26.82 Thursday, after the small molecule cancer drug developer announced positive updated data from the ongoing Phase I/II SOLARA trial (<a href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06706076&data=05%7C02%7C%7C910e8a28d5b44d79e93508df16b4a643%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639254640331799833%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=66HNYXwsL%2FkUCzbwX5byzEvK10dAyp4Qb73DsSj1lSQ%3D&reserved=0" target="_blank" rel="noopener">NCT06706076</a>) assessing BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S. In patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, BH-30643 showed a 45% objective response rate (18 of 40 patients) and an 88% disease control rate (35 of 40 patients). At the time of efficacy follow-up, 25 of 40 patients (63%) remained on treatment with a median follow-up of 6.9 months. BlossomHill presented the data at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul.</li>
<li><strong>Xenon Pharmaceuticals (Nasdaq: XENE)</strong> shares <span><strong>tumbled 31%</strong></span> from $57.35 to $39.75 Friday, after the neuroscience-focused drug developer acknowledged that it voluntarily paused enrollment of new patients in two Phase III programs encompassing five trials assessing its potent KV7 potassium channel opener azetukalner—the three-program X-NOVA program in major depressive disorder (MDD), and the two-trial X-CEED program in bipolar depression—following an analysis of neuropsychiatric adverse events. “In a very small number of patients, we have seen an adverse event captured under the broad preferred term of psychosis,” Xenon chief medical officer Christopher Kenney, MD, told analysts on a conference call. Those events had not previously been seen in the Phase II X‑NOVA trial in MDD (<a href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05376150&data=05%7C02%7C%7C910e8a28d5b44d79e93508df16b4a643%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639254640331924574%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=U1cOhoMva78qYqG5FM%2F4Wz9R%2BKtAqeW0qY9GE4ZsvQ8%3D&reserved=0" target="_blank" rel="noopener">NCT05376150</a>), Xenon said, adding that the observed events, their rate of occurrence, and their severity, were consistent with the known safety and tolerability profile of azetukalner and its mechanism.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-novos-2030-strategy-underwhelms-investors-at-capital-markets-day/">StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Emerging Trends in Fluid Transfers and Freeze&#45;Thaw Workflows</title>
<link>https://edusehat.com/en/emerging-trends-in-fluid-transfers-and-freeze-thaw-workflows</link>
<guid>https://edusehat.com/en/emerging-trends-in-fluid-transfers-and-freeze-thaw-workflows</guid>
<description><![CDATA[ In this GEN webinar, our expert speakers will discuss the latest trends, challenges, and innovations shaping fluid transfer and freeze-thaw workflows. 
The post Emerging Trends in Fluid Transfers and Freeze-Thaw Workflows appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_98412794_LiquidNitrogenContainer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Emerging, Trends, Fluid, Transfers, and, Freeze-Thaw, Workflows</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/AlexanderFuchs_headshot.jpg" class="h-full w-full object-cover" alt="Image of Alex Fuchs">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Alex Fuchs</h2>
                <h5 class="mt-0 !text-[15px]">Director of Product Innovation<br>Single Use Support <br>Colder Products Company</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/AlexanderFuchs_headshot.jpg" alt="Image of Alex Fuchs">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Alex Fuchs</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Alexander Fuchs is the director of product innovation at Single Use Support. Due to his highly technical education and intensive insights, he has a wide range of experience and knowledge in various industries, such as jewelry, manufacturing, and biopharma, as well as multiple areas of activity. Passionate about automation, engineering, and process management, Alexander contributes to the innovative focus of advancing fluid and cold chain management within the biopharmaceutical industry.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/Jascha-Rosenbaum-CPC-Biotech-scaled-e1789775733875.jpg" class="h-full w-full object-cover" alt="Image of Jascha Rosenbaum">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Jascha Rosenbaum</h2>
                <h5 class="mt-0 !text-[15px]">Regional Director for Applications & Business Development<br>Colder Products Company</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/Jascha-Rosenbaum-CPC-Biotech-scaled-e1789775733875.jpg" alt="Image of Jascha Rosenbaum">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Jascha Rosenbaum</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Jascha Rosenbaum is the regional director for applications and business development in Europe. Jascha holds a master’s degree in chemical engineering, and he has worked in the single-use industry for the last 10 years in both the U.S. and Europe. He has supported some of the largest biopharmaceutical manufacturers across Europe, where he has experience at every stage of single-use solutions.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, October 20, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-20T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">In cell and gene therapy manufacturing, fluid transfer and freeze-thaw workflows are paramount to process efficiency, product quality, and operational flexibility. From scaling and closed-system processing to automation and the growing use of cryopreservation, manufacturers are rethinking how materials move through the process—both during manufacturing and between unit operations.<br><br>In this <em>GEN</em> webinar, our expert speakers will discuss the latest trends, challenges, and innovations shaping fluid transfer and freeze-thaw workflows. The panel will explore how cell and gene therapy manufacturers are addressing complex process requirements while reducing manual interventions, minimizing contamination risk, improving workflow efficiency, and preparing processes for scale. Key takeaways from the webinar include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>Emerging approaches to fluid transfers,</li><p></p><p></p><p></p><li>Single-use technologies and sterile connections,</li><p></p><p></p><p></p><li>Freeze-thaw considerations,</li><p></p><p></p><p></p><li>Automation and closed processing,</li><p></p><p></p><p></p><li>Strategies for building more flexible and robust workflows for cell and gene therapy manufacturing</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the conversation offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.cpcworldwide.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="121" src="https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-300x121.jpg" alt="CPC logo" class="wp-image-298424" srcset="https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-300x121.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1024x413.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-768x310.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1536x620.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1041x420.jpg 1041w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-696x281.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1392x562.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo-1068x431.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2024/07/CPC_Logo.jpg 1695w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/emerging-trends-in-fluid-transfers-and-freeze-thaw-workflows/">Emerging Trends in Fluid Transfers and Freeze-Thaw Workflows</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing Cell Therapy for Cardiovascular Disease</title>
<link>https://edusehat.com/en/advancing-cell-therapy-for-cardiovascular-disease</link>
<guid>https://edusehat.com/en/advancing-cell-therapy-for-cardiovascular-disease</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker Joshua Michael Hare, MD, will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular disease. 
The post Advancing Cell Therapy for Cardiovascular Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_2224747882_cardiology.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 05:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, Cell, Therapy, for, Cardiovascular, Disease</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/Hare-headshot-e1789774840810.jpg" class="h-full w-full object-cover" alt="Image of Joshua Michael Hare, MD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Joshua Michael Hare, MD</h2>
                <h5 class="mt-0 !text-[15px]">Founding Director,<br>Interdisciplinary Stem Cell Institute<br>University of Miami<br>Miller School of Medicine</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/Hare-headshot-e1789774840810.jpg" alt="Image of Joshua Michael Hare, MD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Joshua Michael Hare, MD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Joshua Hare, MD, is a board-certified practicing cardiologist and holds the Louis Lemberg Professorship of Medicine at the University of Miami Miller School of Medicine. Hare currently serves as the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami. He is widely published and has authored or co-authored over 450 articles. Hare has pioneered the use of cells as medicines for human heart disease, Alzheimer’s disease, stroke, and diseases of aging. His research has been funded by the National Institutes of Health and the Department of Defense, and he currently oversees multiple clinical trials using cell and gene therapy to treat human ischemic and non-ischemic cardiomyopathy.  Hare is an inducted member of the American Association of Physicians and the National Academy of Inventors.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, October 15, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-15T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Cardiovascular diseases offer a compelling opportunity for regenerative and cellular therapies that can repair damaged tissue, promote vascularization, modulate inflammation, or restore cardiac function. However, translating research advances into meaningful therapeutics requires connecting a strong biological rationale with appropriate cell types, indications and therapeutic strategies, and patients who are most likely to benefit.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular disease. His presentation will cover strategies for selecting indications, biological targets, and cell types based on disease pathophysiology and unmet clinical need. Attendees will also learn about the path from laboratory research to clinical investigation, including considerations around cell delivery and patient selection, and the clinical endpoints needed to evaluate safety and therapeutic benefit.</p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.lonza.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="55" src="https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo-300x55.jpg" alt="LONZA Logo" class="wp-image-162617" srcset="https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo-300x55.jpg 300w, https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo-485x91.jpg 485w, https://www.genengnews.com/wp-content/uploads/2021/03/LONZA_Logo.jpg 500w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/advancing-cell-therapy-for-cardiovascular-disease/">Advancing Cell Therapy for Cardiovascular Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Andelyn Curator Biomanufacturing Platform Supports Fayuvi Gene Therapy Approval</title>
<link>https://edusehat.com/en/andelyn-curator-biomanufacturing-platform-supports-fayuvi-gene-therapy-approval</link>
<guid>https://edusehat.com/en/andelyn-curator-biomanufacturing-platform-supports-fayuvi-gene-therapy-approval</guid>
<description><![CDATA[ Sanfilippo syndrome type A (MPS IIIA) is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood. 
The post Andelyn Curator Biomanufacturing Platform Supports Fayuvi Gene Therapy Approval appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177211585.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 02:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Andelyn, Curator, Biomanufacturing, Platform, Supports, Fayuvi, Gene, Therapy, Approval</media:keywords>
<content:encoded><![CDATA[<p>CDMO Andelyn Biosciences is now manufacturing Fayuvi<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy for commercial supply at its Columbus, OH facility. The FDA last week approved the product developed by Ultragenyx Pharmaceutical for the treatment of Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA (MPS IIIA). Fayuvi is also being manufactured ay Ultragenyx’s gene therapy manufacturing facility in Bedford, MA.</p>
<p>Sanfilippo syndrome type A (MPS IIIA) is a rare, fatal lysosomal storage disease that primarily affects the central nervous system (CNS) and is marked by rapid neurodegeneration beginning in early childhood. MPS IIIA is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years.</p>
<p>‍Fayuvi is the first FDA-approved gene therapy manufactured using the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.andelynbio.com%2Fplatforms%2Faav-curator-platform&data=05%7C02%7CJohn.Sterling%40sagepub.com%7Ce9ba7ce1b68b4a30d66c08df15b65744%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639253545024182941%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FRlIAUjP3H7sTKJUE6mNV1zXPc6IZj4AiS2MHnRyWxU%3D&reserved=0" target="_blank" rel="noopener">Andelyn AAV Curator<sup class="wp-sup-text">®</sup> Platform</a> process. ‍</p>
<p>“We congratulate Ultragenyx on this significant achievement and recognize the MPS IIIA community, investigators, and everyone who contributed to advancing this program,” said Wade Macedone, CEO of Andelyn Biosciences. “We are proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process.”</p>
<p>Andelyn’s AAV Curator Platform uses a configurable, data-informed approach to AAV process development and manufacturing, according to Macedone, who added that it integrates process knowledge, modular manufacturing strategies, and fit-for-purpose analytics to support gene therapy programs from development through commercial launch.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/omics/andelyn-curator-biomanufacturing-platform-supports-fayuvi-gene-therapy-approval/">Andelyn Curator Biomanufacturing Platform Supports Fayuvi Gene Therapy Approval</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Precure Selects Helix as Multiomics Lab and AI Tools Provider</title>
<link>https://edusehat.com/en/precure-selects-helix-as-multiomics-lab-and-ai-tools-provider</link>
<guid>https://edusehat.com/en/precure-selects-helix-as-multiomics-lab-and-ai-tools-provider</guid>
<description><![CDATA[ Mayo Clinic recently launched Precure with founding partner Thermo Fisher Scientific to help transform how the life sciences community understands the biological changes that occur as disease develops before symptoms occur.
The post Precure Selects Helix as Multiomics Lab and AI Tools Provider appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1874099648.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 02:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Precure, Selects, Helix, Multiomics, Lab, and, Tools, Provider</media:keywords>
<content:encoded><![CDATA[<p>Precure officials say they have selected Helix as its multiomic laboratory and AI tools provider supporting plans to generate molecular data from approximately one million biospecimens. The goal is to accelerate the integration of molecular insights into routine clinical care at the Mayo Clinic and across health systems more broadly.</p>
<p>The Mayo Clinic last week launched Precure with founding partner Thermo Fisher Scientific to help transform how the life sciences community understands the biological changes that occur as disease develops before symptoms occur. Precure brings together clinical expertise, de-identified longitudinal health information, and population-scale molecular data to accelerate the development of new approaches with healthcare applications.</p>
<p>Helix will provide both advanced AI tools for delivery of genomics into the clinic and biomarker driven research, and population scale multiomic capability that encompasses clinical whole genome sequencing (WGS) and research grade proteome sequencing. Linked with longitudinal clinical information and high performance compute infrastructure, the objective is to create new opportunities for prevention, diagnosis, and treatment, according to Aaron Mangold, MD, chief medical officer, Precure.</p>
<p>“Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery,” said Mangold. “We are working to make clinical whole genome sequencing and multiomics a foundation of care, helping us detect disease sooner and act earlier.”</p>
<p>Building on Mayo Clinic’s <a href="https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-to-sequence-100k-participants-to-build-genomic-database-for-improved-care-and-research-in-collaboration-with-helix/" target="_blank" rel="noopener">Tapestry study</a>, which utilized Helix’s Exome+ sequencing technology and reached 100,000 participants, Precure is extending that collaboration by leveraging Helix’s experience providing workflow orchestration, (CLIA/CAP) genomic sequencing, data infrastructure, and AI tools to its health system partners.</p>
<p>Precure and Helix have selected Ultima Genomics’ UG200<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Ultra Sequencing Platform as part of the program’s large-scale multiomics initiative. Helix will use a fleet of Ultima’s next-generation platforms to generate genomic data for WGS and read-out for proteomics at scale.</p>
<p>“The genome is becoming an enduring patient resource, providing a precision baseline for a lifetime of care,” noted James Lu, MD, PhD, CEO of Helix. “Helix brings together the laboratory and data capabilities to make this possible at scale.”</p>
<p>Helix joins Precure as a collaborator and minority owner. Mayo Clinic’s involvement in Precure is intended to advance its nonprofit mission. Any financial returns to Mayo Clinic would be reinvested in its mission of patient care, research and education. Visit <a href="https://www.mayo.edu/research/precure" target="_blank" rel="noopener">mayo.edu/research/precure</a> for more information.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/precure-selects-helix-as-multiomics-lab-and-ai-tools-provider/">Precure Selects Helix as Multiomics Lab and AI Tools Provider</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>H5N1 Spreads Among Australian Wildlife as Flu Season Ramps Up</title>
<link>https://edusehat.com/en/h5n1-spreads-among-australian-wildlife-as-flu-season-ramps-up</link>
<guid>https://edusehat.com/en/h5n1-spreads-among-australian-wildlife-as-flu-season-ramps-up</guid>
<description><![CDATA[ Australia is closely monitoring the H5N1 influenza strain after detections in sea lions, seals, dolphins, and foxes, prompting surveillance for mammal adaptation while authorities report low human health risk.
The post H5N1 Spreads Among Australian Wildlife as Flu Season Ramps Up appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/04/GettyImages-1386012927.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 22 Sep 2026 02:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>H5N1, Spreads, Among, Australian, Wildlife, Flu, Season, Ramps</media:keywords>
<content:encoded><![CDATA[<p>With flu season ramping up in certain areas of the world (it’s time to get that flu shot!) everyone is watching what strains are circulating—and how well they may match the current vaccine formulations.</p>
<p>Some strains are watched more closely than others, and the highly pathogenic avian H5N1, a subtype of the influenza A virus that causes avian influenza (“bird flu”), may garner the most attention as it is regarded as one of the largest pandemic threats.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Although H5N1 primarily infects birds, it can also infect mammals. Human infections are uncommon and have generally occurred after close contact with infected animals or contaminated environments. The World Health Organization reports no sustained person-to-person transmission.</p>
<p>The Global Virus Network (GVN) is closely monitoring detections of H5N1 in several mammal species in Australia as the virus continues to spread. Last week, Australian authorities confirmed the first detection in an Australian sea lion, an endangered species, at Seal Bay on Kangaroo Island.</p>
<p>Australia reported its first confirmed detection in a mammal on August 23, when a long-nosed fur seal found at Beachport in South Australia tested positive. A second long-nosed fur seal near Kangaroo Island was confirmed two days later and subsequent detections included red foxes and a common dolphin. Australian authorities report no evidence of mammal-to-mammal transmission of the virus in Australia.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The detections show the virus infecting several mammal species in Australia within weeks of its first reported appearance in the country’s wildlife. Globally, H5N1 has infected a growing range of mammals, including seals and other marine mammals, dairy cattle, cats and wild carnivores. Scientists are monitoring these infections for changes in the virus and evidence of transmission between mammals.</p>
<p>“Given what we have seen with this H5N1 genotype in seal and sea lion populations overseas, a spillover into Australian marine mammals was a possibility we had been concerned about and actively monitoring for,” said Michelle Wille, PhD, an avian influenza researcher affiliated with the University of Melbourne and the WHO Collaborating Centre for Reference and Research on Influenza and the Peter Doherty Institute for Infection and Immunity, a GVN Center of Excellence in Australia. “While it is sobering to see that possibility become a reality, the priority now is detailed genomic analysis of this and any future detections. We need to closely monitor for mutations associated with better adaptation to mammals and determine whether infections represent separate spillover events from birds or evidence of transmission between seals. That distinction will be critical to understanding the risk posed by the virus as it continues to circulate in wildlife.”</p>
<p>Australia first detected H5N1 clade 2.3.4.4b in wild seabirds in June. The virus has since been found in wild birds across several parts of the country. As of September 17, Australia had reported 576 confirmed events in wildlife, including mass mortality events in greater crested terns. An event may involve one or more animals.</p>
<p>In April 2025, GVN published an analysis in <em>The Lancet Regional Health—Americas</em> calling for stronger surveillance, biosecurity, genomic monitoring and preparedness as H5N1 spread. In April 2026, GVN issued a statement on H5N1 vaccine developments, emphasizing the need for continued vaccine development and broader pandemic preparedness.</p>
<p>“Australia is another reminder that H5N1 is a global animal health issue with implications for human health that we need to continue watching closely,” said Sten H. Vermund, MD, PhD, GVN’s chief medical officer and dean of the University of South Florida College of Public Health. “There is no reason for alarm, but there is every reason to remain vigilant. Surveillance across species, rapid genomic analysis and open sharing of what we learn give us the best chance to recognize an important change in the virus early.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/h5n1-spreads-among-australian-wildlife-as-flu-season-ramps-up/">H5N1 Spreads Among Australian Wildlife as Flu Season Ramps Up</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly’s GIP/GLP&#45;1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders</title>
<link>https://edusehat.com/en/lillys-gipglp-1-candidate-brenipatide-shows-early-clinical-promise-in-substance-psych-disorders</link>
<guid>https://edusehat.com/en/lillys-gipglp-1-candidate-brenipatide-shows-early-clinical-promise-in-substance-psych-disorders</guid>
<description><![CDATA[ Brenipatide showed a mean half-life ranging between 9.08 days and 12.5 days, with the longer half-life seen in participants given the highest dose of the drug at 4.5 mg. 
The post Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Lilly-research-33333.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 20 Sep 2026 03:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly’s, GIPGLP-1, Candidate, Brenipatide, Shows, Early, Clinical, Promise, Substance, Psych, Disorders</media:keywords>
<content:encoded><![CDATA[<p>Eli Lilly presented early positive clinical data supporting once-weekly dosing for its GIP/GLP-1 receptor agonist candidate brenipatide in substance use, psychiatric, and immunologic disorders—and detailed the design of Phase III trials that will assess the drug in major depressive disorder (MDD) and alcohol use disorder (AUD).</p>
<p>Brenipatide is a dual-agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors—the same modality as its blockbuster tirzepatide, marketed for type 2 diabetes in adults as Mounjaro® and for obesity as Zepbound®. The two drugs have racked up a combined $27.6 billion-plus in revenue for Lilly so far this year—$18.605 billion for Mounjaro, $9.088 billion for Zepbound—accounting for about 65% of Lilly’s total $42.773 billion in revenue between January and June 2026.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Unlike tirzepatide, brenipatide is designed to target GIP and GLP-1 receptors in central nervous system and inflammatory pathways that include receptors linked to reward and addiction in the brain.</p>
<p>At the Psych Congress 2026, held in New Orleans, Lilly presented “Brenipatide, a GIP/GLP-1 Receptor Agonist: Clinical Data Supporting Dose Selection for Substance Use, Psychiatric and Immunologic Disorders,” a poster detailing results from its Phase I J2S-MC-GZMD trial (<a href="https://clinicaltrials.gov/study/NCT06606106">NCT06606106</a>).</p>
<p>The Lilly-sponsored study was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of brenipatide in healthy, overweight, and obese participants as measured by body mass index (BMI), with the goal of determining a brenipatide dosing regimen suitable for substance use, psychiatric, and immunologic disorders.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Brenipatide showed a mean half-life ranging between 9.08 days and 12.5 days, with the longer half-life seen in participants given the highest dose of the drug at 4.5 mg. Participants treated with brenipatide received doses of 4.5 mg or lower (0.3 mg, 0.75 mg, 1.5 mg, or 3 mg).</p>
<p>“That allows us to have a durability of exposure that can go beyond the weekly dosing interval, which is what we’re testing benepatide in within the neuroscience space,” Robert Nicholson, PhD, associate vice president, U.S. & global neuroscience medical affairs, psychiatry & substance use disorders with Eli Lilly, told <em>GEN</em>.</p>
<p>The data, Lilly researchers concluded in the poster, “support the selection of weekly maintenance doses across a broad range of BMIs, including normal body weight, that optimize safety, tolerability, and incretin pharmacology” in substance use, psychiatric, and immunological disorders.</p>
<p></p><h4><strong>“Potentially a really good option”</strong></h4>

<p>“As we think through those living with substance use disorders, psychiatric disorders, and certainly in our Phase III trials right now within alcohol use disorder and those with recurrent major depressive disorder, that weekly dosing could be potentially a really good option for those people,” Nicholson added. “Having that longer half-life is some of the reason why we think there’s a distinct profile for brenipatide relative to currently available incretin therapies.”</p>
<p>The Phase I trial was an investigator- and participant-blind, multiple ascending dose study of brenipatide with an eight-week follow-up period. More than 200 people participated in the trial, a population split into three parts:</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<ul>
<li>Part A: BMIs of 27.0–45.0 kg/m2, randomized 16:2 (96 to brenipatide, 12 to placebo).</li>
<li>Part B: BMIs of 22.0–26.9 kg/m2: randomized 16:2 (64 to brenipatide, 8 to placebo).</li>
<li>Part C: BMIs of 22.0–26.9 kg/m2 in Japanese and Chinese participants, randomized 6:2 (24 to brenipatide, 8 to placebo).</li>
</ul>
<p>Part A participants at the highest 4.5 mg dose showed a mean plasma concentration of the drug of just over 1,000 ng/mL on Day 78, with plasma concentration being dose-dependent—a correlation that was also seen with participants in parts B and C, Lilly said.</p>
<p>The Phase I trial also showed brenipatide to have met the study’s primary outcome measure of positive safety data measured by one or more adverse events, including severe and treatment-emergent, that investigators considered related to the study drug. Researchers reported no deaths or serious adverse events (SAEs), with only four participants (2.2%) discontinuing the study due to a treatment-emergent adverse event (TEAE). Brenipatide was generally well-tolerated across all doses studied in participants with a wide range of BMI and different ethnicities, Lilly said.</p>
<p>The most frequently reported TEAEs were gastrointestinal (GI)-related, with an overall GI TEAE frequency of 25% in both brenipatide- and placebo-treated participants. Dysesthesia-related TEAEs were reported in 15.2% of brenipatide-treated participants, but none on placebo.</p>
<p>The GI tolerability could be related to brenipatide’s low peak-to-trough ratio, which Nicholson said is more narrow than for the other incretin therapies that are currently available.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>MDD, AUD trial designs</strong></h4>
<p>Lilly is building on that early success in part by carrying out a pair of Phase III trials for brenipatide in two indications with large patient populations. During Psych Congress 2026, Lilly presented posters detailing the designs of those two trials—one assessing brenipatide in MDD, the other in alcohol use disorder AUD.</p>
<p>In MDD, Lilly has launched the Phase III RENEW-MDD-1 trial (<a href="https://clinicaltrials.gov/study/NCT07412756">NCT07412756</a>), a multicenter, double-blind, placebo-controlled study evaluating brenipatide plus standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.</p>
<p>The trial is designed to enroll approximately 1,000 participants across 14 countries. The primary endpoint is time to relapse, measured in days from randomization, while the study has numerous secondary endpoints that include MADRS Total Score, PGI-S, GAD-7 Total Score, ReQoL-20 Total Score, patient-rated symptom and disease severity, PROMIS Short Form, SDS global functional impairment score, and body weight (on and not on an atypical antipsychotic).</p>
<p>In AUD, Lilly has launched a pair of 56-week Phase III trials: RENEW-ALC-1, designed to assess brenipatide in participants with moderate-to-severe AUD (<a href="https://clinicaltrials.gov/study/NCT07219966">NCT07219966</a>); and RENEW-ALC-2 (<a href="https://clinicaltrials.gov/study/NCT07219953">NCT07219953</a>), intended to evaluate the safety and effectiveness of brenipatide compared to placebo in people with AUD and hazardous alcohol use. The two trials are designed to enroll 2,200 participants—1,100 each—in eight countries.</p>
<p>Primary outcome for both studies is change in drinking patterns using the Timeline Followback Method (TFBM).</p>
<p></p><h4><strong>Straight to Phase III</strong></h4>

<p>For both MDD and AUD, Lilly advanced brenipatide straight to Phase III, launching the late-stage trials directly following positive Phase I studies, rather than pursuing Phase II studies first, because of the patient populations for both conditions.</p>
<p>In MDD, an estimated <a href="https://www.nimh.nih.gov/health/statistics/major-depression">21 million American adults</a> (about 8.3% of the adult population) had experienced a major depressive episode each year as of 2021, according to data last updated in 2023 by the NIH’s National Institute of Mental Health. Globally, <a href="https://www.who.int/news-room/fact-sheets/detail/depression">approximately 322 million people</a> have MDD, according to a 2023 study cited by the World Health Organization.</p>
<p>As for AUD, <a href="https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics">27.9 million Americans ages 12 and older</a> had an alcohol use disorder in the past year, according to data from the National Survey on Drug Use and Health published in 2025 by the NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA). An estimated <a href="https://www.who.int/news-room/fact-sheets/detail/alcohol">400 million people</a>, or 7% of the world’s population aged 15 years and older, lived with alcohol use disorders, according to WHO data last updated in 2024.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>“When we look at AUD and MDD, both of those have existing needs that when people think about either having different or better therapies, as well as different types of outcomes, those are the needs where we think about the opportunity and why we thought it was worth going straight to Phase III in those conditions,” Nicholson explained.</p>
<p></p><h4><strong>FDA-approved AUD drugs</strong></h4>

<p>According to NIAAA, three drugs are FDA-approved for AUD: Naltrexone, designed to help reduce the urge to drink, available in several branded or generic versions; acamprosate, a pill sold in several generic versions that is designed to decrease the negative symptoms that are sometimes felt during abstinence from alcohol, making abstinence easier to maintain; and disulfiram<strong>, </strong>a pill that discourages drinking by causing unpleasant symptoms when alcohol is consumed, and is also sold in generic versions.</p>
<p>“The current medications themselves that are approved for alcohol use disorder assume abstinence is what you’re either supporting further or driving towards. But for some individuals, that may not be the outcome that they’re thinking about. So from an AUD perspective, having a different or potentially better treatment or treatment or an outcome that we’re aiming for could be important,” Nicholson said.</p>
<p>That explains, he said, why Lilly’s focus in the AUD trials is an overall change in drinking patterns: “It’s something that is a little different from thinking about abstinence being what we’re aiming for, specifically.”</p>
<p>The Phase III trials in AUD and MDD are among 13 Phase II and III studies in progress for brenipatide, Nicholson said. Other potential indications for the drug that are under study include Phase II studies currently going on for two substance abuse indications, tobacco use disorder and opioid use disorder; and two psychiatric indications, bipolar disorder and schizophrenia.</p>
<p>In the immunology space, brenipatide is being evaluated in forms of asthma, irritable bowel syndrome, and chronic obstructive pulmonary disease (COPD).</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/lillys-gip-glp-1-candidate-brenipatide-shows-early-clinical-promise-in-substance-psych-disorders/">Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Palomar Labs Spins Out Ariadne Bio to Advance Non&#45;Hallucinogenic Therapy for Parkinson’s Apathy</title>
<link>https://edusehat.com/en/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic-therapy-for-parkinsons-apathy</link>
<guid>https://edusehat.com/en/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic-therapy-for-parkinsons-apathy</guid>
<description><![CDATA[ Backed by preclinical data and funding from The Michael J. Fox Foundation, Ariadne Bio is advancing AB-300, a serotonin 2A receptor agonist, as a potential treatment for Parkinson’s-related apathy.
The post Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2162090799.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Palomar, Labs, Spins, Out, Ariadne, Bio, Advance, Non-Hallucinogenic, Therapy, for, Parkinson’s, Apathy</media:keywords>
<content:encoded><![CDATA[<p><span>There is considerable room for innovation in neuropsychiatric drug development and Palomar Labs, a venture studio, is hoping to capitalize on that by building companies around drug candidates with prior human validation. As Shlomi Raz, a managing partner at Palomar Labs, explained it, the company’s “mission is to find promising drug candidates with some history of human use” that specifically target “conditions associated with late life.” The goal is to take candidates, which already have some documented evidence of safety and efficacy, through the clinic and through to proof-of-concept.</span></p>
<p><span>And now the venture studio, which was formerly called Negev Labs, has made its first move towards those goals by spinning out its first portfolio company, Ariadne Bio, with a lead program already in hand. Raz steps into the role of CEO for the company and Daniel Jeffries, PhD, a partner at Palomar Labs, will take on the role of chief development officer for the company. Ariadne Bio will focus on developing AB-300, a clinical-stage molecule that functions as a non-hallucinogenic serotonin 2A receptor agonist. The company is developing the molecule to treat apathy in people with Parkinson’s disease.</span></p>
<figure aria-describedby="caption-attachment-338095" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-338095 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/ShlomiRaz_AriadneBio_Portrait_White-248x300.jpg" alt="Shlomi Raz, Founder & Chief Executive Officer, Ariadne Bio " width="248" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/ShlomiRaz_AriadneBio_Portrait_White-248x300.jpg 248w, https://www.genengnews.com/wp-content/uploads/2026/09/ShlomiRaz_AriadneBio_Portrait_White.jpg 331w" sizes="auto, (max-width: 248px) 100vw, 248px"><figcaption class="wp-caption-text">Shlomi Raz, Founder & CEO, Ariadne Bio</figcaption></figure>
<p><span>“A significant portion of people with Parkinson’s will lose the drive to do the things that make life worth living, and not a single approved medicine is designed to bring it back,” Raz said. “We built Ariadne Bio around a single question: whether motivation can be restored pharmacologically. AB-300 is how we intend to answer it.” </span></p>
<p><span>Ariadne Bio makes a compelling case for targeting apathy. As Jeffries notes, “apathy is among the most disabling non-motor features of Parkinson’s disease.” The condition is defined clinically as a persistent reduction in goal-directed behavior. It is estimated to affect approximately 40% of people with Parkinson’s disease over the course of the illness. </span></p>
<p><span>Higher rates of the condition are reported in people in the mid to late stages of the disease. In fact, studies of caregiver burden in Parkinson’s rank neuropsychiatric symptoms like apathy ahead of motor symptoms as drivers of distress. It is important to note here that while apathy and depression have some overlapping features, they are distinct conditions. Selective serotonin reuptake inhibitors (SSRIs) remain the appropriate treatment for Parkinson’s associated depression, but some evidence links their use to emotional blunting and worsening apathy. </span></p>
<p><span>In contrast, there are currently no approved therapies for apathy in any indication. If AB-300 successfully makes its way through clinical trials and clears regulatory approval, it could be one of the first. And Raz and his team are driven to accomplish that goal. In fact, this is the second neuropsychiatry-focused company that Raz is launching. Previously, he founded Eleusis, which claims to be the first company that was dedicated to developing medicines derived from psychedelic compounds. Eleusis was acquired by Beckley Psytech in 2022. That company combined Atai Life Sciences to form AtaiBeckley in 2025. As of July, 2026, Eli Lilly entered into a definitive agreement to acquire AtaiBeckley. </span></p>
<p></p><h4><b>A non-hallucinogenic history</b></h4>

<p><span>Raz moved to Palomar Labs after a stint at Beckley Psytech because of what he saw as a “significant opportunity” with similar themes to psychedelics—drugs with demonstrated therapeutic potential that never translated into U.S. Food and Drug Administration-approved therapies. There are several drugs that could fall into this category but Raz admits he is a bit biased towards serotonin therapies because of his background in psychedelics. “Coming out of the psychedelic space, the way I view it is that the first generation of that drug class were these very potent classical psychedelics like psilocybin and LSD,” he said during the conversation. The second generation featured drugs with formulation changes that altered their pharmacodynamics in different ways. </span></p>
<p><span>Raz and his team are most interested in what he categorized as the third-generation. These are potential therapies that activate the same receptors as psychedelic drugs without the corresponding hallucinogenic effects, making them ideal for use in older adults. AB-300 is one such compound. For some of its back story, the compound is based on one that was previously tested in the 1970s and documented to lack hallucinogenic effects, Jefferies told <em>GEN</em>. Since then, several groups have dug into why this particular molecule does not cause hallucinations like other serotonin agonists. </span></p>
<p><span>Earlier this year, scientists published a paper in January in </span><a href="https://www.nature.com/articles/s41586-025-10061-7" target="_blank" rel="noopener"><i><span>Nature</span></i></a><span> that pointed to signaling bias as the likely reason. “When you activate serotonin 2A, there’s multiple intracellular pathways that can be engaged,” Jeffries said. According to the paper’s findings in a preclinical model, the parent compound that AB-300 is based on “preferentially activated the non-hallucinogenic pathway” without removing any therapeutic benefit.</span></p>
<figure aria-describedby="caption-attachment-338098" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-338098 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/DanielJeffries_AriadneBio_Portrait_White-300x293.jpg" alt="Daniel Jeffries, PhD, Chief Development Officer, Ariadne Bio" width="300" height="293" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/DanielJeffries_AriadneBio_Portrait_White-300x293.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/DanielJeffries_AriadneBio_Portrait_White.jpg 400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Daniel Jeffries, PhD, Chief Development Officer, Ariadne Bio</figcaption></figure>
<p><span>The fact that this compound does not act on dopamine receptors is crucial. “Classically, mental stimulation comes through a variety of drugs that either block the re-uptake of dopamine or activate dopamine receptors directly,” Raz notes. “The problem of course is that they aren’t necessarily well tolerated by older adults. And so we saw the promise of developing a therapy that indirectly modulates motivation through serotonin receptor activation” without the hallucinogenic effects. Apathy in Parkinson’s disease cases is the immediate target but Raz acknowledged that there are other diseases of aging that involve unaddressed apathy. And Ariadne Bio is actively exploring ways to address those conditions in future. “The more research we did, the more we realized how profound the unmet need there was.”</span></p>
<p></p><h4><b>Building up to Phase Ib</b></h4>

<p><span>In May 2026, at the American Society of Clinical Psychopharmacology, (ASCP) Ariadne Bio presented results from tests of its lead candidate in a preclinical model of tetrabenazine (TBZ)-induced motivational deficit, assessed by progressive-ratio lever pressing. In this model of effort-based motivated behavior, AB-300 plus TBZ increased motivational behavior by 89% relative to the TBZ only group, which is a statistically significant improvement.  </span></p>
<p><span>The company claims that AB-300 is the first serotonin 2A receptor agonist drug candidate shown to restore motivated behavior in a dopamine-depleted model. They also claim that in off-target screening, AB-300 shows no measurable activity at dopamine receptors or the dopamine transporter, which indicates that it engages motivational circuitry through a mechanism independent of dopaminergic signaling. </span></p>
<p><span>Raz and Jeffries dug into the details of the study using the tetrabenazine-induced model in more detail during their conversation with </span><i><span>GEN</span></i><span>. “One of the interesting things about developing apathy, is that this indication has an<em> in vivo</em> model that’s arguably more translatable than some of the other more mainstream neuropsychiatric indications,” Jeffries explained. Tetrabenazine is an FDA-approved drug used in Huntington’s disease with detailed data on its ability to induce a low motivational apathetic phenotype in clinical and preclinical models. Part of what makes the drug so interesting is that it depletes the levels of circulating dopamine in the brain, similar to what is seen in Parkinson’s cases. </span></p>
<p><span>That is an important point, Jefferies emphasized. Because “essentially what that allows developers to do is to test their investigative agent in a motivational model with the background of dopamine depletion,” he said. In terms of the results, the team saw positive effects at doses that are predicted to be within a therapeutic range in the clinic. Furthermore,  the team also observed some of the negative effects of using SSRIs to treat apathy in their model. These results mirrored clinical observations of patients, whose apathy was treated with SSRIs and saw their symptoms worsen. These results show the efficacy of AB-300 and “it’s giving us a lot of motivation … to move forward,” he added. </span></p>
<p><span>That next step is a Phase Ib clinical trial that will test AB-300 in healthy volunteers and Parkinson’s patients, most of whom will be receiving the current standard of care treatments and potentially on antidepressants for their apathy. In addition to assessing safety and efficacy of the treatment, Ariadne’s team and their partners will also assess potential interactions between their compound and those other drugs. </span></p>
<p><span>The trial will begin likely at the end of Q3 or the beginning of Q4 at centers in Austria and Israel. Ariadne Bio has already had a Type B pre-IND meeting with the FDA regarding the development of AB-300 for Parkinson’s disease-associated apathy. </span></p>
<p><span>The planned trial will be a three-part study, Jeffries told<em> GEN.</em> The first part will be a single ascending dose in healthy patients followed by a single ascending dose in Parkinson’s disease patients. In both parts, the scientist will explore “a variety of biomarkers [and a] range of doses” to identify the maximally efficacious dose. “We have the preclinical data [that] tells us generally where we should be looking, but we need to really see that in patients who are on Parkinson’s disease medications to confirm that in fact that is the right range for what we anticipate to be a clinically effective dose or at least to evaluate that potential,” Raz added. The third part of the trial will be a 28-day placebo-controlled double-blind of AB-300 against placebo in patients with clinically relevant apathy. </span></p>
<p><span>Ariadne Bio’s launch is backed by funding from Palomar Labs as well as from The Michael J. Fox Foundation through its Parkinson’s disease therapeutics pipeline program. That program supports preclinical and translation research aimed at evaluating promising therapeutic approaches and helping to support their clinical development. While Ariadne officials declined to disclose exactly how much it has received in funding, Raz told </span><i><span>GEN</span></i><span> that the company has enough in house to complete the proposed clinical trial at this time.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/palomar-labs-spins-out-ariadne-bio-to-advance-non-hallucinogenic-therapy-for-parkinsons-apathy/">Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Two&#45;Organ View of the Human Brain Emerges</title>
<link>https://edusehat.com/en/two-organ-view-of-the-human-brain-emerges</link>
<guid>https://edusehat.com/en/two-organ-view-of-the-human-brain-emerges</guid>
<description><![CDATA[ Research suggests that the brain is two distinct organs that evolved independently and comprise two ancient nervous systems packaged together; a hindbrain that regulates essential functions, and a forebrain that handles higher level thinking.
The post Two-Organ View of the Human Brain Emerges appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/robina-weermeijer-3KGF9R_0oHs-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Two-Organ, View, the, Human, Brain, Emerges</media:keywords>
<content:encoded><![CDATA[<p>Scientists have traditionally thought of the brain as a single, unified organ. But new research by Stanford Medicine scientists, working with collaborators California Institute of Technology and the University of California, San Francisco, indicates that what we call the brain is two distinct organs that evolved independently over hundreds of millions of years.</p>
<p>The discovery overturns a prevailing model of brain development, based on the theory that there is a single progenitor cell early in development that gives rise to the entire brain. This model suggested that all parts of the brain shared a common developmental origin. The newly reported findings show that the human brain consists of two ancient nervous systems cleverly packaged together—a more primitive part that regulates the heart beating, our breathing and other functions, and another part that makes us distinctly human, capable of poetry, mathematics and wondering about our own origins.</p>
<p>The results could help explain why scientists have struggled for decades to grow certain types of brain cells in the laboratory—and it opens new avenues for studying devastating diseases that affect the brain stem, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).</p>
<p>“We’ve shown for the first time that the front of the brain arises from a totally different progenitor cell than the back of the brain,” said Kyle Loh, PhD, associate professor of developmental biology. “Our discovery means that we can now grow neurons from the back of the brain, the hindbrain, in a petri dish and study their functions.” Loh is senior author, and Carolyn Dundes, PhD, and Rayyan Jokhai are co-first authors of the scientists’ published paper in <em>Nature Neuroscience</em>, titled “<a href="https://doi.org/10.1038/s41593-026-02433-7" target="_blank" rel="noopener">Two parallel neural ectoderm progenitors contribute to the developing brain</a>,” in which they concluded that “… the emerging notion of two parallel brain progenitors has a number of ramifications for development, differentiation and evolution.”</p>
<p>The adult brain has three main regions: the forebrain, midbrain and hindbrain. The forebrain handles higher-level thinking—language, consciousness and abstract reasoning. In contrast, the hindbrain, located at the back of the skull and often called the brain stem, controls essential, automatic functions that keep us alive: breathing, sleeping, and regulating our heartbeat and hunger urges. “Consequently, hindbrain injury and diffuse intrinsic pontine glioma (a childhood hindbrain cancer) are both deadly, as they impair consciousness, sensation, reflexes and breathing,” the authors wrote. The hindbrain neurons also control the muscles of the face, tongue and throat, which affect speech and swallowing.</p>
<p>Despite the critical importance of the hindbrain, scientists have struggled for decades to generate human hindbrain neurons in the laboratory. This gap has hampered research into devastating diseases affecting the brain stem, including spinal muscular atrophy and amyotrophic lateral sclerosis.</p>
<p>SMA is a leading genetic cause of death in children under one year of age. ALS, which is often diagnosed between the ages of 40 years and 70 years of age, affects both the forebrain and the hindbrain. In both disorders, certain hindbrain neurons gradually cease to function, and the patient loses the ability to swallow, which can cause pneumonia when food or liquid is inhaled into the lungs; eventually, patients lose the ability to breathe. “… degeneration of hindbrain motor neurons probably compromises eating and swallowing in diseases such as spinal muscular atrophy and amyotrophic lateral sclerosis, leading to choking, aspiration, pneumonia and, in some cases, death,” the team continued.</p>
<p>The researchers’ newly reported discoveries emerged from studying the earliest moments of embryonic development, during a stage called gastrulation when the body first takes shape. Jokhai and Dundes discovered that the hindbrain follows a separate developmental path, running in parallel to, rather than branching off from, the pathway that creates the forebrain and midbrain.</p>
<p>The researchers learned this from examining developing mouse embryos. They identified two different brain progenitor cells. “Two parallel brain progenitors emerge simultaneously during gastrulation: anterior neural ectoderm (forebrain/midbrain progenitor) and posterior neural ectoderm (hindbrain progenitor),” they stated. One, which expresses a gene called <em>Otx2</em>, is destined to become the forebrain and midbrain. The other, which expresses a gene called <em>Gbx2</em>, is committed to forming the hindbrain. They showed that these two cell populations never overlap; they are mutually exclusive from the earliest stages of development. “Differentiation of human pluripotent stem cells into anterior or posterior neural ectoderm-like cells revealed these were lineage committed to forebrain/midbrain versus hindbrain fates, respectively.”</p>
<p>The team then examined the DNA packaging, or chromatin, in these cells. Chromatin is a way cells determine which genes can be easily accessed and which are bundled away out of reach. What they found was striking: The anterior neural ectoderm (aNE; future forebrain and midbrain) and posterior neural ectoderm (pNE; future hindbrain) have fundamentally different chromatin configurations. “They harbored diverging chromatin landscapes foreshadowing future forebrain/midbrain versus hindbrain identities,” the team noted. These differences essentially locked each progenitor cell into its respective fate, like travelers on parallel tracks that never cross.</p>
<p>This revelation explained decades of frustration in the field—scientists had been trying to turn one type of progenitor cell into another that it is fundamentally incapable of becoming. “Previous attempts to make hindbrain neurons likely tried to coax forebrain and midbrain progenitors into hindbrain cells, which our study shows is not possible,” Jokhai said. “In stem cell biology, people are always fixated with creating the end cell type, like the neuron. But it’s important to begin at the earliest stages of embryonic development. Our careful attention to that early time point allowed us to find this fundamental split in brain development.”</p>
<p>Armed with this knowledge, the researchers for the first time successfully coaxed human pluripotent stem cells (a kind of cell that can create any cell in the human body) to become functional hindbrain motor neurons in the laboratory.</p>
<p>These lab-grown neurons displayed all the hallmarks of authentic hindbrain cells: They exhibited waves of electrical activity called action potentials and made proteins that identify the segments of the hindbrain that control facial and swallowing muscles. “Discovering this lineage bifurcation provided a roadmap to differentiate hPS cells into pNE and subsequently specific types of hindbrain neuron <em>in vitro</em>, thus enabling future explorations of human hindbrain biology and disease,” the scientists noted.</p>
<p>Finally, the researchers looked back over 550 million years of evolutionary time. They found the same two-origin brain pattern in chickens, zebrafish and, remarkably, in acorn worms, tiny creatures living on the ocean floor that share a distant common ancestor with humans. “Separate anterior and posterior ectoderm populations arise during gastrulation across deuterostome species as diverse as acorn worm, zebrafish, chicken, mouse and primate, implying that this distinction between two different types of ectoderm predates the origins of chordates and arose ~550–600 million years ago,” the team further stated. Jellyfish, which diverged from humans about 600 to 700 million years ago, have two nervous systems at different ends of their body.</p>
<p>“Our research suggests that evolution took two existing neural systems and pushed them together spatially,” Loh said. “Having the brain as one organ would probably be more efficient, but we rely on this primordial way to make the brain as two separate pieces.”</p>
<p>“I was surprised at our findings because the word ‘brain’ implies a contiguous organ that likely has a singular origin,” Jokhai added. “But even 500 million years ago, there were these separate neural systems, which now almost operate as one, which is very cool.”</p>
<p>The research also has implications for investigating treatments for SMA, ALS and other conditions affecting the brain stem. Until now, studying these diseases has been nearly impossible because scientists cannot obtain brain stem tissue from living patients. The ability to grow these neurons in a dish opens new possibilities for understanding what goes wrong. There’s even an unexpected connection to obesity treatment: The hindbrain contains circuits that regulate hunger—which is precisely how weight-loss drugs like semaglutide work.</p>
<p>The researchers would like to extend their studies to determine the developmental origins of the spinal cord and to learn exactly how SMA and ALS compromise the function of hindbrain neurons. “Now we have a model to better understand these devastating diseases, and work toward regenerative therapies for them,” Jokhai said. “This is a very exciting new frontier in brain research.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/two-organ-view-of-the-human-brain-emerges/">Two-Organ View of the Human Brain Emerges</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Saga of Sickle Cell Disease</title>
<link>https://edusehat.com/en/the-saga-of-sickle-cell-disease</link>
<guid>https://edusehat.com/en/the-saga-of-sickle-cell-disease</guid>
<description><![CDATA[ In his new book Curved Air, Kevin Davies, PhD, portrays the fascinating story of sickle cell disease, from its origins in sub-Saharan Africa to advances in gene therapy, along with powerful personal insights from patients, including some who are finally living pain-free.
The post The Saga of Sickle Cell Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Saga, Sickle, Cell, Disease</media:keywords>
<content:encoded><![CDATA[<p>The approval in December 2023 of Casgevy and Lyfgenia marked a major milestone in the treatment of sickle cell disease (SCD). This genetic disease, caused by a recessive point mutation in the gene for beta-globin, was first described in the medical literature in 1910.</p>
<p>This month—appropriately Sickle Cell Awareness month—sees the publication of a new popular science book on SCD, <em>Curved Air</em>, written by Kevin Davies, PhD, and published by Harvard University Press. I sat down with Kevin to ask him about the genesis of the book and the extraordinary story of SCD.</p>
<p>(<em>This interview has been lightly edited for length and clarity</em>.)</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Kevin, how did the idea for <em>Curved Air</em> come about? </strong></p>
<p><strong>Kevin Davies:</strong> My last book, <em>Editing Humanity</em>, which was about the CRISPR revolution, came out six years ago. Whenever I was asked about the most exciting application of gene editing, I would invariably answer: ‘sickle cell.’ That’s because, like many people, I’d been moved to learn about the journey of Victoria Gray, the first SCD patient to undergo CRISPR cell therapy, back in July 2019. She talked openly about her therapy and recovery in a series of interviews on National Public Radio.</p>
<p>I found it ironic that CRISPR—this incredible 21<sup>st</sup> century, Nobel Prize-winning technology for performing DNA surgery—should find its first clinical success treating patients with a disease that, many would argue, has been underfunded and forgotten by large sections of the medical and pharma communities.</p>
<p>I also have to give a shout-out to John Evans, the CEO of Beam Therapeutics. During an interview he gave to <em>GEN</em> about five years ago, John described SCD as ‘the most famous genetic mutation in the world.’ That quote really hit home and gave me added impetus to write the book proposal that became <em>Curved Air</em>.</p>
<p class="trimmed"> </p>
<figure aria-describedby="caption-attachment-338116" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338116" src="https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-201x300.jpg" alt="Curved Air book cover" width="201" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-201x300.jpg 201w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-685x1024.jpg 685w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-768x1148.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-281x420.jpg 281w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-562x840.jpg 562w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover-696x1041.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Curved-Air-cover.jpg 909w" sizes="(max-width: 201px) 100vw, 201px"><figcaption class="wp-caption-text"><i>Curved Air</i>, the latest book from Kevin Davies, PhD. [Harvard University Press]</figcaption></figure>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> I do like the title of the book. Where did it come from?</strong></p>
<p><strong>Davies:</strong> As you probably know John, ‘Curved Air’ was a British progressive rock band in the 1970s. I’m a huge fan of the genre, although not that band specifically. But the phrase seemed to fit perfectly. ‘Curved’ reflects the trademark crescent- or sickle-shaped red blood cells (RBCs) in SCD. And ‘Air’ corresponds to the compromised ability of those sickled RBCs to transport oxygen around the body, hence the anemia. I kept waiting for my editor at Harvard University Press, Rachel Field, to say something, but she was happy to keep the working title.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> When did you first encounter or remember learning about SCD?</strong></p>
<p><strong>Davies:</strong> That’s the thing. It was the first genetic disease I learned about in school in the U.K. some half a century ago! I remember sketching the healthy and diseased RBCs and learning about the sort of superpower that carriers of the sickle cell gene have against malaria. So many milestones in molecular biology revolve around the study of hemoglobin and SCD. Linus Pauling, PhD, dubbed sickle cell ‘the first molecular disease’ back in 1949. And yet, prior to the advent of CRISPR, the only effective therapy had been hydroxyurea, a generic chemotherapy drug. This community—an estimated 100,000 patients in the United States—has been waiting an eternity for something to get excited about.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> You mentioned Victoria Gray. Is she a big part of the book? What makes her story so compelling?</strong></p>
<p><strong>Davies:</strong> Oh yes, absolutely! She was a guest on one of <a href="https://www.genengnews.com/multimedia/summits/the-state-of-cell-and-gene-therapy-2024/"><em>GEN</em>’s virtual summits a few years ago</a>. I met her in person a few months later and she invited me down to her home in Mississippi for an in-depth interview. We did that in her local church, which was special because I know how important her faith is. She opened up about the many episodes of discrimination that she experienced, something that is all too prevalent in the way people with SCD—almost exclusively persons of color—are treated in the medical system on both sides of the Atlantic.</p>
<figure aria-describedby="caption-attachment-338118" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338118" src="https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-300x225.jpeg" alt="Victoria Gray" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-300x225.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1024x768.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-768x576.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1536x1152.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-560x420.jpeg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1120x840.jpeg 1120w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-80x60.jpeg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-160x120.jpeg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-696x522.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1392x1044.jpeg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1068x801.jpeg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-1920x1440.jpeg 1920w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-265x198.jpeg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church-530x396.jpeg 530w, https://www.genengnews.com/wp-content/uploads/2026/09/Victoria-Gray-church.jpeg 2048w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Victoria Gray, photographed in her local church in Forest, MS. [Kevin Davies]</figcaption></figure>
<p>Victoria deserves all her flowers. By going public with her story, she literally inspired other warriors to enroll in the CRISPR trial (sponsored by Vertex). I’m thrilled that she’s healthy and serving now as a patient advocate to raise awareness and help educate others with the disease. I also interviewed many other warriors in the book. I really hope readers will enjoy meeting LaRae, Danielle, Kwanzaa, Ray’Neshia, Jimi, and others. Every person’s story is unique and special in its own right.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Much of your book is spent detailing the story behind Casgevy. What was notable about that work?</strong></p>
<p><strong>Davies:</strong> Casgevy works not by fixing the SCD mutation directly but via a clever workaround: boosting the levels of fetal hemoglobin (HbF) to compensate for the inherited mutation in adult hemoglobin. The first inkling of that strategy dates back to 1948 and the clinical observations of a New York pediatrician named Janet Watson. Two decades ago, researchers made the key discovery that variants in a transcription factor called <em>BCL11A</em> influence HbF levels. It is great to see the scientists behind that fundamental discovery—Swee-Lay Thein, MD (NIH) and Stuart Orkin, MD (Harvard Medical School)—belatedly receive recognition in the form of the 2026 Breakthrough Prize.</p>
<p>I talk about the work at CRISPR Therapeutics and Vertex that led to the commercial approval of Casgevy. It’s impressive that Vertex has also driven the discovery of life-changing small-molecule drugs for cystic fibrosis, another classic genetic disease that also rose in frequency because carriers had a selective advantage, most likely against an infectious disease.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Many GEN readers will be broadly familiar with the story of SCD. Did you discover anything new or surprising in your research?</strong></p>
<figure aria-describedby="caption-attachment-338121" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338121" src="https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-300x225.jpg" alt="Catoctin Furnace" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1120x840.jpg 1120w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1392x1044.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-1068x801.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin-530x396.jpg 530w, https://www.genengnews.com/wp-content/uploads/2026/09/KevinDavies_Catoctin.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Catoctin Furnace (Catoctin, MD), where DNA evidence points to the presence of sickle cell amongst enslaved people in the early 1800s. [Kevin Davies]</figcaption></figure>
<p><strong>Davies:</strong> Hopefully a few surprises, yes! One is in regard to the first documented case in the United States—Walter Clement Noel, a dental student from Grenada, who was treated in Chicago in 1904. It was his case that was first documented in a medical journal in 1910. But obviously there were thousands of patients with SCD who reached the Americas during the Middle Passage. I spoke to a researcher at 23andMe who was an author on a major paper in <em>Science</em> two years ago analyzing the remains of some 30 enslaved African Americans at the Catoctin Furnace, an iron foundry in northern Maryland. She told me that forensic DNA sequencing revealed that three children buried there, dating back to the early 1800s, carried the SCD mutation.</p>
<p>I also interviewed the first patient to be cured of SCD via gene therapy more than a decade ago, a young Frenchman named Leeroy Tegar. Initially, his physician, Marina Cavazzana, MD, in Paris, didn’t think he’d want to talk to a journalist. But he did, with a big assist from Google Translate and Rodolphe Barrangou, PhD, the editor of <em>The CRISPR Journal</em>, who is French.</p>
<p class="trimmed"> </p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> You also visited the site of Walter Noel’s grave in Grenada?</strong></p>
<p><strong>Davies:</strong> After dental school, Walter returned to his home on the Caribbean island of Grenada in 1907 and set up his own practice, only to die in 1916. His identity was uncovered decades after the famous 1910 medical journal paper by Todd Savitt, PhD, a retired history professor. A few years ago, I felt compelled to follow in Savitt’s footsteps, hiring a driver to take me from the capital of Grenada to Sauteurs, a town on the north coast of the island, where Noel is buried in a Catholic cemetery.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> Despite the excitement over CRISPR and gene therapy, you depict a much darker side of sickle cell care. Tell me about Brittany Hightower.</strong></p>
<p><strong>Davies:</strong> Early on in my reporting, I watched some videos that had been live-streamed by Brittany Hightower, a 30-something sickle cell warrior in Texas. Brittany documented some distressing scenes at a major Dallas hospital, staff not wanting to care for her. In one viral video, two security guards informed her that she was being kicked out of the hospital—in the middle of a pain crisis. She died of pneumonia a couple of years ago.</p>
<p>I tracked down Brittany’s best friend and fellow sickle cell warrior, Kwanzaa, who ironically had taken part in the Lyfgenia gene therapy trial at NIH. Kwanzaa graciously shared Brittany’s final texts to her, sent just days before she died. I included them in the book as a poignant reminder that medical progress is one thing, but we can do so much better in educating medical professionals about this disease.</p>
<p class="trimmed"> </p>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> What impact will Casgevy and Lyfgenia have on sickle cell treatments in the long run?</strong></p>
<p><strong>Davies:</strong> We have to keep these launches in perspective. The experiences of the first cohort of patients taking these therapies have been amazing—almost all report no pain crises or hospitalizations or even the need for blood transfusions. Those that do typically had too much vascular damage before they received therapy. As Haydar Frangoul, MD, the physician who treated Victoria, says: ‘I can take the hammer away, but I can’t fix the wall.’</p>
<p>Remember this is <em>ex vivo </em>therapy, requiring months in hospital and a brutal chemotherapy regimen prior to therapy. The dream is to develop a much less complex <em>in vivo </em>gene therapy. Of course, even that will be of limited benefit to the millions of SCD patients across Africa, India and other parts of the world. I am optimistic that eventually scientists will develop a small molecule drug that can mimic the effects of Casgevy. Wouldn’t that be something?</p>
<p class="trimmed"> </p>
<figure aria-describedby="caption-attachment-338119" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-338119" src="https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-241x300.jpeg" alt="Casgevy display" width="241" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-241x300.jpeg 241w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-822x1024.jpeg 822w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-768x956.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-1234x1536.jpeg 1234w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-337x420.jpeg 337w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-675x840.jpeg 675w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-696x867.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-1392x1733.jpeg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex-1068x1330.jpeg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Casgevy-Vertex.jpeg 1501w" sizes="auto, (max-width: 241px) 100vw, 241px"><figcaption class="wp-caption-text">Display at Vertex facility in Boston marking FDA approval of Casgevy in 2023. [Kevin Davies]</figcaption></figure>
<p><span><strong><em>GEN</em></strong></span><strong><span>:</span> The elephant in the room of course is that Casgevy costs $2.2 million, and Lyfgenia more than $3 million. What happens to patients who really need it but cannot afford the therapy? </strong></p>
<p><strong>Davies:</strong> True, the costs are very high, but that doesn’t appear to be the big stumbling block. Most private insurance companies and a majority of states in the U.S. are covering these therapies. $2–3 million in a one-time therapy is still good value compared to the costs of treating patients for recurring pain crises and organ failure over decades. The manufacturing process is also improving, which is helping to shorten the treatment timeline.</p>
<p class="trimmed"> </p>
<p><strong><span><em>GEN</em>:</span> Thanks for speaking with me and congratulations, Kevin. Best of luck with the book!</strong></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/the-saga-of-sickle-cell-disease/">The Saga of Sickle Cell Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Model&#45;Free, Pure Component Analysis Could Help Biopharma Cut Costs</title>
<link>https://edusehat.com/en/model-free-pure-component-analysis-could-help-biopharma-cut-costs</link>
<guid>https://edusehat.com/en/model-free-pure-component-analysis-could-help-biopharma-cut-costs</guid>
<description><![CDATA[ Spectroscopic analysis techniques rely on empirical models that are time consuming and expensive to make. Biopharma companies could speed development and reduce costs using a model-free measuring approach called pure-component analysis, says Nirrin Technologies.
The post Model-Free, Pure Component Analysis Could Help Biopharma Cut Costs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1356760192.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Model-Free, Pure, Component, Analysis, Could, Help, Biopharma, Cut, Costs</media:keywords>
<content:encoded><![CDATA[<p>Spectroscopy can be used to analyze process streams for proteins and analytes of interest in real-time. The problem is that many spectroscopic techniques, including NIR and Raman, rely on models to separate signals from background noise.</p>
<p>Developing these models takes time and money, according to Nirrin Technologies CEO, Bryan Hassell, who told <em>GEN</em>, “They are built empirically, from large, designed experiments that span every condition the method will ever encounter. They are expensive to build, tied to the process and instrument they were built on, and to be rebuilt when the process, scale, or instrument changes.”</p>
<p></p><h4><strong>Pure component analysis</strong></h4>

<p>An alternative is the model-free approach “pure-component analysis,” continued Hassell. “In PCA each component has a known spectrum, and the measured spectrum is resolved into the concentrations of those components directly. There is no empirical model to develop and no DOE campaign behind it. A method built in development runs the same way in manufacturing, and on a different system at a different site.”</p>
<p>Hassell pointed to Nirrin’s new tunable laser near-infrared (TL-NIR) platform, which will be showcased at the Bioprocess International (BPI) East conference in Boston. to illustrate the potential benefits of pure-component analysis.</p>
<p>“It is a near-infrared measurement platform built around a tunable laser instead of a broadband lamp. The laser puts far more optical power into each individual wavelength, which gives a much higher signal-to-noise ratio than conventional NIR,” he explained. “Spectroscopic methods return spectra that must be interpreted through a model before anyone can act on them. TL-NIR returns concentrations. That is the number an engineer already makes decisions on, available in seconds or continuously, rather than a signal that needs deciphering first.”</p>
<p>But eliminating models is just one of the potential benefits, according to Hassell, who said “For protein analysis, a TL-NIR measurement is five times faster than variable-pathlength UV, and requires no dilution, no sample prep and no pathlength adjustment. The larger savings are upstream of that. Companies avoid the model-building campaigns that Raman and broadband NIR methods require, and they can bring in-house measurements that are currently sent out to HPLC, which removes both the cost per sample and the days of waiting for results.”</p>
<p>At present, five to 10 “top biopharmaceutical companies” use TL-NIR systems in process development, pointed out Hassell, and said the plan now is to raise awareness about the potential benefits of using the technology in commercial production.</p>
<p>“We are at the beginning of bringing this into manufacturing environments. These processes have been in place for a long time, and the industry will not convert to data-driven manufacturing overnight. We start in process development, where the technology is proven and validated and where transferability is demonstrated, and we are now working with key customers on manufacturing deployment from there.”</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/model-free-pure-component-analysis-could-help-biopharma-cut-costs/">Model-Free, Pure Component Analysis Could Help Biopharma Cut Costs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Nu&#45;Tek Brings Topic of Raw&#45;Material Risk to BPI</title>
<link>https://edusehat.com/en/nu-tek-brings-topic-of-raw-material-risk-to-bpi</link>
<guid>https://edusehat.com/en/nu-tek-brings-topic-of-raw-material-risk-to-bpi</guid>
<description><![CDATA[ Nu-Tek BioSciences will use BPI East to highlight animal-origin-free peptones and hydrolysates designed to strengthen media consistency, reduce raw-material risk, and support more reliable cell culture and fermentation processes for biologics manufacturers.
The post Nu-Tek Brings Topic of Raw-Material Risk to BPI appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Nu-Tek-BPI_GBPN_IMAGE.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Nu-Tek, Brings, Topic, Raw-Material, Risk, BPI</media:keywords>
<content:encoded><![CDATA[<p>As biopharmaceutical manufacturers push for tighter process control and more resilient supply chains, raw materials used in cell-culture media are receiving closer scrutiny. Nu-Tek BioSciences is bringing that conversation to BioProcess International East (BPI East) in Boston, where the company will highlight its portfolio of 100% animal-origin-free peptones and protein hydrolysates.</p>
<p>The Minnetonka, MN-based supplier says its plant- and yeast-derived nutrients are intended for cell culture and microbial fermentation applications supporting vaccines, therapeutics, and other biologics. At BPI East, Nu-Tek will focus discussions with pharmaceutical leaders on product performance, media consistency, supply continuity, and the qualification of critical raw materials.</p>
<p>That emphasis reflects a broader challenge in bioprocessing: seemingly upstream choices in media composition can influence process robustness much later in manufacturing. Variability in complex raw materials can complicate process development and scale-up, while supply disruptions can force manufacturers to evaluate alternative sources or requalify components.</p>
<p>According to Joy Aho, PhD, Nu-Tek’s director of technical program management, “Bioprocessing relies on the control of critical raw materials from start to finish.” She added that the company’s products are designed to provide “quality, control, and customization options” for customers seeking to improve production performance while reducing risk.</p>
<p>Animal-origin-free materials can also help manufacturers simplify sourcing strategies where animal-derived components might create additional regulatory, traceability, or contamination concerns. Nu-Tek positions its peptones and hydrolysates as tools for reducing those risks without giving up the nutrient complexity often needed in demanding culture and fermentation systems.</p>
<p>During the meeting, Nu-Tek also plans to discuss its variability reduction program with teams looking to improve media consistency. The company also operates a purpose-built manufacturing facility dedicated to animal-origin-free peptones and protein hydrolysates.</p>
<p>For Nu-Tek, BPI East is less about introducing a single new product than about making the case that raw-material strategy has become a competitive part of bioprocess design. As biologics manufacturing grows more complex, suppliers are increasingly being asked to deliver not only performance, but also consistency, traceability, and dependable access.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/nu-tek-brings-topic-of-raw-material-risk-to-bpi/">Nu-Tek Brings Topic of Raw-Material Risk to BPI</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GBI Biomanufacturing Set to Launch SmartScale GMP Solutions</title>
<link>https://edusehat.com/en/gbi-biomanufacturing-set-to-launch-smartscale-gmp-solutions</link>
<guid>https://edusehat.com/en/gbi-biomanufacturing-set-to-launch-smartscale-gmp-solutions</guid>
<description><![CDATA[ Many early-stage drug developers need a more efficient path to obtaining the GMP material required to reach the clinic. SmartScale was designed to help close that gap.
The post GBI Biomanufacturing Set to Launch SmartScale GMP Solutions appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-936335404.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GBI, Biomanufacturing, Set, Launch, SmartScale, GMP, Solutions</media:keywords>
<content:encoded><![CDATA[<p>CDMO GBI Biomanufacturing will announce the launch of its new SmartScale<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> GMP Solutions platform at BioProcess International (BPI) East 2026. SmartScale is an accelerated, small-scale cGMP manufacturing platform designed to help early-stage biologics developers generate GMP material for first-in-human studies faster and more efficiently, according to Jesse McCool, PhD, CEO.</p>
<p>The platform combines technologies from industry partners ATUM and Thomson Instrument to streamline cell line development, process scaleup, and manufacturing, he added.</p>
<p>“When developing life-saving therapies, speed and simplicity can make a significant difference,” continued McCool. “Many early-stage drug developers need a more efficient path to obtaining the GMP material required to reach the clinic. SmartScale was designed to help close that gap by providing a right-sized manufacturing approach that accelerates the journey to first-in-human studies.”</p>
<p>Developers increasingly seek approaches that enable earlier clinical evaluation of promising candidates while reducing development risk, timelines, and capital requirements.</p>
<p>“SmartScale is a stable pool-based manufacturing platform that can deliver GMP material for first-in-human studies in as little as eight months,” McCool said. “Our goal is to help customers reach the critical milestone of generating human clinical data that supports future regulatory and commercial decisions.”</p>
<p>GBI noted that the platform aligns with the FDA’s Operation TrialBlazer initiative, which seeks to accelerate the development of innovative therapies and modernize drug development pathways.</p>
<p>GBI partnered with ATUM to integrate ATUM’s Leap-In Transposase<sup class="wp-sup-text">®</sup> cell lines into its SmartScale platform, aimed at maximizing drug substance yield at smaller scales. ATUM brings cell line expertise, having enabled over 60 INDs across multiple therapeutic areas.</p>
<p>“The Optimum Growth<sup>®</sup> Flask was designed to simplify scaleup while maintaining high-performance cell culture conditions,” said Sam Ellis, CEO of Thomson Instrument, about his company’s other contribution to the collaboration. “As part of the SmartScale platform, our technology helps streamline the transition from research and development into GMP manufacturing.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/gbi-biomanufacturing-set-to-launch-smartscale-gmp-solutions/">GBI Biomanufacturing Set to Launch SmartScale GMP Solutions</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Asahi Kasei Introduces VANTIJ® SU&#45;VFC Benchtop Virus&#45;Filtration System</title>
<link>https://edusehat.com/en/asahi-kasei-introduces-vantij-su-vfc-benchtop-virus-filtration-system</link>
<guid>https://edusehat.com/en/asahi-kasei-introduces-vantij-su-vfc-benchtop-virus-filtration-system</guid>
<description><![CDATA[ The instrument, the first benchtop-scale platform in Asahi Kasei Bioprocess’s VANTIJ family, extends the automation and operator-focused design principles of the existing portfolio while simplifying virus filtration processes.
The post Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop Virus-Filtration System appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2196602690.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Asahi, Kasei, Introduces, VANTIJ®, SU-VFC, Benchtop, Virus-Filtration, System</media:keywords>
<content:encoded><![CDATA[<p>Asahi Kasei Bioprocess will unveil its VANTIJ<sup class="wp-sup-text">®</sup> SU-VFC benchtop at Bioprocess International (BPI) East in Boston this week. This new small-format system is designed to deliver automated, single-use virus filtration for laboratory-scale and process development applications. The system will be available on site at Booth 606.</p>
<p>The instrument is the first benchtop-scale platform in Asahi Kasei Bioprocess’s <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffluidmgmt.ak-bio.com%2Fproducts%2Fbioprocess-filtration%2Fvirus-filtration-system%2F&esheet=54603648&newsitemid=20260915583092&lan=en-US&anchor=VANTIJ%26%23174%3B+family&index=1&md5=10f9fd865371147b2b354446b44fea72" target="_blank" rel="noopener">VANTIJ family</a>. The system extends the automation and operator-focused design principles of the existing portfolio while simplifying virus filtration processes, according to the company.</p>
<p>Its design accommodates workflows using 0.12 m² or 0.3 m² <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fplanova.ak-bio.com%2Fproducts%2Fplanova-n%2F&esheet=54603648&newsitemid=20260915583092&lan=en-US&anchor=Planova%26%238482%3B+35N+virus-removal+filters&index=2&md5=47eadeec440d90c659459ff059536855" target="_blank" rel="noopener">Planova<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> 35N virus-removal filters</a>. The VANTIJ simplifies small-scale Planova virus filtration while maintaining the process control and data-focused capabilities expected in biopharmaceutical development, explains an Asahi spokesperson.</p>
<p>Initially designed for gene therapy manufacturing, the new benchtop helps address the operational complexities associated with long production timelines, regulatory requirements, operator training, and therapy-specific needs, continues the company official, who adds that the system offers clear setup through a guided shadow-board layout, tool-free tube set installation and replacement, intuitive connection points, and recipe-driven software. It also enables batch reporting and supports the execution of key filtration processes.</p>
<p>“The biopharmaceutical industry continues to pursue more efficient pathways for bringing innovative therapies to patients,” said Chris Rombach, president of Asahi Kasei Bioprocess America. “The VANTIJ SU-VFC Benchtop reflects Asahi Kasei Bioprocess’s commitment to supporting manufacturers with solutions that simplify critical process steps.”</p>
<p><figure aria-describedby="caption-attachment-338074" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-338074" src="https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ%C2%AE_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess-300x169.jpg" alt="VANTIJ® SU-VFC benchtop" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ®_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ®_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess-696x392.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/The_VANTIJ®_SU-VFC_Benchtop_by_Asahi_Kasei_Bioprocess.jpg 711w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">VANTIJ<sup class="wp-sup-text">®</sup> SU-VFC benchtop [Asahi Kasei]</figcaption></figure>Rombach explains that the fluid management business unit of Asahi Kasei Bioprocess focuses on solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, the company’s  bioprocessing systems, columns, and automation solutions advance GMP manufacturing of critical drug substances around the world, he continued.</p>
<p>BPI East attendees can visit Booth 606 in Boston from September 22<sup class="wp-sup-text">nd</sup> to 25<sup class="wp-sup-text">th</sup>.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/asahi-kasei-introduces-vantij-su-vfc-benchtop-virus-filtration-system/">Asahi Kasei Introduces VANTIJ<sup>®</sup> SU-VFC Benchtop Virus-Filtration System</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Time&#45;Restricted Eating Linked to Improved Huntington’s Disease Markers</title>
<link>https://edusehat.com/en/time-restricted-eating-linked-to-improved-huntingtons-disease-markers</link>
<guid>https://edusehat.com/en/time-restricted-eating-linked-to-improved-huntingtons-disease-markers</guid>
<description><![CDATA[ A 12-week pilot study found time-restricted eating was safe and feasible for people with early Huntington’s disease, with improvements in disease severity, neurofilament light, and mitochondrial function.
The post Time-Restricted Eating Linked to Improved Huntington’s Disease Markers appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2266283707.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 19 Sep 2026 06:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Time-Restricted, Eating, Linked, Improved, Huntington’s, Disease, Markers</media:keywords>
<content:encoded><![CDATA[<div>
<p>The first clinical study to understand the potential effects of time-restricted eating in people with Huntington’s disease finds that time-restricted eating is feasible, safe, and linked to improvements in disease markers.</p>
</div>
<div>
<p>In a 12-week pilot study, researchers found that people with early-stage Huntington’s Disease were able to safely follow a form of intermittent fasting known as time-restricted eating—limiting food consumption to a six-to-eight-hour window each day. Participants avoided unintended weight loss and showed improvements in measures of disease severity; in a blood biomarker linked to nerve cell damage; and in cellular energy production.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
</div>
<div>
<p>The findings are published today in<span class="apple-converted-space"> </span><em>Nature Metabolism</em>, in the paper “<a href="https://www.nature.com/articles/s42255-026-01612-x" target="_blank" rel="noopener">Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study.</a>”</p>
</div>
<div>
<p>“This is the first time this approach has been formally studied in people with Huntington’s disease,” said<span class="apple-converted-space"> </span>Russell Wells, a medical student at Oregon Health & Science University. “We found that participants were able to follow the eating schedule, maintain their weight and show encouraging improvements in clinical and biological measures that are important in Huntington’s disease. These results suggest time-restricted eating deserves further study in a larger clinical trial.”</p>
</div>
<div>
<p>Huntington’s disease is a rare, inherited neurological disease that gradually damages nerve cells responsible for movement, cognitive and emotional regulation. Although researchers have known the genetic cause of the disease for decades, no treatments have been approved that slow or stop its progression.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
</div>
<div>
<p>Prior research in animal models suggests that intermittent fasting can activate cellular pathways that help protect brain cells. Yet researchers were unsure whether the approach would be safe for people with Huntington’s disease because unintended weight loss is already a concern.</p>
</div>
<div>
<p>“When Russell first brought me the idea, I was skeptical,” notes Amie Hiller, MD, professor of neurology in the OHSU School of Medicine and director of the Portland Veteran’s Administration Northwest Parkinson’s Disease Research, Education and Clinical Center. “Weight loss is a major challenge for many people with Huntington’s disease, so asking them to eat within a limited time window seemed counterintuitive.</p>
</div>
<div>
<p>“What was exciting about this study is that participants were able to maintain their weight while showing signs that the intervention may be positively affecting the disease itself,” Hiller notes.</p>
</div>
<div>
<p>The 20 participants selected an eating window that fit their daily routine, typically between late morning and early evening, and followed it for 12 weeks. Researchers encouraged participants to maintain their normal calorie intake and monitored weight and safety throughout the study.</p>
</div>
<div>
<p>The approach appeared well-tolerated. Participants followed the eating schedule on average more than five days per week; reported few side effects; and maintained both body weight and lean muscle mass. Most adapted to the schedule within the first one to two weeks. Participants used a smartphone app to document their first meal of the day with a photo and timestamp.</p>
</div>
<div>
<p>Participants experienced an average improvement of 0.5 points on a widely used Huntington’s disease severity scale known as the composite Unified Huntington’s Disease Rating Scale (cUHDRS). The score typically declines by about one point annually in people with early-stage disease.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
</div>
<div>
<p>In addition, blood levels of neurofilament light, a biomarker released when nerve cells are damaged, fell by an average of 13%. In Huntington’s disease, those levels usually increase over time as the disease progresses.</p>
</div>
<div>
<p>“We saw a reversal of the trend we would normally expect,” Wells said. “Neurofilament light typically rises as neurodegeneration continues, but after three months we observed a significant decrease. For a pilot study, that was a remarkable finding.”</p>
</div>
<div>
<p>The research team also examined mitochondrial function in participants’ blood cells and found improvements in several measures of mitochondrial activity after the intervention.</p>
</div>
<div>
<p>“One theory is that fasting acts as a mild stressor that prompts cells to become more efficient,” Wells said. “If cells, including brain cells, become better at producing energy and handling stress, they may be more resilient to the disease process.”</p>
</div>
<div>
<p>Because the study was small and did not include a comparison group, researchers caution that the findings should not be considered proof that time-restricted eating slows Huntington’s disease. Larger, randomized controlled trials will be needed to determine whether the benefits are real and sustained over time.</p>
</div>
<div>
<p>Still, researchers say the results are especially promising because the intervention is relatively simple and could be accessible to many people as there are no disease-modifying treatments for Huntington’s disease currently available. The team is currently pursuing funding for a larger, randomized clinical trial that would compare time-restricted eating with standard dietary habits.</p>
</div>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/time-restricted-eating-linked-to-improved-huntingtons-disease-markers/">Time-Restricted Eating Linked to Improved Huntington’s Disease Markers</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The specter of AI&#45;enabled bioweapons is a wake&#45;up call for biotech</title>
<link>https://edusehat.com/en/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech</link>
<guid>https://edusehat.com/en/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech</guid>
<description><![CDATA[ In recent weeks, leaders of some of the biggest AI companies have warned that the very tech they are developing is dangerous. Last weekend, Anthropic CEO Dario Amodei argued that AI carries serious risk and that progress should be slowed. OpenAI CEO Sam Altman responded on X: “I agree with Dario that we need to pace the… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/260915_TheCheckup.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 23:05:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, specter, AI-enabled, bioweapons, wake-up, call, for, biotech</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul>
<li><strong>AI could make bioweapons disturbingly easy to build:</strong> In 2022, researchers accidentally generated 40,000 potential chemical warfare agents in under six hours using a drug-discovery AI — some more toxic than known nerve agents.</li>
<li><strong>Existing safeguards have real limits:</strong> Anthropic recently confirmed users had tried exploiting its models to make viruses more transmissible and dangerous, highlighting an ongoing cat-and-mouse game between protections and workarounds.</li>
<li><strong>Scientists disagree on how worried to be:</strong> Some biologists argue AI tools aren't yet capable enough to fully develop bioweapons, while others warn that a determined actor would "eventually succeed" — and urge preparing now.</li>
</ul>" data-chronoton-post-id="1144329" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>In recent weeks, leaders of some of the biggest AI companies have warned that the very tech they are developing is dangerous. Last weekend, Anthropic CEO Dario Amodei argued that AI <a href="https://darioamodei.com/post/we-must-pace-the-frontier">carries serious risk</a> and that progress should be slowed. OpenAI CEO Sam Altman <a href="https://x.com/sama/status/2098811563415150910">responded on X</a>: “I agree with Dario that we need to pace the frontier.”</p>



<p>Those posts came a few days after the AI researcher Jacob Coxon announced that he was leaving a role at Anthropic, charging that neither it nor OpenAI (where he had also worked) was acting responsibly. “The people building AI earnestly believe that it could kill us all by the end of the decade,” <a href="https://x.com/hilbertspaess/status/2097476203863224394">he posted on X</a>. Another Anthropic employee, Evan Hubinger, publicly agreed with him. “We really do earnestly believe AI could kill all humans!” <a href="https://x.com/EvanHub/status/2097497037956891126?s=20">he responded on X</a>. “I personally think it is >10% within the next decade.”</p>





<p>One of the ways they fear AI might end us all is by somehow aiding the design, creation, and release of some kind of bioweapon. Let’s take a closer look at why.</p>



<p>A bioweapon might be a highly lethal virus that targets people according to their genes. It could be a fungus that wipes out a crop and causes food insecurity. Perhaps it would be a tasteless, odorless toxin that could be slipped into a region’s water supply, undetected.</p>



<p>The concern is that AI tools can be used to help generate agents like these. In 2022, researchers at Collaborations Pharmaceuticals found that it was remarkably easy to do so using an AI “molecule generator” they’d developed to find potential drugs for human disease. In less than six hours, the model generated <em>40,000 molecules</em> with the potential to serve as chemical warfare agents. Some of them were designed to be even more toxic than known nerve agents. “Without being overly alarmist, this should serve as a wake-up call for our colleagues in the ‘AI in drug discovery’ community,” the authors <a href="https://www.nature.com/articles/s42256-022-00465-9">wrote at the time</a>.</p>



<p>It <em>was</em> a wake-up call for David Magnus, a professor of medicine and biomedical ethics at Stanford University, even though he had been assessing the risks associated with the misuse of medical science and biotechnology since the late 1990s. “That was very scary to me,” he says. “Of course, everything since then has just sort of blown up.”</p>



<p>Today, AI bots can answer questions on topics spanning all realms of science. Anyone can use large language models trained on the knowledge and experience of “almost every scientist who ever lived on this planet,” says Dunja Sabra, a biosecurity researcher at the University of Hamburg in Germany. Those models can provide instructions and video training on how to conduct experiments.</p>



<p>Combine that with advances in biotech that have made gene editing and synthetic biology tools much more accessible (the <a href="https://www.technologyreview.com/2012/02/14/187917/doing-biotech-in-my-bedroom/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-17-26">“DIY biology” movement</a> has already enabled many people to set up labs at home), and you’ve got a potentially very dangerous situation. “The chances are that someone determined would succeed eventually,” Sabra says.</p>



<p>There are safeguards in place. People who want to build new genomes <a href="https://www.technologyreview.com/2025/10/02/1124767/microsoft-says-ai-can-create-zero-day-threats-in-biology/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-17-26">must typically order the pieces of DNA from companies that screen for suspicious requests</a>. Responsible researchers put potentially risky research through rounds of analysis called “red-teaming,” in which independent scientists look for ways the work might be misused, and “blue-teaming,” where others come up with potential mitigations. And AI companies have tweaked their tools in attempts to prevent them from offering up scientific information that could be misused. But none of these protections are ironclad.</p>





<p>In <a href="https://www-cdn.anthropic.com/e50be2e51e7695dc4b1366a37a245a597377d3b5/Anthropic-Detecting-and-countering-091026.pdf">a report</a> published last week, Anthropic acknowledged that people had attempted to use its models to explore ways to make the chikungunya virus more transmissible, create a form of bird flu that is more dangerous to humans, and build an “atlas of venom toxin peptides,” among other things.</p>



<p>“We’ve got a constant back and forth,” says Magnus. “We have to build better surveillance and screening tools, [but] AI is really good at figuring out ways around them.” We’ll probably need to use AI to find ways to restrict the use of AI, he says.</p>



<p>I should add here that not all scientists agree on the level of risk. At a recent media briefing, some biologists at Imperial College London argued that AI tools just aren’t good enough to fully develop bioweapons, and that testing new pathogens requires difficult, time-consuming, human work. Some think the guardrails we have in place are sufficient.</p>



<p>And Wendy Barclay, a professor of infectious disease at Imperial, pointed out that, as things stand, the greatest risk of a pandemic isn’t from a bioweapon, but from pathogens that are already circulating. Take H5N1, <a href="https://www.technologyreview.com/2024/11/29/1107552/risk-of-bird-flu-pandemic-rising/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=09-17-26">the bird flu virus</a> that has already killed millions of birds and spread widely through US dairy cattle; last month it was also <a href="https://www.aphis.usda.gov/livestock-poultry-disease/avian/avian-influenza/hpai-detections/mammals?page=1">detected in captive mink</a> at a farm in Utah.</p>



<p>Sabra, on the other hand, likes to think five to 10 years ahead. Countries should be strengthening their health-care systems, preparing antidotes to known toxins, and stockpiling medicines, she says: “We need to be prepared.”</p>



<p>Kevin Esvelt, an MIT biologist who invented both technology to fast-track the propagation of a genetic feature through an entire population <em>and </em>ways to limit that technology, echoed these concerns in an <a href="https://x.com/kesvelt/status/2100238200207716488">X post</a> on Wednesday, stating that a large language model had “disclosed a novel form of bioweapon that I hadn’t realized was possible.”</p>



<p>He added, “Please, for the love of God, children, the future of humanity, or whatever you consider holy, let’s err on the side of caution here.”</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>A national security priority: BIO pushes PAHPA reauthorization in 2026</title>
<link>https://edusehat.com/en/a-national-security-priority-bio-pushes-pahpa-reauthorization-in-2026</link>
<guid>https://edusehat.com/en/a-national-security-priority-bio-pushes-pahpa-reauthorization-in-2026</guid>
<description><![CDATA[ For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters, […]
The post A national security priority: BIO pushes PAHPA reauthorization in 2026 appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/navy-medicine-jhgw6bsaou8-unsplash-e1789724773236.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 19:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>national, security, priority:, BIO, pushes, PAHPA, reauthorization, 2026</media:keywords>
<content:encoded><![CDATA[<p><span>For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to </span><span>disease outbreaks </span><span>and </span><span>natural disasters</span><span>, but that protection has lapsed.</span></p>
<p><span>The Biotechnology Innovation Organization (BIO) is working to support Congress in ensuring our national health security by reauthorizing the Pandemic and All Hazards Preparedness Act (PAHPA) before year’s end. In a recent action, BIO joined over 80 other organizations and companies in signing</span><a href="https://centerforhealthsecurity.org/2026/biosecurity-partners-co-sign-letter-urging-congress-to-fully-reauthorize-pahpa" target="_blank" rel="noopener"> <span>a Sept. 14 letter</span></a><span> urging congressional leaders to pass a PAHPA bill.</span></p>
<p><span>“This is a national security priority, an important way to protect Americans,” explains Phyllis Arthur, BIO’s EVP and Chief of Global Health. “PAHPA funds so many things that are essential for our national readiness and resilience. We are at a time when Americans care a great deal about what’s happening in terms of our nation being ready for known and unknown threats.”</span></p>
<p><span>Historically reauthorized on a five-year basis since it was initiated in 2005, PAHPA has not been reauthorized after the previous funding period ended in September 2023. While most PAHPA programs continue with short-term, temporary extensions, five-year funding is essential to incentivize research </span><span>and </span><span>development in medical countermeasures (MCMs), which can often take more than a decade to develop.</span></p>
<p><span>As a national security measure protecting civilians and the military, PAHPA has bipartisan support in Congress, and there is reason for optimism about reauthorization before the end of the year, according to Praneel Jadav,</span> <span>Manager, Infectious Disease Policy at BIO. “We commend the bipartisan champions in the House and Senate who are working to reauthorize PAHPA and we are committed to supporting their efforts,” he says.</span></p>
<p><span>While Congress has not yet put forth a bill for PAHPA reauthorization, it is expected to be aligned with earlier legislative proposals that  BIO would support, according to Jadav. He says BIO’s priorities for any PAHPA legislation are:</span></p>
<ul>
<li aria-level="1"><span>Reauthorization of</span> several key <a href="https://www.aspr.gov/" target="_blank" rel="noopener"><span>Administration for Strategic Preparedness and Response (ASPR) programs, </span></a><span>including the Biomedical Advanced Research and Development Authority (BARDA), the Strategic National Stockpile (SNS), Project BioShield, and the Pandemic Influenza Program.</span></li>
<li aria-level="1"><span>Reauthorization of the</span><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/material-threat-medical-countermeasure-priority-review-vouchers-draft-guidance-industry" target="_blank" rel="noopener"> <span>Medical Countermeasure Priority Review Voucher (MCM PRV)</span></a><span> program.</span></li>
<li aria-level="1"><span>Authorization of a Pathogen-Agnostic Viral Family program at BARDA.</span></li>
</ul>
<h2>Why ASPR matters</h2>
<p><span>ASPR oversees most public health preparedness efforts and programs, including BARDA. BARDA works with industry to support the late-stage development of MCMs against chemical, biological, radiological, and nuclear threats, and emerging infectious diseases, all of which pose a real and present danger, Arthur explains.</span></p>
<p><span>“We know for instance that a flu pandemic is a threat every single year,” she says. “BARDA has been seeking to support companies working on vaccines against the various flu pandemic strains that pop up all over the world.”</span></p>
<p><span>ASPR also oversees the Strategic National Stockpile (SNS), a ready supply of MCMs ranging from smallpox vaccines to treatments protecting members of the military against nerve agents. Other vital ASPR programs include Project BioShield, which provides money and market incentives for private development of life-saving products that lack a commercial market.</span></p>
<h2>Why the MCM PRV matters</h2>
<p><span>An important part of the work PAHPA supports is industry-government collaboration to ensure drug companies develop new MCMs against potential threats and produce these drugs for stockpiling in the SNS.</span></p>
<p><span>“You can’t be standing around waiting for drug development in an emergency,” Arthur says. But since the hope is that we never need to use MCMs, regular market considerations would not encourage their development.</span></p>
<p><span>“We must have MCMs ready, though they often cannot be supported commercially,” Arthur explains. “Their marketplace is primarily government, and the U.S. government is the main global purchaser.”</span></p>
<p><span>Government support for this type of drug development is vital because most early research and development of MCMs is handled by small and mid-sized biotechs, with moderate budgets, Jadav notes.</span></p>
<p><span>“Anything we can do to show there is government support really helps these companies make a case with investors to continue funding innovative medical countermeasures that protect both civilians and the warfighter,” he says.</span></p>
<p><span>One mechanism to reduce the financial risks of developing a new MCM is the MCMPRV, a voucher that grants developers of MCMs priority Food and Drug Administration (FDA) review of a future drug candidate.</span></p>
<p><span>The faster time to market is a financial boost to drug developers, and MCM developers seeking capital can also sell the vouchers to other companies. While vouchers offer real value for drug makers, they cost taxpayers nothing.</span></p>
<h2>Why viral families matter</h2>
<p><span>Another key PAHPA initiative BIO wants to see is authorization of a dedicated Pathogen-Agnostic Viral Family program at BARDA. Examples of viral families include mpox and smallpox, which are both treated with one vaccine. We can more quickly achieve a range of treatments by developing vaccines or antivirals for other viral families—like the family that includes Marburg and Ebola, or the COVID-SARS-MERS family.</span></p>
<p><span>“This is more of a progressive method to address threats in emerging infectious diseases,” says Jadav. “It focuses research on medical countermeasures that address a whole host of viruses instead of doing a one bug, one drug approach.”</span></p>
<p><span>While BARDA has initiatives to encourage MCMs for viral families, a dedicated program would improve efficiencies in this area.</span></p>
<p><span>With PAHPA’s power to promote these essential health defense measures, BIO and its co-signers on <a href="https://centerforhealthsecurity.org/2026/biosecurity-partners-co-sign-letter-urging-congress-to-fully-reauthorize-pahpa" target="_blank" rel="noopener">the Sept. 14 letter to Congress</a> see risks in delaying the legislation.</span></p>
<p><span>“Failing to reauthorize PAHPA now would have serious effects on our country’s economic wellbeing, national security, and health given the rapidly changing threat landscape,” the letter explains.</span></p>
<p>The post <a href="https://bio.news/national-security/a-national-security-priority-bio-pushes-pahpa-reauthorization-in-2026/">A national security priority: BIO pushes PAHPA reauthorization in 2026</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>High&#45;Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets</title>
<link>https://edusehat.com/en/high-grade-glioma-biology-varies-by-age-and-sex-revealing-potential-treatment-targets</link>
<guid>https://edusehat.com/en/high-grade-glioma-biology-varies-by-age-and-sex-revealing-potential-treatment-targets</guid>
<description><![CDATA[ Researchers carrying out multiomics analyses of tumors from high-grade glioma patients found distinct molecular profiles and survival outcomes in different age groups and according to sex, and identified candidate treatment targets and potential prognostic markers. 
The post High-Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/04/GettyImages-1426197869.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:15:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>High-Grade, Glioma, Biology, Varies, Age, and, Sex, Revealing, Potential, Treatment, Targets</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified candidate treatment targets and potential prognostic markers for high-grade glioma (HGG), an aggressive brain cancer in children, adolescents, and young adults (AYA). The study found that high-grade glioma varies by developmental stage and sex, showing distinct tumor biology and outcomes across patient groups.</p>
<p>The team carried out proteogenomic analyses of tumors from more than 100 HGG patients aged 0–40 years. Their multiomics analysis identified two AYA age groups with distinct molecular profiles and survival outcomes.</p>
<p>The researchers suggest that using the study results to guide clinical trial design and develop new therapies could advance more precise treatment strategies.</p>
<p>“Our goal was to understand high-grade glioma from infancy through young adulthood and identify tumor-related changes tied to outcomes such as survival,” said Pei Wang, PhD, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. “Because age and sex shape normal brain development, we wanted to separate features of the cancer from those associated with a patient’s developmental stage.”</p>
<p>The study was conducted by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), the Children’s Brain Tumor Network, and the Philadelphia Coalition for a Cure.</p>
<p>Wang, and Avi Ma’ayan, PhD, Mount Sinai endowed professor in bioinformatics and director of the Mount Sinai Center for Bioinformatics, are principal investigators of the Proteogenomic Data Analysis Center at the Icahn School of Medicine, part of CPTAC.</p>
<p>Wang is co-senior and co-corresponding author of the researchers’ published paper in <em>Cell Reports Medicine</em>, titled “<a href="https://doi.org/10.1016/j.xcrm.2026.103024" target="_blank" rel="noopener">Proteogenomic analysis of pediatric and AYA high-grade glioma reveals age-dependent biology, female-male differences, and candidate kinase targets</a>.” In their paper the investigators concluded, “This study provides an integrated multiomics analysis of HGGs across development, establishing a framework in which age and developmental context shape tumor biology.”</p>
<p>High-grade glioma is among the most aggressive primary brain tumors, with a five-year survival rate below 10%. Tumors in children differ markedly from those in adults, while adolescents and young adults remain especially understudied because their tumors do not fit neatly into either pediatric or adult disease. “High-grade gliomas (HGGs) in children and adolescents and young adults (AYA) exhibit distinct biology across the neurodevelopmental spectrum,” the authors wrote. “Differences between male and female patients, which influence both brain development and cancer biology, represent another underexplored dimension.”</p>
<p>Because age and sex shape normal brain development, the researchers sought to distinguish tumor-related molecular features from those associated with developmental stages. Working with CPTAC, the team profiled tumors—samples were collected through the Children’s Brain Tumor Network—from 112 patients aged 83 days to 40 years, measuring DNA, RNA, proteins, and chemical changes made to proteins after they are produced, including phosphorylation and glycosylation.</p>
<p>Those measurements were combined with data from 99 adult glioblastoma tumors and clinical and genetic information from a reference group of more than 5,000 people with high-grade glioma, to trace how tumor biology changes across the lifespan.</p>
<p>Using computational analysis and laboratory validation the team identified as potential treatment targets several kinases—enzymes that help control cell signaling—including CDK8, ATM, ATR, and LCK.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Studies showed that in tumor-derived cell lines, blocking these kinases through gene editing or drug treatment slowed growth when the corresponding kinase was most active. CDK8 emerged as a particularly notable candidate because it is less well characterized in high-grade glioma than established targets such as ATM and ATR. Analyses indicated that CDK8 suppresses oxidative phosphorylation (OXPHOS), a key energy-producing process that the study linked to more favorable survival. “Causal network analysis and cell line studies provide a rationale for personalized therapies targeting candidate kinases, such as CDK8,” the investigators noted.</p>
<p>By tracing molecular profiles continuously across age rather than sorting patients into established tumor subtypes the researchers identified a clear shift around age 26 years within an age range often grouped clinically as adolescents and young adults. The two study groups (adolescents aged 15 years to 26 years and young adults aged 26 years to 40 years) had distinct molecular profiles and survival outcomes and relied on different signaling programs.</p>
<p>Comparing tumors with normal brain tissue across the same age span sharpened the picture. Oxidative phosphorylation showed age- and sex-related changes in tumors that were not seen in normal brains, suggesting these differences arise from tumor processes rather than normal development.</p>
<p>About 27% of the proteins the team measured showed different age-related trajectories in male and female patients. A prognostic score established in earlier work was associated with outcomes in male patients but not in female patients. Glycosylation proved especially informative in male patients, with far more survival-associated features than in female patients. Protein-based grouping also revealed a previously unrecognized male subgroup with the poorest survival in the study, distinguished by immune signaling and features of the tissue surrounding the tumor.</p>
<p>“CPTAC allows us to examine the same genes across several layers of biology, from DNA and RNA to proteins and protein modifications,” said first author Nicole Tignor, PhD, assistant professor of genetics and genomic sciences at the Icahn School of Medicine “In this study, glycosylation captured aspects of tumor biology missed in other molecular data. It may be especially valuable for understanding differences between male and female patients in immune responses and, potentially, treatment response.”</p>
<p>Higher levels of infiltrating T cells were associated with better outcomes in female patients but not in male patients, while a pattern involving the immune checkpoint gene<em> PDCD1</em>, which codes the protein PD-1, was seen only in male pediatric and young adult patients. Because PD-1 inhibitors are already being studied in this population, the authors say the findings support further study of treatment strategies that account for these differences. “Our integrated analysis also revealed immune cell types associated with survival,” they noted. “T cell infiltration was linked with favorable outcomes in female PED/AYA HGG patients but not in male counterparts and correlated with PD-1 expression only in males, a pattern absent in adult tumors (>40 years),” the investigators stated.</p>
<p>They pointed out that that sex-related differences have emerged as an important determinant of immune response in glioblastoma, with evidence indicating that that male patients may exhibit greater sensitivity to the immune checkpoint blockade. “As PD-1 inhibition therapies are under active investigation in clinical trials involving PED/AYA HGG patients, our findings support the development of male and female-specific treatment strategies.”</p>
<p>The authors further noted that sample sizes are limited, which is a persistent challenge in rare pediatric cancers that is more pronounced when patient data are divided by age, sex, and tumor features. The team developed an analytic approach that uses molecular trajectories learned in one group to help interpret survival patterns in another. Even so, the team noted, some findings will need confirmation in larger studies, and targets such as CDK8 will require validation in animal models before clinical testing.</p>
<p>The mechanisms underlying the observed differences between male and female patients also remain to be defined. Nevertheless, the investigators concluded, despite limitations, “… our study advances understanding of the developmental patterns in male and female HGGs and identifies molecular and immunologic features with translational potential.”</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Wang added, “Patient data are becoming increasingly rich, but they also reflect cancers arising at different ages and in different biological settings. How we account for that variation affects which biological signals we can detect. Analyzing tumors in their developmental context can help us make better use of these data and identify patterns that might otherwise be missed.”</p>
<p>The Children’s Brain Tumor Network and CPTAC are continuing to collect samples and generate data across pediatric brain tumors and other childhood cancers. The team will use those larger datasets to determine which patterns hold across cancers, which are specific to high-grade glioma, and which are most promising for therapeutic development.</p>
<p>The study’s proteogenomic datasets are publicly available through the NCI Proteomic Data Commons and the Children’s Brain Tumor Network, and the analysis code has been released openly.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/high-grade-glioma-biology-varies-by-age-and-sex-revealing-potential-treatment-targets/">High-Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research</title>
<link>https://edusehat.com/en/molecular-devices-and-stemcell-technologies-team-up-to-automate-organoid-research</link>
<guid>https://edusehat.com/en/molecular-devices-and-stemcell-technologies-team-up-to-automate-organoid-research</guid>
<description><![CDATA[ Validated on the CellXpress.ai automated cell culture system, the new workflow combines organoid biology expertise and laboratory automation to help researchers reduce variability, expand scale, and move discoveries toward impact with more confidence.
The post Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2254461524.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Molecular, Devices, and, STEMCELL, Technologies, Team, Automate, Organoid, Research</media:keywords>
<content:encoded><![CDATA[<p>Molecular Devices and STEMCELL Technologies said they have a developed a validated automated workflow that can be used with STEMCELL’s IntestiCult<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Plus organoid growth medium for human intestinal organoids culture on the Molecular Devices CellXpress.ai automated cell culture system.</p>
<p>Available as a downloadable protocol, the workflow provides researchers with a ready-to-implement approach to automating organoid culture, helping reduce hands-on time and experimental variability while enabling more consistent, scalable generation of human-relevant research models and accelerating discovery, according to an official at Molecular Devices.</p>
<p>The workflow marks the first milestone in a strategic collaboration to automate STEMCELL’s portfolio of organoid culture kits on the CellXpress.ai system. By combining STEMCELL’s expertise in organoid biology with Molecular Devices’ automation capabilities, the companies aim to help researchers more easily adopt and scale human-relevant models, reducing barriers to implementation and accelerating research workflows in laboratories worldwide, explained Mary Duseau, president of Molecular Devices.</p>
<p>Under the collaboration, Molecular Devices develops and validates automated workflows, while STEMCELL provides tissue-specific science for performance criteria and cell-based functional characterization to support protocol development and validation.</p>
<p>“Organoids have the potential to give researchers a more human-relevant view of disease and treatment response, but their broader use depends on making these models easier to implement at scale,” continued Duseau. “This collaboration is an important step toward giving more scientists practical access to advanced cellular models while freeing them to focus on the biological questions that can inform the development of better therapies.”</p>
<p>The workflow reportedly enables automated culture, monitoring, and analysis of human intestinal organoids within a standardized process on the CellXpress.ai system. Researchers can implement the validated protocol as provided or adapt it to meet specific experimental requirements, providing flexibility for a range of organoid research applications, noted Allen Eaves, PhD, president and CEO of STEMCELL Technologies.</p>
<p>“This collaboration helps make advanced organoid workflows more accessible to scientists working across drug discovery, disease research, and translational biology,” he said. “Together, we’re enabling researchers to combine well-established organoid culture systems with automation, supporting the adoption of new approach methodologies (NAMs) and making it easier to generate reproducible results and scale their work as research needs evolve.”</p>
<p>The companies plan to evaluate additional organoid models and workflows for automation on the CellXpress.ai system, creating a portfolio of validated applications for drug discovery, disease modeling, toxicology, and translational research.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/molecular-devices-and-stemcell-technologies-team-up-to-automate-organoid-research/">Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Kidney Organoids Reveal Inflammatory Drivers of Diabetic Kidney Disease</title>
<link>https://edusehat.com/en/kidney-organoids-reveal-inflammatory-drivers-of-diabetic-kidney-disease</link>
<guid>https://edusehat.com/en/kidney-organoids-reveal-inflammatory-drivers-of-diabetic-kidney-disease</guid>
<description><![CDATA[ In kidney organoids, elevated glucose triggered tissue-intrinsic inflammation and epithelial cell detachment without overt cytotoxicity. Inhibiting MIF, TNF-alpha, or MAPK-related signaling helped protect the organoids, suggesting inflammatory pathways may be targetable in diabetic kidney disease.
The post Kidney Organoids Reveal Inflammatory Drivers of Diabetic Kidney Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/02/Getty_1360263908_kidney.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 18 Sep 2026 12:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Kidney, Organoids, Reveal, Inflammatory, Drivers, Diabetic, Kidney, Disease</media:keywords>
<content:encoded><![CDATA[<p>Diabetic kidney disease is one of the most common and serious complications of diabetes, yet the chain of events linking high blood sugar to kidney damage remains incompletely understood. Now, a stem cell-based model suggests that glucose itself may help trigger an inflammatory response inside kidney tissue—one that can damage key epithelial cells.</p>
<p>Researchers led by Benjamin S. Freedman, PhD, at the University of Washington and University of Miami, report that human kidney organoids exposed to elevated glucose developed tissue-intrinsic inflammation and epithelial cell detachment, including detachment of podocytes, specialized cells essential for the kidney’s filtration barrier. The study, “<a href="https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(26)00292-4" target="_blank" rel="noopener">Elevated glucose in kidney organoids induces tissue-intrinsic inflammation driving epithelial detachment</a>,” was published recently in <em>Stem Cell Reports</em>.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“High sugar causes inflammation in these organoids even though they lack an immune system,” Freedman said. “This was unexpected and gives us a new way to think about how diabetes can affect kidneys and other organs.”</p>
<p>Diabetic kidney disease affects about 40% of people with diabetes and can progress to kidney failure due to persistently high blood pressure. Although current therapies can help control blood sugar and blood pressure, few treatments directly address the cellular damage that occurs in the kidney. The researchers set out to model that damage using human kidney organoids, which are generated from pluripotent stem cells through a stepwise differentiation process that recapitulates aspects of kidney development.</p>
<p>To mimic diabetic conditions, the team cultured kidney organoids in media containing different glucose concentrations. Organoids maintained in lower glucose conditions remained largely intact, but those exposed to higher glucose levels showed progressive morphological deterioration. Importantly, live/dead and lactate dehydrogenase assays suggested the changes were not caused by overt cytotoxicity. Instead, the researchers observed detachment of podocytes and tubular epithelial cells from the main organoid body, a phenotype reminiscent of changes reported in kidney biopsies and urine samples from patients with diabetic kidney disease.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Single-cell RNA sequencing pointed to activation of inflammatory pathways in the high-glucose organoids. MIF emerged as the top upregulated gene across the complete dataset, epithelial cluster, and podocyte subcluster, while TNF-alpha/NF-kB signaling was among the pathways enriched in epithelial and proximal tubule subclusters. Several pathway-level changes, including TNF-alpha/NF-kB signaling, also overlapped with transcriptomic data from human diabetic kidney disease biopsies. “Thus, our scRNA-seq analysis suggested that high glucose levels promote TNF-alpha and MIF expression, driving inflammation and podocyte injury,” the authors wrote.</p>
<p>The researchers then tested whether blocking these inflammatory pathways could blunt the injury phenotype. Inhibiting MIF with ISO-1 or TNF-alpha with etanercept protected organoids from podocyte injury under high-glucose conditions. MAPK pathway inhibitors also partially rescued podocyte morphology. These findings suggest that inflammation may be more than a secondary consequence of diabetic kidney damage.</p>
<p>The authors caution that further work is needed before these findings can be translated into patient therapies. The model required relatively high glucose levels to induce injury in the absence of TNF-alpha, and organoids lack a functional vasculature and immune system. Still, the study provides a controlled human platform for dissecting how hyperglycemia affects kidney cells and for evaluating potential anti-inflammatory strategies.</p>
<p>“While our findings suggest that inhibitors of MIF, TNF-alpha, or MEK can be used to intervene in this process, careful consideration and preclinical studies are needed to determine which of these treatment strategies is likely to be most effective,” the authors wrote.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/kidney-organoids-reveal-inflammatory-drivers-of-diabetic-kidney-disease/">Kidney Organoids Reveal Inflammatory Drivers of Diabetic Kidney Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma</title>
<link>https://edusehat.com/en/mithrl-raises-20m-to-expand-deployment-of-its-biomedical-world-model-across-biopharma</link>
<guid>https://edusehat.com/en/mithrl-raises-20m-to-expand-deployment-of-its-biomedical-world-model-across-biopharma</guid>
<description><![CDATA[ Mithrl’s platform embeds its biomedical world model and AI agents within biopharma companies’ own environments, providing the context and orchestration needed to apply frontier AI to proprietary data and pipelines.
The post Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/GettyImages-2233977474.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 21:55:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mithrl, Raises, 20M, Expand, Deployment, Its, Biomedical, World, Model, Across, Biopharma</media:keywords>
<content:encoded><![CDATA[<p><span>Vivek Adarsh’s reasons for founding Mithrl are quite personal. About 15 years ago, his grandfather passed away from acute kidney disease. And while today there are approved treatments for the disease, 15 years ago there were no FDA-approved drugs specifically for the condition. Adarsh, a trained computer scientist, wanted to address this problem across multiple disease areas that still lack effective treatments today. Three years ago, he co-founded Mithrl, a company whose stated mission is to “help R&D teams go from idea to IND, 50% faster.” </span></p>
<p><span>As he explained in a conversation with </span><i><span>GEN</span></i><span> this week,  “the question for me has been, what can technology do to accelerate getting medicines to patients a lot faster?” He and the Mithrl team believe that their artificial intelligence platform may be one of the keys. This week, the company announced a $20 million Series A funding round led by Obvious Ventures, with participation from Headline, AGI House, and several pharma executives, that will support the development of the second generation of Mithrl’s platform. The platform, dubbed Mithrl-1, comprises the company’s proprietary biomedical world model and an agentic harness for model routing, token optimization, and content orchestration. Mithrl is launching an early access program for the second-generation of the platform that will launch on September 21.</span></p>
<p><span>Mithrl’s platform combines validated biology curated from decades of peer-reviewed research as well as public and partnered datasets with agentic AI. Biopharmaceutical teams that deploy the company’s solution can combine that data, AI agents, and their proprietary data in their own environments. The platform cross-references data across disciplines to surface non-obvious connections using only published and verified data. Because the AI agents only reason over validated biology, rather than searching their way to answer from a broader pool of information, they require much less compute power to complete their tasks, according to the company. </span></p>
<p><span>That assertion is supported by results from a recent benchmark analysis, shared by Mithrl, that showed that running its infrastructure used 45% fewer tokens than standard workflows running the same frontier base models without customization. Finally, when the system generates hypotheses, it includes details about the sources used as well as a confidence score that captures what the system read, how it got there, and how much to trust its output. </span></p>
<p><span>Mithrl-1 is deployed in each client’s environment and harmonizes across existing frontier models. Each client’s implementation is then extended using their own proprietary data and pipelines. From there, teams can build and manage their own bespoke biomedical agents in-house. As new studies come in, Mithrl updates its knowledgebase and those changes are pushed out to customers on a regular basis giving them access to studies that are relevant to their work, and that could influence how they approach research questions. </span></p>
<p><span>These kinds of capabilities are important as AI systems become more embedded in biotech and biopharma labs. “Every player in this category is racing to generate more raw hypotheses, faster. But the industry is cracking under the weight of hypotheses it can’t triage or validate,” said Adarsh, who also serves as the company’s CEO. Mithrl set out to answer a different question. “Which of these will actually hold up in downstream experiments, and ultimately in patients? The platform doesn’t guess. It reasons from trusted studies and each client’s in-house evidence the way a client’s best scientists do, and it shows its work every time.” </span></p>
<p><span>To date, Mithrl’s platform has been used by several top-10 pharmaceutical companies, clinical-stage biotech companies, and genomics platform partners, according to the company. That list includes Elephas Biosciences, a company that develops an<em> ex vivo</em> tumor profiling platform. In April this year, the companies announced a scientific collaboration aimed at combining functional tumor profiling with AI-driven analysis to discover novel immunotherapy responses signals. The company could announce additional customer deals in Q4 of this year.</span></p>
<p><span>Some companies are already “AI-ready” which makes implementing Mithrl’s infrastructure more straightforward but most need some support to efficiently implement the company’s infrastructure, Adarsh says. “We have forward deployed scientists that go in, work with them, [help] them understand what knowledgebase does, and how we can make everything standardized.” </span></p>
<p><span>As the AI market matures, it has also become easier to make the case for implementing AI and communicating their platform’s benefits. A year ago, “you kind of had to work a little bit to educate where the value is” but that has changed in recent months, Adarsh noted. “I think there is a systemic level of education that has gone on over the past 12 months, mostly led by Frontier Labs, which is good for us.” There are also management changes happening across the biopharma industry and those shifts seem to be driving interest in onboarding AI, Adarsh said. He told </span><i><span>GEN</span></i><span> that he has noticed an uptick in conversations with company executives who “have a notion of the value that they are looking for” and are interested in understanding how Mithrl’s platform can help them get there.</span></p>
<p><span>So far the company’s tools seem to be making their mark on the industry. According to Mithrl, discoveries powered by its platform have contributed to over half a dozen customer-owned patent filings. It also claims that its biomedical world model delivers 16x more primary evidence per answer than frontier models alone and scored 0.96 for scientific correctness in expert-rated biomedical benchmarks, compared to 0.6 without its platform. </span></p>
<p><span>These proof points are helpful in a crowded market of AI-focused companies targeting drug discovery. Adarsh acknowledged the hype while discussing what sets Mithrl apart from other companies in the space. “Our north star is to be able to give scientific value and uniqueness to our partners,” he said. “What truly draws the revenue, and the topline for pharmaceutical companies, is uniqueness” specifically “patents.” He pointed to the platform’s contributions to multiple patents noting that customers have highlighted the competitive edge it gives. Those outcomes are “what differentiates us.”</span></p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p><span>And those outcomes, at least in part, are driving growing interest in the company’s platform. Adarsh told </span><i><span>GEN</span></i><span> that the current fundraising round was motivated to an extent by greater customer demand as well as a need to expand its capabilities. To the end, the new funding will support further development of the underlying biomedical world model as well as allow Mithrl add to its headcount, which currently stands at about 30 people. “In the order of priority, we have more demand to do deployments of our platform within big organizations, which obviously requires headcount,” Adarsh said. “Second is expansion across therapeutic areas.” The primary focus for now will be on disease areas that its target customer base works on including, immune-related diseases, oncology, diabetes, metabolic disease, and cardiovascular disease. </span></p>
<p><span>If all goes well, developing new medicines “won’t take 15 years” but “five years,” Adarsh said. “That is the personal motivation that led us to create Mithrl and that’s the path we’re on.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/mithrl-raises-20m-to-expand-deployment-of-its-biomedical-world-model-across-biopharma/">Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center</title>
<link>https://edusehat.com/en/sartorius-and-nibrt-partner-on-intensified-and-continuous-bioprocessing-training-center</link>
<guid>https://edusehat.com/en/sartorius-and-nibrt-partner-on-intensified-and-continuous-bioprocessing-training-center</guid>
<description><![CDATA[ Officials at Sartorius and the NIBRT said their partnership will strengthen global workforce readiness and accelerate the industry transition toward more efficient and sustainable biopharmaceutical production.
The post Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-171225477.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 21:55:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sartorius, and, NIBRT, Partner, Intensified, and, Continuous, Bioprocessing, Training, Center</media:keywords>
<content:encoded><![CDATA[<p>Sartorius and the Ireland-based National Institute for Bioprocessing Research and Training (NIBRT) are partnering to establish a training center for intensified and fully continuous bioprocessing in Dublin. Starting in the fourth quarter of 2026, the center will serve as a hub for practical training and knowledge sharing to help the biopharmaceutical industry adopt intensified, digitalized, and continuous manufacturing processes, according to Sartorius officials.</p>
<p>As part of the collaboration, Sartorius will equip NIBRT with its Pionic technology—an end-to-end modular cGMP platform for integrated continuous bioprocessing with advanced analytics and digital tools. Through the collaboration, the new facility is expected to provide more than 1,000 scientists, engineers, and students each year with hands-on experience in intensified upstream and downstream processes designed for efficiency, flexibility, and sustainability.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>René Fáber, head of the bioprocess solutions division and member of the executive board at Sartorius, pointed out that biopharmaceutical manufacturing is undergoing a major shift from batch processes toward more efficient, continuous processes.</p>
<p>“While technological innovation is the first step, training current and future engineers and operators is critical to making the change a reality,” he said. “Our partnership with NIBRT underscores Sartorius’ commitment to building global capabilities and accelerating the adoption of innovative and sustainable bioprocessing technologies.”</p>
<p>“This collaboration marks a significant step in advancing workforce training and supporting the transition toward intensified and connected manufacturing,” added Darrin Morrissey, CEO of NIBRT. “By integrating the Pionic platform into our training facility, we will give biopharma professionals the chance to gain first-hand experience with cutting-edge technologies that drive process efficiency and performance.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The Process Intensification Training Center will become a key element of NIBRT’s global training and education network, serving industry professionals and academic partners in Ireland, Europe, and worldwide, noted a NIBRT spokesperson. Beyond training, the center will also enable collaborative research and pilot-scale demonstrations, strengthening the global biomanufacturing ecosystem, said the center official.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/sartorius-and-nibrt-partner-on-intensified-and-continuous-bioprocessing-training-center/">Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF&#45;CART01</title>
<link>https://edusehat.com/en/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated-manufacturing-of-gf-cart01</link>
<guid>https://edusehat.com/en/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated-manufacturing-of-gf-cart01</guid>
<description><![CDATA[ The partnership marks Cellares’ first collaboration with a cell therapy developer in Asia and will evaluate automated manufacturing of GenomeFrontier’s virus-free CAR T process for clinical manufacturing in the U.S.
The post Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01 appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Home-CS-Floor-scaled-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 07:35:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cellares, and, GenomeFrontier, Therapeutics, Partner, Advance, Automated, Manufacturing, GF-CART01</media:keywords>
<content:encoded><![CDATA[<p>Cellares, an integrated development and manufacturing organization (IDMO), and GenomeFrontier Therapeutics, a Taiwanese cell therapy company developing virus-free CAR T therapies, formed a partnership to evaluate automated manufacturing for GF-CART01, GenomeFrontier’s investigational CAR T-cell therapy, on Cellares’ Cell Shuttle platform.</p>
<p>The collaboration will focus on the translation of GenomeFrontier’s manufacturing process to the Cell Shuttle, with an emphasis on supporting transfection unit operation using Cellares’ integrated electroporator. The partnership marks Cellares’ first development collaboration in Asia and is intended to support GenomeFrontier’s U.S. clinical initiative as it advances GF-CART01.</p>
<p>GenomeFrontier is developing GF-CART01 for B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma. The company reports that it has demonstrated promising clinical data in Taiwan and is now recruiting for a Phase I clinical trial in the U.S.</p>
<p>“As we advance GF-CART01, it is important that our manufacturing strategy can support both clinical development and future scale,” said Sareina Wu, PhD, founder, CEO, and CSO of GenomeFrontier. “Our virus-free approach is central to the development of GF-CART01, and this collaboration with Cellares allows us to evaluate how that process can be translated to an automated manufacturing platform as we expand our clinical development in the U.S.”</p>
<p>“GenomeFrontier’s approach reflects the increasing complexity of next-generation cell therapy manufacturing,” added Fabian Gerlinghaus, co-founder and CEO of Cellares. “The Cell Shuttle is built to automate complex processes, including electroporation-based workflows, with the scalability and reliability needed as therapies advance through clinical development.”</p>
<p>Autologous CAR T manufacturing remains labor-intensive, variable and difficult to scale, creating challenges for clinical development, manufacturing reliability, cost, and ultimately patient access. The Cell Shuttle is an end-to-end automated cell therapy manufacturing platform designed to improve the scalability and reliability of autologous cell therapy manufacturing, according to Cellares.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cellares-and-genomefrontier-therapeutics-partner-to-advance-automated-manufacturing-of-gf-cart01/">Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection</title>
<link>https://edusehat.com/en/prophylactic-phage-therapy-protects-mice-against-oral-salmonella-infection</link>
<guid>https://edusehat.com/en/prophylactic-phage-therapy-protects-mice-against-oral-salmonella-infection</guid>
<description><![CDATA[ Researchers developed a prophylactic phage therapy targeting Salmonella enterica Typhimurium that in mouse models colonized the gut, and produced lytic phages that protected against future infection by the pathogen, improving survival.
The post Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/06/GettyImages-1264547051-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 07:35:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Prophylactic, Phage, Therapy, Protects, Mice, Against, Oral, Salmonella, Infection</media:keywords>
<content:encoded><![CDATA[<p>Researchers at Virginia Tech have developed a prophylactic phage therapy approach to protecting against potential future infections by pathogenic gut bacteria. Bacteriophages, or phages, are viruses of bacteria and do not infect humans or animals. Headed by associate professor and Blackwood Junior Faculty Fellow Bryan Hsu, PhD, the team engineered a nonpathogenic <em>Escherichia coli</em> bacterium that produces a phage targeting the enteric pathogen <em>Salmonella enterica</em> Typhimurium (STm).</p>
<p>Tests in mouse models of STm-induced colitis showed that the prophage-encoding bacterium colonized the gut, produced high levels of lytic phage and protected mice from subsequent oral salmonella infection, improving survival. The team believes their results represent a step toward the development of new weapons against different diseases.</p>
<p>“Eventually, in the future, this could be used to treat other diseases,” said Rogerio A. Bataglioli, PhD, a postdoctoral fellow in the Department of Biological Sciences. “It’s not about replacing antibiotics but having one more option on the shelf to fight infections.”</p>
<p>Hsu is senior and co-corresponding author, and Bataglioli first and co-corresponding author of the researchers’ published paper in <em>Nature Microbiology</em>, titled “<a href="https://doi.org/10.1038/s41564-026-02484-3" target="_blank" rel="noopener">Prophage-encoding engineered bacteria enable prophylactic lytic phage therapy for enteric infection in mice</a>.” In their paper the authors wrote, “In this study, we show that a nonpathogenic <em>E. coli</em> gut  bacterium can be engineered to produce an obligately lytic antipathogen phage, and the application of this lyto-lysogen before oral STm infection can improve survival in mouse models and reduce intestinal colonization of the pathogen.”</p>
<p>The mammalian gut microbiome is teeming with a delicate balance of bacteria and the bacteriophage viruses that keep them in check phages. Each bacterial species usually has its own set of phage partners.</p>
<p>When bad bacteria enter the gut microbiome ecosystem there are typically no phages present, allowing the bacteria to cause mayhem. By the time the host is sick, it is too late for phages, and they’ll simply reach a balance with the bad bacteria. Hsu said phage therapy, the use of phages to treat bacterial infections, is particularly hard to make successful for treating intestinal pathogens. “Phage therapy is a promising antibacterial approach but it has limited efficacy against enteric bacterial infections, such as <em>Salmonella enterica Typhimurium</em> (STm),” the authors wrote in their paper.</p>
<p><figure aria-describedby="caption-attachment-338006" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-338006" src="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3-300x152.jpg" alt="(From left) Roger Bataglioli and Hiba Baaziz in the lab. [Photo by Felicia Spencer for Virginia Tech.]" width="300" height="152" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3-300x152.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3-696x354.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_image-3.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">(From left) Roger Bataglioli and Hiba Baaziz in the lab. [Felicia Spencer / Virginia Tech]</figcaption></figure>“It’s challenging, especially in the gut, because phages and bacteria tend to coexist for long periods of time,” said Hsu, an affiliate with Fralin Life Sciences Institute’s Center for Emerging, Zoonotic, Arthropod-borne Pathogens.</p>
<p>This coexistence makes establishing the high phage-to-bacteria ratio needed to treat intestinal infections hard to achieve. “That’s extremely challenging to achieve in your gut,” Hsu said. “And then once you have a bacterial infection in your gut, a lot of times it’s just not even accessible to phages. It’s already hidden away in the mucosa or cells of your body; it’s not just free flowing to where the phages would be able to access them.”</p>
<p>But what if the phages in the gut could prepare for the orally ingested pathogen and strike it down as it enters the gut, negating the need for a battle? “… We hypothesized that establishing high concentrations of a pathogen-targeting phage in the gut before infection would prophylactically protect against future infection,” the team further wrote.</p>
<p>For their study they engineered a nonpathogenic <em>E. coli</em> bacterium to encode a prophage that produces lytic phages that only infect the target STm bacterium. Usually, this type of <em>Salmonella</em> phage remains dormant in the <em>Salmonella</em> bacterial genome, but Hsu’s team made several genetic modifications so that the phage is carried by <em>E. coli</em>. Once released into the gut, the phage targets and kills the<em> Salmonella</em> by lysis. This process rapidly increases the number of phages to fight the bacteria. The researchers coined this new type of phage-bacterial combination a “lytic phage-producing lysogen,” or “lyto-lysogen.”</p>
<p><em>Salmonella</em> can typically detect phage DNA produced by non-<em>Salmonella</em> bacteria and prevent it from replicating. But in this case, the researchers were able to disguise the phage. “We were able to trick the <em>Salmonella</em> bacteria into thinking the phage from <em>E. coli </em>was ‘not foreign’ by adding a <em>Salmonella</em> gene into the <em>E. coli</em> genome,” Bataglioli said. “A phage that comes from our <em>E. coli</em> can infect <em>Salmonella</em>, can propagate easily in <em>Salmonella</em>, lyse it, and then all the phages that are produced from <em>Salmonella</em> can just keep replicating.”</p>
<p>This rapid reproduction eventually leads to the eradication of the infection from the gut. “What happens is that this good bacteria, the <em>E. coli</em>, produces all this antipathogen phage, and there is now a protective lining so that when <em>Salmonella</em> comes in, just after passing through the stomach and at its weakest point, it meets this high, killer density of phages,” Hsu said. In their paper the authors further noted, “Within the context of the mouse model of STm infection that we use here, we found that this prophylactic application of prophage therapy was superior to its therapeutic application post infection, and superior to the prophylactic or therapeutic application of free phage.”</p>
<p>The researchers say they targeted <em>Salmonella</em> because the pathogen has high global disease burden, and can be deadly in the elderly, children, and those with HIV. The bacterium also has a high prevalence of antibiotic resistance, and has been upgraded to a high-priority pathogen by the Centers for Disease Control and Prevention.</p>
<p>The researchers believe their work also has strong implications for other illnesses. “We’re starting off with <em>Salmonella</em>, but expanding, obviously, with the correct adaptations to target other diseases; other bacterial pathogens, would be an interesting route to explore,” Bataglioli said. The team further noted, “Collectively, our work shows that the lyto-lysogen strategy is a feasible prophylactic approach and represents an advancement in how phage therapy is conventionally conceived.” Hsu added, “We have a framework in place that shows that we could potentially put other phages in there and target other bacteria.”</p>
<p>Bataglioli plans to continue his bacteriophage research with the School of Chemical Engineering at the State University of Campinas in São Paulo, Brazil, in the fall.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/prophylactic-phage-therapy-protects-mice-against-oral-salmonella-infection/">Prophylactic Phage Therapy Protects Mice Against Oral <i>Salmonella</i> Infection</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Brain Protein in Mice Offers Insights Into Brain Development and ADHD</title>
<link>https://edusehat.com/en/brain-protein-in-mice-offers-insights-into-brain-development-and-adhd</link>
<guid>https://edusehat.com/en/brain-protein-in-mice-offers-insights-into-brain-development-and-adhd</guid>
<description><![CDATA[ Researchers identified a brain protein, NSF, that is important for maintaining dopamine-related cells and normal development, providing new insights into ADHD and potential therapeutic strategies.
The post Brain Protein in Mice Offers Insights Into Brain Development and ADHD appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/Getty_769722823_BrainNeuralNetwork_RESIZE11111.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 07:35:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Brain, Protein, Mice, Offers, Insights, Into, Brain, Development, and, ADHD</media:keywords>
<content:encoded><![CDATA[<p>Attention-deficit/hyperactivity disorder (ADHD), marked by excessive activity and impulsivity, is linked to changes in the brain’s dopamine system, though the mechanisms remain unclear. Researchers at the University of Fukui have now found that in genetically modified, conditional knockout mice, loss of a protein called N-ethylmaleimide-sensitive factor (NSF)—which is linked to dopamine receptors—in D2 receptor-expressing cells led to lower dopamine levels and ADHD-like behaviors. Their results also pointed to a potential therapeutic strategy.</p>
<p>The team, headed by assistant professor Min-Jue Xie, PhD, at the Division of Development of Mental Functions, Research Centre for Child Mental Development, suggests that the results offer insight into how brain changes may contribute to ADHD and informing future treatments.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“This is basic research and will not immediately lead to a new treatment,” Xie acknowledged. “However, it provides important clues for understanding how dopaminergic dysfunction may contribute to ADHD. In the future, these findings may help develop new therapeutic strategies targeting D2R function and striatal dopamine signaling, especially for treatment-resistant ADHD.”</p>
<p>Xie is first and corresponding author of the researchers’ published paper in <em>Neuropsychopharmacology</em>, titled “<a href="https://doi.org/10.1038/s41386-026-02526-8" target="_blank" rel="noopener">Deletion of N-ethylmaleimide-sensitive factor in dopamine D2 receptor-expressing cells impairs striatal development and dopaminergic function and induces ADHD-like behaviors in mice</a>.”</p>
<p>ADHD is a neurodevelopmental disorder that can affect attention, activity levels, and impulse control, with symptoms often beginning in childhood and sometimes continuing into adulthood. Although the exact causes of ADHD are not fully understood, changes in the brain’s dopamine system have long been linked to the condition. Dopamine is a chemical messenger that helps brain cells communicate and plays an important role in movement, motivation, and behavior.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>While dopamine-related changes have been associated with ADHD, it remains unclear how the brain cells that respond to dopamine are maintained and how their disruption may contribute to ADHD-related behaviors. This is particularly relevant to dopamine D2 receptor (D2R)-expressing cells, which are found in the striatum, a brain region involved in movement and behavioral control. Understanding what helps these cells develop and function normally could provide new insights into the biological processes involved in ADHD. “Although D2R has been extensively studied, the upstream mechanisms regulating its function and localization remain unclear,” the authors wrote.</p>
<p>Against this backdrop, a research team from Japan, led by Xie, set out to investigate the role of NSF in these dopamine-related brain cells. NSF regulates membrane fusion, helping brain cells release chemical messengers and move proteins within their membranes. “NSF dysfunction is implicated in neuropsychiatric disorders, with reduced expression in autism spectrum disorder (ASD) and schizophrenia and aggregates in Parkinson’s disease,” the investigators noted.</p>
<p>“The motivation for this study came from previous findings suggesting that NSF may be involved in neurodevelopmental and neuropsychiatric disorders,” Xie explained. “NSF was known to interact with D2R; however, the role of this interaction<em> in vivo</em> remained unclear. Because ADHD is thought to involve reduced striatal dopaminergic function and D2R dysfunction, we hypothesized that NSF may be important for maintaining D2R-expressing neurons and dopaminergic function. This led us to initiate the present study.”</p>
<p>For their study the team created knockout mice in which NSF was removed specifically from D2R-expressing neurons. “… we generated D2R-specific Nsf conditional knockout (<em>Nsf <sup>f/f</sup>;</em>D2R-Cre) mice to examine NSF function in D2R-expressing cells <em>in vivo</em>,” they explained. They then studied the animals’ brain development, dopamine levels, and behavior. The team also tested whether drugs that affect dopamine signaling could reduce the behavioral changes seen in the modified mice.</p>
<p>The loss of NSF affected the developing brain, resulting in fewer dopamine D2R-expressing cells, increased early developmental cell death, and a smaller striatum. The mice also had markedly lower dopamine levels in this brain region. Together, these findings suggest that NSF helps maintain dopamine-related cells and supports normal development and dopamine function.</p>
<p>The brain changes were accompanied by ADHD-like behaviors. “<em>Nsf <sup>f/f</sup>;</em>D2R-Cre mice exhibited attention-deficit/hyperactivity disorder (ADHD)-like behaviors, including hyperactivity and impulsivity,” the team reported. The knockout mice were more hyperactive than control mice and showed more impulsive-like behavior in a test that measured how quickly they jumped from an elevated platform. By the end of the seven-minute test, 86% of the experimental group mice had jumped, compared with 31% of the control group mice. “These findings indicate that a reduction in D2R-expressing cells coincides with ADHD-like behaviors, suggesting a link between D2R dysfunction and these abnormalities.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The researchers then explored whether these behaviors could be reduced by changing dopamine signaling. Methylphenidate, a medicine commonly used to treat ADHD, did not significantly reduce hyperactivity when given alone to the modified mice. However, when it was given together with quinpirole, a drug that activates D2R, the mice became less hyperactive and showed less impulsive-like behavior. During the seven-minute test, the proportion of knockout mice that jumped fell from 78% without treatment to 11% after the two drugs were given together. “Combined administration of methylphenidate and a D2R agonist, quinpirole, alleviated both behaviors, suggesting a potential complementary approach for ADHD treatment,” the investigators wrote.</p>
<p>“This study supports the translational relevance of the<em> Nsf <sup>f/f</sup>;</em>D2R-Cre model for ADHD and indicates that targeting D2R dysfunction, particularly in treatment-resistant ADHD, may be a promising therapeutic strategy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/brain-protein-in-mice-offers-insights-into-brain-development-and-adhd/">Brain Protein in Mice Offers Insights Into Brain Development and ADHD</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Meet a mouse whose brain cortex is made up of human cells</title>
<link>https://edusehat.com/en/meet-a-mouse-whose-brain-cortex-is-made-up-of-human-cells</link>
<guid>https://edusehat.com/en/meet-a-mouse-whose-brain-cortex-is-made-up-of-human-cells</guid>
<description><![CDATA[ Multiple cameras tracked a mouse as it wandered around a small arena. A computer charted its position and speed, leaving Pong-like traces on a monitor.  The reason to watch this rodent so carefully? Nearly half its brain volume had been replaced with human cells. The effort to mix the brain tissues of distant species is… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/260915_HumanBrainTissueMice.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Meet, mouse, whose, brain, cortex, made, human, cells</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Human brain cells, mouse body:</strong> Scientists have grown human brain tissue inside mice, creating a hybrid creature whose cortex is largely made of human cells.</li><br><li><strong>Why it matters:</strong> The research could unlock new ways to study brain injuries.</li><br><li><strong>Ethical questions loom:</strong> Mixing human brain tissue with animals raises uncomfortable questions about what it means to be human.</li><br></ul>" data-chronoton-post-id="1144210" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Multiple cameras tracked a mouse as it wandered around a small arena. A computer charted its position and speed, leaving Pong-like traces on a monitor. </p>



<p>The reason to watch this rodent so carefully? Nearly half its brain volume had been replaced with human cells.</p>



<p>The effort to mix the brain tissues of distant species is being reported today in the journal <em>Nature</em> by a team at Stanford University, led by neuroscientist Sergiu Pașca. </p>



<p>Pașca’s group previously showed that human brain “organoids”—small blobs of neural tissue—could survive, and even function, after being injected<a href="https://www.technologyreview.com/2022/10/12/1061204/human-brain-cells-transplanted-baby-rats-brains/"> into the heads of baby rodents</a>.</p>



<p>Now, Pașca has taken things a step further by genetically modifying mice so their brains don’t fully develop in the first place. These modified mice are missing most cells of both the cortex and the hippocampus, two key brain areas.</p>



<p>That creates much more room for the human cells to take hold, he says. “Human cells that are placed in these animals will divide, will grow, and within a few weeks to a few months they will take most of that space,” he says. Pașca says one surprising discovery is that the mice lacking brain tissue seemed fairly normal—they walked around and squeaked. But they did have memory problems. In a maze test, they couldn’t remember what parts they’d explored. </p>



<p>The mice with the added human cells, by contrast, performed better on the maze test. That means the human tissue is playing some role in the animals’ cognition.</p>



<p>Pașca believes what he is calling “xenocortical mice” could be useful in studying brain injuries. However, the report is also a dramatic demonstration of “the combined power of genetic engineering and stem-cell technology to reshape biology,” says Carsten Charlesworth, a scientist who works in a different Stanford lab and was not involved in the research.</p>



<p>Already, brain organoids are being tested in labs to see if they can be <a href="https://www.technologyreview.com/2023/12/11/1084926/human-brain-cells-chip-organoid-speech-recognition/">connected to computers</a> to play video games. Other scientists have proposed using them like replacement parts to treat stroke victims. </p>



<p>“What’s most remarkable to me is the extent to which human neural tissue introduced after birth grew and connected with the mouse nervous system across a species barrier,” says Charlesworth. “As these technologies advance, they’ll increasingly force us to challenge our traditional assumptions.”</p>



<p>Last year, Pașca <a href="https://neuroscience.stanford.edu/sites/default/files/2026-09/Exec%20Summary%20-%202025%20Asilomar%20Conference%20on%20Oversight%20of%20Neural%20Organoids_0.pdf">convened a group of ethics experts</a> to study the implications of neural organoid technology, including the odds that an animal could develop human consciousness and the risk that “organoid therapy clinics” might offer scam treatments to desperate patients.</p>



<p>For now, he says, he’s not concerned that the rodents have any type of human cognitive capacities. That is because their brains are relatively tiny and the evolutionary distance between man and mouse is so great. </p>



<p>But that’s also why Pașca says this type of experiment should not be carried out on higher species: They could end up with large volumes of functioning human brain tissue, potentially blurring the cognitive boundaries between people and animals. </p>



<p>Pașca specifically cautioned against adding human brain organoids to a monkey engineered to lack a cortex.</p>



<p>“One of the things that I see as a very clear red line is doing this experiment in a primate,” he says. “I don’t think that is justified at this point in any way.”</p>]]> </content:encoded>
</item>

<item>
<title>Lifecycle Approach Could Solve CGT Scale&#45;Up Challenges</title>
<link>https://edusehat.com/en/lifecycle-approach-could-solve-cgt-scale-up-challenges</link>
<guid>https://edusehat.com/en/lifecycle-approach-could-solve-cgt-scale-up-challenges</guid>
<description><![CDATA[ Cell and gene therapy developers often struggle to scale manufacturing, according to the authors of a new review, who suggest that part of the problem is the practice of developing unit operations in isolation. 
The post Lifecycle Approach Could Solve CGT Scale-Up Challenges appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/07/GettyImages-1460261281.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lifecycle, Approach, Could, Solve, CGT, Scale-Up, Challenges</media:keywords>
<content:encoded><![CDATA[<p>Scaleup will remain a challenge for the cell and gene therapy industry until developers adopt a more integrated approach that envisions manufacturing as a single process.</p>
<p>At least, that is according to researchers at the Manipal Academy of Higher Education in Karnataka, India, who argue in a <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/bit.70361?campaign=wolearlyview" target="_blank" rel="noopener">new review</a> that developers struggle because they treat manufacturing, analytics, and regulatory compliance as separate issues.</p>
<p>“Historically, the field has tackled these problems separately: one group focused on CAR T manufacturing, another on viral vector production, and another on logistics or regulatory strategy, rather than treating the whole product lifecycle as a single connected system.</p>
<p>“Our review argues that scalability must be built in from the start, using lifecycle-oriented tools that allow manufacturers to embed flexibility into the process from early development through commercial-scale production, rather than trying to bolt scalability on afterward, once problems appear,” study co-author Sachin Dattram Pawar, PhD, tells <em>GEN</em>.</p>
<p>The key, Pawar and colleagues suggest, is to treat all parts of CGT production as a single, unified process designed with scalability in mind.</p>
<p>“The idea is to stop treating early development, scale-up, and commercial manufacturing as separate problems and instead manage manufacturing knowledge continuously across the product’s lifecycle,” he says.</p>
<p>The lifecycle approach is also in keeping with trends in bioprocessing technology development, Pawar says, pointing to decentralized systems like the CliniMACS Prodigy or Lonza Cocoon platforms as examples.</p>
<p>“The approach would involve closed and automated manufacturing systems, real-time process monitoring, advanced analytics, digital tools, scalable cell and vector platforms, and robust cryopreservation and cold-chain infrastructure.</p>
<p>He adds, “Emerging approaches, such as digital twins, AI, allogeneic and iPSC-derived platforms, and improved vector production technologies, could further enhance scalability and consistency.”</p>
<p>In addition, treating manufacturing as a single process would also be a better reflection of the complex interactions that take place between unit operations, Pawar says, citing cell culture systems as an example.</p>
<p>“Switching from one to another can simultaneously alter product yield, purity, and even cell behavior, which in turn has knock-on effects on analytics and regulatory submissions.”</p>
<p></p><h4><strong>Regulations</strong></h4>

<p>A lifecycle-based view of manufacturing also fits with evolving regulations, according to Pawar, who points to the development of “concrete regulatory mechanisms” as evidence of growing support for the approach.</p>
<p>“ICH Q12 provides tools such as established conditions (ECs) and post-approval change management protocols (PACMPs) to help manufacturers manage process changes based on risk and accumulated knowledge.</p>
<p>“Likewise, the FDA’s flexible CMC approach for CGTs also supports greater flexibility during development, while the agency’s RMAT designation and the EMA’s PRIME scheme encourage early regulatory engagement. Overall, regulators are moving toward a more risk-based, lifecycle-oriented approach that supports innovation while maintaining product quality and patient safety,” he concludes.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/a-lifecycle-approach-could-solve-cgt-scale-up-challenges/">Lifecycle Approach Could Solve CGT Scale-Up Challenges</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Choice of Excipients Dramatically Affects Antibody Solubility</title>
<link>https://edusehat.com/en/choice-of-excipients-dramatically-affects-antibody-solubility</link>
<guid>https://edusehat.com/en/choice-of-excipients-dramatically-affects-antibody-solubility</guid>
<description><![CDATA[ More predictive, rational therapeutic antibody formulation designs can be grounded in interactions between antibodies and common excipients that biomanufacturers often consider generic.
The post Choice of Excipients Dramatically Affects Antibody Solubility appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1124671877-1small-short.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Choice, Excipients, Dramatically, Affects, Antibody, Solubility</media:keywords>
<content:encoded><![CDATA[<p>The excipients added to therapeutic protein formulations are more specific than biomanufacturers typically realize. As it turns out, these inactive ingredients have markedly different effects on solubility, and those differences are based on certain specific physicochemical factors.</p>
<p>In a recent <a href="https://doi.org/10.1080/19420862.2026.2722444" target="_blank" rel="noopener">paper</a>, researchers from the University of Cambridge, Eindhoven University of Technology, and Merck identified solubility differences among commonly used antibodies that ranged from approximately 7-fold to 200-fold. The differences came down to molecular specificity and the complexity of the antibody-excipient interactions. By understanding these indicators and their effects, biomanufacturers can design mAb formulations using a more predictive, rational design approach.</p>
<p>A team of eight, including first author Zexiang Han, a PhD candidate in the Knowles lab; and senior authors Tuomas Knowles, PhD, professor; and Pietro Sormanni, PhD, all of the University of Cambridge, analyzed the effects of four common pharmaceutical excipients (histidine, sodium chloride, arginine, and sucrose) on the solubility of a panel of therapeutic immunoglobulin G (IgG) antibodies using a high-throughput droplet microfluidic platform. They determined that excipient-mediated solubility depends strongly upon the antibodies themselves, and that solubility “can be quantitatively linked to specific molecular features derived from sequence and structure.”</p>
<p>For example, when looking at the solubility of 1 mg mL<sup>−1</sup> cetuximab in the presence of each of the four excipients, they reported that as excipient concentration increased, greater percentages of polyethylene glycol (PEG) crowder were needed to cause mAb precipitation. That was true for each of the excipients.</p>
<p>The scatter plots in the paper showed the relative concentrations of each excipient needed to meaningfully shift the solubility boundary. The histidine plot, for example, stops at about 35 mM, while the plot for sucrose stops at about 500 mM. For cetuximab, a relatively low concentration of histidine shifted the boundary, while a significantly higher concentration of sucrose was needed to cause a similar shift. The contrast among the various excipients, given the same antibody and same concentrations of PEG, underscores that the shifts were caused through molecularly specific interactions between the antibody and the excipient rather than by PEG’s excluded volume effect (i.e., crowding).</p>
<p>More specifically, they noted:</p>
<ul>
<li>“Histidine stabilization is fundamentally polar, correlating with antibody dipole moments.</li>
<li>“Sodium chloride operates via nonspecific electrostatic screening to suppress self-association in low-pI variants [those in which the pI—the isoelectric point—is below that of the pH and have no charge].</li>
<li>“Arginine efficiency reflects a competitive tradeoff between electrostatic screening and chaotropic effect.”</li>
</ul>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The takeaway, they reported, is that “formulation additives do not exert universal actions.” Instead, common excipients behave differently with different molecules. This work, therefore, provides “a mechanistic, physics-based framework that can support the rational design and optimization of antibody formulations,” the team pointed out.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/choice-of-excipients-dramatically-affects-antibody-solubility/">Choice of Excipients Dramatically Affects Antibody Solubility</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Red Light Supercharges Anti&#45;Obesity Drug Precursor</title>
<link>https://edusehat.com/en/red-light-supercharges-anti-obesity-drug-precursor</link>
<guid>https://edusehat.com/en/red-light-supercharges-anti-obesity-drug-precursor</guid>
<description><![CDATA[ Scientists in New Delhi found that red light dramatically boosted lipstatin production in Streptomyces, while reshaping its growth. The work points to illumination as a simple, non-invasive lever for improving yields in microbial biomanufacturing.
The post Red Light Supercharges Anti-Obesity Drug Precursor appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Mike-Dubey_GBPN_IMAGE_17SEPT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Red, Light, Supercharges, Anti-Obesity, Drug, Precursor</media:keywords>
<content:encoded><![CDATA[<p>Sometimes, getting microbes to make more of a valuable compound requires genetic engineering, new nutrients, or a painstakingly redesigned fermentation process. <a href="https://doi.org/10.1007/s00449-026-03411-w" target="_blank" rel="noopener">Researchers in New Delhi have now shown</a> that, for one medically important bacterium, part of the answer could be much simpler: change the color of the light.</p>
<p>Deepanshi Rajput, a doctoral student in biotechnology, and Kashyap Kumar Dubey, PhD, associate professor in the School of Biotechnology at Jawaharlal Nehru University in India, studied <em>Streptomyces toxytricini</em>, a filamentous soil bacterium that naturally produces lipstatin. Lipstatin is especially interesting because it is the natural precursor of orlistat, an anti-obesity drug that works by inhibiting enzymes involved in breaking down dietary fats.</p>
<p>The team grew the bacterium under a spectrum of lighting conditions, including red, green, indigo, blue, yellow, violet, orange, and white light, with darkness serving as a control. What happened under red illumination stood out.</p>
<p>Lipstatin production reached roughly 6 g/L under red light, compared with about 1.2 g/L under white light and just 0.02 g/L in darkness. That translates to roughly a five-fold improvement over white light and about a 300-fold jump over the dark control.</p>
<p>Light was not merely changing how much of the compound the bacteria produced. It was also changing how they physically grew. Microscopy revealed that the bacteria formed dramatically smaller, looser structures under red illumination. Pellets averaged about 81 µm across, compared with roughly 333 µm under white light and 785 µm in darkness.</p>
<p>That architectural shift could matter in industrial fermentation. Dense clumps of filamentous bacteria can hinder the movement of nutrients and oxygen through a culture. Smaller, more dispersed structures might improve mass transfer and create conditions that favor production of secondary metabolites, such as lipstatin.</p>
<p>As the authors reported, their results show that “light acts as an important environmental factor” influencing both the morphology and metabolism of <em>S. toxytricini</em>. A search of the bacterium’s proteins also uncovered two putative bacteriophytochromes—possible red-light-sensing proteins that could help explain how the organism detects illumination.</p>
<p>But the biological mechanism remains unresolved. The researchers stressed that “a direct causal link cannot be established” between the altered pellet structure and increased lipstatin production from the current experiments alone. Functional studies of the suspected photoreceptors, molecular profiling, and validation in larger bioreactors will be needed.</p>
<p>Still, the results suggest that fermentation facilities might eventually gain another surprisingly straightforward control dial. Rather than modifying the microbe itself, a manufacturer could potentially influence what it produces simply by illuminating the bacteria differently—a “useful, non-invasive parameter” that the researchers argued deserves further investigation.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/red-light-supercharges-anti-obesity-drug-precursor/">Red Light Supercharges Anti-Obesity Drug Precursor</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Prime Assembly Expands Genome Editing with Precise, Large&#45;Scale DNA Integration</title>
<link>https://edusehat.com/en/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration</link>
<guid>https://edusehat.com/en/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration</guid>
<description><![CDATA[ A new genome-editing method, prime assembly, precisely inserts long DNA sequences into targeted genomic locations, potentially enabling mutation-agnostic gene therapies for diverse genetic diseases with fewer individualized edits.
The post Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/01/GettyImages-1189916170.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 17 Sep 2026 04:00:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Prime, Assembly, Expands, Genome, Editing, with, Precise, Large-Scale, DNA, Integration</media:keywords>
<content:encoded><![CDATA[<p>The genome editing toolbox provides unprecedented opportunities to engineer the human genome. However, genome editing for therapeutic benefit continues to have its limitations. Most current methods rely on untargeted gene delivery or short DNA edits that need to be individualized to each patient.</p>
<p>Now, a new paper describes a novel genome engineering method, prime assembly, that allows long DNA fragments to be integrated into precise and programmable target positions within living cells. This approach, which leverages CRISPR-targeted dual flap synthesis, may allow for the development of universal gene therapies.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This work is published in <em>Nature</em> in the paper, “<a href="https://www.nature.com/articles/s41586-026-11024-2" target="_blank" rel="noopener">Targeted genomic integration and rearrangement using prime assembly</a>.”</p>
<p>Prime assembly builds upon the techniques of prime editing, a technology that allows for precise yet small insertions, deletions, and base swaps. The new method, the authors note, “enables RNA-programmable site-specific integration of single or double-stranded DNA fragments. Unlike homology-directed repair, prime assembly is similarly active in dividing and non-dividing cells.”</p>
<p>The team applied prime assembly to perform targeted exon recoding, transgene integration, and megabase-scale rearrangements, including at therapeutically relevant loci in primary human cells.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Prime assembly’s single step process writes in new DNA flaps to specific locations in the genome. The flaps serve as tethers designed to grab onto DNA fragments with matching ends. The precisely assembled DNA inserts, which can be one or more gene-sized DNA pieces, become large permanent edits.</p>
<p>“By using prime editing to write in one flap per strand of the genome, the method controls exactly where the DNA replacement starts and ends,” explained Daniel Bauer, MD, PhD, director of the Gene Therapy Program at Boston Children’s Hospital. “Because the method is based on prime editing, it is much less likely to cause off-target effects compared to other gene editing methods.”</p>
<p>One such off-target effect is the potential for toxicity. Untargeted insertion methods can turn on the wrong genes in the wrong context, leading to potentially cancerous outcomes, whereas prime assembly’s targeted insertion approach circumvents the risk. Prime assembly also does not rely on DNA double strand breaks or DNA double strand donors, both of which can be toxic and cause unwanted cell stress. And while other gene editing methods are mostly limited to dividing cells which are rare in the body and more susceptible to unwanted DNA changes, prime assembly works in nondividing cells.</p>
<p>Building on this milestone, the team is looking to further investigate the molecular mechanisms which would allow them to engineer even more efficient and precise systems. As they fine tune their approach, they hope this technology will have downstream impact in the clinic. With the ability to correct multiple mutations at once, this technology could lead to generalizable solutions for treating genetic disorders.</p>
<p>“We’re working to improve the delivery of the prime assembly components to disease-relevant human cells <em>in vivo</em>, such as hematopoietic stem cells for blood disorder therapies,” said Bauer. “We’re also exploring a number of applications of prime assembly to deliver genetic payloads as mutation-agnostic therapies to restore gene control for devastating inherited human diseases with unmet clinical need.”</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/prime-assembly-expands-genome-editing-with-precise-large-scale-dna-integration/">Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s</title>
<link>https://edusehat.com/en/microprotein-atlas-links-brain-immune-cell-dysfunction-to-alzheimers</link>
<guid>https://edusehat.com/en/microprotein-atlas-links-brain-immune-cell-dysfunction-to-alzheimers</guid>
<description><![CDATA[ Built from transcriptomic and mass spectrometry data, the atlas uncovered more than 1,000 previously uncharacterized microproteins and pointed to a potential connection between one microprotein and microglial dysfunction in Alzheimer’s disease.
The post Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1869420709.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 11:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microprotein, Atlas, Links, Brain, Immune, Cell, Dysfunction, Alzheimer’s</media:keywords>
<content:encoded><![CDATA[<p>Scientists studying Alzheimer’s disease have long focused on genes, proteins, and cells, but one class of molecules has remained largely outside the playbook: microproteins. These small proteins, produced from small open reading frames (ORFs) and typically measuring 150 amino acids or fewer, have been difficult to detect and study. Yet growing evidence suggests they may have important roles in health and disease.</p>
<p>Now, researchers at the Salk Institute have created what they describe as the first microprotein atlas of the human frontal cortex with and without Alzheimer’s disease. The study, “<a href="https://www.nature.com/articles/s43587-026-01207-x" target="_blank" rel="noopener">A microprotein atlas of the human frontal cortex in Alzheimer’s disease</a>,” was published in <em>Nature Aging</em>. The resource integrates transcriptomics, mass spectrometry, and deep-learning-predicted spectra across postmortem brain samples to identify microproteins that have been overlooked in standard protein catalogs.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“We still do not fully understand the molecular mechanisms of healthy aging, and that is especially true for microproteins, which have been inadvertently overlooked for decades,” said senior and co-corresponding author Alan Saghatelian, PhD, professor and the Dr. Frederik Paulsen Chair at Salk, in a press release. “Our atlas allows scientists to systemically investigate microproteins in aging and neurodegeneration, which should bring us closer to understanding and tackling diseases like Alzheimer’s or Parkinson’s.”</p>
<p>Saghatelian told <em>GEN </em>the work began with a basic limitation in how proteomes are annotated. “Every reference proteome is built on gene models that exclude smORFs by construction. So the first motivation was straightforward: build a search database that can actually see these sequences, and point it at the deepest human brain proteomics data that exists.”</p>
<p>The atlas was built using data from hundreds of postmortem human frontal cortex samples from individuals with and without Alzheimer’s disease, including samples made available through the Religious Orders Study/Memory and Aging Project cohort. The team analyzed existing native transcriptomic and mass spectrometry data with custom computational tools, including ShortStop, an AI-powered microprotein-finding tool developed in Saghatelian’s lab.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“We were able to take all these technologies and tools and reapply them to existing data from nearly 500 brains to find new microproteins,” said first and co-corresponding author Brendan Miller, PhD, a postdoctoral researcher in Saghatelian’s lab. “We were able to create an entirely new database that researchers can download and use to better interpret functions of genes.”</p>
<p>In total, the researchers identified 1,067 previously uncharacterized microproteins absent from reviewed UniProtKB entries, supported by high-confidence spectral support, according to the paper. Some of these microproteins were expressed differently in Alzheimer’s disease samples compared with non-Alzheimer’s samples, and the paper reports that Alzheimer’s disease cells tended to show higher overall microprotein expression.</p>
<p>The investigators then focused on microglia, which are known to change with aging and neurodegeneration. Their analysis highlighted a small open reading frame at the MKKS locus encoding a 63-amino-acid microprotein that appeared to be the predominant translation product at that locus and is downregulated in Alzheimer’s disease. When the researchers knocked out the microprotein-making gene in microglia, mitochondrial respiration was impaired, suggesting a role for the microprotein in microglial bioenergetics.</p>
<p>The MKKS finding also underscored a broader issue with relying only on canonical protein annotations. “The general implication is uncomfortable: the most abundant and most tissue-relevant protein product at a locus can be the one that isn’t annotated,” added Saghatelian.</p>
<p>He also cautioned that not every microprotein identified in the atlas should be assumed to be functional. “There are two ways to read an expressed microprotein. It may be a marker—evidence that its gene’s transcription or splicing is disrupted—without the peptide itself doing anything. Or it may be a bioactive molecule with biology distinct from the canonical product at that locus.”</p>
<p>The findings point to a possible connection between microproteins and immune cell dysfunction in Alzheimer’s disease. “There is sometimes an assumption that we know everything about our genome, and we know all the genes our cells can make—that’s just not true,” Saghatelian said. “What we know is constantly expanding, and this atlas makes it that much easier to study microproteins in life science research.” Beyond Alzheimer’s disease, the publicly available atlas could serve as a framework for mapping microproteins in other brain regions, tissues, and disease contexts.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/microprotein-atlas-links-brain-immune-cell-dysfunction-to-alzheimers/">Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI models need more data about biology, and OpenAI is paying to create it</title>
<link>https://edusehat.com/en/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it</link>
<guid>https://edusehat.com/en/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it</guid>
<description><![CDATA[ Last year Ruxandra Teslo, a policy analyst who focuses on clinical trials, posted an idea for supercharging medical AI systems: Use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—types of information usually considered trade secrets. She… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/OpenAI-grants.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:35:01 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>models, need, more, data, about, biology, and, OpenAI, paying, create</media:keywords>
<content:encoded><![CDATA[<p></p>





<p>Last year Ruxandra Teslo, a policy analyst who focuses on clinical trials, posted an idea for supercharging medical AI systems: Use data from failed biotech companies.</p>



<p>By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—types of information usually considered trade secrets. She called these documents “<a href="https://ifp.org/biotechs-lost-archive/">biotech’s lost archive</a>” and said they could be used to help train AIs that would act as powerful copilots in the often opaque drug approval process. </p>



<p>Today the OpenAI Foundation, the <a href="https://openai.com/our-structure/">nonprofit parent of OpenAI</a>, said it would fund her idea as part of a new effort it calls Public Data for Health, which aims to help artificial intelligence make big leaps in medicine by paying to create “high-quality scientific datasets.”</p>



<p>The basic idea is that AI isn’t going to be capable of making important breakthroughs in curing disease unless researchers can feed the models much more information than they have so far. </p>



<p>“Everyone is recognizing that data is the biggest bottleneck in successfully applying AI to biology,” says Morgan Levine, a former vice president for computation at Altos Labs, a longevity company.</p>





<p>In its initial round of data grants, the OpenAI Foundation also announced that it would give $40 million to a program to collect data about novel cancer vaccines at the University of North Carolina, Chapel Hill, and support <a href="https://openadmet.org/">OpenAdmet,</a> a group that runs competitions in which researchers try to predict drug effects. </p>



<p>Teslo’s idea for a biotech archive received $500,000 and will be pursued by 1Day Sooner, an advocacy group representing clinical trial volunteers, which she advises.</p>



<p>“We expect many remaining breakthroughs in preventing and curing disease to come from pairing the intelligence of new models with more observations of the world—in other words, more data,” the OpenAI Foundation said in a statement.</p>



<p>OpenAI started as a nonprofit, but leader Sam Altman restructured it to form a for-profit corporation that develops new models, launches products, and is now planning an initial public offering of stock that could value it<a href="https://www.reuters.com/business/openai-lays-groundwork-juggernaut-ipo-up-1-trillion-valuation-2025-10-29/"> at $1 trillion</a>.</p>



<p>Because the foundation holds a<a href="https://openai.com/our-structure"> 26% equity stake</a> in OpenAI, it is now be on track to become the richest charitable organization on the planet, potentially sitting on $250 billion in stock value. (By comparison, the Gates Foundation and a trust associated with it held about $180 billion at the end of 2025.)  </p>



<p>Making good use of that kind of money will not be easy. The foundation, based in San Francisco, is still hiring for<a href="https://openaifoundation.org/careers#open-roles"> many key roles</a> and started ramping up its grantmaking only this year. Its largest single gift so far, of $100 million, was awarded in August to the<a href="https://files.commonhealthcoalition.org/storage/v1/object/public/resource-files/B2FNews.pdf"> Common Health Coalition</a>, an organization that helps patients get access to drugs for hepatitis C.</p>



<p>OpenAI’s charitable efforts come even as apocalyptic fears have broken out about the possibility that runaway AI could<a href="https://www.nytimes.com/2026/09/10/science/ai-humanity-risk.html"> wipe out all human life</a>, possibly by launching a deadly bioweapon.</p>



<p>Those fears have been stoked by AI company insiders, some of whom say the chance of human extinction within the next decade is <a href="https://x.com/EvanHub/status/2097497037956891126">10% or more</a>. Last week, Altman and xAI founder Elon Musk both<a href="https://www.theguardian.com/technology/2026/sep/14/ai-ceo-safety-slowdown"> endorsed</a> a call by Anthropic CEO Dario Amodei to “slow the pace at which we improve the capabilities of AI models” so that risk prevention can catch up.</p>



<p>Jacob Trefethen, an executive at the foundation, says it essentially operates separately from OpenAI but shares an official mission of ensuring that artificial intelligence “benefits all of humanity.”</p>



<p>“We’re starting grantmaking when we think the best way to achieve that mission is to make grants to external nonprofits, research institutions, and other third parties,” Trefethen said in an interview. He says the foundation hopes to give away $1 billion by the end of the year. </p>



<p>The $500,000 grant to 1Day Sooner will help the group prove it can obtain the data troves of bankrupt companies, says the organization’s president and cofounder, Josh Morrison. He thinks nonexclusive copies of company datasets could be acquired for only “a few tens of thousands of dollars” each.</p>





<p>His organization is currently in possession of <a href="https://www.ctdcommons.org/">three datasets,</a> two of them donated by Lumen Bioscience, a biotech that previously used the Chapter 11 strategy to gain insights into another company’s drug development efforts. </p>



<p>Morrison says two other attempts to obtain drug company files this year proved unsuccessful, after 1Day Sooner’s bids were not accepted. </p>



<p>Bankruptcies could become what some are calling a <a href="https://arstechnica.com/tech-policy/2026/09/panic-builds-over-bankrupt-spirits-looming-data-sale-to-google/">“new land grab”</a> for AI training. Last month, Google won a bid to take over the corporate data of the failed carrier Spirit Airlines, <a href="https://time.com/article/2026/08/25/google-spirit-airlines-ai-data-RL/">including 100 million emails</a>. That led to objections from flight attendants and others who worried that private or proprietary data could be exposed. </p>



<p>The drug company files that 1Day Sooner is seeking are known as common technical documents. They typically contain the back-and-forth between companies and regulators, as well as detailed scientific and medical measurements, and essentially provide everything that is known about a drug.</p>



<p>According to Teslo, who is a writer for <a href="https://worksinprogress.co/our-authors/ruxandra-tesloianu/">Works In Progress</a> and a nonresident fellow at the Institute for Progress, a think tank in Washington, DC, a stockpile of such files could help turn an AI into a regulatory expert, which in her view could be one of the main ways AI helps speed cures to market.</p>



<p>“People say ‘We will invent AI, and AI will cure cancer,’ but that’s very removed from the messy reality and the regulatory process,” she says. “About 70% of the money and time in drug development is spent in clinical development—organizing the trials and testing the drug—but despite that, the process is basically a black box, especially for small biotech companies generating the innovations.” </p>]]> </content:encoded>
</item>

<item>
<title>Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles</title>
<link>https://edusehat.com/en/exosomes-linked-to-nerve-irritation-dysfunction-and-lingering-pain-after-shingles</link>
<guid>https://edusehat.com/en/exosomes-linked-to-nerve-irritation-dysfunction-and-lingering-pain-after-shingles</guid>
<description><![CDATA[ The study suggests that exosomes in the blood may promote the continued nerve irritation and dysfunction that underly why some people with shingles experience lingering pain long after the varicella zoster virus has cleared the body. 
The post Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/07/GettyImages-1466684658.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 04:30:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exosomes, Linked, Nerve, Irritation, Dysfunction, and, Lingering, Pain, After, Shingles</media:keywords>
<content:encoded><![CDATA[<p>The results of a study by researchers at the University of Colorado Anschutz suggest that that extracellular vesicles known as exosomes in the blood are the likely culprit behind why some people with shingles experience lingering pain—post-herpetic neuralgia (PHN)—long after the causative varicella zoster virus (VZV) has cleared the body.</p>
<p>Exosomes are microscopic packages released by cells that carry proteins and other molecules throughout the body. The research team found that a shingles infection can cause nerve cells to release inflammatory signals and become highly active. When investigators exposed healthy nerve cells in the lab to exosomes collected from the blood of people with PHN, they found that the exosomes triggered in the nerve cells many of the same harmful changes seen during viral infection, even though no virus was present.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The findings suggest that PHN may develop because the body fails to fully turn off the healing response after shingles. Even after the virus has been cleared, exosomes continue delivering damaging messages that prevent nerves from recovering normally.</p>
<p>The study results indicate that chronic shingles pain may not simply be the result of damage caused during the initial infection, the study authors noted. Instead, biological signals carried by exosomes may continue to keep nerve cells in an irritated, dysfunctional state and prevent them from healing. The researchers describe this as a “failure-to-resolve” model, where the nervous system becomes stuck in a cycle of inflammation and abnormal nerve remodeling. This opens the door to entirely new approaches for predicting, preventing, and treating post-herpetic neuralgia.</p>
<p>The researchers, headed by Andrew Bubak, PhD, associate professor of neurology at CU Anschutz who studies the role of exosomes in infectious disease, reported their findings in Annals of Neurology, in a paper titled, “<a href="https://doi.org/10.1002%2Fana.78352" target="_blank" rel="noopener">Circulating Exosomes Drive Persistent Neuronal Dysfunction in Post-Herpetic Neuralgia Patients</a>,” concluding, “These findings establish a failure-to-resolve model in which persistent exosome-mediated signaling sustains maladaptive neuronal remodeling after viral clearance, identifying circulating exosome cargo as previously unreported mechanistic contributors to PHN pathogenesis and potential therapeutic targets.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Varicella zoster virus can establish lifelong latency in sensory ganglia subsequent to primary infection and reactivate to cause herpes zoster—HZ; shingles—the authors explained. “Whereas most individuals recover from HZ, a substantial subset develop post-herpetic neuralgia (PHN), commonly defined as pain persisting for more than three months after rash …”. However, the mechanisms driving the change from acute viral injury to chronic neuropathic pain aren’t well understood. Bubak said, “We can completely stop the infection, yet in some patients the pain does not go away.”</p>
<p>The team’s prior work had demonstrated that plasma-derived exosomes from individuals with acute zoster infection, while non-infectious, carry prothrombotic and immunoregulatory cargo, and can activate platelets and induce proinflammatory cytokine production in vascular cells, promoting an inflammatory state.</p>
<p>Through their newly reported study the scientists discovered that nerve cells infected with the shingles virus in the laboratory became inflamed and showed signs of stress and irritation. Exposure to PHN patient-derived exosomes triggered inflammation in nerve cells and reduced the ability of nerves to grow and repair themselves. Exosome exposure also caused structural changes that may make nerves function abnormally and led to increased production of molecules associated with chronic pain. The exosomes didn’t kill the nerve cells and rather appeared to keep them in an unhealthy, dysfunctional state.</p>
<p>The researchers expected to see increases in the usual pain-signaling channels found on nerve cells. Instead, they found those channels were actually reduced. At the same time, levels of substance P, a chemical messenger involved in pain transmission, increased. This suggests that chronic shingles pain may be driven less by traditional nerve firing and more by ongoing chemical signals that keep the pain system activated. “Collectively, our findings point toward a potential ‘failure-to- resolve’ model in which PHN arises not from a fundamentally distinct biological process, but from the persistence and amplification of an initially adaptive, exosome-driven neuronal response,” the authors noted. Bubak said the findings could lead to new therapies to target these exosomes and relieve the pain.</p>
<p>Typical antiviral therapies such as acyclovir and valacyclovir target the replicating virus but do not consistently prevent PHN, “… reinforcing the notion that mechanisms independent of ongoing viral replication sustain the pathological state,” the team continued. “This is consistent with our findings, which suggest that non-infectious circulating exosomes, once generated during acute infection, persist and drive neuronal dysfunction independently of ongoing viral replication.”</p>
<p>At the same time, Bubak said, if the exosomes maintain this irritable state within the cell, they could also carry therapeutic agents to the target that block specific proteins and help nerves recover and regrow normally after shingles. “If exosome cargo contributes to the maintenance of the irritable nociceptor state, then circulating exosomes may represent both a source of therapeutic targets and a minimally invasive biomarker platform,” the authors also noted. “Early exosome profiles during acute HZ could potentially identify individuals at risk of developing PHN, enabling stratification and targeted intervention prior to the establishment of chronic symptoms.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Bubak added: “This is an important discovery, one that offers hope to those who continue to struggle with often intense pain following infection with shingles.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/exosomes-linked-to-nerve-irritation-dysfunction-and-lingering-pain-after-shingles/">Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Consolidating Antibody Discovery Data with an AI Platform</title>
<link>https://edusehat.com/en/consolidating-antibody-discovery-data-with-an-ai-platform</link>
<guid>https://edusehat.com/en/consolidating-antibody-discovery-data-with-an-ai-platform</guid>
<description><![CDATA[ The Sapio Scientific AI platform gives scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.
The post Consolidating Antibody Discovery Data with an AI Platform appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1209662272.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 00:20:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Consolidating, Antibody, Discovery, Data, with, Platform</media:keywords>
<content:encoded><![CDATA[<p>FairJourney Bio (FJBio) selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions to replace spreadsheet-based records and manual reporting processes across its international operations.</p>
<p>FJBio is a global antibody discovery and engineering partner. Founded in 2012, the company works on taking programs from target to preclinical candidate within a single integrated workflow, run by one team across three centers of excellence: Porto (Portugal), Cambridge (U.K.), and San Diego (U.S.). The antibody company completed more than 1,400 programs for over 250 industry partners across pharma, biotech, and academia, with 20 partner assets in clinical trials.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The volume and complexity of experimental data generated across those programs made consistent, structured records a scientific and operational priority for FJBio, according to Sapio Sciences’ CCO Mike Hampton, who added that the company’s AI platform will serve as the informatics backbone across all of FJBio’s discovery and cell sciences operations.</p>
<p></p><h4><strong>Provides a single entity registry</strong></h4>

<p>Sapio’s ELN solution will record experimental data across phage display, screening, and cell sciences programs, replacing the need for scientists to capture data on paper templates before manually re-entering results into spreadsheets. As FJBio’s program portfolio has grown across three sites, the Sapio LIMS gives the company a single entity registry, from target registration through clone identification and screening results, searchable across programs, points out Hampton.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The solution is also designed to ensure integration of lab instruments, connecting instrument output directly to Sapio’s experiment records and eliminating manual data transcription at the bench. Structured client data reports, that were assembled by hand from individual experiment records will now come straight out of the platform, expected to return up to 40% of scientific staff time back to discovery, says a Sapio spokesperson.</p>
<p>“FairJourney Bio runs discovery programs of genuine depth and complexity across multiple international sites,” comments the spokesperson. “The Sapio Scientific AI platform gives their scientists a single, structured environment where experimental records connect directly to client deliverables and where time spent on data consolidation becomes time spent on science.”</p>
<p><figure aria-describedby="caption-attachment-337942" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-337942" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-300x150.jpg" alt="digital dna" width="300" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-300x150.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-768x384.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001-696x348.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2244339001.jpg 836w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">FairJourney Bio selected the Sapio Scientific AI platform, including Sapio’s LIMS, ELN, and AI co-scientist solutions. [BlackJack3D/Getty Images]</figcaption></figure>Sapio’s Scientific AI Platform data model, and its ability to support full traceability from target registration through screening and hit identification, provided the technical foundation FJBio needed, states José Vidal, COO at FJBio. The inclusion of Elain, Sapio’s native AI co-scientist, rather than a bolt-on capability, was a further differentiator for FJBio as it looks to build long-term informatics capability alongside its expanding discovery operations.</p>
<p>“As our operations have grown across three international sites, we needed an informatics platform that could keep pace with that responsibility,” says Vidal. “The Sapio Platform gives our scientists a single connected environment for every experiment, every sample and every result, and it holds that data to the integrity and security standards our clients expect.”</p>
<p>Elain brings intelligence directly into FJBio’s scientific workflows, says Hampton. Working across the structured experimental data held within the Sapio Platform, Elain enables scientists to interact with their data using natural language, without leaving the environment where their experiments, samples and results are managed, he explains.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/consolidating-antibody-discovery-data-with-an-ai-platform/">Consolidating Antibody Discovery Data with an AI Platform</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Right Resin, Right Order: A Two&#45;Step Polishing Strategy for Bispecific Antibodies</title>
<link>https://edusehat.com/en/right-resin-right-order-a-two-step-polishing-strategy-for-bispecific-antibodies</link>
<guid>https://edusehat.com/en/right-resin-right-order-a-two-step-polishing-strategy-for-bispecific-antibodies</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study. 
The post Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_2238464565_HPLCAutosampler.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 16 Sep 2026 00:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Right, Resin, Right, Order:, Two-Step, Polishing, Strategy, for, Bispecific, Antibodies</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/EG-Headhsot.jpg" class="h-full w-full object-cover" alt="Image of Emily Gaither">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Emily Gaither</h2>
                <h5 class="mt-0 !text-[15px]">Engineer III, Downstream Purification<br>Thermo Fisher Scientific</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/EG-Headhsot.jpg" alt="Image of Emily Gaither">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Emily Gaither</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Emily Gaither is a bioprocessing engineer specializing in downstream purification at Thermo Fisher Scientific. She has over five years of experience in downstream process development, with expertise in downstream process development, characterization, scale up and manufacturing implementation. Prior to joining Thermo Fisher Scientific in 2021, Emily worked at the University of Illinois Urbana-Champaign, where she supported bioengineering research and laboratory automation. Emily holds a bachelor’s degree in biology from North Central College.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, October 8, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-08T15:00:06.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Bispecific antibodies can create purification challenges that conventional monoclonal antibody platform polishing is not always equipped to solve, with product-related variants “misbehaving” and closely resembling the desired heterodimer. Effective and efficient process development depends not only on identifying the appropriate selectivity from a toolbox of chromatography resins, but also how efficiently complementary unit operations interconnect for manufacturing.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study. She will compare alternative process configurations and examine the purity, recovery, and process-performance tradeoffs used to identify a preferred downstream polishing train. Key takeaways from the webinar include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>A systematic approach to screening polishing resins for bsAbs</li><p></p><p></p><p></p><li>Strategies for matching resin selectivity to key impurities</li><p></p><p></p><p></p><li>Insights into how polishing resin selection affects process performance</li><p></p><p></p><p></p><li>Criteria for balancing purity, yield, loading, and robustness</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.thermofisher.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="138" src="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png" alt="Thermo Fisher logo" class="wp-image-221790" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo.png 558w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/right-resin-right-order-a-two-step-polishing-strategy-for-bispecific-antibodies/">Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Donated livers can be made biologically younger</title>
<link>https://edusehat.com/en/donated-livers-can-be-made-biologically-younger</link>
<guid>https://edusehat.com/en/donated-livers-can-be-made-biologically-younger</guid>
<description><![CDATA[ Once an organ is removed from a donor’s body, the clock starts ticking. Surgeons usually flush the organ with a preservative solution, bag it, and put it on ice—where it immediately starts to degrade. The team has a matter of hours to get it into a recipient’s body. There’s another option—one that has been growing… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/liver-perfusion.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:30:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Donated, livers, can, made, biologically, younger</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul>
<li><strong>Perfusion machines may be turning back the clock on donated organs.</strong> Scientists found that livers kept on nutrient-pumping perfusion machines were biologically younger—by around 30%—than cold-stored livers, even when the perfused organs came from older donors.</li>
<li><strong>Molecular changes hint at why perfusion works.</strong> Researchers spotted shifts in gene activity linked to inflammation, tissue structure, and cellular recycling—clues that could eventually lead to cheaper drug-based treatments that mimic perfusion's rejuvenating effects.</li>
<li><strong>The technology is already reshaping transplant surgery.</strong> Surgeons who once avoided livers from circulatory-death donors over 40 now routinely use organs from donors over 70. "Perfusion has completely changed the landscape of transplantation in the last three years," says transplant surgeon Heidi Yeh.</li>
</ul>" data-chronoton-post-id="1144010" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Once an organ is removed from a donor’s body, the clock starts ticking. Surgeons usually flush the organ <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/university-of-wisconsin-solution">with a preservative solution</a>, bag it, and put it on ice—where it immediately starts to degrade. The team has a matter of hours to get it into a recipient’s body.</p>



<p>There’s another option—one that has been growing in popularity in recent years, especially for donated organs that aren’t in the healthiest state. Some hospitals opt to put them on machines that pump them with nutrients and remove waste products, usually for around six to 12 hours. It’s a bit like being back in a body.</p>





<p>This allows doctors to assess the organs, and some <a href="https://pubmed.ncbi.nlm.nih.gov/34985503/">recent studies</a> suggest that time spent on these perfusion machines helps them do better once they’re transplanted. Now, scientists have found that perfused organs seem to get <em>younger</em>, at least at a molecular level.</p>



<p>The research, shared with <em>MIT Technology Review</em>, provides molecular clues as to why organs from younger donors are known to have a higher success rate. It might also help explain why perfused organs are less likely to fail once they make it into a recipient. </p>



<p>The researchers behind the study hope to find new ways to test the health of donated organs and potentially develop additional tools to repair organs that might otherwise be discarded. “If [we] can improve the utilization of organs beyond what the current systems can do, then that’s a win in my book,” says Jesse Poganik, who studies aging at Brigham and Women’s Hospital in Boston and coauthored the study.</p>



<h3 class="wp-block-heading">Clocking organs</h3>



<p>Poganik—along with colleagues including Heidi Yeh and Alban Longchamp, transplant surgeons at Mass General Brigham—used<a href="https://www.technologyreview.com/2025/10/14/1124977/aging-clocks-biology-mortality-longevity/"> “aging clocks”</a> to assess donated livers. These are scientific tools designed to measure biological age—a result that is meant to convey more about the health status of an organ (or person) than chronological age.</p>



<p>In an initial experiment, the team used a clock to look at the patterns of chemical marks on DNA in 37 samples taken from 19 donated livers. Such epigenetic patterns are known to change as we age. But when the team compared samples from livers kept on ice and those that were perfused, the team found a “striking” pattern in the latter.</p>





<p>“Machine-perfused livers, in spite of being older or having other disadvantageous characteristics, had a biological age that was lower than [non-perfused] livers that were chronologically younger,” says Yeh, who led the work.</p>



<p>To investigate further, Yeh and her colleagues analyzed another 208 samples from 103 donated livers. This time, they used different aging clocks—ones that essentially measure how genes are working. They studied samples biopsied from the livers after they had been stored for up to around six hours either in cold storage or on machine perfusion.</p>



<p>In most cases, they also assessed a second sample taken around an hour after the livers had been transplanted into a recipient. Once the organ’s blood supply is reestablished in the body, “you have a few other things to do,” says Longchamp. “Then you just do a quick biopsy before you close.”</p>



<p>According to the clocks, which were developed to measure age and risk of death, the machine-perfused livers were biologically younger, the team found. “Pumping them at 34 degrees with oxygen and nutrients actually reversed the biological age,” says Longchamp. The results have been been shared with colleagues at an industry conference, he says. </p>



<p>“If you adjust out chronological age … to have a fair head-to-head comparison, the difference between the two is on the order of 30%,” says Poganik. “It’s logical to say that perfusion drives this effect.”</p>



<p>The biological ages of all the livers tended to increase as soon as they were put into a recipient’s body, probably as a result of stresses on the organs. But still, the effect endured—the perfused organs remained biologically younger. </p>



<p>Nathanael Raschzok, a transplant surgeon at Charité Universitätsmedizin Berlin in Germany who was not involved in the research, says the work is impressive. But it’s not yet clear what these changes might mean for the recipients of these organs, he says. The organs in the study were donated by people in their 30s, 40s, and 50s. Raschzok wants to know the effect of perfusion on the liver of an 80-year-old. “Every so often, we use organs from 70-, 80-, 85-year-old donors,” he says.</p>



<p>A better understanding of <em>why</em> the organs appear to be getting biologically younger might lead to therapies that achieve the same effect with a drug that could potentially be used to treat a donated organ for a fraction of the price, he adds. That’s important because perfusion is expensive—Raschzok says it costs around €10,000 in Germany (a quarter of the budget for a transplant), while the cost in the US comes to around $80,000 to $100,000 per organ, says Yeh.</p>



<h3 class="wp-block-heading">Molecular repair</h3>



<p>Yeh and her colleagues weren’t able to study most of the livers before perfusion. That’s because donated organs are generally not considered to be under the purview of the hospital until they’ve been placed on perfusion machines, she says. (Organ procurement procedures vary, but for the team as Mass General Brigham, donated organs are put on perfusion devices at the donor’s hospital. “There’s this sort of nebulous period where it’s not clear who the organ belongs to,” says Yeh.)</p>





<p>Still, by looking at the genes and molecular pathways that seem to be altered in perfused organs, she and her colleagues can garner some clues. At a molecular level, the team saw changes in cell pathways linked to inflammation and the structure of tissues, for example. They also saw more activity in a pathway that allows cells to remove and recycle damaged cell parts, says Yeh.</p>



<p>Poganik hopes to develop some kind of test that would determine which organs, on the basis of their biological age, are suitable for transplantation. He and his colleagues are also experimenting with potential drug treatments that might push the biological age of an organ even lower.</p>



<p>In the meantime, any liver that is not from a “perfect, young, brain-dead donor” could probably benefit from perfusion, says Yeh. The devices are already transforming transplant surgery. Just a few years ago, she says, she and her colleagues would avoid using livers from people who’d suffered a circulatory death (when the heart stops beating and there’s a damaging lack of blood flow to organs) and were over 40. Today, they use livers from such donors over the age of 70. “Perfusion has completely changed the landscape of transplantation in the last three years,” she says.</p>]]> </content:encoded>
</item>

<item>
<title>Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development?</title>
<link>https://edusehat.com/en/why-does-a-particular-genetic-variant-lead-to-accelerated-huntington-disease-development</link>
<guid>https://edusehat.com/en/why-does-a-particular-genetic-variant-lead-to-accelerated-huntington-disease-development</guid>
<description><![CDATA[ Study results suggest how a particular genetic variant can speed onset of Huntington disease motor symptoms by up to 12.5 years and accelerate clinical measures of disease progression, by driving runaway DNA changes inside the brain&#039;s most vulnerable neurons. 
The post Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/05/GettyImages-1495440392.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:25:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Why, Does, Particular, Genetic, Variant, Lead, Accelerated, Huntington, Disease, Development</media:keywords>
<content:encoded><![CDATA[<p>Research headed by scientists at the University of British Columbia has revealed why some people with Huntington disease (HD) may develop an earlier onset, more aggressive form of the disease. The study shows how a particular genetic variant can speed onset of HD motor symptoms by up to 12.5 years and accelerate clinical measures of disease progression by driving runaway DNA changes inside the brain’s most vulnerable neurons.</p>
<p>“People with this genetic variant have dramatically hastened onset of disease, but we didn’t know why,” said Michael Hayden, MBChB, PhD, professor at the Centre for Molecular Medicine and Therapeutics at UBC. “This work answers that question and provides dramatic evidence that repeated expansion of the mutation is an important driver of Huntington disease and a potential treatment target.” Hayden is senior author of the researchers’ published paper in <em>Neuron</em>, titled “<a href="https://doi.org/10.1016/j.neuron.2026.08.010" target="_blank" rel="noopener">Loss of interruption in the <em>HTT</em> CAG repeat is associated with increased somatic expansion and loss of medium spiny neurons in HD</a>.”</p>
<p>Huntington disease is a rare, inherited neurological disorder that causes the progressive breakdown of nerve cells in the brain. The condition affects movement, thinking and emotional well-being, and there is currently no cure or treatment to slow progression.</p>
<p>One way to think about the process is like a typo in a document that keeps getting copied. With every copy, the mistake is replicated and interferes with the message. “HD is caused by 36 or more uninterrupted CAG repeats in exon 1 of the Huntingtin gene (<em>HTT</em>), and the number of inherited CAG repeats is the primary determinant of the age at which symptoms first emerge,” the authors explained.</p>
<p>In Huntington disease the mutation continues to repeat and expand within neurons over time. As those repeats become longer, they interfere with normal cell function and make brain cells increasingly vulnerable to damage and death. “Medium spiny neurons (MSNs) are gradually lost in HD and undergo selective somatic CAG expansion, but it is unclear how somatic expansion relates to MSN pathology,” they continued.</p>
<p>Hayden added, “When we looked at the neurons that are dying in Huntington disease, we saw much greater expansion of the genetic mutation. This continues to strengthen the argument that DNA expansion is an important cause of disease.”</p>
<p>A small proportion of people with HD have a particular genetic variant, and researchers have known for years that these individuals develop Huntington disease earlier in life. “CAG and CCG loss-of-interruption (CAG-CCG LOI) variant hastens the onset of HD motor symptoms by up to 12.5 years and accelerates clinical measures of disease progression when compared with patients with the canonical sequence,” the team noted.</p>
<p>But it wasn’t known why this seemingly small change in DNA had such a dramatic effect on disease onset and progression. People carrying the variant had dramatically larger expansions of the Huntington mutation inside their neurons, occurring about five times more frequently than in patients without the variant. They also had fewer surviving neurons and earlier loss of particularly vulnerable nerve cells.</p>
<p>For their reported study the researchers analyzed blood samples and post-mortem brain tissue. “Here, we apply complementary approaches to assess somatic <em>HTT</em> CAG expansion from peripheral blood, postmortem brain tissues, and isolated MSNs of HD patients with and without the CAG-CCG LOI modifier variant and quantify MSN loss in the CAG-CCG LOI donor caudate.” They found a clue that helps explain one of the mysteries of Huntington disease, which is why a mutation that is present in every cell of the body primarily damages the brain.</p>
<p>Although the mutation exists throughout the body, the researchers found that the expansion process appears to be highly concentrated in certain cells of the brain. Blood samples, by contrast, showed little evidence of the dramatic changes that take place within the brain’s neurons. “Our interrogations of somatic expansion in blood, brain, and striatal MSNs of donors with and without the CAG-CCG LOI show this modifier does not increase small expansions in blood or bulk brain tissues, yet profoundly increases the proportion of genomic large (111–150) and very large (>150) CAG expansions in affected striatal MSNs,” they wrote.</p>
<p>“The mutational expansion seems to be selective for the brain,” Hayden added. “That may help explain why Huntington disease, even though the mutation is in every cell, is fundamentally a brain disease.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The findings suggest blood tests are not a reliable indicator of the disease unfolding inside the brain, which is an important consideration for future Huntington disease research and clinical trials. “Peripheral blood DNA does not capture increased somatic expansion in MSNs, suggesting that blood DNA is a poor biomarker for disease-relevant somatic expansion in HD-affected neurons,” they noted.</p>
<p>While other factors besides expansion likely contribute to neuron loss, the findings provide some of the strongest human evidence to date that expansion of the Huntington mutation is a key factor in disease progression. “It validates repeat expansion of the DNA as an important therapeutic target in Huntington disease,” Hayden said. “If we can suppress that expansion, it may be possible to delay progression or delay the onset of disease.” And as the authors further commented, “Our study further underscores the need for cell-type-specific studies across other repeat expansion disorders that preferentially affect specific neuron populations.”</p>
<p>Several experimental therapies in development aim to slow or prevent this mutation growth before the damage occurs. While more research is needed, this study’s findings show research is moving in the right direction for a disease which has been so difficult to treat.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/why-does-a-particular-genetic-variant-lead-to-accelerated-huntington-disease-development/">Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pneumococcal Subtypes Influence the Impact of Air Pollution on Disease Risk</title>
<link>https://edusehat.com/en/pneumococcal-subtypes-influence-the-impact-of-air-pollution-on-disease-risk</link>
<guid>https://edusehat.com/en/pneumococcal-subtypes-influence-the-impact-of-air-pollution-on-disease-risk</guid>
<description><![CDATA[ Pneumococcal bacterial subtypes influence how air pollution affects invasive disease risk, with certain strains linked to greater or faster risks of pneumonia, sepsis, and meningitis.
The post Pneumococcal Subtypes Influence the Impact of Air Pollution on Disease Risk appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2203265939.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pneumococcal, Subtypes, Influence, the, Impact, Air, Pollution, Disease, Risk</media:keywords>
<content:encoded><![CDATA[<p><em>Streptococcus pneumoniae</em> is a member of the respiratory microbiome and can be found in almost 20 percent of adults globally. While many adults and children carry the bacteria without symptoms, the bacterium can lead to invasive pneumococcal disease (IPD) which includes bacterial sepsis, pneumonia, and meningitis.</p>
<p>There are currently over 100 different serotypes of <em>S. pneumoniae</em>. While it is known that different subtypes of <em>S. pneumoniae</em> can lead to varying infection rates in different populations, important gaps remain in our collective understanding of how things such as humidity, temperature, and air pollution impact the timing of disease, and how risks vary by individual age and bacterial subtype.</p>
<p>Now, researchers suggest that the subtype of <em>S. pneumoniae</em>, together with air pollution exposure, impacts the rate and timing of invasive disease—with some strains linked to immediate infection after air pollution exposure, and others taking several weeks. The findings also suggest that older adults and young children are more vulnerable during periods of high air pollution, and that improving air quality could lower disease risk. Understanding what type of bacterial strains are circulating, and how environmental factors shape infection rates, could inform future public health policies, protect those most at risk, and prepare hospitals for outbreaks.</p>
<p>The work is published in <em>Nature Microbiology</em> in the paper, “<a href="https://www.nature.com/articles/s41564-026-02458-5" target="_blank" rel="noopener">Pneumococcal population structure influences the effects of air pollution on invasive disease risk in South Africa</a>.”</p>
<p>“While we found that temperature and air pollution generally increase the risk of invasive pneumococcal diseases, such as bacterial meningitis, our research also suggests that it is the bacterial subtypes a person is carrying that modulate infection rates,” notes Sophie Belman, PhD, previously at the Wellcome Sanger Institute and Barcelona Supercomputing Center, and currently an assistant professor at Yale School of Public Health. “The strain of bacteria impacts the timing of disease and who might be more at risk depending on their respiratory microbiome, meaning that the risk is not the same in every situation or for every person. By extending our findings to other parts of the globe, we will better understand who has the highest health risk from environmental exposures, and what factors need to be addressed in different regions, such as improving air quality in cities.”</p>
<p>This new study examined roughly 59,000 cases of IPD across 19 years from South Africa’s national GERMS-SA surveillance program. In South Africa, between 40-60 per cent of children carry <em>S. pneumoniae</em>. The researchers found that different subtypes of <em>S. pneumoniae</em> responded differently to higher air pollution exposure, noting three subtypes (14, 19A, and 8) were linked to the greatest risk of IPD following exposure.</p>
<p>Additionally, they found that different subtypes were linked to differences in the timing of disease risk. While the highest risk of IPD peaked roughly two weeks after air pollution exposure, in areas where subtypes 4, 8, 23F, and 19F were common, there was an immediate increase in disease risk, occurring within the same week.</p>
<p>The team accounted for other factors including temperature, humidity, and population density to ensure that the effects were measured as accurately as possible. They also noted that high temperatures were associated with an immediate increase in disease risk, and cold temperatures led to a delayed rise in cases. The team suggests that cold weather slows bacterial transmission or that damage from seasonal viruses could make it easier for bacterial infections to follow.</p>
<p>The authors suggest that integrating environmental monitoring with genomic surveillance of <em>S. pneumoniae</em> could help predict infection spikes, inform vaccination strategies, and support healthcare providers prepare during periods of poor air quality. The study also provides further evidence that reducing air pollution may yield important benefits for infectious disease prevention, particularly in areas with high levels of exposure, such as cities.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/pneumococcal-subtypes-influence-the-impact-of-air-pollution-on-disease-risk/">Pneumococcal Subtypes Influence the Impact of Air Pollution on Disease Risk</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Evonik Expands in Slovakia</title>
<link>https://edusehat.com/en/evonik-expands-in-slovakia</link>
<guid>https://edusehat.com/en/evonik-expands-in-slovakia</guid>
<description><![CDATA[ Compared with the conventional synthesis of chemicals, fermentation-based processes can offer a more sustainable route to selected intermediates by reducing the need for organic solvents and minimizing process-related waste. 
The post Evonik Expands in Slovakia appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2216056406.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 15 Sep 2026 03:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Evonik, Expands, Slovakia</media:keywords>
<content:encoded><![CDATA[<p>Germany-based Evonik has broken ground on a new biotechnology expansion project at its Fermas site in Slovenská Ľupča, Slovakia. The company notes that this marks the next major milestone in the approximately EUR 80 million investment to expand Evonik’s biotechnology capabilities and strengthen its contract manufacturing services for the company’s drug substance business. The project is expected to be completed in early 2028.</p>
<p>The investment will add downstream fermentation technology to the site, increasing capacity for the development and manufacture of complex pharmaceutical intermediate. Creating approximately 50 new jobs, the expansion will further reinforce the Fermas site as one of Evonik’s key biotechnology hubs, said Lauren Kjeldsen, member of the management board and COO at custom solutions, Evonik.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Today is an important step in our strategy to expand our biotechnology platform and support our customers with innovative, scalable, and sustainable manufacturing solutions,” continued Kjeldsen. “Biotechnology demonstrates how economic growth and sustainability can go hand in hand.”</p>
<p>Compared with conventional chemical synthesis, fermentation-based processes can offer a more sustainable route to selected intermediates by reducing the need for organic solvents and minimizing process-related waste. The Fermas site already operates on 100 percent green electricity and uses renewable and certified raw materials in selected production processes.</p>
<p>“This investment demonstrates the company’s confidence in biotechnology and in Slovakia as a location where innovation turns into industrial scale products,” added Miroslav Havlik, general manager of Evonik Fermas.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Evonik Fermas, which was founded in 1992, has evolved from amino acid production into a biotechnology manufacturing hub serving the pharmaceutical, personal care, nutrition, and specialty chemical industries. In recent years, the site has also become a major location for Evonik’s biotechnology activities, including the launch of an industrial-scale <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcisionone-email.news.evonik.com%2Fc%2FeJw0kM2OpSAQhZ9Gd2UE_IGFi974Gp0Cira6URzAvq8_4WZmRfJxTr7U8RtpM2nZ0yZWbZRZ1Gz6YxOzXiahg5FIdkRH0ktrZRidt8LZqedtQdTjvOr2hZ9CULCjGYUR3TQW9vTDf-BEjpQLODM57ecQYH7N325ovI_bUetdOvXRyb2T-_3YyA4rp6sM9Jsu_hlcOju509XJ_STP2GKZSoFMkbBQ6eTuUr5Txkot-a6BfTj6Aq-U2xM4lwp8-afUzBihOIwEd07-cU0Hd8SrQkgZ8oHnlSLf7AuIRU96HY56xv6t_68F9tsbfP4DnfpQ8yjF1OftOx3XUCrlyNdXGwO_6H5su6UvNROdra7M6sgLA9pKCROtAawKCqTxiMt7Z9X_bvJvAAAA__9mhYo7&data=05%7C02%7Cjohn.sterling%40sagepub.com%7C1e24453562fe4ed2c0a208df126d07ed%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639249931683823809%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=NpOk5%2BSj%2FRKwptAHWz2EPag3KnP2l4HwXPls9UTHLMI%3D&reserved=0" target="_blank" rel="noopener">rhamnolipid biosurfactant production</a> facility.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/evonik-expands-in-slovakia/">Evonik Expands in Slovakia</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>With pharmaceutical tariffs looming, guidance on compliance is still lacking</title>
<link>https://edusehat.com/en/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking</link>
<guid>https://edusehat.com/en/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking</guid>
<description><![CDATA[ With tariffs on patented pharmaceuticals and input materials set to take effect for all companies on Sept. 29, the lack of clarity about rules […]
The post With pharmaceutical tariffs looming, guidance on compliance is still lacking appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/rinson-chory-2vPGGOU-wLA-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 14 Sep 2026 20:20:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>With, pharmaceutical, tariffs, looming, guidance, compliance, still, lacking</media:keywords>
<content:encoded><![CDATA[<p><span>With tariffs on patented pharmaceuticals and input materials set to take effect for all companies on Sept. 29, the lack of clarity about rules and exemptions is complicating business decisions and creating uncertainty for investors.</span></p>
<p><span>What does seem certain is that pharmaceutical tariffs will reduce the funds biotechnology firms have to develop treatments, discourage investors, and threaten patients’ access to drugs. For these reasons, pharmaceuticals have traditionally been considered off-limits for tariffs.</span></p>
<p><span>“At a time when the U.S. is competing to maintain global leadership in biotechnology, policies that raise costs, discourage innovation, and weaken our competitive position ultimately make it harder to deliver for patients and strengthen the economy,” warns Kelly Seagraves, VP of National Security & International Affairs at the Biotechnology Innovation Organization (BIO). “We urge the Administration to consider alternative policies for bolstering U.S. manufacturing and resilient supply chains.”</span></p>
<p><span>For now, BIO continuously seeks guidance on tariff compliance and potential exemptions, to inform the industry.</span></p>
<p><span>On Sept. 14, with two weeks until implementation, BIO’s experts say much of the necessary federal guidance is still missing, and the lack of information adds further challenges to an already challenging situation.</span></p>
<h2>What is known</h2>
<p><span>Based on</span><a href="https://www.federalregister.gov/documents/2026/04/09/2026-06956/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states"><span> a </span><span>Presidential Proclamation</span></a><span> signed April 2, 100% </span><i><span>ad valorem</span></i><span> tariffs on patented pharmaceutical products and associated input materials go fully into effect on Sept. 29.</span></p>
<p><span>There are several potential reductions or exemptions for specific companies, countries, and products:</span></p>
<ul>
<li aria-level="1"><span> </span><b>Countries </b><span>of origin matter:</span> <span>The tariff is reduced to 15% for non-exempt products from Japan, the EU, Korea, and Switzerland/Liechtenstein. Tariffs on U.K. imports are 0% following an August 4 Federal Register Notice from the Department of Commerce.</span></li>
<li aria-level="1"><b>Companies</b><span> can reduce tariffs to 20% or 0%, by negotiating an onshoring plan with the Department of Commerce or by negotiating both an onshoring plan and a Most Favored Nation (MFN) pricing agreement with the Department of Health and Human Services. These reductions are temporary, expiring April 2, 2030 and January 20, 2029, respectively.</span></li>
<li aria-level="1"><b>Products</b><span> that are exempt include generics and biosimilars until April 2, 2027, with a mandate to reconsider generic eligibility in 2027. The Proclamation also notes several classes of drugs that may be exempt, but only if they originate from a country with a trade and security framework agreement or they meet an urgent U.S. health need.</span></li>
</ul>
<h2>What is unknown</h2>
<p><span>The lack of specific guidance for the industry on what products will be exempted and how exemptions will be granted means both industry and the U.S. government will be under immense time pressure, making it highly unlikely the pharmaceutical tariff regime can be fully implemented on Sept. 29. Implementation will require further guidance, including:</span></p>
<ul>
<li aria-level="1"><b>Specifics on product exemptions:</b><span> Companies need to know whether their products qualify for Clause (3)(d)</span> <span>exemptions. These may include orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, and medical countermeasures for public health threats. However, there is uncertainty about the details of qualifying for these exemptions. Other questions concern importing branded, off-patent drugs, or the input materials to manufacture in the U.S. patented pre-commercial products that are not yet making money.</span></li>
<li aria-level="1"><b>Case-by-case product decisions for an “urgent U.S. health need”:</b><span> The Commerce Department has indicated decisions about exemptions for meeting an “urgent U.S. heath need” will be made on a case-by-case basis. Yet companies are still awaiting Commerce guidance on the process to request an exemption.</span></li>
<li aria-level="1"><b>Preparing the requested information </b><span>undoubtedly increases compliance and administration costs—a particular challenge for smaller and mid-size biotech companies with small teams and limited capital. Further, application and government review could be time-consuming, adding to uncertainty about when tariffs apply and how much they will be.</span></li>
<li aria-level="1"><b>Countries with trade and security framework agreements: </b><span>The second avenue for a Clause 3(d) exemption is that the product originates from a specific set of countries. The U.S. government has still not shared which countries these are.</span><b> </b></li>
<li aria-level="1"><b>MFNs and onshoring:</b><span> There are no clear parameters for MFN or onshoring deals, which are apparently handled case-by-case.</span></li>
</ul>
<p><span>This continued uncertainty raises questions about short-term implementation. In one scenario, all eligible pharmaceutical products would be charged tariffs based on country of origin, and companies granted exemptions might receive refunds later. Alternatively, the government could delay collection of tariffs on potentially exempt products but collect retroactively. A final option would be a Presidential decision to forego or delay implementation, giving both companies and the government sufficient time to determine eligibility for exemptions.</span></p>
<h2>Impacts on biopharma and patients</h2>
<p><span>Impacts are hard to predict with so many unknowns about the total amount of tariffs that will be collected and what companies and products will be charged, BIO experts say.</span></p>
<p><span>For many companies, an exemption could be the difference between 100% tariff rates and no tariffs. The resulting uncertainty around costs for the industry and individual companies is an impact itself. It frightens investors and complicates business planning, making companies hesitant to spend on R&D when their capital needs are uncertain.</span></p>
<p><span>The challenge is particularly acute for the small- to medium-sized companies that are responsible for 71% of the industry’s output and 54% of the new drug applications,</span><a href="https://www.bio.org/toolkit/human-health/americas-innovation-engine-power-small-and-mid-sized-biotechs"> <span>according to BIO</span></a><span>. The smaller innovative companies generally have less available capital to adjust to shocks like tariffs.</span></p>
<p><span>The anticipated impact on patients will be two-fold. First, out-of-pocket costs can be expected to rise when importing drugs is 100% more expensive. Second, there will be negative impacts on innovation as companies that lose income due to tariffs spend less on R&D. Access challenges may arise if some companies stop importing certain drugs into the U.S. altogether.</span></p>
<h2>What to do instead of tariffs</h2>
<p><span>The tariffs are being implemented after a Department of Commerce Section 232 investigation determined that global supply chains are risky, and that onshoring drug production bolsters national security. But BIO experts note that tariffs actually create new disturbances in the existing supply chain.</span></p>
<p><span>There are better ways to protect global supply and attract manufacturing back to the U.S., according to BIO. These include strategic incentives, such as tax credits for building domestic manufacturing, and investments in U.S. biotechnology and biomanufacturing workforce development.</span></p>
<p><span>Appropriately targeted, non-tariff measures could secure supply chains while freeing small- and medium-sized biotechs to invest more in innovation. The improved clarity and certainty would benefit biotechs, investors, and patients.</span></p>
<p>The post <a href="https://bio.news/federal-policy/with-pharmaceutical-tariffs-looming-guidance-on-compliance-is-still-lacking/">With pharmaceutical tariffs looming, guidance on compliance is still lacking</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Novartis Loses More than Market Value After Phase III Failure</title>
<link>https://edusehat.com/en/stockwatch-novartis-loses-more-than-market-value-after-phase-iii-failure</link>
<guid>https://edusehat.com/en/stockwatch-novartis-loses-more-than-market-value-after-phase-iii-failure</guid>
<description><![CDATA[ Del-desiran was one of three clinical setbacks for Novartis within a week. On September 4, the company and partner Ionis Pharmaceuticals (Nasdaq: IONS) acknowledged that their co-developed pelacarsen failed the Phase III Lp(a)HORIZON trial (NCT04023552) by missing its primary endpoint of reducing the risk, compared with placebo, of cardiovascular events. Two days earlier, Novartis paused eight trials assessing its autoimmune and neurological disease candidate rapcabtagene autoleucel (rap-cel), after three patients treated with the personalized, CD19-directed chimeric antigen receptor T cell (CAR T) therapy died after experiencing immune effector cell-associated hemophagocytic syndrome.
The post StockWatch: Novartis Loses More than Market Value After Phase III Failure appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/reigniting-a-passion-for-1-science.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 14 Sep 2026 05:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Novartis, Loses, More, than, Market, Value, After, Phase, III, Failure</media:keywords>
<content:encoded><![CDATA[<p><strong>Novartis (SIX Swiss: NOVN and NYSE: NVS) </strong>lost more than just the roughly $30 billion in market capitalization (share price times the number of outstanding shares) that dried up this past week when the company said its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a Phase III trial.</p>
<p>Arguably the most dramatic loss faced by Novartis is satisfaction with its direction by major investors—one of which, Artisan Partners, went public with criticism of the company’s board.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>M. David Samra, managing director at Artisan Partners and founding partner of International Value Group, called on the board—specifically, its chairman Giovanni Caforio—to strengthen its oversight of the company’s acquisitions.</p>
<p>“I think he needs to make changes at the board level. One of them should be on improving the team that’s doing ​these deals because clearly they have been uninspiring at best,” Samra told Reuters in an interview.</p>
<p>“The party is over,” Samra declared, complaining that the acquisition deals lowered the value of Novartis shares. “The acquisition track record is not very good.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<figure aria-describedby="caption-attachment-337820" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337820" src="https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-300x300.jpg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE-696x696.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/N-David-Samra-Artisan-Partners-CROP11111SQUARE.jpg 810w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">M. David Samra, managing director at Artisan Partners and founding partner of International Value Group</figcaption></figure>
<p>Among the acquisitions cited by Samra were Novartis’ <a href="https://www.genengnews.com/topics/translational-medicine/novartis-to-acquire-avidity-for-12b-bolstering-neuroscience-pipeline/">$12 billion buyout of Avidity Partners</a>, a deal completed in February with the aim of bolstering the buyer’s neuroscience pipeline with three late-stage programs—del-desiran and two other candidates in a new class of RNA therapeutics that Avidity and now Novartis call Antibody Oligonucleotide Conjugates (AOCs<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">).</p>
<p>The companies have reasoned that the AOC approach can safely and effectively treat serious genetic neuromuscular disorders by delivering RNA to muscle tissue via TfR1 mAb, in order to enable modulation of the genetic mechanism of disease.</p>
<p>But that argument was undermined when Novartis acknowledged that del-desiran <a href="https://www.genengnews.com/topics/translational-medicine/novartis-shares-slide-after-neuromuscular-candidate-acquired-with-avidity-fails-phase-iii-trial/">failed the pivotal trial</a> (HARBOR, <a href="https://clinicaltrials.gov/study/NCT06411288">NCT06411288</a>) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT) through week 54. vHOT is a frequently used measure of hand myotonia, according to a <a href="https://www.nmd-journal.com/article/S0960-8966(24)00692-8/fulltext">2024 study</a>, and involves clinical experts reviewing videos to measure the time from hand grip to opening.</p>
<p>Del-desiran is an AOC candidate designed to target the underlying cause of DM1. The therapy consists of a muscle-targeting monoclonal antibody that binds to the transferrin receptor 1 (TfR1) and is conjugated to a small interfering RNA (siRNA) designed to induce degradation of the disease-causing toxic myotonic dystrophy protein kinase (DMPK) mRNA.</p>
<p>Del-desiran has received the FDA’s Orphan Drug, Fast Track, and Breakthrough Therapy designations, as well as the European Medicines Agency’s Orphan Medicinal Product Designation.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<h4><strong>“Needs to be penalized”</strong></h4>
<p>“If you do a $12 billion deal and it goes to zero, the management needs to be penalized for that,” Samra said, though he acknowledged that the Avidity acquisition may yet yield successful candidates that can be developed into marketable drugs.</p>
<p>Samra also took issue with <a href="https://www.genengnews.com/topics/cancer/novartis-to-acquire-morphosys-for-2-9b-bolstering-oncology-pipeline/">Novartis’ acquisition of MorphoSys</a> for €2.7 billion ($3.1 billion), completed in May 2024. That deal was intended to bolster the buyer’s oncology pipeline with what seemed like a promising late-stage myelofibrosis candidate in pelabresib, as well as an early-stage candidate under study in patients with solid tumors or lymphomas.</p>
<p>Within months, Novartis delayed earlier plans to pursue mid-2024 approval filings for pelabresib and later said more time was needed to decide a regulatory path for the drug based on 48-week data from the Phase III MANIFEST-2 trial (<a href="https://clinicaltrials.gov/study/NCT04603495">NCT04603495</a>). However, the combination of pelabresib plus ruxolitinib met the study’s primary endpoint, a reduction of at least 35% in spleen volume from baseline (SVR35) at 24 weeks: 65.9% of pelabresib-ruxolitinib patients (N=214) vs. 35.2% of placebo-ruxolitinib patients (N=216)</p>
<p>Earlier this year, Novartis launched the Phase III MANIFEST-3 trial (<a href="https://clinicaltrials.gov/study/NCT07357727">NCT07357727</a>) assessing pelabresib in combination with ruxolitinib in patients with myelofibrosis. Novartis markets ruxolitinib outside the United States as Jakavi®, while Incyte markets the drug Stateside as Jakafi®. The trial’s estimated completion date is May 2028.</p>
<p>Del-desiran was one of three clinical setbacks for Novartis within a week. On September 4, the company and partner <strong>Ionis Pharmaceuticals (Nasdaq: IONS)</strong> acknowledged that their co-developed pelacarsen failed the Phase III Lp(a)HORIZON trial (<a href="https://clinicaltrials.gov/study/NCT04023552">NCT04023552</a>) by missing its primary endpoint of reducing the risk, compared with placebo, of cardiovascular events.</p>
<p>Two days earlier, Novartis paused eight trials assessing its autoimmune and neurological disease candidate rapcabtagene autoleucel (rap-cel), after three patients treated with the personalized, CD19-directed chimeric antigen receptor T cell (CAR T) therapy died after experiencing immune effector cell-associated hemophagocytic syndrome.</p>
<p></p><h4><strong>Not Blaming CEO</strong></h4>

<p>Samra stopped short of blaming Vas Narasimhan, who has been Novartis’ CEO since 2018, for the company’s clinical setbacks, saying the chief did a “very good job”—with Reuters suggesting by juxtaposition a possible explanation: The company’s shares have <span><strong>jumped 60%</strong></span> in value during his tenure at the helm.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>But Novartis’ primary shares in Switzerland have only <span><strong>risen 2%</strong></span> from CHF 108.50 ($132.88) so far this year and <span><strong>climbed 11%</strong></span> from CHF 101.78 ($124.65) year-over-year.</p>
<p>Worse, the announced failure of del-desiran on September 8 propelled Novartis shares to their worst one-day selloff since March 2020, early in the COVID-19 pandemic. Shares trading on the SIX Swiss Exchange <span><strong>skidded 11%</strong></span> from CHF 125.46 ($153.64) to CHF 111.80 ($136.91), while Novartis’ American depositary shares traded on the New York Stock Exchange <span><strong>slid 14%</strong></span> from $159.99 to $137.72.</p>
<p>Both shares all but plateaued for the rest of the week, failing to regain momentum. At the end of trading Friday, the SIX Swiss shares <span><strong>inched up 0.2%</strong></span> to CHF 112.04 ($137.21), while the NYSE shares <span><strong>dipped a further 0.4%</strong></span>, finishing the week at $137.16.</p>
<p>Artisan’s flagship fund, the Artisan International Value Fund, listed Novartis as fourth among its top 10 holdings, accounting for <a href="https://www.artisanpartners.com/content/dam/documents/fact-sheets/vr/2026/2q/ARTKX-APDKX-APHKX-Fact-Sheet-2Q26-vR.pdf">3.6% of its total portfolio as of June 30</a>, according to its most recent quarterly fact sheet. As of that date, Artisan reported $45.184 billion in assets, which would have made the value of Artisan’s stake in Novartis approximately $1.627 billion.</p>
<p>That stake likely increased later in the summer before the del-desiran news, since Artisan’s website lists the total value of the value fund at <a href="https://www.artisanpartners.com/individual-investors/investments/international-value-group/international-value-fund-aphkx.html">$46.001 billion as of August 31</a>.</p>
<p>In addition to del-desiran, Novartis acquired delpacibart zotadirsen (del-zota<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">), an Exon 44-targeting AOC designed to treat Duchenne muscular dystrophy (DMD), and delpacibart braxlosiran (del-brax<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">), an AOC intended to treat facioscapulohumeral muscular dystrophy (FSHD) by targeting DUX4.</p>
<p>Del-zota is under evaluation in the Phase II EXPLORE44OLE<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (<a href="https://clinicaltrials.gov/study/NCT06244082">NCT06244082</a>) trial following completion in November 2024 of the Phase I/II EXPLORE44<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (<a href="https://clinicaltrials.gov/study/NCT05670730">NCT05670730</a>) study. Del-brax is being assessed in the Phase III FORTITUDE-3<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> trial (<a href="https://clinicaltrials.gov/study/NCT07038200">NCT07038200</a>).</p>
<p>In June, Novartis trumpeted positive data from the FORTITUDE Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT05747924">NCT05747924</a>) of del-brax, saying the study’s biomarker cohort met its primary and key secondary endpoints, with reductions in KHDC1L (cDUX) and creatine kinase biomarker levels indicating both strong target engagement and reduction in muscle damage in patients with FSHD.</p>
<p></p><h4><strong>Investors weigh in</strong></h4>

<p></p><h4><span>Samra’s criticism of Novartis’ board was echoed by what Reuters said was some of seven other representatives of shareholders, five of whom were quoted by name in a follow-up article.</span></h4>

<div class="my-8"><span data-render-ad="7"></span></div>
<p>“It’s ​going to take a while for confidence to return,” said Gillian Hollenstein, lead manager at Point Capital Navigator Fund, which, as of September 10, listed Novartis as tenth of its top 10 holdings, accounting for 1.8% of its total portfolio. The fund reported CHF 124.38 million ($152.33 million) in total assets as of that date, making Point Capital’s stake total CHF 2,238,840 (more than $2.7 million).</p>
<p>“They ​would have been better off doing some more smaller acquisitions, bolt-on ones rather than trying to hit it out of the park,” Hollenstein added.</p>
<p>Avidity was the largest of 11 biopharma acquisitions Novartis has carried out since 2023. They all could total up to $32.9 billion if Novartis achieves the milestones called for in five of the deals.</p>
<p>“It’s a little bit premature to call for heads at this point,” said Daniel Bolanowski, portfolio manager at investor Arctic Asset Management, since Avidity-created del-zota and del-brax could ultimately succeed in the clinic and generate revenue. But Bolanowski added that the stock selloff suggested “a deeper trust issue” with the company’s business development approach, beyond the failure or reduced value of del-desiran.</p>
<p>Arctic Aurora, <a href="https://cdn.arctic.com/documents/AAM-Documents/Arctic-Funds-Plc-Annual-and-Interim-Report/C21397_C67157_20260630_FSIIFS.pdf">as of June 30,</a> had a Novartis investment it quantified as 2,660 shares valued at a total NOK 4,124,818 ($443,994.25), accounting for 1.23% of its portfolio.</p>
<p>Michael Hannig, a buy-side analyst covering global healthcare and portfolio manager of a DACH [Germany, Austria, and Switzerland] small- and mid-cap fund at DJE Kapital, suggested to Reuters that Novartis could regain investor confidence and replenish its pipeline following patent cliff exclusivity expirations by pursuing deals in the $5 billion to $10 billion range for late-stage assets or ​drugs nearing approval, subject to due diligence: “Larger transactions will likely be assessed carefully by ‌investors considering ⁠the mixed market reception to several prior deals.”</p>
<p>DJE Kapital has disclosed having <a href="https://www.dje.de/en/about-dje/">more than €18.9 billion</a> ($21.9 billion) in total assets under management across its funds as of  but does not disclose the portfolio details of its individual funds.</p>
<p>Executives at two other Novartis investors, Bellevue Asset Management and Union Investment, defended Novartis: Guy Bettschart-Ghassabi, healthcare analyst at Bellevue Asset Management, noted that the HARBOR study was designed by Avidity before its acquisition by Novartis, while Markus Manns, portfolio manager at Union Investment, said the failure of del-desiran and pelacarsen was unfortunate but within normal probabilities of drug development success.</p>
<p>“They have to work harder to fulfill their post-2030 goals,” Manns said, “but it’s in the same camp as most other pharma companies.”</p>
<p>Bellevue Asset Management finished last year with AUM of CHF 5.3 billion (nearly $6.5 billion) while Union Investment reported €534.6 billion (about $620.3 billion), according to public disclosures that also exclude portfolio details.</p>
<p></p><h4><strong>Good news for competitors </strong></h4>

<p>Myles R. Minter, PhD, a partner and biotechnology analyst with William Blair, wrote in a research note that Novartis’ clinical miss for del-desiran is a positive development for several potential competitors, which, like the Swiss pharma giant, are also developing drugs designed to treat DM1 by targeting DMPK. These include:</p>
<ul>
<li><strong>Dyne Therapeutics (Nasdaq: DYN)</strong>, which is developing zeleciment basivarsen (z-basivarsen or DYNE-101), an anti-TfR1 FAb-conjugated antisense oligonucleotide (ASO). Z-basivarsen is under study in the Phase III HARMONIA trial (<a href="https://clinicaltrials.gov/study/NCT07486934">NCT07486934</a>), after generating positive strength and cognition data in March from the Phase I/II ACHIEVE trial (<a href="https://clinicaltrials.gov/study/NCT05481879">NCT05481879</a>), set to read out new one-year data later this month. Topline data is expected from ACHIEVE’s registrational expansion cohort in the first quarter of 2027.</li>
<li><strong>Sarepta Therapeutics (Nasdaq: SRPT)</strong> and <strong>Arrowhead Pharmaceuticals (Nasdaq: ARWR)</strong>, which are co-developing SRP-1003 (formerly ARO-DM1), an RNA interference (RNAi) conjugate being assessed in a Phase I/IIa trial (<a href="https://clinicaltrials.gov/study/NCT06138743">NCT06138743</a>) that generated positive early clinical results and is set to read out multiple ascending dose data later in the second half. Sarepta is in-licensing SRP-1003 from Arrowhead under a collaboration announced in 2024 that generated for Arrowhead $825 million in upfront cash and equity and could generate an eye-popping $10 billion in milestone payments.</li>
<li><strong>PepGen (Nasdaq: PEPG)</strong>, which is developing PGN-EDODM1, which uses the company’s enhanced delivery oligonucleotide (EDO) technology to deliver a therapeutic oligonucleotide designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. PGN-EDODM1 is under study in the Phase II FREEDOM2 trial, where PepGen has fully enrolled the 10 mg/kg MAD cohort, data from which are expected to be reported in November. In August, the trial’s independent data and safety monitoring board (DSMB) approved advancing to the highest dosage cohort of 12.5mg/kg.</li>
<li><strong>Vertex Pharmaceuticals (Nasdaq: VRTX)</strong> and <strong>Entrada Therapeutics (Nasdaq: TRDA)</strong>, which are co-developing VX-670, which is expected to read out data from the Phase I/II GALILEO trial (<a href="https://clinicaltrials.gov/study/NCT06185764">NCT06185764</a>) later in the second half of this year. VX-670 is a phosphorodiamidate morpholino oligonucleotide (PMO) connected to a cyclic peptide containing motif that Vertex in-licenses from Entrada under an up-to-$735 million collaboration announced in 2022.</li>
</ul>
<p>“Today’s miss from del-desiran leaves open space to fill within the DM1 patient class, and we view Vertex/Entrada’s VX-670 as compelling,” Minter wrote, based on its endosomal escape vehicle (EEV) platform: “We view Entrada’s muscle-targeted EEV as possessing an impressive safety profile to date, which we view as important for entrance into higher dosing regimes that may be required for sufficient muscle tissue penetration and vHOT improvements to translate into a registrational trial setting.”</p>
<p></p><h4><strong>Lower projected sales</strong></h4>

<p>Novartis’ disappointing outcome for del-desiran in the HARBOR trial compelled analysts to cut their sales forecasts for the candidate, which Narasimhan projected had “$5 billion-plus peak sales potential” in an interview with Bloomberg TV.</p>
<p>Stefan Schneider, PhD, senior equity analyst, pharma with Vontobel Asset Management, removed the firm’s previous peak annual sales projection of $3 billion for del-desiran from its valuation model and cut its Novartis price target from CHF 128 ($156.77) to CHF 125 ($153.09). Vontobel previously gave Novartis a 50% probability of success for del-desiran.</p>
<p>Michael Schmidt, PhD, a senior biotech analyst and senior managing director at Guggenheim, slashed the firm’s risk-adjusted 2033 sales forecast for del-desiran by 45% from $1.76 billion to $960 million, with a 60% probability of success. The firm previously identified del-desiran and pelecarsen as critical to Novartis’ success from 2030 onward, along with a third candidate that recently succeeded in the clinic—remibrutinib, which generated positive topline data in the Phase III REMODEL-1 (<a href="https://clinicaltrials.gov/study/NCT05147220">NCT05147220</a>) and REMODEL-2 (<a href="https://clinicaltrials.gov/study/NCT05156281">NCT05156281</a>) in relapsing multiple sclerosis, Novartis said.</p>
<p>Remibrutinib is now marketed by the company as Rhapsido® in chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1 antihistamine treatment.</p>
<p>Novartis has maintained its guidance to investors, foreseeing net sales growth at a compound annual rate of 5% to 6% at constant currencies between 2025 and 2030.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/stockwatch-novartis-loses-more-than-market-value-after-phase-iii-failure/">StockWatch: Novartis Loses More than Market Value After Phase III Failure</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bone Marrow&#45;on&#45;a&#45;Chip Model Offers New Window Into Immune Cell Development and Behavior</title>
<link>https://edusehat.com/en/bone-marrow-on-a-chip-model-offers-new-window-into-immune-cell-development-and-behavior</link>
<guid>https://edusehat.com/en/bone-marrow-on-a-chip-model-offers-new-window-into-immune-cell-development-and-behavior</guid>
<description><![CDATA[ By reproducing elements of human bone marrow on a chip, scientists have created a new tool that will help them gain new insights into how immune cells develop and function. 
The post Bone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/04/GettyImages-685024457-e1716932111660.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 12 Sep 2026 06:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bone, Marrow-on-a-Chip, Model, Offers, New, Window, Into, Immune, Cell, Development, and, Behavior</media:keywords>
<content:encoded><![CDATA[<p><span>With support from the National Institutes of Health, a team of scientists have developed a laboratory model that reveals how antibody-producing plasma cells migrate, mature, and survive in human bone marrow. According to its developers, the platform combines a lymph node that mimics an organoid with a tissue chip that mimics bone marrow, and supports studies into the key stages of plasma cell development. Full details of the work are published in a new </span><i><span>Science Advances </span></i><span>study titled “</span><a href="https://www.science.org/doi/10.1126/sciadv.adz3976" target="_blank" rel="noopener"><span><em>Ex Vivo</em> Bone Marrow Subniches Influence the Fate of Human Antibody-Secreting Cells</span></a><span>.”</span></p>
<p><span>The work was done by scientists from Georgia Tech and Vanderbilt University. The human lymphoid organoid was developed by a team led by Ankur Singh, PhD, a professor of bioengineering and director of the Center for Immunoengineering at Georgia Tech. They developed it by isolating B cells from human tonsil tissue and blood sources and growing them in an environment similar to lymphoid tissue. They used inactivated influenza virus to overcome challenges associated with culturing B cells and getting to transform into antibody secreting plasma cells. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Meanwhile, scientists in the lab of Krishnendu Roy, PhD, dean of engineering and professor of biomedical engineering at Vanderbilt University, designed a microfluidics-based vascularized microenvironment for the bone marrow chip that mimics the conditions found in human bone marrow. Essentially, they tried to “mimic the structure, fundamental biological functions, and spatial microenvironments” of human bone marrow in order “to ask questions about human organ-like behavior in this more simplified model,” Roy explained. </span></p>
<p><span>As explained by the developers, the final model is assembled within a three-by-five stack of 96-well plastic plates, that are each less than half-an-inch thick. It features multiple channels that are coated with a gel-like material similar to bone marrow with nutrients and growth factors to support plasma cell function and maintenance.  Its layers correspond to an area at the outer edge of the bone marrow cavity, known as the endosteal subniche, where plasma cells are stored. The model also replicates an area deeper inside the center of the bone marrow, the perivascular subniche, which surrounds a network of blood vessels, where plasma cells proliferate and are activated.</span></p>
<p><span>“It is nearly impossible to achieve high imaging resolution of plasma cells in living human bone marrow,” Singh said. Though it is possible to “do some level of imaging in the bone marrow of a mouse” which is where some previous efforts have been focused. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>Now with this new model, scientists will be able to run new types of experiments. “A fundamental question [that] our study addresses [is] why it is that when B cells are ready to make antibodies, they relocate from lymph nodes, the spleen, and other organs and enter and take up residence in bone marrow,” Singh said. “Another is a question of the role that the environment of bone marrow plays in orienting those cells and responses to reinfection.”</span></p>
<p><span>Furthermore, the model can be seeded with cells from unique patient populations to study things like the effects of aging on plasma cell function. It could also be used to study cells from people with autoimmune or allergic diseases to understand how autoimmunity or allergy-promoting plasma cells are produced and maintained. Other studies could focus on addressing questions such as why B cells show a stop-and-go pattern of movement and whether it is part of a migration pattern in the bone marrow. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/bone-marrow-on-a-chip-model-offers-new-window-into-immune-cell-development-and-behavior/">Bone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology</title>
<link>https://edusehat.com/en/transcenta-therapeutics-and-wuxi-biologics-team-up-to-accelerate-commercialization-of-hicb-technology</link>
<guid>https://edusehat.com/en/transcenta-therapeutics-and-wuxi-biologics-team-up-to-accelerate-commercialization-of-hicb-technology</guid>
<description><![CDATA[ Transcenta, headquartered in China and with a pipeline of over ten therapeutic antibody candidates, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. 
The post Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-115860765.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 12 Sep 2026 03:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Transcenta, Therapeutics, and, WuXi, Biologics, Team, Accelerate, Commercialization, HiCB, Technology</media:keywords>
<content:encoded><![CDATA[<p>Transcenta Therapeutics says it will grant WuXi Biologics and its affiliates a non-exclusive license to certain technologies relating to Transcenta’s intensified continuous bioprocessing (HiCB) platform and ExcelPro cell culture media.</p>
<p>Transcenta will receive an upfront payment of $1.5 million and will be eligible for milestone payments upon the achievement of specified conditions. Through this collaboration, WuXi Biologics will become Transcenta’s strategic partner for CMC development and supporting molecules across Transcenta’s development pipeline.</p>
<p>A Transcenta spokesperson explained that the HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, enabling a step-change in productivity, achieving an increase in productivity compared with conventional fed-batch processes.</p>
<p>HiCB can significantly reduce cost of goods, lower capital investment, and enable agile production, claims the company official, while providing a solution for improving recovering yield and product quality for complex biologics.</p>
<p>Transcenta, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. The company develops a pipeline of over ten therapeutic antibody candidates spanning oncology, bone, and kidney disorders.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/transcenta-therapeutics-and-wuxi-biologics-team-up-to-accelerate-commercialization-of-hicb-technology/">Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice</title>
<link>https://edusehat.com/en/cloudscope-enables-continuous-remote-monitoring-of-brain-activity-in-freely-moving-mice</link>
<guid>https://edusehat.com/en/cloudscope-enables-continuous-remote-monitoring-of-brain-activity-in-freely-moving-mice</guid>
<description><![CDATA[ Johns Hopkins researchers developed CloudScope, a cloud-based microscope enabling continuous, remote brain imaging in freely moving mice, revealing disease progression, seizures, cellular changes and behavior over extended periods.
The post CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Pathak-big.png-e1789134393597.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 12 Sep 2026 03:10:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CloudScope, Enables, Continuous, Remote, Monitoring, Brain, Activity, Freely, Moving, Mice</media:keywords>
<content:encoded><![CDATA[<p>In order to understand and characterize preclinical models of diseases of the central nervous system (CNS), it is critical to be able to conduct continuous neuroimaging of multiple physiological variables—neuronal activity, blood flow, blood volume, oxygenation, and cellular dynamics—within the CNS microenvironment. This continuous multimodality neuroimaging capability is known as neurosurveillance.</p>
<p>However, a long-standing challenge in neuroscience and neuropathology has been how to continuously observe biological processes that unfold over hours, days, and even weeks in the brain.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Now, researchers at Johns Hopkins Medicine have demonstrated a new approach to brain imaging that enables continuous monitoring of brain activity and the physiologic changes associated with neurological disease progression for more than 24 hours in freely moving mouse models. The cloud-based miniaturized microscope, CloudScope, operates autonomously and allows scientists to access live imaging data remotely from anywhere in the world, creating new opportunities to study diseases as they develop over time.</p>
<p>The study demonstrates the ability to remotely capture and analyze changes in brain activity, blood flow, blood vessel remodeling, oxygenation and cellular behavior over extended periods, providing a more holistic picture of brain disease progression than conventional imaging approaches.</p>
<p>This work is published in <em>Nature Methods</em> in the paper, “<a href="https://www.nature.com/articles/s41592-026-03111-z" target="_blank" rel="noopener">A cloud-based miniscope for neurosurveillance of brain health and disease in freely behaving animals</a>.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“We started with a fundamental question: If we wanted to image a seizure or brain tumor formation continuously in a preclinical or animal model over 24 hours or longer, how would we do that?” says Arvind Pathak, PhD, professor of radiology, oncology, and biomedical and electrical engineering at Johns Hopkins. “The consequence of us working through this question and its associated challenges is what resulted in this innovation.”</p>
<p>Using this approach, the team captured spontaneous seizures occurring several hours after a drug-induced seizure in mice, events that would have been missed using conventional short-term imaging methods. In separate studies of brain cancer, researchers were able to characterize the behavior of individual cancer cells and observe dynamic changes in the brain’s microenvironment as the disease progressed. These findings suggest that continuous monitoring may reveal critical biological events that occur outside the limited observation windows typically used in laboratory research.</p>
<p>“Most central nervous system diseases develop over hours, days or even weeks. Yet modern imaging tools are designed to continuously probe only a small fraction of this time window,” says Janaka Senarathna, PhD, assistant professor of radiology at Johns Hopkins. “We developed a device to break this time barrier.”</p>
<p>In addition to advancing neuroimaging research, the investigators have also demonstrated a promising application involving artificial intelligence. By combining the first-ever 24-hour brain imaging dataset with video recordings of the lab animals’ behavior, the team successfully trained an AI framework to predict whether an animal was minimally mobile, moderately active, or running based solely on neuronal activity measurements made with the device. The researchers believe this approach could help scientists better understand the neurological effects of conditions such as stroke or Parkinson’s disease and potentially reveal new insights into the relationship between brain activity and behavior. Additionally, researchers say the device enables time-shared imaging from anywhere in the world, and it creates a pathway to reduce animal use while enabling neuroscientific and neuropathological insights. Lastly, CloudScope’s architecture enables “time-shared” imaging, which potentially reduces animal use.</p>
<p>To explore the effect of disease on different brain regions, the team plans to continue expanding the platform’s capabilities, such as imaging larger regions of the animals’ brains and leveraging AI to accelerate brain imaging and cancer cell tracking.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/cloudscope-enables-continuous-remote-monitoring-of-brain-activity-in-freely-moving-mice/">CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Meet the under&#45;35s shaping the future of biotech</title>
<link>https://edusehat.com/en/meet-the-under-35s-shaping-the-future-of-biotech</link>
<guid>https://edusehat.com/en/meet-the-under-35s-shaping-the-future-of-biotech</guid>
<description><![CDATA[ Every year, MIT Technology Review puts together a list of some of the brightest and best young minds working across science and technology. Our 35 Innovators Under 35 are the ones to watch—people whose research and technical work stands to shape the future of their fields. This year, the list includes nine people who are… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/09/circles-bio2a.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 23:40:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Meet, the, under-35s, shaping, the, future, biotech</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Saving mothers with a $70 device:</strong> Tanzanian innovator Paschal Kija developed Mkanda Salama, a low-cost wrap that stopped dangerous postpartum bleeding in 73% of women within 20 minutes—targeting a complication behind nearly a third of maternal deaths in Tanzania.</li><br><li><strong>Brain electrodes inspired by paper art:</strong> Xiao Yang is designing ultra-small, flexible electrodes that mimic actual neurons, including a kirigami-inspired honeycomb spiral sheet—potentially reducing brain tissue damage while advancing how scientists study neurological activity.</li><br><li><strong>AI-designed viruses that actually work:</strong> Samuel King used generative AI to create genetic blueprints for entirely new bacteriophages, then printed them as DNA strands—and they replicated, burst from bacterial cells, and infected neighboring bacteria, hinting at future uses in medicine or pollution cleanup.</li><br><li><strong>Turning back the clock on aging cells:</strong> Ryan Lu's reprogramming therapy reversed vision loss in aged, blind mice—and now an almost identical version is being tested in humans, with a biotech company dosing its first volunteer in June.</li></ul>" data-chronoton-post-id="1143834" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Every year, <em>MIT Technology Review</em> puts together a list of some of the brightest and best young minds working across science and technology. Our 35 Innovators Under 35 are the ones to watch—people whose research and technical work stands to shape the future of their fields.</p>



<p>This year, the list includes nine people who are transforming biotech. And this week, I’m going to give you a taste of some of the very cool stuff five of them are working on, which includes lifesaving innovations and groundbreaking “age reversal” tech.  </p>



<p><strong>1. Preventing maternal deaths</strong></p>



<p>Let’s start with Paschal Kija, a 28-year-old who has developed a device to treat postpartum hemorrhage—a dangerous birth complication that contributes to around 29% of maternal deaths in his home country, Tanzania. The Mkanda Salama (“Safe Wrap” in Swahili) is easy to use and costs just $70. A study found that it stopped postpartum bleeding in 73% of women within 20 minutes.</p>



<p><strong>2. Making brain electrodes inspired by Japanese art</strong></p>



<p>For decades, scientists have been developing, testing, and implanting brain electrodes. These devices are literally inserted into people’s brains, so while they can help us understand brain activity and treat various neurological disorders, it’s not totally surprising that they can also cause a bit of damage. Xiao Yang, 34, is working on ultra-small electrodes, which she hopes will have less of an impact on surrounding brain tissue. Her electrodes are flexible, too—in fact, they look a lot like actual neurons.</p>



<p>Yang is also creating sheets of electrodes to study brain cells in the lab. Inspired by kirigami—the traditional Japanese art of cutting paper to form three-dimensional shapes—she’s created a sheet of electrodes with a honeycombed structure shaped like a spiral basket. And she’s already using it to study brain cells.</p>



<p><strong>3. Developing an all-new treatment for baby KJ</strong></p>



<p>In 2024, Kyle “KJ” Muldoon Jr. was born with a rare and potentially fatal genetic disorder. Sarah Grandinette was a member of a team that developed an entirely new, personalized treatment for him—a gene-editing therapy essentially designed to correct a genetic misspelling.</p>



<p>Grandinette, who is now 26, created cells with KJ’s genetic variant and used them to screen gene-editing approaches; then she tested potential medicines in mice and monkeys. KJ ultimately got his first dose of the resulting treatment when he was about seven months old. He responded well and was eventually discharged from hospital. He’s “doing pretty great,” she says.</p>



<p><strong>4. Reversing the aging process to treat eye disease</strong></p>



<p>The buzziest tech in longevity right now centers on reprogramming—attempts to rewind the age of cells by resetting them to a more embryonic-like state. In a <a href="https://www.nature.com/articles/s41586-020-2975-4">study</a> published in 2020, Yuancheng (Ryan) Lu (now 34) and his colleagues showed that a reprogramming therapy <em>reversed vision loss</em> in aged, blind mice. Now an almost identical version of that therapy is being tested in people with eye disease. Life Biosciences, the company developing the drug, dosed its first volunteer in June.</p>



<p><strong>5. Using AI to design new viruses</strong></p>



<p>Last year, Samuel King used a generative AI model to come up with new genetic blueprints for <a href="https://www.technologyreview.com/2023/05/12/1072931/tiny-viruses-best-bet-against-antimicrobial-resistance/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">bacteriophages</a>—teeny viruses that can infect bacteria. Once he had those blueprints, he printed them out as strands of DNA. In experiments, he found that those AI-designed viruses could create new copies of themselves, burst out of bacterial cells, and infect other nearby bacteria. Viruses aren’t alive, but King, 27, hopes that AI-designed life forms might one day be used to make drugs or soak up pollution.</p>



<p>You can read more about these innovators, and the others on the biotech list, <a href="https://www.technologyreview.com/innovators-under-35/biotechnology-2026/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=*%7Cdate:m-d-y%7C*">here</a>.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance</title>
<link>https://edusehat.com/en/cancer-treatment-genetic-effects-in-healthy-cells-may-reveal-clues-to-side-effects-and-resistance</link>
<guid>https://edusehat.com/en/cancer-treatment-genetic-effects-in-healthy-cells-may-reveal-clues-to-side-effects-and-resistance</guid>
<description><![CDATA[ Researchers used DNA sequencing to map mutations in normal tissue from cancer patients undergoing different types of treatment. They found significant differences in the genetic mutations in healthy tissue, depending on whether the patients received radiotherapy, chemotherapy, or chemoradiation. 
The post Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/09/GettyImages-1023097228-e1695336230594.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 23:40:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cancer, Treatment, Genetic, Effects, Healthy, Cells, May, Reveal, Clues, Side, Effects, and, Resistance</media:keywords>
<content:encoded><![CDATA[<p>The results of a study by scientists at Wellcome Sanger Institute, University of Cambridge, University College London, and collaborators indicate that cancer treatments, including chemotherapy and radiotherapy, give a growth advantage to cells with particular genetic changes in healthy tissue. The team used DNA sequencing to map mutations in normal esophagus tissue from esophageal cancer patients who had received either chemotherapy, chemotherapy and radiotherapy, or no treatment before surgery.</p>
<p>The results showed that different cancer treatments changed the landscape of mutations in normal tissue. In particular, combined treatment using chemotherapy and radiotherapy led to significantly more normal cells with cancer-related mutations in these patients. The team suggests that sequencing normal tissue from cancer patients receiving treatment could show how our genes regulate our tissue’s response to drugs, including side effects.</p>
<p>Research co-lead Phil Jones, FRS, a professor of cancer development at the University of Cambridge and a senior group leader at the Wellcome Sanger Institute, said: “Our bodies are a Darwinian battleground, where cells are constantly evolving, expanding and fighting for space in our normal tissues. If you change the rules of this competition by introducing a drug, different genetic mutations are going to enable cells to win or lose. We were surprised to find that only a few weeks of cancer treatment can drastically change decades of evolution in our cells. By looking at normal tissues, we can begin to uncover how drugs work in the body, in order to make more effective treatments with fewer side effects in the future.”</p>
<p>Jones is co-senior and co-corresponding author of the researchers’ published paper in <em>Nature Genetics</em>, titled “<a href="https://doi.org/10.1038/s41588-026-02738-0" target="_blank" rel="noopener">Cancer treatment alters mutant selection in normal esophagus</a>,” in which they stated, “Sequencing normal epithelia reveals treatment-specific selection of mutations and may identify genes implicated in cellular responses to therapy.”</p>
<p>Over time, all cells in the body acquire genetic changes, known as somatic mutations. While the majority of these do not affect how the cell functions, some make cells fitter, so they outcompete their neighbors. Sometimes, combinations of these mutations cause uncontrollable growth leading to cancer and the formation of tumors.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>By middle age, the human esophagus has evolved into a patchwork of mutated cells. “Aging epithelial tissues, including the esophagus, are colonized by somatic mutant clones under strong competitive selection,” the authors wrote. “Mutant clones with increased fitness expand, collide and compete for space in the tissue, with only the fittest mutations surviving.” However, as the authors also pointed out, “The effect of cancer treatment on mutant selection in normal epithelium is unknown.”</p>
<p>By age 60 to 70 years almost all of the cells in the esophagus will be mutated. While the majority of these mutations do not lead to cancer, if tumors do form they can be hard to treat, as often symptoms appear when the cancer has started to spread.</p>
<p>Around 9,500 people are diagnosed with esophageal cancer in the U.K. each year, with almost half of new cases in people aged 75 and over. It is treated with surgery, chemotherapy, radiotherapy, a combination of the two—chemoradiotherapy—and immunotherapy. “We hypothesized that anticancer treatment may alter the selection of mutant clones in the already densely mutated normal esophagus,” the team commented.</p>
<p>For their newly reported study the Sanger Institute researchers and their collaborators set out to understand the effects of cancer treatments on normal cells, and whether chemotherapy and radiotherapy treatments give some mutant cells an advantage. The team used DNA sequencing to analyze normal cells from the esophageal lining—esophageal epithelium—that had been removed from 70 patients after treatment for esophageal cancer. The patients had either received combination chemotherapy, chemoradiotherapy, or no treatment before surgery. “The presence of normal esophagus within the surgically excised tissue gave us the opportunity to test if the mutational landscape of the normal esophageal epithelia was altered by cancer treatment using duplex, whole-genome (WGS) and targeted DNA sequencing,” they further explained.</p>
<p>The investigators found significant differences in genetic mutations in the cells from the patients, depending on the treatment they had received. In patients who received chemoradiotherapy, there were significantly more clones, with mutations in <em>TP53</em>—a vital tumor suppressor gene known as the “guardian of the genome”—and in <em>PPM1D, </em>a gene that makes an enzyme that manages cell stress and <em>TP53</em> function.</p>
<p>Among patients who had received combination chemotherapy there was an increase in normal cells carrying mutations associated with resistance to the chemotherapy drug 5-fluorouracil (5-FU). The increased resilience to 5-FU in a patient’s healthy cells during cancer treatment leads to protection from life-threatening toxicities.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“These findings demonstrate that the mutational landscape of a normal epithelium that has evolved over decades may be altered dramatically in just a few weeks under the selective pressure of anticancer treatment,” they noted. “This leads to the selective expansion of preexisting mutant clones in certain treatment groups.”</p>
<p>Chemotherapy drugs usually leave tell-tale patterns of mutations, known as mutational signatures, in the genomes of normal tissues. Despite seeing changes in mutant cell fitness following treatments, the team found no mutational signatures associated with the chemotherapies. “The absence of a chemotherapy mutational signature in both NanoSeq and whole-genome samples of normal epithelium is notable,” they stated.</p>
<p>Cancer treatments can cause severe side effects in normal tissues, which may result in reducing treatment dose. The researchers suggest that their findings begin to uncover the genes and protein domains that make normal cells sensitive or resistant to treatment. The results could help shape cancer treatment in the future to help reduce damage to normal tissues. The study findings might also help inform the development of targeted treatments that destroy cancer cells while leaving normal tissue unharmed.</p>
<p>By identifying the mutant cells in normal tissue that are selected for by cancer treatment, the study may also provide a catalogue of potential genetic targets that modify how our cells respond to treatment, and lead to further research into how tumors become drug resistant. “… mutants in normal tissues provide<em> in vivo</em> evidence of actionable targets for mitigating normal tissue toxicity and may inform strategies for overcoming drug resistance in tumors,” the scientists stated.</p>
<p>For the next steps, the team is conducting a pilot study to investigate these effects in other tissues, taking cheek swabs, blood and urine samples from patients before and after having treatment for skin, head and neck cancers. The researchers are investigating on a larger scale, whether there is further evidence of genetic mutations in normal cells that are being selected for by cancer treatment.</p>
<p>Commenting on the study Hayley Brown, research information manager at Cancer Research UK, said, “People with esophageal cancer often need intensive treatment, but we still have much to learn about how these therapies affect the rest of the body. Cancer treatments can be incredibly effective, but they can also affect healthy tissues. This study gives us an unusual opportunity to see how healthy cells change during treatment, helping us understand what happens elsewhere in the body, not just in the tumor. The more we learn about these changes, the better chance researchers have of finding ways to reduce the impact of treatment on patients without making it less effective against cancer.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/cancer-treatment-genetic-effects-in-healthy-cells-may-reveal-clues-to-side-effects-and-resistance/">Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm</title>
<link>https://edusehat.com/en/samsung-biologics-signs-262-million-manufacturing-agreement-with-european-pharma-firm</link>
<guid>https://edusehat.com/en/samsung-biologics-signs-262-million-manufacturing-agreement-with-european-pharma-firm</guid>
<description><![CDATA[ Alongside decisions involving capacity expansion, officials at Samsung Biologics announced that the company is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities.
The post Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/12/VirusFreeProducts_SamsungBiologics_LabTech_TwoStagePurification-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 23:40:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Samsung, Biologics, Signs, 262, Million, Manufacturing, Agreement, with, European, Pharma, Firm</media:keywords>
<content:encoded><![CDATA[<p>Samsung Biologics reported that it has inked a $262 million manufacturing agreement with an unnamed European pharmaceutical company. The deal includes manufacturing commitments, which will be conducted at Samsung Biologics’ Songdo manufacturing site in South Korea extending through 2033.</p>
<p>A Samsung Biologics’ spokesperson stated that the company’s cumulative contract value surpasses $21.9 billion following the latest agreement.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The company currently operates 845 kL of manufacturing capacity across Korea and the U.S., including 785 kL in Songdo and 60 kL at its Rockville, MD site. Acquired in March 2026, the Rockville facility established Samsung Biologics’ first manufacturing presence in the U.S., expanding the company’s global production network. Officials at Samsung Biologics say the company is also strengthening its regional presence through offices in NJ, Boston, Tokyo, and Amsterdam.</p>
<p>Samsung has secured land for Bio Campus III, establishing the foundation for its next phase of long-term capacity and capability expansion. The planned campus is expected to support dedicated R&D and manufacturing programs for next-generation therapeutics while the company continues to evaluate additional capacity investments in line with long-term market demand and client requirements.</p>
<p>Alongside capacity expansion, Samsung Biologics announced that it is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities. The company has announced an all-cash offer to acquire PolyPeptide Group, which is expected to expand Samsung Biologics’ capabilities into peptide-based therapeutics and further diversify its global manufacturing network, subject to the completion of the proposed transaction.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/samsung-biologics-signs-262-million-manufacturing-agreement-with-european-pharma-firm/">Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PD&#45;L2 Blockade May Reduce Harmful Aging Cell Buildup</title>
<link>https://edusehat.com/en/pd-l2-blockade-may-reduce-harmful-aging-cell-buildup</link>
<guid>https://edusehat.com/en/pd-l2-blockade-may-reduce-harmful-aging-cell-buildup</guid>
<description><![CDATA[ Blocking PD-L2 reduced senescent cell accumulation in aged mice and improved measures tied to metabolic function and physical strength.
The post PD-L2 Blockade May Reduce Harmful Aging Cell Buildup appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/GettyImages-170614889.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 08:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PD-L2, Blockade, May, Reduce, Harmful, Aging, Cell, Buildup</media:keywords>
<content:encoded><![CDATA[<p>A protein better known for its role in immune checkpoint signaling may help harmful aging cells, or senescent cells, remain hidden from the immune system, allowing them to accumulate in tissues and contribute to age-related dysfunction, according to a new study from Cedars-Sinai Health Sciences University investigators.</p>
<p>The study is titled “<a href="https://www.cell.com/cell-metabolism/abstract/S1550-4131(26)00339-6" target="_blank" rel="noopener">Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction</a>.” The findings, published in <em>Cell Metabolism</em>, point to programmed cell death ligand 2, or PD-L2, as a possible target for therapies designed to help clear senescent cells, as well as a potential blood marker for tracking their presence. Senescent cells are damaged cells that stop dividing but do not die. Instead, they can persist in tissues, where they release inflammatory factors and disrupt the function of nearby cells. Their buildup has been linked to metabolic dysfunction, impaired physical fitness, and other health problems associated with aging.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Our findings suggest that PD-L2 may help aging cells stay in the body when they would normally be removed by the immune system,” said Selim Chaib, PhD, research assistant professor of medicine at Cedars-Sinai and first and co-corresponding author of the study.</p>
<p>Immune checkpoint proteins have been studied extensively in cancer, where they can help tumor cells escape immune attack. In the new study, the researchers examined whether a similar process might allow senescent cells to evade immune clearance during aging. They found that PD-L2 was increased in isolated senescent human cells and rose with age in some human tissues. Circulating soluble PD-L2 also increased with aging and declined after senolytic treatment in humans, according to the study’s highlights.</p>
<p>The team then tested the effects of removing or blocking PD-L2 in mice. Older mice lacking PD-L2 accumulated fewer senescent cells than older wild-type mice. They also showed greater insulin sensitivity and grip strength, two measures tied to metabolic function and physical fitness. In aged wild-type mice, anti-PD-L2 therapy restored insulin sensitivity and increased physical strength.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Together, the results suggest that PD-L2 may act as an immune checkpoint on senescent cells, helping them avoid removal and promoting their persistence during aging. The work also adds to the growing interest in senescence-targeted approaches, including senolytics, that aim to reduce the burden of dysfunctional cells rather than treating one age-related disease pathway at a time.</p>
<p>“If we can find a way to block this protein, we may be able to help the immune system get rid of these cells and potentially improve health problems linked with aging,” said James Kirkland, MD, PhD, director of the Center for Advanced Gerotherapeutics and senior author of the study.</p>
<p>The authors cautioned that more research is needed to determine whether blocking PD-L2 can safely produce health benefits in people.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/pd-l2-blockade-may-reduce-harmful-aging-cell-buildup/">PD-L2 Blockade May Reduce Harmful Aging Cell Buildup</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Data Integrity as the Foundation for AI</title>
<link>https://edusehat.com/en/data-integrity-as-the-foundation-for-ai</link>
<guid>https://edusehat.com/en/data-integrity-as-the-foundation-for-ai</guid>
<description><![CDATA[ In this sponsored podcast, LabVantage’s Gary Stimson digs into what it takes to build a data foundation for trustworthy AI. 
The post Data Integrity as the Foundation for AI appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Getty_2218291994_AI.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 05:10:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Data, Integrity, the, Foundation, for</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><p class="wp-block-paragraph">Artificial intelligence is advancing quickly into laboratory operations, which is why thinking about the quality and integrity of the supporting data early on is important. In regulated environments, that means understanding where the data came from, how it changes, and how AI-generated insights or recommendations can be traced, reviewed, trusted, and ultimately defended.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN </em>podcast, LabVantage’s Gary Stimson digs into what it takes to build a data foundation for trustworthy AI. The discussion covers concepts like data lineage, traceability, explainability and governance, and the importance of audit-ready laboratory operations. It also looks at the role of intended use, ongoing monitoring, and human review in deploying AI responsibly.</p><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow"><p></p><h4 class="wp-block-heading has-text-align-center"><strong><strong>Podcast Guest:</strong></strong></h4><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><div class="wp-block-image is-resized"><p><figure class="aligncenter size-full"><img loading="lazy" decoding="async" width="976" height="976" src="https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot.jpg" alt="Gary Stimson" class="wp-image-337716" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot.jpg 976w, https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot-840x840.jpg 840w, https://www.genengnews.com/wp-content/uploads/2026/09/GaryStimson_headshot-696x696.jpg 696w" sizes="auto, (max-width: 976px) 100vw, 976px"></figure></p><p></p></div><p></p><p></p><h6 class="wp-block-heading has-text-align-center"><strong><strong><strong>Gary Stimson</strong></strong></strong><br>Principal Architect, Head of AI Technologies<br>LabVantage Solutions</h6><p></p></div><p></p></div><p></p></div><p></p></div><p></p><p></p><p></p><hr class="wp-block-separator has-alpha-channel-opacity is-style-wide"><p></p><p></p><p class="has-text-align-center wp-block-paragraph"><br><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="aligncenter size-medium is-resized"><a href="https://www.labvantage.com/" target="_blank" rel=" noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="57" src="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg" alt="LabVantage logo" class="wp-image-131319" srcset="https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-300x57.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-696x132.jpg 696w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo-741x142.jpg 741w, https://www.genengnews.com/wp-content/uploads/2019/12/LV_logo.jpg 750w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div><p>The post <a href="https://www.genengnews.com/multimedia/podcasts/gencast/data-integrity-as-the-foundation-for-ai/">Data Integrity as the Foundation for AI</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program</title>
<link>https://edusehat.com/en/manus-and-ut-austin-advance-biomanufacturing-product-recovery-through-biomade-program</link>
<guid>https://edusehat.com/en/manus-and-ut-austin-advance-biomanufacturing-product-recovery-through-biomade-program</guid>
<description><![CDATA[ A new study showed that a prgrammed lysis approach cut mechanical separation energy by over 50 percent at pilot scale, widening the range of bioalternatives that can compete pricewise. 
The post Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Female-worker.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 05:10:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Manus, and, Austin, Advance, Biomanufacturing, Product, Recovery, Through, BioMADE, Program</media:keywords>
<content:encoded><![CDATA[<p>Manus, The BioAlternatives Company<sup class="wp-sup-text">®</sup>, and the University of Texas at Austin say they have completed a <a href="https://www.biomade.org/" target="_blank" rel="noopener">BioMADE</a>-sponsored program to make industrial yeast fermentation more efficient and sustainable.</p>
<p>The project, carried out with Hal Alper, PhD, and the Alper Lab in UT Austin’s McKetta department of chemical engineering, engineered yeast to disrupt their own cell walls at the end of fermentation. This programmed lysis approach simplifies downstream processing by reducing reliance on energy-intensive mechanical disruption and removes the need for hazardous solvent-based extraction, according to the researchers.</p>
<p>The result, they add, is lower production costs and improved sustainability across a broad range of bioalternative products that accumulate inside cells, including lipids, proteins, vitamins, pigments, biosurfactants, and polysaccharides.</p>
<p></p><h4><strong>Reduced mechanical separation energy requirements</strong></h4>

<p>The team said they demonstrated the technology up to pilot scale (300 liters) for two industrially relevant yeasts. In <em>Yarrowia lipolytica</em>, engineered strains enabled a reduction in mechanical separation energy requirements by more than 50 percent. In <em>Saccharomyces cerevisiae</em>, the team achieved autolysis in a relevant production strain. They pointed out that the work advanced the technology from laboratory demonstration to integrated pilot operation.</p>
<p><figure aria-describedby="caption-attachment-337604" class="wp-caption alignleft"><img decoding="async" class="size-full wp-image-337604" src="https://www.genengnews.com/wp-content/uploads/2026/09/Christine-Sanios.jpg" alt="Christine Santos, PhD, CTO, Manus" width="165" height="110"><figcaption class="wp-caption-text">Christine Santos, PhD, CTO, Manus</figcaption></figure></p>
<p>“Downstream processing is one of the largest hidden costs in biomanufacturing, and it heavily influences whether a bioalternative can compete on price. By engineering yeast to disrupt their own cell walls, we reduce cost, energy, and complexity, which widens the range of products that can be made economically and sustainably at scale,” says Christine Santos, PhD, chief technology officer, Manus. By cutting processing intensity and improving recovery, these advances strengthen the case for domestic biomanufacturing.</p>
<p>“This work uniquely combined academic and industrial settings to take bench-scale discoveries and more rapidly translate them to higher technology readiness,” adds Alper. “This technology finally helps to address the challenge of producing cheaper intracellular products that traditionally require high-cost separations and more laborious process steps.”</p>
<p>The scientists note that the technology has broad application across many products that are made and accumulate inside microbial cells. By cutting processing intensity and improving recovery, these advances strengthen the case for domestic biomanufacturing built on abundant, low-cost American feedstocks.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/manus-and-ut-austin-advance-biomanufacturing-product-recovery-through-biomade-program/">Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>What 25 Years of Research Have Revealed About 9/11’s Long&#45;Term Health Effects</title>
<link>https://edusehat.com/en/what-25-years-of-research-have-revealed-about-911s-long-term-health-effects</link>
<guid>https://edusehat.com/en/what-25-years-of-research-have-revealed-about-911s-long-term-health-effects</guid>
<description><![CDATA[ Twenty-five years after 9/11, long-term monitoring of responders and survivors continues to reveal the complex health consequences of exposure to environmental toxins and hazardous materials.
The post What 25 Years of Research Have Revealed About 9/11’s Long-Term Health Effects appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/9-11-26-GettyImages-90809975-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 05:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>What, Years, Research, Have, Revealed, About, 911’s, Long-Term, Health, Effects</media:keywords>
<content:encoded><![CDATA[<p><span>Since the attacks on the World Trade Center in New York City, at the Pentagon in Arlington, Virginia, and near Shanksville, Pennsylvania on September 11, 2001, scientists and clinicians have learned much about the enduring effects of exposure to environmental toxins and hazardous materials. A perspective paper, published today in </span><i><span>JAMA</span></i><span>, highlights some insights from long-term follow-up of people with 9/11-related health effects, lessons learned in terms of care delivery and clinical understanding, as well as some implications for future disaster responses. </span></p>
<p><span>The perspective paper, titled “</span><a href="https://jamanetwork.com/journals/jama/fullarticle/2853932?guestAccessKey=2b2e65c3-0464-47eb-9dff-5cd1b8923bde&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091026" target="_blank" rel="noopener"><span>Twenty-Five Years After 9/11—Lessons From the World Trade Center Health Program</span></a><span>,” is authored by scientists and clinicians affiliated with the World Trade Center Health Program (WTC Health Program), National Institute for Occupational Safety and Health, which is part of the U.S. Centers for Disease Control and Prevention. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>It begins by highlighting some of the health effects experienced by the cohort including the fact that “many affected individuals have experienced multimorbidity” and developed multiple conditions such as “cancer, respiratory disease, gastroesophageal reflux disease, and mental disorders.” Some of these conditions developed years post-exposure “underscoring the importance of sustained clinical monitoring and research.”</span></p>
<p><span>Other findings from their analysis indicate that people in the cohort have a higher prevalence of both chronic conditions and poorer health-related quality of life compared to the general population. They noted that this “multimorbidity contributes to increased disability, more complex clinical management, and higher health care utilization and cost.” However, “access to no-cost care for covered conditions may improve survival, illustrating the interplay between exposure-related risk and access to care.” Elsewhere in the paper, multimorbidity is also listed as a “defining feature of care” as this population ages, although to be clear, not all their conditions are related to 9/11 exposures. The data also suggests that “integrated systems combining surveillance, clinical care, exposure assessment, and research may improve their chronic disease management.” </span></p>
<p><span>Insights from the program have also shaped the patient health management strategies adopted by the program over time and expanded the list of covered conditions. As part of the study, the scientists assessed the effectiveness of the WTC Health Program in helping patients manage their conditions and improve their health outcomes. According to numbers reported in the paper, as of June 2026, more than 154,000 responders and survivors have enrolled in the program. Eligibility is based on documented occupational or environmental 9/11 exposure, and clinical coverage is limited to specific conditions described on the program’s website. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>Their analysis of program data indicates that its efforts have been largely effective. Specifically, the scientists reported  “strong performance in preventative care and chronic disease management” with screening rates for some cancers “exceeding national benchmarks.” They also found that “responders with cancer who participate in the WTC Health Program experienced 26% to 64% lower mortality rates compared with the New York State general population across multiple cancer types.” They further observed a lower smoking prevalence, about four percent, in the cohort compared to the U.S. adult prevalence of 9.1%, which “may reflect the availability and uptake of smoking cessation and related WTC Health Program services.”</span></p>
<p><span>The data for chronic disease management efforts was similarly positive. For people with chronic respiratory disease, “program data indicate high levels of guideline-concordant asthma management, with most members achieving an appropriate balance between controller and rescue medications,” the scientists wrote. </span></p>
<p><span>Overall, there are lessons from the program that could inform future disaster response initiatives and improve public health preparedness programs among other benefits. “First, the health effects of large-scale environmental and occupational exposures may unfold over decades, requiring sustained investment in monitoring and care,” the scientists wrote. The evidence also shows that “integrated systems that link surveillance, research, and clinical care are essential for identifying and responding to emerging health risks” and “access to care at no out-of-pocket cost can help mitigate the long-term health effects of large-scale environmental exposure and support overall member well-being,” they said. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/what-25-years-of-research-have-revealed-about-9-11s-long-term-health-effects/">What 25 Years of Research Have Revealed About 9/11’s Long-Term Health Effects</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Chronic Interferon Exposure Linked to Immunosuppression in Cancer</title>
<link>https://edusehat.com/en/chronic-interferon-exposure-linked-to-immunosuppression-in-cancer</link>
<guid>https://edusehat.com/en/chronic-interferon-exposure-linked-to-immunosuppression-in-cancer</guid>
<description><![CDATA[ A preclinical study uncovered a novel pathway that links chronic IFN-II exposure to mitochondrial dysfunction and ultimately immunosuppression in cancer, creating foundational insights that may point to future therapies that combat immunotherapy resistance.
The post Chronic Interferon Exposure Linked to Immunosuppression in Cancer appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/Microscopic-view-of-mitochondria-image.png" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 05:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Chronic, Interferon, Exposure, Linked, Immunosuppression, Cancer</media:keywords>
<content:encoded><![CDATA[<p>As soon as a cancer cell appears, the immune system jumps into action—and interferons (IFNs) are among the first responders. Interferons are pro-inflammatory cytokines, or signaling proteins, that recruit specialized immune cells, such as like T cells or B cells to destroy the cancer. This is a critical, powerful step in the body’s fight against cancer, but chronic exposure to interferons can turn them from ally to enemy.</p>
<p>A Salk Institute team has now discovered a novel pathway that links chronic interferon II (IFN-II) exposure to mitochondrial dysfunction that ultimately causes immunosuppression. By explaining how interferon II turns from “good” to “bad,” the foundational insights provide a path to future therapies that combat immunotherapy resistance.</p>
<p>“Why interferons, which are initially anti-cancer, can become pro-cancer has been a big question in the field,” says senior author Gerald Shadel, PhD, professor and holder of the Audrey Geisel Chair in Biomedical Science at Salk. “Our study reveals a major reason for why interferons transition from ‘good’ to ‘bad,’ as well as how we can prevent this switch for therapeutic advantage moving forward.”</p>
<p>Shadel is senior and corresponding author of the researchers’ published paper in <em>Science,</em> titled “<a href="https://doi.org/10.1126/science.aec0002" target="_blank" rel="noopener">Chronic type II interferon promotes tumor growth through mitochondrial RNA–induced type I interferon and prostaglandin synthesis</a>.”</p>
<p>Cancer biology and, in turn, cancer treatment have come a long way in the last few decades. Most people recognize this progress in breakthroughs like immunotherapy—a treatment strategy first deployed in 2011 that leverages the body’s own immune cells to fight cancer and revolutionized the treatment landscape. However, progress doesn’t mean all the questions have been answered.</p>
<p>One of those questions is why interferons that recruit the immune system to attack cancer cells can, when they linger too long, start helping the tumor grow rather than shrink. “Interferons (IFNs) are proinflammatory cytokines that promote immune cell engagement to eliminate malignant cells,” the authors wrote. “Paradoxically, chronic interferon signaling can also activate anti-inflammatory mechanisms that allow cancer cells to evade the immune system.”</p>
<p>Shadel’s lab has been studying interferons for a while, and for his team, the context is always mitochondria. The Shadel lab first discovered that mitochondria invoke interferon responses through the release of mitochondrial genetic material (mtDNA) into the rest of the cell. The lab’s research seeks to uncover the ways mitochondrial dysfunction can lead to inflammation, aging, and pathology.</p>
<p>“For this study, we turned our focus around,” Shadel explained. “Instead of asking how mitochondria affect interferons, we asked how interferons affect mitochondria. And cancer is a powerful system to ask this question in, since interferons are so essential to the body’s cancer response.”</p>
<p>To determine how interferons affect mitochondria the team first exposed melanoma cells to interferon I or interferon II for either acute or chronic periods. Little happened to the mitochondria on acute exposure, but chronic exposure led to measurable changes in their energetic function. The researchers then transferred these melanoma cells to a mouse model, finding that chronic interferon II exposure unexpectedly enhanced tumor growth<em>.</em></p>
<p>The team next worked to decipher the cellular mechanisms behind the enhanced tumor growth. They found interferon II causes mitochondrial genetic material (mtRNA) to leave the mitochondria, where the rest of the cell perceives it as an invader and produces interferon I to respond. “We show that chronic type II interferon (IFN-II) exposure distinctively induced tumor growth by activating a type I interferon (IFN-I) response mediated by release of double-stranded mitochondrial RNA (ds-mtRNA) into the cytoplasm,” they noted.</p>
<p>Interferons I and II then work together to boost levels of the enzyme cyclooxygenase 2, which increases the synthesis of the bioactive lipid prostaglandin E2 (PGE<sub>2</sub>). “These IFN-II and IFN-I signals then synergize to up-regulate COX2-dependent PGE2 synthesis, an immunosuppressive pathway implicated in cancer progression and chemo-, immuno-, and targeted therapy resistance,” the team continued.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>If prostaglandin E<sub>2</sub> is causing immunosuppression, the team asked, what then happens if the melanoma cells are incapable of synthesizing PGE<sub>2</sub>?</p>
<p>Anti-PD1 immunotherapies are among the most widely used immunotherapies. They work by blocking a signal that cancer cells use to keep immune cells from attacking the tumor. But tumors can also suppress the immune system through other pathways, allowing them to continue growing despite anti-PD1 treatment.</p>
<p>“Chronic interferon exposure is a major factor in immunotherapy resistance,” says first author Melissa Johnson, a graduate student researcher in Shadel’s lab. “We wondered whether cancer cells that have become resistant to anti-PD1 therapy were upregulating the immunosuppressive mitochondria-centered pathway we identified, and whether that pathway is a viable target for combating immunotherapy resistance.”</p>
<p>The researchers blocked the synthesis of prostaglandin E<sub>2</sub> in mouse melanoma cells. They found that eliminating this signal restored the immune system’s ability to see and fight the cancer cells. Blocking prostaglandin E<sub>2</sub> also reversed resistance to anti-PD1 immunotherapies. In nine of 10 mice evaluated the tumors completely regressed and didn’t return, even though they were previously resistant to immunotherapy.” Elimination of PGE<sub>2 </sub>synthesis in immunotherapy-resistant melanoma cells restored their responsiveness to anti-PD1 treatment, indicating that this covert mtRNA-IFN-prostaglandin pathway could be a therapeutic target to combat immunotherapy resistance,” the team concluded.</p>
<p>The findings demonstrate potential for clinical translation in the future, offering a potential way to sustain the immune system’s attack on cancer and hope in cases of immunotherapy resistance. “Our study enriches our understanding of how the immune system attacks cancer cells but can also be stymied by other factors in the tumor environment,” said Shadel, “and also conveys the importance of integrating mitochondrial signaling functions into cancer studies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/chronic-interferon-exposure-linked-to-immunosuppression-in-cancer/">Chronic Interferon Exposure Linked to Immunosuppression in Cancer</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Highly Multiplexed Droplet Digital PCR for Ultra&#45;Sensitive NSCLC Biomarker Detection in Research Workflows</title>
<link>https://edusehat.com/en/highly-multiplexed-droplet-digital-pcr-for-ultra-sensitive-nsclc-biomarker-detection-in-research-workflows</link>
<guid>https://edusehat.com/en/highly-multiplexed-droplet-digital-pcr-for-ultra-sensitive-nsclc-biomarker-detection-in-research-workflows</guid>
<description><![CDATA[ In this GEN webinar, two experts will discuss the growing role of ddPCR in clinical research and translational oncology. 
The post Highly Multiplexed Droplet Digital PCR for Ultra-Sensitive NSCLC Biomarker Detection in Research Workflows appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.insideprecisionmedicine.com/wp-content/uploads/2026/09/Getty_120542301_LungCamcer.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 05:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Highly, Multiplexed, Droplet, Digital, PCR, for, Ultra-Sensitive, NSCLC, Biomarker, Detection, Research, Workflows</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/SurbhiJain_headshot.jpg" class="h-full w-full object-cover" alt="Image of Surbhi Jain, PhD, MBBS">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Surbhi Jain, PhD, MBBS</h2>
                <h5 class="mt-0 !text-[15px]">Staff Scientist<br>Bio-Rad Laboratories</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/SurbhiJain_headshot.jpg" alt="Image of Surbhi Jain, PhD, MBBS">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Surbhi Jain, PhD, MBBS</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Surbhi Jain, PhD, MBBS, is a staff scientist at Bio-Rad Laboratories and the R&D lead for the ddPLEX <em>EGFR/KRAS/BRAF</em> multiplexed droplet digital PCR panel. She is focused on developing ddPCR assay solutions for precision oncology and has more than 16 years of experience in diagnostic assay development, with expertise spanning liquid biopsy biomarkers and high-throughput molecular workflows. Before joining Bio-Rad, Surbhi developed reagents for CRISPR-enabled massively parallel genome editing and served as principal investigator on SBIR programs developing cell-free DNA technologies for cancer detection and monitoring. She earned her PhD in microbiology and immunology from Temple University in Philadelphia and her medical degree (MBBS) from B.Y.L. Nair Hospital in Mumbai.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/09/PrithwishPal_headshot.jpg" class="h-full w-full object-cover" alt="Image of Prithwish Pal, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Prithwish Pal, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Director, Global Product Marketing – Oncology<br>Director, Global Product Marketing – Oncology</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/09/PrithwishPal_headshot.jpg" alt="Image of Prithwish Pal, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Prithwish Pal, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Prithwish Pal, PhD, is director of global product marketing for oncology at Bio-Rad Laboratories, leading the company’s ddPCR oncology portfolio for liquid biopsy, MRD, and treatment monitoring applications. With over 15 years of experience in precision oncology, he has held leadership roles in product management, market development, and medical affairs at Illumina and other diagnostics companies. He holds a PhD in biophysics from the University of Rochester and an MBA from the University of California, San Diego.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, October 6, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-06T15:00:00.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">National and international guidelines recommend biomarker testing for oncogenic driver mutations in metastatic non-small cell lung cancer (NSCLC). Emerging technologies such as Droplet Digital<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> PCR (ddPCR<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">) enable sensitive detection and quantification of nucleic acid targets and have been widely used in scientific research involving solid and hematologic cancer samples. Such technologies support oncology research applications, including biomarker characterization and molecular profiling studies.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, two experts will discuss the growing role of ddPCR in clinical research and translational oncology. In the first session, Prithwish Pal, PhD, will explore the use of ddPCR in liquid biopsies that require highly sensitive variant detection and precise quantification in research settings. In the second session, Surbhi Jain, PhD, will present analytical data for ddPLEX <em>EGFR/KRAS/BRAF</em> Mutation Detection Assay Kit*, a research-use-only kit developed for the QX600 Droplet Digital PCR System. She will share results from an external analytical validation study of the assay against alternative reference methods that showed 100% concordance in archived plasma cell-free DNA and 96.5% in FFPE specimens.</p><p></p><p></p><p class="wp-block-paragraph">Key takeaways from the webinar include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>Workflow and precision of ddPCR systems ideal for cancer research, including biomarker discovery, development of biomarker driven therapy, and monitoring applications in research settings</li><p></p><p></p><p></p><li>How multiplexing extracts maximum information from limited testing research material with greater sensitivity and precision than qPCR and with less time and cost than next-generation sequencing</li><p></p><p></p><p></p><li>A streamlined RUO ddPCR assay for metastatic NSCLC research that quantifies 37 <em>EGFR, KRAS</em>, and <em>BRAF</em> variants in a single well, paired with a mutation-agnostic total quantification well for variant allele frequency calculations.</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p class="wp-block-paragraph">*For Research Use Only. Not for use in diagnostic procedures.</p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.bio-rad.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="80" src="https://www.genengnews.com/wp-content/uploads/2019/12/bio_rad_Logo-300x80.jpg" alt="BioRad logo" class="wp-image-132129" srcset="https://www.genengnews.com/wp-content/uploads/2019/12/bio_rad_Logo-300x80.jpg 300w, https://www.genengnews.com/wp-content/uploads/2019/12/bio_rad_Logo.jpg 500w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/highly-multiplexed-droplet-digital-pcr-for-ultra-sensitive-nsclc-biomarker-detection-in-research-workflows/">Highly Multiplexed Droplet Digital PCR for Ultra-Sensitive NSCLC Biomarker Detection in Research Workflows</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>10 CDMO Up &amp;amp; Comers 2026</title>
<link>https://edusehat.com/en/10-cdmo-up-comers-2026</link>
<guid>https://edusehat.com/en/10-cdmo-up-comers-2026</guid>
<description><![CDATA[ As one notable company exits the field, growing CDMOs open facilities and secure major contracts. The  companies are listed here for making headlines with facility openings, major contracts, and other significant actions, though not yet large enough to crack the A-List Top 10 CDMOs.
The post 10 CDMO Up &amp; Comers 2026 appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Alist_ResilenceHeadquarters.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 01:35:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDMO, Comers, 2026</media:keywords>
<content:encoded><![CDATA[<p>Below are 10 contract development and manufacturing organizations (CDMOs) listed by <em>GEN</em> as Up & Comers for making headlines with facility openings, major contracts, and other significant actions, though not yet large enough to crack the A-List <a href="https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/" target="_blank" rel="noopener">Top 10 CDMOs</a>.</p>
<p>Among <a href="https://www.genengnews.com/topics/bioprocessing/10-cdmo-up-comers/">last year’s Up & Comers</a> that are not listed this year is Charles River Laboratories. In May, Charles River completed the divestitures of its CDMO and Cell Solutions businesses to GI Partners, a private equity, real estate and data infrastructure investment firm, primarily for undisclosed contingent performance-based payments—part of a series of moves intended “to refine and further strengthen its portfolio.”</p>
<p>The CDMO business provided services related to the production of advanced therapies for gene-modified cell therapies, as well as gene therapies including viral vectors and plasmid DNA, while Cell Solutions provided human-derived cellular materials used for developing and producing cell therapies.</p>
<p>The CDMO and cell solutions businesses generated combined annual revenue of $143 million in 2025, including $117 million in the Manufacturing Solutions segment and $26 million in the Research Models and Services (RMS) segment. CRL also sold specified European assets within its Discovery Services business to IQVIA Holdings for approximately $145 million.</p>
<p class="trimmed"> </p>
<p><strong>1. Artis BioSolutions</strong></p>
<ul>
<li>Rebranded in July by combining Landmark Bio, a Watertown, MA-based development and GMP manufacturing operation, and Syngoi, a Bilbao, Spain-based enzymatic synthetic DNA business. The change unites Artis’ U.S. and European capabilities, completing a transatlantic platform linking proprietary synthetic DNA production directly to advanced therapy development and clinical-grade manufacturing.</li>
<li>Emerged from stealth in April, when it disclosed its acquisition of Landmark Bio. Earlier this year, Artis acquired Syngoi, then used Syngoi’s enzymatic platform to <a href="https://www.genengnews.com/topics/omics/synthetic-dna-manufacturing-hub-set-up-in-boston-by-artis-biosolutions/">establish new synthetic DNA manufacturing capabilities</a> in Boston. The price of both acquisitions was undisclosed.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>2. AsymBio</strong></p>
<ul>
<li>Secured RMB 1.2397 billion (approximately $184 million) from Asymchem Group, Hillhouse Qirui, and other investors. The cash infusion will raise Asymchem Group’s stake in AsymBio to 83.4965%. Asymchem Group will invest RMB 1.05 billion (approximately $156 million), and Hillhouse Qirui will invest RMB 177 million (approximately $26 million).</li>
<li>Generated more than RMB 140 million (approximately $21 million) in first-quarter revenue, and RMB 470 million (approximately $70 million) in revenue in 2025.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>3. Bora Group</strong></p>
<ul>
<li>Completed its up-to-$127.5 million acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics—a $122.5 million deal price plus up to $5 million based on future customer orders. The transaction includes a biologics drug substance manufacturing facility located in Rockville, MD, and an associated warehousing center in Frederick, MD.</li>
<li>Signed a $250 million five-year contract with GlaxoSmithKline (GSK) to renew a manufacturing partnership stretching back to when Bora purchased GSK’s Mississauga, ON, Canada, facility in 2020<strong>. </strong>The renewal will expand the companies’ partnership by allowing GSK to access multiple sites within Bora’s network, including its newest oral solid dose site in Maple Grove, MN. GSK is the largest pharmaceutical partner operating at Bora’s Mississauga facility, where Bora provides end-to-end manufacturing services for 20+ commercial product lines and 335+ individual products.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>4. Curia Global</strong></p>
<ul>
<li>Reached agreement on key terms of a recapitalization transaction that is expected to reinforce the company’s financial foundation and position it for long-term success. The transaction is led by funds managed by affiliates of Apollo and has the support of all of Curia’s key financial stakeholders. The deal is expected to close later this year.</li>
<li>Completed a $4 million upgrade to its two aseptic suites in Valladolid, Spain. The central feature of the upgrade was the transition to a fully closed system, designed to strengthen process and product integrity while minimizing microbiological risk across all stages of production. Enhancements also focused on modernizing core equipment and systems, including installing advanced isolators, as well as upgrades to HVAC, pharmaceutical utilities, automation and sterilization-in-place processes.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>5. Gland Pharma</strong></p>
<ul>
<li>Executed an agreement with “one of the leading global pharmaceutical companies” for the technology transfer, manufacturing, and supply of a portfolio of sterile injectable products for global markets. The portfolio consists of oncology and non-oncology products in vials, lyophilized products, ampoules, and pre-filled syringes. The agreement covers 55 stock-keeping units (SKUs) to be manufactured across three sites, with anticipation of adding more products. Once all products are commercialized, the annualized revenue potential is expected to be approximately $90 million–$100 million.</li>
<li>Launched a long-term strategic partnership with Neuland Laboratories for the manufacture of complex sterile active pharmaceutical ingredients (APIs). Gland plans to establish a dedicated sterile API manufacturing suite at its JNPC facility in Visakhapatnam, India, to support Neuland’s sterile API requirements for global drugmakers. The suite is expected to add roughly 1,400 kg (3,086 pounds) of annual production capacity and provide the flexibility to manufacture multiple sterile products.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>6. Neuland Laboratories</strong></p>
<ul>
<li>Completing a $20 million dedicated process development laboratory and integrated kilo lab at its Genome Valley campus in Hyderabad, India. The 135,000-square-foot facility will be made operational in phases, with full completion expected by October.</li>
<li>Finished the fiscal year ending March 31 with record full-year revenues exceeding ₹2,000 crore (approximately $215 million), and EBITDA of ₹603.4 crore (about $63.4 million), up 448.6% from FY 2025. Growth was driven by commercial-stage new chemical entity (NCE) programs, particularly from North American customers, reflecting what the company said was increasing demand for reliable development and manufacturing partners for complex molecules.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>7. ProBio</strong></p>
<ul>
<li>Successfully delivered adeno-associated virus (AAV) scale-up materials to enable <em>in vivo</em> IND-enabling studies as a strategic partner to the University of California (UC) Irvine School of Medicine and GlyTR Therapeutics, developers of a next-generation AAV-mediated chimeric antigen receptor (CAR) T-cell platform, GlyTR, engineered to target tumor associated carbohydrate antigens that are highly expressed across a broad range of cancers.</li>
<li>Partnered with Curocell to achieve a key CAR T milestone with Biologics License Application (BLA) approval and commercial readiness for anbalcabtagene autoleucel (anbal-cel, also known as CRC01), a next-generation CD19-targeted CAR T-cell therapy developed for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).</li>
<li>Expanded viral vector development capabilities at its Hopewell, NJ, site with its Viral Vector Packaging Test, a new early-stage development platform designed to accelerate decision making and derisk progression from discovery to chemistry, manufacturing, and controls (CMC) in cell and gene therapy programs. The test is designed to provide feasibility level data to support vector design, manufacturability, and scalability decisions at a critical inflection point in development.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>8. Quotient Sciences</strong></p>
<ul>
<li>Successful initiated a Phase I clinical study evaluating a novel drug product developed using artificial intelligence (AI). The study will assess the safety and pharmacokinetics of an undisclosed oral solid dose formulation in healthy volunteers, leveraging Intrepid Labs’ ANDROMEDA advanced machine learning algorithm to support formulation design and optimization. Quotient said the landmark achievement highlights the growing potential of AI to guide formulation design and accelerate drug development.</li>
<li>Extended a commercial supply partnership with Ipsen to manufacture Sohonos® (palovarotene), a retinoid indicated for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease affecting <1,000 people worldwide. Quotient said the collaboration reinforced its commitment as a contract research, development and manufacturing organization (CRDMO) to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>9. Resilience</strong></p>
<ul>
<li>Expanded a three-year-old strategic partnership with Eli Lilly by partnering on a $750 million expansion of its manufacturing operations in the Cincinnati region by adding to its production of Lilly’s KwikPen®device for injecting diabetes and obesity treatments. The addition will create at least 400 new jobs, bringing Resilience’s Ohio workforce to more than 1,400. Full operations are expected to start in early 2027.</li>
<li>Announced plans to relocate its corporate headquarters from San Diego to Blue Ash, OH. Resilience anticipates adding approximately 200 new jobs in Blue Ash, where it also envisions basing a drug product packaging and supply operation spanning more than 450,000square feet. The move will expand an Ohio presence that includes a drug product manufacturing facility in nearby West Chester, OH.</li>
</ul>
<p class="trimmed"> </p>
<p><strong>10. uBriGene</strong></p>
<ul>
<li>Launched its uVivo<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Lentiviral Vector (LVV) Platform, a targeted <em>in vivo</em> CAR T platform designed to enable precise delivery of CAR payloads to T cells, allowing rapid generation of CAR T cells <em>in vivo</em>. uBriGene says the platform can produce thousands of doses from a single 10 L batch.</li>
<li>Initiated a strategic partnership with Cellinfinity BIO, a biotechnology company developing <em>in vivo</em> CAR T therapies targeting hematologic and solid tumors. The partnership is designed to accelerate the clinical advancement of Cellinfinity BIO’s therapeutic programs: CIB-301 for solid tumors and CIB-350 for hematologic malignancies and autoimmune diseases.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/10-cdmo-up-comers-2026/">10 CDMO Up & Comers 2026</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Top 10 Contract Development and Manufacturing Organizations 2026</title>
<link>https://edusehat.com/en/top-10-contract-development-and-manufacturing-organizations-2026</link>
<guid>https://edusehat.com/en/top-10-contract-development-and-manufacturing-organizations-2026</guid>
<description><![CDATA[ A majority of biopharmas are expected to increase their reliance on CDMOs in coming years despite rising costs for their services.
The post Top 10 Contract Development and Manufacturing Organizations 2026 appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Alist_lonza_mammalian_hero-e1789050008879.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 01:35:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Top, Contract, Development, and, Manufacturing, Organizations, 2026</media:keywords>
<content:encoded><![CDATA[<p>A survey of more than 300 biopharma leaders <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/how-customer-expectations-are-reshaping-the-cdmo-market" target="_blank" rel="noopener">published in August</a> by McKinsey delivered some good news for contract development and manufacturing organizations (CDMOs): A majority said they expect to increase their reliance on CDMOs despite rising costs associated with their services.</p>
<p>While batch processing prices have risen since the pandemic and further increases are expected over the rest of this decade, the biopharma leaders concluded that their demand for outsourced services will continue to expand, especially services that increasingly depend on speed, flexibility, and specialized capabilities. Survey respondents expect the share of 2,000 liters (L) single-use bioreactor work carried out by CDMOs for both clinical and commercial supply to soon exceed 50%.</p>
<p>Growing customer dependence on CDMOs is reflected in a <a href="https://www.gminsights.com/industry-analysis/pharmaceutical-cdmo-market" target="_blank" rel="noopener">statistic</a> published in June by Global Market Insights: The global CDMO market is projected to expand by 6.4% this year, from $173.7 billion in 2025 to $184.9 billion this year. By 2035, the market is expected to reach $342 billion, for a compound annual growth rate of 7.1%.</p>
<p>While access to readily available and regulatory-compliant capacity traditionally drove CDMO growth, McKinsey observed, biopharma customers are increasingly emphasizing reliability, execution, and cost competitiveness, as quality is now viewed as more of a baseline requirement than a differentiator. Quality problems can account for 15–20% of cost of goods sold, while the FDA has stepped up <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions">Form 483</a> violation reports by 33% last year vs. pre-COVID-19 levels. And remediation plans to address violations can cost anywhere from $10 million to $50 million.</p>
<p>McKinsey cited three other factors as driving CDMO decisions among customers: Growing pressure to improve operational performance and productivity, rising cost sensitivity among customers, and what McKinsey termed “surprisingly thin” loyalty to CDMOs.</p>
<p></p><h4><strong>“Failing to bridge the gap”</strong></h4>

<p>“This suggests that many CDMOs are failing to bridge the gap from physical capacity and baseline execution to the productivity needed for competitive pricing,” according to McKinsey.</p>
<p>Other CDMO market watchers such as Imen Jelassi, PharmD, founder and CEO of life sciences business development consultancy Corstrate, cite the ongoing reshoring of manufacturing operations by Western biopharmas wrought by the BIOSECURE Act as presenting a <a href="https://www.corstrate.com/post/biosecure-act-cdmo-reshoring-opportunity" target="_blank" rel="noopener">potential opportunity</a> for U.S. and European CDMOs.</p>
<p>Below is <em>GEN</em>’s updated A-List of Top 10 CDMOs. The companies are ranked by 2025 revenues, as disclosed by the companies in regulatory filings or in responses to <em>GEN</em>’s queries. Several of the CDMOs have also furnished quarterly or half-year revenues for 2026. For the first time, <em>GEN</em> offers a year-over-year revenue comparison that offers another interesting insight: Eight of this year’s top 10 CDMOs recorded year-over-year revenue increases, with combined revenue of the top 10 growing to $35.116 billion in 2025, up six percent from $33.127 billion in 2024.</p>
<p>As with last year’s A-List, <em>GEN</em> also spotlights <a href="https://www.genengnews.com/topics/bioprocessing/10-cdmo-up-comers-2026/" target="_blank" rel="noopener">10 “Up & Coming” CDMOs</a> that are not yet large enough to rank within the top 10, based on recent news announcements ranging from facility openings to significant contracts (online only).</p>
<p>Unlike the <a href="https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2025/" target="_blank" rel="noopener">2025 CDMOs A-List</a>, this year’s rankings no longer include Catalent because it no longer publicly reports its revenues—a result of the Bridgewater, NJ-based CDMO having been <a href="https://www.genengnews.com/topics/drug-discovery/novo-holdings-buys-catalent-for-16-5b-sells-three-sites-to-novo-nordisk-for-11b/" target="_blank" rel="noopener">acquired for $16.5 billion</a> by Novo Holdings, the asset manager of the foundation that controls Novo Nordisk, in a deal completed on December 18, 2024.</p>
<p>Just missing the top 10, at No. 11, is Merck KGaA, Darmstadt, Germany, whose Life Sciences business in the U.S. and Canada goes by the name MilliporeSigma. Merck KGaA/MilliporeSigma saw its CDMO revenue fall 8.7% year-over-year, to €659 million ($761 million) last year from €722 million ($834 million) in 2024. The company hopes to reverse that decline through activity in new facilities such as its €300 million ($345 million) Bioprocessing Production Center in Daejeon, South Korea, that is set to open by year’s end, and its new €25 million ($29 million) 2,000-square-meter (21,528-square-foot) BioReliance<sup>®</sup> testing facility in Darmstadt, Germany, which opened in July.</p>
<p>All dollar figures for 2024 revenues differ from the figures reported by <em>GEN</em> in last year’s A-List of Top 10 CDMOs due to currency fluctuations.</p>
<p class="trimmed"> </p>
<p></p><h4><span><strong>#1. Lonza Group</strong></span></h4>

<p><em>Basel, Switzerland</em></p>
<p><strong>2025 Revenue: CHF 6.531 billion ($8.053 billion) <sup>1</sup></strong></p>
<p><strong>2024 Revenue: CHF 6.574 billion ($8.106 billion) <sup>2</sup></strong></p>
<p>% Change: <span><strong>— 0.7%</strong></span></p>
<p>Finished H1 2026 with EBITDA of CHF 1.175 billion ($1.449 billion), up 27 from CHF 922 million ($1.137 billion) in H1 2025, on revenue that grew 16% year-over-year to CHF 3.374 billion ($4.160 billion) from CHF 3.034 billion ($3.741 billion).<sup>1</sup></p>
<p>Considering construction of a $1 billion plant on two parcels totaling 161 acres on land owned by Clermont County, OH, in Williamsburg Township, some 25 miles east of downtown Cincinnati. On June 29, the Ohio Tax Credit Authority approved a 1.860%, 20-year Job Creation Tax Credit for the project, which would create 650 full-time-equivalent positions. Ohio is competing for the project against Texas, North Carolina, and Virginia.</p>
<p>Announced an expanded strategic collaboration with an undisclosed “leading U.S.-based biopharmaceutical company.” The expansion adds two biologics programs to be produced commercially, with the option for two more, and further strengthens an established multi-year relationship, including long-term commitments across a broad portfolio of multiple biologics programs.</p>
<p>Disclosed plans to enhance its drug-linker center of excellence and expand payload-linker manufacturing capacity at its site in Visp, Switzerland. The expansion will establish new commercial-scale capabilities for the manufacture of highly complex and highly potent active pharmaceutical ingredients (HPAPI) and ADC payload-linkers.</p>
<p class="trimmed"> </p>
<p></p><h4><span><strong>#2. Thermo Fisher Scientific</strong></span></h4>

<p><em>Waltham, MA</em></p>
<p><strong>2025 Revenue: $7.142 billion <sup>3</sup></strong></p>
<p><strong>2024 Revenue: $7 billion <sup>4</sup></strong></p>
<p><strong>% Change:</strong> <span><strong>+0.2%</strong></span></p>
<p>Opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. The new facility expands the company’s global bioanalytical and biomarker service capabilities to support pharmaceutical and biotechnology customers across all phases of drug development.</p>
<p>Introduced the Gibco<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> CTS<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> DynaXS<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. The bioreactor is designed to support flexible, cGMP-ready cell expansion from process development to clinical production to support the development of cell therapies.</p>
<p>Opened its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, MA, site, expanding the facility to support customers in developing and scaling biologics. The new center brings together advanced bioproduction capabilities and hands-on collaboration, with the aim of helping customers accelerate process development and bring therapies to patients faster.</p>
<p class="trimmed"> </p>
<p></p><h4><span><strong>#3. WuXi AppTec</strong></span></h4>

<p><em>Shanghai, China</em></p>
<p><strong>2025 Revenue: RMB 45.45 billion ($6.737 billion)</strong></p>
<p><strong>2024 Revenue: RMB 39.241 billion ($5.816 billion)</strong></p>
<p><strong>% Change: <span>+15.8%</span></strong></p>
<p>Finished H1 2026 with adjusted non-IFRS net profit of RMB 11.57 billion ($1.715 billion), up 83.2% year-over-year, on revenue that climbed 38.9% from H1 2025, to RMB 28.90 billion ($4.284 billion). For the first time, WuXi AppTec revenue surpassed that of Lonza Group.</p>
<p>Obtained a preliminary injunction from U.S. District Chief Judge James Boasberg, appointed to the federal district bench in 2011 by President Barack Obama, temporarily blocking the U.S. Department of Defense from designating WuXi AppTec as a “Chinese military company.” Washington has alleged the company is indirectly owned by China’s State-owned Assets Supervision and Administration Commission and indirectly affiliated with China’s State Administration of Science, Technology and Industry for National Defense (SASTIND) and People’s Liberation Army.</p>
<p>Raised full-year 2026 revenue guidance to RMB 58.5 billion to RMB 60.5 billion ($8.672 billion to $8.968 billion), up 10.4% to 14% from previous guidance of RMB 51.3 billion to RMB 53.0 billion ($7.604 billion to $7.855 billion), with continuing operations revenue raised to 35% to 39% year-over-year, up from 18% to 22%.</p>
<p>Raised 2026 capital expenditure or “capex” guidance range to RMB 7.5 billion to RMB 8.5 billion ($1.112 billion to $1.260 billion), up 13.3% to 15.4% from RMB 6.5 billion to RMB 7.5 billion ($963.5 million to $1.112 billion) to support accelerated global capacity expansion, including initiation of a new Changzhou, China, site ahead of schedule.</p>
<p><strong> </strong></p>
<p></p><h4><span><strong>#4. WuXi Biologics</strong></span></h4>

<p><em>Wuxi, China</em></p>
<p><strong>2025 Revenue: RMB 21.790 billion ($3.230 billion)</strong></p>
<p><strong>2024 Revenue: RMB 18.675 billion ($2.768 billion)</strong></p>
<p><strong>% Change: <span>+16.7%</span></strong></p>
<p>Agreed to acquire CDMO assets in Hangzhou, China, from Transcenta Holding for RMB 190 million (approximately $28.2 million), reflecting the buyer’s pivot from physical manufacturing to developing its core biomanufacturing platforms and technologies: “The Company does not consider the provision of CDMO services a core part of its principal business,” Transcenta stated in a Hong Kong Exchange <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0807/2026080700005.pdf" target="_blank" rel="noopener">regulatory filing</a>.</p>
<p>Marked the development of its 1,000<sup>th</sup> molecule on its integrated contract research, development, and marketing organization (CRDMO) platform, a trispecific antibody for ophthalmic diseases that is being developed under a partnership with Earendil Labs.</p>
<p>Secured FDA Pre-License Inspection (PLI) approval for its MFG8 drug substance manufacturing facility in Hebei, China, which is equipped with twelve 4,000 L single-use bioreactors and offers flexible commercial manufacturing at scales ranging from 4,000 L to 20,000 L. The facility supports commercial manufacturing for an undisclosed “potential blockbuster” autoimmune therapy.</p>
<p><strong> </strong></p>
<p></p><h4><span><strong>#5. Samsung Biologics</strong></span></h4>

<p><em>Incheon, South Korea</em></p>
<p><strong>2025 Revenue: KRW 4.557 trillion ($3.222 billion)</strong></p>
<p><strong>2024 Revenue: KRW 4.547 trillion ($3.215 billion) </strong></p>
<p><strong>% Change: <span>+0.2%</span></strong></p>
<p>Finished Q2 with consolidated operating profit of KRW 586.4 billion ($414.6 million), up 23% year-over-year, on KRW 1.321 trillion ($933.9 million) in revenue, up 30% from Q2 2025.</p>
<p>Launched an all-cash public tender offer to acquire PolyPeptide Group, a Baar, Switzerland-based CDMO specializing in peptide-based active pharmaceutical ingredients (APIs), for approximately CHF 1.46 billion ($1.803 billion). The transaction is expected to be completed toward the end of 2026.</p>
<p>Completed the $353 million acquisition of its first manufacturing site in the U.S., a Rockville, MD, facility, from GlaxoSmithKline (GSK). The Rockville site consists of two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales.</p>
<p>Secured land for BioCampus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.</p>
<p class="trimmed"> </p>
<p></p><h4><span><strong>#6.</strong> <strong>Boehringer Ingelheim</strong></span></h4>

<p><em>Ingelheim, Germany</em></p>
<p><strong>2025 Revenue: €1.470 billion ($1.697 billion) <sup>5</sup> </strong></p>
<p><strong>2024 Revenue: €1.235 billion ($1.426 billion) </strong></p>
<p><strong>% Change: <span>+19.0%</span></strong></p>
<p>Selected the osapiens HUB for Maintenance as the frontline mobile platform for its maintenance teams to plan, execute, and document production-critical maintenance work across its regulated manufacturing operations, using a single solution to plan, coordinate, execute, and close out work.</p>
<p>Cut €900 million ($1.039 billion) in planned domestic spending and investments in Germany for 2027–2030, blaming German government plans to cut healthcare spending and require drug developers to grant higher discounts on treatments to insurers. “We have to keep pace with developments in the USA and Asia,” Médard Schoenmaeckers, head of BI’s German division, told German business news outlet <em>Handelsblatt</em>.</p>
<p>Launched a new center for artificial intelligence (AI) and machine learning in King’s Cross, London, U.K., part of the company’s goal of advancing AI for pharmaceutical research and development. The U.K. site adds to BI’s Computational Innovation footprint, which includes locations in Austria, Germany, and the U.S. specializing in AI, machine learning, human genetics, and computational biology.</p>
<p><strong> </strong></p>
<p></p><h4><span><strong>#7. Siegfried</strong></span></h4>

<p><em>Zofingen, Switzerland</em></p>
<p><strong>2025 Revenue: CHF 1.328 billion ($1.640 billion)</strong></p>
<p><strong>2024 Revenue: CHF 1.295 billion ($1.599 billion)</strong></p>
<p><strong>% Change: <span>+2.5%</span></strong></p>
<p>Appointed Eduardo Montanha as COO and member of the Executive Committee, effective September 1. Montanha was previously executive vice president, head of global technical operations and quality at Fresenius Kabi.</p>
<p>Named Frédéric Kahn as head of global business development and sales, drug products. Kahn joins Siegfried from Piramal Pharma Solutions, where he was vice president of business development for Europe and the rest of the world.</p>
<p>Inaugurated a new large-scale production facility for API manufacturing in Minden, Germany. The facility adds 100 cubic meters (3,531 cubic feet) of reactor capacity and is designed to strengthen Siegfried’s position as a leading global CDMO for small molecule drug substances.</p>
<p>Completed acquisition of three Noramco Group companies from SK Capital Partners for “below 10 times Enterprise Value / EBITDA.” The deal involves three small-molecule drug substance sites with about 400 employees: Noramco, a commercial-scale manufacturing site in Wilmington, DE; Purisys, a clinical API development and manufacturing facility in Athens, GA; and Extractas Bioscience, a manufacturer of purified products in Westbury, Tasmania, Australia.</p>
<p class="trimmed"> </p>
<p></p><h4><span><strong>#8.</strong> <strong>Fujifilm Biotechnologies</strong><strong> / Fujifilm Corp.</strong></span></h4>

<p><em>College Station, TX / Tokyo, Japan</em></p>
<p><strong>2025 Revenue: ¥257.2 billion ($1.616 billion) <sup>6</sup></strong></p>
<p><strong>2024 Revenue: ¥219.5 billion ($1.379 billion) </strong></p>
<p><strong>% Change: <span>+17.2%</span></strong></p>
<p>Appointed Maja Pedersen as president, in addition to her role as COO, as part of a planned leadership succession with Lars Petersen transitioning from his role as president and CEO, effective immediately, to strategic advisor through September 30.</p>
<p>Celebrated the selection of its commercial-scale cell culture manufacturing facility in Holly Springs, NC, among seven facilities chosen by the FDA for its <a href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fzwly9k6z.r.us-east-1.awstrack.me%2FL0%2Fhttps%3A%252F%252Fwww.fda.gov%252Fnews-events%252Fpress-announcements%252Ffda-selects-seven-participants-precheck-pilot-program-advance-us-drug-manufacturing%2F2%2F0100019f41d5c98e-fc6da9b9-30ee-4661-b5b3-5f537b25ee37-000000%2FsRAGZ_rh_v8H8-8ig-JWmEvaZmk%3D473&data=05%7C02%7C%7Cfdb61098fe564a9bc7d408dee82dcfe7%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639203481639672557%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=CgXKIMC6WmNt2qGgO6jcPUS2AxjHFSETdMzLPCBkkUE%3D&reserved=0" target="_blank" rel="noopener">PreCheck Pilot Program</a>, designed to strengthen the nation’s pharmaceutical manufacturing capabilities.</p>
<p>Opened a new, 2,000‑square‑meter (21,528-square-foot) quality control (QC) laboratory at its Hillerød, Denmark, commercial‑scale manufacturing site. The expanded QC footprint is designed to enable bioassay and virology operations to meet current and future customer demand and support the site’s planned expansion.</p>
<p>Opened its expanded site in Teesside, U.K., funded through a total investment of approximately £400 million ($540 million) from parent Fujifilm Corp. The expanded site includes the opening of the largest single-use biopharmaceutical CDMO facility in the U.K., a 110,000 square-foot manufacturing facility that introduces 2,000 L and 5,000 L single-use bioreactors with a total capacity up to 19,000 L to provide small- and mid-scale antibody manufacturing.</p>
<p class="trimmed"> </p>
<p></p><h4><span><strong>#9. Recipharm</strong></span></h4>

<p><em>Stockholm, Sweden</em></p>
<p><strong>2025 Revenue: €837 million ($966 million) <sup>7</sup></strong></p>
<p><strong>2024 Revenue: €827 million ($955 million) </strong></p>
<p><strong>% Change: +1.2%</strong></p>
<p>Announced a multi-million-dollar investment in its U.S. operations, designed to strengthen its ability to support pharmaceutical and biotechnology companies with advanced sterile fill and finish services for biologics and advanced therapies.</p>
<p>Launched a strategic collaboration with Fusix Biotech to support the development and GMP manufacturing of next-generation oncolytic virus-based cancer immunotherapies, starting with Fusix’s lead candidate FUSE102, a chimeric oncolytic virus encoding a high-affinity soluble PD-1 intended to enable immune checkpoint inhibition and strengthen anti-tumor activity.</p>
<p>Disclosed a multi-million investment in a new Blow-Fill-Seal (BFS) manufacturing line, expanding capacity to support customer programs from development through commercial supply. The expanded capacity will support a broad range of ophthalmic product programs.</p>
<p class="trimmed"> </p>
<p></p><h4><span><strong>#10. AGC Biologics / AGC Group</strong></span></h4>

<p><em>Seattle, WA / Tokyo, Japan </em></p>
<p><strong>2025 Revenue: Y129.420 billion ($813.253 million) <sup>8</sup></strong></p>
<p><strong>2024 Revenue: ¥137.326 billion ($862.958 million)</strong></p>
<p><strong>% Change: <span>-5.8%</span></strong></p>
<p>Secured half the mammalian manufacturing capacity of its new Yokohama, Japan, facility through a multi-year contract with a “large pharmaceutical company” that is expected to reach hundreds of millions of dollars in value. AGC Biologics agreed to manufacture a minimum of 35 batches per year of five biopharmaceutical products for the undisclosed customer.</p>
<p>Entered a strategic partnership with Pyramid Pharma Services that combines its sterile fill-finish capabilities with AGC’s drug substance development and manufacturing expertise. The integrated offering also includes device assembly, labeling, and secondary packaging services for clinical programs.</p>
<p>Selected by Japan-based transdermal drug delivery technology developer Teikoku Seiyaku to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p>
<p class="trimmed"> </p>
<p><em>References</em></p>
<ol>
<li>Financial information presented for Lonza reflects its continuing CDMO business without the Capsules & Health Ingredients (CHI) business, which Lonza has agreed to divest by selling it to Lone Star Funds for CHF 2.3 billion ($2.836 billion), in a deal set to close by year’s end.</li>
<li>2024 results consist of sales from all operations, since CDMO business results had not been separated in Lonza’s financial results until 2025. CDMO operations excluded Capsules & Health Ingredients segment, which is not figured into CDMO results.</li>
<li>This Thermo Fisher figure, confirmed by a spokesperson, is based on “Pharma Services” activity accounting for ~29% of the $23.984 billion in revenue generated in 2025 by the company’s Laboratory Products and Biopharma Services segment. The “29%” percentage was disclosed by Thermo Fisher during its most recent Investor Day, held May 20, in a presentation that stated that the segment generated $24.4 billion in revenue for the 12 months ending March 31.</li>
<li>This Thermo Fisher figure was disclosed during the company’s Investor Day held September 19, 2024, in a <a href="https://s27.q4cdn.com/797047529/files/doc_presentations/2024/Sep/19/2024-investor-day-full-distribution-vf.pdf" target="_blank" rel="noopener">presentation </a>that stated “$7B Revenue” as being generated by the Pharma Services business of Thermo Fisher’s Laboratory Products and Biopharma Services segment. Through a spokesperson, Thermo Fisher last year confirmed that figure as its most accurate value of 2024 CDMO activity.</li>
<li>This Boehringer Ingelheim figure reflects revenue for the company’s BioXcellence<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> division (biopharmaceutical contract production), furnished by the company within its annual reports.</li>
<li>This Fujifilm Biotechnologies figure is the sum of Q1–Q4 fiscal year 2025 quarterly revenue figures for the “Bio CDMO” business within the Healthcare segment of Fujifilm Holdings, whose subsidiaries include CDMO Fujifilm Biotechnologies—rebranded in 2025 from Fujifilm Diosynth Biotechnologies. Fujifilm operates on a fiscal year that runs from April 1 of the named FY to March 31. FY 2025 covers the 12 months starting April 1, 2025, and ending March 31, 2026.</li>
<li>Does not include £299 million ($403 million) in revenue reported by S&P Global to have been generated in 2025 by the former inhaled and nasal drug-device business, which was spun out of Recipharm into Bespak through a process completed in April 2024.</li>
<li>Figure consists of Life Science Operations segment revenue for calendar year as published by AGC Group, which rebranded itself from Asahi Glass Company Ltd. in 2018.</li>
</ol>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/">Top 10 Contract Development and Manufacturing Organizations 2026</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Revvity Signs Agreement to Acquire Human Cell Design</title>
<link>https://edusehat.com/en/revvity-signs-agreement-to-acquire-human-cell-design</link>
<guid>https://edusehat.com/en/revvity-signs-agreement-to-acquire-human-cell-design</guid>
<description><![CDATA[ As wet-lab validation becomes increasingly important to support artificial intelligence-enhanced science, research science points out that human-relevant cell models provide an important foundation for testing and confirming AI-generated insights.
The post Revvity Signs Agreement to Acquire Human Cell Design appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2224678549.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 01:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Revvity, Signs, Agreement, Acquire, Human, Cell, Design</media:keywords>
<content:encoded><![CDATA[<p>Revvity inked a deal to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity, and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. The transaction is expected to close in Q4, 2026.</p>
<p>“HCD brings differentiated human cell models that complement Revvity’s broad portfolio of technologies supporting drug discovery and development,” said Prahlad Singh, president and CEO of Revvity. “As researchers continue to seek more human-relevant approaches to understanding biology, combining high-quality cell models with our capabilities in screening, detection, automation and analysis creates an opportunity to provide customers with more integrated solutions.”</p>
<p>HCD’s flagship <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.humancelldesign.com%2Fendoc-bh5-diabetes-obesity%2F&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=EndoC-%26%23946%3BH5&index=3&md5=13d6c212f87c580247b163381e14abbf" target="_blank" rel="noopener">EndoC-βH5</a> human pancreatic beta cell model is designed to provide researchers with a human-relevant model for studying beta cell physiology and function across diabetes and obesity research. HCD also offers specialized media and reagents, preclinical research, and its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.humancelldesign.com%2Fthe-natline-platform%2F&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=NatLine&index=4&md5=6b13865a393d381b8b55f9d885f638c1" target="_blank" rel="noopener">NatLine</a> cell-line development platform, which was developed to support the development of functionally consistent human cell models.</p>
<p>“Human Cell Design was founded on the belief that better human models can help transform the way medicines are discovered and developed,” said Guillaume Costecalde, founder and president of Human Cell Design. “Joining Revvity is expected to allow us to bring our human cell models and NatLine technology to a broader global customer base while supporting the development of new physiologically relevant cell models.”</p>
<p>The combination aligns with Revvity’s portfolio of detection and cell analysis technologies, according to a Revvity officials, who adds that EndoC-βH5 cells are well-suited for use with Revvity’s <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.revvity.com%2Fcategory%2Fhtrf&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=HTRF%26%238482%3B&index=5&md5=3d2ae92a658a6804973cd11c352f07fb" target="_blank" rel="noopener">HTRF<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.revvity.com%2Fcategory%2Falpha-assays&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=AlphaLISA&index=6&md5=d8dc46cb8fcb9d76183f21a1dbcd5c21" target="_blank" rel="noopener">AlphaLISA</a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.revvity.com%2Fcategory%2Falpha-assays&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=%26%238482%3B&index=7&md5=9f03a97c0fcdde61854d8dafe4d6b5d2"><img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></a> assays for measuring key pharmacological readouts such as cAMP and insulin as well as<a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.revvity.com%2Fcategory%2Fphsense-reagents&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=pHSense%26%238482%3B&index=8&md5=24b56b5a70bfc906e95f6680038cab5c" target="_blank" rel="noopener"> pHSense<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></a> technology for receptor internalization studies.</p>
<p>The combination also extends to Revvity’s <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.revvity.com%2Fcategory%2Fcytotoxicity-and-cell-proliferation-assays&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=ATPlite%26%238482%3B&index=9&md5=03e4b9e950aa98f91e95ce228d7ef818" target="_blank" rel="noopener">ATPlite<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"></a> assays for cell viability and proliferation analysis. These detection and analysis capabilities are expected to extend to <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.revvity.com%2Fcategory%2Fhigh-content-screening-instruments&esheet=54599611&newsitemid=20260909605073&lan=en-US&anchor=Revvity%26%238217%3Bs+high-content+screening+platform&index=10&md5=607219be5a66d00ec04c2573d25938ad" target="_blank" rel="noopener">Revvity’s high-content screening platform</a> and methods for interpreting complex cellular data. As wet-lab validation becomes increasingly important to support AI-enhanced science, human-relevant cell models provide an important foundation for testing and confirming AI-generated insights.</p>
<p>Revvity also notes that HCD’s technology also has applications beyond early-stage discovery, including research supporting regenerative medicine approaches for Type 1 diabetes and quality control activities as cell-based therapies progress toward commercialization.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/revvity-signs-agreement-to-acquire-human-cell-design/">Revvity Signs Agreement to Acquire Human Cell Design</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CAR T Manufacturing in Japan Gets Boost from Teijin&#45;Shinshu University Research Collaboration</title>
<link>https://edusehat.com/en/car-t-manufacturing-in-japan-gets-boost-from-teijin-shinshu-university-research-collaboration</link>
<guid>https://edusehat.com/en/car-t-manufacturing-in-japan-gets-boost-from-teijin-shinshu-university-research-collaboration</guid>
<description><![CDATA[ Shinshu University Hospital&#039;s expertise in CAR T-cell therapy R&amp;D and clinical application will be combined with Teijin Regenet&#039;s manufacturing and quality-management expertise cultivated through its CDMO business for regenerative medicine products.
The post CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2172899208.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 01:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CAR, Manufacturing, Japan, Gets, Boost, from, Teijin-Shinshu, University, Research, Collaboration</media:keywords>
<content:encoded><![CDATA[<p>Teijin, Teijin Regenet, and Shinshu University Hospital, all based in Japan, entered into a joint research agreement regarding manufacturing technologies for cell and gene therapy products. The collaboration aims to advance manufacturing methods and strengthen Japan’s manufacturing infrastructure for cell and gene therapies with the goal of helping to contribute to the  broader availability of these innovative treatments.</p>
<p>Cell and gene therapies, including CAR T-cell therapies, are expected to become increasingly important treatment options for cancer and other intractable diseases. In Japan, however, expanding the availability of specialized manufacturing personnel and manufacturing facilities remain significant challenges, underscoring the need for a more robust and sustainable supply framework.</p>
<p>Under the joint research agreement, Shinshu University Hospital’s expertise in CAR T-cell therapy R&D and clinical application will be combined with Teijin Regenet’s manufacturing and quality-management expertise cultivated through its CDMO business for regenerative medicine products. The partners said they will work together to enhance manufacturing technologies and strengthen the manufacturing base for cell and gene therapies.</p>
<p>The collaboration will also utilize the Cell Processing Center (CPC) at Shinshu University Hospital to explore future manufacturing automation and efficiency improvements. In addition, the partners will work to accumulate practical knowledge related to quality testing technologies and quality-control methodologies.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/car-t-manufacturing-in-japan-gets-boost-from-teijin-shinshu-university-research-collaboration/">CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Smarter Cell Culture Starts with Better Media</title>
<link>https://edusehat.com/en/smarter-cell-culture-starts-with-better-media</link>
<guid>https://edusehat.com/en/smarter-cell-culture-starts-with-better-media</guid>
<description><![CDATA[ Advances in media optimization, cell engineering, and AI are reshaping intensified bioprocessing for higher productivity, better quality, and greater manufacturing efficiency.
The post Smarter Cell Culture Starts with Better Media appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-1140201067.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 11 Sep 2026 01:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Smarter, Cell, Culture, Starts, with, Better, Media</media:keywords>
<content:encoded><![CDATA[<p>As a graduate student in the early 1980s, part of my funding came through a research assistantship in a cell-culture lab. One of my regular responsibilities was whipping up batches of culture media. I mixed familiar ingredients such as amino acids alongside components that sounded more like something from a witch’s brew than a scientific protocol, including chick-embryo extract and horse serum. Beyond carefully measuring the same volumes from batch to batch, our idea of media optimization was simply buying horse serum from the same herd.</p>
<p>Cell culture has come a long way since then.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Today, media optimization is a sophisticated scientific discipline that influences nearly every aspect of cell culture, from academic research to commercial biomanufacturing. The composition of a culture medium affects cell growth, productivity, product quality, impurity profiles, downstream purification, and, ultimately, manufacturing economics. As biologics manufacturers pursue increasingly intensified production processes, optimizing media has become one of the industry’s most important—and most complex—challenges.</p>
<p>That complexity was the focus of a recent discussion with Bhanu Chandra Mulukutla, PhD, research fellow and group leader at Pfizer, and Wenge Wang, PhD, associate research fellow and group leader at Pfizer.</p>
<p>“The first challenge is understanding more about the cells you’re dealing with and the product you’re trying to make,” says Mulukutla. “Growth characteristics, metabolism, impurity profiles, and product requirements all influence how media should be optimized.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Different production cell lines, such as CHO and HEK293 cells, have distinct nutritional needs and metabolic behaviors. A formulation that performs well for one therapeutic protein might be far from optimal for another. Developers must simultaneously balance multiple priorities, supporting robust cell growth while maximizing productivity, preserving product quality, minimizing impurities, and ensuring downstream purification remains efficient.</p>
<p></p><h4><strong>Beyond simply adding more nutrients</strong></h4>

<p>One of the biggest misconceptions in media development is that adding more nutrients automatically produces better results. In reality, every nutrient has an optimal operating window.</p>
<p>“Cells sense nutrient levels,” Mulukutla explains. “Too little is obviously bad, but too much is also bad.”</p>
<p>Even glucose, one of the most fundamental energy sources, becomes problematic when supplied in excess. Elevated nutrient concentrations can trigger metabolic shifts that reduce productivity, alter protein quality, and generate unwanted waste products.</p>
<p>The challenge becomes even greater as manufacturers intensify production processes. Higher-performing cell cultures require significantly greater nutritional support, but physical chemistry imposes practical limits. Several amino acids—including tyrosine, cysteine, leucine, isoleucine, and valine—have relatively poor solubility, making it difficult to formulate increasingly concentrated media.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<figure aria-describedby="caption-attachment-337677" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337677" src="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-300x200.jpg" alt="Various tissue culture dishes, flasks and plates" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-1024x682.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-1536x1024.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-2048x1365.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-1261x840.jpg 1261w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-1392x928.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-1068x712.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-508056634-1920x1279.jpg 1920w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Hakat / iStock / Getty Images Plus</figcaption></figure>
<p>Developers frequently reach a point where desired nutrient concentrations simply cannot dissolve. That limitation creates a cascade of manufacturing complications. Additional feeds become necessary. Mixing procedures become more complex. Filtration slows because of increased viscosity. Preparation times lengthen, and precipitation risks increase.</p>
<p>In other words, media optimization is constrained not only by biology, but also by chemistry and manufacturing practicality.</p>
<p></p><h4><strong>Intensification raises the stakes</strong></h4>

<p>These challenges become even more significant in intensified fed-batch manufacturing. Unlike conventional fed-batch processes, intensified operations drive cultures to much higher viable cell densities while sustaining elevated productivity over longer production runs.</p>
<p>That combination dramatically increases nutritional demand. Maintaining adequate nutrient availability without excessive feed additions becomes a delicate balancing act. Because all nutrients cannot be supplied in a single highly concentrated formulation, manufacturers often rely on multiple feeds, particularly for poorly soluble amino acids like tyrosine and cysteine. Meanwhile, branched-chain amino acids—leucine, isoleucine, and valine—present another obstacle, because cells consume them rapidly while their solubility remains relatively low. As nutrient requirements increase, formulation complexity grows accordingly.</p>
<p>Even when adequate nutrition is supplied, another challenge begins to emerge—waste accumulation. Unlike perfusion systems, intensified fed-batch processes continually add nutrients without removing spent media. Over 12 to 14 days, metabolic byproducts steadily accumulate. Those byproducts can inhibit cell growth, reduce productivity, and negatively influence product quality. Host-cell proteins can also reach elevated concentrations, creating additional purification challenges and potentially affecting product stability.</p>
<p>As the Pfizer experts note, the objective is no longer simply maximizing titer. Developers must simultaneously optimize productivity, cell health, impurity control, manufacturability, and final product quality.</p>
<p></p><h4><strong>Engineering better cells</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p>Rather than focusing exclusively on media composition, Pfizer has adopted a broader systems-level strategy. After nearly a decade of studying cellular metabolism using omics technologies and systems biology, researchers have identified pathways responsible for generating problematic metabolic byproducts. That understanding has enabled entirely new engineering approaches.</p>
<p>One strategy involves carefully maintaining nutrient concentrations near the lower end of their healthy operating ranges. “When nutrients aren’t in excess,” Mulukutla says, “cells are smart enough to use them for their intended purpose—growth and protein production—rather than funneling them into byproduct formation.”</p>
<p>Another approach directly modifies cellular metabolism. Pfizer researchers have engineered cells by knocking out key enzymatic steps in pathways responsible for producing unwanted metabolic waste. For branched-chain amino acids, eliminating the first step in their breakdown pathway reduced cellular consumption by approximately 30 to 40%. Instead of converting those amino acids into waste products, engineered cells use nutrients more efficiently.</p>
<p>The benefits extend beyond metabolism. Reduced amino-acid demand frees valuable osmolality capacity within the media, allowing scientists to incorporate higher concentrations of other nutrients needed for intensified production.</p>
<p>Perhaps the most intriguing strategy addresses one of media optimization’s oldest challenges. Instead of trying to dissolve more tyrosine and cysteine into increasingly concentrated feeds, Pfizer researchers engineered cells to make them capable of intracellularly synthesizing those amino acids.</p>
<p>Using more soluble precursor molecules—specifically, synthesizing tyrosine from phenylalanine and cysteine from methionine—engineered cells generate their own supplies of these otherwise difficult-to-deliver nutrients. The approach reduces dependence on highly concentrated external feeds while simplifying formulation.</p>
<p>Combined with reduced byproduct formation and improved nutrient efficiency, these engineered cell lines support higher cell densities without proportionally increasing media complexity. Pfizer is now integrating multiple engineering strategies into unified production cell lines designed to support intensified manufacturing across its broader biologics portfolio.</p>
<p></p><h4><strong>AI-driven design</strong></h4>

<p>Media optimization is also becoming increasingly data driven. Rather than treating media development as an isolated upstream activity, the Pfizer experts envision a fully integrated development strategy that simultaneously considers cell engineering, upstream processing, and downstream purification.</p>
<p>Future optimization efforts will likely rely heavily on artificial intelligence and advanced computational modeling. These technologies can help researchers understand complex metabolic networks, predict nutrient requirements, optimize formulations, and identify opportunities that traditional experimentation might overlook.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>The long-term goal is ambitious. Instead of requiring complex perfusion systems to achieve very high cell densities, future mammalian cell lines might eventually approach the metabolic and stoichiometric efficiency currently associated with microbial production systems, enabling higher yields in standard or intensified fed-batch conditions.</p>
<p>In the nearer term, alternative nutrient-delivery strategies are also showing promise. Dipeptide versions of difficult amino acids, including tyrosine-glycine, have been shown to dramatically improve solubility compared with free amino acids. Although these formulations introduce higher material costs and additional supply-chain considerations, they provide valuable flexibility while complementary cell-engineering approaches continue to mature.</p>
<p></p><h4><strong>Building flexible platforms</strong></h4>

<p>One of the most important considerations for any cell culture is ensuring the consistency of the raw materials used to make the media, according to Martin Gawlitzek, PhD, director of bioprocess development at AbbVie. Because media formulations rely on numerous ingredients sourced from different suppliers, even subtle differences—particularly in metal impurities—can influence critical quality attributes and process performance. Close collaboration with media manufacturers and rigorous testing programs are therefore essential to maintaining lot-to-lot consistency and reliable biologics production.</p>
<p>To address these challenges, AbbVie developed a high-performance, modular media platform that supports a wide range of manufacturing strategies, from traditional fed-batch production to intensified bioprocesses. The platform is designed to achieve high cell densities while providing the flexibility to fine-tune product quality attributes. “The same platform can be tailored for different bioprocesses and easily adjusted to modulate product quality,” Gawlitzek explains. As a result, AbbVie can leverage a common foundation across multiple programs with minimal modifications.</p>
<p>“Media development fundamentally involves continuous improvement,” Gawlitzek says. “Our near-term focus is to further optimize our platform to accommodate emerging therapeutic modalities, particularly complex molecules like multi-specific antibodies, which often have distinct media requirements for optimal expression and product quality.”</p>
<p></p><h4><strong>Industry-wide innovation</strong></h4>

<p>The rapid evolution of media optimization extends well beyond individual organizations. Several presentations at the 2026 18th Bioprocessing Summit in Boston reflect how broadly the field is advancing.</p>
<p>Novasign highlighted digital twins that combine mechanistic process models, artificial intelligence, and manufacturing data to improve media optimization, scale-up, and end-to-end process control.</p>
<p>Biogen presented strategies for converting conventional production platforms into intensified fed-batch processes using smart media design, N-1 perfusion, and process analytical technology, demonstrating significant improvements in manufacturing efficiency while maintaining product quality.</p>
<p>Meanwhile, RedShift Bio showcased analytical technologies that provide real-time, chromatography-grade titer measurements directly within upstream workflows, enabling faster feeding decisions and improved bioreactor control.</p>
<p>Together, innovations from AbbVie, Pfizer, and others illustrate how the future of cell culture will depend less on simply feeding cells more—and more on understanding how to help them use every nutrient more intelligently. That integrated approach, combining smarter cells with smarter media and smarter process design, could define the next generation of biomanufacturing.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/smarter-cell-culture-starts-with-better-media/">Smarter Cell Culture Starts with Better Media</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Healthcare AI’s next test is integration</title>
<link>https://edusehat.com/en/healthcare-ais-next-test-is-integration</link>
<guid>https://edusehat.com/en/healthcare-ais-next-test-is-integration</guid>
<description><![CDATA[ The entrance of major AI companies into healthcare is a meaningful and welcome development, accelerating the technical foundation available to the industry. Their models are increasingly capable of processing long clinical records, interpreting complex terminology, comparing documentation against evidence and generating coherent summaries from large volumes of information. For clinicians, operators, and administrative teams who… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/Ensemble-contributed-iStock-2263561985.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 22:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Healthcare, AI’s, next, test, integration</media:keywords>
<content:encoded><![CDATA[<p>The entrance of major AI companies into healthcare is a meaningful and welcome development, accelerating the technical foundation available to the industry.</p>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1365" height="768" src="https://wp.technologyreview.com/wp-content/uploads/2026/08/Ensemble-contributed-iStock-2263561985.jpg?w=840" alt="" class="wp-image-1141428" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/08/Ensemble-contributed-iStock-2263561985.jpg 1365w, https://wp.technologyreview.com/wp-content/uploads/2026/08/Ensemble-contributed-iStock-2263561985.jpg?resize=300,169 300w, https://wp.technologyreview.com/wp-content/uploads/2026/08/Ensemble-contributed-iStock-2263561985.jpg?resize=768,432 768w" sizes="(max-width: 1365px) 100vw, 1365px"></figure>



<p>Their models are increasingly capable of processing long clinical records, interpreting complex terminology, comparing documentation against evidence and generating coherent summaries from large volumes of information. For clinicians, operators, and administrative teams who spend significant time searching through fragmented data, these advances are helping reduce cognitive burden and make high-value information easier to access.</p>



<p>But healthcare leaders should not confuse model capability with operational capability.</p>



<p>Healthcare’s administrative challenges are caused by fragmented information, fragmented workflows, and fragmented accountability, not a lack of information. The industry has spent decades investing in systems that capture activity: electronic health records, billing platforms, payer portals, scheduling systems, call center platforms, and analytics applications. Each system records something important. But few were designed to reason across the full chain of decisions that determines whether patients get timely access, clinicians have the right documentation and providers are reimbursed appropriately.</p>



<p>This is the problem that AI must now confront.</p>



<h3 class="wp-block-heading"><strong>Revenue cycle is becoming one of healthcare AI’s proving grounds</strong></h3>



<p>The revenue cycle is the process healthcare providers use to get paid for care — from scheduling and registration through coding, billing, payer follow-up, and payment collection.</p>



<p>It is unusually suited to rigorous AI deployment because it combines high transaction volume, complex reasoning, structured and unstructured data, measurable outcomes, and significant operational variation. It also sits at the intersection of financial performance, patient access, and administrative workload.</p>



<p>A single claim can be influenced by patient insurance information, clinical documentation, coding rules, payer-specific policies, prior authorization requirements, medical necessity criteria, and many other data sources and operational processes. A breakdown in any one of those areas can create downstream consequences weeks or months later.</p>



<p>This is why generic automation has often fallen short.</p>



<p>Traditional robotic process automation works well when workflows are stable and rules are predictable, but healthcare administration is neither. Payer requirements change. Documentation expectations evolve. Exceptions are common and often material.</p>



<p>Large language models improve part of the equation, extracting meaning from narrative text, summarizing records and supporting reasoning over complex documentation. But when used alone, they inherit important limitations. They may produce plausible outputs without sufficient traceability. They may lack awareness of local workflow constraints. They may miss payer-specific history or context that determines whether an action is likely to change an outcome.</p>



<h3 class="wp-block-heading"><strong>Why foundation models will become necessary but insufficient</strong></h3>



<p>The major AI firms are solving real technical problems for healthcare.</p>



<p>Better context windows make it easier to process longitudinal records. Stronger reasoning improves the interpretation of complex clinical scenarios. Better multimodal capabilities may eventually help connect text, imaging, structured data, and clinical signals in more useful ways. Safer model behavior and healthcare-specific tuning will continue to improve adoption.</p>



<p>These capabilities will make healthcare work faster, more consistent and easier to navigate. But they will not, on their own, solve deep-rooted administrative complexity.</p>



<p>Much of healthcare’s operational knowledge does not live in general medical literature, coding manuals, or public payer guidance. It lives in the accumulated experience of what actually happens after decisions are made. For example:</p>



<ul class="wp-block-list">
<li>Why does one appeal strategy outperform another?</li>



<li>Which documentation gaps are most likely to cause reimbursement delay?</li>



<li>How does a specific payer respond to a particular clinical argument?</li>
</ul>



<p>These insights are behavioral, operational, and longitudinal. They emerge from years of transactions, outcomes, exceptions, and human judgment.</p>



<p>As foundation models become more capable, access to baseline healthcare knowledge will become less differentiating. Most leading systems will be able to interpret ICD-10 codes, recognize medical terminology, summarize payer policies, and reason over public clinical criteria. The durable advantage will come from how organizations combine that model intelligence with proprietary operational data, structured knowledge, workflow context, and governance.</p>



<h3 class="wp-block-heading"><strong>The technical shift: From automation to orchestration</strong></h3>



<p>Agentic orchestration turns foundation model understanding into coordinated action — intelligence that can follow work across systems, apply the right rules, adapt when something changes, and keep learning from what happens next.</p>



<p>A prior authorization workflow, for example, may require retrieving clinical documentation through fast healthcare interoperability resources (FHIR) APIs, mapping patient history to payer criteria, identifying missing evidence, generating a submission packet, routing exceptions to a specialist, monitoring payer response, adjusting patient care pathways, and learning from the outcome.</p>



<p>This type of workflow requires coordination. It also requires guardrails: regulatory requirements, privacy standards, clinical policies, coding rules, payer criteria, and organizational risk thresholds. One promising approach is hybrid architecture that combines LLMs with structured knowledge bases, symbolic logic, reinforcement learning, and deterministic validation layers.</p>



<p>At Ensemble, this is the design principle behind EIQ, our revenue cycle intelligence engine. EIQ brings together operational activity, clinical documentation, payer behavior, and reimbursement outcomes into a continuously learning intelligence layer that’s integrated with the hospital’s electronic health record (EHR). It supplements the system of record with a system of intelligence, designed to connect information and surface actions most likely to improve outcomes.</p>



<p>EIQ uses a neuro-symbolic approach that combines LLMs and custom small language models with rules-based reasoning. That architecture is built on one of the most robust datasets in healthcare, informed by more than a decade of award-winning operational performance, transaction history, payer behavior, and operator decision-making. The language models help interpret information and generate human-readable outputs. The symbolic layer represents policies, rules, payer requirements, and workflow constraints so the system can apply guardrails, make reasoning steps more traceable and recommend actions that fit the specific operational context.</p>



<h3 class="wp-block-heading"><strong>What the next decade will reward</strong></h3>



<p>The contribution of major AI firms to healthcare will be significant. Their models will become faster, safer, more capable, and more accessible.</p>



<p>But the next decade of healthcare AI will be defined by integration, not model capability alone.</p>



<p>The organizations that create the most value will be those that connect models to governed data, operational workflows, domain expertise, human oversight, and measurable outcomes. They will understand that healthcare intelligence cannot live in a separate interface. It has to exist inside the decisions that shape access, documentation reimbursement, and patient experience.</p>



<p><em>This content was produced by Ensemble. It was not written by MIT Technology Review’s editorial staff.</em></p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Microscale Chromatography Moves Toward Manufacturing Readiness</title>
<link>https://edusehat.com/en/microscale-chromatography-moves-toward-manufacturing-readiness</link>
<guid>https://edusehat.com/en/microscale-chromatography-moves-toward-manufacturing-readiness</guid>
<description><![CDATA[ AstraZeneca researchers show that automated microscale chromatography can generate process-characterization insights comparable to traditional bench-scale systems, potentially giving bioprocess developers a faster, material-sparing route to robust manufacturing control strategies for complex biologics.
The post Microscale Chromatography Moves Toward Manufacturing Readiness appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Mike-Rezvani_GBPN_IMAGE_10SEPT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 07:30:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Microscale, Chromatography, Moves, Toward, Manufacturing, Readiness</media:keywords>
<content:encoded><![CDATA[<p>High-throughput chromatography has become a familiar tool in early bioprocess development, where parallel experiments can save time and precious material. But using miniaturized systems to generate data that influence late-stage process characterization, validation, and commercial manufacturing controls has remained a tougher proposition. According to a new <a href="https://doi.org/10.1016/j.chroma.2026.467347" target="_blank" rel="noopener">study</a> by Kamiyar Rezvani, a scientist at AstraZeneca, and his colleagues, that gap might be narrowing.</p>
<p>Researchers evaluated automated 600-µL RoboColumns operated on a Tecan liquid-handling platform against conventional, roughly 20-mL ÄKTA bench-scale chromatography models and manufacturing-scale operations for purification of a bispecific antibody (bsAb). The goal was to determine whether the two scale-down approaches provided equivalent process understanding or introduced scale-dependent biases.</p>
<p>The work covered three purification operations: lambda light-chain affinity, anion exchange, and cation exchange chromatography. The researchers first qualified both scale-down models against manufacturing data and then replicated multivariate design-of-experiments studies across the Tecan and ÄKTA systems.</p>
<p>The attraction of miniaturization is significant. High-throughput purification tools offer “parallelization and material savings” compared with traditional bench-scale experiments and can “enable practical end-to-end integration to automate entire experiment workflows,” Rezvani and his colleagues note.</p>
<p>The results strengthen the argument for extending those benefits deeper into bioprocess development. RoboColumn scale-down models showed “excellent agreement with manufacturing scale at target operating conditions” and aligned with bench-scale results from multivariate studies, according to the authors. Perhaps more important for process characterization, the practical effect of differences between the two models on the resulting control strategy was “negligible,” wrote Rezvani and his colleagues.</p>
<p>That does not mean that microscale chromatography behaves identically to larger systems. Smaller working volumes, offline fraction analysis, intermittent liquid delivery, and differences in flow behavior can introduce variability. In the study, step yields and product column volumes “consistently varied between” scale-down models (SDMs), the researchers point out, although product-volume offsets were highly reproducible across broad process parameter ranges. As the authors emphasize, a “well-characterized SDM does not need to produce data that is identical to manufacturing scale” to be suitable. Instead, differences need to be understood, their risks assessed, and appropriate offsets or controls incorporated into the manufacturing strategy.</p>
<p>There are still practical limitations. The researchers recommend maintaining product-pooling consistency, minimizing evaporation effects, and ensuring sufficient product volumes for reliable analytical testing. For processes showing unusual or highly sensitive host-cell protein washes or protein recovery, they suggest additional microscale characterization or hybrid studies combining microscale and traditional bench-scale experiments. Plus, qualification remains essential. “Comparability to manufacturing scale must be verified through proper SDM qualification and scientific rationale,” the authors caution.</p>
<p>Taken together, the study shifts the question from whether microscale chromatography perfectly reproduces larger columns to whether its differences can be predicted and managed. The researchers reported that RoboColumn differences were “predictable both at target conditions and across varied process parameter ranges” for three chromatography methods commonly used in antibody manufacturing. For bioprocess teams facing increasingly complex biologics and pressure to accelerate development, that finding could move microscale chromatography beyond a screening tool—and closer to a platform for generating the process understanding behind commercial manufacturing decisions.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/microscale-chromatography-moves-toward-manufacturing-readiness/">Microscale Chromatography Moves Toward Manufacturing Readiness</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>No One&#45;Size&#45;Fits&#45;All Solution for Autologous Cell Therapy Manufacturing</title>
<link>https://edusehat.com/en/no-one-size-fits-all-solution-for-autologous-cell-therapy-manufacturing</link>
<guid>https://edusehat.com/en/no-one-size-fits-all-solution-for-autologous-cell-therapy-manufacturing</guid>
<description><![CDATA[ The operational challenges of making patient-specific cell therapies require careful consideration. Choosing the manufacturing model that fits the healthcare infrastructure, the logistical requirements, and the market environment of the specific project is key.
The post No One-Size-Fits-All Solution for Autologous Cell Therapy Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/01/Trends-Bioproduction-GettyImages-2173467777.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 07:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>One-Size-Fits-All, Solution, for, Autologous, Cell, Therapy, Manufacturing</media:keywords>
<content:encoded><![CDATA[<p>Autologous cell therapy production is difficult from an operational standpoint, according to researchers, who say choosing a manufacturing model that addresses the specific logistical and economic challenges of the project involved is vital.</p>
<p>Making cell therapies is always <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10961620/" target="_blank" rel="noopener">complex</a>. The sensitive raw materials must be protected, production plants need to comply with GMP regulations, and the therapies have to be prepared so they retain potency until they reach the patient.</p>
<p>However, for autologous, patient-specific cell therapies, the operational challenges are particularly significant, says Zhaowei Li, a researcher and PhD student at the H. Milton Stewart School of Industrial and Systems Engineering at the Georgia Institute of Technology.</p>
<p>“Making an autologous cell therapy is not universally more difficult than an allogeneic therapy, because allogeneic products have their own biological and manufacturing challenges. Operationally, however, autologous manufacturing is especially demanding because each patient represents an individual batch.</p>
<p>“Patient-specific starting material, end-to-end chain of identity, and the time-sensitive coordination of collection, manufacturing, release, and return all create substantial logistical complexity. Unlike an allogeneic product, an autologous dose generally cannot be replaced from inventory if production is delayed or fails,” he tells <em>GEN</em>.</p>
<p></p><h4><strong>Operational options</strong></h4>

<p>To address these challenges, autologous cell therapy developers have several potential options, according to Li and colleagues who examined the topic in a recent <a href="https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.70316" target="_blank" rel="noopener">study</a> published in <em>Biotechnology and Bioengineering</em>.</p>
<p>They looked at three models: centralized production in a single facility; a coordinated point-of-care (POC) network in which POCs coordinate the transfer of materials and consumables; and an independent network in which each POC operates separately.</p>
<p>Choosing the optimal option depends on the specifics of the project, Li says, citing a coordinated POC network by way of example.</p>
<p>“Under our baseline assumptions, coordinated POC manufacturing provides a strong compromise between cost and turnaround time. In a coordinated POC network, sites share real-time information on patient specimens, reagent inventory, and manufacturing capacity. A network coordinator can then redirect specimens or reagents when a local shortage or capacity constraint would otherwise delay treatment.</p>
<p>“In our case study, coordinated POC manufacturing remained within approximately 1.2% of the centralized system’s expected cost while reducing average turnaround time from 29.5 to 28.2 days. Independent POC manufacturing was slightly faster, at 27.5 days, but approximately 43.5% more expensive,” he says.</p>
<p>Li adds, “Coordinated POC may not be preferable when demand is low or geographically concentrated, centralized transportation is reliable and inexpensive, or the cost and regulatory burden of operating multiple qualified manufacturing sites outweighs the turnaround-time benefit.</p>
<p>“Its success also depends on reliable data sharing, cross-site quality consistency, governance, and the practical feasibility of transferring specimens or reagents between sites. Our findings should therefore be viewed as decision support under specific assumptions rather than a one-size-fits-all prescription,” he says.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/no-one-size-fits-all-solution-for-autologous-cell-therapy-manufacturing/">No One-Size-Fits-All Solution for Autologous Cell Therapy Manufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Increasing CHO Cell Productivity</title>
<link>https://edusehat.com/en/increasing-cho-cell-productivity</link>
<guid>https://edusehat.com/en/increasing-cho-cell-productivity</guid>
<description><![CDATA[ Overexpressing the gene Pabpc1 in CHO cell cultures increases productivity by 30–50%, offering a broadly applicable strategy to engineer highly productive cell lines for antibody production.
The post Increasing CHO Cell Productivity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/09/GettyImages-1413597282.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 07:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Increasing, CHO, Cell, Productivity</media:keywords>
<content:encoded><![CDATA[<p>Overexpressing the cytoplasmic poly(A)-binding protein gene <em>Pabpc1</em> increases protein titers in Chinese hamster ovary (CHO) cell lines by 30–50%, according to researchers from BeOne Medicines (formerly BeiGene). Those results, published in a recent <a href="https://doi.org/10.1007/s00253-026-13846-6" target="_blank" rel="noopener">paper</a>, appear consistent across multispecific and monoclonal antibodies.</p>
<p>For biomanufacturers, this suggests the possibility of a practical screening strategy to identify factors that could enhance expression levels or improve specific product attributes for certain genes expressed in CHO cells. Applicability to HEK293 or PER.C6 cells has not been studied.</p>
<p><em>Pabpc</em> is considered crucial in mRNA stability and translation, and <em>Pabpc1</em>, specifically, extends the half-life of target mRNAs and orchestrates mRNA stability and pre-mRNA splicing. “Up to now, no studies have investigated the impact of <em>Pabpc1</em> gene overexpression on recombinant protein production in CHO cells,” note Zhangying Jia, research scientist; Zheng Zhang, PhD, head of cell line development; Jing Song, PhD, vice president of biologics technical development; and colleagues at BeOne Medicines. This research offers insights regarding <em>Pabpc1</em> that may enhance CHO cell expression in a production setting.</p>
<p>Jia and colleagues overexpressed <em>Pabpc1</em> in a variety of low-expression clones used to produce monoclonal, bispecific, and trispecific antibodies. Growth rates were essentially identical to those of cells transfected with an empty vector, which served as the control. Of the three types of antibodies produced, expression level gains were greatest among bispecific antibodies, showing a 50% productivity increase. Trispecific antibodies showed a 32% productivity increase, and mAbs showed a 30% productivity increase. Other quality attributes were virtually identical between the overexpressed and control groups.</p>
<p>Additionally, “We discovered that <em>Pabpc1</em> overexpression can modulate cellular metabolism to some extent,” according to the team. Consequently, lactic acid and ammonia accumulation were each lower in the overexpression groups than in the control groups. “These findings suggest that <em>Pabpc1</em> overexpression may have a positive effect on regulating cellular metabolism by reducing the accumulation of toxic by-products… thereby creating a more favorable environment for protein production,” the scientists posit.</p>
<p>The team also reports an interaction between <em>Pabpc1 </em>and the eukaryotic initiation factor 4E (<em>eIF4E</em>) that catalyzes subsequent reactions, leading to enhanced efficiency of translation initiation.</p>
<p>The enhanced productivity for both individual cells and overall titer that resulted from overexpressing <em>Pabpc1</em> “is highly contingent upon the congruence between [a gene’s] functions and the intrinsic productivity bottlenecks of host cells,” they observed, noting that none of the other five genes that were overexpressed during this study (<em>Slc25a32</em>, <em>Il19</em>, <em>Ptdss1</em>, <em>Stk3</em>, and <em>Mtdh</em>) showed comparable results.</p>
<p>Exactly how overexpression of <em>Pabpc1</em> enhances productivity of recombinant proteins in CHO cells “remains to be fully elucidated,” the scientists point out, but this strategy appears to be both novel and efficacious and offers “substantial potential for industrial application.”</p>
<p>The team plans to continue refining this strategy and broadening its applicability for biopharmaceutical manufacturing.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/increasing-cho-cell-productivity/">Increasing CHO Cell Productivity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Monoclonal Antibodies Targeting MMP&#45;9 Alleviate Peripheral Neuropathy in Diabetic Mice</title>
<link>https://edusehat.com/en/monoclonal-antibodies-targeting-mmp-9-alleviate-peripheral-neuropathy-in-diabetic-mice</link>
<guid>https://edusehat.com/en/monoclonal-antibodies-targeting-mmp-9-alleviate-peripheral-neuropathy-in-diabetic-mice</guid>
<description><![CDATA[ Scientists developed monoclonal antibodies targeting matrix metalloproteinase-9, which in a newly reported preclinical study slowed and even reversed diabetic nerve damage in mouse models of type I and type II diabetes.
The post Monoclonal Antibodies Targeting MMP-9 Alleviate Peripheral Neuropathy in Diabetic Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/POV-GettyImages-1227553397.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 07:30:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Monoclonal, Antibodies, Targeting, MMP-9, Alleviate, Peripheral, Neuropathy, Diabetic, Mice</media:keywords>
<content:encoded><![CDATA[<p>Diabetic peripheral neuropathy (DPN) describes nerve damage in the hands, legs, and feet caused by diabetes. Over time, high levels of blood sugar can injure nerve fibers, with symptoms ranging from numbness, a tingling or burning sensation, muscle weakness, to pain and cramps.</p>
<p>Scientists headed by a team at the University of Texas Health Science Center at Houston have now developed monoclonal antibodies (mAbs) targeting matrix metalloproteinase-9 (MMP-9), which in a newly reported preclinical study slowed and even reversed diabetic nerve damage in mouse models of type I diabetes (T1D) and type II diabetes (T2D). The team suggests that their results bring researchers one step closer to developing a treatment for humans.</p>
<p>Research lead Xin (Alex) Ge, PhD, professor in the Texas Therapeutics Institute at The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases within McGovern Medical School at UTHealth Houston, is senior and co-corresponding author of the team’s published paper in <em>Science Translational Medicine</em>, titled “<a href="https://doi.org/10.1126/scitranslmed.adw3558" target="_blank" rel="noopener">Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice</a>.”</p>
<p>Up to 50% of diabetes patients will develop peripheral neuropathy, which is the most common chronic complication of diabetes, the authors wrote. “The hallmark of diabetic peripheral neuropathy (DPN) is the length-dependent damage of peripheral nerves because of impaired microvascular circulation and mitochondrial dysfunction,” they explained. In addition to pain, tingling or numbness, symptoms may include loss of balance, slow wound healing and foot ulcers. However, the team further noted, “Despite its substantial impact, there are currently no effective disease-modifying treatments available to prevent or reverse the progression of nerve damage.”</p>
<p>Ge stated, “There is no good drug for managing peripheral neuropathy. There are painkillers and other drugs, but they are only targeting the symptoms.” For their reported study the investigators focused on the enzyme MMP-9. This enzyme can break down other proteins found between tissues. It is responsible for excess immune response in the peripheral nervous system and disease progression that impairs wound healing. “By regulating neuroinflammation, matrix metalloproteinase-9 (MMP-9) is both sufficient and required for the pathogenesis of neuropathy, representing a promising drug target for DPN,” they commented. “However, small-molecule inhibitors that often lack target specificity.”</p>
<p>Ge and the team instead developed monoclonal antibodies targeting MMP-9. “Developing an antibody that selectively targets MMP-9 has been challenging because MMP-9 is closely related to other enzymes,” acknowledged first author Kibaek Lee, PhD, a postdoctoral research fellow at the Institute of Molecular Medicine. “To overcome this challenge, we combined a camelid-inspired antibody library design with a functional selection approach to identify antibodies that specifically inhibit MMP-9. These new biotechnologies separate our antibodies from others.”</p>
<p>In preclinical tests mice injected with the antibodies regenerated nerve fiber and showed improved wound healing in their paws. “MMP-9 mAbs also reduced epidermal nerve fiber degeneration in diabetic mice by enhancing nerve mitochondrial function and promoting skin angiogenesis,” they stated.</p>
<p>“ This gives us hope that we can not only relieve the symptom, but also reverse the progression of disease,” said Ge, who holds the Kay and Ben Fortson Distinguished Chair in Neurodegenerative Disease Research at McGovern Medical School.</p>
<p>In addition, the team showed also showed that MMP-9 expression in human dorsal root ganglia (DRG) is increased among patients with diabetes. Further human genetic analysis found that both rare and common coding variants in the <em>MMP9</em> gene are associated with neuropathic pain phenotypes. “The translational relevance of this study is supported by the observation that MMP-9 expression is increased in satellite glial cells and macrophages in the DRG of patients with T2D,” they stated. “Together, these translational findings indicate that MMP-9–specific mAbs hold potential as disease-modifying therapies for peripheral neuropathy and for reducing lower extremity complications associated with diabetes.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/monoclonal-antibodies-targeting-mmp-9-alleviate-peripheral-neuropathy-in-diabetic-mice/">Monoclonal Antibodies Targeting MMP-9 Alleviate Peripheral Neuropathy in Diabetic Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gene Therapy Extends Lifespan and Reduces Symptoms in Sandhoff Disease Cat Model</title>
<link>https://edusehat.com/en/gene-therapy-extends-lifespan-and-reduces-symptoms-in-sandhoff-disease-cat-model</link>
<guid>https://edusehat.com/en/gene-therapy-extends-lifespan-and-reduces-symptoms-in-sandhoff-disease-cat-model</guid>
<description><![CDATA[ Intravenous gene therapy extended lifespan, reduced neurological symptoms, and improved disease markers in a Sandhoff disease cat model, supporting further investigation of systemic AAV gene therapy for this disorder.
The post Gene Therapy Extends Lifespan and Reduces Symptoms in Sandhoff Disease Cat Model appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/01/Trends-CellGene-GettyImages-217-small.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 07:30:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gene, Therapy, Extends, Lifespan, and, Reduces, Symptoms, Sandhoff, Disease, Cat, Model</media:keywords>
<content:encoded><![CDATA[<p>Sandhoff disease, like Tay-Sachs disease, is a fatal neurodegenerative lysosomal storage disease caused by the absence of ß-hexosaminidase (Hex) which leads to the accumulation of GM2 ganglioside in lysosomes. The disease, for which there are no available therapies, results in the death of children at a young age (around four years old).</p>
<p>Now, in a new study, gene therapy delivered intravenously extended the lifespan and reduced symptoms in a cat model of Sandhoff disease. The findings could extend the potential of gene therapy to treat Sandhoff and Tay-Sachs disease, both of which are marked by toxic accumulations of fat in nerve cells of the brain and spinal cord.</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://dx.doi.org/10.1126/scitranslmed.adx2447" target="_blank" rel="noopener">Intravenous gene therapy improves lifespan and clinical outcomes in a feline model of Sandhoff disease</a>.”</p>
<p>Previous clinical trials showed that adeno-associated virus (AAV) gene therapy for Sandhoff disease could be delivered by injection into the brain or cerebrospinal fluid. More specifically, previous studies “have led to the development of an adeno-associated virus (AAV) vector–delivered gene therapy for children with GM2 gangliosidosis in both expanded access and Phase I/II clinical trials through intrathalamic and cerebrospinal fluid–based delivery.” But intravenous AAV gene therapy has not been evaluated until now.</p>
<p>The AAV gene therapy tested in this study expressed the two Hex enzymes that have been implicated in Sandhoff disease. (Hex consists of two subunits, α and β, encoded by the <em>HEXA </em>and <em>HEXB</em> genes, respectively.) Deficiencies in these enzymes prevent the breakdown of waste in nerve cells’ lysosomes, leading to the toxic fat buildup.</p>
<figure aria-describedby="caption-attachment-337560" class="wp-caption aligncenter"><img decoding="async" class="wp-image-337560 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-1024x894.jpg" alt="Sandhoff disease gene therapy" width="696" height="608" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-1024x894.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-300x262.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-768x670.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-1536x1340.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-2048x1787.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-481x420.jpg 481w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-963x840.jpg 963w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-696x607.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-1392x1215.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-1068x932.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Fig3A_MRI-1920x1675.jpg 1920w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Pathological MRI changes are mitigated by AAV treatment, with the most prominent preservation of brain architecture in the high-dose, short-term cohort. In normal cats, white matter is darker than, or hypointense to, gray matter in the corona radiata of the cerebrum (white arrow) and the DCN of the cerebellum (white arrowhead). The CSF signal (bright) around the meninges is minimal in normal cats. In untreated SD cats at humane endpoint, the DCN are isointense to (same shade as) surrounding gray matter and the corona radiata (black arrow) are hyperintense to (lighter than) gray matter due to hypomyelination and storage in neuron cell bodies. The increased amount of CSF signal (black arrowhead) in untreated SD cats is especially apparent surrounding the gyri and is attributed to generalized atrophy. [Anne Maguire / Auburn University]</figcaption></figure>
<p>The study investigated intravenous delivery of a bicistronic AAV vector–based gene therapy that has not yet been tested in clinical trials to a feline model of Sandhoff disease, treated presymptomatically at one month of age.</p>
<p>In the feline Sandhoff models, intravenous delivery of the AAV gene therapy was safe and efficacious, and cats treated with a low dose lived two times longer than untreated cats; cats treated with a high dose lived three times longer. The authors write, “whereas untreated SD cats lived to 4.3±0.2 months, SD cats treated with low or high doses of the gene therapy lived to 8.3±1.2 or 12.4±2.7 months, respectively.”</p>
<p>The treatment also led to marked improvement in body tremors, reduced markers of central nervous system damage, and improved liver damage in the high-dose treatment group. “These data support the dose-dependent efficacy of IV-delivered gene therapy for restoration of Hex activity and preservation of clinical metrics, supporting potential for translation to patients with SD,” the authors note.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gene-therapy-extends-lifespan-and-reduces-symptoms-in-sandhoff-disease-cat-model/">Gene Therapy Extends Lifespan and Reduces Symptoms in Sandhoff Disease Cat Model</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Emerging Power of Mass Spectrometry in Oncology</title>
<link>https://edusehat.com/en/the-emerging-power-of-mass-spectrometry-in-oncology</link>
<guid>https://edusehat.com/en/the-emerging-power-of-mass-spectrometry-in-oncology</guid>
<description><![CDATA[ Novel approaches are urgently needed to improve availability of diagnostic assays, and recent efforts have shifted toward uncovering the biological pathways and molecular profiles underlying disease onset, progression, and metastasis.
The post The Emerging Power of Mass Spectrometry in Oncology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/mass-spec-scaled-e1788969000527.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 10 Sep 2026 07:30:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Emerging, Power, Mass, Spectrometry, Oncology</media:keywords>
<content:encoded><![CDATA[<p>Globally, the incidence of newly diagnosed cancer cases is projected to increase over the next decade.<sup>1</sup> Despite advancements in personalized medicine and therapeutic options, cancer diagnoses remain challenging.</p>
<p>Many patients are diagnosed at advanced stages (III/IV) when the disease has metastasized, resulting in poorer prognoses and clinical outcomes. Improving patient outcomes requires technological advancements that enable early detection when the disease is localized (stages I/II). However, effective screening options for many cancer types remain limited.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Novel approaches are urgently needed to improve availability and accessibility of diagnostic assays and, to that end, recent efforts in the field have shifted toward uncovering the biological pathways and molecular profiles underlying disease onset, progression, and metastasis.</p>
<p>Liquid biopsy, a minimally invasive blood-based technology that detects tumor-derived biomarkers, has the potential to detect cancer at earlier stages (I/II) and positively impact patient survival. Many liquid biopsy assays are under development or in the early stages of commercial availability, and are designed to detect mutations, methylation patterns, and/or fragmentation patterns in circulating tumor DNA (ctDNA) by next-generation sequencing (NGS)-based technologies.</p>
<p>However, limitations remain due to complexity and cost, and their performance for early-stage cancer detection remains largely unproven.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<h4><strong>Powerful tools for oncology</strong></h4>
<p>A technology that offers the opportunity to rise above these limitations is mass spectrometry. MS-based omics approaches (the study of all biological molecules within an organism, grouped into subdisciplines such as proteomics, lipidomics, and metabolomics; the study of all proteins, lipids, and metabolites, respectively) have emerged as powerful tools for oncology, particularly for liquid biopsy-based early detection. Thanks to its high sensitivity, specificity, and accuracy over other technologies, MS allows for the identification and quantification of a wide range of molecules from small metabolites to larger proteins.</p>
<figure aria-describedby="caption-attachment-337622" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337622" src="https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-300x225.jpg" alt="Mass spectrometry-based omics approaches have emerged as powerful tools for oncology, particularly for liquid biopsy-based early detection. [AOX Dx]" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-1536x1152.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-2048x1536.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-1120x840.jpg 1120w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-1392x1044.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-1068x801.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-1920x1440.jpg 1920w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/Mass-2-530x396.jpg 530w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Mass spectrometry-based omics approaches have emerged as powerful tools for oncology, particularly for liquid biopsy-based early detection. [AOX Dx]</figcaption></figure>
<p>Over the past few decades, MS-based proteomics has matured into a robust, high throughput platform with ever-increasing resolution and acquisition speed, enabling the quantification of thousands of proteins and mapping of the proteome across multiple cancer types. In fact, genetic mutations common across multiple cancer types alter the proteins produced from such genes, leading to changes in cellular function that support pro-cancer cellular activities.</p>
<p>As a result, proteins serve as the critical link between the genotype and the phenotype of a disease. On the clinical front, MS-based proteomics is now used for other disease detection and therapeutic monitoring applications due to its multiplexing capacity and high throughput over conventional methods.<sup>2</sup>   Therefore, the stage is set for MS to deliver proteomics-based profiles for oncology-based applications as well.</p>
<p></p><h4><strong>Profiling the metabolome and lipidome</strong></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p>More recently, MS is being leveraged to profile the metabolome and lipidome, providing insight into tumor metabolism and the surrounding microenvironments. Metabolomics is widely regarded as the omics discipline that most closely reflects the snapshot of the disease phenotype, as metabolites and lipids reflect the cumulative changes occurring due to alterations in the genome, transcriptome, and proteome. Changes in these blood-based molecules, therefore, hold untapped potential for early-stage cancer diagnostics.</p>
<p>Of all the omics disciplines, the newest kid on the block is lipidomics, which has experienced research-based growth in the last few years thanks to major advances in MS technology and bioinformatics tools such as machine learning. Lipidomics can provide a highly detailed, personalized, and quantitative snapshot, capturing thousands of lipid species within a single liquid biopsy.</p>
<p>Lipids are critically linked to cancer biology, and the study of the lipidome allows for the characterization of lipid molecules and their roles in biological pathways and mechanisms tied to cancer development and metastasis.<sup>3</sup></p>
<p>Through standardization and harmonization efforts,<sup>4</sup> lipids have now become highly adaptable to clinical diagnostics.<sup>5</sup> Whether individually or when combined with proteins and metabolites, lipidomics offers the potential for a powerful new tool in clinicians’ toolbox for early cancer detection: by characterizing the lipidome alongside the proteome and metabolome of patients with cancer, we can start to untangle the mechanisms that drive cancer biology.</p>
<p>From there, novel candidate biomarkers can be identified and ultimately translated into clinically actionable diagnostic endpoints.</p>
<p><em>At AOA Dx, Abigail McElhinny, PhD, is CSO, and Rachel Culp-Hill, PhD, serves as senior product scientist. Kim Ekroos, PhD, is founder and CEO at Lipidomics Consulting.</em></p>
<p class="trimmed"> </p>
<p><em>References</em></p>
<ol>
<div class="my-8"><span data-render-ad="6"></span></div>
<li><a href="https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services" target="_blank" rel="noopener">Global cancer burden growing, amidst mounting need for services</a>.</li>
</ol>
<p>2. Birhanu, A. G. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. <em>Clin. Proteomics</em> 20, 32 (2023).</p>
<p>3. Hou, M. <em>et al.</em> The strategic role of lipidomics in biomarker identification and diagnosis of gynecological diseases. <em>Front. Endocrinol.</em> 16, 1546512 (2025).</p>
<p>4. McDonald, J. G. <em>et al.</em> Introducing the Lipidomics Minimal Reporting Checklist. <em>Nat. Metab.</em> 4, 1086–1088 (2022).</p>
<p>5. Ekroos, K. <em>et al.</em> Lipid-based biomarkers for CVD, COPD, and aging – A translational perspective. <em>Prog. Lipid Res.</em> 78, 101030 (2020).</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/the-emerging-power-of-mass-spectrometry-in-oncology/">The Emerging Power of Mass Spectrometry in Oncology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial</title>
<link>https://edusehat.com/en/novartis-shares-slide-after-neuromuscular-candidate-acquired-with-avidity-fails-phase-iii-trial</link>
<guid>https://edusehat.com/en/novartis-shares-slide-after-neuromuscular-candidate-acquired-with-avidity-fails-phase-iii-trial</guid>
<description><![CDATA[ Del-desiran failed the Phase III HARBOR trial (NCT06411288) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT) through week 54. vHOT is a frequently used measure of hand myotonia, according to a 2024 study, and involves clinical experts reviewing videos to measure the time from hand grip to opening. 
The post Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Novartis-process-operator-in-biosafety-cabinet-CROPPED11111.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 13:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Novartis, Shares, Slide, After, Neuromuscular, Candidate, Acquired, with, Avidity, Fails, Phase, III, Trial</media:keywords>
<content:encoded><![CDATA[<p>Novartis shares fell the most in a single day since the COVID-19 pandemic after the pharma giant acknowledged that its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a pivotal Phase III trial assessing the antibody oligonucleotide conjugate (AOC) in patients with myotonic dystrophy type 1 (DM1).</p>
<p>Del-desiran failed the Phase III HARBOR trial (<a href="https://clinicaltrials.gov/study/NCT06411288">NCT06411288</a>) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT) through week 54. vHOT is a frequently used measure of hand myotonia, according to a <a href="https://www.nmd-journal.com/article/S0960-8966(24)00692-8/fulltext">2024 study</a>, and involves clinical experts reviewing videos to measure the time from hand grip to opening.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>However, Novartis added that it saw evidence of clinical activity in exploratory analyses and secondary endpoints—which included hand grip strength and quantitative Muscle Testing composite score, both measured by dynamometer; MD1 activity and participation scale; and 10-Meter Walk/Run Test. Safety findings from HARBOR were generally consistent with previously reported data, according to Novartis.</p>
<p>Novartis did not disclose details of its data but said it is evaluating the full dataset from the HARBOR trial and will engage with authorities to determine the most appropriate development path for del-desiran.</p>
<p>“Developing therapies for a complex disease like DM1 remains challenging, and setbacks are part of scientific progress,” Shreeram Aradhye, president, development and chief medical officer, Novartis, said in a statement. “As we continue to evaluate the full HARBOR dataset, we remain committed to identifying the most appropriate development path for the del-desiran program and advancing innovative approaches for people living with DM1 and other serious neuromuscular diseases.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<h4><strong>Third clinical setback in a week</strong></h4>
<p>Del-desiran’s failure marked Novartis’ third clinical setback in a week. On Friday after the closing bell, the company and partner Ionis Pharmaceuticals acknowledged that their co-developed pelacarsen failed the Phase III Lp(a)HORIZON trial (<a href="https://clinicaltrials.gov/study/NCT04023552">NCT04023552</a>) by missing its primary endpoint of reducing the risk, compared with placebo, of cardiovascular events—a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization.</p>
<p>And on September 2, Novartis paused eight trials assessing its autoimmune and neurological disease candidate rapcabtagene autoleucel (rap-cel), after three patients treated with the personalized, CD19-directed chimeric antigen receptor T cell (CAR T) therapy died after experiencing immune effector cell-associated hemophagocytic syndrome.</p>
<p>Four of the trials were within Novartis’ Phase II AUTOGRAPH program, assessing rap-cel in systemic lupus erythematosus and lupus nephritis (<a href="https://clinicaltrials.gov/study/NCT05849298">NCT06581198</a>), idiopathic inflammatory myopathies (<a href="https://clinicaltrials.gov/study/NCT06665256">NCT06665256</a>), diffuse cutaneous systemic sclerosis (<a href="https://clinicaltrials.gov/study/NCT06655896">NCT06655896</a>), and ANCA-associated vasculitis (<a href="https://thetrialfinder.com/trials/details/NCT06868290">NCT06868290</a>). The other four were Phase I/II studies in forms of multiple sclerosis (<a href="https://clinicaltrials.gov/study/NCT06617793">NCT06617793</a> and <a href="https://clinicaltrials.gov/study/NCT06675864">NCT06675864</a>), myasthenia gravis (<a href="https://clinicaltrials.gov/study/NCT06704269">NCT06704269</a>), and rheumatoid arthritis and Sjögren’s disease (<a href="https://clinicaltrials.gov/study/NCT07048197">NCT07048197</a>).</p>
<p>As a result, investors did not appear to share Novartis’ apparent optimism on del-desiran on Tuesday, instead punishing the company for its latest pipeline failure with a stock selloff that sent its shares trading on the SIX Swiss Exchange tumbling 11% from CHF 125.46 ($155.01) to CHF 111.80 ($138.13)—the pharma giant’s worst one-day decline since March 2020, early in the COVID-19 pandemic.</p>
<p>On the New York Stock Exchange, Novartis’ American depositary shares fared worse, dropping 14% from $159.99 to $137.72.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Del-desiran is an AOC candidate designed to target the underlying cause of DM1. The therapy consists of a muscle-targeting monoclonal antibody that binds to the transferrin receptor 1 (TfR1) and is conjugated to a small interfering RNA (siRNA) designed to induce degradation of disease-causing toxic DMPK messenger RNA (mRNA). Del-desiran has received the FDA’s Orphan Drug, Fast Track, and Breakthrough Therapy designations, as well as the European Medicines Agency’s Orphan Medicinal Product Designation.</p>
<p></p><h4><strong>Inherited from Avidity</strong></h4>

<p>Del-desiran is one of three pipeline AOCs that Novartis inherited when it <a href="https://www.genengnews.com/topics/translational-medicine/novartis-to-acquire-avidity-for-12b-bolstering-neuroscience-pipeline/">acquired Avidity Biosciences for $12 billion</a> in a deal completed February 27 and still among this year’s largest biotech acquisition transactions. In addition to del-desiran, Novartis acquired delpacibart zotadirsen (del-zota<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">), an Exon 44-targeting AOC designed to treat Duchenne muscular dystrophy (DMD) and delpacibart braxlosiran (del-brax<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">), an AOC intended to treat facioscapulohumeral muscular dystrophy (FSHD) by targeting DUX4.</p>
<p>Del-zota is under evaluation in the Phase II EXPLORE44OLE<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (<a href="https://clinicaltrials.gov/study/NCT06244082">NCT06244082</a>) trial following completion in November 2024 of the Phase I/II EXPLORE44<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (<a href="https://clinicaltrials.gov/study/NCT05670730">NCT05670730</a>) study. Del-brax is being assessed in the Phase III FORTITUDE-3<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> trial (<a href="https://clinicaltrials.gov/study/NCT07038200">NCT07038200</a>). In June, Novartis trumpeted positive data from the FORTITUDE Phase I/II trial (<a href="https://clinicaltrials.gov/study/NCT05747924">NCT05747924</a>) of del-brax, saying the study’s biomarker cohort met its primary and key secondary endpoints, with reductions in KHDC1L (cDUX) and creatine kinase biomarker levels indicating both strong target engagement and reduction in muscle damage in patients with FSHD.</p>
<p>In acquiring Avidity, Novartis sought to justify the deal by noting that Avidity’s AOCs held potential to develop into therapies with sizeable annual sales. On the day it announced the deal, Novartis raised its expected 2024-2029 sales compound annual growth rate (CAGR) from +5% to +6%,“representing a significant opportunity to deliver substantial shareholder returns over time,” the company stated in its press release, and said the deal would bolster its mid-single-digit long-term growth.</p>
<p>Speaking with CNBC in July, Novartis CEO Vas Narasimhan projected peak year sales of “$5 billion-plus,” while analyst forecasts for del-brax hovered in the $2 billion range, though projections for del-zota called for peak sales ranging between $315 million and $450 million.</p>
<p>Avidity had aligned with the FDA on a path toward accelerated approval for del-zota, while del-desiran and del-brax were on track to be the first globally approved drugs for their respective conditions.</p>
<p>“Avidity’s pioneering AOC platform for RNA therapeutics ​and its late-stage assets bolster our commitment to delivering innovative, targeted, and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases,” Narasimhan said in a statement at the time.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/novartis-shares-slide-after-neuromuscular-candidate-acquired-with-avidity-fails-phase-iii-trial/">Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NRAS Mutations May Require Mutation&#45;Guided Combination Therapies</title>
<link>https://edusehat.com/en/nras-mutations-may-require-mutation-guided-combination-therapies</link>
<guid>https://edusehat.com/en/nras-mutations-may-require-mutation-guided-combination-therapies</guid>
<description><![CDATA[ Mutant NRAS has remained difficult to target in cancer. New findings suggest that its signaling partnership with wild-type HRAS may offer a targetable vulnerability, but effective strategies may need to be tailored to the specific NRAS mutation.
The post NRAS Mutations May Require Mutation-Guided Combination Therapies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/08/GettyImages-1498385485.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 10:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NRAS, Mutations, May, Require, Mutation-Guided, Combination, Therapies</media:keywords>
<content:encoded><![CDATA[<p>For decades, RAS proteins have occupied a frustrating place in cancer biology: central to tumor growth, yet difficult to drug. Members of the RAS family—KRAS, NRAS, and HRAS—act as molecular switches that help relay growth signals inside cells. When mutated, they can become stuck in a growth-promoting state, driving cancers including melanoma, pancreatic cancers, colorectal cancers, and other malignancies. Although new drug-development efforts have begun to make inroads against KRAS and HRAS, mutant NRAS has remained a particularly challenging target. A new study suggests that one reason is that NRAS-driven cancers may not depend on mutant NRAS alone.</p>
<p>In a paper titled “<a href="https://www.science.org/doi/10.1126/scisignal.aej6209" target="_blank" rel="noopener">HRAS promotes mutant NRAS–driven transformation with codon and allele specificity</a>,” Hyun Lee, a PhD candidate at the Uniformed Services University of the Health Sciences, and colleagues investigated how different NRAS mutations shape cancer signaling and treatment sensitivity. The study examined how mutant NRAS works with nonmutant, or wild-type, RAS proteins to sustain oncogenic signaling.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>To isolate these interactions, the researchers used mouse cells lacking all RAS proteins and studied the effects of expressing mutant NRAS with or without reintroduced wild-type RAS family members. This system allowed the team to test whether mutant NRAS could drive transformation on its own or whether it required help from other RAS proteins. “Global dependency mapping in human cancer cells revealed functional partitioning, wherein mutant NRAS promoted MAPK signaling and wild-type HRAS promoted PI3K-AKT survival signaling,” they added.</p>
<p>The results showed that mutant NRAS proteins do not all behave the same way. NRAS mutations at glycine residues—G12X and G13X—retained some GDP-GTP cycling and showed modest autonomous transforming potential. By contrast, Q61X mutations, which lock NRAS in an active GTP-bound state, were more dependent on wild-type RAS for receptor tyrosine kinase–stimulated signaling and oncogenesis. Among the wild-type RAS proteins, HRAS emerged as a particularly important partner: reintroducing wild-type HRAS was sufficient to restore signaling and transformation in RASless cells expressing mutant NRAS.</p>
<p>The study also suggested that mutant NRAS and wild-type HRAS divide the labor of oncogenic signaling. Mutant NRAS primarily promoted MAPK signaling, while wild-type HRAS supported PI3K-AKT survival signaling. That functional split created therapeutic vulnerabilities, but the most effective drug combinations varied by NRAS mutation. Pan-RAS(ON) and HRAS inhibition showed synergy across the NRAS mutants tested, with Q61X mutants particularly sensitive to the combination. For G12X and G13X mutants, however, adding inhibitors of proximal RAS regulators such as SOS1 or SHP2 was needed to more fully suppress proliferation.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Together, the findings argue against a one-size-fits-all approach to NRAS-mutant cancers and support mutation-guided combination strategies that account for both the mutant allele and its wild-type RAS partners. As the authors wrote, “These findings define the signaling partnership between mutant NRAS and wild-type HRAS as a targetable vulnerability and provide a biochemical blueprint for dual RAS inhibition in NRAS-mutated malignancies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/nras-mutations-may-require-mutation-guided-combination-therapies/">NRAS Mutations May Require Mutation-Guided Combination Therapies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All</title>
<link>https://edusehat.com/en/adcs-mabs-car-ts-one-bioluminescent-platform-measures-them-all</link>
<guid>https://edusehat.com/en/adcs-mabs-car-ts-one-bioluminescent-platform-measures-them-all</guid>
<description><![CDATA[ The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment.
The post ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_SEP_2026_GettyImages-2151620900-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 06:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ADCs, mAbs, CAR, Ts:, One, Bioluminescent, Platform, Measures, Them, All</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.promega.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-321648 size-medium" src="https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-300x98.jpg" alt="promega logo" width="300" height="98" srcset="https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-300x98.jpg 300w, https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-1024x336.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-768x252.jpg 768w, https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-1281x420.jpg 1281w, https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-696x228.jpg 696w, https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-1392x459.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal-1068x350.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2025/09/PromegaLogo_Horizontal.jpg 1400w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>The development and use of biologic-based immunotherapies is one of the fastest-growing areas in the biopharmaceutical sector. These immunotherapies use different mechanisms of action (MoA) and formats, including chimeric antigen receptor (CAR) T cells, monoclonal antibodies (mAbs), and antibody drug conjugates (ADCs).</p>
<p>A crucial step during immunotherapy development is verifying MoA through delivery of the cytotoxic payloads to the targeted cells in a heterogeneous environment. The streamlined Promega HiBiT Target Cell Killing (TCK) platform is a bioluminescent cell-based system that measures cytotoxicity with specificity, simplicity, and sensitivity during therapeutic development. The mix-and-match platform supports broad immunotherapy modality assessment for four killing mechanisms—CAR-T cell-mediated killing, antibody-dependent cellular cytotoxicity (ADCC), T cell-dependent cellular cytotoxicity (TDCC), and antibody-dependent cellular phagocytosis (ADCP).</p>
<p>Off-the-shelf, thaw-and-use HiBiT target cells express an intracellular HiBiT peptide that remains stable in media for >3 days with minimal leakage and is released only upon cell death. Released HiBiT binds cell-impermeable LgBiT to form functional NanoBiT luciferase, generating a bright, quantitative signal. The luminescent signal is proportional to target cell death alone, with no contribution from effector cells, making the platform ideal for co-culture experiments.</p>
<p>The HiBiT TCK platform leverages gain, not loss, of signal detection. This approach avoids the kinetic complications of loss-of-signal assays, where prolonged luminescence decay can obscure cell death timing and complicate endpoint selection. The simplified no wash, load, or staining workflow produces robust signal-to-noise with as few as 2,000 cells in 96-well formats or 500 cells in 384-well formats.</p>
<p></p><h4><strong>Thaw-and-use target cells</strong></h4>

<p>A growing library of off-the-shelf assay components includes thaw-and-use, functionally tested cell lines that address blood cancer targets, including B cell lymphoma and leukemia, myeloid leukemia, and multiple myeloma (Raji, Ramos, H929), as well as solid tumor targets for ovarian carcinoma (OVCAR3), breast adenocarcinoma, and lung carcinoma (SKOV3, SK-BR-3). HiBiT-containing target cell lines can also be custom tailored using ViaScript<sup class="wp-sup-text">®</sup> transfection.</p>
<figure aria-describedby="caption-attachment-332937" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-332937" src="https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA.jpg" alt="Principle of the HiBiT TCK Bioassay" width="500" height="195" srcset="https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA.jpg 1200w, https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA-300x117.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA-1024x400.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA-768x300.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA-1075x420.jpg 1075w, https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA-696x272.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/06/Promega-SC-Image_19122MA-1068x417.jpg 1068w" sizes="auto, (max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Principle of the HiBiT TCK Bioassay. Cytotoxic mAbs and/or effector cells are incubated with target cells expressing a HiBiT fusion protein. Upon killing of the target cell, the HiBiT fusion protein is released and binds extracellular LgBiT to create a functional NanoBiT<sup>®</sup> Luciferase enzyme. Luminescence is measured using a luciferase substrate and the GloMax<sup>®</sup> Discover System.</figcaption></figure>
<p>For cell lines not in the standard panel, the ViaScript (HiBiT) TCK Bioassay enables rapid screening of target cells using transient HiBiT expression. ViaScript is a novel mRNA transfection reagent that enables rapid and titratable transient expression of HiBiT mRNA in a wide range of adherent or suspension target cell types for early high-throughput screening and clone selection. The transfected cell lines can be screened simultaneously and used in a HiBiT TCK Bioassay and paired with qualified primary effector cells and a biologic to measure ADCC, ADCP, TDCC or CAR-T cell killing. Once optimal TCK lines are identified with the ViaScript (HiBiT) TCK Bioassay, Promega’s Tailored R&D Solutions (TRS) offers custom clonal line development.</p>
<p></p><h4><strong>Off-the-shelf primary effector cells</strong></h4>

<p>Promega’s primary effector cells provide a consistent and robust method for target cell killing. The primary effector cells are MoA-qualified to measure the potency and stability of antibodies and other biologics that specifically bind and activate their respective effector cells. Stocked as thaw-and-use products, primary effector cells are functionally tested with the HiBiT Target Cell Killing Bioassays. PBMCs are ADCC-qualified, CD8+ T cells are TDCC-qualified, and macrophages are ADCP-qualified to assess Fc effector-driven activity. Effector cells are available in two product formats: as standalone vials or in bioassay kits.</p>
<p>The homogeneous, sensitive HiBiT TCK platform and bioassay provides a robust assay window for four immunotherapy killing mechanisms. The versatile mix-and-match platform supports experiments with different combinations of effector and target cells. The resulting luminescent signal is specific to target cell killing, making the bioassay well-suited for mixed co-culture experiments during development efforts. The HiBiT TCK platform supports ADCC with PBMC effectors, TDCC with CD8+ T cells, ADCP with macrophages, and CAR-T killing assays across a 4–72-hour time course.</p>
<p class="trimmed"> </p>
<p><em><img loading="lazy" decoding="async" class="alignleft  wp-image-337584" src="https://www.genengnews.com/wp-content/uploads/2026/09/Promega_QRCode-300x300.jpg" alt="September 2026 sponsored content Promega QR Code" width="134" height="134" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Promega_QRCode-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Promega_QRCode-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/Promega_QRCode.jpg 397w" sizes="auto, (max-width: 134px) 100vw, 134px"></em></p>
<p class="trimmed"> </p>
<p><em>Explore More <a href="https://www.promega.com/products/reporter-bioassays/target-cell-killing-bioassays" target="_blank" rel="noopener">promega.com/products/reporter-bioassays/target-cell-killing-bioassays</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/adcs-mabs-car-ts-one-bioluminescent-platform-measures-them-all/">ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Multi&#45;Attribute Method (MAM) as a Biologics Lifecycle Backbone</title>
<link>https://edusehat.com/en/the-multi-attribute-method-mam-as-a-biologics-lifecycle-backbone</link>
<guid>https://edusehat.com/en/the-multi-attribute-method-mam-as-a-biologics-lifecycle-backbone</guid>
<description><![CDATA[ A more coherent approach: a peptide-mapping LC-HRMS (liquid chromatography-high resolution mass spectrometry) workflow that can identify and monitor multiple product quality attributes, including selected critical quality attributes, and resolve modifications to specific sites. In a single analysis, deamidation, oxidation, site-specific glycoforms, sequence variants, and other product-related features monitored, potentially streamlining quality control across the product lifecycle.
The post The Multi-Attribute Method (MAM) as a Biologics Lifecycle Backbone appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Catalent-Hero_shutterstock_vitstudio_339727163_2000x1500.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 06:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Multi-Attribute, Method, MAM, Biologics, Lifecycle, Backbone</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.catalent.com/" target="_blank" rel="noopener"><img decoding="async" class="wp-image-337594 size-medium alignnone" src="https://www.genengnews.com/wp-content/uploads/2026/09/Catalent-Pharma-Services-TM-Logo-Color-CMYK-2-300x123.jpg" alt="Catalent Pharma Services Logo" width="300" height="123" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Catalent-Pharma-Services-TM-Logo-Color-CMYK-2-300x123.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Catalent-Pharma-Services-TM-Logo-Color-CMYK-2.jpg 385w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p> </p>
<p>Surprises that delay manufacturing programs tend to arrive late in the day. A comparability package will not close if reactor scale-up, site transfer, or cell-line improvement produces a new analytical signal that cannot be reconciled with the material dosed in the clinic. Each of those changes was deliberate, yet the divergence it produced was not. What looks like an analytical problem can reflect an underlying product or process change.</p>
<p></p><h4><strong>A council of separate assays</strong></h4>

<div class="my-8"><span data-render-ad="4"></span></div>
<p>The quality of a biologic is conventionally assessed not by one instrument but by a council of specialists, each fluent in one dialect. Charge variants speak through imaged capillary isoelectric focusing, size variants through size-exclusion chromatography, glycans through released-glycan mapping, and identity and modifications through peptide mapping.</p>
<p>Each specialist instrument is an expert, and each offers a partial answer. Across the years from candidate to commercial supply, that council is reconvened as methods, instruments, and qualified reference standards change. What survives is not a story but a stack of testimonies; the seams between them are where late surprises are born.</p>
<p></p><h4><strong>One framework, one language</strong></h4>

<p>The multi-attribute method (MAM) offers a more coherent approach: a peptide-mapping LC-HRMS (liquid chromatography-high resolution mass spectrometry) workflow that can identify and monitor multiple product quality attributes, including selected critical quality attributes, and resolve modifications to specific sites. In a single analysis, MAM can monitor deamidation, oxidation, site-specific glycoforms, sequence variants, and other product-related features, potentially streamlining quality control across the product lifecycle.</p>
<p>MAM is built in two movements: a broad characterization phase that identifies measurable attributes and assembles a product-specific peptide library anchored by accurate mass and retention time; and a monitoring phase that tracks the relative abundance of selected attributes, batch after batch.</p>
<p></p><h4><strong>Catching what no one thought to ask</strong></h4>

<div class="my-8"><span data-render-ad="5"></span></div>
<p>MAM’s distinctive capability is new peak detection, a threshold-based comparison that aligns mass, retention time, and intensity features against a product-specific reference and flags new or significantly changed peaks for review. A conventional release assay reports within its intended analytical dimension. New peak detection asks a broader question: has an unexpected peptide-level feature changed?</p>
<p>Detecting that signal while the process is still being developed, rather than after it is locked, can be valuable because the attribute that ultimately matters may not be the one predicted.</p>
<p></p><h4><strong>When the process changes</strong></h4>

<p>Consider a typical crisis: a perfusion process replaces fed-batch, a step is redesigned, and a campaign moves to a second manufacturing site. Regulators require evidence that relevant quality attributes remain highly similar and that observed differences do not adversely affect safety or efficacy. Assembled from scattered legacy assays, that evidence can require substantial time to build and still show its seams.</p>
<p>When the same peptide mapping-based framework has traveled with the molecule from its earliest characterization, comparability can become less of an emergency and more a continuation of an established data stream. The peptide-level reference and historical attribute data already exist. That continuity can strengthen the broader comparability package.</p>
<p></p><h4><strong>What MAM does not solve</strong></h4>

<p>MAM is not a universal solution. By separating the molecule into peptides, MAM does not directly assess aggregation, particles, higher-order structure, biological activity, or modification combinations on the same intact molecule. It also depends on robust data analysis. MAM has been implemented for release in specific applications, and USP <1060> now provides a practical framework, while broader implementation continues to evolve. MAM works best as a backbone for directed attribute monitoring, supported by orthogonal methods.</p>
<p></p><h4><strong>Analytical continuity by design</strong></h4>

<p>At Catalent’s Kansas City analytical center of excellence, MAM and high-resolution mass spectrometry are applied as independent analytical services, supporting programs wherever the molecule is manufactured. Against a decade of process change, the aim is not more testimony, but a single coherent account, and fewer places for the story to break.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p> </p>
<p><em><img decoding="async" class="alignleft wp-image-337595" src="https://www.genengnews.com/wp-content/uploads/2026/09/Catalent_QRCode-297x300.jpg" alt="Catalent September 2026 sponsored content QR Code" width="139" height="140" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Catalent_QRCode-297x300.jpg 297w, https://www.genengnews.com/wp-content/uploads/2026/09/Catalent_QRCode-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/Catalent_QRCode.jpg 328w" sizes="(max-width: 139px) 100vw, 139px">Comparability is easier to defend when it never had to be reconstructed.</em></p>
<p><em>Learn more about Catalent Biologics Analytical Services.</em></p>
<p><a href="https://www.catalent.com/" target="_blank" rel="noopener"><em>www.Catalent.com</em></a></p>
<p>The post <a href="https://www.genengnews.com/sponsored/the-multi-attribute-method-mam-as-a-biologics-lifecycle-backbone/">The Multi-Attribute Method (MAM) as a Biologics Lifecycle Backbone</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>RNAV8 Bio Joins ARPA&#45;H Team to Pioneer Programmable RNA Medicines</title>
<link>https://edusehat.com/en/rnav8-bio-joins-arpa-h-team-to-pioneer-programmable-rna-medicines</link>
<guid>https://edusehat.com/en/rnav8-bio-joins-arpa-h-team-to-pioneer-programmable-rna-medicines</guid>
<description><![CDATA[ The PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where and when intended, without altering the genome.
The post RNAV8 Bio Joins ARPA-H Team to Pioneer Programmable RNA Medicines appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2286477227.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 02:50:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>RNAV8, Bio, Joins, ARPA-H, Team, Pioneer, Programmable, RNA, Medicines</media:keywords>
<content:encoded><![CDATA[<p>RNAV8 Bio (pronounced Renovate Bio) has been selected to receive funding from the Advanced Research Projects Agency for Health (ARPA-H) for PROPEL (Programmable RNA for Optimal Precision in Therapeutic Efficacy and Localization).</p>
<p>RNAV8, a biofirm applying AI-driven design and laboratory validation to engineer more predictable mRNA medicines, will be part of a team led by the Rouskin Lab at Harvard Medical School with the Weissman Lab at MIT/the Whitehead Institute. The award, a one-year ARPA-H pilot of up to $4.4 million, will fund a program to turn RNA’s natural folding behavior into a precise, drug-tunable control layer for a new generation of RNA medicines. PROPEL is led by ARPA-H program manager Shannon Greene, PhD.</p>
<p>“The promise of mRNA has always been that it’s programmable, but in practice the relationship between a RNA’s sequence and chemistry and what it actually does has been hard to predict,” said Devan Shah, founder and CEO of RNAV8 Bio. “Our work with the Rouskin and Weissman labs is aimed squarely at that gap: learning the rules that connect sequence to function, and building them into logic-gated constructs that express where and when they should.</p>
<p>“Just as important, every element we discover stays answerable in the format a medicine actually ships in. We’re proud to help carry this science from a regulatory element toward a real therapeutic.”</p>
<p>Within PROPEL, RNAV8 Bio focuses on the therapeutic format itself. It screens protein output from pools of transfected mRNA, engineers UTRs in the delivery format, and validates results at the cargo level, for example driving cell-type-selective expression of therapeutic payloads such as gene-editing enzymes or CAR constructs.</p>
<p></p><h4><strong>PROPEL pursues a different kind of control</strong></h4>

<p>Most medicines act wherever their chemistry carries them, and most genetic therapies work by permanently changing DNA. PROPEL pursues a different kind of control. An RNA molecule’s untranslated regions (UTRs) fold into structures, and those structures set how much protein the message produces. When a small molecule binds one of those folds, the structure rearranges and the output changes, turning a dose into a dial on protein expression, without altering the genome. Bacteria use this logic openly, in elements called riboswitches; in human cells it remains largely uncharted.</p>
<p>“For decades we’ve read RNA sequence as a set of instructions for making a protein. What we can now read, at the scale of thousands of sequences at once, is how that sequence folds, and how a small molecule can change the fold and, with it, the output,” said Silvi Rouskin, PhD, assistant professor of microbiology, Harvard Medical School. “Human cells almost certainly already use this kind of structural control; we’ve simply never had the tools to find it systematically. PROPEL is our attempt to map it and put it to work.”</p>
<p><figure aria-describedby="caption-attachment-337444" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-337444" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1324967376-300x169.jpg" alt="mrna" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1324967376-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1324967376-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1324967376-746x420.jpg 746w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1324967376-696x392.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1324967376.jpg 787w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Engineering installs regulatory elements into therapeutic mRNA so that a single construct is selective by cell type through its sequence and tunable through its structure. [Niphon/Getty Images]</figcaption></figure>PROPEL pursues this along two lines of work that share a single screening pipeline. Discovery searches human RNA for naturally occurring elements whose structure responds to a metabolite or an FDA-approved drug, native regulation reachable with existing, well-tolerated molecules.</p>
<p>Engineering installs regulatory elements into therapeutic mRNA so that a single construct is selective by cell type through its sequence and tunable through its structure. Both rely on high-throughput mapping of how a RNA’s folds shift when a ligand binds, which flags the elements that regulate protein output before the team tests which ones a small molecule can move.</p>
<p>The Weissman Lab contributes massively parallel screens of human untranslated-region elements across cell types, measuring which ones set expression where.</p>
<p>“The untranslated regions flanking a message are among the most powerful and least exploited levers on how much protein a cell makes,” said Jonathan Weissman, PhD, professor of biology, MIT and member, Whitehead Institute. “By screening these elements across cell types, we can begin to tell which ones set expression where, turning a vague notion of ‘regulation’ into a defined, reusable parts list. That is what makes a control layer generalizable rather than a one-off trick.”</p>
<p>By the end of its initial phase, the collaboration aims to produce resources that do not exist today: a map of how thousands of human RNA sequences respond to small molecules, with structural models; a ranked catalogue of human UTR elements that set translation cell type by cell type; engineered UTRs that reach meaningful selectivity in a therapeutic format; and RNA sequences, natural or engineered, shown to switch structure inside human cells. Together these are meant to form a generalizable, disease-agnostic foundation for RNA medicine, according to the scientific team.</p>
<p>PROPEL is a program supported by ARPA-H that develops a programmable, drug-tunable control layer for RNA medicines.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/rnav8-bio-joins-arpa-h-team-to-pioneer-programmable-rna-medicines/">RNAV8 Bio Joins ARPA-H Team to Pioneer Programmable RNA Medicines</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Regenerative Medicine in the Bronze Age: MSCs and MSC&#45;EVs Leading the Way</title>
<link>https://edusehat.com/en/regenerative-medicine-in-the-bronze-age-mscs-and-msc-evs-leading-the-way</link>
<guid>https://edusehat.com/en/regenerative-medicine-in-the-bronze-age-mscs-and-msc-evs-leading-the-way</guid>
<description><![CDATA[ The field of regenerative medicine is gaining momentum. Mesenchymal stem cells (MSCs) remain central to this field, with expanding applications as direct therapies and as producers of MSC-derived extracellular vesicles (MSC-EVs). This article examines the biological and regulatory factors shaping their promise.
The post Regenerative Medicine in the Bronze Age: MSCs and MSC-EVs Leading the Way appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 02:50:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Regenerative, Medicine, the, Bronze, Age:, MSCs, and, MSC-EVs, Leading, the, Way</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.lonza.com/" target="_blank" rel="noopener"><img loading="lazy" decoding="async" class="size-medium wp-image-70541 alignnone" src="https://www.genengnews.com/wp-content/uploads/2018/10/LONZA_Logo1743621020-300x55.jpg" alt="" width="300" height="55" srcset="https://www.genengnews.com/wp-content/uploads/2018/10/LONZA_Logo1743621020-300x55.jpg 300w, https://www.genengnews.com/wp-content/uploads/2018/10/LONZA_Logo1743621020-485x91.jpg 485w, https://www.genengnews.com/wp-content/uploads/2018/10/LONZA_Logo1743621020.jpg 500w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></p>
<p>Immunotherapies have dominated cell and gene therapy for the past 5–10 years, but the field of regenerative medicine is gaining momentum. Mesenchymal stem cells (MSCs) remain central to this field, with expanding applications as direct therapies and as producers of MSC-derived extracellular vesicles (MSC-EVs). This article examines the biological and regulatory factors shaping their promise.</p>
<p></p><h4><strong>MSC Therapies: Promise, Frustration, and a Push Toward Biomarkers to Drive Efficacy </strong></h4>

<p>MSC therapies show strong biological promise, but translation remains slow because efficacy and consistency are difficult to demonstrate. A key priority is aligning therapy design with MSC biology. Autoimmune diseases, such as progressive multiple sclerosis, are strong applications because treatment options are limited and early studies suggest MSCs may help reset immunity. Experts recommend biomarker-driven trials to identify appropriate patients earlier and improve evaluation. MSCs are often misunderstood and underutilized, making biomarker-driven design and global harmonization essential for success.</p>
<figure aria-describedby="caption-attachment-337539" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-337539" src="https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-300x225.jpg" alt="Lonza Scientists Discussing Data" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1-530x396.jpg 530w, https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_Scientists_Discussing_Data-2000x1500-1.jpg 933w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Lonza</figcaption></figure>
<p>MSCs are attractive because they can be used in allogeneic therapies: donor cells can be cryopreserved, thawed, and used off-the-shelf to treat larger patient populations, including autoimmune and cardiovascular indications. Developers are moving toward 3D culture systems to increase production, simplify manufacturing, and enable MSC-EV generation. However, shifting from 2D to 3D culture systems can alter confluency, marker profiles, EV productivity, and other critical quality attributes. Teams must optimize media, serum or HPL, additives, and reagents to maintain CQAs at scale.</p>
<p>Process changes in media, microcarriers, or feed schedules can dramatically affect MSC performance, increasing interest in AI-driven optimization of consumables and reagents. As 3D systems advance, developers still rely on serum or HPL to support cell health and consistency, while the industry increasingly demands chemically defined, serum-free systems. Better serum-free and HPL-free solutions are needed for clinical development of MSC therapies and MSC-EVs. Together, these trends show MSC therapies becoming more engineered, precise, and clinically defined, while many MSC developers expand into MSC-EV solutions and fuel excitement around both modalities.</p>
<p></p><h4><strong>MSC-EVs: Increasing Interest in a Novel Therapeutic Solution</strong></h4>

<p>The shift of MSC-EVs from “cells as drugs” to “cells as biological triggers” raises an interesting central question: can developers deliver therapeutic impact without administering the cells themselves?</p>
<p>With more than 500 MSC-derived EV clinical trials underway, the field continues to grow. MSC-EVs lead the EV and exosome space because of the strong foundation built during decades of MSC research. However, key questions remain around classification, safety, efficacy, scale-up, and commercialization. MSC-EVs remain in a regulatory grey zone, with agencies still determining whether they are biologics, cell-based therapies, or a new class. Regulators are likely to focus on process consistency, EV identity, and release testing in later-stage development.</p>
<p>Purity and characterization remain central because upstream and downstream processes can change EV composition. Each indication must show how cell source, processing, and purification affect the final product. With no commercial EV therapeutics approved so far, developers must establish precedent while maintaining consistency through scale-up. As MSC-EV developers scale into larger trials and commercial manufacturing, GMP processes and reagents can change EV outputs and must be addressed early. Early conversion to GMP media and consumables can reduce risk, lower costs, and clarify efficacy, purity, and consistency priorities. MSC-EVs will also face competition from EVs derived from NK cells, macrophages, HEK293 cells, plants, and other sources. These alternatives may offer lower-cost production or different applications, while shared learnings can advance the broader EV field.</p>
<p></p><h4><strong>MSCs and MSC-EVs Drive Progress and Advance Regenerative Medicine</strong></h4>

<p>Immunotherapies have defined a recent Golden Age in cell and gene therapy. As manufacturing matures and refinements become more incremental, the next major wave of innovation may come from regenerative medicine. MSCs and MSC-EVs hold major promise, but many companies still lack the infrastructure and timelines that attract major pharma investment. This places the field in a biotech Bronze Age: rich with opportunity in rare disease, organ failure, allogeneic therapies, and scalable EV platforms, but still building the evidence, biology, and manufacturing precedent needed for broader success. Continued progress in scale-up, process control, and modality definition could unlock a future Golden Age for MSC and MSC-EV therapeutics.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>Jessica Pickrell; Associate Director, Media Solutions, Lonza</p>
<p class="trimmed"> </p>
<p><em>Further Reading</em></p>
<p>1. Wang CK, Tsai TH, Lee CH. Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes. Clin Transl Sci. 2024; Aug 17(8):e13904. doi: 10.1111/cts.13904. PMID: 39115257; PMCID: PMC11307316.</p>
<p>2. Bourcier AJ & Kirkor ZM. Regulatory, ethical, and clinical barriers to exosome use in interventional pain medicine. Intl Pain Medicine 2026; 5(1):100746. doi: 10.1016/j.inpm.2026.100746.</p>
<p>3. nternational Society for Cell & Gene Therapy (ISCT). 2026. Roundtable on Regulation and Policy, ISCT 2026 Annual Meeting, Dublin, Ireland.</p>
<p>Lonza Group Ltd. and its affiliates (collectively and individually, “Lonza”) make efforts to include accurate and up-to-date information. However, Lonza makes no representations or warranties, express or implied, including as to accuracy or completeness of information. All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to third-party owners and are used for only informational purposes. All third-party copyrights have been reproduced with permission from their owners. The user bears the sole responsibility for determining the existence of any third-party rights and obtaining any necessary licenses and approvals. For more information, including regarding legal disclaimers, Lonza’s intellectual property rights, and how Lonza collects, uses and protects personal information: <a href="https://www.lonza.com/legal" target="_blank" rel="noopener">www.lonza.com/legal</a>, <a href="https://www.lonza.com/about-us/intellectual-property" target="_blank" rel="noopener">www.lonza.com/about-us/strategy/intellectual-property</a> and <a href="https://www.lonza.com/privacy" target="_blank" rel="noopener">www.lonza.com/privacy</a>. © 2026 Lonza. All rights reserved</p>
<p class="trimmed"> </p>
<p><em><img loading="lazy" decoding="async" class="alignleft wp-image-337541" src="https://www.genengnews.com/wp-content/uploads/2026/09/Lonza_QRCode.jpg" alt="Lonza September 2026 sponsored content QR code " width="130" height="133"></em></p>
<p class="trimmed"> </p>
<p><em>To learn more, visit <a href="https://bioscience.lonza.com/lonza_bs/US/en/mscs-mesenchymal-stem-cells" target="_blank" rel="noopener">bioscience.lonza.com/lonza_bs/US/en/mscs-mesenchymal-stem-cells</a>.</em></p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/sponsored/regenerative-medicine-in-the-bronze-age-mscs-and-msc-evs-leading-the-way/">Regenerative Medicine in the Bronze Age: MSCs and MSC-EVs Leading the Way</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice</title>
<link>https://edusehat.com/en/anticancer-candidate-strengthens-bones-and-prevents-weight-gain-in-postmenopausal-mice</link>
<guid>https://edusehat.com/en/anticancer-candidate-strengthens-bones-and-prevents-weight-gain-in-postmenopausal-mice</guid>
<description><![CDATA[ A preclinical study in post-menopausal bone loss mouse models found that CADD522, a small-molecule drug targeting RUNX2, protected against osteoporosis, prevented fat gain, and reversed some of the metabolic changes linked to menopause. 
The post Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2019/04/Apr12_2019_Getty_85757866_osteoporosis_cropped.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 02:50:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Anticancer, Candidate, Strengthens, Bones, and, Prevents, Weight, Gain, Postmenopausal, Mice</media:keywords>
<content:encoded><![CDATA[<p>The results of a preclinical study by researchers at the University of East Anglia suggest that an experimental anticancer drug could stop osteoporosis and help women prevent weight gain after the menopause. Their study in mice found that the small molecule drug CADD522 not only protected against osteoporosis but could also reduce body fat and reverse some of the metabolic changes linked to menopause. Currently in development for cancer therapy, CADD522 is a small molecule inhibitor of the transcription factor RUNX2, which is helps to drive the growth and spread of several cancers.</p>
<p>Research lead Darrell Green, PhD, at UEA’s Norwich Medical School, said, “We have uncovered an entirely new way of tackling the disease. We found that a drug originally developed to stop cancer could help millions of women facing the twin challenge of fragile bones and midlife weight gain. We hope our work could lead to a new generation of osteoporosis treatments that tackle bone loss while also addressing some of the wider metabolic consequences of menopause.”</p>
<p>Green is senior and co-corresponding author of the team’s report in <em>npj Drug Discovery</em>, titled “<a href="https://doi.org/10.1038/s44386-026-00076-z" target="_blank" rel="noopener">RUNX2 inhibitor CADD522 improves bone microarchitecture and lipid metabolism in post-menopausal bone loss</a>.” In their paper the team concluded that their collective studies “… identify RUNX2 inhibition as a therapeutic strategy that simultaneously improves skeletal integrity and metabolic homeostasis, supporting further development of CADD522 for osteoporosis and other RUNX2-driven diseases.”</p>
<p>Osteoporosis is a metabolic bone disorder characterized by low bone mass, structural deterioration and increased fracture risk. The disorder affects one in three women and one in five men aged over 50 years globally, the authors wrote, but there are limited therapeutic options. “… existing antiresorptive and anabolic therapies remain limited by safety concerns, contraindications and poor long-term adherence,” the authors stated. “Thus, new treatments with few side effects and broader applicability remain a clinical priority.”</p>
<p>Green said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life. Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.</p>
<p>The researchers had previously evaluated the small molecule RUNX2 antagonist CADD522 in several preclinical cancer models. “RUNX2 is critical for in utero skeletogenesis and cancer metastasis,” they explained. Unexpectedly, studies indicated that CADD522 reduced cancer-induced bone disease, “… suggesting potential utility in osteoporosis.”</p>
<p>For their newly reported study Green and colleagues investigated whether RUNX2 inhibition could protect against post-menopausal bone loss, in an ovariectomy-induced mouse model, to mimic the hormonal changes seen after menopause.</p>
<p>The team found that animals treated using CADD522 for eight weeks showed significant improvements in bone health. Scans revealed increased bone volume and better preservation of the delicate honeycomb-like structures inside bones that are crucial for strength and resilience. Blood tests suggested the drug stimulated new bone growth, without interfering with the body’s normal process of breaking down and rebuilding bone.</p>
<p>Green said: “This is particularly important because many existing osteoporosis drugs work by suppressing bone loss, which can sometimes lead to complications when used for long periods.”</p>
<p>The biggest surprise came when the investigators looked beyond bone health, Green continued. “The mice receiving CADD522 weighed less than their untreated counterparts despite eating the same amount of food. They also had less body fat and fewer fat deposits accumulating inside their bone marrow—a process that is commonly seen after menopause and is linked to declining bone health.” The authors wrote in summary, “A remarkable finding was that the skeletal improvements occurred alongside reduced peripheral and marrow adiposity and selective remodeling of lipid metabolism.”</p>
<p>The team also examined brain tissue and found the drug appeared to reverse several menopause-related changes in fatty acids. Levels of beneficial omega-3 fats, including DHA, remained largely intact, while a number of other lipid abnormalities shifted back towards healthier patterns. “Rather than inducing indiscriminate metabolic disruption, RUNX2 inhibition therefore appears to restore specific lipid pathways perturbed by menopause,” the team noted. “Although the relationship between altered brain lipid composition and cognitive function was not examined in the present study, the selective remodeling of brain lipids following CADD522 treatment raises the possibility that RUNX2 inhibition may influence neurological adaptations to menopause in addition to preserving skeletal integrity.”</p>
<p>Green added: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.” The team suggests that further studies should determine whether the metabolic effects demonstrated translate into improvements in cognition or other measures of brain health.</p>
<p>The prospects for future clinical applications also received a boost from safety testing. Experiments in mice, rats and dogs found CADD522 could be taken orally and was well tolerated. “Cross-species pharmacokinetic and toxicological studies demonstrated oral bioavailability, favorable short-term tolerability and target engagement despite rapid systemic clearance, while cellular thermal shift assays confirmed direct engagement of RUNX2,” they noted.</p>
<p>The team also found the drug appeared to be metabolized more slowly in human tissue than in rodents, potentially improving its performance in people. “This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.</p>
<p>In conclusion, the authors wrote, “In summary, our findings reveal an unexpected role for RUNX2 inhibition in protecting against post-menopausal bone loss while simultaneously improving systemic metabolic homeostasis.” They suggest that their study “… establishes a translational framework for further development of CADD522 and identifies RUNX2 as a therapeutically tractable regulator of skeletal and metabolic adaptation in adulthood.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/anticancer-candidate-strengthens-bones-and-prevents-weight-gain-in-postmenopausal-mice/">Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>ProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell Line</title>
<link>https://edusehat.com/en/probiogen-grants-transgene-additional-license-for-age1crpix-cell-line</link>
<guid>https://edusehat.com/en/probiogen-grants-transgene-additional-license-for-age1crpix-cell-line</guid>
<description><![CDATA[ ProBioGen’s AGE1.CR.pIX is a stable proliferating avian cell line derived from duck embryo primary cells. It was developed as an alternative to the use of chicken eggs for large-scale vaccine production. 
The post ProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell Line appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/210693_ProBioGen_Virology_Cryo_Storage_Cell_Line_AGE1.CR_.PIX_100px.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 02:50:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>ProBioGen, Grants, Transgene, Additional, License, for, AGE1.CR.pIX, Cell, Line</media:keywords>
<content:encoded><![CDATA[<p>ProBioGen and Transgene report that they broadened the scope of their existing collaboration to include an additional license agreement for ProBioGen’s suspension AGE1.CR.plX<sup>R </sup>cell line which is designed to boost Transgene’s manufacturing capabilities with this specialized production technology.</p>
<p>ProBioGen officials describe the cell line as a stable proliferating avian cell line derived from primary cells of a duck embryo. It was developed as an alternative to the use of chicken eggs for large-scale vaccine production. The cell line is available as both a suspension and adherent cell line and has been optimized for viral vaccine production and stability.</p>
<p>The product, which grows in a commercially available, chemically defined medium without animal components and serves as a host for a variety of different virus strains, is aimed at cost-effective production and increased manufacturing productivity.</p>
<p>“This additional license reflects our confidence in the technology to prepare for future clinical needs at scale,” said Alessandro Rive, chairman and CEO of Transgene.</p>
<p>“We value Transgene’s continued confidence in our AGE1.CR.pIX platform,” added Volker Sandig, PhD, CSO at ProBioGen. “A continuous cell line qualified as a GMP master cell bank, grown in chemically defined and animal-component-free medium, means every batch begins from the same fully characterized starting material.”</p>
<p>Transgene focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac<sup class="wp-sup-text">®</sup> platform is Transgene’s lead asset in the adjuvant treatment of head and neck cancers.</p>
<p>TG4070, a second individualized vaccine candidate derived from the myvac platform, is in Phase I clinical development in combination with nivolumab in adjuvant non-small lung cancer (NSCLC). The company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO<sup class="wp-sup-text">®</sup> viral backbone, which is in clinical development.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/probiogen-grants-transgene-additional-license-for-age1-cr-pix-cell-line/">ProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell Line</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Targeted Lentiviral Delivery Without Vector Reengineering</title>
<link>https://edusehat.com/en/targeted-lentiviral-delivery-without-vector-reengineering</link>
<guid>https://edusehat.com/en/targeted-lentiviral-delivery-without-vector-reengineering</guid>
<description><![CDATA[ Rather than requiring genetic modification of the viral glycoprotein, G-Link uses a modular protein adaptor to blind native VSV-G tropism and redirect delivery after vector production.
The post Targeted Lentiviral Delivery Without Vector Reengineering appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Web_Only_Hero-Vyriad-04-18-24_0010-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 02:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Targeted, Lentiviral, Delivery, Without, Vector, Reengineering</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://vyriad.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-337554 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad-Logo-horizontal-300x40.jpg" alt="Vyriad logo" width="300" height="40" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad-Logo-horizontal-300x40.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad-Logo-horizontal-1024x136.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad-Logo-horizontal-768x102.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad-Logo-horizontal-696x93.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad-Logo-horizontal-1068x142.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad-Logo-horizontal.jpg 1293w" sizes="(max-width: 300px) 100vw, 300px"></a></p>
<p>VSV-G is the surface glycoprotein of the vesicular stomatitis virus. VSV-G-pseudotyped lentiviral vectors are widely used for gene delivery, offering broad tropism, substantial transgene cargo capacity, and ease of production. But broad native tropism presents a challenge for targeted delivery, which has traditionally required engineering the viral envelope itself.</p>
<p>Vyriad’s novel G-Link targeting platform takes a different approach. Rather than requiring genetic modification of the viral glycoprotein, G-Link uses a modular protein adaptor to blind native VSV-G tropism and redirect delivery after vector production.</p>
<figure aria-describedby="caption-attachment-337552" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-337552" src="https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV-219x300.jpg" alt="G-Link architecture and mechanism of VSV-G retargeting." width="219" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV-219x300.jpg 219w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV-748x1024.jpg 748w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV-768x1052.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV-307x420.jpg 307w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV-613x840.jpg 613w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV-696x953.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure1-V2-REV.jpg 980w" sizes="auto, (max-width: 219px) 100vw, 219px"><figcaption class="wp-caption-text">Figure 1. G-Link architecture and mechanism of VSV-G retargeting.</figcaption></figure>
<p></p><h4><strong>A modular protein adaptor</strong></h4>

<ul>
<li>G-Link comprises three functional elements (see <em>Fig. 1</em>):</li>
<li>Cysteine-rich (CR) domains derived from the low-density lipoprotein receptor (LDLR) interact with the receptor-binding domain of VSV-G, masking its native LDLR tropism.</li>
<li>A trimerizing peptide positions these domains to complement the trimeric architecture of VSV-G on the vector surface, significantly improving blinding compared with a monomeric adaptor.</li>
<li>Finally, a CD3-targeting moiety redirects vector binding toward T cells.</li>
</ul>
<p>Together, these elements effectively cap VSV-G, simultaneously suppressing its native tropism and introducing new cell specificity without genetically modifying the glycoprotein. G-Link is compatible with VSV-G-pseudotyped lentiviral and gamma-retroviral vectors as well as virus-like particles, providing a flexible platform for post-production retargeting.</p>
<p>When VSV-G-pseudotyped lentiviral vectors carrying a CD19 chimeric antigen receptor (CAR) were pre-mixed with G-Link and applied directly to peripheral blood mononuclear cells (PBMCs), CAR delivery in T cells was dramatically improved (<em>Fig. 2</em>). This reflects G-Link’s ability to both target and activate these cells, supporting efficient transduction without prior isolation or bead-based stimulation. T-cell-specific delivery is also maintained in human whole blood, an important requirement for systemic<em> in vivo</em> administration.</p>
<figure aria-describedby="caption-attachment-337553" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-337553" src="https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure2.jpg" alt="Vyriad sponsored content figure 2 Human PBMCs illustration" width="500" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure2.jpg 980w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure2-300x180.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure2-768x461.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure2-700x420.jpg 700w, https://www.genengnews.com/wp-content/uploads/2026/09/Viyriad-Figure2-696x418.jpg 696w" sizes="auto, (max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Figure 2. Human PBMCs were transduced with uncapped or G-Link-capped lentiviral vectors (LV) carrying a CD19 CAR. Five days post-transduction, CD19 CAR expression was analyzed by flow cytometry.</figcaption></figure>
<p></p><h4><strong>Stable retargeting for systemic delivery</strong></h4>

<p>For systemic applications, G-Link must remain bound to VSV-G after administration, as dissociation could restore the vector’s broad native tropism and increase the potential for off-target transduction. At physiological calcium concentrations, the interaction between G-Link and VSV-G is remarkably stable. G-Link remains associated with the vector through multiple freeze-thaw cycles and tangential flow filtration, as well as following intravenous administration and systemic circulation in mice.</p>
<p>At the same time, G-Link binding is reversible under low-calcium conditions, allowing release as the vector enters the endosomal environment.</p>
<p>This combination of blinding and retargeting has translated into preclinical <em>in vivo</em> safety and efficacy. In a mouse model of multiple myeloma, G-Link-capped lentiviral vectors encoding a B-cell maturation antigen (BCMA) CAR generated CAR T cells <em>in vivo</em> and produced complete tumor clearance in treated animals without notable signs of toxicity. In contrast, uncapped vectors and G-Link alone failed to control tumor burden or substantially prolong survival.</p>
<p></p><h4><strong>One platform, multiple opportunities</strong></h4>

<p>G-Link can simplify <em>ex vivo</em> T-cell engineering by combining targeting, activation and transduction, while also enabling targeted T-cell delivery <em>in vivo</em> through a simple post-production mixing step.</p>
<p>While the current G-Link adaptor targets CD3, its modular architecture provides a foundation for future adaptors directed toward additional cell types—without requiring each new targeting strategy to begin with glycoprotein reengineering.</p>
<p class="trimmed"> </p>
<p><img loading="lazy" decoding="async" class="wp-image-337555 alignleft" src="https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad_Biological_QR-Code.jpg" alt="Vyriad sponsored content QR code " width="114" height="115" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad_Biological_QR-Code.jpg 280w, https://www.genengnews.com/wp-content/uploads/2026/09/Vyriad_Biological_QR-Code-150x150.jpg 150w" sizes="auto, (max-width: 114px) 100vw, 114px">Interested in testing G-Link in your research?</p>
<p>G-Link is available for research use only. Vyriad is currently offering free evaluations to qualified researchers.</p>
<p>Scan the QR code to explore additional technical data and request an evaluation for your lab.</p>
<p><a href="https://vyriad.com/g-link-proteins/" target="_blank" rel="noopener">www.vyriad.com/g-link-proteins/</a></p>
<p>The post <a href="https://www.genengnews.com/sponsored/targeted-lentiviral-delivery-without-vector-reengineering/">Targeted Lentiviral Delivery Without Vector Reengineering</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI Drug Discovery Hits a New Bottleneck: Experimental Validation</title>
<link>https://edusehat.com/en/ai-drug-discovery-hits-a-new-bottleneck-experimental-validation</link>
<guid>https://edusehat.com/en/ai-drug-discovery-hits-a-new-bottleneck-experimental-validation</guid>
<description><![CDATA[ Sponsored content brought to you by Artificial intelligence is dramatically accelerating early drug discovery. Models can screen chemical space, predict structures, optimize properties, and propose new molecules at speeds that were unimaginable […]
The post AI Drug Discovery Hits a New Bottleneck: Experimental Validation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/ProBio-AIDD-GEN-Article-Image_AH.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 09 Sep 2026 02:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Drug, Discovery, Hits, New, Bottleneck:, Experimental, Validation</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.probiocdmo.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-337572 " src="https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-300x99.jpg" alt="ProBio logo" width="252" height="83" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-300x99.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-1024x339.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-768x254.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-1536x509.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-2048x678.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-1268x420.jpg 1268w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-696x231.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-1392x461.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-1068x354.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/probio-dark-logo_tagline-1920x636.jpg 1920w" sizes="(max-width: 252px) 100vw, 252px"></a></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Artificial intelligence is dramatically accelerating early drug discovery. Models can screen chemical space, predict structures, optimize properties, and propose new molecules at speeds that were unimaginable only a few years ago. But that acceleration is creating another challenge: The capacity to generate candidates is beginning to outstrip the industry’s ability to test them.</p>
<p>“AI can rapidly identify and design hundreds or thousands of promising molecules,” says Derek Chen, PhD, senior director, antibody drug discovery at ProBio. As a result, he says, “the challenge has shifted from generating candidates to identifying which candidates are truly worth advancing.”</p>
<p></p><h4><strong>The bottleneck moves downstream</strong></h4>

<div class="my-8"><span data-render-ad="4"></span></div>
<p>Drug discovery has traditionally been constrained by the difficulty and cost of identifying promising starting points. AI is loosening that constraint, enabling researchers to explore more molecular possibilities and computationally prioritize designs.</p>
<p>Experimental biology, however, cannot necessarily accelerate at the same pace. Every AI-generated candidate must still confront biological reality. Researchers need to establish whether a molecule produces the desired functional response, behaves as expected in relevant biological systems, and possesses properties compatible with further development. As Chen says, each candidate must undergo “functional screening, developability assessment, safety evaluation, and preclinical testing.”</p>
<p>That shifts the bottleneck downstream. Instead of struggling to generate enough interesting molecules, discovery organizations can face more computationally attractive candidates than their laboratories can efficiently validate.</p>
<p>Chen says this shift is increasing the importance of experimental capabilities including “high-throughput affinity screening, functional and mechanism-of-action assays, developability assessment, immunogenicity testing, advanced <em>in vitro</em> models, and translational <em>in vivo</em> studies.”</p>
<p></p><h4><strong>A prediction is not a medicine</strong></h4>

<p>Computational promise and therapeutic potential are not the same. Predicted affinity or potency might move a candidate forward, but successful medicines must satisfy a much broader set of requirements.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“A promising computational prediction is only the starting point,” says Wenwan Fang, PhD, product manager, discovery at ProBio. A candidate must demonstrate the desired biological activity and mechanism of action while also possessing “favorable safety, pharmacokinetic, and developability characteristics.”</p>
<p>A molecule that performs impressively computationally or in an early assay might still prove unstable, difficult to manufacture at scale, or unsuitable because of immunogenicity or other development risks.</p>
<p>“Ultimately, the most valuable candidates are those that combine strong biological performance with the practical attributes required for successful development and commercialization,” Fang says.</p>
<p>For Chen, that makes prioritization increasingly important. “Success depends not on creating more molecules, but on validating and prioritizing the right ones quickly and efficiently,” he says.</p>
<p></p><h4><strong>Building validation at AI speed</strong></h4>

<p>Keeping pace with AI will likely require more than simply adding laboratory capacity. Companies might need to rethink how validation is integrated into discovery.</p>
<p>“As AI dramatically increases the number of potential drug candidates generated, organizations will need to invest in technologies that accelerate validation rather than discovery alone,” Fang says.</p>
<p>Those investments could include laboratory automation, robotic liquid handling, high-throughput screening platforms, advanced cell-based and functional assays, and integrated data-management systems. Fang also expects growing demand for technologies that assess developability, safety, and manufacturability earlier, alongside more predictive <em>in vitro</em> and <em>in vivo</em> models.</p>
<p>The objective is a tighter feedback loop: AI proposes candidates, experiments test them, and experimental data inform subsequent designs.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>Finding molecules that matter</strong></h4>
<p>Although better AI models will remain important, Chen sees integration as the larger opportunity. “The greatest competitive advantage is likely to come from tighter integration between computational prediction and experimental validation,” he says. Organizations that create “seamless feedback loops between AI-driven design and high-quality experimental data” will be best positioned to accelerate discovery, reduce development risk, and improve the likelihood of clinical success.</p>
<p>For Fang, the most valuable investments are similarly those that help researchers “rapidly identify which AI-generated candidates are truly worth advancing into development.”</p>
<p class="trimmed"> </p>
<p><em><img decoding="async" class="alignleft wp-image-337577" src="https://www.genengnews.com/wp-content/uploads/2026/09/ProBio_QRCode-295x300.jpg" alt="ProBio September 2026 sponsored content QR code" width="121" height="123" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/ProBio_QRCode-295x300.jpg 295w, https://www.genengnews.com/wp-content/uploads/2026/09/ProBio_QRCode-356x364.jpg 356w, https://www.genengnews.com/wp-content/uploads/2026/09/ProBio_QRCode.jpg 399w" sizes="(max-width: 121px) 100vw, 121px"></em></p>
<p class="trimmed"> </p>
<p><em>Explore More <a href="https://www.probiocdmo.com/solutions/aidd-solutions" target="_blank" rel="noopener">www.probiocdmo.com/add-aidd-solution.html</a></em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/ai-drug-discovery-hits-a-new-bottleneck-experimental-validation/">AI Drug Discovery Hits a New Bottleneck: Experimental Validation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>This geneticist’s age&#45;reversal tech could help restore sight</title>
<link>https://edusehat.com/en/this-geneticists-age-reversal-tech-could-help-restore-sight</link>
<guid>https://edusehat.com/en/this-geneticists-age-reversal-tech-could-help-restore-sight</guid>
<description><![CDATA[ Yuancheng (Ryan) Lu is obsessed with aging. And with eyes. As he steps outside the Whitehead Institute in Cambridge, Massachusetts, his aviator glasses darken automatically in the sun. Age-related blindness runs in his family. A great-aunt in China, the story goes, was killed crossing a road because she couldn’t see oncoming traffic. And Lu’s own… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/733-MITtech-Ryan-RTF-0318.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 23:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>This, geneticist’s, age-reversal, tech, could, help, restore, sight</media:keywords>
<content:encoded><![CDATA[<p>Yuancheng (Ryan) Lu is obsessed with aging. And with eyes. As he steps outside the Whitehead Institute in Cambridge, Massachusetts, his aviator glasses darken automatically in the sun. Age-related blindness runs in his family. A great-aunt in China, the story goes, was killed crossing a road because she couldn’t see oncoming traffic. And Lu’s own 23andMe test came back with a mutation for macular degeneration, a top cause of vision loss in old age. Exposure to bright sunlight is another risk factor—thus the shades. “They protect me,” he says. “Plus, they look cool.”</p>



<p>Lu, 34, works on gene therapies to prevent age-related vision loss. “I think the eye is a really unique system to study aging and rejuvenation,” he says. “I could give a whole presentation.” Pushing up my reading glasses, I lean in to listen.</p>



<p>Lu is behind one of the coolest results in rejuvenation science—and in eye research. In 2018, while earning his PhD at Harvard Medical School, he used an age-reversal technique called reprogramming to repair the optic nerves of mice. He crushed the nerves, blinding the animals, and then injected the cells with a gene therapy meant to restore them to a youthful state. Sixteen days later, the nerves were growing back, their axons showing up through a microscope as spidery orange filaments.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><strong>As hype around age reversal swirls, Lu has been busy in the lab searching for what he calls “the next generation of rejuvenation therapies.”</strong></p>
</blockquote>



<p>The head of that lab, the longevity scientist David Sinclair, remembers when Lu texted him the pictures: “He asked me, ‘What do you see here?’ And I said, ‘I see the future.’” Later tests carried out in a box with rotating bars of light showed the mice were tracking the changes. They could see again.</p>



<p>This year, nearly the exact genetic therapy Lu created for mice entered human clinical trials. On June 9, the startup Life Biosciences, which Sinclair cofounded and in which Lu owns a small stake, announced it had injected the treatment into the eye of a person with glaucoma. The trial has been big news. A headline in the <em>New York Times</em> suggested the technology could “change humanity.” Posters on X gushed, with one declaring that “the fountain of youth is here.”</p>



<p>“It’s remarkable that what he developed as a student is now going into humans,” says Sinclair of the treatment, now called ER-100. “It’s barely even changed since he built it.”</p>



<p>Reprogramming refers to an age-­restoring process that takes place inside an embryo. It’s why babies are born young, not old: The DNA they’ve inherited from their parents has been scrubbed and reset. In 2006, Japanese researchers showed they could cause the process to occur in the lab by introducing just four key genes, known by the acronym OSKM. Add these to a cell from a 100-year-old and it will turn into a stem cell that acts as if it was plucked from an embryo.</p>





<p>That’s powerful stuff. But we don’t want to turn people into blobs of stem-cell protoplasm. Lu figured out a way to control the effect. He trimmed the list of genes to just OSK—leaving out M, for <em>Myc</em>, the one most likely to cause dangerous changes like cancer. His extra flash of insight was that reprogramming could be tested on the optic nerve; the eye is particularly accessible.</p>



<p>Lu’s result, published in <em>Nature</em> in 2020, helped set off an investment rush. Since then, US tech billionaires have placed huge bets on private companies like Altos Labs and NewLimit to explore reprogramming and anti-aging medicine. The day I spoke with Lu, he’d spent the morning meeting with the business magnate Zhong Shanshan, one of China’s richest people.  </p>



<p>Still, as hype around age reversal swirls, Lu has been notably absent from the public conversation. He’s been busy in the lab searching for what he calls “the next generation of rejuvenation therapies.” With a sigh, Lu describes the grueling effort over the last six years to understand what OSK really does. The treatment remains toxic to many cell types, and he says it’s becoming obvious that different factors drive aging in each kind. This year, for example, he identified a gene responsible for protecting the retina from damage by free radicals—the main cause of age-­related macular degeneration.</p>



<p>While Sinclair, his former boss, believes humans could live to be 200, Lu disagrees. There’s just too much that goes wrong as we age. His work with OSK, he says, was more a proof of concept than a silver bullet. But it did change the conversation. “Six years ago, you couldn’t talk about rejuvenation. We didn’t use that word—there was pushback,” Lu tells me. “But I think people have accepted the concept that you can really reverse molecular age.” </p>]]> </content:encoded>
</item>

<item>
<title>Clean Cells Broadens Viral Safety Testing Portfolio with NGS</title>
<link>https://edusehat.com/en/clean-cells-broadens-viral-safety-testing-portfolio-with-ngs</link>
<guid>https://edusehat.com/en/clean-cells-broadens-viral-safety-testing-portfolio-with-ngs</guid>
<description><![CDATA[ The expanded next-generation sequencing offering from Clean Cells now covers GMP-compliant viral safety testing for viral vectors and recombinant preparations, building on existing identity testing capabilities.
The post Clean Cells Broadens Viral Safety Testing Portfolio with NGS appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Clean-Cells-NGS-viral-safey-copyrights-Clean-Cells.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 23:15:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Clean, Cells, Broadens, Viral, Safety, Testing, Portfolio, with, NGS</media:keywords>
<content:encoded><![CDATA[<p>France-based Clean Cells launched its next-generation sequencing (NGS)-based safety testing for viral matrices, such as viral vectors and recombinant preparations. The company also announced that it had acquired French bioinformatics CRO Xegen, which specializes in NGS data analysis.</p>
<p>The acquisition is to help consolidate, develop, and secure Clean Cells’ bioinformatics capabilities to support every NGS method and de-risk the most technically complex part of the workflow, according to Clean Cells CEO Laurent Claisse, who added that a secured bioinformatics backbone, the most critical part of NGS, means reliable, auditable data handling.</p>
<p>Xegen co-founder and CEO, Julien Paganini, PhD, will join Clean Cells as expert project manager of bioinformatics, analytical methods development, and validation, along with his team of two staff.</p>
<p>“With the launch of our NGS viral safety testing and the acquisition of Xegen’s Next-Generation Sequencing bioinformatics expertise, we provide a strong and secure analytical pipeline, with greater control of the full workflow from sample to interpreted result. We can provide our international clients with a more integrated NGS offering to support key questions from identity to viral safety,” said Claisse.</p>
<p>“Sequencing is the technology but turning it into a quality control solution involves much more than simply generating reads. It requires a robust analytical strategy to transform complex data into interpretable, traceable and regulatory-ready results. By joining Clean Cells, we can combine our established bioinformatics structure and deep expertise with its laboratory and regulatory capabilities to build a fully integrated solution and make NGS a powerful and practical tool for quality control in regulated environments,” added Paganini.</p>
<p>A Clean Cells official pointed out that this new offering comes at a critical time, as European regulatory frameworks are making NGS increasingly relevant in checking that biologic medicines are not contaminated with unwanted viruses. Clean Cells’ strategic move strengthens its position in the viral safety testing market in step with European regulations, notably <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fus.list-manage.com%2FMBzDoX5pTNi%3Fe%3D0db00a1eaa%26c2id%3D4481ac2df778746c2179483e99a93556&data=05%7C02%7Cjohn.sterling%40sagepub.com%7C4314bd974d0a4408c4d908df0d76dbd3%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639244476367495275%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=mRp1W5IK%2FEm1LXS9Gr%2FQOgHFPxTXNFq1L42K1CaGiSo%3D&reserved=0" target="_blank" rel="noopener">ICH Q5A(R2) (2024)</a> and <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fus.list-manage.com%2F10ye2oipG0X%3Fe%3D0db00a1eaa%26c2id%3D4481ac2df778746c2179483e99a93556&data=05%7C02%7Cjohn.sterling%40sagepub.com%7C4314bd974d0a4408c4d908df0d76dbd3%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639244476367506324%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=gdTfNFA56336pdmRTV%2BYKxoJHgVXu%2FpgU8y0tr7SffE%3D&reserved=0" target="_blank" rel="noopener">European Pharmacopoeia chapter 2.6.41</a>, which are accelerating NGS adoption from a niche technology to a mainstream viral safety testing tool, explained Elodie Ribert, R&D deputy director, head of analytical development and validation.</p>
<p>“The regulatory ground has shifted. With ICH Q5A(R2) and European Pharmacopoeia chapter 2.6.41, NGS is now a recognized route for adventitious virus detection. It answers a real problem for viral matrices, where classical assays struggle because no anti-serum exists,” said Ribert. “The sequencing alone is not the whole story. A signal still must be investigated and confirmed, and that is where having the full quality control panel alongside it makes a difference.”</p>
<p>Going forward, Clean Cells states that it will extend the validated NGS viral safety method from acellular viral matrices to cell banks (MCB/WCB), a process currently in progress. It will also build additional viral safety expert capacity and business development enablement.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/clean-cells-broadens-viral-safety-testing-portfolio-with-ngs/">Clean Cells Broadens Viral Safety Testing Portfolio with NGS</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Measuring Cell Line Development Quality Within Days of Single&#45;Cell Cloning, Not Months Later</title>
<link>https://edusehat.com/en/measuring-cell-line-development-quality-within-days-of-single-cell-cloning-not-months-later</link>
<guid>https://edusehat.com/en/measuring-cell-line-development-quality-within-days-of-single-cell-cloning-not-months-later</guid>
<description><![CDATA[ For nearly a decade, the Beacon platform has advanced from integrated single-cell cloning to earlier productivity, product-quality, and stability measurements, with AI-assisted clone evaluation pointing toward the next step. Bringing richer evidence forward helps teams focus resources on the candidates most likely to succeed.
The post Measuring Cell Line Development Quality Within Days of Single-Cell Cloning, Not Months Later appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/bruker-cld-kit-hero-1200x900-1-e1788878484845.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 23:15:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Measuring, Cell, Line, Development, Quality, Within, Days, Single-Cell, Cloning, Not, Months, Later</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://brukercellularanalysis.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-157010 " src="https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-300x160.jpg" alt="Bruker logo" width="242" height="129" srcset="https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-300x160.jpg 300w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-1024x546.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-768x410.jpg 768w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-1536x819.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-2048x1092.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-696x371.jpg 696w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-1392x742.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-1068x570.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-787x420.jpg 787w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-1575x840.jpg 1575w, https://www.genengnews.com/wp-content/uploads/2021/01/Bruker_logo-1920x1024.jpg 1920w" sizes="(max-width: 242px) 100vw, 242px"></a></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Every cell line development (CLD) campaign turns on one decision: which clone will manufacture the therapy? When monoclonal antibodies (mAbs) dominated the pipeline, clone selection often centered on titer, the amount of product produced. Bispecific antibodies, antibody-drug conjugates (ADCs), and other complex formats have changed that calculation. Titer remains important, but so does whether a clone consistently makes the intended molecule. That distinction must become visible early enough to avoid advancing weak candidates.</p>
<p><figure aria-describedby="caption-attachment-337506" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-337506" src="https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-1024x406.jpg" alt="Antibody-based clinical trials graph" width="500" height="198" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-1024x406.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-300x119.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-768x304.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-1536x608.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-2048x811.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-1061x420.jpg 1061w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-696x276.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-1392x551.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-1068x423.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker-Figure-1-graphs-1920x760.jpg 1920w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Figure 1. Antibody-based clinical trials by modality (ClinicalTrials.gov and Thera-SAbDab, Feb. 2026). mAbs have declined from roughly 95% to about two-thirds of the pipeline as programs for bispecifics and ADCs have grown. [Bruker Spatial Biology]</figcaption></figure>That shift from mAbs to multispecific modalities is visible in antibody clinical trials. In Bruker’s analysis of ClinicalTrials.gov and Thera-SAbDab, conventional mAbs fell from roughly 95% of trials first posted in 2005 to about two-thirds in 2025 (<em>Fig. 1</em>). The balance increasingly includes bispecifics, ADCs, and other complex formats. Most are produced in Chinese hamster ovary (CHO) cells and can present challenges such as lower titer, incorrect chain pairing, aggregation, or reduced stability. But a BioPhorum survey found that campaign timelines varied most during clone expansion and screening, and that most responding teams did not assess product quality during single-cell cloning.<sup>1</sup></p>
<p>Traditional single-cell cloning methods, including limiting dilution, fluorescence-activated cell sorting (FACS), single-cell printers, and clone pickers, differ in mechanics but generally follow the same selection logic. They establish clonality, sometimes measure titer, then expand and advance clones before detailed product-quality and stability assays months later. This creates a blind spot: clones can progress before aggregation or incorrect chain pairing becomes visible. The Beacon<sup class="wp-sup-text">®</sup> optofluidics platform, used by 38% of survey respondents and reported as the most widely used instrument, was built to close that gap.<sup>1</sup> It cultures and assays live single cells in nanoliter-scale NanoPen<sup class="wp-sup-text">®</sup> chambers, returning growth, specific productivity, and selected product-quality readouts within days, with early stability indicators following within weeks.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<figure aria-describedby="caption-attachment-337507" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-337507" src="https://www.genengnews.com/wp-content/uploads/2026/09/bruker-cld-kit-hero-1200x900-1-e1788878484845-300x187.jpg" alt="cld kit" width="300" height="187" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/bruker-cld-kit-hero-1200x900-1-e1788878484845-300x187.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/bruker-cld-kit-hero-1200x900-1-e1788878484845.jpg 485w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Credit: Bruker</figcaption></figure>
<p>Published studies demonstrate the potential. Amgen reported that early chip-based cloning from bulk pools reduced its CLD timeline by up to eight weeks.<sup>2</sup> A Merck KGaA team using Selective Cell Cloning on freshly transfected samples reported roughly two additional weeks of savings and higher clone specific productivity.<sup>3</sup> In the clearest product-quality example, GSK screened a bispecific during single-cell cloning with two on-chip SpotLight<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> assays. Clones with balanced assay signals averaged 87% heterodimer, while imbalanced signals were associated with lower heterodimer levels.<sup>4</sup> This provided an earlier basis for prioritizing candidates before fed-batch testing. GSK’s head of cell line development separately credited improved biology, the Beacon platform, and the team’s ranking tools with reducing cell lines screened per molecule by more than 98%.<sup>5</sup></p>
<p>For nearly a decade, the Beacon platform has advanced from integrated single-cell cloning to earlier productivity, product-quality, and stability measurements, with AI-assisted clone evaluation pointing toward the next step. Bringing richer evidence forward helps teams focus resources on the candidates most likely to succeed, carry fewer weak clones into later studies, and move toward the clinic with greater confidence. That is the promise of moving beyond titer.</p>
<p class="trimmed"> </p>
<p><em>References</em></p>
<p>1. Clarke H, et al. Biotechnol Prog. 2024:e3449. doi:10.1002/btpr.3449.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>2. Diep J, et al. Biotechnol Prog. 2021;37:e3192. doi:10.1002/btpr.3192.</p>
<p>3. Desmurget C, et al. Biotechnol J. 2024;19:e2300488. doi:10.1002/biot.202300488.</p>
<p>4. Robinson M, et al. Biotechnol Prog. 2026:e88539. doi:10.1002/btpr.88539.</p>
<p>5. Corrigall H. <a href="http://go.brukercellularanalysis.com/light-boxes-and-beyond-maximizing-confidence-in-clone-selection-using-the-beacon-optofluidic-system.html" target="_blank" rel="noopener">Bruker Cellular Analysis webinar</a>, 2025.</p>
<p class="trimmed"> </p>
<p><em>Eric Sackmann, PhD, is a director of product management at Bruker Cellular Analysis.</em></p>
<p class="trimmed"> </p>
<p><em>Bruker September 2026 sponsored content QR Code<img loading="lazy" decoding="async" class="alignleft  wp-image-337514" src="https://www.genengnews.com/wp-content/uploads/2026/09/Bruker_QRCode-296x300.jpg" alt="Bruker Sep.2026 sponsored content QR Code" width="106" height="107" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Bruker_QRCode-296x300.jpg 296w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker_QRCode-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker_QRCode-415x420.jpg 415w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker_QRCode-356x364.jpg 356w, https://www.genengnews.com/wp-content/uploads/2026/09/Bruker_QRCode.jpg 558w" sizes="auto, (max-width: 106px) 100vw, 106px">Explore More <a href="https://brukercellularanalysis.com/applications/cell-line-development/" target="_blank" rel="noopener">brukercellularanalysis.com/applications/cell-line-development</a>.</em></p>
<p>The post <a href="https://www.genengnews.com/sponsored/measuring-cell-line-development-quality-within-days-of-single-cell-cloning-not-months-later/">Measuring Cell Line Development Quality Within Days of Single-Cell Cloning, Not Months Later</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems</title>
<link>https://edusehat.com/en/with-116m-in-series-a-financing-brainchild-bio-targets-cns-tumors-starting-with-one-in-childrens-brainstems</link>
<guid>https://edusehat.com/en/with-116m-in-series-a-financing-brainchild-bio-targets-cns-tumors-starting-with-one-in-childrens-brainstems</guid>
<description><![CDATA[ BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG) by targeting B7-H3, an immune checkpoint protein encoded by the CD276 gene that has been shown to be involved in tumor progression and immune evasion and is highly expressed in anywhere from 60% of solid tumor samples up to 93%, according to past studies cited by BrainChild Bio. 
The post With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-lab-photo-for-GEN-JPEG-RESIZE3512-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>With, 116M, Series, Financing, BrainChild, Bio, Targets, CNS, Tumors, Starting, with, One, Children’s, Brainstems</media:keywords>
<content:encoded><![CDATA[<p>BrainChild Bio has raised a $116 million Series A financing, the proceeds of which will, in part, fund the pivotal registrational trial to assess its lead candidate, an autologous chimeric antigen receptor (CAR) T cell therapy being developed to treat a rare and aggressive pediatric brainstem tumor whose current standard of care <a href="https://dipg.org/treatment/emerging-treatments/">consists of radiation</a>.</p>
<p>BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG) by targeting B7-H3, an immune checkpoint protein encoded by the CD276 gene that has been shown to be involved in tumor progression and immune evasion and is highly expressed in anywhere <a href="https://aacrjournals.org/clincancerres/article/27/5/1227/83893/B7-H3-An-Attractive-Target-for-Antibody-based">from 60%</a> of solid tumor samples <a href="https://aacrjournals.org/clincancerres/article/22/14/3425/79210/Molecular-Pathways-Targeting-B7-H3-CD276-for-Human">up to 93%</a>, according to past studies cited by BrainChild Bio.</p>
<p>BrainChild Bio has dosed the first patient in its pivotal registrational Phase II ILLUMINATE trial (<a href="https://clinicaltrials.gov/study/NCT07680439">NCT07680439</a>), an open-label, single-arm study designed to evaluate the efficacy and confirm the safety of BCB-276 in children and young adults with newly diagnosed DIPG following initial standard-of-care focal radiation therapy. The trial is intended to accelerate BrainChild’s path to a future biologics license application (BLA) filing for BCB-276, which has received the FDA’s Fast Track designation.</p>
<p>The primary endpoint for the trial is overall survival, which “should be prioritized as the primary endpoint when feasible,” the FDA advised last year in its draft guidance for cancer drug developers, “<a href="https://www.fda.gov/media/188274/download">Approaches to Assessment of Overall Survival in Oncology Clinical Trials</a>. Secondary endpoints include safety and tolerability; radiographic response to BCB-276; presence of BCB-276 in cerebrospinal fluid (CSF); and progression-free survival (PFS).</p>
<p>Patients in the ILLUMINATE trial will receive BCB-276 approximately every two weeks for a planned course of up to a total of 15 doses over approximately 7–8 months. BrainChild Bio has aligned ILLUMINATE’s trial details with the FDA, which agreed with researchers against a control arm of young patients receiving palliative radiation, hence the single-arm design.</p>
<p>BrainChild Bio says it has optimized BCB-276 for late-stage clinical development, establishing the manufacturing, quality, and regulatory operations needed to support a registration program. The pivotal study will be conducted at six top-tier pediatric neuro-oncology centers where site activation is either complete or underway across the United States.</p>
<figure aria-describedby="caption-attachment-337474" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337474" src="https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-300x300.jpg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-2048x2048.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-840x840.jpg 840w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-696x696.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-1392x1392.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-1068x1068.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-CEO-Steven-Brugger-CROPSQUARE-RESIZE2242-1920x1920.jpg 1920w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">BrainChild Bio CEO Steven Brugger</figcaption></figure>
<p>“The patients that we’re going to enroll now in the pivotal trial are going to be frontline as soon as possible after radiation,” BrainChild Bio CEO Steven Brugger told <em>GEN</em>.</p>
<p></p><h4><strong>Limited options</strong></h4>

<p>Beyond radiation, treatment options for DIPG are especially limited: DIPG is among aggressive brain tumors that comprise diffuse midline glioma (DMG), which saw the first FDA-approved therapy reach the market last year, when the agency authorized Jazz Pharmaceuticals’ Modeyso (dordaviprone) for DMG harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso has generated net product sales of $89.6 million in the first half of this year and $48 million in all of 2025, with more than 600 patients having received the drug since its launch in August 2025 through Q2 2026.</p>
<p>A <em>GEN</em> spot check of ClinicalTrials.gov showed 36 clinical studies now recruiting patients to assess drug candidates for indications that include DIPG: 20 for candidates in Phase I, 15 in Phase II, and just one in Phase III, Jazz Pharma’s BIOMEDE 2 (<a href="https://clinicaltrials.gov/study/NCT05476939">NCT05476939</a>), a DIPG-focused study intended to compare dordaviprone to everolimus, the cancer drug marketed by Novartis as Afinitor®, with a primary outcome measure of PFS.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Data released last year from the Phase I BrainChild-03 trial (<a href="https://clinicaltrials.gov/ct2/show/NCT04185038">NCT04185038</a>) showed BCB-276 treatment extended the median time from diagnosis to death for all 21 patients treated to 19.8 months—about double both the 10.7-month median survival time from initial CAR T cell infusion and the 8–11-month median time of survival from diagnosis associated with current standard-of-care, palliative focal radiation therapy.</p>
<figure aria-describedby="caption-attachment-337475" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-337475" src="https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-300x300.jpeg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-300x300.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-1024x1024.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-150x150.jpeg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-768x768.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-420x420.jpeg 420w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-840x840.jpeg 840w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-696x696.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111-1068x1068.jpeg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/BrainChild-Bio-Founder-and-CSO-Michael-Jensen-MD-CROPSQUARE111.jpeg 1186w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Michael Jensen, MD, BrainChild Bio’s founder and CSO</figcaption></figure>
<p>“In the 50 years of clinical trials for DIPG, no drug had ever changed the 11-month overall survival mark before, so it was a clear safety signal,” said Michael Jensen, MD, BrainChild Bio’s founder and CSO.</p>
<p>Three patients, all beginning CAR T treatment prior to disease progression, were reported as alive at 44.6 months, 45.6 months, and 52.5 months from diagnosis.</p>
<p>“The thing to keep in mind with the Phase I trial was that we had patients who were started early, close after their radiation, as well as some that were started later, and there was a subset of nine patients that are described in that paper that were started with treatment pretty quickly after their radiation [the nine began treatment before any progression]. And of those nine patients, three of them ended up being long-term survivors, post-diagnosis. That’s what led us to say, let’s engage with the FDA,” Brugger recalled.</p>
<p>BrainChild-03 was BrainChild Bio’s third Phase I trial; the other two excluded DIPG patients as they focused on delivering intracranial human epidermal growth factor receptor 2 [HER2]-specific CAR T cells (BrainChild-01, <a href="https://clinicaltrials.gov/ct2/show/NCT03500991">NCT03500991</a>) and on delivering EGFR806, or epidermal growth factor receptor (EGFR) CAR T cells based on the mAb806 monoclonal antibody (BrainChild-02, <a href="https://clinicaltrials.gov/ct2/show/NCT03638167">NCT03638167</a>).</p>
<p>“We have had several very positive discussions with the FDA around now taking this forward into a single pivotal trial,” Brugger said.</p>
<p></p><h4><strong>Non-traditional investors</strong></h4>

<p>The FDA wasn’t the only one impressed with the Phase I data, Brugger added: “Institutional investors were very impressed with the clinical data in DIPG. They really loved the unique approach that we’re taking here.”</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>But those investors didn’t love the data enough to join BrainChild Bio’s Series A financing. It was a matter, he explained, of numbers: <a href="https://www.cancer.gov/types/brain/patient/diffuse-intrinsic-pontine-glioma">About 300 children</a> in the United States get diagnosed with DIPG each year, according to the National Cancer Institute. “It just didn’t fit with their investment strategy model.”</p>
<p>That explains why the Series A financing attracted several non-traditional investors rather than the customary group of traditional venture investors.</p>
<p>The $116 million round was led by an undisclosed private family fund and foundation supportive of BrainChild Bio’s mission. The financing also saw participation from WRF Capital, the investment vehicle for Washington Research Foundation, a nonprofit funder of academic research, tech licensing, and early-stage startup companies in Washington state, and from Seattle Children’s, which was the company’s first investor when it <a href="https://www.insideprecisionmedicine.com/topics/oncology/seattle-childrens-car-t-spinout-brainchild-bio-launches-with-a-focus-on-pediatric-cns-cancers/">launched in December 2023</a>.</p>
<p>The dearth of traditional venture funders for BrainChild Bio also indicates why the company explains its tumor-fighting focus as “kids-first, but not kids only.”</p>
<p>BrainChild Bio’s second pipeline candidate, BCB-214, is set to enter the clinic next year as a potential treatment for glioblastoma, one of the deadliest adult brain tumors, though it is also being developed for pediatric brain tumors such as DMG. BCB-214 is a next-generation CAR T cell therapy that fights tumors by targeting B7-H3 and two other target antigens—EGFR and interleukin-13 receptor subunit alpha-2 (IL13Ralpha2).</p>
<p>“It’s the story of tumor heterogeneity,” Jensen explained. “Even clades of cells that develop in glioblastoma form subpopulations of cells that can have some heterogeneity. So that’s the overall logic for multiplex targeting. The other feature that we think about a lot with multiplex targeting is, can we define combinations of targets that, if the tumor were to down-regulate all of them, would that result in basically a synthetic lethal outcome for the tumor?</p>
<p>“We did CRISPR studies of these three molecules in glioblastoma cell lines, and what we found is that cells can continue to survive <em>in vitro</em> and engraft <em>in vivo</em> if you knock out one or two antigens, but we could not get cells to tolerate all three antigens being knocked out,” Jensen added.</p>
<p></p><h4><strong>“Laser-focused”</strong></h4>

<p>While BrainChild Bio envisions a larger pipeline over time and is carrying out research to that effect, Brugger said the company was “laser-focused” on developing BCB-276 and -214: “We’re going to stay very focused on these two programs and deliver.”</p>
<p>BrainChild Bio’s path to its $116 million Series A financing began in 2010 when Jensen, a pioneer in CAR T cell cancer immunotherapy, was recruited by Seattle Children’s, which agreed to set up a GMP facility for manufacturing CAR T cells for the academic trials his lab wanted to run.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Jensen’s lab designed the CD19 CAR T candidate for pediatric leukemia that eventually won approval as Breyanzi® (lisocabtagene maraleucel). Breyanzi was developed by Juno Therapeutics, whose co-founders included Jensen, and was <a href="https://www.genengnews.com/news/celgene-to-acquire-juno-for-9b-expanding-car-t-tcr-presence/">acquired in 2018 for $9 billion by Celgene</a>, which a year later was <a href="https://www.genengnews.com/topics/drug-discovery/bristol-myers-squibb-to-acquire-celgene-for-74b/">bought out by Bristol Myers Squibb for $74 billion</a>. The production facility, which has grown into the FACT-accredited and GMP-compliant Therapeutics Cell Production Core (TCPC), has manufactured more than 1,000 products for Phase I and Phase II clinical trials, with over 600 patients from every continent except Antarctica.</p>
<p>“From there, we were very interested in focusing on solid tumors. And in children, the second most common cancer are brain tumors, and brain tumors are now the leading cause of pediatric mortality,” Jensen recalled. “At that juncture, my team and I were thinking about strategy development for how to target tumors of the central nervous system. We felt that taking the generic approach of giving a kid cytoxin and fludarabine and giving them a single dose of IV CAR T cells may not be the best strategy for targeting a tumor that’s solely localized in the central nervous system.”</p>
<p></p><h4><strong>Dosing challenge</strong></h4>

<p>Jensen and colleagues addressed the challenge of dosing directly into the central nervous system—more specifically into the lateral ventricle—by using an Ommaya shunt, an indwelling reservoir-catheter device, and instituting repetitive dosing, reasoning that the lymphoid architecture and biology in the brain are quite different from those outside of the brain.</p>
<p>“We found that CAR T cells that are infused directly into the brain, into the CSF, have much more of a drug-like PK [pharmacokinetics], if you will. You get your peak of cells shortly after infusion. They don’t have this massive proliferation you see in a lymphoma or leukemia patient. We were able to study that and then create dosing regimens in which, basically, we replenished bioactive cells by giving additional doses every two weeks, creating a sustained area under the curve of tumor exposure,” added Jensen, who is also founding chief therapeutics officer and leader of Seattle Children’s Therapeutics, a nonprofit therapeutics-development enterprise formed by Seattle Children’s.</p>
<p>Since 2012, Seattle Children’s Therapeutics has designed, manufactured, and launched a robust portfolio of immunotherapy clinical trials for leukemia and lymphoma, brain tumors, and solid tumors, enrolling more than 500 patients.</p>
<p>Brugger first met Jensen in 2023 after his previous company, Affinivax, a vaccine developer which he headed as CEO, was <a href="https://www.genengnews.com/topics/drug-discovery/gsk-to-acquire-affinivax-for-up-to-3-3b-bolstering-vaccine-portfolio/">acquired by GlaxoSmithKline (GSK) for up-to-$3.3 billion</a> a year earlier. One of Affinivax’s lead bankers in that deal introduced Brugger to Jensen, and the two grew into colleagues, then friends, focused on spinning out BrainChild Bio from Seattle Children’s, initially with the institution as sole investor. Since then, BrainChild Bio has grown its headcount to about 50 people.</p>
<p></p><h4><strong>“Major growth year”</strong></h4>

<p>“This is a major growth year for us,” Brugger added. “We’ll probably plateau off in 2027–2028, but we’ll be in a good position by the end of this year to execute on the Phase II trial through completion, the BLA submission, and then also get the Phase I trial off the ground for BCB-214 next year.”</p>
<p>How does the company plan to grow beyond then? As a stand-alone drug developer? Or by finding a buyer seeking to expand its cancer pipeline?</p>
<p>“I learned back in my days at Affinivax that you explore all options,” Brugger said. “We’ve got a great syndicate; I think that will stay with us. I think that going back for a Series B is a logical path to take. As for partnering opportunities, I think we want this company to move forward, so I think we’ll explore all different avenues that make sense for us.”</p>
<p>What is BrainChild Bio looking for in a partnership?</p>
<p>“It’s very personal for all of us here,” Brugger replied. “We care about kids with DIPG. We care about kids with other pediatric tumors. We care about glioblastoma. So, what we don’t want to do is do some kind of partnership in the future that would not have us be consistent with that mission.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/with-116m-in-series-a-financing-brainchild-bio-targets-cns-tumors-starting-with-one-in-childrens-brainstems/">With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease</title>
<link>https://edusehat.com/en/moonwalk-to-use-70-million-to-develop-rnai-therapies-for-obesity-cardiometabolic-disease</link>
<guid>https://edusehat.com/en/moonwalk-to-use-70-million-to-develop-rnai-therapies-for-obesity-cardiometabolic-disease</guid>
<description><![CDATA[ New financing will help Moonwalk Biosciences expand its pipeline of siRNA medicines targeting adipose tissue while building out its proprietary drug discovery platform.
The post Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/12/GettyImages-1423889316-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 08 Sep 2026 19:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Moonwalk, Use, 70, Million, Develop, RNAi, Therapies, for, Obesity, Cardiometabolic, Disease</media:keywords>
<content:encoded><![CDATA[<p><span>Biotech company Moonwalk Biosciences announced that it has raised $70 million from an oversubscribed series B financing round. The company plans to use the funds to continue developing its adipose-targeted RNAi therapies for obesity and cardiometabolic conditions. </span></p>
<p><span>The financing round was co-led by Alpha Wave Ventures and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures, and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures. According to Moonwalk, some of the proceeds from the financing round will be used to advance its lead obesity candidate, dubbed MW101, into human clinical trials in late 2027 following completion of IND-enabling studies. The funds will also be used to expand the company’s pipeline of siRNA medicines and build out its proprietary discovery platform. </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>“Obesity places an extraordinary physical and emotional burden on millions of people,” said Alex Aravanis, MD, PhD, CEO & co-founder of Moonwalk Biosciences. “This financing brings us closer to developing a new generation of adipose-targeted medicines designed to improve outcomes for people living with obesity and related cardiometabolic diseases.”</span></p>
<p><span>Moonwalk’s programs focus on delivering siRNA therapeutics directly to adipose tissue to modulate pathways involved in energy homeostasis, adipogenesis, lipolysis and thermogenesis while minimizing effects on other tissues. The company exclusively licensed the adipose-targeting chemistry for its pipeline from Suzhou Siran Biotechnology.</span></p>
<p><span>Across multiple preclinical studies, Moonwalk has demonstrated reductions in body weight and fat mass while preserving lean muscle mass without reducing food intake with its approach. Its scientists have also generated translational evidence demonstrating favorable modulation of metabolic pathways consistent with healthy adipose remodeling. In non-human primate studies, Moonwalk demonstrated durable adipose target engagement following a single dose, supporting the potential for quarterly or twice-yearly dosing.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>“Obesity is one of the most significant global health challenges, and Moonwalk is pursuing a fundamentally different approach to treating it,” said Rick Gerson, co-founder, chairman and CEO of Alpha Wave Global. “What stood out to us about Moonwalk is the depth of the science behind the platform and the strength of the preclinical evidence generated to date,” noted Chris Dimitropoulos, managing director, life sciences Investments of Alpha Wave Global. “By combining adipose-selective RNAi delivery with human genetics, epigenomics and multiomics discovery, the Moonwalk team has devised a highly precise way to modulate adipose biology.”</span></p>
<p><span>In addition to the financing, the company announced that Stephen Djedjos, MD, will take the helm as senior vice president, clinical development at Moonwalk, bringing more than 20 years of clinical and drug development experience. Most recently, he served as SVP and head of clinical development at Kailera Therapeutics, where he led clinical development of the company’s incretin therapies for obesity and metabolic diseases. He has also previously held senior clinical development roles at Mineralys Therapeutics, Sana Biotechnology, Gilead Sciences and Amgen.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/moonwalk-to-use-70-million-to-develop-rnai-therapies-for-obesity-cardiometabolic-disease/">Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy</title>
<link>https://edusehat.com/en/newbiologix-and-synastra-join-forces-to-advance-raav-manufacturing-for-duchenne-gene-therapy</link>
<guid>https://edusehat.com/en/newbiologix-and-synastra-join-forces-to-advance-raav-manufacturing-for-duchenne-gene-therapy</guid>
<description><![CDATA[ The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s proprietary cell engineering and rAAV manufacturing technologies.
The post NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-909836410.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 05 Sep 2026 23:35:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>NewBiologix, and, Synastra, Join, Forces, Advance, rAAV, Manufacturing, for, Duchenne, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<p>Switzerland-headquartered NewBiologix signed an agreement with Synastra Biotechnology to develop a stable producer cell line for Synastra’s investigational Duchenne muscular dystrophy (DMD) gene therapy program. Synastra, based in Turkey, was established through a collaboration between Üsküdar University and Unifon-Biotech GSYF Venture Capital Investment Fund.</p>
<p>NewBiologix will use its Xcell<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> stable manufacturing platform to generate and characterize a research cell bank for Synastra’s DMD gene therapy candidate. The agreement also provides an option to transition the program to a commercial license supporting future clinical and commercial manufacturing.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s proprietary cell engineering and rAAV manufacturing technologies. By addressing manufacturing early in development, the companies aim to establish a genetically defined, reproducible, and scalable production system capable of supporting the program’s progression towards clinical translation and, ultimately, commercial supply.</p>
<p></p><h4><strong>Critical manufacturing challenge</strong></h4>

<p>Duchenne muscular dystrophy is a severe, progressive, X-linked neuromuscular disease affecting approximately one in 5,000 male births. It is caused by mutations in the DMD gene that prevent the production of functional dystrophin, leading to progressive degeneration of skeletal and cardiac muscle.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Manufacturing is particularly critical for DMD and, in fact, all gene therapies. Systemic treatment may require some of the highest vector doses in the field, making rAAV productivity, consistency, scalability and cost decisive factors in the development and broad availability of these therapies.</p>
<p>NewBiologix is developing Xcell to address these constraints at their source by replacing repeated transient transfection with genetically engineered, stable producer cell lines designed for reproducible and scalable rAAV manufacturing, according to Igor Fisch, PhD, CEO and co-founder of NewBiologix.</p>
<p>“Gene therapy will not reach its full potential unless manufacturing evolves with it,” he says. “DMD makes this challenge particularly clear because systemic treatment can require large quantities of rAAV vector. Conventional transient transfection remains complex, costly and difficult to scale consistently.</p>
<p>“With Xcell, we integrate manufacturing into therapy development from the outset, through stable, genetically defined producer cell lines designed to reduce complexity and variability. This agreement with Synastra is an important validation of our strategy and of our ambition to make rAAV manufacturing more scalable, reproducible, and economically sustainable.”</p>
<p>“Synastra was established to translate Türkiye’s capabilities in genomic engineering into internationally competitive gene therapies for patients with rare genetic diseases. Our program is an investigational AAV-based micro-dystrophin candidate for DMD, and we are building its scientific, manufacturing, and translational pathway from the outset,” adds Cihan Tastan, PhD, deputy chairman of the board and general manager of Synastra. “We are connecting construct design and preclinical development with scalable rAAV manufacturing.”</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/newbiologix-and-synastra-join-forces-to-advance-raav-manufacturing-for-duchenne-gene-therapy/">NewBiologix and Synastra Join Forces to Advance rAAV Manufacturing for Duchenne Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>C. difficile Have Lasting Effects on the Infant Gut, Challenging Long&#45;Held Assumption</title>
<link>https://edusehat.com/en/c-difficile-have-lasting-effects-on-the-infant-gut-challenging-long-held-assumption</link>
<guid>https://edusehat.com/en/c-difficile-have-lasting-effects-on-the-infant-gut-challenging-long-held-assumption</guid>
<description><![CDATA[ A new study from CHOP challenges the assumption that infant C. difficile colonization is harmless, finding that it can reshape the developing gut and immune system with potentially lasting health effects.
The post C. difficile Have Lasting Effects on the Infant Gut, Challenging Long-Held Assumption appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2174130539.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 05 Sep 2026 02:05:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>difficile, Have, Lasting, Effects, the, Infant, Gut, Challenging, Long-Held, Assumption</media:keywords>
<content:encoded><![CDATA[<p>Although the highly contagious bacterium <em>Clostridioides difficile</em> (<em>C. diff) </em>causes severe disease in adults, it has been reported to not cause symptoms in infants. Based on that, the assumption has been that infant colonization was not a serious health issue. That said, the consequences of early-life colonization on host development remain unknown. Now, in a new study, researchers at Children’s Hospital of Philadelphia (CHOP) are challenging that long-held assumption, with new findings suggesting that the bacterium can reshape the developing infant gut and may have long-term consequences.</p>
<p>This work was published in <em>Science</em> in the paper, “<a href="https://www.science.org/doi/10.1126/science.ady2886" target="_blank" rel="noopener">Early-life colonization with <em>Clostridioides difficile </em>remodels the developing gut</a>.”</p>
<p><em>C. diff </em>causes symptoms ranging from diarrhea to deadly colonic inflammation caused by the production of toxins. It spreads quickly via spores and commonly infects vulnerable populations, including the elderly, those taking antibiotics, and patients in hospitals or nursing homes. Around half a million patients are infected in the U.S. annually, resulting in approximately 30,000 fatal cases.</p>
<p>However, one population always seemed to be resistant to the damaging effects of the bacterium: infants. An estimated 40–90% of infants in industrialized countries are colonized with <em>C. diff</em> without the bacterium producing obvious symptoms.</p>
<p>“For decades, <em>C. diff</em> colonization in infants has been assumed to be harmless,” notes Joseph Zackular, PhD, researcher in the Department of Pathology and Laboratory Medicine and co-director of the Center for Microbial Medicine at CHOP. “But we asked: does asymptomatic really mean inconsequential? Could a toxin-producing pathogen actually be reshaping the developing gut without causing obvious symptoms?”</p>
<p>Researchers used a combination of preclinical models, human infant intestinal biopsies, and lab grown organoids to study the effects of <em>C. diff </em>colonization early in life.</p>
<p>The study found that the presence of <em>C. diff</em> in an otherwise healthy preclinical neonatal model led to a remodeling of the developing epithelium and a reshaping of the mucosal immune system. More specifically, the authors write that “in a neonatal mouse model, <em>C. difficile</em> colonization drove proinflammatory and tissue repair responses in the intestinal epithelium, enriching injury-associated intestinal stem cell populations and skewing differentiation toward secretory lineages.”</p>
<p>These effects were observed long into adulthood and increased the risk of some viral infections, suggesting that <em>C. diff </em>colonization in infants may have a potential long-term effect on health. The impact of <em>C. diff</em> on the developing epithelial layer was also observed in human infants colonized with <em>C. diff</em>. Epithelial responses were toxin dependent, as “colonization with nontoxigenic strains or maternal vaccination with a <em>C. difficile</em>–targeted messenger RNA–lipid nanoparticle vaccine protected neonates.”</p>
<p>This means that an early life exposure to <em>C. diff</em>, although seemingly benign, could have profound effects on healthy development of the gut.</p>
<p>“The infant gut epithelium is still building itself, so <em>C. diff</em> doesn’t just injure it; it can alter the developmental trajectory of the tissue in ways that may last into adulthood,” said Kathryn Hamilton, PhD, a researcher in the Department of Pediatrics and co-director of the Gastrointestinal Epithelium Modeling (GEM) Program at CHOP.</p>
<p>With these findings challenging long-held assumptions, there is enthusiasm to explore whether this exposure can increase the risk of developing metabolic or autoimmune disorders. The study also points to a clear path forward. Much like maternal vaccines already in clinical use to protect newborns against RSV and pertussis, immunizing mothers with a vaccine targeting <em>C. diff</em> shielded neonates from toxin-mediated effects on the developing gut. This shows that a maternal vaccination strategy could be a precise and feasible intervention to protect infants from <em>C. diff</em> during this critical developmental window.</p>
<p>“Our findings challenge a long-held assumption in pediatric medicine: that <em>C. diff</em> colonization in infants is benign,” Zackular said. “We show that even without overt disease, exposure to this toxin-producing pathogen leaves a lasting biological imprint on the developing gut and immune system, and that a maternal vaccine can protect against it.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/c-difficile-have-lasting-effects-on-the-infant-gut-challenging-long-held-assumption/"><i>C. difficile</i> Have Lasting Effects on the Infant Gut, Challenging Long-Held Assumption</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Micro&#45;Bladder Model Demonstrates How Phage Therapy Could Help to Reduce Recurrent UTIs</title>
<link>https://edusehat.com/en/micro-bladder-model-demonstrates-how-phage-therapy-could-help-to-reduce-recurrent-utis</link>
<guid>https://edusehat.com/en/micro-bladder-model-demonstrates-how-phage-therapy-could-help-to-reduce-recurrent-utis</guid>
<description><![CDATA[ Researchers used a novel human 3D micro-bladder model to demonstrate how phage therapy could help to reduce recurrent urinary tract infections (UTIs) by attacking the reservoirs of bacteria hidden deep within the bladder wall, which antibiotics can’t address.
The post Micro-Bladder Model Demonstrates How Phage Therapy Could Help to Reduce Recurrent UTIs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/12/GettyImages-183409163-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 05 Sep 2026 02:05:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Micro-Bladder, Model, Demonstrates, How, Phage, Therapy, Could, Help, Reduce, Recurrent, UTIs</media:keywords>
<content:encoded><![CDATA[<p>Researchers headed by a team at the Centre for Kidney and Bladder Health, Division of Medicine, University College London, have used a novel human 3D micro-bladder model to demonstrate how phage therapy could help to reduce recurrent urinary tract infections (UTIs), which happen when the bacteria responsible “hide” in the tissue of the bladder.</p>
<p>Focusing on infections caused by uropathogenic <em>Escherichia coli</em> (UPEC) the team found that a cocktail of phages—viruses that infect destroy bacteria—can wipe out bacteria hidden deep within the bladder wall, in what the researchers label “reservoirs,” which normal antibiotics can’t touch. Research lead professor Jennifer Rohn, PhD, UCL Division of Medicine, said, “Recurrent UTIs are incredibly frustrating for patients because the bacteria can survive antibiotics by retreating into protected reservoirs inside the bladder wall. Building a micro-bladder has allowed us to mimic real conditions in the urinary tract and see why antibiotics that look powerful in standard lab tests often fall short.”</p>
<p>Rohn is senior and co-corresponding author of the team’s published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-76589-y" target="_blank" rel="noopener">Effect of human urinary microenvironment and fluid flow on antibiotic and phage therapy efficacy against uropathogenic <em>Escherichia coli</em></a>,” in which they concluded that their findings “… demonstrate that the bladder microenvironment profoundly influences UPEC infection dynamics and therapeutic outcomes, underscoring the need for advanced models to guide treatment strategies in the antibiotic resistance era.”</p>
<p>UTIs are one of the world’s most common infections, with around 400 million cases each year. They can be painful and disruptive, and for many people the infection can return after taking a course of antibiotics. Repeated antibiotic exposure contributes to the rising problem of antimicrobial resistance (AMR). “Urinary tract infection (UTI) remains a major global health burden, with frequent recurrences and rising antimicrobial resistance compromising treatment efficacy,” the authors stated.</p>
<p>Rohn and colleagues sought to understand why this happens by engineering a novel human 3D micro-bladder model that includes flowing urine to mimic the environment found in the human bladder. They used this bladder model to test phage therapy on UTI bacteria.</p>
<p>The team centered their studies on uropathogenic <em>Escherichia coli</em>, a strain of <em>E. coli</em> adapted to infect the urinary tract and the cause of most UTIs. In hospitals, bacteria from a patient’s urine can be tested to see which antibiotics stop them growing, but these tests are usually done in a still, nutrient-rich liquid.</p>
<p><figure aria-describedby="caption-attachment-337424" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-337424" src="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-300x225.jpg" alt="Senior author Professor Jennifer Rohn (UCL Division of Medicine) pipetting in her laboratory. [Jennifer Rohn.]" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One-530x396.jpg 530w, https://www.genengnews.com/wp-content/uploads/2026/09/Low-Res_Image-One.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Senior author Professor Jennifer Rohn (UCL Division of Medicine) pipetting in her laboratory. [Jennifer Rohn]</figcaption></figure>A real bladder behaves differently, with constantly moving urine and bacteria interacting with the bladder lining. Realistic bladder models are hard to run with routine laboratory protocols as they can be highly complex. To solve this, first and co-corresponding author Ramon Garcia Maset, PhD, and colleagues at the University of Oxford developed a device that can work with typical cell cultures to recreate the flow conditions of urinary cycles.</p>
<p>The scientists found that UPEC introduced to the micro-bladder became better at sticking to the bladder surface, and were more likely to invade the bladder lining and set up protected reservoirs of bacteria hidden inside bladder cells where they are harder to reach. The team then tested nitrofurantoin (a commonly used antibiotic for UTIs). In standard lab tests this treatment typically works well, but in the micro-bladder it struggled to fully clear the infection.</p>
<p>The researchers also tested a cocktail of phages, which are viruses that infect and destroy bacteria. On its own, the phage cocktail also found it difficult to clear bacteria in a flowing environment. However, when the scientists combined phages with the antibiotic, the results improved, suggesting that a two-pronged approach could be more effective than either treatment alone.</p>
<p>One significant finding was that unlike the antibiotics, the phage treatment was able to reduce the number of protected bacterial reservoirs inside the bladder wall. Because these reservoirs can act like a breeding ground for future infection, reducing them could be an important step towards preventing UTIs from repeatedly returning. “A bacteriophage cocktail (LCPR1) inhibited intracellular bacterial communities, preserved urothelial viability and induced inflammatory cytokine and chemokine secretion,” the team stated.</p>
<p>First and co-corresponding author Garcia Maset, PhD, said “What’s particularly promising is that phage therapy was able to reach these hidden reservoirs of bacteria, rooting out the cause of the infection. We also discovered that urine flow substantially changes how bacteria behave and respond to treatment, suggesting that many conventional laboratory tests may be missing important aspects of the infection process.”</p>
<p>The study findings also indicated that phages may boost the bladder tissue’s own early defense response. Researchers saw signs of increased immune signaling, including cytokines and chemokines (messenger proteins that help the body coordinate inflammation and bring immune cells to the site of infection).</p>
<p>Co-author Martha Clokie, PhD, director of the Becky Mayer Centre for Phage Research at the University of Leicester, “This study shows why it is so important to test phages under conditions that genuinely reflect the human body. By combining a realistic flowing micro-bladder model with phage and antibiotic treatment, we can begin to understand how best to use phages alongside existing medicines to achieve better outcomes for patients.” The authors added, “Collectively, these experiments revealed the profound influence of microenvironmental context on UPEC infection dynamics and treatment response.”</p>
<p>Phage therapy is not yet a routine treatment for UTIs, and more research will be needed to confirm how well it works, how best to deliver it, and which patients are most likely to benefit. However, this study offers a promising route towards longer-lasting relief for people living with repeat UTIs.</p>
<p>The device design and image-analysis tools used in this study have been made freely available to encourage broader adoption across laboratories, with the hope they could find wider application in research focusing on the impact of flow-mediated mechanostimulation on biological systems.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/micro-bladder-model-demonstrates-how-phage-therapy-could-help-to-reduce-recurrent-utis/">Micro-Bladder Model Demonstrates How Phage Therapy Could Help to Reduce Recurrent UTIs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Medicines Discovery Catapult Backs Two U.K. Biotech Companies Tackling Chronic Diseases</title>
<link>https://edusehat.com/en/medicines-discovery-catapult-backs-two-uk-biotech-companies-tackling-chronic-diseases</link>
<guid>https://edusehat.com/en/medicines-discovery-catapult-backs-two-uk-biotech-companies-tackling-chronic-diseases</guid>
<description><![CDATA[ Medicines Discovery Catapult provided its investment and expert support to help two biotech companies accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.
The post Medicines Discovery Catapult Backs Two U.K. Biotech Companies Tackling Chronic Diseases appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/06/MDC_DSV_Strategic_Partnership-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 05 Sep 2026 02:05:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Medicines, Discovery, Catapult, Backs, Two, U.K., Biotech, Companies, Tackling, Chronic, Diseases</media:keywords>
<content:encoded><![CDATA[<p>Medicines Discovery Catapult (MDC) invested in two U.K. biotechs developing new  approaches to treating diseases such as psoriasis. Parkinson’s Flip Therapeutics and Nascent Therapeutics will each receive £500,000 in funding made available by Innovate UK as part of a scheme that enabled Catapult to invest in high-potential companies.</p>
<p>Alongside the investment, MDC officials said they will provide the companies with translational drug discovery expertise and access to its network of advisors and partners.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><figure aria-describedby="caption-attachment-337377" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337377" src="https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-300x225.jpg" alt="Andrew Reeves, PhD, principal scientist (left), and Dave Pajerowski, co-founder, CEO and head of technology, Flip Therapeutics [Medicines Discovery Catapult]" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-1120x840.jpg 1120w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-1068x801.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P-530x396.jpg 530w, https://www.genengnews.com/wp-content/uploads/2026/09/Andrew-Reeves_Principal-Scientist_Left_and_Dave_P.jpg 1200w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Andrew Reeves, PhD, principal scientist (left), and Dave Pajerowski, co-founder, CEO and head of technology, Flip Therapeutics [Medicines Discovery Catapult]</figcaption></figure>Flip Therapeutics is developing a new method designed to program T cells directly in the body to generate long-lasting, controlled immune function in patients with chronic autoimmune and inflammatory diseases, such as alopecia areata and psoriasis. These diseases represent a significant burden for patients and healthcare systems, affecting an estimated <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Flink.mediaoutreach.meltwater.com%2Fls%2Fclick%3Fupn%3Du001.jZUDAP8gwkxFxm4JQKdVAP0vqwcbTcVUzy7Y2AMZsarSLwxm3awNOlaxGZ-2BgB2lM5GWnHoybiQBGCh0JEOnJAYxMtTdT7Ew-2FkpQTGDDpwq-2Bl6MkhDx3OVKgpvjGHn-2B8j5AsEQImXUuaQ9AqAVIqGXg-3D-3DJIrl_OdKJqyAcUibQJc5MJt6voRURIhi-2FS6V3mKIa6fn0DGx5XC9A4YxTvnK0N-2FO4cRzTEwnwHHEJ20z67REJcgre4jCHasSKPkUGIX-2FvUQq9kwOrUvRF5H-2BJ3XOSLjEniUTFr6EMlm-2BeY6Aau5PJUPXryfdFijeY7TVOAE25MiFOK-2F7JEqH2FyIhVLUQ061oqQcaY76T4n8-2FkuSqRS8REVkD2YpkdF4SrYtJhdlWYT8EgZeU3vIzTx-2Fw3bXbub4GB7XmsPWHjjf-2FYYDFqopdsqS85frAyta-2B2Lm-2B-2BtP5qp4mWU6luvr8hbOrDoudnGqbzATvJKbS-2BOfjncURk9UfkHFoNeebk-2BvRfxwBClgLqw20ZsgKuKWuZFcvFS-2BoVGmWn7C4&data=05%7C02%7CJohn.Sterling%40sagepub.com%7C00e42c433a984e769da308df09ba5532%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639240368107985884%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=xlakooCm%2BsfjhVzfYSvps1kyNigOmoyRLMj4rFz3QaM%3D&reserved=0" target="_blank" rel="noopener">one in 10 people in the U.K.</a></p>
<p>When there is an imbalance between specific T cell subtypes, it can cause inflammation, which results in damage to healthy tissue. Flip’s platform is based on the premise that disease-driving T cells can be reprogrammed <em>in vivo</em>, flipping them into anti-inflammatory cells that could restore balance and resolve inflammation for the long term.</p>
<p>This strategy both reduces the number of local disease-causing cells and rebuilds protective immune cells where they are needed most, opening the potential for a new class of immune medicines, noted David Pajerowski, PhD, co-founder and CEO of Flip Therapeutics.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“This combination of financial support and access to expertise gives us the opportunity to execute the experiments that matter most at this stage: validating our payloads, integrating them with nanoparticle delivery technology, and demonstrating that <em>in vivo</em> T cell reprogramming can become a scalable therapeutic platform,” he continued.</p>
<p></p><h4><strong>Mitochondrial biology for neurodegenerative diseases</strong></h4>

<p>Nascent Therapeutics, a University of East Anglia spinout, is using mitochondrial biology to treat neurodegenerative diseases, cancer, and other age-related conditions, such as COPD and osteoporosis. MDC is a co-investor alongside Zinc, a venture capital firm.</p>
<p><figure aria-describedby="caption-attachment-337378" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-337378" src="https://www.genengnews.com/wp-content/uploads/2026/09/Professor_Kristian_Bowles_MBE_and_Professor_Stuart-221x300.jpg" alt="Kristian Bowles, PhD, (left) and Stuart Rushworth, PhD, two of the three co-founders of Nascent Therapeutics [Medicines Discovery Catapult]" width="221" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/Professor_Kristian_Bowles_MBE_and_Professor_Stuart-221x300.jpg 221w, https://www.genengnews.com/wp-content/uploads/2026/09/Professor_Kristian_Bowles_MBE_and_Professor_Stuart-309x420.jpg 309w, https://www.genengnews.com/wp-content/uploads/2026/09/Professor_Kristian_Bowles_MBE_and_Professor_Stuart.jpg 319w" sizes="(max-width: 221px) 100vw, 221px"><figcaption class="wp-caption-text">Kristian Bowles, PhD, (left) and Stuart Rushworth, PhD, two of the three co-founders of Nascent Therapeutics [Medicines Discovery Catapult]</figcaption></figure>As mitochondrial function declines with age, cells become less resilient, accumulate damage and struggle to meet energy demands, contributing to ageing and disease development.</p>
<p>Nascent is building a platform to regulate mitochondrial transfer using tunneling nanotube formation, the biological process through which cells exchange mitochondria and other cellular components in a controlled manner. A <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Flink.mediaoutreach.meltwater.com%2Fls%2Fclick%3Fupn%3Du001.jZUDAP8gwkxFxm4JQKdVAFE-2FKjsybD3SmtdPmb1BeVs6CpQ4GpvOGISdL0FcpMqGpUpfJ9AaWAotbw12oEzw7Q-3D-3D09yZ_OdKJqyAcUibQJc5MJt6voRURIhi-2FS6V3mKIa6fn0DGx5XC9A4YxTvnK0N-2FO4cRzTEwnwHHEJ20z67REJcgre4jCHasSKPkUGIX-2FvUQq9kwOrUvRF5H-2BJ3XOSLjEniUTFr6EMlm-2BeY6Aau5PJUPXryfdFijeY7TVOAE25MiFOK-2F7JEqH2FyIhVLUQ061oqQcaY76T4n8-2FkuSqRS8REVkD2YpkdF4SrYtJhdlWYT8EgZe5bgSnX1MZP7EOKLk0PnsfJuelIjaYJhj2gFiIMfdmhpZVIrPwgvNd0izFQa8y19P-2FZ1k5-2Fsud-2BDiPTIu-2BLcIgVhDNH7nvVON-2B6E12d4Wdb-2ByGdXGfVAcOxnL90CZm4s-2BqP1DYX4lFfyaJmmKm9TS7&data=05%7C02%7CJohn.Sterling%40sagepub.com%7C00e42c433a984e769da308df09ba5532%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639240368108025790%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=P3joAb0scrz2zef1U7XUTXIpq8Myghqtzk8mWvnTMuo%3D&reserved=0" target="_blank" rel="noopener">growing body of evidence</a> suggests this process may have a fundamental role in aging and the pathology of diseases, including Parkinson’s and Alzheimer’s, pointed out Stuart Wood, co-founder and CEO of Nascent Therapeutics.</p>
<p>Wood also explained that through its approach of boosting and restoring mitochondrial transfer, Nascent aims to develop a new class of disease-modifying therapies to address a significant unmet patient need, initially focused on Parkinson’s disease.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“MDC have been highly supportive and engaged investors from the outset,” he said. “With this funding, we will develop our pipeline and platform as we work to develop truly novel therapies for Parkinson’s and other aging diseases, and we look forward to continuing to work with MDC as both investors and scientific partners.”</p>
<p>“By combining exciting science with the right support, we can help accelerate the journey towards new treatments for the patients who need them,” commented Mike Strange, PhD, interim CEO of MDC. “The funding from Innovate UK enables us to back Flip Therapeutics and Nascent Therapeutics in developing innovative approaches to tackling diseases that affect so many people.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/medicines-discovery-catapult-backs-two-u-k-biotech-companies-tackling-chronic-diseases/">Medicines Discovery Catapult Backs Two U.K. Biotech Companies Tackling Chronic Diseases</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Strong IP ecosystems drive biotech R&amp;amp;D and investment, report shows</title>
<link>https://edusehat.com/en/strong-ip-ecosystems-drive-biotech-rd-and-investment-report-shows</link>
<guid>https://edusehat.com/en/strong-ip-ecosystems-drive-biotech-rd-and-investment-report-shows</guid>
<description><![CDATA[ Stronger intellectual property protection statistically correlates with increased development of cutting-edge therapies and greater investment in life sciences research, according to a closely watched […]
The post Strong IP ecosystems drive biotech R&amp;D and investment, report shows appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2024/02/pexels-lil-artsy-1314410-e1707087294965.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 15:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Strong, ecosystems, drive, biotech, R&amp;D, and, investment, report, shows</media:keywords>
<content:encoded><![CDATA[<p><span>Stronger intellectual property protection statistically correlates with increased development of cutting-edge therapies and greater investment in life sciences research, according to a closely watched U.S. Chamber of Commerce study.</span></p>
<p><span>Across all types of industries, countries with strong IP rights feature more nimble, growth-oriented economies that are open to innovation and the utilization of the latest technologies, according to the</span><a href="https://www.uschamber.com/assets/documents/GIPC_IPIndex2026_Annex_v3.pdf"> <span>International IP Index Statistical Annex</span></a><span>, which was</span><a href="https://www.uschamber.com/intellectual-property/want-more-growth-start-with-stronger-ip-protection"> <span>announced in August</span></a><span> and produced by the Chamber’s Global Innovation Policy Center.</span></p>
<p><span>As for biotech, the Statistical Annex highlighted several benefits to maintaining high scores in IP protection. For example: “Economies that score 50% or more on the Index’s life sciences–related indicator host over eight times more clinical trials than low-scoring economies.”</span></p>
<p><span>An accompaniment to the Chamber’s 14</span><span>th</span><a href="https://www.uschamber.com/intellectual-property/2026-international-ip-index"> <span>IP Index</span></a><span>, the Annex is seen as one of the most powerful components of the Index because it demonstrates to global governments why it matters that they invest in more effective IP standards.</span></p>
<p><span>“The Index’s</span><a href="https://www.uschamber.com/assets/documents/GIPC_IPIndex2026_Annex_v3.pdf"> <span>Statistical Annex</span></a><span> shows a consistent pattern,”</span><a href="https://www.uschamber.com/intellectual-property/want-more-growth-start-with-stronger-ip-protection"> <span>writes Kelly Anderson</span></a><span>, VP International Policy at the U.S. Chamber of Commerce. “Economies with stronger IP systems are more innovative, attract more investment, become more competitive, and are better positioned to develop and deploy the technologies that will drive future growth.”</span></p>
<h2>Hosting more clinical trials</h2>
<p><a href="https://bio.news/health/studies-show-value-of-biotech-ip-for-the-economy-and-society/#:~:text=The%20biopharma%20sector,the%20patent%20system."><span>Biotech is one of the most research-intensive industries</span></a><span>, and is therefore an industry that is heavily</span><a href="https://bio.news/bio-convention/ahead-of-bio-ip-conference-research-highlights-why-biotech-needs-strong-patents/"> <span>reliant on IP</span></a><span>, as the Statistical Annex confirms.</span></p>
<p><span>The Statistical Annex looks at several measures of biotech innovation using the number of clinical trials a country hosts as a metric. For example, it found that countries with strong biopharmaceutical IP rights are much more likely to have higher clinical trial activity.</span></p>
<p><span>This is especially true of cutting-edge research and first-in-human clinical trials.</span></p>
<p><span>“Economies that maintain robust IP environments tend to see over 15 times more early-phase clinical trials on average compared with economies whose life sciences–related IP environments trail behind,” according to the Statistical Annex.</span></p>
<p><span>The Statistical Annex also finds a close correlation between economies with strong life-sciences IP protections and those that host more trials in gene-, cellular- or protein-based therapies. There is a similar situation in oncology.</span></p>
<p><span>“Economies with strong to robust IP frameworks for the life-sciences host over 14 times more clinical trials on innovative oncology drugs compared with economies with a weaker environment,” the Statistical Annex says.</span></p>
<h2>General economic benefits of strong IP</h2>
<p><span>General economic benefits revealed by the Statistical Index include close correlations between strong IP protections and:</span></p>
<ul>
<li aria-level="1"><span>Preparedness for the future of growth.</span></li>
<li aria-level="1"><span>Greater capacity for innovation and technological absorption.</span></li>
<li aria-level="1"><span>Attractiveness for foreign investment.</span></li>
<li aria-level="1"><span>Ability to achieve a strong innovation capability.</span></li>
<li aria-level="1"><span>Environments that are conducive to innovation.</span></li>
<li aria-level="1"><span>Companies that are more likely to spend on R&D.</span></li>
<li aria-level="1"><span>Greater attractiveness to investors.</span></li>
<li aria-level="1"><span>Better positioning for competing in the global innovation arena.</span></li>
<li aria-level="1"><span>Inventive intensity.</span></li>
<li aria-level="1"><span>Growth of high-tech sectors.</span></li>
</ul>
<p><a href="https://www.uschamber.com/assets/documents/GIPC_IPIndex2026_Annex_v3.pdf"><b>Read: The International IP Index Statistical Annex.</b></a></p>
<p>The post <a href="https://bio.news/international/strong-ip-ecosystems-drive-biotech-rd-and-investment-report-shows/">Strong IP ecosystems drive biotech R&D and investment, report shows</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Watchmaker Genomics Boosts Manufacturing Capacity with Major Boulder Campus Expansion</title>
<link>https://edusehat.com/en/watchmaker-genomics-boosts-manufacturing-capacity-with-major-boulder-campus-expansion</link>
<guid>https://edusehat.com/en/watchmaker-genomics-boosts-manufacturing-capacity-with-major-boulder-campus-expansion</guid>
<description><![CDATA[ The Flatiron Park facility in Colorado will serve as the Watchmaker Boulder Manufacturing Center of Excellence for reagent manufacturing and will house the company’s manufacturing, quality, R&amp;D, and operations teams.
The post Watchmaker Genomics Boosts Manufacturing Capacity with Major Boulder Campus Expansion appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2221046460.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 11:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Watchmaker, Genomics, Boosts, Manufacturing, Capacity, with, Major, Boulder, Campus, Expansion</media:keywords>
<content:encoded><![CDATA[<p>Watchmaker Genomics signed a long-term lease for approximately 100,000 square feet at Flatiron Park in Boulder, CO. The facility will more than double Watchmaker’s manufacturing capacity and provide room for continued growth across R&D, quality, logistics, and other key functions.</p>
<p>The expansion is expected to support hundreds of new Colorado jobs over the coming years, with hiring occurring in phases as the campus comes online, according to a company official. The site is scheduled to become operational in the second half of 2027, following completion and qualification.</p>
<p>Watchmaker develops and manufactures the specialized enzymes, reagents, and kits used to analyze DNA and RNA. Founded in 2019, it focuses heavily on technologies supporting next-generation sequencing and molecular diagnostics.</p>
<p>“This is an important milestone for Watchmaker,” said Trey Foskett, CEO and co-founder. “We are investing in the infrastructure, quality systems, and manufacturing capabilities required to serve leading genomics and molecular diagnostics companies at commercial scale. It reflects our confidence in the future of precision genetic testing, the strength of our team, and Boulder as a place to build a world-class life science company.”</p>
<p>The Flatiron Park facility will serve as the Watchmaker Boulder Manufacturing Center of Excellence for reagent manufacturing and will house the company’s manufacturing, quality, R&D, and operations teams. It will also support the expansion of activities governed by Watchmaker’s ISO 13485-certified quality management system.</p>
<p>Building on continued growth at Watchmaker’s Cape Town, South Africa, operations, the new Boulder campus further develops the company’s globally connected research, development, and manufacturing network, noted Foskett. Together, the sites support customers and partners across North America, Europe, and Asia.</p>
<p>“This expansion is about more than square footage,” commented Brian Deneau, chief financial and operating officer. “It creates the operational foundation for our next stage of growth and strengthens our ability to pair technical innovation with rigorous quality systems and dependable manufacturing.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/watchmaker-genomics-boosts-manufacturing-capacity-with-major-boulder-campus-expansion/">Watchmaker Genomics Boosts Manufacturing Capacity with Major Boulder Campus Expansion</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cancer Drug Reduces SIV Reservoir in Macaques, May Inform HIV Cure Strategies</title>
<link>https://edusehat.com/en/cancer-drug-reduces-siv-reservoir-in-macaques-may-inform-hiv-cure-strategies</link>
<guid>https://edusehat.com/en/cancer-drug-reduces-siv-reservoir-in-macaques-may-inform-hiv-cure-strategies</guid>
<description><![CDATA[ Venetoclax, a cancer drug that inhibits BCL-2, reduced the intact SIV reservoir in macaques, offering preclinical support for targeting BCL-2 as part of HIV cure strategies.
The post Cancer Drug Reduces SIV Reservoir in Macaques, May Inform HIV Cure Strategies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/Getty_188057801_HIVVirus.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 11:35:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cancer, Drug, Reduces, SIV, Reservoir, Macaques, May, Inform, HIV, Cure, Strategies</media:keywords>
<content:encoded><![CDATA[<p>A cancer drug designed to push malignant cells toward death may also help researchers chip away at one of the toughest barriers to curing HIV: the long-lived viral reservoir that persists despite antiretroviral therapy.</p>
<p>In a study titled, “<a href="https://www.nature.com/articles/s41564-026-02464-7" target="_blank" rel="noopener">BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques</a>,” and published in <em>Nature Microbiology</em>, researchers at Emory University reported that a short course of venetoclax, a BCL-2 inhibitor approved for certain blood cancers, reduced the intact simian immunodeficiency virus (SIV) reservoir in rhesus macaques when given at the start of antiretroviral therapy (ART). SIV infection in macaques is commonly used as a nonhuman primate model for studying HIV persistence and cure strategies.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The work builds on a biological idea with implications for both cancer and HIV: cells that overexpress the anti-apoptotic protein BCL-2 are better able to survive. In cancer, that survival advantage can help malignant cells resist death. In HIV infection, BCL-2 may similarly help infected CD4<sup>+</sup> T cells persist as part of the latent or transcriptionally active reservoir, which can reignite viral replication if ART is interrupted.</p>
<p>“Eliminating the viral reservoir is a priority in the pursuit of a cure for HIV,” said Mirko Paiardini, PhD, senior author of the study and chief of the Microbiology and Immunology Division at the Emory National Biomedical Research Center (ENBRC). “Despite many attempts, there hasn’t been a therapeutic strategy able to do this. Our study, however, offers hope for accelerating the timeline to cure by using an approved medication.”</p>
<p>To test the approach, the investigators infected 24 rhesus macaques with SIV and initiated ART 14 days later. Animals were assigned to receive ART alone, ART plus 10 daily doses of venetoclax, or ART plus venetoclax and CD8α depletion. The animals were followed for nearly 10 months after infection, allowing the team to assess whether a brief period of BCL-2 inhibition had effects that lasted beyond the treatment window.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Venetoclax-treated macaques showed a rapid reduction in intact SIV DNA in CD4<sup>+</sup> T cells in blood compared with ART-only controls, and the reduction was sustained through day 294 post-infection. The researchers also observed reduced reservoir levels in lymph nodes, an important tissue site for viral persistence. By accounting for both the frequency of infected CD4+ T cells and overall CD4+ T-cell counts, the team found that venetoclax also reduced the absolute number of circulating SIV-infected cells.</p>
<p>“We noted the combination of medications reduced the number of SIV-infected CD4<sup>+</sup> T cells more rapidly than ART alone,” said first author Tomas Raul Wiche Salinas, MD, PhD, an ENBRC researcher. “Importantly, the level of infected cells remained lower in the venetoclax-treated animals for months after we stopped administering it but were continuing ART.”</p>
<p>The effect was not complete. CD4<sup>+</sup> T cells that persisted after venetoclax treatment showed signs of partial resistance to apoptosis in <em>ex vivo </em>testing. Those cells had elevated expression of BCL-2 and BCL-xL and reduced expression of pro-apoptotic molecules such as PUMA, pointing to compensatory survival pathways that could limit reservoir clearance.</p>
<p>Still, the authors concluded that the findings support further testing of BCL-2 inhibition as part of HIV cure strategies, including longer venetoclax dosing and determining the cellular mechanisms that allow survival of infected cells despite BCL-3 blockage. The study did not include an analytical treatment interruption, so it remains unknown whether venetoclax would delay or prevent viral rebound after ART is stopped.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/cancer-drug-reduces-siv-reservoir-in-macaques-may-inform-hiv-cure-strategies/">Cancer Drug Reduces SIV Reservoir in Macaques, May Inform HIV Cure Strategies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Psilocybin Prevents Chemotherapy&#45;Related Peripheral Neuropathy in Mice</title>
<link>https://edusehat.com/en/psilocybin-prevents-chemotherapy-related-peripheral-neuropathy-in-mice</link>
<guid>https://edusehat.com/en/psilocybin-prevents-chemotherapy-related-peripheral-neuropathy-in-mice</guid>
<description><![CDATA[ A study found that psilocybin given before chemotherapy prevented the onset of nerve injury in mouse models, even after repeated treatment cycles, and also protected tumor-bearing mice from neuropathy, without impairing antitumor efficacy. 
The post Psilocybin Prevents Chemotherapy-Related Peripheral Neuropathy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/POV-GettyImages-1227553397.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 04:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Psilocybin, Prevents, Chemotherapy-Related, Peripheral, Neuropathy, Mice</media:keywords>
<content:encoded><![CDATA[<p>Peripheral neuropathy is a common side effect of chemotherapy, resulting in symptoms that can include numbness, painful nerve injury and sensitivity. A study by researchers at The University of Texas MD Anderson Cancer Center has now found that in mouse models, as few as two doses of psilocybin given before chemotherapy durably prevented chemotherapy-induced peripheral neuropathy (CIPN) through multiple treatment cycles, while preserving both nerve function and tumor-killing effects of therapy.</p>
<p>The study, co-led by Moran Amit, MD, PhD, professor of Head and Neck Surgery, and Patrick Dougherty, PhD, professor of Pain Medicine, uncovered a previously unrecognized neuroprotective role of serotonin receptors, and points to psilocybin as a potential first-in-class intervention for the prevention of CIPN.</p>
<p>“There is an urgent need for treatments that prevent nerve injury without interfering with lifesaving chemotherapy,” Amit said. “These findings offer important insights into how psilocybin may protect nerves before damage occurs, rather than treating symptoms after they become persistent. At UT MD Anderson, we are actively exploring the multiple facets of psychedelics to pursue interventions that improve the lives of our patients.”</p>
<p>Amit, Dougherty, and colleagues reported on their findings in <em>Science</em>, in a paper titled “<a href="http://www.science.org/doi/10.1126/science.aec6116?adobe_mc=MCMID%3D56735421672242708983937630163745789831%7CMCORGID%3D242B6472541199F70A4C98A6%2540AdobeOrg%7CTS%3D1788386990" target="_blank" rel="noopener">Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation</a>.”</p>
<p>Chemotherapy-induced peripheral neuropathy is a common and serious complication of platinum-based chemotherapies, such as cisplatin, and can affects up to 60% of patients. Some patients may also experience changes that impact their balance or ability to continue life-saving treatments, significantly impacting their quality of life. “Patients experience pain, cold sensitivity, numbness, and impaired touch sensation that can persist for years, frequently forcing dose reductions or discontinuation of otherwise life-saving therapy,” the authors wrote. Established nerve injury often is irreversible, and existing treatments offer limited benefits. “Mechanistically, CIPN is associated with mitochondrial dysfunction and distal axonal degeneration within peripheral sensory pathways,” the team continue. “Despite its enormous clinical burden, no proven preventive strategy exists.”</p>
<p>Psilocybin is a naturally occurring psychedelic compound that is currently is under investigation for neuropsychiatric and neurological disorders. The compound activates serotonin 2A receptors, which have been linked to neuronal plasticity and mitochondrial regulation, indicating that psilocybin might protect the sensory nervous system from chemotherapy-induced injury, the investigators suggested.</p>
<p>For their reported study the researchers used several preclinical models to examine the effects of psilocybin on nerves and evaluate whether the compound could be used to prevent peripheral neuropathy after chemotherapy. “Despite decades of investigation, no effective prophylactic interventions have emerged for CIPN, and current treatments provide only limited benefit.” the investigators commented.</p>
<p>Through the study they discovered that psilocybin directly affects the peripheral nervous system through serotonin 5-HT2A receptors. In preclinical models, as few as two doses of psilocybin given before chemotherapy prevented hypersensitivity to cold, protected sensory nerve endings and preserved touch sensation while also maintaining antitumor effects of the chemotherapy. These results were consistent even when models were given repeated chemotherapy cycles with cisplatin, paclitaxel and docetaxel. “Notably, psilocybin also preserved its protective efficacy in tumor-bearing mice, without measurable changes in tumor growth, positioning it as a safe candidate with true prophylactic potential against CIPN,” the team stated.</p>
<p>Further experiments showed that blocking the 5-HT2A pathway reversed these neuroprotective effects, while using a non-hallucinogenic compound that activates the same receptors produced similar protection to that of psilocybin.</p>
<p>Additionally, researchers found that cisplatin depleted mitochondria and reduced their movement inside nerve fibers. They found that psilocybin activated a specific signaling pathway that preserved mitochondrial trafficking after chemotherapy, maintaining adequate energy levels at the nerve endings. “Human donor sensory neurons and patient skin biopsies independently confirmed that this serotonin 2A–mitochondrial trafficking network is conserved in human tissue,” the investigators further stated.</p>
<p>“Psilocybin does more than reduce pain signals by protecting the nerves, themselves, through energy delivery,” Dougherty said. “This neuroprotective effect could help patients withstand the stress of chemotherapy, maintaining sensation, mobility and quality of life during treatment and long into survivorship.” The authors added “Collectively, our results suggest that psilocybin-mediated restoration of mitochondrial positioning drives its<em> in vivo</em> neuroprotection, ensuring local energy production at sites where it is most needed.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>These preclinical findings are the basis for an upcoming Phase II clinical trial (NeuroGuard, NCT07227909) evaluating psilocybin during chemotherapy in patients with multiple cancer types, to determine whether the mechanisms observed in this trial translate to clinically meaningful reductions in peripheral neuropathy. Other ongoing trials, led by Amit, currently are examining the effects of psilocybin-assisted psychotherapy for patients with anxiety and/or depression.</p>
<p>These studies are part of UT MD Anderson’s Cancer Neuroscience Program, a comprehensive initiative that examines the interactions between cancer and the nervous system, taking a multidisciplinary approach to enhance patient quality of life.</p>
<p>In a related <a href="http://www.science.org/doi/10.1126/science.aek3865?adobe_mc=MCMID%3D56735421672242708983937630163745789831%7CMCORGID%3D242B6472541199F70A4C98A6%2540AdobeOrg%7CTS%3D1788387067" target="_blank" rel="noopener">perspective</a>, Maria Maiarú, PhD, at the Department of Pharmacology, School of Pharmacy, University of Reading, said “The study reframes CIPN not simply as an inevitable con­sequence of neuronal injury but as a failure of resilience that may be amenable to early intervention.” Noting limitations of the reported study, Maiarú commented that the a authors nevertheless “… provide compelling evidence that CIPN may be preventable by preserving mitochondrial positioning and axonal energy homeostasis through plasticity-promoting serotonergic signaling.” The challenge now is to translate these mechanistic insights into carefully designed clinical trials, added Maiarú who acknowledged that the effect of the findings extends beyond chemother­apy-induced neuropathy in terms of potential for disease-modifying approaches to chronic pain.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/psilocybin-prevents-chemotherapy-related-peripheral-neuropathy-in-mice/">Psilocybin Prevents Chemotherapy-Related Peripheral Neuropathy in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Immune Cells Driving Alzheimer’s&#45;Like Neurodegeneration Traced to Lymph Nodes</title>
<link>https://edusehat.com/en/immune-cells-driving-alzheimers-like-neurodegeneration-traced-to-lymph-nodes</link>
<guid>https://edusehat.com/en/immune-cells-driving-alzheimers-like-neurodegeneration-traced-to-lymph-nodes</guid>
<description><![CDATA[ A study in mice traces immune cells that drive neurodegeneration to the body’s lymph nodes, suggesting that processes outside the brain contribute to the damage seen in various tauopathies.
The post Immune Cells Driving Alzheimer’s-Like Neurodegeneration Traced to Lymph Nodes appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Alzheimers_GettyImages-2238757957.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 04:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Immune, Cells, Driving, Alzheimer’s-Like, Neurodegeneration, Traced, Lymph, Nodes</media:keywords>
<content:encoded><![CDATA[<p><span>Previous studies have shown that patients with Alzheimer’s disease and related disorders have much higher levels of immune cells in their brains that appear to contribute to neurodegeneration. What was less clear was where the cells came from and how they are primed to accumulate in the brain. Now a new study, led by scientists at Washington University School of Medicine, St. Louis, may provide some answers. </span></p>
<p><span>According to results published in a </span><i><span>Nature Neuroscience</span></i><span> paper titled “</span><a href="https://www.nature.com/articles/s41593-026-02427-5" target="_blank" rel="noopener"><span>Priming of CD8+ T cells by peripheral dendritic cells exacerbates tau-mediated neurodegeneration</span></a><span>,” T cells in the brain receive their instructions from lymph nodes located outside the brain. The team also showed that they can block these instructions in order to mitigate their neurodegenerative effects. They claim that these findings highlight a new pathway that could potentially slow the progression of primary tauopathies like Alzheimer’s.</span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Scientists in the laboratory of Daniel Holtzman, MD, a professor in the WashU Medicine’s neurology department and the current study’s senior author, have published previously on the immune system’s role in neurodegenerative disease. In an earlier paper, they demonstrated that eliminating T cells in the brain prevented much of the neurodegenerative damage that normally occurs due to tau protein buildup in various tauopathies. </span></p>
<p><span>“One of the issues in developing treatments for neurological diseases is that you need to engineer your treatment so that it gets into the brain and past the blood-brain barrier, but we might not actually need to get the drugs into the central nervous system to mitigate neurodegeneration,” Holtzman said. “There are lots of ways to manipulate T cells that have been studied extensively and that are approved treatments for other diseases, but many haven’t yet been explored for neurodegenerative diseases.”</span></p>
<p><span>In this new study, the team set out to establish where the immune cells came from and what signals directed them to the brain. Certain T cells need dendritic cells to tell them which molecular targets to attack. Studies show that classical dendritic cells type 1 (cDC1), in the brain do not seem to interact with the T cells that appear when tau tangles have developed in the brain. In mouse models, the scientists found that eliminating dendritic cells from the lymph nodes as well as other locations in the brain that ordinarily develop tau tangles wiped out the elevated levels of T cells in the brain and the associated damage. This was true even though there was no change in levels of tau tangles in the brain. </span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>Furthermore, the mice also retained their cognitive abilities, which suggests that halting the activity of the T cells may slow or reduce cognitive decline associated with tauopathies.  </span></p>
<p><span>Holtzman noted that while the specific trigger causing dendritic cells to activate the T cells is not known, it is likely that tau-induced damage to brain cells releases material that moves from  the brain into the lymph nodes. Once there, dendritic cells flag that material as a target for T cells to attack.</span></p>
<p><span>As part of their next steps, Holtzman’s team is investigating possible therapeutic implications of their work. Specifically, they are looking at whether impeding dendritic cell function in midlife, to match the onset of tau protein tangles, could be as effective as blocking it at birth, as was the case in this study. His team is also exploring ways to identify the specific signals the T cells use to target the brain.</span></p>
<p><span>“Until not that long ago, most people, including myself, did not think that the immune response was even involved in neurodegenerative diseases that are due to protein accumulation in the brain,” he said. “That these dendritic cells are involved in neurodegenerative disease is exciting; we’ve shown they’re important, and that they are a potential target for future therapy.”</span></p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/immune-cells-driving-alzheimers-like-neurodegeneration-traced-to-lymph-nodes/">Immune Cells Driving Alzheimer’s-Like Neurodegeneration Traced to Lymph Nodes</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Analytical Blueprint for Cell &amp;amp; Gene Therapy Success</title>
<link>https://edusehat.com/en/the-analytical-blueprint-for-cell-gene-therapy-success</link>
<guid>https://edusehat.com/en/the-analytical-blueprint-for-cell-gene-therapy-success</guid>
<description><![CDATA[ This eBook brings together expert perspectives on several of the most pressing analytical topics facing today’s cell and gene therapy developers.
The post The Analytical Blueprint for Cell &amp; Gene Therapy Success appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Solvias-eBook-cover-image.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 04 Sep 2026 00:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Analytical, Blueprint, for, Cell, Gene, Therapy, Success</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p><div class="my-8"><span data-render-ad="3"></span></div><p></p><p class="wp-block-paragraph">Cell and gene therapies have entered a new phase of maturity. Scientific innovation continues at an unprecedented pace, but so do the analytical and regulatory expectations that determine whether promising therapies ultimately reach patients.</p><p></p><p></p><div class="wp-block-image"><p><figure class="alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-232x300.jpg" alt="Solvias September 2026  eBook cover" class="wp-image-337387" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-325x420.jpg 325w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-649x840.jpg 649w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-696x901.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover-1068x1382.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/09/GEN_Solvias_Cover.jpg 1377w" sizes="(max-width: 232px) 100vw, 232px"></figure></p><p></p></div><p></p><p class="wp-block-paragraph">Throughout 2026, the regulatory landscape has continued to evolve. The FDA introduced new CMC flexibilities designed specifically for cell and gene therapies, recognizing that traditional development paradigms do not always fit these complex products. At the same time, newly published Complete Response Letters have continued to provide valuable insight into the analytical deficiencies that most frequently delay approvals, while upcoming new ICH guidance and USP chapters are further shaping expectations for extractables and leachables.</p><div class="my-8"><span data-render-ad="4"></span></div><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p class="wp-block-paragraph">Taken together, these developments highlight the growing importance of analytical science. Analytics has become a strategic discipline that supports product understanding, guides manufacturing decisions, informs risk assessments, and builds confidence throughout the product lifecycle. Developers must establish an integrated analytical strategy that evolves alongside the product, connecting characterization, potency, safety, manufacturing, and regulatory requirements into a comprehensive understanding of quality.</p><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p class="wp-block-paragraph">This eBook brings together expert perspectives on several of the most pressing analytical topics facing today’s cell and gene therapy developers. Inside, you’ll explore how integrated analytics can help prevent program drift, how next-generation sequencing is transforming product characterization and viral safety, why extractables and leachables require new approaches for CGTs, what FDA Complete Response Letters reveal about potency assays, and how recent FDA CMC flexibilities can be leveraged to accelerate development. You’ll also see how complementary genomic technologies can be combined to solve complex characterization challenges through a real-world case study.</p><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p class="wp-block-paragraph">Although each article addresses a different aspect of development, they all reinforce the same message: thoughtful analytical strategies reduce uncertainty, strengthen regulatory readiness, and ultimately help move innovative therapies from the laboratory to the patients who need them most.</p><div class="my-8"><span data-render-ad="5"></span></div><p>The post <a href="https://www.genengnews.com/resources/ebooks/the-analytical-blueprint-forcell-gene-therapy-success/">The Analytical Blueprint for Cell & Gene Therapy Success</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human Pancreatic Duct Cells Show Diabetes Therapy Potential</title>
<link>https://edusehat.com/en/human-pancreatic-duct-cells-show-diabetes-therapy-potential</link>
<guid>https://edusehat.com/en/human-pancreatic-duct-cells-show-diabetes-therapy-potential</guid>
<description><![CDATA[ Loss of function in the ALDH3B2 gene can convert human pancreatic duct cells into functional β-like cells that in tests secreted insulin in response to glucose, and lowered blood glucose levels when transplanted into diabetic mice.
The post Human Pancreatic Duct Cells Show Diabetes Therapy Potential appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/02/GettyImages-544546223.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 10:25:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, Pancreatic, Duct, Cells, Show, Diabetes, Therapy, Potential</media:keywords>
<content:encoded><![CDATA[<p>A study by researchers at Harvard Medical School has shown that loss of function in the aldehyde dehydrogenase family 3 member B2 (<em>ALDH3B2)</em> gene can convert human pancreatic duct cells into functional β-like cells that can secrete insulin in response to glucose, and which lowered blood glucose levels when transplanted into diabetic mice. The team, headed by Peng Yi, PhD, an investigator at Joslin Diabetes Center, and assistant professor of medicine at Harvard Medical School, suggests that their results point to <em>ALDH3B2</em> as a gene that could potentially be targeted in human pancreatic duct cells to replenish β cell mass for diabetes therapy.</p>
<p>Senior and co-corresponding author Yi, together with first and co-corresponding author, Jian Li, a postdoctoral research fellow in the Yi lab at Joslin Diabetes Center and Harvard Medical School, reported on their findings in <em>Science Translational Medicine</em>, in a paper titled “<a href="http://dx.doi.org/10.1126/scitranslmed.ady2234" target="_blank" rel="noopener">Loss of function of <em>ALDH3B2</em> transdifferentiates human pancreatic duct cells into β-like cells</a>.”</p>
<p>Diabetes, is “… a disease of pancreatic β cell inadequacy,” regardless of cause, the authors wrote. Finding ways to restore a functional pancreatic β cell population in people with diabetes is key to controlling and potentially curing the disease. “To cure diabetes, one has to find a way to stop the recurrent autoimmune attack on β cells (type 1 diabetes) or resolve persistent peripheral insulin resistance (type 2 diabetes), but restoring sufficient functional β-cell mass is critical to a cure for both types of diabetes,” the team continued.</p>
<p>Previous studies have shown that pancreatic duct cells can transdifferentiate into β-like cells, but the process is not well understood. “The critical question is whether transdifferentiation of ducts to β cells occurs in adult humans and, if so, how to stimulate it,” they noted.</p>
<p>For their reported study Li and colleagues developed a genome-wide CRISPR screening strategy to search for genes that regulate the transdifferentiation of human pancreatic duct cells into β cells. They found that loss of function of the <em>ALDH3B2</em> gene was enough to transdifferentiate cell line-based and human pancreatic duct cells into functional β-like cells.  Loss of function in <em>ALDH3B2</em> in human pancreatic duct cells triggered insulin promoter activation and shifted gene expression toward a more β cell-like profile.</p>
<p>The transdifferentiated cells also lowered blood glucose levels in diabetic mice. “The transdifferentiated cells had substantially increased expression of β cell marker genes, secreted insulin in response to glucose, and lowered blood glucose to near normal for six weeks after transplantation into streptozotocin-induced diabetic mice under the kidney capsule,” the investigators wrote in summary.</p>
<p>However, glucose-stimulated insulin production was much lower in these transformed cells compared with natural human β cells, and the researchers say that loss of function in other genes beyond <em>ALDH3B2</em> may be necessary to produce full transdifferentiation. The mechanism by which <em>ALDH3B2</em> restrains duct cell plasticity also needs to be identified, the team noted. “Addressing these limitations will be important for improving conversion efficiency, promoting maturation, and advancing this strategy toward therapeutic application.” Nonetheless, they concluded, “Our study identifies a gene that could potentially be targeted in human pancreatic duct cells to replenish β cell mass for diabetes therapy.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/human-pancreatic-duct-cells-show-diabetes-therapy-potential/">Human Pancreatic Duct Cells Show Diabetes Therapy Potential</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GLP&#45;1 Drug Semaglutide Slows Aging and Extends Lifespan in Mice</title>
<link>https://edusehat.com/en/glp-1-drug-semaglutide-slows-aging-and-extends-lifespan-in-mice</link>
<guid>https://edusehat.com/en/glp-1-drug-semaglutide-slows-aging-and-extends-lifespan-in-mice</guid>
<description><![CDATA[ Semaglutide improved health, reduced aging-related changes, and extended lifespan in older female mice, sometimes outperforming caloric restriction. However, human longevity benefits remain unproven.
The post GLP-1 Drug Semaglutide Slows Aging and Extends Lifespan in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-544546123-e1788367986742.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 06:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GLP-1, Drug, Semaglutide, Slows, Aging, and, Extends, Lifespan, Mice</media:keywords>
<content:encoded><![CDATA[<p>An estimated 11% of Americans are currently taking GLP-1 drugs. Because the drugs, known as a treatment for diabetes and obesity, are widely studied, new research is revealing other, unknown, effects on the human body.</p>
<p>In a new study, the GLP-1 drug semaglutide was shown to extend lifespan in older, healthy mice. When the effects of the treatment were compared to those of caloric restriction, the drug mimicked the anti-aging benefits of calorie restriction, with greater benefits in some areas.</p>
<p>While GLP-1s have been found to delay the onset of many age-related diseases in animals, this new study in healthy older mice offers evidence that these drugs may slow physiological aging itself, a notion that could potentially tie the widespread benefits of GLP-1s to a common source.</p>
<p>This research is published in <em>Nature</em> in the paper, “<a href="https://www.nature.com/articles/s41586-026-10940-7" target="_blank" rel="noopener">Late-life semaglutide treatment slows ageing and extends lifespan in female mice</a>.”</p>
<p>“Most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you’d expect to see,” said Rafael de Cabo, PhD, a senior investigator at the NIH’s National Institute on Aging (NIA).</p>
<p>To understand the impact of GLP-1s at a time when the effects of aging are most pronounced, the study authors administered semaglutide to 20-month-old female mice for three months.</p>
<p>Compared with a control group, mice treated with the drug showed improved muscle and cognitive function. Gene expression analysis showed that several hallmarks of natural aging, such as increased inflammation and reduced regenerative capacity, were reduced in treated animals. Another group of mice treated until the end of life had a median lifespan nearly 100 days longer than that of untreated mice.</p>
<p>More specifically, “treatment of 20-month-old female C57BL/6 mice with the GLP-1R agonist semaglutide for three months improved physiological function, attenuated hallmarks of aging and modulated nutrient sensors and conserved genetic regulators of aging.”</p>
<p>The authors compared semaglutide with calorie restriction to see whether its benefits were simply due to reduced food intake or something else.</p>
<p>Over five months, scientists administered semaglutide to one group of 20-month-old female mice, while another group received a 24% calorie-restricted diet that matched the treated animals’ feeding pattern. The authors drew numerous parallels between the two groups, with most physiological measurements remaining stable. However, semaglutide-treated mice surpassed baseline levels in exploratory behavior, spatial memory, and blood-sugar maintenance. The groups also differed in metabolic rate, which was reduced in the calorie-restricted animals but largely unchanged in the semaglutide-treated mice.</p>
<p>“These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction. Uncovering this potential route and the benefits that may specifically stem from it is an important direction for future research into the development of longevity-enhancing interventions,” said Danica Chen, PhD, professor of metabolic biology and nutrition at UC Berkeley.</p>
<p>While these findings may guide future research, they do not imply that similar results could be achieved immediately in humans. Additional clinical studies, such as the recent post-hoc analysis of the SLIM LIVER trial, will be necessary to determine the clinical efficacy of GLP-1s on longevity in human patients.</p>
<p>Future clinical investigations may also explore benefits in healthy aged individuals, Chen explained, which would greatly broaden the application of GLP-1s.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/glp-1-drug-semaglutide-slows-aging-and-extends-lifespan-in-mice/">GLP-1 Drug Semaglutide Slows Aging and Extends Lifespan in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory Era</title>
<link>https://edusehat.com/en/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-in-an-uncertain-regulatory-era</link>
<guid>https://edusehat.com/en/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-in-an-uncertain-regulatory-era</guid>
<description><![CDATA[ The companies that emerge from this evolving regulatory cycle with clean, rigorous, globally positioned programs will find themselves in a structurally superior competitive position when the environment stabilizes.
The post Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory Era appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2229675668.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 06:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Navigating, the, Regulatory, Labyrinth:, How, Biotech, Leaders, Are, Rethinking, Strategy, Uncertain, Regulatory, Era</media:keywords>
<content:encoded><![CDATA[<p>There is a particular kind of anxiety that settles into a biotech boardroom when the regulatory environment becomes difficult to read. It is not the anxiety of a bad clinical trial result that, at least, has a defined binary outcome. It is the anxiety of ambiguity and uncertainty: when the rules of the game appear to shift or are in flux, often without warning, and no one can say with any certainty in which direction or how far.</p>
<p>That is the environment biotech executives are navigating right now. The strategic responses being formulated quietly, deliberately, at the level of pipeline sequencing, capital allocation, and partnership architecture will shape the competitive landscape of biopharma for months, or even years, to come.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>For most of the past fifteen years, FDA uncertainty was a known and manageable variable. You modeled it into your approval probability estimates, built it into your timelines, and structured your financing accordingly. What has changed is not the presence of uncertainty but its character.</p>
<p>Leadership transitions, shifting enforcement postures, and openly debated policy priorities from advisory committee utilization to accelerated approval pathways have introduced a layer of institutional unpredictability that is qualitatively different from ordinary regulatory risk.</p>
<p>Experienced executives understand that the FDA career staff, consisting of the reviewers, the division directors, and the statistical teams largely perseveres through political cycles. The science does not change. But the signals emanating from the top of the agency shape how sponsors prioritize Pre-IND meetings, how they frame their clinical endpoints, and whether they pursue accelerated pathways aggressively or conservatively. When those signals are mixed or absent, strategic clarity suffers.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<figure aria-describedby="caption-attachment-337351" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337351" src="https://www.genengnews.com/wp-content/uploads/2026/09/david-300x300.jpg" alt="David H. Crean, PhD, is founder and managing partner of Cardiff Advisory" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/david-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/david-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/09/david.jpg 400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">David H. Crean, PhD, is founder and managing partner of Cardiff Advisory</figcaption></figure>
<p>What I am hearing from peers across the industry is a deliberate move toward what I would call <em>regulatory conservatism </em>in the near term, with optionality preserved for the medium term. Companies with programs that could qualify for accelerated approval or breakthrough therapy designation are not abandoning those strategies. They remain enormously valuable, but they are building more robust conventional data packages in parallel, anticipating that the bar for confirmatory evidence may be moving in real time.</p>
<p></p><h4><strong>The Ex-U.S. recalculation</strong></h4>

<p>Perhaps the most consequential strategic shift occurring right now is one that rarely makes headlines: a genuine reassessment of the weight assigned to ex-U.S. regulatory pathways in early-stage pipeline decision-making.</p>
<p>The European Medicines Agency, Japan’s PMDA, and China’s NMPA have historically been framed as secondary considerations in U.S.-centric development strategies that are important for global commercial value, but largely downstream of FDA approval. Given the changes occurring in real time within the FDA, it now appears that calculus is being revisited.</p>
<p>The EMA’s progressive PRIME designation program continues to offer meaningful engagement for high-unmet-need programs, and European regulators have demonstrated sophisticated accommodation of innovative trial designs in areas like neurology and rare disease. The PMDA, often underappreciated by Western developers, operates with a scientific rigor and collaborative approach that can be genuinely advantageous for companies willing to invest early in a Japanese regulatory strategy.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>For programs with genuine global patient populations, NMPA pathways—while carrying their own complexity—are increasingly being assessed as parallel tracks rather than sequential follow-ons.</p>
<p><figure aria-describedby="caption-attachment-337353" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-337353" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177971058-300x158.jpg" alt="medical team" width="300" height="158" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177971058-300x158.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177971058-768x405.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177971058-797x420.jpg 797w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177971058-696x367.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2177971058.jpg 814w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">It is not the anxiety of a bad clinical trial result that has a defined binary outcome. It is the anxiety of ambiguity and uncertainty: when the rules of the game appear to shift or are in flux. [Jacob Wackerhausen/Getty Images]</figcaption></figure>This is not a retreat from the U.S. market. It is a recognition that regulatory portfolio diversification is a risk management strategy, rather than merely a commercial optimization. A company that can demonstrate regulatory momentum across multiple jurisdictions is a materially more attractive asset whether in investment discussions, partnerships, or M&A, than one whose entire approval thesis rests on a single regulatory outcome.</p>
<p>For programs like MediciNova’s COMBAT-ALS trial evaluating ibudilast (MN-166) in ALS, for example, where the unmet need is profound and the global patient community is engaged, the question of regulatory sequencing is not academic. The EMA’s willingness to engage on neurodegenerative programs with novel mechanisms, and Japan’s deep history with ibudilast as an approved compound, creates a genuine strategic landscape that demands sophisticated multi-jurisdictional thinking not as a hedge, but as a core thesis.</p>
<p>The downstream effects on financing are real and increasingly apparent. Smaller biotech companies, those operating below the $500 million market cap threshold where every allocation decision is existential, are experiencing a compression of strategic flexibility. When regulatory timelines extend, cash runways shorten proportionately. When approval probability estimates decline even modestly, the valuation impact cascades through every financing instrument: equity raises, royalty agreements, and debt facilities.</p>
<p>Larger biopharma is not immune, but the dynamic is different. For a company with a diversified portfolio and robust balance sheet, regulatory uncertainty is a portfolio-level risk that can be absorbed and managed. For a single- or two-asset company with limited financial runway, the same uncertainty becomes a potential existential threat. This asymmetry is reshaping the partnership and licensing market in ways that have not yet fully registered in the deal flow landscape.</p>
<p>However, what we are observing is a quiet compression of risk-sharing structures. Milestone-weighted deals with aggressive back-end payments are giving way to structures with more upfront certainty and more conservative milestone definitions as smaller biotechs trade economic upside for near-term financial stability.</p>
<p>At the same time, strategics are taking a more patient approach to deal execution, using uncertainty as a justification for deeper levels of diligence, limitations in participation, or later entry points. This benefits larger acquirers at the expense of smaller developers. It is a market dynamic worth watching carefully.</p>
<p><figure aria-describedby="caption-attachment-337347" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-337347" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1013169284-300x200.jpg" alt="compliance" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1013169284-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1013169284-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1013169284-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-1013169284.jpg 724w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Compliance costs are accumulating in ways that smaller companies absorb disproportionately. [Warchi/Getty Images]</figcaption></figure>Compliance costs, too, are accumulating in ways that smaller companies absorb disproportionately. Increased documentation demands, evolving expectations around real-world evidence and post-market commitments, and the overhead of managing multi-jurisdictional submissions simultaneously are all compressing the operational leverage that makes small biotech companies attractive as nimble innovators.</p>
<p>There is a temptation, particularly in advocacy contexts, to frame regulatory rigor as the adversary of innovation and speed. This is a false narrative and strategically unproductive for the industry.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>The innovation-rigor tension, honestly assessed</strong></h4>
<p>The cases where biotech companies have moved fastest and with the greatest durable success are invariably the cases where the science was strongest, and the clinical signal was clearest. Regulatory agencies do not slow good science down. Where they do slow the process is with insufficiently characterized science in programs where the risk-benefit profile is genuinely uncertain, where the trial design does not clearly answer the question, or where the patient population is ambiguously defined.</p>
<p>The executives I respect most in this industry are not the ones fighting the FDA. They are the ones designing programs that make the regulatory path structurally obvious. They are investing in biomarker development early. They are engaging patient advocacy organizations early as scientific partners, not just communications assets. They are building adaptive trial designs that can accelerate through strong interim signals without sacrificing the statistical integrity that protects patients and allows for eventual approval.</p>
<p>That discipline is more important now than at any point in the past decade. In an environment where the agency is managing through its own internal uncertainties, a sponsor’s ability to present a clear, well-characterized, scientifically rigorous package is a genuine competitive advantage.</p>
<p><figure aria-describedby="caption-attachment-337349" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-337349" src="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2206618558-300x200.jpg" alt="team meeting" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2206618558-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2206618558-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2206618558-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2206618558.jpg 724w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">In an uncertain environment, the temptation to project false confidence is strong. The leaders who resist that temptation, who build regulatory contingencies openly into their strategic plans and communicate them transparently, are the ones who will maintain the credibility and institutional trust that complex, long-duration programs require. [Skynesher/Getty Images]</figcaption></figure>The leaders who will navigate this environment most successfully are not those who find ways to evade regulatory complexity. That is a short-term strategy with long-term costs. They are the ones who are building genuine regulatory intelligence as an organizational competency.</p>
<p>That means regulatory affairs leadership with a seat at the strategic table, not just at the submission desk. It means investing in regulatory intelligence functions such as monitoring policy developments across jurisdictions, maintaining relationships with former agency officials, and participating actively in industry consortia that shape policy discussions. It means building the institutional knowledge to move quickly when clarity emerges, rather than scrambling to catch up.</p>
<p>It also means honesty with the board and investors about what is known and not known. In an uncertain environment, the temptation to project false confidence is strong. The leaders who resist that temptation, who build regulatory contingencies openly into their strategic plans and communicate them transparently, are the ones who will maintain the credibility and institutional trust that complex, long-duration programs require.</p>
<p>The regulatory fog is real, and it will not lift entirely anytime soon. For the executives who are using this period to build deeper regulatory intelligence, more diversified approval strategies, and stronger scientific foundations, it is also an unprecedented opportunity.</p>
<p>The companies that emerge from this cycle with clean, rigorous, globally positioned programs will find themselves in a structurally superior competitive position when the environment stabilizes.</p>
<p>This is a data-driven conviction. It is the calculus of leaders who have navigated regulatory cycles before and learned that clarity is always temporary, but preparation is always an advantage.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p><em>David H. Crean, PhD, is founder and managing partner of Cardiff Advisory, a life sciences M&A and strategic advisory firm and serves as fractional chief business officer of MediciNova. </em></p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-in-an-uncertain-regulatory-era/">Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory Era</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Affordability and Access: Why patient perspectives matter</title>
<link>https://edusehat.com/en/affordability-and-access-why-patient-perspectives-matter</link>
<guid>https://edusehat.com/en/affordability-and-access-why-patient-perspectives-matter</guid>
<description><![CDATA[ “Context around patient-identified affordability and access challenges is really critical,” began Karin Hoelzer, DVM, PhD, Senior Director, Patient Advocacy during the Biotechnology Innovation Organization’s […]
The post Affordability and Access: Why patient perspectives matter appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/09/karin-at-the-coffee-chat.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 03:15:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Affordability, and, Access:, Why, patient, perspectives, matter</media:keywords>
<content:encoded><![CDATA[<p>“<em>Context</em> around patient-identified affordability and access challenges is really critical,” began Karin Hoelzer, DVM, PhD, Senior Director, Patient Advocacy during the Biotechnology Innovation Organization’s (BIO) August Coffee Chat, <em>The Facts are out There! What Patients Really Want (… timely access to treatments)</em>.</p>
<p>“Oftentimes,” she continued, “chronic disease patients take multiple therapies at the same time to manage a number of conditions, and so really looking at the whole picture, and truly understanding the root causes of the challenges patients face—including a lot of the changes we’ve seen to insurance design, the increase in utilization management, etc.—is key to what we’re talking about today.”</p>
<p>And indeed, as many patient advocacy groups have found, <em>affordability</em> and <em>access</em> cannot be considered in isolation.</p>
<div class="ast-oembed-container "></div>
<p>From harmful utilization management tactics like step therapy and prior authorization, to consequences of drug pricing provisions within the Inflation Reduction Act (IRA), to the 340B program being manipulated in ways that harm rather than help patients in need, patients are increasingly facing roadblocks accessing the care they need.</p>
<p>As advocates explained during the Coffee Chat, the patient’s voice and experience must guide health policy.</p>
<p>And there is a great deal of work being done in the patient community to understand and channel those experiences. For example, the Ensuring Access through Collaborative Health (EACH) & Patient Inclusion Council (PIC) coalition published the <a href="https://eachpic.org/wp-content/uploads/2026/03/PIC-Project-V2_03.01.2026.pdf">Patient Experience Project: Patient-Reported Affordability and Unaffordability Survey 2.0</a> report to better understand what affordability really means to patients. One of the survey’s key findings was that “Drug price alone does not determine affordability. Confirming findings from the pilot survey, insurance barriers, high cumulative medication costs, perspectives on how much medication should cost, and evolving life experiences were all primary drivers of reporting a drug as unaffordable.” In fact, the report found that “95% of patients who stopped taking their medication cited insurance-related challenges, not cost, as the primary cause.” Moreover, “72% who never started taking their medication cited insurance-related challenges, including denial of coverage and high out of pocket costs even with insurance.”</p>
<p>Similar findings were reflected in CancerCare’s <a href="https://bio.news/latest-news/cancercare-project-highlights-barriers-to-patient-access/">Red Tape Report</a>, which surveyed 1,201 cancer patients receiving treatment to understand the barriers that utilization management posed.</p>
<p>“We focused particularly on prior authorization, but our work was certainly not limited to that,” said Kim Czubaruk, JD, Vice President of Policy, CancerCare. “In our report, 85% of people treated for cancer were put through prior authorization just in the past year. And several of those had five or more prior authorizations in the past year, particularly those with employer-sponsored insurance.”</p>
<p>But although step therapy and other utilization management tools represent key barriers for patients, the problem goes far beyond utilization management.</p>
<h3>Shrinking Access for Medicare Beneficiaries</h3>
<p>The Inflation Reduction Act (IRA) is creating adverse effects on patients’ access to medications. Parts of the law, like the Part D out-of-pocket cap and Medicare Prescription Payment Plan (MPPP), are meaningful steps towards patient affordability. Other provisions, namely the Medicare Drug Price Negotiation Program (MDPNP), are restricting access for patients.</p>
<p>As Pat Wildman, Senior Vice President, Advocacy & Government Relations, Lupus Foundation of America explained, <a href="https://maprx.info/inflation-reduction-act-access-barriers-undermine-affordability/">some IRA policies have led to accelerate</a> narrow formularies and harmful utilization management practices, rather than putting the brakes on these trends.</p>
<p>“We’ve seen a lot of cost shifting [in Medicare]—moving from fixed copays to cost sharing, which increases people’s out of pocket costs,” Wildman said. “You go from a fixed copay to cost sharing, that’s a little bit harder to manage, harder to predict, and a challenge for folks, particularly when we talk about lupus.”</p>
<p>But it doesn’t stop there. Wildman and his team have also seen insurers narrowing formularies, i.e. covering fewer drugs in a therapeutic class or placing them on higher tiers with greater cost-sharing responsibilities.</p>
<p>“We’re also seeing other changes with the shrinking of the standalone prescription drug plan market, and that’s going to shrink further too,” Wildman said. “And premiums are going to become more of an issue as well with some of the changes that the administration has announced in eliminating the premium stabilization demonstration.”</p>
<p>“We’ve really been emphasizing in our conversations on the Hill that affordability and access aren’t just either-or issues, and you can’t just take one; you’ve got to look at both of them,” said Wildman. “We can improve affordability on the one hand, but undermine those improvements by creating access barriers.”</p>
<p>Patient preferences have to be a key part of the equation, too, advocates reminded the group.</p>
<p>For instance, the route of drug delivery is an important consideration for patients that can have tremendous impacts on the daily lives of patients and caregivers, but unfortunately such patient preferences are often overlooked in the policy debate. As the panelists noted, the Centers for Medicare and Medicaid Services (CMS) recently proposed changes to the definition of ‘Qualified Single Source Drug’ under the IRA ‘negotiation’, that would create strong disincentives to develop drug formulations that offer more patient-friendly administration routes such as injection rather than infusion. This is despite the fact that a <a href="https://pubmed.ncbi.nlm.nih.gov/40248457/">February 2025 study published on PubMed</a> found that patients strongly prefer injection to infusion as this administration route is less time consuming, easier to access, and has less caregiver burden, among other benefits.</p>
<p>This is yet another example of policy falling short of being patient-informed.</p>
<h3>340B and its misuse</h3>
<p>“340B is the largest program that no one’s ever heard of,” explained Wildman. Unfortunately, the program’s obscurity and lack of transparency has long played a strong role in its misuse. Advocates are now shining a light on the patient impact of this program’s misuse.</p>
<p>“Our goal was to humanize 340B because the direct impact on patients, and what the program’s intended to do as far as helping people who are underserved or are low income, is incredibly important,” said CancerCare’s Czubaruk. “But it has not been serving those needs as it was intended to.”</p>
<p><a href="https://www.cancercare.org/press/releases/cancercare-and-pioneer-institute-release-study-on-the-financial-outcomes-and-community-benefit-in-t">CancerCare partnered with the Pioneer Institute</a> to conduct a study that compared the levels of charity care provided by 340B hospitals and non-340B hospitals. This report investigated whether or not 340B hospitals were providing charity care at greater levels than non-340B hospitals.</p>
<p>“After all,” Czubaruk noted, “they are getting the discounts. And they are non-profits so they are getting the tax benefits. So we asked, <em>Were they providing that charity care at a higher level?</em> And the report, in summary, says <em>no</em>.”</p>
<p>While there are some good players in the system, Czubaruk explained, far too many are not acting above board.</p>
<p>“We conducted lengthy interviews with a number of patients who received cancer care at 340B hospitals, and from those interviews, we captured tremendous stories and quotes of how the 340B system has not provided charity care,” she said. “These are people in real need who are on the verge of eviction month to month. Some can’t afford their food. Most of them didn’t even know, understandably, that 340B existed and what its purpose was. The hospital never told them.”</p>
<p>And the lack of transparency in the 340B program does not stop at charity care, <a href="https://www.lupus.org/sites/default/files/media/documents/340BResearch%20Summary%20July2025%20FINAL%28forweb%29.pdf">a report commissioned by LFA and Arthritis Foundation</a> found 340B margin revenue for just arthritis and lupus alone is over $2 billion.</p>
<p>“Where is that money going?” Wildman asked. “It’s certainly not all going to charity care or lowering patient costs.”</p>
<h3>Defrayal and its effects on access</h3>
<p>The final topic addressed in the Coffee Chat was defrayal, a little-known element of the healthcare affordability and access conversation that is coming more and more to the fore.</p>
<p><a href="https://bio.news/latest-news/state-of-play-bio-coffee-chat-covers-how-state-policies-impact-access/">As Bio.News reported earlier this year</a>: “Under the Affordable Care Act (ACA), all health insurance plans offered through the ACA marketplace exchange must, at a minimum, cover federally defined essential health benefits (EHBs)… States can mandate that insurers cover additional benefits beyond the EHBs in all plans offered on the ACA exchange—but, under the original law, the states are required to ‘defray’ the added costs.”</p>
<p>“In the very simplest terms, it is the part of the ACA that is meant to discourage states from enacting new legislation and laws around specific mandated benefits,” explained Catherine Peters, Strategic Director, State & Local Campaigns at the American Cancer Society Cancer Action Network (ACS CAN). “Certain state laws that require insurance companies to cover certain benefits could trigger defrayal.”</p>
<p>As advocates noted, there is still a great deal to be learned about the nuances around this issue, so investigation and communication with stakeholders is key as the situation develops.</p>
<p>“Defrayal dictates that the state has to pay the difference between what a plan would have cost without the new mandate versus what it would cost now with the new mandate,” Peters continued. “There’s been a lot of back and forth between administrations about the enforcement of that provision of the ACA, but with the latest Notice of Benefit and Payment Parameters rule that was just finalized in May, the administration is doubling down on requiring states to pay for any mandated benefit that has passed since 2012.”</p>
<p>But, Peters said, they are already starting to see movement on this issue at the state level.</p>
<p>“We’re already hearing from a couple of states that are considering either repealing laws or appropriating money to cover the defrayal,” she observed. “We’re trying to gather as much intel as we can from state capitals to try to figure out what we’re going to be dealing with. But there’s a lot of unknowns, and some of this is just going to be kind of learning as we go once January comes. Unfortunately, we’re not sure how far state lawmakers are going to take some of this. Are they going to actually repeal statutes that provide important coverage protections to patients or find other workarounds? <em>We don’t know</em>.”</p>
<h3>It all comes back to patients</h3>
<p>Whether it is utilization management, elements of the IRA, 340B, or issues with defrayal, patient advocates remind that one element to the healthcare conversation must always stay front and center: patient need.</p>
<p>“When we talk about costs; people need to look at the bigger picture,” said Wildman. “You need to look at the cost of transportation, the cost of going to get care, the cost of daycare, the cost of missed school, the cost of missed work—those are all barriers to care. When you provide different options to get care, addressing those extra barriers is a good thing. If we ignore that, we are in essence, dismissing the value to the patient.”</p>
<p>“This is a nonpartisan issue,” added Czubaruk. “So we need to make sure that when we go up to the Hill and share our patient stories that they are reflected in the legislation that is being presented and passed.”</p>
<p>As the panelists explained, <em>don’t lose the patient story in the data</em>. Numbers may reflect patient experience, but they cannot express the reality fully. Patient stories and one-on-one interaction do that, and it is always the job of the advocate to maintain the drumbeat of patient-first <em>always.</em></p>
<p>“It’s not just saving money at all costs,” said Wildman. “The question that isn’t being asked is, <em>Saving money for who? </em>And oftentimes on the Hill, they see the dollars, the price tag, and the score, and in their minds it’s to save money for the government. It doesn’t necessarily translate to saving money for patients.”</p>
<p>“We’re on the defense of trying to respond to all of these actions that are actually taking away access for people to promote savings,” concluded Czubaruk. “But if savings to the government means less people are getting care, then we’ve defeated the entire purpose of innovative treatments and having a robust healthcare system in and of itself.”</p>
<p><em>If you are a patient advocate, and want to continue this conversation, consider registering for the Biotechnology Innovation Organization’s </em><a href="https://pace.bio.org/"><em>Patient Advocacy Changemakers Event (PACE)</em></a><em>: an empowering and inspiring event focused on breaking barriers to access and ensuring that innovative medicines reach the patients that need them.</em></p>
<p>The post <a href="https://bio.news/health/affordability-and-access-why-patient-perspectives-matter/">Affordability and Access: Why patient perspectives matter</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Regulatory Demands for More Process Control Data Fueling Innovation</title>
<link>https://edusehat.com/en/regulatory-demands-for-more-process-control-data-fueling-innovation</link>
<guid>https://edusehat.com/en/regulatory-demands-for-more-process-control-data-fueling-innovation</guid>
<description><![CDATA[ Advances in technology are making it easier for biopharma companies to embrace continuous manufacturing. However, they are also changing what regulators expect from drug firms in terms of the process control strategies they use.
The post Regulatory Demands for More Process Control Data Fueling Innovation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/04/GettyImages-675822742-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 03:10:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Regulatory, Demands, for, More, Process, Control, Data, Fueling, Innovation</media:keywords>
<content:encoded><![CDATA[<p>Regulators support the idea of using continuous processes to make drugs, with the caveat being that production is strictly controlled. This expectation is fueling a wave of innovation in tech that is rebounding to reshape manufacturing.</p>
<p>Korean researchers looked at the shifting landscape of process control in continuous manufacturing in a recent <a href="https://www.sciencedirect.com/science/article/pii/S0734975026001928#s0115" target="_blank" rel="noopener">study</a>, concluding that technological advances and regulation are the two most important dynamics.</p>
<p>Study co-author Moo Sun Hong, PhD, a professor from the department of chemical and biological engineering at Seoul National University, tells <em>GEN</em>, “Several advances have converged to make continuous biomanufacturing increasingly practical.</p>
<p>“On the monitoring side, process analytical technologies (PAT), including spectroscopic sensors and soft sensors, now provide much richer real-time information.</p>
<p>“At the same time, mechanistic models, hybrid models, and digital twins enable prediction of process behavior, optimization of operating conditions, and early detection of deviations. Together, these technologies allow manufacturers to move from reactive quality testing toward proactive, model-informed process control,” he adds.</p>
<p></p><h4><strong>Regulatory expectations</strong></h4>

<p>In addition to fueling the adoption of continuous manufacturing, technology advances are also changing what regulators want from developers.</p>
<p>Hong says, “Regulators have shifted from emphasizing end-product testing toward encouraging science- and risk-based process understanding throughout the product lifecycle.</p>
<p>“Recent guidance, including ICH Q13, places greater emphasis on validated process models, real-time monitoring, and robust control strategies that ensure consistent product quality during continuous operation,” he continues.</p>
<p>And, as technologies continue to advance, regulators are likely to want even more information about the models developers use during process development and to control production on the factory floor, according to Hong.</p>
<p>“I expect regulators will become increasingly receptive to advanced model-informed control strategies, provided there is sufficient evidence that the underlying models are reliable for their intended use.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>He adds that, “As continuous manufacturing becomes more widely adopted, regulatory expectations are likely to place greater emphasis on demonstrating that process models remain accurate over time through ongoing performance monitoring and, when appropriate, model updates supported by new data.”</p>
<p></p><h4><strong>AI process control</strong></h4>

<p>Artificial intelligence (AI) is also likely to play an increasingly important role in the control of continuous biopharmaceutical manufacturing processes, according to Hong, who says it will be used in conjunction with, rather than as a replacement for, mechanistic modeling.</p>
<p>“In the near term, AI is likely to have the greatest impact in areas such as soft sensing, anomaly detection, process optimization, and supporting the development and maintenance of digital twins.</p>
<p>“Hybrid approaches that combine AI with first-principles models are particularly promising because they can improve predictive performance while retaining the interpretability and physical consistency needed for industrial deployment and regulatory acceptance,” he says.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/regulatory-demands-for-more-process-control-data-fueling-innovation/">Regulatory Demands for More Process Control Data Fueling Innovation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production</title>
<link>https://edusehat.com/en/bicistornic-vectors-piggybac-improved-antibody-cell-line-production</link>
<guid>https://edusehat.com/en/bicistornic-vectors-piggybac-improved-antibody-cell-line-production</guid>
<description><![CDATA[ To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payloads of three or four cistrons, piggyBac is only the starting point. 
The post Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2204958094-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 03:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bicistornic, Vectors, piggyBac, Improved, Antibody, Cell, Line, Production</media:keywords>
<content:encoded><![CDATA[<p>To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payloads of three or four cistrons (sections of genes that express one complete, functional polypeptide), piggyBac is only the starting point.</p>
<p>For those larger, more complex antibodies, the challenges of multi-cistron vector architecture can lead to such upstream bottlenecks as unbalanced ratios of both heavy and light chains across cistrons, chain mispairing (which contributes to product heterogeneity), and genetic stability over time. Combined, they slow cell line development and hamper titer productivity.</p>
<p>Scientists at Sanofi’s Framingham, MA, site have developed a vector engineering strategy for multicistronic antibodies for coordinated transgene expression. It appears to improve promoter configuration and cassette topology, thus resolving those issues and improving titer productivity up to six-fold. It is, they suggest, “the first reported use of light-chain-selection marker-heavy chain topology for monoclonal antibody expression.”</p>
<p></p><h4><strong>Modified bicistronic vectors</strong></h4>

<p>Rather than use the traditional piggyBac monocistronic method and conventional vector designs, Jason Vitko, senior scientist, and colleagues modified bicistronic vectors and combined them with the piggyBac transposon system. Their work focused on altering promoter sequences, reporter placements, and cassette configurations.</p>
<p>As they <a href="https://doi.org/10.1002/biot.70296" target="_blank" rel="noopener">report</a>, “Double human cytomegalovirus promoter configurations driving both heavy and light chain genes significantly enhanced pool productivity (2 to 2.5-fold) and reporter expression compared to separate promoter designs.” More specifically, the light chain-glutamine synthetase-heavy chain configuration they used improved productivity from 1.5- to 6-fold, heavy chain RNA transcript ratios by 1.4- to 3.8-fold, and light chain RNA transcript ratios by 1.3- to 6.1-fold. The glutamine synthetase selection marker that was placed between the light and heavy chains improved the expression balance and productivity.</p>
<p>Improvements were most notable under fed-batch conditions, but negligible under unfed-batch conditions. The clones produced by the optimized piggyBac/bicistronic system “exhibited significantly high productivity, with the best clone producing 9.6 g/L.</p>
<p>“This approach simplified transfection workflows while providing enhanced control of gene expression and stability,” the scientists point out.</p>
<p>The monoclonal and multi-specific antibodies produced under this optimized piggyBac/bicistronic system are expected to be very stable, highly productive, correctly assembled, more homogeneous, and faster to develop than antibodies produced using standard piggyBac technologies. This work, Vitko and colleagues write, is foundational, establishing “a robust and scalable platform for the development of high-producing cell lines for next-generation therapeutic proteins.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/bicistornic-vectors-piggybac-improved-antibody-cell-line-production/">Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The DNA Balancing Act in Boosting Bacterial Productivity</title>
<link>https://edusehat.com/en/the-dna-balancing-act-in-boosting-bacterial-productivity</link>
<guid>https://edusehat.com/en/the-dna-balancing-act-in-boosting-bacterial-productivity</guid>
<description><![CDATA[ A new mathematical model tracks how plasmids move through competing E. coli populations, revealing how antibiotics, genetic costs, and plasmid loss could shape biotechnology cultures and future probiotic dosing strategies in the gut.
The post The DNA Balancing Act in Boosting Bacterial Productivity appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/Mike-Kojouharov_GBPN_IMAGE_03SEPT26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 03:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, DNA, Balancing, Act, Boosting, Bacterial, Productivity</media:keywords>
<content:encoded><![CDATA[<p>Inside a flask of <em>E. coli</em>, a microscopic power struggle is constantly unfolding. Some bacteria carry plasmids—small, extra pieces of DNA that can provide useful traits such as antibiotic resistance—while others go without them. A new <a href="https://doi.org/10.1007/s11538-026-01708-1" target="_blank" rel="noopener">study</a> suggests mathematics can help predict which group ultimately comes out ahead.</p>
<p>Hristo Kojouharov, PhD, chair of the department of mathematics at the University of Texas at Arlington, and his colleagues introduced a model that follows plasmids as they are lost, picked up, or transferred between bacterial cells. The researchers say the approach could help scientists better control bacterial cultures used to manufacture proteins and other biological products, while potentially informing how engineered probiotics behave in the gut.</p>
<p>Plasmids can give bacteria powerful advantages, but they are not free. Maintaining and replicating the extra DNA consumes resources. Experiments underpinning the model found that plasmid-carrying <em>E. coli</em> had a net growth rate of 0.25 per hour, compared with 0.30 for plasmid-free bacteria. Their estimated carrying capacity was also lower—4.81 million cells per microliter versus 7.11 million. That creates a trade-off: bacteria without plasmids might grow faster, but carrying plasmids can become advantageous when environmental pressure rewards the genes it contains.</p>
<p>The model shows that the eventual bacterial mix depends strongly on plasmid loss and transfer rates. Under certain conditions, plasmid-carrying and plasmid-free bacteria coexist; under others, the population eventually loses the plasmid entirely. Selection pressure can shift that balance by changing how worthwhile the genetic cargo is to its host.</p>
<p>The researchers describe plasmid dynamics as “highly dependent on the benefit vs. burden imparted on the bacterial system.” That balancing act could matter beyond laboratory flasks.</p>
<p>One potential application is engineered probiotic <em>E. coli</em>. The team envisions using the model to design dosing strategies that provide a “consistent and controlled presence of the plasmid” without allowing it to permanently persist in the gut. A sufficiently high plasmid-loss rate could eventually leave the bacteria free of the introduced DNA, which is important because, as the authors note, “permanent modifications of the gut bacterial function are not desirable.”</p>
<p>The work remains a model rather than a ready-made clinical dosing tool. The researchers assume plasmid gain and loss rates remain constant during an experiment, and future studies will investigate whether those rates change over time. Doing that, they say, will require finer measurements capable of distinguishing plasmid-carrying and plasmid-free populations as cultures evolve.</p>
<p>For biotechnology, though, the message is already useful: understanding when extra DNA is an advantage—and when it becomes baggage—could make bacterial cultures more predictable and productive.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/math-model-predicts-plasmid-power-struggles/">The DNA Balancing Act in Boosting Bacterial Productivity</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Spectrometry Technique Could Aid Formulation Development</title>
<link>https://edusehat.com/en/new-spectrometry-technique-could-aid-formulation-development</link>
<guid>https://edusehat.com/en/new-spectrometry-technique-could-aid-formulation-development</guid>
<description><![CDATA[ A new spectrometry technique could help companies better understand what happens when antigens and antibodies bind. Its developers hope it could help with applications including choosing formulation buffers during manufacturing. 
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/12/GettyImages-2147604905.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 03 Sep 2026 03:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Spectrometry, Technique, Could, Aid, Formulation, Development</media:keywords>
<content:encoded><![CDATA[<p>A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.</p>
<p>According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”</p>
<p>Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.</p>
<p>The challenge is understanding the link between these things within a heterogeneous sample, he says.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.</p>
<p>He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.</p>
<p>Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.</p>
<p>Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/new-spectrometry-technique-could-aid-formulation-development/">New Spectrometry Technique Could Aid Formulation Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Andelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene Therapy</title>
<link>https://edusehat.com/en/andelyn-to-support-manufacturing-scaleup-for-genprexs-diabetes-gene-therapy</link>
<guid>https://edusehat.com/en/andelyn-to-support-manufacturing-scaleup-for-genprexs-diabetes-gene-therapy</guid>
<description><![CDATA[ Under the agreement, Andelyn will transition Genprex&#039;s adeno-associated virus (AAV)-based diabetes gene therapy candidate with process optimization, scale-up, and IND-enabling and clinical-stage manufacturing to support clinical trials.
The post Andelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/09/GettyImages-2289017666.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 12:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Andelyn, Support, Manufacturing, Scaleup, for, Genprex’s, Diabetes, Gene, Therapy</media:keywords>
<content:encoded><![CDATA[<p>Genprex selected Andelyn Biosciences to support scale-up manufacturing for its diabetes gene therapy program. Its product candidate is designed to deliver the Pdx1 and MafA genes directly to the pancreas via the pancreatic duct using an AAV vector. The program is being developed as a potential treatment for type 1 and type 2 diabetes.</p>
<p>Under the agreement, Andelyn will transition Genprex’s AAV-based diabetes gene therapy candidate with process optimization, scale-up, and IND-enabling and clinical-stage manufacturing to support clinical trials.</p>
<p>The collaboration will draw on <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.andelynbio.com%2Fplatforms&data=05%7C02%7CJohn.Sterling%40sagepub.com%7Cb843e7c158054c8042f308df0858ad63%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639238849088750000%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=g5l0lKxsYQNTr01zgdmqzf5idOhG9%2BFFmlxdKWP8mis%3D&reserved=0">Andelyn’s Curator® Cell and Gene Therapy Platform </a>and experience in AAV process development, technology transfer, analytical development, and cGMP manufacturing, according to an Andelyn official. Manufacturing activities are expected to include process optimization, scale-up, analytical qualification, potency assay development, and drug product manufacturing in a cGMP-compliant facility.</p>
<p>In type 1 diabetes, Genprex’s candidate is designed to transform pancreatic alpha cells into functional beta-like cells capable of producing insulin. Genprex has reported preclinical findings in type 1 diabetes mouse models showing restoration of normal blood glucose levels for an extended period, as well as findings in nonhuman primate models indicating reduced insulin requirements, increased C-peptide levels, and improved glucose tolerance, according to a company official.</p>
<p>For type 2 diabetes, where autoimmunity is not a primary driver of disease, Genprex is evaluating whether its approach may help replenish and rejuvenate exhausted insulin-producing beta cells.</p>
<p>“Andelyn is pleased to support Genprex as it advances this important diabetes gene therapy program,” said Matt Niloff, CCO at Andelyn. “The transition from academic or research-grade manufacturing to a scalable cGMP process is a pivotal step in developing an advanced therapy. Our team will provide the technical, operational, and quality expertise needed to establish a robust manufacturing foundation for Genprex’s upcoming preclinical and clinical milestones.”</p>
<p>“Selecting Andelyn marks an important step in preparing our diabetes gene therapy program for IND-enabling studies and future clinical evaluation,” added Ryan Confer, president and CEO of Genprex. “Andelyn’s experience in AAV development and cGMP manufacturing will help us advance the manufacturing process as we work to move this program toward the clinic.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/andelyn-to-support-manufacturing-scaleup-for-genprexs-diabetes-gene-therapy/">Andelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>TraceIQ Launched to Maximize Pharmaceutical Traceability</title>
<link>https://edusehat.com/en/traceiq-launched-to-maximize-pharmaceutical-traceability</link>
<guid>https://edusehat.com/en/traceiq-launched-to-maximize-pharmaceutical-traceability</guid>
<description><![CDATA[ TraceIQ, which was developed and being marketing by Systech, combines enterprise traceability, operational intelligence, and AI-assisted investigations to help manufacturers prevent disruptions, accelerate exception resolution, and improve product availability.
The post TraceIQ Launched to Maximize Pharmaceutical Traceability appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1303435702.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 12:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>TraceIQ, Launched, Maximize, Pharmaceutical, Traceability</media:keywords>
<content:encoded><![CDATA[<p>Systech launched TraceIQ<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, an intelligent, enterprise traceability platform designed to address the evolving operational aspects of pharmaceutical and biopharma supply chains.</p>
<p>The first generation of enterprise traceability platforms were developed primarily to meet serialization mandates, exchange data with trading partners, and report to regulators, according to Sreedhar Patnala, general manager, Systech. Those systems established the compliance foundation the industry depends on today. But while compliance remains essential, it is no longer sufficient, Patnala maintained.</p>
<p>As regulations evolve and supply chains grow more complex—across sites, CMOs, logistics providers, and regulators—teams are expected to resolve issues faster and keep product moving with limited resources. Traditional traceability solutions serve as systems of record, capturing events and maintaining compliance. However, when operational issues occur, teams often struggle to quickly determine root causes, coordinate across partners, and take corrective action, continued Patnala, adding that the result can be investigation delays, shipment holds, and avoidable operational inefficiencies.</p>
<p><strong>Evolution from system of record to an intelligence system </strong></p>
<p><a href="https://www.systechone.com/products/pharmaceutical-track-trace/">TraceIQ</a> combines core compliance capabilities with an operational intelligence layer—enhanced by AI-assisted analytics and insights—designed for how pharmaceutical supply chains function today. Intuitive to use, TraceIQ transforms traceability data from a passive record of transactions into an active source of insight, enabling teams to identify patterns, investigate root causes, and collaborate across partners, explained Patnala.</p>
<p>“Serialization created unprecedented visibility into pharmaceutical supply chains, but visibility alone does not solve operational issues,” he pointed out. “Organizations need to quickly understand what happened, why it happened, and what action to take next. TraceIQ helps teams move beyond compliance reporting toward proactive operational decision-making that keeps products moving throughout the supply chain safely and in a timely manner.”</p>
<p>Patnala described how Systech TraceIQ is built around three operational outcomes:</p>
<ol>
<li><strong>Prevent issues before they stop product:</strong> Built-in validation and guardrails help identify bad data and avoidable errors before they create downstream exceptions, rework, or shipment delays.</li>
</ol>
<p>2.<strong> Resolve exceptions before they become disruptions:</strong> Centralized traceability data and AI-assisted investigation help teams determine what happened, identify likely causes, and take corrective action faster across internal operations and external partners.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>3. <strong>Turn traceability data into operational decisions:</strong> Intuitive search, analytics, and intelligent assistance provide supply chain, quality, and compliance teams with the insights they need to make faster decisions, improve partner collaboration, and optimize performance.</p>
<p>“From emerging biopharmaceutical companies preparing for commercial launch to global manufacturers and contract organizations managing complex partner ecosystems, TraceIQ helps organizations unlock greater value from their serialization and traceability investments,” Patnala said. “The result is improved operational visibility, increased productivity, and more informed decision-making.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/traceiq-launched-to-maximize-pharmaceutical-traceability/">TraceIQ Launched to Maximize Pharmaceutical Traceability</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities</title>
<link>https://edusehat.com/en/single-cell-striatum-atlas-reveals-neurological-disorder-vulnerabilities</link>
<guid>https://edusehat.com/en/single-cell-striatum-atlas-reveals-neurological-disorder-vulnerabilities</guid>
<description><![CDATA[ Researchers generated a single-cell atlas of the striatum, identifying 31 neuronal subpopulations and disease-linked vulnerabilities that could inform studies of Huntington’s disease, schizophrenia, depression, and substance use disorder.
The post Single-Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/10/Getty_1322096315__Dorsal_striatum_in_the_brain.webp" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 12:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Cell, Striatum, Atlas, Reveals, Neurological, Disorder, Vulnerabilities</media:keywords>
<content:encoded><![CDATA[<p>The striatum, a brain region involved in movement, decision-making, habit formation, and reward processing, is also implicated in some of the most difficult-to-treat neurological and psychiatric disorders, including Huntington’s disease, schizophrenia, depression, and substance use disorder. Now, MIT researchers have created a single-cell atlas of the striatum that could help explain why particular neuronal populations are vulnerable in different diseases and potentially point toward more targeted drug strategies.</p>
<p>The study, published in <em>Cell</em>, is titled “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)00933-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426009335%3Fshowall%3Dtrue" target="_blank" rel="noopener">Cross-species single-cell atlas of the striatum defines cell type and subregion disease vulnerabilities</a>.” The team used single-nucleus RNA sequencing across 109 human and 22 mouse samples spanning the dorsal and ventral striatum, together with spatial transcriptomics and multiplexed fluorescent <em>in situ</em> hybridization, to map cellular and molecular specialization across the region.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The researchers focused in part on medium spiny neurons, the most abundant neuronal cell type in the striatum. These inhibitory neurons are often divided into two major pathways: a direct pathway that helps promote movement and an indirect pathway that suppresses unwanted movement. But prior studies had suggested that the striatum contained many additional subpopulations, particularly in ventral regions, without a clear consensus on how those cells should be classified.</p>
<p>By profiling postmortem striatal tissue samples from brain banks in the United States and Canada, the MIT-led team identified 31 neuronal subpopulations, including nine types of medium spiny neurons. The atlas revealed two “outlier” populations with potential relevance to neuropsychiatric disease. One, known as D1 outliers, showed high expression of genes involved in substance use disorder, including genes related to opioid response. Another, D2 outliers, showed high expression of genes that respond to antidepressants. Both populations also appeared to respond strongly to the antipsychotic drug clozapine, which is used to treat schizophrenia.</p>
<p>The atlas also helped clarify why the dorsal striatum is especially vulnerable in Huntington’s disease, which is caused by an inherited expansion of CAG repeats in the huntingtin gene. The researchers found that dorsal medium spiny neuron populations expressed higher levels of MSH2 and MSH3, genes involved in increasing CAG repeat length. As those repeats accumulate, the mutant huntingtin protein becomes more toxic to cells.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>In contrast, a rare population of medium spiny neurons forming island-like structures in the ventral striatum appeared more resistant to CAG repeat accumulation. “Looking at the genes that these neurons express or don’t express might give us some clues as to how to make other medium spiny neurons resilient like them,” said Myriam Heiman, PhD, the Picower Professor of Neuroscience and director of MIT’s Picower Institute for Learning and Memory.</p>
<p>Comparisons between human and mouse samples further showed that some disease-relevant features of the human ventral striatum may not be fully captured in standard rodent models. For example, OPRM1, which encodes the mu opioid receptor, was highly expressed in the human D1 outlier population but not in corresponding mouse neurons. “Some of the diversity we’re seeing in the human ventral striatum is species-specific and has implications for modeling substance use disorder in rodents,” Heiman said.</p>
<p>Taken together, the findings provide a cellular roadmap of the striatum and its disease-linked vulnerabilities. The authors wrote that the work “lay[s] the foundation for understanding how striatal cell types and subregions contribute to brain function and neurological disorders,” offering a resource for researchers studying Huntington’s disease, substance use disorder, schizophrenia, and related conditions.</p>
<p>“We see this as the foundation that will allow more studies in our Huntington’s disease and opioid use disorder projects. We needed a roadmap of what is there,” added Heiman.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/single-cell-striatum-atlas-reveals-neurological-disorder-vulnerabilities/">Single-Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples</title>
<link>https://edusehat.com/en/advanced-imaging-technique-reveals-immune-cell-metabolic-states-in-blood-samples</link>
<guid>https://edusehat.com/en/advanced-imaging-technique-reveals-immune-cell-metabolic-states-in-blood-samples</guid>
<description><![CDATA[ Researchers showed how optical metabolic imaging (OMI) can be used to characterize metabolic activity within immune cells from the peripheral blood of patients, which could potentially help to improve disease diagnostics and the production of cell therapies. 
The post Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2018/08/July29_2014_54649943_RedandWhiteBloodCells_SuspectCancerStressTestWBCs3220417970.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 05:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advanced, Imaging, Technique, Reveals, Immune, Cell, Metabolic, States, Blood, Samples</media:keywords>
<content:encoded><![CDATA[<p>When a patient is facing certain cancers or an immune condition, clinicians turn to their white blood cells for clues about disease progression and treatment effects.  Clinical labs isolate peripheral blood mononuclear cells (PBMCs)—which are predominantly immune cells—from a blood draw, and assess the abundance different cell types, along with some basic measures of how they’re functioning. PBMCs are in addition the starting point for CAR T cell therapies, which engineer a patient’s own immune cells to fight certain cancers.</p>
<p>A study by scientists at the Morgridge Institute for Research has demonstrated how an advanced imaging technique, optical metabolic imaging (OMI) can be used to characterize metabolic activity within immune cells from the peripheral blood of patients, which the researchers say could improve disease diagnostics and the production of cell therapies.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The researchers suggest that when paired with current clinical techniques, this can provide a higher level of information beyond simple cell counts. Additionally, the classification of immune cells and their metabolic states in complex samples, rather than in monocultures, provides more accurate insights into the cell’s behavior.</p>
<p>They hope that the technique could help improve diagnosis and treatment of immune system-related conditions such as blood cancers, systemic lupus erythematosus (SLE), sepsis, and cognitive decline. Understanding immune dynamics in these engineered cells in more nuanced and comprehensive ways than are currently available to clinicians could improve the outcomes of patients undergoing treatments including CAR T-cell therapy.</p>
<p>“PBMCs can be isolated clinically really easily, and they’re already used in the clinical workflow,” commented Melissa Skala, PhD, an investigator in biomedical engineering at the Morgridge Institute. “So, the question is, what can we get from them that we aren’t already getting?”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Skala is senior author of the researchers’ published paper in <em>Biophotonics Discovery</em>, titled “<a href="http://dx.doi.org/10.1117/1.BIOS.3.3.035003" target="_blank" rel="noopener">Autofluorescence lifetime imaging resolves cell heterogeneity within peripheral blood mononuclear cells</a>,” in which they concluded that OMI could “… provide additional metabolic information to complement traditional measurements of PBMCs, which could improve disease monitoring, the development of immune therapies, and other applications where touch-free metabolic phenotyping is beneficial.”</p>
<p>PBMCs are a diverse cohort of immune cells comprised of lymphocytes (T cells, B cells, and NK cells) and myeloid cells (monocytes), the authors wrote. “Due to the high degree of immunologic heterogeneity, PBMCs are used in many applications from modeling the immune system to monitoring disease progression.”</p>
<p>Previously, techniques to measure immune cell metabolism needed to isolate individual cell types or add chemical labels that highlight the presence or absence of metabolites. Moreover, the team pointed out, “…  standard flow cytometry does not routinely assess cell metabolism, yet metabolic state reveals unique cell subpopulations and cell functional states compared with surface markers alone.”</p>
<p>First author Jeremiah Riendeau say that the team has, for first time, accurately observed the metabolic state of single immune cells across a complex PBMC sample using a nondestructive analysis. “You can continue using the samples after this analysis,” says Riendeau. With other techniques, Riendeau said, “if you want to study metabolism you have to add different reagents to the sample, and that can be harmful to the cells.” The ability to learn more about immune cells and their function without destroying them means the technique could be used in applications like assessing the fitness of immune cells before they’re administered as a treatment. Skala adds that “a lot of starting material for cell therapies are PBMCs. If you could do something to assess the fitness of those cells before processing them for cell therapy, that would be nice.”</p>
<p>To achieve nondestructive and extremely high-resolution imaging, the team used the optical metabolic imaging technique pioneered by the Skala lab, on samples of undifferentiated PBMCs isolated from donated blood of three human volunteers. “OMI relies on intrinsic sources of contrast, and this label-free imaging technique is attractive because no sample manipulation is required,” the team noted in their paper.</p>
<p>With OMI, a sensitive microscope shoots at the sample two long-wavelength photons, which don’t damage material as do those of a much shorter-wavelength, but have the same effect. This excites the inherent fluorescence of the products of cell metabolism and enables researchers to identify whether PBMCs are metabolically active or quiescent.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>For their reported study, the team achieved this with 93% accuracy only two hours after stimulating the cells. Further, they could specifically identify quiescent and activated monocytes with 96% and 88% accuracy, respectively, and natural killer (NK) cells in both states with 74% accuracy. “Here, we find that OMI provides a label-free measurement of single-cell metabolism that identifies immune cell subsets (monocytes, NK cells) and early activation state (two [hour] post-stimulation) within PBMCs without the need for staining, enabling high-throughput metabolic screens,” they stated.</p>
<p>While methods that use labels to identify immune cells and their metabolism are up to 100% accurate, the new technique’s distinct advantage is that of not needing to destructively manipulate the PBMCs. This makes OMI suitable for monitoring single-cell behavior over time while preserving samples for downstream applications. “Therefore, the same cells can be repeatedly imaged within intact cultures over time before performing endpoint analyses, or cells can be imaged before use in cell manufacturing or cell therapy,” the authors stated.</p>
<p>PBMCs are any blood cell with a single nucleus and consist mostly of immune or white blood cells. This includes cells from both the innate and adaptive immune systems. Innate immune cells like NK cells and monocytes are nonspecific, meaning they respond to any foreign invaders they encounter, and can destroy infectious or cancerous cells before they cause problems. The adaptive immune system, including types of T and B cells, learn from past infections and target specific antigens on foreign cells.</p>
<p>“The innate immune cells,” says Riendeau, “are kind of like the first responders, and then later on the adaptive immune cells will come in and help out with a more target-specific approach.”  The researchers found in the new study that innate immune cells are the most metabolically distinct, which likely is due to their ability to be highly reactive to threats and quickly ramp up their activity. Meanwhile, adaptive immune cells activate more slowly and need to be able to sustain energy over longer periods. However, elevated metabolic activity isn’t always good, and in conditions related to chronic inflammation, markers of activation can be an indicator that something is wrong.</p>
<p>“Generally, you don’t want to have constant, ongoing immune reactions. So, immune cells in the bloodstream are kept locked down in a quiescent state. But when there is some infection or other problem, like cancer, this would cause an immune reaction and activate metabolic pathways,” says Riendeau. “Having an understanding of the relative amounts of white blood cells is already used as a diagnostic biomarker. Adding this metabolic piece can tell you additional facts about the activation state of the immune cells.”</p>
<p>Riendeau says their new type of analysis using OMI can make sense of heterogenous metabolic states between cell types. For example, a subset of immune cells might be hyperactive while others remain quiescent. A bulk measurement averaging across the whole sample would hide those differences and obscure how the immune system is responding to an infection or whether cell therapy is successfully treating a cancer. But with the ability to nondestructively measure metabolism of single immune cells in a complex sample, researchers will be able to push forward how we understand our body’s defense systems.</p>
<p>Their paper, they suggest, “… is the first to show that OMI can classify activation state and immune cell subpopulations within PBMCs from primary human donors. This could provide a new tool to measure single cell metabolism within PBMCs and thereby provide label-free metabolic information to better monitor diseases characterized by immune activation (e.g., sepsis, SLE, rheumatoid arthritis) and screen PBMCs for cell therapy (e.g., verifying metabolic fitness of starting cells and products).”</p>
<p>Going forward, they hope to work with collaborators in hospitals to develop clinical applications for this analysis and bring better diagnosis and treatment outcomes to cancer and immune disorder patients. “Not every lab has access to a two-photon microscope, and so part of the research that’s being done here is making this label-free metabolic information accessible to more labs,” said Riendeau. “Our lab and collaborators are in the process of commercializing our technology so we can make this measurement more available. The idea is, now that we understand how things look in a relevant sample, other labs can have this and do this, too.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/advanced-imaging-technique-reveals-immune-cell-metabolic-states-in-blood-samples/">Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lilly Looks Beyond Obesity with Up&#45;to&#45;$2.9B Acquisition of Merida Biosciences</title>
<link>https://edusehat.com/en/lilly-looks-beyond-obesity-with-up-to-29b-acquisition-of-merida-biosciences</link>
<guid>https://edusehat.com/en/lilly-looks-beyond-obesity-with-up-to-29b-acquisition-of-merida-biosciences</guid>
<description><![CDATA[ Based in Cambridge, MA, Merida develops biologic drugs that are engineered to selectively degrade pathogenic autoantibodies linked to a number of immune-mediated conditions. Merida has said its precision degradation approach aims to address the biological cause of these diseases, rather than broadly suppressing the immune system as done by many current treatments.
The post Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Merida-Biosciences_photo_home_join-us_v2@2x.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 02 Sep 2026 02:05:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lilly, Looks, Beyond, Obesity, with, Up-to-2.9B, Acquisition, Merida, Biosciences</media:keywords>
<content:encoded><![CDATA[<p>Eli Lilly’s biotech buying spree continues as the pharma giant is planning to carry out its 13<sup>th</sup> buyout of a biotech this year, agreeing to acquire Merida Biosciences, a developer of precision therapies for serious autoimmune and allergic diseases, for up to $2.875 billion, the companies said.</p>
<p>Based in Cambridge, MA, Merida develops biologic drugs that are engineered to selectively degrade pathogenic autoantibodies linked to a number of immune-mediated conditions. Merida has said its precision degradation approach aims to address the biological cause of these diseases, rather than broadly suppressing the immune system as done by many current treatments.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“We see this acquisition as further evidence of mgmt [management]’s intent to diversify LLY’s pipeline beyond obesity,” David Risinger, a senior managing director and senior research analyst covering diversified biopharmaceuticals at  Leerink Partners, wrote Monday in a research note.</p>
<p>Merida’s lead program is MER511, a monomeric TSHR-IgG fragment crystallizable region (Fc) fusion protein being developed for Graves’ disease and thyroid eye disease (TED). Both conditions are driven by thyroid-stimulating immunoglobulins that activate thyroid-stimulating hormone receptors (TSHR) in the thyroid gland, triggering excess thyroid hormone production and accelerating metabolic activity.</p>
<p>MER511 is designed to bind and neutralize anti-TSHR autoantibodies, leading to clearance and degradation via FcγRIIB, the sole inhibitory Fc receptor for IgG, in liver sinusoidal endothelial cells (LSECs) while concurrently inhibiting antigen-specific B-cell function.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>At the Endocrine Society’s ENDO2026 conference held June 13-16 in Chicago, a research team shared detailed study plans for the Phase I NEXUS trial (<a href="https://clinicaltrials.gov/study/NCT07305818" target="_blank" rel="noopener">NCT07305818</a>), designed to establish initial safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MER511 to support its further clinical development in Graves’ disease.</p>
<p>“Data from <em>in vitro</em> and <em>in vivo</em> studies provide evidence that MER511 may directly address the underlying pathology of GD [Graves’ disease] by these targeted mechanisms, allowing for restoration of normal thyroid function,” the researchers stated.</p>
<p>NEXUS’ primary endpoints are number of participants with treatment-emergent adverse events, and number of participants with clinically significant changes in ECGs, vital signs, clinical laboratory values, and physical examination.</p>
<p>Graves’ disease affects approximately three million people in the U.S., of which roughly 25% to 40% go on to develop TED. While both conditions can be treated, present-day therapies do not target the autoantibodies that cause both disorders.</p>
<p></p><h4><strong>Beyond lead program</strong></h4>

<p>Lilly and Merida reason that Merida’s platform has potential application well beyond its lead program. The company’s pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria, and other diseases driven by the antibody responsible for triggering allergic reactions.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Also in Merida’s pipeline are earlier preclinical-stage programs in kidney diseases such as membranous nephropathy and other immune-mediated conditions.</p>
<p>“We see potential to apply this precision approach across a broad range of antibody-driven diseases, and we look forward to advancing this novel technology working with the Merida team,” Francisco Ramírez-Valle, MD, PhD, senior vice president, Lilly immunology research and early clinical development, said in a statement.</p>
<p>Ramirez-Valle added that initial Phase I data “already pointed to the potential for improved efficacy and safety.”</p>
<p>Lilly agreed to acquire Merida for up to $2.875 billion consisting of an upfront payment and payments tied to achieving milestones. Lilly is flush with cash on the commercial strength of its blockbuster metabolic drugs</p>
<p>The acquisition deal is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter.</p>
<p>Lilly shares traded on the New York Stock Exchange dipped 1.5% Monday, sliding from $1,174.61 to $1,156.73.</p>
<p>Merida launched last year with $121 million in Series A financing co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, joined by GV (Google Ventures) and Perceptive Xontogeny Venture Funds (PXV Funds).</p>
<p>“Under our CSO and founder Dario Gutierrez’s scientific leadership, our team has advanced that idea from concept to clinical data, and what we’ve seen so far reinforces our conviction that this approach can make a meaningful difference for patients,” Merida CEO Adam Townsend stated. “Today’s announcement reflects the hard work of the entire Merida team, and joining Lilly gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/lilly-looks-beyond-obesity-with-up-to-2-9b-acquisition-of-merida-biosciences/">Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Use Comes of Age—What’s Next?</title>
<link>https://edusehat.com/en/single-use-comes-of-agewhats-next</link>
<guid>https://edusehat.com/en/single-use-comes-of-agewhats-next</guid>
<description><![CDATA[ Single-use systems (SUS) bioprocessing technology has become mainstream. But the more interesting question today is what the industry needs next, and how SUS will enable the future.
The post Single-Use Comes of Age—What’s Next? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1422443070.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 11:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Use, Comes, Age—What’s, Next</media:keywords>
<content:encoded><![CDATA[<p>For much of the past two decades, the biopharmaceutical industry has assessed single-use technologies in terms of adoption: When would they replace stainless steel? How large could disposable bioreactors become? Which unit operations could realistically transition to single use?</p>
<p>At the 2026 Bio-Process Systems Alliance (BPSA) International Single-Use Summit in Boston in July, the conversation had clearly moved on to bigger things. Yes, single-use systems (SUS) bioprocessing has become mainstream. But the more interesting question today is what the industry needs next, and how SUS will enable the future.</p>
<p>Single-use market data presented by BioPlan Associates from <em>the 23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production<sup>1</sup></em> showed an industry continuing its return to normal after the extraordinary volatility of the pandemic. Single-use volume growth fell sharply in 2023 before rebounding strongly in 2024 and remaining positive in 2025.</p>
<p>At the BPSA Annual Summit, Eric Langer, managing partner, BioPlan Associates, characterized the current environment as one of “realistic optimism,” with the industry moving from post-pandemic anxiety toward more disciplined investment and decision-making.</p>
<p>The change is important. More than 200 SUS suppliers now participate in the segment, and disposable technologies are used across every stage of biopharmaceutical development and manufacturing. But maturity also raises expectations. As Langer noted, the honeymoon is over.</p>
<p>The next wave of innovation is increasingly about what can be built around and into single-use technologies: intensified and continuous processing, automation, better integration, and smarter, less expensive manufacturing.</p>
<figure aria-describedby="caption-attachment-337245" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class="wp-image-337245 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1.jpg" alt="Fig 1. Change in Sales VOLUME of SUS Manufacturers, 2023-2026: A Return Toward Normal [BioPlan Associates, Research Data Single Use Bioprocessing Industry Growth Trends, July 2026]" width="520" height="269" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1.jpg 520w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-300x155.jpg 300w" sizes="(max-width: 520px) 100vw, 520px"><figcaption class="wp-caption-text">Fig 1. Change in Sales VOLUME of SUS Manufacturers, 2023-2026: A Return Toward Normal [BioPlan Associates, Research Data Single Use Bioprocessing Industry Growth Trends, July 2026]</figcaption></figure>
<p>Carsten Lau, market development manager at Brückner Group USA, saw a similar change in the conversations at BPSA. A year ago, much of the discussion centered on tariffs, supply chains and whether the single-use industry could successfully navigate another period of disruption. This year, he said, the answer seems clearer: the industry will adapt. Attention has shifted back toward solving technical challenges, with particulate control emerging as a recurring concern.</p>
<p>For Lau, what makes that challenge interesting is how far upstream the pressure now travels. End-user concerns about particulates affect single-use system and bag manufacturers, who in turn are asking equipment suppliers how fabrication can be more automated, controlled, and inspected to reduce these particulate levels.</p>
<p></p><h4><strong>A changing pipeline needs a different manufacturing model</strong></h4>

<p>Reducing manual interventions can potentially improve consistency and particulate control while also increasing productivity. Solving the problem therefore requires collaboration across the single-use value chain, with each supplier understanding how its contribution affects the biopharmaceutical end user.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>One of the clearest signals from the meeting presentations, confirmed by BioPlan annual data, is the changing demands for innovation in the industry.</p>
<p>Manufacturing productivity and efficiency remain among the industry’s highest priorities, and suppliers are increasingly being asked to look beyond incremental improvements to individual single-use components. In upstream new-product development priorities, automation and artificial intelligence rise to the top<sup>1</sup>, while interest in simply lowering the cost of single-use devices and improving specific components has declined.</p>
<p>That does not mean cost, bags, connectors, or sensors no longer matter. Rather, it reflects the maturation of the technology. Many of the basic capabilities the industry spent two decades requesting are now expected, and users are increasingly satisfied with existing solutions.</p>
<figure aria-describedby="caption-attachment-337247" class="wp-caption alignnone"><img decoding="async" class="wp-image-337247 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1.jpg" alt="Fig 2: Upstream New Product Development Areas Where Suppliers Should Focus Development, 2026 (Selected Areas) [BioPlan Associates, 23rd Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026]" width="602" height="261" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1.jpg 602w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1-300x130.jpg 300w" sizes="(max-width: 602px) 100vw, 602px"><figcaption class="wp-caption-text">Fig 2: Upstream New Product Development Areas Where Suppliers Should Focus Development, 2026 (Selected Areas) [BioPlan Associates, 23rd Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026]</figcaption></figure>
<p>At the same time, the medicines being manufactured are changing.</p>
<p>Nishant Bhasin, managing director strategy consulting of PwC, described in his presentation an industry increasingly driven by smaller biotech companies, precision medicines, and therapies addressing more targeted patient populations. Small and mid-sized companies now account for approximately 60% or more of new drug approvals, twice their contribution 15 years ago.</p>
<p>That shift reinforces the manufacturing trends noted by SUS industry suppliers. Higher titers and improved process control increasingly allow manufacturers to create more capacity from smaller footprints, while smaller patient populations reduce the need for the massive, dedicated facilities traditionally associated with blockbuster products.</p>
<p>During a panel discussion, Langer pointed to the convergence of higher titers, manufacturing efficiency, process optimization, and smaller patient populations as reasons why the ability to scale down, rather than simply scale up, is also becoming increasingly important. SUS devices often provide this flexibility in scale, but more needs to be done.</p>
<p>Perfusion and continuous bioprocessing fit directly into this model. Approximately 43% of survey respondents<sup>1</sup> indicated that they expect to evaluate upstream continuous bioprocessing or perfusion during the next 12 months. Combined with single-use technologies, intensified processing can support smaller, highly productive manufacturing units while retaining the flexibility to accommodate changing products and demand.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>This is particularly relevant for emerging biotech companies that rarely intend to build large manufacturing organizations themselves. They increasingly depend on CDMOs and technology providers for flexible capacity that can accommodate smaller campaigns and rapidly changing requirements.</p>
<p>Single-use, perfusion, and process intensification therefore align not simply with a technology trend, but with the changing economics and product mix of the pharmaceutical pipeline.</p>
<p>The transition also raises the bar for suppliers. End users at the meeting noted that some existing single-use products were not originally designed or qualified for the operating conditions now being asked of them in intensified processes. As applications evolve, suppliers and users need to work together to understand operating limits and ensure products are ready for the ways manufacturers increasingly want to use them.</p>
<p></p><h4><strong>Where innovation meets manufacturing reality</strong></h4>

<p>The BPSA Summit also provided an important reality check: while single-use technologies can improve process controls, they do not eliminate the need for operator knowledge and control.</p>
<p>A Sanofi case study, presented by Cheryl Essex, head of industrial excellence, M&S Specialty Care RDOI Cluster at Sanofi, provocatively titled <em>“From Facility of the Future to Warning Letter in Five Years,”</em> highlighted lessons learned from implementing highly intensified single-use manufacturing. Innovation increases the importance of process understanding and operator knowledge. Appropriate controls often require close collaboration with suppliers of technology innovation.</p>
<p>The broader lesson is straightforward. Single use may simplify manufacturing infrastructure and can support more controlled processing. But that does not reduce the need for rigorous process understanding and control. As biologics manufacturers push these technologies into longer, more intensive and increasingly continuous applications, suppliers need to understand how their products are actually being used. End users need access to supplier expertise when designing, qualifying, and troubleshooting those systems.</p>
<p></p><h4><strong>Bioprocess innovation requires partnership and collaboration</strong></h4>

<p>Collaboration was one of the strongest themes running through the BPSA Summit. With more than 200 suppliers now providing single-use equipment and related services<sup>2</sup>, competition is intense. Yet many of the challenges facing the industry cannot be solved by one company acting alone. In that sense, BPSA occupies an unusual space: competitors meet not only to promote their technologies, but to address technical problems whose solutions can increase confidence in single use for everyone.</p>
<p>The joint presentation on filter interchangeability by Monica Cardona, global senior program manager single use at MilliporeSigma, and Samantha Whitney, senior field applications specialist at Meissner, provided a practical example. During the pandemic, component shortages transformed interchangeability from a theoretical discussion into an urgent manufacturing issue. Manufacturers that had previously resisted substitution suddenly needed practical ways to evaluate alternatives.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Yet even basic terminology was not standardized. What constitutes an “identical” SUS component, a “like-for-like” replacement, a “functional equivalent” or a “functional modification”? A cross-industry effort spent more than two years aligning definitions and establishing a framework for evaluating interchangeability. Greater standardization and clearer approaches to interchangeability can make second sourcing easier and make single-use systems simpler and more resilient for end users.</p>
<p>Nina Kaiser, senior sales manager at RENOLIT Healthcare, a supplier of high-performance polymer films used in single-use bioprocessing applications, described the Summit as an opportunity to bring together “innovators, manufacturers, technology providers and industry leaders” and emphasized the value created by openly discussing opportunities and challenges.</p>
<p><figure aria-describedby="caption-attachment-337248" class="wp-caption alignnone"><img decoding="async" class="wp-image-337248 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor.jpg" alt="Single-use bioreactor system undergoing factory acceptance testing. [CC1998USA/Wiki Commons]" width="960" height="640" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor.jpg 960w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-696x464.jpg 696w" sizes="(max-width: 960px) 100vw, 960px"><figcaption class="wp-caption-text">Single-use bioreactor system undergoing factory acceptance testing. [CC1998USA/Wiki Commons]</figcaption></figure>Lorenzo De Benedictis, PhD, senior vp R&D, product innovation and commercial excellence at 3CON Pharma Medical GmbH, a provider of customized single-use systems for bioprocessing, described the dynamic more informally: many participants are simultaneously friends and competitors. He values the opportunity to discuss the status quo with competitors but also sees an opportunity for BPSA to bring more pharmaceutical end users into the conversation.</p>
<p>Although supplier-to-supplier collaboration can develop better technologies, standards and common approaches, end users provide the reality check: what works and what fails in the real world, as the Sanofi case illustrated.</p>
<p></p><h4><strong>Flexibility, resilience and what comes next</strong></h4>

<p>The strategic value of flexibility also extends beyond manufacturing economics. Robert Huffman, director, manufacturability & resilience program, pharmaceutical countermeasures infrastructure division at BARDA, presented on strengthening the pharmaceutical industrial base. He highlighted the importance of preparedness and manufacturing capacity that can respond to future public-health needs, a challenge for which adaptable manufacturing technologies and resilient supply networks can play an important role.</p>
<p>Technology will continue to push this flexibility further. Automation and AI were prominent in BioPlan’s survey, but the immediate message for suppliers may be more practical than futuristic: systems increasingly need to integrate, generate useful process data, and work together seamlessly. As Langer cautioned, “You can’t implement this stuff until you’ve got the data infrastructure to make it work.”</p>
<p>Which of these technologies proves transformative is difficult to predict. The ability of the single-use community to evaluate them quickly, establish common approaches and translate innovation into solutions that work for end users may matter just as much.</p>
<p>The 2026 BPSA Summit suggested an industry at an important transition point. Single-use has succeeded to the point that simply being “single-use” is no longer enough. Its next phase will be defined by what SUS enables: smaller and more productive facilities, intensified and continuous processing, flexible capacity, greater automation, and more resilient supply networks.</p>
<p>Getting there will require more than new products. Suppliers will need to understand increasingly demanding applications, systems will need to integrate more seamlessly, and competitors will need to collaborate where common standards and solutions benefit the industry as a whole. Just as importantly, end users need to remain part of that conversation.</p>
<p>Single-use bioprocessing has come of age. What comes next may depend as much on how suppliers and competitors work together, and how closely they listen to end users, as on the technologies the industry develops.</p>
<p><em>Frances Lasowski, PhD, is director of research at BioPlan Associates (</em><a href="http://www.bioplanassociates.com/"><em>www.bioplanassociates.com</em></a><em>).</em></p>
<p><strong> </strong><strong>References:</strong></p>
<p><strong> </strong><sup>1</sup>23<sup>rd</sup> Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026, BioPlan Associates, Inc. Rockville, MD 20850 <a href="http://www.bioplanassociates.com/23rd">www.bioplanassociates.com/23rd</a></p>
<p><sup>2</sup>BioPlan Associates’ Single-use Biomanufacturing Supplier Directory (see <a href="http://www.bioplanassociates.com/">www.bioplanassociates.com</a>)</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/single-use-comes-of-age-what-comes-next/">Single-Use Comes of Age—What’s Next?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Use Comes of Age—What Comes Next?</title>
<link>https://edusehat.com/en/single-use-comes-of-agewhat-comes-next-13480</link>
<guid>https://edusehat.com/en/single-use-comes-of-agewhat-comes-next-13480</guid>
<description><![CDATA[ Single-use systems (SUS) bioprocessing technology has become mainstream. But the more interesting question today is what the industry needs next, and how SUS will enable the future.
The post Single-Use Comes of Age—What Comes Next? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1422443070.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 08:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Use, Comes, Age—What, Comes, Next</media:keywords>
<content:encoded><![CDATA[<p>For much of the past two decades, the biopharmaceutical industry has assessed single-use technologies in terms of adoption: When would they replace stainless steel? How large could disposable bioreactors become? Which unit operations could realistically transition to single use?</p>
<p>At the 2026 Bio-Process Systems Alliance (BPSA) International Single-Use Summit in Boston in July, the conversation had clearly moved on to bigger things. Yes, single-use systems (SUS) bioprocessing has become mainstream. But the more interesting question today is what the industry needs next, and how SUS will enable the future.</p>
<p>Single-use market data presented by BioPlan Associates from <em>the 23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production<sup>1</sup></em> showed an industry continuing its return to normal after the extraordinary volatility of the pandemic. Single-use volume growth fell sharply in 2023 before rebounding strongly in 2024 and remaining positive in 2025.</p>
<p>At the BPSA Annual Summit, Eric Langer, managing partner, BioPlan Associates, characterized the current environment as one of “realistic optimism,” with the industry moving from post-pandemic anxiety toward more disciplined investment and decision-making.</p>
<p>The change is important. More than 200 SUS suppliers now participate in the segment, and disposable technologies are used across every stage of biopharmaceutical development and manufacturing. But maturity also raises expectations. As Langer noted, the honeymoon is over.</p>
<p>The next wave of innovation is increasingly about what can be built around and into single-use technologies: intensified and continuous processing, automation, better integration, and smarter, less expensive manufacturing.</p>
<figure aria-describedby="caption-attachment-337245" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class="wp-image-337245 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1.jpg" alt="Fig 1. Change in Sales VOLUME of SUS Manufacturers, 2023-2026: A Return Toward Normal [BioPlan Associates, Research Data Single Use Bioprocessing Industry Growth Trends, July 2026]" width="520" height="269" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1.jpg 520w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-300x155.jpg 300w" sizes="(max-width: 520px) 100vw, 520px"><figcaption class="wp-caption-text">Fig 1. Change in Sales VOLUME of SUS Manufacturers, 2023-2026: A Return Toward Normal [BioPlan Associates, Research Data Single Use Bioprocessing Industry Growth Trends, July 2026]</figcaption></figure>
<p>Carsten Lau, market development manager at Brückner Group USA, saw a similar change in the conversations at BPSA. A year ago, much of the discussion centered on tariffs, supply chains and whether the single-use industry could successfully navigate another period of disruption. This year, he said, the answer seems clearer: the industry will adapt. Attention has shifted back toward solving technical challenges, with particulate control emerging as a recurring concern.</p>
<p>For Lau, what makes that challenge interesting is how far upstream the pressure now travels. End-user concerns about particulates affect single-use system and bag manufacturers, who in turn are asking equipment suppliers how fabrication can be more automated, controlled, and inspected to reduce these particulate levels.</p>
<p></p><h4><strong>A changing pipeline needs a different manufacturing model</strong></h4>

<p>Reducing manual interventions can potentially improve consistency and particulate control while also increasing productivity. Solving the problem therefore requires collaboration across the single-use value chain, with each supplier understanding how its contribution affects the biopharmaceutical end user.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>One of the clearest signals from the meeting presentations, confirmed by BioPlan annual data, is the changing demands for innovation in the industry.</p>
<p>Manufacturing productivity and efficiency remain among the industry’s highest priorities, and suppliers are increasingly being asked to look beyond incremental improvements to individual single-use components. In upstream new-product development priorities, automation and artificial intelligence rise to the top<sup>1</sup>, while interest in simply lowering the cost of single-use devices and improving specific components has declined.</p>
<p>That does not mean cost, bags, connectors, or sensors no longer matter. Rather, it reflects the maturation of the technology. Many of the basic capabilities the industry spent two decades requesting are now expected, and users are increasingly satisfied with existing solutions.</p>
<figure aria-describedby="caption-attachment-337247" class="wp-caption alignnone"><img decoding="async" class="wp-image-337247 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1.jpg" alt="Fig 2: Upstream New Product Development Areas Where Suppliers Should Focus Development, 2026 (Selected Areas) [BioPlan Associates, 23rd Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026]" width="602" height="261" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1.jpg 602w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1-300x130.jpg 300w" sizes="(max-width: 602px) 100vw, 602px"><figcaption class="wp-caption-text">Fig 2: Upstream New Product Development Areas Where Suppliers Should Focus Development, 2026 (Selected Areas) [BioPlan Associates, 23rd Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026]</figcaption></figure>
<p>At the same time, the medicines being manufactured are changing.</p>
<p>Nishant Bhasin, managing director strategy consulting of PwC, described in his presentation an industry increasingly driven by smaller biotech companies, precision medicines, and therapies addressing more targeted patient populations. Small and mid-sized companies now account for approximately 60% or more of new drug approvals, twice their contribution 15 years ago.</p>
<p>That shift reinforces the manufacturing trends noted by SUS industry suppliers. Higher titers and improved process control increasingly allow manufacturers to create more capacity from smaller footprints, while smaller patient populations reduce the need for the massive, dedicated facilities traditionally associated with blockbuster products.</p>
<p>During a panel discussion, Langer pointed to the convergence of higher titers, manufacturing efficiency, process optimization, and smaller patient populations as reasons why the ability to scale down, rather than simply scale up, is also becoming increasingly important. SUS devices often provide this flexibility in scale, but more needs to be done.</p>
<p>Perfusion and continuous bioprocessing fit directly into this model. Approximately 43% of survey respondents<sup>1</sup> indicated that they expect to evaluate upstream continuous bioprocessing or perfusion during the next 12 months. Combined with single-use technologies, intensified processing can support smaller, highly productive manufacturing units while retaining the flexibility to accommodate changing products and demand.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>This is particularly relevant for emerging biotech companies that rarely intend to build large manufacturing organizations themselves. They increasingly depend on CDMOs and technology providers for flexible capacity that can accommodate smaller campaigns and rapidly changing requirements.</p>
<p>Single-use, perfusion, and process intensification therefore align not simply with a technology trend, but with the changing economics and product mix of the pharmaceutical pipeline.</p>
<p>The transition also raises the bar for suppliers. End users at the meeting noted that some existing single-use products were not originally designed or qualified for the operating conditions now being asked of them in intensified processes. As applications evolve, suppliers and users need to work together to understand operating limits and ensure products are ready for the ways manufacturers increasingly want to use them.</p>
<p></p><h4><strong>Where innovation meets manufacturing reality</strong></h4>

<p>The BPSA Summit also provided an important reality check: while single-use technologies can improve process controls, they do not eliminate the need for operator knowledge and control.</p>
<p>A Sanofi case study, presented by Cheryl Essex, head of industrial excellence, M&S Specialty Care RDOI Cluster at Sanofi, provocatively titled <em>“From Facility of the Future to Warning Letter in Five Years,”</em> highlighted lessons learned from implementing highly intensified single-use manufacturing. Innovation increases the importance of process understanding and operator knowledge. Appropriate controls often require close collaboration with suppliers of technology innovation.</p>
<p>The broader lesson is straightforward. Single use may simplify manufacturing infrastructure and can support more controlled processing. But that does not reduce the need for rigorous process understanding and control. As biologics manufacturers push these technologies into longer, more intensive and increasingly continuous applications, suppliers need to understand how their products are actually being used. End users need access to supplier expertise when designing, qualifying, and troubleshooting those systems.</p>
<p></p><h4><strong>Bioprocess innovation requires partnership and collaboration</strong></h4>

<p>Collaboration was one of the strongest themes running through the BPSA Summit. With more than 200 suppliers now providing single-use equipment and related services<sup>2</sup>, competition is intense. Yet many of the challenges facing the industry cannot be solved by one company acting alone. In that sense, BPSA occupies an unusual space: competitors meet not only to promote their technologies, but to address technical problems whose solutions can increase confidence in single use for everyone.</p>
<p>The joint presentation on filter interchangeability by Monica Cardona, global senior program manager single use at MilliporeSigma, and Samantha Whitney, senior field applications specialist at Meissner, provided a practical example. During the pandemic, component shortages transformed interchangeability from a theoretical discussion into an urgent manufacturing issue. Manufacturers that had previously resisted substitution suddenly needed practical ways to evaluate alternatives.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Yet even basic terminology was not standardized. What constitutes an “identical” SUS component, a “like-for-like” replacement, a “functional equivalent” or a “functional modification”? A cross-industry effort spent more than two years aligning definitions and establishing a framework for evaluating interchangeability. Greater standardization and clearer approaches to interchangeability can make second sourcing easier and make single-use systems simpler and more resilient for end users.</p>
<p>Nina Kaiser, senior sales manager at RENOLIT Healthcare, a supplier of high-performance polymer films used in single-use bioprocessing applications, described the Summit as an opportunity to bring together “innovators, manufacturers, technology providers and industry leaders” and emphasized the value created by openly discussing opportunities and challenges.</p>
<p><figure aria-describedby="caption-attachment-337248" class="wp-caption alignnone"><img decoding="async" class="wp-image-337248 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor.jpg" alt="Single-use bioreactor system undergoing factory acceptance testing. [CC1998USA/Wiki Commons]" width="960" height="640" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor.jpg 960w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-696x464.jpg 696w" sizes="(max-width: 960px) 100vw, 960px"><figcaption class="wp-caption-text">Single-use bioreactor system undergoing factory acceptance testing. [CC1998USA/Wiki Commons]</figcaption></figure>Lorenzo De Benedictis, PhD, senior vp R&D, product innovation and commercial excellence at 3CON Pharma Medical GmbH, a provider of customized single-use systems for bioprocessing, described the dynamic more informally: many participants are simultaneously friends and competitors. He values the opportunity to discuss the status quo with competitors but also sees an opportunity for BPSA to bring more pharmaceutical end users into the conversation.</p>
<p>Although supplier-to-supplier collaboration can develop better technologies, standards and common approaches, end users provide the reality check: what works and what fails in the real world, as the Sanofi case illustrated.</p>
<p></p><h4><strong>Flexibility, resilience and what comes next</strong></h4>

<p>The strategic value of flexibility also extends beyond manufacturing economics. Robert Huffman, director, manufacturability & resilience program, pharmaceutical countermeasures infrastructure division at BARDA, presented on strengthening the pharmaceutical industrial base. He highlighted the importance of preparedness and manufacturing capacity that can respond to future public-health needs, a challenge for which adaptable manufacturing technologies and resilient supply networks can play an important role.</p>
<p>Technology will continue to push this flexibility further. Automation and AI were prominent in BioPlan’s survey, but the immediate message for suppliers may be more practical than futuristic: systems increasingly need to integrate, generate useful process data, and work together seamlessly. As Langer cautioned, “You can’t implement this stuff until you’ve got the data infrastructure to make it work.”</p>
<p>Which of these technologies proves transformative is difficult to predict. The ability of the single-use community to evaluate them quickly, establish common approaches and translate innovation into solutions that work for end users may matter just as much.</p>
<p>The 2026 BPSA Summit suggested an industry at an important transition point. Single-use has succeeded to the point that simply being “single-use” is no longer enough. Its next phase will be defined by what SUS enables: smaller and more productive facilities, intensified and continuous processing, flexible capacity, greater automation, and more resilient supply networks.</p>
<p>Getting there will require more than new products. Suppliers will need to understand increasingly demanding applications, systems will need to integrate more seamlessly, and competitors will need to collaborate where common standards and solutions benefit the industry as a whole. Just as importantly, end users need to remain part of that conversation.</p>
<p>Single-use bioprocessing has come of age. What comes next may depend as much on how suppliers and competitors work together, and how closely they listen to end users, as on the technologies the industry develops.</p>
<p><em>Frances Lasowski, PhD, is director of research at BioPlan Associates (</em><a href="http://www.bioplanassociates.com/"><em>www.bioplanassociates.com</em></a><em>).</em></p>
<p><strong> </strong><strong>References:</strong></p>
<p><strong> </strong><sup>1</sup>23<sup>rd</sup> Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026, BioPlan Associates, Inc. Rockville, MD 20850 <a href="http://www.bioplanassociates.com/23rd">www.bioplanassociates.com/23rd</a></p>
<p><sup>2</sup>BioPlan Associates’ Single-use Biomanufacturing Supplier Directory (see <a href="http://www.bioplanassociates.com/">www.bioplanassociates.com</a>)</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/single-use-comes-of-age-what-comes-next/">Single-Use Comes of Age—What Comes Next?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response</title>
<link>https://edusehat.com/en/spatial-transcriptomics-tools-may-link-tumor-organization-to-treatment-response</link>
<guid>https://edusehat.com/en/spatial-transcriptomics-tools-may-link-tumor-organization-to-treatment-response</guid>
<description><![CDATA[ A new spatial transcriptomics framework compares tumor “floor plans.&quot; In a study of 262 solid tumors, the team identified recurring spatial groups that may connect spatial structure, biological function, and response to therapy.
The post Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/08/GettyImages_1332513809_TumorMicroenvironment.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 08:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Spatial, Transcriptomics, Tools, May, Link, Tumor, Organization, Treatment, Response</media:keywords>
<content:encoded><![CDATA[<p>Spatial transcriptomics has given cancer researchers a powerful way to see not only which genes are active in a tumor, but where that activity is taking place. Yet the resulting maps can be difficult to compare across tumors because each tumor microenvironment is compositionally and functionally heterogeneous.</p>
<p>Researchers at the University of Chicago now report a framework for comparing these spatial maps across tumor types. In a study titled “<a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00430-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379126004301%3Fshowall%3Dtrue" target="_blank" rel="noopener">Pan-tumor spatial transcriptomics reveals conserved properties of tumor organization</a>,” published in <em>Cell Reports Medicine</em>, the team analyzed spatial transcriptomics data from 262 solid tumors and found that tumor microenvironments could be organized into recurring, hierarchically structured multicellular regions, which the researchers call “spatial groups.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Those spatial groups (SGs) appeared to capture recognizable biological domains, ranging from global tissue context to local cellular neighborhoods. When the researchers compared tumors through these groups, they found that the dominant axis separating tumors was the spatial heterogeneity of immune biology. In a small, independent retrospective cohort of 16 patients with non-small cell lung cancer treated with immune checkpoint blockade, the classification distinguished clinical responders from nonresponders and captured features associated with sensitivity to immunotherapy. “Together, these findings suggest that SGs may be important organizing domains of the TME that relate spatial structure, biological function, and response to therapy,” the authors wrote.</p>
<p>The work addresses a central problem in spatial biology: how to compare tumors at the level of tissue organization. Arjun Raman, MD, PhD, assistant professor of pathology at the University of Chicago and senior author of the study, likened the challenge to understanding a flock of birds. Individual cells behave in their own ways, but they also form collective structures that influence the behavior of the tumor as a whole.</p>
<p>“What we found out was we could describe tumors not as a composition of a whole bunch of cells, but like a flock of birds, where all the cells talk to each other and then create these subunits, and then subunits interact with each other to create meta subunits, and so on and so forth until you get the whole biopsy sample,” Raman said.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>By treating those subunits as spatial groups, the researchers could compare tumor “floor plans” using a statistical and machine learning framework. The approach places tumors in a comparative latent space, where samples are arranged according to spatial similarity. In principle, that could allow researchers or clinicians to ask whether a newly profiled tumor resembles tumors previously associated with response or resistance to a given therapy.</p>
<p>Raman said the longer-term goal is to bring this kind of comparative spatial analysis closer to precision oncology. “You could have a person who comes in with their unicorn of a tumor,” he said. “You then perform profiling on it, put the data into the comparative space, and within a few hours you can see if they should or should not get regimen X.”</p>
<p>For now, the treatment-response finding remains early. The immunotherapy analysis involved only 16 non-small cell lung cancer cases, and the authors framed spatial groups as candidate organizing domains that may relate to tumor structure, biological function, and therapy response. Still, the study suggests that spatial transcriptomics could move beyond producing detailed tumor maps to providing a common language for comparing them.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/spatial-transcriptomics-tools-may-link-tumor-organization-to-treatment-response/">Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO 2026: Are we entering the ‘golden era’ of women’s health?</title>
<link>https://edusehat.com/en/bio-2026-are-we-entering-the-golden-era-of-womens-health</link>
<guid>https://edusehat.com/en/bio-2026-are-we-entering-the-golden-era-of-womens-health</guid>
<description><![CDATA[ For years, advocates have pushed for more research and investment in women’s health. Now, it may be paying off. “I’m excited about the medicine […]
The post BIO 2026: Are we entering the ‘golden era’ of women’s health? appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/womens-health-panel-Michele.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 04:30:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, 2026:, Are, entering, the, ‘golden, era’, women’s, health</media:keywords>
<content:encoded><![CDATA[<p><span>For years, advocates have pushed for more research and investment in women’s health. Now, it may be paying off.</span></p>
<p><span>“I’m excited about the medicine starting to catch up with the conversation,” said Sabrina Martucci-Johnson, founder and CEO of Daré Bioscience, a clinical-stage company advancing innovations for vaginal health, at this summer’s 2026 BIO International Convention. </span></p>
<p><span>The panel, </span><a href="https://convention.bio.org/2026-sessions-and-courses/are-we-there-yet"><i><span>Are We There Yet: The Road to Clinical Development in Women’s Health</span></i></a><span>, explored signs that women’s health is moving from a historically overlooked area into a more robust biotech ecosystem with increased investment, greater regulatory engagement, and growing attention to conditions that have long lacked research, let alone treatment options.</span></p>
<p><span>For Juan Camilo Arjona Ferreira, M.D., Head of Research & Development and Chief Medical Officer at Organon, the largest company dedicated to women’s health, those changes add up to a potentially transformative moment.</span></p>
<p><span>“I think we’re entering the golden era of women’s health,” he said. “The momentum is real.”</span></p>
<h2>Building a women’s health ecosystem</h2>
<p><span>The discussion was moderated by Michele Oshman, BIO’s Chief Patient Advocate and Head of the Patient Advocacy Center of Excellence. She also serves as executive sponsor of BIO’s board-level Women’s Health Task Force, whose mission is to help ensure a robust pipeline of biopharmaceutical innovation for women’s health.</span></p>
<p><span>Achieving that mission requires more than developing individual products.</span></p>
<p><span>Dr. Arjona Ferreira said Organon sees a role for itself beyond its own pipeline because no single company or institution can address all the gaps in women’s health. For example, the company launched an accelerator that gives selected emerging companies access to Organon resources for up to 9 months to help them reach their next milestone, with “no strings attached.”</span></p>
<p><span>Martucci-Johnson described a different experiment in expanding participation. Daré Bioscience created a public offering to allow individual investors to participate with as little as $250.</span></p>
<p><span>The idea, she said, was to give people a way to “vote with their wallet and say, </span><i><span>I want to support the work that’s happening in women’s health.</span></i><span>”</span></p>
<h2>Finding a path through the clinic</h2>
<p><span>Capital is only one barrier. Developing medicines in areas such as pregnancy can also mean navigating unprecedented regulatory pathways.</span></p>
<p><span>Mike Young, President and Co-Founder of Comanche Biopharma, which is developing an investigational siRNA medicine for preterm preeclampsia, said the U.S. Food and Drug Administration (FDA) “still remains the gold standard.” However, he pointed to regulatory approaches abroad that encourage earlier and broader conversations around development and approval.</span></p>
<p><span>In pregnancy specifically, Young said companies and regulators are sometimes developing the playbook together because relatively few novel drugs have been designed specifically for pregnant women. </span></p>
<p><span>Julie Krop, M.D., Chief Medical Officer of DiaMedica Therapeutics—which is also researching preeclampsia—has seen increased openness at FDA to weighing potential benefits alongside risks in pregnancy. This is a particularly complex area because treatment decisions can affect both the mother and the baby.</span></p>
<p><span>Martucci-Johnson said that even repurposing existing medicines—which can reduce some development risk because their safety and pharmacology are already understood—does not eliminate the need to work with FDA to establish an appropriate regulatory roadmap for a new indication.</span></p>
<h2>Changing what, and how, we study women’s health</h2>
<p><span>The panelists argued that progress requires changing how researchers, regulators, clinicians, and the public talk about women and their health needs.</span></p>
<p><span>Young described Comanche’s efforts to integrate patients and survivors throughout the company, including in leadership and advisory roles, and to have patients themselves help create materials and support structures for clinical research.</span></p>
<p><span>“Word choice is extremely important in this space,” he said, explaining how he pushed back on describing pregnant women participating in clinical research as “vulnerable.” Pregnancy is complex, and the way women are characterized can affect how researchers approach their inclusion in clinical research.</span></p>
<p><span>Martucci-Johnson discussed the importance of word choice in ending the stigma surrounding women’s anatomy and sexual and reproductive health.</span></p>
<p><span>Many of Daré’s products use vaginal drug delivery, making it difficult to describe the company’s work without using the words “vagina” or “vaginal.” She recalled recording a podcast and being told she needed to stop saying the word “vagina” or the program would not be able to air.</span></p>
<p><span>“I said, </span><i><span>then you’re not going to be able to air it because I do not believe that I should be calling the vagina something other than the vagina. That is what it is</span></i><span>,” she recalled.</span></p>
<p><span>When “words are not deemed as comfortable or appropriate, it creates more stigma,” making it difficult for women to discuss what they are experiencing, and for developers to create products that address their needs, she explained.</span></p>
<h2>Why women’s health is overall health</h2>
<p><span>What gives these experts optimism is that several pieces may now be coming together at once. </span></p>
<p><span>Dr. Krop pointed to growing interest from large pharmaceutical companies, government investment, and a broader focus beyond traditionally recognized women’s health categories into conditions including pregnancy and endometriosis. As more research and investment enter the women’s health ecosystem, she explained, each can reinforce the other, drawing more researchers, companies, and investors.</span></p>
<p><span>But Young cautioned that women’s health companies must make the same rigorous scientific and financial case as any other biotech company: a validated target, a compelling therapeutic approach, experienced drug developers, strong chemistry, manufacturing, and controls (CMC) and quality capabilities, and sound financial management.</span></p>
<p><span>For Dr. Arjona Ferreira, new data and technology could help address one of the fundamental reasons women were historically understudied: biological variability was treated as complexity that researchers could not adequately analyze.</span></p>
<p><span>“We have the tools to understand massive amounts of data, and this is the time for us to take the noise and make it signal,” he said.</span></p>
<p><span>The ultimate goal, he argued, is not to leave women’s health as a separate vertical, but to “bring women’s health back into overall health.”</span></p>
<p>The post <a href="https://bio.news/latest-news/bio-2026-are-we-entering-the-golden-era-of-womens-health/">BIO 2026: Are we entering the ‘golden era’ of women’s health?</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>‘One&#45;Two Punch’ Targets Resistance Mechanism in Aggressive Triple&#45;Negative Breast Cancer</title>
<link>https://edusehat.com/en/one-two-punch-targets-resistance-mechanism-in-aggressive-triple-negative-breast-cancer</link>
<guid>https://edusehat.com/en/one-two-punch-targets-resistance-mechanism-in-aggressive-triple-negative-breast-cancer</guid>
<description><![CDATA[ Researchers discovered an unexpected role for lysyl oxidase inside triple negative breast cancer cells, and demonstrated that blocking LOX disrupts cellular processes to create a weakness that can be exploited using a second drug.
The post ‘One-Two Punch’ Targets Resistance Mechanism in Aggressive Triple-Negative Breast Cancer appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-2190708939.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 04:25:15 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>‘One-Two, Punch’, Targets, Resistance, Mechanism, Aggressive, Triple-Negative, Breast, Cancer</media:keywords>
<content:encoded><![CDATA[<p>Triple-negative breast cancer (TNBC) may initially respond well to chemotherapy but will often develop resistance to treatment. Researchers at Medical University of South Carolina Hollings Cancer Center have now uncovered one of the mechanisms behind that resistance and a potential approach to its reversal.</p>
<p>The team, headed by Ozgur Sahin, PhD, co-leader of the Hollings Cancer Biology and Immunology Research Program, discovered an unexpected role for a protein called lysyl oxidase, or LOX, inside TNBC cells. They found that blocking LOX disrupted several processes on which the cancer depends, creating a weakness that can then be exploited using a second drug.</p>
<p>Experiments showed that the combination strategy significantly blocked tumor growth in multiple preclinical models of TNBC, without chemotherapy. This is important as chemotherapy treatment is often associated with adverse effects and persistent tumor growth in the clinic. The new strategy offers a safe way to target chemoresistant tumors by first creating a weakness and then exploiting it to close the escape route the tumor cells use to survive.</p>
<p>“It’s a one-two-punch approach,” said Sahin, also program director of science translation for the Hollings Advisory for Rapid Translation, and senior and corresponding author of the team’s published paper in <em>Cell Reports Medicine</em>. “First, we block LOX, which weakens the cancer cells. As they adapt and become dependent on a backup survival pathway, we deliver the second punch by blocking that pathway, too.” The researchers’ paper is titled “<a href="http://dx.doi.org/10.1016/j.xcrm.2026.103015" target="_blank" rel="noopener">Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC</a>.”</p>
<p>TNBC gets its name because the cancer cells lack three common targets used to treat other forms of breast cancer, leaving patients with fewer treatment options. Chemotherapy remains a primary treatment for TNBC, but it comes with significant side effects. Even when tumors initially respond well, they often develop resistance. “TNBCs are characterized by high metabolic heterogeneity and plasticity, contributing to their aggressiveness and therapy resistance,” the authors noted. “Thus, identification of therapeutic vulnerabilities to improve clinical outcomes is urgently needed.”</p>
<p>Sahin added, “Triple-negative breast cancer is one of the most aggressive, deadliest versions of breast cancer. Chemotherapy is really the mainstay, and interestingly, this subtype is sensitive to chemotherapy compared to others, but resistance develops quite quickly.”</p>
<p>Sahin’s laboratory has spent years studying LOX. “High LOX expression has been associated with poor prognosis, chemoresistance, and metastasis across multiple cancer types the researchers noted.</p>
<p><figure aria-describedby="caption-attachment-337231" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-337231" src="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_HCC_Sahin_Ulukan_-Saatci_10082026_DSC09215-300x200.jpg" alt="Dr. Ozgur Sahin and postdoctoral fellows Drs. Burge Ulukan and Ozge Saatci discovered an unexpected role for a protein called lysyl oxidase, or LOX, inside triple-negative breast cancer cells. [Medical University of South Carolina]" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_HCC_Sahin_Ulukan_-Saatci_10082026_DSC09215-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_HCC_Sahin_Ulukan_-Saatci_10082026_DSC09215-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_HCC_Sahin_Ulukan_-Saatci_10082026_DSC09215-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_HCC_Sahin_Ulukan_-Saatci_10082026_DSC09215.jpg 700w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Ozgur Sahin, PhD, and postdoctoral fellows Burge Ulukan, PhD, and Ozge Saatci, PhD, discovered an unexpected role for a protein called lysyl oxidase, or LOX, inside triple-negative breast cancer cells. [Medical University of South Carolina]</figcaption></figure>Traditionally, scientists have focused on what the protein does outside cancer cells, where it reshapes the tissue surrounding tumors. As that tissue becomes denser and stiffer, cancer can spread more easily, and drugs have a harder time reaching the tumor. “LOX promotes collagen crosslinking and matrix stiffening, which contributes to tumor progression, invasion, and the establishment of pre-metastatic niche,” the researchers continued. But despite it’s well-established “extracellular functions,” they noted, “… whether LOX regulates energy metabolism and mitochondrial homeostasis in cancer cells remains poorly understood.</p>
<p>When Sahin and team looked inside cancer cells, they discovered something unexpected. For the first time, they showed that LOX also helps TNBC cells to survive from the inside by supporting energy production, maintaining healthy mitochondria and protecting the cells from stress.</p>
<p>Mitochondria produce the energy on which cells rely, and also help cells to respond to stress and maintain the balance that keeps them alive. The researchers found that LOX plays a key role in both. When they blocked LOX, cancer cells struggled to produce energy, cope with stress and ultimately survive.</p>
<p>“LOX helps cancer cells keep multiple survival systems running,” explained postdoctoral fellow and co-first author Burge Ulukan, PhD. “When we blocked LOX, the cancer cells lost that advantage. When we inhibit it, we are inhibiting multiple arms. We’re disrupting cells’ energy production and making them much more vulnerable to treatment.” By disrupting multiple systems that cancer cells depend on, the researchers had left them vulnerable. The next question was how to capitalize on that weakness. The researchers realized they could do that by triggering ferroptosis, a form of cell death caused by toxic damage inside the cell. Scientists are increasingly interested in harnessing ferroptosis to destroy cancer cells that resist other treatments.</p>
<p>Cancer cells have built-in defenses that protect them from ferroptosis. Blocking LOX weakened two of those defenses. But the cancer cells did not give up. Instead, they relied more heavily on a backup defense controlled by a protein called DHODH. That helped the cells to survive after LOX was blocked—but it also created a new weakness as the cancer cells became increasingly dependent on DHODH.</p>
<p>The researchers saw an opportunity. If blocking LOX was the first punch, blocking DHODH could provide the second. In laboratory experiments, blocking both pathways overwhelmed the cancer cells and caused damaging molecules to build up until the cells underwent ferroptosis.</p>
<p>The team then tested the strategy in several preclinical models, including models developed from patients whose tumors had become resistant to chemotherapy. They paired an experimental drug they developed to block LOX with the FDA-approved drug leflunomide, works by blocking the backup defense on which the cancer cells had become dependent.</p>
<p>The combination significantly blocked tumor growth across multiple patient-derived models. It did so without causing major weight loss or signs of kidney or liver toxicity. It also outperformed a combination of the LOX inhibitor and a standard chemotherapy drug. “Here, we identify non-canonical functions of LOX in promoting glucose metabolism, inhibiting mitophagy, and sustaining redox homeostasis and show that inhibiting LOX generates a targetable vulnerability to DHODH-inhibition-mediated ferroptosis,” the authors wrote in summary.</p>
<p>“One of the most exciting aspects of this work is that we uncovered an entirely new role for LOX inside cancer cells,” said postdoctoral fellow and co-first author Ozge Saatci, PhD. “That discovery revealed a weakness we could exploit. Rather than attacking cancer cells from just one direction, we first weaken the cells and then target the backup system they rely on to survive. That opens the door to a new treatment strategy.”</p>
<p>In their paper the team further commented, “In summary, our study identified non-canonical functions of LOX orchestrating glucose metabolism, mitophagy, and ferroptosis in TNBC. We demonstrated the therapeutic potential of targeting LOX in combination with DHODH inhibitors to eradicate highly aggressive TNBC tumors that could pave the way for clinical testing of LOX inhibitors in combination with DHODH inhibitors.”</p>
<p>The findings are still preclinical and do not mean the combination is ready for patients yet. But use of an existing drug could potentially make that path toward clinical testing far easier. “The good thing is when the drug is FDA approved, you know the side effect profile,” Sahin said. “It makes it faster and potentially safer to repurpose it, in other words, adapt it for a different disease condition.”</p>
<p>For patients, one of the most promising aspects of the research is the possibility of one day reducing reliance on chemotherapy. Although chemotherapy can be highly effective, it can also cause serious side effects, including heart damage and nerve damage that leads to numbness, tingling or pain in hands and feet. A successful nonchemotherapy approach could potentially avoid some of those toxicities. However, more research is needed to determine whether the new strategy is safe and effective in people.</p>
<p>Importantly, the researchers found evidence that the same biology they observed in the laboratory may also be at work in patients. In tumor samples from people with TNBC, higher levels of LOX were linked to increased activity in the same energy and survival pathways identified in the study. “High levels of both LOX and DHODH is associated with worse overall survival in TNBC patients,” the team further pointed out.</p>
<p>Together, the findings raise the possibility that these proteins could eventually serve as biomarkers, helping to identify patients most likely to benefit from treatments targeting this vulnerability. “LOX may act as a biomarker of response or resistance to the metabolic targeting of the tumors,” Ulukan said. “If we can identify patients whose tumors depend on this pathway, those may be the patients who benefit most from this type of treatment.”</p>
<p>The team is already developing a newer version of its LOX-blocking drug in collaboration with the University of South Carolina. The next step is completing the studies needed to test the drug safely in humans. Sahin hopes that process can be completed within the next few years. An earlier goal is to determine whether the strategy can help patients whose cancers have stopped responding to current treatments.</p>
<p>For the researchers, the study represents more than the discovery of a new drug target. It offers a new way to think about how to outsmart one of cancer’s greatest strengths, which is the ability to adapt. That approach could prove especially valuable for aggressive cancers such as TNBC, where treatment resistance remains one of the biggest barriers to long-term success.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/one-two-punch-targets-resistance-mechanism-in-aggressive-triple-negative-breast-cancer/">‘One-Two Punch’ Targets Resistance Mechanism in Aggressive Triple-Negative Breast Cancer</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Single&#45;Use Comes of Age–What Comes Next?</title>
<link>https://edusehat.com/en/single-use-comes-of-agewhat-comes-next</link>
<guid>https://edusehat.com/en/single-use-comes-of-agewhat-comes-next</guid>
<description><![CDATA[ Single-use systems (SUS) bioprocessing technology has become mainstream. But the more interesting question today is what the industry needs next, and how SUS will enable the future.
The post Single-Use Comes of Age–What Comes Next? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1422443070.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 04:25:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Single-Use, Comes, Age–What, Comes, Next</media:keywords>
<content:encoded><![CDATA[<p>For much of the past two decades, the biopharmaceutical industry has assessed single-use technologies in terms of adoption: When would they replace stainless steel? How large could disposable bioreactors become? Which unit operations could realistically transition to single use?</p>
<p>At the 2026 Bio-Process Systems Alliance (BPSA) International Single-Use Summit in Boston in July, the conversation had clearly moved on to bigger things. Yes, single-use systems (SUS) bioprocessing has become mainstream. But the more interesting question today is what the industry needs next, and how SUS will enable the future.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Single-use market data presented by BioPlan Associates from <em>the 23rd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production<sup>1</sup></em> showed an industry continuing its return to normal after the extraordinary volatility of the pandemic. Single-use volume growth fell sharply in 2023 before rebounding strongly in 2024 and remaining positive in 2025.</p>
<p>At the BPSA Annual Summit, Eric Langer, managing partner, BioPlan Associates, characterized the current environment as one of “realistic optimism,” with the industry moving from post-pandemic anxiety toward more disciplined investment and decision-making.</p>
<p>The change is important. More than 200 SUS suppliers now participate in the segment, and disposable technologies are used across every stage of biopharmaceutical development and manufacturing. But maturity also raises expectations. As Langer noted, the honeymoon is over.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The next wave of innovation is increasingly about what can be built around and into single-use technologies: intensified and continuous processing, automation, better integration, and smarter, less expensive manufacturing.</p>
<figure aria-describedby="caption-attachment-337245" class="wp-caption alignnone"><img fetchpriority="high" decoding="async" class="wp-image-337245 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1.jpg" alt="Fig 1. Change in Sales VOLUME of SUS Manufacturers, 2023-2026: A Return Toward Normal [BioPlan Associates, Research Data Single Use Bioprocessing Industry Growth Trends, July 2026]" width="520" height="269" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1.jpg 520w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-300x155.jpg 300w" sizes="(max-width: 520px) 100vw, 520px"><figcaption class="wp-caption-text">Fig 1. Change in Sales VOLUME of SUS Manufacturers, 2023-2026: A Return Toward Normal [BioPlan Associates, Research Data Single Use Bioprocessing Industry Growth Trends, July 2026]</figcaption></figure>
<p>Carsten Lau, market development manager at Brückner Group USA, saw a similar change in the conversations at BPSA. A year ago, much of the discussion centered on tariffs, supply chains and whether the single-use industry could successfully navigate another period of disruption. This year, he said, the answer seems clearer: the industry will adapt. Attention has shifted back toward solving technical challenges, with particulate control emerging as a recurring concern.</p>
<p>For Lau, what makes that challenge interesting is how far upstream the pressure now travels. End-user concerns about particulates affect single-use system and bag manufacturers, who in turn are asking equipment suppliers how fabrication can be more automated, controlled, and inspected to reduce these particulate levels.</p>
<p></p><h4><strong>A changing pipeline needs a different manufacturing model</strong></h4>

<p>Reducing manual interventions can potentially improve consistency and particulate control while also increasing productivity. Solving the problem therefore requires collaboration across the single-use value chain, with each supplier understanding how its contribution affects the biopharmaceutical end user.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>One of the clearest signals from the meeting presentations, confirmed by BioPlan annual data, is the changing demands for innovation in the industry.</p>
<p>Manufacturing productivity and efficiency remain among the industry’s highest priorities, and suppliers are increasingly being asked to look beyond incremental improvements to individual single-use components. In upstream new-product development priorities, automation and artificial intelligence rise to the top<sup>1</sup>, while interest in simply lowering the cost of single-use devices and improving specific components has declined.</p>
<p>That does not mean cost, bags, connectors, or sensors no longer matter. Rather, it reflects the maturation of the technology. Many of the basic capabilities the industry spent two decades requesting are now expected, and users are increasingly satisfied with existing solutions.</p>
<figure aria-describedby="caption-attachment-337247" class="wp-caption alignnone"><img decoding="async" class="wp-image-337247 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1.jpg" alt="Fig 2: Upstream New Product Development Areas Where Suppliers Should Focus Development, 2026 (Selected Areas) [BioPlan Associates, 23rd Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026]" width="602" height="261" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1.jpg 602w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-1-300x130.jpg 300w" sizes="(max-width: 602px) 100vw, 602px"><figcaption class="wp-caption-text">Fig 2: Upstream New Product Development Areas Where Suppliers Should Focus Development, 2026 (Selected Areas) [BioPlan Associates, 23rd Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026]</figcaption></figure>
<p>At the same time, the medicines being manufactured are changing.</p>
<p>Nishant Bhasin, managing director strategy consulting of PwC, described in his presentation an industry increasingly driven by smaller biotech companies, precision medicines, and therapies addressing more targeted patient populations. Small and mid-sized companies now account for approximately 60% or more of new drug approvals, twice their contribution 15 years ago.</p>
<p>That shift reinforces the manufacturing trends noted by SUS industry suppliers. Higher titers and improved process control increasingly allow manufacturers to create more capacity from smaller footprints, while smaller patient populations reduce the need for the massive, dedicated facilities traditionally associated with blockbuster products.</p>
<p>During a panel discussion, Langer pointed to the convergence of higher titers, manufacturing efficiency, process optimization, and smaller patient populations as reasons why the ability to scale down, rather than simply scale up, is also becoming increasingly important. SUS devices often provide this flexibility in scale, but more needs to be done.</p>
<p>Perfusion and continuous bioprocessing fit directly into this model. Approximately 43% of survey respondents<sup>1</sup> indicated that they expect to evaluate upstream continuous bioprocessing or perfusion during the next 12 months. Combined with single-use technologies, intensified processing can support smaller, highly productive manufacturing units while retaining the flexibility to accommodate changing products and demand.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>This is particularly relevant for emerging biotech companies that rarely intend to build large manufacturing organizations themselves. They increasingly depend on CDMOs and technology providers for flexible capacity that can accommodate smaller campaigns and rapidly changing requirements.</p>
<p>Single-use, perfusion, and process intensification therefore align not simply with a technology trend, but with the changing economics and product mix of the pharmaceutical pipeline.</p>
<p>The transition also raises the bar for suppliers. End users at the meeting noted that some existing single-use products were not originally designed or qualified for the operating conditions now being asked of them in intensified processes. As applications evolve, suppliers and users need to work together to understand operating limits and ensure products are ready for the ways manufacturers increasingly want to use them.</p>
<p></p><h4><strong>Where innovation meets manufacturing reality</strong></h4>

<p>The BPSA Summit also provided an important reality check: while single-use technologies can improve process controls, they do not eliminate the need for operator knowledge and control.</p>
<p>A Sanofi case study, presented by Cheryl Essex, head of industrial excellence, M&S Specialty Care RDOI Cluster at Sanofi, provocatively titled <em>“From Facility of the Future to Warning Letter in Five Years,”</em> highlighted lessons learned from implementing highly intensified single-use manufacturing. Innovation increases the importance of process understanding and operator knowledge. Appropriate controls often require close collaboration with suppliers of technology innovation.</p>
<p>The broader lesson is straightforward. Single use may simplify manufacturing infrastructure and can support more controlled processing. But that does not reduce the need for rigorous process understanding and control. As biologics manufacturers push these technologies into longer, more intensive and increasingly continuous applications, suppliers need to understand how their products are actually being used. End users need access to supplier expertise when designing, qualifying, and troubleshooting those systems.</p>
<p></p><h4><strong>Bioprocess innovation requires partnership and collaboration</strong></h4>

<p>Collaboration was one of the strongest themes running through the BPSA Summit. With more than 200 suppliers now providing single-use equipment and related services<sup>2</sup>, competition is intense. Yet many of the challenges facing the industry cannot be solved by one company acting alone. In that sense, BPSA occupies an unusual space: competitors meet not only to promote their technologies, but to address technical problems whose solutions can increase confidence in single use for everyone.</p>
<p>The joint presentation on filter interchangeability by Monica Cardona, global senior program manager single use at MilliporeSigma, and Samantha Whitney, senior field applications specialist at Meissner, provided a practical example. During the pandemic, component shortages transformed interchangeability from a theoretical discussion into an urgent manufacturing issue. Manufacturers that had previously resisted substitution suddenly needed practical ways to evaluate alternatives.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Yet even basic terminology was not standardized. What constitutes an “identical” SUS component, a “like-for-like” replacement, a “functional equivalent” or a “functional modification”? A cross-industry effort spent more than two years aligning definitions and establishing a framework for evaluating interchangeability. Greater standardization and clearer approaches to interchangeability can make second sourcing easier and make single-use systems simpler and more resilient for end users.</p>
<p>Nina Kaiser, senior sales manager at RENOLIT Healthcare, a supplier of high-performance polymer films used in single-use bioprocessing applications, described the Summit as an opportunity to bring together “innovators, manufacturers, technology providers and industry leaders” and emphasized the value created by openly discussing opportunities and challenges.</p>
<p><figure aria-describedby="caption-attachment-337248" class="wp-caption alignnone"><img decoding="async" class="wp-image-337248 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor.jpg" alt="Single-use bioreactor system undergoing factory acceptance testing. [CC1998USA/Wiki Commons]" width="960" height="640" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor.jpg 960w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/Single-use_bioreactor-696x464.jpg 696w" sizes="(max-width: 960px) 100vw, 960px"><figcaption class="wp-caption-text">Single-use bioreactor system undergoing factory acceptance testing. [CC1998USA/Wiki Commons]</figcaption></figure>Lorenzo De Benedictis, PhD, senior vp R&D, product innovation and commercial excellence at 3CON Pharma Medical GmbH, a provider of customized single-use systems for bioprocessing, described the dynamic more informally: many participants are simultaneously friends and competitors. He values the opportunity to discuss the status quo with competitors but also sees an opportunity for BPSA to bring more pharmaceutical end users into the conversation.</p>
<p>Although supplier-to-supplier collaboration can develop better technologies, standards and common approaches, end users provide the reality check: what works and what fails in the real world, as the Sanofi case illustrated.</p>
<p></p><h4><strong>Flexibility, resilience and what comes next</strong></h4>

<p>The strategic value of flexibility also extends beyond manufacturing economics. Robert Huffman, director, manufacturability & resilience program, pharmaceutical countermeasures infrastructure division at BARDA, presented on strengthening the pharmaceutical industrial base. He highlighted the importance of preparedness and manufacturing capacity that can respond to future public-health needs, a challenge for which adaptable manufacturing technologies and resilient supply networks can play an important role.</p>
<p>Technology will continue to push this flexibility further. Automation and AI were prominent in BioPlan’s survey, but the immediate message for suppliers may be more practical than futuristic: systems increasingly need to integrate, generate useful process data, and work together seamlessly. As Langer cautioned, “You can’t implement this stuff until you’ve got the data infrastructure to make it work.”</p>
<p>Which of these technologies proves transformative is difficult to predict. The ability of the single-use community to evaluate them quickly, establish common approaches and translate innovation into solutions that work for end users may matter just as much.</p>
<p>The 2026 BPSA Summit suggested an industry at an important transition point. Single-use has succeeded to the point that simply being “single-use” is no longer enough. Its next phase will be defined by what SUS enables: smaller and more productive facilities, intensified and continuous processing, flexible capacity, greater automation, and more resilient supply networks.</p>
<p>Getting there will require more than new products. Suppliers will need to understand increasingly demanding applications, systems will need to integrate more seamlessly, and competitors will need to collaborate where common standards and solutions benefit the industry as a whole. Just as importantly, end users need to remain part of that conversation.</p>
<p>Single-use bioprocessing has come of age. What comes next may depend as much on how suppliers and competitors work together, and how closely they listen to end users, as on the technologies the industry develops.</p>
<p><em>Frances Lasowski, PhD, is director of research at BioPlan Associates (</em><a href="http://www.bioplanassociates.com/"><em>www.bioplanassociates.com</em></a><em>).</em></p>
<p><strong> </strong><strong>References:</strong></p>
<p><strong> </strong><sup>1</sup>23<sup>rd</sup> Annual Report of Biopharmaceutical Manufacturing Capacity and Production, April 2026, BioPlan Associates, Inc. Rockville, MD 20850 <a href="http://www.bioplanassociates.com/23rd">www.bioplanassociates.com/23rd</a></p>
<p><sup>2</sup>BioPlan Associates’ Single-use Biomanufacturing Supplier Directory (see <a href="http://www.bioplanassociates.com/">www.bioplanassociates.com</a>)</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/single-use-comes-of-age-what-comes-next/">Single-Use Comes of Age–What Comes Next?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Synthetically Engineered Marine Bacteria Could Play Key Role in Decarbonizing the Atmosphere at Industrial Scales</title>
<link>https://edusehat.com/en/synthetically-engineered-marine-bacteria-could-play-key-role-in-decarbonizing-the-atmosphere-at-industrial-scales</link>
<guid>https://edusehat.com/en/synthetically-engineered-marine-bacteria-could-play-key-role-in-decarbonizing-the-atmosphere-at-industrial-scales</guid>
<description><![CDATA[ A group of academic researchers genetically engineered Alteromonas macleodii, a widespread marine bacterium, to produce more siderophores, accelerating olivine weathering 2.6-fold in seawater bioreactors and enhancing atmospheric CO₂ removal.
The post Synthetically Engineered Marine Bacteria Could Play Key Role in Decarbonizing the Atmosphere at Industrial Scales appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-94146417-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:50:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Synthetically, Engineered, Marine, Bacteria, Could, Play, Key, Role, Decarbonizing, the, Atmosphere, Industrial, Scales</media:keywords>
<content:encoded><![CDATA[<p>Rock weathering is a major regulator of Earth’s atmospheric CO<sub>2</sub> levels and climate, according to scientists. Throughout Earth’s history, rock weathering has been faster during warm periods with increased atmospheric CO<sub>2</sub> levels. Dissolved minerals ultimately wash into the ocean, where they draw CO<sub>2</sub> from the atmosphere and cool the planet again. The weathering cycle occurs over hundreds of thousands of years.</p>
<p>Researchers have wondered if the rock weathering cycle could be sped up, resulting in a number of new companies pursuing Enhanced Rock Weathering (ERW). By scattering crushed silicate rocks on agricultural surfaces or into water, they aim to pull excess CO<sub>2</sub> out of the atmosphere. Although this strategy is generally safe and environmentally friendly, it is still too slow to affect the global carbon balance or to be economically viable at industrial scale.</p>
<p>Now, a collaborative team at the Wyss Institute at Harvard University, Harvard Medical School’s (HMS) department of systems of biology, and the Stanford Doerr School of Sustainability, has engineered a potential solution to this problem. They published their study “<a href="https://www.nature.com/articles/s41587-026-03288-w" target="_blank" rel="noopener">Engineered bacterial siderophore production accelerates rock weathering for carbon removal</a>” in <em>Nature Biotechnology</em>.</p>
<p>The researchers, spearheaded by first-author and chemical engineer Neil Dalvie, PhD, from HMS, genetically engineered <em>Alteromonas macleodii</em>, a widespread marine bacterium, to produce much higher amounts of so-called siderophores, molecules that extract iron from silicate minerals. In customized bioreactors with a continuous flow of seawater, the engineered bacterium sped up the weathering of the silicate mineral olivine by 2.6-fold, boosting the amount of CO<sub>2</sub> that was removed from air.</p>
<p><figure aria-describedby="caption-attachment-337188" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337188" src="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Bio-rock-Weathering-Group-Photo-03433-300x200.jpg" alt="(Left to right) Amogh Jalihal, Neil Dalvie, and team member Mohammed Hijaz carry out research in the rockweathering lab that they equipped with multiple rock-seawater bioreactors to pursue their rockweathering study. [Wyss Institute at Harvard University]" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Bio-rock-Weathering-Group-Photo-03433-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Bio-rock-Weathering-Group-Photo-03433-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Bio-rock-Weathering-Group-Photo-03433-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Bio-rock-Weathering-Group-Photo-03433.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">(Left to right) Amogh Jalihal, Neil Dalvie, and team member Mohammed Hijaz carry out research in the rockweathering lab that they equipped with multiple rock-seawater bioreactors to pursue their rockweathering study. [Wyss Institute at Harvard University]</figcaption></figure>“Our study embraces the concept of biologically inspired engineering and how synthetic biology can be applied to enhance normal climate-regulating processes, which ultimately could have a positive impact on our planet,” said Wyss Institute founding core faculty member Pamela Silver, PhD, who, along with Wyss Institute associate faculty member Michael Springer, PhD, led the collaborative research team. “We believe this easily applicable, risk-free environmental engineering strategy could be implemented at many places with real-world decarbonization outcomes.”</p>
<p>Springer, who also is the Elliot T. and Onie H. Adams Professor of Biochemistry and System Biology at HMS, and Silver founded the Synthetic Biology Hive at HMS.</p>
<p></p><h4><strong>Fast-tracking geology with synthetic biology</strong></h4>

<p>During natural rock weathering, silicate minerals like olivine dissolve primarily to release magnesium (Mg), iron (Fe) and silicate (SiO<sub>4</sub>), trapping atmospheric CO<sub>2</sub> in the water as bicarbonate (HCO<sub>3</sub><sup>–</sup>). Specifically, the released iron is not soluble when exposed to the atmosphere. Instead, it covers the mineral surface as rust, slowing down the whole process. By producing siderophores, bacteria can capture, solubilize, and take up oxidized (rusted) iron to sustain their own growth. Conveniently, this effectively de-rusts the mineral surface, speeding up rock weathering.</p>
<p>Investigators used custom bioreactors to tease apart when natural bacteria produce siderophores. They found that even a small amount of iron-containing mineral completely inhibited siderophore production, posing a big problem for siderophore production at industrial scales.</p>
<p>“Once wild bacteria have enough iron to grow, they stop making siderophores completely,” explained Dalvie, PhD, who spearheaded the project as a postdoctoral fellow in Silver’s lab. “To enable enhanced weathering at scale, we engineered <em>A. macleodii</em> to always produce siderophores. We essentially decoupled siderophore production from environmental iron levels.”</p>
<p>While it took the team roughly one month to engineer the microbes, the challenge was showing that they sped up rock weathering and removed more CO<sub>2</sub> from the atmosphere. To get a handle on this validation, Dalvie teamed up with co-author Amogh Jalihal, PhD, a postdoctoral fellow in Springer’s group at the Wyss Institute and HMS.</p>
<p>“We put our heads together and decided that the measurement would be best at steady state. We needed seawater and bacteria to be continuously flowing over the minerals,” noted Dalvie.</p>
<p></p><h4><strong>Role for pilot-scale production</strong></h4>

<p>Springer’s group had recently acquired an entire room full of eVOLVERs, small-scale bioreactors. After small-scale studies showed promise, the team constructed pilot-scale bioreactors, loaded with several kilograms of green olivine sand submerged under gallons of raw seawater from the Boston Harbor.</p>
<p>“Operating at pilot scale allowed us to start solving scale-up problems: How often do we need to add cells? How do we feed them? Eventually we were able to measure actual uptake of 0.5 g of atmospheric CO<sub>2</sub> into our reactors each day, which was a compelling end result,” said Dalvie.</p>
<p>The team also carried out a Life Cycle Analysis (LCA), which accounts for all carbon captured or emitted by the entire system over time, including all living, geological, and chemical parts. Dalvie and Jalihal collaborated with Abigail Fitzgibbon, a PhD student working with Steven Davis, PhD, professor of earth system science at the Stanford Doerr School of Sustainability at Stanford University.</p>
<p>Davis’ group has developed models to quantify the carbon emissions of industrial or agricultural processes and the effects on air quality on human wellbeing.</p>
<p>“Our collaboration with the Stanford group enabled us to precisely calculate the net carbon balance in our system,” pointed out Dalvie. “We could see which process parameters were key to make it an efficient environmental technology when used at industrial scale.”</p>
<p>Dalvie recently received a fellowship from the Burroughs Wellcome Career Awards at the Scientific Interface (CASI) program, which will fund further work on microbial siderophore production and mineral processing. For bio-weathering, more scale-up studies are needed to identify economically viable sources of feedstocks and silicate minerals. The team is also investigating if valuable metals could be extracted from silicate minerals alongside CO<sub>2</sub> sequestration.</p>
<p>“We are currently thinking that the most straight-forward way of creating environmental impact would be to grow our bacterial strains with adequate food sources in large basins resembling those in sewage plants, continuously pumping unprocessed seawater in and releasing alkaline seawater back into the ocean where the bound carbon would be completely harmless and buffered away,” said Springer, who is studying how evolution has shaped and constrained the interactions of organisms with their environments.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/synthetically-engineered-marine-bacteria-could-play-key-role-in-decarbonizing-the-atmosphere-at-industrial-scales/">Synthetically Engineered Marine Bacteria Could Play Key Role in Decarbonizing the Atmosphere at Industrial Scales</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Darpa Awards UC San Diego Up to $11.3 Million for ‘Smarter’ Red Blood Cells</title>
<link>https://edusehat.com/en/darpa-awards-uc-san-diego-up-to-113-million-for-smarter-red-blood-cells</link>
<guid>https://edusehat.com/en/darpa-awards-uc-san-diego-up-to-113-million-for-smarter-red-blood-cells</guid>
<description><![CDATA[ The DARPA-funded UC San Diego project could allow scientists to temporarily improve human performance using redesigned red blood cells, with applications in both the military and in civilian medicine.
The post Darpa Awards UC San Diego Up to $11.3 Million for ‘Smarter’ Red Blood Cells appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2286341317.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:50:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Darpa, Awards, San, Diego, 11.3, Million, for, ‘Smarter’, Red, Blood, Cells</media:keywords>
<content:encoded><![CDATA[<p>Scientists at the University of California San Diego School of Medicine have been awarded a contract of up to $11.312 million from the Defense Advanced Research Projects Agency (DARPA) to pursue a research project aimed at developing optimized red blood cells that can temporarily boost human performance and health.</p>
<p>The three-year project seeks to create “smart” red blood cells capable of temporarily enhancing oxygen delivery in the body and will explore the potential of this technology to improve performance in military personnel, who are frequently placed in unforgiving environments where maintaining peak performance is essential to survival.</p>
<p>“This DARPA award is a testament to UC San Diego’s commitment to advancing cutting-edge research and innovation,” said John Carethers, MD, vice chancellor for health sciences at UC San Diego. “DARPA follows a ‘moonshot’ model, where the goal is nearly impossible but successful projects can be highly impactful, and our researchers tackle those challenges head on in order to push the boundaries of biomedical science.”</p>
<p>Oxygen plays a crucial role in the body’s energy production. By temporarily enhancing oxygen delivery, these smart red blood cells could help mitigate the effects of intense physical activity, improve endurance and support overall health.</p>
<p>“We are thrilled to receive this award from DARPA and to bring together a world-class team to work on this groundbreaking project,” said principal investigator Alejandro Chavez, MD, PhD, associate professor of pediatrics. “Blood cell engineering is still an emerging field, but our team is committed to exploring this technology and maximizing its potential for transforming human performance.”</p>
<p>While the current project focuses on developing the technology for use in military contexts, it also has the potential to improve athletic performance and help treat conditions involving a lack of oxygen in delivery to tissues, such as heart attacks, stroke, vascular diseases and diabetic skin ulcers.</p>
<p>“This project has the potential to revolutionize the field of red blood cell engineering,” said coinvestigator Hojun Li, MD, PhD, assistant professor of pediatrics, attending hematologist/oncologist at Rady Children’s Hospital, and member of UC San Diego Moores Cancer Center.</p>
<p>“While our focus in this current project is improving performance, if we achieve these goals, I’m excited to explore future possibilities of red cell engineering in cancer treatment, where both early detection and treatment of microscopic levels of disease could potentially be achieved by future iterations of ‘smart’ red blood cells.”</p>
<p>The project, which will be conducted in collaboration with colleagues at Northeastern University, University of Pennsylvania and Massachusetts Institute of Technology (MIT), will involve several key steps. First, the team will use gene editing techniques to modify red blood cells to sense when the body is undergoing physical exertion and respond by producing proteins that can improve oxygen delivery to tissue. Next, they will use a hollow fiber reactor to test and optimize the performance of these engineered red blood cells.</p>
<p>While the current project will involve no human testing, this line of research will enable further breakthroughs in regenerative medicine, which will help advance our understanding of human biology and develop new treatments for a range of diseases.</p>
<p>“This science is much bigger than this one project,” said Li. “It has the potential to open up new avenues for treating a wide range of conditions, from anemia to cancer, and we’re excited to be at the forefront of this research. With this award, we’re taking the first steps towards making this vision a reality, and we’re eager to see where this technology will take us.”</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/darpa-awards-uc-san-diego-up-to-11-3-million-for-smarter-red-blood-cells/">Darpa Awards UC San Diego Up to $11.3 Million for ‘Smarter’ Red Blood Cells</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Key Immune Cells Identified That Could Strengthen Flu Vaccines</title>
<link>https://edusehat.com/en/key-immune-cells-identified-that-could-strengthen-flu-vaccines</link>
<guid>https://edusehat.com/en/key-immune-cells-identified-that-could-strengthen-flu-vaccines</guid>
<description><![CDATA[ New research identifies long-lived lung immune cells that support protective T-cell memory, suggesting galectin-1 could enhance flu vaccines and improve respiratory immunity against influenza infection.
The post Key Immune Cells Identified That Could Strengthen Flu Vaccines appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/03/Low-Res_GettyImages-1127490587.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 01 Sep 2026 00:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Key, Immune, Cells, Identified, That, Could, Strengthen, Flu, Vaccines</media:keywords>
<content:encoded><![CDATA[<p>Influenza continues to be a major source of illness in the United States, causing more than 35,000 deaths each year. And while most flu vaccines today are injected into the muscle, and are very effective at preventing severe illness, they do not consistently prevent infection in the nose and lungs. Nasal vaccines aim to solve this problem by targeting immunity at the site where viruses first enter, but their effectiveness has been inconsistent. Now, new research suggests that a previously overlooked group of immune cells may be critical players in improving this process.</p>
<p>This is published in <em>Nature Immunology</em> in the paper, “<a href="https://www.nature.com/articles/s41590-026-02638-9" target="_blank" rel="noopener">Monocyte-derived galectin-1<sup class="wp-sup-text">hi</sup> cells provide innate immune help in the generation of functional memory CD8+ T cells</a>.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>In the lungs, the specialized type of immune cell—a tissue-resident memory T cell—acts as a first line of defense at the site where viruses enter the body. “These cells are positioned right where infection begins, so they can react immediately and help limit viral spread,” said Minsoo Kim, PhD, professor of microbiology and immunology at University of Rochester Medicine. “They are a central goal for next-generation vaccine design because they provide fast, local protection in the respiratory tract.”</p>
<p>However, most current flu vaccines—especially those given by injection—do not reliably build strong immune memory in the airways, leaving a gap in protection against initial infection and transmission.</p>
<p>In the new study, researchers focused on how the immune system builds and maintains these protective memory T cells. They discovered that a subset of monocytes, a type of immune cell thought to be short-lived, can persist in the lungs for months after influenza infection. Instead of disappearing, they support the formation of immune memory by helping memory T cells survive and function in the lung.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>More specifically, a “subset of newly recruited CCR2<sup class="wp-sup-text">+</sup> monocytes differentiated into memory-stage CCR2-tdTomato<sup class="wp-sup-text">+</sup> cells and persisted in the lung for more than four months after infection with the influenza virus.”</p>
<p>“Our work identified a long-lived monocyte-derived population in the lung that provides essential support for durable T cell immunity,” Kim said. “This challenges the traditional view that immune memory is driven only by T and B cells, and shows that innate immune cells also play a lasting role.”</p>
<p>The research also uncovered how these monocyte-derived cells communicate with T cells: they produce the galectin-1 protein, which helps activate and sustain tissue-resident memory T cells. When galectin-1 was added to an experimental nasal flu vaccine in mice, the immune response in the lungs became significantly stronger.</p>
<p>The authors write, “Memory-stage CCR2-tdTomato<sup class="wp-sup-text">+</sup> cells colocalized with lung CD8<sup class="wp-sup-text">+</sup> TRM cells and secreted galectin-1, which activated CD8<sup class="wp-sup-text">+</sup> T cells directly and enhanced transforming growth factor-β sensing.”</p>
<p>The finding opens the door to new vaccine strategies. “We identified galectin-1 as a powerful immune signal that can be used as a vaccine adjuvant to enhance mucosal immunity. This is a completely new approach for improving how vaccines work in the respiratory tract,” said Kim.</p>
<p>Beyond influenza, the findings may have implications for other respiratory viruses, including those that cause seasonal illness and pandemics. “We now see that innate immune cells are not just first responders—they can also shape long-term immune memory,” said Kim. “This opens up the possibility of designing vaccines that intentionally reprogram these cells to improve protection.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Researchers are now working to develop more stable forms of galectin-1 that could be safely used as a vaccine additive. If these findings translate successfully to humans, they could reshape how respiratory vaccines are designed. Instead of focusing only on antibody responses or circulating immune cells, future vaccines may also target the long-term behavior of immune cells that live in the lungs themselves.</p>
<p>By harnessing this newly discovered “helper” population of immune cells, researchers hope to build vaccines that not only prevent severe disease but also stop infection earlier and more effectively at the point of entry.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/key-immune-cells-identified-that-could-strengthen-flu-vaccines/">Key Immune Cells Identified That Could Strengthen Flu Vaccines</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy</title>
<link>https://edusehat.com/en/stockwatch-revolution-shares-stay-flat-despite-historic-fda-approval-of-oral-pancreatic-cancer-therapy</link>
<guid>https://edusehat.com/en/stockwatch-revolution-shares-stay-flat-despite-historic-fda-approval-of-oral-pancreatic-cancer-therapy</guid>
<description><![CDATA[ In April, Revolution shares rocketed 54% after the company announced dazzling data from its Phase III RASolute 302 trial (NCT06625320) evaluating Rasonque in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. In the overall intent-to-treat population of the Phase III RASolute 302 trial (NCT06625320), daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demonstrated for standard-of-care chemotherapy.
The post StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Pancreatic-Cancer-GettyImages-1467893187-696x391-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 31 Aug 2026 03:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, Revolution, Shares, Stay, Flat, Despite, Historic, FDA, Approval, Oral, Pancreatic, Cancer, Therapy</media:keywords>
<content:encoded><![CDATA[<p><strong>Revolution Medicines (Nasdaq: RVMD)</strong> appeared to have the makings of another strong stock surge this past week when the FDA approved the company’s historic oral therapy Rasonque<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (daraxonrasib), the first RAS inhibitor to be authorized as a targeted treatment for the most common form of pancreatic cancer.</p>
<p>Instead, Revolution’s shares stayed relatively flat as investors sat on the proverbial sidelines, apparently split over whether Rasonque has been priced too high to achieve the millions of short-term dollars and billions of longer-term dollars in sales projected by various analysts.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Thursday looked slightly better, as Revolution’s shares <span><b>climbed 2.65%</b></span> to $221.15, but the stock <span><b>skidded 6% Friday</b></span>, closing the week at $207.88 on a mix of profit-taking plus an overall down day for major markets, after Federal Reserve Chair Kevin Warsh suggested that the central bank may raise interest rates unless inflation slows down.</p>
<p><figure aria-describedby="caption-attachment-337204" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337204" src="https://www.genengnews.com/wp-content/uploads/2026/08/rasonque-packaging-final-CROP11111-300x216.jpg" alt="" width="300" height="216" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/rasonque-packaging-final-CROP11111-300x216.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/rasonque-packaging-final-CROP11111-768x552.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/rasonque-packaging-final-CROP11111-584x420.jpg 584w, https://www.genengnews.com/wp-content/uploads/2026/08/rasonque-packaging-final-CROP11111-696x500.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/rasonque-packaging-final-CROP11111.jpg 821w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Rasonque<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (daraxonrasib), which won FDA approval this past week, is a first-in-class RAS(ON) multi-selective and mutant-selective inhibitor to treat adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. [Revolution Medicines]</figcaption></figure>Just four months ago in April, Revolution shares <span><strong><a href="https://www.genengnews.com/topics/cancer/stockwatch-revolutions-phase-iii-pancreatic-cancer-data-dazzles-investors-analysts/">rocketed 54%</a></strong></span> after the company <a href="https://www.genengnews.com/topics/cancer/landmark-pancreatic-cancer-trial-highlights-promise-of-ras-targeting-daraxonrasib/">announced dazzling data</a> from its Phase III RASolute 302 trial (<a href="https://clinicaltrials.gov/study/NCT06625320">NCT06625320</a>) evaluating Rasonque in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. In the trial’s overall intent-to-treat population, <span data-olk-copy-source="MessageBody">daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demonstrated for standard-of-care chemotherapy.</span></p>
<p>That data persuaded the FDA to approve Rasonque for adults with PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Notably, the FDA gave its approval 6.5 months ahead of its March 11, 2027, targeted decision date under the Prescription Drug User Fee Act (PDUFA) following a Priority Review, after the agency had granted Revolution its <a title="Protected by Outlook: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy. Click or tap to follow the link." href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.fda.gov%2Fpatients%2Ffast-track-breakthrough-therapy-accelerated-approval-priority-review%2Fbreakthrough-therapy&data=05%7C02%7C%7C7405bcef372842ae11a808df0541a8d1%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639235453801433529%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=ESZv0mkKFiR9bkqxSwdEx2wVk7uAwEIcNWJhATx4V4c%3D&reserved=0" target="_blank" rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="7">Breakthrough Therapy</a> and <a title="Protected by Outlook: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products. Click or tap to follow the link." href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.fda.gov%2Findustry%2Fmedical-products-rare-diseases-and-conditions%2Fdesignating-orphan-product-drugs-and-biological-products&data=05%7C02%7C%7C7405bcef372842ae11a808df0541a8d1%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639235453801457513%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=XEIFg2bbO1cNWahxnf14m7qITN2HENhfJiZW6qZjeXU%3D&reserved=0" target="_blank" rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="8">Orphan Drug</a> designations for Rasonque—plus acceptance into the <a title="Protected by Outlook: https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program. Click or tap to follow the link." href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.fda.gov%2Findustry%2Fcommissioners-national-priority-voucher-cnpv-pilot-program&data=05%7C02%7C%7C7405bcef372842ae11a808df0541a8d1%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639235453801481596%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Fk6TQoOtpQSZVx7V0XuZ5lGHMO4ZjaAtGBuiO9rM8LM%3D&reserved=0" target="_blank" rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="9">Commissioner’s National Priority Voucher (CNPV) pilot program</a>. CNPV vouchers entitle companies to reviews of their final applications within a target timeframe of 1–2 months rather than the standard 10–12 months.</p>
<p></p><h4><strong>“Unprecedented results”</strong></h4>

<p>“This drug showed unprecedented results in an area of high unmet need,” Angelo de Claro, MD, director of the FDA’s Oncology Center of Excellence, said in the agency’s statement announcing the approval of Rasonque.</p>
<p>The FDA approved Rasonque, a first-in-class RAS(ON) multi-selective and mutant-selective inhibitor, to treat adults with PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.</p>
<p>The now-completed RASolute 302 trial is one of five Phase III studies in which Rasonque is being studied. Three of the four are ongoing: RASolve 301 in previously treated RAS mutant non-small cell lung cancer (NSCLC; <a href="https://clinicaltrials.gov/study/NCT06881784">NCT06881784</a>); RASolute 303 in first-line metastatic PDAC (<a href="https://clinicaltrials.gov/study/NCT07491445">NCT07491445</a>); and RASolute 304 in Adjuvant for resectable PDAC (<a href="https://clinicaltrials.gov/study/NCT07252232">NCT07252232</a>). Revolution recently launched the other Phase III trial, RASolute 309, in first-line RAS G12D metastatic PDAC.</p>
<p>New therapies are especially noteworthy in pancreatic cancer because it is one of the most difficult cancers to treat, with an overall five-year survival rate of 13%, according to the American Cancer Society, stretching from 3% for metastatic (Stage 4) to 44% for localized (Stages 1 and 2).</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p class="x_MsoNormal" data-olk-copy-source="MessageBody">In a conference call with analysts just after the FDA approval, Mark A. Goldsmith, MD, PhD, Revolution’s CEO and chairman, and other executives quantified their potential patient populations: According to the Patient Metrics module of Oracle Life Sciences’ CancerMPact oncology decision support platform, ~55,000 patients are diagnosed annually with de novo or recurrent PDAC—of which 74% or about 41,000 advance to first-line treatment. Of those first-line patients, 46% (about 19,000) proceed to second-line treatment, according to a <a title="Protected by Outlook: https://pmc.ncbi.nlm.nih.gov/articles/PMC9618512/. Click or tap to follow the link." href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9618512%2F&data=05%7C02%7C%7C7405bcef372842ae11a808df0541a8d1%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639235453801504833%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=QcEdLHa3nKnLJOsPPVnkhx%2ByvZ2xA0w0CzwkacwnhdA%3D&reserved=0" target="_blank" rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="10">2022 study</a> cited by Revolution.</p>
<p class="x_MsoNormal">But as attention-getting to investors as the approval was the list price at which Revolution plans to market Rasonque, with the company disclosing a wholesale acquisition cost (WAC) of $39,800 per month—which would translate to $477,600 per year absent discounts, more than twice the list price of a year’s supply of the best-selling drug with a pancreatic cancer indication, <b>Merck & Co. (NYSE: MRK)</b>’s blockbuster cancer immunotherapy Keytruda® (pembrolizumab).</p>
<p class="x_MsoNormal" data-olk-copy-source="MessageBody">Until the approval, Revolution had offered Rasonque at no cost to more than 2,000 patients enrolled in Revolution’s Expanded Access Program, which the company launched upon FDA “Safe to Proceed” authorization in May and closed upon agency approval of Rasonque.</p>
<p class="x_MsoNormal">“With the 2,000+ patient EAP, the pool appears to us as largely identified rather than needing to be built—a positive for a quick launch and uptake, in our view,” Gregory Renza, MD, managing director covering biotechnology with Truist Securities, and two colleagues wrote in a research note.</p>
<p></p><h4 class="x_MsoNormal"><b data-olk-copy-source="MessageBody">“Next oncology titan”</b></h4>

<p class="x_MsoNormal">“The approval transforms RVMD into a commercial-stage oncology company and establishes the first pillar of a durable, multi-tumor RAS franchise,” added Renza and colleagues Supawat Thongthip, PhD, and Anish Nikhanj, PhD. “With daraxon setting a new SOC [standard of care] in 2L PDAC and expansion opportunities across earlier-line PDAC, NSCLC and CRC, we believe RVMD remains on course to emerge as the next oncology titan.”</p>
<p class="x_MsoNormal">Renza and colleagues have projected Rasonque sales of just $12.7 million in the third quarter, growing to $101.7 million by year’s end, roughly $989 million next year, and $2.3 billion by 2028 as Truist’s projections begin to include treatment of first-line PDAC patients. Renza and colleagues have raised their firm’s 12-month price target on Revolution shares by 3.5%, from $231 to $239, maintaining Truist’s “Buy” rating on the stock.</p>
<p class="x_MsoNormal" data-olk-copy-source="MessageBody">Leonid Timashev, PhD, a director and biotechnology analyst at RBC Capital Markets specializing in the neurology, oncology, and cardiology sectors, and colleagues have offered even rosier forecasts for Rasonque. Timashev and colleagues project that the pancreatic cancer drug will rack up $28 million in third-quarter sales—catapulting to $148 million in the fourth quarter, approximately $1.1 billion in 2027, and as much as about $11.5 billion in peak-year sales, according to Reuters.</p>
<p class="x_MsoNormal">Timashev also raised RBC’s price target on Revolution shares by 24%, from $203 to $251, and maintained the firm’s “Outperform” rating on the stock.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4 class="x_MsoNormal"><b data-olk-copy-source="MessageBody">“Flexibility beyond 2L”</b></h4>
<p class="x_MsoNormal">Maury Raycroft, PhD, equity analyst at Jefferies, noted that Revolution’s label for Rasonque was sufficiently broad that it “provides flexibility beyond 2L [second-line treatment], allowing physicians to use Rasonque in some un-tx pts. [un-treated patients] deemed ineligible for multi-agent tx [therapy].” He cited comments by Revolution executives during a conference call that noted 26% of metastatic PDAC patients historically received no systematic treatment—a percentage Raycroft said has also been reported at 33.5% in one past study.</p>
<p class="x_MsoNormal">“With no defined criteria for chemo[therapy] ineligibility, the label is clearly broader than a conventional 2L approval,” Raycroft commented in a research note.</p>
<p class="x_MsoNormal" aria-hidden="true">Raycroft said the Rasonque approval validated RAS inhibition as a treatment strategy, thus de-risking ERAS-0015, an oral pan-RAS molecular glue being developed by <b>Erasca (Nasdaq: ERAS) </b>for RAS-mutant solid tumors including PDAC and NSCLC. However, he said Rasonque also presented challenges to Erasca and a second potential competitor of Revolution in PDAC:</p>
<ul type="disc">
<li class="x_MsoNormal">The availability of Rasonque “could also complicate U.S. enrollment” in Erasca’s planned Phase III trial of ERAS-0015 in first-line PDAC, “increasing the importance of ex-U.S. enrollment and trial design.”</li>
<li class="x_MsoNormal">Rasonque could also potentially de-risk development by <b>Tango Therapeutics (Nasdaq: TNGX)</b> of vopimetostat, an oral, MTA-cooperative PRMT5 inhibitor developed to treat solid tumors with MTAP deletion. Revolution and Tango are partnering on a combination therapy of vopimetostat and daraxonrasib, with the companies announcing positive data in June from a Phase I/II trial (<a title="Protected by Outlook: https://clinicaltrials.gov/study/NCT06922591. Click or tap to follow the link." href="https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06922591&data=05%7C02%7C%7C7405bcef372842ae11a808df0541a8d1%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C639235453801530845%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=U7gzAbrjm5IB8uAgA%2BsTtrgScJjgTtlxP6PBmjUu8sk%3D&reserved=0" target="_blank" rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="11">NCT06922591</a>) in patients with second and third line PDAC, namely a six-month progression-free survival rate of 90%.</li>
</ul>
<p></p><h4 class="x_MsoNormal"><b>$281M sales forecast for 2026</b></h4>

<p class="x_MsoNormal">Faisal Khurshid, a managing director and equity research analyst with Jefferies, projects much stronger sales for Rasonque this year than Truist or RBC at $281 million for this year—nearly double (95% above) a consensus analyst forecast of $148 million for all of 2026. Khurshid also said Revolution’s $39,800 monthly WAC—which translates to a net price of $28,000-$32,000—was “mostly in line with [Wall] Street expectations” of a $40,000 monthly WAC.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p class="x_MsoNormal">“Rasonque approval marks an impt [important] win for the company and for patients,” Khurshi declared in a research note. “The approval caps a strong run for the company, and we think the co[mpany] is well positioned both with the launch and data catalysts.”</p>
<p class="x_MsoNormal">Those catalysts include an announcement of updated clinical data and Revolution’s colorectal cancer development strategy, expected during the fourth quarter, as well as Phase III data in NSCLC expected in 2027.</p>
<p class="x_MsoNormal" data-olk-copy-source="MessageBody">Khurshid raised Jefferies’ price target on Revolution shares by about 12%, from $242 to $270. Also raising their price targets on Revolution shares:</p>
<ul type="disc">
<li class="x_MsoNormal"><b>H.C. Wainwright (Robert Burns)</b>—Up 44% from $195 to $280, maintaining “Buy” rating.</li>
<li class="x_MsoNormal"><b>Evercore ISI (Cory Kasimov)</b>—Up 39% from $230 to $320, maintaining “Buy” rating.</li>
<li class="x_MsoNormal"><b>Oppenheimer (Jay Olson)</b>—Up 13% from $230 to $260, maintaining “Outperform” rating.</li>
<li class="x_MsoNormal"><b>Wedbush Securities (Robert Driscoll, PhD)</b>—Up 12% from $201 to $225, maintaining “Outperform” rating.</li>
<li class="x_MsoNormal"><b>J</b>.<b>P. Morgan</b> <b>(Brian Cheng)</b>—Up 8% from $227 to $246, maintaining “Buy” rating.</li>
<li class="x_MsoNormal"><b>Raymond James (Sean McCutcheon, PhD)</b>—Up 8% from $230 to $248, maintaining “Strong Buy” rating.</li>
</ul>
<p class="x_MsoNormal">“Since we initiated in March, we have called out RVMD as the most impt co [important company] in oncology today, and this remains true, in our view,” Khurshid added.</p>
<p></p><h2><strong>Leaders and laggards</strong></h2>

<ul>
<li><strong>Biohaven (NYSE: BHVN)</strong> shares <span><strong>jumped 18%</strong></span> from $14.38 to $16.95 after the company said it had granted to <strong>SK Biopharmaceuticals</strong> an up-to-$795 million exclusive worldwide license to Biohaven’s Kv7 ion channel platform, led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator being developed for focal epilepsy, with topline results from the Phase II/III RISE3 trial (<a href="https://clinicaltrials.gov/study/NCT06309966">NCT06309966</a>) expected later this year. The companies have agreed to advance opakalim through development and FDA approval. SK has agreed to pay Biohaven $400 million cash—$350 million at closing and $50 million payable in 2027—plus up to $150 million tied to achieving development and regulatory milestones, and royalties on global net sales of opakalim. SK agreed to oversee Kv7 program costs, including $245 million in specified Kv7 future milestone payments and mid-single-digit royalties to <strong>Knopp Biosciences</strong>, from which a Biohaven predecessor acquired the platform in 2022 for up to $1.24 billion. SK is part of a privately held, family-owned chaebol or conglomerate whose parent holding company is public, <strong>SK Inc. (Korea Exchange: 034730). </strong></li>
<li><strong>BioXcel Therapeutics (Nasdaq: BTAI)</strong> shares <span><strong>plunged 75%</strong></span> from 72 cents to 18 cents Friday after the artificial intelligence-based neuroscience drug developer announced that it and two subsidiaries, OnkosXcel Therapeutics and OnkosXcel Employee Holdings, began voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware. The Chapter 11 filing is intended to enable a court-supervised sale process that is expected to include the auction of substantially all of BioXcel’s assets. BioXcel has already agreed to sell substantially all of its assets to a subsidiary of <strong>Teva Pharmaceutical Industries (NYSE: TEVA)</strong>, including Igalmi<sup>® </sup>(dexmedetomidine) sublingual film and the related pending supplemental New Drug Application of BXCL501 for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Teva agreed to serve as a “stalking horse” bidder at a future Chapter 11 auction of BioXcel assets.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/cancer/stockwatch-revolution-shares-stay-flat-despite-historic-fda-approval-of-oral-pancreatic-cancer-therapy/">StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CAR T&#45;Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial</title>
<link>https://edusehat.com/en/car-t-cell-therapy-puts-severe-rheumatoid-arthritis-into-remission-in-first-clinical-trial</link>
<guid>https://edusehat.com/en/car-t-cell-therapy-puts-severe-rheumatoid-arthritis-into-remission-in-first-clinical-trial</guid>
<description><![CDATA[ Researchers at Charité report promising results from the first CAR T-cell trial for treatment-refractory rheumatoid arthritis, with all six patients improving and three achieving sustained medication-free remission.
The post CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_DS_Kniegelenke_Abb_v1.png.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 29 Aug 2026 04:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CAR, T-Cell, Therapy, Puts, Severe, Rheumatoid, Arthritis, Into, Remission, First, Clinical, Trial</media:keywords>
<content:encoded><![CDATA[<p>Immunotherapies, like CAR T-cell therapy, are well known in the cancer field. But they can also be used to treat autoimmune disorders. Now, six patients with severe rheumatoid arthritis (RA) have received this treatment at Charité—Universitätsmedizin Berlin. The results from the world’s first clinical trial showed that disease activity decreased substantially in all participants. By the end of the observation period, three of the patients no longer required any medication for their RA.</p>
<p>This work is published in <em>Nature Medicine</em> in the paper, “<a href="https://www.nature.com/articles/s41591-026-04603-3" target="_blank" rel="noopener">CD19 CAR-T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a Phase 1 trial.</a>”</p>
<p>RA is a chronic disease with recurrent inflammation and joint swelling which can, as the disease progresses, lead to joint damage. Patients require lifelong medication, including anti-inflammatory drugs and medications that suppress the immune system. Treatment-refractory RA can bring persistent pain, restricted mobility, and a substantial impact on quality of life.</p>
<p>CAR T cells could target the B cells that keep the disease persistent, reset the pathological B-cell memory, and give the B-cell system a fresh start.</p>
<p>The COMPARE study is the world’s first clinical trial to evaluate the safety and efficacy of mivocabtagene autoleucel (miv-cel), an autologous fully human CD19 CAR T cell therapy, in RA. The research team at Charité enrolled six patients with particularly severe disease. The three women and three men, aged 31 to 69, had received up to eight targeted or biologic therapies over the previous ten years, none of which had been sufficiently effective.</p>
<p>All six patients with treatment-refractory, anti-citrullinated protein antibody (ACPA)-positive RA were followed for 36–52 weeks after receiving a single infusion of miv-cel after stopping all disease-modifying antirheumatic drug treatments and after standard lymphodepletion therapy.</p>
<p>For the researchers, the results are highly encouraging: “Disease activity decreased markedly in all six patients. During follow-up of up to one year, three patients were in sustained remission without any medication for rheumatoid arthritis,” reports Gerhard Krönke, MD, who leads the joint Clinical Rheumatology research group at Charité and the German Rheumatology Research Center (DRFZ), a Leibniz Institute. “This is particularly remarkable given that none of the established treatments had previously been able to relieve their symptoms adequately.”</p>
<p>Primary endpoints, the authors note, were “the incidence and severity of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and adverse events (AEs) within the first four weeks after treatment. Secondary and explorative endpoints assessed clinical efficacy and cellular and humoral immune responses.”</p>
<p>In addition, the research team found that levels of the autoantibodies characteristic of RA had declined sharply.</p>
<p>For selected patients with RA who have not responded adequately to treatment, it may in the future be possible to reset the pathological immune memory in a targeted way and thereby stop the persistent inflammation, instead of having to suppress it continuously with drugs.</p>
<p>Nevertheless, CAR T-cell therapy for autoimmune diseases, and for RA in particular, remains experimental. There is not yet any long-term experience with this treatment. In addition, responses to the therapy varied among patients in the current trial: some did not achieve a complete response, and in one case the disease returned after an initial medication-free period of remission. In contrast, the researchers consider the safety data obtained thus far to be encouraging.</p>
<p>“After the participants received the CD19 CAR T cells, we observed only a temporary, mild-to-moderate cytokine release syndrome (CRS) in all participants, which was readily manageable. There were no severe neurological complications or other serious adverse events, and infections were rare,” explains Marie Luise Hütter-Krönke, MD, medical director of the Hematology Early Clinical Trial Unit at Charité’s Department of Hematology, Oncology and Cancer Immunology.</p>
<p>In a second phase of the trial involving ten additional patients, the researchers will compare the new treatment approach with a drug already approved for RA that also targets B cells. In this way, they aim to determine whether CAR T cells have a stronger and longer-lasting effect and whether they can indeed reset immune memory. If the new concept is confirmed in this and other, larger trials, it could ultimately become an alternative for patients whose lives are severely affected and for whom no adequate treatment is currently available.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/car-t-cell-therapy-puts-severe-rheumatoid-arthritis-into-remission-in-first-clinical-trial/">CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Notch Signaling Switch Enables Scalable Helper T Cell Production for CAR T</title>
<link>https://edusehat.com/en/notch-signaling-switch-enables-scalable-helper-t-cell-production-for-car-t</link>
<guid>https://edusehat.com/en/notch-signaling-switch-enables-scalable-helper-t-cell-production-for-car-t</guid>
<description><![CDATA[ By modulating Notch and T cell receptor signaling, scientists have produced functional CD4+ T cells from iPSCs, potentially advancing scalable, off-the-shelf CAR T therapies.
The post Notch Signaling Switch Enables Scalable Helper T Cell Production for CAR T appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-2196144747-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 29 Aug 2026 04:45:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Notch, Signaling, Switch, Enables, Scalable, Helper, Cell, Production, for, CAR</media:keywords>
<content:encoded><![CDATA[<p><span>A new </span><i><span>Stem Cell Reports</span></i><span> study describes a scalable method for generating CD4+ helper T cells from induced pluripotent stem cells (iPSCs). The work, which was done by scientists at Boston University’s Center for Regenerative Medicine (CReM) and Boston Medical Center, could boost efforts to generate off-the-shelf CAR T-cell therapies for use in patients with cancers and chronic inflammatory diseases. Their paper is aptly titled “</span><a href="https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(26)00269-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213671126002699%3Fshowall%3Dtrue" target="_blank" rel="noopener"><span>Generation of effector CD4+ T cells from human iPSC</span></a><span>.”</span></p>
<p><span>The team, led by Gustavo Mostoslavsky, MD, PhD, co-director of the CReM and professor of medicine and virology, immunology and microbiology at BU School of Medicine, and Julian Amirault, a doctoral student, claim to have found the key to producing CD4+ cells in the Notch molecular signaling pathway. </span></p>
<p><span>Typically, CAR T-cell therapy works by isolating a patient’s T cells and modifying them to recognize cancer cells. It’s costly to do for each individual patient, which is why iPSCs from donated skin or blood cells are of interest for large-scale T-cell production. However, reliably generating functional helper CD4+ T cells which are important for coordinating and regulating immune responses has been challenging. </span></p>
<p><span>But Mostoslavsky, Amirault, and their colleagues say they have found a simple and potentially scalable protocol for doing so. Notch signaling is critical to early T cell development, but the scientists found that removing it during later stages of maturation, while simultaneously reducing anti-T cell receptor signaling, let developing cells survive and mature into CD4+T cells at scale. As Mostoslavsky put it, their approach results in “T cells that look like those from blood, with a full repertoire of the different subtypes.” </span></p>
<p><span>Beyond the potential clinical benefits, their research also sheds new light on T-cell biology, specifically how Notch signaling shifts over time to direct cells toward either CD8 or CD4 lineage. </span></p>
<p><span>But for now, this study represents a step towards possibly developing a universal CAR T-cell therapy. The next step for the scientists is to introduce chimeric antigen receptors directly into their iPSC-derived CD4+ and CD8+ cells and test their ability to kill cancer in animal models. “The potential is that one day, these cells could be ready and waiting when a patient is diagnosed. No cell collection, no individualized manufacturing, just treatment,” Mostoslavsky said.  </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/notch-signaling-switch-enables-scalable-helper-t-cell-production-for-car-t/">Notch Signaling Switch Enables Scalable Helper T Cell Production for CAR T</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Molecular Pathways Driving Autoantibody Production Following SARS&#45;CoV&#45;2 Infection Identified</title>
<link>https://edusehat.com/en/molecular-pathways-driving-autoantibody-production-following-sars-cov-2-infection-identified</link>
<guid>https://edusehat.com/en/molecular-pathways-driving-autoantibody-production-following-sars-cov-2-infection-identified</guid>
<description><![CDATA[ Researchers identified the immune cell population responsible for producing autoantibodies after SARS-CoV-2 infection, and uncovered the molecular program that drives this response, providing insights that might point to new therapeutic targets.
The post Molecular Pathways Driving Autoantibody Production Following SARS-CoV-2 Infection Identified appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/11/Getty_1368735831_antibody-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 29 Aug 2026 04:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Molecular, Pathways, Driving, Autoantibody, Production, Following, SARS-CoV-2, Infection, Identified</media:keywords>
<content:encoded><![CDATA[<p>When the immune system encounters a virus, it produces antibodies designed to recognize and eliminate the invader. But in some people infected with SARS-CoV-2 the immune response goes awry, producing autoantibodies that mistakenly attack the body’s own tissues.</p>
<p>Scientists <a href="https://doi.org/10.1016/j.cell.2022.01.014" target="_blank" rel="noopener">have long known that these autoantibodies</a> are associated with severe COVID-19, Long COVID, and with an increased risk of developing autoimmune disease. What has remained unclear is where these harmful antibodies come from.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Researchers at the Institute for Systems Biology (ISB) and their collaborators have now identified the immune cell population responsible for producing the autoantibodies and uncovered the molecular program that drives this response.</p>
<p>The team, led by Jim Heath, PhD, ISB president and professor, combined multiple cutting-edge technologies to analyze immune responses from participants enrolled in ISB’s longitudinal INCOV study of COVID-19. Rather than relying on a single experimental approach, the team integrated single-cell RNA sequencing, chromatin accessibility profiling, plasma proteomics, proteome-wide autoantibody profiling, clinical data, laboratory experiments, and genetic analyses to build a detailed picture of how B cells respond during infection.</p>
<p>The findings provide new insight into how viral infections can trigger autoimmune responses and identify biological pathways that could one day become targets for new therapies.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“Our goal was to understand why some people produce autoantibodies after SARS-CoV-2 infection while others do not,” said Heath. “By combining multiple layers of biological data, we were able to pinpoint the immune cells responsible and identify the regulatory mechanisms that distinguish them.”</p>
<p>The team reported on the findings in <em>Immunity</em>, in a paper titled “<a href="http://dx.doi.org/10.1016/j.immuni.2026.08.002" target="_blank" rel="noopener">A distinct effector B cell population drives autoantibody production in SARS-CoV-2 infection</a>,” in which they concluded, that their results “… provide insights into the molecular and genetic basis of infection-induced autoimmunity in COVID-19 and its downstream outcomes, including Long COVID.”</p>
<p>Autoantibodies (autoAbs) are linked to mortality and Long COVID, and acute SARS-CoV-2 infection also increase the risk of new-onset autoimmune disorders, including systemic lupus erythematosus (SLE), the authors noted. “These observations underscore the need to move beyond these associations and define the cellular and molecular mechanisms of autoAb production in COVID-19.”</p>
<p>Through their newly reported study the researchers identified a subset of B cells known as atypical memory B cells (AtMs) as the primary precursors of autoantibody-producing cells during SARS-CoV-2 infection. While these cells are a normal part of the immune system, the researchers found that individuals with high levels of autoantibodies adopted a markedly different biological program.</p>
<p>Laboratory experiments demonstrated that atypical memory cells from these individuals were especially prone to maturing into antibody-secreting cells that produced autoantibodies. The researchers in addition observed that patients with higher autoantibody levels tended to have weaker virus-neutralizing antibody responses, suggesting that this altered response may come at the expense of protective antiviral immunity. “AutoAb abundance inversely correlated with neutralizing IgG and declined as infection resolved, paralleling the contraction of atypical memory B cells (AtMs),” the team noted.</p>
<p>One of the study’s most striking findings was how closely the major subset of atypical memory B cells, called DN2 cells, resembled immune cells previously implicated in autoimmune diseases such as systemic lupus erythematosus. The researchers found that DN2 cells from patients with elevated autoantibodies showed increased activity in immune signaling pathways controlled by Toll-like receptor 7 (TLR7), along with changes involving the transcription factors T-bet and XBP1. “The pronounced enrichment of TLR7 signaling in autoAb-high DN2s mirrors pathways previously described in SLE,” they pointed out. Together, these pathways appear to prime the cells to produce autoantibodies.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Genetic analyses strengthened the connection. Among all B-cell populations examined, DN2 cells showed the strongest enrichment for inherited genetic risk associated with multiple autoimmune diseases, including lupus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, Crohn’s disease, type 1 diabetes, and primary biliary cirrhosis. “Integrated genetic and genomic analyses showed that DN2s had the strongest enrichment for autoimmune trait heritability and inferred regulatory effects of autoimmune risk variants among B cell subsets,” the investigators stated.</p>
<p>“Our findings suggest that SARS-CoV-2 infection can activate an immune program that closely resembles those involved in established autoimmune disorders, helping explain why some individuals experience autoimmune complications following infection,” said ISB lead author Dan Yuan, PhD.</p>
<p>Although the study focused on COVID-19, the implications extend well beyond a single virus. The work suggests that infection can reveal underlying immune tendencies that, in genetically susceptible individuals, favor the production of autoantibodies. Understanding this process may ultimately improve scientists’ ability to identify patients at higher risk for autoimmune complications and guide development of therapies that interrupt these harmful immune responses before they become established.</p>
<p>“Our findings point to specific immune pathways that could become future therapeutic targets,” Yuan noted. “By understanding how these cells become activated, we move closer to interventions that could prevent or reduce harmful autoimmune responses following infection.”</p>
<p>While additional studies will be needed to determine whether directly targeting these pathways can improve patient outcomes, the researchers say the work provides one of the clearest pictures to date of how infection-induced autoantibody production begins.</p>
<p>“The study also demonstrates the power of ISB’s systems biology approach,” Heath commented. “By integrating diverse molecular datasets with clinical information and functional experiments, we were able to move beyond identifying associations to uncover the cellular mechanisms that drive disease.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/molecular-pathways-driving-autoantibody-production-following-sars-cov-2-infection-identified/">Molecular Pathways Driving Autoantibody Production Following SARS-CoV-2 Infection Identified</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Images to Data</title>
<link>https://edusehat.com/en/from-images-to-data</link>
<guid>https://edusehat.com/en/from-images-to-data</guid>
<description><![CDATA[ This eBook introduces the latest trends in quantitative spatial biology and how IMC is accelerating their adoption and success.
The post From Images to Data appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/StandardBioTools_CellSignalingPanel.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 29 Aug 2026 01:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Images, Data</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Read Now</button></p><div class="my-8"><span data-render-ad="3"></span></div><p></p><p class="wp-block-paragraph">Quantitative spatial biology is coming of age. The desire to learn beyond the surface has always been present but now the ability to deepen that knowledge with real data is catching up. High-plex spatial proteomics can provide details into single-cell molecular measurements within a tissue context. This advanced quantitation moves imaging forward to enable reproducibility, mechanistic insight, biomarker validation, patient stratification and regulatory-grade evidence.</p><p></p><p></p><div class="wp-block-image"><p><figure class="alignright size-medium"><img fetchpriority="high" decoding="async" width="232" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-232x300.jpg" alt="Standard BioTools sponsored eBook cover" class="wp-image-337176" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-232x300.jpg 232w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-791x1024.jpg 791w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-768x994.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-1187x1536.jpg 1187w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-1583x2048.jpg 1583w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-325x420.jpg 325w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-649x840.jpg 649w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-696x901.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-1392x1801.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-1068x1382.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-1920x2485.jpg 1920w, https://www.genengnews.com/wp-content/uploads/2026/08/GEN_SBT_IMC_Cover-scaled.jpg 1978w" sizes="(max-width: 232px) 100vw, 232px"></figure></p><p></p></div><p></p><p class="wp-block-paragraph">Tissues can be seen as structured ecosystems in which cell identity, function and interactions depend on precise spatial organization and local microenvironments. Adding quantitative metrics offers the opportunity to not only directly investigate changes in cell behavior and tissue heterogeneity but also the ability to compare these patterns across samples, disease states, individuals or treatment conditions.</p><div class="my-8"><span data-render-ad="4"></span></div><p></p><p class="wp-block-paragraph">The trend toward quantitative harmonization is becoming essential, as only quantitative data can be normalized, benchmarked and reused at scale.</p><p></p><p></p><p class="wp-block-paragraph">Imaging Mass Cytometry<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> (IMC<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">) presents a unique approach to spatial biology, offering three main advantages over fluorescence-based methods: easy assay development, flexible acquisition modes enabling high throughput, and the capability to be extremely quantitative and sensitive. IMC systems image one pixel at a time, where all protein markers are collected simultaneously from each pixel. Each data point thus offers a piece to a puzzle that, when complete, reveals a comprehensive picture of disease dynamics.</p><p></p><p></p><p class="wp-block-paragraph">When investigating cancer progression, immune response to disease or therapeutic response, visualizing and quantifying the spatial organization of proteins across a tissue enables a look into patterns of cell activity as well as advanced modeling and predictive analytics that bring us ever closer to targeted therapeutics and personalized medicine. This eBook introduces the latest trends in quantitative spatial biology and how IMC is accelerating their adoption and success.</p><p></p><p>The post <a href="https://www.genengnews.com/resources/ebooks/from-images-to-data/">From Images to Data</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models</title>
<link>https://edusehat.com/en/inhaled-suppressor-trna-restores-gene-function-in-cystic-fibrosis-models</link>
<guid>https://edusehat.com/en/inhaled-suppressor-trna-restores-gene-function-in-cystic-fibrosis-models</guid>
<description><![CDATA[ A preclinical study showed how chemically enhanced suppressor tRNAs combined with a lung-targeted delivery system can restore production of a critical protein in models of cystic fibrosis caused by nonsense mutations.
The post Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/03/GettyImages-831149000-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 07:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Inhaled, Suppressor, tRNA, Restores, Gene, Function, Cystic, Fibrosis, Models</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Toronto have developed a next-generation RNA therapeutic strategy that could have the potential to treat a wide range of genetic diseases that share certain types of disease-causing mutations. The team showed that chemically enhanced suppressor transfer RNAs (sup-tRNAs) combined with a lung-targeted delivery system can restore production of a critical protein in models of cystic fibrosis (CF) caused by “nonsense mutations.”</p>
<p>These mutations introduce a premature stop signal into the genetic instructions for making a protein. The result is that cells may produce little or no full-length functional protein, disrupting vital functions in ways that are difficult to treat.</p>
<p>The researchers, led by Bowen Li, PhD, an associate professor in U of T’s Leslie Dan Faculty of Pharmacy, engineered sup-tRNAs to help cells read through these premature stop signals introduced by nonsense mutations into the mRNAs, and complete production of full-length proteins that would otherwise be truncated or absent.  They tested the approach in bronchial epithelial cells, mouse models, and patient-derived cystic fibrosis organoids and found that the chemical modifications increased the readthrough of premature termination codons and tRNA aminoacylation, prolonged the tRNAs’ functional activity, and reduced innate immune activation. Moreover, the approach restored CFTR protein production and function across cell, animal, and patient-derived organoid models. The researchers also found that the approach can be combined with existing cystic fibrosis drugs, suggesting the potential for combination therapy.</p>
<p>Li, who is also an affiliate scientist at the University Health Network’s Princess Margaret Cancer Centre, suggests that the research could lay the foundation for a new class of drugs designed to treat a swath of genetic diseases through a common therapeutic strategy. “There are so many types of disease-causing mutations—many affecting only a small number of people—that developing a separate gene therapy for every individual mutation is extremely challenging. With tRNA therapeutics, our goal is to develop a common therapeutic approach that could potentially address the same type of mutation across many different genes and diseases, including rare conditions that currently have few or no effective treatment options.”</p>
<p>Senior and co-corresponding author Li, and colleagues reported on their study in <em>Science</em>, in a paper titled “<a href="http://dx.doi.org/10.1126/science.aeb0054" target="_blank" rel="noopener">Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis</a>,” concluding “These findings provide broadly applicable engineering insights for the future development of tRNA-based medicines.”</p>
<p>Nonsense mutations introduce premature termination codons (PTCs) in messenger RNA, causing protein production in cells to halt early, often resulting in truncated, nonfunctional proteins. Because these mutations account for ~11% of human genetic disorders, there is considerable interest in developing therapies that can restore production of full-length proteins. However, the authors wrote, “Current therapeutic strategies remain limited: Gene-editing approaches can face challenges related to delivery, immunogenicity, and off-target effects, whereas pharmacological readthrough agents have shown limited efficacy or considerable toxicity.”</p>
<p>Suppressor tRNAs (sup-tRNAs) offer a promising approach. By modifying their anticodons to recognize premature stop codons, engineered sup-tRNAs can insert the appropriate amino acid and allow the cell to resume translation of full-length, functional proteins. Yet the clinical potential of sup-tRNAs has been constrained by inefficient readthrough, immunogenicity, and difficulty in delivering them into the body.</p>
<p>To address this, the researchers chemically modified sup-tRNAs and engineered lipid nanoparticles (LNPs) for delivery into the lungs via inhalation, looking to see if they could repair the nonsense mutations in the cystic fibrosis transmembrane conductance regulator (<em>CFTR</em>) gene responsible for cystic fibrosis. “Interdisciplinary collaboration was key to this project,” says co-senior author Haissi Cui, PhD, assistant professor of chemistry in the Faculty of Arts & Science. “We used nature as our design guide and found that adding one specific modification made the engineered tRNA more active and longer lasting. It shows what becomes possible when chemistry and RNA biology come together.”</p>
<p>Jingan (Charles) Chen, a researcher in Li’s lab and co-lead author of the study, noted that another challenge was getting the tRNAs to the cells that needed them. The team settled on lipid nanoparticles, which they designed to deliver tRNA. “No matter how powerful you make those tRNAs, without delivery, they cannot be a drug,” said Chen, a PhD candidate in the Leslie Dan Faculty of Pharmacy and the Institute of Biomedical Engineering. “That cargo-specific delivery system is one of the major advances of our study. We used a tailored lipid nanoparticle delivery system that is specifically developed for tRNA.”</p>
<p>In recent years, cystic fibrosis care has been transformed by CFTR modulators, such as Trikafta. But such drugs are not effective for the roughly one in 10 patients whose disease stems from a nonsense mutation. Cystic fibrosis leaves cells unable to move salt and water, so mucus clogs the airways and gut. Modulators repair and activate the misshapen CFTR protein that controls this flow. But they can’t fix what was never built.</p>
<p>The U of T researchers set out to test if the sup-tRNAs could change that. “We used cystic fibrosis (CF) as a disease model to evaluate the therapeutic efficacy of this sup-tRNA platform because nonsense mutations in the cystic fibrosis transmembrane conductance regulator (<em>CFTR</em>) gene represent an unmet clinical need,” they stated. The question was not just whether the CFTR protein reappeared, but whether it was active. Through their studies the team showed that in human airway cells with two common nonsense mutations, the protein came back and worked as it should, sticking around for more than 40 days. Further preclinical tests pointed in the same direction.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Research team members Jim Hu, PhD, and Tanja Gonska, PhD, both SickKids scientists with appointments in U of T’s Temerty Faculty of Medicine, provided access to tissue from a cystic fibrosis patient with a complex <em>CFTR</em> genotype containing four mutations—two of them nonsense—that left the the patient unresponsive to existing drugs. These samples were grown into miniature organoid models. Test showed that while neither the modified sup-tRNA nor Trikafta did much on its own, the patient’s cells responded when the two were used together. The tRNA restored production of the full-length protein and gave Trikafta something to work with.</p>
<p>“Notably, in a patient-derived organoid model with a complex genotype, cotreatment with modified sup-tRNAs and Trikafta enabled functional rescue of CFTR,” they noted in summary. “In this setting, sup-tRNAs suppressed the nonsense mutations to restore full-length CFTR synthesis, whereas Trikafta supported the folding, trafficking, and activity of CFTR … This finding showcased a promising complementary therapeutic approach and highlighted the importance of combining therapies to rescue complex <em>CFTR</em> genotypes.”</p>
<p>The researchers say the study represents a major step forward in demonstrating tRNA’s therapeutic promise. Li’s lab is looking to expand the approach to other organs, each of which will need a specialized delivery system. For the lungs, the team has shown its particles can survive being turned into a fine mist—a first step toward a treatment that patients could inhale at home.</p>
<p>“The same type of premature stop signal can occur in many different genes, causing diseases that affect the lungs, brain, muscles and other tissues,” said Li. “Our long-term goal is to develop tRNA medicines that recognize these shared stop signals, so that one therapeutic strategy could potentially be applied across many different genetic diseases.”</p>
<p>In a related <a href="https://doi.org/10.1126/science.aek3835" target="_blank" rel="noopener">perspective</a>, Jacob W. Myerson, PhD, and Drew Weissman, PhD, at Perelman School of Medicine, University of Pennsylvania, commented, “The results of Chen <em>et al.</em> have implications for thousands of cystic fibrosis patients.” Myerson and Weissman note that translating the effects reported in the researchers’ preclinical studies to amelioration of respiratory function in cystic fibrosis patients will further work, including characterizing side effects. They suggest that “… a likely therapeutic regimen could include both tRNA to rescue aberrant CFTR expression and drugs to enhance normal CFTR function, a combination that might have an additional side effect profile. Navigating the therapeutic potential of the tRNA, drugs, and LNPs may still be a matter of rethinking both the cargo and the carrier.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/inhaled-suppressor-trna-restores-gene-function-in-cystic-fibrosis-models/">Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Genetic Toolkit Isolates Neuron Types in Drosophila Brain</title>
<link>https://edusehat.com/en/genetic-toolkit-isolates-neuron-types-in-drosophila-brain</link>
<guid>https://edusehat.com/en/genetic-toolkit-isolates-neuron-types-in-drosophila-brain</guid>
<description><![CDATA[ By targeting specific neuron types in the Drosophila brain, researchers linked distinct octopamine/tyramine cell types to behaviors including aggression suppression and visual motion tracking.
The post Genetic Toolkit Isolates Neuron Types in Drosophila Brain appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/09/GettyImages-1024014660-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 07:10:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Genetic, Toolkit, Isolates, Neuron, Types, Drosophila, Brain</media:keywords>
<content:encoded><![CDATA[<p>The fruit fly brain is small enough to map in exquisite detail, but that does not mean its signaling systems are simple. A single neuromodulator can influence behaviors as varied as aggression, feeding, wakefulness, memory, and visual tracking, raising a central question for neuroscientists: how does one chemical messenger produce so many different effects?</p>
<p>Researchers at the Salk Institute have developed a genetic toolkit designed to answer that question one neuron type at a time. In a study published in <em>Current Biology</em>, the team reports a curated set of transgenic driver strains that provide selective access to nearly all long-range octopaminergic and tyraminergic neuron types in the brain of <em>Drosophila melanogaster</em>. The study is titled “<a href="https://www.cell.com/current-biology/fulltext/S0960-9822(26)01007-9" target="_blank" rel="noopener">Cellular and functional dissection of the octopaminergic and tyraminergic system in the <em>Drosophila</em> brain</a>.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Octopamine (OA) is a major biogenic amine found in invertebrates and is often described as a functional analog of vertebrate noradrenaline. Together with its precursor tyramine (TA), OA helps modulate sensory processing, social behavior, and other physiological processes. But researchers have lacked sufficiently specific genetic access to defined OA/TA neuron types, limiting their ability to connect individual cell types with particular behaviors.</p>
<p>“Virtually, no single gene is sufficient for specifying one single cell type,” said Kenta Asahina, PhD, associate professor at Salk and senior author of the study. To increase specificity, the researchers screened several hundred genetically engineered fruit fly lines to identify overlapping expression patterns. They then used those intersections to create split-GAL4 driver combinations that could target distinct OA/TA neuron subtypes, in some cases narrowing access to a single pair of neurons.</p>
<p>The resulting toolkit allowed the group to map cell-type-specific innervation patterns, compare male and female neuroanatomy, and align genetically identified neuron types with electron microscopy connectome datasets. That integration of genetics, anatomy, and connectomics was central to the work: this let the researchers move beyond treating the OA/TA system as a single functional unit.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>They then applied the resource to behavior. One finding addressed a long-standing paradox in octopamine biology: previous studies had linked OA signaling to both increased and decreased aggression. Using the new toolkit, the team identified a previously undescribed OA/TA cell type, ASM4, that suppresses aggression in socially isolated male and female flies. The result suggests that apparently contradictory effects of the same neuromodulator can arise from different neuron types, and possibly from differences in whether those cells signal through tyramine, octopamine, or both.</p>
<p>The researchers also used the toolkit to probe visually guided behaviors. Distinct optic lobe-projecting OA/TA neuron types differentially modulated optomotor stabilization and object tracking, showing that neuron types within the same neuromodulatory system can perform separate behavioral jobs. As Valentina Fajner, PhD, co-first author and staff scientist at Salk, put it, “one modulator, but distinct neurons, distinct jobs.”</p>
<p>The work also has broader implications beyond flies. Although the human brain is far more complex, the authors noted that many neuromodulatory principles are conserved across species. In that sense, parsing how OA/TA neurons organize behavior in <em>Drosophila</em> could help inform future studies of noradrenergic signaling and how failures in neuromodulatory systems alter brain function.</p>
<p>Next, the Salk team plans to map input and output signals across the OA/TA system to define larger circuits involved in social behavior. For now, the toolkit offers a more precise way to ask what individual neuromodulatory neurons are doing—an advance Asahina said is necessary because “almost every brain cell is different.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/genetic-toolkit-isolates-neuron-types-in-drosophila-brain/">Genetic Toolkit Isolates Neuron Types in <i>Drosophila</i> Brain</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A startup claims it’s found a drug to make your blood young</title>
<link>https://edusehat.com/en/a-startup-claims-its-found-a-drug-to-make-your-blood-young</link>
<guid>https://edusehat.com/en/a-startup-claims-its-found-a-drug-to-make-your-blood-young</guid>
<description><![CDATA[ I knew I’d officially become a ‘longevity influencer’ this month when a company called Generation Lab reached out to offer me the chance to write about—and even receive—their new rejuvenation treatment, an injectable combination of two existing drugs which they call 1-Generation. This wasn’t just any antiaging treatment, either. A company fact sheet says that it… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/260824_youngblood_v2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 03:40:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>startup, claims, it’s, found, drug, make, your, blood, young</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Blood made young, maybe:</strong> Scientist Irina Conboy claims she’s found a combination of two existing drugs that mimics the rejuvenating effects of plasma exchange—without any actual blood exchange. Early users report better energy, sharper minds, and yes, improved bowel movements.</li><br><li><strong>Red flags are hard to ignore:</strong> The company won’t reveal what the drugs are, plans to charge participants to enroll in its clinical trial, and is partnering with a doctor who once recommended inhaling amniotic fluid as a covid treatment.</li><br><li><strong>The science underneath is real:</strong> Conboy built a legitimate career at UC Berkeley proving that young blood genuinely rejuvenates old animals—and that old blood is even more powerfully damaging to young ones. That credibility is what makes this pitch harder to simply dismiss.</li><br><li><strong>Buzz is already building:</strong> High-profile scientists, venture capitalists, and biohackers are reportedly clamoring for access. The author, for one, is waiting until someone actually reveals what’s in the syringe.</li></ul>" data-chronoton-post-id="1143037" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>I knew I’d officially become a ‘longevity influencer’ this month when a company called Generation Lab reached out to offer me the chance to write about—and even receive—their new rejuvenation treatment, an injectable combination of two existing drugs which they call 1-Generation.</p>



<p>This wasn’t just any antiaging treatment, either. A company fact sheet says that it “blocks the systemic spread of aging in the bloodstream, reawakens the body’s own repair mechanism and restores health and youth to multiple tissues.”</p>



<p>The exclusive offer to join a “private cohort” receiving access to the treatment was being “extended to a limited number of people whose judgment on the science we trust, under close physician supervision.”</p>



<p>“There’s a long wait list including a lot of celebrities, well-known people, people who you have heard of,” Generation Lab’s CEO Alina Su told me in a conference call. “So we’re super excited to, like, create this drug and [are] letting you know that this first longevity therapeutic in [the] human body is here and it’s actually working.”</p>



<p>This was all clearly a marketing campaign and, like most other claims in the world of longevity medicine, probably too good to be true. What’s more, Generation Lab wouldn’t tell me what the two drugs are, making the proposition hard to take seriously.</p>





<p>Yet this pitch got my interest. The reason? I am a longtime follower of Generation Lab’s irascible scientific founder, Irina Conboy, a take-no-guff specialist in the bizarre, but scientifically fruitful, practice of joining together the circulatory systems of old and young lab animals.</p>



<p>The procedure, called parabiosis, or heterochronic blood exchange, is one of the few things actually proven to make an old animal act younger.<strong> </strong></p>



<p>But you can’t go through life attached by the veins to a younger person. So the quest has been to find practical ways to mimic those benefits. </p>



<p>And that is something Conboy says she’s now achieved by hitting on a combination of two existing drugs that produce youthful effects—but without the need for any bodily fluid exchange. </p>



<p>Over the last two months, Conboy has been taking the drug combination and feeling quite a bit better and more energetic, she says. So have a handful of other insiders, including Su, the company’s 26-year-old CEO, as well as Conboy’s husband and scientific collaborator Michael Conboy.</p>



<p>The company’s public relations staffer sent me a spreadsheet of the supposed benefits experienced by the participants, including improved vision in a 64-year-old female, longer landscaping sessions for a 59-year-old man, longer badminton games, improved hand grip, better erections than with Viagra, as well as “increased bowel movements.”</p>



<p>Obviously, any age-reversal drug that works would be the best-selling product of all time. The problem is that none have ever been shown to do that. And Generation’s approach to evidence raises several red flags. For instance, Su says the company now plans to launch a larger study, involving a hundred or more people. However, these subjects will be asked to pay for their enrollment. Such “pay-to-play” clinical trials are often seen as a sales channel, rather than a scientific pursuit.</p>



<p>In addition, the trial will be led by longevity doctors who practice alternative medicine. These include<strong> </strong>Matt Cook, founder of a network of clinics called BioReset Medical. Cook’s clinics offer what I would characterize as unproven treatments, such as stem-cell injections. <a href="https://www.technologyreview.com/2021/03/11/1020725/diamandis-fraudulent-covid-treatment-peptides-amniotic-fluid/">A 2021 article</a> reported he’d recommended covid-19 treatments designated as “fraudulent” by the FDA. Those included inhaling amniotic fluid from a nebulizer.</p>



<p>In a phone call, Cook says he initially agreed to prescribe the combination to Conboy and a few other insiders as a favor. (Everyone involved, he says, is a member of the same “happening” Silicon Valley scene around life extension.) “My confidence this was going to work was a zero. Like, I did not believe it was actually going to work,” says Cook. That is because “it’s two safe, generic drugs that are not even longevity drugs.<strong>” </strong> </p>



<p>But Cook, who also took the combination, says there was an effect. “And I have to tell you, it was the most surprising thing that ever happened to me,” he says. After taking the weekly injections, he experienced a sense of mental clarity that lasted for a day, and then several days. The other subjects, he says, reported a sense of well-being, as well as old aches and pains that evaporated. </p>



<p>“There was a fairly significant broad set of symptoms that doesn’t really match what either of the drugs do,” he says. “So it’s interesting. [But] I have many more questions than I have answers … I still feel like I don’t understand exactly what the mechanism is.”</p>



<p>Prior to joining Generation Lab full time in 2025, Irina Conboy had a long career at the University of California, Berkeley, where she made her name via a widely cited series of experiments aimed at learning   whether the characteristics of age, or youth, could be transferred between animals via the bloodstream. In 2005, for instance, <a href="https://glennfoundation.org/pdf/Conboy-et-al-%282005%29-Nature.pdf">she surgically connected</a> two-month-old mice to very aged ones, finding that the old animals’ ability to heal from injury dramatically improved.</p>



<p>This suggested that young blood must contain specific, powerful molecular signals capable of restoring the regenerative capacity of an old animal. As researchers zeroed in on candidate signals, several startups, including <a href="https://www.elevian.com/">Elevian</a>, a Harvard spinout, and <a href="https://www.alkahest.com/">Alkahest</a>, tied to Stanford University scientists, were able to raise millions to pursue treatments for stroke or Alzheimer’s. However, those efforts still have not hit commercial paydirt.</p>



<p>Although it’s clear that young blood is good for old mice, scientists also know the reverse is true: Even a single exchange of plasma from an aged mouse has powerful, negative effects on a younger animal. That means that in the battle of age versus youth, says Conboy, “old blood dominates.”  </p>



<p>Conboy next tried a new approach. Instead of giving old animals young blood, in 2020 she removed the plasma (the part of the blood without cells) of old animals and replaced it with a neutral mixture of albumin and salt water. This was like pressing the Delete key on the swarm of hormones, antibodies, and other molecules released by the aged body.</p>





<p>The reset had even stronger rejuvenating effects than sharing a young animal’s blood, and within two years, Conboy had tried it on human volunteers who agreed to have almost half their blood volume removed and thrown away.</p>



<p>Longevity clinics have been quick to follow Conboy’s research. Some began offering “therapeutic plasma exchange” as a wellness intervention, for prices of up to $10,000 a session. One doctor that offers it, <a href="https://www.gladdenlongevity.com/">Jeffrey Gladden</a>, says that after seeing Conboy’s publications, he raced to California to meet her and to get the procedure himself.</p>



<p>By the end of 2025, Conboy had retired from Berkeley and joined her startup full time. Generation Lab has been selling an aging diagnostic test, but Conboy still wanted to find a drug that could mimic the benefits of plasma exchange. To do that, she started using a testing system she’d codeveloped, which allows researchers to bathe human cells kept in a microfluidic device with blood serum from old people.</p>



<p>The new device, described in a paper this year, allowed her to quickly test her intuitions about what drugs might work. “This is an awesome screen or experimental system which allows us then to ask a question: If tissue becomes old in the presence of old blood, which molecule or combination of molecules will prevent that and allow tissue to remain young, even when the circulatory milieu is old?”</p>



<p>And that’s how 1-Generation was discovered, she says. “It allows human cells to remain young even when they are in the presence of old people’s blood serum,” says Conboy. She claims it does that by stimulating cells to regenerate and, simultaneously, neutralizing the old-age factors in a person’s bloodstream.</p>



<p>Without knowing what the drugs are, I can’t give my own opinion about their promise. But some doctors working with Generation Lab expressed surprise that the combination would work. “I will say right now, candidly, it’s an unknown how it will play out. But there’s certainly a lot of enthusiasm based on the quality of her work in the past,” says Gladden, the longevity doctor, who says his Texas clinic will also be involved in the study. “I am skeptical and optimistic at the same time.”</p>



<p>Pressed on why the names of the drugs remain confidential, Su said it’s to avoid imitators. That’s important because Generation doesn’t own the molecules. Instead, it will seek to quickly run a clinical trial,<strong> </strong>taking advantage of an FDA process that gives companies a short period of exclusivity, perhaps three years, if they can show that a combination of existing drugs has a new use.</p>



<p>In the meantime, the company’s effort to generate buzz is having some success. Generation is hosting an August 28 invite-only event that will feature talks by George Church, the noted Harvard University synthetic biologist, as well as researchers from Anthropic, whose CEO, Dario Amodei, has been saying AI will cure all disease within a few years. In an email, Church says he was also offered a chance to take the drug combination.</p>



<p>“People are clamoring for it,” Cook, from BioReset Medical, told me. He says his office has started getting calls “from high-end doctors, venture capitalists, and people in this community who are kind of biohackers.”</p>



<p>“It’s high-level influencer-type people,” he adds. </p>



<p>As for me, no, I won’t be taking the drugs any time soon. Not until I know what they are.</p>



<p></p>]]> </content:encoded>
</item>

<item>
<title>Multi&#45;Academic Study Finds No Link Between Pesticide Exposure and Autism Traits</title>
<link>https://edusehat.com/en/multi-academic-study-finds-no-link-between-pesticide-exposure-and-autism-traits</link>
<guid>https://edusehat.com/en/multi-academic-study-finds-no-link-between-pesticide-exposure-and-autism-traits</guid>
<description><![CDATA[ Study showed nearly all mothers had detectable organophosphate pesticide levels in urine during pregnancy, yet team found no significant relationship in children between this exposure and traits related to autism.
The post Multi-Academic Study Finds No Link Between Pesticide Exposure and Autism Traits appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1290199657.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 03:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Multi-Academic, Study, Finds, Link, Between, Pesticide, Exposure, and, Autism, Traits</media:keywords>
<content:encoded><![CDATA[<p>Prenatal exposure to certain insecticides used in agriculture does not appear to be linked to social communication problems and other traits related to autism, according to a new study, “<a href="https://jamanetwork.com/journals/jamapediatrics/article-abstract/2853247" target="_blank" rel="noopener">Prenatal Organophosphate Exposure and Autism-Related Traits in Children</a>,” published in <em>JAMA Pediatrics</em>.</p>
<p>Evidence over time has suggested that organophosphate pesticides, which work by interfering with the nervous system of insects, increase children’s risk for neurodevelopmental issues such as IQ loss, cognitive challenges, and attention deficit hyperactivity disorder (ADHD) and. However, whether the chemicals may also contribute to autism-related traits has remained unclear.</p>
<p>Led by NYU Langone Health researchers, the study of pairs of mothers and children showed that nearly all mothers had detectable levels of organophosphate pesticides in their urine during pregnancy, yet the team found no significant relationship in the children between this exposure and traits related to autism.</p>
<p></p><h4><strong>Potential role of a healthy diet</strong></h4>

<p>“While we know that that organophosphate pesticides can harm the developing brain, they were not a major driver of characteristics seen in autism at the relatively low exposure levels we observed,” said study lead author Haleigh Cavalier, PhD. “These results should not be interpreted to mean that such pesticides are safe, nor do they rule out autism-related risks at higher exposures or among more vulnerable groups.”</p>
<p>Cavalier, who was a doctoral student at NYU Grossman School of Medicine’s departments of population health and pediatrics during the study and is now a postdoctoral research scientist at Columbia University, noted that outside of agricultural or occupational settings, most Americans primarily encounter the insecticides when they eat fresh produce. One explanation for the results could be that the health benefits of a diet high in fruits and vegetables may partially offset the chemicals’ potential impact on brain development.</p>
<p>Scientists have identified several genetic markers linked to autism-related traits, but environmental factors that could play a role have remained hotly debated. Small studies of prenatal organophosphate-pesticide exposure have yielded inconsistent findings, with some investigations uncovering a connection while others did not.</p>
<p>For the study, the research team analyzed data from 3,339 mother-child pairs enrolled at 20 medical centers in the U.S. National Institutes of Health’s Environmental Influences on Child Health Outcomes (ECHO) Program. This large nationwide study made it possible to consider many environmental, social, and biological factors that may shape children’s health that past smaller ones could not.</p>
<p><figure aria-describedby="caption-attachment-337126" class="wp-caption alignleft"><img decoding="async" class=" wp-image-337126" src="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2201456795-300x162.jpg" alt="A World Autism Day Concept is represented by a Rainbow Infinity Symbol on the Brain" width="282" height="152" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2201456795-300x162.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2201456795-768x415.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2201456795-778x420.jpg 778w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2201456795-696x376.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2201456795.jpg 804w" sizes="(max-width: 282px) 100vw, 282px"><figcaption class="wp-caption-text">A World Autism Day Concept is represented by a Rainbow Infinity Symbol on the Brain. Careful, long-term autism research can help clarify which environmental exposures matter most so that communities and policymakers can make more-informed decisions [Black Salmon/Getty Images]</figcaption></figure>To assess prenatal exposure to the insecticides, the investigators measured levels of metabolites (the components into which the chemicals break down in the body) in urine samples collected during each pregnancy. The tests revealed that 99 percent of mothers had detectable levels of organophosphate pesticides in their urine.</p>
<p>Then, the researchers looked for associations between these metabolite levels and the children’s scores on the Social Responsiveness Scale, a 65-item questionnaire designed to identify social communication problems and autism-related traits.</p>
<p>By rating such challenges on a spectrum, the tool could capture participants who had not been formally diagnosed with autism but displayed many of its common traits, such as avoidance of eye contact, difficulty understanding other people’s emotions, and needing to follow certain routines. The participants were evaluated when they were five to seven years old on average.</p>
<p>“Our results demonstrate that there is still much more to be learned about autism,” said study senior author Akhgar Ghassabian, MD, PhD. “Careful, long-term research can help clarify which environmental exposures matter most so that communities and policymakers can make more-informed decisions.”</p>
<p>Ghassabian, an associate professor in NYU Grossman’s departments of pediatrics and population health, says the researchers next plan to examine how other types of pesticides, as well as microplastics and other toxins, may contribute to autism. They also plan to assess how genes tied to the condition may interact with these environmental hazards.</p>
<p>The authors caution that the metabolites measured in the study are short-lived in the human body, so they can vary over time. They are also influenced by each participant’s metabolism. As a result, the markers might not provide a full picture of pesticide exposure.</p>
<p>The new assessment is the largest and most diverse of its kind to examine whether the insecticides might contribute to autism, the authors point out. Other study co-investigators included researchers from Johns Hopkins University, Drexel University, the New York State Department of Health, University of Washington, Kaiser Permanente in Pleasanton, CA, University of California, Davis, University of Southern California in Los Angeles, University of Utah, Michigan State University, Emory University, University of Michigan, University of Illinois Urbana-Champaign, University of Rochester in New York, Dartmouth College, and Columbia University.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/multi-academic-study-finds-no-link-between-pesticide-exposure-and-autism-traits/">Multi-Academic Study Finds No Link Between Pesticide Exposure and Autism Traits</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Next Wave of ADC Innovation: The Science Behind Dual&#45;Payload Bioconjugates</title>
<link>https://edusehat.com/en/the-next-wave-of-adc-innovation-the-science-behind-dual-payload-bioconjugates</link>
<guid>https://edusehat.com/en/the-next-wave-of-adc-innovation-the-science-behind-dual-payload-bioconjugates</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or complementary mechanisms. 
The post The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_2270842491_AntibodyDrugConjugate.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 03:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Next, Wave, ADC, Innovation:, The, Science, Behind, Dual-Payload, Bioconjugates</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/CindyCheng_headshot.jpg" class="h-full w-full object-cover" alt="Image of Cindy Cheng">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Cindy Cheng</h2>
                <h5 class="mt-0 !text-[15px]">Executive Director, Head of New Technology Discovery<br>WuXi XDC</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/CindyCheng_headshot.jpg" alt="Image of Cindy Cheng">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Cindy Cheng</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Cindy Cheng, PhD, is head of new technology discovery at WuXi XDC, where she leads the exploration and development of next-generation ADC and bioconjugation technologies. With over 20 years of experience in antibody and ADC discovery, cancer biology, and therapeutic innovation, she focuses on translating emerging scientific concepts into differentiated technology platforms and developable therapeutic solutions.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Friday, October 9, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-09T15:00:00.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Dual-payload antibody-drug conjugates (dp-ADCs) are being developed to address tumor heterogeneity, payload resistance, and other limitations of single-drug ADCs. By combining payloads with orthogonal or complementary mechanisms, dp-ADCs have the potential to enhance efficacy, overcome drug-resistance, and improve drug safety. However, success requires validation of safety and efficacy for the payloads, synergy for payload pairing where payload ratio, conjugation sites, linker properties, and release kinetics must be carefully designed and optimized. </p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or complementary mechanisms. She will connect biological rationale with the complicate designs of dp-ADC, including payload ratio, conjugation sites, hydrophilic linker design, and controlled payload release. She will also discuss CMC strategies that ensure the success of an innovative dp-ADC from concepts to a clinical product. Key learning objectives for the webinar include:</p><p></p><p></p><p></p><ol class="wp-block-list"><p></p><li>Understanding how rational dual-payload design can address the limitations of single-payload ADCs</li><p></p><p></p><p></p><li>Sharing key considerations for a dp-ADC design, including payload ratio, conjugation sites, hydrophilic linker design, and controlled release</li><p></p><p></p><p></p><li>Exploring CMC strategies for ensuring product quality when managing complex molecule such as dp-ADC</li><p></p></ol><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://wuxixdc.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="95" src="https://www.genengnews.com/wp-content/uploads/2024/05/WuxiXDC_logo-300x95.jpg" alt="Wuxi XDC logo" class="wp-image-295097" srcset="https://www.genengnews.com/wp-content/uploads/2024/05/WuxiXDC_logo-300x95.jpg 300w, https://www.genengnews.com/wp-content/uploads/2024/05/WuxiXDC_logo-768x244.jpg 768w, https://www.genengnews.com/wp-content/uploads/2024/05/WuxiXDC_logo-696x221.jpg 696w, https://www.genengnews.com/wp-content/uploads/2024/05/WuxiXDC_logo.jpg 1024w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/the-next-wave-of-adc-innovation-the-science-behind-dual-payload-bioconjugates/">The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer</title>
<link>https://edusehat.com/en/aprea-expands-development-of-wee1-inhibitor-after-seeing-early-clinical-activity-signs-vs-cancer</link>
<guid>https://edusehat.com/en/aprea-expands-development-of-wee1-inhibitor-after-seeing-early-clinical-activity-signs-vs-cancer</guid>
<description><![CDATA[ The Phase I dose escalation trial of ACESOT-1051 (NCT06260514) will accelerate its patient enrollment, with Aprea planning to more than triple its number of active clinical sites for the study from three to 10. The expansion is expected to accelerate the pace of clinical data generation by raising monthly enrollment to between six and 10 patients by the fourth quarter.
The post Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_1405940919_Cancer-696x392-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 03:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Aprea, Expands, Development, WEE1, Inhibitor, After, Seeing, Early, Clinical, Activity, Signs, vs., Cancer</media:keywords>
<content:encoded><![CDATA[<p>Aprea Therapeutics is accelerating enrollment in its ongoing Phase I trial of its targeted cancer therapy APR-1051, one of the precision oncology drug developer’s two lead programs, and expanding its indications under study after seeing early signs of clinical activity.</p>
<p>The Phase I dose escalation trial of ACESOT-1051 (<a href="https://clinicaltrials.gov/study/NCT06260514" target="_blank" rel="noopener">NCT06260514</a>) will accelerate its patient enrollment, with Aprea planning to more than triple its number of active clinical sites for the study from three to 10. The expansion is expected to accelerate the pace of clinical data generation by raising monthly enrollment to between six and 10 patients by the fourth quarter.</p>
<p>By then, Aprea expects to share updated clinical data at a medical meeting for the Phase I trial of APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, a DNA damage response (DDR) pathway protein. WEE1 is designed to regulate the G<sub>2</sub> checkpoint, which ensures that cells don’t initiate mitosis until damaged DNA is repaired.</p>
<p>The acceleration aims to help Aprea further characterize the clinical activity of APR-1051 in biomarker-defined tumor populations with a mechanistic rationale for WEE1 inhibition. In addition to accelerating enrollment, Aprea is broadening the development of APR-1051 by advancing it:</p>
<ul>
<li>In uterine serous carcinoma (USC) and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC). Aprea expects to enroll at least 50 patients with USC or PROC.</li>
<li>Into combination regimens, expanding the Phase I study to include arms enrolling human papillomavirus (HPV)-positive head and neck squamous cell carcinoma and colorectal cancer, in combination with standard-of-care therapies.</li>
</ul>
<figure aria-describedby="caption-attachment-337107" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337107" src="https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-300x300.jpg" alt="" width="300" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-1536x1536.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-840x840.jpg 840w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-696x696.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-1392x1392.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-1068x1068.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111-1920x1920.jpg 1920w, https://www.genengnews.com/wp-content/uploads/2026/08/Oren-Gilad-Headshot_APRE-CROP11111.jpg 1945w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Oren Gilad, PhD, Aprea Therapeutics President and CEO</figcaption></figure>
<p>In both cases, Aprea said, it will use dose levels for APR-1051 that have shown single-agent activity and cleared safety review. Dose escalation and “backfill” expansion of the patient population is expected to be completed in the second quarter of 2027.</p>
<p>“Our goal is to see who is responding the strongest, who is the most sensitive to our therapy. These are the patient population that we’re going to be then treating in the next phase of development,” Oren Gilad, PhD, Aprea’s president and CEO, told <em>GEN</em>. “In order to de-risk the next phase of development, which is all about overall survival, we are spending lots of time and resources into this stage of the development, into the dose escalation.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<h4><strong>Positive early results</strong></h4>
<p>In March, Aprea said a patient with PPP2R1A-mutated endometrial cancer showed confirmed partial response after treatment with a 220 mg dose—a 50% reduction in target lesion size and an 87% decline in CA-125 from 362 at baseline to 47 U/mL. A later assessment showed an additional 9.5% reduction in target lesion size, and a reduction in CA125 from 362 to 40.2U/ml.</p>
<p>And in January, Aprea disclosed positive early results from the study that it said showed early clinical proof-of-concept for APR-1051. A patient with PPP2R1A-mutated uterine serous carcinoma, a form of endometrial cancer, showed a 50% reduction in target lesion size and a >90% reduction in cancer antigen 125 (CA-125) levels, from 732 to 70 U/mL, at the protocol-defined eight-week first imaging assessment after treatment with a 150 mg dose of APR-1051.</p>
<p>Aprea shared clinical data on the uterine cancer patient in “<a href="https://ir.aprea.com/static-files/b5350b88-5db9-46a8-8468-35315e6c3860" target="_blank" rel="noopener">Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)</a>,” a poster presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting this past spring.</p>
<p>The presentation showed stable disease in six of 28 patients (23%) with advanced solid tumors harboring specific cancer-associated gene alterations, enrolled up to the 300 mg dose level as of the May 6 cutoff. Half (14 of 28) of the enrolled patients had colorectal cancer, followed by uterine/endometrial cancer (eight patients), pancreatic cancer (two), HPV plus HPV-related oropharyngeal squamous cell carcinoma or OPSCC (two), breast cancer (one), and gastric cancer (one).</p>
<p>Preliminary signs of clinical activity were seen in eight patients (29%), consisting of partial responses (two patients) and disease stabilization (six).</p>
<p>“In this study, APR-1051 has shown manageable safety and early signs of tumor shrinkage and no substantial myelosuppression,” researchers concluded in the poster.</p>
<p>Treatment-emergent adverse events (TEAEs) of any grade were reported in 26 of the 28 patients, who had a median of three prior lines of treatments before being dosed with APR-1051. Treatment-related AEs (TRAEs) were reported in 15 patients, with 13 showing non-serious Grade 1 or 2 gastrointestinal events. Two patients had Grade 3 TRAEs consisting of a lymphocyte decrease in one patient (dose level 50 mg) and increased AST and increased ALT in the other patient (a dose-limiting toxicity or DLT, dose level 50 mg).</p>
<p>The one death reported in the poster was due to treatment deemed unrelated to APR-1051.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>‘The drug is working’</strong></h4>
<p>“When you look at the clinical data, it’s exactly what we were hoping for. We saw tumor shrinkage, and very tolerable side effects,” Gilad said. “The drug is working. It’s doing exactly what it is supposed to be doing. So, the differentiation is that we looked at WEE1 as a target, and WEE1 has been validated to be a good target.”</p>
<p>Gilad and Aprea said APR-1051 holds potential for solving a longtime challenge to treating cancer by targeting WEE1: How to sustain the resulting therapeutic efficacy without achieving harmful side effects in the process? These can include the heavy suppression of bone marrow, which reduces white blood cell production; severe GI distress such as nausea, vomiting, and diarrhea; and systemic fatigue that limits dose size and treatment.</p>
<p>Those effects arose, he said, because earlier WEE1 drugs also inhibited another cell cycle regulatory kinase, Polo-like kinase 1 (PLK). One such dual WEE1/PLK inhibitor, AstraZeneca’s cancer fighting candidate adavosertib (AZD1775), failed a Phase II trial sponsored by the National Cancer Institute (<a href="https://clinicaltrials.gov/study/NCT03284385" target="_blank" rel="noopener">NCT03284385</a>; NCI10170) by failing to exhibit objective response in SETD2-altered clear cell renal cell carcinoma.</p>
<p>Two other Phase II trials of adavosertib were terminated earlier after an interim analysis showed increased toxicity and limited efficacy. One study compared adavosertib plus docetaxel to placebo plus docetaxel in previously treated non-small-cell lung cancer (NSCLC) patients (<a href="https://clinicaltrials.gov/study/NCT02087176" target="_blank" rel="noopener">NCT02087176</a>). The other study compared the effects of adding adavosertib to pemetrexed and carboplatin in patients with previously untreated Stage IV non-squamous NSCLC (<a href="https://clinicaltrials.gov/study/NCT02087241" target="_blank" rel="noopener">NCT02087241</a>).</p>
<p>The trials were among multiple Phase I and II studies whose mixed results prompted AstraZeneca to halt clinical development of adavosertib in 2022.</p>
<p></p><h4><strong>Back to the drawing board</strong></h4>

<p>“There were challenges associated with the other WEE1 inhibitors, because they were not selective, so they became toxic. So, we went back to the drawing board,” Gilad recalled. “PLK inhibitors have been in the clinic. They’re good as single agents, but they also have hem[atological] tox[icity] and they have gut tox, and then you’re adding that on top of the WEE1 inhibition—that’s the one thing we had to resolve. We had to have a WEE1 selective inhibitor, not a WEE1/PLK dual inhibitor.”</p>
<p>“That was our hypothesis, and it seems to be translating pretty nicely to the clinic,” Gilad added. “It’s not that PLK selective inhibitors are not good. They’re good for the patient population that they’re targeting. The argument I’m going to make is that when you’re inhibiting PLK, on top of inhibiting WEE1, It’s not adding; it’s actually taking away.”</p>
<p>Aprea first announced plans to expand the APR-1051 trial on July 31 but restated its expansion plans earlier this month when it reported second quarter earnings. Aprea finished the quarter with a net loss of $3.591 million, about 11% above the $3.239 million net loss of Q2 2025, with no revenue to report during Q2, compared to $118,111 in revenue during Q2 2025.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>However, Aprea ended the second quarter with $41.233 million in cash and cash equivalents, nearly triple (up 182%) from $14.599 million in the year-ago quarter. The surge follows the company’s closing on an oversubscribed $30 million private placement during the first quarter, with the proceeds intended to support general corporate purposes as well as R&D expenses for APR-1051 and Aprea’s other lead candidate, ATRN-119 (Mosipasertib).</p>
<p>ATRN-119 is a macrocyclic ATR inhibitor designed for patients with tumors harboring mutations in DDR-related genes. ATRN-119 is being developed as an oral, once-twice-daily treatment for both advanced solid tumors (ovarian, colorectal, and lung) and blood cancers (acute myeloid leukemia, myelodysplastic syndrome).</p>
<p>Last year, Aprea voluntarily paused the Phase I/IIa ABOYA-119 dose-escalation trial of ATRN-119 monotherapy, saying it needed to focus its limited resources on the development of APR-1051.</p>
<p></p><h4><strong>Talks with academic centers</strong></h4>

<p>Aprea said earlier this month it has been in talks with “leading” academic centers to explore studies assessing ATRN-119 in combination with immune-oncology agents, chemotherapy, antibody-drug conjugates (ADCs), and/or radiation.</p>
<p>“Stay tuned,” Gilad said.</p>
<p>Aprea believes its cash and cash equivalents will be able to fund its projected operating expenses and capital expenditure requirements into Q1 2028: “That will definitely, easily take us through completion of dose escalation with enrichment [of the patient population]” for APR-1051, Gilad added.</p>
<p>Over the rest of 2026, he predicted, “we’re going to open more sites. We are opening more sites. So, our rate of enrollment is going to increase, tremendously: More sites, more patients, more data from us—and from others in the field.”</p>
<p>Those others include Zentalis Pharmaceuticals, which in its second quarter update earlier this month announced that it expects to release a topline data readout from Part 2 of its Phase II DENALI trial (<a href="https://clinicaltrials.gov/study/NCT05128825" target="_blank" rel="noopener">NCT05128825</a>) in the first half of 2027—pushed back from the second half of 2026 as the company told investors in May, “to allow for data maturation post full enrollment.”</p>
<p>DENALI is designed to evaluate the efficacy and safety of Zentalis’ azenosertib in patients with PROC, fallopian tube, or primary peritoneal cancer.</p>
<p>“Hopefully they come out with positive data,” Gilad said, “because it’s going to help all patients. It’s going to help everybody.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/aprea-expands-development-of-wee1-inhibitor-after-seeing-early-clinical-activity-signs-vs-cancer/">Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>UCSF QBI Awarded $46M to Translate Landmark Autism Map Into Precision Therapies</title>
<link>https://edusehat.com/en/ucsf-qbi-awarded-46m-to-translate-landmark-autism-map-into-precision-therapies</link>
<guid>https://edusehat.com/en/ucsf-qbi-awarded-46m-to-translate-landmark-autism-map-into-precision-therapies</guid>
<description><![CDATA[ A landmark molecular map revealed shared pathways connecting diverse autism risk genes. Now, a $46 million investment will help QBI scientists and their collaborators pursue new precision medicines.
The post UCSF QBI Awarded $46M to Translate Landmark Autism Map Into Precision Therapies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2019/06/Jun13_2019_Getty_165801453_AutismPuzzleBoy_cropped.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 03:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>UCSF, QBI, Awarded, 46M, Translate, Landmark, Autism, Map, Into, Precision, Therapies</media:keywords>
<content:encoded><![CDATA[<p><span>A landmark study published this week in </span><i><span>Science</span></i><span> could help scientists answer some fundamental questions about the genetic basis of autism spectrum disorder including how mutations in ASD risk genes lead directly to changes in brain development, and how that knowledge can be translated into more effective therapies.</span></p>
<p><span>The study was led by scientists at the Quantitative Biosciences Institute (QBI) and the department of psychiatry and behavioral sciences at the University of California, San Francisco (UCSF). The paper presents findings from more than a decade of work to build what the scientists claim is the largest molecular interaction map of autism. The map reveals how hundreds of genes and dozens of mutations converge within a small number of shared protein networks. Their paper is titled “</span><a href="https://dx.doi.org/10.1126/science.ady4523" target="_blank" rel="noopener"><span>A foundational autism protein interaction atlas reveals molecular convergence</span></a><span>.” </span></p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><span>Besides the paper’s publication, UCSF’s QBI has received $46 million in grant funding from Aligning Research to Impact Autism (ARIA) that it will use to expand its work into the molecular mechanisms of autism spectrum disorder. According to the institution, this award represents one of the most significant investments in QBI’s history and builds on more than a decade of collaborative research from QBI and UCSF’s department of psychiatry and behavioral sciences, known as the Psychiatric Cell Map Initiative (PCMI). </span></p>
<p><span>Digging into the details of the funding, the grant will support QBI’s work in ARIA’s Protein-Protein Interactions Hub, one of six research hubs in ARIA’s scientific ecosystem. This particular hub brings together international, multidisciplinary research teams to map disrupted protein complexes and develop small molecules that can modulate their activity. </span></p>
<p><span>The funds will allow the UCSF scientists and their collaborators to build on the work reported in the </span><i><span>Science </span></i><span>study. According to the paper, the scientists used affinity purification-mass spectrometry that mapped the proteins encoded by 100 autism-linked genes to discover how individual mutations can rewire the molecular machinery of the developing brain. Their analysis revealed more than 1,800 protein interactions, 87% of which had not been reported previously. Furthermore, by integrating the interaction maps with AlphaFold structural modeling predictions and functional studies in </span><i><span>Xenopus</span></i><span> and human forebrain organoids, the scientists were able to pinpoint exactly where mutations disrupt protein interfaces.</span></p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p><span>The scientists also analyzed 54 patient-derived autism mutations and identified how distinct genetic variants rewire protein interaction networks in the brain. One of the findings reported in the paper is that distinct mutations in different autism genes produced similar changes in how proteins interact. For instance, separate mutations in <em>FOXP1</em> and <em>FOXP2</em> converge on disrupting the same FOXP1-FOXP4 protein interaction, leading to premature development of cortical neurons and increased neural circuit excitability in lab-grown brain organoids. </span></p>
<p><span>That finding points to one of the most important discoveries reported in the paper, which is that several genetically distinct forms of autism disrupt the same protein complexes. In one example, <em>FOXP1</em> mutations that sit at entirely different locations within the protein all converge on disrupting the same FOXP1-FOXP4 interaction. Shared networks like these could be targeted therapeutically to directly address multiple molecular factors associated with autism. Instead of developing distinct therapies for every mutation, scientists could develop single medicines capable of treating multiple genetic forms of autism simultaneously. </span></p>
<p><span>“This study maps the exact molecular machinery that is altered, including the specific protein interactions, down to the interfaces we can target with a drug,” noted Nevan Krogan, PhD, professor at UCSF, director of QBI, and senior investigator at Gladstone Institutes. “Further, what we’ve built here isn’t limited to autism. It’s a blueprint for translating the genetics of almost any disease from neurodegeneration to cancer, into a real therapeutic strategy.” </span></p>
<p><span>The findings are directly relevant to the approximately 30% of individuals with profound autism, many of whom carry rare, high-impact mutations in established autism risk genes. “After the initial excitement of discovering rare mutations that cause common forms of autism, the reality of how hard it would be to develop medicines to target the most severe end of the autism spectrum became abundantly clear,” said Matthew State, MD, PhD, a senior author and chair of the department of psychiatry and behavioral sciences at UCSF. “This current work opens up a whole new world of possibilities for therapeutic targets and promises a generation of novel drugs that can transform what we are able to do in the clinic.”  </span></p>
<p><span>Commenting on QBI’s grant funding from ARIA, Krogan added that “translating fundamental science into medicines that help patients requires not just the right ideas, but the sustained investment to follow those ideas all the way through. ARIA’s commitment does exactly that. It accelerates our ability to move from molecular insight to therapeutic impact, for autism and ultimately for many other diseases.”</span></p>
<p>The post <a href="https://www.genengnews.com/topics/omics/ucsf-qbi-awarded-46m-to-translate-landmark-autism-map-into-precision-therapies/">UCSF QBI Awarded $46M to Translate Landmark Autism Map Into Precision Therapies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO applauds efforts targeting early drug development efficiency, provides suggestions</title>
<link>https://edusehat.com/en/bio-applauds-efforts-targeting-early-drug-development-efficiency-provides-suggestions</link>
<guid>https://edusehat.com/en/bio-applauds-efforts-targeting-early-drug-development-efficiency-provides-suggestions</guid>
<description><![CDATA[ A Food and Drug Administration (FDA) pilot program to expedite approval of new drugs contains potentially impactful initiatives but risks adding burdens, says the […]
The post BIO applauds efforts targeting early drug development efficiency, provides suggestions appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2023/07/louis-reed-pwcKF7L4-no-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 28 Aug 2026 00:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, applauds, efforts, targeting, early, drug, development, efficiency, provides, suggestions</media:keywords>
<content:encoded><![CDATA[<p><span>A Food and Drug Administration (FDA) pilot program to expedite approval of new drugs contains potentially impactful initiatives but risks adding burdens, says the Biotechnology Innovation Organization (BIO).</span></p>
<p><a href="https://www.regulations.gov/comment/FDA-2026-N-4699-0150" target="_blank" rel="noopener"><span>BIO’s Aug. 24 comments</span></a><span> respond to FDA’s</span><a href="https://www.federalregister.gov/documents/2026/07/21/2026-14672/expedited-investigational-new-drug-pilot-program-request-for-information-extension-of-the-comment" target="_blank" rel="noopener"> <span>request for information (RFI)</span></a><span> on its</span><a href="https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development" target="_blank" rel="noopener"> <span>Expedited Investigational New Drug Pilot Program</span></a><span>. The pilot is part of the FDA’s Trialblazer initiative to test potential efficiency enhancements that could enable more rapid clinical trials and drug approvals.</span></p>
<p><span>BIO lauds the concept of “rolling review,” which lets a drug sponsor provide individual modules of their investigational new drug (IND) application instead of holding the application until all modules are complete. But BIO expresses concerns that the pilot’s proposal to make applicants partner with a Qualified Research Institution (QRI) adds a “third-party layer” to the process without clear benefits.</span></p>
<h2>QRI questions</h2>
<p><a href="https://www.fda.gov/news-events/fda-voices/america-must-address-early-clinical-development" target="_blank" rel="noopener"><span>FDA’s pilot envisions</span></a><span> “enlisting expert Qualified Research Institutions (QRIs), such as academic medical centers, contract research organizations, and other organizations with deep subject matter area expertise, to take on the role of a scientific partner during IND preparation.” FDA says it wants to test the “hypothesis” that QRIs would ensure applicants provide complete data, meet FDA standards, and provide submissions with recommendations from external experts.</span></p>
<p><span>BIO acknowledges that a QRI might help review an application but questions the benefits, given potential delays in an IND application.</span></p>
<p><span>“The principal risk is that the pilot could add an additional layer of review rather than reduce time to safe-to-proceed, particularly if FDA must review both the QRI’s output and the underlying components,” </span><a href="https://www.regulations.gov/comment/FDA-2026-N-4699-0150"><span>BIO says</span></a><span>. “Unless QRI review is clearly decoupled from FDA’s own review, the model risks increasing workload rather than delivering efficiency gains.”</span></p>
<p><span>BIO lists several additional concerns about QRIs, including the new body’s unclear regulatory status, potential for variable QRI quality, over-reliance on QRI recommendations, and new bottlenecks related to a QRI’s limited resources or FDA questions about QRI qualification.</span></p>
<h2>Support for rolling review</h2>
<p><span>BIO supports the pilot program’s concept of rolling review, which</span><a href="https://www.fda.gov/news-events/fda-voices/america-must-address-early-clinical-development" target="_blank" rel="noopener"> <span>FDA describes</span></a><span> as follows: “FDA plans to review and accept individual components of an IND submission as they are completed, rather than waiting for a complete package.”</span></p>
<p><span>FDA adds that rolling review makes more sense regarding preparation for a first-in-human (FIH) clinical trial.</span></p>
<p><span>“In a well-designed FIH program, the nonclinical package is typically the first body of evidence ready for review, establishing the scientific rationale and safety basis for proceeding to humans. CMC (Chemistry, Manufacturing and Controls) data follows as product characterization matures. Clinical protocols and safety information come last, informed by what the nonclinical and manufacturing data have established,”</span><a href="https://www.fda.gov/news-events/fda-voices/america-must-address-early-clinical-development" target="_blank" rel="noopener"> <span>according to FDA.</span></a><span> “Today’s process ignores this natural sequence, requiring sponsors to hold everything until the full package is assembled.”</span></p>
<p><span>The pilot envisions QRIs overseeing rolling review, but BIO recommends that the pilot focus on proving the potential benefits of rolling review alone.</span></p>
<p><span>“Rolling review offers a more direct mechanism to enable earlier issue resolution and parallel preparation of nonclinical, CMC, and clinical components, and warrants continued exploration independent of the QRI framework,” </span><a href="https://www.regulations.gov/comment/FDA-2026-N-4699-0150" target="_blank" rel="noopener"><span>BIO says</span></a><span>. “Rolling reviews would likely result in significant time savings by enabling earlier FDA engagement and parallel preparation and earlier resolution of nonclinical, CMC, and clinical issues.”</span></p>
<h2>Other considerations and recommendations</h2>
<p><span>Other aspects of the pilot include clarifying IND requirements, but BIO’s comments question the benefit of “incremental improvement” and call for broader process improvements.</span></p>
<p><span>“In practice, delays in FIH initiation arise from a combination of factors, including front-end uncertainty, iterative rework, and downstream bottlenecks such as IRB (Institutional Review Board) review, contracting, site activation, and FDA protocol review,” along with other cost and logistics considerations, BIO says. “Meaningful impact will require a comprehensive approach that addresses the full ecosystem.”</span></p>
<p><span>BIO identifies a wide range of potential FDA efficiencies in recent research, including its October report on “</span><a href="https://www.bio.org/enhancing-fda-gold-standard" target="_blank" rel="noopener"><span>Strategies for Enhancing FDA as Global Gold Standard</span></a><span>,” produced in consultation with its members. BIO’s collaboration in an industry-FDA roundtable earlier this year produced detailed recommendations </span><a href="https://www.reaganudall.org/publications/enhancing-early-stage-drug-development-united-states" target="_blank" rel="noopener"><span>published in June by the Reagan-Udall Foundation for the FDA</span></a><span>. Some recommendations from these reports are mentioned in BIO’s Aug. 24 comments.</span></p>
<p><span>For the current pilot program as envisioned by FDA, BIO recommends a methodology that identifies what works and what does not.</span></p>
<p><span>“Given the number of variables FDA appears to be testing—including the QRI model, rolling submissions, IRB review, and site activation—BIO urges FDA to design the pilot with clear success metrics that can distinguish the impact of each component,” BIO says. “Critically, success should reflect net improvement, not just faster IND clearance, and should account for whether gains are offset by delays or burdens elsewhere.”</span></p>
<p><a href="https://www.regulations.gov/comment/FDA-2026-N-4699-0150" target="_blank" rel="noopener"><b>Read BIO’s full comments for the RFI.</b></a></p>
<p>The post <a href="https://bio.news/federal-policy/bio-applauds-efforts-targeting-early-drug-development-efficiency-provides-suggestions/">BIO applauds efforts targeting early drug development efficiency, provides suggestions</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Myotis Bat Genomes Reveal How They Fight Viruses, Cancer, and Cellular Damage</title>
<link>https://edusehat.com/en/myotis-bat-genomes-reveal-how-they-fight-viruses-cancer-and-cellular-damage</link>
<guid>https://edusehat.com/en/myotis-bat-genomes-reveal-how-they-fight-viruses-cancer-and-cellular-damage</guid>
<description><![CDATA[ Scientists studying eight Myotis bat species uncovered genetic adaptations that may explain their exceptional longevity, cancer resistance, viral defense, and ability to repair or eliminate damaged cells.
The post Myotis Bat Genomes Reveal How They Fight Viruses, Cancer, and Cellular Damage appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-520069342.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 06:00:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Myotis, Bat, Genomes, Reveal, How, They, Fight, Viruses, Cancer, and, Cellular, Damage</media:keywords>
<content:encoded><![CDATA[<p>Bats are among the most diverse mammalian species—second only to rodents—and are anomalies in the mammalian world: they fly, have long lifespans for their size, and rarely get cancer.</p>
<p>Scientists now provide insights into these unique characteristics in the new study published in <em>Nature</em> entitled, “<a href="https://www.nature.com/articles/s41586-026-10932-7" target="_blank" rel="noopener">Insights into longevity and virus-driven adaptation from <em>Myotis</em> bat genomes.</a>”</p>
<p>The team generated cell lines and near-complete genome assemblies for eight closely related <em>Myotis</em> bat species. They collected tissue from <em>Myotis</em> bats in the American West using a novel sampling approach. Instead of harvesting organ tissue, the scientists biopsied tiny circular patches from the wings akin to an ear piercing. The tissue was used to grow cell lines and build genomes for the eight species. Using genome-wide screens of positive selection, analyses of structural variation, and experiments, the team identified patterns of adaptation contributing to longevity, cancer resistance and viral interactions.</p>
<figure aria-describedby="caption-attachment-337089" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="wp-image-337089 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Myotis-thysanodes-e1787765205738-300x286.jpg" alt="" width="300" height="286" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Myotis-thysanodes-e1787765205738-300x286.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Myotis-thysanodes-e1787765205738-441x420.jpg 441w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Myotis-thysanodes-e1787765205738.jpg 525w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A researcher in the study holds a tiny <i>Myotis thysanodes</i> of Fringed Myotis. [Elise Lauterbur]</figcaption></figure>
<p>“Pathogen adaption, longevity, and cancer resistance—they are fundamentally linked,” says Elise Lauterbur, PhD, assistant professor of evolutionary biology at the University of Vermont. “Many of the genes that have adapted to viruses in bats are genes that are also involved in longevity and cancer resistance.”</p>
<p>The team discovered that bats exhibit a unique gene copy mechanism for DNA-repair. And more specifically, they write that their findings show “distinct modes of adaptation to DNA and RNA viruses compared with all other mammals, with bats exhibiting genome-wide over-representation of positive selection for DNA-virus-interacting proteins and elevated rates of copy-number variation for RNA-virus-interacting proteins.”</p>
<p>Characterization of <em>Myotis</em>-specific duplications led the research team to home in on the key immune factor EIF2AK2 (also known as PKR) found in every mammal to understand what made the <em>Myotis</em> bat’s antiviral response so different.</p>
<figure aria-describedby="caption-attachment-337090" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-337090" src="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-300x225.jpg" alt="Bat genome study" width="300" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot-530x396.jpg 530w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Manny-Vazquez-field-shot.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Manny Vazquez sequences genomes for insights into aging and age-related diseases. He is an assistant professor at Penn State University and co-lead author of the study. This photo is of him in the field. [Manny Vazquez]</figcaption></figure>
<p>They show that the recurrent evolution of longevity seen in <em>Myotis</em> is associated with positive selection in cancer pathways and demonstrate a unique response to DNA damage in primary cells of the long-lived <em>Myotis lucifugus. </em>“In every single other mammal that has been looked at, there is one copy of this gene,” Lauterbur explains. “That means there is some important pressure keeping it at one copy. In our very special <em>Myotis</em> bats, there are two copies—or so we thought.” When she teased apart the genome, Lauterbur found some <em>Myotis</em> bats had one, two, or even three copies of PKR, suggesting additional copies have a protective effect that promote longevity.</p>
<p>Collaborators conducted experiments on the various cell lines, splicing copies of PKR into different species and then introduced the cells with a pox virus to gauge their reaction and dosed the cells with chemotherapeutic drug to test how they tolerate and repair damage. The team found little brown bats—the longest living bats of the group—responded differently at high doses where cell damage would most likely occur.</p>
<p>This adaptation could be critical for curbing the spread of cancer. As organisms age and cellular processes decline, some particularly long-lived species have developed specialized responses from repairing damaged cells, isolating the damage, to throwing cells out upon damage detection.</p>
<p>While it may be too early to use the unique immune adaptations of bats to solve human pathology, some lessons may be particularly valuable. Moving forward, Lauterbur wants to explore underappreciated adaptations such as changes in gene copy number, she says. “Those kinds of changes can give evolution additional ways to generate diversity and respond to changing environments, and I think we’re only beginning to understand their importance.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/myotis-bat-genomes-reveal-how-they-fight-viruses-cancer-and-cellular-damage/"><i>Myotis</i> Bat Genomes Reveal How They Fight Viruses, Cancer, and Cellular Damage</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Ancient Peptides Resurrected from Lactoferrin’s Evolutionary Past Could Point to New Antibiotics</title>
<link>https://edusehat.com/en/ancient-peptides-resurrected-from-lactoferrins-evolutionary-past-could-point-to-new-antibiotics</link>
<guid>https://edusehat.com/en/ancient-peptides-resurrected-from-lactoferrins-evolutionary-past-could-point-to-new-antibiotics</guid>
<description><![CDATA[ Scientists working their way back through millions of years of the evolutionary past of mammalian lactoferrin reconstructed extinct peptides, some of which in laboratory were more potent against drug-resistant bacteria than present-day counterparts. 
The post Ancient Peptides Resurrected from Lactoferrin’s Evolutionary Past Could Point to New Antibiotics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/06/GettyImages-1574239031.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 06:00:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Ancient, Peptides, Resurrected, from, Lactoferrin’s, Evolutionary, Past, Could, Point, New, Antibiotics</media:keywords>
<content:encoded><![CDATA[<p>University of Oregon biologists have resurrected prehistoric proteins up to 160 million years old that carry natural antimicrobial properties. The scientists worked their way up the tree of life of the iron-binding protein lactoferrin, reconstructing peptides dating back to the earliest placental mammals, the diverse lineage that includes humans and nearly all mammals alive today. In laboratory tests, the researchers found that some of the extinct peptides were more potent against drug-resistant bacteria than some of their present-day counterparts.</p>
<p>Evolution’s ancient remedies could offer new starting points for scientists designing treatments that supplement or replace antibiotics that no longer work, said research lead Matt Barber, PhD, evolutionary biologist at the UO College of Arts and Sciences. “For anybody who studies pathogenic bacteria, it’s always in the back of our minds that antibiotics are one of the most important breakthroughs in medicine in the 20<sup class="wp-sup-text">th</sup> century. But bacteria are, and have been for a long time, evolving resistance to them. We’re definitely interested in whether by resurrecting or engineering some enhanced antimicrobial peptides, we could use these as therapeutics down the road.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Barber is senior author of the researchers’ published paper in <em>PLOS Biology</em>, titled “<a href="http://dx.doi.org/10.1371/journal.pbio.3003932" target="_blank" rel="noopener">Retracing the origin and evolution of a cryptic antimicrobial peptide within mammalian lactoferrin</a>.”</p>
<p>Some 160 million years ago, near the end of the Jurassic period, the ancestor of all placental mammals emerged and so did lactoferrin, an immune protein found in nearly every body fluid (except blood), including breast milk, tears, saliva, and various types of mucus. The main function of lactoferrin is to withhold iron from pathogens. Bacteria in the body need iron to fuel their advances, but lactoferrin acts as a vault, tightly sealing the key resource away.</p>
<p>In addition to securing iron from bacterial reach, lactoferrin has evolved built-in tools to fight against pathogens. Most notably, it has an antimicrobial peptide (AMP), lactoferricin, that punches holes in the membranes of bacteria, rupturing the cell. “Antimicrobial peptides are a key part of the body’s first line of defense,” said first author Titas Sil, a doctoral student in Barber’s lab. “They can target a broad range of pathogens, and due to their potency, scientists have been trying to synthesize a variety for therapeutic uses.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>None of lactoferrin’s close protein relatives have that bacteria-killing ability, suggesting that the property arose sometime after lactoferrin emerged in the mammalian lineage. To find out when and how it has evolved since, the researchers worked backward through its evolutionary history and resurrected its ancestors. “Here we retrace the origin and evolution of the abundant mammalian protein lactoferrin and it embedded AMP, lactoferricin,” they wrote.</p>
<p>A look at the past might give ideas for a healthier future, Barber said. “Evolution is essentially a billions-year-old science experiment, right? We’re seeing the results of what worked and what didn’t work. Looking at how traits are naturally produced and selected through evolution, you can get information that could be useful for designing new antimicrobial tools.”</p>
<p>To resurrect the extinct antimicrobial peptide, Sil first compared the gene sequences of lactoferrin in present-day humans and cows. Mapping their evolutionary relationships, she statistically inferred the most likely sequences of their common ancestors, reaching back about 160 million years. That state-of-the-art technique is known as ancestral sequence reconstruction, <a href="https://www.science.org/doi/10.1126/science.317.5840.884b" target="_blank" rel="noopener">which was pioneered by Joseph Thornton</a>, a former UO scientist whose previous lab space is now home to Barber’s group. “To retrace the mutations that led to the emergence of a novel antimicrobial function, we reconstructed ancestral lactoferrin and transferrin sequences across diverse mammals,” the researchers noted. “Ancestral sequence reconstruction (ASR) provides a powerful approach to characterize the function of ancient proteins.”</p>
<p>After synthesizing the predicted gene and regenerating the ancient protein in cells, Sil then tested their potency against several pathogens associated with human diseases, including <em>Pseudomonas aeruginosa</em>, <em>Staphylococcus aureus</em>, <em>Escherichia coli</em>, and <em>Streptococcus</em>. The earliest resurrected antimicrobial peptides disturbed the bacterial membranes, but the pathogens were somehow able to repair the damage and tolerate the peptide. But peptides of later mammalian ancestors, about a few million years old, displayed progressively stronger antimicrobial activity, sometimes outperforming the modern, human versions.</p>
<p>“Leveraging mammalian lactoferrin and its embedded AMP lactoferricin as a model, we observed that even the earliest lactoferricin ancestor possessed the ability to permeabilize bacterial membranes and alter membrane potential, a property that was further enhanced in later ancestors,” they stated. The collective findings, they added, “… indicate that the lactoferricin domain initially possessed membrane permeabilizing activity, which intensified during evolution to produce potent bactericidal effects.”</p>
<p>That difference came down to a small structural change: a single mutation in the amino acid chain, that made the antimicrobial peptide more potent. “What was surprising and unexpected was how small changes in these domains could have such large effects,” Barber said. “There have been clinical trials using derivatives of human lactoferrin peptides to treat infections. But there were several instances where (Sil) showed that you don’t need a lot of changes for evolution to enhance the activity of these peptides beyond the human versions.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Barber and Sil caution that the development of new drugs with extinct antimicrobial peptides is unlikely to be immediate. Compared to conventional antibiotics, the peptides are structurally less stable and quickly broken down in the body.</p>
<p>Even so, tracing their history matters, Barber said. Understanding how antimicrobial peptides evolved in the past is one of the best ways to inspire new treatment designs that pathogens can’t attack. “Similar to antibiotics, pathogens are going to be able to evolve against antimicrobial peptides,” he said. “But if we understand and can anticipate how they become resistant to these molecules, we can hopefully find better ways to target them or develop combination treatments that better avoid resistance.” In their paper the authors concluded, “Together, our study illustrates how novel immune protein functions can arise, evolve, and diversify to strengthen host defense against microbial pathogens.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/ancient-peptides-resurrected-from-lactoferrins-evolutionary-past-could-point-to-new-antibiotics/">Ancient Peptides Resurrected from Lactoferrin’s Evolutionary Past Could Point to New Antibiotics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Centrix and University of Sussex Collaborate to Drive Data&#45;Driven Pharma Development</title>
<link>https://edusehat.com/en/centrix-and-university-of-sussex-collaborate-to-drive-data-driven-pharma-development</link>
<guid>https://edusehat.com/en/centrix-and-university-of-sussex-collaborate-to-drive-data-driven-pharma-development</guid>
<description><![CDATA[ The KTP provides access to academic expertise while embedding that capability within Centrix’s business. This project represents an opportunity to apply advanced data science techniques to a real-world pharmaceutical development challenge.
The post Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1483266787.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 02:25:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Centrix, and, University, Sussex, Collaborate, Drive, Data-Driven, Pharma, Development</media:keywords>
<content:encoded><![CDATA[<p>Centrix Pharma Solutions, a U.K.-based CDMO, reports that it partnered with the University of Sussex on a new Knowledge Transfer Partnership (KTP) that will use advanced data analytics and predictive modeling to transform pharmaceutical product development by enabling smarter, data-driven decision-making.</p>
<p>Supported by Innovate UK, the £375,000 ($510,000) project, including £250,000 ($340,000) in grant funding, combines Centrix’s pharma development expertise with the University of Sussex’s research in data science to create “more reliable” approaches to product development.</p>
<p>As pharmaceutical development becomes increasingly data-rich, companies generate extensive formulation, analytical, and process data throughout development programs. However, this information is often fragmented across projects and systems, limiting its use in identifying trends, predicting outcomes and informing future development strategies.</p>
<p><figure aria-describedby="caption-attachment-337061" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-337061" src="https://www.genengnews.com/wp-content/uploads/2026/08/centrix2-300x200.jpg" alt="Centrix Pharma Solutions says it will develop new capabilities to analyze and interpret datasets obtained from pharmaceutical product development operations. [Centrix Pharma Solutions]" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/centrix2-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/centrix2-768x511.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/centrix2-632x420.jpg 632w, https://www.genengnews.com/wp-content/uploads/2026/08/centrix2-696x463.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/centrix2.jpg 1000w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Centrix Pharma Solutions says it will develop new capabilities to analyze and interpret datasets obtained from pharmaceutical product development operations. [Centrix Pharma Solutions]</figcaption></figure>As a result, critical decisions such as formulation selection, dosage form optimization and development pathway planning frequently rely on manual analysis and individual experience, increasing the risk of costly rework, delays and suboptimal program outcomes.</p>
<p>Through the KTP, Centrix says it will develop new capabilities to analyze and interpret these datasets, initially focusing on early-stage product development. The project aims to create new data-driven tools and methodologies that help identify development risks earlier, reduce unnecessary experimentation, improve confidence in decision-making and accelerate the progression of promising medicines from development to clinical evaluation.</p>
<p>The partnership will also establish in-house data science expertise by recruiting a dedicated KTP Associate, strengthening Centrix Pharma’s research and development capabilities, and enhancing its service offering for customers.</p>
<p>“The pharmaceutical industry generates an enormous amount of valuable data throughout product development, but there is still significant untapped potential to use that information more effectively,” says Chris Davison, CEO of Centrix. “We recognized an opportunity to combine our pharmaceutical expertise with advanced data analytics to make better-informed decisions throughout the development process.</p>
<p>“The Knowledge Transfer Partnership gives us access to specialist academic expertise while embedding those capabilities within our business. This project represents an exciting opportunity to apply advanced data science techniques to a real-world pharmaceutical development challenge. Beyond the immediate project, we’re creating a long-term capability that will benefit both our team and our clients, helping us deliver more efficient development programs.”</p>
<p>“Knowledge Transfer Partnerships bring together academic expertise and real-world industrial challenges,” adds Kate Thorpe, head of innovation and business partnerships at the University of Sussex. “Our ambition is not only to solve today’s challenges but also to establish new ways of working that continue delivering value and innovation long after the project has concluded.”</p>
<p>Centrix Pharma Solutions’ new KTP Associate will lead the project, working across both organizations to embed new analytical approaches and act as a bridge between academic research and industrial application.</p>
<p>“The partnership showcases how collaboration between industry, academia and government can accelerate innovation across the UK’s life sciences sector, create skilled jobs, and help pharmaceutical companies bring new medicines to patients more efficiently.”</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/centrix-and-university-of-sussex-collaborate-to-drive-data-driven-pharma-development/">Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Affordable Bioreactor Helps Prep Students for Biomanufacturing Careers</title>
<link>https://edusehat.com/en/affordable-bioreactor-helps-prep-students-for-biomanufacturing-careers</link>
<guid>https://edusehat.com/en/affordable-bioreactor-helps-prep-students-for-biomanufacturing-careers</guid>
<description><![CDATA[ A bioreactor designed to test biosensors that measure multiple parameters in real time is being developed as a simple, budget-friendly bioreactor for high schools and colleges to help prepare the biomanufacturing workforce of the future.
The post Affordable Bioreactor Helps Prep Students for Biomanufacturing Careers appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1441665028.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 02:25:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Affordable, Bioreactor, Helps, Prep, Students, for, Biomanufacturing, Careers</media:keywords>
<content:encoded><![CDATA[<p>The biomanufacturing workforce of the future is hampered by a lack of familiarity with the technology today. Consequently, when those students choose careers, biotech isn’t top of mind and, even when it is, they may not have developed the deep understanding to help them succeed in biomanufacturing careers.</p>
<p>The challenge is that high schools and community colleges typically can’t afford advanced equipment such as bioreactors to provide the hands-on experience that leads to such understanding.</p>
<p>To help address that challenge, BioMADE, Novonesis, and Iowa State University (ISU) have designed a simple bioreactor to produce enzymes and other proteins, which they are adapting into an educational kit. The bioreactor’s eventual price target, estimated at roughly $200, is designed to be budget-friendly, even for rural schools. The goal is to make biomanufacturing as integral to the curriculum as typing and drafting once were and in doing so, help sustain the industry.</p>
<p>“By allowing each student to build their own reactor and see the awesome power of biology to create novel catalysts, materials, and small molecules, there will be more creative minds choosing this career path to support the burgeoning biomanufacturing economy,” Nigel Reuel, PhD, professor of chemical and biological engineering, Iowa State University, and CTO for the NSF RuralSTAMINA Biomanufacturing Engine of Iowa and Nebraska alliance.</p>
<p>Reuel is working to make the BioReactor Educational Activity Kit (BREAK) a robust educational tool under continued support from BioMADE and Schmidt Sciences, a science-focused philanthropic organization. BREAK will include labs and curriculum co-developed with Julie Gonzalez, PhD, the biotechnology program chair at Des Moines Area Community College, and will be initially disseminated through the NSF RuralSTAMINA Biomanufacturing Engine coalition to provide the hands-on learning experiences needed to stimulate a robust workforce.</p>
<p></p><h4><strong>Offshoot of sensor work</strong></h4>

<p>BREAK is an offshoot of sensor and AI control strategies development by Reuel and his team. One of Reuel’s recent <a href="https://doi.org/10.1021/acsanm.6c00322" target="_blank" rel="noopener">papers</a> explores the use of substrate-wrapped single-walled carbon nanotube-based photoluminescent probes in a circulating flow cell system. Reactions are accelerated by agitation and therefore can’t be accurately measured in a static microplate.</p>
<p>“Rather than buying multiple bioreactors to prove [his sensors] work in the real world, Reuel built an array of low-cost reactors his team could scale for machine learning,” David Nathan, program director, BioMADE, tells <em>GEN</em>.</p>
<p>Novonesis is developing that bioreactor for student use. “It’s designed so students can basically build it and know the ins and outs.  A lot of ingenuity went into using common components rather than bespoke technology,” Mike Hess, PhD, senior manager of regional technical strategy, Novonesis, elaborates.</p>
<p>“It can’t do everything a million-dollar bioreactor can,” Hess says, but it measures multiple indicators, such as enzyme activity and cell concentration, in real time, thus lessening reliance on surrogates.</p>
<p>It also employs a <a href="https://pubmed.ncbi.nlm.nih.gov/42124384/" target="_blank" rel="noopener">reinforcement learning agent</a>—another feature from Reuel. “This speeds the learning loop,” Hess says. Rather than extracting process knowledge offline over weeks or months, the machine learning component “lets you do it in real time so you can optimize [the culture] in a matter of minutes.”</p>
<p>“We’re at the proof-of-concept stage,” Nathan says. “We’re bringing ISU’s testing kit to Novonesis for at-line and on-line work.” The next steps are to design a wireless control system that controls the basic parameters such as temperature, mix speed, and feed, and to link the operating system to pilot-scale reactors before developing a kit for high school and community colleges.</p>
<p>Novonesis is also exploring expanded options to make this basic bioreactor industrially relevant for the biotechnology industry, Hess says. “The application of the machine learning control system will be critical going forward, to help biotechnology manufacturers increase output and, therefore, profits.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/affordable-bioreactor-helps-prep-students-for-biomanufacturing-careers/">Affordable Bioreactor Helps Prep Students for Biomanufacturing Careers</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sterilization Posits Biomanufacturing Next Scaling Challenge</title>
<link>https://edusehat.com/en/sterilization-posits-biomanufacturing-next-scaling-challenge</link>
<guid>https://edusehat.com/en/sterilization-posits-biomanufacturing-next-scaling-challenge</guid>
<description><![CDATA[ Steam sterilization has underpinned biomanufacturing for decades, but its infrastructure burden is increasingly difficult to ignore. Alternative technologies could reduce capital costs, accelerate plant construction, and help unlock industrial biotechnology capacity at much larger scales.
The post Sterilization Posits Biomanufacturing Next Scaling Challenge appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Mike-UV-Sterilization_GBPN_IMAGE_27AUG26.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 02:25:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sterilization, Posits, Biomanufacturing, Next, Scaling, Challenge</media:keywords>
<content:encoded><![CDATA[<p>Biomanufacturing has spent years pushing the limits of biology. Yet scaling these treatments to more patients and diseases might depend on solving a less glamorous problem: sterilization.</p>
<p>Steam-in-place systems have long been the standard for keeping bioprocessing equipment sterile. They are proven, familiar, and infrastructure-intensive. Large installations can require extensive networks of hygienic piping and valves, along with substantial boiler capacity and specialized reactor vessels.</p>
<p>“Aseptic design is a critical constraint on biomanufacturing capacity and a major cost driver,” said Arye Lipman, COO and co-founder of Biosphere.</p>
<p>Biopharmaceutical manufacturers have spent roughly the past 15 years adopting disposable, single-use bioreactors that can sidestep some of the complexity associated with traditional sterilization. Their economics, however, are difficult to translate to industrial biotechnology, where production volumes can be orders of magnitude larger and margins substantially thinner. So, industrial producers are often left with conventional steam-based infrastructure.</p>
<p>“The industrial sector has been largely abandoned by biopharma equipment vendors,” Lipman said, arguing that producers frequently have to assemble bespoke systems around decades-old approaches.</p>
<p>The implications go beyond equipment costs. Complex aseptic systems can take longer to design, construct, validate, and commission. Maintaining sterile conditions at commercial scale also remains a persistent operational challenge, meaning advances in strain engineering do not necessarily translate into economical production. That mismatch is putting renewed attention on alternative sterilization technologies.</p>
<p>Several approaches are being investigated, including ultraviolet radiation, vaporized hydrogen peroxide, chlorine-dioxide gas, ozone, and supercritical carbon dioxide. Each presents different engineering trade-offs, but they share an objective: reducing dependence on the sprawling steam infrastructure traditionally needed to maintain aseptic operations.</p>
<p>Biosphere, for example, is developing a reactor architecture that uses UV radiation for sterilization. Lipman said the system is intended to dramatically reduce steam piping and boiler requirements while lowering the energy required for fluid sterilization.</p>
<p>If alternative approaches can prove reliable at industrial scale, the larger effect could be a change in the economics of where—and how—biomanufacturing plants are built. Facilities requiring less supporting infrastructure could potentially be constructed faster and at lower capital cost. That question is particularly relevant as the United States looks to strengthen domestic biomanufacturing capacity.</p>
<p>Lower capital requirements could also change how manufacturers manage technology risk. Instead of committing enormous sums to a single product and facility, companies could potentially distribute investment across smaller plants and expand the most successful processes later. Still, displacing steam will not be easy.</p>
<p>Alternative sterilization methods must demonstrate consistent performance from bench scale through commercial operation. They also need to integrate with downstream purification and other unit operations while delivering economics compelling enough to justify replacing familiar equipment.</p>
<p>“The chemicals industry is notoriously reluctant to adopt new technology,” Lipman said.</p>
<p>That conservatism means the next biomanufacturing breakthrough might not come solely from a better organism. Scaling the bioeconomy could depend just as much on redesigning the infrastructure surrounding it, and reconsidering a sterilization paradigm that has endured for generations.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/rethinking-sterilization-could-unlock-biomanufacturing-scale/">Sterilization Posits Biomanufacturing Next Scaling Challenge</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Extracellular Secretion System Could Solve Industry Endonuclease Production Challenges</title>
<link>https://edusehat.com/en/extracellular-secretion-system-could-solve-industry-endonuclease-production-challenges</link>
<guid>https://edusehat.com/en/extracellular-secretion-system-could-solve-industry-endonuclease-production-challenges</guid>
<description><![CDATA[ A new extracellular secretion system could help biopharmaceutical manufacturers bypass the problems that make traditional Escherichia coli-based recombinant endonuclease production a major challenge, according to the authors of a new study.
The post Extracellular Secretion System Could Solve Industry Endonuclease Production Challenges appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1498384714-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 02:25:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Extracellular, Secretion, System, Could, Solve, Industry, Endonuclease, Production, Challenges</media:keywords>
<content:encoded><![CDATA[<p>Endonuclease enzymes play a vital role in modern biopharmaceutical production, yet manufacturing them in bulk using traditional <em>E. coli</em> systems is challenging. New research suggests secretory expression could be a more effective alternative.</p>
<p>In biopharmaceutical manufacturing, endonucleases are used to digest any unwanted DNA and RNA that is released when the host cells of the expression system are lysed during the protein harvesting process.</p>
<p>The problem for manufacturers is that endonucleases have the same effect in the cells in which they are produced, says lead study author Ramakrishna Vadde, PhD, a professor from Yogi Vemana University in Andhra Pradesh, India.</p>
<p>“It is very difficult to express recombinant endonucleases using the bacteria <em>Escherichia coli</em> as the expression system,” he tells <em>GEN</em>. “This problem is mainly attributed to the fact that both DNA and RNA, the natural substrate molecules of these enzymes, play an important role in the growth and survival of the host bacteria themselves.”</p>
<p>A further complication is that endonuclease production puts a heavy burden on host cell metabolism. Vadde says, “Overexpression of these proteins may impair cellular processes such as proper protein folding, leading to protein aggregation, inclusion body formation, and enhanced protein degradation by host cell proteases.</p>
<p>“These combined challenges make recombinant endonuclease production in <em>E. coli</em> technically demanding and require carefully optimized expression and purification strategies.”</p>
<p></p><h4><strong>Extracellular secretion</strong></h4>

<p>A potential solution—presented in the new <a href="https://link.springer.com/article/10.1186/s13036-025-00590-0" target="_blank" rel="noopener">study</a>—is to use an expression system that ensures the endonucleases are transported outside the cell, where they cannot degrade any host genetic materials.</p>
<p>Vadde says, “Our solution is based on the use of a proprietary secretion-based expression platform, BacSec, which directs the recombinant nuclease out of the cytoplasm and into the extracellular medium during production.</p>
<p>“By physically separating the enzyme from the host cell’s genomic DNA, plasmid DNA, and RNA, the risk of intracellular nucleic acid degradation is significantly minimized. This allows the production host to maintain normal growth, replication, and protein synthesis while expressing the endonuclease at high levels.</p>
<p>In addition to reducing toxicity, extracellular secretion offers several manufacturing advantages, according to Vadde, who cites reduced contamination risk as an example.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“The enzyme is produced directly in the culture supernatant, eliminating the need for cell disruption and reducing contamination from host-cell proteins and intracellular components. This simplifies downstream purification, improves product recovery, and lowers production costs. Furthermore, secretion often promotes proper protein folding and activity, avoiding the challenges associated with inclusion body formation and complex refolding procedures commonly encountered with intracellular expression of toxic proteins,” he says.</p>
<p>The approach can also reduce the cost of goods sold (COGs), according to Vadde, who adds, “Our platform enables the cost-effective production of active recombinant endonucleases such as Serratia marcescens endonuclease and bovine DNase I while overcoming the host-cell toxicity limitations that have traditionally hindered their manufacture.</p>
<p>“It represents a significant commercial opportunity, as these enzymes are essential consumable reagents used routinely by biologics manufacturers, vaccine developers, gene therapy companies, cell therapy producers, and contract development and manufacturing organizations (CDMOs) worldwide,” he says.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/extracellular-secretion-system-could-solve-industry-endonuclease-production-challenges/">Extracellular Secretion System Could Solve Industry Endonuclease Production Challenges</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Cytometry Technique for Characterizing Viral Vectors</title>
<link>https://edusehat.com/en/new-cytometry-technique-for-characterizing-viral-vectors</link>
<guid>https://edusehat.com/en/new-cytometry-technique-for-characterizing-viral-vectors</guid>
<description><![CDATA[ Kite Pharma has developed a flow virometry technique to analyze single lentiviral particles, which they hope will improve product consistency by characterizing viral vector size and surface features.
The post New Cytometry Technique for Characterizing Viral Vectors appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Vivienne-image-2.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 27 Aug 2026 02:25:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Cytometry, Technique, for, Characterizing, Viral, Vectors</media:keywords>
<content:encoded><![CDATA[<p>Kite Pharma, a Gilead Company, has developed a technique for analyzing individual lentiviral vector particles, which it hopes will allow better characterization of future in vivo CAR T therapy products than traditional Western blotting.</p>
<p>“The virus is going to be our product, and we want to have the deepest understanding we can have of that,” explains Kristen Kellar, a scientist working in analytical development at Kite.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“Given how new and nascent the <em>in vivo</em> lentiviral vector delivery space is, we’re trying to understand what the methods are by which we can more robustly characterize our products,” adds Priti Hegde, PhD, senior vice president of research and development, also at Kite.</p>
<p>According to Kellar, the new technique will be of interest to everyone in gene and cell therapies based on enveloped viruses like lentiviruses. “As reagents are developed,” she says, “more people will be on board with how powerful this technology can be.”</p>
<p>The new technique is based on flow virometry and involves individual particles passing a detector where attributes, such as their size and proteins on the surface, can be characterized, she says.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>This allows for, as an example, the mapping of protein distribution as differences in protein abundance between particles are not lost during averaging. As Kellar explains, if one vector particle has, for example, 10 times more of a specific protein than another, a Western blot would characterize both particles as the average of five times for both particles.</p>
<p>According to Kellar, while flow virometrry has been used in the past, new instruments focused on analysis of nanoparticles allow for deeper characterization.</p>
<p>“They’ve brought the technology to a place where we feel very confident that we’re seeing all the particles and they seem the right size,” she says. “What’s relatively new is we’re able to stain the protein on the surface, and there’s one abundant protein we can see.”</p>
<p>Going forward, Kite Pharma hopes to use the technology throughout the development process, including during the final stages to assess the consistency from batch-to-batch. They’re also investigating some quantitation bead sets, which will allow them to quantify viral proteins on the vector surface, she says.</p>
<p>Hegde adds, “Given how nascent the field [of <em>in vivo</em> cell therapy] is, what’s exciting for us is we’re already seeing clinical proof of concept and, so, the next challenge at Kite is knowing how to scale robustly.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/new-cytometry-technique-for-characterizing-viral-vectors/">New Cytometry Technique for Characterizing Viral Vectors</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>New Zika Virus Vaccine Approach Harnesses the Power of T Cells in Mice</title>
<link>https://edusehat.com/en/new-zika-virus-vaccine-approach-harnesses-the-power-of-t-cells-in-mice</link>
<guid>https://edusehat.com/en/new-zika-virus-vaccine-approach-harnesses-the-power-of-t-cells-in-mice</guid>
<description><![CDATA[ An experimental Zika vaccine protected mice through CD8+ T cells, suggesting a possible path around antibody-dependent enhancement concerns that have complicated vaccine development for Zika and related viruses.
The post New Zika Virus Vaccine Approach Harnesses the Power of T Cells in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2019/04/GettyImages-685027969_2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 19:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>New, Zika, Virus, Vaccine, Approach, Harnesses, the, Power, Cells, Mice</media:keywords>
<content:encoded><![CDATA[<p>Zika virus is easy to underestimate. For many people, infection causes no symptoms at all, or only a fever, rash, and joint pain. But when the mosquito-borne virus spread explosively through the Americas in 2015 and 2016, it exposed a far darker side: infection during pregnancy could impact fetal brain development, causing microcephaly and other birth defects now grouped as congenital Zika syndrome.</p>
<p>Part of the challenge is that Zika does not circulate alone. The virus belongs to the same mosquito-borne family as dengue, yellow fever, West Nile, and Japanese encephalitis viruses, and it is especially similar to dengue, which spreads in many of the same regions.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>That resemblance matters because antibodies raised against one virus can sometimes recognize another without fully neutralizing it. In some cases, those cross-reactive antibodies can make infection worse through antibody-dependent enhancement (ADE), raising concerns that a conventional Zika vaccine could complicate later dengue infection—or that prior dengue immunity could reshape responses to Zika. That concern has prompted some researchers to look beyond antibodies and toward another arm of immunity: virus-killing CD8+ T cells.</p>
<p>Now, researchers at La Jolla Institute for Immunology (LJI) have shown that an experimental Zika vaccine can protect mice by leaning heavily on those T cells rather than on neutralizing antibodies. The study, published in <em>Nature Microbiology</em>, is titled “<a href="https://dx.doi.org/10.1038/s41564-026-02465-6" target="_blank" rel="noopener">A Zika Virus Vaccine with E Protein Fusion Loop Mutations Fails to Elicit Neutralizing Antibodies Against Mature Virions but Protects via CD8+ T Cells</a>.”</p>
<p>Led by senior author Sujan Shresta, PhD, the team compared two experimental Zika vaccines in mice bred to be susceptible to the virus. Both vaccine candidates were built around Zika’s outer envelope proteins, which are common targets for antibody-based vaccines. But one vaccine carried mutations in a small region of the envelope protein called the fusion loop—a site known to generate many of the cross-reactive antibodies implicated in ADE.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The unmodified vaccine worked as expected, producing both antibodies and T cell responses. When the researchers transferred CD8+ T cells from vaccinated mice into unvaccinated animals, those cells alone reduced Zika levels, suggesting that T cells were contributing meaningful protection even when antibodies were also present.</p>
<p>Although the fusion-loop mutant vaccine’s antibodies looked similar to those generated by the unmodified vaccine in cell-based and test-tube assays, they did not protect animals when transferred to unvaccinated mice. Removing CD8+ T cells, however, eliminated the vaccine’s protection. “This vaccine wasn’t protecting via antibodies,” Shresta said. “It was protecting via T cells.”</p>
<p>The finding points to a possible way around one of the thorniest issues in Zika vaccine development: how to avoid antibody responses that might worsen later infection with a related virus. But the approach also revealed a limitation. Twelve weeks after the final dose, mice that received the fusion-loop mutant vaccine were no better protected than unvaccinated animals, while mice that received the unmodified vaccine remained protected.</p>
<p>In other words, the mutation reduced a potential antibody liability but also cost the vaccine its staying power. Shresta and colleagues are now investigating how to build a more durable pool of Zika-fighting T cells that could persist for years after vaccination.</p>
<p>“Our study highlights the importance of considering T cell-mediated immunity alongside neutralizing antibodies,” said first author Kantinan Chuensirikulchai, PhD. “This concept may inspire new vaccine strategies for other orthoflaviviruses, particularly in situations where antibody responses alone are insufficient or may contribute to unwanted immune effects.”</p>
<p>The work may also have implications beyond Zika. Because T cells can recognize features shared across related orthoflaviviruses, the researchers say the findings could help guide efforts toward broader vaccines that protect against Zika, dengue, and other mosquito-borne threats without relying solely on antibodies.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/new-zika-virus-vaccine-approach-harnesses-the-power-of-t-cells-in-mice/">New Zika Virus Vaccine Approach Harnesses the Power of T Cells in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas</title>
<link>https://edusehat.com/en/in-massachusetts-latest-annual-snapshot-shows-a-tale-of-two-biopharmas</link>
<guid>https://edusehat.com/en/in-massachusetts-latest-annual-snapshot-shows-a-tale-of-two-biopharmas</guid>
<description><![CDATA[ The job contraction, according to MassBio, reflected pipeline reprioritization by biopharma giants plus contraction by smaller companies, with R&amp;D jobs dropping significantly between Q2 and Q3 of 2025, then starting to bounce back by Q4. The mid-year drop explains last year’s overall 3.9% or 2,563-job decrease in R&amp;D employment statewide, which fell to 62,991 from 65,554 jobs.
The post In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/gettyimages-136634401-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 04:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Massachusetts, Latest, Annual, Snapshot, Shows, Tale, Two, Biopharmas</media:keywords>
<content:encoded><![CDATA[<p>Massachusetts, the home of the nation’s leading biopharma cluster <a href="https://www.genengnews.com/topics/drug-discovery/top-10-u-s-biopharma-clusters-2026/" target="_blank" rel="noopener">as ranked by <em>GEN</em></a>, offers a study in contrasts when it comes to the health of the sector, as revealed by an industry group.</p>
<p>In a report released Tuesday, life sciences group Massachusetts Biotechnology Council (MassBio) found that companies based in the Bay State, especially at growth stages, are reaping the fruits of growth in venture capital (VC), the initial public offering (IPO) market, and merger-and-acquisition (M&A) activity.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>But Massachusetts—whose nation-leading cluster is centered in Boston and neighboring Cambridge, MA—is seeing three challenging trends unfolding in recent months. One is a 39% decline in seed-stage venture capital awarded to startups in the first half of this year vs. H1 2025, to $4.65 million from $7.65 million—even though Massachusetts saw 21 seed deals during Q1-Q2 2026, from 15 a year ago.</p>
<p>Another concerning trend for the industry was a 1.3% dip in NIH grant funding for the research that underpins biopharma, to $3.413 billion in 2025 from $3.458 billion a year earlier—and especially a six percent drop in the number of grants awarded, to 5,423 from 5,782.</p>
<p>Even worse, Massachusetts’ biopharma workforce shrank three percent or 3,605 jobs in 2025 compared with a year earlier, sliding from 117,108 to 113,503 jobs. And the state’s biopharma community is assessing the competitive challenge posed by China’s biopharma ecosystem.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“In the big picture, things look good. But when you drill a little bit deeper, there’s some places that are potentially worrisome,” Ben Bradford, MassBio’s head of external affairs, told <em>GEN</em>.</p>
<p></p><h4><strong>‘Fewer shots on goal’</strong></h4>

<p>“A one percent drop in NIH funding is not great, but also not the end of the world. The more concerning number for me is seeing the 6+% drop in number of awards. That’s just fewer shots on goal,” Bradford said. “And in an industry that has such a high failure rate, we need as many shots on goal as possible.”</p>
<p>He said MassBio is working to address the need for further NIH funding through talks with Massachusetts’ Congressional delegation and building relations with delegations of U.S. lawmakers from other states. The effort faces a political hurdle, however: Massachusetts’ delegation consists entirely of Democrats while Republicans control both the U.S. Senate and House of Representatives heading into November’s elections.</p>
<p>“We need to spread the wealth of these grants as much as we can, so that we get as many shots at good science as possible,” Bradford said.</p>
<p>He said MassBio was committed to supporting startups, citing the Drive accelerator program through which MassBio partners with South Carolina’s life-sci industry group SCbio to advance the breakthrough science and technology of pre-seed companies, as well as equip their founders with the tools for long-term success. Drive is intended to enable startups to access the knowledge of industry experts, the guidance of experienced mentors, and the connections essential for life-sci success.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“We have been approved by our board to take some of our reserves and give non-dilutive grant funding to some of the graduates of that program. And we’re trying to pull in other organizations to provide non-dilutive capital to really well-vetted early-stage companies as well,” Bradford explained.</p>
<p>The job contraction, he said, reflected pipeline reprioritization by biopharma giants plus contraction by smaller companies, with R&D jobs dropping significantly between Q2 and Q3 of 2025, then starting to bounce back by Q4. The mid-year drop explains last year’s overall 3.9% or 2,563-job decrease in R&D employment statewide, which fell to 62,991 from 65,554 jobs.</p>
<p>Of the 20 largest biopharma industry employers whose headcounts were included in the report, eight showed year-over-year job declines—Takeda Pharmaceutical, Moderna, Bristol Myers Squibb, EMD/MilliporeSigma, Merck & Co., Foundation Medicine, Lantheus, and Sarepta Therapeutics. Another two employers (Novartis and AstraZeneca/Alexion) showed no change from 2025.</p>
<p></p><h4><strong>Reducing headcount</strong></h4>

<p>Takeda, which is Massachusetts’ largest biopharma employer, was reported as reducing its Massachusetts headcount by three percent or 181 jobs this year, shrinking to 5,628 from 5,809 in 2025. That total will likely shrivel further next year, since Takeda announced plans in May to shed 4,500 jobs worldwide, about 10% of its total workforce. In March, Takeda eliminated 247 jobs in Massachusetts, where the company has facilities in Lexington, MA, and Cambridge, part of a $1.3 billion restructuring that cut 634 jobs nationwide.</p>
<p>Among companies that expanded their workforces, the biggest creator of new jobs was Eli Lilly, whose headcount nearly tripled, zooming 164% to 1,423 from 540 jobs. The pharma giant has carried out a companywide expansion fueled by more activity in genetic medicines—Lilly opened its $700 million Institute for Genetic Medicine in Boston’s Fort Point section in 2021—plus blockbuster-level sales for its obesity and type 2 diabetes drugs. In June, for example, Lilly agreed to partner with Ascidian Therapeutics to <a href="https://www.genengnews.com/topics/drug-discovery/lilly-ascidian-launch-up-to-1-9b-rna-exon-editor-collaboration-targeting-inherited-kidney-diseases/" target="_blank" rel="noopener">develop RNA exon editors intended to treat inherited kidney diseases</a>, through a collaboration that could generate more than $1.9 billion for Boston-based Ascidian.</p>
<p>And twice so far this year, Lilly has agreed to acquire Massachusetts-based oncology and autoimmune drug developers among the 11 biopharmas it has announced plans to buy out. In April, Lilly said it was <a href="https://www.genengnews.com/topics/cancer/lilly-to-acquire-kelonia-for-up-to-7b-expanding-cancer-cell-therapy-pipeline/" target="_blank" rel="noopener">shelling out up to $7 million for Kelonia Therapeutics</a>, while in February Lilly announced it would <a href="https://www.genengnews.com/topics/translational-medicine/beyond-obesity-lilly-inks-up-to-11-25b-in-cancer-immune-system-deals/" target="_blank" rel="noopener">spend $2.4 billion for genetic medicine developer Orna Therapeutics</a>. Among Massachusetts-based buyers, the biggest dealmaker was Cambridge-based Biogen, which in May completed its <a href="https://www.genengnews.com/topics/translational-medicine/lilly-acquires-centessa-for-up-to-7-8b-biogen-buys-apellis-for-up-to-6-1b/" target="_blank" rel="noopener">up to $5.6 billion purchase of Apellis Pharmaceuticals</a>, a Waltham, MA-based developer of immunology and rare disease treatments.</p>
<p></p><h4><strong>China watch</strong></h4>

<p>MassBio’s report included for the first time a “China Watch” section devoted to the world’s most populous country’s biopharma industry, citing its numerous successes of recent years. They include a 36% year-over-year jump in clinical pipeline drugs, to 7,105, compared with Massachusetts’ nine percent growth for its pipeline of 2,175 treatment candidates. China has more than double the state’s number of candidates in advanced modalities such as cell and gene therapies (1,322 to 561) and has racked up $79 billion in out-licensing deal value compared with just $10.9 billion for the Bay State.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>China’s advantage over Massachusetts is most pronounced in numbers of ongoing clinical trials, including Phase IV (17,150 to 2,690).</p>
<p>China’s pipeline grew 36.2% year over year, surpassing Europe’s for the first time; China out-licensed roughly $79 billion in disclosed potential deal value in 2025, up from about $1 billion in 2019; and China now runs more early-stage clinical trials than any geography analyzed.</p>
<p>“The companies being impacted most are really those early-stage companies,” Bradford acknowledged. “Right now, we need to make sure that clinical trials can be faster in the U.S., so that companies don’t want to go to China to do it. We need to make sure that we have a full incentive package to help companies grow in the U.S. So it’s not just walling off China; it’s creating a full suite of competitiveness programs, that allow the U.S. to maintain our leadership.”</p>
<p>Can Massachusetts act alone? Or must it wait for an American biopharma-first policy to emerge from Washington?</p>
<p>“Does some of that take waiting for D.C.? Yes. Do we need our voice in D.C. to make sure that those programs are created for what the U.S. needs? Yes, we do. And do we need industry to step up, like we’re doing through our Drive program? Absolutely,” Bradford added. “It’s all of the above, really.”</p>
<p>Boston, Cambridge, and their suburbs comprise the nation’s top biopharma cluster as ranked in <em>GEN</em>’s nationally- and regionally-cited A-List of <a href="https://www.genengnews.com/topics/drug-discovery/top-10-u-s-biopharma-clusters-2026/" target="_blank" rel="noopener">Top 10 U.S. Biopharma Clusters</a>. As of June when the updated ranking was published, Boston/Cambrdge scored lowest in jobs, placing just fifth—while finishing third in patents, second in VC and NIH funding, and tops in lab space.</p>
<p></p><h4><strong>No lab space growth</strong></h4>

<p>MassBio recorded no growth in the amount of lab and biomanufacturing space this year. It remained at a nation-leading amount of 63.2 million square feet as developers scrambled to fill a glut of available space. Despite no increase, the statewide vacancy rate for life-sci space climbed year-over-year to approximately 31% by mid-2026, up from about 28% a year earlier. MassBio contrasted the current inventory size with the 21.5 million square feet it recorded in 2015.</p>
<p>Also on the positive side, Massachusetts biopharma startups raised $3.45 billion in VC in the first half of 2026, the largest amount for a half-year period since 2023 and an increase of 25% from $2.75 billion last year. Parabilis Medicines raised the largest VC award of the half, a $305 million Series F round in January completed five months before it <a href="https://www.genengnews.com/topics/cancer/stockwatch-parabilis-medicines-makes-wall-street-history-with-770-5m-ipo/" target="_blank" rel="noopener">completed the largest-ever IPO to date by a drug developer</a>, raising an eye-popping $770.5 million in gross proceeds.</p>
<p>Massachusetts-based biopharmas completed eight IPOs in the first half of 2026—compared with two in all of 2025 and six in all of 2024. Going public between January and June were Kailera Therapeutics ($719 million); <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-ai-drug-developer-generates-400m-ipo/" target="_blank" rel="noopener">Generate: Biomedicines ($400 million)</a>; Hemab Therapeutics ($347 million); Aktis Oncology ($318 million), Avalyn Pharma ($300 million), Odyssey Therapeutics ($279 million); and Seaport Therapeutics ($255 million). This year’s eight IPOs accounted for about two-thirds of the 13 total biopharma IPOs carried out in U.S. markets so far in 2026.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Beeline Medicines, a developer of precision autoimmune and inflammatory disease therapies, closed in June on a $126.3 million VC extension that boosted its total Series A round to $426.3 million, inclusive of a $300 million financing commitment announced last year and led by Bain Capital.</p>
<p>Massachusetts accounted for 25% of the nation’s total VC haul and placed second only to California’s $5.979 billion among individual states. Massachusetts also attracted $7.63 billion in VC last year, 3% below the $7.89 billion recorded for 2024.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/in-massachusetts-latest-annual-snapshot-shows-a-tale-of-two-biopharmas/">In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pioneering Study of Alpha&#45;Gal Syndrome Launched at Martha’s Vineyard Hospital</title>
<link>https://edusehat.com/en/pioneering-study-of-alpha-gal-syndrome-launched-at-marthas-vineyard-hospital</link>
<guid>https://edusehat.com/en/pioneering-study-of-alpha-gal-syndrome-launched-at-marthas-vineyard-hospital</guid>
<description><![CDATA[ Martha’s Vineyard Hospital launches a two-year study tracking up to 300 residents to understand who develops alpha-gal syndrome after lone star tick exposure and why.
The post Pioneering Study of Alpha-Gal Syndrome Launched at Martha’s Vineyard Hospital appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1629610212.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 01:20:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pioneering, Study, Alpha-Gal, Syndrome, Launched, Martha’s, Vineyard, Hospital</media:keywords>
<content:encoded><![CDATA[<p>Alpha-gal syndrome (AGS)—also known as red meat allergy—is an allergy transmitted through ticks. Alpha-gal (galactose-α-1,3-galactose) is naturally produced in the bodies of most mammals, but not people. It is also found in the saliva of some ticks and is transferred in a tick bite into a person’s blood, leading to an allergic reaction. Symptoms, which can include hives, gastrointestinal distress, breathing difficulties and, in severe cases, anaphylaxis, occur after people eat red meat or are exposed to other products made from mammals. Unlike many food allergies, reactions often occur several hours after eating, which can make diagnosis difficult.</p>
<p>The number of AGS cases in the U.S. is difficult to determine because AGS is not a nationally notifiable disease. Between 2010 and 2022, there were more than 100,000 suspected cases of AGS but the number could be as many as 450,000. More data and research, notes the CDC, are needed to understand how many people are affected by this condition.</p>
<p>Now, a hospital in Martha’s Vineyard, MA, is leading that effort.</p>
<p>Martha’s Vineyard Hospital has begun recruiting participants for a research study designed to better understand AGS. Researchers will follow up to 300 participants over two years to examine how often AGS develops after tick bites, which factors may increase risk, how the immune system changes over time and how the condition affects patients’ daily lives and health care use.</p>
<p>Led by Jacob Lemieux, MD, PhD, assistant professor at Harvard Medical School and Ellen McMahon, MD, chief of medicine and ambulatory medical director for Martha’s Vineyard Hospital, the study seeks to answer several key questions: who develops AGS after lone star tick exposure, who becomes sensitized without developing symptoms, and what biological or demographic factors may influence risk. Researchers also hope to identify immune, inflammatory and other markers that could help predict who is most likely to develop the condition.</p>
<p>“Alpha-gal syndrome is an emerging health concern in our region, but there are still many unanswered questions about why some people develop the condition after a tick bite while others do not,” said Lemieux. “By following participants over time, we hope to better understand the biological and environmental factors that influence risk and generate information that can help guide future diagnosis, prevention and patient care.”</p>
<p>The study will enroll Martha’s Vineyard residents age 15 and older who live on the island for at least three months each year, including pregnant individuals. Participants will complete an initial visit and periodic follow-up visits that include medical history reviews, blood testing and other assessments.</p>
<p>“One of the challenges of alpha-gal syndrome is that symptoms can be delayed and vary widely from person to person, making the condition difficult to recognize and diagnose,” added McMahon. “This study will help us better understand the patient experience, identify potential warning signs and improve our ability to support individuals and families who may be affected by this increasingly important health issue.”</p>
<p>The study comes at a time of growing concern about AGS on Martha’s Vineyard, with hospital data showing a significant increase in alpha-gal testing over recent years, while local clinicians and biologists have observed growing numbers of lone star ticks and increasing concern about tick-related illnesses. The island’s wildlife population, seasonal population shifts and outdoor environment make it a useful setting to study the condition.</p>
<p>“Martha’s Vineyard is uniquely positioned to contribute to our understanding of alpha-gal syndrome because clinicians here are seeing firsthand how tick-related health concerns are evolving in our community,” said Claire Seguin, DNP, president and COO, Martha’s Vineyard Hospital.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/pioneering-study-of-alpha-gal-syndrome-launched-at-marthas-vineyard-hospital/">Pioneering Study of Alpha-Gal Syndrome Launched at Martha’s Vineyard Hospital</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>One Standard, Multiple Platforms: ICH Q2(R2) Qualification of Host Cell Protein Analysis by LC–MS/MS</title>
<link>https://edusehat.com/en/one-standard-multiple-platforms-ich-q2r2-qualification-of-host-cell-protein-analysis-by-lcmsms</link>
<guid>https://edusehat.com/en/one-standard-multiple-platforms-ich-q2r2-qualification-of-host-cell-protein-analysis-by-lcmsms</guid>
<description><![CDATA[ In this GEN webinar, USP and Alphalyse present the work qualifying beta-lactoglobulin (LACB) as a cross-platform standard for LC-MS/MS HCP analysis.
The post One Standard, Multiple Platforms: ICH Q2(R2) Qualification of Host Cell Protein Analysis by LC–MS/MS appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1454330735_BovineBeta-LactoglobulinProtein.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 01:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>One, Standard, Multiple, Platforms:, ICH, Q2R2, Qualification, Host, Cell, Protein, Analysis, LC–MSMS</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/Derrick-Zhang-headshot.jpg" class="h-full w-full object-cover" alt="Image of Derrick Zhang">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Derrick Zhang</h2>
                <h5 class="mt-0 !text-[15px]">Senior Scientist II<br>United States Pharmacopeia (USP)</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/Derrick-Zhang-headshot.jpg" alt="Image of Derrick Zhang">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Derrick Zhang</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Derrick Zhang is a senior scientist II at the United States Pharmacopeia (USP), where he leads the development of strategies and standards supporting the analytical evaluation of monoclonal antibodies (mAbs) and therapeutic proteins, with deep expertise in Host Cell Protein (HCP) analysis and LC-MS proteomics. He holds an MS in biotechnology from John Hopkins University and an MBA from University of Maryland.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/Ejvind-Mortz-headshot.jpg" class="h-full w-full object-cover" alt="Image of Ejvind Mørtz, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Ejvind Mørtz, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Co-Founder and CSO<br>Alphalyse</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/Ejvind-Mortz-headshot.jpg" alt="Image of Ejvind Mørtz, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Ejvind Mørtz, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Ejvind Mørtz, PhD, is co-founder and CSO of Alphalyse. Ejvind has a PhD in protein mass spectrometry from University of Southern Denmark and has more than 25 years of experience in development of protein analyses and mass spectrometry methods in the research and development of protein biologics.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, September 30, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-09-30T15:00:00.000Z">08:00 PDT, 11:00 EDT, 15:00 GMT</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Two labs can analyze the same sample and report different Host Cell Protein (HCP) levels. With ELISA, the total number of HCP (ng/mg) is tied to the antibody reagent. With LC-MS, it is tied to whichever MS quantitation method the lab used. Neither result travels beyond the lab that generated it. </p><p></p><p></p><p class="wp-block-paragraph">USP General Chapter <1132.1> <em>Residual Host Cell Protein Measurement in Biopharmaceuticals by Mass Spectrometry </em>helped address the MS quantitation gap by defining HCP quantitation relative to a spiked-in intact protein standard. What the industry lacked was the protein itself: a single, consistently sourced material characterized well enough to serve as a common anchor across expression systems, biopharmaceutical modalities, and MS instrument platforms. </p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, USP and Alphalyse present the work qualifying beta-lactoglobulin (LACB) as a cross-platform standard for LC-MS/MS HCP analysis. LACB was characterized by intact mass, quantitative peptide mapping, and amino acid analysis, confirming a defined composition, an accurately assigned concentration, and greater than 99% purity. It was then qualified as a spike-in standard per ICH Q2(R2) across three host cell systems—CHO (monoclonal antibodies and recombinant fusion proteins), <em>E. coli</em> (recombinant proteins and vaccine antigens), and HEK293 (viral vectors and gene therapies)—meeting linearity, accuracy, precision, and specificity criteria across more than three orders of magnitude. Key takeaways from the webinar include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>Why the choice of spike-in standard drives your HCP number as much as your acquisition method does </li><p></p><p></p><p></p><li>What “well characterized” should mean for a material serving as an anchor across expression systems, modalities, and instrument platforms </li><p></p><p></p><p></p><li>How to implement <1132.1> quantitation relative to spiked-in protein in your own workflow </li><p></p><p></p><p></p><li>Where a common standard can change the conversation with regulators on impurity clearance </li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-medium"><a href="https://www.usp.org/" target="_blank" rel=" noreferrer noopener"><img fetchpriority="high" decoding="async" width="300" height="169" src="https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-300x169.jpeg" alt="U.S. Pharmacopeia logo" class="wp-image-332257" srcset="https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-300x169.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-1024x576.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-768x432.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-1536x864.jpeg 1536w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-747x420.jpeg 747w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-1493x840.jpeg 1493w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-696x392.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-1392x783.jpeg 1392w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo-1068x601.jpeg 1068w, https://www.genengnews.com/wp-content/uploads/2026/05/USP-200-Logo.jpeg 1920w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/one-standard-multiple-platforms-ich-q2r2-qualification-of-host-cell-protein-analysis-by-lc-ms-ms/">One Standard, Multiple Platforms: ICH Q2(R2) Qualification of Host Cell Protein Analysis by LC–MS/MS</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Neural Mechanism Identified That Drives Increased Alcohol Use in Isolated Male Mice</title>
<link>https://edusehat.com/en/neural-mechanism-identified-that-drives-increased-alcohol-use-in-isolated-male-mice</link>
<guid>https://edusehat.com/en/neural-mechanism-identified-that-drives-increased-alcohol-use-in-isolated-male-mice</guid>
<description><![CDATA[ A study in mice has found that loneliness can reprogram the brain in ways that promote alcohol consumption, and identified a neural mechanism through which isolation escalates alcohol use in male mice, but suppresses it in females. 
The post Neural Mechanism Identified That Drives Increased Alcohol Use in Isolated Male Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/02/GettyImages-827580658.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 01:20:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Neural, Mechanism, Identified, That, Drives, Increased, Alcohol, Use, Isolated, Male, Mice</media:keywords>
<content:encoded><![CDATA[<p>A preclinical study led by researchers at Northwestern University and the Salk Institute for Biological Studies has found that loneliness can reprogram the brain in ways that push alcohol consumption, in males.</p>
<p>The scientists identified, for the first time, a brain mechanism through which isolation escalates alcohol use in male mice but suppresses it in females. They discovered a role for a subpopulation of basolateral amygdala (BLA) neurons, projecting into the medial prefrontal cortex (mPFC), in driving alcohol consumption during social isolation. Experiments showed that isolation increased BLA–mPFC excitability in males but decreased it in females.</p>
<p>“This is the first study to identify a specific brain circuit that explains how social isolation can drive increased alcohol use in males, marking a major advance for the field,” said Reesha Patel, PhD, assistant professor of general psychiatry and neuroscience at Northwestern University Feinberg School of Medicine. “These findings provide a much clearer biological target for understanding and eventually treating alcohol misuse that arises from isolation, a problem that is becoming increasingly common.”</p>
<p>Patel is first author of the researchers’ published paper in <em>Nature Neuroscience</em>, titled “<a href="http://dx.doi.org/10.1038/s41593-026-02413-x" target="_blank" rel="noopener">Social isolation recruits amygdala–medial prefrontal cortex projections to escalate alcohol drinking in male mice</a>,” in which they conclude that their collective results  “… identify a BLA–mPFC pathway mechanism through which social isolation reconfigures prefrontal processing to promote alcohol intake.”</p>
<p>Alcohol use disorder is the most prevalent substance use disorder worldwide, affecting an estimated seven percent of the global population over age 15 years, the authors wrote, citing World Health Organization figures. Social isolation is rising worldwide and is now recognized as a major public health risk, with strong links to substance misuse, they continued. “… social isolation in adults is associated with heavy drinking in humans and increased alcohol intake in mice, highlighting the sensitivity of the adult brain to social experience.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Yet scientists don’t fully understand how feeling isolated rewires the brain in ways that increase vulnerability to alcohol abuse. “Identifying the neural circuit mechanisms through which social experiences, such as isolation, modulate alcohol drinking will reveal how social context shapes vulnerability to alcohol misuse,” the investigators stated.</p>
<p>The team focused their study on the basolateral amygdala and medial prefrontal cortex, which are key brain regions involved in processing emotion, stress responses and social information. Their independent contributions to alcohol drinking are well established, the authors noted. “This led us to investigate whether BLA circuits adapt to social isolation in ways that influence alcohol use.”</p>
<p>They were particularly interested in connections from the basolateral amygdala, which processes emotional and stress signals, to the medial prefrontal cortex, which regulates decision making. “Using whole-cell patch-clamp electrophysiology, optogenetics and cellular-resolution calcium imaging, we tested the hypothesis that the BLA–mPFC circuit drives maladaptive alcohol drinking patterns in response to social isolation.”</p>
<p>To carry out the research the team first housed adult male and female mice socially, then moved some to single housing, to model adult social isolation, while keeping others socially housed as controls. The mice were given daily one-hour opportunities to drink from a bottle of water or a bottle filled with a 15% alcohol solution. Their consumption and choices were tracked over roughly two weeks, during which male mice progressively increased their alcohol intake, while females reduced it. “We found that isolation increases alcohol drinking in males, while females show reduced alcohol intake,” they stated.</p>
<p>The scientists recorded brain activity in the BLA and mPFC while the animals freely moved around and elected whether to drink alcohol. “Whole-cell recordings revealed that neurons in the basolateral amygdala projecting to the medial prefrontal cortex (BLA–mPFC) track alcohol intake in both sexes,” they noted. But while isolation increased BLA–mPFC excitability in males it decreased it in females, mirroring their opposite behavioral adaptations.</p>
<p>“Our work shows that a defined pathway becomes overactive during isolation and directly increases drinking, and that males and females rely on different neural strategies when they’re lonely,” Patel said. “This may help explain long-standing sex differences in neuropsychiatric disorders.” Patel said she cannot say definitively why isolation increased alcohol consumption in male mice but reduced it in females.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>But she noted that the sex differences observed in the study mirror <a href="https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1236410/full" target="_blank" rel="noopener">patterns reported</a> in some <a href="https://psycnet.apa.org/record/2023-95771-001" target="_blank" rel="noopener">human research</a>. The team then tested whether this brain pathway merely reflected drinking or caused it. Using optogenetics—brief pulses of light that turn brain circuits on or off—they artificially activated the circuit in non-isolated male mice. This caused their brains to respond to alcohol as if they had been socially isolated. Conversely, when the same circuit was silenced in isolated male mice, alcohol consumption decreased. “BLA–mPFC circuit stimulation mimicked the heightened mPFC alcohol responses observed during social isolation,” they noted. “Furthermore, inhibition of the BLA–mPFC circuit during social isolation reduced alcohol intake, suggesting a causal role of the BLA–mPFC circuit in alcohol drinking.”</p>
<p>The scientists say they now want to understand what keeps this circuit overactive during social isolation and how downstream brain regions, including the medial prefrontal cortex, contribute to the effect. They also plan to explore why males and females respond so differently to isolation and whether hormones or deeper circuit-level differences play a role. Another important step is determining how these findings translate to humans.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neural-mechanism-identified-that-drives-increased-alcohol-use-in-isolated-male-mice/">Neural Mechanism Identified That Drives Increased Alcohol Use in Isolated Male Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Expanded Synthetic Promoter Library Introduced to Boost Biomanufacturing Operations</title>
<link>https://edusehat.com/en/expanded-synthetic-promoter-library-introduced-to-boost-biomanufacturing-operations</link>
<guid>https://edusehat.com/en/expanded-synthetic-promoter-library-introduced-to-boost-biomanufacturing-operations</guid>
<description><![CDATA[ Developed de novo using the company’s proprietary transcriptional analysis and sequence engineering platform, SynGenSys’ CHO.SET synthetic promoters combine advanced computational design with empirical validation.
The post Expanded Synthetic Promoter Library Introduced to Boost Biomanufacturing Operations appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2152076964.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 26 Aug 2026 01:20:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Expanded, Synthetic, Promoter, Library, Introduced, Boost, Biomanufacturing, Operations</media:keywords>
<content:encoded><![CDATA[<p>SynGenSys, based in Sheffield, U.K., reports that it has introduced its CHO.SET<sup class="wp-sup-text">®</sup> 2.0 synthetic gene promoter system to improve protein production in CHO (Chinese Hamster Ovary) cells.</p>
<p><figure aria-describedby="caption-attachment-337022" class="wp-caption alignleft"><img decoding="async" class=" wp-image-337022" src="https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-300x249.jpg" alt="Andy Racher, PhD, CEO, SynGenSys [SynGenSys]" width="242" height="201" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-300x249.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-1024x851.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-768x638.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-506x420.jpg 506w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-1011x840.jpg 1011w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-696x578.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-1392x1156.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher-1068x887.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Andy-Racher.jpg 1489w" sizes="(max-width: 242px) 100vw, 242px"><figcaption class="wp-caption-text">Andy Racher, PhD, CEO, SynGenSys [SynGenSys]</figcaption></figure>Developed <em>de novo</em> using the company’s proprietary transcriptional analysis and sequence engineering platform, CHO.SET synthetic promoters combine advanced computational design with empirical validation to deliver a promoter library applicable across a wide range of CHO expression systems and biomanufacturing requirements, according to Andy Racher, PhD, CEO, adding that new supporting data demonstrate that CHO.SET promoters deliver enhanced transcriptional activity and improved protein production metrics.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Selected vectors have been shown to achieve over 4x higher antibody productivity, with titers exceeding 2 g/L in a simple fed-batch flask model, he continues, while pointing out that the synthetic promoter pools also contain a higher proportion of high-expressing cells, increasing the likelihood of isolating top-performing clones.</p>
<p>“CHO cells are the pharmaceutical industry’s gold-standard cell factories, and CHO cell-specific synthetic promoters provide an elegant solution to overcoming key productivity limitations in the industry,” says Racher. “We are excited to release this latest update and to continue providing solutions that address evolving biomanufacturing needs.”</p>
<p>The CHO.SET Promoter Library will be displayed at <a href="https://informaconnect.com/bioprocessinternational/?utm_source=tag-digital&gad_source=1&gad_campaignid=23882961100&gbraid=0AAAAADnpY3fyzk3ju9dRbBH1gqUXosK_5&gclid=CjwKCAjw-rTUBhAiEiwADv8gBK4M_Cnn0zzhZ0MGPqTn8_QcNFUDxyR9jKG--e0rHL7OQOmlPLyVyRoC79wQAvD_BwE" target="_blank" rel="noopener">BioProcess International</a> next month as part of Biotech Week Boston.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/expanded-synthetic-promoter-library-introduced-to-boost-biomanufacturing-operations/">Expanded Synthetic Promoter Library Introduced to Boost Biomanufacturing Operations</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PDUFA letter stresses stability, transparency, maturity, says BIO negotiator</title>
<link>https://edusehat.com/en/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator</link>
<guid>https://edusehat.com/en/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator</guid>
<description><![CDATA[ An agreement designed to shape the future of drug approval recommends new efficiencies while leaning into the existing strengths of a system that makes […]
The post PDUFA letter stresses stability, transparency, maturity, says BIO negotiator appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/US_Food_and_Drug_Administration_Seal.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 18:15:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PDUFA, letter, stresses, stability, transparency, maturity, says, BIO, negotiator</media:keywords>
<content:encoded><![CDATA[<p><span>An agreement designed to shape the future of drug approval recommends new efficiencies while leaning into the existing strengths of a system that makes America the world leader in biotech.</span></p>
<p><span>The agreement, the</span><a href="https://go2.bio.org/NDkwLUVIWi05OTkAAAGjrwAavUINt1jdPGfYEJOPwzl_KPXvrP2ZuagAQNCh2X_jRc4SyTVVZAKFSeqFnLzrC1YNAUo="> <span>Prescription Drug User Fee Act (PDUFA) VIII commitment letter</span></a><span>, was released on Aug. 13. It was negotiated by the Food and Drug Administration (FDA) and representatives of the biopharmaceutical industry, including the industry’s association, the Biotechnology Innovation Organization (BIO).</span></p>
<p><span>Renewed by Congress every five years since 1992, PDUFA allows the FDA to collect user fees from biopharmaceutical companies to support the review of new therapies. These resources fund FDA’s scientific staff, modernize review systems, and strengthen drug safety monitoring.</span></p>
<p><span>The commitment letter is intended to set goals for the new PDUFA legislation, which will guide FDA’s review process between 2028-32.</span></p>
<p><span>“This commitment letter achieves a focus on stability, a focus on transparency, and a focus on maturity for the FDA,” said Steve Berman, BIO VP for Science and Regulatory Affairs Strategy, who was involved in negotiating the letter. “All three of those themes are reflected in the details of the document.”</span></p>
<h2><b>Stability</b></h2>
<p><span>“On the stability side, we address all of the things that industry relies on from the FDA: Can we get our meetings on time? Can we get our reviews done in the time that we expected?” Berman said. “All of that is maintained. Despite all the changes of 2025, for the future of 2028-2032, that stability remains in place.”</span></p>
<p><span>Stability is also emphasized in the goals set for financing, according to Berman. While the commitment letter recognizes that FDA needs to rebuild its staff, it does not call for a costly expansion that would require a much higher industry contribution.</span></p>
<p><span>“We’ve set FDA up on a path towards making sure that it has every dollar that it needs for all of the staff that it needs, but not $1 more,” he said. “The growth of the program would be constrained in a way that it hasn’t been in the past, so the fees are more stable than they have been in the past.”</span></p>
<h2><b>Transparency</b></h2>
<p><span>Improved communication between FDA and applicants can help to clear questions efficiently and keep new drug or biologic applications moving more quickly. To this end, the commitment letter encourages changes to refine the use of written response only (WRO) communication. It seeks to increase opportunities for in-person meetings and to enable multi-division meetings for more efficient discussions about multi-indication products.</span></p>
<p><span>“One thing that we’ve noticed over time is that there are many applications that are ultimately approved but aren’t approved on the first cycle,” Berman said. “That tells us that there are drugs that the FDA determines have a positive benefit-risk ratio—a good safety and efficacy profile—but for whatever reason, FDA doesn’t approve them on the first cycle, which means patients are delayed in accessing those innovations.”</span></p>
<p><span>The commitment letter calls for having a third party investigate what is happening during first-cycle review, to reduce unnecessary delays during this stage of the process.</span></p>
<p><span>Many of the questions coming from FDA during first-cycle review involve the Chemistry, Manufacturing, and Controls (CMC) segment of the application, Berman said.</span></p>
<p><span>The commitment letter recommends two new meeting types to address this challenge.</span></p>
<p><span>“The first of those is an opportunity to meet with FDA, even before you submit your New Drug Application (NDA) or Biologics License Application (BLA), to discuss your manufacturing with them,” Berman explained. “And then the second one of those is while FDA is reviewing the application: If they go and inspect a facility and find something there that might otherwise lead to a first cycle Complete Response Letter (CRL), there’s an opportunity to discuss and to potentially mitigate any of those findings and get those drugs to patients sooner.”</span></p>
<h2><b>Maturity, and next steps</b></h2>
<p><span>Using the latest advances in regulatory science, the FDA has developed many innovative methods for improving the speed and accuracy of its review processes. Several of these approaches have been tested as pilot projects and now have matured to where they are ready to become standard practice, according to Berman.</span></p>
<p><span>“We’re able take a look at all of those successes from past cycles and say, ‘It’s great that these pilots have been successful, but they’ve been sort of limited in size and scope,’ ” he said. “It’s time for us to move beyond pilots and into regular regulatory review practice, and that’s what PDUFA VIII does.”</span></p>
<p><span>The next step in PDUFA VIII approval is discussion in a</span><a href="https://www.fda.gov/drugs/news-events-human-drugs/public-meeting-recommendations-reauthorization-prescription-drug-user-fee-act-pdufa-09162026"> <span>hybrid public meeting on Sept. 16</span></a><span>. Following any adjustments to the commitment letter based on the public discussion, Congress will review the recommendations and weigh reauthorization of PDUFA for fiscal years 2028-32. A vote on PDUFA VIII is expected next year.</span></p>
<p><b>Read more:</b></p>
<ul>
<li aria-level="1"><a href="https://www.fda.gov/media/193977/download?attachment&mkt_tok=NDkwLUVIWi05OTkAAAGjrwAavUDCDC7RTMEp1cxsL3Av9_HqZr_iERUzE3qc7NqMHoujaUhYGe1e6JbYX7glyh7CtgTvRHgtJ2fPFpIZGbHE82DITwCjQS_3WW3-UHyhog"><b>The PDUFA commitment letter</b></a></li>
<li aria-level="1"><a href="https://www.bio.org/press-release/bio-supports-pdufa-viii-commitment-letter-and-urges-timely-reauthorization"><b>BIO’s statement on the commitment letter</b></a></li>
<li aria-level="1"><a href="https://go2.bio.org/NDkwLUVIWi05OTkAAAGjrwAavRVf-HyVnCa7rV5UFMX59C5C-Ywe-q2Aa4J3lN1AplANkgHbeKE7bMpCG6uFuD1Eo0c="><b>BIO’s PDUFA resources</b></a></li>
</ul>
<p>The post <a href="https://bio.news/federal-policy/pdufa-letter-stresses-stability-transparency-maturity-says-bio-negotiator/">PDUFA letter stresses stability, transparency, maturity, says BIO negotiator</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Welcome to the spiderverse, a world measured through webs</title>
<link>https://edusehat.com/en/welcome-to-the-spiderverse-a-world-measured-through-webs</link>
<guid>https://edusehat.com/en/welcome-to-the-spiderverse-a-world-measured-through-webs</guid>
<description><![CDATA[ Counting the creatures in the world around us is critical for a raft of conservation efforts. It helps scientists gauge biodiversity, track migration, and spot invasive species. That census-taking, though, often requires humans to tabulate what they see, trap, or otherwise sense—a potentially laborious, costly process that can still leave gaps. But developments over the… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/MIT-TR-SEPTOCT26-DNA-HANGERS-094.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 18:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Welcome, the, spiderverse, world, measured, through, webs</media:keywords>
<content:encoded><![CDATA[<p>Counting the creatures in the world around us is critical for a raft of conservation efforts. It helps scientists gauge biodiversity, track migration, and spot invasive species. That census-taking, though, often requires humans to tabulate what they see, trap, or otherwise sense—a potentially laborious, costly process that can still leave gaps.</p>



<p>But developments over the last decade have revolutionized eco-surveillance. Biologists have tapped into sequencing technology to analyze environmental DNA, or eDNA—genetic material shed by living things. Samples collected from scat, soil, water, and air have opened up a new avenue scientists can use to monitor endangered species and detect invasive ones before anyone can even lay eyes on them.</p>





<p>More recently, they’ve uncovered an eDNA gold mine: spiderwebs. The naturally sticky stuff traps material from its arachnid creators, crumbs from their suppers, and, crucially, bio-detritus like saliva and pollen from nearby plants and animals. Every living thing, it seems, sheds copious DNA all over the place, including into the air, and webs then easily ensnare it. “It’s probably one of the best substrates we’ve used and tried to date,” says Joshua Newton, a molecular ecologist at Curtin University in Perth, Australia, who’s sampled flowers, streams, hollows of dead trees, and even filters on moving cars to study vertebrate populations.</p>



<p>Newton <a href="https://www.curtin.edu.au/news/media-release/natures-dna-traps-spider-webs-put-new-spin-on-wildlife-research/">recently compared</a> the biological diversity in spider­webs with that found in other sources—including vegetation swabs, water, soil, and a fan outfitted with a filter—near a zoo and wildlife sanctuary outside Perth. Each had its obvious strengths: The vegetation swabs revealed more forest mammals, and the water samples identified more fish. But no passive tool matched spiderwebs’ ability to ID vertebrates, echoing results from a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12550491/">similar study</a> conducted in France. </p>



<p>Here’s where things get sticky: To gather meaningful data, they had to destroy about 40 webs. “It kind of goes against everything that we’re trying to do if we’re collecting the home of an organism,” Newton says. </p>



<p>Fortunately, his research caught the attention of Angela McGaughran, a genomicist at New Zealand’s University of Waikato. She bought a bag of faux webs from her local Halloween store, wrapped a few coat hangers, and hung them outside. The synthetic material <a href="https://onlinelibrary.wiley.com/doi/10.1002/edn3.70194">snagged eDNA</a> from nearby cows and sheep, as well as from exotic birds at a nearby aviary. It also detected fungal spores better than real webs—a boon for plant pathologists watching for agricultural threats. Her group is now developing larger experiments to see whether artificial webs can unlock a cheap and ruthlessly efficient way to mimic spiderwebs’ DNA-snagging superpowers anywhere and everywhere. </p>



<p><em>Stephen Ornes is a science writer based in Nashville.</em></p>]]> </content:encoded>
</item>

<item>
<title>Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale&#45;Up, and Sustainability</title>
<link>https://edusehat.com/en/small-molecules-big-expectations-how-cdmos-are-helping-sponsors-navigate-complexity-speed-scale-up-and-sustainability</link>
<guid>https://edusehat.com/en/small-molecules-big-expectations-how-cdmos-are-helping-sponsors-navigate-complexity-speed-scale-up-and-sustainability</guid>
<description><![CDATA[ In this sponsoredGEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. 
The post Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and Sustainability appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_1939530453_PharmaceuticalLab.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 06:55:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Small, Molecules, Big, Expectations:, How, CDMOs, Are, Helping, Sponsors, Navigate, Complexity, Speed, Scale-Up, and, Sustainability</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph">Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.</p><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p class="wp-block-paragraph">In this GEN Podcast – part 2 in a 3-part series – a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.</p><p></p><p></p><p class="wp-block-paragraph"> </p><p></p><p></p><p></p><h4 class="wp-block-heading"><strong>Podcast Guests:</strong></h4><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><div class="wp-block-image is-resized"><p><figure class="aligncenter size-full"><img decoding="async" width="200" height="200" src="https://www.genengnews.com/wp-content/uploads/2026/08/Steve-Barr.jpg" alt="Steve Barr" class="wp-image-336984" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Steve-Barr.jpg 200w, https://www.genengnews.com/wp-content/uploads/2026/08/Steve-Barr-150x150.jpg 150w" sizes="(max-width: 200px) 100vw, 200px"></figure></p><p></p></div><p></p><p></p><h6 class="wp-block-heading has-text-align-center"><strong><strong><strong><strong>Steve Barr, PhD</strong></strong></strong></strong><br>Head of Small Molecule Business Unit<br>and VP Global Alliances<br>SK pharmteco</h6><p></p></div><p></p><p></p><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><div class="wp-block-image is-resized"><p><figure class="aligncenter size-full"><img fetchpriority="high" decoding="async" width="800" height="800" src="https://www.genengnews.com/wp-content/uploads/2026/08/Darryl-Ratty.jpg" alt="Darryl Ratty " class="wp-image-336987" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Darryl-Ratty.jpg 800w, https://www.genengnews.com/wp-content/uploads/2026/08/Darryl-Ratty-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Darryl-Ratty-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/08/Darryl-Ratty-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Darryl-Ratty-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/08/Darryl-Ratty-696x696.jpg 696w" sizes="(max-width: 800px) 100vw, 800px"></figure></p><p></p></div><p></p><p></p><h6 class="wp-block-heading has-text-align-center"><strong><strong><strong><strong>Darryl Ratty</strong></strong></strong></strong><br>Executive Director of Global ESG<br>ESG (Environmental, Social and Governance)<br>SK pharmteco</h6><p></p></div><p></p><p></p><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><div class="wp-block-image"><p><figure class="aligncenter size-full is-resized"><img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/William-DuBay-SKPT.jpg" alt="Bill DuBay " class="wp-image-336987"></figure></p><p></p></div><p></p><p></p><h6 class="wp-block-heading has-text-align-center"><strong><strong><strong><strong><strong>Bill DuBay</strong></strong></strong></strong></strong><br>Vice President,<br>Global Research and Development<br>SK pharmteco</h6><p></p></div><p></p></div><p></p><p><!-- /wp:post-content --></p><p><!-- /wp:post-content --></p><p><!-- wp:separator {"className":"is-style-wide"} --></p><p></p><hr class="wp-block-separator has-alpha-channel-opacity is-style-wide"><p><!-- /wp:separator --></p><p><!-- wp:paragraph {"align":"center"} --></p><p> </p><p class="has-text-align-center"><strong>Produced with support from:</strong></p><p><!-- /wp:paragraph --></p><p><!-- wp:image {"lightbox":{"enabled":false},"id":331275,"sizeSlug":"medium","linkDestination":"custom","align":"center"} --></p><p><figure class="wp-block-image aligncenter size-medium"><a href="https://www.skpharmteco.com/" target="_blank" rel="noreferrer noopener"><img loading="lazy" decoding="async" width="300" height="106" class="wp-image-331275" src="https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-300x106.jpg" alt="skpharmteco logo" srcset="https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-300x106.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1024x361.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-768x270.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1193x420.jpg 1193w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-696x245.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1392x493.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo-1068x376.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/04/skpharmteco_logo.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"></a></figure></p><p><!-- /wp:image --></p><p>The post <a href="https://www.genengnews.com/multimedia/podcasts/gencast/small-molecules-big-expectations-how-cdmos-are-helping-sponsors-navigate-complexity-speed-scale-up-and-sustainability/">Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and Sustainability</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models</title>
<link>https://edusehat.com/en/parp-inhibitor-combination-therapy-boosts-antitumor-activity-in-nsclc-models</link>
<guid>https://edusehat.com/en/parp-inhibitor-combination-therapy-boosts-antitumor-activity-in-nsclc-models</guid>
<description><![CDATA[ Pairing HER3-DXd with the PARP inhibitor olaparib increased DNA damage, induced apoptosis, and slowed tumor progression in vivo in preclinical non-small cell lung cancer models.
The post PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/GettyImages-172267826.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 06:55:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>PARP, Inhibitor, Combination, Therapy, Boosts, Antitumor, Activity, NSCLC, Models</media:keywords>
<content:encoded><![CDATA[<p>Drug resistance remains a central obstacle in the treatment of non-small cell lung cancer (NSCLC) and other lung cancers, even as targeted therapies have improved outcomes for patients whose tumors are driven by mutations in EGFR, KRAS, or other oncogenes. Now, a preclinical study suggests that pairing the HER3-targeting antibody-drug conjugate HER3-DXd with the PARP inhibitor olaparib could offer a way to intensify DNA damage in tumor cells while also stimulating antitumor immune activity.</p>
<p>The study, “<a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00419-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379126004192%3Fshowall%3Dtrue" target="_blank" rel="noopener">PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer</a>,” was published in <em>Cell Reports Medicine</em>. Researchers from Tampere University, the University of Helsinki, Harvard Medical School, and Dana-Farber Cancer Institute investigated whether HER3-DXd, also known as patritumab deruxtecan, could be made more effective through rational combination strategies involving modulators of the cell cycle and DNA damage response.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>HER3 is expressed in many NSCLC tumors and has been associated with poor prognosis when overexpressed, making it an attractive therapeutic target. HER3-DXd is designed to bind HER3 on cancer cells and deliver a topoisomerase I inhibitor payload that damages DNA. Olaparib, meanwhile, blocks PARP-mediated DNA repair. The combination was intended to push cancer cells beyond their capacity to repair DNA damage.</p>
<p>The researchers screened HER3-DXd alongside drugs that affect cell-cycle regulation and DNA damage repair, identifying PARP inhibition as a strong synergistic partner. In NSCLC models carrying either EGFR or KRAS mutations, the HER3-DXd and olaparib combination was more effective than either agent alone. The dual treatment increased markers of DNA damage, induced apoptosis, and slowed tumor progression <em>in vivo</em>.</p>
<p>Those effects were not limited to direct tumor-cell killing. The combination also activated the cGAS-STING pathway, an innate immune signaling pathway that can be triggered by cytosolic DNA. In the study, this immune activation appeared to enhance natural killer cell-mediated tumor killing, suggesting that the regimen may have antibody-dependent immunomodulatory effects in addition to its DNA-damaging activity.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“A key finding was that the treatment combination was effective across multiple genetically distinct forms of lung cancer and was not dependent on any specific mutation. In fact, the HER3 protein could eventually serve as a biomarker for identifying patients who are likely to benefit from this type of treatment,” said Heidi Haikala, PhD, senior research fellow at Tampere University and assistant professor at the University of Helsinki.</p>
<p>The findings point to a possible strategy for patients whose tumors do not respond adequately to existing targeted therapies or develop resistance after treatment. Because HER3 is also present in other solid tumors, the authors suggested that the approach could have applications beyond NSCLC.</p>
<p>Still, the authors cautioned that the work remains preclinical. The study relied on a limited number of organoid lines and used immunocompromised mice for <em>in vivo</em> experiments, which may restrict how broadly the immune findings can be generalized. The researchers also noted that potential toxicities, including possible liver-related effects with prolonged combination treatment, will require more detailed evaluation before the regimen can move toward human trials.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/parp-inhibitor-combination-therapy-boosts-antitumor-activity-in-nsclc-models/">PARP Inhibitor Combination Therapy Boosts Antitumor Activity in NSCLC Models</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development</title>
<link>https://edusehat.com/en/rznomics-joins-lilly-gateway-labs-to-quicken-rna-therapeutic-candidate-discovery-and-development</link>
<guid>https://edusehat.com/en/rznomics-joins-lilly-gateway-labs-to-quicken-rna-therapeutic-candidate-discovery-and-development</guid>
<description><![CDATA[ Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets.
The post Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1355065925.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 02:20:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rznomics, Joins, Lilly, Gateway, Labs, Quicken, RNA, Therapeutic, Candidate, Discovery, and, Development</media:keywords>
<content:encoded><![CDATA[<p>Rznomics is joining Lilly Gateway Labs (LGL) in San Diego. The company is a clinical-stage biopharmaceutical firm based in South Korea focused on developing RNA-based gene therapies.</p>
<p>Lilly Gateway Labs is an innovation hub designed to help biotechnology companies advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives. Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and R&D  capabilities.</p>
<p>Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets, while simultaneously driving long-term efforts to establish global clinical infrastructure for the company’s lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the U.S.</p>
<p>“Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics’ proprietary RNA platform,” said Seong-Wook Lee, CEO of Rznomics. “We intend to advance the development and commercialization of our RNA therapeutics by active collaboration with the global biotech ecosystem.”</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/rznomics-joins-lilly-gateway-labs-to-quicken-rna-therapeutic-candidate-discovery-and-development/">Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Male Sex Hormones Suppress Lung Allergies by Acting on Neurons in Mice</title>
<link>https://edusehat.com/en/male-sex-hormones-suppress-lung-allergies-by-acting-on-neurons-in-mice</link>
<guid>https://edusehat.com/en/male-sex-hormones-suppress-lung-allergies-by-acting-on-neurons-in-mice</guid>
<description><![CDATA[ A study in mice found that male sex hormones can suppress allergic responses by promoting sympathetic nerve connections and norepinephrine release in the lungs.
The post Male Sex Hormones Suppress Lung Allergies by Acting on Neurons in Mice appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/03/POV-GettyImages-1227553397.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 25 Aug 2026 02:20:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Male, Sex, Hormones, Suppress, Lung, Allergies, Acting, Neurons, Mice</media:keywords>
<content:encoded><![CDATA[<p>Sex-related differences in the rates of asthma onset and remission suggest that sex hormones may play a role in the pathogenic mechanisms that underly some forms of asthma. A study led by researchers at Peking University Third Hospital Cancer Center, Peking University, has now found that in mice, male sex hormones can suppress allergic responses by promoting sympathetic nerve connections and norepinephrine release in the lungs. The findings help to illuminate mechanisms that underlie sex differences in allergic diseases and could help inform future therapeutics to treat type 2 immune inflammatory conditions such as asthma.</p>
<p>Xiaofan Tu, PhD, is first and co-corresponding author of the researchers’ published paper in <em>Science Immunology</em>, titled “<a href="http://dx.doi.org/10.1126/sciimmunol.aed0186" target="_blank" rel="noopener">Androgen signaling via sympathetic neurons regulates allergic pulmonary inflammation</a>.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Prior research has shown that asthma and other allergic diseases are more common in young males but shift during puberty to become more prevalent in adult females. The authors explained, “During puberty—a critical developmental period marked by substantial changes in gonadal hormone levels—a significant proportion of pediatric patients experience asthma remission, a phenomenon that is more common in males than females. Coincident with the sharp rise in gonadal hormone production during puberty, there is also an age-dependent shift in asthma prevalence and severity, from a predominance in males before puberty to a predominance in females in adulthood.”</p>
<p>But while sex hormones can influence immune cell functions in asthma, it has been unclear whether they also regulate nonimmune cells in the lungs. For their reported study Xiaofan Tu and colleagues evaluated sex differences in a mouse model of allergic asthma. They showed that early house dust mite (HDM) exposure induced greater type 2 inflammation in female mice when compared with males. However, gonad removal surgery prior to allergen exposure eliminated these sex differences.</p>
<p>To confirm the immunosuppressive capabilities of male gonadal hormones, the team then administered testosterone to male and female mice that had undergone a gonadectomy and were exposed to house dust mites. The testosterone treatment reduced type 2 immune cell infiltration and cytokine expression, suppressing allergic inflammation. “… male gonadal hormones dampen allergic inflammation and contribute to sexually dimorphic type 2 responses during peripubertal stages,” they wrote.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The researchers in addition determined that androgen receptor signaling upregulated sympathetic nerve development in the lungs and showed that inactivating these receptors exacerbated eosinophil recruitment and allergic inflammation. Treatment with norepinephrine—which sympathetic neurons produce in the lungs—lowered levels of eosinophil-recruiting cytokines in immune cells. “In contrast to earlier findings focused on the direct interactions between androgens and pulmonary type 2 cells, our present study describes a sex hormone–driven neuroimmune mechanism that modulates pulmonary immunity, whereby androgens suppress allergen-induced inflammation indirectly by enhancing pulmonary sympathetic innervation,” they wrote in summary.</p>
<p>The authors speculate that this neuroimmune pathway might contribute to the reduction of allergies in males after puberty and note that further work is needed to elucidate how norepinephrine regulates immune function, including characterizing how gonadal hormones affect both lung-innervating sensory and parasympathetic neurons at various developmental stages.</p>
<p>The team also suggest that investigating neuroimmune crosstalk with other hormones such, as growth hormones, thyroid hormones, and corticosteroids may represent a promising area for future research. “Elucidating how these hormones interact with afferent and efferent lung-innervating neurons may enhance our understanding of the temporal dynamics of asthma progression and unravel additional targetable features to induce asthma remission,” they concluded.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/male-sex-hormones-suppress-lung-allergies-by-acting-on-neurons-in-mice/">Male Sex Hormones Suppress Lung Allergies by Acting on Neurons in Mice</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too</title>
<link>https://edusehat.com/en/stockwatch-merckmoderna-cancer-vaccine-gives-a-shot-in-the-arm-to-sequencing-companies-too</link>
<guid>https://edusehat.com/en/stockwatch-merckmoderna-cancer-vaccine-gives-a-shot-in-the-arm-to-sequencing-companies-too</guid>
<description><![CDATA[ Because intismeran autogene is a personalized cancer therapy made for each patient based on the individual genetic mutations of their tumors, the Merck-Moderna stock surge extended to sequencing giants such as Illumina, Pacific Biosciences of California, and to a degree Oxford Nanopore Technologies.
The post StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Moderna-Therapeutics_busy-working-in-the-lab-CROPPED111.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 24 Aug 2026 04:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>StockWatch:, MerckModerna, Cancer, Vaccine, Gives, Shot, the, Arm, Sequencing, Companies, Too</media:keywords>
<content:encoded><![CDATA[<p>Investors of<strong> Merck & Co. (NYSE: MRK) </strong>and <strong>Moderna (Nasdaq: MRNA)</strong> were the most obvious—but not the only—beneficiaries when the companies announced what they said were the first-ever positive Phase III results for their mRNA-based cancer vaccine, the individualized neoantigen therapy (INT) intismeran autogene.</p>
<p>Merck and Moderna made both Wall Street and biotech news by trumpeting positive topline results from the Phase III INTerpath-001 trial (<a href="https://clinicaltrials.gov/study/NCT05933577">NCT05933577</a>) showing that patients treated with intismeran plus Merck’s blockbuster cancer immunotherapy Keytruda<sup class="wp-sup-text">®</sup> (pembrolizumab) showed greater improvement than patients treated with Keytruda alone. The cancer INT surpassed Keytruda on both the trial’s primary endpoint of recurrence-free survival (RFS) and the study’s key secondary endpoint of distant metastasis-free survival (DMFS).</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>While Merck and Moderna saw their shares jump far above normal increases, several sequencing companies caught the proverbial tailwind and surged as well. That happened because intismeran is a personalized cancer therapy made for each patient based on the individual genetic mutations of their tumors.</p>
<p>As a result, the Merck-Moderna surge extended to sequencing giants such as <strong>Illumina (Nasdaq: ILMN)</strong>, <strong>Pacific Biosciences of California (Nasdaq: PACB)</strong>, and, to a degree <strong>Oxford Nanopore Technologies</strong> <strong>(London Stock Exchange: ONT)</strong>, though a strong first-half earnings report and other positive announcements propelled Oxford Nanopore’s climb.</p>
<p>Between Wednesday’s announcement and Friday, Illumina shares <span><strong>jumped 16%</strong></span>, from $188.29 to $219.40, while PacBio <span><strong>climbed 18%</strong></span>, from $1.14 to $1.35. Oxford Nanopore <span><strong>rocketed 39%</strong></span> from £122.20 ($166.68) to an even £170 ($231.97), for reasons that go beyond Merck-Moderna.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>In addition to the cancer INT, those reasons include an announced 10.5% revenue jump from £105.6 million ($144 million) to £116.7 million ($159.2 million) during the first half of this year, a restated commitment by new CEO Francis Van Parys to grow annual revenue to £700 million+ ($955 million+) by 2030, plus an intellectual property cross-licensing agreement with an undisclosed diagnostics developer that agreed to pay Oxford Nanopore $20 million in fees to be included in H2 2026 results, plus $15 million in committed purchases in 2027–2028, and low- to mid-single digit royalties.</p>
<p></p><h4><strong>Data to be presented</strong></h4>

<p>Merck and Moderna saw their shares surge despite not sharing any specific data for either the intismeran-plus-Keytruda arm or the Keytruda-alone arm of their trial.</p>
<p>That data, the companies said, will be presented at an “upcoming international medical meeting”—which analysts speculated could be either the European Society for Medical Oncology (ESMO) or the Society for Immunotherapy of Cancer (SITC) conferences—and shared with regulators.</p>
<p>Yet the absence of specific data did not stop analysts from sharing mostly very positive vibes about Moderna, whose shares had already <span><strong>more than doubled, soaring 124%</strong></span> in the year preceding the cancer INT announcement, from $28.09 to $62.96. The announcement sent Moderna’s shares into the stratosphere, <span><strong>catapulting them 177%</strong></span> to $174.38 and adding $45 billion to the company’s market capitalization (share price times the number of outstanding shares).</p>
<p>Moderna shares <span><strong>tumbled nearly 24%</strong></span> the following day to $133.32 on a combination of profit-taking plus expectations of a longer Iran war that sank most of the markets. But Moderna’s stock resumed its upward climb Friday, <span><strong>jumping 9%</strong></span> to finish the week at $145.13 and a <span><strong>130.5% three-day gain</strong></span>. That’s a far cry from the 10% rise Moderna saw in December 2023 when it <a href="https://www.genengnews.com/topics/cancer/stockwatch-positive-cancer-vaccine-data-wows-moderna-investors/">joined Merck to report positive Phase IIb data in stage III/IV melanoma</a>.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“We see [Wednes]day’s update as a clear positive for shares and Moderna’s fundamental business,” Myles R. Minter, PhD, a partner and biotechnology analyst with William Blair, declared in a research note.</p>
<p></p><h4><strong>“Watershed moment” and “landmark win”</strong></h4>

<p>Minter also upgraded Moderna shares from “Market Perform” to “Outperform.” He was one of two analysts who raised their ratings on the company’s shares. Alec Stranahan, PhD, BofA Securities vp, equity research covering U.S. small- to mid-cap biotechnology companies, upgraded his firm’s rating from “Underperform” to “Neutral” and set a 12-month price target of $170, calling the positive data announcement “a watershed moment for Moderna,” as reported by <em>Forbes</em>. At Needham & Co., senior analyst Joseph Stringer, PhD, declared the results a “landmark win,” according to <em>Investors Business Daily</em>.</p>
<p>Behind the upbeat assessments of analysts is a view, shared by a consensus, that the cancer INT will significantly broaden Moderna’s sales beyond its two marketed mRNA-based COVID-19 vaccines.</p>
<p>Spikevax<sup class="wp-sup-text">®</sup> and mNexspike<sup class="wp-sup-text">®</sup> accounted for 97% ($91 million) of the company’s $94 million in second-quarter net product sales, down 17.5% from $114 million in Q2 2025, all of that from Spikevax (mNexspike did not reach the market until the third quarter of last year). The remaining $3 million in Q2 2026 sales came from respiratory syncytial virus (RSV) vaccine mResvia<sup class="wp-sup-text">®</sup>. A fourth FDA-approved vaccine, mCombriax<sup class="wp-sup-text">®</sup>, is an influenza/COVID-19 combination jab that has yet to be commercialized.</p>
<p>“We believe Moderna has a clear line of sight to revenue diversification from the COVID-19 business,” Minter added.</p>
<p>Andrew Tsai, equity analyst with Jefferies, wrote in a research note that market watchers were “likely to ascribe multibillion peak sales pot’l to melanoma,” as well as to conclude that those strong sales will read across intismeran’s numerous Phase II and Phase III programs in various solid tumor indications.</p>
<p>As for what the positive data is likely to show, Tsai continued, “We can infer RFS (and DMFS) could imply at least an HR [hazard ratio of between] 0.5–0.8, which seems clinically meaningful, especially if OS [overall survival] trends are favorable. Tsai noted that an earlier Phase IIb trial of the cancer INT in Stage III/IV melanoma showed a durable HR=0.51 on RFS stretching as far as year 5 after treatment, including an HR of 0.561 (p=0.0266) on two years of follow-up data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.</p>
<p>The Merck-Moderna announcement led to gains for the stocks of two leading rivals in cancer INT vaccine development: <strong>BioNTech (Nasdaq: BNTX)</strong> is partnering with <strong>Roche (SIX Swiss: RO and ROP)</strong>-owned Genentech on an mRNA-based individualized cancer vaccine, autogene cevumeran (BNT122/ RO7198457), that is in Phase II trials for advanced colorectal cancer and adjuvant pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>BioNTech shares <span><strong>jumped 26%</strong></span> this week from $92.75 to $116.59, while Roche’s RO bearer shares <span><strong>rose 3.5%</strong></span>, from CHF 366.80 ($457.93) to CHF 379.60 ($473.91), while its ROP participation certificates <span><strong>increased 4%</strong></span> from CHF 360.90 ($450.57) to CHF 375.60 ($468.96).</p>
<p></p><h4><strong>“Overly optimistic”</strong></h4>

<p>Daina M. Graybosch, PhD, senior managing director, immuno-oncology, and a senior research analyst with Leerink Partners, took a more cautious view on the Merck-Moderna announcement: “While we were thrilled to see a positive market reaction for the definitive success of the therapeutic cancer vaccine intismeran autogene (INT), the reception was overly optimistic and creates expectations that we believe will be difficult to meet.”</p>
<p>Graybosch said her caution reflected her views that:</p>
<ul>
<li>There will be less read-across to other cancer indications since melanoma is a tumor that is most immune-sensitive and has the highest tumor mutational burden (TMB).</li>
<li>Rosy multi-billion-dollar sales forecasts won’t materialize for the cancer INT since its per-patient manufacturing cost as a personalized therapy will result in a lower gross margin of ~50–75% compared with the ~90% of monoclonal antibodies.</li>
<li>HR will be no worse than 0.76 to 0.79, and could be much better.</li>
</ul>
<p>Despite those cautions, Graybosch and colleagues at Leerink raised their projected 2032 sales forecast for intismeran 17%, from $1.2 billion to $1.4 billion. Karen Andersen, a director with Morningstar, went much further, projecting $16.8 billion in sales by 2035, more than double its previous projection of $7.2 billion. Morningstar also doubled its “fair value” or long-term, intrinsic value estimates on Moderna shares from $79 to $163, and on Merck shares by 29%, from $111 to $143.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>INTerpath-001 is one of nine Phase II and Phase III trials within the INTerpath clinical development program assessing intismeran as a monotherapy and in combination with Keytruda and other anti-cancer therapies. In addition to melanoma, intismeran is being studied in non-small cell lung cancer (NSCLC), bladder cancer, and renal cell carcinoma.</p>
<p>The cancer INT is also under study in the Phase IIb KEYNOTE-942/mRNA-4157-P201 trial (<a href="https://clinicaltrials.gov/study/NCT03897881">NCT03897881</a>) in adjuvant melanoma, and a Phase I study evaluating intismeran in adjuvant pancreatic ductal adenocarcinoma, perioperative gastric carcinoma, and perioperative NSCLC.</p>
<p>In NSCLC, Merck and Moderna are studying intismeran in two Phase III trials, INTerpath-009 (<a href="https://clinicaltrials.gov/study/NCT06623422">NCT06623422</a>) in patients with resectable Stage II to IIIB (N2) NSCLC; and INTerpath-014 (<a href="https://clinicaltrials.gov/study/NCT07513376">NCT07513376</a>), in patients with completely resected high-risk Stage I NSCLC.</p>
<p></p><h4><strong>“Critical” read-across</strong></h4>

<p>“We see the read-across to other indications as critical, and even more important, to thinking about value from here” for Moderna stock, J.P. Morgan analyst Jessica Fye and four colleagues wrote in a research note.</p>
<p>While viewing a launch of intismeran in adjuvant melanoma as key to Moderna returning to profitability, Fye and colleagues said the positive results announced Wednesday were less a driver of value for Moderna shares than the other cancer indications since the cancer INT is a partnered product in a relatively small indication by immuno-oncology standards whose probability of success in adjuvant melanoma was pegged at 85% and already priced into the company’s shares before the announcement.</p>
<p>A day later, Fye and colleagues nearly doubled her firm’s price target on Moderna shares, raising it 92.5% from $40 per share as of December to $77 per share as of December 2027. The J.P. Morgan analysts also stopped risk-adjusting Moderna’s economic prospects in adjuvant melanoma. And they raised their probability of success forecasts for Moderna generating future profits in three other cancer indications—adjuvant lung cancer, adjuvant kidney cancer, and adjuvant bladder cancer—from 55% to 70%.</p>
<p>“While we have the most questions around whether this efficacy in adjuvant melanoma can read across to the metastatic setting, we are adding more heavily risk-adjusted credit for the possibility of activity in metastatic disease,” Fye and colleagues wrote.</p>
<p>As with Moderna, Merck enjoyed a mostly positive week that started with its shares <span><strong>jumping nearly 13%</strong></span> from $135.17 to $152.20 on Wednesday—an all-time high closing price and an unusual one-day double-digit leap for a pharma giant.</p>
<p>“These first Phase III findings for intismeran in combination with Keytruda as adjuvant therapy reinforce the promise of a more personalized approach to cancer treatment,” Dean Y. Li, MD, PhD, president, Merck Research Laboratories, said in a statement. “We believe individualized neoantigen therapies have the potential to redefine how patients with completely resected stage IIB-IV melanoma are treated.”</p>
<p>Merck shares <span><strong>slid 2%</strong></span> Thursday to $148.99 before <span><strong>bouncing back 2%</strong></span> Friday, finishing the week at a new all-time high close of $152.52 and a <span><strong>13% three-day gain</strong></span>.</p>
<p>Merck needs a new blockbuster to help it recoup sales it will lose when Keytruda loses exclusivity for key U.S. patents in 2028—<a href="https://www.genengnews.com/topics/drug-discovery/top-20-drugs-heading-for-the-patent-cliff-2026-2029/">the most successful drug facing the proverbial patent cliff over the remainder of this decade</a>. Keytruda racked up $15.81 billion in Q1–Q2 2026 sales in addition to the $31.641 billion it generated last year. Keytruda Qlex, a subcutaneous injection form of Keytruda, generated $590 million in the first half of this year and $40 million in 2025, since Qlex didn’t win FDA approval till September of last year.</p>
<p>“We expect positive investor reaction that will help sustain momentum for MRK into the fall,” Graybosch wrote. “Whether INT will be a large contributor to Merck’s bottom line is still uncertain, as we await pricing, COGS [cost of goods sold], and whether this success in the most immune-sensitive tumor will translate to non-small cell lung cancer.”</p>
<p></p><h4><strong>Leaders and laggards</strong></h4>

<ul>
<li><b>Capricor Therapeutics (Nasdaq: CAPR) </b>shares yo-yoed in recent days, <span><strong>soaring 77%</strong></span> over two days from $4.21 to $7.45 on August 17 after the company told analysts on its second quarter earnings call that the FDA had agreed to review an amendment to its Biologics License Application (BLA) with additional 24-month data showing improved upper limb function following treatment with its drug candidate deramiocel. Capricor shares rose further to $7.98 by Wednesday, then <span><strong>nosedived 21%</strong></span> over two days to $6.29 at Friday’s close, on speculation that the FDA will reject deramiocel a second time.</li>
<li><b>Tenax Therapeutics (Nasdaq: TENX)</b> shares <span><b>cratered 90%</b></span> from $13.44 to $1.38 on August 10 after the cardiopulmonary drug developer said its lead candidate TNX-103 (oral levosimendan), a first-in-class K-ATP channel activator/calcium sensitizer developed to treat pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), failed the Phase III LEVEL trial (<a class="x_OWAAutoLink" title="https://clinicaltrials.gov/study/NCT05983250" href="https://clinicaltrials.gov/study/NCT05983250" target="_blank" rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="0"><u>NCT05983250</u></a>). TNX-103 missed the study’s primary endpoint of improvement in the six-minute walk distance vs. placebo, and the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score. Tenax said it will request a Type C meeting with the FDA to present the complete LEVEL dataset together with the company’s recommendations and will seek scientific consultation from the European Medicines Agency. Tenax said it intends to enrich the study population of its ongoing Phase III LEVEL-2 trial (<a class="x_OWAAutoLink" title="https://clinicaltrials.gov/study/NCT07288398" href="https://clinicaltrials.gov/study/NCT07288398" target="_blank" rel="noopener noreferrer" data-auth="NotApplicable" data-linkindex="1"><u>NCT07288398</u></a>), citing subgroup data from LEVEL that identified a substantial beneficial treatment effect in patients with greater disease burden, supported by clinically meaningful changes in predefined cardiac biomarker and pulmonary hemodynamic measures across the overall trial population.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/cancer/stockwatch-merck-moderna-cancer-vaccine-gives-a-shot-in-the-arm-to-sequencing-companies-too/">StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DeepCyte Launches Single&#45;Cell Metabolomic Reference Atlas of Drug Toxicity Mechanisms</title>
<link>https://edusehat.com/en/deepcyte-launches-single-cell-metabolomic-reference-atlas-of-drug-toxicity-mechanisms</link>
<guid>https://edusehat.com/en/deepcyte-launches-single-cell-metabolomic-reference-atlas-of-drug-toxicity-mechanisms</guid>
<description><![CDATA[ Rather than generating new wet-lab data for every compound, DeepCyte trains a foundation model that is capable of predicting toxicity mechanisms for compounds that it has never measured.
The post DeepCyte Launches Single-Cell Metabolomic Reference Atlas of Drug Toxicity Mechanisms appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-966765790.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 22 Aug 2026 01:45:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DeepCyte, Launches, Single-Cell, Metabolomic, Reference, Atlas, Drug, Toxicity, Mechanisms</media:keywords>
<content:encoded><![CDATA[<p><span>DeepCyte launched the DeeTox Atlas<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, a single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies are expected to begin in the coming months.</span></p>
<p><span>DeeTox Atlas is described as a foundation dataset built from two independent single-cell metabolomics perturbation studies, spanning approximately 100 toxicant compounds, 300,000 cells, and ~500 metabolites per cell—over 3,000 single-cell measurements<b> </b>per compound across six biological replicates. Each compound is mapped to a curated four-level hierarchy of toxicity mechanisms anchored to established Adverse Outcome Pathways (AOPs), according to the company.</span></p>
<p><span>Rather than generating new wet-lab data for every compound, DeepCyte trains a foundation model capable of predicting toxicity mechanisms for compounds it has never measured, said Theodore Alexandrov, co-founder and CEO of DeepCyte, adding that as the atlas expands, the platform becomes increasingly scalable, reducing laboratory dependence while improving predictive performance.</span></p>
<p><span>“AI in toxicology is only as good as the biological data it learns from. DeeTox Atlas lets us find subtle molecular patterns tied to key toxicity mechanisms—patterns our validation studies show are expressed in small subpopulations of cells and are effectively invisible to methods lacking single-cell resolution—and turn them into predictive models,” explained Alexandrov. “Our vision is to move toxicology from reactive laboratory testing toward predictive, mechanism-based AI that surfaces and explains safety liabilities earlier in drug discovery.”</span></p>
<p><span>The Atlas will expand with more compounds, mechanisms, and biochemical and clinical data, making predictions more actionable for toxicologists, medicinal chemists, and safety scientists, noted </span><span>Alexandrov.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/deepcyte-launches-single-cell-metabolomic-reference-atlas-of-drug-toxicity-mechanisms/">DeepCyte Launches Single-Cell Metabolomic Reference Atlas of Drug Toxicity Mechanisms</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>From Models to Agents: The Next Phase of AI Adoption in Molecular Discovery</title>
<link>https://edusehat.com/en/from-models-to-agents-the-next-phase-of-ai-adoption-in-molecular-discovery</link>
<guid>https://edusehat.com/en/from-models-to-agents-the-next-phase-of-ai-adoption-in-molecular-discovery</guid>
<description><![CDATA[ Despite advances, AI applications in scientific research have not experienced their “Claude Code” moment. The compute power exists. The models exist. What’s missing is a system that coordinates them.
The post From Models to Agents: The Next Phase of AI Adoption in Molecular Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_2234447381_AIMedicalIdea.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 22 Aug 2026 01:45:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>From, Models, Agents:, The, Next, Phase, Adoption, Molecular, Discovery</media:keywords>
<content:encoded><![CDATA[<p>In recent years, the artificial intelligence (AI) conversation has been dominated by increasingly capable large language models. Every few months, models improve on mathematical reasoning and coding benchmarks, while inference costs drop. Since 2025, programmers have become more familiar with Claude Code and OpenAI Codex, autonomous software engineering agents running locally in a developer’s terminal, navigating code repositories and editing files across codebases.</p>
<p>For the biotech and pharmaceutical industry, AI’s impact has also been profound. Researchers can now identify potential drug targets faster, predict protein structures with remarkable accuracy (thanks to advances like AlphaFold and RoseTTAFold), analyze vast scientific literature in seconds, and generate molecular insights that would previously have taken months to uncover.</p>
<p>Yet despite these advances, AI applications in scientific research have not experienced their “Claude Code” moment. A scientist investigating a drug target for a specific disease may consult multiple databases, retrieve scientific papers, run molecular analyses, compare outputs from different AI models, and move a protein structure prediction from one platform into a docking tool on another, and then wonder whether a different model would have given a better answer.</p>
<p>The compute power exists. The models exist. What’s missing is a system that coordinates them.</p>
<p></p><h4><strong>Why Agentic AI Matters</strong></h4>

<p>For all the excitement surrounding AI, much of the infrastructure required to apply it effectively in scientific research remains out of reach for many organizations. Access to frontier AI models, large-scale computing resources, molecular simulation platforms, scientific retrieval systems, and workflow orchestration tools often requires substantial investment and technical expertise. This creates a growing divide between organizations that can afford to assemble sophisticated AI-driven discovery environments and those that cannot.</p>
<p>Unlike traditional AI systems that generate outputs in response to prompts, agentic AI systems are designed to function more like a coordinated research team. They understand objectives, plan tasks, retrieve context, coordinate tools, evaluate results, and recommend next actions. In other words, agentic AI offers a potential path to democratize drug discovery by bridging the gap between generating an insight and acting on it.</p>
<p>Even with AI, scientific discovery rarely occurs in a single step. New therapies often emerge through a chain of interconnected discoveries. By handling the iterative workflows necessary for drug discovery, agentic systems free up researchers to pursue breakthroughs that depend on creativity, intuition, and the ability to ask questions nobody has thought to ask before.</p>
<p></p><h4><strong>How Agentic AI Actually Works</strong></h4>

<p>The preclinical drug discovery process flows across distinct phases, from target identification and hit screening through lead optimization, preclinical validation, and ultimately translational readiness. Across all of them, a central challenge repeats: knowing which model to use, and when.</p>
<p>We encountered this challenge firsthand when building Vecura, NYB.AI’s agentic AI platform for molecular discovery, to support our own internal drug discovery operations. As our work expanded across molecular screening, docking, protein structure prediction, bioactivity scoring, ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling, and molecular design, we managed a fragmented collection of specialized tools including:</p>
<ul>
<li>AlphaFold for structure prediction</li>
<li>DiffDock for blind docking</li>
<li>EquiBind for binding pose estimation</li>
<li>ESMFold for sequence-based folding</li>
<li>Drug-Target Interaction Graph Neural Network (DTIGN) and</li>
<li>LigoSPACE models for drug-target interaction scoring.</li>
</ul>
<p>Each tool generated useful outputs but we needed a system that could integrate these into a single workflow, reduce manual hand-offs, and help our team move faster from hypothesis to candidate prioritization. That need drove us to add an agentic AI layer, moving beyond tool access toward workflow execution.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<figure aria-describedby="caption-attachment-336904" class="wp-caption aligncenter"><img fetchpriority="high" decoding="async" class="wp-image-336904" src="https://www.genengnews.com/wp-content/uploads/2026/08/Vecura_figure1.jpg" alt="Vecura AI Screenshot" width="696" height="585" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Vecura_figure1.jpg 930w, https://www.genengnews.com/wp-content/uploads/2026/08/Vecura_figure1-300x252.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Vecura_figure1-768x646.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Vecura_figure1-499x420.jpg 499w, https://www.genengnews.com/wp-content/uploads/2026/08/Vecura_figure1-696x585.jpg 696w" sizes="(max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">Credit: NYB.AI</figcaption></figure>
<p>A recent peer-reviewed paper from our team, published in <a href="https://vecura.com/en/insights/from-prediction-to-decision-choosing-graph-based-ai-models-for-drug-target-interaction-research-2" target="_blank" rel="noopener"><em>Briefings in Bioinformatics</em></a>, examined this “which model to use, and when” problem further in the field of graph-based drug-target interaction modeling.<sup>1</sup> The field has produced a wealth of powerful models, but they operate at fundamentally different levels.<sup>2</sup> Some work at the network level, capturing broad associations between drugs and targets. Others work at the sequence level, representing proteins as strings of amino acids. Still others require full 3D structural data, modeling interactions at the resolution of individual atoms and binding pockets. And a fourth category focuses specifically on interaction mechanisms. Each level answers a different kind of question; using the wrong one wastes time and compute.</p>
<p>This paper<sup>1</sup> proposes a practical framework: before selecting any model, clarify what decision you actually need to make. Is your task association discovery, interaction classification, affinity estimation, candidate ranking, pocket identification, pose assessment, or mechanistic hypothesis generation? Only then do you examine inputs, choose the right resolution, scrutinize how candidate models were evaluated, and plan experimental validation.</p>
<p>This is precisely the kind of reasoning an agentic layer can encode, and it’s the philosophy around which we built Vecura. Throughout every phase, agentic workflows automatically route tasks and generate decision support. Model interaction likelihood ensures the right AI models are engaged at the right moments, operationalizing the output-driven logic. When a project shifts from target identification to lead optimization, the required model resolution moves from network-level associations toward pocket geometry and pose-ranking, where the agentic layer recommends for researchers to accept rather than through manual tool reconfiguration. And iterative scoring continuously refines predictions based on real-world validation data, so each cycle gets smarter.</p>
<p>Agentic AI fundamentally differs from traditional tools. It doesn’t just process your request and hand you an answer. It understands the scientific journey you’re on, anticipates what comes next, and coordinates the entire apparatus to get you there faster. A lead that might have taken months to optimize with scattered tools and manual hand-offs can now be systematically enhanced in weeks.</p>
<p></p><h4><strong>What Industry Leaders Should Be Thinking About Now</strong></h4>

<p>For executives across biotechnology, pharmaceuticals, healthcare, and scientific research, the strategic opportunity is orchestration, not automation, which remains largely limited to single tasks. The organizations most likely to benefit from the next wave of AI adoption may not be those deploying the latest or best-performing models but those who can most effectively integrate models, data, expertise, and workflows into a coherent research process.</p>
<p>If executed thoughtfully, agentic approaches could help organizations:</p>
<ul>
<li>Accelerate research cycles by reducing workflow bottlenecks</li>
<div class="my-8"><span data-render-ad="7"></span></div>
<li>Improve utilization of scientific knowledge across teams and projects</li>
<li>Scale expertise beyond individual researchers or departments</li>
<li>Enable scientists to spend more time on high-value decision-making</li>
</ul>
<p>The next phase of AI adoption is about leveraging agentic AI to integrate fit-for-purpose AI models and the supporting technology ecosystem around them, available to more skilled and passionate research teams worldwide. That’s how breakthroughs get democratized. For research-driven industries, such increased access may prove to be the most important breakthrough of all.</p>
<p class="trimmed"> </p>
<p><em>Giang Nguyen</em> <em>is </em><em>the </em><em>CEO of NYB.AI, a Singapore-based company developing agentic AI infrastructure for molecular discovery and life science research. He is also the CTO of Nanyang Biologics. In June</em><em> 2026</em><em>, NYB.AI was featured in the opening showcase video at </em><a href="https://www.nyb.group/newsroom/featured-at-nvidia-gtc-taiwan-2026-nyb-ai-stands-alongside-leading-ai-innovators" target="_blank" rel="noopener"><em>NVIDIA GTC Taiwan 2026</em></a><em>, highlighting agentic AI designed to coordinate actions to speed up molecular discovery.</em><em> Vecura is currently in </em><a href="https://vecura.com/en" target="_blank" rel="noopener"><em>early access mode</em></a><em>. </em></p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Nguyen T, To HM, Nguyen DA, et al. Graph-based drug-target interaction modeling: from representation learning to output-driven drug discovery. <em>Briefings Bioinformatics</em>. 2026;27(4):bbag392. <a href="https://doi.org/10.1093/bib/bbag392" target="_blank" rel="noopener">doi: 10.1093/bib/bbag392</a></li>
<li>Ahmad B, Quahada K, Hamam H. Machine learning for drug-target interaction prediction: A comprehensive review of models, challenges, and computational strategies. <em>Comp. Struct. Biotech. J. </em>2026;31:316-345. <a href="https://doi.org/10.1016/j.csbj.2025.12.033" target="_blank" rel="noopener">doi: 10.1016/j.csbj.2025.12.033</a></li>
</ol>
<p class="trimmed"> </p>
<p>FIGURE LEGEND</p>
<p>Vecura, an agentic AI platform for molecular discovery.</p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/from-models-to-agents-the-next-phase-of-ai-adoption-in-molecular-discovery/">From Models to Agents: The Next Phase of AI Adoption in Molecular Discovery</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Lab&#45;Grown Neocortex Models Mimic Early Brain Organization</title>
<link>https://edusehat.com/en/lab-grown-neocortex-models-mimic-early-brain-organization</link>
<guid>https://edusehat.com/en/lab-grown-neocortex-models-mimic-early-brain-organization</guid>
<description><![CDATA[ By using chemical signals to guide cells to adopt distinct regional identities, scientists created lab-grown human organoids that mimic early brain development and could illuminate how specialized brain areas emerge.
The post Lab-Grown Neocortex Models Mimic Early Brain Organization appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/02/GettyImages-1489195647-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 22 Aug 2026 01:45:05 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Lab-Grown, Neocortex, Models, Mimic, Early, Brain, Organization</media:keywords>
<content:encoded><![CDATA[<p><span>During brain development, distinct areas emerge that take on different jobs including movement, vision, memory, and language. At this stage of development, chemical signals help tell developing cells where they are, contributing to differences between areas at the front and the back of the cerebral cortex. This process, dubbed arealization by scientists, is believed to underpin much of the brain’s activity and may help explain what occurs in some brain disorders. </span></p>
<p><span>To date, this type of organization has been difficult to reproduce in lab-grown models of the human brain. But now, scientists at the University of California (UC), Irvine, have developed a new approach that lets them engineer lab-grown human brain tissue with a defined regional identity. The result is brain organoids with characteristics of either the front or back of the developing cerebral cortex that could be used in studies of how neurodevelopmental disorders develop. Full details are provided in a </span><i><span>Cell Stem Cell</span></i><span> paper titled “</span><a href="https://www.sciencedirect.com/science/article/pii/S1934590926002742"><span>Morphogen-guided neocortical organoids with anteroposterior areal identity</span></a><span>.”</span></p>
<p><span>According to the paper, the UC Irvine team used the approach to generate neocortical organoids from human stem cells that copy important features of the developing cerebral cortex. Each organoid was steered to take on the identity of either a front or back region using carefully selected chemical signals. It is an important step, one that ordinary organoids lack. Without this step, organoids end up with a patchwork of random regions rather than a clear front or back. </span></p>
<p><span>In this study, after exposing the organoids to the chemical signals, the scientists examined the individual cells to determine whether those differences resembled actual human development. Their analysis of more than 200,000 cells showed that the organoids reproduced molecular characteristics that were associated with different regions of the prenatal human context. </span></p>
<p><span>As an example of how these organoids can be used, the scientists used their new model to investigate fragile X syndrome. They wanted to know whether this genetic condition might affect both individual brain cells and broader developmental patterns that help organize those cells across the cortex.</span></p>
<p><span>Specifically, they looked at two proteins important to brain development, SOX4 and SOX11, that normally appear at different levels in front and back tissue. That difference showed up reliably in organoids grown from donors without the condition. In organoids modeling fragile X syndrome, it largely disappeared. </span><span>The broad front-to-back patterning was still there, but this particular difference had flattened out. </span></p>
<p><span>This finding is supported by other research in donated tissue from people with autism. Importantly, the findings do not show that disrupted brain patterning causes autism. Instead, they highlight a potential developmental process that researchers can now investigate in a human tissue model with greater spatial detail.</span></p>
<p><span>These more fine-grained models could also be used in other types of studies, according to the scientists. Neurological and neurodevelopmental disorders do not necessarily affect every part of the brain in the same way. So by giving organoids defined regional characteristics, researchers can begin studying not only what changes in a disorder but also where those changes emerge during development.</span></p>
<p><span>Furthermore, the platform contributes to growing efforts to develop human tissue-based research models that can complement animal studies. The scientists believe that the approach could be used to examine how genetic and environmental factors affect different regions of the developing cortex and, over time.</span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/lab-grown-neocortex-models-mimic-early-brain-organization/">Lab-Grown Neocortex Models Mimic Early Brain Organization</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>DANDELION Computational Tool Identifies Previously Unknown Asthma&#45;Related Genes and Pathway</title>
<link>https://edusehat.com/en/dandelion-computational-tool-identifies-previously-unknown-asthma-related-genes-and-pathway</link>
<guid>https://edusehat.com/en/dandelion-computational-tool-identifies-previously-unknown-asthma-related-genes-and-pathway</guid>
<description><![CDATA[ Researchers developed a computational tool that could help to finding genes most directly related to disease, and which in a reported study identified 21 genes related to asthma, most of which hadn’t been discovered by other methods.
The post DANDELION Computational Tool Identifies Previously Unknown Asthma-Related Genes and Pathway appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2019/04/Jan1_2019_GettyImages_91559819_NurseBoyAsthmaInhaler_1400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 22 Aug 2026 01:45:04 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>DANDELION, Computational, Tool, Identifies, Previously, Unknown, Asthma-Related, Genes, and, Pathway</media:keywords>
<content:encoded><![CDATA[<p>A growing view among geneticists holds that nearly every gene active in the relevant tissue plays some part in a disease, but the vast majority act only indirectly and from a distance, nudging a much smaller set of “central” genes that sit at the heart of the disease. Those central genes are the ones that directly drive the biology and therefore are the ones most worth targeting with drugs. Until now, scientists had no reliable way to pick them out of the crowd and experimentally test them.</p>
<p>An interdisciplinary research team headed by scientists at University of Chicago and at Columbia University has now developed a computational tool that could make the challenge of finding genes most directly related to disease much easier. Their newly reported study in <em>Cell </em>showed how the tool, called DANDELION, was able to identify 21 genes related to asthma, most of which hadn’t been discovered by other methods. The researchers used both CRISPR gene-editing screens and mouse models to validate that these genes lead to asthma phenotypes and demonstrated that two of the genes are in the same pathway involved in fatty acid metabolism and protein palmitoylation, which hasn’t yet been studied for asthma.</p>
<p>In their paper (“<a href="https://doi.org/10.1016/j.cell.2026.07.034" target="_blank" rel="noopener"><em>Trans</em>-regulatory gene mapping prioritizes disease drivers in asthma</a>,”) co-senior author Xuanyao Liu, PhD, assistant professor of medicine and human genetics at the University of Chicago, and colleagues, wrote, “DANDELION identifies genes that are not detected by existing approaches or gene prioritization methods, such as GWAS and polygenic priority score (PoPS) … Our study establishes DANDELION as a powerful framework for prioritizing novel, therapeutically actionable genes and pathways underlying disease pathogenesis.”</p>
<p>One of the most important goals of studying genetics is to find the genes that are important for specific diseases. The problem is that most diseases aren’t caused by a single gene or mutation. They’re the result of complex interactions among dozens, if not hundreds or thousands of genes, plus environmental factors, lifestyle, and a host of other variables. That flood of genes creates a needle-in-a-haystack problem. The authors wrote, “Deciphering which genes are most important to disease etiology is a central challenge in human genetics … However, the highly polygenic nature of complex disease makes it challenging to distinguish central disease drivers from many, sometimes hundreds, of genetic associations.”</p>
<p>The DANDELION tool focuses on a process known as trans-gene regulation. In complex diseases like asthma, many genetic variants may contribute to disease by changing the expression of other genes. This has a cascading effect where one variant changes the expression of a nearby gene, and then that gene changes the expression of another, and so on. This creates what’s called a gene regulatory network that ultimately drives the development of disease. “Here, we define disease-proximal genes (DPGs) as those that centrally mediate the effects of other, more distal disease-associated genes within <em>trans</em>-regulatory networks,” they explained.</p>
<p>Existing approaches like genome-wide association studies (GWAS) instead focus on genes that are often in the periphery of the gene regulatory network, however, and only indirectly affect disease. “All these existing tools assume that the actual disease genes are always going to be very close to the disease variants, but when you search for clues around that variant, you don’t always find much,” said Liu, PhD, who developed DANDELION. The authors further commented, “Genome-wide association studies (GWASs) are not suited for DPG identification because they are inherently weighted toward discovery of common variants, which generally have small effect sizes and, due to the pressure of selection, are less likely to impact genes involved in critical biological pathways.”</p>
<p>“What’s unique about our method is that we believe the disease genes are not just next to the genetic variants. They’re embedded in this gene regulatory network, and the actual disease-driving gene is downstream of those associated variants, maybe on different chromosomes. So, they’re on the receiving end of a genetic effect that is very far away,” Liu said. Liu named the tool DANDELION in reference to the puffy heads of dandelion flowers once they go to seed. The puffball resembles an interconnected, branching network of genes, ultimately pointing to the center of the core disease genes, the DPGs.</p>
<p>For the reported study, Liu analyzed a large set of data from the human transcriptome and the UK Biobank, a repository of health and genetic data from more than 500,000 volunteers. She used DANDELION to search for DPGs for asthma and found 21 candidates, 19 of which have not been discovered before using tools like GWAS. Liu showed the data to Marcelo Nóbrega, MD, PhD, chair of the department of human genetics at the University of Chicago, who has developed experimental platforms to manipulate the expression of genes in human cell types that are relevant to asthma, such as epithelial cells from the lining of the airways, inflammatory cells, and immune T cells.</p>
<p>At first, he was skeptical. “Xuanyao showed me a list of genes, and we didn’t recognize almost any of them,” Nóbrega said. “I thought that either this is going to be really cool and groundbreaking or it’s going to be wrong. But we had the experimental validation system running, so I thought, ‘Let’s test them all.”</p>
<p>Nóbrega’s team, led by postdoctoral scholar Isabella Salamone, PhD, conducted a series of experiments to test the effects of the genes predicted by DANDELION. Surprisingly, most of the genes Liu identified had a direct, measurable impact on the function of asthma-related cell types, producing phenotypes that model those seen in asthma at a much higher rate than the distal genes, or any other genes in the genome that they also tested. Looking more closely, Salamone saw that two genes had opposite effects. Knocking out one gene called SLC27A3 protected against the effects of asthma in both epithelial and T cells, while knocking out another gene, SCD, contributed to disease.</p>
<p>Looking at the effects of mutations of these genes in a large human cohort of almost half a million people, the researchers found that mutations in SLC27A3 are protective of asthma, supporting their findings in the cell-based phenotyping screens. “We saw this really striking pattern,” Salamone said. “Knocking out SLC27A3 had the strongest protective effect of all the genes we tested, and knocking out SCD was very detrimental to whatever cellular function we assayed. When we dug into patient data that had been collected by other labs, we saw the same pattern repeat itself—expression of SLC27A3 is increased in lung cells of patients with severe asthma, and SCD expression is decreased.”</p>
<p>Intriguingly, both SLC27A3 and SCD are involved in the same biochemical pathway for fatty acid metabolism. To understand how this might be linked to asthma, the investigators turned to chemical biologist Hening Lin, PhD, the James and Karen Frank Family Professor of Medicine and Professor of Chemistry at the Univereity of Chicago, who is a world-leading expert on the process, especially its role in protein palmitoylation, the addition of a long-chain fatty acyl group to proteins that regulate protein activity. Lin helped them confirm that both genes are involved in palmitoylation, and that reducing palmitoylation by knocking out SLC27A3 causes lung epithelial cells to dampen several immune-related and inflammatory processes.</p>
<p>“My lab has been working on the role of protein palmitoylation in immune signaling. We know many immune signaling pathways are regulated by palmitoylation, but I am still amazed by the finding that disrupting a lipid metabolic protein, SLC27A3, could offer protection in asthma models at least in part via affecting protein palmitoylation,” Lin said.</p>
<p>Finally, to test whether these genetic, biochemical, and cellular findings ultimately translate into asthma susceptibility, Salamone developed mice in which SLC27A3 or SCD were inactivated. They found that SLC27A3 knock-out mice are protected against allergy-induced lung inflammation, while SCD knock-out mice are more prone to lung inflammation compared to control mice, demonstrating that the new pathway the team uncovered is indeed capable of changing susceptibility to asthma.</p>
<p>“…our results show that loss of two enzymes with opposing effects on protein palmitoylation also has opposing CD4+ effects on cellular phenotypes in human epithelial and T cells and a mouse model of allergic sensitization,” the team wrote in summary. In their paper, the investigators suggested, “Our findings represent a new direction for understanding mediators of asthma pathogenesis and a new potential therapeutic intervention in the treatment of asthma, either by targeting SLC27A3 specifically or palmitoylation more broadly.”</p>
<p>Encouraged by this initial success Liu looks forward to testing it with other diseases, such as inflammatory bowel disease or type 2 diabetes. Historically, one of the limitations of drug development has been finding the true protein targets for treatment. DANDELION has the potential to overcome this challenge by identifying new and more effective drug targets.</p>
<p>“We’re really excited about this direction because for these diseases, GWAS has identified tons of signal, but we still don’t know the actual disease-driving genes that we can target for therapies,” Liu said. “I think our collaboration has been really powerful because we closed the gap at both the computational level and the experimental level.”</p>
<p>The authors further concluded, “We expect that the deployment of DANDELION to new traits and diseases will reveal a wealth of DPGs, with high drug development potential while also facilitating a deeper understanding of the roles these genes play in disease etiology.”</p>
<p>Nóbrega emphasized the importance of this collaboration as well, especially the advantage of being able to confirm their findings with a leading expert like Lin. “None of this would have come to fruition if any one of us were working on this alone,” he said. “We would have three papers buried in separate journals and virtually nobody would know how to put these stories back together. So, the power of having this complementary expertise across the division is really important.”</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/dandelion-computational-tool-identifies-previously-unknown-asthma-related-genes-and-pathway/">DANDELION Computational Tool Identifies Previously Unknown Asthma-Related Genes and Pathway</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Five&#45;Year Brain Organoids Reveal New Insights Into Human Development</title>
<link>https://edusehat.com/en/five-year-brain-organoids-reveal-new-insights-into-human-development</link>
<guid>https://edusehat.com/en/five-year-brain-organoids-reveal-new-insights-into-human-development</guid>
<description><![CDATA[ Researchers kept human brain organoids developing for over five years, revealing prolonged maturation that mirrors human brain development and creating new opportunities to study disorders and test drugs.
The post Five-Year Brain Organoids Reveal New Insights Into Human Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Organoids.png-e1787246962451.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 22 Aug 2026 01:45:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Five-Year, Brain, Organoids, Reveal, New, Insights, Into, Human, Development</media:keywords>
<content:encoded><![CDATA[<p>The human brain continues to develop for two decades. To study this prolonged process, researchers have traditionally relied on donated human brain tissue and animal models, both of which have limitations: donated tissue provides snapshots of brain development, and animal brains differ from the human brain in cell-type composition and timing of development.</p>
<p>Despite their increasing utility, organoids have proven challenging to maintain over long periods. Now, researchers have successfully maintained brain organoids for longer than ever before. For over five years, the tissue continued to mature in ways that closely resemble human brain development. By extending the lifespan of these organoids, the researchers create new opportunities to investigate neurodevelopment, model brain disorders, and test potential drugs.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This work is published in <em>Nature</em> in the paper, “<a href="https://www.nature.com/articles/s41586-026-10877-x" target="_blank" rel="noopener">Human brain organoids record the passage of time over multiple years.</a>”</p>
<p>Brain organoids have become increasingly important for studying human brain development. “These models allow us to track development over time and examine how different brain cell types emerge,” said Noelia Antón-Bolaños, PhD, assistant professor at UMC Utrecht. So far, most studies have focused on the earliest stages of development because researchers could not maintain brain organoids in culture for extended periods.</p>
<p>Antón-Bolaños and her colleagues investigated how far human brain organoids can continue to mature. However, standard culture conditions did not adequately support neuronal activity over extended periods.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“During human brain development, neurons display spontaneous activity,” Antón-Bolaños explained. “By adapting the composition of the culture medium, we supported that activity, kept the neurons active, and maintained the neuronal populations for much longer.”</p>
<p>Using this approach, the team maintained organoids for over five years. At defined time points, the researchers profiled the cell types present, gene-expression patterns, epigenetic changes, and neuronal activity.</p>
<p>The researchers then examined whether the organoids simply stayed alive or continued to develop. Different brain cell types appeared in the same order as during human brain development, neurons formed increasingly complex connections, and genes became active or inactive at the expected times.</p>
<p>Some of the strongest evidence came from epigenetic changes. “In the human brain, these epigenetic changes accumulate according to a characteristic developmental pattern,” Antón-Bolaños said. “We observed the same pattern in the brain organoids.”</p>
<p>After approximately one year, the organoids displayed features that normally emerge only after birth. “The cells are outside the body, yet they still follow approximately the same developmental timeline as we do—and even more closely than we had anticipated.”</p>
<p>The team also found that mature cells retained a memory of developmental time. “When we dissociated an older organoid and allowed the cells to grow again, they produced the cell types associated with a late developmental stage,” Antón-Bolaños said. “Yet when we combined older cells with younger cells, the older cells regained the ability to produce neurons—but only the types associated with later stages of development.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The organoids are still developing in the laboratory. The researchers now want to determine how environmental cues, such as stimulation with light, improve further maturation. The field also aims to improve features that remain incomplete, including vascularization and the layered organization of the cerebral cortex.</p>
<p>“We now know that these models have the capacity to continue developing for years,” Antón-Bolaños said. “The next step is to understand how to provide optimal conditions for that capacity to unfold. That will bring us closer to more faithful models of the human brain.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/five-year-brain-organoids-reveal-new-insights-into-human-development/">Five-Year Brain Organoids Reveal New Insights Into Human Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>When AI designs a drug, who gets the credit?</title>
<link>https://edusehat.com/en/when-ai-designs-a-drug-who-gets-the-credit</link>
<guid>https://edusehat.com/en/when-ai-designs-a-drug-who-gets-the-credit</guid>
<description><![CDATA[ When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/AI-scientist-IP.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 22:10:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>When, designs, drug, who, gets, the, credit</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>AI invents, humans get the credit:</strong> Insilico Medicine credited its AI platform with discovering a pulmonary fibrosis drug—then named five humans, including its CEO, as inventors on the patent. Courts have ruled that only humans can legally be inventors, because US law defines an inventor as an "individual."</li><br><li><strong>A legal system struggling to keep up:</strong> The US Patent and Trademark Office has swung from publishing guidance on AI co-inventorship under Biden to simply declaring AI a tool—like a calculator—under Trump. Legal experts warn the law will need to evolve as AI does more of the creative heavy lifting.</li><br><li><strong>A loophole that could backfire:</strong> Listing the wrong inventors is one way to invalidate a patent, meaning AI-generated drugs could face legal challenges down the road. If AI-created inventions can't be protected, some worry it could quietly chill investment in the very drug development these tools promise to accelerate</li></ul>" data-chronoton-post-id="1142627" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform.</p>



<p>Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think of, potentially speeding the race to new cures. AI models are now able to generate atomic designs for drugs almost as easily as ChatGPT can write a thank-you note.</p>



<p>However, when it came time to file for an all-important patent to protect that new chemical structure, the company made no mention of AI. Instead the patent names five humans, including CEO Alex Zhavoronkov, as the drug’s “inventors.”</p>





<p>The discrepancy points to a fascinating wrinkle in intellectual-property law. No matter how fundamental an AI is to a discovery, when it comes to winning rights to an invention, it’s humans—and only humans—who can take the credit.</p>



<p>US courts reached that conclusion after <a href="https://artificialinventor.com/">Ryan Abbott</a>, a partner at the LA law firm Brown, Neri, Smith & Khan, brought a pro bono test case naming an AI called DABUS as an inventor of a better food container, whose intricate geometric surface lets it transfer heat well and stack easily. Because no human contributed to the design, Abbott argued that the AI should be named the inventor.</p>



<p>The case might have raised philosophical questions, like whether AIs deserve legal rights or what the true nature is of that eureka moment that leads to a better mousetrap. But in 2022, an appeals court in Washington, DC, said these “metaphysical matters” were beside the point. Instead, <a href="https://www.cafc.uscourts.gov/opinions-orders/21-2347.OPINION.8-5-2022_1988142.pdf">it noted</a> that US statutes describe an inventor as an “individual,” the plain meaning of which is a human being.</p>



<p>Since machines aren’t people, they can’t be inventors. Case closed.</p>



<p>“There needs to be a human inventor or there’s no invention and no patent,” says Sarah Korman, a patent attorney who is now chief business officer and legal officer of Isomorphic Labs, an Alphabet spinout with big ambitions for AI cures. Korman, who made her remarks at <em>MIT Technology Review</em>’s EmTech event last year, added that there is “no doubt” our laws will need to evolve to keep pace with AI.</p>



<p>That’s partly because no one is denying that AIs <em>can</em> invent things. In the future, they may do so with less and less human intervention. As the US Patent and Trademark Office has itself acknowledged, “an AI system—like other tools—may perform acts that, if performed by a human, could constitute inventorship under our laws.”</p>





<p>Instead, the key question going forward may actually be whether or not any <em>human</em> contributed enough to be named as an inventor. Abbott believes there could be legal challenges to AI-generated drugs, since one way to invalidate a patent is to show it has the wrong inventors listed.</p>



<p>Abbott’s worry is that if US policy excludes AI-generated outputs from protection, that could put a damper on future drug development. Already, the US Copyright Office is refusing to grant copyrights to images and text generated by AI, raising <a href="https://perma.cc/9W9X-3EZE">concerns</a> from organizations like the Motion Picture Association of America, whose members are using those tools. </p>



<p>The point of our intellectual-property laws is to encourage innovation, Abbott says. It’s right there in Article 1 of the US Constitution, which says inventors and authors need to be given exclusive rights to their ideas, for a limited time, in order “to promote the Progress of Science and the Useful Arts.”</p>



<p>Currently, the US patent office seems to be taking a don’t-ask-don’t-tell approach to the use of AI. Under the Biden administration, the agency published guidance to help applicants determine whether and when humans would truly qualify as co-inventors of an AI discovery. But after Trump arrived in office, it reversed course. Now the patent office says AI is merely a tool, like a calculator. No need to even mention it.</p>



<p>You can bet that pioneering AI drug companies are keeping humans in the loop, at least for now, and documenting everything carefully. At Insilico, Zhavoronkov says, human chemists still have to synthesize the drugs, create variants, and test them on animals. “That’s the person who is going to be named on the patent,” he says. “And even if you decided to completely roboticize this process, including the experiments, someone will still push the button and give the budget.”</p>



<p>Should pushing a button count as being an inventor? Abbott says that’s a question for future legal cases. “What if I asked Claude to cure cancer, and it did?” he says. “I think it would be inappropriate to claim that I invented that.” </p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>BIO 2026: Generative genomics helps biotechs design better, not just faster</title>
<link>https://edusehat.com/en/bio-2026-generative-genomics-helps-biotechs-design-better-not-just-faster</link>
<guid>https://edusehat.com/en/bio-2026-generative-genomics-helps-biotechs-design-better-not-just-faster</guid>
<description><![CDATA[ Generative genomics uses AI to analyze genetic sequences for innovative treatments. Every industry is racing to optimize AI in their operations. For many biotech […]
The post BIO 2026: Generative genomics helps biotechs design better, not just faster appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/warren-umoh-KxwkcAe5Cpc-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 15:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BIO, 2026:, Generative, genomics, helps, biotechs, design, better, not, just, faster</media:keywords>
<content:encoded><![CDATA[<h5>Generative genomics uses AI to analyze genetic sequences for innovative treatments.</h5>
<p><span>Every industry is racing to optimize AI in their operations. For many biotech research teams and investors that means “generative genomics.”</span></p>
<p><span>Generative genomics is an emerging field of study using AI to analyze genetic sequences. Researchers hope that, with AI, they can efficiently assess the world’s collected stores of DNA/RNA data, discovering overlooked patterns that lead to new treatments. </span></p>
<p><span>Experts believe this technology will lead to faster results and increase the success rate of clinical trials. The possibilities were discussed during a panel at the BIO International Convention (BIO 2026) entitled “</span><a href="https://convention.bio.org/2026-sessions-and-courses/how-can-generative-genomics-help-us-design-biology-better-not-just-faster"><span>How Can Generative Genomics Help Us Design Biology Better, Not Just Faster</span></a><span>.”  </span></p>
<h2>Cause for excitement</h2>
<p><span>When it comes to reducing time and costs of developing medicine, there is potential for major efficiency gains. It can take more than a decade for a new product to go from the planning stage to rollout, and according to Genentech CEO Ashley Margagee, the cost of developing a drug is </span><a href="https://bio.news/health/ai-drug-discovery-biotech-nvidia-genentech-anniversary-bio-international-convention-2026/"><span>$2 billion on average</span></a><span>.</span></p>
<p><span>The most optimistic proponents of generative genomics say AI </span><a href="https://www.youtube.com/watch?v=Cltf2oLo7LA"><span>could shorten drug development time from years to months</span></a><span>, creating money savings too.</span></p>
<p><span>Accuracy could also improve. Currently, 90% of clinical trials fail, a figure that has remained stubbornly stable despite decades of advancements in the industry. Any change in that situation could be impactful.</span></p>
<p><span>“Just increasing success by five percent is a massive deal,” said John Androsavich, General Manager of Ginkgo Datapoints at Ginkgo Bioworks. “Investments that move the success rate by small increments would be huge.” </span></p>
<p><span>Generative genomics could be the technology that finally moves the needle, according to experts. AI categorizes and processes data at a speed never seen before. As the global biotech industry continues producing more data, AI can recognize patterns from across different sources and present its own conclusions. It will become easier than ever before for scientists to learn from research conducted by others. </span></p>
<h2>Ensuring trust and quality</h2>
<p><span>Biotech is a high-stakes industry: a literal matter of life and death. For biotech researchers to engage with generative genomics to its full potential, their model must be able to earn their trust.</span></p>
<p><span>“If the most beautiful, accurate model doesn’t change a decision, it’s not useful,” said Julie Rytlewski, a Senior Director at Bristol Myers Squibb. </span></p>
<p><span>She explained the real proof of success will not come from generating accurate hypotheses, but instead when those hypotheses start changing researchers’ decisions. </span></p>
<p><span>“There has to be trust in what these models are doing, especially when it comes to treating people,” Rytlewski said. “As we build trust, people value the output of the models more. It won’t be a switch overnight.”</span></p>
<p><span>The panelists agreed that developers cannot—and should not—rush the process in which AI wins over its skeptics. </span></p>
<p><span>“There is no single modality that can unlock biology,” said Justin Guinney, Senior Vice President of Cancer Genomics at Tempus AI. “It requires a multimodal perspective.”</span></p>
<h2>‘We’re seed-planters, not tree-buyers’</h2>
<p><span>It is no secret that AI is a darling of investors, and their enthusiasm extends to generative genomics’ potential. But with so many options to choose from, companies have to be strategic about which platforms they rely upon.</span></p>
<p><span>Danjuma Quarless, Senior Director of AI Innovation at Lilly Ventures gave the BIO 2026 panel insight on the industry’s decision-making process. Lilly Ventures, as the investment branch of biotech titan Eli Lilly, is tasked with “intersecting with the next great generation of biotechs” ahead of their rise to prominence. His strategy is to partner with as many promising developers as possible, a process which involves much speculation.</span></p>
<p><span>“I like to say that we are seed-planters, not tree buyers. We foster many small options without fear of redundancy.” </span></p>
<p><span>Rytlewski agreed, and explained why large companies are taking chances with early-stage models.</span></p>
<p><span>“One of key ideas is blended innovation: it’s not ‘build’ or ‘buy’ but partnering. It’s not uncommon for us to place multiple bets. It’s all about finding the right tool for the right ambition.”</span></p>
<p><span>This tactic of backing several developers at once is indicative of the optimism that established biotech companies have in generative genomics.</span> <span> It reflects the confidence that the industry will prove incredibly lucrative, and that it is better to pick the eventual winning companies early on.</span></p>
<p><span>“Most foundation models are in the ‘preclinical stage,’” said Jeff Leek, Co-CEO of Synthesize BIO, which is developing its own generative genomics model. “We are at the very beginning of the game.”</span></p>
<p><span>Much has been said about the ways AI will reshape the world, but its introduction into biotech could lead to unprecedented streamlining of the discovery to approval pipeline. And in biotech, time saved means lives saved.</span></p>
<p>The post <a href="https://bio.news/latest-news/bio-2026-generative-genomics-helps-biotechs-design-better-not-just-faster/">BIO 2026: Generative genomics helps biotechs design better, not just faster</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Protecting Scientific Intent in AI&#45;Enabled Labs by Not Letting AI Set the Mission</title>
<link>https://edusehat.com/en/protecting-scientific-intent-in-ai-enabled-labs-by-not-letting-ai-set-the-mission</link>
<guid>https://edusehat.com/en/protecting-scientific-intent-in-ai-enabled-labs-by-not-letting-ai-set-the-mission</guid>
<description><![CDATA[ Scientists see a positive trend toward using AI in a way that’s human, rather than as a self-driving lab. AI is simply a tool—albeit a  powerful, adaptive one.
The post Protecting Scientific Intent in AI-Enabled Labs by Not Letting AI Set the Mission appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2248539094.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 04:10:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Protecting, Scientific, Intent, AI-Enabled, Labs, Not, Letting, Set, the, Mission</media:keywords>
<content:encoded><![CDATA[<p>AI is neither saint nor demon. Nor should it be a replacement for human scientists. As AI takes on greater roles in designing, executing, and analyzing experiments and processes, scientists understand that even the best AI needs human supervision.</p>
<p>The big question is how much oversight is needed and whether—or the extent to which—AI interactions should be documented and reported in regulatory filings.</p>
<p><figure aria-describedby="caption-attachment-336813" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-full wp-image-336813" src="https://www.genengnews.com/wp-content/uploads/2026/08/Le-Cong-Stanford.jpg" alt="Le Cong, PhD" width="225" height="225" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Le-Cong-Stanford.jpg 225w, https://www.genengnews.com/wp-content/uploads/2026/08/Le-Cong-Stanford-150x150.jpg 150w" sizes="auto, (max-width: 225px) 100vw, 225px"><figcaption class="wp-caption-text">Le Cong, PhD, associate professor, Stanford University, and co-founder of LabOS and MedOS</figcaption></figure></p>
<p>Although the lab of the future may be envisioned as a self-driving lab, that’s actually a bad idea, noted Le Cong, PhD, associate professor, Stanford University, and co-founder of LabOS and MedOS. Instead, he and leaders in the AI and biopharmaceutical industries see the future of scientific AI as agentic, with humans in charge.</p>
<p>“We think there is a positive trend toward using AI in a way that’s human, rather than as a self-driving lab,” he said. In that environment, AI is simply a tool—albeit a powerful, adaptive one—that can be managed as long as scientists use the right prompts.</p>
<p></p><h4><strong>Humans in the lead</strong></h4>

<p>“Today, much of the scientific research process remains inaccessible to machines,” Cong and colleagues wrote in a recent <a href="https://www.preprints.org/manuscript/202608.0213">paper</a>. Despite automation and some use of AI, “Scientific discovery remains fragmented.” Specifically, AIs lack the tacit knowledge, evolving experimental context, human observations, and adaptive decision-making inherent in human scientists.</p>
<p>Human involvement is needed, therefore, not just to oversee AI-based activities and check the output, but to ask the right questions and to ensure that analyses make sense in context. Specifically, he describes a scientific setting in which an AI would handle an experiment’s execution, and the scientists would be responsible for:</p>
<ul>
<li>Framing objectives</li>
<li>Interpreting results</li>
<li>Setting constraints</li>
<li>Governing risks</li>
</ul>
<p>“If AI can interpret everything, then it will start to generate fake stuff, right?” Cong asks. “We’ve seen this when AIs begin guessing in an effort to return results and supply citations that don’t exist. There are certain things that are useful for AI to do in the lab.”</p>
<p>But, as last summer’s sandbox breakouts illustrated, an AI needs firm guidelines as to what it can do, where it can access information, and the degree of autonomy it has in meeting a request.</p>
<p>For example, he recommends adding this phrase to instructions: “Any actions not explicitly stated in the protocol need human approval.” That default to human judgment also should apply to determining the risks associated with certain actions, such as editing a human gene, Cong said. With those guardrails, the paper points out, agentic AIs can freely handle “routine execution and coordination across models, instruments, protocols, and laboratory states.”</p>
<p>Cong equates the scientific use of AI to autonomous vehicles, which, according to the Insurance Institute for Highway Safety, have a 68% lower <a href="https://www.iihs.org/news/detail/waymos-driverless-cars-crash-less-often-than-people">crash rate</a> per mile traveled than human drivers in the same environment. Given those statistics, he added, “My thought is to elevate humans to setting destinations. We do not need humans to always execute the driving.”</p>
<p>In a university scientific lab, that equates to staffing a principal investigator and trainees, without much of the hierarchy that exists today. In a corporate environment, the hierarchy flattens to scientists who propose, design, execute, and interpret experiments, and a lab manager. The distinctions between senior and junior scientists blur because much of the hands-on work is automated.</p>
<p>The combination of AI and lab automation is expected to reduce human errors. Cong cited a <a href="https://www.nature.com/articles/533452a">2016 Nature study</a> of 1,500 scientists. When asked, “’Can you replicate other people’s experiments, and can you replicate your own after a few months?’ approximately 70% could not replicate others’ experiments, and half could not replicate their own!” Cong said. “AI can improve that.”</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p><figure aria-describedby="caption-attachment-336818" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-336818" src="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-610584356-300x214.jpg" alt="autonomous car" width="300" height="214" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-610584356-300x214.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-610584356-588x420.jpg 588w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-610584356-696x497.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-610584356-100x70.jpg 100w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-610584356.jpg 700w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Cong equates the scientific use of AI to autonomous vehicles, which, according to the Insurance Institute for Highway Safety, have a 68% lower crash rate per mile traveled than human drivers in the same environment. Given those statistics, “My thought is, elevate humans to setting destinations,” said Cong. “We do not need humans to always execute the driving.” [Chesky_W/Getty Images]</figcaption></figure>Reasons for such poor reproducibility rest in the details, he elaborated. Was a step omitted? Was the protocol followed exactly? Is the protein being used identical to the one in the original experiment? Were the temperatures the same? Details like this—which AI can duplicate precisely—are behind many reproducibility challenges.</p>
<p></p><h4><strong>AI risks minimal</strong></h4>

<p>As yet, it’s unclear how AI involvement in experiments should be preserved and reported in regulatory submissions, Cong continued. “We’re still early in this journey.”</p>
<p>That said, the risk that AI will escape its constraints and cause physical harm—like designing and developing a physical virus—appears relatively low, according to Cong. That’s because a rogue AI still needs a human accomplice to allow a virus, for example, to be manufactured and released. “In areas where there is a physical execution step, I think AI is still incapable,” he said, “although we are seeing progress in connecting AI to biomedical labs and applications, and the physical execution layer.”</p>
<p>That’s due to the fact that there are multiple layers of human intervention needed to actually manufacture a product. Aside from logistics, he cites good manufacturing practices, safety and efficacy regulations, and digital safeguards like track and trace and the FDA’s 21 CFR Part 11, as well as real-time monitoring, periodic inspections, and quality control activities. Those regulations and checkpoints should also be sufficient to manage variations that occur during manufacturing as real-time conditions drift from specifications.</p>
<p>The catch, as last summer’s breakouts of frontier AIs underscore, is that sometimes AIs exceed their parameters. Whether there is sufficient appreciation of this among AI users remains to be seen, Cong said.</p>
<p>“A lot of people are connecting AI systems, which have access to more and more information and key decision-making systems,” Cong pointed out, without deeply understanding the risks and establishing appropriate guardrails. “People might be overly trusting of AI, perhaps.</p>
<p>“The more powerful the AI, the more capable it is of doing something. Are people keeping pace [with the technology and its risks]?”</p>
<p>Sometimes, small, highly specific AIs may be a better choice than always leveraging the large frontier models, Cong suggested. The reason, Cong, senior corresponding author Mengdi Wang, PhD, professor, Princeton University, and a dozen colleagues, noted in a 2025 <a href="https://www.nature.com/articles/s41551-025-01463-z">paper</a> in <em>Nature Biomedical Engineering,</em> is that “Large language models often lack domain-specific knowledge and struggle to accurately solve biological design problems.”</p>
<p>Whatever level of AI is used, however, “Humans need to be in the lead throughout the process,” Cong stressed.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/protecting-scientific-intent-in-ai-enabled-labs-by-not-letting-ai-set-the-mission/">Protecting Scientific Intent in AI-Enabled Labs by Not Letting AI Set the Mission</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Skull Immune Structures May Provide First Response Against Brain Cancer</title>
<link>https://edusehat.com/en/skull-immune-structures-may-provide-first-response-against-brain-cancer</link>
<guid>https://edusehat.com/en/skull-immune-structures-may-provide-first-response-against-brain-cancer</guid>
<description><![CDATA[ Researchers discovered lymph node-like structures in the skull bone marrow of mice for the first time and demonstrated that they act as rapid first responders against brain cancer, in advance of distant lymph nodes. 
The post Skull Immune Structures May Provide First Response Against Brain Cancer appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/04/Getty-Copilot_147218826_brain.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 04:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Skull, Immune, Structures, May, Provide, First, Response, Against, Brain, Cancer</media:keywords>
<content:encoded><![CDATA[<p>For decades, scientists assumed that the brain and the immune system did not communicate. A study by researchers at Washington University School of Medicine (WashU Medicine) in St. Louis has now revealed that the brain not only communicates with the immune system but also has positioned immune “security stations” nearby.</p>
<p>The team discovered lymph node-like structures in the skull bone marrow of mice for the first time and demonstrated that they act as rapid first responders against brain cancer before distant lymph nodes get the signal that abnormal cells are present. The researchers also found evidence of similar immune cells in human skull bone marrow. The study is the first to find such immune hubs in bone.</p>
<p>“This study reveals that the skull bone marrow is far more than just a structural framework—it harbors previously unrecognized hubs for brain-specific immune responses,” said Jonathan Kipnis, PhD, the Alan A. and Edith L. Wolff Distinguished Professor of Pathology & Immunology and a BJC Investigator at WashU Medicine. “Uncovering this localized immune niche changes how we view neuroimmune interactions and opens exciting new avenues for treating brain tumors and other neurological diseases.”</p>
<p>Kipnis is senior author of the researchers’ published paper in <em>Nature</em>, titled “<a href="https://doi.org/10.1038/s41586-026-10951-4" target="_blank" rel="noopener">Functional role of skull lymphoid structures in CNS immunosurveillance</a>.”</p>
<p>The Kipnis lab challenged the once widely accepted idea that the brain is shielded from the immune system when they discovered lymphatic vessels running through the dura mater, the outer tissue layer enveloping the brain underneath the skull. More recently, the team identified <a href="https://pubmed.ncbi.nlm.nih.gov/35301477/" target="_blank" rel="noopener">tiny physical channels bridging the skull, dura, and brain tissue</a>, revealing a direct conduit for immune cells and cellular waste to move between the brain and local skull bone marrow. “Recent findings reveal that channels between the skull and the dura mater facilitate the exchange of cerebrospinal fluid and immune cells between the CNS and skull bone marrow of mice under both homeostatic and disease conditions,” the authors wrote in their newly published paper in <em>Nature</em>.</p>
<p>However, they pointed out, while accumulating evidence demonstrates that the CNS is not disconnected from the peripheral immune system, “… precisely how the adaptive immune system surveils the CNS remains a critical question … Skull bone marrow functions as a source of immune cells for the CNS5, yet its role in CNS antigen-specific adaptive immune responses remains unclear.”</p>
<p>For their newly reported research in mice, the team tracked the movement of proteins from the brain through the channels directly into the skull’s bone marrow, where they uncovered immune-system structures typically found in the lymph nodes. These act as the immune system’s training hub where T follicular helper (T<sub>FH</sub>) immune cells assist B cells in creating large amounts of antibodies that help fight disease and infection. “…we demonstrate that the skull BM of mice contains cellular components that are characteristic of peripheral lymphoid organs,” they wrote. “We have never seen such structures in healthy bone marrow before,” said Jang Hyun Park, PhD, the study’s first author and a postdoctoral research fellow in the Kipnis lab who is starting his own lab at the Korea Advanced Institute of Science and Technology this year. “It is an exciting discovery that points out that a complex brain requires its own specialized immune structures to defend it.”</p>
<p><figure aria-describedby="caption-attachment-336852" class="wp-caption alignright"><img decoding="async" class="size-medium wp-image-336852" src="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_3-S1PR2-copy-1200-by-800-300x201.jpg" alt="Researchers at WashU Medicine discovered lymph node-like structures (cyan) in the skull bone marrow of mice that play a role in mounting a rapid immune response in the brain. [Jang Hyun Park]" width="300" height="201" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_3-S1PR2-copy-1200-by-800-300x201.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_3-S1PR2-copy-1200-by-800-628x420.jpg 628w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_3-S1PR2-copy-1200-by-800-696x465.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_3-S1PR2-copy-1200-by-800.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Researchers at WashU Medicine discovered lymph node-like structures (cyan) in the skull bone marrow of mice that play a role in mounting a rapid immune response in the brain. [Jang Hyun Park]</figcaption></figure>To test whether these nearby hubs actively protect against brain disease, the team used a model of glioblastoma, an aggressive form of brain cancer. They found that in mice with brain cancer, disrupting the skull immune hubs with a drug caused tumors to grow faster than in mice with intact hubs. Impairing their function caused a drop in survival, showing that the brain actively relies on these local centers for defense against cancer.</p>
<p>The researchers also developed a targeted therapy designed to supercharge antibody production inside the skull marrow. By delivering the mixture of the three immune-boosting proteins using a gel applied directly under the scalp, the researchers prompted a wave of tumor-fighting immune responses to attack the cancer. These responses, the research found, occurred first in the immune hubs in the skull bone marrow, then later in nearby lymph nodes outside the skull. Mice given the gel experienced better tumor rejection and lived longer compared with control mice. The collective data, the team wrote, “… indicate that skull-targeting CD40 agonism combined with administration of the IL-21 and IFNγ supports IgG responses in the skull BM and subsequently enhances intratumoural microglial, NK and CD8+ T cell anti-tumor responses while attenuating suppressive immune cells.”</p>
<p>Kipnis said, “The finding fundamentally changes our current understanding of neuroimmunology. Knowing that the brain relies on first responders in the surrounding skull for defense has the potential to change how we think about developing therapies for many neurological conditions, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, long COVID, and many others that have an immune component to them. Such therapies could access these immune hubs directly through the skull, without major peripheral side effects.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/skull-immune-structures-may-provide-first-response-against-brain-cancer/">Skull Immune Structures May Provide First Response Against Brain Cancer</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases</title>
<link>https://edusehat.com/en/scientists-analyze-267-receptors-that-control-protein-fate-in-rare-diseases</link>
<guid>https://edusehat.com/en/scientists-analyze-267-receptors-that-control-protein-fate-in-rare-diseases</guid>
<description><![CDATA[ Cells constantly control the fate of their proteins. They remove proteins that are worn out or no longer needed, but can also alter their activity, localization, or interactions with other molecules. 
The post Scientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2254461523.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 04:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scientists, Analyze, 267, Receptors, That, Control, Protein, Fate, Rare, Diseases</media:keywords>
<content:encoded><![CDATA[<p>Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) say they have created the first systematic catalog of the substrate receptors of cullin–RING ligases and analyzed how their genetic variants may translate into disease symptoms. Their review article “<a href="https://www.sciencedirect.com/science/article/pii/S0962892426000036">Cullin-RING receptors in rare disease biology</a>” appears in <em>Trends in Cell Biology</em>.</p>
<p><figure aria-describedby="caption-attachment-336855" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-336855" src="https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-200x300.jpg" alt="Wojciech Pokrzywa, PhD [IIMCB]" width="200" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-200x300.jpg 200w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-683x1024.jpg 683w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-768x1152.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-1024x1536.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-1365x2048.jpg 1365w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-280x420.jpg 280w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-560x840.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-696x1044.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-1392x2088.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa-1068x1602.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Prof-Pokzywa.jpg 1600w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Wojciech Pokrzywa, PhD [IIMCB]</figcaption></figure>“In rare diseases, we often identify a variant in a particular gene without immediately understanding its biological consequences. Our work shows that when such a variant affects a substrate receptor, it can disrupt protein recognition, impair the ligase complex, or disturb other cellular processes important for the organism’s development and function. This makes it easier to connect a genetic change with the disease mechanism and understand why it leads to particular symptoms,” said Wojciech Pokrzywa, PhD, head of the laboratory of protein metabolism at IIMCB.</p>
<p>Cells constantly control the fate of their proteins. They remove proteins that are worn out or no longer needed, but can also alter their activity, localization, or interactions with other molecules. The ubiquitin–proteasome system plays a key role in this process. Its enzymes tag selected proteins with ubiquitin, which acts as a molecular label. Depending on the type of tag, a protein may be directed for degradation by the proteasome—the cell’s molecular “shredder”—or subjected to another form of regulation.</p>
<p>Cullin–RING ligases belong to the largest family of E3 enzymes responsible for attaching these tags. Their precision depends on substrate receptors, which recognize the specific proteins that the ligase acts upon. The IIMCB scientists focused their work on the role of these receptors in genetic diseases.</p>
<p>The authors combined data on receptors’ function, tissue expression, and associations with different types of disease. They found that neurodevelopmental and neuromuscular symptoms are particularly common in diseases linked to these receptors, even though most of the receptors do not clearly show tissue-specific expression.</p>
<p>Their analyses therefore indicate that the clinical presentation cannot be explained solely by the sites of protein expression. Instead, other important factors may include the substrates they recognize, gene activity at different stages of development, the vulnerability of particular cell types, gene dosage, and the effect of a specific variant on the function of the entire cullin–RING ligase complex.</p>
<p></p><h3><strong>267 receptors, 93 linked to genetic diseases  </strong></h3>

<p>“We created the first systematic catalog of 267 cullin–RING ligase substrate receptors, 93 of which have already been linked to genetic diseases. This resource can serve as a reference point for research into rare diseases and the ubiquitin–proteasome system,” noted Natalia Szulc, a PhD student in the laboratory of protein metabolism at IIMCB and the first author of the article.</p>
<p>“It can help identify further potential disease genes and interpret variants detected in patients. It also facilitates studies into why different mutations in the same gene can produce different symptoms and disease courses. The catalog may also help reconstruct networks of relationships between receptors, their substrates, and other ligases, which is important for understanding why cells can sometimes compensate for the effects of a mutation, while in other cases disease develops.”</p>
<p>Targeted protein degradation is now an important direction in the development of new therapies, Pokrzywa added.</p>
<p>“Rare diseases show how precisely the ubiquitin–proteasome system must operate: altering a single component can have serious consequences that emerge only in particular tissues or at specific stages of development,” Szulc said.</p>
<p>“By analyzing variants found in patients, we can better understand which features of substrate receptors determine the function of cullin–RING complexes, which substrate interactions might be amenable to modulation, and where the limitations of therapies based on targeted protein degradation may lie. This provides valuable guidance for designing safer and more precise therapeutic strategies,” said Pokrzywa.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/scientists-analyze-267-receptors-that-control-protein-fate-in-rare-diseases/">Scientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Is Targeted Protein Degradation the “Break” Neurology Needs?</title>
<link>https://edusehat.com/en/is-targeted-protein-degradation-the-break-neurology-needs</link>
<guid>https://edusehat.com/en/is-targeted-protein-degradation-the-break-neurology-needs</guid>
<description><![CDATA[ In this webinar, 
The post Is Targeted Protein Degradation the “Break” Neurology Needs? appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_1170994090_DeathOfNeurons.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 04:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Targeted, Protein, Degradation, the, “Break”, Neurology, Needs</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/AngelaCacace_headshot.jpg" class="h-full w-full object-cover" alt="Image of Angela M. Cacace, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Angela M. Cacace, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Chief Scientific Officer<br>Arvinas</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/AngelaCacace_headshot.jpg" alt="Image of Angela M. Cacace, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Angela M. Cacace, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Dr. Angela Cacace serves as Chief Scientific Officer (CSO) at Arvinas. Prior to her role as CSO, Dr. Cacace most recently served as our Senior Vice President, Neuroscience and Platform Biology. Dr. Cacace has three decades of drug discovery experience in neuroscience and oncology research across modalities. During her time at Arvinas, Dr. Cacace has led the continuous evolution of our PROTAC Discovery Engine to employ new E3 ligases and cross the blood-brain barrier for multiple neurologic disease targets.</p>
<p>Previously, Dr. Cacace served as the Vice President of Biology at Fulcrum Therapeutics, where she built the biology platform, grew talented scientific teams, delivered the first development candidates, and guided the development of translational biomarkers to enable clinical development programs.</p>
<p>Additionally, Dr. Cacace served in positions of increasing responsibility at Bristol Myers Squibb, including as the Director of Neuroscience and Genetically Defined Diseases, where she spearheaded alternative therapeutic modalities and was a co-inventor on several development candidates. Throughout her time at Bristol Myers Squibb, she was responsible for building research-wide teams and initiatives, including the Lead Discovery and Optimization functions. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer, together with her team, she discovered a novel anti-angiogenic antibody development candidate. Dr. Cacace currently serves on the Board of Directors for BioCT.</p>
<p>Dr. Cacace received her B.S. in Biology from Fairfield University, Ph.D. in Pharmacology from Columbia University and completed her postdoctoral research in Oncology at Bristol Myers Squibb and the National Cancer Institute.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, October 1, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-10-01T15:00:00.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Neurodegenerative diseases have long challenged researchers developing treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative conditions. Small‑molecule inhibitors have shown limited clinical benefit, amyloid‑beta–focused approaches address only one of many underlying disease drivers, and repeated late‑stage failures have underscored the biological complexity of these disorders.</p><p></p><p></p><p class="wp-block-paragraph">Within this landscape, the emergence of LRRK2 protein degraders and early data to date have reignited optimism—particularly as biomarker science begins to clarify which patients may benefit most. Learn more about the increasing rationale for targeting LRRK2 with PROTAC degraders and how protein degradation may enable deeper, more precise modulation of disease biology and open new avenues across neurodegenerative diseases.</p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-full is-resized"><a href="https://www.arvinas.com/" target="_blank" rel=" noreferrer noopener"><img fetchpriority="high" decoding="async" width="1197" height="416" src="https://www.genengnews.com/wp-content/uploads/2026/08/Arvinas_Logo_blue-e1787250070368.jpg" alt="Arvinas logo" class="wp-image-336870" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Arvinas_Logo_blue-e1787250070368.jpg 1197w, https://www.genengnews.com/wp-content/uploads/2026/08/Arvinas_Logo_blue-e1787250070368-300x104.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Arvinas_Logo_blue-e1787250070368-1024x356.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Arvinas_Logo_blue-e1787250070368-768x267.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Arvinas_Logo_blue-e1787250070368-696x242.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Arvinas_Logo_blue-e1787250070368-1068x371.jpg 1068w" sizes="(max-width: 1197px) 100vw, 1197px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/is-targeted-protein-degradation-the-break-neurology-needs/">Is Targeted Protein Degradation the “Break” Neurology Needs?</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>AI Identifies Pre&#45;existing Antimicrobial Antibody Profile That May Predict Immune Response to Vaccination</title>
<link>https://edusehat.com/en/ai-identifies-pre-existing-antimicrobial-antibody-profile-that-may-predict-immune-response-to-vaccination</link>
<guid>https://edusehat.com/en/ai-identifies-pre-existing-antimicrobial-antibody-profile-that-may-predict-immune-response-to-vaccination</guid>
<description><![CDATA[ Researchers analyzing antibody profiles in thousands of individuals have discovered that pre-existing antibodies to common microbes can predict the strength of new vaccine responses.
The post AI Identifies Pre-existing Antimicrobial Antibody Profile That May Predict Immune Response to Vaccination appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_labaer-cell-press-asu-banner.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 21 Aug 2026 04:10:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Identifies, Pre-existing, Antimicrobial, Antibody, Profile, That, May, Predict, Immune, Response, Vaccination</media:keywords>
<content:encoded><![CDATA[<p>Researchers analyzing antibody profiles in thousands of individuals have discovered that pre-existing antibodies to common microbes can predict the strength of new vaccine responses. The Arizona State University (ASU) team measured antibodies against 185 antigens—including those from common viruses, bacteria, and targets associated with autoimmune diseases—in blood samples from 4,000 immunosuppressed and healthy individuals.</p>
<p>The researchers then used artificial intelligence to analyze antibody patterns in samples collected before and after COVID-19 vaccination, identifying antibody signatures that helped distinguish strong vaccine responders from weak ones. In particular, they found that pre-existing antibodies to common microbes consistently predicted post-vaccination antibody responses in both healthy and immunosuppressed individuals.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>These “sentinel antibodies,” the researchers suggest, may represent biomarkers of immune responsiveness to vaccination. “What our study found is that certain biomarkers, when analyzed with AI, can predict who is likely to respond well to a vaccine, even before they receive it,” said study lead Joshua LaBaer, PhD, executive director of the Biodesign Institute at ASU and director of the Virginia G. Piper Center for Personalized Diagnostics. “This suggests that some people may be more immune-ready than others.”</p>
<p>The team’s approach is one of the first to use a broad, pre-vaccine antibody “fingerprint” to assess immune readiness. Unlike some prediction methods that rely on genetic analyses, this strategy uses antibody patterns in blood, which may be easier to adapt for clinical use.</p>
<p>LaBaer and colleagues reported their findings in <em>Cell Press Blue</em>, in a paper titled “<a href="https://doi.org/10.1016/j.cpblue.2026.100088" target="_blank" rel="noopener">Pre-vaccine sentinel antibodies predict blunted vaccine responses</a>,” stating that their results “… identify pre-existing antimicrobial antibody profiles as scalable biomarkers of humoral immune responsiveness and provide a framework for predicting vaccine responses before immunization.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Vaccines protect most people from serious illness, but the strength of that protection can vary considerably from one person to another. Before a vaccine ever enters the body, the immune system may already hold clues to how strongly it will respond. Age, sex, genetics, prior illnesses, and underlying health conditions have all been linked to how strongly people respond to vaccines. People with immune-compromising conditions are often at higher risk of weaker responses. But even within these groups, outcomes can differ sharply.</p>
<p>Usually, scientists evaluate vaccine response after the shot has been given by measuring whether the immune system has produced antibodies against the target. For their newly reported study, LaBaer and team asked whether antibody patterns already present in the blood might predict an individual’s immune readiness and response to vaccination.</p>
<p>The team looked at antibody responses to 185 antigens, including SARS-CoV-2 antigens, other common viral and bacterial antigens, and targets associated with autoimmune diseases. To do this, the researchers analyzed 8,687 samples from 4,089 participants, including 2,445 healthy volunteers and 1,644 people with conditions or treatments linked to immune suppression, such as HIV, multiple myeloma, solid organ malignancy, autoimmune disease, inflammatory bowel disease, and solid organ transplantation.</p>
<p>They found that several immunosuppressed groups were more likely to have blunted responses to COVID-19 vaccination. But those categories were imperfect predictors. Some immunosuppressed participants mounted strong responses, while about 5% to 6% of healthy participants demonstrated weak responses. The results did find that higher levels of certain preexisting antibodies, including antibodies to common bacteria and viruses, such as<em> Staphylococcus aureus</em>, respiratory syncytial virus, and human respirovirus 3, were associated with stronger COVID-19 vaccine responses.</p>
<p>The researchers describe these as “sentinel” antibodies because they may indicate a person’s baseline immune readiness. They are not necessarily fighting the vaccine target directly. Instead, they may reflect how responsive the antibody-producing arm of the immune system is likely to be. “These broadly prevalent antimicrobial antibodies represent sentinel antibodies that may serve as biomarkers of system-level humoral immune competence,” the team stated.</p>
<p>The researchers then asked whether the full antibody fingerprint, not just a few individual markers, could help identify people likely to have weak vaccine responses. A deep-learning model analyzed patterns across the antibody panel, combining measurements into a broader immune profile. “Using global antimicrobial antibody profiles, we developed a deep-learning predictive model that stratified individuals according to their likelihood of mounting blunted vaccine responses,” they explained.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The study highlights a key strength of AI in health research: its ability to find subtle, predictive patterns in millions of biological data points that might otherwise remain hidden. The approach suggests that vaccine readiness may be better understood by looking at the immune system as a whole, rather than focusing only on a single disease or a single antibody.</p>
<p>The work also highlights the value of newer technologies that can measure large numbers of antibody responses at once. Instead of asking whether someone has antibodies to one pathogen, the method can scan a wider immune landscape, capturing patterns formed by many previous encounters with viruses, bacteria, and other immune targets.</p>
<p>The researchers say the findings could have implications beyond COVID-19 if they are validated in additional studies and with other vaccines. Sentinel antibody profiling could help guide vaccine testing, vaccine development, and clinical care for people at risk of weak immune responses. “Together, these findings identify pre-existing antimicrobial antibody profiles as scalable biomarkers of humoral immune responsiveness and provide a framework for predicting vaccine responses before immunization,” the authors wrote in summary.</p>
<p>The approach might eventually help doctors identify patients who need additional vaccine doses, closer follow-up, or alternative protective measures. It could also help researchers better understand why some people respond well to vaccination while others do not. The work points toward a future in which vaccine decisions could be guided by a person’s own immune readiness.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/ai-identifies-pre-existing-antimicrobial-antibody-profile-that-may-predict-immune-response-to-vaccination/">AI Identifies Pre-existing Antimicrobial Antibody Profile That May Predict Immune Response to Vaccination</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Built Without Bacteria: Bringing Cell&#45;Free Synthesis to the Bench</title>
<link>https://edusehat.com/en/built-without-bacteria-bringing-cell-free-synthesis-to-the-bench</link>
<guid>https://edusehat.com/en/built-without-bacteria-bringing-cell-free-synthesis-to-the-bench</guid>
<description><![CDATA[ In this GEN webinar, speakers from Flock Bio and Ribbon Bio will explore how bench-based, cell-free DNA production can complement expertise in custom DNA design and manufacturing.
The post Built Without Bacteria: Bringing Cell-Free Synthesis to the Bench appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_2277447646_DNADoubleHelix.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 21:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Built, Without, Bacteria:, Bringing, Cell-Free, Synthesis, the, Bench</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/MatthewYoungblut_headshot.jpg" class="h-full w-full object-cover" alt="Image of Matthew D. Youngblut, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Matthew D. Youngblut, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Co-founder and Chief Scientific Officer<br>Flock Bio</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/MatthewYoungblut_headshot.jpg" alt="Image of Matthew D. Youngblut, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Matthew D. Youngblut, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Matthew Youngblut, PhD, is the co-founder and CSO of Flock Bio, where he leads the development of high-quality DNA library technologies for protein engineering, genetic medicines, crop science, and synthetic biology. His work focuses on solving the practical challenges that sit between library design and useful experimental data, including DNA synthesis, cloning bias, barcoding, library assembly, and NGS-based quality control. Prior to Flock Bio, Matthew worked across synthetic biology and DNA technology at companies including Ginkgo Bioworks and Twist Bioscience.</p>
<p>Matthew holds a PhD in chemistry from the University of Wisconsin-Milwaukee and has spent his career developing and applying high-throughput molecular biology technologies to make biological experimentation more scalable and quantitative.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/DivyaVijayPratheek_headshot.jpg" class="h-full w-full object-cover" alt="Image of Divya Vijay Pratheek">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Divya Vijay Pratheek</h2>
                <h5 class="mt-0 !text-[15px]">Vice President of Product<br>Ribbon Bio </h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/DivyaVijayPratheek_headshot.jpg" alt="Image of Divya Vijay Pratheek">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Divya Vijay Pratheek</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Divya Vijay Pratheek is the Vice President of Product at Ribbon Bio. She played a pivotal part leading the launch of the MiroMine product to ensure laboratories can access cell-free DNA synthesis at their bench. She previously had impactful roles at QIAGEN and various startups, where she led cross-functional teams and managed product portfolios and growth strategies for large portfolios across automation, reagents, and software.</p>
<p>Divya holds a BS degree in microbiology, zoology, and chemistry from Mount Carmel College, Bangalore, and an MS in Communications Science from North Carolina State University.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, September 10, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-09-10T15:00:00.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">Complex DNA workflows are often slowed by bacterial cloning, challenging genome sequences, and lengthy production cycles. A technology that brings cell-free DNA synthesis directly to the bench would give researchers an accessible, on-demand way to build high-fidelity DNA sequences without bacteria. Such an approach is now offered by Ribbon Bio’s MiroMine<sup>TM</sup>: this helps avoid bacterial contaminants such as endotoxins and host-cell DNA, while supporting complex or sensitive sequences that can be difficult to produce through conventional cloning.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, speakers from Flock Bio and Ribbon Bio will explore how bench-based, cell-free DNA production can complement expertise in custom DNA design and manufacturing. Drawing on applications including CRISPR screening, enzyme evolution, lineage tracing, and massively parallel reporter assays (MPRAs), they will discuss how MiroMine<sup>TM</sup> can reduce dependence on conventional cloning, shorten production cycles, and give researchers greater control and confidentiality. Attendees will learn how accessible cell-free synthesis can accelerate the path from design to experiment and enable cleaner, faster, and more flexible research workflows.</p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-large is-resized"><a href="https://ribbonbio.com/" target="_blank" rel=" noreferrer noopener"><img fetchpriority="high" decoding="async" width="1024" height="330" src="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1024x330.jpg" alt="Ribbon Bio logo" class="wp-image-336834" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1024x330.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-300x97.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-768x247.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1536x495.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1303x420.jpg 1303w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-696x224.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1392x449.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB-1068x344.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/RibbonBio_logo_primary_RGB.jpg 1921w" sizes="(max-width: 1024px) 100vw, 1024px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/built-without-bacteria-bringing-cell-free-synthesis-to-the-bench/">Built Without Bacteria: Bringing Cell-Free Synthesis to the Bench</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Connecting more patients with psoriasis to the care they need</title>
<link>https://edusehat.com/en/connecting-more-patients-with-psoriasis-to-the-care-they-need</link>
<guid>https://edusehat.com/en/connecting-more-patients-with-psoriasis-to-the-care-they-need</guid>
<description><![CDATA[ For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation […]
The post Connecting more patients with psoriasis to the care they need appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/pexels-ron-lach-8624600.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 06:20:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Connecting, more, patients, with, psoriasis, the, care, they, need</media:keywords>
<content:encoded><![CDATA[<p>For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation (NPF) set out to understand why progress in treatment has not consistently translated into progress in patients’ lives.</p>
<p><em>Bio.News sat down with Katie Southwick, Vice President of Marketing & Communications at NPF to discuss their research on unreached patient populations and the lived experiences shaping their decisions.</em></p>
<h5>Tell us more about your research on unreached patient populations. What inspired it? Why is there such a great need for this research?</h5>
<p>There has been tremendous progress in psoriatic disease treatments. Today, patients are surrounded by messaging about the disease and new treatment options, whether on television, social media, or online. Despite that visibility, a significant portion of people living with psoriatic diseases remain undiagnosed or are still not taking advantage of modern treatment options. That disconnect led us to ask a simple question: <em>Why?</em></p>
<p>As we dug deeper, we found that out-of-pocket cost and concerns about side effects were certainly a big driver. Importantly, we found that patients’ lived experiences often have a great impact on whether they continue engaging with the healthcare system. Negative encounters with healthcare providers, feeling dismissed, feeling unheard, or becoming discouraged after unsuccessful treatments can all influence future decisions about seeking care.</p>
<p>The need for this research is substantial. There are approximately 8 million people living with psoriatic disease in the United States, and another roughly 600,000 remain undiagnosed. Not managing psoriasis often leads to soaring health care expenses, productivity losses, and expensive long-term medical comorbidities such as cardiovascular disease or diabetes. Yet, many patients have no formal care plan or lack access to specialist care, particularly in rural communities. Understanding <em>why</em> patients disengage is essential if we want advances in treatment to translate into better outcomes for patients.</p>
<h5>Your research suggests that the biggest barrier to care is “patient momentum.” Can you explain what this means?</h5>
<p>Our research showed that many patients become stuck in what we call a “doom loop.”</p>
<p>Living with a psoriatic disease can be exhausting. Symptoms affect physical health, mental health, confidence, relationships, and daily routines. Over time, patients may experience frustration with the healthcare system, disappointment with not immediately finding the right treatment option that works best for them, or feelings of hopelessness. All of those factors build on one another and make it harder to take the next step toward care.</p>
<p>“Patient momentum” is really about helping people move forward again. Effective engagement is not simply telling someone there is a new treatment available. It is helping them believe that things can improve, that support exists, and that they do not have to continue struggling alone.</p>
<h5>The study found that patients often settle into a “good enough” mindset, managing symptoms without seeking better outcomes. What are the risks of this approach?</h5>
<p>Psoriasis is not just a skin condition. It is a chronic, systemic immune-mediated disease that can have serious long-term consequences when left inadequately managed.</p>
<p>When patients settle for “good enough,” they may not realize they are still at risk for disease progression and related health complications. For some individuals, that can mean the development or worsening of psoriatic arthritis, which can cause irreversible joint damage if not treated appropriately. Psoriatic disease is also associated with several comorbid conditions that can affect overall health and quality of life.</p>
<p>That is why one of our key messages is that <em>good enough is not actually good enough</em>. We want patients to understand that better outcomes are possible, and that staying engaged in care can help reduce the risk of more serious issues down the road.</p>
<h5>What role does trust play in keeping patients engaged in care?</h5>
<p>Trust is everything.</p>
<p>Patients are navigating an overwhelming amount of information today, and it is often difficult to determine what is evidence-based and what is not.</p>
<p>Organizations like NPF play an important role because patients need trusted sources of information and guidance. We work alongside leading clinicians, researchers, and patient advocates to help connect people with credible resources and support.</p>
<p>Trust also means recognizing that every patient’s journey is different. The same treatment approach does not work for everyone. Patients want to be seen, heard, and respected in their decision-making. Building that trust is critical to helping people move toward optimal care.</p>
<h5>What needs to happen next to ensure that advances in treatment translate into action for the patients who remain disengaged from care?</h5>
<p>Patients need to be met where they are. Disengaged patients are not necessarily choosing to ignore their disease. Many have experienced setbacks that have slowed their momentum. By listening to patients, validating their experiences, and demonstrating that better outcomes are possible, we can help more people move beyond the doom loop and toward a healthier future. The encouraging reality is that today’s treatments, combined with trusted support and education, can make a meaningful difference.</p>
<p>August is Psoriasis Action Month. NPF has launched our <a href="https://www.psoriasis.org/psoriasis-action-month/"><em>Is This a Thing</em></a> campaign, which has the goal of empowering patients through education on psoriasis and validation that: “No matter what this disease does to make you ask: Is this a thing? The answer is typically: Yes, this is psoriasis.</p>
<p>NPF has also recently launched our <a href="https://www.psoriasis.org/milestones-to-a-cure-rfp/">Milestones to a Cure</a> initiative<em>. </em>As part of this initiative, NPF is investing in innovative research designed to accelerate progress toward a cure for psoriatic disease. This funding opportunity will support researchers pursuing transformative, high-impact projects aimed at advancing our understanding of disease mechanisms, improving treatment approaches, and ultimately bringing us closer to a cure.</p>
<p><em>If you are interested in learning more about NPF and Psoriasis Action Month, visit</em> <a href="https://www.psoriasis.org/psoriasis-action-month"><em>https://www.psoriasis.org/psoriasis-action-month</em></a><em>. Letters of intent for Milestones to a Cure are due Aug. 31. You can learn more here:</em> <a href="https://www.psoriasis.org/milestones-to-a-cure-rfp/"><em>https://www.psoriasis.org/milestones-to-a-cure-rfp/</em></a></p>
<p><em>Additionally, if you are a patient advocate, consider registering for the Biotechnology Innovation Organization’s </em><a href="https://pace.bio.org/"><em>Patient Advocacy Changemakers Event (PACE)</em></a><em>: an empowering and inspiring event focused on breaking barriers to access and ensuring that innovative medicines reach the patients who need them.</em></p>
<p>The post <a href="https://bio.news/health/connecting-more-patients-with-psoriasis-to-the-care-they-need/">Connecting more patients with psoriasis to the care they need</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rare Immune Cell Type in Supercentenarians May Help Maintain Healthy Aging</title>
<link>https://edusehat.com/en/rare-immune-cell-type-in-supercentenarians-may-help-maintain-healthy-aging</link>
<guid>https://edusehat.com/en/rare-immune-cell-type-in-supercentenarians-may-help-maintain-healthy-aging</guid>
<description><![CDATA[ Researchers studying immune cells in Japanese supercentenarians have found that normally rare, CD4 cytotoxic T lymphocytes become increasingly abundant with extreme age, and may help to stave off cancer.
The post Rare Immune Cell Type in Supercentenarians May Help Maintain Healthy Aging appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2021/11/GettyImages-1056771278-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 06:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rare, Immune, Cell, Type, Supercentenarians, May, Help, Maintain, Healthy, Aging</media:keywords>
<content:encoded><![CDATA[<p>Aging is accompanied by an increased risk of certain diseases, alongside weakened immunity to illnesses that younger individuals might easily overcome. This has raised an important question for researchers, which is why do some people live to a very old age while avoiding major diseases?</p>
<p>The results of research by a team at Osaka University studying Japanese supercentenarians aged 110 years and older, now suggest that a rare type of immune cell known as CD4 cytotoxic T lymphocytes, or CD4 CTLs, becomes increasingly abundant with extreme age. These rare cells have the ability to both recognize threats and destroy dangerous cells.</p>
<p>“Immune aging is not simply a process of decline,” said Kosuke Hashimoto, PhD, an associate professor at the University of Osaka in Japan. “The selective expansion of certain T cells suggests that, even in extreme old age, the immune system may continue to adapt to age-related challenges … CD4 CTLs are an atypical and relatively rare T cell population. So their marked increase in supercentenarians may provide important clues as to how the immune system is maintained in extreme old age.”</p>
<p>Hashimoto is first author of the researchers’ published paper in <em>Cell Reports</em>, titled “<a href="http://dx.doi.org/10.1016/j.celrep.2026.117728" target="_blank" rel="noopener">CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging</a>,” in which they say that their collective findings “… suggest that CD4 CTLs expand and diversify as an adaptation to persistent antigens, potentially contributing to longevity through cancer suppression.”</p>
<p>While maintaining good health as we age is important, it is also difficult, considering that the risk of certain diseases increases with age, alongside weakened immunity to some illnesses. “Aging is an inevitable biological process, characterized by gradual declines in physical and cognitive functions. This process is driven by the accumulation of molecular and cellular alterations, including DNA mutations, mitochondrial dysfunction, and cellular senescence,” the authors wrote.</p>
<p>Among the various changes that occur at the cellular and molecular level, the team continued, “… aging of the immune system compromises its ability to defend against external pathogens and eliminate internal abnormal cells such as precancerous or senescent cells, increasing the risk of various diseases.”</p>
<p>This has raised an important question for researchers: why do some people live to a very old age while avoiding major diseases? Aging itself is not a disease, they commented, nor does it necessarily lead to the failure of essential physiological systems.</p>
<p>“Supercentenarians—individuals who live to or beyond 110 years—provide a model of healthy aging, achieving longevity while avoiding or delaying major age-related diseases such as cardiovascular disorders and cancer,” the investigators commented. “They maintain immune, cardiovascular, and epigenomic profiles that appear younger than expected for their chronological age.”</p>
<p>One class of immune cells, T cells, is traditionally divided into two groups: helper cells that coordinate immune responses and killer cells that destroy infected or cancerous cells. However, supercentenarians accumulate an unusual hybrid known as CD4 cytotoxic T lymphocytes, or CD4 CTLs. “Our previous study identified CD4 cytotoxic T lymphocytes (CD4 CTLs) as a hallmark of supercentenarians,” the team stated. These rare cells have the ability to both recognize threats and destroy dangerous cells. “CD4 CTLs are an atypical and relatively rare T cell population,” Hashimoto said. “So, their marked increase in supercentenarians may provide important clues as to how the immune system is maintained in extreme old age.”</p>
<p>To understand exactly how rare these hybrid cells are, the scientists analyzed blood samples of 28 adults who had been divided into three age groups: 70–99 years, 100–109 years, and 110 years and older. “In this study, we conducted integrated single-cell profiling of T cells, combining transcriptome, surface protein, and TCR sequence data across different age groups, including rare cohorts of centenarians and supercentenarians,” the investigators explained.</p>
<p>They found that the proportion of CD4 CTLs increased with age, with median percentages of 4%, 9.6%, and 17.6%, respectively. The hybrid cells remained uncommon throughout most of life, but were found to expand dramatically around the age of 100. In supercentenarians, these cells made up nearly one-fifth of all T cells in the blood, whereas they only comprised about 4% of total cells in the younger study participants. “We analyzed a rare cell population that is enriched in supercentenarians and found signs of immune remodeling in extreme old age,” said Hashimoto. “Rather than showing signs of exhaustion, they remain highly active and may help the body cope with persistent threats that increase with age.”</p>
<p>While the study findings suggest CD4 CTL expansion begins around 100, this phenomenon was not unique to centenarians and supercentenarians; one participant younger than 100 had the highest proportion of these cells. The team then looked at participants’ T cell receptors and determined that clonal expansion helps drive this increase. CD4 CTLs clone themselves when the immune system is under attack. The newly reported study found that the most prominent clone accounted for an average of 33.3% of CD4 CTLs, indicating that older adults may be responding to persistent immune threats. In one centenarian’s blood sample, a single clone accounted for 53.8% of their CD4 CTLs.</p>
<p>Next, the researchers matched the receptor sequences of each participant’s top CD4 CTL clone to those in a public database. Nearly three dozen matches belonged to people with cancer—namely lung, breast, and liver cancers. Because none of the centenarians or supercentenarians studied had been diagnosed with these cancers, the researchers theorized that their CD4 CTL expansion may reflect early immune responses. “Some CD4 CTLs may recognize cancer-related targets, although their exact targets remain unknown,” Hashimoto said. “The similarity between these receptor sequences and those found in T cells from tumors suggests that these cells may help recognize tumors before they become clinically detectable. It may be that immune changes in extreme old age are better understood as the immune system reorganizing itself rather than just wearing out.”</p>
<p>The study, which focused on T cells circulating in the blood, does not prove that having an abundance of CD4 CTLs prevents cancer or causes a person to live longer. However, the findings provide one of the clearest pictures yet of how the immune system adapts in people who achieve exceptional lifespans, offering insight into healthy aging and potentially contributing to protection against disease in supercentenarians.</p>
<p>“Our results revealed that CD4 CTLs expand with age and exhibit plasticity in cytokine production,” the team wrote in summary. “This suggests that CD4 CTLs may contribute to cancer suppression and longevity through adaptive responses to persistent antigens, emphasizing their role in immune resilience and healthy aging.”</p>
<p>Hashimoto noted that the team’s next step is to research how these cells behave in human tissues. “As we age, abnormal cells, including senescent and cancerous cells, become more common,” Hashimoto stated. “Our findings suggest that immune adaptation to these changes may contribute to exceptional longevity.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/abundance-of-rare-immune-cell-type-in-supercentenarians-may-help-maintain-healthy-aging/">Rare Immune Cell Type in Supercentenarians May Help Maintain Healthy Aging</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human Multi&#45;Organ Chip Offers New Insight Into Cancer Metastasis</title>
<link>https://edusehat.com/en/human-multi-organ-chip-offers-new-insight-into-cancer-metastasis</link>
<guid>https://edusehat.com/en/human-multi-organ-chip-offers-new-insight-into-cancer-metastasis</guid>
<description><![CDATA[ A human multi-organ chip models how breast cancer spreads from blood vessels to bone and lung, offering a patient-specific tool to study metastasis and potential treatments.
The post Human Multi-Organ Chip Offers New Insight Into Cancer Metastasis appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 06:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, Multi-Organ, Chip, Offers, New, Insight, Into, Cancer, Metastasis</media:keywords>
<content:encoded><![CDATA[<p>Cancer metastasis is responsible for at least two-thirds of cancer deaths. Drugs targeting the metastatic progression have largely failed, in part due to the lack of predictive models that would help identify the underlying mechanisms of metastasis.</p>
<p>Now, new work reports the development of a multi-organ chip that mimics how cancer cells spread from vascular flow to distant organs—the first model of cancer metastasis of its kind. The chip includes compartments with millimeter-sized engineered human bone and lung tissues, and the vascular flow that contains circulating breast cancer cells and allows the dynamic cross-talk of the tissues being colonized.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“The key advantages of this advanced model of metastasis are that it is human and can be patient-specific,” said Gordana Vunjak-Novakovic, PhD, university professor and professor of biomedical engineering and professor of medical sciences at Columbia University. “It faithfully mimics some of the key aspects of human metastasis that are otherwise largely inaccessible for direct study.”</p>
<p>This work is published in <em>Science Translational Medicine</em> in the paper, “<a href="https://www.science.org/doi/10.1126/scitranslmed.adv6871">Organ-specific colonization and niche remodeling in a human tissue model of metastasis</a>.”</p>
<p>“The pressing need for developing human tissue models of metastasis has been a key motivation for our study,” said Vunjak-Novakovic. “Our objective was to probe the ability of cancer cells to adhere to and traverse across endothelium [inner lining of blood vessels], and to determine their capacity to survive in the tissues they are colonizing through cell reprogramming and niche remodeling.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The study sheds light on a critical phase of metastasis, known as organ colonization, which is difficult to study using animal models. The process is highly complex, requiring the cancer cells to evade tissue defense and adapt to the specific organs they invade.</p>
<p>The multi-organ chip allows scientists to investigate, in detail, metastatic progression with patient cells and tissues. The platform enables controlled experimentation of cancer cell-tissue interactions within organ-specific microenvironments, toward revealing molecular pathways and therapeutic targets for metastasis.</p>
<p>To demonstrate the chip’s capabilities, the team examined the colonization of circulating human breast cancer cells in bone and lung. Bone and lung, common sites of metastasis for breast cancer, and the vascular endothelium were engineered from induced pluripotent stem cells (iPSCs) using tissue-specific scaffold-bioreactor culture systems. The engineered tissues were maintained in individual compartments of the chip, which were each optimized for tissue maturation and long-term maintenance of functionality, and linked to each other by vascular circulation.</p>
<p>A selectively permeable endothelial barrier separates tissue compartments from the vascular channel, as in the human body. Once the platform was established, the researchers introduced breast cancer cells into the vascular circulation to observe patterns of organ-specific colonization. In line with what happens inside the human body, cancer cells that typically gravitate toward the bone showed stronger bone colonization and induced more pronounced bone degeneration. In contrast, cancer cells that typically gravitate toward the lung caused greater disruption in the lung tissue and only modest colonization of bone. Distinct patterns of tissue colonization and secreted factors demonstrate that this device mimics key features of organ-specific metastasis observed in the human body.</p>
<p>In addition, a post-analysis of the engineered tissue revealed that cancer cells condition the distant organs to be more receptive to colonization. The team saw signs of this process—called pre-metastatic niche formation—across both tissue compartments.</p>
<p>“Cancer is very smart, unfortunately. We learned how the cells cross barriers to get from blood circulation into the tissues,” said Vunjak-Novakovic. “We were also able to reproduce something that happens in patients, where cancer cells condition the target tissues, even before they colonize them, to make them more receptive.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The work is aligned with the trend of more preclinical research in the future, including engineered human tissues that can complement what is learned from animal models. “As the FDA and NIH place growing emphasis on new approach methodologies, this study is a concrete example of what that shift can look like in practice, applied to one of cancer’s most challenging hallmarks: metastasis,” noted Ilaria Baldassarri, a PhD student at Columbia University.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/human-multi-organ-chip-offers-new-insight-into-cancer-metastasis/">Human Multi-Organ Chip Offers New Insight Into Cancer Metastasis</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Not all patients benefit from progress against psoriasis</title>
<link>https://edusehat.com/en/not-all-patients-benefit-from-progress-against-psoriasis</link>
<guid>https://edusehat.com/en/not-all-patients-benefit-from-progress-against-psoriasis</guid>
<description><![CDATA[ For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation […]
The post Not all patients benefit from progress against psoriasis appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/pexels-ron-lach-8624600.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 02:45:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Not, all, patients, benefit, from, progress, against, psoriasis</media:keywords>
<content:encoded><![CDATA[<p>For people living with psoriatic disease, treatment innovation has advanced dramatically. Yet too many patients remain undiagnosed, untreated, or undertreated. The National Psoriasis Foundation (NPF) set out to understand why progress in treatment has not consistently translated into progress in patients’ lives.</p>
<p><em>Bio.News sat down with Katie Southwick, Vice President of Marketing & Communications at NPF to discuss their research on unreached patient populations and the lived experiences shaping their decisions.</em></p>
<h5>Tell us more about your research on unreached patient populations. What inspired it? Why is there such a great need for this research?</h5>
<p>There has been tremendous progress in psoriatic disease treatments. Today, patients are surrounded by messaging about the disease and new treatment options, whether on television, social media, or online. Despite that visibility, a significant portion of people living with psoriatic diseases remain undiagnosed or are still not taking advantage of modern treatment options. That disconnect led us to ask a simple question: <em>Why?</em></p>
<p>As we dug deeper, we found that out-of-pocket cost and concerns about side effects were certainly a big driver. Importantly, we found that patients’ lived experiences often have a great impact on whether they continue engaging with the healthcare system. Negative encounters with healthcare providers, feeling dismissed, feeling unheard, or becoming discouraged after unsuccessful treatments can all influence future decisions about seeking care.</p>
<p>The need for this research is substantial. There are approximately 8 million people living with psoriatic disease in the United States, and another roughly 600,000 remain undiagnosed. Not managing psoriasis often leads to soaring health care expenses, productivity losses, and expensive long-term medical comorbidities such as cardiovascular disease or diabetes. Yet, many patients have no formal care plan or lack access to specialist care, particularly in rural communities. Understanding <em>why</em> patients disengage is essential if we want advances in treatment to translate into better outcomes for patients.</p>
<h5>Your research suggests that the biggest barrier to care is “patient momentum.” Can you explain what this means?</h5>
<p>Our research showed that many patients become stuck in what we call a “doom loop.”</p>
<p>Living with a psoriatic disease can be exhausting. Symptoms affect physical health, mental health, confidence, relationships, and daily routines. Over time, patients may experience frustration with the healthcare system, disappointment with not immediately finding the right treatment option that works best for them, or feelings of hopelessness. All of those factors build on one another and make it harder to take the next step toward care.</p>
<p>“Patient momentum” is really about helping people move forward again. Effective engagement is not simply telling someone there is a new treatment available. It is helping them believe that things can improve, that support exists, and that they do not have to continue struggling alone.</p>
<h5>The study found that patients often settle into a “good enough” mindset, managing symptoms without seeking better outcomes. What are the risks of this approach?</h5>
<p>Psoriasis is not just a skin condition. It is a chronic, systemic immune-mediated disease that can have serious long-term consequences when left inadequately managed.</p>
<p>When patients settle for “good enough,” they may not realize they are still at risk for disease progression and related health complications. For some individuals, that can mean the development or worsening of psoriatic arthritis, which can cause irreversible joint damage if not treated appropriately. Psoriatic disease is also associated with several comorbid conditions that can affect overall health and quality of life.</p>
<p>That is why one of our key messages is that <em>good enough is not actually good enough</em>. We want patients to understand that better outcomes are possible, and that staying engaged in care can help reduce the risk of more serious issues down the road.</p>
<h5>What role does trust play in keeping patients engaged in care?</h5>
<p>Trust is everything.</p>
<p>Patients are navigating an overwhelming amount of information today, and it is often difficult to determine what is evidence-based and what is not.</p>
<p>Organizations like NPF play an important role because patients need trusted sources of information and guidance. We work alongside leading clinicians, researchers, and patient advocates to help connect people with credible resources and support.</p>
<p>Trust also means recognizing that every patient’s journey is different. The same treatment approach does not work for everyone. Patients want to be seen, heard, and respected in their decision-making. Building that trust is critical to helping people move toward optimal care.</p>
<h5>What needs to happen next to ensure that advances in treatment translate into action for the patients who remain disengaged from care?</h5>
<p>Patients need to be met where they are. Disengaged patients are not necessarily choosing to ignore their disease. Many have experienced setbacks that have slowed their momentum. By listening to patients, validating their experiences, and demonstrating that better outcomes are possible, we can help more people move beyond the doom loop and toward a healthier future. The encouraging reality is that today’s treatments, combined with trusted support and education, can make a meaningful difference.</p>
<p>August is Psoriasis Action Month. NPF has launched our <a href="https://www.psoriasis.org/psoriasis-action-month/"><em>Is This a Thing</em></a> campaign, which has the goal of empowering patients through education on psoriasis and validation that: “No matter what this disease does to make you ask: Is this a thing? The answer is typically: Yes, this is psoriasis.</p>
<p>NPF has also recently launched our <a href="https://www.psoriasis.org/milestones-to-a-cure-rfp/">Milestones to a Cure</a> initiative<em>. </em>As part of this initiative, NPF is investing in innovative research designed to accelerate progress toward a cure for psoriatic disease. This funding opportunity will support researchers pursuing transformative, high-impact projects aimed at advancing our understanding of disease mechanisms, improving treatment approaches, and ultimately bringing us closer to a cure.</p>
<p><em>If you are interested in learning more about NPF and Psoriasis Action Month, visit</em> <a href="https://www.psoriasis.org/psoriasis-action-month"><em>https://www.psoriasis.org/psoriasis-action-month</em></a><em>. Letters of intent for Milestones to a Cure are due Aug. 31. You can learn more here:</em> <a href="https://www.psoriasis.org/milestones-to-a-cure-rfp/"><em>https://www.psoriasis.org/milestones-to-a-cure-rfp/</em></a></p>
<p><em>Additionally, if you are a patient advocate, consider registering for the Biotechnology Innovation Organization’s </em><a href="https://pace.bio.org/"><em>Patient Advocacy Changemakers Event (PACE)</em></a><em>: an empowering and inspiring event focused on breaking barriers to access and ensuring that innovative medicines reach the patients who need them.</em></p>
<p>The post <a href="https://bio.news/health/not-all-patients-benefit-from-progress-against-psoriasis/">Not all patients benefit from progress against psoriasis</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Gene Switch Uses Electromagnetic Fields to Control Genes Remotely</title>
<link>https://edusehat.com/en/gene-switch-uses-electromagnetic-fields-to-control-genes-remotely</link>
<guid>https://edusehat.com/en/gene-switch-uses-electromagnetic-fields-to-control-genes-remotely</guid>
<description><![CDATA[ DNA regulatory elements, which control when, where, and to what extent specific genes are turned on or off, can be co-opted by scientists to create gene switches. 
The post Gene Switch Uses Electromagnetic Fields to Control Genes Remotely appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-122375517.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 02:40:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Gene, Switch, Uses, Electromagnetic, Fields, Control, Genes, Remotely</media:keywords>
<content:encoded><![CDATA[<p>Researchers say gene switches currently offer limited temporal and spatial precision and can also have adverse effects. Now, a recent study, “<a href="https://www.sciencedirect.com/science/article/abs/pii/S0092867426003302?via%3Dihub">Electromagnetic field-inducible <em>in vivo</em> gene switch for remote spatiotemporal control of gene expression</a>” in <em>Cell,</em> describes an electromagnetic field-inducible gene switch that enables fully reversible, safe, and precise control over gene expression.</p>
<p>The scientific team from Dongguk University in South Korea believes this represents a powerful non-invasive tool for understanding gene expression and for gene therapy.</p>
<p>DNA contains regulatory elements that control when, where, and to what extent specific genes are turned on or off. They can be co-opted to create “gene switches” that hold significant potential for understanding gene expression and for therapeutic applications, particularly for the non-invasive treatment or management of genetic disorders.</p>
<p>In recent years, researchers have developed several gene switches that enable the remote control of gene expression in living organisms using stimuli such as drugs, light, heat, ultrasound, and electrical signals. However, current versions are limited in offering precise control over the timing and duration of gene expression, according to the Dongguk University investigators. Additionally, drug-based gene switches can have undesirable adverse effects, while some stimuli, such as light, can make penetrating deeper tissues challenging.</p>
<p>Addressing these limitations, Jongpil Kim, PhD, and doctoral student Yerim Hwang from the Institute for Stem Cells and Regenerative Medicine at Dongguk led a group that developed a novel electromagnetic field (EMF)-responsive gene switch.</p>
<p><figure aria-describedby="caption-attachment-336732" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-336732" src="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-483291233-300x200.jpg" alt="Researchers have developed several gene switches that enable the remote control of gene expression in living organisms using stimuli such as drugs, light, heat, ultrasound, and electrical signals. However, current versions are limited in offering precise control over the timing and duration of gene expression [Nicolas/Getty Images]Getty-483291233 " width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-483291233-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-483291233-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-483291233-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-483291233.jpg 724w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Researchers have developed several gene switches that enable the remote control of gene expression in living organisms using stimuli such as drugs, light, heat, ultrasound, and electrical signals. However, current versions are limited in offering precise control over the timing and duration of gene expression. [Nicolas/Getty Images]<br>Getty-483291233</figcaption></figure>“In previous studies, extremely low frequency EMF fields have been shown to modulate expression of specific genes involved in stress response, epigenetic remodeling, and cellular signaling pathways. Moreover, EMF is non-invasive, fully reversible, and can precisely penetrate target tissues or areas of the body, making it highly attractive for remote control of gene switches,” explained Kim. “In this study, we utilized the promoter of the Lgr4 gene to create a robust EMF-inducible gene switch and demonstrated its applications in Alzheimer’s disease (AD) modeling and reversing aging markers in mice.”</p>
<p>To identify EMF-responsive genes, the researchers performed single-cell RNA sequencing (scRNA-seq) on mouse brain tissue following exposure to an EMF of 2.0 millitesla at 60 hertz. The team found exclusive upregulation of Lgr4 expression. Through a series of validation experiments, the team found that the promoter of Lgr4 was well suited for constructing an EMF-inducible (Ei) gene switch, exhibiting precise activation with no detectable adverse effects during the study.</p>
<p>To evaluate the system in living animals, the researchers linked the Ei element to a reporter that produces green fluorescent protein (GFP), allowing gene activity to be visualized. They then generated transgenic mice carrying this reporter. Following EMF exposure, the mice showed strong GFP expression throughout the body, while targeted EMF exposure produced localized gene expression in specific organs.</p>
<p>When EMF stimulation was discontinued, gene expression returned to baseline within 24 hours, demonstrating that the Ei gene switch is highly tunable, reversible, and capable of precise remote control of gene expression.</p>
<p>Using a genome-wide CRISPR-Cas9 knockout screen, the researchers identified cytochrome b5 type B (Cyb5b), a membrane-associated protein, as the biological sensor for EMF. “This may be the first reported molecular sensor for electromagnetic fields,” noted Kim. Further tests revealed that due to EMF exposure, Cyb5b produces rhythmic calcium influx oscillations in cells, functioning as a specific code for activating the target gene.</p>
<p>The researchers also demonstrated several applications of the Ei gene switch, e.g., they established an AD mouse model that decouples brain aging from amyloid β plaque deposition. In addition, cyclic EMF exposure was used to achieve partial cellular reprogramming in aged and progeroid mice, improving several aging-associated markers without detectable adverse effects. The team also restored serotonin levels and reduced depression-like behaviors in mice by controlling expression of the Tph2 gene.</p>
<p>“This technology could move gene therapy away from a single, irreversible dose and toward simpler, real-time treatments administered by physicians or even wearable devices,” said Hwang.</p>
<p>Although further validation and testing are required, the Ei gene switch represents a promising platform for developing non-invasive, remotely controlled gene therapies, she added.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/gene-switch-uses-electromagnetic-fields-to-control-genes-remotely/">Gene Switch Uses Electromagnetic Fields to Control Genes Remotely</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Vector Production a Bottleneck for Gene Therapy Sector</title>
<link>https://edusehat.com/en/vector-production-a-bottleneck-for-gene-therapy-sector</link>
<guid>https://edusehat.com/en/vector-production-a-bottleneck-for-gene-therapy-sector</guid>
<description><![CDATA[ More effective purification materials would make viral vector production more efficient, say researchers working on an affinity adsorbent-based method they claim can differentiate between full and empty capsids more effectively than current methods.
The post Vector Production a Bottleneck for Gene Therapy Sector appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/03/GettyImages-723505881-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 02:40:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Vector, Production, Bottleneck, for, Gene, Therapy, Sector</media:keywords>
<content:encoded><![CDATA[<p>Inefficiencies that limit the global supply of viral vectors are negatively impacting the gene therapy industry, according to researchers, who say there is an urgent need for better downstream purification materials.</p>
<p>The call came from Stefano Menegatti, PhD, professor, Department of Chemical and Biomolecular Engineering at North Carolina State University, who says the limited availability of viral vectors has become a major bottleneck.</p>
<p>“Gene therapy is one of the most transformative frontiers in modern medicine. It holds the promise of curing devastating diseases with a single treatment. Adeno-associated viruses (AAVs) are the leading delivery vehicles for these therapies.</p>
<p>“Yet for all the excitement in the field, manufacturing remains a critical bottleneck: producing AAVs at the purity, potency, and scale needed for clinical use is enormously challenging,” he tells <em>GEN</em>.</p>
<p>A key obstacle is that current purification materials—usually resin-based affinity adsorbents—cannot distinguish between full AAV capsids that carry genetic material and empty capsids that have no payload.</p>
<p>Another issue with current purification technologies is the need to use low flow rates, which increases processing costs and, ultimately, gene therapy prices, Menegatti says.</p>
<p>“Purification technologies operate at slow flow rates, require harsh chemical conditions that can damage the product, and wear out quickly, all of which drive up manufacturing time and cost.</p>
<p>“For patients waiting on life-saving treatments, these are not abstract engineering problems. They translate directly into delayed access and higher prices,” he says.</p>
<p></p><h4><strong>Purification materials research</strong></h4>

<p>In <a href="https://www.niimbl.org/news/niimbl-announces-8-new-technology-and-workforce-projects/" target="_blank" rel="noopener">May</a>, Menegatti and colleague Michael Daniele, PhD, were awarded a NIIMBL grant to further develop a purification method with novel materials that they claim can differentiate between full and empty capsids.</p>
<p>“At the heart of it are AvXcel affinity adsorbents—developed by ChromaGenix—which substantially accelerate purification. More importantly, they selectively enrich full, gene-loaded AAV capsids directly at the capture step.</p>
<p>“Our preliminary data show that the fraction of full capsids increases from roughly 20−30% in the raw material to 34−48% in the affinity eluate, far outperforming the industry benchmark,” he says.</p>
<p>In addition, the membranes can also withstand harsh cleaning processes—up to 50 cycles with caustic solutions—which is in line with industry needs, Menegatti adds.</p>
<p>“The combination of speed, selectivity, and durability is genuinely unprecedented. We are not making incremental improvements; we are redesigning the purification step from the ground up, with the goal of transforming a months-long process development campaign into one that takes weeks.”</p>
<p></p><h4><strong>Machine learning</strong></h4>

<p>The NIIMBL grant will also support the ongoing development of a machine learning-based analytical software platform, called Beacon, designed to help manufacturers optimize vaccine purification.</p>
<p>Daniele tells <em>GEN</em>, “Even with next-generation purification materials, optimizing the process for each new AAV target remains a major challenge.</p>
<p>“Today, the standard approach is a trial-and-error methodology that requires dozens to hundreds of experiments to map out the right operating conditions for each new product. This must be repeated essentially from scratch for every new AAV serotype and transgene combination, which is both time-consuming and expensive.”</p>
<p>Beacon, or Bayesian-Enhanced AAV Chromatography Optimization Network, is a machine learning platform designed to help process developers avoid such repetition.</p>
<p>“It uses a Gaussian Process algorithm, a type of Bayesian AI that learns from each experiment and predicts the next most informative one to run. Rather than blindly sweeping through conditions, Beacon intelligently navigates the optimization landscape, reducing the experimental burden by 30−50% compared to conventional DOE while simultaneously optimizing multiple performance criteria: yield, full capsid enrichment, impurity clearance and productivity,” Daniele continues.</p>
<p>Another key Beacon feature is the use of North Carolina’s VVIRAL database, which comprises thousands of AAV purification experiments, to “warm-start” new campaigns.</p>
<p>Danielle tells <em>GEN</em>, “In other words, it doesn’t start from zero for each new product; it leverages everything we’ve already learned. And unlike a black-box AI, Beacon provides interpretable, quantitative outputs through SHAP analysis, so scientists understand why a particular protocol works, enabling smarter decisions and better risk management.</p>
<p>“Beacon will be released as an open-access, cloud-hosted platform to the broader biomanufacturing community, democratizing access to cutting-edge AI tools that were previously available only to a handful of computational specialists,” he adds.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/vector-production-a-bottleneck-for-gene-therapy-sector/">Vector Production a Bottleneck for Gene Therapy Sector</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cell Therapy Company Aims to Pioneer Analytics Automation</title>
<link>https://edusehat.com/en/cell-therapy-company-aims-to-pioneer-analytics-automation</link>
<guid>https://edusehat.com/en/cell-therapy-company-aims-to-pioneer-analytics-automation</guid>
<description><![CDATA[ BlueRock says it’s helping advance the cell therapy industry by developing an automated system for analytical auditing. They say it’s among the few systems specifically designed for this application.
The post Cell Therapy Company Aims to Pioneer Analytics Automation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2249282772-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 02:40:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cell, Therapy, Company, Aims, Pioneer, Analytics, Automation</media:keywords>
<content:encoded><![CDATA[<p>BlueRock Therapeutics says it has developed an automated system for high-throughput auditing of this relatively new class of therapeutics. According to BlueRock, the system, which accommodates cell culture, liquid handling, and processing with small volume samples, is designed to fill a gap between the need for solutions and those currently available.</p>
<p>“In modalities like small molecules, platforms are more or less plug-and-play and so are the systems used for automation, but there’s been a gap as people have moved to this new modality,” explains Ronnie Lum, PhD, director of analytical and quality control.</p>
<p>To contribute to the growing cell therapy ecosystem, Lum and his team have adapted readily available tools and systems to the smaller batch volumes produced in cell therapies.</p>
<p>“This field is new,” he says. “We want to be a pioneer and really push the envelope of where we can go with automation. Specifically in the analytical audit space, there aren’t many solutions out there, so we’ve really put the effort in.”</p>
<p>The customized system has been designed and built in collaboration with Hamilton Robotics and involves adapting the company’s existing analytical systems to liquid handling and, they hope, high-throughput automation with the aim of scaling up to commercial volumes in this new field.</p>
<p>The company hopes their new system will help them reach the market faster with their own pipeline of therapies and can be adapted easily afterward to the processes involved with their new products.</p>
<p>In general, they hope these technologies will drive down the cost of analytics across the cell therapy industry by reducing the sample volumes needed for testing and, thus, the cost of reagents used in complex assays.</p>
<p>Going forward, BlueRock Therapeutics urges other companies to join them in developing systems to address technological gaps. “We’re willing to push the boundaries by investing in these technologies and trying to innovate.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cell-therapy-company-aims-to-pioneer-analytics-automation/">Cell Therapy Company Aims to Pioneer Analytics Automation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cutting Costs in Serum&#45;Free FGF2 Processing With Recycled Media</title>
<link>https://edusehat.com/en/cutting-costs-in-serum-free-fgf2-processing-with-recycled-media</link>
<guid>https://edusehat.com/en/cutting-costs-in-serum-free-fgf2-processing-with-recycled-media</guid>
<description><![CDATA[ Reusing spent culture media in an L. lactis cell fermentation model streamlines continuous bioprocessing and cuts costs for FGF2 production, making serum-free production increasingly cost-effective and productive.
The post Cutting Costs in Serum-Free FGF2 Processing With Recycled Media appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/02/GettyImages-200554028-001.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 02:40:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cutting, Costs, Serum-Free, FGF2, Processing, With, Recycled, Media</media:keywords>
<content:encoded><![CDATA[<p>Producing fibroblast growth factor 2 (FGF2) using fortified spent cell culture media from <em>Lactococcus lactis </em>can cut the costs of serum-free cell culture media while maintaining high production titers, according to recent research from Singapore’s Agency for Science, Technology and Research (A*STAR). This approach helps overcome some of the barriers associated with serum-free media and eventually may even eliminate the need for the vast quantities of fetal bovine serum used today.</p>
<p>“This project establishes a high-value circular manufacturing framework by capturing nutrient-rich spent media side-streams generated during biopharmaceutical cell culture and repurposing them as low-cost feedstock for precision microbial fermentation,” Dave Ow, PhD, a principal scientist and group leader, microbial cell bioprocessing at Bioprocessing Technology Institute (BTI), A*STAR, tells <em>GEN</em>.</p>
<p>The Singaporean team led by Ow and Prashant Mainali, PhD, a bioprocess scientist and researcher at the BTI, A*STAR, chose <em>L. lactis</em> as the production cell because it has a doubling time of 35−60 minutes and can secrete recombinant proteins, thus minimizing downstream purification steps. Because the spent fermentation media still contains nutrients, reusing and fortifying it lowers the cost of formulating fresh media, thereby enhancing productivity and lowering FGF2’s cost per gram.</p>
<p>For further gains, the team adapted this approach for a continuing manufacturing process for both intracellular production and secretion of FGF2, optimizing process conditions and integrating that model with downstream purification. Using it, they achieved 16 mg/L titers for intracellular forms and 396 µg/L titers for secreted forms of FGF2. Optimal conditions, they report, are 10 g/L glucose, 35°C cultivation temperature, and 100 ng/mL nisin.</p>
<p>Optimization focused around glucose concentration, temperature, and nisin concentration. “The interaction between glucose concentration and temperature was statistically significant,” they note. The glucose/nisin interaction was not. Increasing dilution rates increased FGF2 production to a point, after which washout occurred. Therefore, balancing the tradeoffs—for example, minimizing nutrient loss or maximizing FGF2 concentration or total output—is critical.</p>
<p>The scientists used a chemostat process, which enables continuous bioprocessing under steady-state culture conditions, to simulate process outcomes under varying conditions. The results, they report, “captured overall trends…[and] accurately predict the final concentrations of cells, glucose, lactate, and total intracellular FGF2 at the end of the chemostat run.” It underpredicts FGF2 concentrations, however.</p>
<p>Then they added depth filtration and crossflow filtration to the chemostat process, mimicking typical purification steps used in <em>Escherichia coli</em>, showing that such integration and streamlining is feasible. The FGF2 from this process was used without further purification to supplement cell cultures. When applied to a culture of <em>Anguilla japonica</em> (Japanese eel) cells, “Their growth was comparable to cells cultured with commercially available FGF2 and FBS-supplemented media,” Mainali and colleagues note.</p>
<p>“Our findings demonstrate that fortified spent cell culture media can support the growth of <em>L. lactis</em> and the secretion of FGF2,” Ow, Mainali, and colleagues conclude. Secretion simplified downstream purification, and the reuse of spent media is both cost-effective and environmentally sound, “potentially lower[ing] the cost of FGF2”…and “helping to overcome one of the principal economic barriers to serum-free media.”</p>
<p>Already, Ow says, “There is interest from biopharma manufacturers to potentially use this approach to upcycle spent media for their cell culture production processes to reduce media waste toward a more sustainable biomanufacturing future.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cutting-costs-in-serum-free-fgf2-processing-with-recycled-media/">Cutting Costs in Serum-Free FGF2 Processing With Recycled Media</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CAR T Manufacturing Innovation Expands Patient Access</title>
<link>https://edusehat.com/en/car-t-manufacturing-innovation-expands-patient-access</link>
<guid>https://edusehat.com/en/car-t-manufacturing-innovation-expands-patient-access</guid>
<description><![CDATA[ Advances in manufacturing, automation, and lentiviral vector technologies are reshaping the future of CAR T therapies. Ex vivo and in vivo approaches will evolve together, helping improve scalability, lower costs, and expand patient access worldwide.
The post CAR T Manufacturing Innovation Expands Patient Access appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Mike-CAR-T-Manufacturing_image.png" length="49398" type="image/jpeg"/>
<pubDate>Thu, 20 Aug 2026 02:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CAR, Manufacturing, Innovation, Expands, Patient, Access</media:keywords>
<content:encoded><![CDATA[<p>As the next generation of CAR T therapies moves closer to broader commercialization, industry leaders say the future will depend less on choosing between <em>ex vivo</em> and <em>in vivo</em> approaches and more on advancing both in parallel. Improvements in manufacturing, automation, and vector engineering are expected to expand patient access while addressing long-standing challenges around scalability, cost, and consistency.</p>
<p>Speaking to <em>GEN</em>, experts from VIVEbiotech, Terumo Blood and Cell Technologies, and Bracco describe an industry transitioning from demonstrating scientific feasibility to building robust manufacturing systems capable of delivering life-changing therapies to many more patients.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<h4><strong>Parallel paths for CAR T innovation</strong></h4>
<p>“<em>Ex vivo</em> CAR T therapies will continue to play a critical role, while <em>in vivo</em> approaches are rapidly advancing and have the potential to broaden patient access by simplifying treatment pathways,” Natalia Elizalde, PhD, chief business development officer at VIVEbiotech, says.</p>
<p>Rather than viewing the two technologies as competitors, she expects them to develop side by side, each serving different clinical and operational needs. According to Elizalde, the industry’s priorities are shifting beyond proof-of-concept toward making therapies more widely available and economically sustainable.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>She identifies advances in lentiviral vector engineering and targeted delivery technologies as major drivers of future progress. Improvements in manufacturing scalability and process robustness will also be crucial as commercial demand grows.</p>
<p>“The future of CAR T will not be defined by a single technological approach,” Elizalde says. “It will be defined by the ability of different platforms to address unmet patient needs while improving scalability, accessibility, and sustainability.”</p>
<p></p><h4><strong>Automation tackles manufacturing variability</strong></h4>

<p>While scientific innovation continues, manufacturing remains one of the biggest barriers to broader adoption. According to Wenyan Leong, PhD, director, APAC commercial, cell and gene therapies at Terumo Blood and Cell Technologies, the greatest challenge in <em>ex vivo</em> CAR T production is not any individual manufacturing step but the cumulative variability created throughout the workflow.</p>
<p>“Every manual intervention, open manipulation, operator-dependent activity, and process handoff introduces opportunities for variability, deviation, and operational complexity,” Leong says.</p>
<p>That variability extends from cell collection through processing, expansion, quality control, and final-product release. As manufacturers scale production, maintaining consistent product quality becomes increasingly difficult and expensive.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Leong believes automation offers a practical solution, although implementation should be tailored to each developer’s manufacturing strategy rather than applied universally.</p>
<p>“A useful framework is to automate where risk is highest, where variability has the greatest impact on product quality, and where scaling creates the most operational burden,” she explains.</p>
<p>For many manufacturers, cell expansion represents the most logical place to automate because it is labor-intensive, highly dependent on operator expertise, and difficult to reproduce consistently across multiple sites. By reducing manual processes and simplifying operations, manufacturers can lower costs while improving reproducibility and expanding patient access, Leong says.</p>
<p></p><h4><strong>Integrated manufacturing supports industrialization</strong></h4>

<p>Sophie He, PhD, vice president, cell therapy at Bracco, points to additional manufacturing bottlenecks that continue to slow commercialization. For example, she says <em>ex vivo</em> CAR T manufacturing must overcome complex supply chains, logistical challenges, and significant analytical demands that increase both timelines and production costs.</p>
<p>“In autologous manufacturing, patient-to-patient variability and poor starting-cell quality lead to inconsistent transfection and expansion,” He says. “In allogeneic approaches, the priority is obtaining highly pure starting material before stem cell differentiation into T cells.”</p>
<p>He also highlights fragmented cell selection and activation workflows as major contributors to cellular stress, inconsistent yields, and reduced product quality across both therapy modalities.</p>
<p>“Integrating multiple processing steps, such as cell selection and activation, into a single closed, continuous workflow reduces handling, washing, production time, and cost while improving cell viability and consistency,” He says.</p>
<p>According to He, combining workflow integration with automation and flexible manufacturing models, including point-of-care production, will enable reliable, high-throughput, and cost-effective CAR T manufacturing.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>Taken together, these experts see the future of CAR T therapies resting on a combination of scientific advances and manufacturing innovation. As vector technologies mature and automated production becomes more sophisticated, both <em>ex vivo</em> and <em>in vivo</em> approaches are expected to complement one another, creating a more scalable and accessible ecosystem capable of bringing advanced cell therapies to far more patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/car-t-manufacturing-innovation-expands-patient-access/">CAR T Manufacturing Innovation Expands Patient Access</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Build patient access by strengthening innovation, BIO tells senators</title>
<link>https://edusehat.com/en/build-patient-access-by-strengthening-innovation-bio-tells-senators</link>
<guid>https://edusehat.com/en/build-patient-access-by-strengthening-innovation-bio-tells-senators</guid>
<description><![CDATA[ BIO’s response to a request for information from the Drug Price Working Group explains why price setting won’t work. Improving patient access to new […]
The post Build patient access by strengthening innovation, BIO tells senators appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/connor-gan-R8NnEiKp_Vo-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 23:10:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Build, patient, access, strengthening, innovation, BIO, tells, senators</media:keywords>
<content:encoded><![CDATA[<h5>BIO’s response to a request for information from the Drug Price Working Group explains why price setting won’t work.</h5>
<p><span>Improving patient access to new treatments requires policy that supports America’s innovation ecosystem—not price setting that discourages investment, BIO tells a Senate working group.</span></p>
<p><span>Written comments by the Biotechnology Innovation Organization (BIO) advise against importing foreign pricing or increasing government setting of prescription drug prices.</span></p>
<p><span>Instead, BIO recommends reducing patient out-of-pocket costs, through measures like pharmacy benefit manager (PBM) reform, as well as policy to encourage investment in innovation and address aggressive biotech competition from China.</span></p>
<p><a href="https://www.bio.org/letters-testimony-comments/bio-response-senate-finance-committee-minoritys-rfi-commonsense-policy" target="_blank" rel="noopener"><span>BIO’s 46-page policy analysis</span></a><span> is a response to a “</span><a href="https://www.finance.senate.gov/imo/media/doc/061626_sfc_drug_pricing_rfi.pdf" target="_blank" rel="noopener"><span>Request for Information: Commonsense Policy Options to Lower Drug Prices for Patients</span></a><span>,” issued by the Drug Price Working Group led by Senate Finance Committee Ranking Member Ron Wyden (D-OR) with Sens. Catherine Cortez Masto (D-NV), Peter Welch (D-VT), Ruben Gallego (D-AZ), Mark Kelley (D-AZ), Tammy Baldwin (D-WI), Maggie Hassan (D-NH), Jeff Merkley (D-OR), Chris Van Hollen (D-MD), Tammy Duckworth (D-IL), and Richard Blumenthal (D-CT). </span></p>
<p><span>The goal of the RFI is to provide detail that can shape proposals from the Democratic working group.</span></p>
<p><span>“Sustaining America’s world-leading biotechnology pipeline will require policymakers to ensure that policies intended to improve affordability strengthen, rather than weaken, the ecosystem that makes continued innovation possible,” </span><a href="https://www.bio.org/letters-testimony-comments/bio-response-senate-finance-committee-minoritys-rfi-commonsense-policy" target="_blank" rel="noopener"><span>BIO’s Aug. 17 comments say</span></a><span>.</span></p>
<p><span>BIO addresses various areas for action suggested by the Working Group’s RFI.</span></p>
<h3>Price setting</h3>
<p><span>The current drug-price negotiation program (DPNP), which will set prices on 100 drugs within the next five years, is already a drag on investment, and there is no need to increase its reach, BIO says. In particular, proposals to use international reference pricing ignore the realities of the U.S. market, which provides quicker and more robust access to medicines, the comments note.</span></p>
<p><span>To ensure investment in needed innovation, it is recommended that certain protections from DPNP are added or extended. Biologics and small molecule drugs should both have 13 years of protection from the DPNP, and there should be additional exemptions to promote development of orphan drugs for rare diseases, BIO says. Furthermore, the IRA Small Biotech Exception should not be allowed to expire in 2028:</span></p>
<p><span>“Protections for small biotech companies from the DPNP should be extended to support small and emerging companies that drive early-stage innovation,” say BIO’s comments. </span></p>
<p><span>Across the more than 2,000 biotech companies in the U.S., approximately 300 are publicly listed, and most are small or mid-sized companies, </span><a href="https://www.bio.org/toolkit/human-health/americas-innovation-engine-power-small-and-mid-sized-biotechs" target="_blank" rel="noopener"><span>according to a BIO fact sheet</span></a><span>. Today, these small and mid-sized companies account for 71% of the industry’s total employment, originate 49% of all new drugs launched globally, and account for 54% of Food and Drug Administration (FDA) filings. </span></p>
<p><span>BIO’s comments to the RFI also recommend policies to enable value-based pricing: “A holistic consideration of a treatment’s value to patients, families, and society should be the overarching principle when developing policies to provide sustainable access to novel, innovative, and transformative therapies.”</span></p>
<h3>Increasing patient access</h3>
<p><span>BIO’s recommendations for reducing the amount patients pay for drugs include reforming PBM practices and a range of other steps to ensure patients have access to needed medicines.</span></p>
<p><span>For example, automatic enrollment in the Medicare Prescription Payment Plan (MPPP) would make sure all patients have help in “smoothing” out payments over the course of a year.</span></p>
<p><span>Regarding “step therapy,” in which patients are expected to “fail first” on a cheaper medicine before receiving coverage for the drug their doctor prescribes, BIO calls for establishing clear exemption standards for patients in all types of coverage and eliminating step therapy for Part B drugs in Medicare Advantage.</span></p>
<p><span>BIO also encourages Congress to address other insurer practices that can restrict access, including eliminating copay accumulator programs, “so all forms of copay assistance count toward patient deductibles.” Furthermore, alternative funding programs (AFPs) that delay or prevent access by diverting insured patients to charitable assistance programs should be prohibited, BIO says.</span></p>
<p><span>Regarding PBMs, which use their market power to profit by driving up the cost of prescription drugs, BIO recommends several reforms, including:</span></p>
<ul>
<li aria-level="1"><span>“Requiring fees to be transparent, delinked from medicine prices and formulary placement, consistent with fair market value, and not contingent on business conducted with PBM affiliates.”</span></li>
<li aria-level="1"><span>Insulating clinical decision-making from rebate and fee incentives.</span></li>
<li aria-level="1"><span>“Addressing vertical integration and associated value extraction enabled by self-dealing.”</span></li>
<li aria-level="1"><span>Expanding PBM transparency requirements.</span></li>
<li aria-level="1"><span>“Removing contractual barriers that prevent plans, employers, manufacturers, and patients from pursuing lower-cost options.”</span></li>
</ul>
<h3>Encouraging innovation to maintain U.S. biotech leadership</h3>
<p><span>BIO notes the remarkable advances achieved through biotech innovation.</span></p>
<p><span>“Continued progress depends on a research ecosystem that supports scientific discovery, rewards risk-taking, and enables innovators to efficiently translate breakthrough science into therapies that reach patients,” BIO says.</span></p>
<p><span>BIO’s comments urge expansion of federal programs supporting translational research, such as the National Institutes of Health (NIH) and ARPA-H, as well as addition of new types of support for acceleration and commercialization.</span></p>
<p><span>Along with providing new treatments, innovation in the U.S. allows America to maintain its global biotech leadership in the face of China’s concerted efforts at competition, which can pose supply chain and security threats, BIO says.</span></p>
<p><span>“Investments in clinical trial infrastructure, regulatory modernization, workforce development, and manufacturing capacity can make the United States more competitive, while maintaining the scientific standards that distinguish FDA and the broader American system,” according to BIO.</span></p>
<p><span>China has become particularly competitive in conducting first-in-human clinical trials by enabling these trials to take place more rapidly there than in the U.S. BIO recommends several clinical trial reforms, including: streamlining regulatory processes, reducing operational burdens, improving patient participation and site activation, and modernizing Investigational New Drug (IND) requirements and review processes.</span></p>
<p><span>Overall, BIO recommends leaning into the natural strengths of the U.S. biotech ecosystem. “America’s advantage has always been its ability to innovate,” say BIO’s comments. Policies that drive innovation by enabling investment are therefore encouraged.</span></p>
<p><a href="https://www.bio.org/letters-testimony-comments/bio-response-senate-finance-committee-minoritys-rfi-commonsense-policy" target="_blank" rel="noopener"><b>Read BIO’s full comments on the RFI.</b></a></p>
<p>The post <a href="https://bio.news/federal-policy/build-patient-access-by-strengthening-innovation-bio-tells-senators/">Build patient access by strengthening innovation, BIO tells senators</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Mid&#45;year review: State&#45;level legislative action impacting biotech</title>
<link>https://edusehat.com/en/mid-year-review-state-level-legislative-action-impacting-biotech</link>
<guid>https://edusehat.com/en/mid-year-review-state-level-legislative-action-impacting-biotech</guid>
<description><![CDATA[ 2026 was a busy year on the state level. Whether it was the expected healthcare policy priorities or newer ones, there was plenty to […]
The post Mid-year review: State-level legislative action impacting biotech appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/kjrstie-america-875164_1280.png" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 16:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Mid-year, review:, State-level, legislative, action, impacting, biotech</media:keywords>
<content:encoded><![CDATA[<p>2026 was a busy year on the state level. Whether it was the expected healthcare policy priorities or newer ones, there was plenty to keep legislators, patient advocates, and industry leaders busy.</p>
<p>“Given the majority of state legislatures are adjourned and the fact we have a major election in November, which includes 39 gubernatorial elections, I think we’ve pretty much seen what we’re going to see from the states this year, says Patrick Plues, Senior Vice President, State Government Affairs and Affiliate Relations at the Biotechnology Innovation Organization (BIO).</p>
<p>So what were some of the major policy areas this year, and how are they affecting patients?</p>
<h3>340B, PDABs, and PBMs</h3>
<p>“The issues we saw this year on prescription drug affordabihlity boards (PDABs), Most Favored Nation (MFN) and Maximum Fair Price (MFP) reference pricing, continued scrutiny of vaccines—we’ll anticipate seeing those again next year,” says Plues.</p>
<p>When it comes to PDABs, there was legislation happening in a number of states, including Colorado, Hawaii, Illinois, Louisiana, Minnesota, Virginia, Vermont, and West Virginia. However, these boards are having trouble proving their financial viability and usefulness when established.</p>
<p>“No new PDABs were introduced this year, and I think that is because of a better understanding of the many actors within the supply chain who impact prescription drug prices,” explains Plues. “There is also the question: <em>Do PDABs actually work?</em> These boards are expensive, and to date, we have not seen them successfully bring down drug prices for patients, and legislators see that.”</p>
<p>BIO has also tracked 63 340B-related bills across 20 states and Puerto Rico.</p>
<p>“340B is a perennial issue in the US,” says Plues. “There needs to be more transparency and accountability from the entities that are receiving 340B dollars on where those dollars are going, and there needs to be better tracking of how 340B products are being dispensed.”</p>
<p>In particular, advocates and biotech leaders are calling out the issue of <em>duplicate discounts</em>, a prohibited practice where a 340B hospital might receive a 340B upfront discount and the state would also receive a Medicaid rebate.</p>
<p>If a hospital provides medication to a Medicaid patient, Plues explains, then that product needs to be reimbursed either through the Medicaid program with the State claiming a rebate, or the state forgoes the rebate and reimburses the providers at the 340B discount rate—often because it may be lower. However, what ends up happening is that manufacturers often end up paying both the Medicaid rebate and discount, with hospitals being the ultimate beneficiary because they get 340B revenue that they are not entitled to.</p>
<p>“Those duplicate discounts are prohibited in the federal statute that governs the 340B program,” Plues says. “Hospitals must work to protect against duplicate discounts, but their current practices only obfuscate and make it harder to identify them. There needs to be legislation to address that because it costs the state and patients more money in the long run.”</p>
<p>And that is not the only 340B-related issue either. In Arkansas, the Attorney General has moved to file a complaint in federal court against manufacturers who are not complying with Arkansas Act 1103 enacted in 2021. This is significant because Arkansas Act 1103 was one of the earliest state laws to address certain 340B-related practices between contract pharmacies, manufacturers, pharmacy benefit managers (PBMs), and payers.</p>
<p>“This is the first court case we’re seeing of a state trying to sue manufacturers for non-compliance of a state 340B law,” explains Plues. “That’s pretty significant, and it is something we are watching closely.”</p>
<p>Lastly, there have been a number of bills aimed at addressing PBM transparency and pharmacy vertical integration in the states.</p>
<p>While BIO currently remains neutral on vertical integration bills, it does agree that comprehensive structural reforms addressing PBM vertical integration and practices are best overseen through coordinated federal and state action.</p>
<h3>The vaccine battle</h3>
<p>“One trend that began popping up in a number of states are bills aimed at holding manufacturers liable for any injury caused by a vaccine,” says Plues. “Really it is just another attempt by the anti-vaccine movement to curb vaccine usage in their states.”</p>
<p>The federal Vaccine Injury Compensation Program (VICP), formed by bipartisan legislation in 1986, is a program, funded by a tax on manufacturers, that has ensured people injured by certain vaccines are provided with a fair and efficient process for compensation. People who have been injured have their cases heard by dedicated judges with experience in vaccine injury, making the process oftentimes faster and more efficient than civil litigation.</p>
<p>BIO maintains the VICP program is the most effective and efficient mechanism to address vaccine-related injuries. BIO counters state-level vaccine-injury bills with a focus on educating state policymakers on why the VICP program is a better alternative for people seeking relief and restitution than developing state liability bills. Learn more about VICP with this <a href="https://www.bio.org/toolkit/human-health/vaccine-injury-compensation-program-protects-patients">BIO resource</a>.</p>
<p>Thankfully, there is also some positive vaccine legislation on the state level.</p>
<p>“We just saw Pennsylvania become the first state to make immunization rates public for all of their school districts, and that’s something we think is a good idea—no other state has done that yet,” says Plues. Learn more with the <a href="https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/healthstatistics/school-immunizations/current/school-immunization-rates.html">Pennsylvania School Immunization Rates Interactive Data Tool</a>.</p>
<h3>Artificial Intelligence</h3>
<p>“There is great interest among state legislators to regulate AI, particularly given that we don’t have a federal law in place yet,” says Plues. “So the states are taking it upon themselves to regulate it.”</p>
<p>In particular, AI’s potential to help drug manufacturers research and develop newer and more effective medicines could change the healthcare landscape as we know it. AI’s use, BIO notes, should be facilitated and protected.</p>
<p>Yet, there is another area of the healthcare world where the use of AI has already caused some concern: insurance coverage. BIO supports legislation that would implement safeguards around insurers’ use of AI in coverage and reimbursement decisions. State and federal guardrails need to be in place to ensure that AI is not being used to systematically deny or restrict access to care.</p>
<p>As we round out 2026 and head into 2027, BIO will continue to work on the ground in the states to ensure that patients of all kinds not only have access to the drugs and treatments they need, but that biotech can continue to innovate and develop breakthroughs.</p>
<p>The post <a href="https://bio.news/state-policy/mid-year-review-state-level-legislative-action-impacting-biotech/">Mid-year review: State-level legislative action impacting biotech</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Sugar&#45;Sweetened Beverages Daily Can Lead to Higher Stomach Cancer Risk</title>
<link>https://edusehat.com/en/sugar-sweetened-beverages-daily-can-lead-to-higher-stomach-cancer-risk</link>
<guid>https://edusehat.com/en/sugar-sweetened-beverages-daily-can-lead-to-higher-stomach-cancer-risk</guid>
<description><![CDATA[ Participants who consumed at least one serving of a sugar-sweetened beverage per day had a 2.45X higher risk of gastric cancer compared with those consuming less than one serving per month.
The post Sugar-Sweetened Beverages Daily Can Lead to Higher Stomach Cancer Risk appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-155073322.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 05:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Sugar-Sweetened, Beverages, Daily, Can, Lead, Higher, Stomach, Cancer, Risk</media:keywords>
<content:encoded><![CDATA[<p>Mass General Brigham Cancer Institute researchers found that consuming one or more sugar-sweetened beverages every day was associated with an increased risk of developing gastric cancer, while artificially sweetened beverages were not associated with an increased risk. Results from the study were published in <em>Gastro Hep Advances, </em>in an article titled <em>“<a href="https://www.ghadvances.org/article/S2772-5723(26)00218-9/fulltext">Association between sugar-sweetened and artificially sweetened beverage intake and gastric cancer incidence.</a>”</em></p>
<p>Previous research has linked sugar-sweetened beverages with an increased risk of colorectal, breast, and liver cancers, but evidence on gastric cancer has been limited. The study analyzed data from 112,284 participants in the Nurses’ Health Study and Health Professionals Follow-Up Study. Both studies gathered detailed diet, lifestyle, and health information on U.S. adults over many decades. During the follow-up period, which spanned decades, 278 participants developed gastric cancer.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“This is the first study to demonstrate an association between sugar-sweetened beverage intake and gastric cancer in a U.S. population,” said senior author Andrew T. Chang, MD, a gastroenterologist and epidemiologist with the Mass General Brigham Cancer Institute. Gastric cancer is the fifth leading cause of cancer death worldwide, but we’ve known little about how diet might contribute to this cancer.</p>
<p>After accounting for other potential risk factors, participants who consumed at least one serving of a sugar-sweetened beverage per day had a 2.45 times higher risk of gastric cancer compared with those who consumed less than one serving per month. The association was observed in both women and men. Higher total fructose intake (fructose is the main sweetener in these drinks) was also associated with greater gastric cancer incidence.</p>
<p>For instance, among women in the Nurses’ Health Study, consuming more than one such beverage per day was associated with a 3.04-fold higher risk of gastric cancer, compared to those who rarely consumed sugar-sweetened beverages. In contrast, after controlling for other factors, higher consumption of artificially sweetened beverages wasn’t associated with a higher incidence of gastric cancer.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Researchers defined sugar-sweetened beverages as carbonated beverages, punch, lemonade, and sports drinks, while artificially sweetened beverages were defined as low-calorie carbonated beverages.</p>
<p>Because <em>Helicobacter pylori </em>infection increases the risk of gastric cancer, researchers also assessed <em>H. pylori</em> status in a subset of 940 participants. While just over one-third of these participants had evidence of <em>H. pylori</em> infection, there was no association between sugar-sweetened beverage consumption and infection.</p>
<p>Limitations of the study include its observational design. It is possible that higher rates of gastric cancer in people who consumed more sugar-sweetened beverages were related to other factors. The study had limited information on <em>H. pylori</em> status and family history of gastric cancer. In addition, participants were predominantly white, limiting the researchers’ ability to examine differences across racial and ethnic groups.</p>
<p>However, the large study population and detailed health and lifestyle information gathered over many years allowed the researchers to control for many other possible potential risk factors for gastric cancer.</p>
<p>The researchers say further studies are needed to confirm the findings and investigate why these beverages might increase gastric cancer risk.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/sugar-sweetened-beverages-daily-can-lead-to-higher-stomach-cancer-risk/">Sugar-Sweetened Beverages Daily Can Lead to Higher Stomach Cancer Risk</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Embedding Regulatory Strategy in Cell and Gene Therapy Development</title>
<link>https://edusehat.com/en/embedding-regulatory-strategy-in-cell-and-gene-therapy-development</link>
<guid>https://edusehat.com/en/embedding-regulatory-strategy-in-cell-and-gene-therapy-development</guid>
<description><![CDATA[ In this GEN webinar, experts from Rose BioSolutions, a CDMO and Cell Solutions organization formed from Charles River Laboratories’ businesses, will discuss how integrating regulatory strategy at the earliest stages of development can reduce overall risk and improve program outcomes. 
The post Embedding Regulatory Strategy in Cell and Gene Therapy Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_2206096604_ClinicalTrialsConcept.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 05:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Embedding, Regulatory, Strategy, Cell, and, Gene, Therapy, Development</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/mocny-headshot-e1787076505118.jpg" class="h-full w-full object-cover" alt="Image of Jeffrey Mocny, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Jeffrey Mocny, PhD</h2>
                <h5 class="mt-0 !text-[15px]">VP Scientific Leadership<br>Rose BioSolutions</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/mocny-headshot-e1787076505118.jpg" alt="Image of Jeffrey Mocny, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Jeffrey Mocny, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Jeffrey Mocny, PhD, VP Scientific Leadership for Rose BioSolutions translates client needs into actionable development and manufacturing programs that help clients achieve their therapeutic development goals. Mocny leads a team of scientists with expertise in cell and molecular biology, virology, immunology, immunotherapy, T-cell biology, and viral vector transduction techniques. Central to the Scientific Leadership team’s approach is developing phase-appropriate strategies that ensure regulatory compliance and provide the scientific rationale for the manufacturing approaches employed by Rose’s clients. A product strategy and development executive leader, he leverages experience in quality management, strategic planning, and risk mitigation to guide programs from conceptualization to completion. Mocny has a PhD from the State University of New York at Buffalo (SUNY at Buffalo), an MS and BS from Gannon University, and has completed postdoctoral fellowships at the University of North Carolina at Chapel Hill and Duke University. As an innovator in the CDMO and CRO sectors for more than 20 years, his experience in product development spans analytical, manufacturing, market entry/positioning, and regulatory strategy.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/Felicia-Irons-headshot-e1787076414316.jpg" class="h-full w-full object-cover" alt="Image of Felicia Irons, BS, CSSGB">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Felicia Irons, BS, CSSGB</h2>
                <h5 class="mt-0 !text-[15px]">Global CDMO Regulatory Affairs & Compliance Lead<br>Rose BioSolutions</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/Felicia-Irons-headshot-e1787076414316.jpg" alt="Image of Felicia Irons, BS, CSSGB">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Felicia Irons, BS, CSSGB</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Felicia Irons, global CDMO regulatory affairs & compliance lead for Rose BioSolutions, ensures the highest level of quality, regulatory compliance and safety are adhered to for cell and gene therapy programs across Rose BioSolutions CDMO business unit. An expert in Quality Management Systems (QMS), Felicia is a member of the Regulatory Affairs Professionals Society (RAPS), American Society of Quality (ASQ), and Parenteral Drug Association (PDA). Prior to her position at Rose BioSolutions, Felicia served as the global CDMO regulatory affairs & compliance lead for Charles River Laboratories’ CDMO business unit, head of quality at Natureplex, quality manager and regulatory liaison for PharMEDium Services (an AmerisourceBergen company), and corporate quality manager with Drexel Chemical. Felicia has a BS in chemistry and biochemistry from the University of Memphis, certification in Six Sigma Green Belt from Villanova University and certificate in quality culture and investigations from PDA. Active in her community with many organizations involving healthcare, education and youth, Felicia founded the JusLuv Community Foundation in 2006 to assist youth and young adults in career mentorship.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Thursday, September 17, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-09-17T15:00:00.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">For cell and gene therapy programs, early development decisions can have a significant impact on regulatory success, development timelines, and overall program risk. Embedding regulatory strategy from the outset helps developers identify critical challenges early, align development activities with product-specific requirements, and build a stronger foundation for future clinical and commercial milestones.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN </em>webinar, experts from Rose BioSolutions, a CDMO and Cell Solutions organization formed from Charles River Laboratories’ businesses, will discuss how integrating regulatory strategy at the earliest stages of development can reduce overall risk and improve program outcomes. Attendees will learn how a well-defined Target Product Profile (TPP) can guide decision-making across the drug development lifecycle, and help teams prioritize activities, anticipate regulatory expectations, and develop a fit-for-purpose CGT manufacturing and testing strategy. Presenters will use real-world case studies to highlight common cell and gene therapy product development challenges and practical approaches to addressing issues such as sterility testing, interim product release, and device compatibility at patient infusion.</p><p></p><p></p><p></p><h4 class="wp-block-heading"><strong>Key Takeaways</strong></h4><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>How to implement a regulatory strategy during program scoping to align development activities with product-specific risks and compliance expectations</li><p></p><p></p><p></p><li>Why a Target Product Profile (TPP) should be established at the beginning of development and how it guides strategy, critical quality requirements, and risk mitigation plans</li><p></p><p></p><p></p><li>How early identification of product-specific challenges can help minimize unnecessary regulatory information requests, avoid manufacturing delays, and support timely patient treatment</li><p></p><p></p><p></p><li>Practical strategies for developing a more efficient, inspection-ready path from early development through clinical manufacturing and commercialization</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-full is-resized"><a href="https://rosebiosolutions.com/" target="_blank" rel=" noreferrer noopener"><img fetchpriority="high" decoding="async" width="813" height="285" src="https://www.genengnews.com/wp-content/uploads/2026/08/rose_logo_digital_pos_blk_rgb_260421.jpg" alt="Rose Biosolutions logo" class="wp-image-336749" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/rose_logo_digital_pos_blk_rgb_260421.jpg 813w, https://www.genengnews.com/wp-content/uploads/2026/08/rose_logo_digital_pos_blk_rgb_260421-300x105.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/rose_logo_digital_pos_blk_rgb_260421-768x269.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/rose_logo_digital_pos_blk_rgb_260421-696x244.jpg 696w" sizes="(max-width: 813px) 100vw, 813px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/embedding-regulatory-strategy-in-cell-and-gene-therapy-development/">Embedding Regulatory Strategy in Cell and Gene Therapy Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Exercise&#45;Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes</title>
<link>https://edusehat.com/en/exercise-boosting-molecule-may-help-improve-muscle-health-in-type-2-diabetes</link>
<guid>https://edusehat.com/en/exercise-boosting-molecule-may-help-improve-muscle-health-in-type-2-diabetes</guid>
<description><![CDATA[ Researchers discovered that a key molecule released during exercise strengthens muscles, improves exercise performance and could be a therapeutic treatment for muscle damage caused by type 2 diabetes.
The post Exercise-Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2019/02/Feb12_2019_Fotolia_58261043_Exercise.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 19 Aug 2026 01:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Exercise-Boosting, Molecule, May, Help, Improve, Muscle, Health, Type, Diabetes</media:keywords>
<content:encoded><![CDATA[<p>An international research team headed by scientists at the University of Leeds discovered that a key molecule released during exercise strengthens muscles, improves exercise performance, and could be a therapeutic treatment for muscle damage caused by type 2 diabetes. Their collective results of the study, involving experiments in mice, and human plasma analyses, identified the muscle-derived metabolite beta-aminoisobutyric acid (BAIBA) as a central regulator of how muscles remodel, strengthen, and improve their endurance in response to exercise training. The findings further showed that it’s the L-enantiomer, L-BAIBA, that acts as the primary mediator of muscular effects.</p>
<p>Research lead Lee Roberts, PhD, professor of molecular physiology and metabolism at the University of Leeds, said, “Our research identifies L-BAIBA as an exercise-induced signal that helps muscles adapt, improve their metabolic capacity and ability to contract, and ultimately enhances physical performance. This gives us exciting new insight into how exercise benefits the body and highlights a promising target for future therapies aimed at preserving muscle function in chronic conditions such as diabetes.”</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Roberts is senior and corresponding author of the team’s published paper in <em>Nature Communications</em>, titled “<a href="https://doi.org/10.1038/s41467-026-76307-8">The metabokine β-aminoisobutyric acid mediates exercise performance and skeletal muscle adaptation through a PGC1α-BAIBA-PPARδ axis</a>.” In their paper, the team noted, “It may be that BAIBA can offer a novel therapy for other diseases with a skeletal muscle atrophy or dysfunction component, such as chronic heart failure, cancer cachexia, or sarcopenia. Conducting intervention studies using BAIBA to target muscle function, exercise capacity, and quality of life in these clinical populations will be important for future translation.”</p>
<p>Exercise training involves multiple bouts of activity that challenge whole-body physiology, driving adaptations across cells, tissues, and organs, the author wrote. “Exercise is also an effective intervention for the prevention or treatment of a range of diseases and pathological risk factors, including obesity, type 2 diabetes (T2D), and cardiovascular disease, and may facilitate improvements in age-related reduction in quality of life.”</p>
<p>But how exercise impacts the body’s ability to respond to challenges is not fully understood. The team continued, “Elucidating the fundamental molecular mechanisms and intra- and inter-organ signals through which exercise mediates systemic adaptations, driving beneficial effects, holds potential for the identification of both therapeutic targets and new strategies to treat a range of diseases, including T2D.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Given the health benefits of exercise, Roberts and colleagues set out to discover whether this mechanism could hold the potential for treatment for chronic conditions such as type 2 diabetes. L-BAIBA has been studied in the past, and Roberts carried out <a href="https://doi.org/10.1016/j.cmet.2013.12.003">research</a> in 2014, which showed that it had beneficial effects on metabolism, boosting the fat-burning effects of exercise. It can now be purchased as a nutritional supplement.</p>
<p>The newly reported study has found that it triggers muscles to respond and change, linking exercise to beneficial alterations in muscle structure and metabolism. “Circulating L-BAIBA associated with aerobic fitness in humans,” the team noted in summary. “The current study identified that in mice, BAIBA supplementation in drinking water increases skeletal muscle mitochondrial number and functional capacity, improves muscle contractile function, and drives phenotypic remodelling similar to aerobic exercise training. We find that BAIBA supplementation in mice, when combined with exercise training through wheel running, leads to an increased adaptive response in skeletal muscle.”</p>
<p>L-BAIBA also protected muscle from damage that occurs in type 2 diabetes, which can limit a person’s quality of life, such as loss of muscle and strength, and impaired metabolism. Improving muscle resistance to fatigue could be transformative, as exercise can help to manage diabetes. The discovery that BAIBA not only mimics the adaptive response of muscle to exercise but can also contribute to translating the benefits of exercise to improved muscle and systemic function may have important clinical implications, the investigators continued. “In our study, BAIBA treatment exhibited therapeutic potential by improving the free-wheel running capacity and skeletal muscle molecular, metabolic, and functional phenotype in a mouse model of obesity and T2D-induced skeletal muscle dysfunction.”</p>
<p>Anna Morris, assistant director of research strategy and partnership at Diabetes UK, said, “Exercise plays an important role in managing type 2 diabetes, but for many people, muscle weakness and fatigue can make staying active a real challenge. This research helps us better understand how muscles adapt to exercise and identifies a potential new target for improving muscle health. While these findings are still at an early stage, they could help shape future approaches that support people with type 2 diabetes to remain active and live healthier, longer lives.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/exercise-boosting-molecule-may-help-improve-muscle-health-in-type-2-diabetes/">Exercise-Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Albumin&#45;Fused Antibodies May Reduce Fetal Exposure to Therapeutics</title>
<link>https://edusehat.com/en/albumin-fused-antibodies-may-reduce-fetal-exposure-to-therapeutics</link>
<guid>https://edusehat.com/en/albumin-fused-antibodies-may-reduce-fetal-exposure-to-therapeutics</guid>
<description><![CDATA[ Preclinical study found that fusing immunoglobulin G (IgG) antibodies to albumin minimized antibody transport across the placenta and prevented adverse effects in offspring in mice, pointing to albumin as an attractive fusion partner for IgG-based therapeutics.
The post Albumin-Fused Antibodies May Reduce Fetal Exposure to Therapeutics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2022/10/Getty_183878409_FetusWithDNAUmbilicalCord-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 07:40:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Albumin-Fused, Antibodies, May, Reduce, Fetal, Exposure, Therapeutics</media:keywords>
<content:encoded><![CDATA[<p>Researchers at the University of Oslo and Oslo University Hospital, together with national and international collaborators, have reported on the results of preclinical research that could reshape the future design of biologic medicines that can be delivered during pregnancy with limited fetal exposure.</p>
<p>Led by Jan Terje Andersen, PhD, at the University of Oslo and Oslo University Hospital, the team’s studies in mice and in <em>ex vivo</em> human tissues found that the placenta distinguishes between antibodies and albumin. The scientists showed that although the neonatal Fc receptor binds both immunoglobulin G (IgG) antibodies and albumin, FcRn expressed in the placenta selectively transports IgG to the fetus, while largely excluding albumin. Their experiments demonstrated that fusing IgG antibodies to albumin minimized their transport across the placenta and prevented adverse effects in offspring in mice.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The findings address a rapidly growing unmet need. While monoclonal IgG antibodies are increasingly used to treat chronic diseases that affect women during their reproductive years, decisions concerning treatment during pregnancy often involve balancing the benefits of disease control against risks to the developing fetus.</p>
<p>Andersen said, “Rather than asking whether existing biologic medicines are safe to use during pregnancy, our findings show that we can now design them differently. The placenta selectively transfers protective IgG antibodies while preventing albumin from crossing. By understanding this, we now have the opportunity to develop a new generation of biologic medicines that combine long-lasting efficacy with improved safety during pregnancy. This study shows how fundamental discoveries in biology can directly inspire the design of better medicines.”</p>
<p>Andersen is corresponding author of the team’s published paper in <em>Science Immunology</em>, titled “<a href="http://dx.doi.org/10.1126/sciimmunol.aee5151" target="_blank" rel="noopener">Fusion of IgG antibodies to albumin inhibits transport across the placenta</a>,” in which they concluded, “These findings identify albumin as an attractive fusion partner for biologics intended to minimize fetal exposure during pregnancy.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Albumin and IgG antibodies are the most prevalent soluble proteins in blood, the team explained. “Whereas IgG is pivotal in the fight against infectious diseases, albumin transports a plethora of insoluble ligands, such as fatty acids, hormones, and waste products, for delivery to tissues and organs.”</p>
<p>IgG-based monoclonal antibodies are among the fastest-growing class of biologics that are being used to treat a range of acute and chronic diseases, the team noted, and are effective therapies for cancer, autoimmune diseases, and migraine. “However, they are actively transported across the placenta by the neonatal Fc receptor (FcRn), limiting their use during pregnancy.” Evidence that supports safe use of such therapeutics during pregnancy remains limited.</p>
<p>For their studies, the team focused on albumin, a transport protein that also has a long half-life and binds FcRn at a different site to IgG. The researchers showed that FcRn transferred maternal IgG, but not albumin, across the placenta and into fetal pups in mice. To uncover the mechanism, the researchers combined studies in conventional and genetically humanized mouse models with an advanced <em>ex vivo</em> human placental perfusion system using placentas donated immediately after childbirth. Across all models, the findings were strikingly consistent: IgG antibodies were transferred efficiently, whereas albumin was not.</p>
<p>The researchers then took advantage of the discovery to make a platform for engineering next-generation biologics. They found that fusion of albumin to therapeutic IgG antibodies produced biologics with both FcRn-mediated long plasma half-life and substantially reduced placental transport. An even greater effect was achieved by fusing antibody fragments to an engineered albumin variant (QMP) with optimized human FcRn binding, demonstrating that both reduced placental transfer and long plasma half-life can be tuned through rational protein design.</p>
<p>The concept was validated in human placental tissue and disease models. In a mouse model of fetal and neonatal alloimmune thrombocytopenia (FNAIT)—a potentially life-threatening pregnancy complication in which maternal antibodies attack fetal platelets—the engineered antibodies resulted in substantially reduced fetal exposure and associated adverse effects in the offspring.</p>
<p>“This is first and foremost a discovery of how the placenta works,” Andersen said. “For decades, we have known that FcRn binds both IgG and albumin, yet only IgG reaches the fetus by an FcRn-dependent mechanism. We show that the placenta has a remarkable ability to distinguish between these two soluble proteins, revealing a level of biological selectivity that was previously unrecognized.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The findings address a rapidly growing unmet need. While monoclonal IgG antibodies are increasingly used to treat chronic diseases that affect women during their reproductive years, decisions concerning treatment during pregnancy often involve balancing the benefits of disease control against risks to the developing fetus. The authors propose that further research is needed to understand the mechanisms that restrict albumin transport, which could inform more tailored therapeutics with varied fetal exposure profiles.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/albumin-fused-antibodies-may-reduce-fetal-exposure-to-therapeutics/">Albumin-Fused Antibodies May Reduce Fetal Exposure to Therapeutics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human Cell Atlas at 10: A Decade of Discovery and the Road to HCA 2.0</title>
<link>https://edusehat.com/en/human-cell-atlas-at-10-a-decade-of-discovery-and-the-road-to-hca-20</link>
<guid>https://edusehat.com/en/human-cell-atlas-at-10-a-decade-of-discovery-and-the-road-to-hca-20</guid>
<description><![CDATA[ Marking its 10th anniversary, the Human Cell Atlas reflects on a decade of breakthroughs while charting an ambitious course for the next decade. GEN&#039;s Julianna LeMieux, PhD, spoke with Holger Heyn, PhD, ICREA professor at the Centro Nacional de Análisis Genómico (CNAG) and co-founder of Omniscope about the meeting and what the next 10 years may bring.
The post Human Cell Atlas at 10: A Decade of Discovery and the Road to HCA 2.0 appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/OMI-Human-Cell-Atlas-Kyle-Klein-KK4_7945-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 04:05:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, Cell, Atlas, 10:, Decade, Discovery, and, the, Road, HCA, 2.0</media:keywords>
<content:encoded><![CDATA[<p>The Human Cell Atlas (HCA) was co-founded in 2016 by Aviv Regev, PhD, currently the head, executive vice president of research and early development at Genentech and Sarah Teichmann, FMedSci FRS, professor at the University of Cambridge and vice president translational research at GSK.</p>
<p>This year, the group celebrated its 10-year anniversary, at the annual meeting in June, held in Boston. The first day was focused on the successes of the past decade. The second day looked ahead to the future, and the impact the HCA will make on research and drug discovery. <em>GEN </em>spoke with Holger Heyn, PhD, ICREA professor at the Centro Nacional de Análisis Genómico (CNAG) and co-founder of Omniscope about the meeting and what the next 10 years may bring. Heyn has been with the HCA since (almost) the beginning and currently serves as the co-chair of the Standards and Technologies working group, co-chair of the Industry Partnership Program, an organizing committee member, and a member of the task force to design HCA 2.0.</p>
<p class="trimmed"> </p>
<p><strong><span><em>LeMieux: </em></span><em>Let’s start with the meeting, which covered a lot of ground. Can you share what the main takeaways were? </em></strong></p>
<p><strong>Heyn:</strong> The first day was about the past—the last 10 years. The second day was about the future. And the third day was reserved for working group meetings.</p>
<figure aria-describedby="caption-attachment-336670" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336670 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/07/OM-HolgerHeyn-Topaz-Gigapixel-4x-scale.jpg" alt="Holger Heyn" width="160" height="160" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/OM-HolgerHeyn-Topaz-Gigapixel-4x-scale.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/07/OM-HolgerHeyn-Topaz-Gigapixel-4x-scale-150x150.jpg 150w" sizes="auto, (max-width: 160px) 100vw, 160px"><figcaption class="wp-caption-text">Holger Heyn, PhD<br>Co-founder, Omniscope</figcaption></figure>
<p>Talking about the past, the first day celebrated the completion of most organ and tissue atlases of the HCA. The HCA activities are broken down into 18 different biological networks (or bionetworks): lung, liver, heart, etc. All of those will have either published or submitted their atlases in 2026.</p>
<p>After 10 years, we have come a long way and we delivered what we set out to do, which was the generation of the HCA, single-cell resolved, for all main tissue and organ systems. That is exactly the mission of the HCA: completely grassroots—to deliver representative atlases of tissues and organs with openly available data. In total, we have already 450 publications, that have been cited 100,000 times, and a global representation with almost 4,000 members from a hundred countries. Recently, the representation from Africa and South America has grown a lot. The HCA is now a really global effort.</p>
<p class="trimmed"> </p>
<p><strong><span><em>LeMieux:</em></span><em> On the point of increasing the globalization of the HCA, how is the technology being democratized to reach more areas of the world? </em></strong></p>
<p><strong>Heyn</strong>: This has been approached in two separate ways. One was when my group published a method to cryopreserve cells, about eight years ago. It allowed researchers to put cells in the freezer and then thaw them to run them anywhere. The idea was to centralize data processing, so each hospital or each center does not need to have a single-cell instrument. More recently, we have been able to use formalin fixation, which allows researchers to fix and sequence later. Both technologies offer flexibility in terms of where the data is generated and to disconnect the sampling from the processing time. Being able to collect and store, then process later, makes single-cell analysis much more accessible.</p>
<p>In addition, there has been a drop of cost per cell. Although the assay is still costly, over the years, people get more cells per dollar, allowing the generation of scalable atlases. Now, most of these atlases are represented by millions of cells. Ten years ago, there was no way to afford that.</p>
<p class="trimmed"> </p>
<p><strong><span><em>LeMieux:</em></span><em> Now let’s move into the future. The first day of the meeting was called HCA 1.0. But now let’s talk about day two, or HCA 2.0. </em></strong></p>
<p><strong>Heyn:</strong> Day two was all about the future roadmap and where the project is going. Aviv Regev highlighted this in her talk. Even though the HCA is now split into phase one and phase two, the that was published 10 years ago in <em>eLife</em> laid everything out clearly. There are the two pillars, single-cell and spatial, to build atlases. Single-cell technology was available earlier and only now is spatial becoming scalable. The initial plan was always to do a single-cell and the spatial cell atlas—to profile cells in their tissue context. But technology had to catch up.</p>
<p>For HCA 2.0, we now have a five-year time frame where we scale the atlas in multiple different directions. One is the already mentioned spatially resolved atlases: we will use spatial methods, very advanced capture-based sequencing methods, and full transcriptome imaging-based methods. The focus of HCA 2.0 is to move away from cells in dissociation and toward generating spatial data at scale. With this, we can use the single cell references that we have generated in the past and map cells back into their natural context.</p>
<p>The second focus is the global representation. One area where this goal has been very nicely implemented is in Asia. HCA Asia is one of the largest, most active communities. In HCA 2.0, we aim at better diversity, representing not only blood, which is the best represented sample type right now, but also other major tissue types.</p>
<p>The third, and very important one, is opening from a healthy reference atlas to include a disease focus. We had a discussion with the HCA community at the meeting where to focus first. We asked, what are global disease burdens, what are local efforts we want to support, and what samples are available?</p>
<p>Disease also brings us closer to collaborating with pharma partners. We are in discussion with multiple partners to make our atlas generation efforts useful for diagnostics and drug development. For increasing impact, you eventually need commercialization and innovation on top of that. Pharma partners are already developing drugs using our healthy atlases. Now it will be crucial to align with these collaborators for diseased atlas efforts as well.</p>
<p>Fourth, imagine a Venn diagram with the single-cell atlases, spatial, disease, and genetic diversity. And now picture in the middle a small circle as a union: these are the foundation models. The HCA is generating a unique resource to build foundation models. Most foundation models to date are already built on single cells from our atlases. However, many recent initiatives are also building foundation models based on spatial data, in order to have the tissue context represented. To make these foundation models useful, you have to train them on a specific task. And this is where the disease context becomes important. With the healthy atlases, you have the representation of cellular biology of the human system. Fine tuning models can then be based on predictive tasks, such as drug target identification, prediction of therapy outcome, and patient stratification. This brings out the real value of those models, to make them actionable and to use them for predictive tasks.</p>
<p class="trimmed"> </p>
<p><strong><span><em>LeMieux:</em></span><em> It seems like every time I turn around there is a new virtual cell project, whether it’s being done by CZI or Tahoe or another group. So how do all of these come together with HCA? </em></strong></p>
<p><strong>Heyn: </strong>We are a virtual cell community. HCA is in active discussion with all of the stakeholders. We all have the same goal to build a virtual cell that is representative of biology and diseases. We all have very different approaches. The approach that the HCA is offering is that we use spatial technology to put cells back in their natural context and then to use such data to train models on the natural perturbation of interacting cells. But everyone has their own niche. There is no right or wrong for now. We are following strategies that will be complementary and synergistic in the future.</p>
<p class="trimmed"> </p>
<p><span><strong><em>LeMieux:</em></strong></span><em> Moving toward disease, where do you think that the HCA will start to make inroads? </em></p>
<p><strong>Heyn:</strong> Today it is still hard to say. We did some analysis, asking what our community chooses as diseases of interest? We also talked to the main stakeholders to make those atlases impactful. We are basically in the landscaping phase to see what disease areas are suitable for pilot flagship projects on specific tissues and diseases. But we already want to connect this initial phase to the end goal. Therefore, we need the different stakeholders on board to make informed decisions together with all parties.</p>
<p>There are two main objectives for a pharma company when using the atlases. One is to find new drug targets. The second is to predict toxicity to have on target and not off target effects. To do that, they need both a healthy reference and a disease cohort. Traditionally, you would have done a differential expression analysis to find something in the disease cohort that is missing in the healthy reference. Now you can actually map that out spatially at cellular resolution.</p>
<p class="trimmed"> </p>
<p><strong><span><em>LeMieux:</em></span><em> How much of a spatial focus do you think there will be in a decade from now?  </em></strong></p>
<p><strong>Heyn:</strong> Over the next five years, there will be a heavy focus on spatial data generation. There will be large-scale, flagship projects using spatial technologies. Single-cell will not go away though. For immune related references, diversity, and certain diseases, you still need single-cell analysis. Spatial will be the driver though toward more clinical applications. Spatial is the way forward to really look at clinical cohorts and diseased tissue at scale and for digital pathology implementations.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/human-cell-atlas-at-10-a-decade-of-discovery-and-the-road-to-hca-2-0/">Human Cell Atlas at 10: A Decade of Discovery and the Road to HCA 2.0</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Rewriting Disease: Oligonucleotides Take Aim at the Untreatable</title>
<link>https://edusehat.com/en/rewriting-disease-oligonucleotides-take-aim-at-the-untreatable</link>
<guid>https://edusehat.com/en/rewriting-disease-oligonucleotides-take-aim-at-the-untreatable</guid>
<description><![CDATA[ How synthetic DNA and RNA are becoming the discovery engines behind a new generation of precision therapies.
The post Rewriting Disease: Oligonucleotides Take Aim at the Untreatable appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/10/Getty_2147604870_AptamerTherapeutic.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 04:05:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Rewriting, Disease:, Oligonucleotides, Take, Aim, the, Untreatable</media:keywords>
<content:encoded><![CDATA[<p>For decades, drug discovery has revolved around a familiar challenge: finding ways to modulate proteins that drive disease. Small molecules and biologics have transformed medicine, yet vast portions of the human genome remain stubbornly out of reach. Many disease-causing targets are considered undruggable, leaving researchers with few options for intervention, but oligonucleotide therapeutics are changing that equation.</p>
<p>Built from short, synthetic strands of DNA or RNA, oligonucleotides offer a fundamentally different way to influence disease biology. Rather than targeting proteins after they are produced, these molecules act upstream, engaging RNA and gene-regulatory pathways to alter protein expression with remarkable precision and duration. Their growing success has transformed them from a niche modality into one of the most promising frontiers in therapeutic discovery.</p>
<p>Today, advances in artificial intelligence (AI), multiomics analysis, human genetics, and disease modeling are accelerating the identification of new oligonucleotide targets. Across neurodegeneration, fibrosis, metabolic disease, and rare genetic disorders, companies are using these technologies to uncover biological mechanisms that were previously hidden. The result is a rapidly expanding therapeutic landscape where researchers are no longer limited by conventional notions of druggability.</p>
<p></p><h4><strong>A new class of precision medicines</strong></h4>

<p>Oligonucleotides are engineered sequences of nucleic acids, typically ranging from 10 to 50 nucleotides in length. Because they can be designed to recognize specific genetic sequences, they provide highly selective control over biological processes. Chemical modifications give sustained effects with patients receiving maintenance doses every three to 12 months.</p>
<p>As explained by Evotec: “Unlike gene therapy, oligonucleotide drugs targeting RNA, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) have a transient effect in the body, and do not permanently modify the patients’ genome. Sequence-based targeting of RNA uses synthetically produced, matching stretches of oligonucleotides to bind with exquisite precision to a specific RNA target, causing subsequent changes in protein expression, either by altering splicing of the immature RNA or causing rapid turnover of that RNA before a protein can be made.” This temporary and programmable nature has made oligonucleotides an attractive therapeutic platform.</p>
<p>The field has expanded far beyond simple gene silencing. Modern oligonucleotide approaches can redirect RNA splicing, edit RNA transcripts, enhance protein expression, block RNA-binding proteins, and even target proteins directly through aptamers, which are structured nucleic acid molecules capable of binding proteins with antibody-like affinity.</p>
<p>Overall, oligonucleotides are increasingly viewed not merely as another therapeutic modality, but as a platform capable of unlocking entirely new classes of targets.</p>
<p></p><h4><strong>Guiding drug discovery with microRNA</strong></h4>

<p>One area generating significant excitement involves microRNAs, which David Salzman, PhD, CEO of Gatehouse Bio, describes as “master regulators of biological pathways.” Rather than targeting a single gene, a microRNA can control entire biological programs, including cellular stress responses, inflammation, fibrosis, and protein production. Because these pathways are often disrupted across multiple diseases, microRNAs offer an opportunity to intervene at key regulatory nodes, particularly in central nervous system (CNS) disorders where distinct diseases frequently share underlying mechanisms.</p>
<p>Beyond their regulatory functions, microRNAs offer another advantage as druggable targets, Salzman explained. “They have dual roles as both biomarkers and drug targets.”</p>
<p>Researchers can inhibit harmful microRNAs using ASOs or restore beneficial microRNAs with synthetic mimetics, creating a direct bridge between diagnosis and therapeutic intervention.</p>
<p><figure aria-describedby="caption-attachment-336680" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-336680" src="https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-300x152.jpg" alt="Lung Images" width="300" height="152" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-300x152.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-1024x517.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-768x388.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-832x420.jpg 832w, https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-696x351.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-1392x707.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images-1068x539.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/DD_MAY_Gatehouse-Bio_Lung-Images.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">These images from lung slices grown ex vivo from healthy tissue and patients with idiopathic pulmonary fibrosis show the distribution in lung tissue of the microRNA isomer, GHB1589, which localizes to disease-driving fibroblasts and alveolar cells. [Gatehouse Bio]</figcaption></figure>AI has become a powerful tool for identifying clinically relevant oligonucleotide targets. While much of the industry focuses on molecule design, Gatehouse Bio uses AI to identify patient subgroups most likely to respond to specific therapies. “Even the best AI-designed molecules will fail if they’re tested in the wrong patient population. We use microRNAs to tell us which patients to treat and also how to treat them.” Salzman says.</p>
<p>The approach reflects growing recognition that many diseases are more heterogeneous than clinical diagnoses suggest. In neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and vascular dementia, patients with similar symptoms might have different molecular drivers. By analyzing thousands of microRNA measurements alongside clinical outcomes, pathology, imaging, and other molecular datasets, AI can uncover patterns that traditional methods often miss.</p>
<p>“Ultimately, our goal is not simply to identify biomarkers,” Salzman said. “We use AI to connect microRNAs to disease biology, patient subgroups, and therapeutic opportunities.” The strategy moves researchers beyond correlation and toward causal, mechanistic understandings, a crucial step in validating therapeutic targets.</p>
<p></p><h4><strong>Multiomics and biomarkers</strong></h4>

<p>Although AI can identify disease-associated signals, determining whether those signals drive disease requires additional biological context. This is where multiomics approaches have become indispensable.</p>
<p>By integrating microRNA sequencing with transcriptomics, proteomics, genomics, pathology information, and clinical-outcome data, researchers can reconstruct disease networks. If a microRNA appears altered in patients with a specific outcome or pathology, investigators can assess whether related genes and proteins change in a coordinated manner. This helps distinguish passengers from drivers when prioritizing therapeutic targets.</p>
<p>“The power of multiomics is that it allows us to connect microRNAs to disease biology, patient subgroups, and therapeutic opportunities with much greater confidence than any single data type alone,” Salzman noted.</p>
<p>Gatehouse Bio’s fibrosis program illustrates how oligonucleotide discovery combines AI, multiomics, patient stratification, and experimental validation. In fibrotic tissues and blood samples from patients with idiopathic pulmonary fibrosis, the company identified reduced levels of a microRNA called miR-92.</p>
<p>Initially, the finding appeared to be only a biomarker. However, integrated analyses revealed something more significant. Reduced miR-92 activity mapped to fibrosis-related pathways involving TGF-beta signaling, WNT signaling, extracellular matrix remodeling, and integrin biology. Patients with lower circulating miR-92 levels experienced worse outcomes, and experiments showed that reducing miR-92 activity worsened fibrosis, whereas restoring it produced anti-fibrotic effects. The result was GHB1589, an miR-92 mimetic.</p>
<p>For Gatehouse Bio, the program represents a blueprint for target discovery: identify disease-associated RNA signatures, connect them to biological mechanisms, stratify patients, validate causality, and translate the findings into therapeutics.</p>
<p></p><h4><strong>Recreating disease in human neurons</strong></h4>

<p>Another major challenge in oligonucleotide discovery involves generating disease models that accurately reflect human pathology. AcuraStem has addressed this problem by using patient-derived induced pluripotent stem cells (iPSCs) that are directly converted into induced motor neurons. Unlike many traditional laboratory models, these neurons preserve aging characteristics and disease-specific pathology from the original donor.</p>
<p>According to AcuraStem’s CEO Sam Alworth these patient-derived models have been instrumental in uncovering novel therapeutic targets. “AcuraStem uses transcription factor-mediated lineage conversion to reprogram patient-derived iPSCs into induced motor neurons that retain the aging and pathological markers of the donor,” Alworth explained. The company’s iNeuroRx platform integrates these disease models with ASO design, screening, and pharmacology tools, creating a comprehensive discovery engine.</p>
<p><figure aria-describedby="caption-attachment-336682" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="size-medium wp-image-336682" src="https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-300x169.jpg" alt="amyotrophic lateral sclerosis (ALS), antisense oligonucleotides" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-747x420.jpg 747w, https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-696x391.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-1392x783.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839-1068x600.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/DD-p19-GettyImages-1328336839.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">In patients with the motor-neuron disease amyotrophic lateral sclerosis (ALS), antisense oligonucleotides might lead to new treatments. [Kateryna Kon/Science Photo Library/Getty Images]</figcaption></figure>AcuraStem’s work centers on TDP-43, a protein whose dysfunction is implicated in the majority of amyotrophic lateral sclerosis (ALS) cases and several forms of dementia. “TDP-43 pathology is a crucial contributor to neurodegeneration,” said Marcel van der Brug, PhD, AcuraStem’s CSO. Normally, TDP-43 regulates RNA processing. In disease, however, it becomes depleted from the nucleus, leading to widespread RNA dysregulation and altered gene expression.</p>
<p>AcuraStem’s disease models reproduce TDP-43 pathology without requiring artificial stressors or genetic manipulation—a capability the company believes is unique. This platform has enabled the discovery of several therapeutic targets, including the gene <em>SYF2</em>, which appears capable of restoring TDP-43 localization and function.</p>
<p>The work highlights a broader trend within oligonucleotide discovery: targeting upstream molecular mechanisms rather than downstream symptoms. “RNA dysregulation, as a direct and measurable consequence of TDP-43 dysfunction, is a target that can be modulated by technologies such as antisense oligonucleotides,” Alworth said.</p>
<p></p><h4><strong>An expanding oligonucleotide toolbox</strong></h4>

<p>While some companies begin with disease biology, others start with genetics. Aperture Therapeutics, for example, is building its discovery strategy around naturally occurring protective human genetic variants. The company’s platform analyzes large-scale genomic and clinical datasets to identify resilience mechanisms that protect individuals from neurodegenerative disease. These insights are then translated into oligonucleotide strategies, including gene-expression modulation and splice-switching approaches. By focusing on genetically validated targets, Aperture aims to reduce development risk and improve the probability of clinical success. The strategy reflects a growing industry consensus: human genetics provides one of the strongest forms of biological validation available.</p>
<p>The oligonucleotide field is also expanding beyond traditional antisense and RNA interference approaches. As an example, Opprtna Therapeutics is developing aptamer-based therapeutics for CNS diseases. Unlike many aptamers that primarily serve delivery functions, the company is designing molecules that directly influence disease biology. Using structured DNA molecules capable of binding proteins associated with RNA and DNA regulation, Opprtna hopes to target pathways that have traditionally been inaccessible to conventional drug modalities. The approach underscores how oligonucleotide chemistry itself continues to evolve, creating entirely new therapeutic opportunities.</p>
<p>Meanwhile, Riboway Therapeutics is pursuing RNA-targeting technologies capable of increasing, decreasing, activating, or inhibiting protein expression depending on the therapeutic need. The company’s AI-driven platform focuses on decoding RNA regulation to identify previously inaccessible intervention points.</p>
<p>In many ways, oligonucleotides are redefining what drug discovery can be. Rather than asking whether a target is druggable, researchers are increasingly asking how RNA biology can be leveraged to reach it. That shift may ultimately prove to be one of the most important developments in modern therapeutics.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/rewriting-disease-oligonucleotides-take-aim-at-the-untreatable/">Rewriting Disease: Oligonucleotides Take Aim at the Untreatable</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Microbiome Field Enters Its Next Chapter</title>
<link>https://edusehat.com/en/the-microbiome-field-enters-its-next-chapter</link>
<guid>https://edusehat.com/en/the-microbiome-field-enters-its-next-chapter</guid>
<description><![CDATA[ New analytical tools and microbiome-based therapies are pushing the field beyond early hype toward clinical and scientific progress.
The post The Microbiome Field Enters Its Next Chapter appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/OM-2-Bac3Gel_scientist2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 04:05:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Microbiome, Field, Enters, Its, Next, Chapter</media:keywords>
<content:encoded><![CDATA[<figure aria-describedby="caption-attachment-336689" class="wp-caption alignleft"><img decoding="async" class="wp-image-336689" src="https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477-300x300.jpg" alt="Sebastião van Uden" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477-840x840.jpg 840w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477-696x696.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-1-Sebastiao_bac3gel-e1786987257477.jpg 970w" sizes="(max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Sebastião van Uden, PhD<br>CEO, Bac3Gel</figcaption></figure>
<p>When scientists at Bac<sup>3</sup>Gel hear from potential customers, they typically express a mixture of frustration, curiosity, and skepticism, Sebastião van Uden, PhD, the company’s CEO, tells <em>GEN</em>. Usually, they approach the company after their own culture efforts have failed to produce consistent results, or they are on the hunt for a solution for bacteria “that is hard to grow,” or they are concerned about the costs and duration of current bioreactor experiments.</p>
<p>These are issues that the company believes it can address with its proprietary biomaterial platform, which uses a synthetic, organic gel, made from food-grade ingredients, to reproduce the structural and chemical properties of human mucus. The gel is designed to support the growth of highly complex microbial communities in the laboratory setting and is used for applications in academia, biotech, and pharma research and nutrition. Importantly, the gel can be customized to grow microbial communities that are found in different environments including the gut, lung, skin, and vagina.</p>
<p>The company claims that its technology addresses key industry pain points, including hard-to-culture bacteria as well as the high cost and low throughput of existing bioreactors. According to numbers shared with <em>GEN</em>, the company’s gel can enable growth of up to 92% of a microbiome sample’s species, which is a significant improvement over the 2–3% that is achievable with standard methods.</p>
<p>Bac<sup>3</sup>Gel is adopting a three-step market strategy that starts with research tools, moving into the food supplement space in partnership with existing corporations, and finally developing live biotherapeutics. It is the most prudent path for the early-stage startup, van Uden says. “Our business strategy lies in [moving] step-by-step, increasing risk while we expand in markets.”</p>
<p>Like most biotech companies, Bac<sup>3</sup>Gel is exploring ways to deploy artificial intelligence (AI) that make sense for its portfolio. One avenue is to leverage the large datasets that it has generated to create digital twins of the human body that allow it to test how particular strains affect the existing microbiome population or how particular probiotics impact people in different geographies with unique diets. “This is something very interesting, and we started working on it,” van Uden says. “I think AI has a place here in the microbiome.”</p>
<p></p><h4><strong>Prebiotic substrates for phenotyping</strong></h4>

<p>As consumables product manager at Biolog, Juan Sanchez, has a good overview of the company’s microbiome portfolio. In fact, “I actually introduced our first microbiome target product,” he tells <em>GEN</em>. “We had other products that could be used for this type of research, but this one is really for the gut microbiome.” Specifically, these are three different plates with prebiotic substrates that at their core are designed to help scientists who are studying human or animal gut microbiomes simplify their work.</p>
<figure aria-describedby="caption-attachment-336691" class="wp-caption alignright"><img decoding="async" class="wp-image-336691" src="https://www.genengnews.com/wp-content/uploads/2026/08/OM-6-Juan-Sanchez_Biolog-227x300.jpg" alt="Juan Sanchez" width="200" height="200"><figcaption class="wp-caption-text">Juan Sanchez<br>Product Manager, Biolog</figcaption></figure>
<p>The so-called PreBioM<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> line of microplates is designed for phenotyping gut microbiomes by testing their ability to metabolize various prebiotic substrates. Plates come pre-loaded with 90 different prebiotic substrates, removing the need for scientists to handle the plate formulation and testing on their own. And though the product was designed for the gut microbiome initially, it is applicable to other mammalian microbiomes such as oral and skin. “We remove all of the trouble from the researcher having to guess which substrates are relevant, what concentrations should these substrates be at,” Sanchez says. “We did all of that work for them.”</p>
<p>Primary customers for PreBioM plates are scientists in universities, university hospitals, and pharmaceutical companies that are developing live biotherapeutics. “The live biotherapeutic space is really one direction where the microbiome research has been evolving to,” Sanchez says. “Before it was just making probiotic pills, but now they are a lot more specialized.”</p>
<p>And that brings up a new challenge: the need to standardize not just the final product but also what goes into producing the product. This is another area where Biolog stands out. “We’ve actually been making media for growing the bacteria that will be used for the live biotherapeutic in bioprocess bags,” he tells <em>GEN</em>. This product, TruPRAS<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">, is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, according to Biolog.</p>
<p>The evolving live biotherapeutics market is also driving greater interest in customized media offerings, Sanchez notes. In fact, it is “one of the bigger trends for live biotherapeutics that I’ve seen coming up,” he says.</p>
<p></p><h4><strong>Building immune tolerance </strong></h4>

<p>“The big bold vision that we’ve always had at Siolta Therapeutics is that we can actually stop diseases before they start,” Nikole Kimes, PhD, tells <em>GEN</em>. Kimes co-founded the company with Susan Lynch, PhD, a professor in the department of medicine and director of the Colitis and Crohn’s Disease Microbiome Research Core at the University of California, San Francisco (UCSF).</p>
<figure aria-describedby="caption-attachment-336690" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336690" src="https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-300x300.jpg" alt="Nikole Kimes" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-1024x1024.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-768x768.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-420x420.jpg 420w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-840x840.jpg 840w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-696x696.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web-1068x1068.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-7-Nikole_Kimes_Headshot_Web.jpg 1200w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Nikole Kimes, PhD<br>Co-founder and CEO<br>Siolta Therapeutics</figcaption></figure>
<p>Kimes, who serves as the company’s CEO, joined Lynch’s lab at UCSF back in 2014 at a time when scientists were learning a lot about how allergic disease develops. “What we kept seeing was that early life risk factors were the most highly associated with disease development downstream,” she says. “We started to look into the gut microbiome early in life” for “signatures that were consistent across kids who went on to develop either atopic dermatitis, food allergy, asthma [or] any of the IgE-mediated atopic diseases.” Their idea was to create a cocktail of beneficial microbes that could be used to treat infants whose signatures suggested they were at greater risk of disease. In theory, by replenishing the gut microbiome, they would be able to support immune tolerance rather than immune inflammation.</p>
<p>Their research led them to examine the microbial communities of infants in different cohort studies globally, looking for signals that indicated they lacked beneficial microbes. “What we’re really interested in is the functionality, what role are they playing?” Kimes explains. This is an important point because two people might have drastically different strains in their microbiomes that have functionally similar roles. They also looked at the functional capacity of the microbes that conferred healthy benefits to their hosts. This way, they identified a subset of potential candidates for the cocktail that would have the greatest efficacy and be easy to manufacture.</p>
<p><figure aria-describedby="caption-attachment-336696" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-336696" src="https://www.genengnews.com/wp-content/uploads/2026/08/OM-8b-Siolta-scientists-at-work-300x171.jpg" alt="Siolta Therapeutics scientists" width="300" height="171" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/OM-8b-Siolta-scientists-at-work-300x171.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-8b-Siolta-scientists-at-work.jpg 493w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">At Siolta Therapeutics, scientists are developing a cocktail of beneficial microbes gleaned from the gut microbiome that could improve outcomes for babies at risk of developing IgE-mediated atopic disease. [Siolta Therapeutics]</figcaption></figure>The team at Siolta has spent the last nine years building out its Precision Symbiotics Platform<sup>TM</sup>, which includes all the computational tools, biobanks, and assays needed to develop its therapeutics. “We started the company out of necessity,” Kimes says. At the time, “there was nobody out there developing preventative drugs from a novel modality” because “it was considered too challenging to do. We thought it was too much of an opportunity to not try.”</p>
<p>The company has now completed a Phase II proof-of-concept clinical trial of its live biotherapeutic in 238 newborn infants with a familial history of allergic disease. “We have great data showing that this cocktail of organisms, when given over the first year of life, is reducing atopic dermatitis and food allergy at one year of age.” By age two, “we actually see reductions across atopic dermatitis, food allergy, and even asthma.”</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<h4><strong>An edge in the obesity market</strong></h4>
<p>For years, the ketogenic diet has been effectively used to treat drug-resistant epilepsy and other metabolic conditions by pushing the body to burn fat as an energy source. Bloom Science is turning to the microbiome to develop therapeutics for neurological and metabolic disorders that work in much the same way without dietary changes. “Our core technology and program is actually based on what we like to say is reverse engineering the ketogenic diet,” says Chris Reyes, the company’s CEO and founder. “We looked at the ketogenic diet as our reference point” and asked, “How does it work? What are the key bioactive molecules that have been shown or are being focused on to explain this effect?”</p>
<figure aria-describedby="caption-attachment-336692" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336692" src="https://www.genengnews.com/wp-content/uploads/2026/08/OM-3-Chris-Reyes_Bloom-Science-e1786987485698.jpg" alt="Chris Reyes" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/OM-3-Chris-Reyes_Bloom-Science-e1786987485698.jpg 240w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-3-Chris-Reyes_Bloom-Science-e1786987485698-150x150.jpg 150w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Christopher Reyes, PhD<br>Founder, CEO, Bloom Science</figcaption></figure>
<p>Underpinning the company’s therapeutic pipeline is a proprietary platform dubbed IrisRx<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley">. Leveraging this platform, it has developed live biotherapeutics that treat obesity, Dravet syndrome, Alzheimer’s disease, and amyotrophic lateral sclerosis. Its lead candidate, BL-001, is currently in Phase Ib testing for obesity. Early signals indicate that the biotherapeutic is well tolerated with no serious adverse events, and patients with overweight had statistically significant placebo-adjusted weight loss.</p>
<p>“We took a very traditional drug discovery and development approach,” Reyes explains to <em>GEN</em>. After identifying strains of bacteria that could replicate the diet, “we created a library of strains within these species and other species, and we screened them like we would an antibody library or a small molecule library looking for optimal functional fit.” The company is also working on engineering specific improvements to some strains to further optimize them for different indications.</p>
<p>If Bloom’s first candidate is successful, BL-001 could become an alternative to GLP-1s. In fact, Reyes believes that even with the success of GLP-1s, the population of people with obesity in the United States is still underserved. “Maybe about a third of the obese population is actually on or has been on GLP-1s,” meaning “two-thirds are not.” He attributes this partly to hesitation among this population due to factors like drug cost and tolerability.</p>
<p><figure aria-describedby="caption-attachment-336693" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-336693" src="https://www.genengnews.com/wp-content/uploads/2026/08/OM-4-Bloom-Scientists-At-Work-Photos_8x10-300x240.jpg" alt="Bloom Science lab" width="300" height="240" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/OM-4-Bloom-Scientists-At-Work-Photos_8x10-300x240.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/OM-4-Bloom-Scientists-At-Work-Photos_8x10.jpg 420w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Bloom Science is mining the microbiome to develop live biotherapeutics for neurological and metabolic disorders. Its lead candidate for obesity, currently in Phase Ib testing, is targeting one of healthcare’s largest markets. [Bloom Science]</figcaption></figure>“What we’ve seen is that there’s a huge preference for therapies that have steady weight loss with fewer side effects than rapid weight loss with higher side effects,” he continues. And though it is still in the testing, the Phase I results for its lead candidate are very promising. “We think we’re going to be competitive on the efficacy side with other oral obesity drugs” and “we believe we’ll have a much more tolerable profile.” Also, “we have very preliminary data to suggest that we might be able to identify a responder class based on their starting baseline metabolic state,” he adds, stressing that this research is still in its very early stages.</p>
<p></p><h4><strong>Macrophages to aid immunotherapies </strong></h4>

<p>The constant interaction between the microbiome and the immune system is of particular interest to scientists at Exeliom Biosciences. As Benjamin Hadida, the company’s co-founder and CEO, explains it, “we are trying to modulate the immune system by using some components that come from the microbiome.”</p>
<p>The French biotech company is developing a single asset, dubbed EXL01, that is delivered orally and is currently in Phase II testing in six different clinical studies across three therapeutic areas, Hadida tells <em>GEN</em>. EXL01, the company’s immunomodulator, is a strain of the bacterium <em>Faecalibacterium prausnitzii</em>, which is prevalent in healthy human guts. It is also one of the first to be impacted in systemic inflammation seen with conditions like inflammatory bowel disease or in patients undergoing chemotherapy.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Four of their studies are focused on oncology where the asset is being evaluated in combination with several approved checkpoint inhibitors in gastric cancer, renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer. Essentially, “we’re developing an immunomodulator that acts on the innate part of the immune system,” he explains. “We activate macrophages so that we can make patients more able to respond to immunotherapies.”</p>
<p>The company is positioning EXL01 as an add-on to existing immunotherapies since it targets a different type of immune cell. For patients on these treatments, whether that is in oncology or immune disease, “one of the key issues is the durability of the effect. We work on macrophages so that we keep the response to these treatments sustainable,” he says.</p>
<p>“We took it to the lab and tested it in some models trying to identify the mechanism at play,” he continues. It turns out that this bacterium has a unique component on its membrane that makes it a specific agonist of a key receptor in macrophages. Upon binding, it activates the NOD<sub>2</sub>-CARD<sub>9</sub> pathway that reprograms the macrophages to resist the immunosuppressive tumor environment and keep the T cell pool in shape.</p>
<p>Industry skepticism toward microbiome therapeutics in the last several years has created both challenges and opportunities for companies like Exeliom. “In the oncology world, [there have been a] number of Phase III failures that we’ve seen when [pharmas] try to combine things with checkpoint inhibitors to increase the efficacy,” Hadida says. “Some of them were able to increase the response rate, but they all failed in terms of progression-free survival. What’s interesting is when you look at all these strategies, they are all focusing on the adaptive immune system. None of them tried to act on the innate immune system.” It is a common blind spot that Exeliom is targeting. “People are maybe a bit more open [to] new strategies that look somewhere else,” Hadida says.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/the-microbiome-field-enters-its-next-chapter/">The Microbiome Field Enters Its Next Chapter</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Malaria Mosquito Bites Turned Into Immune Boosters in New Chemovaccination Strategy</title>
<link>https://edusehat.com/en/malaria-mosquito-bites-turned-into-immune-boosters-in-new-chemovaccination-strategy</link>
<guid>https://edusehat.com/en/malaria-mosquito-bites-turned-into-immune-boosters-in-new-chemovaccination-strategy</guid>
<description><![CDATA[ A malaria chemovaccination strategy, using antimalarial compounds to arrest parasites in the liver, turns mosquito bites into immune-boosting vaccination events that protected mice long-term.
The post Malaria Mosquito Bites Turned Into Immune Boosters in New Chemovaccination Strategy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Vaccination-events_Parasite_Extended.png.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 04:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Malaria, Mosquito, Bites, Turned, Into, Immune, Boosters, New, Chemovaccination, Strategy</media:keywords>
<content:encoded><![CDATA[<p>More than 600,000 people—predominantly pregnant women and children under the age of five—die from malaria every year. According to the World Health Organization, one child in Africa dies from malaria every two minutes.</p>
<p><em>Plasmodium</em> parasites multiply and mature in the liver before exiting the tissue and infecting red blood cells, triggering the symptoms of malaria. Vaccines that arrest infection during the liver stage of <em>Plasmodium</em> infection can induce potent immunity; however, they have challenges such as complex production and repeated rounds of IV delivery in field settings. With drug resistance continuing to undermine malaria control, there is an urgent need for new strategies to stop infections.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Now, researchers developed a novel immunization strategy, chemovaccination, that paired mosquito-delivered malaria parasites with an investigational class of antimalarial drug compounds. The compounds blocked the parasite’s development at a critical stage of the malaria lifecycle, preventing disease and triggering a robust immune response that provided durable protection against malaria. Subsequent mosquito bites then reinforced this immunity and protection.</p>
<p>In chemovaccination, exposure to live parasites is accompanied by the administration of antimalarial drugs that arrest the parasite life cycle, preventing illness and allowing the immune system to respond to the attenuated parasite.</p>
<p>Now, researchers from WEHI (Melbourne, Australia) have demonstrated that chemovaccination can prime the immune system to fight malaria parasites before they cause disease, with subsequent mosquito bites acting as boosters to strengthen immunity over time—turning mosquito bites into ongoing immune boosters</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>This approach protected mice against malaria for the study period—a rare outcome that could inform the development of next-generation prevention strategies for one of the world’s deadliest infectious diseases. The study is the first to target malaria parasites at the late liver stage using an antimalarial drug candidate discovered by WEHI and the global biopharmaceutical company MSD (tradename of Merck & Co., Inc., Rahway, NJ).</p>
<p>The research is published in <em>Science</em> in the paper, “<a href="https://www.science.org/doi/10.1126/science.aea7605" target="_blank" rel="noopener">Chemovaccination with a late-liver-stage antimalarial induces durable immunity against malaria</a>.”</p>
<p>“Using this new drug compound, we’ve found a way to turn mosquito bites—the very thing that spreads malaria—into vaccination events in mice,” said Justin Boddey, PhD, associate professor at WEHI. “This represents a shift in the way drugs could be employed to prevent malaria.”</p>
<p><figure aria-describedby="caption-attachment-336703" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-336703" src="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Vaccination-Events_Justin-Boddey-300x200.jpg" alt="" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Vaccination-Events_Justin-Boddey-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Vaccination-Events_Justin-Boddey-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Vaccination-Events_Justin-Boddey-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Vaccination-Events_Justin-Boddey.jpg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Justin Boddey, PhD, in the dissection room of a high-containment insectary at WEHI, used for studying malaria infection. [WEHI]</figcaption></figure>“This means the parasite was stopped just before it could cause illness, while giving the immune system a fuller preview of the potential threats,” Boddey said. “The immune response generated required only a very small dose of parasites but was broader and longer-lasting than most current vaccine approaches. This is because our approach allowed parasites to amplify and then triggered both antibodies and CD8+ T cells to protect against reinfection. Importantly, this included liver‑resident memory T cells, which have the potential to respond rapidly to future infections and eliminate them before disease develops.”</p>
<p>The antimalarial drug candidates used in the study, WM382 and MK-7602, are both dual inhibitors of plasmepsin IX and X—two “master regulators” that are crucial for parasite survival. The drug candidates are the result of a decade-long research collaboration between WEHI and MSD.</p>
<p>John A. McCauley, senior director, discovery chemistry at MSD, said: “Current approaches often rely on genetically attenuated parasites, which can provide strong protection but require high doses and are difficult to produce, scale, and administer in real‑world settings. By using a drug to arrest parasites at the late liver stage, we’ve enabled the immune system to recognize a broader range of malaria antigens using a smaller parasite dose. This approach may provide a broader response against the diversity of malaria parasites seen in the real-world and go beyond what genetically attenuated laboratory strains can achieve.”</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>As WM382 and MK-7602 target enzymes that are highly conserved across malaria species, researchers hope this will enable their approach to provide protection against a wide range of malaria “variants” in the future—potentially allowing people in endemic areas to build immunity from natural mosquito bites over time. A <a href="https://wellcome.org/research-funding/funding-portfolio/funded-grants/long-acting-injectable-dual-plasmepsin-inhibitor">long-acting injectable</a> based on the compounds is in preclinical development.</p>
<p></p><div class="mceTemp"></div>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/malaria-mosquito-bites-turned-into-immune-boosters-in-new-chemovaccination-strategy/">Malaria Mosquito Bites Turned Into Immune Boosters in New Chemovaccination Strategy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>University of Rhode Island Wins Grant to Study Cerebral Amyloid Angiopathy Prevalent in Alzheimer’s Patients</title>
<link>https://edusehat.com/en/university-of-rhode-island-wins-grant-to-study-cerebral-amyloid-angiopathy-prevalent-in-alzheimers-patients</link>
<guid>https://edusehat.com/en/university-of-rhode-island-wins-grant-to-study-cerebral-amyloid-angiopathy-prevalent-in-alzheimers-patients</guid>
<description><![CDATA[ The University of Rhode Island $1.5 million grant is part of a $9 million five-year Transatlantic Networks of Excellence grant from the Leducq Foundation. The initiative is known as TRAFFIC.
The post University of Rhode Island Wins Grant to Study Cerebral Amyloid Angiopathy Prevalent in Alzheimer’s Patients appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Cerebral_amyloid_angiopathy.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 04:05:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>University, Rhode, Island, Wins, Grant, Study, Cerebral, Amyloid, Angiopathy, Prevalent, Alzheimer’s, Patients</media:keywords>
<content:encoded><![CDATA[<p>A professor of pharmaceutical and biomedical sciences at the University of Rhode Island’s (URI) College of Pharmacy received a $1.5 million grant to research cerebral amyloid angiopathy (CAA), a disease prevalent in the elderly population and commonly found in patients with Alzheimer’s disease.</p>
<p>CAA is characterized by the abnormal buildup of amyloid-beta protein in the walls of the brain’s blood vessels. Over time, vascular amyloid accumulation can damage and ultimately weaken the vessels, increasing a person’s risk for brain bleeds, hemorrhagic stroke, and contributing to cognitive decline. The condition is difficult to accurately diagnose and lacks targeted treatment options.</p>
<p>“Despite the prevalence of the disease, there are no reliable early-stage biomarkers, and disease-modifying therapies currently do not exist,” said William Van Nostrand, PhD, co-executive director of the George & Anne Ryan Institute for Neuroscience at URI.</p>
<p>The grant is part of a $9 million five-year Transatlantic Networks of Excellence grant from the Leducq Foundation. The initiative is known as <a href="https://www.fondationleducq.org/network/translational-framework-for-innovation-in-cerebral-amyloid-angiopathy-traffic-26cvd03/">TRAFFIC</a> (Translational Framework For Innovation in Cerebral Amyloid Angiopathy).</p>
<p>The goals of the TRAFFIC study are to find and clarify disease mechanisms, identify early-stage biomarkers, and reveal potential targets for disease intervention.</p>
<p>“Our role at URI will be to perform studies to address why CAA develops in people and how certain risk factors for disease can increase the chance for bleeding in the brain,” explained Van Nostrand. “This will be done using an animal model developed here at URI that mimics CAA found in humans.”</p>
<p>The project will begin in January 2027, and Van Nostrand will collaborate with scientists from Harvard Medical School, Vanderbilt University Medical Center, Vall d’Hebron Research Institute (Spain), and Otto von Guericke University Magdeburg (Germany).</p>
<p>Since 2024, Van Nostrand has been working on another project funded by the Leducq Foundation that focuses on the disruption of <a href="https://www.uri.edu/news/2023/06/uri-neuroscientist-is-part-of-8m-grant-for-u-s-and-european-consortium-on-brain-clearance-research/">brain waste clearance mechanisms</a> that contribute to the biological processes by which CAA develops.</p>
<p>“Support from these highly competitive and prestigious transatlantic networks will reveal new insights into the disease, paving the way for better diagnosis and development of disease-modifying therapies,” said Van Nostrand.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/university-of-rhode-island-wins-grant-to-study-cerebral-amyloid-angiopathy-prevalent-in-alzheimers-patients/">University of Rhode Island Wins Grant to Study Cerebral Amyloid Angiopathy Prevalent in Alzheimer’s Patients</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CancerCare project highlights barriers to patient access</title>
<link>https://edusehat.com/en/cancercare-project-highlights-barriers-to-patient-access</link>
<guid>https://edusehat.com/en/cancercare-project-highlights-barriers-to-patient-access</guid>
<description><![CDATA[ When it comes to fighting cancer, time is of the essence. But far too often, utilization management (UM) practices such as prior authorization and […]
The post CancerCare project highlights barriers to patient access appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/CancerCare-vid-still.png" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 00:35:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CancerCare, project, highlights, barriers, patient, access</media:keywords>
<content:encoded><![CDATA[<p>When it comes to fighting cancer, time is of the essence. But far too often, utilization management (UM) practices such as prior authorization and step therapy create precarious delays to care. These delays consume patients’ valuable time and money, create mental anguish, interfere with treatment decisions, and can often lead to worse health outcomes.</p>
<p>To capture the human impact of UM practices and to empower patients to effectively advocate for themselves, CancerCare, a national non-profit organization that provides emotional, practical and financial support for anyone affected by cancer, recently launched the <em>Micro Insights, Macro Impact</em> project.</p>
<p>The resources developed in conjunction with the project include the Focus Group Report, “Behind the Barriers: Patient Voices on Access to Treatment,” an Advocacy Toolkit, and three videos.</p>
<h3>‘Fail first’ policies fail cancer patients</h3>
<p>“My insurance company asked me to try and fail one treatment before I can get the actual treatment that I needed, and I was devastated by that,” said Maria, a patient living in New Jersey, with stage 3b uterine cancer. In a video testimony for <em>Micro Insights, Macro Impact</em>, <a href="https://www.youtube.com/watch?v=IqZ2IaSLQ_g" target="_blank" rel="noopener">Maria details her experience with step therapy</a>, a utilization management practice where health insurance companies require patients to try other, often less effective, treatments first before they provide access to the treatment the patient was actually prescribed by their healthcare provider.</p>
<p>Maria’s case demonstrates the devastating impacts of step therapy on patients: only after experiencing harmful effects from the insurance-required treatment did Maria become eligible for the treatment her doctors prescribed. “I was then informed by doctors, <em>Oh, you had the rash, so now you’re actually eligible for the better chemo.</em> And I was like, <em>What do you mean, better chemo?</em> You have to have a side effect first before we allow you to advance to the better chemo. I was shocked,” explained Maria.</p>
<h3>‘Prior authorization’ prioritizes insurers, not patients</h3>
<p>Maria also experienced barriers from prior authorization, a process most patients know all too well. Prior authorization is a strategy used by health insurance plans that requires providers to obtain approval from the health insurance plan for a medicine before insurance will cover it.  Oftentimes, prior authorization increases administrative burden on patients and providers and delays access to medically necessary treatments.</p>
<p>“It was really hard to get anything filled,” said Maria. “I had to wait until I got an authorization. I had a waiting period of about a month and a half. No treatment, no medication, just waiting for the new coverage.”</p>
<p>Maria’s experience is all too common, and costs patients and caregivers valuable time. As Cancer<em>Care</em>’s 2025 Insurance Red Tape report found, among patients directly impacted by prior authorization protocols, 51% lost up to a full business day, 27% lost up to 2–3 business days, and 12% lost a full business week or more dealing with a single authorization incident. The Red Tape report labeled this issue as “time toxicity,” where a patient or caregiver spent substantial time communicating with insurers, gathering documentation, and appealing decisions. And patients are not just losing time out of their day, they are losing valuable treatment days. The report also found 29% of participants reported diagnosis delays, and 40% reported treatment delays due to authorizations. Additionally, 14% experienced abrupt coverage stoppages in the past year and 64% of those experienced treatment interruption.</p>
<p>The <em>Micro Insights, Macro Impact</em> project conducted a series of patient focus groups which captured poignant, real-life examples of the UM challenges and barriers documented in the Red Tape Report. These stories culminated in a telling report titled, “Behind the Barriers: Patient Voices on Access to Treatment.”</p>
<p>Like Maria, Steven, a patient from the suburbs of New York with stage four colorectal cancer, provided additional context to the focus group report through his video testimony about his UM challenges and how they affected his life. “They don’t know who you are. They don’t care who you are. You’re just a number,” said <a href="https://www.youtube.com/watch?v=RyDGCOL5IMM" target="_blank" rel="noopener">Steven</a>. “When you have cancer, it’s stressful enough. And when you’re dealing with insurance companies, it’s a double whammy, right? From prior authorizations to delays to denials, they throw a bunch of terms at you, but you know no one bothers to translate what it actually means. How do I navigate through this?”</p>
<p>“This isn’t a game. This is my health,” said Steven, “Why is this so difficult? It can be a bit dehumanizing. I think it’s important for the decision makers to really think about it from a more humane perspective. The system’s broken, and I think we could do a better job in making people’s lives easier.”</p>
<p>In a third video, “What It Feels Like When Insurance Stands Between You and Your Care,” three cancer patients succinctly and boldly speak about the unacceptable consequences of UM on their lives and what they would say to the people who denied their coverage.</p>
<h3>Improving access and affordability</h3>
<p>Individuals living with cancer deserve better. Utilization management practices are causing real harm to patients for whom time is of the essence.</p>
<p>“It is a nightmare waking up every day wondering if some people halfway across the country will approve what my doctors have said is my only chance,” said a patient in the <em>Micro Insights, Macro Impact</em> report.</p>
<p>Ultimately, many of the barriers imposed by utilization management are wholly unnecessary. “Among the 1,201 respondents who experienced prior authorization,” the Red Tape report states, “95% ultimately had their most recent request approved—89% after initial review and 6% after appeals—yet delays still frequently occurred, even when the initial request was approved.” These findings put in question the premise behind utilization management – WHY the initial treatment was denied at all in the first place, which jeopardizes the health of cancer patients who cannot afford to wait.</p>
<h3>Empowering patients</h3>
<p>Another key takeaway of the <em>Micro Insights, Macro Impact</em> project is the importance of empowering patients and caregivers to engage in policy advocacy by sharing their personal stories with decision makers. To help facilitate this goal, the project’s Advocacy Toolkit helps familiarize patients with UM health policy terms and provides an easy-to-understand framework for people to reach out to policy makers via letter writing, social media posts, and meetings. The Toolkit provides “how-to” examples of the different policy advocacy methods to help demystify the process and boost the confidence of patients and caregivers.</p>
<p><em>Micro Insights, Macro Impact </em>marks a critical step forward in moving the needle toward meaningful utilization management reform, showcasing the people and stories behind the numbers.</p>
<p>“Utilization management practices are being implemented in ways that harm patients. <em>Micro Insights, Macro Impact</em> spotlights the shared challenges that disrupt patients’ daily lives from diagnosis and beyond. These stories put a human face to the data, point to where policy change is needed most, and empower patients and caregivers to help drive necessary change” said Kim Czubaruk, JD, Vice President of Policy, Cancer<em>Care</em>.</p>
<p><em>If you are interested in learning more, you can visit </em><a href="https://www.cancercare.org/" target="_blank" rel="noopener"><em>https://www.cancercare.org/</em></a><em>, where you can read </em><a href="https://www.cancercare.org/advocacy/micro-insights,-macro-impact-initiative" target="_blank" rel="noopener"><em>Micro Insights, Macro Impact</em></a><em>, the </em><a href="https://www.cancercare.org/redtape" target="_blank" rel="noopener"><em>2025 Red Tape Report,</em></a><em> and </em><a href="https://www.cancercare.org/services" target="_blank" rel="noopener"><em>other CancerCare resources</em></a><em>. </em></p>
<p><em>Additionally, if you are a patient advocate, consider registering for the Biotechnology Innovation Organization’s </em><a href="https://pace.bio.org/" target="_blank" rel="noopener"><em>Patient Advocacy Changemakers Event (PACE)</em></a><em>: an empowering and inspiring event focused on breaking barriers to access and ensuring that innovative medicines reach the patients that need them.</em></p>
<p>The post <a href="https://bio.news/health/cancercare-project-highlights-barriers-to-patient-access/">CancerCare project highlights barriers to patient access</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Your AI Is Only as Good as Your Inputs</title>
<link>https://edusehat.com/en/your-ai-is-only-as-good-as-your-inputs</link>
<guid>https://edusehat.com/en/your-ai-is-only-as-good-as-your-inputs</guid>
<description><![CDATA[ Augustė Užuotaitė of Thermo Fisher Scientific feels the real innovation ahead is not just smarter software or technology. It is robust assay design, reagent chemistry, and consumables designed for automated workflows: stable at room temperature, tolerant to inhibitors, and consistent in multiplex performance. Don&#039;t miss this insightful August issue Thought Leader article.
The post Your AI Is Only as Good as Your Inputs appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/TL-Thermo-p39-GettyImages-2273265469.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 00:30:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Your, Only, Good, Your, Inputs</media:keywords>
<content:encoded><![CDATA[<figure aria-describedby="caption-attachment-336625" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336625" src="https://www.genengnews.com/wp-content/uploads/2026/08/TL_THERMO_Auguste-Uzuotaite-headshot-e1786971983756.jpg" alt="Augustė Užuotaitė" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/TL_THERMO_Auguste-Uzuotaite-headshot-e1786971983756.jpg 166w, https://www.genengnews.com/wp-content/uploads/2026/08/TL_THERMO_Auguste-Uzuotaite-headshot-e1786971983756-150x150.jpg 150w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Augustė Užuotaitė<br>R&D Supervisor, Genetic Sciences<br>Thermo Fisher Scientific</figcaption></figure>
<p>Lab leaders are under pressure to adopt AI and automation, and most of that pressure is well-founded. When properly implemented, AI and robotic systems, including automated polymerase chain reaction (PCR) workflows, can reduce manual variability, ease workflow bottlenecks, and produce high-quality data. When integration runs ahead of the science underneath it, new tools can introduce errors and slow down the work they were meant to accelerate.</p>
<p>In genetic analysis, credibility is built on reproducibility. New instruments and software continue to enter the market with the promise of faster and higher-quality results. However, the variable that is most often overlooked is also the most consequential: the reagents and consumables that influence every reaction. Real-time PCR (qPCR) assays, master mixes, primers, probes, plates, seals, and tips quietly determine whether a workflow can be trusted, especially as new platforms enter the market with the promise of faster, cleaner results.</p>
<p>When labs chase speed without stabilizing the basics, they risk building sophisticated workflows on unstable foundations. AI and automation cannot reduce variability on their own. They depend on consistent consumables, robust chemistry, and strong traceability. Without that foundation, small issues can scale into batch-level failures. Labs that want to succeed with new technology must first invest in analytically validated reagents that make that technology trustworthy.</p>
<p></p><h4><strong>Automation amplifies everything </strong></h4>

<p>Automation can generate more data faster, but it can also scale small problems into larger ones when inputs from genetic analysis experiments, such as assay design, reagent chemistry, and consumables, are inconsistent. For example, a master mix that performs well in a manual benchtop workflow may behave differently after sitting on an automated deck for an extended period. If evaporation, temperature exposure, or incomplete mixing shifts reaction concentration in only a subset of wells, the result may not appear as a complete run failure. Instead, the lab may see subtle threshold cycle (Ct) shifts, increased well-to-well variation, or edge effects that are difficult to trace after the run is complete. In high-throughput qPCR, reproducibility often depends less on the thermal cycler than on reagent performance and reaction assembly.</p>
<p>Automation without consumable consistency across assays and master mixes does not always save time. Rather, it shifts time from pipetting to troubleshooting. Before scaling, labs should evaluate whether assays, master mixes, and consumables can perform under real automated conditions (e.g., hold times, ambient exposure, and mixing steps); not just under ideal bench conditions.</p>
<p></p><h4><strong>Consumable quality is critical </strong></h4>

<p>Multiplex qPCR leaves almost no margin for uncontrolled variability, which makes consumable consistency across qPCR assay design and chemistries an especially important consideration in genetic analysis labs. When several targets are amplified in a single reaction, noise sources, such as baseline instability, spectral bleed, and inconsistent fluorescence transmission, can compete with the real signal. The result is curves that are difficult to interpret and translate into action.</p>
<p>Consumables that perform consistently lot-to-lot, with low-binding surfaces, robust sealing, and low-background optics, paired with multiplex-stable master mixes, give labs fewer reruns and cleaner target differentiation. The practical step is to qualify every new lot under the conditions where it will actually run, including hold times, mixing steps, and full multiplex panels, before releasing it into production. That requires evaluating plates, seals, and tips for autofluorescence, adsorption, and lot-to-lot optical consistency, not just for sterility or general compatibility.</p>
<p></p><h4><strong>What your controls aren’t saying  </strong></h4>

<p>Common assumptions about consumable quality create blind spots that can become dangerous at scale. Three are worth calling out. First, “sterile” does not automatically mean nuclease-free or DNA-free. These certifications cover different things, and a label that satisfies a procurement specification may not satisfy a sensitive amplification reaction. Second, passing controls does not guarantee an entire plate is unaffected. Controls can miss edge effects; low-input loss and mild inhibition can still distort results in target wells. Third, master mixes are not interchangeable. Formulation and lot variation change efficiency, inhibitor tolerance, and multiplex behavior, sometimes in ways that only surface after a method transfer.</p>
<p>A practical step that genetic analysis labs can take is to test consumables under worst-case conditions: low input, edge wells, and extended hold times. That is closer to how an automated workflow actually behaves.</p>
<p></p><h4><strong>AI is not a guarantee  </strong></h4>

<p>AI has the potential to add real value in genetic analysis workflows, but only when it sits on top of consistent physical inputs and good metadata. It does not replace the need for widely used consumables and traceability.</p>
<p>AI has the potential to flag issues early, including Ct drift, edge effects, and unusual amplification curves. It tracks trends over time and links problems to reagent lots, instruments, or staging conditions. However, the dependency runs in both directions. AI-driven quality monitoring is only as good as the data it receives. If consumables introduce uncontrolled variability through inconsistent optics, adsorption losses, or leachables, AI may detect symptoms without identifying root causes. Even worse, it may normalize drift if the baseline itself is unstable. The difference between a useful flag and a misleading one usually comes down to whether the lab can trace what changed.</p>
<p>Consider this scenario: A lab uses AI to monitor plate-to-plate performance, and the system flags a subtle upward Ct trend. With appropriate traceability, meaning lot numbers for plates, seals, master mix, and tips linked to each run, the team traces the issue to a new consumable lot with higher autofluorescence. Without that metadata, the trend is visible but unexplainable. The model can flag that something is wrong, but it cannot explain it.</p>
<p>The implication: traceability is a workflow discipline problem, not a software problem. Scientists need to build traceability into every run (e.g., link reagent lots, consumable lots, staging conditions, and instrument IDs to results). Without this metadata for AI to consume, there is no AI-driven quality monitoring.</p>
<p></p><h4><strong>Get the foundation, then scale  </strong></h4>

<p>The real innovation ahead is not just smarter software or technology. It is robust assay design, reagent chemistry, and consumables designed for automated workflows: stable at room temperature, tolerant to inhibitors, and consistent in multiplex performance. Better traceability, with reagents and labware tracked by lot and linked to QC data, supports more unattended runs, fewer failures, and faster troubleshooting when something does go wrong.</p>
<p>AI and automation can move genetic analysis forward, but only when the underlying workflow is already controlled. The lab of the future will not be defined by how much human judgment it removes. It will be defined by how well it preserves that judgment with better data, better context, and fewer avoidable sources of variation. That starts with unglamorous work: qualifying consumable lots, documenting reagent and labware changes, stress-testing chemistries on automated decks, and making traceability part of every run. These are not side details. They are the foundation that determines whether AI-enabled genetic analysis produces insight or simply scales uncertainty.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/your-ai-is-only-as-good-as-your-inputs/">Your AI Is Only as Good as Your Inputs</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Roundup: Removing Impurities from Biomanufacturing</title>
<link>https://edusehat.com/en/roundup-removing-impurities-from-biomanufacturing</link>
<guid>https://edusehat.com/en/roundup-removing-impurities-from-biomanufacturing</guid>
<description><![CDATA[ GEN asked leaders in biomanufacturing: What technologies do you use to carry out effective impurity removal at specific points throughout upstream and downstream processing to ensure product quality and patient safety?
The post Roundup: Removing Impurities from Biomanufacturing appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/gettyimages-1134447619-170667-BW-a-Topaz-Gigapixel-4x-scale-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 18 Aug 2026 00:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Roundup:, Removing, Impurities, from, Biomanufacturing</media:keywords>
<content:encoded><![CDATA[<p>Effective impurity control is critical to biomanufacturing, supporting process, cell line, and formulation stability while preserving biotherapeutic potency and shelf life. Residual impurities can drive oxidation, enzymatic degradation, protein unfolding, and aggregation. <em>GEN</em> asked leaders in biomanufacturing: What technologies do you use to carry out effective impurity removal at specific points throughout upstream and downstream processing to ensure product quality and patient safety?</p>
<p class="trimmed"> </p>
<p></p><h4><strong>Agilent Technologies</strong></h4>

<figure aria-describedby="caption-attachment-336636" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336636" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Elizabeth-Nye-agilent.jpg" alt="Elizabeth Nye" width="200" height="209"><figcaption class="wp-caption-text">Lizzy Nye, PhD<br>Global Biopharma Segment Manager</figcaption></figure>
<p>Effective impurity removal in biomanufacturing requires strategically integrated separation and analytics across both upstream and downstream workflows. Early-stage control focuses on removing process-related impurities, such as host cell proteins (HCPs), DNA, and media components, where affinity chromatography remains foundational for bulk clearance and process robustness</p>
<p data-wp-editing="1">As molecules increase in complexity, orthogonal analytical approaches become critical. High-resolution multidimensional separations enable deeper interrogation of complex mixtures and reduce the risk of co-eluting impurities. Agilent Bio-inert LC platforms are developed to minimize metal interactions that can compromise protein integrity or mask low-level impurities, improving sensitivity and reproducibility for biologics and metal-sensitive analytes.</p>
<figure aria-describedby="caption-attachment-336635" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336635" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_David-Wong-agilent-e1786973391817.jpg" alt="David Wong" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RU_David-Wong-agilent-e1786973391817.jpg 240w, https://www.genengnews.com/wp-content/uploads/2026/08/RU_David-Wong-agilent-e1786973391817-150x150.jpg 150w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">David Wong, PhD<br>Global Biopharma Segment Manager</figcaption></figure>
<p>Downstream purification strategies are increasingly tailored to modality. LC solutions paired with integrated software workflows, support efficient peptide purification with yield and purity tradeoffs. For oligonucleotides, impurity removal often relies on orthogonal ion-pairing reverse phase (IP-RP) and anion exchange (AEX) chromatography to resolve sequence failures and closely related variants.</p>
<p>Ultimately, combining robust purification technologies with advanced analytical workflows ensures not only effective impurity clearance, but also comprehensive characterization critical to maintaining product stability, regulatory compliance, and patient safety.</p>
<p class="trimmed"> </p>
<p></p><h4><strong>Lonza</strong></h4>

<p>Driving effective impurity control in biomanufacturing requires orthogonal diversity coupled with capacity redundancy and holistic process stewardship.</p>
<figure aria-describedby="caption-attachment-336646" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336646" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sam-Maurice-Lonza-Topaz-1-254x300.jpg" alt="Sam Maurice" width="200" height="236" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sam-Maurice-Lonza-Topaz-1-254x300.jpg 254w, https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sam-Maurice-Lonza-Topaz-1-356x420.jpg 356w, https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sam-Maurice-Lonza-Topaz-1.jpg 631w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Sam Maurice<br>Associate Director, Global Process and Analytical Sciences<br>Integrated Biologics</figcaption></figure>
<p>Bioinformatics can inform liabilities before even picking up a pipette. Cell line stability, clone selection and high-throughput upstream optimization reduce host cell protein (HCP) accumulation by preventing upregulation of lipases and proteases that cause oxidation and unfolding but serve to protect cellular function under prolonged stress.</p>
<p>Often overlooked, effective primary harvest depth filtration combined with charged media is the first line of defense, separating impurities based on size and electrostatic, hydrophobic, and hydrogen bonding mechanisms. This focus is central as upstream processes intensify.</p>
<p>Downstream processing should leverage heterogeneous product characteristics: selection of specialized affinity resins, enhanced washes that disrupt “hitchhiking” HCP-target molecule-histone complexes, and reduced proteases that contribute to ligand leachate. Viral inactivation precipitates impurities to aid physical removal when followed by charged depth filtration, which should be optimized for pH and conductivity conditions. Multimodal resins combining IEX, HIC and hydrogen bonding provide powerful synergistic polishing for removing aggregates, fragments, stubborn HCPs, endotoxins, viruses, and residual affinity ligand to provide representatively pure product, essential for successful liquid formulation studies. Changes to regulatory guidance mandate future HCP characterization using LC-MS informed early process development, to ensure patient safety, product stability, and promote the maximum possible shelf life.</p>
<p class="trimmed"> </p>
<p></p><h4><strong>MilliporeSigma</strong></h4>

<figure aria-describedby="caption-attachment-336634" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336634" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Chad-Rogers-milliporesigma.jpg" alt="Chad Rogers" width="200" height="225"><figcaption class="wp-caption-text">Chad Rogers<br>Strategic Product Manager<br>Process Materials and Cell Culture</figcaption></figure>
<p>Effective impurity control is enabled through a combination of advanced analytics, targeted purification technologies, and upstream material design. Upstream, MilliporeSigma minimizes impurity introduction through stringent raw material qualification, trace element (TE) control strategies, and high-sensitivity analytical platforms such as ICP-MS for multi-element profiling. These capabilities allow precise characterization and specification of low-level metal impurities that can catalyze oxidation or destabilize proteins. Engineered cell culture media further reduce variability by controlling impurity ingress at the source, supported by supplier qualification and risk-based raw material selection. In-process controls and real-time monitoring ensure consistency throughout bioreactor operations.</p>
<p>A recent supply chain disruption involving ferric ammonium citrate (FAC) put these capabilities to the test. When alternative sourcing introduced material with markedly different TE impurity profiles, MilliporeSigma leveraged its integrated chemical manufacturing expertise and ICP-MS analytical platforms to engineer an FAC solution aligned with historically established TE baselines. Defined impurity targets preserved process comparability and avoided customer reformulation, demonstrating how analytical comparability and change management frameworks keep impurity profiles within defined limits when supply or process adjustments are required.</p>
<p>In summary, MilliporeSigma integrates analytical rigor, engineered impurity control, and robust purification technologies across upstream processes, providing a scalable, supply-resilient foundation that safeguards product quality, process consistency, and patient safety while reinforcing leadership in differentiated bioprocessing solutions.</p>
<p class="trimmed"> </p>
<p></p><h4><strong>Repligen</strong></h4>

<p>Effective impurity control begins with a well-designed purification strategy. Across downstream processing, the objective is straightforward: remove process- and product-related impurities while preserving the quality, potency, and stability of the therapeutic.</p>
<figure aria-describedby="caption-attachment-336633" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336633" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Brian-Douglass-repligen-e1786976817799.jpg" alt="Brian Douglass" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Brian-Douglass-repligen-e1786976817799.jpg 240w, https://www.genengnews.com/wp-content/uploads/2026/08/RU_Brian-Douglass-repligen-e1786976817799-150x150.jpg 150w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Brian Douglass<br>Senior Vice President<br>Chief Product Officer</figcaption></figure>
<p>Repligen has built a comprehensive portfolio of purification and analytical technologies designed to address impurity challenges across a wide range of biologics. Affinity chromatography remains one of the most powerful tools available, routinely removing more than 95% of process-related impurities in a single step while maintaining yields above 90%. Our portfolio includes both catalog affinity resins and industry-leading capabilities for the rapid development and commercialization of custom affinity ligands. These custom solutions can address particularly challenging separations, including product-related impurities that are difficult to resolve using conventional polishing techniques.</p>
<p>Filtration plays an equally important role throughout the purification workflow. Tangential flow filtration, using either flat-sheet or hollow-fiber formats, supports impurity clearance, enhances chromatography performance, and enables efficient formulation of the final drug product. Together, chromatography and filtration create a highly effective platform for delivering consistent product quality and process robustness.</p>
<p>What differentiates Repligen is the integration of purification technologies with advanced process analytical technologies (PAT). We believe effective impurity control requires not only removing contaminants but also measuring and understanding them in real time. Our portfolio spans at-line, on-line, and real-time analytical solutions that provide actionable process insight directly to operators and manufacturing teams.</p>
<p>Because no single analytical technology can address every challenge, we have deliberately built a broad PAT portfolio that enables customers to apply the right tool to the right problem. Repligen provides solutions that provide real-time UV-Vis and Raman analytics for upstream and downstream process monitoring, while platforms enable deeper characterization of media components, proteins, and critical impurities.</p>
<p>Ultimately, successful impurity control requires the seamless integration of purification, filtration, and analytics. By combining these capabilities into a connected bioprocessing ecosystem, Repligen helps customers accelerate development, strengthen process understanding, and consistently manufacture safe, high-quality biologics.</p>
<p class="trimmed"> </p>
<p></p><h4><strong>Sartorius Stedim Biotech</strong></h4>

<p>Effective impurity control is essential in biomanufacturing, with strategies tailored to the target molecule and process. Downstream processes for monoclonal antibodies (mAbs) have demonstrated a direct impact on product quality and patient safety. Key impurities—host cell proteins (HCPs), residual DNA, endotoxins, aggregates, and process-related chemicals—originate from the expression system or manufacturing steps. If not adequately removed, HCPs and DNA can trigger immune responses or toxicity in patients, aggregates may induce immunogenicity or reduce efficacy, and endotoxins can cause severe inflammation. Process chemicals, like Protein A leachates or buffer residues, further contribute to safety risks.</p>
<figure aria-describedby="caption-attachment-336632" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336632" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Anke-Boerdgen-sartorius-e1786976925269.jpg" alt="Anke Boerdgen" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Anke-Boerdgen-sartorius-e1786976925269.jpg 209w, https://www.genengnews.com/wp-content/uploads/2026/08/RU_Anke-Boerdgen-sartorius-e1786976925269-150x150.jpg 150w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Anke Boerdgen<br>Head of Product Management Chromatography Consumables<br>Separation Technologies</figcaption></figure>
<p>Industry-leading technologies are applied in downstream processing to ensure impurity removal. Protein A affinity chromatography captures mAbs and eliminates bulk HCPs and DNA, mostly followed by a prolonged hold step at low pH to facilitate virus inactivation. Polishing steps with ion exchange as well as hydrophobic interaction chromatography remove charged contaminants, viruses, and aggregates. Sartorius membrane chromatography enables a complete membrane-based workflow for efficient impurity removal and high productivity, while bioburden, sterile, and virus filters ensure reliable removal of particulates, bacteria, and viruses, maintaining the critical quality attributes before final formulation. All process steps are usually complemented by several ultrafiltration and diafiltration steps, which facilitate further impurity removal, buffer exchange, as well as concentration of the molecule of interest.</p>
<p>Regulatory entities rigorously assess these purification steps during drug approval, ensuring impurity removal meets stringent safety standards to protect patient health, as demonstrated in many commercial processes.</p>
<p class="trimmed"> </p>
<p></p><h4><strong>Veranova</strong></h4>

<p>For antibody-drug conjugates (ADCs), it is critical to tightly control reaction stoichiometry, buffer composition, temperature, and reaction time. Hold times during antibody modification and conjugation should also be assessed, as delays in processing the antibody-linker intermediate may alter reaction stoichiometry or increase product-related impurities that complicate downstream purification.</p>
<figure aria-describedby="caption-attachment-336639" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336639" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Tom-Rohrer_Veranova-270x300.jpg" alt="Thomas Rohrer" width="200" height="200"><figcaption class="wp-caption-text">Thomas Rohrer <br>Vice President of Bioconjugation</figcaption></figure>
<p>Tangential flow filtration (TFF) is widely used with minimal yield loss to remove small-molecule stabilizers from antibody storage buffers prior to conjugation, as well as for ADC concentration, buffer exchange, and clearance of process-related impurities such as free payload, linker, and organic solvents. Compared to chromatography, TFF is typically more scalable, cost-effective, and higher yielding, largely due to the significant size difference between the ADC (~150 kDa) and payload (<2 kDa).</p>
<p>In some cases, carbon filtration is applied after TFF as an orthogonal step to remove residual linker-payload species. Depending on antibody subtype, conjugation method, and payload, product-related impurities may include aggregates and undesired isoforms. In these situations, size exclusion chromatography or hydrophobic interaction chromatography may be necessary, although they can reduce yield and increase manufacturing cost.</p>
<p>As novel conjugation technology evolves using bispecific mAbs, Fc-fusion proteins, and chemical site-specific conjugation, traditional TFF systems will be sufficient for purification alone or in combination with chromatographic separation techniques to deliver homogeneous ADCs with uniform drug-to-antibody ratios.</p>
<p class="trimmed"> </p>
<p></p><h4><strong>WuXi Biologics</strong></h4>

<p>Residual impurities are primarily process-related, including DNA, host cell proteins (HCPs), leached Protein A, and upstream additives. Effective control of these impurities requires an integrated strategy across both upstream and downstream processes. While cell line and process development help define and minimize the initial impurity burden, downstream purification takes the main responsibility for their removal.</p>
<figure aria-describedby="caption-attachment-336638" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336638" src="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sherry-Gu-WuXi-295x300.jpg" alt="Sherry Gu" width="200" height="204" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sherry-Gu-WuXi-295x300.jpg 295w, https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sherry-Gu-WuXi-356x364.jpg 356w, https://www.genengnews.com/wp-content/uploads/2026/08/RU_Sherry-Gu-WuXi.jpg 384w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Sherry Gu, PhD<br>Executive Vice President, CTO and Chief Client Officer</figcaption></figure>
<p>Among the residual impurities, lipases and metal ions can be particularly detrimental due to their roles in protein degradation and instability. In downstream processing, Protein A affinity chromatography is one of the most effective unit operations for removing such impurities, owing to its high selectivity for antibodies/Fc-fusions. However, certain HCPs and other impurities may interact with the target molecule and copurify.</p>
<p>To address this, it is critical to disrupt these interactions. Therefore, we extensively optimize Protein A wash conditions using additives such as amino acids, chaotropic salts, organic solvents, or detergents to enhance HCP clearance. In one case, we successfully removed cathepsin B, a CHO endogenous protease that chops the target antibody, by adding sodium caprylate into the wash buffer.<sup>1</sup> Similarly, EDTA is used in the wash buffer to remove metal ions. High-pH eluting Protein A resins and Protein A membranes have also demonstrated advantages for HCP clearance, reducing HCP levels to below those achieved with regular Protein A resins.<sup>2,3</sup></p>
<p>Beyond the affinity step, intermediate depth filtration following low-pH inactivation/ neutralization and subsequent polishing steps are further optimized to reduce residual impurities. Among polishing techniques, hydrophobic interaction chromatography (HIC) has shown particular effectiveness in removing lipases, and ongoing evaluations focus on resins with varying hydrophobicity to enhance performance.</p>
<p class="trimmed"> </p>
<p><em>References</em></p>
<p>1. Hu L, Tang J, Zhang X, Li Y. Sodium caprylate wash during Protein A chromatography as an effective means for removing protease(s) responsible for target antibody fragmentation. Protein Expr Purif. 2021, 186: 105907.</p>
<p>2. Li Z, Hu L, Li Y. The advantage of high pH eluting Protein A resins over their regular counterparts in aggregate and host cell protein clearance. Protein Expr Purif. 2026, 239: 106859.</p>
<p>3. Yang Y, Zhang X, Li Y. Deciphering the inconsistent performance of Protein A membrane on host cell protein clearance. Protein Expr Purif. 2026, 240: 106891.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/roundup-removing-impurities-from-biomanufacturing/">Roundup: Removing Impurities from Biomanufacturing</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Malaria&#45;Causing Plasmodium in Uganda Show Rapid Spread of Drug Resistance Mutations</title>
<link>https://edusehat.com/en/malaria-causing-plasmodium-in-uganda-show-rapid-spread-of-drug-resistance-mutations</link>
<guid>https://edusehat.com/en/malaria-causing-plasmodium-in-uganda-show-rapid-spread-of-drug-resistance-mutations</guid>
<description><![CDATA[ Researchers identified rapidly spreading genetic mutations in Ugandan malaria parasites linked to reduced susceptibility to artemisinin, lumefantrine, and mefloquine, offering new markers for resistance surveillance.
The post Malaria-Causing Plasmodium in Uganda Show Rapid Spread of Drug Resistance Mutations appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/08/Getty_476872691_PlasmodiumCausingMalaria.jpg" length="49398" type="image/jpeg"/>
<pubDate>Mon, 17 Aug 2026 17:20:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Malaria-Causing, Plasmodium, Uganda, Show, Rapid, Spread, Drug, Resistance, Mutations</media:keywords>
<content:encoded><![CDATA[<p>Drug resistance is one of the biggest threats to controlling malaria in endemic areas of the world. This issue was first recognized as early as the 1950s when chloroquine resistance was identified in <em>Plasmodium falciparum</em>. Since then, chloroquine resistance has spread to nearly all areas where malaria is endemic and <em>P. falciparum</em> has acquired resistances to all currently available drugs including sulfadoxine/pyrimethamine, mefloquine, and quinine.</p>
<p>Now, researchers have identified new mutations associated with the parasite’s decreased susceptibility to current treatments. By sequencing the whole genomes of <em>Plasmodium falciparum </em>from the blood of hundreds of infected people in Uganda, the team found that a cluster of genetic variants showed significantly decreased susceptibilities to the drugs most commonly used to treat malaria in Africa and the United States.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The findings were published in <em>Nature Medicine</em> in the paper, “<a href="https://dx.doi.org/10.1038/s41591-026-04590-5." target="_blank" rel="noopener">Emergence and spread of <em>Plasmodium falciparum</em> PX1 polymorphisms associated with decreased susceptibility to antimalarials in Uganda</a>.”</p>
<p>“It’s very concerning that these new mutations are spreading so rapidly—it tells us they are important to the parasite’s survival,” said Jeffrey Bailey, MD, PhD, associate professor of translational research and of pathology and laboratory medicine at Brown University. “Malaria still is a major killer, particularly in sub-Saharan Africa. As drug resistance continues to emerge, we worry it will undermine control of its spread and result in even more deaths for a large number of people there and beyond.”</p>
<p>Because of growing drug resistance, surveillance systems are being built to track known mutations in the pathogen as well as drug performance over time and identify biological markers of drug resistance.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“We knew that the parasites were changing so that over time, their susceptibility to malaria treatments was decreasing, and we wanted to know the exact genetic determinants of this shift,” said Karamoko Niaré, PhD, formerly a postdoctoral researcher in Bailey’s lab and now an adjunct assistant professor of pathology and laboratory medicine at Brown. “We decided to sequence the entire genome to get a better sense of what was going on.”</p>
<p>For the last two decades or so, the primary treatment for uncomplicated malaria in Uganda has been artemether-lumefantrine (AL), the most used artemisinin-based combination therapy (ACT) across sub-Saharan Africa. As of 2026, the Centers for Disease Control and Prevention has been recommending a longer course of therapy because standard doses failed to cure several travelers returning home, suggesting that the parasites are becoming less susceptible to treatment.</p>
<p>The researchers identified an area in the genome with 69 genes. More specifically, three specific mutations and two deletions were associated with decreased susceptibilities to the drugs artemisinin and lumefantrine (both components of AL) as well as the malaria drug mefloquine. The mutations most likely to drive this selection were found in a gene that encodes phosphoinositide-binding protein (PX1 protein) which is often found near another gene known to cause moderate resistance to the drug artemisinin.</p>
<p>This is the first time researchers have correlated a gene mutation with reduced susceptibility to multiple drugs used in the combination therapy for malaria.</p>
<p>“We didn’t have any validated molecular marker of lumefantrine resistance—we knew that there was a gene involved in partial resistance to artemisinin but couldn’t explain changes observed for lumefantrine,” Niaré said. “Our work identifies a molecular marker that could be used by surveillance studies to track the emergence and spread of reduced susceptibility to front-line malaria treatments across Africa. That’s a very important tool for public health.”</p>
<p>Since this effect was studied in the lab in parasites that had been collected from malaria patients, Bailey said future research should investigate how these mutant parasites impact clinical outcomes of malaria treatment with ACTs. While the authors found that the mutation was spreading rapidly in Uganda, how far it has spread beyond Uganda’s borders is unknown and needs to be examined.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>The finding has major implications for sustaining an effective malaria treatment program, Bailey said. “It underscores the need to develop prediction models for when the drug will stop working altogether and also highlights the urgency to develop new drugs to treat malaria.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/malaria-causing-plasmodium-in-uganda-show-rapid-spread-of-drug-resistance-mutations/">Malaria-Causing <i>Plasmodium</i> in Uganda Show Rapid Spread of Drug Resistance Mutations</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>CDMOs Expand and Build for Future Growth</title>
<link>https://edusehat.com/en/cdmos-expand-and-build-for-future-growth</link>
<guid>https://edusehat.com/en/cdmos-expand-and-build-for-future-growth</guid>
<description><![CDATA[ Executives from Fujifilm Biotechnologies, Lonza Group, MilliporeSigma, Samsung Biologics, and Thermo Fisher Scientific discuss their companies&#039; recent service expansions and new facilities in interviews with GEN.
The post CDMOs Expand and Build for Future Growth appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/MERCK-KGaA-DAEJEON-SOUTH-KOREA-videoframe_9724-JPEG.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Sun, 16 Aug 2026 01:50:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>CDMOs, Expand, and, Build, for, Future, Growth</media:keywords>
<content:encoded><![CDATA[<p>The top contract development and manufacturing organizations (CDMOs) have been busy in recent months expanding their service offerings, building new facilities, and navigating how to incorporate artificial intelligence (AI) into their operations. Following is a roundup of recent activity by five CDMOs, based on recent interviews with <em>GEN</em>:</p>
<p></p><h3><strong>Fujifilm Biotechnologies </strong></h3>

<div class="my-8"><span data-render-ad="3"></span></div>
<p>Fujifilm Biotechnologies has celebrated the selection of its commercial-scale cell culture manufacturing facility in Holly Springs, NC, among seven facilities chosen by the FDA for its <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fzwly9k6z.r.us-east-1.awstrack.me%2FL0%2Fhttps%3A%252F%252Fwww.fda.gov%252Fnews-events%252Fpress-announcements%252Ffda-selects-seven-participants-precheck-pilot-program-advance-us-drug-manufacturing%2F2%2F0100019f41d5c98e-fc6da9b9-30ee-4661-b5b3-5f537b25ee37-000000%2FsRAGZ_rh_v8H8-8ig-JWmEvaZmk%3D473&data=05%7C02%7Cjohn.sterling%40sagepub.com%7C663be3ff1d2349c9c2e108dedcf1a749%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639191127927468146%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=aoA%2FiCz4cYis3E4r5MA8suLopXsLOQ0tdsAXevopVME%3D&reserved=0">PreCheck Pilot Program</a>, designed to strengthen the nation’s pharmaceutical manufacturing capabilities.</p>
<p>Last year, Fujifilm Biotechnologies opened the first phase of its $3.2 billion end-to-end biomanufacturing facility in Holly Springs. The company initially committed $2 billion to a facility consisting of eight 20,000 L mammalian cell culture bioreactors, then in 2024 announced plans to invest an additional $1.2 billion by building eight additional 20,000 L bioreactors at the site by 2028. About 800 people are based at Holly Springs, a figure set to grow to 1,400 when the second phase is completed.</p>
<p>One biopharma customer has been announced for the second phase—the immunology drug developer argenx, which has agreed to manufacture drug substance for efgartigimod alfa-fcab marketed as intravenous Vyvgart<sup class="wp-sup-text">®</sup> and combined with hyaluronidase-qvfc as injectable Vyvgart Hytrulo<sup class="wp-sup-text">®</sup>, both indicated for adults with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Holly Springs is one of Fujifilm Biotechnologies’ two large-scale biomanufacturing facilities. The other is Hillerød, Denmark, where in April the company cut a ceremonial ribbon to mark the opening of a 2,000‑square‑meter (21,528-square-foot) quality control (QC) laboratory at its commercial‑scale manufacturing site.</p>
<p>Approximately 100 members of the company’s Quality team are based at the lab, where they conduct viral safety testing for drug substance/product release, scale capacity for complex cell‑based potency and ELISA methods, and perform raw material and critical total organic carbon cleanability studies. The QC lab also includes robotics and supports the implementation of an ongoing laboratory information management system (LIMS) across company sites to enable digital harmonization and data integrity.</p>
<p>Operations began in May at the QC lab, which is housed within a new 7,600-square-meter (81,806-square-foot) building with employee amenities, office and collaboration space, utility services, and an emergency generator to ensure uninterrupted operations and timely delivery of test results. The Hillerød site—which parent company Fujifilm Corp. acquired from Biogen in 2019 for $890 million—was expanded in 2024 from 6 to 12 x 20,000 L mammalian cell culture bioreactors, increasing the complexity and volume for QC testing.</p>
<p>“Simply, we needed more QC analytical capacities to support all the increased number of batches and the increased number of testing programs,” Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and the Bio CDMO Division of Fujifilm, told <em>GEN</em>.</p>
<p>“Our current focus is to get all our facilities online, go live, and focus on operational excellence because we already have big contracts with big clients. Our mission is to deliver as promised,” Iida said. “Before we decide on any next-phase investment, we will really focus on investing more in our people, investing more in our quality system, getting first-class operations, then delivering to our clients.”</p>
<p>Fujifilm Biotechnologies is part of the Fujifilm Life Sciences Group along with Fujifilm Biosciences (formerly Fujifilm Irvine Scientific), a provider of products and services from discovery research through large-scale production—and three other companies, one of which is Fujifilm Cellular Dynamics, a developer and manufacturer of human induced pluripotent stem cells (iPSCs) used in drug discovery, toxicity testing, stem cell banking, and cell therapy development.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>In May, Fujifilm Cellular Dynamics celebrated the opening of its new 175,000-square-foot headquarters and iPSC development and manufacturing facility in Madison, WI, which features cell culture manufacturing laboratories, process development laboratories, and a center of excellence for gene editing—all designed to support both research-grade iPSC products and development services for partners developing next-generation cell therapies. The nearly 200-employee facility is part of a previously announced $200 million strategic investment by Fujifilm.</p>
<p></p><h3><strong>Lonza Group</strong></h3>

<p>As AI reshapes how drugs are discovered, developed, clinically studied, and commercialized, Lonza Group says its operations are evolving to reflect that change. Lonza is in the process of building a team of 20 to 30 AI-focused professionals that tap into the CDMO’s experience stretching back to the early 1980s of helping customers launch more than 80 drugs.</p>
<p>“There is retained expertise that customers come to us for, and what I’m excited about is that we should use AI to enhance that,” Matthew Moorcroft, PhD, Lonza’s chief intelligence and analytics officer and head of the CEO office, told <em>GEN</em>. “What we’ve learned over the last nearly 45 years is in our DNA, and it’s in our people. Using AI to further enhance that further empowers us to do better product launches, to serve customers quicker, and to interact with them in better ways. That’s our ambition.”</p>
<p>Customers have shown interest, he said, in incorporating AI into molecule discovery and designing molecules, as well as into their clinical trial processes.</p>
<p>In addition to strengthening its AI capabilities, Lonza is enhancing its two major operational facilities in Switzerland. The company announced plans to expand its aseptic drug product capacity in Stein by adding another commercial-scale multi-purpose filling line for antibody-drug conjugates (ADCs), expected to be operational in 2030. The Stein expansion is supported by a long-term collaboration agreement with an undisclosed “major pharmaceutical” company for clinical and commercial ADC supply. Also at Stein, Lonza is expanding its commercial capabilities to high-value small molecule drug products, with those operations expected to start in 2028.</p>
<p>In June, Lonza also revealed plans to expand its Visp site to establish new commercial-scale capabilities for manufacturing highly potent active pharmaceutical ingredients (HPAPI) and ADC payload-linkers, reinforcing Lonza’s position as a fully integrated CDMO partner in ADC development. Lonza says the expanded Visp facility—set to be fully operational in 2028—will be able to offer additional payload-linker production and purification alongside dedicated analytical and process development labs.</p>
<p>Beyond facilities, Lonza Group is transforming into a pure-play CDMO, announcing plans in March to sell its Capsules & Health Ingredients (CHI) business to Lone Star Funds for CHF 2.3 billion (2.836 billion), a sale expected to close before year’s end. The deal—set to close in the second half—will give Lonza CHF 1.7 billion ($2.2 billion) upfront, and a 40% stake in CHI—which finished the first half of 2026 with core earnings before interest, taxes, depreciation, and amortization (EBITDA) of CHF 1.152 billion ($1.42 billion) on revenue of CHF 3.374 billion ($4.16 billion), up 11% year-over-year.</p>
<p>Once the deal closes, Lonza says it plans to invest its upfront proceeds into growth-focused activity reflecting its “One Lonza” strategy, which simplified operations from three divisions and nine business units into three integrated CDMO business platforms (Integrated Biologics, Advanced Synthesis, and Specialized Modalities), as well as fund acquisitions of smaller complementary or “bolt-on” businesses. Through a share buyback program, Lonza plans to return CHF 500 million ($616 million) to shareholders.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>“What we’ve agreed and what we’ve decided is to be purely focused on delivering value to our CDMO customers. That’s where Lonza’s experience is; that’s what we do,” Moorcroft explained. “When we did our organizational review two years ago, we asked, ‘What is non-core to that vision, in terms of our vision, purpose, and values?’ And being a contract manufacturer for our customers—not making our own products, not competing with them—was actually core to what we believed in. And we believe that pure play focus is really important to keep winning business and to convince our customers to stay with us. There’s no distraction.”</p>
<p></p><h3><strong>MilliporeSigma (Merck KGaA, Darmstadt, Germany)</strong></h3>

<p>Merck KGaA, Darmstadt, Germany, whose Life Sciences business in the United States and Canada is known as MilliporeSigma, is completing construction of a €300 million ($346.5 million) Bioprocessing Production Center in Daejeon, South Korea, that is set to open by year’s end.</p>
<p>“Since COVID-19, we have implemented a global manufacturing region-for-region strategy where we are building manufacturing capacity in every geography, on every continent. And we continue to do that,” Sebastián Arana, the head of Process Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany, told <em>GEN</em>.</p>
<p>Over the past four to five years, Arana added, Merck KGaA’s Life Sciences business has deployed more than €3 billion ($3.465 billion) in capital expenditures (capex) toward building out capacity to meet customer demand.</p>
<p>In Daejeon, Arana said Merck KGaA aims to be closer to customers in Korea and the rest of the Asia-Pacific region. He cited growth momentum in South Korea, fueled by business activity as well as President Lee Jae Myung committing his government last year to easing regulation of biotech R&D, and catapulting the nation into a top-five biotech industry powerhouse by 2030.</p>
<p>“Korea has intentionally invested in creating a life science ecosystem in the last few years,” Arana said, “with wonderful government support for life science being a critical area to invest in the economy, that’s number one. Korea is an easy country to do business with, so a lot of the Western pharma companies feel very safe working with Korean suppliers. All of the supply chain is very reliable, very, very quick. Plus, they have a history of very good manufacturing capabilities and have now expanded to bioprocessing. They are very flexible and super quick—things that pharma is looking for. They can do technology transfers in months.”</p>
<p>Another portion of capex investment for expansion of manufacturing came in Cork, Ireland, where Merck KGaA last year opened a €150 million ($173.25 million) filtration manufacturing facility in Blarney Business Park. The 3,000-square-meter (32,292-square-foot) cleanroom facility was designed to support global demand for filtration products used in the manufacturing of vaccines and therapies, including monoclonal antibodies, and emerging modalities such as cell and gene therapies.</p>
<p>“More and more, customers are asking for supply chain resiliency, redundancy, to make sure that if something happens with their supply chain, they’re ready to jump from one side to the other. That’s the fundamental strategy we’re executing,” Arana said. “Ideally, they want the closest site for them, but also, we try to have a second or even a third site qualified in case something happens.”</p>
<p>Another factor driving increased business for Merck KGaA is ongoing reshoring efforts by U.S.-based biopharmas that are shifting more production to the United States, whether to meet growing Stateside customer demand, or to avoid tariffs from the administration of President Donald J. Trump, or both.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>“We see some good traction in our U.S. business with customers feeling pretty good about the next two years,” Arana said. “It’s not modality-driven. It’s more just global expansion-driven, and you see some of the large molecules continue to grow and be manufactured in the United States. And on top of that, you need to think that the biopharma space is growing. So, there’s a natural investment that should come every year just to keep up the global demand.”</p>
<p>Merck KGaA expects that demand to continue to grow: “We see the market growing in the 8 to 10% range in the coming years,” Arana said, citing what he called an extremely healthy market for bioproduction of pipeline molecules by drug developers. “MilliporeSigma is very well positioned to continue to grow above market or in the upper side of the range.”</p>
<p></p><h3><strong>Samsung Biologics</strong></h3>

<p>Samsung Biologics expanded into the United States earlier this year when it completed its $353 million acquisition of a former GlaxoSmithKline (GSK) manufacturing site in Rockville, MD. The Rockville site adds two cGMP plants totaling 60,000 L of drug substance capacity, capable of supporting both clinical and commercial biologics production across multiple manufacturing scales, to Samsung Biologics’ total global capacity, which now stands at 845,000 L.</p>
<p>Samsung Biologics retained the workforce of more than 500 that had worked for GSK, which took over the site when it completed its $3.6 billion acquisition of Human Genome Sciences in 2012.</p>
<p>“The Rockville facility gives us our first U.S. footprint and allows us to move into a strategic area within the United States East Coast that is closer to clients, allowing for some additional flexibility with supply from U.S. soil,” John Gagliardi, sales director, key account management with Samsung Biologics, told <em>GEN</em> in a recent interview. “We also wanted to be in a major life science hub, which we have within the DMV [District of Columbia-Maryland-Virginia] area.”</p>
<p>The region, which brands itself BioHealth Capital Region, ranks No. 3 in <em>GEN’s</em> A-List of “<a href="https://www.genengnews.com/topics/drug-discovery/top-10-u-s-biopharma-clusters-2026/">Top 10 U.S. Biopharma Clusters.</a>”</p>
<p>The remainder of Samsung Biologics’ capacity is the 785,000 liters available at its Bio Campus I and II in Songdo, Incheon,<strong> </strong>South Korea, where the company is headquartered. Within Bio Campus II, Samsung Biologics will be collaborating with Lilly Gateway Labs (LGL) to establish an open innovation center, a hub designed to support early-stage and emerging biotechnology companies. The center will have capacity for up to 30 companies to be jointly selected by Lilly and Samsung Biologics, and will occupy a five-story, 125,000-square-foot facility set to be completed in July 2027.</p>
<p>Samsung Biologics has also secured land for BioCampus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.</p>
<p>“BioCampus III is meant to house additional complex modalities or new modalities that we would get into outside of mAbs [monoclonal antibodies],” Gagliardi explained. “This is meant for cell and gene therapies or peptides, depending on how the market needs shape up. We will bring that capacity to the market to help as the biopharma industry grows.”</p>
<p>Most recently, on July 19, Samsung Biologics signaled its intent to expand further in the United States, as well as across Europe and India, by announcing plans to acquire publicly traded PolyPeptide Group, a CDMO specializing in the production of peptide-based active pharmaceutical ingredients (APIs), for CHF 1.46 billion (about $1.8 billion).</p>
<p>Samsung Biologics said the purchase of PolyPeptide will enable it to expand its capabilities beyond antibodies and antibody-drug conjugates (ADCs) to include peptide therapeutics, whose fast growth has been fueled by a surge in global demand for obesity treatments and continued expansion of peptide-based therapies into new disease areas.</p>
<p>Headquartered in Baar, Switzerland, PolyPeptide has manufactured APIs for some 70 years and has produced more than 1,000 therapeutic peptides to date.</p>
<p>At CHF44.31 ($54.63) a share, Samsung Biologics’ offer represents a 40% premium to PolyPeptide’s closing price of CHF31.65 ($39.02) on the SIX Swiss Exchange as of April 10, before the company’s acquisition became the subject of market speculation.</p>
<p>Samsung Biologics says its buyout of PolyPeptide is expected to be completed “toward the end of 2026,” subject to customary conditions that include owners of at least 66⅔% of PolyPeptide shares accepting the deal, regulatory approvals, publication of the offer prospectus in accordance with Swiss takeover law, and other conditions.</p>
<p>PolyPeptide’s largest shareholder, representing approximately 55.65% of outstanding shares (excluding treasury shares), supports the deal through an irrevocable tender offer, while the company’s independent and non-conflicted board members have unanimously endorsed the planned acquisition.</p>
<p></p><h3><strong>T</strong><strong>hermo Fisher Scientific</strong></h3>

<p>Thermo Fisher Scientific says its two-year-old  <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.thermofisher.com%2Fus%2Fen%2Fhome%2Fproducts-and-services%2Fservices%2Fcrdmo.html&esheet=54131932&newsitemid=20241006366584&lan=en-US&anchor=Accelerator%26%238482%3B+Drug+Development&index=2&md5=f9c29f41efbdce904e6ad31d5c9b81da">Accelerator<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Drug Development</a> platform, a suite of expanded contract research organization (CRO) and CDMO services, has attracted customers seeking an end-to-end partner for services ranging from drug substance development and manufacturing, no matter the modality, to packaging, labeling, distribution, and carrying out clinical trials through the company’s Clinical Research group.</p>
<p>“All of these services within the same company help reduce the time and complexity and bring all the things required for a robust CMC package that our sponsors would then submit for approval and get these effective medicines to patients faster,” Anil Kane, PhD, executive director, global head of technical and scientific affairs at Thermo Fisher Scientific, told <em>GEN</em>.</p>
<p>The company enhanced its ability to glean insights from clinical trial data in March, when it completed its acquisition of Clario Holdings, a provider of endpoint data solutions for clinical trials, for $8.875 billion cash, plus potential additional milestone and other payments.</p>
<p>Thermo Fisher launched Accelerator in 2024, three years after acquiring the CRO PPD for $17.4 billion, and seven years after expanding into the CDMO market by <a href="https://www.genengnews.com/topics/drug-discovery/thermo-fisher-scientific-to-acquire-patheon-for-7-2b/">buying Patheon for $7.2 billion</a>. At its Investor Day in May, Mike Shafer, Thermo Fisher’s executive vice president and president of biopharma services, offered examples of how two undisclosed customers benefited from Accelerator.</p>
<p>For a large U.S.-based biopharma seeking a fast commercial launch for its respiratory drug candidate for competitive reasons. Thermo Fisher ramped up a Phase III trial by activating over 160 sites in less than eight weeks, reducing enrollment time and the dosage timeline by more than 50%. The other was a South Korean drug developer that saved 12 months of activity by using Accelerator to eliminate bottlenecks that included formulation issues, trial design issues, and regulatory alignment requirements.</p>
<p>“We took something that was delayed to accelerating it by almost a year,” Shafer said.</p>
<p>In April, Thermo Fisher opened its flagship U.S. Bioprocess Design Center (BDC) at the company’s Plainville, MA, site, expanding the facility to support customers in developing and scaling biologics. The new center brings together advanced bioproduction capabilities and hands-on collaboration, with the aim of helping customers accelerate process development and bring therapies to patients faster.</p>
<p>“Our customers have been asking about opportunities to develop on a small scale, within a U.S. site,” Kane said. “Our Plainville site was ideally located for our customers based in North America to perform experimentation in the development center. We also have sterile fill-finish capability at the Plainville site. By combining the capabilities of bioprocessing as well as sterile fill-finish, our customers could develop their molecule and the product, then decide the next steps of a clinical product that they can take to Phase I and beyond.”</p>
<p>Thermo Fisher agreed in January to integrate into its lab instruments the AI technology of Nvidia, with the aim of developing intelligent and increasingly autonomous laboratories. The Nvidia announcement came three months after Thermo Fisher agreed to embed OpenAI application programming interfaces into areas ranging from product development, service delivery, customer engagement, and operational efficiency.</p>
<p>“We have applied AI tools in quality management, quality operations, and manufacturing. The idea here is to bring efficiencies and reduce that turnaround time of quality deviations, CAPA [Corrective and Preventive Action] management, to bring efficiencies in planning, scheduling of operations, and reduce the downtime of equipment,” Kane said.</p>
<p>Thermo Fisher has yet to publicly quantify the savings in time and cost from AI applications, though it says it has seen promising results: “We will continue to monitor those and quantify those as we generate more case studies, as we generate more data, because this is certainly of importance to us and our partners.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/cdmos-expand-and-build-for-future-growth/">CDMOs Expand and Build for Future Growth</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>A Decade of Advances in Single&#45;Cell Functional Immunomics</title>
<link>https://edusehat.com/en/a-decade-of-advances-in-single-cell-functional-immunomics</link>
<guid>https://edusehat.com/en/a-decade-of-advances-in-single-cell-functional-immunomics</guid>
<description><![CDATA[ In this August issue Thought Leader article Tania Konry, PhD, cofounder of Feromics and associate professor at Northeastern University, lends his insight on how the convergence of functional biology, AI, and translational medicine is beginning to reshape how immune systems are studied, modeled, and therapeutically engineered.
The post A Decade of Advances in Single-Cell Functional Immunomics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/TL-Feromics-p25-GettyImages-544457383.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 15 Aug 2026 00:30:25 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Decade, Advances, Single-Cell, Functional, Immunomics</media:keywords>
<content:encoded><![CDATA[<p></p><h4><strong>The field in 2015</strong></h4>

<p>When <em>GEN</em> first covered our work in single-cell functional assays in 2015,<sup>1</sup> immunology was entering a new era of molecular resolution. Researchers were gaining deeper insight into immune-cell heterogeneity through rapidly advancing single-cell technologies, reshaping how disease biology could be studied.</p>
<p><figure aria-describedby="caption-attachment-336583" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336583 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/07/TL_FEROMICS_Konry.jpg" alt="Tania Konry" width="147" height="160"><figcaption class="wp-caption-text">Tania Konry, PhD<br>Co-founder, Feromics</figcaption></figure></p>
<p>Yet an important challenge remained unresolved: molecular measurements could describe what immune cells appeared to be, but they did not always predict what immune cells would actually do over time.</p>
<p>Immune cells with activated molecular profiles sometimes failed to sustain durable antitumor activity, while cells that expanded efficiently during manufacturing did not necessarily maintain persistence or therapeutic efficacy. The biological processes that determine therapeutic outcome unfold dynamically through behavior, adaptation, persistence, and dysfunction over time, requiring approaches capable of observing immune behavior directly alongside molecular state.</p>
<p>At Northeastern University, our laboratory focused on developing technologies designed to study immune function in a more dynamic and biologically relevant way. Much of this work centered on creating single-cell systems capable of observing immune-cell behavior in real time while preserving the biological context required for meaningful downstream molecular analysis.</p>
<p>Over the following decade, advances in microfluidics, live-cell imaging, computational analysis, and single-cell biology made it possible to connect directly observed immune behavior with downstream molecular and clinical information at scales that were previously unattainable. What began as an effort to observe immune-cell behavior more faithfully evolved into integrated functional-immunomics systems capable of supporting translational analysis, therapeutic characterization, and more sophisticated computational modeling.</p>
<p>These efforts contributed to the emergence of functional immunomics—an approach centered on understanding immune behavior and its relationship to disease and therapeutic outcome.</p>
<p></p><h4><strong>A shift toward functional immunomics</strong></h4>

<p>One of the major transitions in immunology over the past decade has been the recognition that immune-cell behavior represents a critical biological variable.</p>
<p>Traditional molecular approaches continue to provide essential insight into gene expression, signaling state, and cellular composition. Functional approaches extend those modalities, adding behavioral context to molecular information.</p>
<p>Persistence, resistance to dysfunction, therapeutic durability, and effective immune response are fundamentally functional properties. Behaviors such as serial killing, sustained cytotoxicity, and resistance to exhaustion cannot be fully captured through static measurements alone because they emerge over time.</p>
<p>Advances in microfluidics, live-cell imaging, and single-cell analysis made it increasingly possible to observe these processes directly. In our own work, controlled single-cell pairing systems enabled immune cells to be placed into defined microenvironments with tumor targets, allowing functional behavior to be observed before downstream molecular analysis was performed.<sup>2,3</sup></p>
<p>This sequence—observing what a cell does before analyzing what it contains—represented an important conceptual shift. Rather than inferring function from molecular correlation alone, functional approaches make it possible to anchor molecular interpretation to directly observed biological behavior.<sup>4</sup></p>
<p>In our early single-cell experiments, what struck me most was how often immune cells with strong activation signatures failed to sustain functional killing over time, and how often cells that appeared less remarkable molecularly turned out to be the ones driving effective cytotoxic responses. After seeing that pattern repeatedly across experiments, it became increasingly difficult to think about immune behavior as something a molecular state alone could fully explain. That observation gradually shifted my own perspective from focusing primarily on what immune cells contained to focusing on what they actually did.</p>
<p>A growing number of academic and industry groups are now contributing to this growing emphasis on function-linked immune analysis. Over time, our own work evolved into what we described internally as “Function-to-Omics”—a conceptual framework in which immune behavior serves as a foundational reference point for understanding disease and therapeutic response.</p>
<p>Much of the foundational intellectual property underlying this work originated through my research at Northeastern University and was later advanced translationally through Feromics, a functional immunomics company focused on AI-enabled immune analysis. The broader goal has been to establish function as a key framework for immune analysis, therapeutic development, and predictive modeling.</p>
<p></p><h4><strong>The AI inflection point</strong></h4>

<p>The rise of AI in biology has amplified the importance of this transition.</p>
<p>Machine-learning systems are fundamentally shaped by the biological quality and structure of the data used to train them. Bulk population-averaged datasets introduce biological noise by averaging across heterogeneous cell states, whereas function-linked analyses resolve this heterogeneity and yield cleaner, more therapeutically informative immune signatures.</p>
<p>A mixture of cells in different states—some highly cytotoxic, some exhausted, some transitional—may produce a population-level signal that reflects none of those states precisely. In practice, this means that cells expressing canonical activation markers may still fail to demonstrate sustained cytotoxic activity when observed functionally over time. Functional analysis makes it possible to separate those behaviors rather than averaging them into a single composite measurement.</p>
<p>As functional single-cell datasets mature, they create opportunities for computational systems capable of linking immune behavior more directly to therapeutic outcome.</p>
<p>More importantly, they change the structure of the learning problem itself.</p>
<p>Rather than training models primarily on correlative molecular associations, function-linked datasets allow computational systems to learn from experimentally observed biological outcomes at the level of individual cells.</p>
<p>This represents an important conceptual shift for the field: moving from systems built primarily on correlation toward approaches informed by experimentally observed biology.</p>
<p>At Feromics, this convergence between functional biology and AI is now being advanced through the development of large functional immunomics datasets linking immune behavior with downstream molecular and clinical information.<sup>5</sup> Supported in part through a contract with the Advanced Research Projects Agency for Health (ARPA-H)<sup>6</sup>, these efforts have shown potential to predict response to immune-based therapies using function-labeled immune datasets linked to clinical outcome.</p>
<p>In these systems, models are trained on datasets in which observed immune-cell behavior—including cytotoxic activity, persistence, and resistance to dysfunction—is connected directly to downstream molecular and clinical data. The goal is to generate biologically meaningful datasets capable of supporting more predictive and clinically relevant computational models.</p>
<p>The long-term implication is the possibility of improved biological analysis and computational systems that better represent patient-specific immune behavior and therapeutic response.</p>
<p></p><h4><strong>Clinical translation</strong></h4>

<p>The clinical implications of functional immunomics are beginning to emerge across multiple areas of immunotherapy and translational medicine.</p>
<p>In cell therapy, conventional metrics alone often do not fully capture therapeutic potential. Functional approaches create opportunities to improve therapy characterization, donor evaluation, patient stratification, and response prediction through a deeper understanding of immune behavior.</p>
<p>This is already becoming visible in donor-derived immune-cell studies, including work in acute myeloid leukemia (AML) and lymphoma, where functional stratification prior to molecular analysis has begun to reveal distinct transcriptomic programs associated with antitumor activity. These types of approaches create opportunities to identify high-performing immune subsets based on directly observed function rather than molecular inference alone.</p>
<p>Therapy-response prediction represents another important area of development. Profiling patient immune cells based on how they behave in the presence of disease-relevant targets creates the possibility of predicting therapeutic response before treatment begins.</p>
<p>Functional approaches may also influence target discovery and biomarker development by connecting biological activity more directly with therapeutic outcome. In this context, molecular information becomes most powerful when interpreted alongside observed behavior rather than independently from it.</p>
<p>Several of these concepts are now transitioning from academic research into translational development. Through Feromics, technologies originating from my research at Northeastern University are being advanced toward applications in immunotherapy development, precision immune profiling, AI-enabled therapeutic prediction, and next-generation engineered immune-cell therapies.</p>
<p>Over time, functional immunomics may support more individualized therapeutic strategies and more predictive models of immune response across oncology, autoimmune disease, and broader immune-mediated disorders.</p>
<p></p><h4><strong>Looking ahead</strong></h4>

<p>The next decade will likely focus less on proving the value of functional biology and more on integrating it into scalable research and clinical frameworks.</p>
<p>Reproducibility, standardization, data integration, and clinical translation remain major challenges for the field. Functional biology is inherently complex and capturing immune-cell behavior in ways that faithfully reflect human disease remains an ongoing scientific challenge.</p>
<p>For much of modern immunology, the central challenge was describing the immune state with increasing molecular precision. The next phase of the field may be defined not only by molecular description, but also by the ability to measure how immune systems behave dynamically over time—functionally, adaptively, and in ways directly connected to therapeutic outcome.</p>
<p>The question that motivated much of our work in 2015—what is the immune system actually doing?—is now becoming possible to answer at single-cell resolution, at a meaningful scale, and in ways increasingly connected to clinical decision-making.</p>
<p>The convergence of functional biology, AI, and translational medicine is beginning to reshape how immune systems are studied, modeled, and therapeutically engineered.</p>
<p class="trimmed"> </p>
<p><em>References</em></p>
<ol>
<li>Marusina K. <a href="https://www.genengnews.com/insights/single-cell-is-no-longer-a-limit/" target="_blank" rel="noopener">Single Cell Is No Longer a Limit</a>. <em>Genetic Engineering & Biotechnology News</em>. March 15, 2015;35(6).</li>
<li>Sharkey C, Akligoh H, Finocchiaro M, et al. <a href="https://advanced.onlinelibrary.wiley.com/doi/10.1002/admt.202501801" target="_blank" rel="noopener">High-throughput 3D matrigel-based droplet microfluidics for single-cell function-to-omics analysis of cytotoxic immune cells in solid tumor interactions</a>. <em>Adv Mater Technol</em>. 2026;202501801.</li>
<li>Sullivan MR, White RP, Dashnamoorthy Ravi, et al. <a href="https://www.nature.com/articles/s41419-023-06299-6" target="_blank" rel="noopener">Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model</a>. <em>Cell Death Dis</em>. 2024;15(1):18.</li>
<li>Sharkey C, White R, Finocchiaro M, Thomas J, Estevam J, Konry T. <a href="https://www.annualreviews.org/content/journals/10.1146/annurev-bioeng-110222-102142" target="_blank" rel="noopener">Advancing point-of-care applications with droplet microfluidics: from single-cell to multicellular analysis</a>. <em>Annu Rev Biomed Eng</em>. 2024;26(1):119-139.</li>
<li>White R, Sharkey C, Vyas J, et al. <a href="https://ashpublications.org/blood/article/146/Supplement%201/2566/551464/Transcriptomic-profiling-of-T-cell-immune-states" target="_blank" rel="noopener">Transcriptomic profiling of T cell immune states before and after donor lymphocyte infusion in a patient with acute myeloid leukemia</a>. <em>Blood</em>. 2025;146(Suppl 1):2566.</li>
<li>ARPA-H Contract No. 75N91024C00036. Advanced Research Projects Agency for Health. (Contract awarded to Feromics Inc., $4.1 million; publicly disclosed.)</li>
</ol>
<p><em> </em></p>
<p><em>Tania Konry, PhD, is the cofounder of Feromics and associate professor at Northeastern University</em>.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/a-decade-of-advances-in-single-cell-functional-immunomics/">A Decade of Advances in Single-Cell Functional Immunomics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Back&#45;to&#45;School at USP</title>
<link>https://edusehat.com/en/back-to-school-at-usp</link>
<guid>https://edusehat.com/en/back-to-school-at-usp</guid>
<description><![CDATA[ Brian McNally, PhD, director of global biologics marketing &amp; strategic collaborations at USP provides his insight on building the workforce behind the next generation of medicines. Don&#039;t miss this August issue Point of View.
The post Back-to-School at USP appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/07/POV-USP-p15-GettyImages-2274968300.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 15 Aug 2026 00:30:20 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Back-to-School, USP</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-336588" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336588 size-full" src="https://www.genengnews.com/wp-content/uploads/2026/07/POV_USP_Headshot-e1786719217266.jpg" alt="Brian McNally " width="145" height="145"><figcaption class="wp-caption-text">Brian McNally, PhD <br>Director, Global Biologics Marketing & Strategic Collaborations, USP</figcaption></figure></p>
<p>The pharmaceutical and biotechnology sectors are experiencing a historic wave of investment. Across the United States and around the world, companies are expanding manufacturing capacity, establishing new facilities, and accelerating development of innovative medicines ranging from monoclonal antibodies and antibody-drug conjugates to mRNA vaccines, gene therapies, and other advanced modalities.</p>
<p>Recent announcements show the scale of this momentum. In Virginia, AstraZeneca committed $4.5 billion near Charlottesville, Merck broke ground on a $3 billion manufacturing center in Elkton, and Eli Lilly announced a $5 billion facility in Goochland County. Lilly also announced a separate $3.5 billion Pennsylvania investment to support advanced therapies and injectable medicines. Together, these projects represent thousands of new jobs and more than $16 billion in capital investment.<sup>1,2,3,4.</sup></p>
<p>Yet facilities, technologies, and equipment are only part of the equation. Realizing the full value of these investments depends on something equally important: a skilled workforce capable of developing, manufacturing, testing, and regulating high-quality medicines.</p>
<p>This need has become a central theme across industry. At the BIO International Convention in June, workforce readiness featured prominently in discussions such as <em>Future-Ready Solutions to the Global Biomanufacturing Talent Challenge</em>. The message was consistent: maintaining growth in life sciences requires parallel investments in education, training, and talent development.</p>
<p>In many ways, the industry is already responding. In Virginia, AstraZeneca, Eli Lilly, and Merck have committed up to $120 million toward development of the Virginia Center for Advanced Pharmaceutical Manufacturing, a workforce initiative expected to support thousands of future workers through credentialing and education pathways.<sup>5</sup> Similarly, Eli Lilly has partnered with Lehigh Carbon Community College in Pennsylvania to help establish a pharmaceutical workforce development hub aligned with regional manufacturing growth.</p>
<p>Importantly, this trend extends far beyond the United States. In Australia, the State of Victoria partnered with Monash University to establish the Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training, supporting the growing ecosystem surrounding Moderna and BioNTech investments.<sup>6</sup> In South Korea, Yonsei University’s K-NIBRT Education Center, developed in collaboration with Ireland’s National Institute for Bioprocessing Research and Training (NIBRT), was created to address anticipated shortages in biopharmaceutical manufacturing talent and provide hands-on training at scale.<sup>7</sup></p>
<p>These examples illustrate a broader reality: successful pharmaceutical ecosystems require sustained investment not only in manufacturing infrastructure, but also in people.</p>
<p></p><h4><strong>Workforce development for quality</strong></h4>

<p>For USP, workforce development is closely tied to medicine quality and accessibility. As an independent scientific organization whose standards are used in more than 150 countries, USP has long viewed education as a critical enabler of quality across the pharmaceutical lifecycle.</p>
<p>The importance of training grows as technologies evolve. Analytical methods become more sophisticated, regulatory expectations expand, and novel therapeutic modalities introduce new scientific considerations. The ability to consistently produce quality medicines increasingly depends on access to current knowledge and practical training.</p>
<p>USP’s approach reflects a simple principle: workforce development should not be limited to a single audience or delivery model. Instead, it should serve the broader ecosystem responsible for bringing medicines to patients.</p>
<p>USP pursues this mission through three complementary lenses: broad-based professional education, regulatory capacity building, and practical training solutions.</p>
<p></p><h4><strong>Global manufacturing workforce support</strong></h4>

<p>The first lens focuses on providing education that can support professionals regardless of geography, employer, or therapeutic modality.</p>
<p>USP Education was established to help pharmaceutical scientists, quality professionals, manufacturers, regulators, and laboratory personnel effectively understand and apply public quality standards. The mission is straightforward: ensuring that the education required to interpret and apply USP quality standards remains accessible to those who need it. The program currently reaches more than 25,000 learners annually across thirty-eight countries.</p>
<p>Because a pharmacopeia’s primary role centers on quality standards and analytical science, much of USP’s educational portfolio focuses on analytical methodologies, quality systems, and the practical application of standards. Courses cover topics spanning compendial methods, microbiology, biologics characterization, pharmaceutical manufacturing, and regulatory science.</p>
<p>A distinguishing feature of the program is its connection to the standards development process itself. USP courses are developed by subject matter experts, either Expert Volunteers or USP staff, who are involved in creating USP standards. Course instructors are separately selected and qualified using a formal framework designed to assess both subject matter expertise and teaching capabilities.</p>
<p>Developing effective education, however, requires more than subject matter expertise. USP has invested considerable effort into the pedagogy behind its training programs. In a 2022 LTEN Focus article, USP Education leader Tim Greiner described a structured methodology for evaluating instructor qualifications that emphasizes both technical expertise and teaching effectiveness.<sup>9</sup> The framework includes standardized instructor assessments, defined content ownership, feedback mechanisms, and continuous qualification processes designed to ensure consistency and instructional quality. This approach reflects a broader philosophy that educational excellence requires the same rigor applied to scientific and operational processes.</p>
<p>As the pharmaceutical and biotechnology industry’s workforce evolves, scalable training approaches such as online learning, virtual instruction, and blended educational models increasingly allow organizations to develop talent independent of location or facility-specific investments.</p>
<p></p><h4><strong>Strengthening regulatory capacity </strong></h4>

<p>Workforce development extends beyond manufacturers: medicine quality also depends on regulators who review applications, evaluate manufacturing processes, interpret analytical data, and oversee product quality throughout the lifecycle. For this reason, USP places significant emphasis on regulatory education and capacity building.</p>
<p>One recent example is USP’s growing collaboration with the African Medicines Agency (AMA). In April 2026, USP and AMA signed a Memorandum of Understanding establishing a framework for cooperation in regulatory science, pharmacopeial standards, capacity building, product quality monitoring, and regulatory harmonization across Africa.<sup>8</sup> The partnership aims to strengthen regulatory systems and advance access to quality-assured medical products throughout the continent.</p>
<p>The agreement builds upon decades of USP engagement with national and regional regulatory authorities across Africa and complements broader efforts focused on local manufacturing, regulatory convergence, and post-market quality systems.</p>
<p>Strong science-based regulatory systems are increasingly important for advancing local manufacturing, enabling regulatory harmonization, and supporting access to innovative technologies. These activities help ensure that growing pharmaceutical manufacturing capacity is matched by corresponding regulatory readiness.</p>
<p>In the Asia-Pacific region, USP likewise supports regulator education through participation in the Asia-Pacific Economic Cooperation’s APEC regulatory training initiatives and centers of excellence. Training programs have included educational activities focused on advanced therapy products, including gene therapies. For example, USP recently conducted specialized training on qualification of raw and starting materials for gene therapies, helping regulators and industry professionals navigate evolving quality expectations associated with emerging therapeutic modalities.</p>
<p>By investing in regulator education alongside manufacturer training, USP seeks to strengthen the broader quality ecosystem that supports medicine availability and patient confidence.</p>
<p></p><h4><strong>Training beyond the classroom</strong></h4>

<p>As pharmaceutical manufacturing expands, workforce development increasingly requires more than traditional classroom-based instruction. Employers need personnel who can enter manufacturing environments with practical familiarity and direct experience relevant to current production technologies.</p>
<p>One example is the Maryland Tech Council’s BioHub Maryland program, which recently celebrated its first group of graduates. The program was designed in collaboration with regional life science employers and prioritizes curriculum development based on feedback from an industry advisory panel. This model helps to align workforce preparation with the skills most needed by local manufacturers.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>Importantly, the curriculum adapts as the industry evolves. With companies such as Kite Pharma expanding cell therapy manufacturing capabilities in the region and AstraZeneca announcing significant investments in advanced therapeutics, BioHub has incorporated training focused on cell therapy production and microbial contamination control. By connecting educators directly with employers, programs such as BioHub help ensure that workforce development efforts remain relevant to emerging manufacturing needs.</p>
<p>These initiatives illustrate an important principle: workforce development is most effective when educational institutions, industry, regulators, and scientific organizations work together to align training with evolving technologies and quality expectations.</p>
<p>While hands-on programs provide valuable experiential learning, organizations may also seek objective ways to measure competency as personnel begin performing critical activities. In high-growth manufacturing environments where employee turnover and rapid hiring may occur, objective competency assessment tools can provide additional confidence that critical techniques are being performed correctly and consistently.</p>
<p>Importantly, these tools do not replace training. Instead, they complement educational programs by helping organizations measure practical performance and reinforce quality-focused behaviors.</p>
<p></p><h4><strong>A holistic model </strong></h4>

<p>The pharmaceutical sector’s expansion presents an extraordinary opportunity. Billions of dollars are flowing into new manufacturing facilities, advanced technologies are progressing across biologics, mRNA therapeutics, cell and gene therapies, and precision medicines, and regional life sciences ecosystems continue to grow around the world.</p>
<p>Realizing the long-term value of these investments will require a workforce prepared to sustain them.</p>
<p>Examples from the United States, Australia, South Korea, and many other regions show that workforce development is increasingly recognized as a strategic necessity, not a supporting activity.</p>
<p>USP’s experience points to a holistic model: accessible education for industry professionals, support for regulators who shape medicine quality ecosystems, and practical tools that reinforce competency and continuous improvement.</p>
<p>As students return to classrooms and professionals continue building new skills, the life sciences industry is entering its own global back-to-school season. Facilities may be new, and technologies may evolve, but the objective remains constant: ensuring that high-quality medicines reach patients everywhere.</p>
<p>And that objective starts with people.</p>
<p class="trimmed"> </p>
<p><em>References </em></p>
<ol>
<li>Eli Lilly Pennsylvania manufacturing investment announcement (January 2026)</li>
<li>Eli Lilly Virginia manufacturing facility announcement (September 2025)</li>
<li>AstraZeneca Virginia manufacturing investment announcement (October 2025)</li>
<li>Merck Elkton, Virginia manufacturing center announcement (October 2025)</li>
<li>Virginia Center for Advanced Pharmaceutical Manufacturing MOU announcements (October–November 2025)</li>
<li>Monash University and Victoria Government mRNA workforce training initiative</li>
<li>Yonsei University K-NIBRT Education Center and NIBRT partnership</li>
<li>African Medicines Agency–USP Memorandum of Understanding (April 2026)</li>
<li>Tim Greiner, “<a href="https://read.nxtbook.com/lten/focus/fall_2022/the_who_how_and_when_of_instr.html" target="_blank" rel="noopener">The Who, How and When of Instructor Qualification</a>,” LTEN Focus Magazine (Fall 2022)</li>
<li>AMA–USP Regulators Forum educational program materials</li>
</ol>
<p class="trimmed"> </p>
<p><em>Brian McNally, PhD, Director of Global Biologics Marketing & Strategic Collaborations at USP</em></p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/back-to-school-at-usp/">Back-to-School at USP</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>SFA Spectroscopy Chases Away Cloudy Samples</title>
<link>https://edusehat.com/en/sfa-spectroscopy-chases-away-cloudy-samples</link>
<guid>https://edusehat.com/en/sfa-spectroscopy-chases-away-cloudy-samples</guid>
<description><![CDATA[ Scatter-free absorption spectroscopy quantifies RNA and ligands in cloudy LNPs within 15 seconds, accurately and repeatably.
The post SFA Spectroscopy Chases Away Cloudy Samples appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Marama-Labs-Launch-in-DCU-ALPHA.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 15 Aug 2026 00:30:16 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>SFA, Spectroscopy, Chases, Away, Cloudy, Samples</media:keywords>
<content:encoded><![CDATA[<p></p><div class="wp-block-image"><p><figure class="alignleft size-medium is-resized td-caption-align-center"><img fetchpriority="high" decoding="async" width="300" height="300" src="https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Brendan-e1786720463389-300x300.jpg" alt="Brendan Darby" class="wp-image-336598" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Brendan-e1786720463389-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Brendan-e1786720463389-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Brendan-e1786720463389.jpg 305w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-element-caption">Brendan Darby, PhD<br>Co-founder and CEO<br>Marama Labs</figcaption></figure></p><p></p></div><p></p><p class="wp-block-paragraph">Characterizing the RNA and ligands in nanoparticle-based therapeutics has, historically, been a cumbersome process. The lipid nanoparticles (LNPs) that encase RNA and payloads are cloudy by nature, which means analysis can’t be accomplished using the UV/Vis spectrometers that are ubiquitous throughout the life sciences industry.</p><p></p><p></p><p class="wp-block-paragraph">Marama Labs has developed a technology that eliminates the light scatter in cloudy samples—even in samples as cloudy as milk—thereby “unlocking a huge capability for complex particle analysis,” Brendan Darby, PhD, co-founder and CEO of Marama Labs, tells <em>GEN</em>.</p><p></p><p></p><p class="wp-block-paragraph">The technology, CloudSpec, employs scatter-free absorbance to remove the signal interference caused by a solution’s cloudiness, in effect, chasing away the clouds. To do this, Darby and colleagues created a highly reflective spherical chamber called an integrating sphere, which harnesses the properties of physics—specifically, the Beer-Lambert Law regarding light attenuation—and an algorithm to precisely measure analyte concentrations. This enables clean measurements similar to those of a standard spectrometer. Using this device, LNP lysing and fluorescent dyes are unnecessary for payload quantification.</p><p></p><p></p><p class="wp-block-paragraph">Research from Victoria University of Wellington (New Zealand), University College Cork (Ireland), and Marama Labs <a href="https://pubs.acs.org/doi/full/10.1021/acs.analchem.5c03644?utm_campaign=16756572-CRS%202025&utm_source=hs_email&utm_medium=email&_hsenc=p2ANqtz-8z8BMLs_bx6pslxuIjpDj_kz78KkDXkhdbfEdlmQvH84hwAejyF2NmRO0qaeRV1SDZyo6U" target="_blank" rel="noreferrer noopener">indicates</a> this analysis method outperforms fluorescence-based quantification assays in terms of precision and agreement with expected RNA concentrations.</p><p></p><p></p><p class="wp-block-paragraph">CloudSpec delivers results across the 240 to 850-nm spectral range that are “within 10% of the nominal value expected for RNA concentration,” Darby says. And, he adds, “The technique is very precise.” It’s also fast and simple. Sample dilution is the only preparation needed, and the measurement itself takes only 15 seconds.<br>Alternative technologies, in contrast, he says, can involve eight to 10 steps and between 30 minutes and two hours to analyze each sample, with significant variability between samples and also between operators.</p><p></p><p></p><div class="wp-block-image"><p><figure class="aligncenter size-full"><img loading="lazy" decoding="async" width="600" height="400" src="https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Marama-Labs-Launch-in-DCU-ALPHA.jpg" alt="CloudSpec scatter-free absorption spectroscopy technology" class="wp-image-336597" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Marama-Labs-Launch-in-DCU-ALPHA.jpg 600w, https://www.genengnews.com/wp-content/uploads/2026/08/OYR_Marama-Labs-Launch-in-DCU-ALPHA-300x200.jpg 300w" sizes="auto, (max-width: 600px) 100vw, 600px"><figcaption class="wp-element-caption">Marama Labs’ CloudSpec scatter-free absorption spectroscopy technology eliminates the light scatter in cloudy samples, making complex particle analysis possible even for extremely cloudy samples. [Marama Labs]</figcaption></figure></p><p></p></div><p></p><p></p><h4 class="wp-block-heading"><strong>Physics, wine, and RNA</strong></h4><p></p><p></p><p class="wp-block-paragraph">The idea for this novel quantification technology emerged during Darby’s doctoral work in the RAMAN Lab of Eric Le Ru, PhD, professor at Victoria University of Wellington, now Marama Labs’ CSO.</p><p></p><p></p><p class="wp-block-paragraph">“We were trying to understand how light interacts with nanoparticles from a very fundamental physics point of view,” Darby recalls. “We were looking at the fundamental optics of scattering and light absorbance with nanoparticles and found that what we were trying to measure was impossible with the existing instruments at our university. We realized that light scattering was causing a major source of error in measurements.”</p><p></p><p></p><p class="wp-block-paragraph">“Most liquids are cloudy by nature, unless they are purified in a lab or filtered. When we (produced) the same quality and repeatability as UV/Vis, but in unprocessed samples, we immediately understood that this technology could potentially become the gold standard for characterization of complex samples,” Darby says. UV/Vis, he explains, measures extinction—both scatter and absorption. CloudSpec, however, measures extinction and absorption directly and uses those measurements to determine scattering.</p><p></p><p></p><p class="wp-block-paragraph">At that point, Darby, Le Ru, and Matthias Meyer, PhD, CTO and co-founder, began the process of forming Marama Labs, which was incorporated in 2019.</p><p></p><p></p><p class="wp-block-paragraph">In his thesis research, Darby measured molecules on the surface of metallic nanoparticles at ultra-low, previously unmeasurable, concentrations accurately. That finding was extended to RNA therapeutics and <a href="https://pubs.acs.org/doi/10.1021/acs.nanolett.5c01491" target="_blank" rel="noreferrer noopener">validated</a> in collaboration with CureVac<strong> </strong>researchers.</p><p></p><p></p><p class="wp-block-paragraph">From the beginning, though, the team understood that CloudSpec’s greatest contributions would be in the life sciences, but its first applications were in the New Zealand wine industry.</p><p></p><p></p><p class="wp-block-paragraph">“Winemakers in New Zealand are very technology-centric and innovative,” he says. At the time, “There was no easy method to measure color and tannin at the very earliest stage of winemaking. They used their palettes and their eyes.” CloudSpec’s advanced analytics provided the data that those winemakers needed to better control their processes and thus craft the style of wine they needed for their market needs, while, he says, “being respectful of the grape.”</p><p></p><p></p><p class="wp-block-paragraph">To transition to life sciences, the challenge was how to evolve the technology and apply learnings from the wine industry to the pharmaceutical industry. “Our primary focus is in life sciences and RNA therapeutics,” he reiterates.</p><p></p><p></p><p></p><h4 class="wp-block-heading"><strong>Formulations to QA</strong></h4><p></p><p></p><p class="wp-block-paragraph">Currently, most of CloudSpec’s applications are in therapeutic formulation development. There, this technology helps companies optimize formulations to provide both effective nanoparticle delivery and effective therapeutic response. Additional applications include manufacturing and quality assurance.</p><p></p><p></p><p class="wp-block-paragraph">CloudSpec technology is currently single-parameter focused, measuring RNA and targeting-ligand concentrations. While these are quite important, they are only one of several chemical and physical parameters that must be measured. The size of the nanoparticles, their distribution, and surface charge, for instance, are among the critical quality parameters that biomanufacturers must measure.</p><p></p><p></p><p class="wp-block-paragraph">With that in mind, Darby hints that an additional measurement capability “for one of the most widely-used attributes in the LNP formulation space” may be added to the CloudSpec soon. “It’s been demonstrated and validated internally that CloudSpec can do this measurement, and do it faster and more repeatably than the existing method. We don’t just add on capability for the sake of adding,” he stresses. What that new measurement is couldn’t be released at the time of the interview.</p><p></p><p></p><p class="wp-block-paragraph">In addition to expanding its technology, Marama Labs is also growing its global presence. Its core research and development team and manufacturing facilities are based in Wellington, NZ. Darby heads the company’s commercial and strategic development from his office in Dublin. The company also recently opened an office in Boston to support its growing customer base there.</p><p></p><p></p><p class="wp-block-paragraph">That combination provides access to the major European and North American markets while maintaining close ties to its innovation team, effectively chasing away the clouds wherever LNP analysis is performed.</p><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column sidebar is-layout-flow wp-block-column-is-layout-flow"><p></p><h3 class="wp-block-heading"><strong><strong><strong><strong><strong>Marama Labs</strong></strong></strong></strong></strong></h3><p></p><p></p><p class="wp-block-paragraph"><strong>Location:</strong> Dublin, Ireland</p><p></p><p></p><p class="wp-block-paragraph"><strong>Contact:</strong> <a href="mailto:info@maramalabs.com" target="_blank" rel="noreferrer noopener">info@maramalabs.com</a></p><p></p><p></p><p class="wp-block-paragraph"><strong>Website:</strong> <a href="https://maramalabs.com/" target="_blank" rel="noreferrer noopener">maramalabs.com</a></p><p></p><p></p><p class="wp-block-paragraph"><strong>Principal:</strong> Brendan Darby, PhD, Co-founder and CEO</p><p></p><p></p><p class="wp-block-paragraph"><strong>Number of Employees:</strong> 18</p><p></p><p></p><p class="wp-block-paragraph"><strong>Focus:</strong> Developed CloudSpec, a UV/Viz spectrometer that measures RNA and ligands even in cloudy solutions with 15-second analysis.</p><p></p></div><p></p></div><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p>The post <a href="https://www.genengnews.com/insights/sfa-spectroscopy-chases-away-cloudy-samples/">SFA Spectroscopy Chases Away Cloudy Samples</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Newly Discovered Role for Polyamines Could Point to Potential Anticancer Strategies</title>
<link>https://edusehat.com/en/newly-discovered-role-for-polyamines-could-point-to-potential-anticancer-strategies</link>
<guid>https://edusehat.com/en/newly-discovered-role-for-polyamines-could-point-to-potential-anticancer-strategies</guid>
<description><![CDATA[ Researchers discovered that polyamines protect living cells against iron overload, and suggest the finding could point to potential therapeutic strategies against cancer, and provide new insights into disorders including Parkinson’s disease.
The post Newly Discovered Role for Polyamines Could Point to Potential Anticancer Strategies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_Ratiometric_2023-09-21T22-49-11.201-2.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 15 Aug 2026 00:30:13 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Newly, Discovered, Role, for, Polyamines, Could, Point, Potential, Anticancer, Strategies</media:keywords>
<content:encoded><![CDATA[<p>Our cells need iron to produce energy, carry oxygen throughout the body and power countless chemical reactions that sustain life. But when too much iron is left free inside cells it can trigger destructive reactions that break down DNA, proteins, and even cell membranes.</p>
<p>Researcher headed by a team at the Whitehead Institute have now discovered that cells rely on small molecules called polyamines as an unexpected protector against this threat. The newly reported study by White Institute member Ankur Jain, PhD, together with former postdoc Whitney Henry, PhD, and graduate student Pushkal Sharma, and colleagues, revealed that polyamines act like storage lockers for iron, safely holding the metal in a non-reactive state until cells need it. As part of their research the team developed a genetically encoded fluorescent reporter allowing them to quantitatively measure redox-active iron in living cells.</p>
<p>The collective findings solve a decades-old mystery about why cells maintain such extraordinarily high levels of polyamines and also uncover a previously unknown defense mechanism that protects cells from toxic iron overload. The discovery could potentially help scientists develop better cancer treatments, by allowing iron overload to trigger cancer cell death. The study results could also offer up new clues about disorders such as early-onset Parkinson’s disease, in which mutations affect polyamine levels within neurons.</p>
<p>Jain and Henry are co-senior and co-corresponding authors of the team’s published paper in <em>Cell</em> titled “<a href="https://doi.org/10.1016/j.cell.2026.07.040" target="_blank" rel="noopener">Polyamines buffer labile iron to suppress ferroptosis</a>,” in which they stated that the findings “… reposition polyamines as key regulators of iron homeostasis, with implications for ferroptosis-linked disease states and cellular redox balance.”</p>
<p>The Jain Lab studies RNA and is particularly interested in how RNA folds, misfolds, and sometimes clumps inside cells. Jain and Sharma first began studying polyamines because these molecules bind to RNA and help to shape its structure. However, they suspected that polyamines must be playing other roles inside cells. Polyamines are among the most abundant small molecules within cells, present at levels comparable to ATP, the molecule that cells use as their energy currency.</p>
<p>“We’ve known that without polyamines, cells stop growing and dividing,” explained Jain, who is also an associate professor of biology at the Massachusetts Institute of Technology (MIT). “But their best-known function only requires a small fraction of the polyamine levels cells actually have.”</p>
<p>To uncover the hidden function of polyamines inside cells the researchers used a large-scale genetic approach that allows them to screen the entire genome at once, rather than testing genes one-by-one, in order to find out which cellular processes are impacted when polyamine levels are changed within cells. “To identify cellular dependencies that emerge during polyamine stress, we performed a genome-wide CRISPR-Cas9 screen in human cells under polyamine-depleted conditions,” they noted.</p>
<p>The screen revealed that when cells have reduced levels of polyamines, a protein called GPX4 becomes essential for survival. GPX4 is known to prevent harmful chemical reactions that damage the fatty molecules that make up cell membranes. “This synthetic lethal screen revealed a surprising link between polyamines and iron homeostasis: polyamine depletion rendered cells highly dependent on glutathione peroxidase 4 (GPX4), an antioxidant enzyme that protects membranes from lethal lipid peroxidation and ferroptotic cell death,” the team added.</p>
<p>The team also found that cells with lower polyamine levels have higher amounts of another protein that acts as an iron sponge and keeps the metal in a mineralized form. Together, these findings led the researchers to hypothesize that polyamines might be helping keep iron in a safe, non-reactive state within cells.</p>
<p>To test this idea, they developed a new fluorescent sensor that would allow them to measure chemically reactive iron inside living cells. The new sensor causes living cells to glow based on the amount of chemically reactive iron they contain, allowing researchers to track any changes under a microscope in real time.</p>
<p>The team paired the new iron sensor with another sensor they had previously developed that measures polyamine levels within cells. By employing them simultaneously, they observed a striking pattern: as polyamine levels dropped within cells, the amount of chemically reactive iron went up, offering new evidence that polyamines play a key role in preventing toxic iron build up inside cells. “Single-cell analysis revealed that labile iron levels increase as polyamines decline,” the team wrote in summary. They suggest that their collective findings “… support a model in which millimolar polyamines help restrain labile iron availability, linking polyamine metabolism to redox balance and ferroptosis sensitivity … Altogether, these data demonstrate a tight, inverse coupling between polyamine and labile iron levels at the single-cell level and establish our genetically encoded reporter as a robust tool for the quantitative dissection of iron biology.”</p>
<p>Beyond answering a fundamental biological question, these findings could have implications for cancer treatment. Cancer cells often rely on high polyamine levels to support their rapid growth and division. However, cancer drugs designed to lower polyamine levels to stop cell division have had limited success.</p>
<p>“We saw that when polyamine levels fall, cells rely on GPX4 to protect themselves from iron toxicity,” said first author Sharma. “This could mean that combining drugs that lower polyamine levels with those that block GPX4 might be more effective for killing cancer cells than targeting either pathway alone.”</p>
<p>The discovery may also have implications beyond cancer. Mutations in genes that help move polyamines around cells are linked to a rare form of early-onset Parkinson’s disease, and scientists have long observed unusually high levels of iron in the brains of Parkinson’s patients.</p>
<p>While it is still unclear whether excess iron directly contributes to neuron death in Parkinson’s, the discovery that polyamines help buffer reactive iron inside cells offers a possible explanation for this link and opens new directions for future investigation.</p>
<p>In addition, the researchers expect the new iron sensor to be a valuable tool for other scientists. By allowing them to track chemically reactive iron inside living cells, it could power new discoveries in aging, cancer, and neurodegeneration. “We anticipate that this reporter will provide a powerful platform to facilitate future discoveries into iron biology, ferroptosis, and disease mechanisms,” they stated.</p>
<p>“There are a lot of promising future directions for this work,” Jain noted. “It’s exciting to think about how these tools and findings could help answer further questions about disease pathways and potentially help design better therapies.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/newly-discovered-role-for-polyamines-could-point-to-potential-anticancer-strategies/">Newly Discovered Role for Polyamines Could Point to Potential Anticancer Strategies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>BMS’s New Facility, Recursion–Genentech Partnership, Long&#45;COVID and Persistent C. auris</title>
<link>https://edusehat.com/en/bmss-new-facility-recursiongenentech-partnership-long-covid-and-persistent-c-auris</link>
<guid>https://edusehat.com/en/bmss-new-facility-recursiongenentech-partnership-long-covid-and-persistent-c-auris</guid>
<description><![CDATA[ In this episode of GEN&#039;s Touching Base, editors discuss BMS’s new manufacturing facility, and a Recursion–Genentech partnership. Editors also discuss infectious diseases including some long-term consequences of COVID and persistent C. auris.  
The post BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C. auris appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/01/COVID19-Getty-1201772531-Design-Cells-1068x601-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Sat, 15 Aug 2026 00:30:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>BMS’s, New, Facility, Recursion–Genentech, Partnership, Long-COVID, and, Persistent, auris</media:keywords>
<content:encoded><![CDATA[<p>Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant <em>Candida auris</em> was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.</p><p class="trimmed"> </p><div class="my-8"><span data-render-ad="3"></span></div><p class="trimmed"> </p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>:</p><div class="my-8"><span data-render-ad="4"></span></div><a href="https://www.genengnews.com/topics/bioprocessing/bms-chooses-houston-for-2-3b-manufacturing-facility/">BMS Chooses Houston for $2.3B Manufacturing Facility</a><br>By Alex Philippidis, <em>GEN Edge</em>, Aug 10, 2026<p><a href="https://www.genengnews.com/topics/drug-discovery/next-10-u-s-biopharma-clusters/?_gl=1*1am4j3p*_up*MQ..*_ga*MTIxNjk5MDgwMS4xNzYwNTUyNDU2*_ga_F1EYPPYL3X*czE3ODY1NTcwMDUkbzEkZzAkdDE3ODY1NTgyODYkajQyJGwwJGgxMDA3NTk4Njgw">Next 10 U.S. Biopharma Clusters</a><br>By Alex Philippidis, <em>GEN</em>, Aug 12, 2026</p><p><a href="https://www.genengnews.com/topics/artificial-intelligence/recursion-partners-with-genentech-to-advance-first-validated-neuro-target-discovered-through-ai-map/">Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map</a><br>By Alex Philippidis, <em>GEN Edge</em>, Aug 5, 2026</p><p><a href="https://www.genengnews.com/topics/coronavirus/covid-19-reactivates-dormant-viruses-offering-new-clues-to-long-covid/">COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID</a><br><em>GEN</em>, Aug 5, 2026</p><p><a href="https://www.genengnews.com/insights/trumps-treatments-regenerons-antibodies-and-gileads-remdesivir-explained/">Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir Explained</a><br>By Alex Philippidis, <em>GEN</em>, Oct 5, 2020</p><p><a href="https://www.genengnews.com/gen-edge/lessons-from-the-covid-crisis-an-interview-with-peter-hotez/">Lessons from the COVID Crisis: An Interview with Peter Hotez</a><br>By Alex Philippidis, <em>GEN Edge</em>, Oct 19, 2022</p><div class="my-8"><span data-render-ad="5"></span></div><a href="https://www.genengnews.com/a-lists/how-to-conquer-coronavirus-top-35-treatments-in-development/">How to Conquer Coronavirus: Top 35 Treatments in Development</a><br>By Alex Philippidis, <em>GEN</em>, March 2, 2020<p><a href="https://www.genengnews.com/topics/infectious-diseases/candida-auris-persists-in-hair-follicles-hijacks-immune-signaling/">Candida auris Persists in Hair Follicles, Hijacks Immune Signaling</a><br><em>GEN</em>, August 10, 2026</p><p><a href="https://www.genengnews.com/multimedia/summits/the-state-of-biotech-2026/">The State of Biotech Summit</a><br>September 23, 2026</p><p><a href="https://www.genengnews.com/category/multimedia/podcasts/touching-base/">Touching Base Podcast</a><br>Hosted by Corinna Singleman, PhD</p><p><a href="https://www.insideprecisionmedicine.com/category/multimedia/podcasts/">Behind the Breakthroughs</a><br>Hosted by Jonathan D. Grinstein, PhD</p><p><a href="https://www.genengnews.com/resources/the-state-of-biologics-testing-2026/">The State of Biologics Testing 2026</a></p><p><br>Charles River Laboratories and <em>GEN</em>, June 10, 2026</p><p><a href="https://www.genengnews.com/newsletter-sign-up/?_gl=1*1of46um*_up*MQ..*_ga*MTIxNjk5MDgwMS4xNzYwNTUyNDU2*_ga_F1EYPPYL3X*czE3ODY2MDMzMzckbzEkZzAkdDE3ODY2MDMzMzckajYwJGwwJGgxMjE3MTEyMTkx">Subscribe to <em>GEN</em>’s newsletters</a></p><p></p><p> </p><div class="my-8"><span data-render-ad="6"></span></div><hr class="wp-block-separator has-alpha-channel-opacity is-style-wide"><p></p><p class="wp-block-paragraph"> </p><p class="has-text-align-center"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="aligncenter size-medium"><a href="https://www.criver.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-150820 size-medium" src="https://www.genengnews.com/wp-content/uploads/2020/10/charles_river_logo-300x64.jpg" alt="charles river logo" width="300" height="64" srcset="https://www.genengnews.com/wp-content/uploads/2020/10/charles_river_logo-300x64.jpg 300w, https://www.genengnews.com/wp-content/uploads/2020/10/charles_river_logo-1024x218.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2020/10/charles_river_logo-768x164.jpg 768w, https://www.genengnews.com/wp-content/uploads/2020/10/charles_river_logo-696x148.jpg 696w, https://www.genengnews.com/wp-content/uploads/2020/10/charles_river_logo-1068x228.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2020/10/charles_river_logo.jpg 1200w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p></div><p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/bmss-new-facility-recursion-genentech-partnership-long-covid-and-persistent-c-auris/">BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent <i>C. auris</i></a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>This scientist is helping build a missing map of childhood</title>
<link>https://edusehat.com/en/this-scientist-is-helping-build-a-missing-map-of-childhood</link>
<guid>https://edusehat.com/en/this-scientist-is-helping-build-a-missing-map-of-childhood</guid>
<description><![CDATA[ In 2017, Deanne Taylor attended a presentation at the University of Pennsylvania, just a short walk from her office. A researcher was there to unveil the Human Cell Atlas, an ambitious project that aimed to map every cell in the human body. Taylor was floored, and then concerned. As details emerged, she discovered that the… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5931-thumb.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 21:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>This, scientist, helping, build, missing, map, childhood</media:keywords>
<content:encoded><![CDATA[<p>In 2017, Deanne Taylor attended a presentation at the University of Pennsylvania, just a short walk from her office. A researcher was there to unveil the Human Cell Atlas, an ambitious project that aimed to map every cell in the human body. Taylor was floored, and then concerned. As details emerged, she discovered that the project’s researchers had only made plans to study adults. “That’s when my little alarm went off,” she says. “<em>Not again.</em>”</p>



<p>Since joining the Children’s Hospital of Philadelphia (CHOP) as the director of bioinformatics three years earlier, Taylor had been disappointed by the lack of investment in medical research focused on children. The dominant view, she says, was that children are exactly like small adults. They’re not. Children’s cells are different from grownups’ cells in the way they express genes—switching them on and off or turning them up or down. Those variations can cause drastically different and even deadly responses to drugs that adults tolerate well. </p>



<p>The 2017 talk was the moment Taylor didn’t know she’d been waiting for. She quickly channeled her concern into a campaign, joining the Human Cell Atlas’s volunteer team and helping write a section on children for a <a href="https://arxiv.org/pdf/1810.05192">white paper</a> outlining the group’s goals and plans. She then rallied a cross-hospital coalition of pediatric researchers to contribute to the project and spearheaded a <a href="https://pubmed.ncbi.nlm.nih.gov/30930166/">2019 paper</a> that outlined the case for studying children—a bid to attract more interest and funding to the field. “It put a flag in the ground,” she says. “Why don’t we have healthy models of children’s development?”</p>





<p>So far, the push has paid off. In 2021 the NIH awarded a $38.5 million grant to the Developmental Genotype-Tissue Expression Project (dGTEx), a major initiative aimed at establishing the first comprehensive database of healthy pediatric tissue. The project banks samples collected from otherwise healthy children who have died and whose parents agreed to donate their bodies, and maps how genes across all the major organ systems are expressed. Taylor and her team curate and standardize the information associated with each tissue donation, including family history and details about the samples. A separate group does analysis on the samples themselves, and then all the information is combined to create a database­—a baseline of what gene expression looks like in children. It’s the first step to enabling research that could advance our knowledge of normal development, disease, drug effectiveness, and other phenomena. </p>



<p>The dGTEx team will eventually feed its data into the Human Cell Atlas, which, thanks to Taylor and many of the coauthors of the 2019 paper, now includes a pediatric section.</p>



<p>Taylor’s primary responsibility may be collecting and organizing data for dGTEx, but colleagues say she’s also the glue holding diverse research projects together. That’s especially important for the Human Cell Atlas, which depends on contributions from a loose coalition of researchers, all pursuing their own objectives. “Deanne took a big-picture view and said, <em>We don’t just need to understand the pediatric kidney or the pediatric brain or the pediatric immune system. We need a holistic view of pediatric development</em>,” says Sarah Teichmann, a cofounder of the Human Cell Atlas. “She embodies that interdisciplinary spirit.” </p>



<h3 class="wp-block-heading">A healthy baseline</h3>



<p>Taylor describes her career as a “random walk,” driven by a singular intensity she now attributes to undiagnosed autism and ADHD. At five, she began reading her mom’s medical texts. By 12, she was checking out physics books from the library. Physics provided mysteries to solve, and she wanted to understand how things worked. </p>



<p>Taylor got her PhD in biophysics, in 2001, but was inspired by the then-active Human Genome Project to change gears and take on a postdoc at Pfizer, writing code to handle complex data in rare-disease research. Then she moved to reproductive medicine, where she worked on some of the first computer programs to screen embryos for chromosomal abnormalities—many of which are still in use today.</p>


<div class="wp-block-image">
<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" height="2000" width="1500" src="https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5999.jpg?w=840" alt="" class="wp-image-1141541" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5999.jpg 1919w, https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5999.jpg?resize=225,300 225w, https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5999.jpg?resize=768,1024 768w, https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5999.jpg?resize=1500,2000 1500w, https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5999.jpg?resize=1152,1536 1152w, https://wp.technologyreview.com/wp-content/uploads/2026/08/HLY_5999.jpg?resize=1536,2048 1536w" sizes="(max-width: 1500px) 100vw, 1500px"><div class="image-credit">HANNAH YOON</div>
</figure>
</div>


<p>Despite this seemingly winding road, Taylor says her focus has always been on understanding why the same illness hits people differently. How can two people carry the same disease-­associated gene variant, but only one get sick? </p>



<p>The Human Cell Atlas—including all the data feeding into it from dGTEx and other projects—could at last help researchers find answers. The effort is a natural extension of the Human Genome Project. That initiative, which wrapped up in 2003, helped researchers link specific genes to specific diseases. But a map of the genome is a bit like a DIY kit with all the parts and no assembly manual. It doesn’t tell you where and how cells use each gene throughout the body.</p>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><strong>After all, “we’re just older kids,” Taylor says. “By ignoring the pediatric side of things, I think people are missing a window of intervention in human disease.”</strong></p>
</blockquote>



<p>For that, you need to know how the genes are expressed. Gene expression generally involves making a protein that does a specific job in the body, like building tissue or sending signals. Unlike DNA, which largely remains the same throughout our lives, the way the genes in DNA are expressed changes as we develop. </p>



<p>Differences in gene expression can determine whether a therapy will work—or could harm more than it helps. Because of the way cardiac genes are expressed in children, chemotherapy drugs can attack not only tumors but also children’s developing hearts, potentially causing lifelong damage. Other treatments can affect the entire body, sometimes triggering a reversible but potentially fatal immune-system reaction called cytokine release syndrome.</p>



<p>The dGTEx database aims to create a baseline for gene expression in children—a molecular map of how the body’s roughly 20,000 genes do their work in healthy tissue cells. It is only one of the collaborations Taylor manages. She’s a principal investigator for the Kids First Data Resource Center, which sequences diseased tissues collected from children enrolled in other studies nationwide. And she has been collaborating with researchers on HubMAP, an effort that’s building a resource complementary to the Human Cell Atlas, to secure funding to create 3D maps of children’s cells like the ones it’s already made for adults.</p>



<p>Extending such initiatives to children is important, Teichmann argues. Much of human development happens in childhood; key brain cells called astrocytes form in the first five years, for instance, and the immune system matures in puberty. “Those changes are really important to understand from a disease point of view,” she says. A granular view of how individual cells work “will change pediatric medicine, for sure.” </p>



<h3 class="wp-block-heading">Herding cats</h3>



<p>Taylor helps the dGTEx machine run, coordinating researchers across multiple organizations that each contribute different pieces to the puzzle. These include a nonprofit group that secures tissue samples from deceased children soon after death and CHOP pathologists who assess each sample’s quality and type. Tissues are frozen and stored for future researchers to use with the group’s permission, while samples are sent to organizations including the nonprofit Broad Institute, which analyze gene expression. Data streams in at all these steps—information that the Human Cell Atlas effort can eventually draw on.</p>





<p>This coordination is “like herding cats,” says Rebecca Linn, a pediatric pathologist at CHOP. “So many individuals with different goals.” Taylor says an important part of her role is mediating among participants. That means, for example, explaining to researchers who want to use dGTEx’s tissues that it’s impossible to divide a one-month-old’s tiny testes 20 ways. </p>



<p>Colleagues describe Taylor as a well-connected collaborator who unites people across diverse specialties—essential qualities for a multidisciplinary, international effort like the Human Cell Atlas. It also helps that Taylor is full of surprises. She has tattoos of Schrödinger’s and Boltzmann’s equations and dabbles in painting and photography; a non­descript rock from Burning Man, where she volunteered in the kitchen, sits on her desk. “She can make friends and be memorable through her interests and knowledge and questions about all these different subjects. It really draws you in,” says Linn. </p>



<p>Taylor, however, believes the life-changing potential of the work itself is enough to motivate colleagues. Comparing a sick person’s cells with the healthy, age-matched baseline the Human Cell Atlas provides could yield biomarkers of health and disease that could serve as drug targets or diagnostic markers. A pediatric chapter in that atlas could produce similar insights for children—and strengthen our understanding of how our genetics and environments affect health and disease at various stages of development. </p>



<p>Extending the atlas to children may even help reveal how adult diseases trace back to distinct signals in childhood, raising the possibility that we could screen for and treat chronic conditions years or even decades before they surface. That could not only improve outcomes but help people prevent debilitating symptoms before they ever develop. After all, “we’re just older kids,” Taylor says. “By ignoring the pediatric side of things, I think people are missing a window of intervention in human disease.” </p>



<p>Taylor hopes the project will shift how research views pediatrics. It’s a big goal, one that will require big data—and forces like her to help pull everything together. </p>



<p><em>Colleen de Bellefonds is a science journalist based in Paris.</em></p>]]> </content:encoded>
</item>

<item>
<title>Cloning could be used to save species—or make human “organ sacks”</title>
<link>https://edusehat.com/en/cloning-could-be-used-to-save-speciesor-make-human-organ-sacks</link>
<guid>https://edusehat.com/en/cloning-could-be-used-to-save-speciesor-make-human-organ-sacks</guid>
<description><![CDATA[ This week I spoke to scientists who have found a way to turn male mouse embryos female. They’ve developed a CRISPR-based approach to essentially cut out the Y chromosome. It allowed them to create female clones of male mice. That’s right: female animals that are genetically identical to males, except for the missing Y chromosome.… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/clone-mice.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 21:00:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cloning, could, used, save, species—or, make, human, “organ, sacks”</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary='<ul><br><li><strong>Male mice, meet your female clones:</strong> Scientists have used CRISPR to snip out the Y chromosome from male mouse embryos, producing female animals genetically identical to males. The researchers hope the technique could help conservation efforts when only a handful of individuals of a species remain.</li><br><li><strong>Cloning has a long, strange history:</strong> From Dolly the sheep in 1996 to replicated celebrity pets—Barbra Streisand and Tom Brady have both done it—cloning has moved from livestock science to luxury service. Critics call pet cloning "the exploitation of the canine underclass," given the egg donors and surrogates required.</li><br><li><strong>Frozen zoos and second chances:</strong> Cryopreserved tissues from over 1,300 species sit in storage at San Diego Zoo alone, and have already helped clone near-extinct animals like the black-footed ferret. One extinct wild goat was even briefly brought back—though it died minutes after birth, making it the only species known to have gone extinct twice.</li><br><li><strong>The creepiest pitch in biotech:</strong> A startup founder has floated the idea of growing brainless human clones as personal organ reserves. No one has cloned a human yet—as far as we know</li></ul>' data-chronoton-post-id="1141919" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>This week I spoke to scientists who have found a way to turn male mouse embryos female. They’ve developed a CRISPR-based approach to essentially cut out the Y chromosome. It allowed them <a href="https://www.technologyreview.com/2026/08/12/1141768/scientists-just-created-female-clones-of-male-mice/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=08-13-26">to create female clones of male mice</a>.</p>



<p>That’s right: female animals that are genetically identical to males, except for the missing Y chromosome. Takashi Ishiuchi, a reproductive biologist at the University of Yamanashi who co-led the work, told me it felt a bit like sci-fi.</p>





<p>Ishiuchi and his colleague Shogo Matoba of the Riken BioResource Research Center hope their approach could be helpful in conservation efforts, especially in cases where we might have only a few individuals of a species left. But cloning has multiple uses, ranging from the cool to the outright creepy.</p>



<p><strong>We can’t talk about cloning without mentioning Dolly</strong>, the celebrity sheep born in 1996 and the first mammal successfully cloned from an adult cell. In that case, scientists took the DNA-containing nucleus of an adult mammary cell from one sheep and transferred it into an egg cell that had had its own nucleus removed. The resulting embryo was transferred to a surrogate sheep, which gave birth to Dolly—an animal genetically identical to the DNA donor.</p>



<p>The scientists behind that work were interested in genetically modifying livestock. Farmers have essentially been doing this for thousands of years through selective breeding, but cloning allows scientists to create genetic replicas of animals with desirable traits.</p>



<p>Cloning is also being used to replicate <a href="https://www.technologyreview.com/2025/11/07/1127692/cloning-celebrity-pets-tom-brady-dog-conservation/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=08-13-26">deceased pets</a>, including, famously, those of Barbra Streisand and Tom Brady, among others. For a price somewhere in the tens of thousands of dollars, a company can take cells from your pet and turn them into a living, breathing clone.</p>



<p>Considering that cloning also requires egg cells from another animal, and a surrogate animal to carry the pregnancy, not everyone is on board with this, especially since there is no medical or environmental need for the procedures. One bioethicist, Jessica Pierce, has <a href="https://www.nytimes.com/2018/03/06/opinion/clone-pet-streisand-dog.html">described</a> this aspect of dog cloning as “the exploitation of the canine underclass.”</p>



<p><strong>The case for cloning is stronger when it comes to conservation</strong>—where some argue there <em>is</em> environmental value.</p>



<p>Scientists have been preserving animal tissues for years. Some of these tissues are cryopreserved at low temperatures in “frozen zoos.” The facility at the <a href="https://sandiegozoowildlifealliance.org/frozen-zoo">San Diego Zoo</a>, for example, currently has cells from over 1,300 species. Some of these samples were taken decades ago.</p>





<p>Preserved tissues like these have enabled scientists to create clones of animals considered close to extinction, including black-footed ferrets and Przewalski’s horse. But they might also help us bring back extinct animals.</p>



<p>In 2009, researchers in Spain described how they’d <a href="https://www.sciencedirect.com/science/article/pii/S0093691X08007784">cloned an extinct wild goat</a>, the Pyrenean ibex, using skin cells that had been cryopreserved a decade earlier. In that research, the team used egg cells from domestic goats to create a total of 439 embryos. Ultimately, only one goat—a female—was born. She died minutes later because of a defect in her lungs.</p>



<p>Poor Pyrenean ibex. It’s the only animal we know of that has gone extinct twice.</p>



<p>The biotech company Colossal Biosciences is hoping to use old—and potentially ancient—genetic material to bring back long-extinct species like the thylacine and woolly mammoth. So far, the company’s efforts have <a href="https://www.technologyreview.com/2025/04/08/1114371/game-of-clones-colossals-new-wolves-are-cute-but-are-they-dire/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=08-13-26">largely involved modifying the genomes of modern-day animals</a>.</p>



<p>Technically, it’s also possible to clone humans. As far as we know, no one has done it. But some have played with the idea. One biotech startup founder has pitched an idea for “brainless clones”—human clones that lack a brain but contain all the organs people might need to replace their own in future. My colleague Antonio Regalado <a href="https://www.technologyreview.com/2026/03/30/1134780/r3-bio-brainless-human-clones-full-body-replacement-john-schloendorn-aging-longevity/?utm_source=the_checkup&utm_medium=email&utm_campaign=the_checkup.unpaid.engagement&utm_content=08-13-26">described that pitch</a> in March. (I had to pause eating my lunch while rereading it.)</p>



<p>Scientists have done a hell of a lot with cloning over the last few decades. I’m excited—but also slightly nervous—about what the coming decades will bring.</p>



<p><em>This article first appeared in The Checkup, </em>MIT Technology Review’s<em> weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, </em><a href="https://forms.technologyreview.com/newsletters/biotech-the-checkup/?_ga=2.241810882.15113993.1664981064-43237434.1647441349"><em>sign up here</em></a>.</p>]]> </content:encoded>
</item>

<item>
<title>Studies show value of biotech IP for the economy and society</title>
<link>https://edusehat.com/en/studies-show-value-of-biotech-ip-for-the-economy-and-society</link>
<guid>https://edusehat.com/en/studies-show-value-of-biotech-ip-for-the-economy-and-society</guid>
<description><![CDATA[ Biotech innovation provides better-than-average salaries and pumps hundreds of billions of dollars into the U.S. economy annually—and the societal benefits of this innovation can […]
The post Studies show value of biotech IP for the economy and society appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/national-cancer-institute-gO-iULv-qbU-unsplash.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 17:25:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Studies, show, value, biotech, for, the, economy, and, society</media:keywords>
<content:encoded><![CDATA[<p><span>Biotech innovation provides better-than-average salaries and pumps hundreds of billions of dollars into the U.S. economy annually—and the societal benefits of this innovation can be measured in hundreds of trillions, according to recent research.</span></p>
<p><span>Industries based on intellectual property, including biotech, are responsible for $11.4 trillion in U.S. gross domestic product, or 44% of total private sector GDP, according to</span><a href="https://www.uspto.gov/about-us/news-updates/ip-intensive-industries-provide-better-paying-jobs-employ-one-third-total"> <span>a report released by the U.S. Patent and Trademark Office (USPTO) on Aug. 3</span></a><span>. Out of this total, pharmaceuticals contributed $247 billion to the U.S. GDP in 2024, the report says.</span></p>
<p><span>When looking at the broader societal value of biotech, the impact is much greater, according to</span><a href="https://www.uschamber.com/health-care/estimating-the-full-value-of-medical-innovation"> <span>a recent analysis</span></a><span> produced by a University of Chicago economist for the U.S. Chamber of Commerce.</span></p>
<p><span>“Medical innovations in four disease areas: HIV, heart disease, breast cancer, and obesity generated $167.5 trillion in societal value over a 30-year horizon across all four disease areas,” the U.S. Chamber report finds.</span></p>
<h2>The importance of patents to biotech</h2>
<p><span>The USPTO report highlights the importance of patents to the overall U.S. economy, with patent-reliant industries providing 65.8 million jobs, or 44% of total private sector jobs. These are also better-paying jobs, “with average weekly earnings 53% higher than those received by workers in other industries,” USPTO says.</span></p>
<p><span>Pharmaceuticals rely on several types of IP, according to the report, including utility patents, design patents, and trademarks.</span></p>
<p><span>The biopharma sector is</span><a href="https://bio.news/federal-policy/bayh-dole-coalition-celebrates-and-protects-an-act-that-supercharged-innovation/"> <span>one of the most research-intensive industries</span></a><span>, which means IP provides its value. When a biotech firm sells investors on the promise of an innovative new drug, what they are really selling is IP developed through research. That’s why biotech firms need a strong patent system to safeguard their IP. </span><a href="https://bio.news/bio-convention/ahead-of-bio-ip-conference-research-highlights-why-biotech-needs-strong-patents/"><span>Research has shown</span></a><span> that venture capital funding for life sciences startups plummeted after legal changes weakened the patent system.</span></p>
<p><span>Given the importance of IP to biotech, the Biotechnology Innovation Organization (BIO) advocates policy to strengthen patent protections.</span><a href="https://bio.news/federal-policy/bio-is-expanding-its-work-to-defend-ip/"> <span>BIO continues to expand its efforts</span></a><span> in this area, working on Capitol Hill, through courts, and in international fora, with initiatives like BIO’s IP Task Force.</span></p>
<h2>The importance of biotech to society</h2>
<p><span>Beyond providing jobs, biotech provides treatments that patients need. The U.S. Chamber of Commerce report looks at the social benefits of medical innovation and assesses the monetary value of “saving lives, extending lifespans, and driving economic growth through increased productivity and tax revenue.”</span></p>
<p><span>The study analyzes the period 30 years after the introduction of breakthrough therapies for HIV (1995–2024), heart disease (1986–2024), and breast cancer (1991–2020), and projects the benefits of obesity drugs (2021–2050).</span></p>
<p><span>“HIV patients who would have died within two years in 1995 now live full lifespans—an average of 40 additional years,”</span><a href="https://www.uschamber.com/health-care/estimating-the-full-value-of-medical-innovation"> <span>says a summary of the report</span></a><span>. It notes that heart disease and breast cancer patients are living years longer. It projects that “new obesity treatments are poised to add nearly a year of life while dramatically reducing the chronic disease burden that has plagued millions of Americans.”</span></p>
<p><span>Based on these findings, “every dollar invested in medical R&D has returned 27 dollars in societal value—demonstrating that innovation is an investment, not a cost,” according to</span><a href="https://www.uschamber.com/economy/groundbreaking-study-reveals-167-trillion-in-societal-value-generated-by-american-medical-innovation"> <span>the U.S. Chamber</span></a><span>.</span></p>
<p><span>As these studies underline, biotech’s productive output, job creation, and additional years of healthy living provide huge benefits for America’s economy and society.</span></p>
<p>The post <a href="https://bio.news/health/studies-show-value-of-biotech-ip-for-the-economy-and-society/">Studies show value of biotech IP for the economy and society</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Pangenome&#45;Guided Breeding Boosts Yield and High&#45;Altitude Adaptation in Buckwheat</title>
<link>https://edusehat.com/en/pangenome-guided-breeding-boosts-yield-and-high-altitude-adaptation-in-buckwheat</link>
<guid>https://edusehat.com/en/pangenome-guided-breeding-boosts-yield-and-high-altitude-adaptation-in-buckwheat</guid>
<description><![CDATA[ Pangenome-guided breeding helped researchers combine high-altitude adaptation and improved yield in Tartary buckwheat by recovering useful wild alleles.
The post Pangenome-Guided Breeding Boosts Yield and High-Altitude Adaptation in Buckwheat appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-1442985851.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 10:10:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Pangenome-Guided, Breeding, Boosts, Yield, and, High-Altitude, Adaptation, Buckwheat</media:keywords>
<content:encoded><![CDATA[<p>Agricultural genomics is beginning to move beyond the limits of a single “reference” crop genome. In a proof-of-concept study, researchers used pangenome-guided breeding to recover useful DNA variation left behind during domestication and combine two traits that often work against each other in the field: high-altitude adaptation and yield.</p>
<p>The study, “<a href="https://www.cell.com/cell/abstract/S0092-8674(26)00867-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426008676%3Fshowall%3Dtrue" target="_blank" rel="noopener">Pangenome-guided breeding restores high-altitude adaptation and improves yield in Tartary buckwheat</a>,” was published in <em>Cell</em>. The international team was led by the Chinese Academy of Agricultural Sciences and included researchers from 22 institutions across 10 countries, including scientists at Murdoch University’s Centre for Crop and Food Innovation (CCFI). Tartary buckwheat (<em>Fagopyrum tataricum)</em>, a nutrient-dense grain grown in the Himalayan highlands, was selected as a model because its wild relatives tolerate harsh conditions such as cold and intense UV-B radiation.</p>
<p>Most genomics-assisted breeding compares crop lines with a single reference genome and focuses heavily on single-nucleotide polymorphisms. But that approach can miss larger structural variants, including gene copy-number changes, that influence agriculturally important traits. To capture that hidden variation, the team generated a telomere-to-telomere reference genome and assembled a graph-based pangenome from 16 accessions spanning Himalayan wild populations and globally distributed landraces. They also integrated genomic data from 994 accessions across 15 countries and cataloged 123,131 nonredundant structural variants.</p>
<p>“Most modern breeding compares a crop’s genome against a single reference, which is like judging a language by a single dictionary,” said Rajeev Varshney, FRS, FAA, CCFI director, and co-corresponding author of the study. “A pangenome captures the whole vocabulary, including the words a crop lost along the way. And that’s where a lot of the useful genetics for resilience is hiding.”</p>
<p><figure aria-describedby="caption-attachment-336536" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-336536" src="https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-300x206.jpg" alt="Drone image of RKV AC RRM" width="300" height="206" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-300x206.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-1024x704.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-768x528.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-1536x1056.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-611x420.jpg 611w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-1221x840.jpg 1221w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-218x150.jpg 218w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-436x300.jpg 436w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-696x479.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-1392x957.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-1068x735.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM-100x70.jpg 100w, https://www.genengnews.com/wp-content/uploads/2026/08/Drone-image-of-RKV-AC-RRM.jpg 1550w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">CCFI contributing authors Rajeev Varshney, Anu Chitikineni, and associate professor Reyazul Rouf Mir pictured by drone at a field trial for wheat in Northam, Western Australia. [CCFI]</figcaption></figure>The analysis identified FtRNH, a wild-specific gene present in high-altitude wild plants but missing from cultivated varieties. The gene is associated with the repair of UV-B–induced DNA damage and enhanced high-altitude adaptability. The researchers also identified structural variation at the FtPLATZ locus, including copy-number variation and a 28-bp promoter insertion linked to seed-size variation.</p>
<p>Using marker-assisted selection, the team crossed these superior FtRNH and FtPLATZ alleles into candidate breeding lines, effectively stacking high-altitude adaptation with larger seed size. In high-altitude field trials, the resulting lines showed improved growth, larger seeds, and significantly higher yields compared with the standard variety.</p>
<p>“Resilience and yield are usually a trade-off, meaning that when you increase one, you lose the other,” Varshney said. “What the pangenome lets us do is identify the specific DNA segments underlying each trait and deliberately stack them. That’s a template other breeding programs can follow.”</p>
<p>Whether the approach will translate broadly remains to be tested, but the study provides a framework for looking beyond elite crop genomes. By capturing variation in wild relatives and landraces, pangenomes may give breeders a clearer view of alleles that could be combined to improve adaptation without sacrificing yield.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/pangenome-guided-breeding-boosts-yield-and-high-altitude-adaptation-in-buckwheat/">Pangenome-Guided Breeding Boosts Yield and High-Altitude Adaptation in Buckwheat</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Thermo and Michael J. Fox Foundation Collaborate to Advance Proteomics&#45;Enabled Parkinson’s Therapy</title>
<link>https://edusehat.com/en/thermo-and-michael-j-fox-foundation-collaborate-to-advance-proteomics-enabled-parkinsons-therapy</link>
<guid>https://edusehat.com/en/thermo-and-michael-j-fox-foundation-collaborate-to-advance-proteomics-enabled-parkinsons-therapy</guid>
<description><![CDATA[ PPMI creates a large-scale proteomics resource designed to help researchers study Parkinson’s disease at the protein level and investigate biological signals associated with disease progression, patient heterogeneity, and potential biomarker development.
The post Thermo and Michael J. Fox Foundation Collaborate to Advance Proteomics-Enabled Parkinson’s Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/PPMI-Meeting.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 10:10:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Thermo, and, Michael, Fox, Foundation, Collaborate, Advance, Proteomics-Enabled, Parkinson’s, Therapy</media:keywords>
<content:encoded><![CDATA[<p>Thermo Fisher Scientific completed an Olink Explore HT proteomic analysis of approximately 5,500 research samples from the Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ppmi-info.org%2Faccess-data-specimens%2Fdownload-data&data=05%7C02%7CJohn.Sterling%40sagepub.com%7C2522145ee7c7466cc23508def962a894%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639222399300241537%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=JfSbgq0W3nPHPmDghdppPowv6UE%2Bl%2F6hI72PA4ub9tM%3D&reserved=0" data-outlook-id="ebad4c91-daf9-4860-ae7b-d95cdad2c34b">data repository</a>, where they are available to the global research community.</p>
<p>The project creates a large-scale proteomics resource designed to help researchers study Parkinson’s disease at the protein level and investigate biological signals associated with disease progression, patient heterogeneity, and potential biomarker development. By applying Olink technology to deeply characterized PPMI samples, Thermo Fisher officials said the company is expanding access to MJFF’s dataset that may help advance precision medicine approaches to Parkinson’s research.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<h4><strong>Deep proteomic insights </strong></h4>
<p>An estimated 10 million people worldwide are living with Parkinson’s disease, and that number is expected to rise as populations age. Although the disease is still diagnosed and monitored largely through clinical symptoms, research increasingly shows Parkinson’s disease involves multiple biological pathways and distinct patient subtypes. That complexity has made it difficult to develop biomarkers that reliably identify patient groups, track disease progression, and support more targeted therapeutic development.</p>
<p>As the field shifts toward biology-driven precision medicine, large-scale proteomic datasets are helping researchers better understand disease biology and generate hypotheses that can be tested across cohorts and methods.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Olink, part of Thermo Fisher, was designed to enable high-throughput, affinity-based proteomic analysis using Proximity Extension Assay (PEA) technology. Olink’s PEA-based platform is a scalable solution for protein biomarker analysis, supporting applications from discovery through translation and population-scale proteogenomics, according to Thermo.</p>
<p>Proteomics can help researchers identify patient subtypes, characterize disease progression, uncover biological pathways linked to inflammation, lysosomal function, and neuronal stress, and discover candidate biomarkers for future validation. Combining proteomic insights with longitudinal clinical, genetic, imaging, and other molecular data can further enrich understanding of health and disease.</p>
<p><strong>Defining Parkinson’s by its underlying biology</strong></p>
<p>PPMI, sponsored by the Michael J. Fox Foundation, launched in 2010 and was recently renamed the Parkinson’s Precision Medicine Initiative to reflect the field’s shift toward defining Parkinson’s by its underlying biology rather than clinical symptoms alone. PPMI’s open-access data are available to researchers worldwide and have been downloaded more than 50 million times.</p>
<p><figure aria-describedby="caption-attachment-336548" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-336548" src="https://www.genengnews.com/wp-content/uploads/2026/08/Researcher-working-in-lab_Resize-300x202.jpg" alt="As the field shifts toward biology-driven precision medicine, large-scale proteomic datasets are helping researchers better understand disease biology and generate hypotheses that can be tested across cohorts and methods. [Michael J. Fox Foundation]" width="300" height="202" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Researcher-working-in-lab_Resize-300x202.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Researcher-working-in-lab_Resize.jpg 368w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">As the field shifts toward biology-driven precision medicine, large-scale proteomic datasets are helping researchers better understand disease biology and generate hypotheses that can be tested across cohorts and methods. [Michael J. Fox Foundation]</figcaption></figure>“Parkinson’s disease is incredibly complex, and understanding the biological changes that drive its onset and progression requires looking across many layers of biology,” explained Samantha Hutten, PhD, principal biomarker scientist, translational research, MJFF. “This is what the Foundation’s global PPMI study was built to do. By expanding proteomic analyses within the study, including through partners like Olink, we’re creating new opportunities to identify biomarkers and uncover pathways that may lead to earlier diagnosis, better disease monitoring, and more targeted therapeutic approaches for people living with Parkinson’s disease.”</p>
<p>The analysis was completed as proteomics and multi-omics approaches gain broader use in neurodegenerative disease research. These methods can reveal dynamic biological changes that may not be captured through genomics or clinical assessment alone. Biobanks and large population studies are also adopting proteomic analysis to build richer molecular datasets that support biomarker discovery and precision medicine.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“Discovery is only the beginning in Parkinson’s research,” said Yan Zhang, PhD, president of proteomic sciences at Thermo Fisher. “The next challenge is determining which molecular signals are reproducible, clinically meaningful, and useful for advancing Parkinson’s precision medicine. Making these data available to the research community helps put that validation work into motion.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/thermo-and-michael-j-fox-foundation-collaborate-to-advance-proteomics-enabled-parkinsons-therapy/">Thermo and Michael J. Fox Foundation Collaborate to Advance Proteomics-Enabled Parkinson’s Therapy</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The Coming Shift from Biomarkers to Biological Trajectories</title>
<link>https://edusehat.com/en/the-coming-shift-from-biomarkers-to-biological-trajectories</link>
<guid>https://edusehat.com/en/the-coming-shift-from-biomarkers-to-biological-trajectories</guid>
<description><![CDATA[ The next era of medicine will not be defined by earlier detection alone, but by understanding dynamics.
The post The Coming Shift from Biomarkers to Biological Trajectories appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/TL-Aqtual-hero-image.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 06:35:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, Coming, Shift, from, Biomarkers, Biological, Trajectories</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-336521" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336521" src="https://www.genengnews.com/wp-content/uploads/2026/08/TL_AQTUAL_Diana_AbduevaPhD_Headshot-2-e1786646363922-300x300.jpg" alt="Diana Abdueva" width="200" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/TL_AQTUAL_Diana_AbduevaPhD_Headshot-2-e1786646363922-300x300.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/TL_AQTUAL_Diana_AbduevaPhD_Headshot-2-e1786646363922-150x150.jpg 150w, https://www.genengnews.com/wp-content/uploads/2026/08/TL_AQTUAL_Diana_AbduevaPhD_Headshot-2-e1786646363922.jpg 336w" sizes="auto, (max-width: 200px) 100vw, 200px"><figcaption class="wp-caption-text">Diana Abdueva, PhD<br>Founder and CEO, Aqtual</figcaption></figure></p>
<p>For most of modern medicine, we have treated disease as a static condition. A patient has cancer. A patient has rheumatoid arthritis. A patient has inflammatory bowel disease. Diagnosis has largely meant identifying the condition, assigning a label, and selecting a treatment based on the standard of care.</p>
<p>But disease is not static, it is a dynamic biological process that evolves over time. Biology operates through change, and what we call a disease is often just the name we assign to a single point along a continuous biological journey, shaped by interactions among cells, tissues, and the immune system, by environmental exposures, and by the selective pressures of therapy itself. The lines we draw between health and disease, response and progression, are snapshots of a process that never stops moving.</p>
<p>Seen this way, the most consequential questions in healthcare are not about presence but about direction. Where is the patient today? Where are they heading? Which future states remain possible, and how can we change the path? The next era of medicine will be defined not by earlier detection alone, but by the ability to measure biological trajectories and ultimately intervene to change them.</p>
<p></p><h4><strong>A state-transition problem</strong></h4>

<p>Consider the decisions that actually determine patient outcomes. Diagnosis asks what biological state a patient is in. Therapy selection asks which intervention is most likely to move them toward a better one. Treatment monitoring asks whether they are moving in the expected direction. Drug development asks how an intervention alters biological trajectories across an entire population.</p>
<p>These look like distinct challenges, but at their core they are the same problem: understanding how biological systems move from one state to another. Yet most of our measurement tools were never designed to answer that question. They were built to detect the presence of something—a mutation, a protein, a lesion, a biomarker. Those measurements have transformed medicine, but they are static snapshots. They tell us what is present at a given moment far better than they reveal what is changing, why, or where the biology is headed next.</p>
<p>The challenge facing medicine is no longer detection alone. It is understanding dynamics.</p>
<p></p><h4><strong>A larger transformation</strong></h4>

<p>The evolution of liquid biopsy mirrors this broader shift. In 1997, Dennis Lo, DM, DPhil, and colleagues showed that cell-free fetal DNA circulates in maternal plasma, establishing that biological information could be read non-invasively from blood. The first generation of tests asked a simple question: Can disease-associated DNA be detected non-invasively?</p>
<p>The second generation moved from detection to sequence. Circulating tumor DNA assays identified cancer-associated mutations, monitored molecular residual disease, and flagged emerging resistance. The third generation went further still, using methylation and fragmentomic patterns to infer tissue of origin—which organs or cell types had contributed DNA to circulation.</p>
<p>Each advance extracted more information from a single blood draw. But all three generations remained focused on what was present and where it came from. A more fundamental question is now emerging: What was happening inside the cell before that DNA entered circulation? Not which tissue released it, nor which mutations it carried, but the functional state that generated the signal in the first place. Answering that question moves liquid biopsy beyond measuring static signals and toward measuring the biological processes that produced them.</p>
<p></p><h4><strong>Tissue of origin to biological state</strong></h4>

<p>The field has already begun to move past the question of where DNA comes from. The harder question is what those tissues were doing. Disease is rarely the work of isolated cells acting alone. Cancer emerges through interactions among tumor, stromal, and immune compartments. Autoimmune disease arises from cross-talk between infiltrating immune cells and tissue-resident populations. Fibrosis develops through coordinated remodeling across multiple cell types. These processes are not defined by single genes or mutations, but by regulatory programs, cell-to-cell communication, and transitions between biological states. And traces of that functional information appear to persist in circulation: A growing body of work indicates that cell-free DNA can carry signals of immune activation, fibroblast activity, and tissue remodeling, making aspects of gene regulation and cellular state readable directly from plasma.</p>
<p>This shifts liquid biopsy from identifying tissue of origin toward measuring tissue and disease states. Across a range of immune-mediated diseases, circulating signals increasingly reflect the stromal and immune programs seen in tissue and single-cell studies—not isolated molecular changes, but coordinated states of matrix remodeling, immune activation, and tissue stress. Just as important, repeated measurements turn these signals from snapshots into longitudinal trajectories, letting clinicians watch how biology evolves and responds to treatment over time. The critical question is no longer only what state a patient is in today, but where that state is heading next.</p>
<p></p><h4><strong>The emergence of trajectory medicine</strong></h4>

<p>Once biological states become measurable, a different model of care becomes possible. Many diseases are still managed by observation and iteration. In rheumatoid arthritis, for example, patients often cycle through therapies until one happens to work. The problem is not a shortage of options, but limited visibility into the biology driving disease in a given patient. The same constraint runs through oncology, inflammatory bowel disease, fibrosis, neurodegeneration, and transplantation.</p>
<p>This is no longer purely theoretical. In a peer-reviewed study led by investigators at Princess Margaret Cancer Center,<sup>1</sup> a single blood-based assay simultaneously measured immune, stromal, and tumor-associated biology in leiomyosarcoma—a cancer where low tumor mutation burden limits conventional circulating tumor DNA approaches and repeat biopsies are rarely feasible. Plasma-derived promoter activity showed strong concordance with matched tumor RNA sequencing, and longitudinal sampling captured shifts in immune and stromal biology tied to immunotherapy response and resistance.</p>
<p>Similar observations are beginning to appear beyond oncology. In immune-</p>
<p>mediated diseases such as rheumatoid arthritis<sup>2</sup> plasma-derived signals have recovered distinct, tissue-anchored stromal and immune programs consistent with the biology of the affected tissue. These findings are still early—generated in relatively small cohorts and in need of validation in larger, independent studies—but together they suggest that functional biological state, across both cancer and chronic inflammatory disease, can be measured from blood and followed over time.</p>
<p>When biological state becomes measurable, treatment shifts from reacting to symptoms toward managing trajectories. The questions change: not where a patient is today, but which path they are on, which intervention is most likely to change course, and how early a divergence from the expected response can be caught. Answering them requires a measurement framework built to capture biological change, not just biological presence.</p>
<p></p><h4><strong>The next platform layer in medicine</strong></h4>

<p>Every major advance in medicine has been unlocked by a new layer of measurement. Clinical chemistry enabled laboratory medicine. Imaging-enabled anatomical medicine. Genomics enabled precision medicine. The next layer will come from the ability to measure functional biological states and how they change over time.</p>
<p>The implications reach well beyond diagnostics. Therapy selection becomes a question of which intervention is most likely to alter a patient’s course. Drug development becomes a question of mapping how interventions reshape biology across populations. Disease interception becomes a question of recognizing an unfavorable path before symptoms appear. Healthcare itself becomes organized around how biological systems evolve, respond, adapt, and recover.</p>
<p>The organizations that define this future will not simply identify biomarkers. They will build the technologies and analytical frameworks that make biological change measurable, predictable, and ultimately actionable. The next era of medicine will be defined not by detecting disease earlier, but by understanding where biology is headed and learning how to change its course.</p>
<p></p><h4><strong>Problems that will define the field</strong></h4>

<p>None of this will come easily, and the challenges are worth stating plainly. Reading regulatory signal from cell-free DNA demands sophisticated computational methods and large, well-annotated datasets that account for variation across individuals, disease states, and platforms. Without rigorous analytical and technical standardization, such measurements will be hard to compare, reproduce, and interpret at scale.</p>
<p>The challenges of clinical translation are greater still. Prospective studies must show that measuring biological state from plasma improves clinical decisions and patient outcomes, especially where treatment selection remains largely empirical. Regulatory and reimbursement frameworks, built for mutation- and burden-based tests, may be a further hurdle. Functional biomarkers will need to prove that they can reliably characterize biological state, predict clinically meaningful change, and shift management in ways that improve outcomes.</p>
<p>These are not reasons for doubt. They are the next set of problems that will define the field and the test any serious platform will have to pass.</p>
<p></p><h4><strong>Where biology is going next</strong></h4>

<p>Twenty-five years of liquid biopsy trace a steady expansion of what blood can tell us: from detecting DNA fragments, to identifying their tissue of origin, to understanding the functional states that produced them. The patients who stand to benefit reach far beyond oncology, into the many chronic diseases whose underlying biology is increasingly understood but still hard to measure in routine care.</p>
<p>The shift from detection to function is already underway. How much it ultimately changes medicine will depend on how well we translate biological insight into clinical decisions. The question is no longer whether disease can be detected from blood, but whether we can see where biology is going next and intervene before the outcome is set.</p>
<p><em> </em></p>
<p><em>References</em></p>
<ol>
<li>Lopes, C.D.H., Wu, HT., Dilger, K. et al. Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling. <em>npj Precis. Onc.</em> (2026). doi: 10.1038/s41698-026-01451-9.</li>
<li>Taylor P., Antonova J., Geis J. et al. Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay [abstract]. <em>Arthritis Rheumatol.</em> 2023; 75 (suppl 9).</li>
</ol>
<p class="trimmed"> </p>
<p><em>Diana Abdueva, PhD, is the founder and CEO of Aqtual.</em></p>
<p class="trimmed"> </p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/the-coming-shift-from-biomarkers-to-biological-trajectories/">The Coming Shift from Biomarkers to Biological Trajectories</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Producing Recombinant Antibodies  for In Vivo Research</title>
<link>https://edusehat.com/en/producing-recombinant-antibodies-for-in-vivo-research</link>
<guid>https://edusehat.com/en/producing-recombinant-antibodies-for-in-vivo-research</guid>
<description><![CDATA[ Antibody reagent variability is a leading but frequently underappreciated source of irreproducible preclinical data. For in vivo studies, the problem is multidimensional: supply must simultaneously meet specifications for yield, purity, endotoxin control, […]
The post Producing Recombinant Antibodies  for In Vivo Research appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_695234246_FemaleScientistsPipetting_1400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 06:35:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Producing, Recombinant, Antibodies, for, Vivo, Research</media:keywords>
<content:encoded><![CDATA[<p><figure aria-describedby="caption-attachment-336506" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336506 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-300x148.jpg" alt="Average expression yield (mg/L) for IgG and bispecific antibody formats " width="300" height="148" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-300x148.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-1024x505.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-768x379.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-852x420.jpg 852w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-696x343.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-1392x690.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-1068x526.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-324x160.jpg 324w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-648x320.jpg 648w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-533x261.jpg 533w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2-1066x522.jpg 1066w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure-1-2.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Average expression yield (mg/L) for IgG and bispecific antibody formats produced using Bio X Cell’s recombinant transient expression platform, compared with representative published transient expression benchmarks.</figcaption></figure></p>
<p>Antibody reagent variability is a leading but frequently underappreciated source of irreproducible preclinical data. For <em>in vivo</em> studies, the problem is multidimensional: supply must simultaneously meet specifications for yield, purity, endotoxin control, and lot-to-lot consistency, and standard production approaches commonly treat at least one of these as a flexible trade-off. Higher yield at the expense of purity, or rigorous quality control at volumes too small to support multi-cohort designs, are the familiar compromises. Specifying all four attributes together as non-negotiable engineering targets, rather than aspirational outcomes, changes what study designs can responsibly assume and what data can be trusted.</p>
<p>This article examines what that specification looks like in practice, using recombinant antibody production and analytical data across multiple formats to illustrate how yield, purity, endotoxin performance, and lot-to-lot consistency can each be controlled simultaneously. Bispecific antibodies are the most technically demanding format in this analysis and serve as a useful reference point for understanding the production architecture required across all formats.</p>
<p></p><h4><strong>Why platform design matters</strong></h4>

<p>A standard Immunoglobulin G (IgG) is a symmetric homodimer, and its production, while technically demanding, benefits from that symmetry at every stage from expression through purification. Bispecific formats deliberately break that symmetry by pairing two distinct heavy chains, two distinct light chains, or both simultaneously, and every stage of production is harder as a result.<sup>1</sup></p>
<p>A common challenge in bispecific antibody production is chain mispairing and the correct assembly of complex antibody formats. Compared with conventional IgG molecules, bispecific antibodies require coordinated expression and pairing of multiple antibody components, increasing production complexity and placing greater demands on expression, purification, and analytical workflows.<sup>1–3</sup></p>
<p>As a result, achieving strong yield, high purity, low endotoxin, and lot-to-lot consistency simultaneously is substantially more challenging for bispecific formats than for conventional monoclonal antibodies.</p>
<p>This is why platform design matters. The combination of attributes that preclinical researchers need, sufficient yield to supply multi-cohort studies, purity adequate for <em>in vivo</em> use, endotoxin control across independent lots, and analytical consistency that makes lots interchangeable, is harder to deliver simultaneously for bispecific formats than for any other. A platform that can consistently produce bispecific antibodies at high yield and quality demonstrates the ability to maintain consistent production performance across recombinant antibody formats.</p>
<p></p><h4><strong>Yield across formats</strong></h4>

<p>Transient transfection of mammalian cells, principally HEK293 and CHO systems, is the standard expression approach for research-grade recombinant antibody production. One advantage of transient mammalian expression systems is rapid material generation, enabling recombinant antibody production within weeks rather than the months often required for stable cell line development. These systems are also compatible with the co-transfection strategies used for complex antibody formats such as bispecifics.</p>
<p>When expression workflows are properly optimized across DNA mass ratios, transfection reagent formulations, culture media composition, and harvest timing, yields well above historical benchmarks are achievable across formats. Data from this platform demonstrate conventional murine IgG production averaging 633 mg/L, compared to previously published transient murine expression examples averaging approximately 114 mg/L, a more than five-fold improvement. For murine bispecific formats, the same platform averaged 180.5 mg/L versus previously reported transient murine bispecific examples averaging 35.5 mg/L. The proportional improvement is comparable across both format classes. Gram-scale preclinical production is achievable even for the most structurally demanding formats without requiring stable cell line development.</p>
<p></p><h4><strong>Purity and endotoxin control</strong></h4>

<p>Yield at the expense of purity is not a viable tradeoff for <em>in vivo</em> applications. Recombinant antibodies intended for <em>in vivo</em> use must meet quality standards across multiple dimensions simultaneously: product-related impurities, including aggregates, fragments, and endotoxin, must be controlled within defined specifications at every lot.</p>
<p>Endotoxin is a particular concern for studies measuring immune activation, cytokine biology, or tumor microenvironment dynamics, where uncontrolled endotoxin burden can introduce signals that are indistinguishable from treatment effects. Endotoxin control is therefore not a release formality but a scientific requirement for study interpretability.</p>
<p>Across 300 released custom service lots spanning multiple antibody formats, endotoxin levels were consistently maintained within defined internal release specifications. Ninety-one percent of lots measured ≤0.4 EU/mg, well within the 0.5 EU/mg threshold commonly referenced for <em>in vivo</em> study readiness.<sup>4</sup> That distribution reflects process consistency rather than occasional good performance: the same controlled purification conditions and quality checkpoints applied across every lot produce a predictable endotoxin outcome, independent of format or production scale.</p>
<p></p><h4><strong>Lot-to-lot consistency</strong></h4>

<p>Purity and endotoxin performance on a single lot are necessary but not sufficient for multi-cohort <em>in vivo</em> research. The question that governs longitudinal and multi-site study design is whether lot three will be analytically interchangeable with lot one. Lot-to-lot antibody variability is among the most common and most underappreciated contributors to irreproducible preclinical data, and it is a confounder that experimental design cannot correct for retrospectively.</p>
<p>Treating lot-to-lot consistency as a built-in specification rather than a hoped-for outcome requires that the same analytical release package be applied to every lot, and that the production process be controlled tightly enough to make the results of that package predictable. High-performance SEC (HP-SEC) provides the most sensitive window into that consistency, resolving monomer from high-molecular-weight aggregate species and capturing subtle process drift through retention time and peak shape metrics.</p>
<p>HP-SEC data from four independently produced lots of two representative antibodies, MAR1-5A3-CP056 and 29F.1A12-CP005 (n=8 total), demonstrate what that consistency looks like in practice. Monomer purity exceeded 98.7% in every lot across both antibodies, with a combined range of 98.57 to 99.35% and within-antibody RSD of ≤0.05%. HMW pre-peak area remained ≤1.43% across all eight lots (range 0.65 to 1.43%), with within-antibody variability of ≤0.78 percentage points. Monomer retention time was stable within each antibody to ≤0.05% RSD, and peak width at half maximum, a sensitive indicator of column performance and process consistency, remained stable within each antibody across all lots. Together, these metrics demonstrate that the production and analytical processes are sufficiently controlled to deliver interchangeable lots across independent production runs.</p>
<p></p><h4><strong>Translating analytical requirements</strong></h4>

<div class="my-8"><span data-render-ad="6"></span></div>
<p><figure aria-describedby="caption-attachment-336504" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336504 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1-300x138.jpg" alt="Endotoxin values measured" width="300" height="138" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1-300x138.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1-1024x472.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1-768x354.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1-910x420.jpg 910w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1-696x321.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1-1068x493.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure2-1.jpg 1318w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Endotoxin Control Across Released Lots. Endotoxin values measured across 300 released lots. Ninety-one percent of lots measured ≤0.4 EU/mg, reflecting consistent endotoxin control within defined internal release specifications across independent production runs.</figcaption></figure></p>
<p>Treating antibody reagent quality as a study design variable, rather than a procurement decision, changes how specifications should be set before work begins. For endotoxin, the relevant question is not whether a lot passes a generic release threshold but whether that threshold is appropriate for the biology being measured. Studies interrogating immune activation, cytokine signaling, or tumor microenvironment dynamics require more stringent endotoxin limits than studies where immune readouts are not the primary endpoint; the specification should follow the assay, not the other way around.</p>
<p>For lot-to-lot consistency, the practical requirement is that the same analytical release package, minimally, SEC purity profile, monomer retention time, and HMW aggregate content, be obtained for every lot used in a study, and that acceptable ranges be pre-specified rather than assessed retrospectively. When those ranges are defined in advance, an out-of-specification lot can be identified before animals are dosed rather than after results are in hand.</p>
<p>Yield determines whether these specifications are enforceable at the scale a study actually requires. A consistency specification that cannot be met at the multi-gram scale is not a specification; it is an estimate. The data presented here illustrate that strong yield is achievable for both conventional and bispecific formats, while analytical consistency can be maintained across independent recombinant antibody lots. For researchers designing studies where the antibody must behave the same way every time, that combination is the starting point for a defensible experimental design.</p>
<p><figure aria-describedby="caption-attachment-336503" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-336503 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-1024x634.jpg" alt="HP-SEC lot-to-lot consistency graph" width="696" height="431" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-1024x634.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-300x186.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-768x476.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-678x420.jpg 678w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-1356x840.jpg 1356w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-696x431.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-1392x862.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-1068x661.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-356x220.jpg 356w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1-712x440.jpg 712w, https://www.genengnews.com/wp-content/uploads/2026/08/TUT_bioXcell_Figure3-1.jpg 1400w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">HP-SEC lot-to-lot consistency for MAR1-5A3-CP056 and 29F.1A12-CP005 (n=4 lots per antibody, 8 lots total). Panel A: normalized HP-SEC overlays for MAR1-5A3-CP056. Panel B: normalized HP-SEC overlays for 29F.1A12-CP005. Panel C: summary statistics table reporting monomer RT, monomer area, HMW pre-peak area, HMW RT, and FWHM for each antibody (mean ± SD), combined range across all eight lots, and within-antibody variability. Monomer purity ≥98.7% across all lots; monomer RSD ≤0.05%. Method: AdvanceBio SEC 300Å, 2.7μm, 4.6×150mm; 35mM sodium phosphate, 0.25M NaCl, 0.1M arginine, pH 6.8; 10μL injection; 280nm detection.</figcaption></figure></p>
<p class="trimmed"> </p>
<p><em>References</em></p>
<ol>
<li>Chen S, et al. Immunoglobulin gamma-like therapeutic bispecific antibody formats for tumor therapy. <em>J Immunol Res. </em>2019 Feb 11; 2019:4516041. doi:10.1155/2019/4516041.</li>
<li>Wei H, et al. Structural basis of a novel heterodimeric Fc for bispecific antibody production. <em>Oncotarget</em>. 2017 May 2;8(31):51037-51049. doi: 10.18632/oncotarget.17558.</li>
<div class="my-8"><span data-render-ad="7"></span></div>
<li>Schaefer W, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. <em>Proc Natl Acad Sci USA</em>. 2011;108(27):11187–11192. doi:10.1073/pnas.1019002108.</li>
<li>Malyala P, Singh M. Endotoxin limits in formulations for preclinical research. <em>J Pharm Sci. </em>2008;97(6):2041–2044. doi: 10.1002/jps.21152.</li>
</ol>
<p class="trimmed"> </p>
<p><em>Christina Bouwens is a marketing manager at Bio X Cell.</em></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/producing-recombinant-antibodies-for-in-vivo-research/">Producing Recombinant Antibodies  for In Vivo Research</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Long&#45;Term Memory Loss Secrets Revealed with Artificial Hibernation</title>
<link>https://edusehat.com/en/long-term-memory-loss-secrets-revealed-with-artificial-hibernation</link>
<guid>https://edusehat.com/en/long-term-memory-loss-secrets-revealed-with-artificial-hibernation</guid>
<description><![CDATA[ A study involving artificial hibernation in mice has shown how memories survive even after the brain temporarily loses more than half of its synaptic connections, challenging the long-held view that long-term memories depend on stable individual synapses.
The post Long-Term Memory Loss Secrets Revealed with Artificial Hibernation appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/low-res-1.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 06:35:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Long-Term, Memory, Loss, Secrets, Revealed, with, Artificial, Hibernation</media:keywords>
<content:encoded><![CDATA[<p>Memories can survive even after the brain temporarily loses more than half of its synaptic connections, according to the results of a study in mice that challenge the long-held view that long-term memories depend on stable individual synapses. The researchers, headed by a team at Okinawa Institute of Science and Technology (OIST), and including teams at the University of Tsukuba, Exploratory Research Center on Life and Living Systems (ExCELLS), and National Institutes of Physiological Sciences, used a mouse model of artificial hibernation to examine structural mechanisms underlying memory retention.</p>
<p>Their findings indicate that memory may be preserved not through individual synapses, but through resilient patterns of neural architecture, including specific clusters of connected synapses that remain protected during widespread hibernation-associated brain remodeling. These preserved structural motifs could act as a “core memory trace,” allowing the brain to rebuild functional networks after major disruptions.</p>
<p>Research lead Kazumasa Tanaka, PhD, head of OIST’s Memory Research Unit, said, “Previously, synaptic strengthening was thought to be key to memory recall, and that stronger synapses with larger dendritic spines were fundamental to long-term memory retention. Here, we show that not every synapse matters, and demonstrate instead the vital importance of engram architecture. The study indicates that small clusters of engram-engram synapses are preserved to enable accurate recall even after hibernation.”</p>
<p>Tanaka is senior and corresponding author of the team’s published paper in <em>Science</em>, titled “<a href="http://dx.doi.org/10.1126/science.aee7004" target="_blank" rel="noopener">Artificial hibernation reveals synaptic engram architecture associated with memory retention</a>.”</p>
<p>Understanding how memories are stored in the brain is one of the central challenges in neuroscience, the authors wrote. For decades, scientists have believed synaptic potentiation—the adaptive strengthening of our brain’s cellular connections—to be the key to memory retention. The newly reported research by Tanaka and colleagues now demonstrates the importance of higher-order synaptic architecture, suggesting that specific clustered patterns of connections between brain cells may be key to retaining long term memory.</p>
<p>“The structural underpinning of memory has been one of the most fundamental topics in neuroscience for decades,” the authors wrote. Much like computer storage, we humans require a physical memory trace to be stored in the brain. This physical trace, known as an engram, is encoded through a dedicated network of brain cells undergoing changes at their synapses, the junctions where they meet. When connecting brain cells repeatedly fire together, their synapses strengthen, increasing neurotransmitter release and triggering structural changes, such as larger dendritic spines, which expand the contact area between the two cells. Conversely, when a particular connection isn’t very active, the synaptic bonds between the cells weaken, and may eventually disappear altogether.</p>
<p>The synapses with larger, more stable dendritic spines have traditionally been seen as key for memory. While we might expect these connections to stay consistent over the course of a memory, recent studies have found that the structures and numbers of cells involved in a particular engram can change over time, without affecting recall. “… recent studies have revealed that synapses can be highly dynamic, with dendritic spines frequently appearing and disappearing, neuronal representations drifting over time, and memories remaining retrievable even after previously strengthened synaptic connections are disrupted,” the team continued. These observations raise a fundamental question, they noted. “How can memories remain stable despite extensive structural remodeling of neuronal networks?”</p>
<p>To investigate, the researchers turned to an artificial model of hibernation, as an experimental model for studying memory stability. In a hibernation state, decreased metabolism enables creatures to survive harsh, wintery conditions with little food, and can also causes brain activity to dramatically reduce.</p>
<p>In 2020, a team led by coauthor Takeshi Sakurai, PhD, at the International Institute for Integrative Sleep Medicine (WPI-IIIS), Tsukuba Institute for Advanced Research (TIAR), University of Tsukuba, <a href="https://www.nature.com/articles/s41586-020-2163-6" target="_blank" rel="noopener">induced artificial hibernation for the first time in mice</a>. Their research uncovered the brain circuitry necessary for inducing hibernation, unlocking a new tool for neuroscience research. They later reached out to Tanaka to collaborate. “Our brains are incredibly complex. If hibernation can reduce and simplify brain activity and structure, it could make studying these convoluted systems a bit easier. That’s why I wanted to use artificial hibernation techniques to study memories,” he said.</p>
<p>By imaging mouse brains before, during and after artificial hibernation, the researchers found that more than half of synapses in the hippocampus region of the brain disappeared in hibernation, and neuronal firing rate, a measure of brain activity, reduced by roughly 70%. Synapse elimination didn’t seem to be influenced by dendritic spine size, with synapses involving both large and small spines equally likely to be removed.</p>
<p>“Artificial hibernation caused a profound reduction in neuronal activity and eliminated more than half of hippocampal synapses,” the investigators noted.</p>
<p>The surprise came in behavioral tests after artificial hibernation, which showed that the animals’ memory recall remained the same, or even improved in some instances. “Despite these large-scale structural changes, mice retained previously acquired memories and preserved neuronal representations of experience,” they stated.</p>
<p><figure aria-describedby="caption-attachment-336485" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-336485" src="https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-300x208.jpeg" alt="This diagram shows two characteristic patterns found within the study. On the left, we see a multi-synaptic bouton (MSB), where one presynaptic terminal joins to multiple different dendritic spines on different cells. The researchers found that MSBs were more likely to be conserved following hibernation, suggesting their essential role in memory retention. On the right, we see clustered engram patterns. Dendritic spines that are close together but that connect to various axons of neurons in a different section of the brain are active within the same engram. Again, the researchers found that clustered engram synapses were preferentially conserved after artificial hibernation, which suggests their importance in memory retention. [Luo-chu Yang]" width="300" height="208" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-300x208.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-605x420.jpeg 605w, https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-218x150.jpeg 218w, https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-696x483.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-100x70.jpeg 100w, https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2-200x140.jpeg 200w, https://www.genengnews.com/wp-content/uploads/2026/08/low-res-2.jpeg 700w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">This diagram shows two characteristic patterns found within the study. On the left, we see a multi-synaptic bouton (MSB), where one presynaptic terminal joins to multiple different dendritic spines on different cells. The researchers found that MSBs were more likely to be conserved following hibernation, suggesting their essential role in memory retention. On the right, we see clustered engram patterns. Dendritic spines that are close together but that connect to various axons of neurons in a different section of the brain are active within the same engram. Again, the researchers found that clustered engram synapses were preferentially conserved after artificial hibernation, which suggests their importance in memory retention. [Luo-chu Yang]</figcaption></figure>First author Yu-Ju Lin, PhD, commented, “It was astonishing. Logically, if all our engram synapses were essential in memory retention as traditionally thought, memory should have massively deteriorated.”</p>
<p>To investigate why memory retention may have stayed intact or improved, the researchers used a technique called CLEM—correlative light and electron microscopy. “CLEM combines fluorescence microscopy with high-resolution electron microscopy, explained co-author and technician Ai Takahashi. “By labelling samples with fluorescent tags, we can see different parts of the cell or organism in different colors. This can, for example, help us to pinpoint important proteins. Then using electron microscopy, we can zoom in on those same areas, to examine substructures in much higher detail.”</p>
<p>The team’s study is the first to use CLEM to observe engrams, a significant achievement given how small and sparse engram synapses are. “Successfully correlating the light microscopy and electron microscopy datasets to image engrams is a very technically challenging feat,” added Tanaka. “We hope our contributions to developing this method may provide new platforms for studying other important neuroscientific questions in future.”</p>
<p>The team fluorescently labelled the synapses thought to be involved in a particular memory trace and examined these before and after artificial hibernation. They found a significant decrease in synapses. However, certain clusters of synapses seemed to be spared. “Dendritic spines were eliminated regardless of their size, but many reappeared at the same dendritic locations after recovery,” they wrote. “Notably, synaptic connections between neurons encoding the memory were organized into spatially clustered groups.” Tanaka said, “This suggests that for long-term memory, only particular clusters of synapses matter—the rest may be dispensable. Interestingly, dendritic spine size, which has been shown to increase in initial memory encoding, doesn’t seem to play a factor in memory retention.”</p>
<p>Lin added, “We’ve observed this interesting correlation between clusters and memory retention, but not yet proven a causal link. As technology develops, it will be interesting to study these clusters in more detail, to answer these remaining questions.”</p>
<p>Looking forward, the researchers hope to continue their studies on memories, with the aim of understanding the mechanisms by which these core clusters are protected. “A deeper understanding of the mechanism by which hibernation protects the core memory trace and maintains the network integrity would reveal more comprehensive principles of memory,” the investigators concluded. “</p>
<p>Tanaka noted, “We’ve unlocked some insights into the architecture needed for memory retention. But there are many more questions to explore. How does the brain maintain this structure over time? How do different memories interplay? We have so much left to learn.”</p>
<p>The researchers also plan to study other aspects of artificial hibernation. “This work focused on mice, but the same neuronal circuitry for hibernation is well-conserved across many mammals, including humans,” Tanaka pointed out. “Therefore, through artificial hibernation studies, we may be able to discover new insights or applications that can translate to human health and neuroscience.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/long-term-memory-loss-secrets-revealed-with-artificial-hibernation/">Long-Term Memory Loss Secrets Revealed with Artificial Hibernation</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Financial Value of AI Agents in Drug Development</title>
<link>https://edusehat.com/en/financial-value-of-ai-agents-in-drug-development</link>
<guid>https://edusehat.com/en/financial-value-of-ai-agents-in-drug-development</guid>
<description><![CDATA[ Net present value modeling based on actual use and benchmark data was applied to quantify the net financial impact of an agentic AI solution to support a drug development program.
The post Financial Value of AI Agents in Drug Development appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2250769923.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 06:35:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Financial, Value, Agents, Drug, Development</media:keywords>
<content:encoded><![CDATA[<p>A new Tufts Center for the Study of Drug Development (CSDD) analysis shows that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment.</p>
<p>The findings are based on benchmarked oncology program and clinical trial data from Tufts CSDD and contract value data from Medable, which provides a cloud-based software platform designed to modernize and accelerate clinical trials for the pharma and life sciences industries.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p><figure aria-describedby="caption-attachment-336490" class="wp-caption alignleft"><img decoding="async" class="size-medium wp-image-336490" src="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2203178449-300x200.jpg" alt="analyzing clinical trial data with ai" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2203178449-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2203178449-631x420.jpg 631w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2203178449-696x463.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2203178449.jpg 724w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Tufts CSDD officials believe that the study marks the first time that eNPV modeling based on actual use and benchmark data has been applied to quantify the net financial impact of an agentic AI solution deployed to support a drug development program. [Prime Images/Getty Images]</figcaption></figure>The Tufts CSDD analysis specifically assessed the impact of Medable’s Clinical Monitoring Agent across three top-line metrics:</p>
<ul>
<li><em>Expected net present value</em>: The agent showed expected net present value (eNPV) gains of approximately $7.5 million (Phase II trial), $11.3 million (combined Phase II and Phase III) development, and $21 million (Phase III trial).</li>
<div class="my-8"><span data-render-ad="4"></span></div>
<li><em>Overall return on investment:</em> The study found an estimated ROI of 64x for Phase II and 82x for Phase III clinical trials.</li>
<li>Direct operating cost savings: Tufts CSDD estimated direct operating cost reductions in on-site monitoring per clinical trial of approximately $4.4 million per Phase II and $5.6 million per Phase III study.</li>
</ul>
<p>“To our knowledge, this is the first time that eNPV modeling based on actual use and benchmark data has been applied to quantify the net financial impact of an agentic AI solution deployed to support a drug development program,” said Ken Getz, Tufts CSDD executive director. “The financial value created by the investment and deployment of the monitoring agent was driven by operational efficiencies such as the reduction in the number of on-site visits and reduced travel costs as well as accelerated enrollment and database lock timelines.”</p>
<p>Additional analysis identified and valued administrative off-site monitoring task efficiencies of approximately $600,000 (Phase II) and $1.7 million (Phase III). These savings reflect clinical research associate time that could be reallocated to other studies and were not included in the eNPV calculations.</p>
<p>The analysis also found that agentic AI can accelerate clinical development by approximately 10 weeks. By shortening activities on the critical path of development, agents help sponsors complete studies sooner, advancing regulatory submission and potential commercialization while increasing the expected financial value, according to the study.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Key contributors include faster patient enrollment, reducing enrollment timelines by approximately 109–119 days, earlier database lock, shortening closeout activities by about two weeks, and earlier realization of future revenue and lower development costs.</p>
<p>“The potential impact is magnified when applied across a large oncology portfolio,” said Pamela Tenaerts, MD, chief medical officer at Medable. “For a sponsor with 20 active indications, deploying a clinical monitoring agent across Phase II and III studies could generate as much as $226 million in incremental portfolio eNPV.</p>
<p>“For a sponsor with 50 active indications, that figure could jump to as much as $565 million. Bottom line? We now have evidence demonstrating sizable value creation of agents in clinical research, helping break longstanding barriers.”</p>
<p>In addition to these high-level findings, Tufts and Medable will publish a more detailed peer-reviewed paper later this year. Sign-up to be the first to receive the final published paper<a href="https://info.medable.com/20260810-Tufts-CSDD-Research-PaperLP-Signup.html" target="_blank" rel="noopener"> here</a>.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/financial-value-of-ai-agents-in-drug-development/">Financial Value of AI Agents in Drug Development</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Advancing Microbial&#45;Derived Biologics from Scale&#45;Up to Commercial Production</title>
<link>https://edusehat.com/en/advancing-microbial-derived-biologics-from-scale-up-to-commercial-production</link>
<guid>https://edusehat.com/en/advancing-microbial-derived-biologics-from-scale-up-to-commercial-production</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Sam Zhang, PhD, will discuss emerging trends and capacity needs across the global late-stage microbial pipeline and CDMO landscape. 
The post Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyI_1404942924_PharmaceuticalManufacturing.jpg" length="49398" type="image/jpeg"/>
<pubDate>Fri, 14 Aug 2026 06:35:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Advancing, Microbial-Derived, Biologics, from, Scale-Up, Commercial, Production</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><p></p><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2025/09/ThoughtLeader_WuXi-Sheng-Sam-Zhang-e1757963357588.jpg" class="h-full w-full object-cover" alt="Image of Sam Zhang, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Sam Zhang, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Vice President, Head of Microbial and Viral Platforms (MVP)<br>WuXi Biologics</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2025/09/ThoughtLeader_WuXi-Sheng-Sam-Zhang-e1757963357588.jpg" alt="Image of Sam Zhang, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Sam Zhang, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Sam Zhang, PhD, has more than 18 years of experience in the biopharmaceutical industry, with extensive expertise in CMC management, cell line development, process development, and clinical manufacturing. In his current role as vice president and head of the MVP site at WuXi Biologics, Sam leads innovative efforts across microbial, <em>in vivo</em> CAR, and HEK293 platforms to provide end-to-end CRDMO solutions. His career spans key technical leadership roles at Pfizer, Amgen, and AbbVie, where he specialized in recombinant protein expression, bioprocess development, and CMC management.</p>
<p>Sam holds a PhD in cell biology from the University of California, San Diego, an MS in microbiology from the National University of Singapore, and a BS in biology from Nanjing University. His areas of expertise include rProtein expression, cell culture process development, business development, and regulatory filings.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Tuesday, September 29, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-09-29T15:00:00.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph">In biomanufacturing, there are complex demands around fermentation scale-up, process consistency, technology transfer, and manufacturing capacity that must be addressed for microbial-derived biologics to complete commercialization. Meeting those demands depends on specialized infrastructure and an integrated strategy for process validation, process performance qualification (PPQ), and long-term operational readiness.</p><p></p><p></p><p class="wp-block-paragraph">In this <em>GEN</em> webinar, our expert speaker, Sam Zhang, PhD, will discuss emerging trends and capacity needs across the global late-stage microbial pipeline and CDMO landscape. He will introduce WuXi Biologics’ integrated late-stage microbial capabilities including the newly constructed commercial facility in Chengdu, China, designed for microbial-derived biologics. He will demonstrate features of the comprehensive tech transfer and scale-up platform, as well as PPQ and commercial readiness strategies. He will also share a case study featuring a peptide program that will elucidate WuXi Biologics’ tailored solutions for microbial-derived biologics. Key takeaways will include:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>Critical success factors for technology transfer, process scale-up, PPQ readiness and commercial manufacturing</li><p></p><p></p><p></p><li>Large-scale microbial manufacturing capabilities at the Chengdu site, with fermentation scales of up to 15,000 L</li><p></p><p></p><p></p><li>Practical learnings from a complex peptide program, with broader relevance to recombinant proteins and other microbial-derived modalities</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.</em></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="alignleft size-large is-resized"><a href="https://www.wuxibiologics.com/" target="_blank" rel=" noreferrer noopener"><img fetchpriority="high" decoding="async" width="1024" height="290" src="https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-1024x290.jpg" alt="WuXi Biologics logo" class="wp-image-336357" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-1024x290.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-300x85.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-768x218.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-696x197.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-1392x395.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-1068x303.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo.jpg 1400w" sizes="(max-width: 1024px) 100vw, 1024px"></a></figure></p><p></p></div></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/advancing-microbial-derived-biologics-from-scale-up-to-commercial-production/">Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Scientists just created female clones of male mice</title>
<link>https://edusehat.com/en/scientists-just-created-female-clones-of-male-mice</link>
<guid>https://edusehat.com/en/scientists-just-created-female-clones-of-male-mice</guid>
<description><![CDATA[ Scientists have deliberately turned male mouse embryos into females for the first time. A team based in Japan used a CRISPR-based approach to remove the Y chromosome from male cells and create female clones of male mice.  “No one has done this before,” says Monika Ward, a reproductive biologist at the University of Hawaii, who… ]]></description>
<enclosure url="https://wp.technologyreview.com/wp-content/uploads/2026/08/mice.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 09:05:02 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Scientists, just, created, female, clones, male, mice</media:keywords>
<content:encoded><![CDATA[<div data-chronoton-summary="<ul><br><li><strong>Sex reversal in the lab:</strong> Japanese scientists used a CRISPR-based tool called Y-CUT to eliminate the Y chromosome from male mouse embryos, producing healthy, fertile females. </li><br><li><strong>Male mice cloned as females:</strong> The team went further, creating female clones of male mice — animals genetically identical to the original male, minus the Y chromosome. "It's like sci-fi," said one researcher.</li><br><li><strong>A lifeline for endangered species:</strong> The technique could help rescue species where only males survive, by generating females for reproduction. Frozen cell banks already exist for hundreds of species that could benefit.</li><br><li><strong>Still imperfect, but promising:</strong> Y-CUT still needs egg cells from a female of the same or similar species, and XO chromosomes cause infertility in most mammals beyond mice — but complementary technologies are emerging fast.</li><br></ul>" data-chronoton-post-id="1141768" data-chronoton-expand-collapse="1" data-chronoton-analytics-enabled="1"></div>


<p>Scientists have deliberately turned male mouse embryos into females for the first time. A team based in Japan used a CRISPR-based approach to remove the Y chromosome from male cells and create female clones of male mice. </p>



<p>“No one has done this before,” says Monika Ward, a reproductive biologist at the University of Hawaii, who was not involved in the research.</p>





<p>The feat could change the way scientists think about reproduction, says Takashi Ishiuchi, a reproductive biologist at the University of Yamanashi, who co-led the work. The findings were published in <a href="https://www.biorxiv.org/content/10.64898/2026.08.03.742506v1">a preprint paper</a> shared on bioRxiv earlier this month, which has not yet been through the peer-review process. “There’s a fixed concept in our scientific field that we need both females and males for reproduction,” says Ishiuchi. “I think we could change this concept.”</p>



<p>He and his colleague Shogo Matoba of the Riken BioResource Research Center in Ibaraki also hope their technique could help rescue endangered species, particularly in cases where only a few individuals remain.</p>



<p>“It’s exciting to see,” says Ben Novak, lead scientist at the wildlife conservation organization Revive & Restore, who was not involved in the work. “I am confident there will be plenty of applications, particularly for conservation purposes.”</p>



<h3 class="wp-block-heading">Sex change</h3>



<p>Ishiuchi says he and his colleagues were inspired by the <a href="https://royalsocietypublishing.org/rsos/article/10/12/231450/91949/Transcriptomic-signatures-associated-with">Okinawa rubble goby</a>, a fish that can change its sex in certain situations. If no males are present, a female can do this in order to reproduce with the other females. Males can also change sex to female.</p>



<p>This ability to change sex might be useful when it comes to rescuing endangered species, including mammals. There’s some precedent in the lab—albeit not intentional. In 2009, <a href="https://pubmed.ncbi.nlm.nih.gov/19602850/" data-type="link" data-id="https://pubmed.ncbi.nlm.nih.gov/19602850/">researchers reported</a> the accidental birth of a single female pup in a batch of 27 clones created from male mouse cells.</p>



<p>Sometimes the surviving population of a species falls so low that scientists will try to clone those animals. Cloning isn’t perfect—it can be tricky and inefficient, and it creates genetically identical individuals whose offspring might be more vulnerable to disease. But it has helped scientists with efforts to bring some species back from the brink of extinction, including <a href="https://www.technologyreview.com/2025/11/07/1127692/cloning-celebrity-pets-tom-brady-dog-conservation/">black-footed ferrets</a> and <a href="https://sandiegozoowildlifealliance.org/pr/SecondClonedPrzewalski%E2%80%99sHorse">Przewalski’s horse</a>.</p>



<p>Cloning an individual can only replicate its genes, so cloning a male animal will create all male offspring, for example. That won’t help much in the hypothetical situation where only male individuals of a species are left.</p>



<p>Ishiuchi has been working on a way to overcome this challenge by altering the chromosomes in cells. Mammals’ DNA is organized in pairs of chromosomes, including one pair of sex chromosomes. These sex chromosomes are typically XX in females and XY in males.</p>



<p>It’s the Y chromosome that makes mammals male. Ishiuchi and his colleagues have developed a CRISPR-based tool to get rid of it. Their approach targets a section of the Y chromosome that plays an important role in ensuring that, each time a cell divides, the “daughter” cells inherit the Y chromosome.</p>



<h3 class="wp-block-heading">Cutting the Y</h3>



<p>When the researchers tested their technique—which they call Y-CUT—in early-stage mouse embryos, they found they were able to eliminate the Y chromosome. Treated XY embryos were transferred to surrogate mice, which gave birth to female pups. The effect can be described as a “sex reversal,” say the researchers.</p>



<p>The female pups had XO chromosomes, which means they had one X chromosome rather than the usual two. But this didn’t seem to affect the animals, which grew up healthy and fertile, say Ishiuchi and Matoba.</p>



<p>In a second experiment, the researchers found they could also use Y-CUT to create female clones from male mice.</p>



<p>A standard approach to cloning involves taking the DNA-containing nucleus of a cell from an adult animal and inserting it into an egg cell that has had its own DNA removed. Under the right conditions, the resulting cell can develop into an animal that is genetically identical to the original donor.</p>



<p>Matoba and his colleagues used a similar method. Once they had a glut of these cloned cells, they treated some with Y-CUT before transferring them to surrogate mice to carry the pregnancies.</p>



<p>This allowed them to create female clones of male mice. The females are genetically identical to the original male, apart from the missing Y chromosome, says Matoba. “It’s like sci-fi,” says Ishiuchi.</p>



<figure class="wp-block-image size-full"><img fetchpriority="high" decoding="async" width="612" height="494" src="https://wp.technologyreview.com/wp-content/uploads/2026/08/Cloned-mice.jpg" alt="" class="wp-image-1141786" srcset="https://wp.technologyreview.com/wp-content/uploads/2026/08/Cloned-mice.jpg 612w, https://wp.technologyreview.com/wp-content/uploads/2026/08/Cloned-mice.jpg?resize=300,242 300w" sizes="(max-width: 612px) 100vw, 612px"><figcaption class="wp-element-caption">Courtesy of Takashi Ichiushi and Shogo Matoba, as published in their <a href="https://www.biorxiv.org/content/10.64898/2026.08.03.742506v1">bioRxiv preprint</a>.</figcaption></figure>



<p>In other experiments, the scientists were able to create female clones from male cells that had been cryopreserved—and the cloned males and females could mate to produce healthy pups. This suggests the Y-CUT approach might allow scientists to create female clones from male samples in <a href="https://www.technologyreview.com/2015/11/10/165137/using-virtual-reality-to-save-the-white-rhino/">“frozen zoos”</a> that store cryopreserved cells and tissues from a range of animal species.</p>



<p>It could have uses beyond conservation efforts, too. “This could be used potentially for producing genetically engineered animals,” says Ward. Creating an animal with multiple genetic edits can be time-consuming and expensive; creating male and female clones of that animal could help scientists time and money. Ward also hopes the technique could be a useful tool to study the biology of sex chromosomes.</p>



<h3 class="wp-block-heading">Complementary techniques</h3>



<p>The Y-CUT approach isn’t perfect. For now, it still requires hollowed-out egg cells, which need to come from females of the same species or at least a closely related one. And it won’t be useful for endangered species in which only females survive.</p>



<p>The technique works well in mice, partly because XO female mice are fertile. But while the approach might help some of the <a href="https://www.iucnredlist.org/">355 endangered and vulnerable species of rodents</a>, other mammals with XO chromosomes tend to experience infertility.</p>





<p>But other new technologies could complement Y-CUT. In 2023, Katsuhiko Hayashi of Osaka University and his colleagues showed they could turn cells taken from male mice into egg cells. This enabled them to create <a href="https://www.nature.com/articles/d41586-023-00717-7">mice with two dads</a>—but the same approach could also provide the hollowed-out egg cells needed for the Y-CUT technique. “It’s a complementary story,” says Matoba.</p>



<p>Ishiuchi is also working on a technique that involves inserting a second X chromosome into cells, which might restore the fertility of the resulting female animals.</p>



<p>In addition, there might be a work-around for situations where scientists have females but need males. A couple of months ago, Sayaka Wakayama of the University of Yamanashi in Japan and colleagues <a href="https://www.nature.com/articles/s41598-026-55500-1">showed they could insert rat chromosomes into mice</a>. That could potentially be used to create XY male embryos, says Novak.</p>



<p>That would be useful in cases like that of the black-footed ferret, he adds. A conservation team recently cloned a female ferret using cells taken from another animal in the 1980s. That female is considered incredibly valuable, says Novak. But females can produce only a few litters in their lifetime. A male clone, which might be able to contribute to dozens of litters in a lifetime, would be “desirable.”</p>



<p>“It’s really exciting to see more diverse tools being developed,” says Novak. “There are so many different scenarios in which they could be used for rare and endangered species.”</p>]]> </content:encoded>
</item>

<item>
<title>Biopharma’s Drawdown Is a Chance to Build Biotech Back Better</title>
<link>https://edusehat.com/en/biopharmas-drawdown-is-a-chance-to-build-biotech-back-better</link>
<guid>https://edusehat.com/en/biopharmas-drawdown-is-a-chance-to-build-biotech-back-better</guid>
<description><![CDATA[ American biotechnology hubs like Boston, Seattle, and San Diego are starting to wake up again. But will they be able to learn from the lessons of the recent past?
The post Biopharma’s Drawdown Is a Chance to Build Biotech Back Better appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GettyImages-2249359741.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 05:25:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Biopharma’s, Drawdown, Chance, Build, Biotech, Back, Better</media:keywords>
<content:encoded><![CDATA[<p>The biopharma industry is emerging from one of the sharpest boom-and-bust cycles in its history. Following a sharp decline in biotech venture funding (2025 deal counts down by two-thirds since 2021, according to <a href="https://news.crunchbase.com/venture/biotech-us-funding-share-lowest-2025/">Crunchbase</a>) and rising lab vacancies (over 50% in Seattle, according to <a href="https://hughesmarino.com/seattle/blog/2025/11/03/seattles-wet-lab-market-from-pandemic-boom-to-historic-imbalance/">HughesMarino</a>), the industry is now rebounding.</p>
<p>American biotech hubs like Boston, Seattle, and San Diego are starting to wake up again. But will they be able to learn from the lessons of the recent past? For many biopharma industry stakeholders, the post-COVID downturn provides a truly constructive opportunity: a forced reset of how biotech companies are built, and an opportunity to build them with an eye towards the future.</p>
<p></p><h4><strong>How we got here</strong></h4>

<p>Simply put, over the past 25 years, biopharma’s business model grew unsustainable.</p>
<p>The headline numbers tell the story. In Deloitte’s annual <a href="https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/measuring-return-from-pharmaceutical-innovation.html">analysis</a> of biopharma R&D productivity, the industry’s internal rate of return (IRR, a common measure of investment profitability) from drug discovery fell to just 1.2% in 2022 as prices soared and sales diminished. R&D productivity recovered somewhat in 2024 (5.9%), but this is still far below the industry’s average cost of capital (>11%), especially given rising interest rates.</p>
<p>The dismal data echoes the infamous “Eroom’s Law” (Moore’s Law backward)—the <a href="https://www.nature.com/articles/nrd3681.pdf">observation</a> that, unlike the famously improving productivity of microchips, the number of drug approvals per billion dollars invested has been declining for at least 30 years.</p>
<p>When incorporating the cost of drug development failures and capital costs, a two-decade analysis in the <em>Journal of the American Medical Association</em> <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820562">showed</a> that the total cost of drug development rose from $172 million (in 2018 dollars) to $879 million. The need to effectively control costs was listed as paramount amidst further barriers to getting drugs to market.</p>
<p>Academics debate the reasons for Eroom’s law, but the Baumol effect is likely a key part of the story. Named after economist William J. Baumol, emerged in the 1960s to explain why prices rise in some areas of the economy (especially services) and fall in others (especially manufacturing). Briefly summarized, costs generally to rise faster than inflation in labor-intensive sectors—ones that experience lower productivity growth.</p>
<p><figure aria-describedby="caption-attachment-336441" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336441 " src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-e1786545898568-1-300x267.png" alt="" width="444" height="396" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-e1786545898568-1-300x267.png 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-e1786545898568-1-768x683.png 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-e1786545898568-1-945x840.png 945w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-e1786545898568-1-696x619.png 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-e1786545898568-1.png 972w" sizes="auto, (max-width: 444px) 100vw, 444px"><figcaption class="wp-caption-text">As the Baumol effect predicts, between 1998 and 2018, services became more expensive while many manufactured goods became cheaper. Note the modest increase in average wages in the middle. [Creative Commons license CC BY-SA 4.0]</figcaption></figure>One classic example is a live performance of a string quartet: it takes just as many labor hours to perform today as 300 years ago. By contrast, manufactured goods like television sets grow cheaper every year. As the Baumol effect predicts, between 1998 and 2018, services became more expensive while many manufactured goods became cheaper. And few activities in the economy are more labor intensive than clinical-stage drug development.</p>
<p>The COVID-19 pandemic dramatically amplified those pressures. Predictably, when a wall of public research money (Operation Warp Speed and other programs) rammed into the hard realities of biomedical research, scarcity ensued. In many cases supply was simply unavailable at any price. Even mundane items like pipette tips—<a href="https://www.statnews.com/2021/04/28/pipette-tips-shortage/">became scarce</a>.</p>
<p>To be sure, 2021 was experienced by most in biotech as a boom time—low interest rates ensured plenty of capital was available to meet biotech payrolls. But this capital also meant a lack of incentives to control spending, resulting in spiraling costs and short-term decision-making. Boom times breed bloat and complacency, and we’re living through the aftermath.</p>
<p></p><h4><strong>Masking the malaise</strong></h4>

<p>For a time, however, these warning signs were easy to ignore due to the existence of two counter-trends: declining interest rates and increasing drug prices.</p>
<p>As interest rates decline, the value of any capital asset increases—it works the same for single-family homes and drug development programs. Moreover, biopharma is unusually <a href="https://www.genengnews.com/industry-news/double-impact-interest-rates-and-prospects-for-biotech-growth/?utm_source=chatgpt.com">sensitive</a> to interest rates, given their long development timelines and heavy upfront costs. Steadily declining interest rates therefore created an appearance that ever‑rising expenditures were sustainable.</p>
<p>A second counter-trend unfolded on the revenue side, as big pharma explored the upper limits of what American taxpayers and insurance policyholders would tolerate. When Gilead priced Harvoni at $84,000 in 2014, it sparked an outrage, despite solid health economics justifications; ten years later, six-figure pricing was commonplace. The high water mark of this phenomenon was surely the 2017 <a href="https://www.justice.gov/usao-edny/pr/martin-shkreli-sentenced-seven-years-imprisonment-multi-million-dollar-fraud-scheme">conviction</a> of “pharma bro” Martin Shkreli, who had become a household name for <a href="https://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html">buying and price-jacking</a> the ultra-rare disease drug Daraprim from $15 to $750 overnight.</p>
<p>In short, it was interest rates and pricing power, not innovation, that arguably carried industry financials forward through the 2010s—masking the structural decline in efficiency and encouraging capital allocation decisions that could not withstand tighter pricing or financing conditions.</p>
<p></p><h4><strong>The tide goes out in a perfect storm </strong></h4>

<p>These counter trends that had been masking declining productivity came to an abrupt halt in 2022. As Warren Buffett famously quipped about financial bubbles, “Only when the tide goes out do you discover who’s been swimming naked.”</p>
<p>First, the Federal Reserve began the fastest series of interest <a href="https://www.reuters.com/markets/us/fed-expected-combine-interest-rate-cut-with-hawkish-2025-outlook-2024-12-18/">rate hikes</a> in four decades in response to surging post-pandemic inflation.</p>
<p><figure aria-describedby="caption-attachment-336406" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336406 " src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-1024x718.jpg" alt="" width="357" height="250" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-1024x718.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-300x210.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-768x539.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-599x420.jpg 599w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-1198x840.jpg 1198w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-696x488.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-1068x749.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-100x70.jpg 100w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679-200x140.jpg 200w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-e1786545801679.jpg 1380w" sizes="auto, (max-width: 357px) 100vw, 357px"><figcaption class="wp-caption-text">The inflation dinosaur that devoured a thousand biotechs. U.S. federal funds target rate, 2014-2024. Data is the midpoint of the federal funds target range. [U.S. Federal Reserve Bank. www.federalreserve.gov/aboutthefed/fedexplained/accessible-version.htm]</figcaption></figure>Meanwhile, U.S. drug pricing tolerance hit its political limits, culminating in the passage of the Inflation Reduction Act in August 2022, which introduced government price controls on biopharmaceuticals for the first time in the U.S. These pressures have continued, with President Trump <a href="https://www.reuters.com/legal/litigation/several-top-drugmakers-lower-us-prices-some-drugs-sources-2025-12-19/">continuing</a> to pressure drug companies to lower prices.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>As if that weren’t enough, drug development costs were also spiking. During the boom years, more and more late-stage clinical development migrated to the United States, colliding with a relatively inelastic supply of trial sites, specialized labor, GMP manufacturing capacity, and experienced managers. The result was predictable: costs exploded. And the resulting downturn affected everything from venture funding to lab vacancies.</p>
<p>This downturn has understandably been painful for many due to steady industry <a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026?utm_source=chatgpt.com">layoffs</a>. Layoffs in early 2026 have so far <a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026?utm_source=chatgpt.com">exceeded</a> the comparable prior year period, despite hopes of a turnaround. And despite recent gains in public biotech stock indices, venture capital fundraising—the lifeblood of the biotech industry—<a href="https://www.venturecapitaljournal.com/download-vc-fundraising-hits-eight-year-low/?utm_source=chatgpt.com">hit</a> an eight-year low in 2025.</p>
<p>But history suggests that periods like this often precede fundamental reinvention. The reinvention of the technology sector, driven by cloud computing and mobile broadband led to lower costs, and durable, scalable innovation that reshaped the global economy. Biotech now stands at a comparable inflection point. The old model was viable only under extraordinary macroeconomic conditions for a limited window of time. Instead of waiting for them to return, the industry has an opportunity to evolve.</p>
<p>But glimpses of a new, even more value-accretive future are already apparent, and changes are apparent on both sides of the supply and demand equation.</p>
<p>Start with supply: signs of regeneration are already visible, even in the absence of significant interest rate cuts. The collapse in demand for lab space and equipment has sharply reduced barriers to entry.</p>
<p>More fundamentally, emerging technologies like <a href="https://www.genengnews.com/insights/automation-the-future-of-labs-is-autonomous-not-just-automated/">lab automation</a> and <a href="https://www.anthropic.com/news/healthcare-life-sciences">generative AI</a> are promising to revolutionize workflows.</p>
<p>Regulatory innovation in Australia, the U.K. and—above all—China, is eroding clinical development costs so rapidly that even the FDA is talking about serious reforms to accelerate innovation.</p>
<p>The success of Ozempic and its GLP-1 competitors shows the powerful appeal of mass-market drugs priced accessibly to the global middle class and for preventing disease—investment themes that defy the conventional wisdom of the pre-COVID era, with its strong bias for specialty-pharma and orphan-disease drugs with niche markets and ultra-high prices.</p>
<p>With newly opened minds—and newly affordable drug-development infrastructure—a new world stands waiting, at least for those with the ambition and cunning to <a href="https://substack.com/home/post/p-182661233">scale and price their products</a> commensurate with global demand.</p>
<p>In sum, the winning strategies for the next wave of biotech—Biotech 2.0—are probably staring us in the face. Just like the rise of cloud computing and mobile were obvious to certain tech entrepreneurs amid the carnage of the dot-com bubble burst, the seeds of the next wave of innovation are quietly germinating right now in the U.S. Some of the most important opportunities, especially for products that can deliver better health outcomes at lower cost, are simply waiting for an opportunity in the marketplace.</p>
<div class="my-8"><span data-render-ad="7"></span></div>
<p>As biotech markets finish working through the messy process of creative destruction, we must remain alive to the amazing possibilities it creates for innovators—newcomers, no longer crowded out by old ways of thinking.</p>
<p><em>Brian Finrow is co-founder and CEO of </em><em>Lumen Bioscience</em><em>, a clinical-stage biotechnology company in Seattle. Kevin Klowden works as a global economist and strategist, and a fellow at the </em><em>Milken Institute</em><em>, an economic think tank.</em></p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/biopharmas-drawdown-is-a-chance-to-build-biotech-back-better/">Biopharma’s Drawdown Is a Chance to Build Biotech Back Better</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human Biological Datacenter to Launch to Train World Model of Human Biology</title>
<link>https://edusehat.com/en/human-biological-datacenter-to-launch-to-train-world-model-of-human-biology</link>
<guid>https://edusehat.com/en/human-biological-datacenter-to-launch-to-train-world-model-of-human-biology</guid>
<description><![CDATA[ Vivodyne confirms that it grows over 20 types of different human organ tissues, both healthy and with patient-linked diseases, including liver, lungs, gut, bone marrow, pancreas, kidney, eyes, and lymph nodes.
The post Human Biological Datacenter to Launch to Train World Model of Human Biology appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/6a5156e97215b1f019eebbae_65c1501946fecb29765d655f_Dan-Huh-and-Andrei-Georgescu_sm.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 05:25:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, Biological, Datacenter, Launch, Train, World, Model, Human, Biology</media:keywords>
<content:encoded><![CDATA[<p>Vivodyne reports that it has launched “the world’s largest human biological datacenter,” with 12 robotic HIVE laboratories and the annual capacity to perform controlled trials on 3.1 million large human tissues per year—estimated at twice the scale of every clinical trial in the U.S. combined.</p>
<p><figure aria-describedby="caption-attachment-336456" class="wp-caption aligncenter"><img loading="lazy" decoding="async" class="wp-image-336456 size-large" src="https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-1024x683.jpg" alt="A row of automated human-tissue testing machines in Vivodyne’s Human Datacenter. [Vivodyne]" width="696" height="464" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-1024x683.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-1536x1024.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-2048x1365.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-1260x840.jpg 1260w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-1392x928.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-1068x712.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/A-row-of-automated-human-tissue-testing-machines-in-Vivodynes-Human-Datacenter-1920x1280.jpg 1920w" sizes="auto, (max-width: 696px) 100vw, 696px"><figcaption class="wp-caption-text">A row of automated human-tissue testing machines in Vivodyne’s Human Datacenter. [Vivodyne]</figcaption></figure>The company also introduced its Series 2 TissueDisk, a wafer-scale biological chip that simultaneously grows hundreds of large, functional, living human tissues and is manufactured end-to-end on Vivodyne’s own robotic production line.</p>
<p>Eight of the world’s largest pharmaceutical companies have paid for early access to the platform, according to Vivodyne, to discover and test new medicines “in humans” before ever testing in people, notes Andrei Georgescu, PhD, CEO and co-founder of Vivodyne.</p>
<p>Together, the TissueDisk and Vivodyne’s robotic HIVE laboratories create something that neither pharmaceutical research nor artificial intelligence has possessed before: a large-scale experimental environment in which the same reinforcement learning technique that has driven the explosion in AI language models can finally be harnessed to learn the workings of our physiology, explains Georgescu.</p>
<p>For pharmaceutical companies, that means learning how actual human tissue responds to a drug while decisions about targets, chemistry, dosing, and safety can still be made, he continues adding that Vivodyne’s approach allows millions of therapeutic interventions to be introduced into living human tissues, and their causal biological consequences measured directly with the most advanced, paired-data modalities available today: 3D scanning, transcriptomic sequencing, and deep proteomic analysis.</p>
<p>Vivodyne’s platform provides the foundation of the first world model of human biology, claims Georgescu. Previously, the controlled experiments required to reveal complex, physiological cause-and-effect could not be performed safely in patients or at nearly the needed scale, and Vivodyne makes those experiments possible in living human tissue outside the body, he says.</p>
<p>“Superintelligence in biology is needed more than ever, because we’re running out of diseases that can be cured with the simple, single-target medicines of today,” states Georgescu. “You cannot fix a car by turning a single screw, and the idea that the complex malfunctions in cancer, fibrosis, autoimmune disorders, or neurological disease can be fixed with a conventional single-target drug is wishful denial. To create AI that understands our intricate human biology, we need to continuously generate and train on huge amounts of <em>human</em> data, and we can’t get that by risking people. So, we grow these functional human tissues by the millions instead; large living tissues that grow their own blood vessels and immune cells and all the structures of native tissues. They mature, get diseases, bleed, scar, and, at huge scale, we learn how to make them heal.</p>
<p>“Every human response gives our AI something it cannot learn from a paper or a simulation: a living substrate to poke so that it can learn, from richer data than has ever been gathered, how it pokes back. At Vivodyne’s scale of automated human-tissue trials, all those learned consequences together become the training landscape for a world model of the human body, and the physical evidence that a pharmaceutical company needs before a drug is brought to patients.”</p>
<p></p><h4><strong>22 human organ systems grown</strong></h4>

<p>Vivodyne grows over 20 types of different human organ tissues, both healthy and with patient-linked diseases, including liver, lungs, gut, bone marrow, pancreas, kidney, eyes, lymph nodes, and more, with disease-specific versions spanning fibrosis, site-specific solid tumors, inflammation, metabolic disorders, vascular disease, and countless others. The company trains causal, multimodal AI models on the experiments conducted within each organ type, alone and combined.</p>
<p>Connecting those models across organ systems builds a world model of the human body that can answer what happens when a pair of receptors is drugged, a biological pathway is interrupted, a therapy causes an unexpected side effect, how cells respond and communicate, and whether disease is aggravated, stopped, or reversed, points out a company official. These predictions can then be real-world tested at scale to confirm what actually happens in human tissue, and then refined and advanced.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/human-biological-datacenter-to-launch-to-train-world-model-of-human-biology/">Human Biological Datacenter to Launch to Train World Model of Human Biology</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cortical Organoids Reveal Radial Glial Progenitor Lineage Dynamics</title>
<link>https://edusehat.com/en/cortical-organoids-reveal-radial-glial-progenitor-lineage-dynamics</link>
<guid>https://edusehat.com/en/cortical-organoids-reveal-radial-glial-progenitor-lineage-dynamics</guid>
<description><![CDATA[ Researchers reveal that radial glial progenitor lineage progression in cortical organoids differs from the developing mouse brain, highlighting the importance of stem-cell niche signals for faithful cortical development.
The post Cortical Organoids Reveal Radial Glial Progenitor Lineage Dynamics appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BTUFETSBPcmdhbm9pZCDCqSBTdG91ZmZlciBldCBhbC4gIE5hdHVyZS5qcGc-e1786467193624.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 05:25:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cortical, Organoids, Reveal, Radial, Glial, Progenitor, Lineage, Dynamics</media:keywords>
<content:encoded><![CDATA[<p>The cerebral cortex of the brain, responsible for higher-level cognitive processes, movement control, and sensory input processing, is composed of a wide variety of neurons and glial cells. Radial glial progenitors (RGPs) produce all excitatory neurons in the developing cerebral cortex. Now, for the first time, a quantitative framework of RGP lineage progression has been revealed. The team of researchers from the Institute of Science and Technology Austria (ISTA) established Mosaic analysis with double markers (MADM)-based lineage tracing <em>in vivo—</em>in mouse embryonic stem cells in a self-organizing cortical organoid system. The findings present critical time windows in development when compared to the real mouse brain.</p>
<p>This work is published in <em>Nature</em> in the paper, “<a href="https://www.nature.com/articles/s41586-026-10916-7" target="_blank" rel="noopener">Temporal uncoupling of radial glia lineage progression in cortical organoids</a>.”</p>
<p>“In our lab we study how the brain develops from stem cells,” Simon Hippenmeyer, PhD, professor at the ISTA explains. “How a brain reaches the right size, how stem cells know when and into which neurons they should develop, but also what happens when something goes wrong during development or disease—for example, in microcephaly or macrocephaly, where the brain is unusually small or large.”</p>
<p><figure aria-describedby="caption-attachment-336424" class="wp-caption alignleft"><img decoding="async" class=" wp-image-336424" src="https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-300x225.jpg" alt="organoids" width="323" height="242" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-300x225.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-1024x768.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-768x576.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-1536x1152.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-2048x1536.jpg 2048w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-560x420.jpg 560w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-1120x840.jpg 1120w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-696x522.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-1392x1044.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-1068x801.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-1920x1440.jpg 1920w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-265x198.jpg 265w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BVHdvIG1vdXNlIGNvcnRpY2FsIG9yZ2Fub2lkcyBhdCAxMyBkYXlzIGluIGN1bHR1cmUgwqkgU3RvdWZmZXIgZXQgYWwuICBOYXR1cmUuanBn-530x396.jpg 530w" sizes="(max-width: 323px) 100vw, 323px"><figcaption class="wp-caption-text">Two mouse cortical organoids at 13 days in culture. Cortical rosettes, the actual portions of the organoids that resemble aspects of the developing brain, are seen as lumps along the outer edge of the organoid. [Stouffer et al. / Nature]</figcaption></figure></p>
<p>The researchers compared specific developmental stages of the mouse brain with those of the organoids. Using single-cell sequencing, they examined which cell types show up in both systems, their relative abundance, and at what point in time they emerge or disappear again.</p>
<p>“In the developmental stages we examined, we see very similar cell populations of the mouse brain with those of the organoids,” Hippenmeyer explains. “The molecular programs are similar.”</p>
<p>“Now that we had this rigorous organoid system, we were able to examine even more closely what happens to stem cells during cortical structure development—and compare these processes directly with our <em>in vivo</em> model, the mouse,” he continues.</p>
<p>Using MADM technology—a unique genetic method that makes it possible to track stem cell division during organogenesis—the group produced a clear roadmap of development in the mouse brain at the single progenitor cell level.</p>
<p>The team found that “RGPs exhibit a high level of plasticity in proliferative potential in organoids rather than strict temporally stereotyped lineage progression as observed in vivo.” In addition, RGPs in organoids showed “increased lineage restriction, diminishing cell-type diversity in clones of cortical projection neurons, despite uniform single-cell transcriptional signatures of RGPs and a unitary lineage trajectory.”</p>
<p>The researchers suspect that organoids lack certain external signals. The microstructures in Petri dishes form through self-organization, and due to being cultured in the lab, they lack many of the external influences that are present in the living organism.</p>
<p><figure aria-describedby="caption-attachment-336435" class="wp-caption alignright"><img decoding="async" class=" wp-image-336435" src="https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-201x300.jpg" alt="Hippenmeyer group" width="247" height="369" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-201x300.jpg 201w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-685x1024.jpg 685w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-768x1148.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-1028x1536.jpg 1028w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-281x420.jpg 281w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-562x840.jpg 562w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-696x1040.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc-1068x1596.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/utf-8BSGlwcGVubWV5ZXIgR3JvdXAgwqkgSVNUQS5qcGc.jpg 1200w" sizes="(max-width: 247px) 100vw, 247px"><figcaption class="wp-caption-text">Researchers from the Hippenmeyer group at ISTA who carried out the study. From left to right: Simon Hippenmeyer, Osvaldo Miranda Romero, Fabrizia Pipicelli, and Carmen Streicher. [ISTA]</figcaption></figure></p>
<p>“In our organoids, this does not seem to work perfectly,” says Hippenmeyer. “The physical force of self-organization alone is apparently not enough. Factors present in <em>in vivo</em> systems are missing—the so-called stem-cell niche.”</p>
<p>The stem-cell niche is the specific microenvironment in which stem cells live and are regulated. It includes, for example, neighboring cells, blood vessels, signaling molecules, and growth factors, as well as mechanical signals.</p>
<p>They write, “critical non-cell-autonomous cues that are absent in self-organizing systems and/or the genuine stem cell niche are essential for faithful temporal control of RGP lineage progression and the generation of clonal cortical cell-type diversity.</p>
<p>This work presents a robust protocol for producing cortical organoids from mouse cells. It also highlights the processes in development which are sensitive to changes to—or a lack of—the stem cell niche.</p>
<p>These findings are important for organoid research. They show how similarly certain developmental processes unfold in organoids and in the mouse brain—and up to what point, based on current knowledge, specific aspects of brain development can be reliably studied in an organoid.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/cortical-organoids-reveal-radial-glial-progenitor-lineage-dynamics/">Cortical Organoids Reveal Radial Glial Progenitor Lineage Dynamics</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>In Vivo Protein Generation Using Nanoparticle Delivery: Emerging Platforms and CMC Strategies</title>
<link>https://edusehat.com/en/in-vivo-protein-generation-using-nanoparticle-delivery-emerging-platforms-and-cmc-strategies</link>
<guid>https://edusehat.com/en/in-vivo-protein-generation-using-nanoparticle-delivery-emerging-platforms-and-cmc-strategies</guid>
<description><![CDATA[ In this GEN webinar, our expert speaker, Tao (Tony) Li, PhD, will discuss nanoparticle delivery opportunities beyond oncology and infectious disease, compare emerging nanocarrier platforms, and examine important CMC considerations critical for progressing from research through IND. 
The post In Vivo Protein Generation Using Nanoparticle Delivery: Emerging Platforms and CMC Strategies appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Getty_1441708461_AntiviralSirnaLipidNanoparticle.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 05:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Vivo, Protein, Generation, Using, Nanoparticle, Delivery:, Emerging, Platforms, and, CMC, Strategies</media:keywords>
<content:encoded><![CDATA[<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p><div class="my-8"><span data-render-ad="3"></span></div><p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/TaoLi_Headshot.jpg" class="h-full w-full object-cover" alt="Image of Tao (Tony) Li, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Tao (Tony) Li, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Senior Director, Head of mRNA & Nanoparticle Platform<br>WuXi Biologics</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/TaoLi_Headshot.jpg" alt="Image of Tao (Tony) Li, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Tao (Tony) Li, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Tao Li, PhD, is a results-driven senior director at WuXi Biologics who leads the design, scale-up, and commercialization of integrated mRNA and nanoparticle (NP) platforms—delivering end-to-end solutions from DNA synthesis to IND-enabling studies. He directs innovations in synthetic DNA, mRNA and targeted LNP technologies and partners across CMC, analytical/QC, and regulatory functions to accelerate clinical translation and ensure manufacturing and testing readiness.</p>
<p>Previously he set corporate R&D strategy at BCF, aligning product specifications with U.S., EU, and Asian regulations. At the U.S. FDA he specialized in analytical testing, lab automation, quality systems, audits, and training, standardizing workflows that strengthened compliance. Earlier roles include building LC–MS/MS testing programs, achieving >$150K in annual operational savings, expanding Asian market share by 50%, and conducting research on peptide conjugated PEGylated liposomes and bioinformatics. He holds a PhD from University of California, Davis in chemical engineering with designated emphasis in biotechnology.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, September 9, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-09-09T15:00:09.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p class="wp-block-paragraph"><em>In vivo</em> protein generation using nanoparticle delivery has evolved from vaccine applications into protein replacement, immunotherapy, and gene editing. Lipid nanoparticles (LNPs) and other nanocarriers remain the platform of choice for protecting cargo, enhancing cellular uptake, and facilitating endosomal escape. Scaling across oncology, infectious diseases, and genetic disorders demands progress on mRNA/DNA design, nanoparticle delivery, manufacturability, CMC strategy, cost, timeline, and speed. In this <em>GEN</em> webinar, our expert speaker, Tao (Tony) Li, PhD, will discuss nanoparticle delivery opportunities beyond oncology and infectious disease, compare emerging nanocarrier platforms, and examine important CMC considerations critical for progressing from research through IND. He will also present a case study on decorated mRNA/LNP for <em>in vivo</em> CAR T, from R&D gap evaluation and process development to full GMP manufacturing. Key takeaways from the webinar include:</p><div class="my-8"><span data-render-ad="4"></span></div><p></p><p></p><ul class="wp-block-list"><p></p><li>A deeper understanding of the landscape beyond vaccine and oncology applications</li><p></p><p></p><p></p><li>How emerging platforms compare including their advantages, limitations, and development considerations</li><p></p><p></p><p></p><li>Key CMC challenges from research through IND including manufacturing, analytical characterization, and quality attributes</li><p></p><p></p><p></p><li>Strategic insights for future directions derived from fundamental questions</li><p></p></ul><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><em>A live Q&A will follow the presentation offering you a chance to pose questions to our expert panelist.</em></p><div class="my-8"><span data-render-ad="5"></span></div><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p class="wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><p><figure class="wp-block-image size-full is-resized"><a href="https://www.wuxibiologics.com/" target="_blank" rel=" noreferrer noopener"><img fetchpriority="high" decoding="async" width="1400" height="397" src="https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo.jpg" alt="WuXi Biologics logo" class="wp-image-336357" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo.jpg 1400w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-300x85.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-1024x290.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-768x218.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-696x197.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-1392x395.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/WuXiBiologics_logo-1068x303.jpg 1068w" sizes="(max-width: 1400px) 100vw, 1400px"></a></figure></p><p></p><p>The post <a href="https://www.genengnews.com/multimedia/webinars/in-vivo-protein-generation-using-nanoparticle-delivery-emerging-platforms-and-cmc-strategies/"><i>In Vivo</i> Protein Generation Using Nanoparticle Delivery: Emerging Platforms and CMC Strategies</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Cancer&#45;Fighting Abilities of NK Immune Cells May Be Disrupted by Some Omega Fatty Acids</title>
<link>https://edusehat.com/en/cancer-fighting-abilities-of-nk-immune-cells-may-be-disrupted-by-some-omega-fatty-acids</link>
<guid>https://edusehat.com/en/cancer-fighting-abilities-of-nk-immune-cells-may-be-disrupted-by-some-omega-fatty-acids</guid>
<description><![CDATA[ Omega polyunsaturated fatty acids are recognized for their myriads of health benefits, but a preclinical study has found that some omega fatty acids can restrain the cancer-killing capabilities of natural killer cells by acting through a receptor, LRP5.
The post Cancer-Fighting Abilities of NK Immune Cells May Be Disrupted by Some Omega Fatty Acids appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2020/07/Jul20_2020_GettyImages-651138712_Omegas-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 05:25:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Cancer-Fighting, Abilities, Immune, Cells, May, Disrupted, Some, Omega, Fatty, Acids</media:keywords>
<content:encoded><![CDATA[<p>Polyunsaturated fatty acids (PUFAs), and especially some omega PUFAs, are recognized for their myriad health benefits, but their role in the biology of cancer cells and tumor immunity has been less clear. The results of a preclinical study by researchers at Yale University School of Medicine now indicate that some omega fatty acids can restrain the cancer-killing capabilities of natural killer (NK) cells by acting through a receptor, LRP5.</p>
<p>In their paper in <em>Science Signaling</em>, titled “<a href="https://www.science.org/doi/10.1126/scisignal.ady2865" target="_blank" rel="noopener">LRP5-dependent transport of polyunsaturated fatty acids serves as an immune checkpoint for natural killer cells</a>,” first author Yi Luan, PhD, and colleagues stated, “Given the widespread promotion of polyunsaturated fatty acids (PUFAs) as beneficial dietary supplements, greater public awareness of their potential unintended effects is warranted.” The authors call for further work to explore the mechanisms that shape the expression of LRP5 in different contexts, which they say could unveil potential therapeutic targets.</p>
<p>PUFAs are essential lipid molecules characterized by multiple double bonds in their hydrocarbon chains, the authors wrote. They are broadly classified into two groups, omega-3 (n-3) and omega-6 (n-6) PUFAs, which are found mostly in fish, nuts, and vegetable oils. They play many essential roles in the body, including by maintaining the fluidity of cell membranes and supporting signaling within cells. “Their uptake and intracellular distribution rely on lipid transporters, which facilitate their availability for metabolic and signaling functions,” the team explained.</p>
<p>PUFAs, especially the omega-3s, have become widely touted for their various health benefits and anti-inflammatory properties. However, PUFAs have a more complex role in tumor biology than generally assumed, as some research indicates they can influence the biology of both tumor cells and anticancer immune cells such as natural killer cells. Research has highlighted the role of n-3 PUFAs in preventing tumor progression, the team noted. “Beyond their direct influence on tumor cells, they also modulate immune cell function within the tumor microenvironment, further emphasizing the complex role of PUFAs in tumor development,” they commented. “However, their specific impact on NK cell biology remains poorly understood.”</p>
<p>For their newly reported study, Luan and colleagues<em> </em>probed how PUFAs shape the biology of natural killer cells, which play a central role in immune surveillance. They knocked out the LRP5 receptor, which acts as the conduit for PUFA transport into natural killer cells, and found that this reduced the intake of PUFAs. However, the loss of LRP5 enhanced the cells’ ability to eliminate colon cancer cells and slowed the growth of tumors in mice.</p>
<p>Feeding wild-type mice a diet free of PUFAs similarly suppressed tumor growth. Additional work showed that PUFAs constrained natural killer cells by suppressing the mTORC1 signaling pathway and glycolysis metabolism. “Mechanistically, LRP5-mediated PUFA transport suppressed mTORC1 signaling and glycolysis in NK cells, a metabolic pathway essential for NK cell cytotoxicity,” they stated. “Thus, our study identified LRP5 as an immune checkpoint that restrains NK cell activity through PUFA transport–dependent suppression of mTORC1 signaling.” They suggest that future studies should further explore the regulatory mechanisms governing LRP5 expression in different contexts, “… potentially revealing therapeutic opportunities.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/cancer-fighting-abilities-of-nk-immune-cells-may-be-disrupted-by-some-omega-fatty-acids/">Cancer-Fighting Abilities of NK Immune Cells May Be Disrupted by Some Omega Fatty Acids</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Next 10 U.S. Biopharma Clusters</title>
<link>https://edusehat.com/en/next-10-us-biopharma-clusters</link>
<guid>https://edusehat.com/en/next-10-us-biopharma-clusters</guid>
<description><![CDATA[ For the first time, GEN&#039;s Alex Philippidis examines the top regions and top states just below the 10 largest regions for life sciences activity, as the field looks beyond the East and West Coasts for growth
The post Next 10 U.S. Biopharma Clusters appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/11/GettyImages-913456668.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 01:45:14 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Next, U.S., Biopharma, Clusters</media:keywords>
<content:encoded><![CDATA[<p>The days of biotech businesses and institutions limiting their research and commercial activity to top clusters like Boston/Cambridge, MA, and the San Francisco Bay Area are passing, as the life sciences expand their horizons to regions and states not usually thought of as hotspots for the industry.</p>
<p>“Life science entrepreneurship and new product development is flourishing outside traditional coastal epicenters, creating a dynamic and distributed map of regional hubs across the United States,” wrote John Flavin, founder and CEO of venture capital firm Portal Innovations, and Pat Flavin, John’s brother and Portal’s president, in <a href="https://timmermanreport.com/2025/12/biotechs-future-will-be-more-distributed/" target="_blank" rel="noopener">Biotech’s Future Will Be More Distributed</a>, a guest editorial published December 15, 2025, by <em>Timmerman Report</em>.</p>
<p>Portal itself reflects that trend, having U.S. locations not only in Chicago (No. 9 on <em>GEN</em>’s most recent A-List of <a href="https://www.genengnews.com/topics/drug-discovery/top-10-u-s-biopharma-clusters-2026/" target="_blank" rel="noopener">Top 10 U.S. Biopharma Clusters</a>, published June 1), but in Providence, RI; the New York suburb of New Brunswick, NJ; and Houston (Portal also has a fifth office in Dublin, Ireland).</p>
<p>The Flavin brothers cited several factors in the industry becoming more ‘‘distributed” or scattered beyond the largest clusters:</p>
<ul>
<li><strong>Academic research shifting</strong>—Over the past decade, research has shifted to a translational focus, to address the need for more practical application in life sciences.</li>
<li><strong>Federal funding flattening</strong>—Cutbacks in or leveling amounts of NIH funding (depending on the region) have forced universities to adopt new avenues for attracting and retaining research talent—such as pursuing closer relationships with industry.</li>
<li><strong>COVID-19</strong>—The pandemic that wreaked havoc on the world “acted as a global shock to the life sciences innovation system, accelerating pre-existing trends and forcing a rapid re-evaluation of how and where innovation happens,” John and Pat Flavin wrote.</li>
</ul>
<p>The growth of biotech hubs outside of the top 10 regions and states ranked since 2014 in <em>GEN</em>’s <a href="https://www.bostonglobe.com/2021/04/03/metro/bostons-hospital-chiefs-moonlight-corporate-boards-rates-far-beyond-national-rate/" target="_blank" rel="noopener">nationally-</a> and <a href="https://www.bizjournals.com/philadelphia/news/2025/08/08/philadelphia-biotechnology-pharmaceuticals-ranking.html" target="_blank" rel="noopener">regionally-cited</a> top 10 clusters A-List has increasingly sparked a question among readers: What are the next up-and-coming hubs for life sciences activity?</p>
<p><em>GEN </em>attempts to answer this question through this first-ever A-List of Next 10 U.S. Biopharma Clusters. This list is actually three lists in one: A top five ranking of emerging regions below the top 10 long highlighted by this publication; a top five ranking of states that have shown initiative and accomplishment in building up their life-sci ecosystems but whose individual regional clusters alone do not rise to the top; and an unranked list of up-and-coming regions and states to watch, based on recent announcements.</p>
<p><em>GEN</em> bases its regional rankings on five criteria:</p>
<ul>
<li><strong>Patents</strong>: Figures from the Patent Public Search database of the U.S. Patent and Trademark Office, showing the number of patent families containing the word “biotechnology” and towns and cities within a given region or state.</li>
<li><strong>NIH funding</strong>: Figures for NIH funding were taken from the publicly available NIH Research Portfolio Online Reporting Tools (RePORT) database for the current federal fiscal year through July 6, plus all of fiscal year 2025 (October 1, 2024, through September 30, 2025).</li>
<li><strong>Venture capital funding</strong>: Figures for all of 2025 and, where available, the first quarter of 2026 as compiled by regional life sciences groups and PitchBook, which joins with the National Venture Capital Association to publish the quarterly Venture Monitor reports.</li>
<li><strong>Laboratory space</strong>: The total-size-of-market figure, in millions of square feet, as furnished by regional life sciences groups. In regions that did not compile such information, the figure cited is the highest by any of several commercial real estate companies, including CBRE Group, Colliers, Cushman & Wakefield, JLL, and Newmark.</li>
<li><strong>Number of jobs</strong>: The preferred sources for job figures were regional life sciences groups. Alternative sources included commercial real estate firms.</li>
</ul>
<p>The ranking of states proved tougher than anticipated because while the sources of lab space info (commercial real estate firms and industry groups) do not compile statistics for entire states, or have not done so recently, sources for venture capital and workforce numbers either collect only regional info or have not collected it within the past year.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p> </p>
<p></p><h4><u class="wp-underline-text"><strong>Next 5 Regions</strong></u></h4>

<p class="trimmed"> </p>
<p><strong>1. Houston, TX </strong></p>
<figure aria-describedby="caption-attachment-335622" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-335622 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-HOUSTON-Eli_Lilly_Manufacturing_Facility_Generation_Park_Texas-300x169.jpg" alt="Eli Lilly Manufacturing Facility Generation Park Texas" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-HOUSTON-Eli_Lilly_Manufacturing_Facility_Generation_Park_Texas-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-HOUSTON-Eli_Lilly_Manufacturing_Facility_Generation_Park_Texas.jpg 400w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Eli Lilly is planning a $6.5 billion manufacturing site to produce active pharmaceutical ingredients for oral drugs—including Foundayo<sup class="wp-sup-text">®</sup> (orforglipron), the glucagon-like peptide-1 (GLP-1) receptor agonist obesity drug. [Eli Lilly]</figcaption></figure>
<p>Like many of the largest biopharma clusters, Greater Houston is reaping the fruits of Eli Lilly’s investment surge: The pharma giant is planning a $6.5 billion manufacturing site to produce active pharmaceutical ingredients for oral drugs—including Foundayo<sup class="wp-sup-text">®</sup> (orforglipron), the glucagon-like peptide-1 (GLP-1) receptor agonist obesity drug. Lilly grew its regional footprint in April by acquiring Houston startup CrossBridge Bio, a developer of next-generation dual-payload antibody-drug conjugates (ADCs), for up to $300 million. Another Houston startup, Duracyte, was formally launched to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, designed to produce therapeutic proteins continuously inside the human body. Duracyte’s co-founders include Robert Langer, ScD, institute professor at MIT: “He sees a lot of potential for the Houston ecosystem,” Omid Veiseh, PhD, another Duracyte co-founder and managing partner of RBL LLC, an incubator evolved from Rice University Biotech Launch Pad, told <em>GEN</em>. “There’s a lot of great talent. But the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights. There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”</p>
<p>Houston’s Generation Park, a 4,300-acre master planned mixed-use campus, has been selected by Bristol Myers Squibb for a $1 billion, 600,000-square-foot manufacturing site set to create about 500 jobs by 2031. The region’s largest life-sci campus is the world’s largest medical complex, the 1,345-acre, 54 million-square-foot Texas Medical Center (TMC), home to The University of Texas MD Anderson Cancer Center and Baylor College of Medicine’s primary campus. TMC and the Korea Health Industry Development Institute (KHIDI) on June 29 expanded their TMC Korea BioBridge, a partnership designed to assist South Korean biotech, digital health and medtech companies seeking to enter and expand Stateside.</p>
<p>Among emerging regions, Greater Houston leads in NIH funding (2,262 awards totaling $1.251 billion), is second highest among emerging regions in jobs (28,000+, according to BioHouston), and places second in lab space with about eight million square feet. “We have a very good supply of lab space in this area,” BioHouston’s chairman Jeff Wade told <em>GEN</em>. He said the region scooped up about a half-billion dollars in VC funding between 2025-2026 to date, which would propel Houston to second, significantly more than the approximately $300 million tallied by PitchBook. In patents, Houston finishes sixth with 2,760 families.</p>
<p class="trimmed"> </p>
<p><strong>2. Minneapolis-St. Paul, MN</strong></p>
<div class="my-8"><span data-render-ad="7"></span></div>
<figure aria-describedby="caption-attachment-335623" class="wp-caption alignright"><img decoding="async" class="wp-image-335623 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-MINNEAPOLIS-BIO-TECHNE-HQ22222-v3-bt-headquarters-300x169.jpeg" alt="Bio-Techne Minneapolis" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-MINNEAPOLIS-BIO-TECHNE-HQ22222-v3-bt-headquarters-300x169.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-MINNEAPOLIS-BIO-TECHNE-HQ22222-v3-bt-headquarters-768x432.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-MINNEAPOLIS-BIO-TECHNE-HQ22222-v3-bt-headquarters-747x420.jpeg 747w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-MINNEAPOLIS-BIO-TECHNE-HQ22222-v3-bt-headquarters-696x392.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-MINNEAPOLIS-BIO-TECHNE-HQ22222-v3-bt-headquarters.jpeg 800w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The Minneapolis headquarters of Bio-Techne. The tools, analytical technologies, and consumables giant has agreed to be acquired for $11.3 billion by Merck KGaA, Darmstadt, Germany. [Bio-techne]</figcaption></figure>
<p>Minneapolis-St. Paul’s life sciences sector was jolted June 25 when Minneapolis-based tools, analytical technologies, and consumables giant Bio-Techne <a href="https://www.genengnews.com/topics/bioprocessing/merck-kgaa-to-acquire-bio-techne-for-11-3b-expanding-life-science-tools-presence/" target="_blank" rel="noopener">agreed to be acquired for $11.3 billion</a> by Merck KGaA, Darmstadt, Germany. The news raised fears that Bio-Techne would shed at least some local jobs within its 3,100-person global workforce (2,300 in the U.S.), since Merck KGaA said it will carry out cost-cutting “synergies” of approximately €140 million (about $160 million) that are expected to be fully realized by the third year after closing. The region’s life-sci industry has long been heavy on medical device and medtech: “We are seeing some demand from pharmaceutical companies, too, but we are nowhere near the power of Raleigh or the Boston-Cambridge area,” Chris Lyles, director of life science and technology with Minneapolis-based Knutson Construction, told <em>REjournals</em> in April.</p>
<p>In St. Paul, nonprofit University Enterprise Laboratories (UEL), which is unaffiliated with the University of Minnesota, is working to raise the $3 million it says is needed to convert a 4,000-square-foot storage area into a shared lab space with 45 lab benches for companies at the earliest stages, plus an adjacent “learning lab” for student training and engagement. “The market is telling us there’s demand,” UEL board chair Barbara Nelsen told <em>The Minnesota Star Tribune</em> in April. The current space has been filled for five years, with UEL executive director Sam Shuster telling the news outlet it receives a constant two to three requests for lab space weekly.</p>
<p>“MSP,” as locals call the region, indeed lacks lab space, with just 4.4 million square feet (Revista, 2024), placing fifth, but leads emerging regions in jobs (32,748 biopharma, agritech, and distribution jobs in 2022, though the state touts 334,500 by including healthcare and medical device positions) and places a strong second in patents (3,924 families). The “Twin Cities” also finishes sixth in life-sci VC funding with $157 million last year (Colliers) but just eighth in NIH funding with 1,206 awards totaling $649.987 million.</p>
<p class="trimmed"> </p>
<p><strong>3. Denver-Boulder, CO</strong></p>
<figure aria-describedby="caption-attachment-335624" class="wp-caption alignright"><img decoding="async" class="wp-image-335624 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-300x206.jpg" alt="CordenPharma Boulder CO" width="300" height="206" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-300x206.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-768x528.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-611x420.jpg 611w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-218x150.jpg 218w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-436x300.jpg 436w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-970x670.jpg 970w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-696x479.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web-100x70.jpg 100w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DENV-BOULDER-CO-CordenPharma-Flatiron-park-5505-Central-Ave-web.jpg 974w" sizes="(max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">CordenPharma, a peptide drug substance contract development and manufacturing organization (CDMO), leased 64,000 square feet in Boulder at BioMed Realty’s Flatiron Park (5505 Central Ave.) in March [BioMed Realty]</figcaption></figure>
<p>Area biotech executives joined 430+ executives and investors across tech specialties to form Ensuring Colorado’s Innovation Future. The group has voiced to Gov. Jared Polis (D) its concern that the Denver-Boulder region and the rest of Colorado were losing their luster with tech—a perception fueled when Palantir Technologies in February announced the relocation of its HQ from Denver to Miami. Polis responded by seeking to reassure the group of his commitment to improving the state’s business climate: “We always want to double down on our successes, and we want to change whatever isn’t working,” the governor told <em>The Denver Post</em>.</p>
<p>Denver-Boulder has had its share of biopharma successes in recent months: CordenPharma, a peptide drug substance contract development and manufacturing organization (CDMO), leased 64,000 square feet in Boulder, CO, at 5505 Central Ave. within Flatiron Park in March. Also, that month at Flatiron Park, vaccine platform tech developer VitriVax signed a lease for 31,450 square feet at 5500 Central Ave., relocating within Boulder from 3415 Colorado Ave. near the University of Colorado. The deal came five months after VitriVax closed a $17.25 million Series B financing round whose proceeds were intended to fund development and commercialization of the company’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA<sup class="wp-sup-text"><strong>®</strong></sup>) technology.</p>
<p>However, Boulder, CO-based Enliven Therapeutics last month said it was moving to the San Francisco suburb of Burlingame, CA. CEO Rick Fair, a former Genentech executive, told the <em>San Francisco Business Times</em> the move will enable Enliven to tap into the Bay Area’s deeper talent pool and life sciences cluster, which ranked second in <em>GEN</em>’s A-List of Top 10 U.S. Biopharma Clusters. Yet Intero Biosystems, the developer of an induced pluripotent stem cell (iPSC)-derived human miniature intestine for predictive preclinical testing, moved to Denver from Michigan after receiving a $250,000 Advanced Industries grant from the Colorado Office of Economic Development & International Trade (OEDIT). Intero’s co-founders told <em>The Denver</em> <em>Post</em> that Denver offered the potential for a better quality of life than possible within the top-tier biopharma clusters on the East and West coasts.</p>
<p>Among emerging regions, Denver-Boulder scored best in VC funding, leading with $565 million (Colliers), and placed fourth in patents (3,062 families) and lab space (6.2 million square feet, according to Revista). The region ranked fifth in NIH funding (1,833 awards totaling $862.286 million), but ninth in workforce (14,856 jobs, according to Colliers).</p>
<p class="trimmed"> </p>
<p><strong>4. St. Louis, MO</strong></p>
<figure aria-describedby="caption-attachment-335625" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335625 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-300x226.jpg" alt="Donald Danforth Plant Science Center, St. Louis, MI" width="300" height="226" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-300x226.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-1024x770.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-768x577.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-559x420.jpg 559w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-1118x840.jpg 1118w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-80x60.jpg 80w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-160x120.jpg 160w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-696x523.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172-1068x803.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-ST-LOUIS-Donald-Danforth-Plant-Science-Center__5468-e1785163073172.jpg 1200w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">The Donald Danforth Plant Science Center in the St. Louis suburb of Creve Coeur, MO, has played a key role in positioning the region as a global leader in plant science. [Donald Danforth Plant Science Center]</figcaption></figure>
<p>This year marks 25 years of BioSTL, a regional life-sci industry group whose co-founders include William Danforth, MD, the civic leader who established the Donald Danforth Plant Science Center (named for his father) in the St. Louis suburb of Creve Coeur, MO, serving as its chairman through 2013. “It was never plant science or medical science. It was always both,” Donn Rubin, BioSTL’s founding president and CEO, <a href="https://www.stlmag.com/branded-content/biostl-25-years-innovation-st-louis/" target="_blank" rel="noopener">told <em>St. Louis Magazine</em></a> in May: “Our region has remarkable strengths across that entire spectrum.”</p>
<p>Those strengths include top-tier districts like the 35+ company, agtech-focused 39 North AgTech Innovation District, anchored by Bayer Crop Science and the Danforth Center; and the Cortex Innovation District, which finished 2025 as home to 406 companies employing 5,400 people and generating $163.8 million in taxes between 2014–2025. Cortex also achieved 100% occupancy last year when pathogen detection tools developer Varro Life Sciences moved in, investing $42.5 million and creating 33 new jobs. Within Cortex, C2N Diagnostics—a developer of tests for Alzheimer’s disease and related forms of neurodegeneration—is set to move into Catalyst: Powered by WashU, where it will anchor the $100 million redevelopment of the former Goodwill building (4140 Forest Park Ave.) spearheaded by Washington University in St. Louis and a developer affiliated with the school, BOBB. The project consists of renovating the existing seven stories and adding a four-story addition. In June, C2N agreed to bring its tests to Latin America and the Caribbean through a collaboration with Miami-based diagnostics developer SouthGenetics. As for the Danforth Center, it named a new COO in June: Derek Rapp, previously a managing director with life-sci focused VC firm RiverVest Venture Partners, which has an office in St. Louis as well as in Cleveland and San Diego.</p>
<p>Reflecting the strength of its institutions, St. Louis dominates emerging regions in patents, where it leads with 11,049 families, and is a strong second in NIH funding with 1,855 awards totaling $1.186 billion. The region places sixth in VC funding with $134 million (BioSTL), seventh in workforce with 21,376 life-sci jobs (BioSTL), and 10<sup>th</sup> in lab space (an estimated 3.185 million square feet based on Cortex’s 1.9 million, 39 North’s 1 million, and 285,000 square feet of incubator space (BioSTL + <em>GEN</em> research).</p>
<p class="trimmed"> </p>
<p><strong>5. Dallas-Fort Worth, TX</strong></p>
<figure aria-describedby="caption-attachment-335626" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335626 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-300x200.jpg" alt="Pegasus-Park-Exterior Dallas , TX" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-1024x684.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-768x513.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-629x420.jpg 629w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-1258x840.jpg 1258w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-696x465.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-1392x930.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003-1068x713.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-DALLAS-Pegasus-Park-Exterior-Photo-Quad-4-003.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">In suburban Plano, TX, Dallas-based investment firm NexPoint is spearheading development of the $4 billion Texas Research Quarter, which is envisioned to transform the former Electronic Data Systems HQ into 4 million square feet of R&D space on 200 acres, in four phases. [Texas Research Quarter]</figcaption></figure>
<p>The city of Dallas calls itself “<a href="https://www.dallasecodev.org/699/Dallas-Biotechs-Next-Frontier" target="_blank" rel="noopener">Biotech’s Next Frontier</a>” while Fort Worth boasted during the recent BIO International Convention about its “Location, Location, Location.” The region’s life-sci attractions include Pegasus Park, the 23-acre former ExxonMobil HQ off Stemmons Freeway, where four buildings totaling 750,000 square feet have been activated. The park’s Biotech+ hub has attracted three anchors in recent years: BioLabs Pegasus Park, a 37,000-square-foot facility offering flexible lab, training, and office space; the Advanced Research Projects Agency for Health (ARPA-H) Customer Experience Hub; and Bridge Labs at Pegasus Park, which offers 135,000 square feet of R&D space. At Bridge Labs, the University of Texas at Arlington and Texas A&M Engineering Experiment Station opened a new biomanufacturing training and research hub in December.</p>
<p>Dallas is also home to de-extinction-focused Colossal Biosciences, whose nonprofit Colossal Foundation pledged in June to collect, sequence, and preserve the genetic material of more than 2,300 threatened and endangered plant and animal species, and release the resulting data at no cost through a partnership with the U.S. Fish and Wildlife Service. In suburban Plano, TX, Dallas-based investment firm NexPoint is spearheading development of another campus for life-sci users, the $4 billion Texas Research Quarter, which is envisioned to transform the former Electronic Data Systems HQ into four million square feet of R&D space on 200 acres, in four phases. Another Dallas suburb, Denton, TX, is where Novartis plans to build a 46,000-square-foot radioligand therapy (RLT) manufacturing site, announced by the pharma giant in February. The site—Novartis’ first in Texas—is expected to become fully operational in 2028.</p>
<p>Dallas-Fort Worth only has 3.3 million square feet of lab space, says Cushman & Wakefield (good for eighth), but that number is expected to multiply in coming years since no less than 61.2 million square feet are under construction. “DFW” fares best in workforce size and VC funding, scoring third with 26,000+ jobs (Dallas’ Office of Economic Development) and $218 million (Dealroom.com data cited by the 2025 Austin Bio & Health Report, published in February). The region also finishes sixth among emerging regions in NIH funding (1,566 awards totaling $858.342 million) and eighth in patents (1,497 families).</p>
<p class="trimmed"> </p>
<p></p><h4><u class="wp-underline-text"><strong>Next 5 States</strong></u></h4>

<p class="trimmed"> </p>
<p><strong>1. Ohio (including Cincinnati, Cleveland, and Columbus)</strong></p>
<figure aria-describedby="caption-attachment-335627" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335627 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-OHIO-Amgen-New-Albany-OH-300x200.jpg" alt="Amgen, New Albany, OH" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-OHIO-Amgen-New-Albany-OH-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-OHIO-Amgen-New-Albany-OH-631x420.jpg 631w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-OHIO-Amgen-New-Albany-OH-696x463.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-OHIO-Amgen-New-Albany-OH.jpg 769w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">In the Columbus suburb of New Albany, OH, Amgen is completing a $900 million expansion of its final product advanced assembly and packaging plant, which when completed in 2027 will expand the company’s investment to $1.4 billion and its workforce from 400 to 750 [Amgen]</figcaption></figure>
<p>Columbus, Cleveland, Cincinnati, and their suburbs have enough life sciences activity for the Buckeye State to emerge first among states with emerging clusters. In June, the Ohio legislature approved $3.7 billion for 2027–28 that included $1.5 million for the Ohio Life Science Training Center (OLSTC), designed to train adults for entry-level biomanufacturing and cGMP jobs. An effort between JobsOhio, a private, nonprofit promoting economic development statewide (which last year committed $30 million to the effort) and the Ohio Life Sciences Association, OLSTC will rise in the Columbus suburb of New Albany, OH—where Amgen is completing a $900 million expansion of its final product advanced assembly and packaging plant, which when completed in 2027 will expand the company’s investment to $1.4 billion and its workforce from 400 to 750. In June, Resilience announced plans to move its corporate headquarters from San Diego to the Cincinnati suburb of Blue Ash, OH, and expand sterile injectable manufacturing at its plant in another Cincy suburb, West Chester, OH.</p>
<p>Some 25 miles east of downtown Cincinnati in Williamsburg Township, OH, Lonza Group is considering construction of a $1 billion plant on two parcels totaling 161 acres at Half Acre Road and State Route 32 (James A. Rhodes Appalachian Highway) on land owned by Clermont County. On June 29, the Ohio Tax Credit Authority approved a 1.860%, 20-year Job Creation Tax Credit for the project, which would create 650 full-time-equivalent positions.</p>
<p>In June, Hikma Pharmaceuticals announced a $267 million, two-site expansion that will grow its injectable pharmaceutical manufacturing capabilities, adding 300 jobs in the Cleveland suburb of Bedford, OH, while adding 50 jobs by expanding its oral solid dose and nasal inhalation manufacturing operations in Columbus. Also in June, Cleveland Clinic launched a partnership with 10x Genomics to advance research in novel diagnostics for bladder cancer. Cleveland Clinic patients with advanced bladder cancer who are undergoing emerging therapeutic regimens will have their tumor samples examined using 10x’s spatial and single-cell biology tools—part of 10x’s <a href="https://www.genengnews.com/topics/omics/clinical-ambitions-10x-expands-beyond-research-with-trio-of-collaborations/" target="_blank" rel="noopener">expansion into clinical applications</a>.</p>
<p>Among emerging states, Ohio leads in NIH funding (2,763 awards totaling $1.538 billion), patents (54,536 families), and jobs (54,536 biopharma, research/testing, agritech, and distribution jobs according to Ohio Life Sciences Association).</p>
<p class="trimmed"> </p>
<p><strong>2. Indiana (including Indianapolis)</strong></p>
<figure aria-describedby="caption-attachment-335628" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335628 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN-300x169.jpg" alt="Indiana Lilly Lebanon, IN" width="300" height="169" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN-300x169.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN-1024x576.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN-768x432.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN-747x420.jpg 747w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN-696x392.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN-1068x601.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT-10-INDIANA-LILLY-Lebanon-IN.jpg 1280w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Eli Lilly has announced plans to spend an additional $4.5 billion across its two manufacturing sites in Lebanon, IN, where on May 6 it opened its first dedicated genetic medicine facility in Lebanon’s LEAP Innovation District. [Eli Lilly]</figcaption></figure>
<p>Indianapolis-based Eli Lilly intends to be an even larger presence in the Hoosier State, announcing plans in May to spend an additional $4.5 billion across its two manufacturing sites in Lebanon, IN, where it opened a new genetic medicine facility in Lebanon’s LEAP Innovation District. The capital will cover new process designs and technologies at Lilly Lebanon API, a future active pharmaceutical ingredient site set to open in 2027, and Lilly Lebanon Advanced Therapies, which opened May 6 as the pharma giant’s first dedicated genetic medicine manufacturing facility. Since 2020, Lilly says, it has spent $21 billion+ on capital expansion projects statewide.</p>
<p>Lilly is hardly Indiana’s only biopharma headliner: In March, Gov. Mike Braun (R) announced that the Indiana Economic Development Corp. is committing $1 billion in tax credits over 10 years to add 100,000 jobs to the Hoosier State’s life-sci and agritech workforce. That would nearly double a statewide life-sci workforce of 52,526 biopharma, life-sci distribution, and agritech jobs (not including 17,473 medical device jobs), according to the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fbiocrossroads.com%2Flife-sciences-in-indiana%2Flife-sciences-dashboard%2F&data=05%7C02%7CAlex.Philippidis%40sagepub.com%7C8b2ceba4ae8540d883b108dedec091b1%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639193116581376691%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=%2FA6aGvCXt8dLhm%2Fd57H4EontqDbhnueSLzcpQGrfAiE%3D&reserved=0" target="_blank" rel="noopener">online dashboard</a> of state life-sci industry group BioCrossroads. “This investment will make Indiana the re-shoring and expansion epicenter and premier destination for human therapeutics, animal health, agritech, biotechnology, and environmental innovation,” Braun vowed.</p>
<p>Also expanding is Roche Diagnostics, which last year announced plans to grow its North American headquarters campus in Indianapolis by spending up to $550 million through 2030 to establish the 170-acre site as a central manufacturing hub for its next-generation continuous glucose monitoring systems. The expansion is expected to add 650 manufacturing and distribution jobs to the site’s existing 3,200+ employees.</p>
<p>Indiana lags in NIH funding (1,161 awards totaling about $611.594 million) but finished a strong second in both patents (52,526 families) and jobs (49,211 biopharma, research/testing, agritech, and distribution jobs, according to BioCrossroads).</p>
<p class="trimmed"> </p>
<p><strong>3. Florida (including Jacksonville and Miami-Fort Lauderdale)</strong></p>
<figure aria-describedby="caption-attachment-335629" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335629 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-FLORIDA-GBI-Biomanufacturing-__-TFL-L-BIO-lab-tour-7-050526-300x200.jpg" alt="GBI Biomanufacturing Florida" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-FLORIDA-GBI-Biomanufacturing-__-TFL-L-BIO-lab-tour-7-050526-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-FLORIDA-GBI-Biomanufacturing-__-TFL-L-BIO-lab-tour-7-050526-768x511.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-FLORIDA-GBI-Biomanufacturing-__-TFL-L-BIO-lab-tour-7-050526-631x420.jpg 631w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-FLORIDA-GBI-Biomanufacturing-__-TFL-L-BIO-lab-tour-7-050526-696x463.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-FLORIDA-GBI-Biomanufacturing-__-TFL-L-BIO-lab-tour-7-050526.jpg 862w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Andrew Majdoch, vice president of technical operations at GBI Biomanufacturing in Plantation, FL. Earlier this year GBI, a biologics CDMO, doubled its stem-cell manufacturing capacity by expanding its Plantation site to all of the 40,000-square-foot 1850 N.W. 69th Ave. from 28,000 square feet. GBI has long manufactured therapeutic proteins and antibodies there. [GBI Biomanufacturing]</figcaption></figure>
<p>Johnson & Johnson (J&J) Vision Care in June announced a $1 billion expansion of its Jacksonville, FL, operations for its Acuvue<sup class="wp-sup-text">®</sup> contact lenses. Plans call for a new Northwest distribution facility (50 jobs), set to be fully operational in 2028, and new equipment at its existing Southside manufacturing and corporate site within the Deerwood Park campus. Earlier this year GBI Biomanufacturing, a biologics CDMO, doubled its stem-cell manufacturing capacity by expanding at its Plantation, FL, site to all of the 40,000-square-foot 1850 N.W. 69th Ave. from 28,000 square feet. GBI Bio has long manufactured therapeutic proteins and antibodies there. And in January, Novartis chose the Orlando suburb of Winter Park, FL, for its fourth of five planned radioligand therapy (RLT) manufacturing facilities across the United States. The 35,000-square-foot site is set to open in 2029.</p>
<p>In Pensacola, FL, biotech manufacturing tools and services giant Cytiva last year completed the construction of new filtration manufacturing lines designed to increase the production capacity for filter membranes for North America by 20%. ILiAD Biotechnologies, based in the Fort Lauderdale suburb of Weston, FL, closed in February on an oversubscribed $115 million Series B VC financing whose proceeds are intended to fund advancement of a next-generation pertussis vaccine candidate, BPZE1. And in the Miami suburb of Coral Gables, FL, Catalyst Pharmaceuticals found a buyer in May when Italy’s Angelini Pharma agreed to acquire the rare neuromuscular and neurological disease drug developer for approximately $4.1 billion.</p>
<p>South Florida’s emergence as a biotech hub is reflected in the region hosting the first conferences held in the region by three industry groups, the Biotechnology Innovation Organization (BIO), LSX, and the Miami Biotech Collective. Last December, the Collective partnered with J.P. Morgan to launch an annual summit after being created earlier in 2025 by about 500 industry executives and investors.</p>
<p>Florida is a strong second in NIH funding (2,232 awards totaling $1.38 billion) but third in jobs (40,000 according to BioFlorida, which includes medical device jobs, a category tallied by <em>South Florida Business Journal</em> at 24,000 alone) and fourth in patents (4,682 families).</p>
<p class="trimmed"> </p>
<p><strong>4. Georgia (including Atlanta and Augusta)</strong></p>
<figure aria-describedby="caption-attachment-335631" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335631 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-300x167.jpg" alt="UCB Georgia" width="300" height="167" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-300x167.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-1024x569.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-768x427.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-756x420.jpg 756w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-696x385.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-1392x770.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S-1068x594.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GEORGIA-UCB-U.S.jpg 1400w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">UCB announced plans in March for a $2 billion, 460,000-square-foot biologics manufacturing facility near Atlanta in suburban Gwinnett County. The Belgian biopharma bought 79 acres from the Rowen Foundation, which is developing a 1,900-acre campus on Highway 316. [Rowen Foundation]</figcaption></figure>
<p>UCB announced plans in March for a $2 billion, 460,000-square-foot biologics manufacturing facility near Atlanta in suburban Gwinnett County. The Belgian biopharma bought 79 acres from the Rowen Foundation, which is developing a 1,900-acre campus on Highway 316, launched in 2020 as a “knowledge” community for biopharma and other innovation-based fields. Gwinnett County has committed $174 million in incentives and infrastructure investments to support UCB’s project, which is expected to create more than 330 permanent jobs once operational.</p>
<p>UCB’s project is the brightest recent success of Georgia life sciences leaders, who are working through industry group Georgia Life Sciences, laid out a 10-year “Roadmap” last year with the aim of “positioning Georgia as the scale-up manufacturing hub of the Southeast.” Other smaller-scale successes include Micron Biomedical, which in May celebrated the grand opening of a 26,000-square-foot manufacturing site for its dissolvable vaccine and therapeutic technology in the Atlanta suburb of Alpharetta, GA. And two hours east of Atlanta in Augusta, GA, Manus Bio broke ground in May on an expansion that will enable its biomanufacturing facility to domestically produce artemisinin, a key ingredient in anti-malaria treatments. The project, first announced in 2024 with the Administration for Strategic Preparedness and Response (ASPR), marks the first project of a partnership that has grown to $47.4 million—including $15 million awarded in February toward domestic production of shikimic acid, a key component of the active ingredient in Tamiflu<sup class="wp-sup-text">®</sup> (oseltamivir phosphate).</p>
<p>Atlanta is known for longtime life-sci anchors Emory University and the U.S. Centers for Disease Control and Prevention, the state’s largest life-sci employer at 6,500 people, according to Georgia Power’s Select Georgia economic development initiative. More recently, Portal Innovations’ Portal Atlanta at Science Square has grown in less than a year to 30+ startups in biotech and other industries, plus established companies like vaccine developer GeoVax, which relocated its lab and R&D staffers there late last year while moving its HQ within suburban Smyrna, GA.</p>
<p>Georgia showed third in NIH funding (2,153 awards totaling $1.184 billion, fourth in jobs (36,000 according to Lightcast data cited by SelectGeorgia), and fifth in patents (3,447 families).</p>
<p class="trimmed"> </p>
<p><strong>5. Wisconsin (including Madison and Kenosha)</strong></p>
<figure aria-describedby="caption-attachment-335634" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335634 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop-300x200.jpeg" alt="FCDI Ribbon Cutting Wisconsin" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop-300x200.jpeg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop-1024x682.jpeg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop-768x512.jpeg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop-631x420.jpeg 631w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop-696x464.jpeg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop-1068x711.jpeg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-WISCONSIN-FCDI-Ribbon-Cutting-crop.jpeg 1150w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Wisconsin Gov. Tony Evers (D) (center) joins Fujifilm Biotechnologies executives in May to officially open Fujifilm Cellular Dynamics Inc. (FDCI)’s new headquarters and human-induced pluripotent stem cell (iPSC) development and manufacturing facility in Madison, WI. [Fujifilm Biotechnologies]</figcaption></figure>
<p>Wisconsin’s manufacturing heritage has helped the Badger State build a life sciences industry that, while heavy on diagnostics and medical device development, also includes growing biopharma activity. South of Kenosha in Pleasant Prairie, WI, Eli Lilly has committed $4 billion toward expanding its production of injectable diabetes and obesity therapies by repurposing the 84,000-square-foot facility it acquired from Nexus Pharmaceuticals in 2024 for $925 million and adding two facilities, a 54,166-square-foot office-manufacturing building and a 13,940-square-foot, four-dock warehouse. The project is expected to create 750 jobs.</p>
<p>In May, Fujifilm Biotechnologies executives joined state officials in officially opening Fujifilm Cellular Dynamics Inc. (FCDI)’s new headquarters and human-iPSC development and manufacturing facility in Madison, WI. The facility employs nearly 200 people and will quadruple FCDI’s capacity for its iPSC-based research products and services manufacturing footprint, with an eye to meeting future demand for contract manufacturing of cell therapy products.</p>
<p>Thermo Fisher Scientific in February signed two 20-year lease extensions for 8500-8551 Research Way, a pair of lab buildings totaling 233,694 square feet in the Madison suburb of Middleton, WI, where the life-sci tools giant carries out pharmaceutical product development and clinical research. Catalent last year completed a $45 million production facility expansion in Madison, WI, creating about 200 jobs. The Madison facility provides development, manufacturing, and analytical services for new biologics; houses Catalent’s GPEx<sup class="wp-sup-text">®</sup> Lightning cell line technology, designed to create high-yielding mammalian cell lines genetically modified to create large quantities of a desired protein; and features development and manufacturing labs for flexible preclinical, clinical, and commercial production of biologics from 50- to 4,000-liter scale.</p>
<p>The manufacturing heritage gives the state a competitive advantage, according to the public-private Wisconsin Economic Development Corp. (WEDC), which says suppliers from across the state provide $7.8 billion in products to “biohealth” companies, including pharma and life-sci R&D businesses, as well as medical device developers.</p>
<p>Among emerging states, Wisconsin is fourth in both NIH funding (1,557 awards totaling $913.388 million) and patents (17,944 families), and sixth in jobs (30,749 biopharma, research/testing, agritech, and distribution jobs according to WEDC).</p>
<p class="trimmed"> </p>
<p></p><h4><u class="wp-underline-text"><strong>Regional and State Clusters to Watch</strong></u></h4>

<p class="trimmed"> </p>
<p><strong>Phoenix, AZ</strong></p>
<figure aria-describedby="caption-attachment-335635" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335635 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PHOENIX-ROIS_Team-celebrates-e1785163704747-222x300.jpg" alt="ROIS Team Phoenix, AZ" width="222" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PHOENIX-ROIS_Team-celebrates-e1785163704747-222x300.jpg 222w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PHOENIX-ROIS_Team-celebrates-e1785163704747.jpg 244w" sizes="auto, (max-width: 222px) 100vw, 222px"><figcaption class="wp-caption-text">Staffers at Madrid-based ROIS, the contract development and manufacturing organization (CDMO) arm of ROVI, celebrate plans to add U.S.-based sterile production capacity after acquiring a 370,000-square-foot Phoenix manufacturing site from Bristol Myers Squibb. ROIS plans to install an Optima pre-filled syringe (PFS) isolator line in a segregated non-potent area in 2027, which is projected to add ~65–70 million PFS capacity annually once operational. [ROIS]</figcaption></figure>
<p>Madrid-based ROIS, the CDMO arm of ROVI, said April 1 it plans to add U.S.-based sterile production capacity by acquiring a 370,000-square-foot Phoenix manufacturing site from Bristol Myers Squibb.  ROIS plans to install an Optima pre-filled syringe (PFS) isolator line in a segregated non-potent area in 2027, which is projected to add ~65–70 million PFS capacity annually once operational. The U.S. facility will be equipped for commercial-scale sterile fill-finish and packaging across vials, PFS and cartridges. Also, cancer drug developer Breakthru Medicine emerged from stealth mode in January, closing on $60 million in Series A VC financing. Breakthru is developing a molecular glue platform, as well as a pipeline of small molecule and ADC candidates.</p>
<p>Regional co-anchors include the downtown 30-acre Phoenix Bioscience Core, home to Arizona’s three public research universities—the University of Arizona, Northern Arizona University, and Arizona State University (ASU). In April, ASU broke ground on a 200,000-square-foot “ASU Health” building in Phoenix that will house the John Shufeldt School of Medicine and Medical Engineering, set to matriculate its inaugural class in August. Another anchor district is the 120-acre Discovery Oasis site, home to Mayo Clinic and MedTech Accelerator, a flagship program of Mayo and Arizona State University Alliance for Health Care. Mayo Clinic is carrying out a $1.9 billion, 1.2 million-square-foot expansion that will increase clinical space at the Phoenix campus by nearly 60% with a new procedural building, a four-floor expansion of the Mayo Clinic Specialty Building, 11 new operating rooms, and two new patient units with 48 additional beds.</p>
<p>Phoenix-area bioscience grew by 8+ million square feet between 2019-25, Mayor Kate Gallego said last year in her <a href="https://app.box.com/s/yv3fx2oaopcu0lb2xzfpj0c4ko4d9zqd" target="_blank" rel="noopener">State of the City address</a>. The region’s life-sci workforce expanded to 26,000+ by 2024 (Greater Phoenix Economic Council), up 66% since 2015. Greater Phoenix institutions have won 1,470 NIH awards totaling $538.4 million, while inventors have been granted patents totaling 1,470 families.</p>
<p class="trimmed"> </p>
<p><strong>Pittsburgh, PA</strong></p>
<figure aria-describedby="caption-attachment-335636" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335636 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PITTSBURGH-ELEVATEBIO-PITT-life-sci-hub-278x300.jpg" alt="ELEVATEBIO Pittsburgh" width="278" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PITTSBURGH-ELEVATEBIO-PITT-life-sci-hub-278x300.jpg 278w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PITTSBURGH-ELEVATEBIO-PITT-life-sci-hub-389x420.jpg 389w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PITTSBURGH-ELEVATEBIO-PITT-life-sci-hub-696x751.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-PITTSBURGH-ELEVATEBIO-PITT-life-sci-hub.jpg 755w" sizes="auto, (max-width: 278px) 100vw, 278px"><figcaption class="wp-caption-text">ElevateBio and the University of Pittsburgh (Pitt) next year are set to open the 185,000-square-foot BioForge Biomanufacturing Center within Hazelwood Green, a former steel mill site along the Monongahela River. ElevateBio, a Waltham, MA-based CDMO for advanced therapies, will occupy 70% of the BioForge site as anchor tenant and a scientific partner for Pitt by operating BaseCamp Pittsburgh, a 125,000-square-foot commercial gene and cell therapy biomanufacturing hub. [University of Pittsburgh]</figcaption></figure>
<p>The “Steel City” and vicinity have pivoted to life sciences and healthcare since the region’s steel industry began shriveling in the 1970s, with some 95,000 manufacturing jobs lost between 1980-83 alone. A key milestone in Pittsburgh’s life-sci revival should come next year, when ElevateBio and the University of Pittsburgh (Pitt) are set to open the 185,000-square-foot BioForge Biomanufacturing Center within Hazelwood Green, a former steel mill site along the Monongahela River. ElevateBio, a Waltham, MA-based CDMO for advanced therapies, will occupy 70% of the BioForge site as anchor tenant and a scientific partner for Pitt by operating BaseCamp Pittsburgh, a 125,000-square-foot commercial gene and cell therapy biomanufacturing hub.</p>
<p>Among home-grown companies, Peptilogics in March launched its pivotal Phase II/II RETAIN registration trial (<a href="https://clinicaltrials.gov/study/NCT07214311" target="_blank" rel="noopener">NCT07214311</a>) assessing its lead program of its first-in-class anti-biofilm drug candidate PLG0206 as an irrigation solution to treat prosthetic joint infections. Peptilogics last year completed an oversubscribed $78 million Series B2 financing whose proceeds are funding the trial. Pittsburgh is one of the Top 20 metropolitan statistical areas (MSAs) <a href="https://nasdaqcenter.org/arie/" target="_blank" rel="noopener">identified</a> last November by Nasdaq Entrepreneurial Center as “America’s Entrepreneurial Growth Engines,” a report that included three other regions listed here: Atlanta, Minneapolis-St. Paul, and Richmond, VA.</p>
<p>Pittsburgh’s life-sci efforts won national attention in February, when members of the National Security Commission on Emerging Biotechnology visited BioForge and the Carnegie Mellon University (CMU) Biological and Chemical Innovation Cloud Lab at the AI Science Foundry, which enables AI-guided autonomous research within and across biology, chemistry, and metals and alloys. According to Pittsburgh Life Sciences Alliance, the region has a life-sci workforce of 22,268, a lab/life-sci space inventory of 1.7 million square feet, and finished last year with $247 million in VC raised over 15 years.</p>
<p class="trimmed"> </p>
<p><strong>Greater Richmond, VA</strong></p>
<figure aria-describedby="caption-attachment-335638" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335638 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GTR-RICHMOND-VA-Eli_Lilly_Goochland-County-300x150.jpg" alt="Eli Lilly, Richmond VA" width="300" height="150" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GTR-RICHMOND-VA-Eli_Lilly_Goochland-County-300x150.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-GTR-RICHMOND-VA-Eli_Lilly_Goochland-County.jpg 600w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">A rendering of the $5 billion manufacturing facility that Eli LIlly plans to build in Virginia’s Goochland County near Richmond. The planned manufacturing plant will be the company’s first-ever dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for the pharma giant’s bioconjugate platform and monoclonal antibody portfolio. [Eli Lilly]</figcaption></figure>
<p>Greater Richmond last year attracted the largest of Virginia’s three multi-billion-dollar biomanufacturing projects announced by pharma giants: Eli Lilly last September announced a <a href="https://www.genengnews.com/topics/bioprocessing/lilly-chooses-virginia-site-for-5b-api-manufacturing-facility-with-adcs-in-mind/" target="_blank" rel="noopener">$5 billion manufacturing plant</a> just west of Richmond in suburban Goochland County that will be the first-ever dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for the pharma giant’s bioconjugate platform and monoclonal antibody portfolio. The plant, set to employ 650 people, will manufacture APIs for therapies designed to treat cancer, autoimmune diseases, and other disorders—including ADCs.</p>
<p>The Richmond region’s life-sci anchors include the Alliance for Building Better Medicine, a stakeholder group in Richmond and nearby Petersburg, VA, that promotes advanced pharmaceutical manufacturing, workforce development, and supply chain development; and the 34-acre VA Bio+Tech Park, home to nearly 70 companies, research institutions, and state and federal labs, plus the VA Bio+Tech Center incubator. Also in Richmond is Phlow, a CDMO emphasizing advanced development and manufacturing within the U.S. Last October, the company won inclusion in the FDA’s first Commissioner’s National Priority Voucher (CNPV) Pilot Program when the agency selected Phlow-produced ketamine among nine products for accelerated agency reviews.</p>
<p>Haleon last year committed $54.2 million toward upgrading and expanding its global R&D Center of Excellence, one of three it operates worldwide. The project will also enable the over-the-counter drugmaker to launch a five-year paid internship program with Richmond-based Virginia Commonwealth University and other state schools. Haleon is the former consumer healthcare business of GlaxoSmithKline (GSK), spun out in 2022.</p>
<p>Greater Richmond’s numbers, smaller than many emerging regions, are trending positively: The region has won 1,203 NIH awards totaling $707.5 million and generated patents totaling 904 families. According to the Greater Richmond Partnership, the region has a life-sci workforce of 7,650 jobs while its startups raised $80.135 million in VC funding last year.</p>
<p class="trimmed"> </p>
<p><strong>South Carolina</strong></p>
<figure aria-describedby="caption-attachment-335639" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335639 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-300x200.jpg" alt="RiteDose, South Carolina" width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-1024x683.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-1536x1024.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-1260x840.jpg 1260w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-1392x928.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos-1068x712.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-SO-CAROLINA-RITEDOSE-__The-new-facility-features-two-custom-murals-by-local-Columbia-artist-Ija-Charles-depicting-Ritedos.jpg 1920w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">In Columbia, SC, Ritedose, a contract development and manufacturing organization (CDMO) specializing in blow-fill-seal (BFS) technology and generic drug manufacturing, has a $17 million, two-phase expansion of its 16,000-square-foot cGMP laboratory coming on line later this year. [Ritedose]</figcaption></figure>
<p>Swedish-based Octapharma, the world’s largest privately owned and independent fractionator of plasma used toward creating hematology, immunotherapy, and critical care treatments, announced plans June 29 to expand within South Carolina by moving its North American headquarters and its 300 jobs from Charlotte, NC, to its suburb of Rock Hill, SC. There, Octapharma plans to build a $1.5 billion combined HQ/advanced manufacturing facility with 1,200 new jobs. In June, GNQ Insilico—which helps precision medicine developers through a platform integrating AI, quantum computing, and multiomics insights at the systems biology level—opened an initial lab at the Clemson University Biomedical Engineering Innovation Campus (CUBEInC), with plans to relocate its headquarters to Greenville from Pleasanton, CA, and base 20-30 people there by year’s end.</p>
<p>Greenville is one of the Palmetto State’s hubs for life-sci activity; others include Charleston, SC, and Sumter, SC. In Columbia, SC, Ritedose, a CDMO specializing in blow-fill-seal (BFS) technology and generic drug manufacturing, has a $17 million, two-phase expansion of its 16,000-square-foot cGMP laboratory coming on line later this year.</p>
<p>According to life-sci industry group SCbio, South Carolina has a life-sci workforce of 63,725 people and saw $63.1 million in bioscience VC raised in 2023 (latest available figure), with Medical University of South Carolina launching two funds totaling $30 million last year to help grow life-sci and healthcare companies. James Chappell, PhD, SCbio’s president and CEO, acknowledges the state needs more lab space for startups. SCbio hopes to meet that need by partnering with a developer—but that challenge could be met if any of several life-sci employers proceed with new or expanded facility projects now in the works but not yet disclosed.</p>
<p class="trimmed"> </p>
<p><strong>Utah</strong></p>
<figure aria-describedby="caption-attachment-335642" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-335642 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-300x200.jpg" alt="Cytiva, Logan, UT " width="300" height="200" srcset="https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-300x200.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-1024x683.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-768x512.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-1536x1024.jpg 1536w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-630x420.jpg 630w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-1260x840.jpg 1260w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-696x464.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-1392x928.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-1068x712.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n-1920x1280.jpg 1920w, https://www.genengnews.com/wp-content/uploads/2026/07/NEXT10-UTAH-Cytiva-expand-Logan-UT-team____738011396_1510764531095994_542353042071069646_n.jpg 2048w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Cytiva staffers outside the company’s newly expanded Logan, UT, facility at a ceremony celebrating completion of the company’s animal-derived component-free (ADCF) liquid media expansion facility (A1X) project. The expansion effectively doubles the site’s liquid media production capacity, a project designed to support supply chain continuity for customers relying on the company for their cell culture needs. [Utah Governor’s Office of Economic Development, Gov. Spencer Cox (R)]</figcaption></figure>
<p>Salt Lake City is home to AI-based drug developer Recursion, which is making news beyond its pipeline. In May, Recursion-supported accelerator Altitude Lab—SLC is an average 4,327 feet above sea level—announced that its portfolio companies had raised more than $205 million in early-stage funding since its launch in 2020.</p>
<p>Two of those companies raised Series A rounds last year: Peel Therapeutics garnered $20 million toward development of PEEL-224, an optimized TOP1 inhibitor, while Rebel Medicine collected $7.5 million to help develop its non-opioid pain candidate Alevatrix, a bupivacaine reformulation. As for Recurison, the company in May reported encouraging initial safety and PK data in its Phase I/II DAHLIA trial (<a href="https://clinicaltrials.gov/study/NCT06678659" target="_blank" rel="noopener">NCT06678659</a>) of RBM39 degrader REC-1245, a candidate vs. solid tumors and lymphoma, and dosed its first patient in a Phase I ENLYGHT trial (<a href="https://clinicaltrials.gov/study/NCT07517198" target="_blank" rel="noopener">NCT07517198</a>) assessing another cancer-fighting candidate, REC-4539, one designed to target epigenetic drivers.</p>
<p>In March, VC firm Portal Innovations announced plans to expand into Salt Lake City, where it will establish “Woodbine Labs, Powered by Portal,” a 30,000-square-foot incubator set to open in the second quarter of 2027, and create a fund to support early-stage life sciences and biotech startups. Statewide industry group BioUtah is supporting Portal, whose new facility would nurture startups spinning out of the University of Utah and Brigham Young University.</p>
<p>Outside the Salt Lake City region, biotech manufacturing tools and services company Cytiva has completed an expansion of its Logan, UT, facility—namely a new animal-derived component-free (ADCF) liquid media expansion facility (A1X)—that <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Fbioprocessing%2Fcytiva-completes-doubling-of-utah-sites-liquid-media-production-capacity%2F&data=05%7C02%7Calex.philippidis%40sagepub.com%7C4dfc1d5b033a4f61c1f908dedb977be5%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639189641387132467%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=WZ%2FTWV4suaFDGGOwfOp%2BjVd3g86pEPHvQkZS%2B2CmSPw%3D&reserved=0" target="_blank" rel="noopener">effectively doubles its liquid media production capacity</a>, a project designed to support supply chain continuity for customers relying on the company for their cell culture needs.</p>
<p>The post <a href="https://www.genengnews.com/topics/drug-discovery/next-10-u-s-biopharma-clusters/">Next 10 U.S. Biopharma Clusters</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Five Steps to Enable Self&#45;Optimizing Process Purification</title>
<link>https://edusehat.com/en/five-steps-to-enable-self-optimizing-process-purification</link>
<guid>https://edusehat.com/en/five-steps-to-enable-self-optimizing-process-purification</guid>
<description><![CDATA[ Self-optimization is the next evolutionary step for bioprocessing purification systems and, although that step is near, it currently is hindered by missing integrations among its many parts and by loose usage of precise concepts.
The post Five Steps to Enable Self-Optimizing Process Purification appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/11/GettyImages-1405788998-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 01:45:12 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Five, Steps, Enable, Self-Optimizing, Process, Purification</media:keywords>
<content:encoded><![CDATA[<p>Self-optimization is the next evolutionary step for bioprocessing purification systems and, although that step is near, it currently is hindered by missing integrations among its many parts and by loose usage of precise concepts.</p>
<p>At an operational level, self-optimized purification is supported by process analytical technology, hard and soft sensors, digital twins and digital shadows, physics-informed modeling, and real-time optimization capabilities. In that milieu, biopharmaceutical processing is the most advanced. What it lacks, however, is operational comparability linking measurement, state estimation, model updating, decision support, and closed-loop actions for purification platforms and components such as membranes, adsorption and cyclic gas separations, chromatography, and integrated purification trains.</p>
<p>“The limiting factor across domains…is the incomplete integration of measurement design, hidden-state estimation, updating, uncertainty, control authority, governance, and economic justification under realistic drift and scale change,” Vasileios M. Pappas, PhD, post-doctoral senior researcher, University of Thessaly in Greece, explains in a recent <a href="https://doi.org/10.3390/purification2030010" target="_blank" rel="noopener">review</a>.</p>
<p>To remedy this, Pappas recommends:</p>
<ol>
<li>Prioritizing sensors and sampling strategies that identify the critical hidden states of each purification platform</li>
<li>Reporting model-updating, recalibration and invalidation rules explicitly, “rather than treating them as implementation details”</li>
<li>Including “drift, delay, sensor failure, feed disturbance, cleaning/regeneration history, and scale transfer [data] as part of the validation process, in addition to nominal operating data</li>
<li>“Distinguish[ing] advisory, supervisory, and autonomous authority as well as fallback logic when model confidence is insufficient”</li>
<li>Reporting economic, regulatory, cybersecurity, and data-governance constraints alongside predictive accuracy</li>
</ol>
<p>For biomanufacturers, these steps enable more thorough integration throughout the purification process. They enable “trustworthy self-optimizing purification…by demonstrating that process state, model confidence, and operating authority remain linked under disturbances that matter industrially,” Pappas elaborates. “The central test is whether the system can infer the hidden state early enough, update itself responsibly, and support or execute an operating action that protects purity, recovery, productivity, safety, and robustness.”</p>
<p></p><h4><strong>The path to self-optimization</strong></h4>

<p>Before implementing those suggestions, however, Pappas stresses the importance of “conceptual precision” as a starting point, noting loose usage of the defining terms. “A regressor trained on historical campaigns is not a twin simply because it runs online,” he notes, by way of illustration.</p>
<p>“Conceptional precision matters because the operational value of a digital layer depends on what it can infer, how it stays calibrated, how uncertainty is treated, and whether its output can support a qualified operating decision,” he points out. Using the correct specifications for the digital layers minimizes misunderstandings, thereby increasing the chances that the initial concept and the final design agree.</p>
<p>Otherwise, Pappas notes, the system may revert to monitoring and offline optimization or becomes a digital shadow—a model updated from processing data—rather than the operationally-significant bidirectional model known as a digital twin.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/5-steps-to-enable-self-optimizing-process-purification/">Five Steps to Enable Self-Optimizing Process Purification</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Allogeneic CAR T Company Prepares to Widen Access to Patients</title>
<link>https://edusehat.com/en/allogeneic-car-t-company-prepares-to-widen-access-to-patients</link>
<guid>https://edusehat.com/en/allogeneic-car-t-company-prepares-to-widen-access-to-patients</guid>
<description><![CDATA[ An allogeneic CAR T-cell therapy company is planning a pivotal Phase III randomized-control trial, hoping their products can reach more patients and help those who can’t access autologous therapies.
The post Allogeneic CAR T Company Prepares to Widen Access to Patients appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/10/GettyImages-1317697233.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 01:45:11 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Allogeneic, CAR, Company, Prepares, Widen, Access, Patients</media:keywords>
<content:encoded><![CDATA[<p>A CAR T-cell therapy company using donor cells is planning to move to a pivotal Phase III clinical trial thanks to their genome editing strategies and optimization of their product, including choice of donors under 30.</p>
<p>Caribou Biosciences says its allogeneic CAR T-cell therapies have been shown to be as effective and long lasting as approved autologous CAR T therapies in certain blood cancers.</p>
<p>“We’ve figured out how to make allogeneic CAR T cells work as well as autologous CAR T cells through a combination of gene editing strategies as well as optimization of the product, such as selecting donors under age thirty,” explains Justin Skoble, PhD, vice president of technical operations at Caribou Biosciences.</p>
<p>According to Skoble, the benefits of allogeneic therapy include having off-the-shelf products available, which will improve patient access.</p>
<p>“What’s novel is our ability to begin addressing the access issues that have been a struggle,” he says. “Depending on indication and who you’re talking with, 75 to 90% of patients eligible for CAR T don’t receive it.”</p>
<p>Skoble says this is “Either because their disease is progressing too rapidly to go through the referral process, cell collection, and manufacture of an autologous CAR T or they face challenges, such as socioeconomic barriers or insurance issues, that prevent them from getting to a center where it’s available.</p>
<p>“We believe an off-the-shelf approach […] reduces the logistical burden because the patient can be dosed with our allogeneic CAR T cells without the need to wait for bespoke manufacturing. We have a donor match strategy where we pick the best match we have in inventory and, because we can scale to hundreds of doses per manufacturing batch, the cost of goods is low.”</p>
<p>The company’s approach involves what Skoble describes as a high-fidelity genome-editing technology chRDNA (pronounced chardonnay), which Caribou Biosciences uses to reduce off-target effects and armor the CAR T cells for functional persistence.</p>
<p>They’ve also found they had better durability of response if they matched the patient’s human leukocyte antigens (HLAs) to donor HLA in inventory, and also if they use donors aged under 30, he says.</p>
<p>The company hopes their approach will transform, and inspire, the CAR T therapy industry. Over the next few months, they hope to start their randomized-controlled Phase III study with the goal of launching their first product, vispa-cel, as a second-line treatment for patients with large B cell lymphoma.</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/allogeneic-car-t-company-prepares-to-widen-access-to-patients/">Allogeneic CAR T Company Prepares to Widen Access to Patients</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bioprocessing’s Green Shift Gains Momentum</title>
<link>https://edusehat.com/en/bioprocessings-green-shift-gains-momentum</link>
<guid>https://edusehat.com/en/bioprocessings-green-shift-gains-momentum</guid>
<description><![CDATA[ Bioprocessing companies face pressure to cut emissions while maintaining production standards. CRB experts said better data collection, strategic planning, and emerging technologies are helping facilities reduce energy use, improve efficiency, and build more sustainable operations.
The post Bioprocessing’s Green Shift Gains Momentum appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Mike-WFI-system-CRB.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 01:45:10 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bioprocessing’s, Green, Shift, Gains, Momentum</media:keywords>
<content:encoded><![CDATA[<p>As bioprocessing companies race to meet ambitious sustainability goals, the industry’s biggest environmental challenges are becoming increasingly clear, and increasingly solvable. To find out more about this, <em>GEN</em> reached out to CRB—a provider of sustainable engineering, architecture, construction and consulting solutions—and interviewed two of its experts by email: Zach Page-Belknap and Maya DeHart, both energy and sustainability specialists.</p>
<p>According to the CRB experts, reducing carbon emissions and minimizing waste remain formidable obstacles. However, advances in facility design, data management, and energy optimization are giving manufacturers practical ways to make meaningful progress without compromising production.</p>
<p>“Sustainability in bioprocessing presents many challenges, but two of the most difficult to solve at scale are process-heating decarbonization and single-use waste diversion,” they said.</p>
<p>Historically, high-temperature processes have relied on natural-gas boilers, making them among the largest contributors to operational carbon emissions. Electrifying these systems can dramatically reduce fossil-fuel use, but it also places greater demand on a facility’s electrical infrastructure and backup power systems. As Page-Belknap and DeHart pointed out, “emerging technologies such as high-temperature heat pumps offer promising alternatives, although adoption has been slowed by high upfront costs, safety considerations, and the relatively immature market for the technology.”</p>
<p>Meanwhile, facilities that depend heavily on disposable plastic equipment—particularly those involved in autologous manufacturing—face a different challenge. Although methods exist to divert decontaminated single-use plastics from landfills, economics and limited recycling infrastructure continue to restrict widespread implementation.</p>
<p>The CRB team noted that waste diversion can be financially competitive when facilities are located near processors capable of handling specialized materials. However, organizations without local treatment options often face disposal costs more than twice those of conventional waste management.</p>
<p></p><h4><strong>Data makes the difference</strong></h4>

<p>Despite those challenges, one of the industry’s biggest sustainability breakthroughs has come from something far less visible: better data. Rather than relying on isolated information from individual systems, many companies are investing in centralized platforms that track energy, water, and waste across entire facilities. That broader view allows operators to identify inefficiencies, prioritize upgrades, and increasingly leverage artificial intelligence to optimize performance.</p>
<p>“It’s fair to say that meters and monitors themselves do not improve sustainability in bioprocessing directly,” continued Page-Belknap and DeHart. “They are only a means to improve visibility into the actual operational performance of a facility.”</p>
<p>Installing that monitoring infrastructure is often far less expensive than major equipment replacements. Individual meters typically cost around $5,000 to install, although larger projects involving dozens of monitoring points and upgraded management systems can range into the hundreds of thousands of dollars.</p>
<p>For commercial bioprocessors looking to improve sustainability, resisting the temptation to chase the newest technology first was recommended. Instead, facilities should begin by aligning site-level priorities with broader corporate sustainability goals, benchmarking current performance, and understanding where the greatest opportunities exist.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>For newer facilities, existing operational data might already reveal low-cost improvements, such as optimizing cleanroom air change rates or making better use of building management systems. Older facilities should take a phased approach by establishing utility baselines, identifying major energy and water consumers, evaluating equipment lifecycles, and incorporating sustainability improvements into planned capital replacement schedules.</p>
<p>As the CRB experts concluded: “Ultimately, sustainability improvement is less about any single technology and more about building the data infrastructure and decision framework needed to invest in the right measures, at the right time, for each specific site.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/bioprocessings-green-shift-gains-momentum/">Bioprocessing’s Green Shift Gains Momentum</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Software Can Solve CGT’s Sectors Traceability Challenges</title>
<link>https://edusehat.com/en/software-can-solve-cgts-sectors-traceability-challenges</link>
<guid>https://edusehat.com/en/software-can-solve-cgts-sectors-traceability-challenges</guid>
<description><![CDATA[ Cell and gene therapy developers should use software to help trace materials and data through the complex multi-stakeholder supply chains, manufacturing and distribution processes on which such products rely according to an industry expert. 
The post Software Can Solve CGT’s Sectors Traceability Challenges appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2023/01/GettyImages-723505991-scaled.jpg" length="49398" type="image/jpeg"/>
<pubDate>Thu, 13 Aug 2026 01:45:09 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Software, Can, Solve, CGT’s, Sectors, Traceability, Challenges</media:keywords>
<content:encoded><![CDATA[<p>The most important role of industrial software for the cell and gene therapy sector is the ability to precisely trace materials from collection site through the plant and back to the patient. So says Jonathan Wofford, CCO at Phoenix, Arizona software developer, Title21 Health Solutions, who told <em>GEN</em>, “CGT manufacturing typically involves fragmented, bespoke workflows.</p>
<p>“The complexity is compounded by several variables, including diverse collection methods and protocols, highly variable starting materials, operator techniques, and challenging logistics. Therapies are time-sensitive and orchestration between collection centers, manufacturing facilities, and treatment centers is critical.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>“As a result, CGT manufacturing requires coordination across a complex ecosystem that includes clinical operations, manufacturing, supply chain, quality, and data management, unlike mature and standardized mAb production processes.”</p>
<p>And this is where software makes its biggest, if somewhat underacknowledged, impact, according to Wofford.</p>
<p>“The primary value of software systems is not replacing or automating manufacturing processes, but rather bringing control, standardization, and traceability of manual data workflows,” he pointed out. “CGT manufacturing is variable and typically involves multiple changes in custody…each handoff creates opportunities for human error, documentation discrepancies, and compliance risk.”</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<h4><strong>Traceability in the plant</strong></h4>
<p>Software can also enhance the traceability of data within the manufacturing facility.</p>
<p>“Software platforms can help bring quality control and standardization to data entry and workflow management manufacturing through multiple features,” he continued, using electronic batch records as an example. “Industrial software system can also facilitate real-time chain-of-identity and chain-of-custody tracking, with live dashboards and analytics capabilities to drive enhanced insights into production runs, as well as real-time automated warnings for in-process issues or data values.”</p>
<p>The ability to trace materials and data in the plant is always going to be important, even if technology advances allow CGT process developers reduce the requirement for manual handling.</p>
<p>“Adoption of closed-system manufacturing may increase over time. However, today, software systems remain a more immediate solution for improving data accuracy, reducing manual data entry and processes, strengthening compliance controls, and driving analytics,” said Wofford, noting that this is where the emerging cell and gene therapy industry should focus its efforts rather than on promising yet untested technologies like artificial intelligence (AI) based process control systems.</p>
<p>“CGT organizations should be prioritizing technologies that can deliver meaningful and measurable operational and compliance benefits now,” he emphasized. “In the not-too-distant future, AI will likely contribute to predictive manufacturing and autonomous process control. But the greatest value today lies in targeted applications that improve efficiency, strengthen compliance, accelerate batch reviews, and generate actionable insights from complex data.”</p>
<p>The post <a href="https://www.genengnews.com/topics/bioprocessing/software-can-solve-cgts-sectors-traceability-challenges/">Software Can Solve CGT’s Sectors Traceability Challenges</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Steroid Curbs Chronic Lung Inflammation Without Weakening Immune Defenses</title>
<link>https://edusehat.com/en/steroid-curbs-chronic-lung-inflammation-without-weakening-immune-defenses</link>
<guid>https://edusehat.com/en/steroid-curbs-chronic-lung-inflammation-without-weakening-immune-defenses</guid>
<description><![CDATA[ Dexamethasone reduced inflammatory signaling in human macrophages infected with Mycobacterium avium without increasing bacterial growth, suggesting a potential host-directed approach for nontuberculous mycobacterial disease.
The post Steroid Curbs Chronic Lung Inflammation Without Weakening Immune Defenses appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2024/11/Oct26_2020_Getty_545863899_Lung-1068x894-1.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 11:25:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Steroid, Curbs, Chronic, Lung, Inflammation, Without, Weakening, Immune, Defenses</media:keywords>
<content:encoded><![CDATA[<p>Nontuberculous mycobacterial infections have become an increasing concern for people with chronic lung disease, in part because the infections can linger despite months of antibiotic treatment. Among the most common culprits is <em>Mycobacterium avium</em>, which can trigger persistent inflammation in the lungs and leave patients with ongoing symptoms even when antimicrobial therapy is underway.</p>
<p>Now, researchers from Trinity College Dublin and St. James’s Hospital report that dexamethasone, a widely used anti-inflammatory steroid, reduced inflammatory signaling in human macrophages infected with <em>M. avium</em> without compromising the cells’ ability to control bacterial growth. The study, “<a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiag394/8756879" target="_blank" rel="noopener">Dexamethasone Reduces Glycolysis and Inflammation in Human Macrophages Infected With <em>Mycobacterium avium</em> Without Compromising Bacterial Control</a>,” was published in <em>The Journal of Infectious Diseases</em>.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>The findings point to a possible host-directed strategy for nontuberculous mycobacterial disease—one aimed not at killing the bacteria directly, but at limiting the damaging inflammation that can accompany chronic infection. “Our study suggests that it may be possible to fine-tune this response by reducing damaging inflammation while still preserving the immune defenses that help control infection,” said Donal Cox, PhD, senior author of the research at Trinity College Dublin.</p>
<p>To test that idea, the team studied human monocyte-derived macrophages—immune cells that serve as a first line of defense against infection. The cells were treated with dexamethasone before being infected with <em>M. avium</em> subsp. <em>hominissuis</em> 104. The researchers then used real-time metabolic flux analysis to measure glycolysis and oxygen consumption, RT-qPCR to assess metabolic and antimicrobial gene expression, colony-forming unit assays to measure bacterial burden, and ELISA assays to quantify inflammatory cytokines.</p>
<p>The study showed that <em>M. avium</em> infection drove a glycolytic response in macrophages, but dexamethasone dampened that metabolic shift. The steroid reduced glycolytic proton efflux and lowered expression of glycolysis-associated enzymes, including PFKFB3, GAPDH, and PKM2, while leaving oxygen consumption unchanged. Importantly, dexamethasone did not increase the recoverable bacterial burden over 120 hours, according to the authors.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>The anti-inflammatory effects were broad. Dexamethasone significantly reduced production of TNF, IL-6, IL-8, and IL-1β in infected macrophages, and at the higher dose abrogated induction of IL-10, the authors report. It also did not alter the expression of several NADPH oxidase complex genes, supporting the authors’ conclusion that key antimicrobial functions may be preserved. The paper stated that the findings support “further investigation of dexamethasone as a potential host-directed strategy to limit inflammation while preserving host defense in nontuberculous mycobacterial disease.”</p>
<p>“Current treatment strategies for NTM disease focus primarily on killing the bacteria,” added Cox. “However, inflammation itself can contribute significantly to symptoms and tissue damage in patients, so finding ways to control inflammation without impairing antimicrobial innate immunity offers a potential gateway to much more effective therapies.”</p>
<p>The authors cautioned that the work was performed in macrophages from healthy donors and used a single <em>M. avium</em> strain, so the results will need to be validated in models that better reflect patients with NTM disease, including alveolar macrophages, macrophages from susceptible patients, and clinical <em>M. avium</em> isolates. Future studies will also need to test steroid treatment after infection and in combination with antimycobacterial therapy before dexamethasone can be considered as an adjunctive approach for chronic NTM lung disease.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/steroid-curbs-chronic-lung-inflammation-without-weakening-immune-defenses/">Steroid Curbs Chronic Lung Inflammation Without Weakening Immune Defenses</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Parasite&#45;Specific Protein Helps Toxoplasma Adapt to Crowded Conditions</title>
<link>https://edusehat.com/en/parasite-specific-protein-helps-toxoplasma-adapt-to-crowded-conditions</link>
<guid>https://edusehat.com/en/parasite-specific-protein-helps-toxoplasma-adapt-to-crowded-conditions</guid>
<description><![CDATA[ Scientists identified a previously unknown way that the parasite Toxoplasma can adapt to growing in crowded environments of tissue cysts, and identified the protein TgPRO, as a dedicated regulator of metabolic gene expression in parasites.
The post Parasite-Specific Protein Helps Toxoplasma Adapt to Crowded Conditions appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/Low-Res_TgPRO-article-image.jpeg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 07:50:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Parasite-Specific, Protein, Helps, Toxoplasma, Adapt, Crowded, Conditions</media:keywords>
<content:encoded><![CDATA[<p><em>Toxoplasma gondii </em>is a parasite that infects hundreds of millions of people around the world. Although cases are often mild, it can cause severe symptoms in people with weakened immune systems and in developing fetuses. <em>Toxoplasma </em>can also persist for years by forming long-lived cysts in tissues, allowing infection to become chronic.</p>
<p>During chronic infection, hundreds of <em>Toxoplasma </em>parasites can pack into a tissue cyst inside a brain or muscle cell. That crowded life carries a cost: nutrients become harder to obtain, waste accumulates, and energy-producing reactions can become damaging. How <em>Toxoplasma</em> reshapes its metabolism to keep growing under such strained conditions has been unclear.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>Now, a study by researchers in the lab of Whitehead Institute Member Sebastian Lourido, PhD, who is also an associate professor of biology at the Massachusetts Institute of Technology (MIT), has identified a parasite-specific protein that helps coordinate this response in <em>Toxoplasma</em>.</p>
<p>The preclinical study carried out in cells and including tests in infected mice revealed a previously unknown way that parasites regulate metabolism and identified a dedicated regulator of metabolic gene expression in apicomplexans, the group of parasites that includes <em>Toxoplasma</em> and the <em>Plasmodium</em> parasites that cause malaria.</p>
<p>The protein, TgPRO, allows <em>Toxoplasma</em> to manage oxidative stress—the buildup of reactive oxygen molecules that can damage cells—by controlling genes involved in energy production and iron use. Led by Christopher Giuliano, PhD, a former graduate student, and by graduate student Chinmay Kalluraya in the Lourido lab, the study in addition points to a possible future therapeutic strategy, indicating that inhibiting pathways controlled by TgPRO could make <em>Toxoplasma</em> more vulnerable to antiparasitic drugs that induce oxidative stress.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>Giuliano and Kalluraya are co-lead authors of the researchers’ published paper in <em>Cell</em>, titled “<a href="https://doi.org/10.1016/j.cell.2026.07.029" target="_blank" rel="noopener">Convergent evolution of metabolic regulation governs redox adaptation in <em>Toxoplasma</em></a>,” commenting in their report, “TgPRO is likely critical for the efficient transmission of <em>T. gondii</em> by enabling metabolic adaptation during chronic stages.”</p>
<p>Different organisms adjust metabolic gene expression during crowding, when they encounter nutrient scarcity, oxidative stress, and waste accumulation, the authors noted. “Organisms adapt to these stresses through either broad repression of biomass production or focused modulation of specific pathways.” Apicomplexans also encounter crowded environments as part of their infection cycles, the team continued. “However, while apicomplexan parasites experience these stresses during intracellular growth within host cells, they lack known regulators of metabolic adaptation.”</p>
<p>To discover the genes that support <em>Toxoplasma</em>’s ability to live in crowded cells, the researchers used a genome-wide CRISPR screen to compare <em>Toxoplasma</em> growing at low and high densities. The screen tests the effects of turning off genes one by one at both population densities in order to determine which genes are essential, specifically in crowded conditions. The results highlighted pathways that make or recycle NAD and NADP, molecules important for energy production and defending against oxidative damage. It also pointed to TgPRO, a previously unstudied protein that was especially important when parasites became crowded. “Nicotinamide adenine dinucleotide (NAD)(P)+ biosynthesis was required at high parasite density, along with several parasite-specific factors, including an RNA-binding protein we named ‘‘T. gondii parasite response to oxidation,’’ (TgPRO),” they stated.</p>
<p>“A genome-wide screen was a powerful way to ask how crowding affects parasite fitness,” Kalluraya said. “TgPRO emerged as very important at high density. Because almost nothing was known about it, we wanted to understand what it was doing.”</p>
<p>The researchers’ study showed that parasites lacking functional TgPRO accumulated more reactive oxygen molecules and struggled to compete at high density. Experiments showed that the loss of TgPRO disrupted the mitochondria and changed how parasites processed glucose and other nutrients. Providing additional iron or restoring an important chemical balance inside the mitochondrion improved parasite growth, connecting TgPRO’s effects to iron-dependent energy metabolism. “Collectively, TgPRO enables parasites to maintain redox balance under the metabolic strain that accompanies crowded environments,” they noted.</p>
<p>The team then traced the response to a molecular mechanism. TgPRO is an RNA-binding protein, attaching to the molecular messages (RNAs) that cells use to make proteins. The researchers found that it binds and stabilizes a select set of messages involved in nutrient use, mitochondrial activity, and the assembly of iron-sulfur clusters, small structures that many enzymes need to function. The experiments connected the original observation—that some parasites faltered only when crowded—to a precise interaction between a regulatory protein and its RNA targets.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>“One of the really nice elements of the story is our ability to connect it all the way through—from the original observation and genome-wide screen to the metabolic consequences and the direct interaction between TgPRO and its target RNAs,” Lourido said. The researchers found that lowering oxygen levels also reduced oxidative stress and partially restored the growth of parasites without TgPRO. Toxoplasma is commonly grown in laboratories at atmospheric oxygen levels, which are considerably higher than those found in most animal tissues. The result suggests that oxygen conditions can strongly shape parasite metabolism, and the researchers caution others studying <em>Toxoplasma</em> to take this into consideration.</p>
<p>After testing the role of TgPRO in artificially crowded settings, the team also tested whether TgPRO matters during chronic infection, when <em>Toxoplasma</em> forms cysts in the brain. Mice infected with parasites lacking functional TgPRO developed smaller brain cysts, suggesting TgPRO supports parasite growth in the naturally dense environment of a chronic-stage cyst.</p>
<p>“The chronic stage is still somewhat elusive,” Giuliano said. “Showing that TgPRO affects cyst growth suggests that these same metabolic changes are needed in the brain and gives us clues about how the parasites persist there for months or years.”</p>
<p>TgPRO bears little resemblance to the proteins that regulate similar metabolic programs in mammals, yeast, and bacteria, yet it controls many of the same kinds of genes that these organisms adjust when cells face oxidative stress or changing nutrient conditions. This is an example of convergent evolution: distantly related organisms evolved different molecular machinery to solve a similar biological problem. That convergence suggests that coordinating these metabolic pathways may be a fundamental requirement for cells adapting to stress.</p>
<p>The study establishes a new paradigm for how apicomplexan parasites regulate their metabolism and advances the foundation for investigating how <em>Toxoplasma</em> persists inside its hosts. “Through posttranscriptional control of a coherent set of metabolic pathways, TgPRO allows <em>T. gondii</em> to adapt to oxidative stress, which particularly impacts chronic-stage cation,” the authors concluded. “Within apicomplexan parasites, this pathway represents a unique example of an environmentally responsive regulator driving metabolic adaptation.”</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/parasite-specific-protein-helps-toxoplasma-adapt-to-crowded-conditions/">Parasite-Specific Protein Helps <i>Toxoplasma</i> Adapt to Crowded Conditions</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Bispecific Antibody Purification’s Complexity Problem and How to Fix It</title>
<link>https://edusehat.com/en/bispecific-antibody-purifications-complexity-problem-and-how-to-fix-it</link>
<guid>https://edusehat.com/en/bispecific-antibody-purifications-complexity-problem-and-how-to-fix-it</guid>
<description><![CDATA[ Bispecific antibodies are gaining momentum, and the demands on downstream purification will continue to grow. The case studies presented here illustrate how analytical insight forms the foundation of effective process development.
The post Bispecific Antibody Purification’s Complexity Problem and How to Fix It appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/GEN-bsAb-article-header-image.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 04:15:08 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Bispecific, Antibody, Purification’s, Complexity, Problem, and, How, Fix</media:keywords>
<content:encoded><![CDATA[<p>Sponsored content brought to you by</p>
<p><a href="https://www.thermofisher.com/" target="_blank" rel="noopener"><img decoding="async" class="alignnone wp-image-221790 " src="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png" alt="Thermo Fisher logo" width="252" height="116" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo.png 558w" sizes="(max-width: 252px) 100vw, 252px"></a></p>
<p>Much has been written about how bispecific antibodies have expanded the biologics landscape by making it possible to engage multiple targets simultaneously and unlock new mechanisms of action. But their structural complexity introduces significant workflow challenges for downstream purification that are often more pronounced than those associated with traditional monoclonal antibodies.</p>
<p><figure aria-describedby="caption-attachment-336074" class="wp-caption alignright"><img fetchpriority="high" decoding="async" class="wp-image-336074" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-972x1024.jpg" alt="figure 1" width="500" height="527" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-972x1024.jpg 972w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-285x300.jpg 285w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-768x809.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-399x420.jpg 399w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-797x840.jpg 797w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-696x733.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-1392x1466.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats-1068x1125.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture1-bsab-formats.jpg 1440w" sizes="(max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Figure 1: Bispecific antibodies come in a multitude of different formats. Examples are shown above. [Thermo Fisher Scientific]</figcaption></figure>Part of the challenge is that unlike monoclonal antibodies, bispecifics frequently generate a different array of product-related variants, including mispaired light and heavy chains, half antibodies, homodimers, and aggregates that can be difficult to resolve due to their physicochemical differences. Additionally, some bispecific formats exhibit reduced compatibility with conventional purification approaches such as protein A affinity chromatography.</p>
<p>To move bispecific therapies into the clinic faster, developers need robust purification processes that can achieve high purity and yield. This is where approaches that leverage analytical insights with flexible process design become increasingly important. In a recent webinar, Joshua Orchard, a field applications staff scientist at Thermo Fisher Scientific, used a series of case studies to outline the key purification challenges of bispecific antibodies and how analytical insights can guide the selection and optimization of affinity and non-affinity chromatography steps.</p>
<p>A central theme of the webinar is that the purification should be guided by the analytics. The diversity in format, size, domain architecture, and binding configurations of bispecifics create something of a moving target, where no single platform can be universally applied. Being successful requires “listening to what the analytics are telling us” and “what directions we need to go” in terms of what technologies to use, Orchard said. “We’ve got all of these bispecific antibodies that have so many different challenges [and] so many unique situations” and so “we have to make smart decisions.”</p>
<p class="trimmed"> </p>
<p><figure aria-describedby="caption-attachment-336076" class="wp-caption alignright"><img loading="lazy" decoding="async" class="size-medium wp-image-336076" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-bsab-formats-kappa-lambda-300x289.jpg" alt="figure 2" width="300" height="289" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-bsab-formats-kappa-lambda-300x289.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture2-bsab-formats-kappa-lambda.jpg 375w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 2: Structure of bsAb target molecules and related impurities. [Thermo Fisher Scientific]</figcaption></figure></p>
<p></p><h4><strong>Case study one: light chain–driven separation</strong></h4>

<p>The first case study involved bispecifics that contained both kappa and lambda light chains. Initial experiments focused on screening several resins to identify those with a high dynamic binding capacity for different bispecifics. Within the kappa-targeting resins, the CaptureSelect<sup>TM</sup> KappaXP Affinity Resin and a protein L affinity resin demonstrated the strongest performance of those tested with binding capacities exceeding 40 mg/mL.</p>
<p>Subsequent pH-gradient elution experiments (from pH 6 to pH 2.5) revealed a clear separation between the target bispecifics and homodimer impurities, with the highest resolution coming from the CaptureSelect KappaXP resin.</p>
<p><figure aria-describedby="caption-attachment-336082" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336082" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders-1024x625.png" alt="figure 3" width="400" height="244" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders-1024x625.png 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders-300x183.png 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders-768x469.png 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders-688x420.png 688w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders-696x425.png 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders-1068x652.png 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture3-DBC-light-chain-binders.png 1303w" sizes="auto, (max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">Figure 3: Comparison of the dynamic binding capacities of commercially available affinity resins targeting antibody light chains. [Thermo Fisher Scientific]</figcaption></figure>Further optimization required the use of ­elution modifiers. Experiments were conducted at 10 g/L loading over a 20-column volume gradient, evaluating various modifiers including sodium citrate and magnesium chloride. Of the modifiers tested, magnesium chloride had the most pronounced increase in separation.  Elution modifiers also increased the retention of bispecific product on the CaptureSelect<sup>TM</sup> LambdaXP Affinity Resin and successfully removed mispaired species. Purity increased from approximately 87% in the load to as high as 98% post-separation, with substantial reductions in aggregates, half antibodies, and free light chains.</p>
<p><figure aria-describedby="caption-attachment-336086" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336086" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance-1024x622.jpg" alt="lambdaXP performance" width="400" height="243" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance-1024x622.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance-300x182.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance-768x467.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance-691x420.jpg 691w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance-696x423.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance-1068x649.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture4-lambdaXP-performance.jpg 1182w" sizes="auto, (max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">Figure 4: Credit: Thermo Fisher Scientific</figcaption></figure></p>
<p>Despite these gains, there are trade-offs. Specifically, better separation often came at the cost of reduced yield, and the higher elution modifier concentrations required to achieve separation may be challenging to scale-up.</p>
<p></p><h4><strong>Case study two: aggregate reduction at capture </strong></h4>

<p>Improving process efficiency is at the heart of this next case study. Specifically, reducing the burden on downstream polishing by addressing high aggregate levels earlier in the workflow. The starting point was a bispecific antibody with elevated aggregate content (~17–23%) that was not effectively removed during traditional protein A capture. For the study, the scientists evaluated another Fc-targeting resin that binds a different epitope than protein A, CaptureSelect<sup>TM</sup> FcXP Affinity Resin.</p>
<p>According to the results, the MabSelect SuRe<sup>TM</sup> LX protein A resin had a typical elution profile and the resulting pool contained ~91.3% monomer and ~8.4% aggregate. In contrast, the CaptureSelect FcXP resin produced a distinct elution profile with about 99.7% monomer and only about 0.2% aggregate.</p>
<p>The scientists then extended the approach to a more challenging bispecific with 23% aggregate. Using the alternative Fc-binding resin, scientists obtained a clearer separation with reduced aggregate content of less than 5% in the elution pool, monomer purity of up to 99% in optimal fractions, and overall recovery of above 80%.</p>
<p></p><h4><strong>Case study three: leveraging CH1 selectivity for complex mixtures</strong></h4>

<p><figure aria-describedby="caption-attachment-336089" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336089" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-1024x496.jpg" alt="Teneobio Molecule illustration" width="400" height="194" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-1024x496.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-300x145.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-768x372.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-867x420.jpg 867w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-696x337.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-1392x674.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule-1068x517.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture5-TeneobioMolecule.jpg 1530w" sizes="auto, (max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">Figure 5: Variant forms of BsAb CD3-TAA–expressed products. [BioProcess International]</figcaption></figure>This next case study demonstrated how the molecular architecture of bispecifics can directly inform resin selection. In this case, the target bispecific presented a key challenge. Specifically, protein A co-eluted both active and inactive species which limited its effectiveness for purification. Additionally, the impurity profile included homodimers and half antibodies along with excess free light chain.</p>
<div class="my-8"><span data-render-ad="6"></span></div>
<p>These characteristics made CH1 affinity chromatography a logical alternative. That is because CH1 resins selectively bind antibodies containing the CH1 domain but do not bind free light chains making it possible to exclude the three types of impurity during capture, with only minor residual impurities.</p>
<p><figure aria-describedby="caption-attachment-336095" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336095 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture6-Teneobio-results-300x243.jpg" alt="Teneobio results" width="300" height="243" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture6-Teneobio-results-300x243.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture6-Teneobio-results-768x622.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture6-Teneobio-results-518x420.jpg 518w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture6-Teneobio-results-696x564.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture6-Teneobio-results.jpg 818w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 6: Analytical SEC HPLC results post affinity purification. [Thermo Fisher Scientific]</figcaption></figure>According to the results, using the CaptureSelect<sup>TM</sup> CH1-XL Affinity Resin produced a markedly cleaner elution profile than protein A, particularly for homodimer species. In fact, monomer purity improved from 72% with protein A to 98% with CH1-XL. Also, the mild elution conditions used in this experiment reduced the aggregation levels significantly.</p>
<p></p><h4><strong>Case study four: charge-based separation of complex variants</strong></h4>

<p>A particularly challenging case study focused on a bispecific with an Fc domain fused to single-chain variable fragments, leading to the formation of multiple variants including disulfide-linked diabodies. This example shifts the focus away from affinity chromatography toward the application of ion exchange resins for the removal of product-related impurities.</p>
<p>According to the data, initial weak cation exchange HPLC analysis revealed separation between monomer charge variants and the diabody species suggesting that charge-based methods might be an effective preparative tool. As a first step, scientists evaluated separation across increasing pH conditions. The clearest separation was achieved at pH 8.1 which resulted in about 98% monomer purity and effective variant removal. Then the team evaluated the performance of the POROS<sup>TM</sup> 50 HS Strong Cation Exchange Resin against a smaller particle size resin. Though the initial chromatogram showed a slightly lower resolution of the species, the analytical data revealed a better performance. Starting from a load with about 89% purity and 12.5% diabody content, the resin reduced the  diabody to below detectable levels in the elution and achieved ~74% yield, compared to 68% from thealternative resin in the study.</p>
<p><figure aria-describedby="caption-attachment-336097" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336097" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-1024x324.jpg" alt="case study 4 results table" width="500" height="158" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-1024x324.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-300x95.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-768x243.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-1327x420.jpg 1327w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-696x220.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-1392x441.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table-1068x338.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture7-case-study-4-results-table.jpg 1532w" sizes="auto, (max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Figure 7: Yield and purity results of two resins and flowrates. {Thermo Fisher Scientific]</figcaption></figure></p>
<p>Furthermore, the data showed that increasing the flow rate improved process efficiency with some tradeoffs including reduced yield and partial reappearance of the diabody species. It suggests that further gradient optimization could improve the resin performance.</p>
<p class="trimmed"> </p>
<p class="trimmed"> </p>
<p></p><h4></h4>

<div class="my-8"><span data-render-ad="7"></span></div>
<h4><strong>Case study five: exploiting pI differences</strong></h4>
<p><figure aria-describedby="caption-attachment-336099" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336099" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-1024x390.jpg" alt="case study 5" width="500" height="191" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-1024x390.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-300x114.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-768x293.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-1102x420.jpg 1102w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-696x265.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-1392x531.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5-1068x407.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture8-case-study-5.jpg 1537w" sizes="auto, (max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Figure 8. Target bsAb and homodimer impurities. [Thermo Fisher Scientific]</figcaption></figure>This case study demonstrated how charge differences can enable high-resolution separation. In this example, the system consisted of the target bispecific and a homodimer impurity.  Here the target bispecific with a pI of ~7 was successfully separated from a homodimer impurity with a pI of ~6 using anion exchange chromatography.</p>
<p>Initial screening across multiple resins identified the POROS<sup>TM</sup> 50 HQ Anion Exchange Resin as offering superior separation potential of the resins screened in this study. By optimizing the pH, conductivity, and loading conditions, this approach achieved greater that 90% heterodimer yield and about 99% removal of the homodimer impurity. An additional benefit of the approach was a three-fold reduction in aggregate levels.</p>
<p></p><h4><strong>Case study six: reversing the strategy based on charge profile</strong></h4>

<p>This case study builds on the previous example with a variation in impurity behavior. It involves an asymmetric IgG captured using protein A followed by a polishing step to reduce product-related impurities that accounted for about 30% of the product pool. Importantly, these impurities had a higher isoelectric point (pI) than the intact bispecific unlike the previous case where the target molecule had a higher pI.</p>
<p><figure aria-describedby="caption-attachment-336100" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336100" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6-1024x521.jpg" alt="case study 6" width="400" height="204" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6-1024x521.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6-300x153.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6-768x391.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6-826x420.jpg 826w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6-696x354.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6-1068x543.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture9-case-study-6.jpg 1313w" sizes="auto, (max-width: 400px) 100vw, 400px"><figcaption class="wp-caption-text">Figure 9. Purity results with POROS 50 HQ AEX resin at different column loadings. [Thermo Fisher Scientific]</figcaption></figure>This flip in pI necessitates a different purification strategy. For this product, scientists evaluated a bind-and-elute anion exchange approach using the POROS 50 HQ Anion Exchange Resin. The goal was to selectively retain and remove higher pI impurities during washing while recovering the target bispecific. After testing a range of conditions, the scientists found that at pH 8 and 5 mS/cm conductivity, the intermediate wash demonstrated effectiveness with higher loading column which correlates to improved removal of byproducts.</p>
<p>There was a trade-off as step yield decreased when loading increased, with overall recovery ranging from about 53% to 63% pointing to some possible opportunities for optimization particularly balancing impurity clearance with yield.</p>
<p></p><h4><strong>Case study seven: resolving light chain mispairing using charge-based separation</strong></h4>

<p>Charge-based separation can also address light chain mispairing as this next case study demonstrated. Correctly paired bispecifics display distinct, positively charged surface patches, while mispaired species disrupt this charge distribution. The differences in surface changes point to the possibility of using cation exchange chromatography.</p>
<p>Initial experiments identified a range of pH 5.5–6.5 and 200–350 mM sodium acetate as the optimal condition for achieving selective separation. Under these conditions, the wash step effectively removed mispaired species while the elution step selectively recovered the bispecific. The process increased product purity from ~60% to ~95%.</p>
<p></p><h4><strong>Resolving aggregate challenges across modalities</strong></h4>

<p>Aggregates remain one of the most persistent challenges for bispecifics developers. While they can be difficult to manage, there are a range of chromatography options that can be helpful for addressing them. “Traditional cation exchange chromatography works very well” and “our POROS<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> XS Strong Cation Exchange Resin has a high dynamic binding capacity, which should help alleviate some of [the] more moderate aggregate issues.”  For slightly more severe cases, hydrophobic interaction chromatography can be effective. Resins such as POROS<sup>TM</sup> Benzyl Ultra Hydrophobic Interaction Chromatography Resin operate in flowthrough mode and can be easily coupled to upstream anion exchange.</p>
<p><figure aria-describedby="caption-attachment-336101" class="wp-caption alignright"><img loading="lazy" decoding="async" class="wp-image-336101" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-1024x547.jpg" alt="POROS agg removal" width="500" height="267" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-1024x547.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-300x160.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-768x410.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-786x420.jpg 786w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-696x372.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-1392x744.jpg 1392w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_-1068x571.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture10-POROS-agg-removal_.jpg 1473w" sizes="auto, (max-width: 500px) 100vw, 500px"><figcaption class="wp-caption-text">Figure 10. POROS-based chromatography resins that can be used for aggregate removal. [Thermo Fisher Scientific]</figcaption></figure>For exceptionally high aggregate content, a mixed-mode chromatography solution can provide an added layer of control. By combining ionic and hydrophobic interactions, this approach, using POROS<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> Caprylate Mixed-Mode Cation Exchange Resin, demonstrates aggregate reductions of up to 20%. However, it typically requires more extensive process development.</p>
<p>Also, cation exchange chromatography can contribute to aggregate reduction. Internal studies comparing multiple resins showed that aggregate levels could be reduced from ~7% to below 2% under optimized conditions for a model IgG (pI ~8) following protein A capture.</p>
<p></p><h4><strong>Conclusion</strong></h4>

<p>Bispecific antibodies present a wide range of structural and physicochemical challenges, that makes applying standardized platform approaches significantly more challenging. For the most optimal results, manufacturers need customized purification strategies that account for the structural diversity of these therapeutics. Affinity-based approaches, including CaptureSelect<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> affinity resins, provide valuable options when protein A binding is altered or absent.</p>
<p><figure aria-describedby="caption-attachment-336096" class="wp-caption alignleft"><img loading="lazy" decoding="async" class="wp-image-336096 size-medium" src="https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-300x218.jpg" alt="affinity resins antibody_" width="300" height="218" srcset="https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-300x218.jpg 300w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-1024x743.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-768x557.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-579x420.jpg 579w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-696x505.jpg 696w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-1068x775.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-324x235.jpg 324w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_-648x470.jpg 648w, https://www.genengnews.com/wp-content/uploads/2026/08/Picture11-affinity-resins-antibody_.jpg 1092w" sizes="auto, (max-width: 300px) 100vw, 300px"><figcaption class="wp-caption-text">Figure 11. Affinity resin toolbox from Thermo Fisher Scientific, including a traditional Protein A resin as well as CaptureSelect<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley"> resins targeting other antibody subdomains. [Thermo Fisher Scientific]</figcaption></figure>At the same time, ion exchange and mixed-mode resins offer flexible solutions for separating product-related variants by exploiting differences in charge and hydrophobicity.</p>
<p>Bispecific antibodies are gaining momentum, and the demands on downstream purification will continue to grow. The case studies presented here illustrate how analytical insight forms the foundation of effective process development. Ultimately, effective purification depends on selecting appropriate tools based on analytical insights and systematically exploring process conditions to build workflows that balance purity, yield, and scalability.</p>
<p>The post <a href="https://www.genengnews.com/sponsored/bispecific-antibody-purifications-complexity-problem-and-how-to-fix-it/">Bispecific Antibody Purification’s Complexity Problem and How to Fix It</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>Human iPSC&#45;Derived Heart Assembloids Reproduce Valve Development and Disease</title>
<link>https://edusehat.com/en/human-ipsc-derived-heart-assembloids-reproduce-valve-development-and-disease</link>
<guid>https://edusehat.com/en/human-ipsc-derived-heart-assembloids-reproduce-valve-development-and-disease</guid>
<description><![CDATA[ Different types of organoids grown from pluripotent, adult human stem cells can be combined into &quot;assembloids&quot; to better model complex organs that natively originate from combinations of different tissues.
The post Human iPSC-Derived Heart Assembloids Reproduce Valve Development and Disease appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2025/01/GettyImages-1337210935-RESIZE-2400.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 04:15:07 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>Human, iPSC-Derived, Heart, Assembloids, Reproduce, Valve, Development, and, Disease</media:keywords>
<content:encoded><![CDATA[<p>A multi-disciplinary, multi-institutional group of researchers said they relied on their expertise in genetics, mechanics, chemistry, and biology to create a chip the size of a postage stamp to model a particular class of heart conditions.</p>
<p>The team, led by Guang Li, PhD, an associate professor in the University of Pittsburgh School of Medicine’s department of cell biology, has grown heart valves on organoids. The study “<a href="https://www.sciencedirect.com/science/article/pii/S1934590926002717?via%3Dihub">Human iPSC-derived heart valve-like assembloids model valve development and disease pathology</a>” appears in <em>Cell Stem Cell</em> and is an important step toward better understanding and treating a number of serious heart disorders, according to the scientists.</p>
<div class="my-8"><span data-render-ad="3"></span></div>
<p>This kind of research often depends on animal models, where researchers can study the development of heart valves that grow much quicker than those of humans (which take nearly 10 weeks to fully develop), and don’t raise the same ethical dilemmas as it would in humans. But, Li said, “human valves are very different from animal valves.” Imagine the physiological and genetic differences between a person and, for instance, a zebrafish. “To study human valve diseases, we need human valve models.”</p>
<p>The organoids were grown from pluripotent, adult human stem cells, which can be generated from skin, blood, or other cells, then coaxed into developing into cells from a body part of interest; in this case, a human heart. Different types of organoids can be combined into “assembloids” to better model complex organs that natively originate from combinations of different tissues.</p>
<p>However, a functioning heart is more than a cluster of certain types of cells. Its development and continued operation are dependent, among other things, on a complex interaction of different forces. To build analogs of those forces into the model, Li sought the engineering expertise of colleagues, including Lance Davidson, PhD, the William Kepler Whiteford Professor of bioengineering in the Swanson School of Engineering and Si-Yang Zhen, PhD, a professor of biomedical engineering at Carnegie Mellon University.</p>
<div class="my-8"><span data-render-ad="4"></span></div>
<p>“This kind of project is really a hallmark of the community of researchers in Pittsburgh,” Davidson said.</p>
<p></p><h4><strong>Valve grown on heart assembloid surface</strong></h4>

<p>To create a model, Li grew a valve on the surface of a heart assembloid. Then the team stimulated growth by designing ways to mimic the forces that would act on an embodied heart, a flowing medium to simulate blood, an endothelial culture which simulates cells that line heart valves, and even a set of magnetized beads that moved according to the placement of a magnetic belt to simulate muscle contraction.</p>
<p>With the organoid working to simulate a heart with valves, the team now had a model they could use to study four types of valve disorders, including mitral valve prolapse (MVP), a genetic disorder affecting seven to eight million individuals in the US at any given time.</p>
<p>When Li introduced a mutation associated with the disease, the developing valves showed signs of MVP. In other cases, damage was simulated or introduced to mirror the damage that can occur to a person’s valves throughout life in conditions such as valve calcification; cryo-injury; and complications from hypoglycemia and diabetes.</p>
<p>Li was able to begin studying the organoids, identifying some pathways responsible for the development problems associated with MVP and ways they can be corrected. He was also able to develop models for the acquired deficiencies and will go on to look for ways to treat them.</p>
<div class="my-8"><span data-render-ad="5"></span></div>
<p>Next, however, Li plans to add complexity to his assembloids, growing them with two chambers and growing the valves inside them, instead of on the surface, to better model a real human heart.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/human-ipsc-derived-heart-assembloids-reproduce-valve-development-and-disease/">Human iPSC-Derived Heart Assembloids Reproduce Valve Development and Disease</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>The State of Biotech 2026</title>
<link>https://edusehat.com/en/the-state-of-biotech-2026</link>
<guid>https://edusehat.com/en/the-state-of-biotech-2026</guid>
<description><![CDATA[ The world of biotech is showing strong signs of growth and clinical impact while also experiencing new challenges. The explosion of AI is reshaping areas from drug discovery and protein folding to gene editing and clinical trials. In GEN’s flagship virtual event we hear from a distinguished group of business executives, award-winning scientists, and journalists.
The post The State of Biotech 2026 appeared first on GEN - Genetic Engineering and Biotechnology News. ]]></description>
<enclosure url="https://www.genengnews.com/wp-content/uploads/2026/08/getty_1500368452_MolecularStructure.jpg" length="49398" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 04:15:06 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>The, State, Biotech, 2026</media:keywords>
<content:encoded><![CDATA[<p></p><h3 class="w-full text-left">
    <strong>
            </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/02/JohnMaraganore-web.webp" class="h-full w-full object-cover" alt="Image of John Maraganore, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">John Maraganore, PhD</h2>
                <h5 class="mt-0 !text-[15px]">Co-Founder and Executive Chair<br>City Therapeutics</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/02/JohnMaraganore-web.webp" alt="Image of John Maraganore, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">John Maraganore, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>John Maraganore, PhD, is a co-founder and executive chair of City Therapeutics. He was the founding CEO and a director of Alnylam Pharmaceuticals, the leading RNAi therapeutics company, which he led for nearly 20 years from 2002 to 2021. John built Alnylam from early platform research on RNAi through global approval and commercialization of the first five RNAi medicines. He led the company’s value creation strategy, raising more than $7.5 billion in capital, forming more than 20 major pharmaceutical alliances and creating more than $25 billion in market capitalization. Prior to Alnylam, John held senior leadership roles at Millennium Pharmaceuticals and at Biogen, where he invented and led the development of ANGIOMAX® (bivalirudin) for injection, marketed by The Medicines Company. Prior to Biogen, John was a scientist at ZymoGenetics and the Upjohn Company.</p>
<p>John is currently the CEO and principal of JMM Innovations, which is committed to the advancement of biomedical innovation to patients. He serves on the boards of Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics, and Takeda Pharmaceuticals, in addition to several private company and non-profit boards. He is a member of the BIO board, where he was chair from 2017 to 2019.</p>
<p>John received his MS and PhD in biochemistry and molecular biology from the University of Chicago.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/JeremyLevin_headshot.jpg" class="h-full w-full object-cover" alt="Image of Jeremy Levin, DPhil, MB BChir">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Jeremy Levin, DPhil, MB BChir</h2>
                <h5 class="mt-0 !text-[15px]">Co-Founder and Executive Chairman<br>Ovid Therapeutics</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/JeremyLevin_headshot.jpg" alt="Image of Jeremy Levin, DPhil, MB BChir">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Jeremy Levin, DPhil, MB BChir</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Jeremy Levin, DPhil, MB BChir, is co-founder, executive chairman and former CEO of Ovid Therapeutics, a public company developing novel medicines to treat epilepsies and seizure-related disorders. Jeremy is concurrently the chairman of Ceryvyn Therapeutics. Prior to founding Ovid, he was president and CEO of Teva Pharmaceutical Industries and a member of the executive committee of Bristol Myers Squibb Company (BMS), where he was the architect, lead, and implementer of the String of Pearls Strategy, which transformed BMS and facilitated the massive growth of the immuno-oncology revolution in the biopharmaceutical industry.</p>
<p>Jeremy joined BMS from Novartis, where he was the global head of strategic alliances. He has previously served as a member of the board of directors of various public biopharmaceutical companies, including Biocon and Lundbeck. Levin also serves on the board and executive committee of the Biotechnology Innovation Organization (BIO) as the immediate past chairman.</p>
<p>Jeremy holds a BA in zoology and MA and DPhil degrees from the University of Oxford.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/08/ShwetaManiarheadshot.jpeg" class="h-full w-full object-cover" alt="Image of Shweta Maniar">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Shweta Maniar</h2>
                <h5 class="mt-0 !text-[15px]">Director, Healthcare & Life Sciences<br>Google Cloud</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/08/ShwetaManiarheadshot.jpeg" alt="Image of Shweta Maniar">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Shweta Maniar</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Shweta Maniar leads Google’s Life Sciences Strategic Industries practice, joining the company in 2018. She is motivated by creating a collaborative ecosystem to maximize value from data within the healthcare and life sciences ecosystem to ultimately benefit patients. With more than 20 years’ experience in healthcare, pharma, and biotech, she has enabled dozens of start-up firms with access to capital from federal grants and venture capital firms alike. She has been recognized as a trailblazer for Life Sciences in the PharmaVoice 100. Shweta also serves on the Scientific Advisory Board of the Allen Institute.</p>
<p>Shweta holds a degree in economics from University of California, San Diego. After research spells at Scripps Health and Cleveland Clinic, she moved into commercial development during a five-year stint at Genentech.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3 presenter-card">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2024/10/DaphneZohar-CROP11111.jpg" class="h-full w-full object-cover" alt="Image of Daphne Zohar">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Daphne Zohar</h2>
                <h5 class="mt-0 !text-[15px]">Founder and CEO<br>Seaport Therapeutics</h5>
            </div>
            <button type="button" class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="https://www.genengnews.com/wp-content/themes/genengnews/assets/svg/icons8-close-18.svg" alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2024/10/DaphneZohar-CROP11111.jpg" alt="Image of Daphne Zohar">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Daphne Zohar</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"></p><p>Daphne is a serial biotech entrepreneur. She serves as founder, CEO, and board member of Seaport Therapeutics, a developer of therapies for neuropsychiatric disorders that was publicly launched last year with a $100-million Series A round. She successfully took Seaport public in May 2026, raising more than $250 million. Previously, she was the founder, chief executive officer, and board member of PureTech Health, where she also co-founded PureTech’s entities, including Karuna Therapeutics (acquired by Bristol Myers Squibb). She is widely recognized as a leader in biotech innovation. In 2023, Daphne was named as one of the most influential people in biopharma by Fierce Media, and earlier, was recognized by <i>MIT Technology Review</i> as one of its “Innovators Under 35.”</p>
<p>Daphne is the co-founder and host of <i>Biotech Hangout</i>, a weekly podcast on the latest news in the biotech industry. She also sits on the board of Biotechnology Innovation Organization (BIO) and is a member of the Biotech CEO Sisterhood.</p>
                    
                    <div class="dui-modal-action">
                    
                        <!-- if there is a button in form, it will close the modal -->
                        <button type="button" class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>

<p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p></p><p></p><div class="wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-fe48e5de wp-block-buttons-is-layout-flex"><p></p><div class="wp-block-button"><a class="wp-block-button__link wp-element-button" href="https://events.zoom.us/ev/Ap-pPBMWHHsMRNcqRGPW8EAuFz8lUT3Yy3G9W-0rMEFQpqpORQAz~AhENWIA0ieFr2UxucK6fudVKavvNp4WLei-zWc1q1ENzs1GJPHB5KoSqLtVzdbtG25D_fY_dJaYXTjI6AF0W8CDIpQ" target="_blank" rel="noreferrer noopener">REGISTER NOW</a></div><p></p></div><p></p><p></p><p></p><div aria-hidden="true" class="wp-block-spacer"></div><p></p><p></p><p></p><div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex"><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-malblocks-webinars-info"></p><div><strong>Broadcast Date:</strong> <time>Wednesday, September 23, 2026</time><br><ul><li><strong>Time:</strong> <time datetime="2026-09-23T15:00:00.000Z">08:00 PDT, 11:00 EDT, 17:00 CET</time></li></ul></div><p></p><p></p><p class="wp-block-paragraph">The world of biotech is showing strong signs of growth and clinical impact while also experiencing new challenges. The explosion of artificial intelligence is reshaping areas from drug discovery and protein folding to gene editing and clinical trials. Recent successes in developing GLP-1s and inhibiting once undruggable cancer targets show the immense power of biotechnology. But upheaval at the FDA, the looming patent cliffs facing several big pharma companies, and growing competition from China, are among the many challenges confronting the industry.</p><p></p><p></p><p class="wp-block-paragraph">In <em>GEN</em>’s flagship virtual event, <strong><em>The State of Biotech</em></strong>—with exclusive sponsorship by Cytiva—we hear from a distinguished group of business executives, award-winning scientists, and journalists. Among the highlights:</p><p></p><p></p><p></p><ul class="wp-block-list"><p></p><li>A keynote conversation with <strong>John Maraganore</strong>, <strong>PhD</strong>, the founding CEO of Alnylam.</li><p></p><p></p><p></p><li>In honor of Sickle Cell Awareness month, 2026 Breakthrough Prize winner<strong> Stuart Orkin, MD</strong>, presents the research behind the discovery of the fetal-to-adult hemoglobin switch that powered the approval of Casgevy.</li><p></p><p></p><p></p><li>A timely conversation about the challenges faced by life sciences and healthcare users in applying artificial intelligence effectively for maximum ROI with<strong> Shweta Maniar</strong>, global director of Life Sciences Strategy & Solutions for Google Cloud.</li><p></p><p></p><p></p><li><strong>Jeremy Levin, MB BChir, DPhil</strong>, chairman of Ovid Therapeutics and author of a new book, <em>Biotech in the Balance</em>, argues that we need a globally competitive biotechnology industry built to serve patients and earn lasting public trust.</li><p></p><p></p><p></p><li>Our annual catch-up with the hosts of the popular <em>Biotech Hangout</em> podcast—<strong>Daphne Zohar</strong>, <strong>Brad Loncar</strong>, and<strong> Chris Garabedian</strong>.</li><p></p><p></p><p></p><li>And in closing, an interview with <em>GEN</em>’s veteran editor in chief,<strong> John Sterling</strong>, as he prepares to step down after more than four decades with the publication.r) discussing the intersection of AI and CRISPR. </li><p></p><p></p><p></p><li>Breakout sessions from the summit sponsors.</li><p></p></ul><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p class="wp-block-paragraph">Registration is free. We look forward to welcoming you to <strong><em>The State of Biotech</em></strong>! </p><p></p></div><p></p><p></p><p></p><div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><p class="wp-block-paragraph"></p><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p class="wp-block-paragraph"></p><p></p><p></p><p class="has-text-align-center wp-block-paragraph"><strong>Produced with support from:</strong></p><p></p><p></p><div class="wp-block-image"><p><figure class="aligncenter size-medium is-resized"><a href="https://www.cytivalifesciences.com/" target="_blank" rel=" noreferrer noopener"><img decoding="async" width="300" height="87" src="https://www.genengnews.com/wp-content/uploads/2020/08/cytiva_logo_hz_color_pos_CMYK-300x87.jpg" alt="cytiva logo" class="wp-image-148470" srcset="https://www.genengnews.com/wp-content/uploads/2020/08/cytiva_logo_hz_color_pos_CMYK-300x87.jpg 300w, https://www.genengnews.com/wp-content/uploads/2020/08/cytiva_logo_hz_color_pos_CMYK-1024x296.jpg 1024w, https://www.genengnews.com/wp-content/uploads/2020/08/cytiva_logo_hz_color_pos_CMYK-768x222.jpg 768w, https://www.genengnews.com/wp-content/uploads/2020/08/cytiva_logo_hz_color_pos_CMYK-696x201.jpg 696w, https://www.genengnews.com/wp-content/uploads/2020/08/cytiva_logo_hz_color_pos_CMYK-1068x309.jpg 1068w, https://www.genengnews.com/wp-content/uploads/2020/08/cytiva_logo_hz_color_pos_CMYK.jpg 1216w" sizes="(max-width: 300px) 100vw, 300px"></a></figure></p><p></p></div></div><p></p><p></p><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p><p></p><p class="is-layout-flow wp-block-column-is-layout-flow"></p><div class="wp-block-column"></div><p></p></div><p></p><p>The post <a href="https://www.genengnews.com/multimedia/summits/the-state-of-biotech-2026/">The State of Biotech 2026</a> appeared first on <a href="https://www.genengnews.com/">GEN - Genetic Engineering and Biotechnology News</a>.</p>]]> </content:encoded>
</item>

<item>
<title>GLOBE and GUARD approaches ignore the realities of out&#45;licensing at small&#45; and mid&#45;size biotech companies, threaten innovation</title>
<link>https://edusehat.com/en/globe-and-guard-approaches-ignore-the-realities-of-out-licensing-at-small-and-mid-size-biotech-companies-threaten-innovation</link>
<guid>https://edusehat.com/en/globe-and-guard-approaches-ignore-the-realities-of-out-licensing-at-small-and-mid-size-biotech-companies-threaten-innovation</guid>
<description><![CDATA[ There are a lot of reasons to be skeptical of the HHS effort to bring international reference prices into Medicare via the proposed GLOBE […]
The post GLOBE and GUARD approaches ignore the realities of out-licensing at small- and mid-size biotech companies, threaten innovation appeared first on Bio.News. ]]></description>
<enclosure url="https://bio.news/wp-content/uploads/2026/08/publicdomainpictures-mixture-69523_640.jpg" length="49398" type="image/jpeg"/>
<pubDate>Tue, 11 Aug 2026 21:15:03 +0700</pubDate>
<dc:creator>Edusehat</dc:creator>
<media:keywords>GLOBE, and, GUARD, approaches, ignore, the, realities, out-licensing, small-, and, mid-size, biotech, companies, threaten, innovation</media:keywords>
<content:encoded><![CDATA[<p>There are a lot of reasons to be skeptical of the HHS effort to bring international reference prices into Medicare via the proposed GLOBE and GUARD models. <a href="https://bio.news/latest-news/bio-warns-mfn-models-are-illegal-ineffective-and-a-threat-to-innovation/">Such efforts are counterproductive, hampering innovation without improving patient affordability</a>.</p>
<p>But the GLOBE and GUARD models are also problematic because they pose a unique danger to small- and mid-size biotechnology companies that develop over half of all new drugs that patients need. These companies are the backbone of an American innovation ecosystem that is the envy of the world, driving the successive waves of innovation that have transformed the treatment of disease after disease.</p>
<p>When smaller companies invent new medicines, the funding that allows them to pursue research and development goals often comes from selling the rights to market their medicines in different countries. That means that the company that developed a given treatment may have no say in how its licensee sells that medicine in another country.</p>
<p>In some cases, a smaller biotech company may sell the rights to market the medicine to multiple different companies, creating an even more complicated arrangement where the company that holds the patent is different from the company that sells the product in the United States, with a third company marketing the medicine overseas.</p>
<p>This is a standard part of the biotech life cycle, a way for companies to raise the funds needed to finance R&D and keep a focus on moving science forward rather than making investments in commercial infrastructure in dozens of countries. But out-licensing also injects complexity into cross-border policymaking. The company that created a drug may have no control over the commercial decisions made by its licensees selling the product in Europe or Asia.</p>
<p>That’s a problem, because GLOBE and GUARD both demand that the prices paid in Europe and countries in other regions be used to determine prices in Medicare. As BIO detailed in its comment letters (see <a href="https://www.bio.org/letters-testimony-comments/bio-comments-global-benchmark-efficient-drug-pricing-globe-model-cms">BIO’s comment letter on GLOBE here</a>, and <a href="https://www.bio.org/letters-testimony-comments/bio-comments-guarding-us-medicare-against-rising-drug-costs-guard-model?_gl=1*vhd3m7*_gcl_au*MTk4MDM5NzkxNy4xNzY4NDIxODAx">the BIO letter on GUARD here</a>), the realities of biotech out-licensing make those programs unworkable. Once a medicine is licensed, the originator company often has no right to determine commercial decisions, such as price. Additionally, country-specific confidentiality rules create a further hurdle; in some cases, the company selling a medicine in Europe is prohibited by law from providing the licensing company details about net prices.</p>
<p>As a result, the company that controls the pricing of a medicine in the United States may have no legal authority or practical leverage to change international prices. <strong>That creates the risk that price controls will be imposed in the United States—harming innovation, particularly the work of smaller companies—without any mechanism to deter foreign freeloading. </strong></p>
<h2>BIO’s View</h2>
<p>International reference pricing is inherently fraught, imposing values around access and innovation that have devastated drug development in Europe and deprived patients in Europe and other countries of many new treatments. The damage that would be inflicted by international reference pricing is exacerbated by creating new barriers to the kind of collaborative arrangements that have served as a critical tool that sustains smaller biopharma companies at the early stage of research.</p>
<p>These smaller companies already face long odds, and out-licensing provides the fuel to accelerate efforts to bring new medicines to patients at exactly the moment those resources are needed.</p>
<p>Laws that create obstacles to this kind of licensing will inevitably harm the companies that need capital the most, raising the risk that tomorrow’s cures won’t make it over the finish line.</p>
<p>The post <a href="https://bio.news/bios-view/globe-and-guard-approaches-ignore-the-realities-of-out-licensing-at-small-and-mid-size-biotech-companies-threaten-innovation/">GLOBE and GUARD approaches ignore the realities of out-licensing at small- and mid-size biotech companies, threaten innovation</a> appeared first on <a href="https://bio.news/">Bio.News</a>.</p>]]> </content:encoded>
</item>

</channel>
</rss>